15882284
D001241_D007674 NONE aspirin_6\NN\2707683|NONE (r_pobj) with_5\IN\0|NONE (r_prep) associated_4\VBN\628491|The|of (r_acl) risk_1\NN\14541044|was|was|to|and|, (r_nsubjpass) related_8\VBN\628491|NONE (l_conj) was_20\VBD\0|was|risk|to|and|, (l_acomp) high_22\JJ\5093890|.|it|] (l_prep) among_23\IN\0|particularly (l_pobj) subset_25\NN\7999699|NONE (l_prep) of_26\IN\0|the (l_pobj) patients_27\NNS\9898892|NONE (l_prep) with_28\IN\0|as (l_pobj) nephropathy_30\NN\14573196|NONE
D001241_D007676 CID aspirin_11\NN\2707683|NONE (l_conj) drugs_20\NNS\14778436|and (l_appos) nsaids_22\NNPS\2721538|other|(|inflammatory|analgesic (l_conj) disease_29\NN\14061805|)|and
D001241_D007676 CID aspirin_11\NN\2707683|NONE (l_conj) drugs_20\NNS\14778436|and (l_appos) nsaids_22\NNPS\2721538|other|(|inflammatory|analgesic (l_conj) disease_29\NN\14061805|)|and (l_appos) esrd_31\NNP\0|stage|)|(|renal
D001241_D007676 CID aspirin_6\NN\2707683|NONE (r_pobj) with_5\IN\0|NONE (r_prep) associated_4\VBN\628491|The|of (r_acl) risk_1\NN\14541044|was|was|to|and|, (l_prep) of_2\IN\0|The|associated (l_pobj) esrd_3\NNS\0|NONE
D001241_D007676 CID aspirin_6\NN\2707683|NONE (r_pobj) of_5\IN\0|chronic|the (r_prep) use_4\NN\407535|However|risk|.|,|may (r_nsubj) increase_8\VB\13576355|NONE (l_dobj) risk_10\NN\14541044|However|.|,|may|use (l_prep) of_11\IN\0|the (l_pobj) esrd_12\NNP\0|NONE
17159032
D006886_D014786 CID hydroxychloroquine_8\NN\2721538|NONE (r_dobj) taking_7\VBG\37396|NONE (r_acl) patients_6\NNS\9898892|NONE (r_pobj) in_5\IN\13603305|field|paracentral|visual|. (r_prep) loss_4\NN\13252973|NONE
D006886_D014786 CID hydroxychloroquine_17\JJ\2721538|in (r_compound) treatment_18\NN\654885|NONE (r_pobj) to_16\IN\0|were|which (r_prep) attributed_15\VBN\670261|field|, (r_relcl) abnormalities_11\NNS\14034177|.|patients
7018927
D006220_D006966 CID haloperidol_9\NN\3713736| (r_npadvmod) induced_11\VBN\1627355|NONE (r_amod) hyperprolactinemia_12\NN\0|NONE
D006220_D006966 CID haloperidol_4\NN\3713736|NONE (r_amod) infusions_5\NNS\14589223|NONE (r_pobj) of_3\IN\0|the (r_prep) course_2\NN\883297|NONE (r_pobj) during_0\IN\0|,|was|with|.|hyperprolactinemia|,|,|compared (r_prep) found_10\VBN\13279262|NONE (l_nsubjpass) hyperprolactinemia_8\NN\0|,|was|with|During|.|,|,|compared
6305660
2553470
D010862_D013226 CID pilocarpine_8\NN\14712692|of|the (r_compound) model_9\NN\5888929|MK (r_pobj) on_4\IN\0|.|in|actions (r_prep) epilepticus_12\NN\0|NONE
D010862_D013226 CID pilocarpine_14\NN\14712692|and (r_conj) lithium_12\NN\14625458|NONE (r_pobj) by_11\IN\0|by|prior (r_agent) induced_10\VBN\1627355|NONE (r_acl) seizures_9\NNS\14081375|to (r_dobj) block_8\VB\21939|easy|it|although (r_xcomp) is_4\VBZ\0|it|,|ongoing|,|difficult|.|Third (r_advcl) is_24\VBZ\0|NONE (l_xcomp) ongoing_29\JJ\0|it|,|is|,|difficult|.|Third (l_advmod) epilepticus_31\NN\0|NONE
D010862_D013226 CID pilocarpine_21\NN\14712692|NONE (r_pobj) to_20\IN\0|NONE (r_prep) prior_19\RB\10675876|by|by (r_advmod) induced_10\VBN\1627355|NONE (r_acl) seizures_9\NNS\14081375|to (r_dobj) block_8\VB\21939|easy|it|although (r_xcomp) is_4\VBZ\0|it|,|ongoing|,|difficult|.|Third (r_advcl) is_24\VBZ\0|NONE (l_xcomp) ongoing_29\JJ\0|it|,|is|,|difficult|.|Third (l_advmod) epilepticus_31\NN\0|NONE
D010862_D013226 CID pilocarpine_8\NN\14712692|NONE (r_pobj) after_7\IN\0| (r_prep) min_6\NN\15154774|NONE (r_pobj) of_1\IN\0|NONE (r_prep) administration_0\NN\1133281|i.e.|gradually|.|,|,|enhanced|activity|,|during|and (r_nsubj) reduced_17\VBD\441445|NONE (l_prep) during_12\IN\0|i.e.|gradually|.|,|Administration|,|enhanced|activity|,|and (l_pobj) epilepticus_14\NN\0|status
D010862_D013226 CID pilocarpine_22\NN\14712692|the (r_compound) model_23\NN\5888929|NONE (r_pobj) in_18\IN\13603305|status|epilepticus (r_prep) damage_17\NN\7296428|NONE (l_amod) epilepticus_14\NN\0|status|in
D010862_D013226 CID pilocarpine_13\NN\14712692|and (r_conj) nmda_11\NNP\0|NONE (r_pobj) of_10\IN\0|that|nonconvulsive (r_prep) doses_9\NNS\3740161|NONE (r_dobj) showing_6\VBG\6887726|NONE (r_acl) results_5\NNS\34213|NONE (r_pobj) by_4\IN\0|further|were|.|was|This (r_agent) supported_3\VBN\0|NONE (l_conj) were_14\VBD\0|by|further|.|was|This (l_advcl) resulting_17\VBG\2633881|synergistic|, (l_prep) in_18\IN\13603305|NONE (l_pobj) mortality_23\NN\5054863|NONE (l_amod) epilepticus_20\NN\0|status
D016291_D013226 NONE mk-801_3\NNP\0|model (r_punct) on_4\IN\0|.|in|actions (r_prep) epilepticus_12\NN\0|NONE
D016291_D013226 NONE mk-801_2\NNP\0||or (r_punct) 30_3\CD\13745420|after (r_nummod) min_6\NN\15154774|NONE (r_pobj) of_1\IN\0|NONE (r_prep) administration_0\NN\1133281|i.e.|gradually|.|,|,|enhanced|activity|,|during|and (r_nsubj) reduced_17\VBD\441445|NONE (l_prep) during_12\IN\0|i.e.|gradually|.|,|Administration|,|enhanced|activity|,|and (l_pobj) epilepticus_14\NN\0|status
D016202_D013226 NONE nmda_6\NNP\0|NONE (r_compound) receptors_7\NNS\5225602|NONE (r_pobj) of_5\IN\0|NONE (r_prep) activation_4\NN\13561719|that|role (r_nsubj) plays_8\VBZ\7007684|.|results (l_dobj) role_11\NN\719494|activation|that (l_prep) in_12\IN\13603305|important|an (l_pobj) damage_17\NN\7296428|NONE (l_amod) epilepticus_14\NN\0|status|in
D016202_D013226 NONE nmda_11\NNP\0|NONE (r_pobj) of_10\IN\0|that|nonconvulsive (r_prep) doses_9\NNS\3740161|NONE (r_dobj) showing_6\VBG\6887726|NONE (r_acl) results_5\NNS\34213|NONE (r_pobj) by_4\IN\0|further|were|.|was|This (r_agent) supported_3\VBN\0|NONE (l_conj) were_14\VBD\0|by|further|.|was|This (l_advcl) resulting_17\VBG\2633881|synergistic|, (l_prep) in_18\IN\13603305|NONE (l_pobj) mortality_23\NN\5054863|NONE (l_amod) epilepticus_20\NN\0|status
D010862_D001930 NONE pilocarpine_22\NN\14712692|the (r_compound) model_23\NN\5888929|NONE (r_pobj) in_18\IN\13603305|status|epilepticus (r_prep) damage_17\NN\7296428|NONE
D016202_D001930 NONE nmda_6\NNP\0|NONE (r_compound) receptors_7\NNS\5225602|NONE (r_pobj) of_5\IN\0|NONE (r_prep) activation_4\NN\13561719|that|role (r_nsubj) plays_8\VBZ\7007684|.|results (l_dobj) role_11\NN\719494|activation|that (l_prep) in_12\IN\13603305|important|an (l_pobj) damage_17\NN\7296428|NONE
D010862_D012640 NONE pilocarpine_33\NN\14712692|and (r_conj) lithium_31\NN\14625458|NONE (r_pobj) of_30\IN\0|and|administration (r_prep) coadministration_29\NN\0|two|seizure|,|of (r_conj) models_27\NNS\5888929|NONE (l_compound) seizure_26\NN\14081375|two|,|of|coadministration
D010862_D012640 NONE pilocarpine_41\NN\14712692|NONE (r_pobj) of_40\IN\0|a|high|alone (r_prep) dose_39\NN\3740161|NONE (r_pobj) of_36\IN\0|two|seizure|,|coadministration (r_prep) models_27\NNS\5888929|NONE (l_compound) seizure_26\NN\14081375|two|,|of|coadministration
D010862_D012640 NONE pilocarpine_18\NN\14712692|the (r_compound) model_19\NN\5888929|NONE (r_pobj) with_14\IN\0|an|anticonvulsant|effective (r_prep) action_13\NN\30358|pretreatment|.|,|with|First|MK|,|suggesting|but (r_dobj) produced_5\VBD\1617192|NONE (l_advcl) suggesting_29\VBG\1010118|pretreatment|.|,|with|action|First|MK|,|but (l_dobj) seizures_35\NNS\14081375|NONE
D010862_D012640 NONE pilocarpine_26\NN\14712692|NONE (r_pobj) with_25\IN\0|alone (r_prep) treated_24\VBN\2376958|NONE (r_acl) rats_23\NNS\2329401|not (r_pobj) with_22\IN\0|pretreatment|.|,|action|First|MK|,|suggesting|but (r_conj) produced_5\VBD\1617192|NONE (l_advcl) suggesting_29\VBG\1010118|pretreatment|.|,|with|action|First|MK|,|but (l_dobj) seizures_35\NNS\14081375|NONE
D010862_D012640 NONE pilocarpine_11\NN\14712692|the (r_compound) model_12\NN\5888929|MK (r_pobj) in_7\IN\13603305|only|,|.|effect|after|Second (r_prep) occurred_14\VBD\0|NONE (l_prep) after_15\IN\0|only|,|.|effect|in|Second (l_pobj) periods_17\NNS\13575869|NONE (l_prep) of_18\IN\0|initial (l_pobj) activity_20\NN\30358|NONE (l_compound) seizure_19\NN\14081375|NONE
D010862_D012640 NONE pilocarpine_14\NN\14712692|and (r_conj) lithium_12\NN\14625458|NONE (r_pobj) by_11\IN\0|by|prior (r_agent) induced_10\VBN\1627355|NONE (r_acl) seizures_9\NNS\14081375|to
D010862_D012640 NONE pilocarpine_14\NN\14712692|and (r_conj) lithium_12\NN\14625458|NONE (r_pobj) by_11\IN\0|by|prior (r_agent) induced_10\VBN\1627355|NONE (r_acl) seizures_9\NNS\14081375|to (r_dobj) block_8\VB\21939|easy|it|although (r_xcomp) is_4\VBZ\0|it|,|ongoing|,|difficult|.|Third (r_advcl) is_24\VBZ\0|NONE (l_xcomp) ongoing_29\JJ\0|it|,|is|,|difficult|.|Third (l_advmod) epilepticus_31\NN\0|NONE (l_conj) block_33\VB\21939|and|status (l_dobj) lethality_35\NN\4790449|NONE (l_prep) of_36\IN\0|the (l_pobj) seizures_38\NNS\14081375|NONE
D010862_D012640 NONE pilocarpine_21\NN\14712692|NONE (r_pobj) to_20\IN\0|NONE (r_prep) prior_19\RB\10675876|by|by (r_advmod) induced_10\VBN\1627355|NONE (r_acl) seizures_9\NNS\14081375|to
D010862_D012640 NONE pilocarpine_21\NN\14712692|NONE (r_pobj) to_20\IN\0|NONE (r_prep) prior_19\RB\10675876|by|by (r_advmod) induced_10\VBN\1627355|NONE (r_acl) seizures_9\NNS\14081375|to (r_dobj) block_8\VB\21939|easy|it|although (r_xcomp) is_4\VBZ\0|it|,|ongoing|,|difficult|.|Third (r_advcl) is_24\VBZ\0|NONE (l_xcomp) ongoing_29\JJ\0|it|,|is|,|difficult|.|Third (l_advmod) epilepticus_31\NN\0|NONE (l_conj) block_33\VB\21939|and|status (l_dobj) lethality_35\NN\4790449|NONE (l_prep) of_36\IN\0|the (l_pobj) seizures_38\NNS\14081375|NONE
D010862_D012640 NONE pilocarpine_8\NN\14712692|NONE (r_pobj) after_7\IN\0| (r_prep) min_6\NN\15154774|NONE (r_pobj) of_1\IN\0|NONE (r_prep) administration_0\NN\1133281|i.e.|gradually|.|,|,|enhanced|activity|,|during|and (r_nsubj) reduced_17\VBD\441445|NONE (l_dobj) activity_22\NN\30358|i.e.|gradually|.|,|Administration|,|enhanced|,|during|and (l_compound) seizure_21\NN\14081375|NONE
D008094_D012640 NONE lithium_31\NN\14625458|NONE (r_pobj) of_30\IN\0|and|administration (r_prep) coadministration_29\NN\0|two|seizure|,|of (r_conj) models_27\NNS\5888929|NONE (l_compound) seizure_26\NN\14081375|two|,|of|coadministration
D008094_D012640 NONE lithium_16\NN\14625458| (r_compound) pilocarpine_18\NN\14712692|the (r_compound) model_19\NN\5888929|NONE (r_pobj) with_14\IN\0|an|anticonvulsant|effective (r_prep) action_13\NN\30358|pretreatment|.|,|with|First|MK|,|suggesting|but (r_dobj) produced_5\VBD\1617192|NONE (l_advcl) suggesting_29\VBG\1010118|pretreatment|.|,|with|action|First|MK|,|but (l_dobj) seizures_35\NNS\14081375|NONE
D008094_D012640 NONE lithium_9\NN\14625458| (r_compound) pilocarpine_11\NN\14712692|the (r_compound) model_12\NN\5888929|MK (r_pobj) in_7\IN\13603305|only|,|.|effect|after|Second (r_prep) occurred_14\VBD\0|NONE (l_prep) after_15\IN\0|only|,|.|effect|in|Second (l_pobj) periods_17\NNS\13575869|NONE (l_prep) of_18\IN\0|initial (l_pobj) activity_20\NN\30358|NONE (l_compound) seizure_19\NN\14081375|NONE
D008094_D012640 NONE lithium_12\NN\14625458|NONE (r_pobj) by_11\IN\0|by|prior (r_agent) induced_10\VBN\1627355|NONE (r_acl) seizures_9\NNS\14081375|to
D008094_D012640 NONE lithium_12\NN\14625458|NONE (r_pobj) by_11\IN\0|by|prior (r_agent) induced_10\VBN\1627355|NONE (r_acl) seizures_9\NNS\14081375|to (r_dobj) block_8\VB\21939|easy|it|although (r_xcomp) is_4\VBZ\0|it|,|ongoing|,|difficult|.|Third (r_advcl) is_24\VBZ\0|NONE (l_xcomp) ongoing_29\JJ\0|it|,|is|,|difficult|.|Third (l_advmod) epilepticus_31\NN\0|NONE (l_conj) block_33\VB\21939|and|status (l_dobj) lethality_35\NN\4790449|NONE (l_prep) of_36\IN\0|the (l_pobj) seizures_38\NNS\14081375|NONE
D008094_D013226 CID lithium_6\NN\14625458| (r_compound) pilocarpine_8\NN\14712692|of|the (r_compound) model_9\NN\5888929|MK (r_pobj) on_4\IN\0|.|in|actions (r_prep) epilepticus_12\NN\0|NONE
D008094_D013226 CID lithium_12\NN\14625458|NONE (r_pobj) by_11\IN\0|by|prior (r_agent) induced_10\VBN\1627355|NONE (r_acl) seizures_9\NNS\14081375|to (r_dobj) block_8\VB\21939|easy|it|although (r_xcomp) is_4\VBZ\0|it|,|ongoing|,|difficult|.|Third (r_advcl) is_24\VBZ\0|NONE (l_xcomp) ongoing_29\JJ\0|it|,|is|,|difficult|.|Third (l_advmod) epilepticus_31\NN\0|NONE
D008094_D013226 CID lithium_20\NN\14625458| (r_compound) pilocarpine_22\NN\14712692|the (r_compound) model_23\NN\5888929|NONE (r_pobj) in_18\IN\13603305|status|epilepticus (r_prep) damage_17\NN\7296428|NONE (l_amod) epilepticus_14\NN\0|status|in
D016291_D012640 NONE mk-801_0\NNP\0|,|was|.|for|antagonist (r_punct) tested_18\VBN\670261|NONE (l_prep) for_19\IN\0|,|was|.|MK|antagonist (l_pobj) effects_21\NNS\13245626|NONE (l_acl) using_24\VBG\418025|anticonvulsant|in (l_dobj) models_27\NNS\5888929|NONE (l_compound) seizure_26\NN\14081375|two|,|of|coadministration
D016291_D012640 NONE mk-801_4\NNP\0|pretreatment|.|,|with|action|First|,|suggesting|but (r_punct) produced_5\VBD\1617192|NONE (l_advcl) suggesting_29\VBG\1010118|pretreatment|.|,|with|action|First|MK|,|but (l_dobj) seizures_35\NNS\14081375|NONE
D016291_D012640 NONE mk-801_6\NNP\0|model (r_punct) in_7\IN\13603305|only|,|.|effect|after|Second (r_prep) occurred_14\VBD\0|NONE (l_prep) after_15\IN\0|only|,|.|effect|in|Second (l_pobj) periods_17\NNS\13575869|NONE (l_prep) of_18\IN\0|initial (l_pobj) activity_20\NN\30358|NONE (l_compound) seizure_19\NN\14081375|NONE
D016291_D012640 NONE mk-801_2\NNP\0||or (r_punct) 30_3\CD\13745420|after (r_nummod) min_6\NN\15154774|NONE (r_pobj) of_1\IN\0|NONE (r_prep) administration_0\NN\1133281|i.e.|gradually|.|,|,|enhanced|activity|,|during|and (r_nsubj) reduced_17\VBD\441445|NONE (l_dobj) activity_22\NN\30358|i.e.|gradually|.|,|Administration|,|enhanced|,|during|and (l_compound) seizure_21\NN\14081375|NONE
D008094_D001930 NONE lithium_20\NN\14625458| (r_compound) pilocarpine_22\NN\14712692|the (r_compound) model_23\NN\5888929|NONE (r_pobj) in_18\IN\13603305|status|epilepticus (r_prep) damage_17\NN\7296428|NONE
D016202_D012640 NONE aspartate_10\NNP\0|receptor|,|NMDA|a|)|(|noncompetitive (r_nmod) antagonist_15\NN\7846|,|was|.|MK|for (r_nsubjpass) tested_18\VBN\670261|NONE (l_prep) for_19\IN\0|,|was|.|MK|antagonist (l_pobj) effects_21\NNS\13245626|NONE (l_acl) using_24\VBG\418025|anticonvulsant|in (l_dobj) models_27\NNS\5888929|NONE (l_compound) seizure_26\NN\14081375|two|,|of|coadministration
D016202_D012640 NONE nmda_12\NNP\0|receptor|,|a|)|aspartate|(|noncompetitive (r_nmod) antagonist_15\NN\7846|,|was|.|MK|for (r_nsubjpass) tested_18\VBN\670261|NONE (l_prep) for_19\IN\0|,|was|.|MK|antagonist (l_pobj) effects_21\NNS\13245626|NONE (l_acl) using_24\VBG\418025|anticonvulsant|in (l_dobj) models_27\NNS\5888929|NONE (l_compound) seizure_26\NN\14081375|two|,|of|coadministration
9132810
D008727_D054198 NONE methotrexate_34\NN\2722166|NONE (r_pobj) with_30\IN\0|NONE (r_prep) treated_29\VBN\2376958|acute|lymphoblastic (r_acl) leukemia_28\NN\14239918|NONE
D008727_D056784 CID methotrexate_34\NN\2722166|NONE (r_pobj) with_30\IN\0|NONE (r_prep) treated_29\VBN\2376958|acute|lymphoblastic (r_acl) leukemia_28\NN\14239918|NONE (r_pobj) from_25\IN\0|which (r_prep) developed_24\VBD\1753788|necrotizing|,|disseminated (r_relcl) leukoencephalopathy_21\JJ\0|NONE
10219427
12828076
D000082_D062787 NONE paracetamol_12\JJ\0|NONE (r_compound) overdose_13\NN\84738|to
D000082_D062787 NONE paracetamol_12\JJ\0|(|median|mL|range|,|; (r_compound) overdose_13\NN\84738|to|than
D000082_D017114 CID paracetamol_12\JJ\0|NONE (r_compound) overdose_13\NN\84738|to (r_pobj) due_10\IN\5174653|Increased|in|Fas|. (r_prep) serum_1\NN\5397468|NONE (l_prep) in_4\IN\13603305|Increased|Fas|.|due (l_pobj) patients_5\NNS\9898892|NONE (l_prep) with_6\IN\0|NONE (l_pobj) failure_9\NN\66216|NONE
D000082_D017114 CID paracetamol_12\JJ\0|(|median|mL|range|,|; (r_compound) overdose_13\NN\84738|to|than (r_pobj) due_10\IN\5174653|with (r_prep) patients_5\NNS\9898892|NONE (l_prep) with_6\IN\0|due (l_pobj) failure_9\NN\66216|NONE
D000082_D056486 NONE paracetamol_12\JJ\0|(|median|mL|range|,|; (r_compound) overdose_13\NN\84738|to|than (r_pobj) due_10\IN\5174653|with (r_prep) patients_5\NNS\9898892|NONE (r_pobj) in_4\IN\13603305|significantly (r_prep) greater_3\JJR\0|.|Levels|mL (r_acomp) were_1\VBD\0|NONE (l_npadvmod) ml_51\NN\13616054|.|Levels|greater (l_punct) ,_47\,\0|range|)|U|;|P|/ (l_punct) to_42\IN\0|A (l_pobj) hepatitis_44\NN\14127211|NONE
11229942
C066444_D002303 CID ce_1\NNP\14625458|NONE (r_compound) levels_2\NNS\4916342|with|decrease|were|. (r_nsubjpass) associated_4\VBN\628491|NONE (l_conj) decrease_25\NN\7296428|with|were|.|levels (l_prep) in_26\IN\13603305|)|(|)|p|CI|.|)|(|(|,|)|%|. (l_pobj) output_28\NN\4007894|NONE
C066444_D000437 NONE cocaethylene_5\NN\0|,|and (l_prep) in_7\IN\13603305|cardiotoxity (l_pobj) model_10\NN\5888929|NONE (l_prep) of_11\IN\0|an|animal (l_pobj) cocaine_12\NN\3492717|NONE (l_conj) abuse_15\NN\418025|and
D003042_D019970 NONE cocaine_0\NN\3492717|NONE (l_appos) ethanol_2\NN\14708720|,|. (l_conj) cocaethylene_5\NN\0|,|and (l_prep) in_7\IN\13603305|cardiotoxity (l_pobj) model_10\NN\5888929|NONE (l_prep) of_11\IN\0|an|animal (l_pobj) cocaine_12\NN\3492717|NONE (l_conj) abuse_15\NN\418025|and
C066444_D066126 NONE cocaethylene_5\NN\0|,|and (l_dobj) cardiotoxity_6\NN\0|in
C066444_D066126 NONE cocaethylene_22\NN\0|to (r_pobj) due_20\JJ\5174653|they|;|.|be|also|,|however|may (r_acomp) be_19\VB\14625458|NONE (l_ccomp) be_5\VB\14625458|they|;|.|also|,|however|due|may (l_nsubj) toxicity_3\NN\13576101|due|may
C066444_D066126 NONE ce_24\NNP\14625458|,|metabolite (r_appos) cocaethylene_22\NN\0|to (r_pobj) due_20\JJ\5174653|they|;|.|be|also|,|however|may (r_acomp) be_19\VB\14625458|NONE (l_ccomp) be_5\VB\14625458|they|;|.|also|,|however|due|may (l_nsubj) toxicity_3\NN\13576101|due|may
C066444_D066126 NONE ce_11\NNP\14625458|NONE (r_pobj) of_10\IN\0|the|in (r_prep) role_9\NN\719494|to (l_prep) in_12\IN\13603305|the|of (l_pobj) cardiotoxicity_15\NN\0|NONE
C066444_D019970 NONE cocaethylene_5\NN\0|,|and (l_prep) in_7\IN\13603305|cardiotoxity (l_pobj) model_10\NN\5888929|NONE (l_prep) of_11\IN\0|an|animal (l_pobj) cocaine_12\NN\3492717|NONE (l_conj) abuse_15\NN\418025|and
D003042_D000437 NONE cocaine_0\NN\3492717|NONE (l_appos) ethanol_2\NN\14708720|,|. (l_conj) cocaethylene_5\NN\0|,|and (l_prep) in_7\IN\13603305|cardiotoxity (l_pobj) model_10\NN\5888929|NONE (l_prep) of_11\IN\0|an|animal (l_pobj) cocaine_12\NN\3492717|NONE (l_conj) abuse_15\NN\418025|and
D000431_D000437 NONE ethanol_2\NN\14708720|,|. (l_conj) cocaethylene_5\NN\0|,|and (l_prep) in_7\IN\13603305|cardiotoxity (l_pobj) model_10\NN\5888929|NONE (l_prep) of_11\IN\0|an|animal (l_pobj) cocaine_12\NN\3492717|NONE (l_conj) abuse_15\NN\418025|and
C066444_D009202 NONE cocaethylene_2\NN\0|serum|Peak (r_compound) concentrations_3\NNS\4916342|were|.|with (r_nsubjpass) associated_5\VBN\628491|NONE (l_prep) with_6\IN\0|were|concentrations|. (l_pobj) depression_9\NN\14373582|NONE
D000431_D019970 NONE ethanol_2\NN\14708720|,|. (l_conj) cocaethylene_5\NN\0|,|and (l_prep) in_7\IN\13603305|cardiotoxity (l_pobj) model_10\NN\5888929|NONE (l_prep) of_11\IN\0|an|animal (l_pobj) cocaine_12\NN\3492717|NONE (l_conj) abuse_15\NN\418025|and
D003042_D066126 NONE cocaine_0\NN\3492717|NONE (l_appos) ethanol_2\NN\14708720|,|. (l_conj) cocaethylene_5\NN\0|,|and (l_dobj) cardiotoxity_6\NN\0|in
D003042_D066126 NONE cocaine_28\NN\3492717|a|formed (r_compound) metabolite_29\NN\20090|,|CE (r_appos) cocaethylene_22\NN\0|to (r_pobj) due_20\JJ\5174653|they|;|.|be|also|,|however|may (r_acomp) be_19\VB\14625458|NONE (l_ccomp) be_5\VB\14625458|they|;|.|also|,|however|due|may (l_nsubj) toxicity_3\NN\13576101|due|may
D003042_D066126 NONE cocaine_17\NN\3492717|NONE (r_pobj) of_16\IN\0|combined|the|in (r_prep) cardiotoxicity_15\NN\0|NONE
D000431_D066126 NONE ethanol_2\NN\14708720|,|. (l_conj) cocaethylene_5\NN\0|,|and (l_dobj) cardiotoxity_6\NN\0|in
D000431_D066126 NONE ethanol_36\NN\14708720|NONE (r_pobj) of_35\IN\0|the (r_prep) presence_34\NN\13954253|only (r_pobj) in_32\IN\13603305|NONE (r_prep) formed_30\VBN\1617192|a|cocaine (r_acl) metabolite_29\NN\20090|,|CE (r_appos) cocaethylene_22\NN\0|to (r_pobj) due_20\JJ\5174653|they|;|.|be|also|,|however|may (r_acomp) be_19\VB\14625458|NONE (l_ccomp) be_5\VB\14625458|they|;|.|also|,|however|due|may (l_nsubj) toxicity_3\NN\13576101|due|may
D000431_D066126 NONE ethanol_19\NN\14708720|and (r_conj) cocaine_17\NN\3492717|NONE (r_pobj) of_16\IN\0|combined|the|in (r_prep) cardiotoxicity_15\NN\0|NONE
12487093
C009591_D006973 NONE triphenyltetrazolium_15\NN\0|NONE (r_dobj) using_14\VBG\418025|which|was (r_advcl) evaluated_13\VBN\670261|,|the (r_relcl) bbb_9\NN\0|to (r_dobj) destroy_7\VB\1619231|was|hypertension (r_xcomp) used_5\VBN\0|NONE (l_nsubjpass) hypertension_3\NN\14057371|destroy|was
C009591_D006973 NONE ttc_17\NNP\0|staining|) (r_appos) triphenyltetrazolium_15\NN\0|NONE (r_dobj) using_14\VBG\418025|which|was (r_advcl) evaluated_13\VBN\670261|,|the (r_relcl) bbb_9\NN\0|to (r_dobj) destroy_7\VB\1619231|was|hypertension (r_xcomp) used_5\VBN\0|NONE (l_nsubjpass) hypertension_3\NN\14057371|destroy|was
D004837_D006973 CID adrenaline_0\NN\14807929| (r_npadvmod) induced_2\VBN\1627355|NONE (r_amod) hypertension_3\NN\14057371|destroy|was
D004837_D006973 CID adrenaline_27\NN\14807929|for (r_dobj) giving_26\VBG\1085793|just (r_pcomp) after_25\IN\0|of (r_prep) staining_19\NN\275424|TTC|) (r_appos) triphenyltetrazolium_15\NN\0|NONE (r_dobj) using_14\VBG\418025|which|was (r_advcl) evaluated_13\VBN\670261|,|the (r_relcl) bbb_9\NN\0|to (r_dobj) destroy_7\VB\1619231|was|hypertension (r_xcomp) used_5\VBN\0|NONE (l_nsubjpass) hypertension_3\NN\14057371|destroy|was
256433
D002228_D007239 NONE carbenicillin_5\NN\0|NONE (l_prep) for_6\IN\0|NONE (l_pobj) infections_7\NNS\14052046|NONE
D014031_D007239 NONE tobramycin_2\NN\2716866|NONE (l_acl) combined_3\VBN\2630189|Continuous|.|infusion (l_prep) with_4\IN\0|NONE (l_pobj) carbenicillin_5\NN\0|NONE (l_prep) for_6\IN\0|NONE (l_pobj) infections_7\NNS\14052046|NONE
D002228_D009503 NONE carbenicillin_18\NN\0|NONE (r_pobj) with_16\IN\0|NONE (r_prep) combined_15\VBN\2630189|tobramycin|overcome|.|and|,|by|was (r_conj) given_10\VBN\5892096|NONE (l_advcl) overcome_1\VB\0|tobramycin|.|combined|and|,|by|was (l_dobj) effects_4\NNS\13245626|To (l_prep) of_5\IN\0|the|adverse (l_pobj) neutropenia_6\NN\14196405|NONE
D003404_D053099 NONE creatinine_4\NN\0|(|)|Major (r_appos) azotemia_1\NN\14204950|in|.
D014031_D053099 CID tobramycin_10\JJ\2716866|therapy (r_amod) concentration_11\NN\4916342|NONE (r_pobj) of_6\IN\0|NONE (r_prep) duration_5\NN\15113229|NONE (r_pobj) to_4\IN\0|was|.|not|Azotemia (r_prep) related_3\VBN\628491|NONE (l_nsubjpass) azotemia_0\NNP\14204950|was|.|not|to
D002228_D009369 NONE carbenicillin_5\NN\0|NONE (l_prep) for_6\IN\0|NONE (l_pobj) infections_7\NNS\14052046|NONE (l_prep) in_8\IN\13603305|NONE (l_pobj) patients_10\NNS\9898892|NONE (l_compound) cancer_9\NN\14239425|NONE
D014031_D009503 NONE tobramycin_8\JJ\2716866|overcome|.|combined|and|,|by|was (r_nsubjpass) given_10\VBN\5892096|NONE (l_advcl) overcome_1\VB\0|tobramycin|.|combined|and|,|by|was (l_dobj) effects_4\NNS\13245626|To (l_prep) of_5\IN\0|the|adverse (l_pobj) neutropenia_6\NN\14196405|NONE
D014031_D009369 NONE tobramycin_2\NN\2716866|NONE (l_acl) combined_3\VBN\2630189|Continuous|.|infusion (l_prep) with_4\IN\0|NONE (l_pobj) carbenicillin_5\NN\0|NONE (l_prep) for_6\IN\0|NONE (l_pobj) infections_7\NNS\14052046|NONE (l_prep) in_8\IN\13603305|NONE (l_pobj) patients_10\NNS\9898892|NONE (l_compound) cancer_9\NN\14239425|NONE
612112
D005045_D009207 CID etomidate_5\NN\0|will|that|be (r_nsubj) prove_7\VB\2604760|is|It|.|unlikely (l_xcomp) be_9\VB\14625458|will|etomidate|that (l_prep) because_22\IN\0|to|hypnotic (l_pobj) incidence_26\NN\13821570|of (l_prep) of_27\IN\0|high|after|the (l_pobj) myoclonia_28\NN\0|NONE
12752472
D010862_D006985 NONE pilocarpine_11\NN\14712692||and|control (r_npadvmod) treated_13\VBN\2376958|NONE (r_amod) rats_16\NNS\2329401|NONE (r_pobj) in_10\IN\13603305|spontaneous (r_prep) ventilation_9\NN\248977|NONE (r_pobj) in_7\IN\13603305|a (r_prep) decrease_6\NN\7296428|maneuver|.|: (r_dobj) caused_4\VBD\1617192|NONE (l_nsubj) maneuver_3\NN\955060|.|:|decrease (l_compound) hyperventilation_2\NN\831191|The
D010862_D004827 CID pilocarpine_15\NN\14712692| (r_npadvmod) induced_17\VBN\1627355|NONE (r_amod) epilepsy_18\NN\14085708|NONE
15096374
D016559_D003872 NONE tacrolimus_11\NN\0|NONE (r_compound) ointment_12\NN\4074482|NONE (r_pobj) with_10\IN\0|facial|inflammatory (r_prep) dermatoses_9\NNS\14219661|NONE (r_pobj) of_6\IN\0|NONE (r_prep) treatment_5\NN\654885|NONE (r_pobj) during_4\IN\0|of|. (r_prep) induction_0\NN\7450842|NONE (l_prep) of_1\IN\0|during|. (l_pobj) dermatitis_3\NN\14226056|NONE
D016559_D003872 NONE tacrolimus_11\NN\0|NONE (r_compound) ointment_12\NN\4074482|NONE (r_pobj) with_10\IN\0|NONE (r_prep) treatment_9\NN\654885|NONE (r_pobj) of_8\IN\0|a (r_prep) complication_7\NN\1073995|NONE (r_pobj) as_5\IN\14622893|We|on|. (r_prep) report_1\VBP\6470073|NONE (l_prep) on_2\IN\0|We|.|as (l_pobj) dermatitis_4\NN\14226056|NONE
D016559_D003872 NONE tacrolimus_15\NN\0|NONE (r_compound) ointment_16\NN\4074482|NONE (r_pobj) with_14\IN\0|NONE (r_prep) treatment_13\NN\654885|NONE (r_pobj) of_12\IN\0|a (r_prep) complication_11\NN\1073995|NONE (r_pobj) as_9\IN\14622893|of|the (r_prep) spectrum_5\NN\7939382|that|heterogeneous (l_prep) of_6\IN\0|as|the (l_pobj) dermatitis_8\NN\14226056|NONE
D016559_D005148 NONE tacrolimus_11\NN\0|NONE (r_compound) ointment_12\NN\4074482|NONE (r_pobj) with_10\IN\0|facial|inflammatory (r_prep) dermatoses_9\NNS\14219661|NONE
D016559_D005148 NONE tacrolimus_10\NN\0|NONE (r_compound) ointment_11\NN\4074482|NONE (r_pobj) with_9\IN\0|were|patients|because|. (r_prep) treated_8\VBN\2376958|NONE (l_nsubjpass) patients_2\NNS\9898892|with|were|because|. (l_prep) with_3\IN\0|adult|Six (l_pobj) dermatoses_6\NNS\14219661|NONE
D016559_D019557 NONE tacrolimus_0\NNP\0|NONE (r_compound) ointment_1\NN\4074482|and|indicate|is|,|for|increasingly (r_nsubjpass) used_4\VBN\0|NONE (l_conj) indicate_21\VBP\952524|and|is|,|for|increasingly|ointment (l_ccomp) is_25\VBZ\0|.|observations (l_acomp) effective_26\JJ\0|treatment|that (l_prep) in_27\IN\13603305|NONE (l_pobj) rosacea_31\NN\14222112|NONE (l_conj) dermatitis_34\NN\14226056|aggravated|and
D013256_D012393 NONE steroid_28\NN\14727670| (r_npadvmod) aggravated_30\VBN\126264|dermatitis|and (r_amod) rosacea_31\NN\14222112|NONE
D013256_D019557 NONE steroid_28\NN\14727670| (r_npadvmod) aggravated_30\VBN\126264|dermatitis|and (r_amod) rosacea_31\NN\14222112|NONE (l_conj) dermatitis_34\NN\14226056|aggravated|and
D016559_D012393 CID tacrolimus_0\NNP\0|NONE (r_compound) ointment_1\NN\4074482|and|indicate|is|,|for|increasingly (r_nsubjpass) used_4\VBN\0|NONE (l_conj) indicate_21\VBP\952524|and|is|,|for|increasingly|ointment (l_ccomp) is_25\VBZ\0|.|observations (l_acomp) effective_26\JJ\0|treatment|that (l_prep) in_27\IN\13603305|NONE (l_pobj) rosacea_31\NN\14222112|NONE
20495512
D006493_D013921 CID heparin_0\NNP\2718259| (r_npadvmod) induced_2\VBN\1627355|:|review|. (r_amod) thrombocytopenia_3\NN\14189204|NONE
D006493_D013921 CID heparin_0\NNP\2718259| (r_npadvmod) induced_2\VBN\1627355|HIT (r_amod) thrombocytopenia_3\NN\14189204|.|recognized
D006493_D013921 CID heparin_0\NNP\2718259| (r_npadvmod) induced_2\VBN\1627355|HIT (r_amod) thrombocytopenia_3\NN\14189204|.|recognized (l_appos) hit_5\NN\36762|induced
D006493_D013921 CID heparin_16\JJ\2718259|NONE (r_compound) exposure_17\NN\5042871|NONE (r_pobj) after_15\IN\0|whenever|thrombosis (r_prep) occurs_14\VBZ\0|NONE (r_ccomp) suspected_11\VBN\916909|HIT|must|be|.|for|and (r_conj) acknowledged_3\VBN\822367|NONE (l_nsubjpass) hit_0\NNP\36762|suspected|must|be|.|for|and
D006493_D013921 CID heparin_10\JJ\2718259|all|and|institution (r_compound) exposure_11\NN\5042871|NONE (r_pobj) of_8\IN\0|an|immediate (r_prep) cessation_7\NN\7365849|treatment|,|using|. (r_dobj) mandates_4\NNS\6479665|NONE (l_nsubj) treatment_1\NN\654885|cessation|,|using|. (l_prep) of_2\IN\0|The (l_pobj) hit_3\NNP\36762|NONE
D006493_D013921 CID heparin_11\NN\2718259|NONE (l_prep) in_12\IN\13603305|NONE (l_pobj) patients_13\NNS\9898892|NONE (l_prep) with_14\IN\0|NONE (l_pobj) history_16\NN\15120823|NONE (l_prep) of_17\IN\0|need|,|a (l_pobj) hit_18\NN\36762|NONE
D006493_D013921 CID heparin_1\NN\2718259|one|with|today|As (r_nsubj) remains_2\VBZ\2684|must|be|,|.|vigilance|initiated (l_prep) with_11\IN\0|one|heparin|today|As (l_pobj) potential_12\NN\14481929|NONE (l_prep) for_13\IN\0|with (l_pobj) hit_14\NN\36762|NONE
D006493_D013921 CID heparin_17\JJ\2718259|every (r_compound) exposure_18\NN\5042871|NONE (r_pobj) with_15\IN\0|for (r_prep) potential_12\NN\14481929|NONE (l_prep) for_13\IN\0|with (l_pobj) hit_14\NN\36762|NONE
D006493_D013921 CID heparin_30\JJ\2718259|is|whenever (r_nsubjpass) initiated_32\VBN\1617192|must|be|,|remains|.|vigilance (r_advcl) practiced_28\VBN\0|NONE (l_advcl) remains_2\VBZ\2684|must|be|,|.|vigilance|initiated (l_prep) with_11\IN\0|one|heparin|today|As (l_pobj) potential_12\NN\14481929|NONE (l_prep) for_13\IN\0|with (l_pobj) hit_14\NN\36762|NONE
D006493_D013927 CID heparin_16\JJ\2718259|NONE (r_compound) exposure_17\NN\5042871|NONE (r_pobj) after_15\IN\0|whenever|thrombosis (r_prep) occurs_14\VBZ\0|NONE (r_ccomp) suspected_11\VBN\916909|HIT|must|be|.|for|and (r_conj) acknowledged_3\VBN\822367|NONE (l_prep) for_4\IN\0|suspected|HIT|must|be|.|and (l_pobj) predilection_7\NN\6200178|NONE (l_prep) for_8\IN\0|intense|its (l_pobj) thrombosis_9\NN\14100769|NONE
D006493_D013927 CID heparin_16\JJ\2718259|NONE (r_compound) exposure_17\NN\5042871|NONE (r_pobj) after_15\IN\0|whenever|thrombosis (r_prep) occurs_14\VBZ\0|NONE (l_nsubj) thrombosis_13\NN\14100769|whenever|after
D000991_D013921 NONE inhibitor_26\NN\20090|commonly (r_dobj) using_22\VBG\418025|cessation|treatment|,|. (r_advcl) mandates_4\NNS\6479665|NONE (l_nsubj) treatment_1\NN\654885|cessation|,|using|. (l_prep) of_2\IN\0|The (l_pobj) hit_3\NNP\36762|NONE
D000991_D013921 NONE inhibitors_2\NNS\20090|.|alternatives (r_nsubj) are_3\VBP\13600404|NONE (l_attr) alternatives_9\NNS\5788149|inhibitors|. (l_prep) to_10\IN\0|based|appropriate|, (l_pobj) heparin_11\NN\2718259|NONE (l_prep) in_12\IN\13603305|NONE (l_pobj) patients_13\NNS\9898892|NONE (l_prep) with_14\IN\0|NONE (l_pobj) history_16\NN\15120823|NONE (l_prep) of_17\IN\0|need|,|a (l_pobj) hit_18\NN\36762|NONE
8825380
D011692_D006130 NONE pan_15\NNP\3101986|chronic (r_compound) nephropathy_16\NN\14573196|NONE (r_pobj) with_13\IN\0|NONE (r_prep) rats_12\NNS\2329401|NONE (r_pobj) in_11\IN\13603305|growth (r_prep) failure_10\NN\66216|NONE
D011692_D007674 CID aminonucleoside_15\JJ\0|in (r_amod) nephropathy_16\NN\14573196|on
D011692_D007674 CID aminonucleoside_15\NN\0|model|(|,|PAN (r_nmod) nephropathy_19\NN\14573196|puromycin
D011692_D007674 CID aminonucleoside_15\NN\0|model|(|,|PAN (r_nmod) nephropathy_19\NN\14573196|puromycin (l_appos) model_23\NN\5888929|(|aminonucleoside|,|PAN (l_prep) of_24\IN\0|experimental|an (l_pobj) disease_26\NN\14061805|NONE
D011692_D007674 CID pan_17\NNP\3101986|model|(|aminonucleoside|, (r_nmod) nephropathy_19\NN\14573196|puromycin
D011692_D007674 CID pan_17\NNP\3101986|model|(|aminonucleoside|, (r_nmod) nephropathy_19\NN\14573196|puromycin (l_appos) model_23\NN\5888929|(|aminonucleoside|,|PAN (l_prep) of_24\IN\0|experimental|an (l_pobj) disease_26\NN\14061805|NONE
D011692_D007674 CID pan_15\NNP\3101986|chronic (r_compound) nephropathy_16\NN\14573196|NONE
D011692_D007674 CID pan_9\NNP\3101986|NONE (r_pobj) of_8\IN\0|serial|seven (r_prep) injections_7\NNS\320852|NONE (r_pobj) by_4\IN\0|glomerulopathy|.|was|over (r_agent) induced_3\VBN\1627355|NONE (l_nsubjpass) glomerulopathy_1\NN\0|.|by|was|over
D011692_D007674 CID pan_6\NNP\3101986|chronic (r_compound) nephropathy_7\NN\14573196|NONE
D011692_D007674 CID pan_33\NNP\3101986|NONE (r_compound) nephropathy_34\NN\14573196|untreated
D011692_D007674 CID pan_3\NNP\3101986|administration|, (r_compound) nephropathy_4\NN\14573196|NONE
D011692_D007674 CID pan_19\NNP\3101986|chronic (r_compound) nephropathy_20\NN\14573196|NONE
D008315_-1 NONE malondialdehyde_22\NN\0|renal (r_compound) content_23\NN\7951464|or|,|tubulointerstitial (r_conj) injury_17\NN\14052046|,|increased|segmental
D008315_D007674 NONE malondialdehyde_22\NN\0|renal (r_compound) content_23\NN\7951464|or|,|tubulointerstitial (r_conj) injury_17\NN\14052046|,|increased|segmental (r_conj) glomerulosclerosis_14\NN\0|glomerular|or|enhanced (r_conj) hypertrophy_10\NN\14365950|NONE
D008315_D007674 NONE malondialdehyde_35\NN\0|renal|damage|or|, (r_compound) content_36\NN\7951464|glomerular|,|planar (l_conj) damage_42\NN\7296428|renal|malondialdehyde|or|,
D008315_D005921 NONE malondialdehyde_22\NN\0|renal (r_compound) content_23\NN\7951464|or|,|tubulointerstitial (r_conj) injury_17\NN\14052046|,|increased|segmental (r_conj) glomerulosclerosis_14\NN\0|glomerular|or|enhanced
D008315_D011507 NONE malondialdehyde_35\NN\0|renal|damage|or|, (r_compound) content_36\NN\7951464|glomerular|,|planar (r_conj) area_31\NN\8630985|, (r_conj) gfr_27\NNP\0|, (r_conj) proteinuria_25\NN\14299637|blood|,
20192893
D003287_D064420 NONE cm_13\NNP\13649268|NONE (r_compound) toxicity_14\NN\13576101|NONE
D003287_D007674 CID medium_1\NN\3575240|.|Contrast|after (r_amod) nephrotoxicity_2\NN\0|NONE
D003287_D007674 CID medium_6\NN\3575240|iodinated|(|contrast (r_amod) cm_8\NNP\13649268|) (r_nmod) administration_10\NN\1133281|NONE (r_pobj) by_3\IN\0|NONE (r_agent) induced_2\VBN\1627355|Renal (r_acl) dysfunction_1\NN\14204950|.|)|benefit|can
D003287_D007674 CID cm_8\NNP\13649268|) (r_nmod) administration_10\NN\1133281|NONE (r_pobj) by_3\IN\0|NONE (r_agent) induced_2\VBN\1627355|Renal (r_acl) dysfunction_1\NN\14204950|.|)|benefit|can
D003287_D007674 CID cm_8\NNP\13649268|NONE (r_pobj) of_7\IN\0|nephrotoxic|in (r_prep) effect_6\NN\34213|NONE (l_amod) nephrotoxic_5\JJ\0|in|of
D003287_D007674 CID cm_17\NNP\13649268|than (r_compound) administration_18\NN\1133281|NONE (r_pobj) by_16\IN\0|NONE (r_agent) induced_15\VBN\1627355|renal (r_acl) damage_14\NN\7296428|NONE
7739955
D002220_D004802 CID carbamazepine_10\NN\0| (r_npadvmod) induced_12\VBN\1627355|eosinophilic|a|acute (r_amod) myocarditis_15\NN\14338942|and|had|one|had|,|,
D002220_D009205 CID carbamazepine_10\NN\0| (r_npadvmod) induced_12\VBN\1627355|eosinophilic|a|acute (r_amod) myocarditis_15\NN\14338942|and|had|one|had|,|, (r_dobj) had_8\VBD\0|NONE (l_ccomp) had_2\VBD\0|and|one|had|myocarditis|,|, (l_dobj) myocarditis_5\NN\14338942|patients
D002220_D009205 CID carbamazepine_10\NN\0| (r_npadvmod) induced_12\VBN\1627355|eosinophilic|a|acute (r_amod) myocarditis_15\NN\14338942|and|had|one|had|,|,
D002220_D012770 NONE carbamazepine_10\NN\0| (r_npadvmod) induced_12\VBN\1627355|eosinophilic|a|acute (r_amod) myocarditis_15\NN\14338942|and|had|one|had|,|, (r_dobj) had_8\VBD\0|NONE (l_conj) had_19\VBD\0|and|had|one|myocarditis|,|, (l_dobj) hemosiderosis_21\NN\14299637|one|. (l_acl) resulting_22\VBG\2633881|cardiac (l_prep) in_23\IN\13603305|NONE (l_pobj) shock_26\NN\7510495|NONE
24653743
C042288_D016757 CID pilsicainide_8\NNP\0| (r_npadvmod) induced_10\VBN\1627355|de|Torsades (r_amod) pointes_13\NNP\831651|to (r_pobj) due_6\IN\5174653|of|A|. (r_amod) case_1\NN\7283608|NONE (l_prep) of_2\IN\0|A|.|due (l_pobj) death_5\NNP\7296428|NONE
C042288_D016757 CID pilsicainide_7\NN\0|male|convert (r_dobj) received_5\VBD\2210855|.|later|;|death|patient (r_ccomp) developed_32\VBD\1753788|NONE (l_dobj) death_35\NN\7296428|.|later|;|received|patient
C042288_D016171 CID pilsicainide_8\NNP\0| (r_npadvmod) induced_10\VBN\1627355|de|Torsades (r_amod) pointes_13\NNP\831651|to
C042288_D016171 CID pilsicainide_14\NN\0|NONE (r_pobj) of_13\IN\0|the (r_prep) dose_12\NN\3740161|low (r_nsubj) was_15\VBD\0|Although|and|not|impaired|function (r_conj) was_6\VBD\0|may|concentration|,|high|,|.|have|produce (r_advcl) been_25\VBN\0|NONE (l_advcl) produce_30\VB\7555863|may|concentration|,|high|,|.|have|was (l_dobj) pointes_33\FW\831651|can|which
C042288_D016171 CID pilsicainide_22\NN\0|NONE (r_pobj) of_21\IN\0|the|plasma (r_prep) concentration_20\NN\4916342|may|,|high|,|.|have|was|produce (r_nsubj) been_25\VBN\0|NONE (l_advcl) produce_30\VB\7555863|may|concentration|,|high|,|.|have|was (l_dobj) pointes_33\FW\831651|can|which
C042288_D001281 NONE pilsicainide_7\NN\0|male|convert (r_dobj) received_5\VBD\2210855|.|later|;|death|patient (l_advcl) convert_20\VB\7846|pilsicainide|male (l_dobj) fibrillation_24\NN\14361664|to|to
C042288_D001281 NONE pilsicainide_10\NN\0|NONE (r_pobj) including_9\VBG\0|,|the|oral|of (r_prep) administration_3\NN\1133281|Although|effective|, (r_nsubj) is_12\VBZ\0|.|be|before|must|consideration|, (l_acomp) effective_13\JJ\0|Although|administration|, (l_xcomp) terminate_15\VB\126264|NONE (l_dobj) fibrillation_17\NN\14361664|to
D012964_D001281 NONE sodium_11\NN\14625458|pure (r_compound) channel_12\NN\6251781|a|with (r_compound) blocker_13\NN\10101634|,|oral|, (r_appos) pilsicainide_7\NN\0|male|convert (r_dobj) received_5\VBD\2210855|.|later|;|death|patient (l_advcl) convert_20\VB\7846|pilsicainide|male (l_dobj) fibrillation_24\NN\14361664|to|to
D012964_D016757 NONE sodium_11\NN\14625458|pure (r_compound) channel_12\NN\6251781|a|with (r_compound) blocker_13\NN\10101634|,|oral|, (r_appos) pilsicainide_7\NN\0|male|convert (r_dobj) received_5\VBD\2210855|.|later|;|death|patient (r_ccomp) developed_32\VBD\1753788|NONE (l_dobj) death_35\NN\7296428|.|later|;|received|patient
9071336
D017239_D064420 NONE paclitaxel_0\NNP\0|fluorouracil|.|cytotoxicity (r_nsubj) have_3\VBP\7846|NONE (l_dobj) cytotoxicity_5\NN\13583478|fluorouracil|Paclitaxel|.
D005472_D064420 NONE 5-fluorouracil_2\CD\0|Paclitaxel|.|cytotoxicity (r_punct) have_3\VBP\7846|NONE (l_dobj) cytotoxicity_5\NN\13583478|fluorouracil|Paclitaxel|.
D017239_D001943 NONE paclitaxel_0\NNP\0|.|trial (l_conj) acid_6\NN\14818238|,|and|, (l_prep) in_7\IN\13603305|folinic|: (l_pobj) cancer_10\NN\14239425|NONE
D017239_D001943 NONE paclitaxel_3\NN\0|and|folinic (r_conj) acid_1\NN\14818238|Taxol|therapies|. (r_nsubj) are_17\VBP\13600404|NONE (l_attr) therapies_20\NNS\657604|acid|Taxol|. (l_prep) for_21\IN\0|salvage|effective (l_pobj) patients_25\NNS\9898892|NONE (l_compound) cancer_24\NN\14239425|metastatic
D017239_D001943 NONE taxol_5\NNP\0|acid|therapies|. (r_nsubj) are_17\VBP\13600404|NONE (l_attr) therapies_20\NNS\657604|acid|Taxol|. (l_prep) for_21\IN\0|salvage|effective (l_pobj) patients_25\NNS\9898892|NONE (l_compound) cancer_24\NN\14239425|metastatic
D017239_D001943 NONE paclitaxel_7\NN\0|NONE (r_pobj) of_6\IN\0|II (r_prep) trial_5\NN\786195|We|m|phase|. (r_dobj) performed_1\VBD\0|NONE (l_dobj) phase_3\NN\15113229|trial|We|m|. (l_relcl) followed_18\VBD\1835496|a (l_agent) by_19\IN\0|I (l_pobj) acid_21\NN\14818238|NONE (l_prep) in_44\IN\13603305|folinic|before|days|on (l_pobj) women_45\NNS\9605289|NONE (l_prep) with_46\IN\0|NONE (l_pobj) cancer_49\NN\14239425|NONE
D016179_D009503 NONE factor_54\NN\7326557|reported|;|due|cycles (r_dobj) required_49\VBN\0|;|patient|.|transfusions (l_ccomp) reported_2\VBN\831651|;|due|factor|cycles (l_ccomp) associated_32\VBN\628491|is|Analysis|on (l_prep) with_33\IN\0|cycles|were (l_pobj) hospitalization_38\NN\15113229|NONE (l_det) neutropenia_36\NN\14196405|/|requiring
D016179_D009503 NONE factor_54\NN\7326557|reported|;|due|cycles (r_dobj) required_49\VBN\0|;|patient|.|transfusions (l_prep) due_55\JJ\5174653|reported|;|factor|cycles (l_pobj) neutropenia_57\NN\14196405|to
D002955_D001943 NONE acid_6\NN\14818238|,|and|, (l_prep) in_7\IN\13603305|folinic|: (l_pobj) cancer_10\NN\14239425|NONE
D002955_D001943 NONE acid_1\NN\14818238|Taxol|therapies|. (r_nsubj) are_17\VBP\13600404|NONE (l_attr) therapies_20\NNS\657604|acid|Taxol|. (l_prep) for_21\IN\0|salvage|effective (l_pobj) patients_25\NNS\9898892|NONE (l_compound) cancer_24\NN\14239425|metastatic
D002955_D001943 NONE acid_21\NN\14818238|NONE (l_prep) in_44\IN\13603305|folinic|before|days|on (l_pobj) women_45\NNS\9605289|NONE (l_prep) with_46\IN\0|NONE (l_pobj) cancer_49\NN\14239425|NONE
D005472_D001943 NONE 5-fluorouracil_2\CD\0|NONE (r_punct) ,_3\,\0|acid|and|, (r_punct) paclitaxel_0\NNP\0|.|trial (l_conj) acid_6\NN\14818238|,|and|, (l_prep) in_7\IN\13603305|folinic|: (l_pobj) cancer_10\NN\14239425|NONE
D005472_D001943 NONE 5-fluorouracil_28\CD\0|mg||/ (r_punct) m2_32\NN\13357178|hour (r_pobj) before_27\IN\0|folinic|days|in|on (r_prep) acid_21\NN\14818238|NONE (l_prep) in_44\IN\13603305|folinic|before|days|on (l_pobj) women_45\NNS\9605289|NONE (l_prep) with_46\IN\0|NONE (l_pobj) cancer_49\NN\14239425|NONE
19967075
D005839_D007674 CID gentamicin_17\NNP\2716866| (r_npadvmod) induced_19\VBN\1627355|NONE (r_amod) nephropathy_20\NNP\14573196|NONE
D005839_D007674 CID gentamicin_17\NN\2716866| (r_npadvmod) induced_19\VBN\1627355|NONE (r_amod) nephropathy_20\NN\14573196|NONE
D005839_D007674 CID gentamicin_0\NNP\2716866| (r_npadvmod) induced_2\VBN\1627355|NONE (r_amod) nephropathy_3\NN\14573196|in|.|be|causally|with|may
D011188_D007674 NONE k_5\NNP\13608598|/||NHE|Na|in|, (r_compound) atpase_7\NNP\0|NONE (l_prep) in_16\IN\13603305|/||NHE|Na|K|, (l_pobj) nephropathy_20\NNP\14573196|NONE
D011188_D007674 NONE na(+)/k(+)-atpase_17\NNP\0|NONE (r_pobj) of_16\IN\0|a|decreased (r_prep) expression_15\NN\4679549|NONE (r_pobj) with_12\IN\0|nephropathy|in|.|be|causally|may (r_prep) related_11\VBN\628491|NONE (l_nsubjpass) nephropathy_3\NN\14573196|in|.|be|causally|with|may
D012964_D007674 NONE na_3\NNP\14625458|/||NHE|in|K|, (r_nmod) atpase_7\NNP\0|NONE (l_prep) in_16\IN\13603305|/||NHE|Na|K|, (l_pobj) nephropathy_20\NNP\14573196|NONE
D012964_D007674 NONE na(+)/k(+)-atpase_17\NNP\0|NONE (r_pobj) of_16\IN\0|a|decreased (r_prep) expression_15\NN\4679549|NONE (r_pobj) with_12\IN\0|nephropathy|in|.|be|causally|may (r_prep) related_11\VBN\628491|NONE (l_nsubjpass) nephropathy_3\NN\14573196|in|.|be|causally|with|may
17879100
D001241_D005334 NONE aspirin_4\JJ\2707683|NONE (r_pobj) on_3\IN\0|.|following|was|took|He|and (r_prep) put_2\VBN\13241600|NONE (l_conj) took_8\VBD\2367363|.|following|was|He|and|on (l_prep) for_10\IN\0|for|ibuprofen (l_pobj) fever_11\NN\14299637|NONE
D007052_D005334 NONE ibuprofen_9\NN\3828465|for|for (r_dobj) took_8\VBD\2367363|.|following|was|He|and|on (l_prep) for_10\IN\0|for|ibuprofen (l_pobj) fever_11\NN\14299637|NONE
24999722
D005446_D007249 NONE acetonide_5\NN\0|(|mg|) (r_compound) implant_6\NN\4013729|that (r_dobj) fluocinolone_4\NN\0|helps|.|data (r_ccomp) suggest_2\VBP\1010118|NONE (l_ccomp) helps_11\VBZ\407535|.|fluocinolone|data (l_xcomp) control_13\VB\5190804|NONE (l_dobj) inflammation_14\NN\14299637|to
D005446_C537630 NONE acetonide_5\NN\0|intravitreal|Safety|)|in|mg|(|. (r_compound) implant_7\NN\4013729|NONE (l_prep) in_12\IN\13603305|intravitreal|Safety|)|acetonide|mg|(|. (l_pobj) retinochoroidopathy_14\JJ\0|NONE
D005446_C537630 NONE acetonide_8\NN\0|)|mg|intravitreal|in|( (r_amod) implant_10\NN\4013729|.|To|outcomes (l_prep) in_15\IN\13603305|)|acetonide|mg|intravitreal|( (l_pobj) patients_16\NNS\9898892|NONE (l_prep) with_17\IN\0|NONE (l_pobj) retinochoroidopathy_19\JJ\0|NONE
D005446_C537630 NONE acetonide_5\NN\0|(|mg|) (r_compound) implant_6\NN\4013729|that (r_dobj) fluocinolone_4\NN\0|helps|.|data (r_ccomp) suggest_2\VBP\1010118|NONE (l_ccomp) helps_11\VBZ\407535|.|fluocinolone|data (l_xcomp) control_13\VB\5190804|NONE (l_dobj) inflammation_14\NN\14299637|to (l_prep) in_15\IN\13603305|NONE (l_pobj) cases_20\NNS\7283608|NONE (l_prep) of_21\IN\0|refractory|otherwise (l_pobj) retinochoroidopathy_23\JJ\0|NONE
9323412
D015742_D009325 NONE propofol_3\JJ\0|a|avoidance|of|and (r_amod) infusion_4\NN\14589223|NONE (r_pobj) with_1\IN\0|NONE (r_prep) anaesthesia_0\NNP\14034177|without|.|course (r_nsubj) provided_10\VBD\2199590|NONE (l_dobj) course_16\NN\883297|without|Anaesthesia|. (l_amod) free_14\JJ\7942152|a|postoperative (l_npadvmod) nausea_12\NN\14299637|
D015742_D003866 NONE propofol_3\JJ\0|a|avoidance|of|and (r_amod) infusion_4\NN\14589223|NONE (r_pobj) with_1\IN\0|NONE (r_prep) anaesthesia_0\NNP\14034177|without|.|course (r_nsubj) provided_10\VBD\2199590|NONE (l_prep) without_17\IN\0|Anaesthesia|.|course (l_pobj) exacerbation_18\NN\374224|NONE (l_prep) of_19\IN\0|NONE (l_pobj) disorder_22\NN\14034177|NONE
D017294_D003866 NONE ondansetron_7\NN\0|NONE (r_pobj) following_3\VBG\8180190|Acute|severe|. (r_prep) depression_2\NN\14373582|NONE
D012701_D003865 NONE serotonin_20\NN\14807737|a (r_compound) antagonist_21\NN\7846|NONE (r_pobj) of_18\IN\0|the (r_prep) use_17\NN\407535|NONE (r_pobj) to_15\IN\0|possibly (r_prep) related_14\VBN\628491|disorder|She|thereafter|had|,|. (r_advcl) developed_2\VBN\1753788|NONE (l_dobj) disorder_8\NN\14034177|She|related|thereafter|had|,|.
D012701_D003866 NONE serotonin_8\NN\14807737|NONE (r_compound) antagonists_9\NNS\7846|NONE (r_pobj) of_7\IN\0|a|avoidance|propofol|and (r_prep) infusion_4\NN\14589223|NONE (r_pobj) with_1\IN\0|NONE (r_prep) anaesthesia_0\NNP\14034177|without|.|course (r_nsubj) provided_10\VBD\2199590|NONE (l_prep) without_17\IN\0|Anaesthesia|.|course (l_pobj) exacerbation_18\NN\374224|NONE (l_prep) of_19\IN\0|NONE (l_pobj) disorder_22\NN\14034177|NONE
D017294_D020250 NONE ondansetron_25\NN\0|NONE (r_compound) prophylaxis_26\NN\1077350|had|been|where (r_nsubjpass) used_29\VBN\0|a|previous (r_relcl) anaesthetic_23\NN\3247620|months (r_pobj) after_20\IN\0|woman|.|for (r_prep) presented_14\VBN\2137132|NONE (l_nsubj) woman_4\NN\9605289|.|for|after (l_prep) with_5\IN\0|A|old (l_pobj) history_8\NN\15120823|NONE (l_prep) of_9\IN\0|a|strong (l_pobj) nausea_11\NN\14299637|NONE (l_conj) vomiting_13\NN\116687|postoperative|and
D012701_D009325 NONE serotonin_8\NN\14807737|NONE (r_compound) antagonists_9\NNS\7846|NONE (r_pobj) of_7\IN\0|a|avoidance|propofol|and (r_prep) infusion_4\NN\14589223|NONE (r_pobj) with_1\IN\0|NONE (r_prep) anaesthesia_0\NNP\14034177|without|.|course (r_nsubj) provided_10\VBD\2199590|NONE (l_dobj) course_16\NN\883297|without|Anaesthesia|. (l_amod) free_14\JJ\7942152|a|postoperative (l_npadvmod) nausea_12\NN\14299637|
2131034
D008727_D020258 CID methotrexate_8\NNP\2722166|NONE (r_pobj) with_5\IN\0|have|toxicities|been|. (r_prep) described_4\VBN\1001294|NONE (l_nsubjpass) toxicities_1\NNS\13576101|have|with|been|.
D008727_D020258 CID mtx_16\NNP\0|NONE (r_pobj) with_15\IN\0|its (r_prep) combination_14\NN\7951464|.|,|In|could|neurotoxicity (r_nsubj) cause_24\VB\7323922|NONE (l_dobj) neurotoxicity_26\NN\0|.|,|combination|In|could
D013852_D020258 CID thiotepa_19\NNS\2722458|NONE (r_pobj) including_18\VBG\0|intrathecal|combination|IT (r_prep) chemotherapy_17\NN\661091|NONE (r_pobj) of_11\IN\0|the (r_prep) administration_10\NN\1133281|NONE (r_pobj) to_8\IN\0|NONE (r_prep) related_7\VBN\628491|neurologic|delayed|severe (r_acl) toxicity_6\NN\13576101|NONE
D013852_D020258 CID tspa_21\NNS\0|NONE (r_appos) thiotepa_19\NNS\2722458|NONE (r_pobj) including_18\VBG\0|intrathecal|combination|IT (r_prep) chemotherapy_17\NN\661091|NONE (r_pobj) of_11\IN\0|the (r_prep) administration_10\NN\1133281|NONE (r_pobj) to_8\IN\0|NONE (r_prep) related_7\VBN\628491|neurologic|delayed|severe (r_acl) toxicity_6\NN\13576101|NONE
D013852_D020258 CID tspa_17\NNP\0|,|and|cytosine (r_conj) arabinoside_13\NN\0||IT (r_conj) methotrexate_8\NNP\2722166|NONE (r_pobj) with_5\IN\0|have|toxicities|been|. (r_prep) described_4\VBN\1001294|NONE (l_nsubjpass) toxicities_1\NNS\13576101|have|with|been|.
D013852_D020258 CID tspa_6\NNP\0|agent|that (r_nsubj) is_7\VBZ\0|the (r_acl) fact_4\NN\5816287|NONE (r_pobj) of_2\IN\0|NONE (r_prep) spite_1\NN\7550369|NONE (r_pobj) in_0\IN\13603305|.|,|combination|could|neurotoxicity (r_prep) cause_24\VB\7323922|NONE (l_dobj) neurotoxicity_26\NN\0|.|,|combination|In|could
D013852_D011115 CID thiotepa_7\NNS\2722458|NONE (r_compound) combination_8\NN\7951464|:|description (r_compound) chemotherapy_9\NN\661091|NONE (r_pobj) after_5\IN\0|.|loss|and|Severe (r_prep) polyneuropathy_1\NN\0|NONE
D003561_D020258 CID arabinoside_13\NN\0||IT (r_conj) methotrexate_8\NNP\2722166|NONE (r_pobj) with_5\IN\0|have|toxicities|been|. (r_prep) described_4\VBN\1001294|NONE (l_nsubjpass) toxicities_1\NNS\13576101|have|with|been|.
D003561_D020258 CID c_20\NN\13714184|, (r_conj) mtx_16\NNP\0|NONE (r_pobj) with_15\IN\0|its (r_prep) combination_14\NN\7951464|.|,|In|could|neurotoxicity (r_nsubj) cause_24\VB\7323922|NONE (l_dobj) neurotoxicity_26\NN\0|.|,|combination|In|could
10672628
D009569_D002375 NONE oxide_7\NN\14818238|NONE (r_compound) synthesis_8\NN\13446390|NONE (r_pobj) of_4\IN\0|chronic (r_prep) inhibition_3\NN\1068773|.|catalepsy (r_nsubj) modifies_9\VBZ\109660|NONE (l_dobj) catalepsy_13\NN\14023236|.|inhibition
D009569_D002375 NONE oxide_18\NN\14818238|)|NOS|( (r_compound) synthase_19\NN\0|NONE (r_pobj) of_15\IN\0|an (r_prep) inhibitor_14\NN\20090|NOARG|nitro|,|L|,|| (r_appos) arginine_6\NN\14605787|.|in|catalepsy (r_nsubj) induces_24\VBZ\1627355|NONE (l_dobj) catalepsy_25\NN\14023236|arginine|.|in
D004298_D002375 NONE dopamine_8\NN\14807737|NONE (r_compound) receptors_9\NNS\5225602|which (r_dobj) block_7\VBP\21939|,|, (r_relcl) haloperidol_4\NN\3713736|such (r_pobj) as_3\IN\14622893|Neuroleptic (r_prep) drugs_1\NNS\14778436|also|.|in|catalepsy (r_nsubj) cause_12\VBP\7323922|NONE (l_dobj) catalepsy_13\NN\14023236|also|.|in|drugs
D009249_D002375 NONE nadph_18\NNP\0| (r_compound) diaphorase_20\NN\0|NONE (r_compound) neurons_21\NNS\5430628|NONE (r_pobj) of_17\IN\0|in|the (r_prep) number_16\NN\5107765|and|induced (r_conj) catalepsy_13\NN\14023236|.|inhibition
D006220_D002375 CID haloperidol_10\NN\3713736| (r_npadvmod) induced_12\VBN\1627355|and|number (r_amod) catalepsy_13\NN\14023236|.|inhibition
D006220_D002375 CID haloperidol_4\NN\3713736|such (r_pobj) as_3\IN\14622893|Neuroleptic (r_prep) drugs_1\NNS\14778436|also|.|in|catalepsy (r_nsubj) cause_12\VBP\7323922|NONE (l_dobj) catalepsy_13\NN\14023236|also|.|in|drugs
D006220_D002375 CID haloperidol_11\NN\3713736| (r_npadvmod) induced_13\VBN\1627355|NONE (r_amod) catalepsy_14\NN\14023236|NONE
D006220_D002375 CID haloperidol_16\NN\3713736| (r_npadvmod) induced_18\VBN\1627355|NONE (r_amod) catalepsy_19\NN\14023236|NONE
D019335_D002375 NONE arginine_6\NN\14605787|.|in|catalepsy (r_nsubj) induces_24\VBZ\1627355|NONE (l_dobj) catalepsy_25\NN\14023236|arginine|.|in
D019335_D002375 NONE noarg_10\NNP\0|nitro|,|L|,|||inhibitor (r_appos) arginine_6\NN\14605787|.|in|catalepsy (r_nsubj) induces_24\VBZ\1627355|NONE (l_dobj) catalepsy_25\NN\14023236|arginine|.|in
D019335_D002375 NONE noarg_8\NNP\0|number|and|in|subchronic (r_compound) treatment_9\NN\654885|NONE (l_prep) in_10\IN\13603305|number|NOARG|and|subchronic (l_pobj) catalepsy_14\NN\14023236|NONE
D019335_D002375 NONE noarg_3\NNP\0|chronic (r_nmod) administration_7\NN\1133281|tolerance|.|: (r_nsubj) produced_8\VBD\1617192|NONE (l_dobj) tolerance_9\NN\5032565|.|:|administration (l_prep) of_10\IN\0|NONE (l_conj) of_15\IN\0|and|NOARG (l_pobj) catalepsy_19\NN\14023236|NONE
D019335_D002375 NONE noarg_13\NNP\0|and|of (r_pobj) of_10\IN\0|NONE (l_conj) of_15\IN\0|and|NOARG (l_pobj) catalepsy_19\NN\14023236|NONE
3711722
D003035_D009202 CID cobalt_4\NN\14625458|NONE (r_compound) cardiomyopathy_5\NN\14103288|,|In|in|was
D004317_D006333 CID doxorubicin_4\RB\2716866| (r_npadvmod) induced_6\VBN\1627355|heart (r_amod) failure_8\NN\66216|NONE
19020118
11988250
D007052_D004374 NONE ibuprofen_8\NNP\3828465|NONE (r_compound) administration_9\NN\1133281|NONE (r_pobj) after_7\IN\0|We|during|.|cases (r_prep) report_1\VBP\6470073|NONE (l_prep) during_10\IN\0|We|after|.|cases (l_pobj) trial_14\NN\786195|NONE (l_prep) of_15\IN\0|randomised|in|a|controlled (l_pobj) treatment_17\NN\654885|NONE (l_prep) of_18\IN\0|with|prophylactic (l_pobj) arteriosus_21\NN\0|NONE
D007052_D004374 NONE ibuprofen_23\NN\3828465|NONE (r_pobj) with_22\IN\0|of|prophylactic (r_prep) treatment_17\NN\654885|NONE (l_prep) of_18\IN\0|with|prophylactic (l_pobj) arteriosus_21\NN\0|NONE
D007052_D006976 CID ibuprofen_3\NNP\3828465|in (r_compound) prophylaxis_4\NN\1077350|NONE (r_pobj) after_2\IN\0|.|Pulmonary (r_prep) hypertension_1\NN\14057371|NONE
D009569_D000860 NONE oxide_6\NN\14818238|nitric|inhaled (r_compound) therapy_7\NN\657604|NONE (r_pobj) on_3\IN\0|Hypoxaemia|.|quickly (r_prep) resolved_1\VBD\352826|NONE (l_nsubj) hypoxaemia_0\NNP\0|.|quickly|on
D007052_D000860 CID ibuprofen_8\NNP\3828465|NONE (r_compound) administration_9\NN\1133281|NONE (r_pobj) after_7\IN\0|We|during|.|cases (r_prep) report_1\VBP\6470073|NONE (l_dobj) cases_3\NNS\7283608|We|after|during|. (l_prep) of_4\IN\0|three (l_pobj) hypoxaemia_6\JJ\0|NONE
D007052_D000860 CID ibuprofen_23\NN\3828465|NONE (r_pobj) with_22\IN\0|of|prophylactic (r_prep) treatment_17\NN\654885|NONE (r_pobj) of_15\IN\0|randomised|in|a|controlled (r_prep) trial_14\NN\786195|NONE (r_pobj) during_10\IN\0|We|after|.|cases (r_prep) report_1\VBP\6470073|NONE (l_dobj) cases_3\NNS\7283608|We|after|during|. (l_prep) of_4\IN\0|three (l_pobj) hypoxaemia_6\JJ\0|NONE
D007052_D000860 CID ibuprofen_21\NNP\3828465|NONE (r_pobj) of_20\IN\0|prophylactic (r_prep) administration_19\NN\1133281|NONE (r_pobj) after_17\IN\0|hypoxaemia|if (r_prep) occurs_16\VBZ\0|investigators|that|to|attention (l_nsubj) hypoxaemia_15\JJ\0|after|if
17351238
D001285_D007022 NONE sulphate_23\NN\15010703|NONE (r_pobj) by_21\IN\0|.|was|,|experienced|this (r_agent) rectified_20\VBN\918872|NONE (l_advcl) experienced_7\VBD\2108377|by|.|was|,|this (l_dobj) drop_10\NN\13899200|after|GTN|minutes (l_prep) in_11\IN\13603305|sudden|a (l_pobj) pressure_13\NN\11419404|NONE
D005996_D007022 CID gtn_8\NNP\0|prehospital (r_compound) administration_9\NN\1133281|NONE (r_pobj) following_6\VBG\8180190|in|dramatic|.|A (r_prep) drop_2\NN\13899200|NONE (l_prep) in_3\IN\13603305|dramatic|.|A|following (l_pobj) pressure_5\NN\11419404|NONE
D005996_D007022 CID gtn_4\NNP\0|after|drop|minutes (r_nsubj) experienced_7\VBD\2108377|by|.|was|,|this (l_dobj) drop_10\NN\13899200|after|GTN|minutes (l_prep) in_11\IN\13603305|sudden|a (l_pobj) pressure_13\NN\11419404|NONE
17223814
D015251_D054537 CID epirubicin_11\NNS\0|NONE (r_pobj) with_10\IN\0|NONE (r_prep) chemotherapy_9\NN\661091|NONE (r_pobj) of_8\IN\0|a (r_prep) result_7\NN\34213|NONE (r_pobj) as_5\IN\14622893|.|atrioventricular|operative (r_prep) block_4\NN\21939|NONE
D017239_D054537 CID paclitaxel_13\NN\0|and (r_conj) epirubicin_11\NNS\0|NONE (r_pobj) with_10\IN\0|NONE (r_prep) chemotherapy_9\NN\661091|NONE (r_pobj) of_8\IN\0|a (r_prep) result_7\NN\34213|NONE (r_pobj) as_5\IN\14622893|.|atrioventricular|operative (r_prep) block_4\NN\21939|NONE
7457821
25031906
D017311_D012678 NONE amlodipine_14\NN\0|NONE (r_pobj) with_13\IN\0|drug (r_prep) treatment_12\NN\654885|NONE (r_pobj) on_10\IN\0|essential (r_prep) hypertension_9\NN\14057371|NONE (r_pobj) with_7\IN\0|a (r_prep) female_6\NN\15388|NONE (r_pobj) about_4\IN\0|a (r_prep) case_3\NN\7283608|We|.|loss (r_dobj) report_1\VBP\6470073|NONE (l_dobj) loss_16\NN\13252973|We|.|case (l_prep) of_17\IN\0|developed (l_pobj) sensation_19\NN\5708432|NONE
D017311_D006973 NONE amlodipine_14\NN\0|NONE (r_pobj) with_13\IN\0|drug (r_prep) treatment_12\NN\654885|NONE (r_pobj) on_10\IN\0|essential (r_prep) hypertension_9\NN\14057371|NONE
D017311_D004408 CID amlodipine_14\NNP\0|NONE (r_pobj) of_13\IN\0||Rare (r_prep) effect_12\NN\34213|to (r_attr) be_4\VB\14625458|Is|?|Dysguesia (r_xcomp) going_2\VBG\30358|NONE (l_compound) dysguesia_1\NNP\0|Is|?|be
D017311_D004408 CID amlodipine_7\NN\0|NONE (r_pobj) of_6\IN\0||rare|side|A (r_prep) effect_5\NN\34213|dysguesia|. (r_nsubj) is_8\VBZ\0|NONE (l_acomp) dysguesia_9\JJ\0|effect|.
D017311_D004408 CID amlodipine_3\NN\0|that|can|dysguesia (r_nsubj) cause_5\VB\7323922|We|. (l_dobj) dysguesia_6\NN\0|that|amlodipine|can
D017311_D004408 CID amlodipine_13\NN\0|NONE (l_conj) dysguesia_15\NN\0|and
4082192
D000082_D007683 CID acetaminophen_0\NNP\2707683|.|necrosis|in (r_nsubj) produces_4\VBZ\7555863|NONE (l_dobj) necrosis_7\NN\11444117|Acetaminophen|.|in
D000082_D007683 CID apap_2\NNP\0|)|( (r_appos) acetaminophen_0\NNP\2707683|.|necrosis|in (r_nsubj) produces_4\VBZ\7555863|NONE (l_dobj) necrosis_7\NN\11444117|Acetaminophen|.|in
D000082_D007683 CID apap_18\NNP\0| (r_npadvmod) induced_20\VBN\1627355|renal|tubular (r_amod) necrosis_23\NN\11444117|NONE
C026729_D007683 CID pap_4\NNP\6612266|NONE (r_compound) formation_5\NN\7938773|that|,|,|,|for|in|in|, (r_nsubj) accounts_10\NNS\6647206|It|is|. (l_prep) for_17\IN\0|that|formation|,|,|,|in|in|, (l_pobj) necrosis_23\NN\11444117|NONE
D000082_D007674 NONE acetaminophen_7\RB\2707683| (r_advmod) induced_9\VBN\1627355|NONE (r_amod) nephrotoxicity_10\NN\0|NONE
D000082_D007674 NONE acetaminophen_7\RB\2707683| (r_advmod) induced_9\VBN\1627355|NONE (r_amod) nephrotoxicity_10\NN\0|NONE (r_pobj) in_6\IN\13603305|effect|The|.|:|of (r_prep) role_1\NN\719494|NONE (l_appos) effect_12\NN\34213|in|The|.|:|of (l_prep) of_13\IN\0|NONE (l_pobj) phosphate_18\NN\15010703|NONE (l_conj) nephrotoxicity_25\NN\0|on|)|nitrophenyl|and
D000082_D007674 NONE acetaminophen_20\NN\2707683|NONE (r_pobj) on_19\IN\0|nephrotoxicity|)|nitrophenyl|and (r_prep) phosphate_18\NN\15010703|NONE (r_pobj) of_13\IN\0|NONE (r_prep) effect_12\NN\34213|in|The|.|:|of (r_appos) role_1\NN\719494|NONE (l_prep) in_6\IN\13603305|effect|The|.|:|of (l_pobj) nephrotoxicity_10\NN\0|NONE
D000082_D007674 NONE acetaminophen_20\NN\2707683|NONE (r_pobj) on_19\IN\0|nephrotoxicity|)|nitrophenyl|and (r_prep) phosphate_18\NN\15010703|NONE (l_conj) nephrotoxicity_25\NN\0|on|)|nitrophenyl|and
D000082_D007674 NONE apap_16\NNP\0| (r_npadvmod) induced_18\VBN\1627355|NONE (r_amod) nephrotoxicity_19\NN\0|NONE
D000082_D007674 NONE apap_19\NNP\0|NONE (l_conj) nephrotoxicity_22\NN\0|and
D000082_D007674 NONE apap_7\NNP\0|NONE (r_pobj) to_6\IN\0|NONE (r_prep) prior_5\RB\10675876|of (r_advmod) pretreatment_0\NN\0|in|. (r_nsubj) resulted_11\VBD\2633881|NONE (l_prep) in_12\IN\13603305|.|Pretreatment (l_pobj) reduction_14\NN\351485|NONE (l_appos) nephrotoxicity_25\NN\0|marked|of (l_nmod) nephrotoxicity_21\NN\0|not|PAP
D000082_D007674 NONE apap_7\NNP\0|NONE (r_pobj) to_6\IN\0|NONE (r_prep) prior_5\RB\10675876|of (r_advmod) pretreatment_0\NN\0|in|. (r_nsubj) resulted_11\VBD\2633881|NONE (l_prep) in_12\IN\13603305|.|Pretreatment (l_pobj) reduction_14\NN\351485|NONE (l_appos) nephrotoxicity_25\NN\0|marked|of
D000082_D007674 NONE apap_16\NNP\0|NONE (r_pobj) of_15\IN\0|marked|nephrotoxicity (r_prep) reduction_14\NN\351485|NONE (l_appos) nephrotoxicity_25\NN\0|marked|of (l_nmod) nephrotoxicity_21\NN\0|not|PAP
D000082_D007674 NONE apap_16\NNP\0|NONE (r_pobj) of_15\IN\0|marked|nephrotoxicity (r_prep) reduction_14\NN\351485|NONE (l_appos) nephrotoxicity_25\NN\0|marked|of
D000082_D007674 NONE apap_8\NNP\0| (r_npadvmod) induced_10\VBN\1627355|NONE (r_amod) nephrotoxicity_11\NN\0|NONE
D000082_D007674 NONE apap_19\NNP\0|NONE (r_compound) deacetylation_20\NN\0|NONE (r_pobj) of_18\IN\0|NONE (r_prep) inhibition_17\NN\1068773|to (r_pobj) due_15\JJ\5174653|to (r_acomp) be_14\VB\14625458|Therefore|,|reduction|. (r_xcomp) appears_12\VBZ\2604760|NONE (l_nsubj) reduction_6\NN\351485|Therefore|,|be|. (l_prep) in_7\IN\13603305|the|induced (l_pobj) nephrotoxicity_11\NN\0|NONE
C026729_D007674 NONE aminophenol_5\NN\0|NONE (r_pobj) of_2\IN\0|in|effect|The|.|: (r_prep) role_1\NN\719494|NONE (l_prep) in_6\IN\13603305|effect|The|.|:|of (l_pobj) nephrotoxicity_10\NN\0|NONE
C026729_D007674 NONE aminophenol_5\NN\0|NONE (r_pobj) of_2\IN\0|in|effect|The|.|: (r_prep) role_1\NN\719494|NONE (l_appos) effect_12\NN\34213|in|The|.|:|of (l_prep) of_13\IN\0|NONE (l_pobj) phosphate_18\NN\15010703|NONE (l_conj) nephrotoxicity_25\NN\0|on|)|nitrophenyl|and
C026729_D007674 NONE aminophenol_24\NN\0|metabolism|and|in (r_amod) nephrotoxicity_25\NN\0|on|)|nitrophenyl|and (r_conj) phosphate_18\NN\15010703|NONE (r_pobj) of_13\IN\0|NONE (r_prep) effect_12\NN\34213|in|The|.|:|of (r_appos) role_1\NN\719494|NONE (l_prep) in_6\IN\13603305|effect|The|.|:|of (l_pobj) nephrotoxicity_10\NN\0|NONE
C026729_D007674 NONE aminophenol_24\NN\0|metabolism|and|in (r_amod) nephrotoxicity_25\NN\0|on|)|nitrophenyl|and
C026729_D007674 NONE pap_9\NNP\6612266|NONE (r_compound) formation_10\NN\7938773|if|step (r_nsubj) is_11\VBZ\0|to (l_attr) step_14\NN\168237|if|formation (l_prep) in_15\IN\13603305|requisite|a (l_pobj) nephrotoxicity_19\NN\0|NONE
C026729_D007674 NONE pap_21\NNP\6612266|metabolism|and (r_compound) nephrotoxicity_22\NN\0|and
C026729_D007674 NONE pap_9\NNP\6612266|NONE (r_compound) administration_10\NN\1133281|or (r_conj) apap_7\NNP\0|NONE (r_pobj) to_6\IN\0|NONE (r_prep) prior_5\RB\10675876|of (r_advmod) pretreatment_0\NN\0|in|. (r_nsubj) resulted_11\VBD\2633881|NONE (l_prep) in_12\IN\13603305|.|Pretreatment (l_pobj) reduction_14\NN\351485|NONE (l_appos) nephrotoxicity_25\NN\0|marked|of (l_nmod) nephrotoxicity_21\NN\0|not|PAP
C026729_D007674 NONE pap_9\NNP\6612266|NONE (r_compound) administration_10\NN\1133281|or (r_conj) apap_7\NNP\0|NONE (r_pobj) to_6\IN\0|NONE (r_prep) prior_5\RB\10675876|of (r_advmod) pretreatment_0\NN\0|in|. (r_nsubj) resulted_11\VBD\2633881|NONE (l_prep) in_12\IN\13603305|.|Pretreatment (l_pobj) reduction_14\NN\351485|NONE (l_appos) nephrotoxicity_25\NN\0|marked|of
C026729_D007674 NONE pap_24\NNP\6612266|not|nephrotoxicity (r_compound) nephrotoxicity_25\NN\0|marked|of (l_nmod) nephrotoxicity_21\NN\0|not|PAP
C026729_D007674 NONE pap_24\NNP\6612266|not|nephrotoxicity (r_compound) nephrotoxicity_25\NN\0|marked|of
C002887_D007674 NONE phosphate_18\NN\15010703|NONE (r_pobj) of_13\IN\0|NONE (r_prep) effect_12\NN\34213|in|The|.|:|of (r_appos) role_1\NN\719494|NONE (l_prep) in_6\IN\13603305|effect|The|.|:|of (l_pobj) nephrotoxicity_10\NN\0|NONE
C002887_D007674 NONE phosphate_18\NN\15010703|NONE (l_conj) nephrotoxicity_25\NN\0|on|)|nitrophenyl|and
C002887_D007674 NONE phosphate_9\NN\15010703|NONE (r_pobj) of_4\IN\0|on|the (r_prep) effect_3\NN\34213|Therefore|.|,|was (l_prep) on_18\IN\0|of|the (l_pobj) apap_19\NNP\0|NONE (l_conj) nephrotoxicity_22\NN\0|and
C002887_D007674 NONE bnpp_11\NNP\0|,|inhibitor|nitrophenyl|, (r_appos) phosphate_9\NN\15010703|NONE (r_pobj) of_4\IN\0|on|the (r_prep) effect_3\NN\34213|Therefore|.|,|was (l_prep) on_18\IN\0|of|the (l_pobj) apap_19\NNP\0|NONE (l_conj) nephrotoxicity_22\NN\0|and
C002887_D007674 NONE bnpp_4\NNP\0|NONE (r_pobj) with_3\IN\0|NONE (r_prep) animals_2\NNS\4475|NONE (r_pobj) of_1\IN\0|prior (r_prep) pretreatment_0\NN\0|in|. (r_nsubj) resulted_11\VBD\2633881|NONE (l_prep) in_12\IN\13603305|.|Pretreatment (l_pobj) reduction_14\NN\351485|NONE (l_appos) nephrotoxicity_25\NN\0|marked|of (l_nmod) nephrotoxicity_21\NN\0|not|PAP
C002887_D007674 NONE bnpp_4\NNP\0|NONE (r_pobj) with_3\IN\0|NONE (r_prep) animals_2\NNS\4475|NONE (r_pobj) of_1\IN\0|prior (r_prep) pretreatment_0\NN\0|in|. (r_nsubj) resulted_11\VBD\2633881|NONE (l_prep) in_12\IN\13603305|.|Pretreatment (l_pobj) reduction_14\NN\351485|NONE (l_appos) nephrotoxicity_25\NN\0|marked|of
C002887_D007674 NONE bnpp_3\NNP\0| (r_npadvmod) induced_5\VBN\1627355|in|the (r_amod) reduction_6\NN\351485|Therefore|,|be|. (l_prep) in_7\IN\13603305|the|induced (l_pobj) nephrotoxicity_11\NN\0|NONE
6299641
D007545_D013610 CID isoproterenol_28\NN\3740161| (r_npadvmod) induced_30\VBN\1627355|NONE (r_amod) tachycardia_31\NN\14110674|both|in|and
D007545_D013610 CID isoproterenol_3\NN\3740161|NONE (r_compound) tachycardia_4\NNS\14110674|NONE
D007545_D013610 CID isoproterenol_29\NN\3740161||whereas|blocked|remains (r_nsubj) activates_30\VBZ\1641914|data|,|.|consistent (r_advcl) are_2\VBP\13600404|NONE (l_acomp) consistent_3\JJ\0|activates|data|,|. (l_prep) with_4\IN\0|NONE (l_pobj) hypothesis_6\NN\7162194|NONE (l_relcl) results_12\NNS\34213|the (l_nsubj) tachycardia_11\NN\14110674|from|largely|that
D001262_D013610 NONE atenolol_10\NN\2832168|NONE (r_pobj) of_7\IN\0|single (r_prep) doses_6\NNS\3740161|NONE (r_pobj) of_4\IN\0|the (r_prep) effects_3\NNS\13245626|We (r_dobj) compared_1\VBD\644583|mg|,|placebo|(|)|nonselective|and|.|, (r_ccomp) propranolol_17\NN\0|NONE (l_conj) placebo_23\NN\3740161|mg|,|(|)|nonselective|and|.|compared|, (l_prep) on_24\IN\0|NONE (l_pobj) exercise-_26\JJ\0|NONE (l_conj) tachycardia_31\NN\14110674|both|in|and
D011433_D013610 NONE propranolol_17\NN\0|NONE (l_conj) placebo_23\NN\3740161|mg|,|(|)|nonselective|and|.|compared|, (l_prep) on_24\IN\0|NONE (l_pobj) exercise-_26\JJ\0|NONE (l_conj) tachycardia_31\NN\14110674|both|in|and
D001285_D013610 NONE atropine_10\NN\14712692|NONE (r_pobj) after_9\IN\0|mg/kg (r_prep) iv_14\NNP\13741022|and (r_conj) before_7\RB\0|.|were|effects|) (r_prep) determined_6\VBN\0|NONE (l_nsubjpass) effects_1\NNS\13245626|.|before|were|) (l_prep) on_2\IN\0|The (l_pobj) tachycardia_4\NNS\14110674|NONE
24132704
D003976_D006949 CID diazinon_7\NN\0| (r_npadvmod) induced_9\VBN\1627355|NONE (r_amod) hyperlipemia_10\NN\14299637|ERK|and
D003976_D006949 CID diazinon_10\NN\0| (r_npadvmod) induced_12\VBN\1627355|NONE (r_amod) hyperlipemia_13\NN\14299637|NONE
C029036_D006949 NONE crocin_0\NNS\0|levels|.|inhibition|and (r_nsubj) reduced_1\VBD\441445|NONE (l_dobj) inhibition_2\NN\1068773|levels|.|Crocin|and (l_prep) of_3\IN\0|NONE (l_pobj) activation_5\NN\13561719|NONE (l_conj) hyperlipemia_10\NN\14299637|ERK|and
C029036_D006949 NONE crocin_0\NNS\0|may|through|.|as|be (r_nsubjpass) considered_3\VBN\689344|NONE (l_prep) as_4\IN\14622893|may|through|.|be|Crocin (l_pobj) agent_8\NN\7347|NONE (l_prep) in_9\IN\13603305|a|protective|novel (l_pobj) hyperlipemia_13\NN\14299637|NONE
6321816
D003900_D006973 CID doca_9\NNP\0| (r_compound) salt_11\NN\14818238|NONE (r_compound) hypertension_12\NN\14057371|NONE
D003900_D006973 CID doca_33\NNP\0| (r_compound) salt_35\NN\14818238|NONE (r_compound) treatment_36\NN\654885|NONE (r_pobj) after_32\IN\0|not|elevation|substantial|since (r_prep) was_20\VBD\0|.|Vasopressin|role|,|in (r_advcl) plays_1\VBZ\7007684|NONE (l_prep) in_5\IN\13603305|.|Vasopressin|role|,|was (l_pobj) pathogenesis_7\NN\13533470|NONE (l_prep) of_8\IN\0|the (l_pobj) hypertension_12\NN\14057371|NONE
D008094_D003919 CID lithium_27\NN\14625458| (r_npadvmod) treated_29\VBN\2376958|NONE (r_amod) diabetes_30\NN\14075199|NONE (r_compound) insipidus_31\NN\0|NONE
D008094_D006973 NONE lithium_27\NN\14625458| (r_npadvmod) treated_29\VBN\2376958|NONE (r_amod) diabetes_30\NN\14075199|NONE (r_compound) insipidus_31\NN\0|NONE (r_pobj) with_26\IN\0|the (r_prep) rats_25\NNS\2329401|NONE (r_pobj) in_23\IN\13603305|NONE (r_prep) substantial_22\JJ\0|after|not|elevation|since (r_acomp) was_20\VBD\0|.|Vasopressin|role|,|in (r_advcl) plays_1\VBZ\7007684|NONE (l_prep) in_5\IN\13603305|.|Vasopressin|role|,|was (l_pobj) pathogenesis_7\NN\13533470|NONE (l_prep) of_8\IN\0|the (l_pobj) hypertension_12\NN\14057371|NONE
D014667_D003919 NONE vasopressin_0\NNP\5407119|.|role|,|was|in (r_nsubj) plays_1\VBZ\7007684|NONE (l_advcl) was_20\VBD\0|.|Vasopressin|role|,|in (l_acomp) substantial_22\JJ\0|after|not|elevation|since (l_prep) in_23\IN\13603305|NONE (l_pobj) rats_25\NNS\2329401|NONE (l_prep) with_26\IN\0|the (l_pobj) insipidus_31\NN\0|NONE
D014667_D006973 NONE vasopressin_0\NNP\5407119|NONE (l_prep) as_1\IN\14622893|. (l_pobj) contributor_4\NN\10025730|NONE (l_prep) to_5\IN\0|possible|a (l_pobj) hypertension_6\NN\14057371|NONE
D014667_D006973 NONE vasopressin_3\NN\5407119|NONE (r_pobj) of_2\IN\0|as|The (r_prep) role_1\NN\719494|.|was (l_prep) as_4\IN\14622893|The|of (l_pobj) agent_7\NN\7347|NONE (l_prep) to_8\IN\0|a|pressor (l_pobj) process_11\NN\407535|NONE (l_amod) hypertensive_10\JJ\10405694|the
D014667_D006973 NONE vasopressin_0\NNP\5407119|.|role|,|was|in (r_nsubj) plays_1\VBZ\7007684|NONE (l_prep) in_5\IN\13603305|.|Vasopressin|role|,|was (l_pobj) pathogenesis_7\NN\13533470|NONE (l_prep) of_8\IN\0|the (l_pobj) hypertension_12\NN\14057371|NONE
D014667_D006973 NONE vasopressin_6\NN\5407119|NONE (r_pobj) of_5\IN\0|the|pressor (r_prep) action_4\NN\30358|.|,|observed|,|be|Furthermore (r_nsubj) appears_7\VBZ\2604760|NONE (l_xcomp) be_9\VB\14625458|.|,|observed|action|,|Furthermore (l_prep) in_11\IN\13603305|important|to (l_pobj) development_13\NN\248977|NONE (l_prep) of_14\IN\0|the (l_pobj) model_16\NN\5888929|NONE (l_prep) of_17\IN\0|this (l_pobj) hypertension_18\NN\14057371|NONE
D014667_D006973 NONE vasopressin_6\NN\5407119|NONE (r_pobj) of_5\IN\0|the|pressor (r_prep) action_4\NN\30358|.|,|observed|,|be|Furthermore (r_nsubj) appears_7\VBZ\2604760|NONE (l_advcl) observed_29\VBN\2163746|.|,|action|,|be|Furthermore (l_prep) in_30\IN\13603305|since|responsiveness|was (l_pobj) stage_33\NN\15113229|NONE (l_prep) of_34\IN\0|the|initial (l_pobj) hypertension_35\NN\14057371|NONE
D014667_D006973 NONE vasopressin_3\NN\5407119|NONE (r_pobj) of_2\IN\0|Increased|from (r_prep) secretion_1\NN\13526110|also|.|function (r_nsubj) promotes_7\VBZ\2556126|NONE (l_dobj) function_9\NN\13783581|also|.|secretion (l_prep) as_13\IN\14622893|of|the (l_pobj) factor_16\NN\7326557|NONE (l_prep) in_17\IN\13603305|a|pathogenetic (l_pobj) hypertension_18\NN\14057371|NONE
D014667_D006973 NONE vasopressin_5\NN\5407119|NONE (r_pobj) of_4\IN\0|the (r_prep) role_3\NN\719494|However|,|.|determined (r_nsubj) remains_6\VBZ\2684|NONE (l_xcomp) determined_9\VBN\0|However|,|role|. (l_prep) in_10\IN\13603305|to|be (l_pobj) hypertension_13\NN\14057371|NONE
D003900_D003919 NONE doca_9\NNP\0| (r_compound) salt_11\NN\14818238|NONE (r_compound) hypertension_12\NN\14057371|NONE (r_pobj) of_8\IN\0|the (r_prep) pathogenesis_7\NN\13533470|NONE (r_pobj) in_5\IN\13603305|.|Vasopressin|role|,|was (r_prep) plays_1\VBZ\7007684|NONE (l_advcl) was_20\VBD\0|.|Vasopressin|role|,|in (l_acomp) substantial_22\JJ\0|after|not|elevation|since (l_prep) in_23\IN\13603305|NONE (l_pobj) rats_25\NNS\2329401|NONE (l_prep) with_26\IN\0|the (l_pobj) insipidus_31\NN\0|NONE
D003900_D003919 NONE doca_33\NNP\0| (r_compound) salt_35\NN\14818238|NONE (r_compound) treatment_36\NN\654885|NONE (r_pobj) after_32\IN\0|not|elevation|substantial|since (r_prep) was_20\VBD\0|.|Vasopressin|role|,|in (l_acomp) substantial_22\JJ\0|after|not|elevation|since (l_prep) in_23\IN\13603305|NONE (l_pobj) rats_25\NNS\2329401|NONE (l_prep) with_26\IN\0|the (l_pobj) insipidus_31\NN\0|NONE
6884395
D003276_D000784 CID contraceptives_19\NNS\3183080|and|, (r_conj) smoke_15\NN\11422597|, (r_conj) hypertension_13\NN\14057371|NONE (r_pobj) with_12\IN\0|NONE (r_prep) association_11\NN\8008335|NONE (r_pobj) in_10\IN\13603305|basilar|the (r_prep) artery_9\NN\5417975|NONE (r_pobj) of_6\IN\0|dissecting (r_prep) aneurysm_5\NN\14057371|NONE
D003276_D011782 NONE contraceptives_19\NNS\3183080|and|, (r_conj) smoke_15\NN\11422597|, (r_conj) hypertension_13\NN\14057371|NONE (r_pobj) with_12\IN\0|NONE (r_prep) association_11\NN\8008335|NONE (r_pobj) in_10\IN\13603305|basilar|the (r_prep) artery_9\NN\5417975|NONE (r_pobj) of_6\IN\0|dissecting (r_prep) aneurysm_5\NN\14057371|NONE (r_pobj) of_2\IN\0|A (r_prep) case_1\NN\7283608|in|.|is (r_nsubjpass) reported_21\VBN\831651|NONE (l_prep) in_22\IN\13603305|.|is|case (l_pobj) patient_26\NN\9898892|NONE (l_prep) with_27\IN\0|young|a|female (l_pobj) syndrome_32\NN\5870365|NONE
D003276_D006973 NONE contraceptives_19\NNS\3183080|and|, (r_conj) smoke_15\NN\11422597|, (r_conj) hypertension_13\NN\14057371|NONE
24739405
D006220_D006948 NONE haloperidol_23\NN\3713736|used (r_nsubj) induced_29\VBD\1627355|climbing|and|, (r_conj) induced_19\VBN\1627355|sc|Amphetamine|)|.|locomotion (r_conj) induced_6\VBD\1627355|NONE (l_dobj) locomotion_8\NN\4773351|sc|Amphetamine|)|.|induced (l_amod) hyper_7\JJ\0|,|apomorphine
D001058_D002375 NONE apomorphine_10\NN\3786417|,|hyper (r_conj) locomotion_8\NN\4773351|sc|Amphetamine|)|.|induced (r_dobj) induced_6\VBD\1627355|NONE (l_conj) induced_19\VBN\1627355|sc|Amphetamine|)|.|locomotion (l_conj) induced_29\VBD\1627355|climbing|and|, (l_ccomp) used_33\VBN\0|haloperidol (l_nsubjpass) tests_31\NNS\5798043|as|were (l_compound) catalepsy_30\NN\14023236|NONE
D001058_D012559 CID apomorphine_10\NN\3786417|,|hyper (r_conj) locomotion_8\NN\4773351|sc|Amphetamine|)|.|induced (r_dobj) induced_6\VBD\1627355|NONE (l_conj) induced_19\VBN\1627355|sc|Amphetamine|)|.|locomotion (l_conj) induced_29\VBD\1627355|climbing|and|, (l_ccomp) used_33\VBN\0|haloperidol (l_prep) as_34\IN\14622893|tests|were (l_pobj) models_36\NNS\5888929|NONE (l_prep) of_37\IN\0|animal (l_pobj) schizophrenia_38\NN\14398067|NONE
D000661_D002375 NONE amphetamine_0\NN\3248958|sc|)|.|locomotion|induced (r_nsubj) induced_6\VBD\1627355|NONE (l_conj) induced_19\VBN\1627355|sc|Amphetamine|)|.|locomotion (l_conj) induced_29\VBD\1627355|climbing|and|, (l_ccomp) used_33\VBN\0|haloperidol (l_nsubjpass) tests_31\NNS\5798043|as|were (l_compound) catalepsy_30\NN\14023236|NONE
D006220_D002375 CID haloperidol_23\NN\3713736|used (r_nsubj) induced_29\VBD\1627355|climbing|and|, (l_ccomp) used_33\VBN\0|haloperidol (l_nsubjpass) tests_31\NNS\5798043|as|were (l_compound) catalepsy_30\NN\14023236|NONE
D006220_D002375 CID haloperidol_9\NN\3713736| (r_npadvmod) induced_11\VBN\1627355|the|)|p<.|(|catalepsy (r_amod) test_13\NN\5798043|NONE (l_compound) catalepsy_12\NN\14023236|the|)|p<.|(|induced
D000661_D006948 NONE amphetamine_0\NN\3248958|sc|)|.|locomotion|induced (r_nsubj) induced_6\VBD\1627355|NONE (l_dobj) locomotion_8\NN\4773351|sc|Amphetamine|)|.|induced (l_amod) hyper_7\JJ\0|,|apomorphine
D001058_D006948 NONE apomorphine_10\NN\3786417|,|hyper (r_conj) locomotion_8\NN\4773351|sc|Amphetamine|)|.|induced (l_amod) hyper_7\JJ\0|,|apomorphine
D000661_D012559 CID amphetamine_4\NN\3248958| (r_npadvmod) induced_6\VBN\1627355|schizophrenia|in (r_amod) models_8\NNS\5888929|NONE (l_compound) schizophrenia_7\NN\14398067|induced|in
D000661_D012559 CID amphetamine_0\NN\3248958|sc|)|.|locomotion|induced (r_nsubj) induced_6\VBD\1627355|NONE (l_conj) induced_19\VBN\1627355|sc|Amphetamine|)|.|locomotion (l_conj) induced_29\VBD\1627355|climbing|and|, (l_ccomp) used_33\VBN\0|haloperidol (l_prep) as_34\IN\14622893|tests|were (l_pobj) models_36\NNS\5888929|NONE (l_prep) of_37\IN\0|animal (l_pobj) schizophrenia_38\NN\14398067|NONE
D006220_D012559 CID haloperidol_23\NN\3713736|used (r_nsubj) induced_29\VBD\1627355|climbing|and|, (l_ccomp) used_33\VBN\0|haloperidol (l_prep) as_34\IN\14622893|tests|were (l_pobj) models_36\NNS\5888929|NONE (l_prep) of_37\IN\0|animal (l_pobj) schizophrenia_38\NN\14398067|NONE
D003687_D002375 NONE dhea_3\NNP\0|catalepsy|and|reduced|locomotor (r_nsubj) activity_6\NN\30358|We|.|had|,|that (l_conj) catalepsy_9\NN\14023236|and|reduced|DHEA|locomotor
D003687_D012559 NONE dehydroepiandrosterone_2\NN\0|NONE (l_prep) in_3\IN\13603305|NONE (l_pobj) models_8\NNS\5888929|NONE (l_compound) schizophrenia_7\NN\14398067|induced|in
D003687_D012559 NONE dehydroepiandrosterone_5\NN\0|NONE (r_pobj) of_4\IN\0|on|the (r_prep) effects_3\NNS\13245626|To|. (l_prep) on_9\IN\0|of|the (l_pobj) models_11\NNS\5888929|NONE (l_prep) of_12\IN\0|animal (l_pobj) schizophrenia_13\NN\14398067|NONE
D003687_D012559 NONE dhea_7\NNP\0|NONE (r_appos) dehydroepiandrosterone_5\NN\0|NONE (r_pobj) of_4\IN\0|on|the (r_prep) effects_3\NNS\13245626|To|. (l_prep) on_9\IN\0|of|the (l_pobj) models_11\NNS\5888929|NONE (l_prep) of_12\IN\0|animal (l_pobj) schizophrenia_13\NN\14398067|NONE
D003687_D012559 NONE dhea_3\NNP\0|,|effects|that|used|and (r_nsubj) displays_4\VBZ\6879180|We|. (l_conj) used_14\VBN\0|DHEA|,|effects|that|and (l_prep) in_15\IN\13603305|may|be (l_pobj) treatment_17\NN\654885|NONE (l_prep) of_18\IN\0|the (l_pobj) schizophrenia_19\NN\14398067|NONE
23871786
C006780_D001008 CID a_4\DT\13649268|NONE (r_pobj) to_2\IN\0|Pubertal (r_prep) exposure_1\NN\5042871|and|.|decreases|behavior (r_nsubj) increases_5\VBZ\13576355|NONE (l_dobj) behavior_9\NN\407535|and|.|decreases|exposure (l_amod) like_8\JJ\5839024|NONE (l_npadvmod) anxiety_6\NN\14373582|
C006780_D001008 CID bpa_17\NNP\0|NONE (r_pobj) to_16\IN\0|NONE (r_prep) exposed_15\VBN\2110927|NONE (r_acl) mice_14\NNS\2329401|NONE (r_pobj) in_13\IN\13603305|was|behavior|that (r_prep) increased_12\VBN\169651|Results|. (l_nsubjpass) behavior_10\NN\407535|was|in|that (l_amod) like_9\JJ\5839024|NONE (l_npadvmod) anxiety_7\NN\14373582|
C006780_D001008 CID bpa_5\NNP\0|pubertal (r_compound) exposure_6\NN\5042871|that|behavior (r_nsubj) increased_7\VBN\169651|findings|. (l_dobj) behavior_11\NN\407535|that|exposure (l_amod) like_10\JJ\5839024|,|associated (l_npadvmod) anxiety_8\NN\14373582|NONE
12699527
D002712_-1 NONE chloride_14\NN\14818238|NONE (r_compound) channel_15\NN\6251781|muscle|the|, (r_compound) function_16\NN\13783581|NONE (r_pobj) in_10\IN\13603305|a|cause (r_prep) defect_9\NN\14462666|NONE (l_relcl) cause_20\VB\7323922|a|in (l_dobj) depolarisation_23\NN\11412727|may|which
D002712_D009224 NONE chloride_14\NN\14818238|NONE (r_compound) channel_15\NN\6251781|muscle|the|, (r_compound) function_16\NN\13783581|NONE (r_pobj) in_10\IN\13603305|a|cause (r_prep) defect_9\NN\14462666|NONE (r_pobj) by_7\IN\0|is|congenita|. (r_agent) caused_6\VBN\1617192|NONE (l_nsubjpass) congenita_1\NN\0|is|.|by
D002712_D009224 NONE chloride_14\NN\14818238|NONE (r_compound) channel_15\NN\6251781|muscle|the|, (r_compound) function_16\NN\13783581|NONE (r_pobj) in_10\IN\13603305|a|cause (r_prep) defect_9\NN\14462666|NONE (r_pobj) by_7\IN\0|is|congenita|. (r_agent) caused_6\VBN\1617192|NONE (l_nsubjpass) congenita_1\NN\0|is|.|by (l_appos) mc_3\NNP\15286249|(|)|Myotonia
D013390_D013035 CID suxamethonium_26\NN\0|NONE (r_pobj) of_25\IN\0|preoperative|a (r_prep) injection_24\NN\320852|NONE (r_pobj) following_21\VBG\8180190|spasm|who (r_prep) developed_10\VBD\1753788|a|healthy|old (l_dobj) spasm_16\NN\14299637|following|who
7315949
D009638_D013035 CID norepinephrine_9\NN\14807929|NONE (r_pobj) by_6\IN\0|NONE (r_agent) induced_5\VBN\1627355|in|Medial|. (r_acl) changes_1\NNS\7283608|NONE (l_prep) in_2\IN\13603305|induced|Medial|. (l_pobj) spasm_4\NN\14299637|NONE
D009638_D006547 NONE norepinephrine_17\NN\14807929|NONE (r_pobj) by_14\IN\0|NONE (r_agent) induced_13\VBN\1627355|NONE (r_acl) vasoconstriction_12\NN\1149911|within|hernias|In|,|. (r_nsubj) produced_18\VBD\1617192|NONE (l_dobj) hernias_25\NNS\14295248|within|In|,|.|vasoconstriction
3439580
D007099_D009447 NONE imipramine_5\NN\4482543|NONE (r_pobj) by_4\IN\0|.|Hypertension (r_prep) induced_3\VBN\1627355|NONE (l_nsubj) hypertension_0\NN\14057371|.|by (l_prep) in_1\IN\13603305|NONE (l_pobj) neuroblastoma_2\NN\14239425|NONE
D007099_D009447 NONE imipramine_23\NNP\4482543|control|who|was (r_dobj) given_22\VBN\5892096|NONE (r_relcl) neuroblastoma_19\NN\14239425|NONE
D007099_D002653 NONE imipramine_23\NNP\4482543|control|who|was (r_dobj) given_22\VBN\5892096|NONE (l_advcl) control_25\VB\5190804|who|was|Imipramine (l_dobj) disorder_28\NN\14034177|to
D007099_D006973 CID imipramine_5\NN\4482543|NONE (r_pobj) by_4\IN\0|.|Hypertension (r_prep) induced_3\VBN\1627355|NONE (l_nsubj) hypertension_0\NN\14057371|.|by
D007099_D006973 CID imipramine_23\NNP\4482543|control|who|was (r_dobj) given_22\VBN\5892096|NONE (r_relcl) neuroblastoma_19\NN\14239425|NONE (r_pobj) with_18\IN\0|old|a (r_prep) girl_17\NN\10787470|NONE (r_pobj) in_12\IN\13603305|/|)|blood|( (r_prep) pressure_9\NN\11419404|severe (r_appos) hypertension_6\NN\14057371|NONE
D007099_D006973 CID imipramine_16\NNP\4482543|NONE (r_pobj) of_14\IN\0|NONE (r_prep) discontinuation_13\NN\209943|NONE (r_dobj) following_12\VBG\8180190|)|was|( (r_acl) none_11\NN\15228378|pressure|and|at|no (r_conj) elevation_6\NN\7445480|she|Since (r_dobj) had_2\VBD\0|caused|,|.|we (r_advcl) believe_27\VBP\686447|NONE (l_ccomp) caused_37\VBD\1617192|had|,|.|we (l_dobj) hypertension_39\NN\14057371|that|drug
17151160
D018967_D011618 NONE risperidone_58\NN\0|)|(|day|with|or|to (r_conj) treatment_46\NN\654885|were|,|disorder|randomly (r_xcomp) assigned_44\VBN\2475922|)|with|years|subjects|. (l_nsubjpass) disorder_29\NN\14034177|were|treatment|,|randomly
D018967_D011618 NONE risperidone_58\NN\0|)|(|day|with|or|to (r_conj) treatment_46\NN\654885|were|,|disorder|randomly (r_xcomp) assigned_44\VBN\2475922|)|with|years|subjects|. (l_nsubjpass) disorder_29\NN\14034177|were|treatment|,|randomly (l_conj) disorder_37\NN\14034177|%|schizophreniform|)|or|,|(
D018967_D015430 CID risperidone_9\NN\0|NONE (r_pobj) with_8\IN\0|NONE (r_prep) than_7\IN\0|gain|was|:|with (r_prep) occurred_4\VBD\0|NONE (l_nsubj) gain_3\NN\13576355|was|:|with|than
D018967_D015430 CID risperidone_43\NN\0|NONE (r_pobj) with_42\IN\0|(|)|.|% (r_prep) %_35\NN\0|and (r_conj) olanzapine_32\NN\0|NONE (r_pobj) with_31\IN\0|.|%|( (r_prep) %_24\NN\0|increase|. (r_attr) was_22\VBD\0|gain|:|with|than (r_conj) occurred_4\VBD\0|NONE (l_nsubj) gain_3\NN\13576355|was|:|with|than
D018967_D001480 CID risperidone_28\NN\0|NONE (r_pobj) with_27\IN\0|.|.|differ|) (r_prep) were_18\VBD\0|NONE (l_ccomp) differ_11\VB\0|.|with|.|) (l_prep) between_12\IN\0|did|not|outcomes (l_pobj) scores_17\NNS\13757724|NONE (l_compound) symptom_15\NN\5823932|severity|Extrapyramidal
C076029_D012559 NONE olanzapine_3\NN\0|NONE (l_prep) versus_4\IN\0|NONE (l_pobj) risperidone_5\NN\0|NONE (l_prep) for_6\IN\0|NONE (l_pobj) treatment_8\NN\654885|NONE (l_prep) of_9\IN\0|the (l_pobj) schizophrenia_13\NN\14398067|NONE
C076029_D012559 NONE olanzapine_9\NN\0|NONE (l_prep) versus_10\IN\0|NONE (l_pobj) risperidone_11\NN\0|NONE (l_prep) in_12\IN\13603305|NONE (l_pobj) patients_13\NNS\9898892|NONE (l_prep) with_14\IN\0|NONE (l_pobj) disorders_20\NNS\14034177|NONE (l_compound) schizophrenia_18\NN\14398067|episode|spectrum
C076029_D012559 NONE olanzapine_48\NN\0|NONE (r_pobj) with_47\IN\0|risperidone|)|(|day|or|to (r_prep) treatment_46\NN\654885|were|,|disorder|randomly (r_xcomp) assigned_44\VBN\2475922|)|with|years|subjects|. (r_conj) mean_9\JJ\6021761|NONE (l_prep) with_18\IN\0|)|assigned|years|subjects|. (l_pobj) schizophrenia_22\NN\14398067|NONE
C076029_D001480 CID olanzapine_39\NN\0|NONE (r_pobj) with_38\IN\0|and|%|CI=.|) (r_prep) risperidone_28\NN\0|NONE (r_pobj) with_27\IN\0|.|.|differ|) (r_prep) were_18\VBD\0|NONE (l_ccomp) differ_11\VB\0|.|with|.|) (l_prep) between_12\IN\0|did|not|outcomes (l_pobj) scores_17\NNS\13757724|NONE (l_compound) symptom_15\NN\5823932|severity|Extrapyramidal
D018967_D012559 NONE risperidone_5\NN\0|NONE (l_prep) for_6\IN\0|NONE (l_pobj) treatment_8\NN\654885|NONE (l_prep) of_9\IN\0|the (l_pobj) schizophrenia_13\NN\14398067|NONE
D018967_D012559 NONE risperidone_11\NN\0|NONE (l_prep) in_12\IN\13603305|NONE (l_pobj) patients_13\NNS\9898892|NONE (l_prep) with_14\IN\0|NONE (l_pobj) disorders_20\NNS\14034177|NONE (l_compound) schizophrenia_18\NN\14398067|episode|spectrum
D018967_D012559 NONE risperidone_58\NN\0|)|(|day|with|or|to (r_conj) treatment_46\NN\654885|were|,|disorder|randomly (r_xcomp) assigned_44\VBN\2475922|)|with|years|subjects|. (r_conj) mean_9\JJ\6021761|NONE (l_prep) with_18\IN\0|)|assigned|years|subjects|. (l_pobj) schizophrenia_22\NN\14398067|NONE
C076029_D015430 CID olanzapine_6\NN\0|NONE (r_pobj) with_5\IN\0|gain|was|:|than (r_prep) occurred_4\VBD\0|NONE (l_nsubj) gain_3\NN\13576355|was|:|with|than
C076029_D015430 CID olanzapine_32\NN\0|NONE (r_pobj) with_31\IN\0|.|%|( (r_prep) %_24\NN\0|increase|. (r_attr) was_22\VBD\0|gain|:|with|than (r_conj) occurred_4\VBD\0|NONE (l_nsubj) gain_3\NN\13576355|was|:|with|than
C076029_D015430 CID olanzapine_14\NN\0|NONE (r_pobj) with_13\IN\0|NONE (r_prep) greater_12\JJR\0|.|gain (r_acomp) was_11\VBD\0|medications|but|gain|, (r_conj) caused_2\VBD\1617192|NONE (l_dobj) gain_6\NN\13576355|medications|but|,|was
C076029_D015430 CID olanzapine_14\NN\0|NONE (r_pobj) with_13\IN\0|NONE (r_prep) greater_12\JJR\0|.|gain (r_acomp) was_11\VBD\0|medications|but|gain|, (l_nsubj) gain_10\NN\13576355|.|greater
C076029_D011618 NONE olanzapine_48\NN\0|NONE (r_pobj) with_47\IN\0|risperidone|)|(|day|or|to (r_prep) treatment_46\NN\654885|were|,|disorder|randomly (r_xcomp) assigned_44\VBN\2475922|)|with|years|subjects|. (l_nsubjpass) disorder_29\NN\14034177|were|treatment|,|randomly
C076029_D011618 NONE olanzapine_48\NN\0|NONE (r_pobj) with_47\IN\0|risperidone|)|(|day|or|to (r_prep) treatment_46\NN\654885|were|,|disorder|randomly (r_xcomp) assigned_44\VBN\2475922|)|with|years|subjects|. (l_nsubjpass) disorder_29\NN\14034177|were|treatment|,|randomly (l_conj) disorder_37\NN\14034177|%|schizophreniform|)|or|,|(
C076029_D017109 NONE olanzapine_39\NN\0|NONE (r_pobj) with_38\IN\0|and|%|CI=.|) (r_prep) risperidone_28\NN\0|NONE (r_pobj) with_27\IN\0|.|.|differ|) (r_prep) were_18\VBD\0|NONE (l_ccomp) differ_11\VB\0|.|with|.|) (l_nsubj) outcomes_2\NNS\7291312|did|not|between (l_conj) akathisia_8\NN\0|and|symptom|measures|Negative|and
C076029_D010302 NONE olanzapine_39\NN\0|NONE (r_pobj) with_38\IN\0|and|%|CI=.|) (r_prep) risperidone_28\NN\0|NONE (r_pobj) with_27\IN\0|.|.|differ|) (r_prep) were_18\VBD\0|NONE (l_ccomp) differ_11\VB\0|.|with|.|) (l_nsubj) outcomes_2\NNS\7291312|did|not|between (l_conj) measures_4\NNS\168237|and|akathisia|symptom|Negative|and (l_prep) of_5\IN\0|NONE (l_pobj) parkinsonism_6\NN\14085708|NONE
D018967_D017109 NONE risperidone_28\NN\0|NONE (r_pobj) with_27\IN\0|.|.|differ|) (r_prep) were_18\VBD\0|NONE (l_ccomp) differ_11\VB\0|.|with|.|) (l_nsubj) outcomes_2\NNS\7291312|did|not|between (l_conj) akathisia_8\NN\0|and|symptom|measures|Negative|and
D018967_D010302 NONE risperidone_28\NN\0|NONE (r_pobj) with_27\IN\0|.|.|differ|) (r_prep) were_18\VBD\0|NONE (l_ccomp) differ_11\VB\0|.|with|.|) (l_nsubj) outcomes_2\NNS\7291312|did|not|between (l_conj) measures_4\NNS\168237|and|akathisia|symptom|Negative|and (l_prep) of_5\IN\0|NONE (l_pobj) parkinsonism_6\NN\14085708|NONE
439781
D012964_D007022 NONE sodium_4\NN\14625458|NONE (r_npadvmod) depleted_7\VBN\2267060|NONE (r_amod) rats_8\NNS\2329401|hypotension|Indomethacin|. (r_dobj) induced_1\VBD\1627355|NONE (l_dobj) hypotension_2\NN\14057371|Indomethacin|.|rats
D007213_D007022 CID indomethacin_0\NNP\3828465|hypotension|.|rats (r_nsubj) induced_1\VBD\1627355|NONE (l_dobj) hypotension_2\NN\14057371|Indomethacin|.|rats
19419794
C005177_D004409 NONE dopa+benserazide_4\NNP\0|NONE (r_pobj) with_1\IN\0|) (r_prep) treatment_0\NN\654885|.|in (r_nsubj) resulted_9\VBD\2633881|NONE (l_prep) in_10\IN\13603305|Treatment|. (l_pobj) dyskinesias_13\NNS\14084880|NONE
D016627_D004409 NONE 6-hydroxydopamine_3\CD\0|and|development (r_compound) lesion_4\NN\14204950|NONE (l_conj) development_7\NN\248977|and|hydroxydopamine (l_prep) of_8\IN\0|reduced|in (l_pobj) dyskinesias_9\NNS\14084880|NONE
D007980_D004409 CID dopa_24\NNP\14601829||L| (r_compound) induced_26\VBN\1627355|NONE (r_amod) dyskinesias_27\NNS\14084880|NONE
D007980_D004409 CID dopa_19\NNP\14601829|L|| (r_compound) induced_21\VBN\1627355|NONE (r_amod) dyskinesias_22\NNS\14084880|NONE
D004298_D004409 NONE da_17\NNP\10484858|NONE (r_compound) lesion_18\NN\14204950|motor|and (r_conj) impairment_15\NN\7296428|NONE (r_pobj) of_13\IN\0|the (r_prep) severity_12\NN\5036394|,|reduced|and|that|lack (r_dobj) increased_10\VBD\169651|.|results (l_conj) reduced_21\VBN\441445|,|and|severity|that|lack (l_dobj) dyskinesias_27\NNS\14084880|NONE
23864035
C400082_D009101 NONE bortezomib_0\NNP\0|NONE (l_conj) dexamethasone_2\NN\2721538|.|and (l_prep) in_6\IN\13603305|as (l_pobj) patients_7\NNS\9898892|NONE (l_prep) with_8\IN\0|NONE (l_pobj) myeloma_13\NN\14239425|NONE
C400082_D009101 NONE bortezomib_0\NNP\0|.|therapy (r_nsubj) is_6\VBZ\0|NONE (l_attr) therapy_9\NN\657604|.|Bortezomib (l_prep) for_10\IN\0|an|effective (l_pobj) r_17\NNP\13635336|NONE (l_appos) myeloma_20\NN\14239425|relapsed|)|/|R|(|refractory|/
C400082_D009101 NONE bortezomib_0\NNP\0|.|therapy (r_nsubj) is_6\VBZ\0|NONE (l_attr) therapy_9\NN\657604|.|Bortezomib (l_prep) for_10\IN\0|an|effective (l_pobj) r_17\NNP\13635336|NONE (l_appos) myeloma_20\NN\14239425|relapsed|)|/|R|(|refractory|/ (l_appos) mm_22\NNP\13649268|)|multiple
C400082_D009101 NONE bort)-dexamethasone_2\NNP\0|(|(|) (r_nmod) dex_4\NN\0|NONE (r_appos) bortezomib_0\NNP\0|.|therapy (r_nsubj) is_6\VBZ\0|NONE (l_attr) therapy_9\NN\657604|.|Bortezomib (l_prep) for_10\IN\0|an|effective (l_pobj) r_17\NNP\13635336|NONE (l_appos) myeloma_20\NN\14239425|relapsed|)|/|R|(|refractory|/
C400082_D009101 NONE bort)-dexamethasone_2\NNP\0|(|(|) (r_nmod) dex_4\NN\0|NONE (r_appos) bortezomib_0\NNP\0|.|therapy (r_nsubj) is_6\VBZ\0|NONE (l_attr) therapy_9\NN\657604|.|Bortezomib (l_prep) for_10\IN\0|an|effective (l_pobj) r_17\NNP\13635336|NONE (l_appos) myeloma_20\NN\14239425|relapsed|)|/|R|(|refractory|/ (l_appos) mm_22\NNP\13649268|)|multiple
C400082_D009101 NONE bort_7\NN\0|NONE (r_pobj) of_6\IN\0|m(|)|the|on|( (r_prep) combination_5\NN\7951464|and|)|.|after|dex|study (r_dobj) investigated_3\VBD\644583|NONE (l_conj) dex_29\NN\0|combination|and|)|.|after|study (l_prep) as_43\IN\14622893|(|mg|)|day|and (l_pobj) treatment_45\NN\654885|NONE (l_prep) in_46\IN\13603305|salvage (l_pobj) patients_48\NNS\9898892|NONE (l_prep) with_49\IN\0| (l_pobj) mm_53\NNP\13649268|NONE
C400082_D009101 NONE bort_41\NN\0|NONE (r_pobj) after_40\IN\0|the (r_prep) day_39\NN\15154774|(|mg|)|and|as (r_conj) dex_29\NN\0|combination|and|)|.|after|study (l_prep) as_43\IN\14622893|(|mg|)|day|and (l_pobj) treatment_45\NN\654885|NONE (l_prep) in_46\IN\13603305|salvage (l_pobj) patients_48\NNS\9898892|NONE (l_prep) with_49\IN\0| (l_pobj) mm_53\NNP\13649268|NONE
C400082_D009101 NONE bort_0\NNP\0| (r_compound) dex_2\NN\0|.|treatment (r_nsubj) was_3\VBD\0|NONE (l_attr) treatment_7\NN\654885|dex|. (l_prep) for_8\IN\0|effective|an|for|salvage|, (l_pobj) patients_10\NNS\9898892|NONE (l_compound) mm_9\NNP\13649268|NONE
D003907_D009101 NONE dexamethasone_2\NN\2721538|.|and (l_prep) in_6\IN\13603305|as (l_pobj) patients_7\NNS\9898892|NONE (l_prep) with_8\IN\0|NONE (l_pobj) myeloma_13\NN\14239425|NONE
D003907_D009101 NONE bort)-dexamethasone_2\NNP\0|(|(|) (r_nmod) dex_4\NN\0|NONE (r_appos) bortezomib_0\NNP\0|.|therapy (r_nsubj) is_6\VBZ\0|NONE (l_attr) therapy_9\NN\657604|.|Bortezomib (l_prep) for_10\IN\0|an|effective (l_pobj) r_17\NNP\13635336|NONE (l_appos) myeloma_20\NN\14239425|relapsed|)|/|R|(|refractory|/
D003907_D009101 NONE bort)-dexamethasone_2\NNP\0|(|(|) (r_nmod) dex_4\NN\0|NONE (r_appos) bortezomib_0\NNP\0|.|therapy (r_nsubj) is_6\VBZ\0|NONE (l_attr) therapy_9\NN\657604|.|Bortezomib (l_prep) for_10\IN\0|an|effective (l_pobj) r_17\NNP\13635336|NONE (l_appos) myeloma_20\NN\14239425|relapsed|)|/|R|(|refractory|/ (l_appos) mm_22\NNP\13649268|)|multiple
D003907_D009101 NONE dex_4\NN\0|NONE (r_appos) bortezomib_0\NNP\0|.|therapy (r_nsubj) is_6\VBZ\0|NONE (l_attr) therapy_9\NN\657604|.|Bortezomib (l_prep) for_10\IN\0|an|effective (l_pobj) r_17\NNP\13635336|NONE (l_appos) myeloma_20\NN\14239425|relapsed|)|/|R|(|refractory|/
D003907_D009101 NONE dex_4\NN\0|NONE (r_appos) bortezomib_0\NNP\0|.|therapy (r_nsubj) is_6\VBZ\0|NONE (l_attr) therapy_9\NN\657604|.|Bortezomib (l_prep) for_10\IN\0|an|effective (l_pobj) r_17\NNP\13635336|NONE (l_appos) myeloma_20\NN\14239425|relapsed|)|/|R|(|refractory|/ (l_appos) mm_22\NNP\13649268|)|multiple
D003907_D009101 NONE dex_29\NN\0|combination|and|)|.|after|study (l_prep) as_43\IN\14622893|(|mg|)|day|and (l_pobj) treatment_45\NN\654885|NONE (l_prep) in_46\IN\13603305|salvage (l_pobj) patients_48\NNS\9898892|NONE (l_prep) with_49\IN\0| (l_pobj) mm_53\NNP\13649268|NONE
D003907_D009101 NONE dex_2\NN\0|.|treatment (r_nsubj) was_3\VBD\0|NONE (l_attr) treatment_7\NN\654885|dex|. (l_prep) for_8\IN\0|effective|an|for|salvage|, (l_pobj) patients_10\NNS\9898892|NONE (l_compound) mm_9\NNP\13649268|NONE
7931490
D017829_D009325 NONE granisetron_4\NN\0|NONE (r_pobj) of_3\IN\0|and|in|antagonist|.|safety|,|, (r_prep) efficacy_0\NN\5199286|NONE (l_prep) in_12\IN\13603305|of|and|antagonist|.|safety|,|, (l_pobj) prevention_14\NN\1073995|NONE (l_prep) of_15\IN\0|vomiting|induced|the|and (l_pobj) nausea_16\NN\14299637|NONE
D017829_D009325 NONE granisetron_13\NN\0|NONE (r_pobj) of_12\IN\0|Kytril|;|Pharmaceuticals|four|)|(|different (r_prep) doses_11\NNS\3740161|NONE (r_pobj) of_8\IN\0|safety (r_prep) profile_7\NN\6999802|the|and|antiemetic (r_conj) effects_4\NNS\13245626|.|administered|To (r_dobj) assess_1\VB\5220461|NONE (l_advcl) administered_26\VBN\2436349|effects|.|To (l_dobj) dose_34\NN\3740161|when|as (l_prep) for_35\IN\0|NONE (l_pobj) prophylaxis_36\NN\1077350|NONE (l_prep) of_37\IN\0|NONE (l_pobj) nausea_41\NN\14299637|NONE
D017829_D009325 NONE kytril_15\NNP\0|;|Pharmaceuticals|of|four|)|(|different (r_appos) doses_11\NNS\3740161|NONE (r_pobj) of_8\IN\0|safety (r_prep) profile_7\NN\6999802|the|and|antiemetic (r_conj) effects_4\NNS\13245626|.|administered|To (r_dobj) assess_1\VB\5220461|NONE (l_advcl) administered_26\VBN\2436349|effects|.|To (l_dobj) dose_34\NN\3740161|when|as (l_prep) for_35\IN\0|NONE (l_pobj) prophylaxis_36\NN\1077350|NONE (l_prep) of_37\IN\0|NONE (l_pobj) nausea_41\NN\14299637|NONE
D002945_D009325 CID cisplatin_24\NN\0|NONE (r_pobj) by_20\IN\0|NONE (r_agent) induced_19\VBN\1627355|of|vomiting|the|and (r_acl) prevention_14\NN\1073995|NONE (l_prep) of_15\IN\0|vomiting|induced|the|and (l_pobj) nausea_16\NN\14299637|NONE
D002945_D009325 CID cisplatin_38\NN\0| (r_advmod) induced_40\VBN\1627355|and|vomiting (r_amod) nausea_41\NN\14299637|NONE
D012701_D014839 NONE 5-hydroxytryptamine-3_8\CD\0|a|receptor|selective (r_nummod) antagonist_10\NN\7846|of|and|in|.|safety|,|, (r_appos) efficacy_0\NN\5199286|NONE (l_prep) in_12\IN\13603305|of|and|antagonist|.|safety|,|, (l_pobj) prevention_14\NN\1073995|NONE (l_conj) vomiting_18\VBG\116687|of|induced|the|and
D017829_D014839 NONE granisetron_4\NN\0|NONE (r_pobj) of_3\IN\0|and|in|antagonist|.|safety|,|, (r_prep) efficacy_0\NN\5199286|NONE (l_prep) in_12\IN\13603305|of|and|antagonist|.|safety|,|, (l_pobj) prevention_14\NN\1073995|NONE (l_conj) vomiting_18\VBG\116687|of|induced|the|and
D017829_D014839 NONE granisetron_13\NN\0|NONE (r_pobj) of_12\IN\0|Kytril|;|Pharmaceuticals|four|)|(|different (r_prep) doses_11\NNS\3740161|NONE (r_pobj) of_8\IN\0|safety (r_prep) profile_7\NN\6999802|the|and|antiemetic (r_conj) effects_4\NNS\13245626|.|administered|To (r_dobj) assess_1\VB\5220461|NONE (l_advcl) administered_26\VBN\2436349|effects|.|To (l_dobj) dose_34\NN\3740161|when|as (l_prep) for_35\IN\0|NONE (l_pobj) prophylaxis_36\NN\1077350|NONE (l_prep) of_37\IN\0|NONE (l_pobj) nausea_41\NN\14299637|NONE (l_conj) vomiting_43\NN\116687|and|induced
D017829_D014839 NONE kytril_15\NNP\0|;|Pharmaceuticals|of|four|)|(|different (r_appos) doses_11\NNS\3740161|NONE (r_pobj) of_8\IN\0|safety (r_prep) profile_7\NN\6999802|the|and|antiemetic (r_conj) effects_4\NNS\13245626|.|administered|To (r_dobj) assess_1\VB\5220461|NONE (l_advcl) administered_26\VBN\2436349|effects|.|To (l_dobj) dose_34\NN\3740161|when|as (l_prep) for_35\IN\0|NONE (l_pobj) prophylaxis_36\NN\1077350|NONE (l_prep) of_37\IN\0|NONE (l_pobj) nausea_41\NN\14299637|NONE (l_conj) vomiting_43\NN\116687|and|induced
D017829_D014839 NONE granisetron_1\NN\0||of|, (r_compound) doses_2\NNS\3740161|NONE (l_appos) 10_6\CD\13745420|of|granisetron|, (l_conj) micrograms_12\NNS\13717155|,|and| (l_appos) response_18\NN\11410625||/|,|kg (l_acl) vomiting_24\NN\116687|a|rescue|major|,|(|and
D017829_D014839 NONE granisetron_1\NN\0||of|, (r_compound) doses_2\NNS\3740161|NONE (r_pobj) after_0\IN\0|and|was|response|in|. (r_prep) recorded_35\VBN\2225492|NONE (l_conj) response_57\NN\11410625|and|was|After|in|. (l_appos) vomiting_60\NN\116687|a|)|(|complete|in
D017829_D014839 NONE granisetron_10\NN\0|NONE (r_pobj) of_9\IN\0|kg (r_prep) dose_8\NN\3740161|,|or (r_conj) 20-_2\CD\0|, (r_conj) 10-_0\LS\0|.|effective (r_nsubj) was_11\VBD\0|NONE (l_acomp) effective_12\JJ\0|.| (l_prep) in_13\IN\13603305|NONE (l_pcomp) controlling_14\VBG\0|NONE (l_dobj) vomiting_15\NN\116687|NONE
D017829_D014839 NONE granisetron_10\NN\0|NONE (r_pobj) of_9\IN\0|kg (r_prep) dose_8\NN\3740161|,|or (r_conj) 20-_2\CD\0|, (r_conj) 10-_0\LS\0|.|effective (r_nsubj) was_11\VBD\0|NONE (l_acomp) effective_12\JJ\0|.| (l_prep) in_13\IN\13603305|NONE (l_pcomp) controlling_14\VBG\0|NONE (l_dobj) vomiting_15\NN\116687|NONE (l_prep) in_16\IN\13603305|NONE (l_pobj) %_21\NN\0|NONE (l_prep) of_22\IN\0| (l_pobj) patients_23\NNS\9898892|NONE (l_relcl) received_25\VBD\2210855|NONE (l_conj) prevented_37\VBN\0|who|cisplatin|at|and (l_dobj) vomiting_38\VBG\116687|to|totally
D002945_D014839 CID cisplatin_24\NN\0|NONE (r_pobj) by_20\IN\0|NONE (r_agent) induced_19\VBN\1627355|of|vomiting|the|and (r_acl) prevention_14\NN\1073995|NONE (l_conj) vomiting_18\VBG\116687|of|induced|the|and
D002945_D014839 CID cisplatin_38\NN\0| (r_advmod) induced_40\VBN\1627355|and|vomiting (r_amod) nausea_41\NN\14299637|NONE (l_conj) vomiting_43\NN\116687|and|induced
D002945_D014839 CID cisplatin_26\NN\0|prevented|who|at|and (r_dobj) received_25\VBD\2210855|NONE (r_relcl) patients_23\NNS\9898892|NONE (r_pobj) of_22\IN\0| (r_prep) %_21\NN\0|NONE (r_pobj) in_16\IN\13603305|NONE (r_prep) vomiting_15\NN\116687|NONE
D002945_D014839 CID cisplatin_26\NN\0|prevented|who|at|and (r_dobj) received_25\VBD\2210855|NONE (l_conj) prevented_37\VBN\0|who|cisplatin|at|and (l_dobj) vomiting_38\VBG\116687|to|totally
D012701_D009325 NONE 5-hydroxytryptamine-3_8\CD\0|a|receptor|selective (r_nummod) antagonist_10\NN\7846|of|and|in|.|safety|,|, (r_appos) efficacy_0\NN\5199286|NONE (l_prep) in_12\IN\13603305|of|and|antagonist|.|safety|,|, (l_pobj) prevention_14\NN\1073995|NONE (l_prep) of_15\IN\0|vomiting|induced|the|and (l_pobj) nausea_16\NN\14299637|NONE
931801
D000617_D003681 NONE aminoglycoside_11\NN\0|NONE (r_compound) antibiotics_12\NNS\2716205|NONE (r_pobj) of_10\IN\0|combined|single (r_prep) injection_9\NN\320852|NONE (r_pobj) following_7\VBG\8180190|acute|renal (r_acl) failure_6\NN\66216|.|regularly|rats (r_dobj) develop_3\VBP\1753788|NONE (l_nsubj) rats_1\NNS\2329401|failure|.|regularly (l_amod) dehydrated_0\JJ\212414|NONE
D009005_D007674 NONE monosaccharides_12\NNS\14792703|NONE (r_pobj) by_11\IN\0|when|from|were|they (r_agent) spared_7\VBN\2725714|urine|.|Rats (l_prep) from_8\IN\0|when|were|by|they (l_pobj) lesions_10\NNS\14204950|NONE
D007612_D051437 NONE kanamycin_21\NN\2716866| (r_compound) dextran_23\NN\0|NONE (r_pobj) by_20\IN\0|NONE (r_agent) induced_19\VBN\1627355|renal (r_acl) failure_18\NN\66216|NONE
D000617_D007674 NONE aminoglycoside_16\NN\0|peptide|as (r_conj) antibiotics_11\NNS\2716205|NONE (r_pobj) by_9\IN\0|NONE (r_agent) induced_8\VBN\1627355|renal (r_acl) damage_7\NN\7296428|NONE
C038936_D051437 NONE 6,3-dilactone_13\CD\0||acetyl|| (r_appos) d_9\NNP\15089472|O|against|protected (r_nmod) rats_15\NNS\2329401|NONE (l_prep) against_16\IN\0|O|D|protected (l_pobj) failure_18\NN\66216|NONE
D005937_D007674 NONE glucarates_4\NNP\0|NONE (r_pobj) of_1\IN\0|on|. (r_prep) effect_0\NN\34213|NONE (l_prep) on_5\IN\0|of|. (l_pobj) damage_11\NN\7296428|NONE
D005937_D007674 NONE glucarates_2\NNP\0|.|effective|antibitocis (r_nsubj) were_3\VBD\0|NONE (l_acomp) effective_4\JJ\0|Glucarates|.|antibitocis (l_prep) against_5\IN\0|NONE (l_pobj) damage_7\NN\7296428|NONE
D005937_D007674 NONE glucarate_4\NN\0|NONE (r_pobj) with_0\IN\0|.|,|against|degree|was (r_prep) obtained_19\VBN\2210855|NONE (l_prep) against_20\IN\0|With|.|,|degree|was (l_pobj) damages_22\NNS\13282550|NONE
D005937_D007674 NONE glucarates_2\NNP\0|ability|but|cure|. (r_nsubj) had_3\VBD\0|NONE (l_dobj) ability_5\NN\4723816|Glucarates|but|cure|. (l_acl) prevent_7\VB\0|the (l_dobj) damage_9\NN\7296428|to
D005937_D007674 NONE glucarates_6\NNS\0|NONE (l_prep) against_7\IN\0||D (l_pobj) nephrotoxicity_8\NN\0|NONE
D000617_D058186 CID aminoglycoside_11\NN\0|NONE (r_compound) antibiotics_12\NNS\2716205|NONE (r_pobj) of_10\IN\0|combined|single (r_prep) injection_9\NN\320852|NONE (r_pobj) following_7\VBG\8180190|acute|renal (r_acl) failure_6\NN\66216|.|regularly|rats
7967231
D002118_D020195 NONE calcium_11\NN\14625458|type (r_compound) channel_12\NN\6251781|NONE (r_compound) antagonists_13\NNS\7846|not|,|, (r_conj) s-312-l_6\NNP\0|S|,|but (r_conj) s-312-d_2\NNP\0|effects|and|were|; (r_nsubj) showed_15\VBD\2137132|NONE (l_dobj) effects_17\NNS\13245626|and|were|Sd|; (l_prep) on_18\IN\0|anticonvulsant (l_pobj) convulsions_22\NNS\14081375|NONE
D010852_D012640 CID picrotoxin_49\NN\0|D|,|methyl| (r_conj) aspartate_47\NNP\0|NONE (r_pobj) by_40\IN\0|in (r_agent) induced_39\VBN\1627355|NONE (r_acl) convulsions_38\NNS\14081375|NONE (r_pobj) in_37\IN\13603305|effects|mice|were|,|:|.|observed (r_prep) observed_36\VBN\2163746|NONE (l_advcl) observed_10\VBN\2163746|effects|mice|were|,|:|.|in (l_prep) against_11\IN\0|were|effects|Although (l_pobj) convulsions_14\NNS\14081375|NONE
D010852_D012640 CID picrotoxin_49\NN\0|D|,|methyl| (r_conj) aspartate_47\NNP\0|NONE (r_pobj) by_40\IN\0|in (r_agent) induced_39\VBN\1627355|NONE (r_acl) convulsions_38\NNS\14081375|NONE
C059447_D004827 NONE s-312-d_0\NN\0|may|.|in|useful (r_nsubj) be_2\VB\14625458|NONE (l_prep) in_4\IN\13603305|Sd|may|.|useful (l_pobj) therapy_6\NN\657604|NONE (l_prep) of_7\IN\0|the (l_pobj) types_9\NNS\5839024|NONE (l_prep) of_10\IN\0|certain (l_pobj) epilepsy_12\NN\14085708|NONE
-1_D020195 NONE s-312-l_6\NNP\0|S|,|but (r_conj) s-312-d_2\NNP\0|effects|and|were|; (r_nsubj) showed_15\VBD\2137132|NONE (l_dobj) effects_17\NNS\13245626|and|were|Sd|; (l_prep) on_18\IN\0|anticonvulsant (l_pobj) convulsions_22\NNS\14081375|NONE
D001534_D012640 CID bemegride_25\NN\0|mg/kg|or|)|( (r_conj) pentylenetetrazole_17\NN\0|NONE (r_pobj) by_16\IN\0|NONE (r_agent) induced_15\VBN\1627355|the|clonic (r_acl) convulsions_14\NNS\14081375|NONE
D001534_D012640 CID bemegride_25\NN\0|mg/kg|or|)|( (r_conj) pentylenetetrazole_17\NN\0|NONE (r_pobj) by_16\IN\0|NONE (r_agent) induced_15\VBN\1627355|the|clonic (r_acl) convulsions_14\NNS\14081375|NONE (r_pobj) against_11\IN\0|were|effects|Although (r_prep) observed_10\VBN\2163746|effects|mice|were|,|:|.|in (r_advcl) observed_36\VBN\2163746|NONE (l_prep) in_37\IN\13603305|effects|mice|were|,|:|.|observed (l_pobj) convulsions_38\NNS\14081375|NONE
C059447_D012640 NONE s-312-d_5\NN\0|NONE (r_pobj) of_4\IN\0|anticonvulsant|moderate (r_prep) effects_3\NNS\13245626|were|Although|against (r_nsubjpass) observed_10\VBN\2163746|effects|mice|were|,|:|.|in (l_prep) against_11\IN\0|were|effects|Although (l_pobj) convulsions_14\NNS\14081375|NONE
C059447_D012640 NONE s-312-d_5\NN\0|NONE (r_pobj) of_4\IN\0|anticonvulsant|moderate (r_prep) effects_3\NNS\13245626|were|Although|against (r_nsubjpass) observed_10\VBN\2163746|effects|mice|were|,|:|.|in (r_advcl) observed_36\VBN\2163746|NONE (l_prep) in_37\IN\13603305|effects|mice|were|,|:|.|observed (l_pobj) convulsions_38\NNS\14081375|NONE
D005444_D020195 NONE flunarizine_57\NN\0|NONE (r_pobj) of_56\IN\0|NONE (r_prep) that_55\DT\0|.|while (r_nsubj) was_58\VBD\0|mg/kg|p.o.|,|.|values (r_advcl) were_31\VBD\0|effects|and|Sd|; (r_conj) showed_15\VBD\2137132|NONE (l_dobj) effects_17\NNS\13245626|and|were|Sd|; (l_prep) on_18\IN\0|anticonvulsant (l_pobj) convulsions_22\NNS\14081375|NONE
C059447_D020195 NONE s-312_0\NNP\0|,|Sl|but (r_punct) s-312-d_2\NNP\0|effects|and|were|; (r_nsubj) showed_15\VBD\2137132|NONE (l_dobj) effects_17\NNS\13245626|and|were|Sd|; (l_prep) on_18\IN\0|anticonvulsant (l_pobj) convulsions_22\NNS\14081375|NONE
C059447_D020195 NONE s-312-d_2\NNP\0|effects|and|were|; (r_nsubj) showed_15\VBD\2137132|NONE (l_dobj) effects_17\NNS\13245626|and|were|Sd|; (l_prep) on_18\IN\0|anticonvulsant (l_pobj) convulsions_22\NNS\14081375|NONE
D010433_D012640 CID pentylenetetrazole_17\NN\0|NONE (r_pobj) by_16\IN\0|NONE (r_agent) induced_15\VBN\1627355|the|clonic (r_acl) convulsions_14\NNS\14081375|NONE
D010433_D012640 CID pentylenetetrazole_17\NN\0|NONE (r_pobj) by_16\IN\0|NONE (r_agent) induced_15\VBN\1627355|the|clonic (r_acl) convulsions_14\NNS\14081375|NONE (r_pobj) against_11\IN\0|were|effects|Although (r_prep) observed_10\VBN\2163746|effects|mice|were|,|:|.|in (r_advcl) observed_36\VBN\2163746|NONE (l_prep) in_37\IN\13603305|effects|mice|were|,|:|.|observed (l_pobj) convulsions_38\NNS\14081375|NONE
D016202_D012640 NONE aspartate_47\NNP\0|NONE (r_pobj) by_40\IN\0|in (r_agent) induced_39\VBN\1627355|NONE (r_acl) convulsions_38\NNS\14081375|NONE (r_pobj) in_37\IN\13603305|effects|mice|were|,|:|.|observed (r_prep) observed_36\VBN\2163746|NONE (l_advcl) observed_10\VBN\2163746|effects|mice|were|,|:|.|in (l_prep) against_11\IN\0|were|effects|Although (l_pobj) convulsions_14\NNS\14081375|NONE
D016202_D012640 NONE aspartate_47\NNP\0|NONE (r_pobj) by_40\IN\0|in (r_agent) induced_39\VBN\1627355|NONE (r_acl) convulsions_38\NNS\14081375|NONE
17828434
D008094_D012640 NONE lithium_15\NN\14625458|NONE (r_pobj) of_14\IN\0|the|in (r_prep) effects_13\NNS\13245626|NONE (l_prep) in_16\IN\13603305|of|the (l_pobj) model_24\NN\5888929|NONE (l_compound) seizures_23\NNS\14081375|sensitive|the
D007294_D012640 NONE inositol_18\JJ\15090742|NONE (r_npadvmod) sensitive_19\JJ\10488309|seizures|the (r_amod) model_24\NN\5888929|NONE (l_compound) seizures_23\NNS\14081375|sensitive|the
C002647_D012640 NONE mip_4\NNP\0|synthase (r_compound) inhibition_6\NN\1068773|not|that|does|or|augment (r_nsubj) replicate_9\VB\2035919|.|study (l_conj) augment_11\VB\153263|not|that|does|or|inhibition (l_dobj) effects_13\NNS\13245626|NONE (l_prep) in_16\IN\13603305|of|the (l_pobj) model_24\NN\5888929|NONE (l_compound) seizures_23\NNS\14081375|sensitive|the
D010862_D012640 CID pilocarpine_20\NN\14712692| (r_npadvmod) induced_22\VBN\1627355|NONE (r_amod) seizures_23\NNS\14081375|sensitive|the
20859899
D000450_D006947 NONE aldosterone_14\NN\14751863|an (r_compound) antagonist_15\NN\7846|, (r_appos) spiranolactone_11\NN\0|NONE (r_pobj) of_10\IN\0|several (r_prep) doses_9\NNS\3740161|,|to|in (r_attr) be_7\VB\14625458|.|cause|was (r_xcomp) considered_5\VBN\689344|NONE (l_nsubjpass) cause_1\NN\7323922|.|be|was (l_prep) of_2\IN\0|The (l_pobj) hyperkalemia_3\NN\14299637|NONE
D011188_D007674 NONE potassium_21\NN\14625458|sparing (r_compound) agents_23\NNS\7347|NONE (r_pobj) with_20\IN\0|NONE (r_prep) combination_19\NN\7951464|NONE (r_pobj) in_18\IN\13603305|ARB (r_prep) using_14\VBG\418025|elderly (r_acl) patients_13\NNS\9898892|especially|have|and (r_pobj) in_11\IN\13603305|Clinicians|.|alert|should|, (l_conj) have_26\VBP\7846|patients|especially|and (l_dobj) disturbance_29\NN\407535|who
D000809_D013575 NONE angiotensin_12\NN\4522421| (r_npadvmod) converting_14\VBG\126264|enzyme|the|spironolactone|and (r_amod) inhibitor_16\NN\20090|NONE (r_pobj) with_10\IN\0|a|combined (r_prep) therapy_9\NN\657604|NONE (r_pobj) of_6\IN\0|NONE (r_prep) use_5\NN\407535|NONE (r_pobj) during_4\IN\0|by (r_prep) caused_1\VBD\1617192|. (r_acl) syncope_0\NNP\7478169|NONE
D011188_D006947 NONE potassium_21\NN\14625458|sparing (r_compound) agents_23\NNS\7347|NONE (r_pobj) with_20\IN\0|NONE (r_prep) combination_19\NN\7951464|NONE (r_pobj) in_18\IN\13603305|ARB (r_prep) using_14\VBG\418025|elderly (r_acl) patients_13\NNS\9898892|especially|have|and (r_pobj) in_11\IN\13603305|Clinicians|.|alert|should|, (r_prep) be_2\VB\14625458|NONE (l_acomp) alert_3\JJ\14031108|Clinicians|.|in|should|, (l_prep) to_4\IN\0|NONE (l_pobj) possibility_6\NN\5944958|NONE (l_prep) of_7\IN\0|the (l_pobj) hyperkalemia_8\NN\14299637|NONE
D013148_D006947 CID spironolactone_18\NN\2721160|converting|enzyme|the|and (r_conj) inhibitor_16\NN\20090|NONE (r_pobj) with_10\IN\0|a|combined (r_prep) therapy_9\NN\657604|NONE (r_pobj) of_6\IN\0|NONE (r_prep) use_5\NN\407535|NONE (r_pobj) during_4\IN\0|by (r_prep) caused_1\VBD\1617192|. (l_agent) by_2\IN\0|during (l_pobj) hyperkalemia_3\NN\14299637|NONE
D013148_D006947 CID spiranolactone_11\NN\0|NONE (r_pobj) of_10\IN\0|several (r_prep) doses_9\NNS\3740161|,|to|in (r_attr) be_7\VB\14625458|.|cause|was (r_xcomp) considered_5\VBN\689344|NONE (l_nsubjpass) cause_1\NN\7323922|.|be|was (l_prep) of_2\IN\0|The (l_pobj) hyperkalemia_3\NN\14299637|NONE
D013148_D013575 NONE spironolactone_18\NN\2721160|converting|enzyme|the|and (r_conj) inhibitor_16\NN\20090|NONE (r_pobj) with_10\IN\0|a|combined (r_prep) therapy_9\NN\657604|NONE (r_pobj) of_6\IN\0|NONE (r_prep) use_5\NN\407535|NONE (r_pobj) during_4\IN\0|by (r_prep) caused_1\VBD\1617192|. (r_acl) syncope_0\NNP\7478169|NONE
D017257_D006947 CID ramipril_26\NN\2673637|NONE (r_pobj) of_25\IN\0|,|term|inhibitor|the (r_prep) intake_24\NN\13440063|NONE (r_pobj) to_19\IN\0|NONE (r_prep) addition_18\NN\3081021|NONE (r_pobj) in_17\IN\13603305|,|to|doses (r_prep) be_7\VB\14625458|.|cause|was (r_xcomp) considered_5\VBN\689344|NONE (l_nsubjpass) cause_1\NN\7323922|.|be|was (l_prep) of_2\IN\0|The (l_pobj) hyperkalemia_3\NN\14299637|NONE
D000809_D006947 NONE angiotensin_12\NN\4522421| (r_npadvmod) converting_14\VBG\126264|enzyme|the|spironolactone|and (r_amod) inhibitor_16\NN\20090|NONE (r_pobj) with_10\IN\0|a|combined (r_prep) therapy_9\NN\657604|NONE (r_pobj) of_6\IN\0|NONE (r_prep) use_5\NN\407535|NONE (r_pobj) during_4\IN\0|by (r_prep) caused_1\VBD\1617192|. (l_agent) by_2\IN\0|during (l_pobj) hyperkalemia_3\NN\14299637|NONE
26115410
D001152_D009369 CID ias_14\NNP\0|to|in|, (r_compound) exposure_15\NN\5042871|that (l_prep) in_25\IN\13603305|to|iAs|, (l_pobj) relationship_26\NN\31921|particularly (l_prep) to_27\IN\0|NONE (l_pobj) cancer_28\NN\14239425|NONE
D001152_D009369 CID ias_25\NNP\0|NONE (r_compound) exposure_26\NN\5042871|NONE (r_pobj) with_21\IN\0|is|that (r_prep) associated_20\VBN\628491|of|the|increased|in (r_relcl) risk_12\NN\14541044|that (l_prep) of_13\IN\0|associated|the|increased|in (l_pobj) development_15\NN\248977|NONE (l_compound) cancer_14\NN\14239425|NONE
D001152_D009369 CID ias_28\NNP\0|NONE (r_compound) exposure_29\NN\5042871|by|effects (r_nsubj) elicits_30\VBZ\1617192|underlying|plausible (r_relcl) mechanisms_22\NNS\13446390|,|reprogramming|development|. (r_attr) are_19\VBP\13600404|NONE (l_nsubj) development_11\NN\248977|,|reprogramming|mechanisms|. (l_prep) of_12\IN\0|and|immunomodulation|the|, (l_pobj) cells_15\NNS\3080309|NONE (l_compound) cancer_13\NN\14239425|stem
D001152_D009369 CID ias_8\NNP\0|and|development (r_compound) exposure_9\NN\5042871|later|that (l_conj) development_12\NN\248977|iAs|and (l_compound) cancer_11\NN\14239425|NONE
1359137
D014150_D000568 CID neuroleptic_12\NN\4470232| (r_npadvmod) associated_14\VBN\628491|and|galactorrhea (r_amod) hyperprolactinemia_15\NN\0|NONE (l_conj) galactorrhea_19\NN\0|and|associated (l_nmod) amenorrhea_17\NN\14299637|/
D001971_D005687 NONE bromocriptine_3\NN\0|should|be|as|that|further (r_nsubjpass) evaluated_7\VBN\670261|.|This (l_prep) as_8\IN\14622893|should|be|that|bromocriptine|further (l_pobj) therapy_10\NN\657604|NONE (l_prep) for_11\IN\0|potential (l_pobj) hyperprolactinemia_15\NN\0|NONE (l_conj) galactorrhea_19\NN\0|and|associated
D014150_D006966 CID neuroleptic_0\RB\4470232| (r_npadvmod) associated_2\VBN\628491|. (r_amod) hyperprolactinemia_3\NN\0|NONE
D014150_D006966 CID neuroleptic_12\NN\4470232| (r_npadvmod) associated_14\VBN\628491|and|galactorrhea (r_amod) hyperprolactinemia_15\NN\0|NONE
D001971_D009839 NONE bromocriptine_9\NN\0|NONE (r_pobj) with_8\IN\0|were (r_prep) treated_7\VBN\2376958|oligomenorrhea|.|with (r_advcl) associated_1\VBN\628491|NONE (l_nsubj) oligomenorrhea_0\NN\13513747|treated|.|with
D014150_D005687 NONE neuroleptic_12\NN\4470232| (r_npadvmod) associated_14\VBN\628491|and|galactorrhea (r_amod) hyperprolactinemia_15\NN\0|NONE (l_conj) galactorrhea_19\NN\0|and|associated
D014150_D009839 CID medications_5\NNS\3247620|NONE (r_pobj) with_2\IN\0|oligomenorrhea|treated|. (r_prep) associated_1\VBN\628491|NONE (l_nsubj) oligomenorrhea_0\NN\13513747|treated|.|with
D001971_D000568 NONE bromocriptine_3\NN\0|should|be|as|that|further (r_nsubjpass) evaluated_7\VBN\670261|.|This (l_prep) as_8\IN\14622893|should|be|that|bromocriptine|further (l_pobj) therapy_10\NN\657604|NONE (l_prep) for_11\IN\0|potential (l_pobj) hyperprolactinemia_15\NN\0|NONE (l_conj) galactorrhea_19\NN\0|and|associated (l_nmod) amenorrhea_17\NN\14299637|/
D001971_D011618 CID bromocriptine_11\NN\0|while (r_dobj) taking_10\VBG\37396|,|discontinued|woman|however|,|and|symptoms|, (r_advcl) developed_5\VBN\1753788|NONE (l_dobj) symptoms_8\NNS\5823932|,|discontinued|woman|however|,|and|taking|,
D001971_D006966 NONE bromocriptine_3\NN\0|should|be|as|that|further (r_nsubjpass) evaluated_7\VBN\670261|.|This (l_prep) as_8\IN\14622893|should|be|that|bromocriptine|further (l_pobj) therapy_10\NN\657604|NONE (l_prep) for_11\IN\0|potential (l_pobj) hyperprolactinemia_15\NN\0|NONE
24067251
C418563_D007674 NONE fumarate_17\NN\0|NONE (r_pobj) to_14\IN\0|NONE (r_prep) exposed_13\VBN\2110927|positive (r_acl) persons_12\NNS\7347|NONE (r_pobj) in_8\IN\13603305|kidney (r_prep) injury_7\NN\14052046|NONE
C418563_D007674 NONE tdf_12\NNP\0| (r_npadvmod) related_14\VBN\628491|)|kidney|,|% (r_amod) disease_16\NN\14061805|NONE
C418563_D007674 NONE tdf_12\NNP\0| (r_npadvmod) related_14\VBN\628491|)|kidney|,|% (r_amod) disease_16\NN\14061805|NONE (r_pobj) for_11\IN\0|satisfied|,| (r_prep) criteria_10\NNS\13577171|NONE (r_dobj) analysed_6\VBN\0|Card||the (r_acl) records_5\NNS\6643408|NONE (r_pobj) of_0\IN\0|found|had|.|features (r_prep) had_25\VBD\0|NONE (l_dobj) features_26\NNS\5849040|found|had|.|Of (l_prep) of_27\IN\0|%|)|(||, (l_pobj) dysfunction_30\NN\14204950|NONE
C418563_D007674 NONE tdf_12\NNP\0| (r_npadvmod) related_14\VBN\628491|)|kidney|,|% (r_amod) disease_16\NN\14061805|NONE (r_pobj) for_11\IN\0|satisfied|,| (r_prep) criteria_10\NNS\13577171|NONE (r_dobj) analysed_6\VBN\0|Card||the (r_acl) records_5\NNS\6643408|NONE (r_pobj) of_0\IN\0|found|had|.|features (r_prep) had_25\VBD\0|NONE (l_conj) found_38\VBN\13279262|had|.|Of|features (l_advcl) have_40\VB\7846|were (l_dobj) features_41\NNS\5849040|to (l_prep) of_42\IN\0|%|and (l_pobj) dysfunction_44\NN\14204950|NONE
C418563_D005198 CID tdf_12\NNP\0| (r_npadvmod) related_14\VBN\628491|)|kidney|,|% (r_amod) disease_16\NN\14061805|NONE (r_pobj) for_11\IN\0|satisfied|,| (r_prep) criteria_10\NNS\13577171|NONE (r_dobj) analysed_6\VBN\0|Card||the (r_acl) records_5\NNS\6643408|NONE (r_pobj) of_0\IN\0|found|had|.|features (r_prep) had_25\VBD\0|NONE (l_conj) had_51\VBD\0|found|.|Of|features (l_dobj) syndrome_53\NN\5870365|NONE
C418563_D005198 CID tdf_5\NNP\0|adverse|kidney (r_compound) effects_8\NNS\13245626|NONE (r_pobj) for_4\IN\0|NONE (r_prep) hospitalisation_3\NN\657604|NONE (r_pobj) of_2\IN\0|The (r_prep) incidence_1\NN\13821570|high|,|amongst|. (r_nsubj) was_9\VBD\0|NONE (l_prep) amongst_13\IN\0|high|,|incidence|. (l_pobj) patients_14\NNS\9898892|particularly (l_prep) with_15\IN\0|NONE (l_pobj) features_16\NNS\5849040|NONE (l_prep) of_17\IN\0|NONE (l_pobj) syndrome_19\NN\5870365|NONE
8659767
D002045_D009203 NONE bupivacaine_4\NN\0|dysrhythmogenicity|whether|in (r_nsubj) alters_5\VBZ\0|We|.|therefore (l_prep) in_13\IN\13603305|dysrhythmogenicity|whether|bupivacaine (l_conj) in_19\IN\13603305|and|dogs (l_pobj) dogs_21\NNS\2083346|NONE (l_prep) with_22\IN\0|anesthetized (l_pobj) infarction_24\NN\14204950|NONE
D002045_D017180 NONE bupivacaine_0\NNP\0|dysrhythmogenicity|. (r_nsubj) antagonizes_1\VBZ\1787955|NONE (l_dobj) dysrhythmogenicity_3\NN\0|Bupivacaine|. (l_prep) in_4\IN\13603305|epinephrine (l_pobj) dogs_6\NNS\2083346|in|and (l_amod) susceptible_7\JJ\0|conscious (l_prep) to_8\IN\0|NONE (l_pobj) vt_9\NNP\0|NONE
D002045_D001145 NONE bupivacaine_1\NN\0|NONE (r_pobj) since_0\IN\0|could|dysrhythmias|.|effects (r_prep) potentiate_15\VB\229605|NONE (l_nsubj) dysrhythmias_7\NNS\0|could|.|Since|effects
D002045_D001145 NONE bupivacaine_10\NN\0|both|may|,|precipitate (r_appos) dysrhythmias_7\NNS\0|could|.|Since|effects
D002045_D001145 NONE bupivacaine_0\NNP\0|dysrhythmogenicity|. (r_nsubj) antagonizes_1\VBZ\1787955|NONE (l_dobj) dysrhythmogenicity_3\NN\0|Bupivacaine|. (l_prep) in_4\IN\13603305|epinephrine (l_conj) in_11\IN\13603305|dogs|and (l_pobj) dogs_13\NNS\2083346|NONE (l_prep) with_14\IN\0|anesthetized (l_pobj) dysrhythmias_17\NNS\0|NONE
D004837_D001145 NONE epinephrine_3\NN\14807929|and (r_conj) bupivacaine_1\NN\0|NONE (r_pobj) since_0\IN\0|could|dysrhythmias|.|effects (r_prep) potentiate_15\VB\229605|NONE (l_nsubj) dysrhythmias_7\NNS\0|could|.|Since|effects
D004837_D001145 NONE epinephrine_19\NN\14807929|NONE (r_pobj) of_18\IN\0|dysrhythmogenic (r_prep) effects_17\NNS\13245626|could|dysrhythmias|.|Since (r_dobj) potentiate_15\VB\229605|NONE (l_nsubj) dysrhythmias_7\NNS\0|could|.|Since|effects
D004837_D001145 NONE epinephrine_2\NN\14807929|in (r_amod) dysrhythmogenicity_3\NN\0|Bupivacaine|. (l_prep) in_4\IN\13603305|epinephrine (l_conj) in_11\IN\13603305|dogs|and (l_pobj) dogs_13\NNS\2083346|NONE (l_prep) with_14\IN\0|anesthetized (l_pobj) dysrhythmias_17\NNS\0|NONE
D006221_D017180 NONE halothane_9\NN\3570838| (r_npadvmod) anesthetized_11\VBN\84738|additional|six (r_amod) dogs_12\NNS\2083346|.|appeared|after|,|epinephrine (r_nsubj) received_13\VBD\2210855|NONE (l_advcl) appeared_19\VBD\2604760|.|dogs|after|,|epinephrine (l_nsubj) vt_18\NNP\0|until
D004837_D009203 NONE epinephrine_12\NN\14807929|NONE (r_pobj) of_11\IN\0|subsequent (r_prep) administration_10\NN\1133281|NONE (r_pobj) of_8\IN\0|the (r_prep) dysrhythmogenicity_7\NN\0|whether|bupivacaine|in (r_dobj) alters_5\VBZ\0|We|.|therefore (l_prep) in_13\IN\13603305|dysrhythmogenicity|whether|bupivacaine (l_conj) in_19\IN\13603305|and|dogs (l_pobj) dogs_21\NNS\2083346|NONE (l_prep) with_22\IN\0|anesthetized (l_pobj) infarction_24\NN\14204950|NONE
D004837_D009203 NONE epinephrine_16\NN\14807929|.|appeared|dogs|after|, (r_dobj) received_13\VBD\2210855|NONE (l_prep) after_2\IN\0|.|appeared|dogs|,|epinephrine (l_pobj) infarction_5\NN\14204950|day
D006221_D009203 NONE halothane_9\NN\3570838| (r_npadvmod) anesthetized_11\VBN\84738|additional|six (r_amod) dogs_12\NNS\2083346|.|appeared|after|,|epinephrine (r_nsubj) received_13\VBD\2210855|NONE (l_prep) after_2\IN\0|.|appeared|dogs|,|epinephrine (l_pobj) infarction_5\NN\14204950|day
D004837_D017180 CID epinephrine_16\NN\14807929|.|appeared|dogs|after|, (r_dobj) received_13\VBD\2210855|NONE (l_advcl) appeared_19\VBD\2604760|.|dogs|after|,|epinephrine (l_nsubj) vt_18\NNP\0|until
D004837_D017180 CID epinephrine_2\NN\14807929|in (r_amod) dysrhythmogenicity_3\NN\0|Bupivacaine|. (l_prep) in_4\IN\13603305|epinephrine (l_pobj) dogs_6\NNS\2083346|in|and (l_amod) susceptible_7\JJ\0|conscious (l_prep) to_8\IN\0|NONE (l_pobj) vt_9\NNP\0|NONE
12678199
D004077_D007008 NONE digoxin_19\JJ\15060131|NONE (r_compound) excess_20\NN\5119367|and (r_conj) hypokalemia_17\NN\14299637|NONE
D004077_D016171 NONE digoxin_19\JJ\15060131|NONE (r_compound) excess_20\NN\5119367|and (r_conj) hypokalemia_17\NN\14299637|NONE (r_pobj) including_16\VBG\0|multiple|exacerbating (r_prep) factors_15\NNS\7326557|NONE (r_pobj) of_12\IN\0|the (r_prep) context_11\NN\6284777|NONE (r_pobj) in_9\IN\13603305|case|.|Consistent (r_prep) occurred_8\VBD\0|NONE (l_nsubj) case_5\NN\7283608|.|in|Consistent (l_prep) of_6\IN\0|this (l_pobj) tdp_7\NNP\0|NONE
D000638_D016171 CID amiodarone_0\NN\2715941| (r_npadvmod) induced_2\VBN\1627355|NONE (r_amod) torsade_3\NN\0|de|.|presentation|:|during (r_nmod) pointes_5\FW\831651|NONE
D000638_D016171 CID amiodarone_23\NN\2715941|oral (r_compound) therapy_24\NN\657604|NONE (r_pobj) with_21\IN\0|NONE (r_prep) associated_20\VBN\628491|torsade|de|TdP|)|( (r_acl) pointes_16\FW\831651|NONE
D000638_D016171 CID amiodarone_23\NN\2715941|oral (r_compound) therapy_24\NN\657604|NONE (r_pobj) with_21\IN\0|NONE (r_prep) associated_20\VBN\628491|torsade|de|TdP|)|( (r_acl) pointes_16\FW\831651|NONE (l_appos) tdp_18\NN\0|torsade|associated|de|)|(
D000638_D016171 CID amiodarone_4\NN\2715941|NONE (r_compound) therapy_5\NN\657604|NONE (r_pobj) of_3\IN\0|the (r_prep) absence_2\NN\14449405|NONE (r_pobj) in_0\IN\13603305|did|,|TdP|irrigation|despite|not|. (r_prep) induce_13\VB\1627355|NONE (l_dobj) tdp_14\NN\0|did|In|,|irrigation|despite|not|.
D000638_C537153 NONE amiodarone_4\NN\2715941|NONE (r_compound) therapy_5\NN\657604|NONE (r_pobj) of_3\IN\0|the (r_prep) absence_2\NN\14449405|NONE (r_pobj) in_0\IN\13603305|did|,|TdP|irrigation|despite|not|. (r_prep) induce_13\VB\1627355|NONE (l_prep) despite_15\IN\7501545|did|In|,|TdP|irrigation|not|. (l_pobj) hypokalemia_16\NN\14299637|NONE (l_conj) hypomagnesemia_18\NN\0|and
D000638_D007008 NONE amiodarone_4\NN\2715941|NONE (r_compound) therapy_5\NN\657604|NONE (r_pobj) of_3\IN\0|the (r_prep) absence_2\NN\14449405|NONE (r_pobj) in_0\IN\13603305|did|,|TdP|irrigation|despite|not|. (r_prep) induce_13\VB\1627355|NONE (l_prep) despite_15\IN\7501545|did|In|,|TdP|irrigation|not|. (l_pobj) hypokalemia_16\NN\14299637|NONE
D000638_-1 NONE amiodarone_20\NN\2715941|NONE (r_compound) therapy_21\NN\657604|NONE (r_pobj) of_19\IN\0|the (r_prep) context_18\NN\6284777|NONE (r_pobj) in_16\IN\13603305|in|tone|that (r_prep) resulted_22\VBD\2633881|.|authors (l_prep) in_23\IN\13603305|tone|in|that (l_pobj) proarrhythmia_27\NN\0|NONE
D000638_-1 NONE amiodarone_24\NN\2715941| (r_npadvmod) induced_26\VBN\1627355|NONE (r_amod) proarrhythmia_27\NN\0|NONE
20828385
C401859_D009369 NONE temsirolimus_19\NN\0|NONE (r_compound) treatment_20\NN\654885|months (r_pobj) after_18\IN\0|,|regression|who (r_prep) had_13\VBD\0|refractory (l_dobj) regression_15\NN\14501726|,|after|who (l_compound) tumor_14\NN\14234074|NONE
C401859_D009369 NONE temsirolimus_7\NN\0|but|induce|through|that|proliferation|, (r_nsubj) inhibited_8\JJ\2510337|Comparison|. (l_dobj) proliferation_11\NN\13489037|but|temsirolimus|induce|through|that|, (l_compound) cell_10\NN\3080309|NONE (l_compound) tumor_9\NN\14234074|NONE
C401859_D009369 NONE temsirolimus_7\NN\0|but|induce|through|that|proliferation|, (r_nsubj) inhibited_8\JJ\2510337|Comparison|. (l_conj) induce_20\VB\1627355|but|temsirolimus|through|that|proliferation|, (l_dobj) change_22\NN\7283608|did|not (l_prep) in_23\IN\13603305|any (l_pobj) number_25\NN\5107765|NONE (l_prep) of_26\IN\0|the (l_pobj) cells_29\NNS\3080309|NONE (l_compound) tumor_28\NN\14234074|apoptotic
C401859_D009369 NONE temsirolimus_6\NNS\0|,|effect|Apart|. (r_nsubj) had_7\VBD\0|NONE (l_dobj) effect_10\NN\34213|,|Apart|.|temsirolimus (l_prep) with_11\IN\0|an|antiangiogenic (l_pobj) decrease_12\NN\7296428|and|of (l_prep) of_13\IN\0|NONE (l_pobj) density_16\NN\4941325|NONE (l_compound) tumor_14\NN\14234074|microvessel
C401859_D009369 NONE temsirolimus_2\NNS\0|Thus|,|.|through|burden (r_nsubj) reduced_3\VBN\441445|NONE (l_dobj) burden_5\NN\5832264|Thus|,|temsirolimus|.|through (l_compound) tumor_4\NN\14234074|NONE
C401859_D009369 NONE temsirolimus_4\NN\0|NONE (r_pobj) of_3\IN\0|dual|This|on (r_prep) effect_2\NN\34213|to|.|could (l_prep) on_5\IN\0|dual|of|This (l_pobj) tissue_7\NN\5220461|NONE (l_compound) tumor_6\NN\14234074|NONE
C401859_D020522 NONE temsirolimus_7\NN\0|NONE (r_pobj) of_6\IN\0|Cytostatic|angiogenic|in|. (r_prep) effects_5\NNS\13245626|NONE (l_prep) in_8\IN\13603305|Cytostatic|angiogenic|.|of (l_pobj) lymphoma_12\NN\14239918|NONE
C401859_D020522 NONE temsirolimus_16\NN\0|NONE (r_pobj) with_15\IN\0|NONE (r_prep) treated_14\VBN\2376958|However|been|rate|recently|in|.|,|has (r_advcl) reported_10\VBN\831651|NONE (l_prep) in_11\IN\13603305|However|been|rate|recently|.|,|treated|has (l_pobj) mcl_13\NN\0|NONE
C401859_D020522 NONE temsirolimus_19\NN\0|NONE (r_compound) treatment_20\NN\654885|months (r_pobj) after_18\IN\0|,|regression|who (r_prep) had_13\VBD\0|refractory (r_relcl) mcl_11\NNP\0|NONE
C401859_D020522 NONE temsirolimus_4\NN\0|NONE (r_pobj) of_3\IN\0|dual|This|on (r_prep) effect_2\NN\34213|to|.|could (r_nsubj) contribute_9\VB\126264|NONE (l_prep) to_10\IN\0|.|could|effect (l_pobj) efficiency_14\NN\13819207|NONE (l_prep) in_15\IN\13603305|its|reported|resistant (l_pobj) mcl_17\NN\0|NONE
C401859_D009336 CID temsirolimus_23\NN\0|month (r_compound) therapy_24\NN\657604|NONE (r_pobj) after_21\IN\0|areas|.|were|Moreover|,|, (r_prep) found_20\VBN\13279262|NONE (l_nsubjpass) areas_9\NNS\8630985|.|were|Moreover|after|,|, (l_amod) compatible_11\JJ\0|fibrotic|,|limited|numerous|,|patchy (l_prep) with_12\IN\0|NONE (l_pobj) repair_17\NN\248977|NONE (l_amod) necrotic_15\JJ\0|tissue
15696449
D003404_D058186 NONE creatinine_31\NN\0|the|serum (r_compound) level_32\NN\4916342|NONE (r_pobj) in_28\IN\13603305|is|minimum|of|a (r_prep) increase_16\NN\13576355|NONE (r_pobj) by_13\IN\0|insufficiency|was|melphalan|.|after (r_agent) defined_12\VBN\2604760|NONE (l_nsubjpass) insufficiency_2\NN\14462946|was|melphalan|.|by|after
D003404_D058186 NONE creatinine_31\NN\0|the|serum (r_compound) level_32\NN\4916342|NONE (r_pobj) in_28\IN\13603305|is|minimum|of|a (r_prep) increase_16\NN\13576355|NONE (r_pobj) by_13\IN\0|insufficiency|was|melphalan|.|after (r_agent) defined_12\VBN\2604760|NONE (l_nsubjpass) insufficiency_2\NN\14462946|was|melphalan|.|by|after (l_appos) ari_4\NNP\0|renal|(|Acute|)
D008558_C531616 NONE melphalan_7\NN\2722458|NONE (l_prep) in_8\IN\13603305|dose (l_pobj) patients_9\NNS\9898892|NONE (l_prep) with_10\IN\0|NONE (l_pobj) amyloidosis_13\NN\14061805|NONE
D008558_D058186 CID melphalan_7\NN\2722458|NONE (r_pobj) after_3\IN\0|.|Acute|renal (r_prep) insufficiency_2\NN\14462946|NONE
D008558_D058186 CID melphalan_12\NN\2722458|NONE (r_compound) conditioning_13\NN\5752544|immediately (r_pobj) after_11\IN\0|the|of (r_prep) development_5\NN\248977|have|.|authors (l_prep) of_6\IN\0|after|the (l_pobj) insufficiency_9\NN\14462946|NONE
D008558_D058186 CID melphalan_10\NN\2722458|insufficiency|was|.|by|after (r_nsubjpass) defined_12\VBN\2604760|NONE (l_nsubjpass) insufficiency_2\NN\14462946|was|melphalan|.|by|after
D008558_D058186 CID melphalan_10\NN\2722458|insufficiency|was|.|by|after (r_nsubjpass) defined_12\VBN\2604760|NONE (l_nsubjpass) insufficiency_2\NN\14462946|was|melphalan|.|by|after (l_appos) ari_4\NNP\0|renal|(|Acute|)
D008558_D058186 CID melphalan_18\NN\2722458|NONE (r_pobj) after_14\IN\0|,|Of|.|ARI|in (r_prep) developed_7\VBD\1753788|NONE (l_nsubj) ari_6\NNP\0|,|after|Of|.|in
D008558_D058186 CID melphalan_8\NN\2722458|P|often|dialysis|.|had|and|Patients|, (r_nsubj) underwent_9\VBD\109660|NONE (l_nsubj) patients_0\NNS\9898892|P|often|dialysis|.|melphalan|had|and|, (l_relcl) had_2\VBD\0|NONE (l_dobj) ari_3\NNP\0|who|after
D008558_D058186 CID melphalan_7\NN\2722458|.|strongly|timing (r_dobj) suggests_6\VBZ\1010118|NONE (l_nsubj) timing_1\NN\5044673|.|strongly|melphalan (l_prep) of_2\IN\0|The (l_pobj) injury_4\NN\14052046|NONE
D008558_D058186 CID melphalan_11\NN\2722458|NONE (r_pobj) by_10\IN\0|renal (r_prep) injury_9\NN\14052046|NONE
D008558_-1 NONE melphalan_11\NN\2722458|NONE (r_pobj) by_10\IN\0|renal (r_prep) injury_9\NN\14052046|NONE (r_pobj) for_7\IN\0|a (r_prep) prerequisite_6\NN\1129920|may|evidenced|injury|. (r_attr) be_4\VB\14625458|NONE (l_nsubj) injury_2\NN\14052046|prerequisite|may|evidenced|.
19139825
D019772_D005910 NONE topotecan_0\NNP\0|exhibits|option|. (r_nsubj) is_1\VBZ\0|NONE (l_advcl) exhibits_7\VBZ\6733939|option|.|Topotecan (l_dobj) inhibition_9\NN\1068773|as|it (l_prep) of_10\IN\0|growth (l_pobj) glioma_12\NN\14236743|NONE
D019772_D005909 NONE topotecan_0\JJ\0|NONE (l_prep) in_1\IN\13603305|. (l_pobj) combination_2\NN\7951464|NONE (l_prep) with_3\IN\0|NONE (l_pobj) radiotherapy_4\NN\661091|NONE (l_prep) in_5\IN\13603305|NONE (l_pobj) glioblastoma_7\NN\14236743|NONE
D019772_D005909 NONE topotecan_15\JJ\0|combination|study|. (l_prep) in_34\IN\13603305|m()/day (l_pobj) adults_36\NNS\7846|NONE (l_prep) with_37\IN\0| (l_pobj) gbm_42\NNP\0|NONE
3383127
D002945_D015179 NONE cisplatin_18\NN\0|CDDP (r_pobj) with_17\IN\0|while|being (r_prep) treated_16\VBN\2376958|.|symptoms|in|FU (r_advcl) developed_6\VBN\1753788|NONE (l_prep) in_7\IN\13603305|treated|.|symptoms|FU (l_pobj) patients_9\NNS\9898892|NONE (l_prep) with_10\IN\0|three (l_pobj) carcinoma_13\NN\14239918|NONE
D002945_D015179 NONE cddp_20\NNP\0|cisplatin (r_pobj) with_17\IN\0|while|being (r_prep) treated_16\VBN\2376958|.|symptoms|in|FU (r_advcl) developed_6\VBN\1753788|NONE (l_prep) in_7\IN\13603305|treated|.|symptoms|FU (l_pobj) patients_9\NNS\9898892|NONE (l_prep) with_10\IN\0|three (l_pobj) carcinoma_13\NN\14239918|NONE
D005472_D007022 CID 5-fluorouracil_12\CD\0|NONE (r_punct) ._13\.\0|as (r_punct) hypotension_0\NN\14057371|NONE
D005472_D007022 CID 5-fluorouracil_23\CD\0|)|( (r_punct) 5-fu_25\CD\0|treated|.|symptoms|in (r_npadvmod) developed_6\VBN\1753788|NONE (l_nsubj) symptoms_1\NNS\5823932|treated|.|in|FU (l_prep) including_3\VBG\0|Cardiac|,|, (l_pobj) hypotension_4\NN\14057371|NONE
D005472_D007022 CID 5-fu_25\CD\0|treated|.|symptoms|in (r_npadvmod) developed_6\VBN\1753788|NONE (l_nsubj) symptoms_1\NNS\5823932|treated|.|in|FU (l_prep) including_3\VBG\0|Cardiac|,|, (l_pobj) hypotension_4\NN\14057371|NONE
D005472_D015179 NONE 5-fluorouracil_23\CD\0|)|( (r_punct) 5-fu_25\CD\0|treated|.|symptoms|in (r_npadvmod) developed_6\VBN\1753788|NONE (l_prep) in_7\IN\13603305|treated|.|symptoms|FU (l_pobj) patients_9\NNS\9898892|NONE (l_prep) with_10\IN\0|three (l_pobj) carcinoma_13\NN\14239918|NONE
D005472_D015179 NONE 5-fu_25\CD\0|treated|.|symptoms|in (r_npadvmod) developed_6\VBN\1753788|NONE (l_prep) in_7\IN\13603305|treated|.|symptoms|FU (l_pobj) patients_9\NNS\9898892|NONE (l_prep) with_10\IN\0|three (l_pobj) carcinoma_13\NN\14239918|NONE
D002945_D066126 NONE cisplatin_10\NN\0|NONE (r_dobj) receiving_9\VBG\2210855|three (r_acl) patients_8\NNS\9898892|NONE (r_pobj) in_6\IN\13603305|of|a (r_prep) manifestation_3\NN\7321772|NONE (l_prep) of_4\IN\0|a|in (l_pobj) cardiotoxicity_5\NN\0|NONE
D002945_D066126 NONE cddp_27\NNP\0|NONE (r_pobj) by_26\IN\0|be|that|may (r_agent) influenced_25\VBN\137313|new|of (r_relcl) manifestations_18\NNS\7321772|presentation|. (l_prep) of_19\IN\0|influenced|new (l_pobj) cardiotoxicity_21\NN\0|NONE
D005472_D066126 NONE 5-fluorouracil_12\CD\0|NONE (r_punct) ._13\.\0|as (r_punct) hypotension_0\NN\14057371|NONE (l_prep) as_1\IN\14622893|. (l_pobj) manifestation_3\NN\7321772|NONE (l_prep) of_4\IN\0|a|in (l_pobj) cardiotoxicity_5\NN\0|NONE
D005472_D066126 NONE 5-fu_20\CD\0|NONE (r_compound) cardiotoxicity_21\NN\0|NONE
D002945_D007022 CID cisplatin_10\NN\0|NONE (r_dobj) receiving_9\VBG\2210855|three (r_acl) patients_8\NNS\9898892|NONE (r_pobj) in_6\IN\13603305|of|a (r_prep) manifestation_3\NN\7321772|NONE (r_pobj) as_1\IN\14622893|. (r_prep) hypotension_0\NN\14057371|NONE
D002945_D007022 CID cisplatin_18\NN\0|CDDP (r_pobj) with_17\IN\0|while|being (r_prep) treated_16\VBN\2376958|.|symptoms|in|FU (r_advcl) developed_6\VBN\1753788|NONE (l_nsubj) symptoms_1\NNS\5823932|treated|.|in|FU (l_prep) including_3\VBG\0|Cardiac|,|, (l_pobj) hypotension_4\NN\14057371|NONE
D002945_D007022 CID cddp_20\NNP\0|cisplatin (r_pobj) with_17\IN\0|while|being (r_prep) treated_16\VBN\2376958|.|symptoms|in|FU (r_advcl) developed_6\VBN\1753788|NONE (l_nsubj) symptoms_1\NNS\5823932|treated|.|in|FU (l_prep) including_3\VBG\0|Cardiac|,|, (l_pobj) hypotension_4\NN\14057371|NONE
20431083
D014859_-1 NONE warfarin_57\NN\2718259|(|)|difference=. (r_amod) users_58\NNS\7846|NONE (r_pobj) in_56\IN\13603305|(|)|.|, (r_prep) range_50\NN\5123416|)|in|. (r_parataxis) 3.4_40\CD\0|(|,|. (r_appos) range_38\NN\5123416|NONE (r_pobj) to_35\IN\0|odds|(|;|range|in (r_prep) ratio_24\NN\13815152|. (r_pobj) from_20\IN\0|excess|. (r_prep) increased_19\VBD\169651|,|but|vs|frequent|MB|in|, (r_conj) were_2\VBD\0|NONE (l_nsubj) mb_1\NNS\13601596|increased|,|but|vs|frequent|in|,
D014859_-1 NONE warfarin_8\JJ\2718259|vs (r_amod) users_9\NNS\7846|NONE (r_pobj) in_7\IN\13603305|of|an (r_prep) excess_4\NN\5119367|also|There|but|.|none (l_prep) of_5\IN\0|in|an (l_pobj) mb_6\NN\13601596|NONE
D014859_-1 NONE warfarin_32\JJ\2718259|with (r_amod) users_33\NNS\7846|NONE (r_pobj) in_31\IN\13603305|NONE (r_prep) none_30\NN\15228378|also|There|but|excess|. (r_attr) was_1\VBD\0|NONE (l_attr) excess_4\NN\5119367|also|There|but|.|none (l_prep) of_5\IN\0|in|an (l_pobj) mb_6\NN\13601596|NONE
D014859_-1 NONE warfarin_5\JJ\2718259|with (r_amod) users_6\NNS\7846|NONE (r_pobj) in_4\IN\13603305|of|The|compared (r_prep) excess_1\NN\5119367|.|increase (l_prep) of_2\IN\0|The|in|compared (l_pobj) mb_3\NN\13601596|NONE
D014859_-1 NONE warfarin_5\JJ\2718259|with (r_amod) users_6\NNS\7846|NONE (r_pobj) in_4\IN\13603305|of|The|compared (r_prep) excess_1\NN\5119367|.|increase (r_nsubj) suggests_13\VBZ\1010118|NONE (l_ccomp) increase_16\VBP\13576355|.|excess (l_nsubj) mb_15\NN\13601596|risk|that
D014859_-1 NONE warfarin_20\NN\2718259| (r_npadvmod) associated_22\VBN\628491|NONE (r_amod) ich_23\NNP\0|NONE (r_pobj) of_19\IN\0|the (r_prep) risk_18\NN\14541044|MB|that (r_dobj) increase_16\VBP\13576355|.|excess (r_ccomp) suggests_13\VBZ\1010118|NONE (l_nsubj) excess_1\NN\5119367|.|increase (l_prep) of_2\IN\0|The|in|compared (l_pobj) mb_3\NN\13601596|NONE
D014859_-1 NONE warfarin_20\NN\2718259| (r_npadvmod) associated_22\VBN\628491|NONE (r_amod) ich_23\NNP\0|NONE (r_pobj) of_19\IN\0|the (r_prep) risk_18\NN\14541044|MB|that (r_dobj) increase_16\VBP\13576355|.|excess (l_nsubj) mb_15\NN\13601596|risk|that
D014859_D002543 CID warfarin_57\NN\2718259|(|)|difference=. (r_amod) users_58\NNS\7846|NONE (r_pobj) in_56\IN\13603305|(|)|.|, (r_prep) range_50\NN\5123416|)|in|. (r_parataxis) 3.4_40\CD\0|(|,|. (r_appos) range_38\NN\5123416|NONE (r_pobj) to_35\IN\0|odds|(|;|range|in (r_prep) ratio_24\NN\13815152|. (r_pobj) from_20\IN\0|excess|. (r_prep) increased_19\VBD\169651|,|but|vs|frequent|MB|in|, (r_conj) were_2\VBD\0|NONE (l_prep) in_5\IN\13603305|increased|,|but|vs|frequent|MB|, (l_pobj) ich_6\NNP\0|NONE
D014859_D002543 CID warfarin_8\JJ\2718259|vs (r_amod) users_9\NNS\7846|NONE (l_prep) vs_10\IN\13634784|warfarin (l_pobj) nonusers_11\NNS\0|NONE (l_prep) with_12\IN\0|NONE (l_pobj) ich_13\NNP\0|NONE
D014859_D002543 CID warfarin_32\JJ\2718259|with (r_amod) users_33\NNS\7846|NONE (r_pobj) in_31\IN\13603305|NONE (r_prep) none_30\NN\15228378|also|There|but|excess|. (r_attr) was_1\VBD\0|NONE (l_attr) excess_4\NN\5119367|also|There|but|.|none (l_prep) in_7\IN\13603305|of|an (l_pobj) users_9\NNS\7846|NONE (l_prep) vs_10\IN\13634784|warfarin (l_pobj) nonusers_11\NNS\0|NONE (l_prep) with_12\IN\0|NONE (l_pobj) ich_13\NNP\0|NONE
D014859_D002543 CID warfarin_5\JJ\2718259|with (r_amod) users_6\NNS\7846|NONE (l_prep) with_7\IN\0|warfarin (l_pobj) ich_8\NNP\0|NONE
D014859_D002543 CID warfarin_5\JJ\2718259|with (r_amod) users_6\NNS\7846|NONE (r_pobj) in_4\IN\13603305|of|The|compared (r_prep) excess_1\NN\5119367|.|increase (r_nsubj) suggests_13\VBZ\1010118|NONE (l_ccomp) increase_16\VBP\13576355|.|excess (l_dobj) risk_18\NN\14541044|MB|that (l_prep) of_19\IN\0|the (l_pobj) ich_23\NNP\0|NONE
D014859_D002543 CID warfarin_20\NN\2718259| (r_npadvmod) associated_22\VBN\628491|NONE (r_amod) ich_23\NNP\0|NONE (r_pobj) of_19\IN\0|the (r_prep) risk_18\NN\14541044|MB|that (r_dobj) increase_16\VBP\13576355|.|excess (r_ccomp) suggests_13\VBZ\1010118|NONE (l_nsubj) excess_1\NN\5119367|.|increase (l_prep) in_4\IN\13603305|of|The|compared (l_pobj) users_6\NNS\7846|NONE (l_prep) with_7\IN\0|warfarin (l_pobj) ich_8\NNP\0|NONE
D014859_D002543 CID warfarin_20\NN\2718259| (r_npadvmod) associated_22\VBN\628491|NONE (r_amod) ich_23\NNP\0|NONE
D014859_D002544 NONE warfarin_57\NN\2718259|(|)|difference=. (r_amod) users_58\NNS\7846|NONE (r_pobj) in_56\IN\13603305|(|)|.|, (r_prep) range_50\NN\5123416|)|in|. (r_parataxis) 3.4_40\CD\0|(|,|. (r_appos) range_38\NN\5123416|NONE (r_pobj) to_35\IN\0|odds|(|;|range|in (r_prep) ratio_24\NN\13815152|. (r_pobj) from_20\IN\0|excess|. (r_prep) increased_19\VBD\169651|,|but|vs|frequent|MB|in|, (r_conj) were_2\VBD\0|NONE (l_prep) vs_7\IN\13634784|increased|,|but|frequent|MB|in|, (l_pobj) tia_10\NNP\14166118|NONE (l_nmod) is_8\NNP\0|in|/
D014859_D002544 NONE warfarin_8\JJ\2718259|vs (r_amod) users_9\NNS\7846|NONE (r_pobj) in_7\IN\13603305|of|an (r_prep) excess_4\NN\5119367|also|There|but|.|none (r_attr) was_1\VBD\0|NONE (l_attr) none_30\NN\15228378|also|There|but|excess|. (l_prep) in_31\IN\13603305|NONE (l_pobj) users_33\NNS\7846|NONE (l_prep) with_34\IN\0|warfarin (l_pobj) tia_37\NNP\14166118|NONE (l_nmod) is_35\NNP\0|/|OR|(|;|)|CI
D014859_D002544 NONE warfarin_32\JJ\2718259|with (r_amod) users_33\NNS\7846|NONE (l_prep) with_34\IN\0|warfarin (l_pobj) tia_37\NNP\14166118|NONE (l_nmod) is_35\NNP\0|/|OR|(|;|)|CI
D014859_D002546 NONE warfarin_57\NN\2718259|(|)|difference=. (r_amod) users_58\NNS\7846|NONE (r_pobj) in_56\IN\13603305|(|)|.|, (r_prep) range_50\NN\5123416|)|in|. (r_parataxis) 3.4_40\CD\0|(|,|. (r_appos) range_38\NN\5123416|NONE (r_pobj) to_35\IN\0|odds|(|;|range|in (r_prep) ratio_24\NN\13815152|. (r_pobj) from_20\IN\0|excess|. (r_prep) increased_19\VBD\169651|,|but|vs|frequent|MB|in|, (r_conj) were_2\VBD\0|NONE (l_prep) vs_7\IN\13634784|increased|,|but|frequent|MB|in|, (l_pobj) tia_10\NNP\14166118|NONE
D014859_D002546 NONE warfarin_8\JJ\2718259|vs (r_amod) users_9\NNS\7846|NONE (r_pobj) in_7\IN\13603305|of|an (r_prep) excess_4\NN\5119367|also|There|but|.|none (r_attr) was_1\VBD\0|NONE (l_attr) none_30\NN\15228378|also|There|but|excess|. (l_prep) in_31\IN\13603305|NONE (l_pobj) users_33\NNS\7846|NONE (l_prep) with_34\IN\0|warfarin (l_pobj) tia_37\NNP\14166118|NONE
D014859_D002546 NONE warfarin_32\JJ\2718259|with (r_amod) users_33\NNS\7846|NONE (l_prep) with_34\IN\0|warfarin (l_pobj) tia_37\NNP\14166118|NONE
16920333
D010852_D012640 CID picrotoxin_17\NN\0|NONE (r_pobj) of_16\IN\0|in (r_prep) microperfusion_15\NN\0|NONE (r_pobj) by_14\IN\0|NONE (r_agent) induced_13\VBN\1627355|NONE (r_acl) seizures_12\NNS\14081375|NONE
D010852_D012640 CID picrotoxin_8\NN\0|NONE (r_pobj) of_7\IN\0|threshold (r_prep) doses_6\NNS\3740161|NONE (r_pobj) with_4\IN\0|NONE (r_prep) treated_3\VBN\2376958|the (r_acl) animals_2\NNS\4475|NONE (r_pobj) in_0\IN\13603305|.+/.|,|number|,|was|and (r_prep) was_15\VBD\0|NONE (l_nsubj) number_12\NN\5107765|.+/.|,|,|was|In|and (l_prep) of_13\IN\0|average|the (l_pobj) seizures_14\NNS\14081375|NONE
D010852_D012640 CID picrotoxin_8\NN\0|NONE (r_pobj) of_7\IN\0|threshold (r_prep) doses_6\NNS\3740161|NONE (r_pobj) with_4\IN\0|NONE (r_prep) treated_3\VBN\2376958|the (r_acl) animals_2\NNS\4475|NONE (r_pobj) in_0\IN\13603305|.+/.|,|number|,|was|and (r_prep) was_15\VBD\0|NONE (l_conj) was_22\VBD\0|.+/.|,|number|,|In|and (l_nsubj) duration_21\NN\15113229|.|.+/.s (l_compound) seizure_20\NN\14081375|average
D010852_D012640 CID picrotoxin_11\NN\0|NONE (r_compound) microperfusion_12\NN\0|before|seizures|treatment|in|. (r_nsubj) prevented_13\VBD\0|NONE (l_dobj) seizures_14\NNS\14081375|microperfusion|before|treatment|in|.
C416835_D012640 NONE acetate_4\NN\15010703|NONE (r_pobj) of_2\IN\0|Anticonvulsant|on|. (r_prep) effect_1\NN\34213|NONE (l_prep) on_11\IN\0|Anticonvulsant|of|. (l_pobj) seizures_12\NNS\14081375|NONE
C416835_D012640 NONE 093_9\CD\0|eslicarbazepine (r_appos) acetate_4\NN\15010703|NONE (r_pobj) of_2\IN\0|Anticonvulsant|on|. (r_prep) effect_1\NN\34213|NONE (l_prep) on_11\IN\0|Anticonvulsant|of|. (l_pobj) seizures_12\NNS\14081375|NONE
C416835_D012640 NONE acetate_10\NN\15010703|NONE (l_prep) on_11\IN\0|eslicarbazepine (l_pobj) model_16\NN\5888929|NONE (l_relcl) elicited_23\VBN\1617192|a|animal (l_nsubjpass) seizures_20\NNS\14081375|on|can|repeatedly|without|be|in
C416835_D012640 NONE acetate_10\NN\15010703|NONE (l_prep) on_11\IN\0|eslicarbazepine (l_pobj) model_16\NN\5888929|NONE (l_relcl) elicited_23\VBN\1617192|a|animal (l_prep) without_28\IN\0|on|can|repeatedly|seizures|be|in (l_pobj) changes_29\NNS\7283608|NONE (l_prep) in_30\IN\13603305|NONE (l_pobj) threshold_31\NN\15265518|NONE (l_conj) patterns_34\NNS\5726345|or (l_compound) seizure_33\NN\14081375|NONE
15482540
D012254_D000743 CID ribavirin_2\RB\2725367|and (r_conj) interferon_0\NNP\2725367|for|combination (r_nmod) therapy_4\NN\657604|.|anemia (r_nsubj) produces_9\VBZ\7555863|NONE (l_dobj) anemia_11\NN\14189204|.|therapy
D012254_D019698 NONE ribavirin_2\RB\2725367|and (r_conj) interferon_0\NNP\2725367|for|combination (r_nmod) therapy_4\NN\657604|.|anemia (l_prep) for_5\IN\0|Interferon|combination (l_pobj) c_8\NNP\13714184|NONE
D012254_D019698 NONE ribavirin_27\RB\2725367|NONE (r_pobj) with_26\IN\0|NONE (r_prep) combination_25\NN\7951464|NONE (r_pobj) in_24\IN\13603305|intramuscularly|for (r_prep) administered_19\VBN\2436349|a|of (r_acl) dose_15\NN\3740161|NONE (r_pobj) at_13\IN\14622893|alphab|who (r_prep) received_9\VBD\2210855|hepatitis|chronic (r_relcl) c_7\NNP\13714184|NONE
D016898_D019698 NONE interferon_0\NNP\2725367|for|combination (r_nmod) therapy_4\NN\657604|.|anemia (l_prep) for_5\IN\0|Interferon|combination (l_pobj) c_8\NNP\13714184|NONE
D016898_D019698 NONE alpha-2b_12\NN\0|at|who (r_dobj) received_9\VBD\2210855|hepatitis|chronic (r_relcl) c_7\NNP\13714184|NONE
D012254_D000740 NONE ribavirin_3\RB\2725367| (r_npadvmod) induced_5\VBN\1627355|NONE (r_amod) anemia_6\NN\14189204|NONE
D012254_D000740 NONE ribavirin_10\RB\2725367| (r_npadvmod) induced_12\VBN\1627355|NONE (r_amod) anemia_13\NN\14189204|NONE
D012254_D000740 NONE ribavirin_12\RB\2725367| (r_npadvmod) induced_14\VBN\1627355|NONE (r_amod) anemia_15\NN\14189204|NONE
D012254_D000740 NONE ribavirin_0\RB\2725367| (r_npadvmod) induced_2\VBN\1627355|NONE (r_amod) anemia_3\NN\14189204|in|.|during
D016898_D000743 CID interferon_0\NNP\2725367|for|combination (r_nmod) therapy_4\NN\657604|.|anemia (r_nsubj) produces_9\VBZ\7555863|NONE (l_dobj) anemia_11\NN\14189204|.|therapy
19549709
D010984_D002289 NONE platinum_18\NN\14627081|based|)|or||chemotherapy|inhibitors|( (r_nmod) stratum_21\NN\8591680|two|chemotherapy|prior|,|, (r_appos) regimens_15\NNS\5898568|NONE (r_pobj) with_9\IN\0|IIIb|:|, (r_prep) methods_0\NNS\5616786|RAD|day|.|until (l_appos) iiib_3\NNS\0|with|:|, (l_conj) patients_7\NNS\9898892|or|Stage (l_compound) nsclc_6\NNP\0|IV
C107135_D064420 NONE rad001_41\NNP\0|METHODS|day|.|until (r_dobj) received_40\VBD\2210855|NONE (l_prep) until_46\IN\0|METHODS|RAD|day|. (l_pobj) progression_47\NN\8457976|NONE (l_conj) toxicity_50\NN\13576101|or
D014443_D002289 NONE tyrosine_32\NN\14601829|)|stratum|(|kinase (r_compound) inhibitors_34\NNS\20090|based|platinum|)|or||chemotherapy|( (r_conj) stratum_21\NN\8591680|two|chemotherapy|prior|,|, (r_appos) regimens_15\NNS\5898568|NONE (r_pobj) with_9\IN\0|IIIb|:|, (r_prep) methods_0\NNS\5616786|RAD|day|.|until (l_appos) iiib_3\NNS\0|with|:|, (l_conj) patients_7\NNS\9898892|or|Stage (l_compound) nsclc_6\NNP\0|IV
D020123_D002289 NONE rapamycin_10\NNS\0|)|( (r_nmod) mtor_12\NNP\0|NONE (r_pobj) of_9\IN\0|mammalian|the (r_prep) target_8\NN\7258332|NONE (r_pobj) of_5\IN\0|an|oral (r_prep) inhibitor_4\NN\20090|,|, (r_appos) rad001_0\NNP\0|.|has|phase (r_nsubj) shown_16\VBN\2137132|NONE (l_dobj) phase_17\NN\15113229|.|has|RAD (l_prep) in_20\IN\13603305|efficacy|I (l_pobj) nsclc_21\NNP\0|NONE
D014443_D064420 NONE tyrosine_32\NN\14601829|)|stratum|(|kinase (r_compound) inhibitors_34\NNS\20090|based|platinum|)|or||chemotherapy|( (r_conj) stratum_21\NN\8591680|two|chemotherapy|prior|,|, (r_appos) regimens_15\NNS\5898568|NONE (r_pobj) with_9\IN\0|IIIb|:|, (r_prep) methods_0\NNS\5616786|RAD|day|.|until (r_nsubj) received_40\VBD\2210855|NONE (l_prep) until_46\IN\0|METHODS|RAD|day|. (l_pobj) progression_47\NN\8457976|NONE (l_conj) toxicity_50\NN\13576101|or
C107135_D002289 NONE everolimus_2\NN\0|NONE (r_pobj) of_1\IN\0|.|in (r_prep) efficacy_0\NN\5199286|NONE (l_prep) in_6\IN\13603305|.|of (l_pobj) patients_7\NNS\9898892|or|with (l_prep) with_8\IN\0|treated (l_pobj) nsclc_10\NNP\0|NONE
C107135_D002289 NONE rad001_4\NNP\0|(|) (r_appos) everolimus_2\NN\0|NONE (r_pobj) of_1\IN\0|.|in (r_prep) efficacy_0\NN\5199286|NONE (l_prep) in_6\IN\13603305|.|of (l_pobj) patients_7\NNS\9898892|or|with (l_prep) with_8\IN\0|treated (l_pobj) nsclc_10\NNP\0|NONE
C107135_D002289 NONE rad001_0\NNP\0|.|has|phase (r_nsubj) shown_16\VBN\2137132|NONE (l_dobj) phase_17\NN\15113229|.|has|RAD (l_prep) in_20\IN\13603305|efficacy|I (l_pobj) nsclc_21\NNP\0|NONE
C107135_D002289 NONE rad001_41\NNP\0|METHODS|day|.|until (r_dobj) received_40\VBD\2210855|NONE (l_nsubj) methods_0\NNS\5616786|RAD|day|.|until (l_appos) iiib_3\NNS\0|with|:|, (l_conj) patients_7\NNS\9898892|or|Stage (l_compound) nsclc_6\NNP\0|IV
C107135_D002289 NONE rad001_2\NNP\0|NONE (r_pobj) of_1\IN\0|therapy|plus (r_prep) evaluation_0\NN\874067|.|NSCLC (r_nsubj) continues_9\VBZ\2367363|NONE (l_nsubj) nsclc_8\NNP\0|Evaluation|.
D010984_D064420 NONE platinum_18\NN\14627081|based|)|or||chemotherapy|inhibitors|( (r_nmod) stratum_21\NN\8591680|two|chemotherapy|prior|,|, (r_appos) regimens_15\NNS\5898568|NONE (r_pobj) with_9\IN\0|IIIb|:|, (r_prep) methods_0\NNS\5616786|RAD|day|.|until (r_nsubj) received_40\VBD\2210855|NONE (l_prep) until_46\IN\0|METHODS|RAD|day|. (l_pobj) progression_47\NN\8457976|NONE (l_conj) toxicity_50\NN\13576101|or
7671401
D000806_D000799 CID inhibitor_19\NN\20090|NONE (r_pobj) with_14\IN\0|term (r_prep) therapy_13\NN\657604|NONE (r_pobj) to_9\IN\0|NONE (r_prep) related_8\VBN\628491|angio| (r_acl) oedema_7\NN\14315192|NONE
D000806_D000799 CID inhibitors_6\NNS\20090|NONE (r_pobj) of_4\IN\0|the (r_prep) introduction_3\NN\235435|NONE (r_pobj) after_1\IN\0|in|.|bouts|Soon|were|, (r_prep) reported_15\VBN\831651|NONE (l_nsubjpass) bouts_9\NNS\5867413|after|in|.|Soon|were|, (l_prep) of_10\IN\0|acute (l_pobj) oedema_13\NN\14315192|NONE
D000806_D000799 CID inhibitors_13\NNS\20090|NONE (r_pobj) to_11\IN\0|adverse|after (r_prep) reactions_10\NNS\13446390|NONE (l_prep) after_14\IN\0|adverse|to (l_conj) in_20\IN\13603305|use|and (l_pobj) patients_21\NNS\9898892|NONE (l_prep) with_22\IN\0|NONE (l_pobj) oedema_28\NN\14315192|NONE
D000806_D006973 NONE inhibitors_7\NNS\20090|converting (l_acl) used_9\VBD\0|(|,|)|ACE|, (l_xcomp) treat_11\VB\7570720|NONE (l_dobj) hypertension_12\NN\14057371|to
D000806_D006333 NONE inhibitors_7\NNS\20090|converting (l_acl) used_9\VBD\0|(|,|)|ACE|, (l_xcomp) treat_11\VB\7570720|NONE (l_dobj) hypertension_12\NN\14057371|to (l_conj) failure_16\NN\66216|and
24464946
D015251_D008228 NONE epirubicin_13\NNS\0|NONE (r_pobj) with_12\IN\0|NONE (r_prep) treated_11\VBN\2376958|five|with (r_acl) patients_5\NNS\9898892|: (l_prep) with_6\IN\0|five|treated (l_pobj) lymphoma_10\NN\14239918|NONE
D015251_D006331 NONE epirubicin_25\NNS\0|NONE (r_compound) exposure_26\NN\5042871|NONE (r_pobj) after_24\IN\0|dysfunction|alterations|could|whether (r_prep) predict_18\VB\916909|.|To (l_dobj) dysfunction_21\NN\14204950|alterations|could|after|whether
D015251_D066126 CID epirubicine_22\NN\0| (r_npadvmod) based_24\VBN\0|NONE (r_amod) chemotherapy_25\NN\661091|NONE (r_pobj) during_21\IN\0|prediction|early|and (r_prep) detection_16\NN\5708432|NONE (l_conj) prediction_18\NN\5772356|during|early|and (l_prep) of_19\IN\0|NONE (l_pobj) cardiotoxicity_20\NN\0|NONE
D015251_D009202 NONE epirubicin_25\NNS\0|NONE (r_compound) exposure_26\NN\5042871|NONE (r_pobj) after_24\IN\0|dysfunction|alterations|could|whether (r_prep) predict_18\VB\916909|.|To (l_nsubj) alterations_3\NNS\7283608|dysfunction|could|after|whether (l_prep) of_4\IN\0|NONE (l_pobj) strain_6\NN\7358060|NONE
D018943_D006331 NONE anthracycline_20\NN\0| (r_advmod) based_22\VBN\0|NONE (r_amod) chemotherapy_23\NN\661091|NONE (r_dobj) receiving_19\VBG\2210855|NONE (r_acl) patients_18\NNS\9898892|NONE (r_pobj) in_17\IN\13603305|cardiac (r_prep) dysfunction_16\NN\14204950|to
1756784
D010862_D013226 CID pilocarpine_7\NN\14712692| (r_npadvmod) induced_9\VBN\1627355|NONE (r_amod) status_10\NN\24720|NONE (r_pobj) during_6\IN\0|of (r_prep) damage_0\NN\7296428|in|study|.|: (r_nsubj) epilepticus_11\NN\0|NONE
D010862_D013226 CID pilocarpine_12\NN\14712692|NONE (r_pobj) of_11\IN\0|systemic|in (r_prep) injection_10\NN\320852|NONE (r_pobj) by_8\IN\0|In|epilepticus|,|.|was (r_agent) induced_7\VBN\1627355|NONE (l_nsubjpass) epilepticus_5\NN\0|by|In|,|.|was
D002118_D009422 NONE calcium_10\NN\14625458| (r_npadvmod) binding_12\VBG\4688246|the|specific|,|parvalbumin (r_amod) protein_13\NN\14944888|NONE (r_pobj) against_5\IN\0||Nissl|antibodies|and|, (r_prep) staining_2\VBG\275424|.|detect (r_nsubj) served_17\VBD\2669789|NONE (l_xcomp) detect_19\VB\2163746|.|staining (l_dobj) damage_21\NN\7296428|to
D010862_D001930 CID pilocarpine_7\NN\14712692| (r_npadvmod) induced_9\VBN\1627355|NONE (r_amod) status_10\NN\24720|NONE (r_pobj) during_6\IN\0|of (r_prep) damage_0\NN\7296428|in|study|.|: (l_prep) of_1\IN\0|during (l_pobj) reticulata_5\NNS\0|NONE
9570197
D003042_D002637 NONE hydrochloride_78\NN\14817592|)|control|or (r_conj) subjects_74\NNS\6598915|,|( (r_appos) n=10_71\NNP\0|fraction|and|LV|before (r_appos) volumes_50\NNS\33615|referred|we|,|.|and|,|rate (r_conj) measured_28\VBD\697589|NONE (l_ccomp) referred_16\VBD\730052|we|,|.|and|,|rate|volumes (l_prep) for_17\IN\0|In|:|patients (l_pobj) catheterization_19\NN\671351|NONE (l_prep) for_20\IN\0|cardiac (l_pobj) evaluation_22\NN\874067|NONE (l_prep) of_23\IN\0|the (l_pobj) pain_25\NN\14299637|NONE
D003042_D018487 CID cocaine_8\NN\3492717|NONE (r_pobj) of_6\IN\0|large|a (r_prep) amount_5\NN\13329641|.|In|,|deterioration (r_nsubj) causes_9\VBZ\7323922|NONE (l_dobj) deterioration_12\NN\14560612|.|amount|In|, (l_prep) of_13\IN\0|profound|and|a|increase (l_pobj) function_20\NN\13783581|NONE
D003042_D018487 CID cocaine_7\NN\3492717|NONE (r_pobj) of_6\IN\0|the|intracoronary|sufficient (r_prep) infusion_5\NN\14589223|deterioration|,|.|In (r_nsubj) causes_21\VBZ\7323922|NONE (l_dobj) deterioration_23\NN\14560612|,|.|infusion|In (l_prep) of_24\IN\0|a (l_pobj) performance_29\NN\6619065|NONE
24691439
C075773_D009798 NONE 4-phenylbutyrate_11\RB\0|NONE (r_pobj) with_9\IN\0|of (r_prep) reduction_2\NN\351485|hypertension|,|.|Furthermore (r_nsubj) prevented_12\VBN\0|NONE (l_dobj) hypertension_17\NN\14057371|,|reduction|.|Furthermore
D003907_D009798 CID dexamethasone_2\NN\2721538| (r_npadvmod) induced_4\VBN\1627355|ocular (r_amod) hypertension_6\NN\14057371|was|with|,|Furthermore|.
D003907_D009798 CID dexamethasone_0\NN\2721538|CHOP|,|in|and|reduced (r_nsubj) induced_1\VBD\1627355|NONE (l_conj) reduced_23\VBN\441445|CHOP|,|in|and|Dexamethasone (l_conj) prevented_30\VBN\0|deletion|stress|in|.|and (l_dobj) hypertension_35\NN\14057371|NONE
D003907_D009798 CID dexamethasone_31\NN\2721538| (r_npadvmod) induced_33\VBN\1627355|ocular (r_amod) hypertension_35\NN\14057371|NONE
D003907_D009798 CID dexamethasone_13\NN\2721538| (r_npadvmod) induced_15\VBN\1627355|in|ocular (r_amod) hypertension_17\NN\14057371|,|reduction|.|Furthermore
D003907_D009410 CID dexamethasone_9\NN\2721538|NONE (r_pobj) with_4\IN\0|of (r_prep) treatment_0\NN\654885|to|,|.|resembling (r_nsubj) led_10\VBN\3202760|NONE (l_prep) to_11\IN\0|,|Treatment|.|resembling (l_pobj) elevation_12\NN\7445480|NONE (l_prep) of_13\IN\0|NONE (l_pobj) pressure_15\NN\11419404|NONE (l_appos) loss_23\NN\13252973|(|intraocular|IOP (l_conj) degeneration_31\NN\29677|functional|,|of|and
D003907_D012173 NONE dexamethasone_9\NN\2721538|NONE (r_pobj) with_4\IN\0|of (r_prep) treatment_0\NN\654885|to|,|.|resembling (r_nsubj) led_10\VBN\3202760|NONE (l_prep) to_11\IN\0|,|Treatment|.|resembling (l_pobj) elevation_12\NN\7445480|NONE (l_prep) of_13\IN\0|NONE (l_pobj) pressure_15\NN\11419404|NONE (l_appos) loss_23\NN\13252973|(|intraocular|IOP (l_prep) of_24\IN\0|functional|degeneration|,|and (l_pobj) cells_27\NNS\3080309|NONE (l_compound) ganglion_26\NN\5462674|retinal
D003907_D005901 CID dexamethasone_9\NN\2721538|NONE (r_pobj) with_4\IN\0|of (r_prep) treatment_0\NN\654885|to|,|.|resembling (r_nsubj) led_10\VBN\3202760|NONE (l_advcl) resembling_33\VBG\2657219|to|,|Treatment|. (l_dobj) glaucoma_37\NN\14252864|NONE
24971338
D004801_D007674 NONE eosin_7\NN\14987695|,|and|Schiff (r_conj) hematoxylin_5\NN\0|NONE (r_pobj) in_4\IN\13603305|.|lesions|were (r_prep) analyzed_3\VBN\0|NONE (l_nsubjpass) lesions_1\NNS\14204950|.|in|were
D006416_D007674 NONE hematoxylin_5\NN\0|NONE (r_pobj) in_4\IN\13603305|.|lesions|were (r_prep) analyzed_3\VBN\0|NONE (l_nsubjpass) lesions_1\NNS\14204950|.|in|were
D020123_D011507 CID srl_0\NN\0| (r_npadvmod) treated_2\VBN\2376958|NONE (r_amod) rats_3\NNS\2329401|as|.|proteinuria|) (r_nsubj) presented_4\VBD\2137132|NONE (l_dobj) proteinuria_5\NN\14299637|rats|as|.|)
D020123_D007674 NONE sirolimus_2\VB\0|NONE (r_relcl) conversion_0\NN\7359599|in|nephropathy (r_nsubj) ameliorates_3\VBZ\126264|.|:|on (l_dobj) nephropathy_7\NN\14573196|Conversion|in
D020123_D007674 NONE sirolimus_10\VB\0|NONE (r_pobj) to_9\TO\0|from (r_prep) conversion_2\NN\7359599|NONE (r_pobj) of_1\IN\0|NONE (r_prep) protocols_0\NNS\6652242|after|SRL|,|(|)|have|in|been|widely|but|remain (r_nsubjpass) used_17\VBN\0|NONE (l_prep) after_20\IN\0|SRL|,|(|)|Protocols|have|in|been|widely|but|remain (l_pobj) transplantation_21\NN\671351|NONE (l_relcl) prevent_23\VB\0|NONE (l_dobj) nephropathy_27\NN\14573196|to
D020123_D007674 NONE srl_12\NN\0|after|,|(|)|Protocols|have|in|been|widely|but|remain (r_nsubjpass) used_17\VBN\0|NONE (l_prep) after_20\IN\0|SRL|,|(|)|Protocols|have|in|been|widely|but|remain (l_pobj) transplantation_21\NN\671351|NONE (l_relcl) prevent_23\VB\0|NONE (l_dobj) nephropathy_27\NN\14573196|to
D020123_D007674 NONE srl_0\NN\0| (r_npadvmod) treated_2\VBN\2376958|NONE (r_amod) rats_3\NNS\2329401|as|.|proteinuria|) (r_nsubj) presented_4\VBD\2137132|NONE (l_prep) as_13\IN\14622893|rats|.|proteinuria|) (l_pobj) markers_16\NNS\21939|NONE (l_prep) of_17\IN\0|best|the (l_pobj) impairment_19\NN\7296428|NONE
D020123_D007674 NONE srl_2\NNP\0|NONE (r_pobj) to_1\IN\0|NONE (r_prep) conversion_0\NN\7359599|seems|.|evolution|, (r_nsubj) prevented_3\VBN\0|NONE (l_dobj) evolution_9\NN\29677|Conversion|seems|.|, (l_compound) damage_8\NN\7296428|renal|induced|lesions
D020123_D007674 NONE srl_35\NNP\0|NONE (r_pobj) to_34\IN\0|CsA (r_prep) replacement_33\NN\196485|NONE (r_pobj) of_31\IN\0|feasible|a (r_prep) biomarker_30\NN\0|to (r_attr) be_27\VB\14625458|while|NGAL (r_xcomp) seems_25\VBZ\2604760|Conversion|.|evolution|, (r_advcl) prevented_3\VBN\0|NONE (l_dobj) evolution_9\NN\29677|Conversion|seems|.|, (l_compound) damage_8\NN\7296428|renal|induced|lesions
D016572_D007674 CID cyclosporine_4\NN\0| (r_npadvmod) induced_6\VBN\1627355|NONE (r_amod) nephropathy_7\NN\14573196|Conversion|in
D016572_D007674 CID a_5\NNP\13649268|NONE (r_pobj) from_3\IN\0|to (r_prep) conversion_2\NN\7359599|NONE (r_pobj) of_1\IN\0|NONE (r_prep) protocols_0\NNS\6652242|after|SRL|,|(|)|have|in|been|widely|but|remain (r_nsubjpass) used_17\VBN\0|NONE (l_prep) after_20\IN\0|SRL|,|(|)|Protocols|have|in|been|widely|but|remain (l_pobj) transplantation_21\NN\671351|NONE (l_relcl) prevent_23\VB\0|NONE (l_dobj) nephropathy_27\NN\14573196|to
D016572_D007674 CID csa_7\NNP\0|cyclosporin (r_appos) a_5\NNP\13649268|NONE (r_pobj) from_3\IN\0|to (r_prep) conversion_2\NN\7359599|NONE (r_pobj) of_1\IN\0|NONE (r_prep) protocols_0\NNS\6652242|after|SRL|,|(|)|have|in|been|widely|but|remain (r_nsubjpass) used_17\VBN\0|NONE (l_prep) after_20\IN\0|SRL|,|(|)|Protocols|have|in|been|widely|but|remain (l_pobj) transplantation_21\NN\671351|NONE (l_relcl) prevent_23\VB\0|NONE (l_dobj) nephropathy_27\NN\14573196|to
D016572_D007674 CID csa_24\NNP\0| (r_npadvmod) induced_26\VBN\1627355|NONE (r_amod) nephropathy_27\NN\14573196|to
D016572_D007674 CID csa_1\NNP\0|Short (r_compound) treatment_2\NN\654885|CTGF|.|KIM|and|lesions|, (r_nsubj) presented_3\VBD\2137132|NONE (l_dobj) lesions_9\NNS\14204950|CTGF|.|treatment|KIM|and|,
D016572_D007674 CID csa_1\NNP\0|Prolonged (r_compound) exposure_2\NN\5042871|.|b|damage|,|without (r_nsubj) aggravated_3\VBD\126264|NONE (l_dobj) damage_5\NN\7296428|.|exposure|b|,|without
D016572_D007674 CID csa_4\NNP\0| (r_npadvmod) induced_6\VBN\1627355|renal|damage|lesions (r_amod) evolution_9\NN\29677|Conversion|seems|.|, (l_compound) damage_8\NN\7296428|renal|induced|lesions
D016572_D007674 CID csa_32\NNP\0|to (r_compound) replacement_33\NN\196485|NONE (r_pobj) of_31\IN\0|feasible|a (r_prep) biomarker_30\NN\0|to (r_attr) be_27\VB\14625458|while|NGAL (r_xcomp) seems_25\VBZ\2604760|Conversion|.|evolution|, (r_advcl) prevented_3\VBN\0|NONE (l_dobj) evolution_9\NN\29677|Conversion|seems|.|, (l_compound) damage_8\NN\7296428|renal|induced|lesions
24671324
D003907_D001424 NONE dexamethasone_5\NN\2721538| (r_npadvmod) containing_7\VBG\2632940|dose (r_amod) regimens_8\NNS\5898568|and (r_conj) bortezomib_0\NNP\0|be|.|are (r_nsubjpass) considered_10\VBN\689344|NONE (l_xcomp) be_12\VB\14625458|.|Bortezomib|are (l_acomp) tolerable_14\JJ\0|to (l_prep) with_15\IN\0|generally (l_pobj) infections_19\NNS\14052046|NONE
D003907_D001424 NONE dexamethasone_16\NN\2721538|NONE (r_pobj) to_10\IN\0|NONE (r_prep) related_9\VBN\628491|bacterial|fatal (r_acl) infections_8\NNS\14052046|NONE
C400082_D008258 NONE bortezomib_3\NNS\0|in|containing (r_amod) regimen_8\NN\5898568|NONE (l_prep) in_9\IN\13603305|bortezomib|containing (l_pobj) patient_12\NN\9898892|NONE (l_prep) of_13\IN\0|elderly|an (l_pobj) macroglobulinaemia_15\NN\0|NONE
C400082_D008258 NONE bortezomib_24\NNS\0|,|and|dose|rituximab (r_amod) dexamethasone_29\NN\2721538|NONE (r_pobj) with_23\IN\0|combination|the (r_prep) treatment_22\NN\654885|NONE (r_pobj) after_19\IN\0|who|fasciitis|without (r_prep) suffered_14\VBD\2110220|old|with|a (r_relcl) man_9\NN\9605289|NONE (l_prep) with_10\IN\0|old|suffered|a (l_pobj) macroglobulinaemia_12\NN\0|NONE
C400082_D009369 NONE bortezomib_0\NNP\0|be|.|are (r_nsubjpass) considered_10\VBN\689344|NONE (l_xcomp) be_12\VB\14625458|.|Bortezomib|are (l_acomp) tolerable_14\JJ\0|to (l_prep) with_15\IN\0|generally (l_pobj) infections_19\NNS\14052046|NONE (l_prep) in_20\IN\13603305|severe|bacterial|few (l_pobj) patients_21\NNS\9898892|NONE (l_prep) with_22\IN\0|NONE (l_pobj) malignancies_26\NNS\14070360|NONE
D003907_D008258 NONE dexamethasone_5\NN\2721538| (r_npadvmod) containing_7\VBG\2632940|in|bortezomib (r_amod) regimen_8\NN\5898568|NONE (l_prep) in_9\IN\13603305|bortezomib|containing (l_pobj) patient_12\NN\9898892|NONE (l_prep) of_13\IN\0|elderly|an (l_pobj) macroglobulinaemia_15\NN\0|NONE
D003907_D008258 NONE dexamethasone_29\NN\2721538|NONE (r_pobj) with_23\IN\0|combination|the (r_prep) treatment_22\NN\654885|NONE (r_pobj) after_19\IN\0|who|fasciitis|without (r_prep) suffered_14\VBD\2110220|old|with|a (r_relcl) man_9\NN\9605289|NONE (l_prep) with_10\IN\0|old|suffered|a (l_pobj) macroglobulinaemia_12\NN\0|NONE
D003907_D009503 NONE dexamethasone_29\NN\2721538|NONE (r_pobj) with_23\IN\0|combination|the (r_prep) treatment_22\NN\654885|NONE (r_pobj) after_19\IN\0|who|fasciitis|without (r_prep) suffered_14\VBD\2110220|old|with|a (l_prep) without_17\IN\0|who|fasciitis|after (l_pobj) neutropenia_18\NN\14196405|NONE
C400082_D019115 CID bortezomib_3\NNS\0|in|containing (r_amod) regimen_8\NN\5898568|NONE (r_pobj) after_2\IN\0|.|Necrotising (r_prep) fasciitis_1\NN\0|NONE
C400082_D019115 CID bortezomib_24\NNS\0|,|and|dose|rituximab (r_amod) dexamethasone_29\NN\2721538|NONE (r_pobj) with_23\IN\0|combination|the (r_prep) treatment_22\NN\654885|NONE (r_pobj) after_19\IN\0|who|fasciitis|without (r_prep) suffered_14\VBD\2110220|old|with|a (l_dobj) fasciitis_16\NN\0|who|without|after
C400082_D009503 NONE bortezomib_24\NNS\0|,|and|dose|rituximab (r_amod) dexamethasone_29\NN\2721538|NONE (r_pobj) with_23\IN\0|combination|the (r_prep) treatment_22\NN\654885|NONE (r_pobj) after_19\IN\0|who|fasciitis|without (r_prep) suffered_14\VBD\2110220|old|with|a (l_prep) without_17\IN\0|who|fasciitis|after (l_pobj) neutropenia_18\NN\14196405|NONE
D003907_D009369 NONE dexamethasone_5\NN\2721538| (r_npadvmod) containing_7\VBG\2632940|dose (r_amod) regimens_8\NNS\5898568|and (r_conj) bortezomib_0\NNP\0|be|.|are (r_nsubjpass) considered_10\VBN\689344|NONE (l_xcomp) be_12\VB\14625458|.|Bortezomib|are (l_acomp) tolerable_14\JJ\0|to (l_prep) with_15\IN\0|generally (l_pobj) infections_19\NNS\14052046|NONE (l_prep) in_20\IN\13603305|severe|bacterial|few (l_pobj) patients_21\NNS\9898892|NONE (l_prep) with_22\IN\0|NONE (l_pobj) malignancies_26\NNS\14070360|NONE
C400082_D001424 NONE bortezomib_0\NNP\0|be|.|are (r_nsubjpass) considered_10\VBN\689344|NONE (l_xcomp) be_12\VB\14625458|.|Bortezomib|are (l_acomp) tolerable_14\JJ\0|to (l_prep) with_15\IN\0|generally (l_pobj) infections_19\NNS\14052046|NONE
C400082_D001424 NONE bortezomib_11\NNS\0|dose|in (r_amod) dexamethasone_16\NN\2721538|NONE (r_pobj) to_10\IN\0|NONE (r_prep) related_9\VBN\628491|bacterial|fatal (r_acl) infections_8\NNS\14052046|NONE
D003907_D019115 CID dexamethasone_5\NN\2721538| (r_npadvmod) containing_7\VBG\2632940|in|bortezomib (r_amod) regimen_8\NN\5898568|NONE (r_pobj) after_2\IN\0|.|Necrotising (r_prep) fasciitis_1\NN\0|NONE
D003907_D019115 CID dexamethasone_29\NN\2721538|NONE (r_pobj) with_23\IN\0|combination|the (r_prep) treatment_22\NN\654885|NONE (r_pobj) after_19\IN\0|who|fasciitis|without (r_prep) suffered_14\VBD\2110220|old|with|a (l_dobj) fasciitis_16\NN\0|who|without|after
16801510
D008691_D016171 NONE methadone_8\NN\3808564|the (r_compound) group_9\NN\2137|NONE (r_pobj) in_6\IN\13603305|%|)|(|Six (r_prep) patients_1\NNS\9898892|.|pointes (r_nsubj) presented_10\VBD\2137132|NONE (l_dobj) pointes_13\FW\831651|.|patients
D008691_D007008 NONE methadone_12\NN\3808564|NONE (r_compound) dose_13\NN\3740161|NONE (r_pobj) to_11\IN\0|of (r_prep) attribution_4\NN\5732756|analysis|.|cytochrome (r_dobj) allowed_3\VBD\0|NONE (l_conj) cytochrome_15\NN\14888884|analysis|.|attribution (l_dobj) interactions_21\NNS\37396|, (l_appos) hypokalemia_23\NN\14299637|drug|A|,
D011188_D008133 NONE potassium_3\NN\14625458|,|function|and (r_compound) level_4\NN\4916342|,|A (r_conj) inhibitors_1\NNS\20090|.|to (r_nsubj) contribute_9\VBP\126264|NONE (l_prep) to_10\IN\0|.|inhibitors (l_pobj) prolongation_12\NN\1017987|NONE
D008691_D008133 CID methadone_11\NN\3808564|NONE (r_dobj) receiving_10\VBG\2210855|drug (r_acl) users_9\NNS\7846|NONE (r_pobj) in_6\IN\13603305|long|.|induced|QT (r_prep) syndrome_5\NN\5870365|NONE
D008691_D008133 CID methadone_12\NN\3808564|NONE (r_compound) treatment_13\NN\654885|NONE (r_pobj) with_11\IN\0|interval|QT (r_prep) prolongation_10\NN\1017987|NONE
D008691_D008133 CID methadone_3\NN\3808564|NONE (r_compound) dose_4\NN\3740161|NONE (r_pobj) to_2\IN\0|NONE (r_prep) addition_1\NN\3081021|NONE (r_pobj) in_0\IN\13603305|as|were|,|.|variables (r_prep) considered_15\VBN\689344|NONE (l_prep) as_16\IN\14622893|were|In|,|.|variables (l_pobj) factors_19\NNS\7326557|NONE (l_prep) for_20\IN\0|potential|risk (l_pobj) prolongation_22\NN\1017987|NONE
D008691_D008133 CID methadone_4\NN\3808564|hospitalized|maintenance (r_compound) patients_6\NNS\9898892|NONE (r_pobj) in_3\IN\13603305|interval|QT (r_prep) prolongation_2\NN\1017987|finding|.
D008691_D008133 CID methadone_9\NN\3808564|NONE (r_pobj) of_8\IN\0|low (r_prep) doses_7\NNS\3740161|NONE (r_pobj) with_5\IN\0|syndrome|.|can (r_prep) occur_4\VB\0|NONE (l_nsubj) syndrome_2\NN\5870365|.|can|with
24158386
D002945_D064420 NONE cisplatin_2\NN\0|and (r_conj) gemcitabine_0\NNP\0|.|,|and|delivered|activity (r_nsubj) have_3\VBP\7846|NONE (l_dobj) activity_4\NN\30358|.|,|and|delivered|Gemcitabine (l_prep) in_5\IN\13603305|NONE (l_pobj) toxicity_11\NN\13576101|NONE
C056507_D064420 NONE gemcitabine_0\NNP\0|.|,|and|delivered|activity (r_nsubj) have_3\VBP\7846|NONE (l_dobj) activity_4\NN\30358|.|,|and|delivered|Gemcitabine (l_prep) in_5\IN\13603305|NONE (l_pobj) toxicity_11\NN\13576101|NONE
D002945_D006689 NONE cisplatin_2\NN\0|and (r_conj) gemcitabine_0\NNP\0|.|,|and|delivered|activity (r_nsubj) have_3\VBP\7846|NONE (l_dobj) activity_4\NN\30358|.|,|and|delivered|Gemcitabine (l_prep) in_5\IN\13603305|NONE (l_pobj) toxicity_11\NN\13576101|NONE (l_amod) overlapping_10\VBG\3122748|with (l_npadvmod) hl_6\NNP\13616054|
D002945_D006689 NONE cisplatin_38\NN\0|.|were (r_nsubjpass) included_55\VBN\0|with|methylprednisolone|In|;|and|patients|, (r_conj) treated_14\VBN\2376958|NONE (l_nsubj) patients_8\NNS\9898892|with|methylprednisolone|In|;|included|and|, (l_prep) with_9\IN\0|NONE (l_pobj) hl_13\NN\13616054|NONE
D008775_D006689 NONE methylprednisolone_30\NN\0|with|In|;|included|and|patients|, (r_advcl) treated_14\VBN\2376958|NONE (l_nsubj) patients_8\NNS\9898892|with|methylprednisolone|In|;|included|and|, (l_prep) with_9\IN\0|NONE (l_pobj) hl_13\NN\13616054|NONE
C056507_D006689 NONE gem_0\NN\2743547| (r_compound) p_2\NN\14622893|NONE (r_compound) chemotherapy_3\NN\661091|active|. (r_nsubj) is_4\VBZ\0|NONE (l_acomp) active_5\JJ\14779550|chemotherapy|. (l_prep) in_6\IN\13603305|NONE (l_pobj) treatment_8\NN\654885|NONE (l_prep) of_9\IN\0|the (l_pobj) lymphoma_12\NN\14239918|NONE
C056507_D006689 NONE gemcitabine_0\NNP\0|.|,|and|delivered|activity (r_nsubj) have_3\VBP\7846|NONE (l_dobj) activity_4\NN\30358|.|,|and|delivered|Gemcitabine (l_prep) in_5\IN\13603305|NONE (l_pobj) toxicity_11\NN\13576101|NONE (l_amod) overlapping_10\VBG\3122748|with (l_npadvmod) hl_6\NNP\13616054|
C056507_D006689 NONE gemcitabine_16\NN\0|D)|(|)|; (r_amod) day_22\NN\15154774|NONE (r_pobj) with_15\IN\0|methylprednisolone|In|;|included|and|patients|, (r_prep) treated_14\VBN\2376958|NONE (l_nsubj) patients_8\NNS\9898892|with|methylprednisolone|In|;|included|and|, (l_prep) with_9\IN\0|NONE (l_pobj) hl_13\NN\13616054|NONE
C056507_D006689 NONE gem_50\NNP\2743547| (r_compound) p_52\NNP\14622893|every||)|( (r_appos) days_48\NNS\15140892|,|)|m( (r_appos) d15_44\NNP\0|NONE (r_dobj) cisplatin_38\NN\0|.|were (r_nsubjpass) included_55\VBN\0|with|methylprednisolone|In|;|and|patients|, (r_conj) treated_14\VBN\2376958|NONE (l_nsubj) patients_8\NNS\9898892|with|methylprednisolone|In|;|included|and|, (l_prep) with_9\IN\0|NONE (l_pobj) hl_13\NN\13616054|NONE
C056507_D006689 NONE gem_0\NN\2743547| (r_compound) p_2\NNP\14622893|in|.|leading|,|chemotherapy|, (r_nsubj) is_3\VBZ\0|NONE (l_prep) in_21\IN\13603305|P|.|leading|,|chemotherapy|, (l_pobj) treatment_23\NN\654885|NONE (l_prep) of_24\IN\0|the (l_pobj) hl_28\NN\13616054|NONE
2931989
D015474_C563492 NONE isotretinoin_0\NNP\0|because|.|in|is (r_nsubjpass) contraindicated_2\VBN\872886|NONE (l_prep) because_5\IN\0|Isotretinoin|.|in|is (l_pobj) abnormalities_11\NNS\14034177|of (l_prep) after_12\IN\0|congenital|reported|the|many (l_pobj) use_14\NN\407535|NONE (l_prep) including_16\VBG\0|maternal|(|) (l_pobj) microphthalmos_17\NNS\0|NONE (l_conj) hypertelorism_20\NN\0|, (l_conj) hypoplasia_25\NN\14365950|orbital|,|and
D015474_D000013 NONE isotretinoin_0\NNP\0|because|.|in|is (r_nsubjpass) contraindicated_2\VBN\872886|NONE (l_prep) because_5\IN\0|Isotretinoin|.|in|is (l_pobj) abnormalities_11\NNS\14034177|of
D015474_D000152 NONE isotretinoin_13\JJ\0|who (r_dobj) received_12\VBD\2210855|drug||, (r_relcl) patients_10\NNS\9898892|NONE (l_appos) drug_18\NN\14778436||,|received (l_prep) in_19\IN\13603305|a|used (l_pobj) treatment_21\NN\654885|NONE (l_prep) of_22\IN\0|the (l_pobj) acne_25\NN\14171682|NONE
D015474_D006972 NONE isotretinoin_0\NNP\0|because|.|in|is (r_nsubjpass) contraindicated_2\VBN\872886|NONE (l_prep) because_5\IN\0|Isotretinoin|.|in|is (l_pobj) abnormalities_11\NNS\14034177|of (l_prep) after_12\IN\0|congenital|reported|the|many (l_pobj) use_14\NN\407535|NONE (l_prep) including_16\VBG\0|maternal|(|) (l_pobj) microphthalmos_17\NNS\0|NONE (l_conj) hypertelorism_20\NN\0|,
D015474_D008850 NONE isotretinoin_0\NNP\0|because|.|in|is (r_nsubjpass) contraindicated_2\VBN\872886|NONE (l_prep) because_5\IN\0|Isotretinoin|.|in|is (l_pobj) abnormalities_11\NNS\14034177|of (l_prep) after_12\IN\0|congenital|reported|the|many (l_pobj) use_14\NN\407535|NONE (l_prep) including_16\VBG\0|maternal|(|) (l_pobj) microphthalmos_17\NNS\0|NONE
18987260
D004317_D014511 CID adr_9\NNP\0|advanced|in (r_compound) nephropathy_10\NN\14573196|NONE (r_pobj) in_7\IN\13603305|urea (r_prep) clearance_6\NN\5089947|NONE (r_dobj) increased_4\VBN\169651|.|uraemia|Losartan|and (r_conj) reduced_1\VBD\441445|NONE (l_dobj) uraemia_2\RB\14204950|.|Losartan|increased|and
D004317_D006973 NONE adriamycin_3\JJ\0|NONE (r_amod) nephropathy_4\NN\14573196|NONE (r_pobj) of_2\IN\0|Reduced|.|in (r_prep) progression_1\NN\8457976|NONE (l_prep) in_5\IN\13603305|Reduced|.|of (l_pobj) rats_8\NNS\2329401|NONE (l_amod) hypertensive_7\JJ\10405694|treated
D004317_D006973 NONE adriamycin_37\NNS\0|ADR|)|( (r_nmod) nephropathy_41\NN\14573196|NONE (r_pobj) with_36\IN\0|renal|disease|in (r_prep) progression_28\NN\8457976|down (l_prep) in_29\IN\13603305|with|renal|disease (l_pobj) rats_32\NNS\2329401|NONE (l_amod) hypertensive_31\JJ\10405694|SHR|)|(
D004317_D006973 NONE adr_39\NNP\0|adriamycin|)|( (r_nmod) nephropathy_41\NN\14573196|NONE (r_pobj) with_36\IN\0|renal|disease|in (r_prep) progression_28\NN\8457976|down (l_prep) in_29\IN\13603305|with|renal|disease (l_pobj) rats_32\NNS\2329401|NONE (l_amod) hypertensive_31\JJ\10405694|SHR|)|(
D014508_D007674 NONE urea_5\NN\14727670|in (r_compound) clearance_6\NN\5089947|NONE (l_prep) in_7\IN\13603305|urea (l_pobj) nephropathy_10\NN\14573196|NONE
D004317_D007674 NONE adriamycin_3\JJ\0|NONE (r_amod) nephropathy_4\NN\14573196|NONE
D004317_D007674 NONE adriamycin_37\NNS\0|ADR|)|( (r_nmod) nephropathy_41\NN\14573196|NONE (r_pobj) with_36\IN\0|renal|disease|in (r_prep) progression_28\NN\8457976|down (l_compound) disease_27\NN\14061805|with|renal|in
D004317_D007674 NONE adriamycin_37\NNS\0|ADR|)|( (r_nmod) nephropathy_41\NN\14573196|NONE
D004317_D007674 NONE adr_39\NNP\0|adriamycin|)|( (r_nmod) nephropathy_41\NN\14573196|NONE (r_pobj) with_36\IN\0|renal|disease|in (r_prep) progression_28\NN\8457976|down (l_compound) disease_27\NN\14061805|with|renal|in
D004317_D007674 NONE adr_39\NNP\0|adriamycin|)|( (r_nmod) nephropathy_41\NN\14573196|NONE
D004317_D007674 NONE adr_9\NNP\0|advanced|in (r_compound) nephropathy_10\NN\14573196|NONE
D004317_D007674 NONE adr_15\NNP\0|NONE (r_compound) nephropathy_16\NN\14573196|NONE
D000804_D007674 NONE ii_13\CD\13741022|losartan|receptor|,|type (r_compound) blocker_16\NN\10101634|NONE (l_conj) losartan_18\NN\0|receptor|II|,|type (l_conj) potential_22\NN\14481929|,|and (l_prep) in_23\IN\13603305|its (l_pcomp) slowing_24\VBG\7296428|NONE (l_dobj) progression_28\NN\8457976|down (l_compound) disease_27\NN\14061805|with|renal|in
D000804_D007674 NONE ii_13\CD\13741022|losartan|receptor|,|type (r_compound) blocker_16\NN\10101634|NONE (l_conj) losartan_18\NN\0|receptor|II|,|type (l_conj) potential_22\NN\14481929|,|and (l_prep) in_23\IN\13603305|its (l_pcomp) slowing_24\VBG\7296428|NONE (l_dobj) progression_28\NN\8457976|down (l_prep) with_36\IN\0|renal|disease|in (l_pobj) nephropathy_41\NN\14573196|NONE
D019808_D011507 NONE losartan_4\NN\0|term (r_amod) treatment_5\NN\654885|.|besides|,|,|:|rate (r_nsubj) improved_11\VBD\126264|NONE (l_dobj) rate_14\NN\13815152|.|treatment|besides|,|,|: (l_acl) resulting_18\VBG\2633881|and|glomerulosclerosis|glomerular|filtration (l_prep) in_19\IN\13603305|NONE (l_pobj) proteinuria_21\NN\14299637|NONE
D019808_D011507 NONE losartan_3\NN\0|NONE (r_pobj) with_2\IN\0|Prolonged (r_prep) treatment_1\NN\654885|preventing|.|reduction|, (r_nsubj) showed_4\VBD\2137132|NONE (l_advcl) preventing_21\VBG\0|treatment|.|reduction|, (l_dobj) proteinuria_23\NN\14299637|thus
D004317_D001284 NONE adr_15\NNP\0|NONE (r_compound) nephropathy_16\NN\14573196|NONE (r_pobj) in_14\IN\13603305|infiltration|tubular|, (r_prep) atrophy_8\NN\14299637|that|losartan|could
D019808_D001284 NONE losartan_3\NN\0|NONE (r_pobj) with_2\IN\0|Prolonged (r_prep) treatment_1\NN\654885|preventing|.|reduction|, (r_nsubj) showed_4\VBD\2137132|NONE (l_dobj) reduction_6\NN\351485|preventing|treatment|.|, (l_prep) of_7\IN\0|further (l_pobj) glomerulosclerosis_8\NN\0|NONE (l_acl) associated_9\VBN\628491|NONE (l_prep) with_10\IN\0|NONE (l_pobj) progression_12\NN\8457976|NONE (l_prep) of_13\IN\0|reduced (l_pobj) atrophy_15\NN\14299637|NONE
D019808_D001284 NONE losartan_4\NN\0|that|atrophy|could (r_nsubj) prevent_6\VB\0|examination|. (l_dobj) atrophy_8\NN\14299637|that|losartan|could
D019808_D007674 NONE losartan_11\NN\0|NONE (r_pobj) by_10\IN\0|NONE (r_agent) treated_9\VBN\2376958|hypertensive (r_acl) rats_8\NNS\2329401|NONE (r_pobj) in_5\IN\13603305|Reduced|.|of (r_prep) progression_1\NN\8457976|NONE (l_prep) of_2\IN\0|Reduced|.|in (l_pobj) nephropathy_4\NN\14573196|NONE
D019808_D007674 NONE losartan_18\NN\0|receptor|II|,|type (l_conj) potential_22\NN\14481929|,|and (l_prep) in_23\IN\13603305|its (l_pcomp) slowing_24\VBG\7296428|NONE (l_dobj) progression_28\NN\8457976|down (l_compound) disease_27\NN\14061805|with|renal|in
D019808_D007674 NONE losartan_18\NN\0|receptor|II|,|type (l_conj) potential_22\NN\14481929|,|and (l_prep) in_23\IN\13603305|its (l_pcomp) slowing_24\VBG\7296428|NONE (l_dobj) progression_28\NN\8457976|down (l_prep) with_36\IN\0|renal|disease|in (l_pobj) nephropathy_41\NN\14573196|NONE
D019808_D007674 NONE losartan_0\NNP\0|.|uraemia|increased|and (r_nsubj) reduced_1\VBD\441445|NONE (l_conj) increased_4\VBN\169651|.|uraemia|Losartan|and (l_dobj) clearance_6\NN\5089947|NONE (l_prep) in_7\IN\13603305|urea (l_pobj) nephropathy_10\NN\14573196|NONE
D019808_D007674 NONE losartan_4\NN\0|that|atrophy|could (r_nsubj) prevent_6\VB\0|examination|. (l_dobj) atrophy_8\NN\14299637|that|losartan|could (l_prep) in_14\IN\13603305|infiltration|tubular|, (l_pobj) nephropathy_16\NN\14573196|NONE
D019808_D005921 NONE losartan_4\NN\0|term (r_amod) treatment_5\NN\654885|.|besides|,|,|:|rate (r_nsubj) improved_11\VBD\126264|NONE (l_dobj) rate_14\NN\13815152|.|treatment|besides|,|,|: (l_conj) glomerulosclerosis_17\NN\0|and|resulting|glomerular|filtration
D019808_D005921 NONE losartan_3\NN\0|NONE (r_pobj) with_2\IN\0|Prolonged (r_prep) treatment_1\NN\654885|preventing|.|reduction|, (r_nsubj) showed_4\VBD\2137132|NONE (l_dobj) reduction_6\NN\351485|preventing|treatment|.|, (l_prep) of_7\IN\0|further (l_pobj) glomerulosclerosis_8\NN\0|NONE
D019808_D007676 NONE losartan_3\NN\0|NONE (r_pobj) with_2\IN\0|Prolonged (r_prep) treatment_1\NN\654885|preventing|.|reduction|, (r_nsubj) showed_4\VBD\2137132|NONE (l_advcl) preventing_21\VBG\0|treatment|.|reduction|, (l_dobj) proteinuria_23\NN\14299637|thus (l_conj) failure_27\NN\66216|heavy|and
D019808_D007676 NONE losartan_0\NNP\0|to|.|rate (r_nsubj) reduces_1\VBZ\441445|NONE (l_prep) to_13\IN\0|.|rate|Losartan (l_pobj) disease_18\NN\14061805|NONE
D019808_D014511 NONE losartan_0\NNP\0|.|uraemia|increased|and (r_nsubj) reduced_1\VBD\441445|NONE (l_dobj) uraemia_2\RB\14204950|.|Losartan|increased|and
D004317_D007676 NONE adr_7\NNP\0| (r_npadvmod) induced_9\VBN\1627355|segmental|focal (r_amod) glomerulosclerosis_12\NN\0|NONE (r_pobj) of_6\IN\0|NONE (r_prep) progression_5\NN\8457976|NONE (r_pobj) of_4\IN\0|the (r_prep) rate_3\NN\13815152|to|.|Losartan (r_dobj) reduces_1\VBZ\441445|NONE (l_prep) to_13\IN\0|.|rate|Losartan (l_pobj) disease_18\NN\14061805|NONE
D019808_D006973 NONE losartan_11\NN\0|NONE (r_pobj) by_10\IN\0|NONE (r_agent) treated_9\VBN\2376958|hypertensive (r_acl) rats_8\NNS\2329401|NONE (l_amod) hypertensive_7\JJ\10405694|treated
D019808_D006973 NONE losartan_18\NN\0|receptor|II|,|type (l_conj) potential_22\NN\14481929|,|and (l_prep) in_23\IN\13603305|its (l_pcomp) slowing_24\VBG\7296428|NONE (l_dobj) progression_28\NN\8457976|down (l_prep) in_29\IN\13603305|with|renal|disease (l_pobj) rats_32\NNS\2329401|NONE (l_amod) hypertensive_31\JJ\10405694|SHR|)|(
D004317_D005923 CID adr_7\NNP\0| (r_npadvmod) induced_9\VBN\1627355|segmental|focal (r_amod) glomerulosclerosis_12\NN\0|NONE
D000804_D006973 NONE ii_13\CD\13741022|losartan|receptor|,|type (r_compound) blocker_16\NN\10101634|NONE (l_conj) losartan_18\NN\0|receptor|II|,|type (l_conj) potential_22\NN\14481929|,|and (l_prep) in_23\IN\13603305|its (l_pcomp) slowing_24\VBG\7296428|NONE (l_dobj) progression_28\NN\8457976|down (l_prep) in_29\IN\13603305|with|renal|disease (l_pobj) rats_32\NNS\2329401|NONE (l_amod) hypertensive_31\JJ\10405694|SHR|)|(
D019808_D005355 NONE losartan_3\NN\0|NONE (r_pobj) with_2\IN\0|Prolonged (r_prep) treatment_1\NN\654885|preventing|.|reduction|, (r_nsubj) showed_4\VBD\2137132|NONE (l_dobj) reduction_6\NN\351485|preventing|treatment|.|, (l_prep) of_7\IN\0|further (l_pobj) glomerulosclerosis_8\NN\0|NONE (l_acl) associated_9\VBN\628491|NONE (l_prep) with_10\IN\0|NONE (l_pobj) progression_12\NN\8457976|NONE (l_prep) of_13\IN\0|reduced (l_pobj) atrophy_15\NN\14299637|NONE (l_conj) fibrosis_18\NN\14204950|tubular|and
D019808_D005355 NONE losartan_4\NN\0|that|atrophy|could (r_nsubj) prevent_6\VB\0|examination|. (l_dobj) atrophy_8\NN\14299637|that|losartan|could (l_conj) infiltration_11\NN\975452|tubular|in|, (l_conj) fibrosis_13\NN\14204950|and|interstitial
D019808_D005923 NONE losartan_0\NNP\0|to|.|rate (r_nsubj) reduces_1\VBZ\441445|NONE (l_dobj) rate_3\NN\13815152|to|.|Losartan (l_prep) of_4\IN\0|the (l_pobj) progression_5\NN\8457976|NONE (l_prep) of_6\IN\0|NONE (l_pobj) glomerulosclerosis_12\NN\0|NONE
D004317_D005355 NONE adr_15\NNP\0|NONE (r_compound) nephropathy_16\NN\14573196|NONE (r_pobj) in_14\IN\13603305|infiltration|tubular|, (r_prep) atrophy_8\NN\14299637|that|losartan|could (l_conj) infiltration_11\NN\975452|tubular|in|, (l_conj) fibrosis_13\NN\14204950|and|interstitial
D014508_D014511 NONE urea_5\NN\14727670|in (r_compound) clearance_6\NN\5089947|NONE (r_dobj) increased_4\VBN\169651|.|uraemia|Losartan|and (r_conj) reduced_1\VBD\441445|NONE (l_dobj) uraemia_2\RB\14204950|.|Losartan|increased|and
1522360
D012293_D006461 CID rifampin_8\NN\2716205|intermittent (r_amod) therapy_9\NN\657604|NONE (r_dobj) following_6\VBG\8180190|failure|.|Intravascular|and (r_prep) hemolysis_1\NN\13509528|NONE
D012293_D006461 CID rifampin_8\NN\2716205|therapy|hemolysis|rare|. (r_advmod) is_10\VBZ\0|NONE (l_nsubj) hemolysis_1\NN\13509528|therapy|rifampin|rare|.
D012293_D006461 CID rifampin_12\NN\2716205|NONE (r_pobj) following_11\VBG\8180190|who|failure (r_prep) developed_5\VBD\1753788|with|Two (l_dobj) failure_10\NN\66216|who|following (l_nmod) hemolysis_6\NN\13509528|renal|acute
D012293_D007918 NONE rifampin_12\NN\2716205|NONE (r_pobj) following_11\VBG\8180190|who|failure (r_prep) developed_5\VBD\1753788|with|Two (r_relcl) patients_1\NNS\9898892|are|. (l_prep) with_2\IN\0|developed|Two (l_pobj) leprosy_3\NN\14127211|NONE
D012293_D058186 CID rifampin_8\NN\2716205|intermittent (r_amod) therapy_9\NN\657604|NONE (r_dobj) following_6\VBG\8180190|failure|.|Intravascular|and (r_prep) hemolysis_1\NN\13509528|NONE (l_conj) failure_5\NN\66216|.|Intravascular|and|following
D012293_D058186 CID rifampin_8\NN\2716205|therapy|hemolysis|rare|. (r_advmod) is_10\VBZ\0|NONE (l_nsubj) hemolysis_1\NN\13509528|therapy|rifampin|rare|. (l_acl) leading_2\VBG\4339291|Intravascular (l_prep) to_3\IN\0|NONE (l_pobj) failure_6\NN\66216|NONE
D012293_D058186 CID rifampin_12\NN\2716205|NONE (r_pobj) following_11\VBG\8180190|who|failure (r_prep) developed_5\VBD\1753788|with|Two (l_dobj) failure_10\NN\66216|who|following
D012293_D051437 NONE rifampin_11\NN\2716205|NONE (r_pobj) of_10\IN\0|the (r_prep) use_9\NN\407535|NONE (r_pobj) with_7\IN\0|NONE (r_prep) associated_6\VBN\628491|a|rare (r_acl) complication_5\NN\1073995|.|failure (r_attr) is_2\VBZ\0|NONE (l_nsubj) failure_1\NN\66216|.|complication
24283660
D016559_D012640 CID tacrolimus_0\NNP\0| (r_npadvmod) related_2\VBN\628491|experience|.||after (r_amod) seizure_3\NN\14081375|NONE
D016559_D012640 CID tac_41\NNP\0|NONE (r_compound) level_42\NN\4916342|NONE (r_pobj) trough_40\NN\9366017|and|,|after|total (r_conj) bilirubin_35\NN\14756039|showed|.|,|before|Pugh|, (r_conj) score_29\NN\5736149|NONE (l_ccomp) showed_2\VBD\2137132|bilirubin|.|,|before|Pugh|, (l_ccomp) included_13\VBD\0|analysis (l_nsubj) factors_6\NNS\7326557|after|LT|gender|that (l_acl) associated_7\VBN\628491|risk|the (l_prep) with_8\IN\0|NONE (l_pobj) seizures_9\NNS\14081375|NONE
D016559_D012640 CID tac_5\NNP\0|trough (r_compound) level_6\NN\4916342|that|factor (r_nsubj) was_7\VBD\0|.|analysis (l_attr) factor_12\NN\7326557|that|level (l_acl) associated_13\VBN\628491|risk|the|independent|only (l_prep) with_14\IN\0|NONE (l_pobj) seizures_16\NNS\14081375|NONE
D016559_D012640 CID tac_2\NNP\0|High|trough (r_compound) level_3\NN\4916342|.|factor (r_nsubj) was_4\VBD\0|NONE (l_attr) factor_7\NN\7326557|.|level (l_relcl) contributed_9\VBD\126264|predominant|the (l_prep) to_10\IN\0|that (l_pobj) seizures_11\NNS\14081375|NONE
D016559_D012640 CID tac_22\NNP\0| (r_npadvmod) related_24\VBN\628491|NONE (r_amod) seizures_25\NNS\14081375|NONE
D001663_D012640 NONE bilirubin_35\NN\14756039|showed|.|,|before|Pugh|, (r_conj) score_29\NN\5736149|NONE (l_ccomp) showed_2\VBD\2137132|bilirubin|.|,|before|Pugh|, (l_ccomp) included_13\VBD\0|analysis (l_nsubj) factors_6\NNS\7326557|after|LT|gender|that (l_acl) associated_7\VBN\628491|risk|the (l_prep) with_8\IN\0|NONE (l_pobj) seizures_9\NNS\14081375|NONE
D016559_D058625 NONE tac_41\NNP\0|NONE (r_compound) level_42\NN\4916342|NONE (r_pobj) trough_40\NN\9366017|and|,|after|total (r_conj) bilirubin_35\NN\14756039|showed|.|,|before|Pugh|, (r_conj) score_29\NN\5736149|NONE (l_ccomp) showed_2\VBD\2137132|bilirubin|.|,|before|Pugh|, (l_ccomp) included_13\VBD\0|analysis (l_dobj) gender_14\NN\6309383|factors|after|LT|that (l_conj) score_22\NN\5736149|, (l_compound) disease_21\NN\14061805|before
D001663_D058625 NONE bilirubin_35\NN\14756039|showed|.|,|before|Pugh|, (r_conj) score_29\NN\5736149|NONE (l_ccomp) showed_2\VBD\2137132|bilirubin|.|,|before|Pugh|, (l_ccomp) included_13\VBD\0|analysis (l_dobj) gender_14\NN\6309383|factors|after|LT|that (l_conj) score_22\NN\5736149|, (l_compound) disease_21\NN\14061805|before
2453942
D005680_D012640 NONE gaba_21\NNP\14601829|NONE (r_pobj) of_20\IN\0|the (r_prep) concentration_19\NN\4916342|at|in (r_dobj) measuring_17\VBG\407535|NONE (l_prep) at_31\IN\14622893|concentration|in (l_pobj) onset_33\NN\7325190|NONE (l_prep) of_34\IN\0|the (l_pobj) seizures_35\NNS\14081375|NONE
D001556_D012640 CID lindane_5\NN\14919948|NONE (r_pobj) of_4\IN\0|)|(|mg/kg|the|on (r_prep) effect_3\NN\34213|We|by|. (r_dobj) studied_1\VBD\0|NONE (l_prep) by_16\IN\0|We|.|effect (l_pcomp) measuring_17\VBG\407535|NONE (l_prep) at_31\IN\14622893|concentration|in (l_pobj) onset_33\NN\7325190|NONE (l_prep) of_34\IN\0|the (l_pobj) seizures_35\NNS\14081375|NONE
D001556_D012640 CID lindane_11\NN\14919948|NONE (r_compound) administration_12\NN\1133281|NONE (r_pobj) after_10\IN\0|+/|. (r_prep) min_9\NN\15154774|NONE (r_pobj) at_5\IN\14622893|convulsions|animals|. (r_prep) suffered_2\VBD\2110220|NONE (l_dobj) convulsions_4\NNS\14081375|at|animals|.
D001556_D020258 NONE lindane_0\NN\14919948|.|insecticide (r_nsubj) is_6\VBZ\0|NONE (l_attr) insecticide_9\NN\14980215|.|Lindane (l_prep) with_10\IN\0|an|organochlorine (l_pobj) effects_13\NNS\13245626|NONE (l_amod) neurotoxic_12\JJ\0|known
D001556_D020258 NONE hexachlorocyclohexane_4\NN\0|(|) (r_appos) lindane_0\NN\14919948|.|insecticide (r_nsubj) is_6\VBZ\0|NONE (l_attr) insecticide_9\NN\14980215|.|Lindane (l_prep) with_10\IN\0|an|organochlorine (l_pobj) effects_13\NNS\13245626|NONE (l_amod) neurotoxic_12\JJ\0|known
D004298_D012640 NONE dopamine_23\NN\14807737|, (r_conj) gaba_21\NNP\14601829|NONE (r_pobj) of_20\IN\0|the (r_prep) concentration_19\NN\4916342|at|in (r_dobj) measuring_17\VBG\407535|NONE (l_prep) at_31\IN\14622893|concentration|in (l_pobj) onset_33\NN\7325190|NONE (l_prep) of_34\IN\0|the (l_pobj) seizures_35\NNS\14081375|NONE
20009434
D008727_D001656 NONE mtx_11\NNP\0|in (r_compound) therapy_12\NN\657604|NONE (r_pobj) after_8\IN\0|We|case (r_prep) report_1\VBP\6470073|.|patient|,|boy (r_ccomp) was_21\VBD\0|NONE (l_attr) boy_26\NN\9624168|.|patient|,|report (l_relcl) received_29\VBN\2210855|old|a (l_dobj) transplantation_35\NN\671351|who|had (l_prep) for_36\IN\0|related|liver|a (l_pobj) atresia_39\NN\14501726|NONE
D008727_D002051 NONE methotrexate_3\NN\2722166|treatment|,|.|cause|but (r_nsubj) is_9\VBZ\0|NONE (l_attr) treatment_12\NN\654885|methotrexate|,|.|cause|but (l_prep) for_13\IN\0|important|an (l_pobj) lymphoma_15\NN\14239918|NONE
D008727_D002051 NONE mtx_7\NNP\0|)|dose (r_appos) methotrexate_3\NN\2722166|treatment|,|.|cause|but (r_nsubj) is_9\VBZ\0|NONE (l_attr) treatment_12\NN\654885|methotrexate|,|.|cause|but (l_prep) for_13\IN\0|important|an (l_pobj) lymphoma_15\NN\14239918|NONE
D008727_D007674 NONE methotrexate_3\NN\2722166|treatment|,|.|cause|but (r_nsubj) is_9\VBZ\0|NONE (l_conj) cause_19\VB\7323922|methotrexate|treatment|,|.|but (l_dobj) toxicity_23\NN\13576101|can|delayed
D008727_D007674 NONE mtx_7\NNP\0|)|dose (r_appos) methotrexate_3\NN\2722166|treatment|,|.|cause|but (r_nsubj) is_9\VBZ\0|NONE (l_conj) cause_19\VB\7323922|methotrexate|treatment|,|.|but (l_dobj) toxicity_23\NN\13576101|can|delayed
D008727_D056486 NONE methotrexate_3\NN\2722166|treatment|,|.|cause|but (r_nsubj) is_9\VBZ\0|NONE (l_conj) cause_19\VB\7323922|methotrexate|treatment|,|.|but (l_dobj) toxicity_23\NN\13576101|can|delayed
D008727_D056486 NONE mtx_7\NNP\0|)|dose (r_appos) methotrexate_3\NN\2722166|treatment|,|.|cause|but (r_nsubj) is_9\VBZ\0|NONE (l_conj) cause_19\VB\7323922|methotrexate|treatment|,|.|but (l_dobj) toxicity_23\NN\13576101|can|delayed
D008727_D058186 CID methotrexate_7\NN\2722166|dose|in (r_compound) therapy_8\NN\657604|NONE (r_pobj) after_3\IN\0|.|Acute|renal (r_prep) failure_2\NN\66216|NONE
D008727_D058186 CID mtx_11\NNP\0|in (r_compound) therapy_12\NN\657604|NONE (r_pobj) after_8\IN\0|We|case (r_prep) report_1\VBP\6470073|.|patient|,|boy (l_dobj) case_3\NN\7283608|We|after (l_prep) of_4\IN\0|a (l_pobj) failure_7\NN\66216|NONE
D008727_D058186 CID mtx_3\NNP\0|Subsequent (r_compound) therapy_4\NN\657604|failure|. (r_nsubj) caused_5\VBD\1617192|NONE (l_dobj) failure_8\NN\66216|therapy|.
14616590
D015742_D010146 CID disoprivan_32\NNP\0|NONE (r_pobj) with_31\IN\0|NONE (r_prep) than_30\IN\0|AM (r_prep) with_28\IN\0|Pain|frequently|. (r_prep) occurred_25\VBD\0|NONE (l_nsubj) pain_0\NN\14299637|frequently|.|with
D015742_D013924 CID disoprivan_32\NNP\0|NONE (r_pobj) with_31\IN\0|NONE (r_prep) than_30\IN\0|AM (r_prep) with_28\IN\0|Pain|frequently|. (r_prep) occurred_25\VBD\0|NONE (l_nsubj) pain_0\NN\14299637|frequently|.|with (l_conj) thrombophlebitis_14\NN\14352890|and|,|(|)|on|%|.
23846525
C055162_D056486 CID clopidogrel_4\NN\0|NONE (r_pobj) with_3\IN\0|NONE (r_prep) associated_2\VBD\628491|:|Acute|.|report (r_acl) hepatitis_1\NN\14127211|NONE
C055162_D056486 CID clopidogrel_5\RB\0| (r_npadvmod) related_7\VBN\628491|acute (r_amod) hepatitis_9\NN\14127211|NONE
C055162_D056486 CID clopidogrel_7\NN\0|to (r_pobj) due_5\JJ\5174653|about (r_amod) reports_0\NNS\6470073|.|,|after|are|in (l_prep) about_1\IN\0|due (l_pobj) cases_2\NNS\7283608|NONE (l_prep) of_3\IN\0|NONE (l_pobj) hepatotoxicity_4\NN\0|NONE
C055162_D056486 CID clopidogrel_19\JJ\0|is|when (r_nsubjpass) prescribed_21\VBN\748282|should|carefully|that|physicians|risk (r_advcl) consider_9\VB\689344|,|.|In|we (l_dobj) risk_11\NN\14541044|should|carefully|that|physicians|prescribed (l_prep) of_12\IN\0|the (l_pobj) injury_17\NN\14052046|NONE
1779253
D002211_D051474 NONE capsaicin_3\NN\15032661|NONE (l_prep) in_4\IN\13603305|:|%|.|efficacy|Topical (l_pobj) neuralgia_9\NN\14322699|NONE
D002211_D051474 NONE capsaicin_18\NN\15032661|NONE (r_pobj) to_16\IN\0|NONE (r_prep) response_15\NN\11410625|NONE (r_pobj) of_14\IN\0|predictors|and (r_prep) action_11\NN\30358|NONE (r_pobj) of_10\IN\0|time| (r_prep) course_9\NN\883297|,|duration||,|with (r_nmod) patients_21\NNS\9898892|were|.|In|,|,|for|with (l_prep) with_22\IN\0|course|,|duration||, (l_pobj) neuralgia_27\NN\14322699|NONE
D002211_D051474 NONE capsaicin_18\NN\15032661|NONE (r_pobj) to_16\IN\0|NONE (r_prep) response_15\NN\11410625|NONE (r_pobj) of_14\IN\0|predictors|and (r_prep) action_11\NN\30358|NONE (r_pobj) of_10\IN\0|time| (r_prep) course_9\NN\883297|,|duration||,|with (r_nmod) patients_21\NNS\9898892|were|.|In|,|,|for|with (l_prep) with_22\IN\0|course|,|duration||, (l_pobj) neuralgia_27\NN\14322699|NONE (l_appos) phn_29\NNP\0|herpetic|(|)|chronic
D002211_D051474 NONE capsaicin_42\NN\15032661|% (r_compound) cream_43\NN\8386555|NONE (r_pobj) with_39\IN\0|were|.|In|,|patients|,|for (r_prep) treated_38\VBN\2376958|NONE (l_nsubjpass) patients_21\NNS\9898892|were|.|In|,|,|for|with (l_prep) with_22\IN\0|course|,|duration||, (l_pobj) neuralgia_27\NN\14322699|NONE
D002211_D051474 NONE capsaicin_42\NN\15032661|% (r_compound) cream_43\NN\8386555|NONE (r_pobj) with_39\IN\0|were|.|In|,|patients|,|for (r_prep) treated_38\VBN\2376958|NONE (l_nsubjpass) patients_21\NNS\9898892|were|.|In|,|,|for|with (l_prep) with_22\IN\0|course|,|duration||, (l_pobj) neuralgia_27\NN\14322699|NONE (l_appos) phn_29\NNP\0|herpetic|(|)|chronic
D002211_D051474 NONE capsaicin_26\NN\15032661|NONE (l_prep) in_27\IN\13603305|NONE (l_pobj) phn_28\NNP\0|NONE
D002211_D008413 CID capsaicin_28\NN\15032661| (r_npadvmod) induced_30\VBN\1627355|;|||(|intolerable|burning (r_amod) sensations_32\NNS\5708432|such (l_appos) 4_34\CD\13741022|;||(|induced|intolerable|burning (l_conj) mastitis_37\NN\14336539|)|or
573555
D011433_D006932 NONE propranolol_27\NN\0|chronic (r_amod) therapy_28\NN\657604|NONE (r_pobj) with_25\IN\0|can|not|statistically|be (r_prep) correlated_24\VBN\2657219|that|hypoglycemia|and|invariable|not (r_conj) are_16\VBP\13600404|We|. (l_nsubj) hypoglycemia_5\NN\14299637|that|and|correlated|invariable|not (l_conj) hyperbilirubinemia_7\NN\14204950|,|reported
D011433_D001049 NONE propranolol_27\NN\0|chronic (r_amod) therapy_28\NN\657604|NONE (r_pobj) with_25\IN\0|can|not|statistically|be (r_prep) correlated_24\VBN\2657219|that|hypoglycemia|and|invariable|not (r_conj) are_16\VBP\13600404|We|. (l_nsubj) hypoglycemia_5\NN\14299637|that|and|correlated|invariable|not (l_conj) hyperbilirubinemia_7\NN\14204950|,|reported (l_conj) polycythemia_9\NN\14189204|, (l_conj) apnea_12\NN\14299637|,
D011433_D007003 NONE propranolol_27\NN\0|chronic (r_amod) therapy_28\NN\657604|NONE (r_pobj) with_25\IN\0|can|not|statistically|be (r_prep) correlated_24\VBN\2657219|that|hypoglycemia|and|invariable|not (r_conj) are_16\VBP\13600404|We|. (l_nsubj) hypoglycemia_5\NN\14299637|that|and|correlated|invariable|not
D011433_D001919 NONE propranolol_27\NN\0|chronic (r_amod) therapy_28\NN\657604|NONE (r_pobj) with_25\IN\0|can|not|statistically|be (r_prep) correlated_24\VBN\2657219|that|hypoglycemia|and|invariable|not (r_conj) are_16\VBP\13600404|We|. (l_nsubj) hypoglycemia_5\NN\14299637|that|and|correlated|invariable|not (l_conj) hyperbilirubinemia_7\NN\14204950|,|reported (l_conj) polycythemia_9\NN\14189204|, (l_conj) apnea_12\NN\14299637|, (l_conj) bradycardia_15\NN\14110674|neonatal|and|,
D011433_D011086 NONE propranolol_27\NN\0|chronic (r_amod) therapy_28\NN\657604|NONE (r_pobj) with_25\IN\0|can|not|statistically|be (r_prep) correlated_24\VBN\2657219|that|hypoglycemia|and|invariable|not (r_conj) are_16\VBP\13600404|We|. (l_nsubj) hypoglycemia_5\NN\14299637|that|and|correlated|invariable|not (l_conj) hyperbilirubinemia_7\NN\14204950|,|reported (l_conj) polycythemia_9\NN\14189204|,
7173007
D003287_D064420 NONE media_9\NNS\3575240|polyvidone|and|are|preferred|. (r_oprd) considered_5\VBN\689344|NONE (l_conj) preferred_22\VBN\1777210|polyvidone|and|are|media|. (l_prep) because_14\IN\0|Hexabrix|be|should (l_pobj) toxicity_18\NN\13576101|perhaps|of
C025504_D004244 CID x_3\NNP\13745420|The (r_compound) group_4\NN\2137|incidence|. (r_nsubj) had_5\VBD\0|NONE (l_dobj) incidence_8\NN\13821570|group|. (l_prep) of_9\IN\0|higher|a (l_pobj) nausea_10\NN\14299637|NONE (l_conj) dizziness_12\NN\14299637|and
C025504_D009325 CID x_3\NNP\13745420|The (r_compound) group_4\NN\2137|incidence|. (r_nsubj) had_5\VBD\0|NONE (l_dobj) incidence_8\NN\13821570|group|. (l_prep) of_9\IN\0|higher|a (l_pobj) nausea_10\NN\14299637|NONE
D007485_D064420 NONE hexabrix_0\NNP\0|NONE (r_nmod) polyvidone_3\NN\0|and|are|media|preferred|. (r_nsubjpass) considered_5\VBN\689344|NONE (l_conj) preferred_22\VBN\1777210|polyvidone|and|are|media|. (l_prep) because_14\IN\0|Hexabrix|be|should (l_pobj) toxicity_18\NN\13576101|perhaps|of
D007485_D064420 NONE hexabrix_19\NNP\0|because|be|should (r_nsubjpass) preferred_22\VBN\1777210|polyvidone|and|are|media|. (l_prep) because_14\IN\0|Hexabrix|be|should (l_pobj) toxicity_18\NN\13576101|perhaps|of
D000100_D064420 NONE polyvidone_3\NN\0|and|are|media|preferred|. (r_nsubjpass) considered_5\VBN\689344|NONE (l_conj) preferred_22\VBN\1777210|polyvidone|and|are|media|. (l_prep) because_14\IN\0|Hexabrix|be|should (l_pobj) toxicity_18\NN\13576101|perhaps|of
C006753_D015746 CID endografine_1\NNP\0|The (r_compound) group_2\NN\2137|incidence|. (r_nsubj) had_3\VBD\0|NONE (l_dobj) incidence_6\NN\13821570|.|group (l_prep) of_7\IN\0|a|higher (l_pobj) pain_9\NN\14299637|NONE
1449452
D004077_D001281 NONE digoxin_5\NN\15060131|NONE (l_compound) fibrillation_4\NN\14361664|NONE
D004077_D009203 NONE digoxin_19\NN\15060131|mortality|that|may|after (r_nsubj) increase_21\VB\13576355|a (l_prep) after_23\IN\0|mortality|digoxin|that|may (l_pobj) infarction_25\NN\14204950|NONE
D004077_D009203 NONE digoxin_19\NN\15060131|mortality|that|may|after (r_nsubj) increase_21\VB\13576355|a (l_prep) after_23\IN\0|mortality|digoxin|that|may (l_pobj) infarction_25\NN\14204950|NONE (l_appos) mi_27\NNP\14207561|myocardial|(|)
D004077_D001145 CID digoxin_2\NN\15060131|,|effects|.|Also (r_nsubj) has_3\VBZ\13888491|NONE (l_dobj) effects_5\NNS\13245626|digoxin|,|.|Also (l_prep) as_7\IN\14622893|undesirable (l_pcomp) increasing_8\VBG\169651|such (l_conj) causing_16\VBG\30358|and|resistance|, (l_dobj) arrhythmias_17\NNS\14103288|NONE
9197951
D004053_D011681 NONE dep_4\NNP\0|while (l_appos) changes_7\NNS\7283608|, (l_prep) in_8\IN\13603305|especially (l_pobj) power_11\NN\4723816|NONE (l_prep) of_12\IN\0|the|total (l_pobj) oscillation_14\NN\13518963|NONE
D004053_D001714 CID diethylpropion_23\NN\0|NONE (r_pobj) of_19\IN\0|anticraving|the (r_prep) efficacy_18\NN\5199286|NONE (r_dobj) evaluating_15\VBG\670261|a (r_acl) study_14\NN\635850|NONE (r_pobj) in_12\IN\13603305|a (r_prep) subject_11\NN\6598915|who (r_attr) was_9\VBD\0|A|dependent|old (r_relcl) man_7\NN\9605289|manic|during|. (r_nsubj) became_27\VBD\146138|NONE (l_acomp) manic_28\JJ\0|during|.|man
D004053_D001714 CID dep_25\NNP\0|stimulant|the|medication (r_appos) diethylpropion_23\NN\0|NONE (r_pobj) of_19\IN\0|anticraving|the (r_prep) efficacy_18\NN\5199286|NONE (r_dobj) evaluating_15\VBG\670261|a (r_acl) study_14\NN\635850|NONE (r_pobj) in_12\IN\13603305|a (r_prep) subject_11\NN\6598915|who (r_attr) was_9\VBD\0|A|dependent|old (r_relcl) man_7\NN\9605289|manic|during|. (r_nsubj) became_27\VBD\146138|NONE (l_acomp) manic_28\JJ\0|during|.|man
D004053_D001714 CID dep_4\NNP\0|while (r_pobj) on_3\IN\0|Pupillometric (r_prep) changes_1\NNS\7283608|,|different|. (r_nsubj) were_16\VBD\0|NONE (l_acomp) different_18\JJ\0|,|.|changes (l_prep) than_19\IN\0|dramatically (l_pobj) those_20\DT\0|NONE (l_acl) observed_21\VBN\2163746|NONE (l_prep) in_22\IN\13603305|NONE (l_pobj) subjects_27\NNS\6598915|NONE (l_relcl) become_31\VB\146138|the|other|eight|study (l_acomp) manic_32\JJ\0|who|did|not
D003042_D001714 NONE cocaine_4\NN\3492717| (r_npadvmod) dependent_6\JJ\9627906|A|old|was (r_amod) man_7\NN\9605289|manic|during|. (r_nsubj) became_27\VBD\146138|NONE (l_acomp) manic_28\JJ\0|during|.|man
25006961
D008094_D011141 CID lithium_20\NN\14625458| (r_npadvmod) induced_22\VBN\1627355|NONE (r_amod) polyuria_23\NN\14113228|NONE
D008094_D011141 CID lithium_18\NN\14625458| (r_npadvmod) induced_20\VBN\1627355|NONE (r_amod) ndi_21\NNP\0|NONE (r_pobj) in_17\IN\13603305|prevents|ablation|,|that|and|expression (r_prep) preserves_7\VBZ\7597145|.|data (l_conj) prevents_24\VBZ\0|ablation|,|that|and|expression|in (l_dobj) development_26\NN\248977|NONE (l_prep) of_27\IN\0|the (l_pobj) polyuria_30\NN\14113228|NONE
D008094_D011141 CID lithium_33\NN\14625458|NONE (r_compound) therapy_34\NN\657604|NONE (r_pobj) with_32\IN\0|NONE (r_prep) associated_31\VBN\628491|severe|the (r_acl) polyuria_30\NN\14113228|NONE
D008094_D018500 CID lithium_6\NN\14625458| (r_npadvmod) induced_8\VBN\1627355|diabetes (r_amod) insipidus_11\NN\0|Absence|.
D008094_D018500 CID lithium_0\NN\14625458|.|in|insipidus (r_nsubj) induces_6\VBZ\1627355|NONE (l_dobj) insipidus_9\NN\0|.|Lithium|in
D008094_D018500 CID lithium_0\NN\14625458|.|in|insipidus (r_nsubj) induces_6\VBZ\1627355|NONE (l_dobj) insipidus_9\NN\0|.|Lithium|in (l_appos) ndi_11\NNP\0|)|diabetes|(|nephrogenic
D008094_D018500 CID lithium_18\NN\14625458| (r_npadvmod) induced_20\VBN\1627355|NONE (r_amod) ndi_21\NNP\0|NONE
D008094_D018500 CID lithium_33\NN\14625458|NONE (r_compound) therapy_34\NN\657604|NONE (r_pobj) with_32\IN\0|NONE (r_prep) associated_31\VBN\628491|severe|the (r_acl) polyuria_30\NN\14113228|NONE (r_pobj) of_27\IN\0|the (r_prep) development_26\NN\248977|NONE (r_dobj) prevents_24\VBZ\0|ablation|,|that|and|expression|in (r_conj) preserves_7\VBZ\7597145|.|data (l_prep) in_17\IN\13603305|prevents|ablation|,|that|and|expression (l_pobj) ndi_21\NNP\0|NONE
6316193
D010852_D012640 CID picrotoxin_12\NN\0| (r_npadvmod) induced_14\VBN\1627355|by (r_amod) seizures_15\NNS\14081375|NONE
D010852_D012640 CID picrotoxin_24\NN\0|NONE (r_pobj) by_23\IN\0|in (r_agent) induced_22\VBN\1627355|NONE (r_acl) seizures_21\NNS\14081375|NONE
D010852_D012640 CID picrotoxin_31\NN\0| (r_npadvmod) induced_33\VBN\1627355|mortality|and (r_amod) seizures_34\NNS\14081375|,|,|totally|mumol
D002766_D012640 NONE cholecystokinin_17\NN\5408684|NONE (r_pobj) by_16\IN\0|induced (r_prep) seizures_15\NNS\14081375|NONE
D002766_D012640 NONE cholecystokinin_23\NN\5408684|NONE (r_pobj) of_22\IN\0|NONE (r_prep) analogues_21\NNS\4743605|and (r_conj) fragments_19\NNS\9385911|,|in (r_conj) cholecystokinin_17\NN\5408684|NONE (r_pobj) by_16\IN\0|induced (r_prep) seizures_15\NNS\14081375|NONE
D003975_D012640 NONE diazepam_27\NN\2830852|NONE (r_preconj) ,_26\,\0|,|seizures|totally|mumol (r_punct) prevented_30\VBD\0|,|peptide|activity|. (l_dobj) seizures_34\NNS\14081375|,|,|totally|mumol
D012844_D012640 NONE octapeptide_4\JJ\0|sulphate (r_compound) ester_6\NN\14727670|NONE (r_appos) cholecystokinin_3\NN\5408684|NONE (r_pobj) of_2\IN\0|cholecystokinin|and|CCKSE|Intraperitoneal (r_prep) administration_1\NN\1133281|.|latency (r_nsubj) enhanced_17\VBD\227165|NONE (l_dobj) latency_19\NN\15269513|administration|. (l_prep) of_20\IN\0|the (l_pobj) seizures_21\NNS\14081375|NONE
D012844_D012640 NONE cck-8-se_8\NNP\0|cholecystokinin|of|and|Intraperitoneal (r_parataxis) administration_1\NN\1133281|.|latency (r_nsubj) enhanced_17\VBD\227165|NONE (l_dobj) latency_19\NN\15269513|administration|. (l_prep) of_20\IN\0|the (l_pobj) seizures_21\NNS\14081375|NONE
D012844_D012640 NONE octapeptide_13\RB\0|)|nonsulphated (r_appos) cholecystokinin_12\NN\5408684|of|and|CCKSE|Intraperitoneal (r_conj) administration_1\NN\1133281|.|latency (r_nsubj) enhanced_17\VBD\227165|NONE (l_dobj) latency_19\NN\15269513|administration|. (l_prep) of_20\IN\0|the (l_pobj) seizures_21\NNS\14081375|NONE
D012844_D012640 NONE cck-8-ns_15\NNP\0|NONE (r_appos) octapeptide_13\RB\0|)|nonsulphated (r_appos) cholecystokinin_12\NN\5408684|of|and|CCKSE|Intraperitoneal (r_conj) administration_1\NN\1133281|.|latency (r_nsubj) enhanced_17\VBD\227165|NONE (l_dobj) latency_19\NN\15269513|administration|. (l_prep) of_20\IN\0|the (l_pobj) seizures_21\NNS\14081375|NONE
4631913
D014750_D007970 CID sulfate_11\NN\15010703|NONE (r_pobj) of_9\IN\0|NONE (r_prep) mg_8\NN\13717155|to|. (r_quantmod) 2.5_7\CD\0|NONE (r_pobj) of_4\IN\0|intratracheal (r_prep) inoculation_3\NN\828990|or (r_conj) intravenous_0\JJ\0|by|was|. (r_nsubjpass) followed_13\VBN\1835496|NONE (l_agent) by_14\IN\0|Intravenous|was|. (l_pobj) leukopenia_15\NN\14189204|NONE
D014750_D011552 CID sulfate_3\NN\15010703|NONE (l_prep) on_4\IN\0|vincristine (l_pobj) infections_6\NNS\14052046|NONE
19681452
D000431_D020520 NONE alcohol_10\NN\7881800|and (r_conj) cocaine_8\NN\3492717|NONE (r_nmod) intoxication_11\NN\14034177|NONE (r_pobj) after_7\IN\0|the|globus (r_prep) pallidus_6\NN\0|NONE
D003042_D020520 NONE cocaine_8\NN\3492717|NONE (r_nmod) intoxication_11\NN\14034177|NONE (r_pobj) after_7\IN\0|the|globus (r_prep) pallidus_6\NN\0|NONE
D003042_D020520 NONE cocaine_8\NN\3492717|NONE (r_pobj) of_7\IN\0|the (r_prep) use_6\NN\407535|NONE (r_pobj) after_4\IN\0|Bilateral|ganglia|basal|,|without|, (r_prep) infarcts_3\NNS\14204950|been|.|never|have
D003042_D001145 NONE cocaine_12\NN\3492717|NONE (r_pobj) to_11\IN\0|NONE (r_prep) related_10\VBN\628491|or|cardiac|transient|dysfunction (r_acl) arrhythmia_6\NN\14103288|causes|.|,|In
D000431_D002543 NONE alcohol_10\NN\7881800|and (r_conj) cocaine_8\NN\3492717|NONE (r_nmod) intoxication_11\NN\14034177|NONE (r_pobj) after_7\IN\0|the|globus (r_prep) pallidus_6\NN\0|NONE
D000431_D002545 NONE alcohol_19\NN\7881800|NONE (r_pobj) after_17\IN\0|of|the (r_prep) case_3\NN\7283608|We|. (l_prep) of_4\IN\0|the|after (l_pobj) man_9\NN\9605289|NONE (l_prep) with_10\IN\0|old|a (l_pobj) ischemia_12\NN\14195315|NONE (l_prep) of_13\IN\0|bilateral (l_pobj) pallidus_16\NN\0|NONE
D003042_D012131 NONE cocaine_12\NN\3492717|NONE (r_pobj) to_11\IN\0|NONE (r_prep) related_10\VBN\628491|or|cardiac|transient|dysfunction (r_acl) arrhythmia_6\NN\14103288|causes|.|,|In (l_conj) dysfunction_9\NN\14204950|or|cardiac|transient|related
D000431_D012131 NONE ethanol_14\NN\14708720|NONE (r_compound) use_15\NN\407535|and/or (r_conj) cocaine_12\NN\3492717|NONE (r_pobj) to_11\IN\0|NONE (r_prep) related_10\VBN\628491|or|cardiac|transient|dysfunction (r_acl) arrhythmia_6\NN\14103288|causes|.|,|In (l_conj) dysfunction_9\NN\14204950|or|cardiac|transient|related
D003042_D002543 NONE cocaine_8\NN\3492717|NONE (r_nmod) intoxication_11\NN\14034177|NONE (r_pobj) after_7\IN\0|the|globus (r_prep) pallidus_6\NN\0|NONE
D000431_D001145 NONE ethanol_14\NN\14708720|NONE (r_compound) use_15\NN\407535|and/or (r_conj) cocaine_12\NN\3492717|NONE (r_pobj) to_11\IN\0|NONE (r_prep) related_10\VBN\628491|or|cardiac|transient|dysfunction (r_acl) arrhythmia_6\NN\14103288|causes|.|,|In
D003042_D002545 CID cocaine_22\NN\3492717|intranasal (r_compound) use_23\NN\407535|excessive|and (r_conj) alcohol_19\NN\7881800|NONE (r_pobj) after_17\IN\0|of|the (r_prep) case_3\NN\7283608|We|. (l_prep) of_4\IN\0|the|after (l_pobj) man_9\NN\9605289|NONE (l_prep) with_10\IN\0|old|a (l_pobj) ischemia_12\NN\14195315|NONE (l_prep) of_13\IN\0|bilateral (l_pobj) pallidus_16\NN\0|NONE
D000431_-1 NONE ethanol_14\NN\14708720|NONE (r_compound) use_15\NN\407535|and/or (r_conj) cocaine_12\NN\3492717|NONE (r_pobj) to_11\IN\0|NONE (r_prep) related_10\VBN\628491|or|cardiac|transient|dysfunction (r_acl) arrhythmia_6\NN\14103288|causes|.|,|In (r_nsubj) were_16\VBD\0|NONE (l_attr) causes_20\NNS\7323922|.|arrhythmia|,|In (l_prep) of_21\IN\0|the|likely (l_pobj) hypoperfusion_23\NN\0|NONE
D003042_D002544 NONE cocaine_0\NN\3492717|.|factor (r_nsubj) is_1\VBZ\0|NONE (l_attr) factor_4\NN\7326557|.|Cocaine (l_prep) for_5\IN\0|a|risk (l_pobj) stroke_10\NN\556313|NONE
D003932_D020520 CID heroin_11\NN\3492717|NONE (r_pobj) with_10\IN\0|often|are|.|infarctions (r_prep) associated_9\VBN\628491|NONE (l_nsubjpass) infarctions_5\NNS\14204950|with|often|are|.
D003932_D020520 CID heroin_12\NN\3492717|concurrent (r_compound) use_13\NN\407535|NONE (r_pobj) without_10\IN\0|Bilateral|ganglia|after|basal|,|, (r_prep) infarcts_3\NNS\14204950|been|.|never|have
D003042_-1 NONE cocaine_12\NN\3492717|NONE (r_pobj) to_11\IN\0|NONE (r_prep) related_10\VBN\628491|or|cardiac|transient|dysfunction (r_acl) arrhythmia_6\NN\14103288|causes|.|,|In (r_nsubj) were_16\VBD\0|NONE (l_attr) causes_20\NNS\7323922|.|arrhythmia|,|In (l_prep) of_21\IN\0|the|likely (l_pobj) hypoperfusion_23\NN\0|NONE
D003042_D020521 NONE cocaine_0\NN\3492717|.|factor (r_nsubj) is_1\VBZ\0|NONE (l_attr) factor_4\NN\7326557|.|Cocaine (l_prep) for_5\IN\0|a|risk (l_pobj) stroke_10\NN\556313|NONE
2320485
D008750_D000743 CID methyldopa_0\NNP\2721160|presenting||.|in|anemia (r_nsubj) induced_2\VBN\1627355|NONE (l_dobj) anemia_4\NN\14189204|presenting||.|Methyldopa|in
D008750_D000743 CID methyldopa_5\NN\2721160| (r_npadvmod) induced_7\VBN\1627355|hemolytic|in (r_amod) anemia_9\NN\14189204|NONE
D008750_D014947 NONE methyldopa_7\NN\2721160|NONE (r_pobj) with_5\IN\0|boy|been|during|.|had (r_prep) treated_4\VBN\2376958|NONE (l_prep) during_8\IN\0|boy|been|.|had|with (l_pobj) admission_11\NN\49003|NONE (l_compound) trauma_10\NN\14052046|prior|a
D008750_D000744 NONE methyldopa_0\NNP\2721160|.|anemia (r_nsubj) causes_1\VBZ\7323922|NONE (l_dobj) anemia_5\NN\14189204|.|Methyldopa
D008750_D013575 NONE methyldopa_0\NNP\2721160|presenting||.|in|anemia (r_nsubj) induced_2\VBN\1627355|NONE (l_advcl) presenting_10\VBG\2137132||.|Methyldopa|in|anemia (l_prep) as_11\IN\14622893|NONE (l_pobj) syncope_14\NN\7478169|NONE
D008750_D013575 NONE methyldopa_5\NN\2721160| (r_npadvmod) induced_7\VBN\1627355|hemolytic|in (r_amod) anemia_9\NN\14189204|NONE (l_prep) in_10\IN\13603305|hemolytic|induced (l_pobj) boy_15\NN\9624168|NONE (l_relcl) presented_17\VBD\2137132|a|old (l_prep) with_22\IN\0|who|to (l_pobj) syncope_25\NN\7478169|NONE
D008750_D004630 NONE methyldopa_5\NN\2721160| (r_npadvmod) induced_7\VBN\1627355|hemolytic|in (r_amod) anemia_9\NN\14189204|NONE (l_prep) in_10\IN\13603305|hemolytic|induced (l_pobj) boy_15\NN\9624168|NONE (l_relcl) presented_17\VBD\2137132|a|old (l_prep) to_18\IN\0|who|with (l_pobj) department_21\NN\8220714|NONE
16092435
D004317_D066126 NONE adriamycin_10\NNS\0| (r_npadvmod) evoked_12\VBN\1617192|in (r_amod) cardiotoxicity_13\NN\0|NONE
D004317_D066126 NONE adriamycin_0\NNP\0|in|.|toxicity (r_cc) evoked_8\VBN\1617192|NONE (l_dobj) toxicity_12\NN\13576101|Adriamycin|in|.
D004317_D066126 NONE adr_13\NNP\0|NONE (r_compound) cardiotoxicity_14\NN\0|not|.|did|ribose
D004317_D009202 CID adriamycin_7\NNS\0| (r_npadvmod) induced_9\VBN\1627355|NONE (r_amod) myocardiopathy_10\NN\14103288|NONE
D012266_D009202 NONE ribose_5\NN\14792703|NONE (l_prep) on_6\IN\0||in|d (l_pobj) myocardiopathy_10\NN\14103288|NONE
D012266_D066126 NONE ribose_8\NN\14792703|NONE (l_prep) on_9\IN\0||d (l_pobj) cardiotoxicity_13\NN\0|NONE
D012266_D066126 NONE ribose_2\NN\14792703|not|.|cardiotoxicity|did (r_nsubj) influence_12\VB\5190804|NONE (l_dobj) cardiotoxicity_14\NN\0|not|.|did|ribose
2782734
D000420_D001249 NONE salbutamol_15\NN\0|Tachyphylaxis|in|. (r_dobj) inhaled_14\VBN\1198101|NONE (l_prep) in_16\IN\13603305|Tachyphylaxis|.|salbutamol (l_pobj) asthmatics_17\NNS\7846|NONE
D000420_D001249 NONE salbutamol_4\NN\0|NONE (r_pobj) of_2\IN\0|High (r_prep) doses_1\NNS\3740161|and|,|.|improvements|associated (r_nsubj) produce_5\VB\7555863|NONE (l_dobj) improvements_7\NNS\7359599|doses|and|,|.|associated (l_prep) in_8\IN\13603305|substantial (l_pobj) response_10\NN\11410625|NONE (l_prep) in_11\IN\13603305|airway (l_pobj) patients_12\NNS\9898892|NONE (l_prep) with_13\IN\0|NONE (l_pobj) asthma_14\NN\14145095|NONE
D000420_D001249 NONE salbutamol_34\NN\0|high (r_appos) dose_32\NN\3740161|NONE (r_pobj) with_30\IN\0|a|day (r_prep) treatment_29\NN\654885|were|predicted|daily|.|salbutamol (r_dobj) given_26\VBN\5892096|NONE (l_nsubjpass) predicted_10\VBD\916909|treatment|were|daily|.|salbutamol (l_nsubj) patients_2\NNS\9898892|requiring|,|,|)|% (l_amod) asthmatic_1\JJ\7846|(|FEV|Twelve
D000420_D001249 NONE salbutamol_46\NN\0|treatment|were|predicted|daily|. (r_dobj) given_26\VBN\5892096|NONE (l_nsubjpass) predicted_10\VBD\916909|treatment|were|daily|.|salbutamol (l_nsubj) patients_2\NNS\9898892|requiring|,|,|)|% (l_amod) asthmatic_1\JJ\7846|(|FEV|Twelve
24675088
D004317_D066126 NONE doxorubicin_12\RB\2716866| (r_npadvmod) induced_14\VBN\1627355|NONE (r_amod) cardiotoxicity_15\NN\0|NONE
D004317_D064420 NONE doxorubicin_12\NN\2716866|NONE (r_pobj) of_10\IN\0|a|rat (r_prep) model_9\NN\5888929|In|we|.|,|,|have|applying (r_dobj) utilized_6\VBN\0|NONE (l_advcl) applying_17\VBG\0|In|we|.|,|model|,|have (l_conj) provide_31\VB\2199590|,|approaches (l_dobj) characterization_35\NN\6724763|to (l_prep) to_36\IN\0|comprehensive|the (l_pobj) date_37\NN\15155220|NONE (l_prep) of_38\IN\0|NONE (l_pobj) timecourse_40\NN\0|NONE (l_prep) of_41\IN\0|the (l_pobj) events_48\NNS\23100|NONE (l_acl) underlying_49\VBG\2604760|serological (l_dobj) toxicity_51\NN\13576101|NONE
D004317_D064420 NONE dox)-induced_14\VBN\0|( (r_amod) cardiomyopathy_15\NN\14103288|progressive (r_appos) doxorubicin_12\NN\2716866|NONE (r_pobj) of_10\IN\0|a|rat (r_prep) model_9\NN\5888929|In|we|.|,|,|have|applying (r_dobj) utilized_6\VBN\0|NONE (l_advcl) applying_17\VBG\0|In|we|.|,|model|,|have (l_conj) provide_31\VB\2199590|,|approaches (l_dobj) characterization_35\NN\6724763|to (l_prep) to_36\IN\0|comprehensive|the (l_pobj) date_37\NN\15155220|NONE (l_prep) of_38\IN\0|NONE (l_pobj) timecourse_40\NN\0|NONE (l_prep) of_41\IN\0|the (l_pobj) events_48\NNS\23100|NONE (l_acl) underlying_49\VBG\2604760|serological (l_dobj) toxicity_51\NN\13576101|NONE
D005682_D018754 NONE gadolinium_9\NN\14625458|,|grading|contrast (r_compound) enhancement_11\NN\248977|NONE (l_conj) grading_14\NN\1009871|,|contrast|gadolinium (l_conj) dysfunction_18\NN\14204950|,|and|histopathological
D004317_D009202 CID doxorubicin_12\NN\2716866|NONE (l_appos) cardiomyopathy_15\NN\14103288|progressive
D004317_D009202 CID dox)-induced_14\VBN\0|( (r_amod) cardiomyopathy_15\NN\14103288|progressive
24100055
D006493_D013921 CID heparin_2\NN\2718259| (r_npadvmod) induced_4\VBN\1627355|type|thrombocytopenia (r_amod) ii_7\NNP\13741022|NONE
D006493_D013921 CID heparin_6\NN\2718259| (r_npadvmod) induced_8\VBN\1627355|mediated|thrombocytopenia|)|(|II|type (r_amod) ii_11\NNP\13741022|NONE
D006493_D013921 CID heparin_6\NN\2718259| (r_npadvmod) induced_8\VBN\1627355|mediated|thrombocytopenia|)|(|II|type (r_amod) ii_11\NNP\13741022|NONE (l_appos) ii_15\NNP\13741022|mediated|thrombocytopenia|)|induced|(|type
D006493_D013921 CID heparin_6\NN\2718259| (r_npadvmod) induced_8\VBN\1627355|mediated|thrombocytopenia|)|(|II|type (r_amod) ii_11\NNP\13741022|NONE (r_pobj) of_2\IN\0|as|The (r_prep) impact_1\NN\7339329|is|,|yet|with|not|. (l_prep) as_17\IN\14622893|of|The (l_pobj) cause_19\NN\7323922|NONE (l_prep) of_20\IN\0|a (l_pobj) thrombocytopenia_21\NN\14189204|NONE
D006493_D013921 CID heparin_12\NN\2718259|NONE (r_pobj) of_10\IN\0|the (r_prep) use_9\NN\407535|For|performed|,|and|should|be (r_nsubjpass) avoided_15\VBN\0|NONE (l_prep) for_0\IN\0|performed|use|,|and|should|be (l_pobj) reduction_2\NN\351485|NONE (l_prep) of_3\IN\0|further (l_pobj) ii_6\NNP\13741022|NONE
D006493_D013921 CID heparin_29\NN\2718259|NONE (r_pobj) with_23\IN\0|after|.|anticoagulation|should|be (r_prep) performed_22\VBN\0|For|use|,|and|should|be (r_conj) avoided_15\VBN\0|NONE (l_prep) for_0\IN\0|performed|use|,|and|should|be (l_pobj) reduction_2\NN\351485|NONE (l_prep) of_3\IN\0|further (l_pobj) ii_6\NNP\13741022|NONE
1837756
D012701_D003866 NONE serotonin_37\NN\14807737|reuptake (r_compound) inhibitors_39\NNS\20090|NONE (r_pobj) with_36\IN\0|NONE (r_prep) associated_35\VBN\628491|paranoid (r_acl) exacerbations_34\NNS\374224|NONE (r_pobj) to_32\IN\0|.|may|disorders|vulnerability (r_prep) present_29\VB\28270|NONE (l_nsubj) disorders_2\NNS\14034177|.|may|vulnerability|to
D005473_D010259 CID fluoxetine_10\NN\4169152|Five|of (r_advmod) cases_1\NNS\7283608|are|here|. (l_prep) of_2\IN\0|fluoxetine|Five (l_pobj) exacerbation_4\NN\374224|NONE (l_amod) paranoid_3\JJ\10490141|with
D004298_D010259 NONE dopamine_18\NN\14807737|mediated|HT (r_compound) release_19\NN\3748886|NONE (r_pobj) including_13\VBG\0|several|,|cryptic|, (r_prep) mechanisms_11\NNS\13446390|pharmacology|Although (r_attr) remain_7\VBP\2604760|downregulation|to|,|might|,|. (l_nsubj) pharmacology_2\NN\6043075|mechanisms|Although (l_prep) of_5\IN\0|neurobiology|the|and (l_pobj) paranoia_6\NN\14398067|NONE
D012701_D011605 NONE serotonin_37\NN\14807737|reuptake (r_compound) inhibitors_39\NNS\20090|NONE (r_pobj) with_36\IN\0|NONE (r_prep) associated_35\VBN\628491|paranoid (r_acl) exacerbations_34\NNS\374224|NONE (r_pobj) to_32\IN\0|.|may|disorders|vulnerability (r_prep) present_29\VB\28270|NONE (l_nsubj) disorders_2\NNS\14034177|.|may|vulnerability|to (l_prep) including_4\VBG\0|depressive|)|(|Complicated (l_pobj) atypicality_5\NN\14501726|in (l_conj) chronicity_11\NN\0|,|of (l_conj) psychosis_13\NN\14380140|,
D012701_D011605 NONE serotonin_37\NN\14807737|reuptake (r_compound) inhibitors_39\NNS\20090|NONE (r_pobj) with_36\IN\0|NONE (r_prep) associated_35\VBN\628491|paranoid (r_acl) exacerbations_34\NNS\374224|NONE (r_pobj) to_32\IN\0|.|may|disorders|vulnerability (r_prep) present_29\VB\28270|NONE (l_nsubj) disorders_2\NNS\14034177|.|may|vulnerability|to (l_prep) including_4\VBG\0|depressive|)|(|Complicated (l_prep) in_20\IN\13603305|atypicality (l_pobj) course_22\NN\883297|NONE (l_prep) of_23\IN\0|the (l_pobj) psychosis_26\NN\14380140|NONE
D012701_D010259 NONE serotonin_0\NNP\14807737|.|reuptake|,|paranoia (r_compound) inhibitors_2\NNS\20090|NONE (l_appos) paranoia_4\NN\14398067|.|reuptake|,|Serotonin
D012701_D010259 NONE serotonin_7\NN\14807737|reuptake|the (r_compound) inhibitors_9\NNS\20090|NONE (r_pobj) with_5\IN\0|paranoid (r_prep) exacerbation_4\NN\374224|NONE (l_amod) paranoid_3\JJ\10490141|with
D012701_D010259 NONE serotonin_37\NN\14807737|reuptake (r_compound) inhibitors_39\NNS\20090|NONE (r_pobj) with_36\IN\0|NONE (r_prep) associated_35\VBN\628491|paranoid (r_acl) exacerbations_34\NNS\374224|NONE (l_amod) paranoid_33\JJ\10490141|associated
D012701_D010259 NONE serotonin_9\NN\14807737|reuptake (r_compound) blockers_11\NNS\10101634|NONE (r_pobj) with_8\IN\0|possible|paranoid|in (r_prep) exacerbations_7\NNS\374224|NONE (l_amod) paranoid_6\JJ\10490141|with|possible|in
D012701_D010259 NONE serotonin_9\NN\14807737|reuptake (r_compound) blockers_11\NNS\10101634|NONE (r_pobj) with_8\IN\0|possible|paranoid|in (r_prep) exacerbations_7\NNS\374224|NONE (r_pobj) to_4\IN\0|and|.|raise|cases|attention (r_prep) call_2\VBP\6272290|NONE (l_conj) raise_16\VB\5108947|and|.|to|cases|attention (l_dobj) considerations_18\NNS\5770926|NONE (l_acl) regarding_19\VBG\689344|neurobiological (l_pobj) paranoia_20\NN\14398067|NONE
D000639_D010259 CID amitriptyline_12\NN\4482543|and (r_conj) fluoxetine_10\NN\4169152|Five|of (r_advmod) cases_1\NNS\7283608|are|here|. (l_prep) of_2\IN\0|fluoxetine|Five (l_pobj) exacerbation_4\NN\374224|NONE (l_amod) paranoid_3\JJ\10490141|with
3297909
D013827_D007565 NONE thiabendazole_12\NN\2720201|NONE (r_pobj) to_11\IN\0|NONE (r_prep) exposure_10\NN\5042871|wk (r_pobj) after_9\IN\0|jaundice|man|. (r_prep) developed_5\VBD\1753788|NONE (l_dobj) jaundice_6\NN\14299637|man|after|.
D013827_D001649 NONE thiabendazole_5\NN\2720201|NONE (r_compound) administration_6\NN\1133281|NONE (r_pobj) after_4\IN\0|duct|Progressive|. (r_prep) injury_3\NN\14052046|NONE
6106951
D005479_D012640 CID fzp_2\NNP\0|in (r_compound) toxocity_3\NN\0|NONE (r_pobj) of_1\IN\0|NONE (r_prep) signs_0\NNS\6643763|retching|salivation|. (r_nsubj) included_6\VBD\0|NONE (l_advcl) retching_14\NN\72989|salivation|.|Signs (l_dobj) tremors_17\NNS\345926|, (l_conj) convulsions_19\NNS\14081375|and|muscle
D005479_D012640 CID fzp_6\NNP\0|first|.|against|As|, (r_nsubj) protected_8\VBD\1127795|NONE (l_prep) against_9\IN\0|first|.|FZP|As|, (l_pobj) convulsions_10\NNS\14081375|NONE
D005479_D012640 CID fzp_3\NNP\0|NONE (r_pobj) of_2\IN\0|These (r_prep) doses_1\NNS\3740161|cause|.|lower (r_nsubj) were_4\VBD\0|NONE (l_prep) cause_11\VB\7323922|doses|.|lower (l_dobj) convulsions_12\NNS\14081375|NONE
D005479_D014202 NONE fzp_2\NNP\0|in (r_compound) toxocity_3\NN\0|NONE (r_pobj) of_1\IN\0|NONE (r_prep) signs_0\NNS\6643763|retching|salivation|. (r_nsubj) included_6\VBD\0|NONE (l_advcl) retching_14\NN\72989|salivation|.|Signs (l_dobj) tremors_17\NNS\345926|,
D005479_D012798 NONE fzp_2\NNP\0|in (r_compound) toxocity_3\NN\0|NONE (r_pobj) of_1\IN\0|NONE (r_prep) signs_0\NNS\6643763|retching|salivation|. (r_nsubj) included_6\VBD\0|NONE (l_dobj) salivation_8\NN\13553916|retching|.|Signs
D005479_D064420 NONE fzp_2\NNP\0|in (r_compound) toxocity_3\NN\0|NONE
D005479_D004827 NONE fzp_9\NNP\0|NONE (r_pobj) of_8\IN\0|in|the (r_prep) use_7\NN\407535|NONE (l_prep) in_10\IN\13603305|of|the (l_pobj) situations_12\NNS\24720|NONE (l_relcl) is_16\VBZ\0|clinical (l_attr) excitability_19\NN\5653575|in|there (l_prep) as_22\IN\14622893|neural|,|increased (l_pobj) epilepsy_23\NN\14085708|such
44072
C024986_D001145 CID bacl2_9\NN\0|with|,|, (r_pobj) with_8\IN\0|with|.||types|are (r_prep) used_6\VBN\0|NONE (l_nsubjpass) types_1\NNS\5839024|with|.||with|are (l_prep) of_2\IN\0|Four (l_pobj) arrhythmia_4\NN\14103288|NONE
C024986_D001145 CID bacl2_32\NN\0|NONE (r_pobj) with_31\IN\0||and|) (r_conj) in_25\IN\13603305|inhibition|( (r_prep) causing_13\VBG\30358|compound|.|,|activity (r_advcl) manifests_2\VBZ\6479665|NONE (l_dobj) activity_4\NN\30358|compound|.|causing|, (l_prep) in_5\IN\13603305|antiarrhythmic|used (l_pobj) models_7\NNS\5888929|NONE (l_prep) of_8\IN\0|all (l_pobj) arrhythmia_10\NN\14103288|NONE
C024986_D001145 CID bacl2_32\NN\0|NONE (r_pobj) with_31\IN\0||and|) (r_conj) in_25\IN\13603305|inhibition|( (r_prep) causing_13\VBG\30358|compound|.|,|activity (l_dobj) inhibition_15\NN\1068773|(|in (l_prep) on_16\IN\0|greatest (l_pobj) arrhythmia_18\NN\14103288|NONE
D000157_D001145 CID aconitine_21\NN\0|NONE (r_pobj) with_20\IN\0|and|G (r_conj) with_16\IN\0|.||types|with|are (r_prep) used_6\VBN\0|NONE (l_nsubjpass) types_1\NNS\5839024|with|.||with|are (l_prep) of_2\IN\0|Four (l_pobj) arrhythmia_4\NN\14103288|NONE
D002725_D001145 CID chloroform_12\NN\14620895| (r_compound) adrenaline_14\NN\14807929|NONE (r_pobj) with_11\IN\0|,|BaCl|, (r_conj) with_8\IN\0|with|.||types|are (r_prep) used_6\VBN\0|NONE (l_nsubjpass) types_1\NNS\5839024|with|.||with|are (l_prep) of_2\IN\0|Four (l_pobj) arrhythmia_4\NN\14103288|NONE
D002725_D001145 CID chloroform_21\NN\14620895| (r_compound) adrenaline_23\NN\14807929|NONE (r_pobj) by_20\IN\0|NONE (r_agent) induced_19\VBN\1627355|the (r_acl) arrhythmia_18\NN\14103288|NONE (r_pobj) on_16\IN\0|greatest (r_prep) inhibition_15\NN\1068773|(|in (r_dobj) causing_13\VBG\30358|compound|.|,|activity (r_advcl) manifests_2\VBZ\6479665|NONE (l_dobj) activity_4\NN\30358|compound|.|causing|, (l_prep) in_5\IN\13603305|antiarrhythmic|used (l_pobj) models_7\NNS\5888929|NONE (l_prep) of_8\IN\0|all (l_pobj) arrhythmia_10\NN\14103288|NONE
D002725_D001145 CID chloroform_21\NN\14620895| (r_compound) adrenaline_23\NN\14807929|NONE (r_pobj) by_20\IN\0|NONE (r_agent) induced_19\VBN\1627355|the (r_acl) arrhythmia_18\NN\14103288|NONE
D010042_D001145 CID g_18\NN\13717155|with|and (r_pobj) with_16\IN\0|.||types|with|are (r_prep) used_6\VBN\0|NONE (l_nsubjpass) types_1\NNS\5839024|with|.||with|are (l_prep) of_2\IN\0|Four (l_pobj) arrhythmia_4\NN\14103288|NONE
D004837_D001145 CID adrenaline_14\NN\14807929|NONE (r_pobj) with_11\IN\0|,|BaCl|, (r_conj) with_8\IN\0|with|.||types|are (r_prep) used_6\VBN\0|NONE (l_nsubjpass) types_1\NNS\5839024|with|.||with|are (l_prep) of_2\IN\0|Four (l_pobj) arrhythmia_4\NN\14103288|NONE
D004837_D001145 CID adrenaline_23\NN\14807929|NONE (r_pobj) by_20\IN\0|NONE (r_agent) induced_19\VBN\1627355|the (r_acl) arrhythmia_18\NN\14103288|NONE (r_pobj) on_16\IN\0|greatest (r_prep) inhibition_15\NN\1068773|(|in (r_dobj) causing_13\VBG\30358|compound|.|,|activity (r_advcl) manifests_2\VBZ\6479665|NONE (l_dobj) activity_4\NN\30358|compound|.|causing|, (l_prep) in_5\IN\13603305|antiarrhythmic|used (l_pobj) models_7\NNS\5888929|NONE (l_prep) of_8\IN\0|all (l_pobj) arrhythmia_10\NN\14103288|NONE
D004837_D001145 CID adrenaline_23\NN\14807929|NONE (r_pobj) by_20\IN\0|NONE (r_agent) induced_19\VBN\1627355|the (r_acl) arrhythmia_18\NN\14103288|NONE
10087562
D004280_D006333 NONE dobutamine_9\NN\0|dose|intermittent|low|in (r_compound) treatment_10\NN\654885|NONE (l_prep) in_11\IN\13603305|dose|dobutamine|intermittent|low (l_pobj) patient_13\NN\9898892|NONE (l_prep) with_14\IN\0|a (l_pobj) failure_20\NN\66216|NONE
D004280_D006333 NONE dobutamine_52\NN\0|NONE (r_pobj) of_40\IN\0|one (r_prep) cycle_39\NN\15269513|NONE (r_pobj) during_37\IN\0|who|prolongation (r_prep) developed_28\VBD\1753788|significant|ventricular (r_relcl) arrhythmias_26\NNS\14103288|NONE (r_pobj) of_23\IN\0|NONE (r_prep) absence_22\NN\14449405|cardiomyopathy|and|to (r_conj) dilated_19\VBN\303465|.|case|authors (r_xcomp) describe_2\VBP\1001294|NONE (l_dobj) case_4\NN\7283608|.|authors|dilated (l_prep) of_5\IN\0|the (l_pobj) woman_10\NN\9605289|NONE (l_prep) with_11\IN\0|old|a (l_pobj) failure_16\NN\66216|NONE
D004280_D008133 NONE dobutamine_52\NN\0|NONE (r_pobj) of_40\IN\0|one (r_prep) cycle_39\NN\15269513|NONE (r_pobj) during_37\IN\0|who|prolongation (r_prep) developed_28\VBD\1753788|significant|ventricular (l_dobj) prolongation_30\NN\1017987|who|during
D004280_D001145 NONE dobutamine_52\NN\0|NONE (r_pobj) of_40\IN\0|one (r_prep) cycle_39\NN\15269513|NONE (r_pobj) during_37\IN\0|who|prolongation (r_prep) developed_28\VBD\1753788|significant|ventricular (r_relcl) arrhythmias_26\NNS\14103288|NONE
D004280_D001145 NONE dobutamine_10\NN\0|NONE (r_pobj) during_8\IN\0|of|This (r_prep) report_1\NN\6470073|.|hypothesis (r_nsubj) supports_11\VBZ\407535|NONE (l_dobj) hypothesis_13\NN\7162194|report|. (l_acl) occur_19\VB\0|the (l_nsubj) arrhythmias_17\NNS\14103288|may|with|that
D004280_D016171 CID dobutamine_9\NN\0|dose|intermittent|low|in (r_compound) treatment_10\NN\654885|NONE (r_pobj) during_5\IN\0|de|tachycardia|.|Torsade (r_prep) pointes_2\VBZ\831651|NONE
D004280_D016171 CID dobutamine_52\NN\0|NONE (r_pobj) of_40\IN\0|one (r_prep) cycle_39\NN\15269513|NONE (r_pobj) during_37\IN\0|who|prolongation (r_prep) developed_28\VBD\1753788|significant|ventricular (l_dobj) prolongation_30\NN\1017987|who|during (l_conj) tachycardia_36\NN\14110674|QT|and (l_nmod) pointes_34\FW\831651|ventricular
D004280_D016171 CID dobutamine_10\NN\0|NONE (r_pobj) during_8\IN\0|of|This (r_prep) report_1\NN\6470073|.|hypothesis (l_prep) of_2\IN\0|during|This (l_pobj) tachycardia_7\NN\14110674|NONE (l_nmod) pointes_5\FW\831651|ventricular
D004280_D002311 NONE dobutamine_9\NN\0|dose|intermittent|low|in (r_compound) treatment_10\NN\654885|NONE (l_prep) in_11\IN\13603305|dose|dobutamine|intermittent|low (l_pobj) patient_13\NN\9898892|NONE (l_prep) with_14\IN\0|a (l_pobj) failure_20\NN\66216|NONE (l_amod) cardiomyopathy_16\NN\14103288|dilated|heart
D004280_D002311 NONE dobutamine_52\NN\0|NONE (r_pobj) of_40\IN\0|one (r_prep) cycle_39\NN\15269513|NONE (r_pobj) during_37\IN\0|who|prolongation (r_prep) developed_28\VBD\1753788|significant|ventricular (r_relcl) arrhythmias_26\NNS\14103288|NONE (r_pobj) of_23\IN\0|NONE (r_prep) absence_22\NN\14449405|cardiomyopathy|and|to (r_conj) dilated_19\VBN\303465|.|case|authors (l_advmod) cardiomyopathy_20\NN\14103288|absence|and|to
D004280_D017180 NONE dobutamine_9\NN\0|dose|intermittent|low|in (r_compound) treatment_10\NN\654885|NONE (r_pobj) during_5\IN\0|de|tachycardia|.|Torsade (r_prep) pointes_2\VBZ\831651|NONE (l_appos) tachycardia_4\NN\14110674|de|during|.|Torsade
D004280_D017180 NONE dobutamine_52\NN\0|NONE (r_pobj) of_40\IN\0|one (r_prep) cycle_39\NN\15269513|NONE (r_pobj) during_37\IN\0|who|prolongation (r_prep) developed_28\VBD\1753788|significant|ventricular (l_dobj) prolongation_30\NN\1017987|who|during (l_conj) tachycardia_36\NN\14110674|QT|and
D004280_D017180 NONE dobutamine_10\NN\0|NONE (r_pobj) during_8\IN\0|of|This (r_prep) report_1\NN\6470073|.|hypothesis (l_prep) of_2\IN\0|during|This (l_pobj) tachycardia_7\NN\14110674|NONE
3083835
D010406_D000707 CID penicillin_0\NNP\2716866|. (r_compound) anaphylaxis_1\NN\14533203|NONE
D010406_D000707 CID penicillin_4\NN\2716866|oral (r_compound) anaphylaxis_5\NN\14533203|NONE
D010406_D000707 CID penicillin_4\NN\2716866|oral (r_compound) anaphylaxis_5\NN\14533203|NONE (r_pobj) of_2\IN\0|A (r_prep) case_1\NN\7283608|,|and|reviewed|is (r_nsubjpass) described_7\VBN\1001294|NONE (l_conj) reviewed_27\VBN\644583|,|and|case|is (l_nsubjpass) terminology_11\NN\6286395|.|are (l_conj) occurrence_13\NN\29378|the|, (l_conj) manifestations_16\NNS\7321772|, (l_conj) pathogenesis_18\NN\13533470|,|clinical (l_conj) prevention_20\NN\1073995|, (l_conj) treatment_23\NN\654885|and|, (l_prep) of_24\IN\0|NONE (l_pobj) anaphylaxis_25\NN\14533203|NONE
D010406_D000707 CID penicillin_7\NN\2716866|oral (r_compound) anaphylaxis_8\NN\14533203|NONE
2767010
D013327_D001145 CID strophanthidin_9\NN\0| (r_npadvmod) induced_11\VBN\1627355|in (r_amod) arrhythmias_12\NNS\14103288|NONE
C043114_D001145 NONE acc-9653_4\NN\0|necessary|phenytoin (r_nmod) sodium_7\NN\14625458|NONE (l_amod) necessary_8\JJ\2452|ACC|phenytoin (l_xcomp) convert_10\VB\7846|NONE (l_dobj) arrhythmia_12\NN\14103288|to|to
C043114_D001145 NONE sodium_7\NN\14625458|NONE (l_amod) necessary_8\JJ\2452|ACC|phenytoin (l_xcomp) convert_10\VB\7846|NONE (l_dobj) arrhythmia_12\NN\14103288|to|to
C043114_D001145 NONE sodium_2\NN\14625458|.|in (r_nsubj) displayed_3\VBD\2137132|NONE (l_prep) in_4\IN\13603305|.|sodium (l_pobj) activity_7\NN\30358|NONE (l_prep) against_8\IN\0|vitro|antiarrhythmic (l_pobj) arrhythmias_12\NNS\14103288|NONE
D010042_D017180 CID ouabain_7\NN\0| (r_npadvmod) induced_9\VBN\1627355|ventricular (r_amod) tachycardia_11\NN\14110674|NONE
C043114_D064420 NONE acc-9653_4\NNP\0|phenytoin (r_nmod) sodium_7\NN\14625458|NONE (r_pobj) of_3\IN\0|toxicity|Acute (r_prep) studies_2\NNS\635850|out|by|in|.|were (l_compound) toxicity_1\NN\13576101|Acute|of
C043114_D064420 NONE sodium_7\NN\14625458|NONE (r_pobj) of_3\IN\0|toxicity|Acute (r_prep) studies_2\NNS\635850|out|by|in|.|were (l_compound) toxicity_1\NN\13576101|Acute|of
C043114_D017180 NONE sodium_1\NN\14625458|in|activity|. (r_nsubj) have_2\VBP\7846|NONE (l_dobj) activity_5\NN\30358|sodium|in|. (l_prep) against_6\IN\0|antiarrhythmic|similar (l_pobj) tachycardia_11\NN\14110674|NONE
C043114_D012640 NONE acc-9653_0\NN\0|NONE (l_conj) have_4\VBP\7846|and (l_dobj) activity_7\NN\30358|.|sodium (l_prep) against_8\IN\0|anticonvulsant|equivalent (l_pobj) seizures_9\NNS\14081375|NONE
C043114_D012640 NONE sodium_3\NN\14625458|activity|. (r_nsubj) have_4\VBP\7846|and (l_dobj) activity_7\NN\30358|.|sodium (l_prep) against_8\IN\0|anticonvulsant|equivalent (l_pobj) seizures_9\NNS\14081375|NONE
9272404
D007052_D010146 CID ibuprofen_6\NNP\3828465|NONE (r_pobj) of_5\IN\0|NONE (r_prep) administration_4\NN\1133281|described|,|,|was|indicating|.|by (r_nsubjpass) followed_8\VBN\1835496|NONE (l_agent) by_9\IN\0|described|,|,|was|indicating|administration|. (l_pobj) decrease_11\NN\7296428|NONE (l_prep) in_12\IN\13603305|a|increase| (l_pobj) pain_14\NN\14299637|NONE
D007052_D010146 CID ibuprofen_6\NNP\3828465|NONE (r_pobj) of_5\IN\0|NONE (r_prep) administration_4\NN\1133281|described|,|,|was|indicating|.|by (r_nsubjpass) followed_8\VBN\1835496|NONE (l_agent) by_9\IN\0|described|,|,|was|indicating|administration|. (l_pobj) decrease_11\NN\7296428|NONE (l_appos) increase_22\NN\13576355|a||in (l_prep) in_23\IN\13603305|an (l_pobj) correlates_24\NNS\5857459|NONE (l_prep) of_25\IN\0|NONE (l_pobj) pain_27\NN\14299637|NONE
D007052_D010146 CID ibuprofen_6\NNP\3828465|NONE (r_pobj) of_5\IN\0|NONE (r_prep) administration_4\NN\1133281|described|,|,|was|indicating|.|by (r_nsubjpass) followed_8\VBN\1835496|NONE (l_advcl) indicating_29\VBG\952524|described|,|,|was|administration|.|by (l_dobj) effect_32\NN\34213|NONE (l_prep) on_35\IN\0|specific|a|of (l_pobj) interaction_37\NN\37396|NONE (l_prep) between_38\IN\0|the (l_pobj) stimuli_41\NNS\5816287|NONE (l_compound) pain_40\NN\14299637|under|the
D007052_D010146 CID ibuprofen_34\NN\3828465|NONE (r_pobj) of_33\IN\0|on|specific|a (r_prep) effect_32\NN\34213|NONE (r_dobj) indicating_29\VBG\952524|described|,|,|was|administration|.|by (r_advcl) followed_8\VBN\1835496|NONE (l_agent) by_9\IN\0|described|,|,|was|indicating|administration|. (l_pobj) decrease_11\NN\7296428|NONE (l_prep) in_12\IN\13603305|a|increase| (l_pobj) pain_14\NN\14299637|NONE
D007052_D010146 CID ibuprofen_34\NN\3828465|NONE (r_pobj) of_33\IN\0|on|specific|a (r_prep) effect_32\NN\34213|NONE (r_dobj) indicating_29\VBG\952524|described|,|,|was|administration|.|by (r_advcl) followed_8\VBN\1835496|NONE (l_agent) by_9\IN\0|described|,|,|was|indicating|administration|. (l_pobj) decrease_11\NN\7296428|NONE (l_appos) increase_22\NN\13576355|a||in (l_prep) in_23\IN\13603305|an (l_pobj) correlates_24\NNS\5857459|NONE (l_prep) of_25\IN\0|NONE (l_pobj) pain_27\NN\14299637|NONE
D007052_D010146 CID ibuprofen_34\NN\3828465|NONE (r_pobj) of_33\IN\0|on|specific|a (r_prep) effect_32\NN\34213|NONE (l_prep) on_35\IN\0|specific|a|of (l_pobj) interaction_37\NN\37396|NONE (l_prep) between_38\IN\0|the (l_pobj) stimuli_41\NNS\5816287|NONE (l_compound) pain_40\NN\14299637|under|the
D002245_D010146 NONE co2_10\NN\14836127|NONE (r_pobj) of_9\IN\0|short (r_prep) pulses_8\NNS\7345593|NONE (r_pobj) of_6\IN\0|NONE (r_prep) means_5\NNS\44150|NONE (r_pobj) by_4\IN\0|was|duration|pain|to (r_agent) applied_3\VBN\0|NONE (l_nsubjpass) pain_1\NN\14299637|was|duration|by|to
D002245_D010146 NONE co2_10\NN\14836127|NONE (r_pobj) of_9\IN\0|short (r_prep) pulses_8\NNS\7345593|NONE (r_pobj) of_6\IN\0|NONE (r_prep) means_5\NNS\44150|NONE (r_pobj) by_4\IN\0|was|duration|pain|to (r_agent) applied_3\VBN\0|NONE (l_parataxis) duration_17\NN\15113229|was|by|pain|to (l_conj) induced_31\VBN\1627355|interval|,|,|ms|stimulus|and|( (l_nsubjpass) pain_29\NN\14299637|%|by|.|was|in|)
D002245_D010146 NONE co2_17\NN\14836127|the (r_compound) stimuli_18\NNS\5816287|NONE (r_pobj) to_15\IN\0|NONE (r_prep) response_14\NN\11410625|NONE (r_pobj) in_13\IN\13603305|were|CSSEPs|. (r_prep) obtained_12\VBN\2210855|NONE (l_nsubjpass) csseps_1\NNS\0|were|.|in (l_prep) as_6\IN\14622893|as|Both (l_pobj) correlates_8\NNS\5857459|NONE (l_prep) of_9\IN\0|peripheral (l_pobj) pain_10\NN\14299637|NONE
18340638
D010718_D000740 NONE phosphatidylserine_19\NN\0|NONE (r_pobj) of_18\IN\0|at (r_prep) exposure_17\NN\5042871|NONE (r_pobj) by_16\IN\0|which|is (r_agent) characterized_15\VBN\609683|or|eryptosis|,|accelerated|suicidal|erythrocyte (r_relcl) death_9\NN\7296428|NONE (r_pobj) from_5\IN\0|,|Alternatively|anemia|.|could (r_prep) result_4\VB\34213|NONE (l_nsubj) anemia_2\NN\14189204|from|,|Alternatively|.|could
D010718_D000740 NONE ps_21\NNP\6763273|NONE (r_appos) phosphatidylserine_19\NN\0|NONE (r_pobj) of_18\IN\0|at (r_prep) exposure_17\NN\5042871|NONE (r_pobj) by_16\IN\0|which|is (r_agent) characterized_15\VBN\609683|or|eryptosis|,|accelerated|suicidal|erythrocyte (r_relcl) death_9\NN\7296428|NONE (r_pobj) from_5\IN\0|,|Alternatively|anemia|.|could (r_prep) result_4\VB\34213|NONE (l_nsubj) anemia_2\NN\14189204|from|,|Alternatively|.|could
D001379_D000740 CID azathioprine_4\NN\3740161|NONE (r_pobj) of_3\IN\0|The|side (r_prep) effects_2\NNS\13245626|anemia|. (r_nsubj) include_5\VBP\0|NONE (l_dobj) anemia_6\NN\14189204|effects|.
D001379_D000740 CID azathioprine_0\NN\3740161|.|,|death|effect (r_nsubj) triggers_1\VBZ\3659292|NONE (l_npadvmod) effect_7\NN\34213|Azathioprine|.|,|death (l_acl) contributing_9\VBG\126264|an (l_prep) to_10\IN\0|presumably (l_pobj) anemia_14\NN\14189204|NONE
D001379_D000740 CID azathioprine_11\RB\3740161| (r_advmod) induced_13\VBN\1627355|NONE (r_amod) anemia_14\NN\14189204|NONE
10726030
D006493_D013927 NONE heparin_3\NN\2718259| (r_npadvmod) induced_5\VBN\1627355|and|thrombosis (r_amod) thrombocytopenia_6\NN\14189204|NONE (l_conj) thrombosis_8\NN\14100769|induced|and
D006493_D013927 NONE heparin_14\JJ\2718259|NONE (r_compound) therapy_15\NN\657604|NONE (r_pobj) of_13\IN\0|other|side (r_prep) effects_12\NNS\13245626|and (r_conj) thrombosis_8\NN\14100769|induced|and
D006493_D013927 NONE heparin_0\NNP\2718259|prevent|first|, (r_nsubj) used_3\VBD\0|treat|,|.|clinically|has|been (r_ccomp) used_16\VBN\0|NONE (l_xcomp) treat_18\VB\7570720|,|.|clinically|used|has|been (l_dobj) thrombosis_19\NN\14100769|for|to
D006493_D013927 NONE heparin_9\NN\2718259|.|are|treat|anticoagulant|, (r_nsubj) remains_10\VBZ\2684|NONE (l_xcomp) treat_16\VB\7570720|.|are|heparin|anticoagulant|, (l_dobj) episodes_19\NNS\7283608|to (l_amod) thrombotic_18\JJ\0|acute
D006493_D013927 NONE heparin_18\NN\2718259|NONE (r_pobj) of_17\IN\0|widespread|the (r_prep) use_16\NN\407535|NONE (r_pobj) given_12\VBN\5892096|common|,|.|some (r_prep) are_21\VBP\13600404|effects|in|but|rare|, (l_acomp) common_23\JJ\8673395|given|,|.|some (l_conj) hitt_26\NNP\0|quite|,
D006493_D006994 CID heparin_7\JJ\2718259|NONE (r_compound) therapy_8\NN\657604|NONE (r_pobj) of_6\IN\0|additional|important|untoward (r_prep) effects_5\NNS\13245626|However|.|thrombocytopenia|, (r_nsubj) include_9\VBP\0|NONE (l_dobj) thrombocytopenia_13\NN\14189204|However|.|,|effects (l_conj) osteoporosis_18\NN\14204950|induced|, (l_conj) eosinophilia_20\NN\14299637|,|associated (l_conj) reactions_23\NNS\13446390|, (l_conj) reactions_26\NNS\13446390|skin|, (l_amod) other_27\JJ\0|allergic (l_prep) than_28\IN\0|NONE (l_pobj) thrombocytopenia_29\JJ\14189204|NONE (l_conj) alopecia_31\NN\14457041|, (l_conj) transaminasemia_33\NN\0|, (l_conj) hyperkalemia_35\NN\14299637|, (l_conj) hypoaldosteronism_37\NN\0|,
D006493_D006994 CID heparin_10\NN\2718259| (r_npadvmod) induced_12\VBN\1627355|osteoporosis|, (r_amod) thrombocytopenia_13\NN\14189204|However|.|,|effects (l_conj) osteoporosis_18\NN\14204950|induced|, (l_conj) eosinophilia_20\NN\14299637|,|associated (l_conj) reactions_23\NNS\13446390|, (l_conj) reactions_26\NNS\13446390|skin|, (l_amod) other_27\JJ\0|allergic (l_prep) than_28\IN\0|NONE (l_pobj) thrombocytopenia_29\JJ\14189204|NONE (l_conj) alopecia_31\NN\14457041|, (l_conj) transaminasemia_33\NN\0|, (l_conj) hyperkalemia_35\NN\14299637|, (l_conj) hypoaldosteronism_37\NN\0|,
D006493_D006994 CID heparin_15\NN\2718259| (r_npadvmod) associated_17\VBN\628491|,|eosinophilia (r_amod) osteoporosis_18\NN\14204950|induced|, (l_conj) eosinophilia_20\NN\14299637|,|associated (l_conj) reactions_23\NNS\13446390|, (l_conj) reactions_26\NNS\13446390|skin|, (l_amod) other_27\JJ\0|allergic (l_prep) than_28\IN\0|NONE (l_pobj) thrombocytopenia_29\JJ\14189204|NONE (l_conj) alopecia_31\NN\14457041|, (l_conj) transaminasemia_33\NN\0|, (l_conj) hyperkalemia_35\NN\14299637|, (l_conj) hypoaldosteronism_37\NN\0|,
D006493_D000505 CID heparin_7\JJ\2718259|NONE (r_compound) therapy_8\NN\657604|NONE (r_pobj) of_6\IN\0|additional|important|untoward (r_prep) effects_5\NNS\13245626|However|.|thrombocytopenia|, (r_nsubj) include_9\VBP\0|NONE (l_dobj) thrombocytopenia_13\NN\14189204|However|.|,|effects (l_conj) osteoporosis_18\NN\14204950|induced|, (l_conj) eosinophilia_20\NN\14299637|,|associated (l_conj) reactions_23\NNS\13446390|, (l_conj) reactions_26\NNS\13446390|skin|, (l_amod) other_27\JJ\0|allergic (l_prep) than_28\IN\0|NONE (l_pobj) thrombocytopenia_29\JJ\14189204|NONE (l_conj) alopecia_31\NN\14457041|,
D006493_D000505 CID heparin_10\NN\2718259| (r_npadvmod) induced_12\VBN\1627355|osteoporosis|, (r_amod) thrombocytopenia_13\NN\14189204|However|.|,|effects (l_conj) osteoporosis_18\NN\14204950|induced|, (l_conj) eosinophilia_20\NN\14299637|,|associated (l_conj) reactions_23\NNS\13446390|, (l_conj) reactions_26\NNS\13446390|skin|, (l_amod) other_27\JJ\0|allergic (l_prep) than_28\IN\0|NONE (l_pobj) thrombocytopenia_29\JJ\14189204|NONE (l_conj) alopecia_31\NN\14457041|,
D006493_D000505 CID heparin_15\NN\2718259| (r_npadvmod) associated_17\VBN\628491|,|eosinophilia (r_amod) osteoporosis_18\NN\14204950|induced|, (l_conj) eosinophilia_20\NN\14299637|,|associated (l_conj) reactions_23\NNS\13446390|, (l_conj) reactions_26\NNS\13446390|skin|, (l_amod) other_27\JJ\0|allergic (l_prep) than_28\IN\0|NONE (l_pobj) thrombocytopenia_29\JJ\14189204|NONE (l_conj) alopecia_31\NN\14457041|,
D006493_D006947 CID heparin_7\JJ\2718259|NONE (r_compound) therapy_8\NN\657604|NONE (r_pobj) of_6\IN\0|additional|important|untoward (r_prep) effects_5\NNS\13245626|However|.|thrombocytopenia|, (r_nsubj) include_9\VBP\0|NONE (l_dobj) thrombocytopenia_13\NN\14189204|However|.|,|effects (l_conj) osteoporosis_18\NN\14204950|induced|, (l_conj) eosinophilia_20\NN\14299637|,|associated (l_conj) reactions_23\NNS\13446390|, (l_conj) reactions_26\NNS\13446390|skin|, (l_amod) other_27\JJ\0|allergic (l_prep) than_28\IN\0|NONE (l_pobj) thrombocytopenia_29\JJ\14189204|NONE (l_conj) alopecia_31\NN\14457041|, (l_conj) transaminasemia_33\NN\0|, (l_conj) hyperkalemia_35\NN\14299637|,
D006493_D006947 CID heparin_10\NN\2718259| (r_npadvmod) induced_12\VBN\1627355|osteoporosis|, (r_amod) thrombocytopenia_13\NN\14189204|However|.|,|effects (l_conj) osteoporosis_18\NN\14204950|induced|, (l_conj) eosinophilia_20\NN\14299637|,|associated (l_conj) reactions_23\NNS\13446390|, (l_conj) reactions_26\NNS\13446390|skin|, (l_amod) other_27\JJ\0|allergic (l_prep) than_28\IN\0|NONE (l_pobj) thrombocytopenia_29\JJ\14189204|NONE (l_conj) alopecia_31\NN\14457041|, (l_conj) transaminasemia_33\NN\0|, (l_conj) hyperkalemia_35\NN\14299637|,
D006493_D006947 CID heparin_15\NN\2718259| (r_npadvmod) associated_17\VBN\628491|,|eosinophilia (r_amod) osteoporosis_18\NN\14204950|induced|, (l_conj) eosinophilia_20\NN\14299637|,|associated (l_conj) reactions_23\NNS\13446390|, (l_conj) reactions_26\NNS\13446390|skin|, (l_amod) other_27\JJ\0|allergic (l_prep) than_28\IN\0|NONE (l_pobj) thrombocytopenia_29\JJ\14189204|NONE (l_conj) alopecia_31\NN\14457041|, (l_conj) transaminasemia_33\NN\0|, (l_conj) hyperkalemia_35\NN\14299637|,
D006493_D010024 CID heparin_7\JJ\2718259|NONE (r_compound) therapy_8\NN\657604|NONE (r_pobj) of_6\IN\0|additional|important|untoward (r_prep) effects_5\NNS\13245626|However|.|thrombocytopenia|, (r_nsubj) include_9\VBP\0|NONE (l_dobj) thrombocytopenia_13\NN\14189204|However|.|,|effects (l_conj) osteoporosis_18\NN\14204950|induced|,
D006493_D010024 CID heparin_10\NN\2718259| (r_npadvmod) induced_12\VBN\1627355|osteoporosis|, (r_amod) thrombocytopenia_13\NN\14189204|However|.|,|effects (l_conj) osteoporosis_18\NN\14204950|induced|,
D006493_D010024 CID heparin_15\NN\2718259| (r_npadvmod) associated_17\VBN\628491|,|eosinophilia (r_amod) osteoporosis_18\NN\14204950|induced|,
D006493_D010024 CID heparin_18\NN\2718259|NONE (r_pobj) of_17\IN\0|widespread|the (r_prep) use_16\NN\407535|NONE (r_pobj) given_12\VBN\5892096|common|,|.|some (r_prep) are_21\VBP\13600404|effects|in|but|rare|, (l_acomp) common_23\JJ\8673395|given|,|.|some (l_conj) hitt_26\NNP\0|quite|, (l_conj) osteoporosis_28\NN\14204950|and|particularly
D006493_D004802 CID heparin_7\JJ\2718259|NONE (r_compound) therapy_8\NN\657604|NONE (r_pobj) of_6\IN\0|additional|important|untoward (r_prep) effects_5\NNS\13245626|However|.|thrombocytopenia|, (r_nsubj) include_9\VBP\0|NONE (l_dobj) thrombocytopenia_13\NN\14189204|However|.|,|effects (l_conj) osteoporosis_18\NN\14204950|induced|, (l_conj) eosinophilia_20\NN\14299637|,|associated
D006493_D004802 CID heparin_10\NN\2718259| (r_npadvmod) induced_12\VBN\1627355|osteoporosis|, (r_amod) thrombocytopenia_13\NN\14189204|However|.|,|effects (l_conj) osteoporosis_18\NN\14204950|induced|, (l_conj) eosinophilia_20\NN\14299637|,|associated
D006493_D004802 CID heparin_15\NN\2718259| (r_npadvmod) associated_17\VBN\628491|,|eosinophilia (r_amod) osteoporosis_18\NN\14204950|induced|, (l_conj) eosinophilia_20\NN\14299637|,|associated
D006493_D013921 CID heparin_3\NN\2718259| (r_npadvmod) induced_5\VBN\1627355|and|thrombosis (r_amod) thrombocytopenia_6\NN\14189204|NONE
D006493_D013921 CID heparin_14\JJ\2718259|NONE (r_compound) therapy_15\NN\657604|NONE (r_pobj) of_13\IN\0|other|side (r_prep) effects_12\NNS\13245626|and (r_conj) thrombosis_8\NN\14100769|induced|and (r_conj) thrombocytopenia_6\NN\14189204|NONE
D006493_D013921 CID heparin_7\JJ\2718259|NONE (r_compound) therapy_8\NN\657604|NONE (r_pobj) of_6\IN\0|additional|important|untoward (r_prep) effects_5\NNS\13245626|However|.|thrombocytopenia|, (r_nsubj) include_9\VBP\0|NONE (l_dobj) thrombocytopenia_13\NN\14189204|However|.|,|effects
D006493_D013921 CID heparin_7\JJ\2718259|NONE (r_compound) therapy_8\NN\657604|NONE (r_pobj) of_6\IN\0|additional|important|untoward (r_prep) effects_5\NNS\13245626|However|.|thrombocytopenia|, (r_nsubj) include_9\VBP\0|NONE (l_dobj) thrombocytopenia_13\NN\14189204|However|.|,|effects (l_conj) osteoporosis_18\NN\14204950|induced|, (l_conj) eosinophilia_20\NN\14299637|,|associated (l_conj) reactions_23\NNS\13446390|, (l_conj) reactions_26\NNS\13446390|skin|, (l_amod) other_27\JJ\0|allergic (l_prep) than_28\IN\0|NONE (l_pobj) thrombocytopenia_29\JJ\14189204|NONE
D006493_D013921 CID heparin_10\NN\2718259| (r_npadvmod) induced_12\VBN\1627355|osteoporosis|, (r_amod) thrombocytopenia_13\NN\14189204|However|.|,|effects
D006493_D013921 CID heparin_10\NN\2718259| (r_npadvmod) induced_12\VBN\1627355|osteoporosis|, (r_amod) thrombocytopenia_13\NN\14189204|However|.|,|effects (l_conj) osteoporosis_18\NN\14204950|induced|, (l_conj) eosinophilia_20\NN\14299637|,|associated (l_conj) reactions_23\NNS\13446390|, (l_conj) reactions_26\NNS\13446390|skin|, (l_amod) other_27\JJ\0|allergic (l_prep) than_28\IN\0|NONE (l_pobj) thrombocytopenia_29\JJ\14189204|NONE
D006493_D013921 CID heparin_15\NN\2718259| (r_npadvmod) associated_17\VBN\628491|,|eosinophilia (r_amod) osteoporosis_18\NN\14204950|induced|, (r_conj) thrombocytopenia_13\NN\14189204|However|.|,|effects
D006493_D013921 CID heparin_15\NN\2718259| (r_npadvmod) associated_17\VBN\628491|,|eosinophilia (r_amod) osteoporosis_18\NN\14204950|induced|, (l_conj) eosinophilia_20\NN\14299637|,|associated (l_conj) reactions_23\NNS\13446390|, (l_conj) reactions_26\NNS\13446390|skin|, (l_amod) other_27\JJ\0|allergic (l_prep) than_28\IN\0|NONE (l_pobj) thrombocytopenia_29\JJ\14189204|NONE
D006493_D013921 NONE heparin_18\NN\2718259|NONE (r_pobj) of_17\IN\0|widespread|the (r_prep) use_16\NN\407535|NONE (r_pobj) given_12\VBN\5892096|common|,|.|some (r_prep) are_21\VBP\13600404|effects|in|but|rare|, (l_acomp) common_23\JJ\8673395|given|,|.|some (l_conj) hitt_26\NNP\0|quite|,
D006493_D004342 CID heparin_7\JJ\2718259|NONE (r_compound) therapy_8\NN\657604|NONE (r_pobj) of_6\IN\0|additional|important|untoward (r_prep) effects_5\NNS\13245626|However|.|thrombocytopenia|, (r_nsubj) include_9\VBP\0|NONE (l_dobj) thrombocytopenia_13\NN\14189204|However|.|,|effects (l_conj) osteoporosis_18\NN\14204950|induced|, (l_conj) eosinophilia_20\NN\14299637|,|associated (l_conj) reactions_23\NNS\13446390|, (l_conj) reactions_26\NNS\13446390|skin|,
D006493_D004342 CID heparin_10\NN\2718259| (r_npadvmod) induced_12\VBN\1627355|osteoporosis|, (r_amod) thrombocytopenia_13\NN\14189204|However|.|,|effects (l_conj) osteoporosis_18\NN\14204950|induced|, (l_conj) eosinophilia_20\NN\14299637|,|associated (l_conj) reactions_23\NNS\13446390|, (l_conj) reactions_26\NNS\13446390|skin|,
D006493_D004342 CID heparin_15\NN\2718259| (r_npadvmod) associated_17\VBN\628491|,|eosinophilia (r_amod) osteoporosis_18\NN\14204950|induced|, (l_conj) eosinophilia_20\NN\14299637|,|associated (l_conj) reactions_23\NNS\13446390|, (l_conj) reactions_26\NNS\13446390|skin|,
D006493_D012871 CID heparin_7\JJ\2718259|NONE (r_compound) therapy_8\NN\657604|NONE (r_pobj) of_6\IN\0|additional|important|untoward (r_prep) effects_5\NNS\13245626|However|.|thrombocytopenia|, (r_nsubj) include_9\VBP\0|NONE (l_dobj) thrombocytopenia_13\NN\14189204|However|.|,|effects (l_conj) osteoporosis_18\NN\14204950|induced|, (l_conj) eosinophilia_20\NN\14299637|,|associated (l_conj) reactions_23\NNS\13446390|,
D006493_D012871 CID heparin_10\NN\2718259| (r_npadvmod) induced_12\VBN\1627355|osteoporosis|, (r_amod) thrombocytopenia_13\NN\14189204|However|.|,|effects (l_conj) osteoporosis_18\NN\14204950|induced|, (l_conj) eosinophilia_20\NN\14299637|,|associated (l_conj) reactions_23\NNS\13446390|,
D006493_D012871 CID heparin_15\NN\2718259| (r_npadvmod) associated_17\VBN\628491|,|eosinophilia (r_amod) osteoporosis_18\NN\14204950|induced|, (l_conj) eosinophilia_20\NN\14299637|,|associated (l_conj) reactions_23\NNS\13446390|,
D006493_D006470 NONE heparin_7\NN\2718259|NONE (r_pobj) of_6\IN\0|untoward|primary|the (r_prep) effect_5\NN\34213|.|Bleeding (r_attr) is_1\VBZ\0|NONE (l_nsubj) bleeding_0\VBG\14285662|.|effect
D006493_D006470 NONE heparin_9\JJ\2718259|NONE (r_compound) therapy_10\NN\657604|NONE (r_dobj) receiving_8\VBG\2210855|NONE (r_acl) patients_7\NNS\9898892|NONE (r_pobj) in_6\IN\13603305|primary (r_prep) concern_5\NN\5682950|NONE (r_pobj) of_3\IN\0|.|bleeding (r_prep) is_2\VBZ\0|NONE (l_nsubj) bleeding_1\NN\14285662|of|.
D006493_D011317 CID heparin_7\JJ\2718259|NONE (r_compound) therapy_8\NN\657604|NONE (r_pobj) of_6\IN\0|additional|important|untoward (r_prep) effects_5\NNS\13245626|However|.|thrombocytopenia|, (r_nsubj) include_9\VBP\0|NONE (l_dobj) thrombocytopenia_13\NN\14189204|However|.|,|effects (l_conj) osteoporosis_18\NN\14204950|induced|, (l_conj) eosinophilia_20\NN\14299637|,|associated (l_conj) reactions_23\NNS\13446390|, (l_conj) reactions_26\NNS\13446390|skin|, (l_amod) other_27\JJ\0|allergic (l_prep) than_28\IN\0|NONE (l_pobj) thrombocytopenia_29\JJ\14189204|NONE (l_conj) alopecia_31\NN\14457041|, (l_conj) transaminasemia_33\NN\0|, (l_conj) hyperkalemia_35\NN\14299637|, (l_conj) hypoaldosteronism_37\NN\0|, (l_conj) priapism_40\NN\14204950|,|and
D006493_D011317 CID heparin_10\NN\2718259| (r_npadvmod) induced_12\VBN\1627355|osteoporosis|, (r_amod) thrombocytopenia_13\NN\14189204|However|.|,|effects (l_conj) osteoporosis_18\NN\14204950|induced|, (l_conj) eosinophilia_20\NN\14299637|,|associated (l_conj) reactions_23\NNS\13446390|, (l_conj) reactions_26\NNS\13446390|skin|, (l_amod) other_27\JJ\0|allergic (l_prep) than_28\IN\0|NONE (l_pobj) thrombocytopenia_29\JJ\14189204|NONE (l_conj) alopecia_31\NN\14457041|, (l_conj) transaminasemia_33\NN\0|, (l_conj) hyperkalemia_35\NN\14299637|, (l_conj) hypoaldosteronism_37\NN\0|, (l_conj) priapism_40\NN\14204950|,|and
D006493_D011317 CID heparin_15\NN\2718259| (r_npadvmod) associated_17\VBN\628491|,|eosinophilia (r_amod) osteoporosis_18\NN\14204950|induced|, (l_conj) eosinophilia_20\NN\14299637|,|associated (l_conj) reactions_23\NNS\13446390|, (l_conj) reactions_26\NNS\13446390|skin|, (l_amod) other_27\JJ\0|allergic (l_prep) than_28\IN\0|NONE (l_pobj) thrombocytopenia_29\JJ\14189204|NONE (l_conj) alopecia_31\NN\14457041|, (l_conj) transaminasemia_33\NN\0|, (l_conj) hyperkalemia_35\NN\14299637|, (l_conj) hypoaldosteronism_37\NN\0|, (l_conj) priapism_40\NN\14204950|,|and
10427794
C065757_D056486 CID meloxicam_0\NNP\0| (r_npadvmod) induced_2\VBN\1627355|.|liver (r_amod) toxicity_4\NN\13576101|NONE
C065757_D056486 CID meloxicam_18\NN\0|to (r_pobj) due_16\IN\5174653|hepatitis|who (r_prep) developed_12\VBD\1753788|rheumatoid (l_dobj) hepatitis_15\NN\14127211|due|who
C065757_D056486 CID meloxicam_7\NNP\0|NONE (r_compound) administration_8\NN\1133281|NONE (r_pobj) after_6\IN\0|rapidly|.|and|hepatitis|associated (r_prep) occurred_4\VBD\0|NONE (l_nsubj) hepatitis_3\NN\14127211|rapidly|.|after|and|associated
C065757_D056486 CID meloxicam_4\NNP\0|related|liver (r_nmod) toxicity_7\NN\13576101|NONE
C065757_D056486 CID meloxicam_4\NNP\0|related|liver (r_nmod) toxicity_7\NN\13576101|NONE (r_pobj) of_3\IN\0|first|This (r_prep) case_2\NN\7283608|induce|.|potential (r_nsubj) demonstrates_8\VBZ\2137132|NONE (l_xcomp) induce_15\VB\1627355|.|case|potential (l_dobj) damage_17\NN\7296428|to
C065757_D004342 CID meloxicam_7\NNP\0|NONE (r_compound) administration_8\NN\1133281|NONE (r_pobj) after_6\IN\0|rapidly|.|and|hepatitis|associated (r_prep) occurred_4\VBD\0|NONE (l_conj) associated_11\VBN\628491|rapidly|.|after|and|hepatitis (l_advcl) suggesting_18\VBG\1010118|with|was (l_dobj) mechanism_21\NN\13446390|NONE (l_compound) hypersensitivity_20\NN\14531772|a
C065757_D001172 NONE meloxicam_18\NN\0|to (r_pobj) due_16\IN\5174653|hepatitis|who (r_prep) developed_12\VBD\1753788|rheumatoid (r_relcl) arthritis_10\NN\14171682|NONE
19184102
D014635_D009765 CID vpa_20\NNP\0|NONE (r_compound) treatment_21\NN\654885|NONE (r_pobj) during_19\IN\0|who|obesity (r_prep) developed_17\VBD\1753788|a (l_dobj) obesity_18\NN\4999401|during|who
D014635_D009765 CID vpa_18\NNP\0|NONE (r_pobj) with_17\IN\0|term (r_prep) treatment_16\NN\654885|,|insulin|and (r_conj) resistance_10\NN\37396|, (r_conj) hyperinsulinemia_7\NN\0|, (r_conj) obesity_5\NN\4999401|with|all|be|that|may
D014635_D009765 CID vpa_35\NNP\0|NONE (r_compound) withdrawal_36\NN\7206096|NONE (r_pobj) after_34\IN\0|reversible|suggests|;|.|effect (r_prep) is_32\VBZ\0|NONE (l_ccomp) suggests_3\VBZ\1010118|reversible|;|after|.|effect (l_ccomp) associated_22\VBN\628491|case (l_nsubjpass) obesity_5\NN\4999401|with|all|be|that|may
D014635_D006946 CID vpa_18\NNP\0|NONE (r_pobj) with_17\IN\0|term (r_prep) treatment_16\NN\654885|,|insulin|and (r_conj) resistance_10\NN\37396|, (r_conj) hyperinsulinemia_7\NN\0|,
D014635_D006946 CID vpa_35\NNP\0|NONE (r_compound) withdrawal_36\NN\7206096|NONE (r_pobj) after_34\IN\0|reversible|suggests|;|.|effect (r_prep) is_32\VBZ\0|NONE (l_ccomp) suggests_3\VBZ\1010118|reversible|;|after|.|effect (l_ccomp) associated_22\VBN\628491|case (l_nsubjpass) obesity_5\NN\4999401|with|all|be|that|may (l_conj) hyperinsulinemia_7\NN\0|,
D014635_D007333 CID vpa_18\NNP\0|NONE (r_pobj) with_17\IN\0|term (r_prep) treatment_16\NN\654885|,|insulin|and (r_conj) resistance_10\NN\37396|,
D014635_D007333 CID vpa_35\NNP\0|NONE (r_compound) withdrawal_36\NN\7206096|NONE (r_pobj) after_34\IN\0|reversible|suggests|;|.|effect (r_prep) is_32\VBZ\0|NONE (l_ccomp) suggests_3\VBZ\1010118|reversible|;|after|.|effect (l_ccomp) associated_22\VBN\628491|case (l_nsubjpass) obesity_5\NN\4999401|with|all|be|that|may (l_conj) hyperinsulinemia_7\NN\0|, (l_conj) resistance_10\NN\37396|,
D014635_D065626 CID valproate_5\NN\0|NONE (r_amod) therapy_6\NN\657604|NONE (r_pobj) during_4\IN\0|liver|Nonalcoholic|.|fatty (r_prep) disease_3\NN\14061805|NONE
D014635_D065626 CID vpa_20\NNP\0|NONE (r_compound) treatment_21\NN\654885|NONE (r_pobj) during_19\IN\0|who|obesity (r_prep) developed_17\VBD\1753788|a (r_relcl) child_15\NN\9622049|NONE (r_pobj) in_13\IN\13603305|NONE (r_prep) arising_12\VBG\2623529|fatty|NAFLD|liver|)|nonalcoholic|( (r_acl) disease_8\NN\14061805|NONE
D014635_D065626 CID vpa_20\NNP\0|NONE (r_compound) treatment_21\NN\654885|NONE (r_pobj) during_19\IN\0|who|obesity (r_prep) developed_17\VBD\1753788|a (r_relcl) child_15\NN\9622049|NONE (r_pobj) in_13\IN\13603305|NONE (r_prep) arising_12\VBG\2623529|fatty|NAFLD|liver|)|nonalcoholic|( (r_acl) disease_8\NN\14061805|NONE (l_appos) nafld_10\NNP\0|arising|fatty|liver|)|nonalcoholic|(
D014635_D065626 CID vpa_18\NNP\0|NONE (r_pobj) with_17\IN\0|term (r_prep) treatment_16\NN\654885|,|insulin|and (r_conj) resistance_10\NN\37396|, (r_conj) hyperinsulinemia_7\NN\0|, (r_conj) obesity_5\NN\4999401|with|all|be|that|may (r_nsubjpass) associated_22\VBN\628491|case (l_prep) with_23\IN\0|obesity|all|be|that|may (l_pobj) development_25\NN\248977|NONE (l_prep) of_26\IN\0|the (l_pobj) nafld_27\NNP\0|NONE
D014635_D065626 CID vpa_35\NNP\0|NONE (r_compound) withdrawal_36\NN\7206096|NONE (r_pobj) after_34\IN\0|reversible|suggests|;|.|effect (r_prep) is_32\VBZ\0|NONE (l_ccomp) suggests_3\VBZ\1010118|reversible|;|after|.|effect (l_ccomp) associated_22\VBN\628491|case (l_prep) with_23\IN\0|obesity|all|be|that|may (l_pobj) development_25\NN\248977|NONE (l_prep) of_26\IN\0|the (l_pobj) nafld_27\NNP\0|NONE
D014635_D004827 NONE acid_1\NN\14818238|associated|,|effective|but (r_nsubj) is_5\VBZ\0|NONE (l_acomp) effective_6\JJ\0|associated|,|acid|but (l_prep) for_7\IN\0|NONE (l_pobj) treatment_9\NN\654885|NONE (l_prep) of_10\IN\0|the (l_pobj) types_12\NNS\5839024|NONE (l_prep) of_13\IN\0|many (l_pobj) epilepsy_14\NN\14085708|NONE
D014635_D004827 NONE vpa_3\NNP\0|(|Valproic|) (r_appos) acid_1\NN\14818238|associated|,|effective|but (r_nsubj) is_5\VBZ\0|NONE (l_acomp) effective_6\JJ\0|associated|,|acid|but (l_prep) for_7\IN\0|NONE (l_pobj) treatment_9\NN\654885|NONE (l_prep) of_10\IN\0|the (l_pobj) types_12\NNS\5839024|NONE (l_prep) of_13\IN\0|many (l_pobj) epilepsy_14\NN\14085708|NONE
D014635_D015431 NONE vpa_4\NNP\0|NONE (r_compound) therapy_5\NN\657604|NONE (r_pobj) of_3\IN\0|the (r_prep) withdrawal_2\NN\7206096|NONE (r_pobj) after_0\IN\0|patient|loss|, (r_prep) showed_9\VBD\2137132|normalization|measurements|moreover|;|.|, (l_dobj) loss_13\NN\13252973|patient|After|,
18399341
D004837_D007022 NONE epinephrine_24\NN\14807929|,|treat|P=|required|. (r_amod) infusion_25\NN\14589223||and|Four|in (l_relcl) treat_27\VB\7570720|,|P=|required|.|epinephrine (l_dobj) hypotension_28\NN\14057371|to
24742750
D015283_D016171 CID citalopram_8\NNP\0|and (r_conj) terfenadine_6\NNP\0|reported|IKr|,|Finally|,|.|, (r_appos) blockers_4\NNS\10101634|NONE (l_relcl) reported_12\VBN\831651|IKr|,|Finally|,|.|Terfenadine|, (l_xcomp) cause_14\VB\7323922|are|which (l_ccomp) produced_25\VBD\1617192|to (l_nsubj) pointes_17\NNP\831651|)|EAD
D015283_D016171 CID citalopram_8\NNP\0|and (r_conj) terfenadine_6\NNP\0|reported|IKr|,|Finally|,|.|, (r_appos) blockers_4\NNS\10101634|NONE (l_relcl) reported_12\VBN\831651|IKr|,|Finally|,|.|Terfenadine|, (l_xcomp) cause_14\VB\7323922|are|which (l_ccomp) produced_25\VBD\1617192|to (l_nsubj) pointes_17\NNP\831651|)|EAD (l_appos) tdp_19\NNP\0|Torsade|in|(|de|,|)
D016593_D016171 CID terfenadine_6\NNP\0|reported|IKr|,|Finally|,|.|, (r_appos) blockers_4\NNS\10101634|NONE (l_relcl) reported_12\VBN\831651|IKr|,|Finally|,|.|Terfenadine|, (l_xcomp) cause_14\VB\7323922|are|which (l_ccomp) produced_25\VBD\1617192|to (l_nsubj) pointes_17\NNP\831651|)|EAD
D016593_D016171 CID terfenadine_6\NNP\0|reported|IKr|,|Finally|,|.|, (r_appos) blockers_4\NNS\10101634|NONE (l_relcl) reported_12\VBN\831651|IKr|,|Finally|,|.|Terfenadine|, (l_xcomp) cause_14\VB\7323922|are|which (l_ccomp) produced_25\VBD\1617192|to (l_nsubj) pointes_17\NNP\831651|)|EAD (l_appos) tdp_19\NNP\0|Torsade|in|(|de|,|)
2358093
D003613_D054179 NONE danazol_6\NN\0|NONE (r_pobj) of_5\IN\0|term|in|with|The|. (r_prep) safety_4\NN\13920835|NONE (l_prep) with_9\IN\0|term|in|of|The|. (l_pobj) angioedema_11\NN\14316714|NONE
D003613_D054179 NONE danazol_9\NN\0|NONE (r_pobj) of_8\IN\0|term|the (r_prep) safety_7\NN\13920835|We|by|therefore|. (r_dobj) investigated_2\VBD\644583|NONE (l_prep) by_10\IN\0|We|safety|therefore|. (l_pcomp) performing_11\VBG\407535|NONE (l_dobj) review_15\NN\5733583|NONE (l_prep) of_16\IN\0|a|treated|chart|retrospective (l_pobj) patients_19\NNS\9898892|NONE (l_prep) with_20\IN\0||female (l_pobj) angioedema_22\NN\14316714|NONE
D003613_D054179 NONE danazol_25\NN\0|NONE (r_pobj) with_24\IN\0|for (r_prep) treated_23\VBN\2376958|a|of|chart|retrospective (r_acl) review_15\NN\5733583|NONE (l_prep) of_16\IN\0|a|treated|chart|retrospective (l_pobj) patients_19\NNS\9898892|NONE (l_prep) with_20\IN\0||female (l_pobj) angioedema_22\NN\14316714|NONE
15859361
C105934_D004342 NONE ce_5\NNP\14625458|NONE (r_pobj) to_4\IN\0|one|hypersensitivity (r_prep) reaction_3\NN\13446390|was|among|. (l_compound) hypersensitivity_2\NN\14531772|one|to
D000082_D004342 NONE p_7\NN\14622893|NONE (r_pobj) to_6\IN\0|with (r_prep) hypersensitivity_5\NN\14531772|NONE
D000082_D004342 NONE p_10\NN\14622893||intolerant|NSAIDs (r_nmod) patients_17\NNS\9898892|NONE (r_pobj) among_8\IN\0|was|.|reaction (r_prep) documented_7\VBN\1000214|NONE (l_nsubjpass) reaction_3\NN\13446390|was|among|. (l_compound) hypersensitivity_2\NN\14531772|one|to
D000082_D003875 CID acetaminophen_10\RB\2707683|NONE (r_pobj) to_9\IN\0|adverse|paracetamol|skin (r_prep) reactions_8\NNS\13446390|NONE
D000082_D003875 CID paracetamol_12\NNP\0|adverse|to|skin (r_appos) reactions_8\NNS\13446390|NONE
D000082_D003875 CID p_20\NN\14622893|NONE (r_pobj) to_19\IN\0|cutaneous|adverse|associated (r_prep) reactions_18\NNS\13446390|NONE
D000082_D003875 CID p_3\NN\14622893|skin (r_nmod) reactions_9\NNS\13446390|NONE
C012655_D004342 NONE n_9\NN\14622893|and (r_conj) p_7\NN\14622893|NONE (r_pobj) to_6\IN\0|with (r_prep) hypersensitivity_5\NN\14531772|NONE
C012655_D004342 NONE n_12\NN\14622893|and (r_conj) p_10\NN\14622893||intolerant|NSAIDs (r_nmod) patients_17\NNS\9898892|NONE (r_pobj) among_8\IN\0|was|.|reaction (r_prep) documented_7\VBN\1000214|NONE (l_nsubjpass) reaction_3\NN\13446390|was|among|. (l_compound) hypersensitivity_2\NN\14531772|one|to
C105934_D003875 NONE celecoxib_2\NN\3124700|NONE (r_pobj) of_1\IN\0|.|in (r_prep) safety_0\NN\13920835|NONE (l_prep) in_3\IN\13603305|.|of (l_pobj) patients_4\NNS\9898892|NONE (l_prep) with_5\IN\0|NONE (l_pobj) reactions_8\NNS\13446390|NONE
C105934_D003875 NONE ce_6\NNP\14625458|NONE (r_pobj) of_5\IN\0|the (r_prep) tolerability_4\NN\0|.|We|:|in (r_dobj) evaluated_2\VBD\670261|NONE (l_prep) in_7\IN\13603305|.|tolerability|We|: (l_pobj) group_9\NN\2137|NONE (l_prep) of_10\IN\0|a (l_pobj) patients_11\NNS\9898892|NONE (l_prep) with_12\IN\0|NONE (l_pobj) history_14\NN\15120823|NONE (l_prep) of_15\IN\0|documented (l_pobj) reactions_18\NNS\13446390|NONE
C012655_D003875 CID nimesulide_15\NN\0|and|(|) (r_conj) paracetamol_12\NNP\0|adverse|to|skin (r_appos) reactions_8\NNS\13446390|NONE
C012655_D003875 CID n_22\NNP\14622893|and (r_conj) p_20\NN\14622893|NONE (r_pobj) to_19\IN\0|cutaneous|adverse|associated (r_prep) reactions_18\NNS\13446390|NONE
C012655_D003875 CID n_5\NN\14622893| (r_npadvmod) induced_7\VBN\1627355|and (r_conj) p_3\NN\14622893|skin (r_nmod) reactions_9\NNS\13446390|NONE
3088653
D012601_D000647 CID scopolamine_2\NN\14712692| (r_npadvmod) induced_4\VBN\1627355|of (r_amod) amnesia_5\NN\5669934|NONE
D012601_D000647 CID scopolamine_0\NNP\14712692|amnesia|measured|. (r_nsubj) induced_13\VBD\1627355|NONE (l_dobj) amnesia_15\NN\5669934|Scopolamine|measured|.
D012601_D000647 CID scopolamine_21\NN\14712692| (r_npadvmod) induced_23\VBN\1627355|the (r_amod) amnesia_24\NN\5669934|also|.|administration
D012601_D008569 NONE scopolamine_14\NN\14712692| (r_npadvmod) induced_16\VBN\1627355|a|retention (r_amod) deficit_18\NN\5113133|NONE
D012601_D008569 NONE scopolamine_38\NN\14712692| (r_npadvmod) induced_40\VBN\1627355|retention|the (r_amod) deficit_42\NN\5113133|NONE
D019832_D000647 NONE scopolamine_5\NN\14712692|,|but (r_conj) scopolamine_0\NNP\14712692|amnesia|measured|. (r_nsubj) induced_13\VBD\1627355|NONE (l_dobj) amnesia_15\NN\5669934|Scopolamine|measured|.
D009270_D008569 NONE naloxone_11\NN\3808977|NONE (l_prep) on_12\IN\0|in (l_pobj) deficit_18\NN\5113133|NONE
D009270_D008569 NONE naloxone_0\NN\3808977|prior|.|attenuated (r_nsubj) injected_12\VBD\81072|NONE (l_advcl) attenuated_16\VBD\224901|prior|.|Naloxone (l_dobj) deficit_19\NN\5113133|with|at
D009270_D008569 NONE naloxone_14\NN\3808977|pain (r_appos) sensitivity_9\NN\5651971|NONE (r_pobj) in_7\IN\13603305|nor|neither|an|state|) (r_prep) increase_6\NN\13576355|be|that (r_nsubj) appear_27\VBP\2604760|experiments|. (l_xcomp) be_29\VB\14625458|that|increase (l_acomp) responsible_30\JJ\0|to (l_prep) for_31\IN\0|NONE (l_pobj) influence_33\NN\5190804|NONE (l_prep) of_34\IN\0|the (l_pobj) naloxone_35\NN\3808977|NONE (l_prep) on_36\IN\0|NONE (l_pobj) deficit_42\NN\5113133|NONE
D009270_D008569 NONE naloxone_25\NN\3808977|)|induced|aversive|an (r_appos) state_20\NN\8491826|nor|neither|an|in|) (r_conj) increase_6\NN\13576355|be|that (r_nsubj) appear_27\VBP\2604760|experiments|. (l_xcomp) be_29\VB\14625458|that|increase (l_acomp) responsible_30\JJ\0|to (l_prep) for_31\IN\0|NONE (l_pobj) influence_33\NN\5190804|NONE (l_prep) of_34\IN\0|the (l_pobj) naloxone_35\NN\3808977|NONE (l_prep) on_36\IN\0|NONE (l_pobj) deficit_42\NN\5113133|NONE
D009270_D008569 NONE naloxone_35\NN\3808977|NONE (l_prep) on_36\IN\0|NONE (l_pobj) deficit_42\NN\5113133|NONE
D009270_D000647 NONE naloxone_15\NN\3808977|NONE (r_pobj) by_9\IN\0|passive (r_prep) avoidance_8\NN\203342|NONE (r_pobj) of_6\IN\0|induced (r_prep) amnesia_5\NN\5669934|NONE
D009270_D000647 NONE naloxone_5\NN\3808977|NONE (r_pobj) of_4\IN\0|training|as (r_prep) administration_3\NN\1133281|also|.|amnesia (r_nsubj) attenuated_19\VBD\224901|NONE (l_dobj) amnesia_24\NN\5669934|also|.|administration
D012601_D010146 NONE scopolamine_38\NN\14712692| (r_npadvmod) induced_40\VBN\1627355|retention|the (r_amod) deficit_42\NN\5113133|NONE (r_pobj) on_36\IN\0|NONE (r_prep) naloxone_35\NN\3808977|NONE (r_pobj) of_34\IN\0|the (r_prep) influence_33\NN\5190804|NONE (r_pobj) for_31\IN\0|NONE (r_prep) responsible_30\JJ\0|to (r_acomp) be_29\VB\14625458|that|increase (r_xcomp) appear_27\VBP\2604760|experiments|. (l_nsubj) increase_6\NN\13576355|be|that (l_prep) in_7\IN\13603305|nor|neither|an|state|) (l_pobj) sensitivity_9\NN\5651971|NONE (l_compound) pain_8\NN\14299637|naloxone
D009270_D010146 NONE naloxone_14\NN\3808977|pain (r_appos) sensitivity_9\NN\5651971|NONE (l_compound) pain_8\NN\14299637|naloxone
D009270_D010146 NONE naloxone_25\NN\3808977|)|induced|aversive|an (r_appos) state_20\NN\8491826|nor|neither|an|in|) (r_conj) increase_6\NN\13576355|be|that (l_prep) in_7\IN\13603305|nor|neither|an|state|) (l_pobj) sensitivity_9\NN\5651971|NONE (l_compound) pain_8\NN\14299637|naloxone
D009270_D010146 NONE naloxone_35\NN\3808977|NONE (r_pobj) of_34\IN\0|the (r_prep) influence_33\NN\5190804|NONE (r_pobj) for_31\IN\0|NONE (r_prep) responsible_30\JJ\0|to (r_acomp) be_29\VB\14625458|that|increase (r_xcomp) appear_27\VBP\2604760|experiments|. (l_nsubj) increase_6\NN\13576355|be|that (l_prep) in_7\IN\13603305|nor|neither|an|state|) (l_pobj) sensitivity_9\NN\5651971|NONE (l_compound) pain_8\NN\14299637|naloxone
8808730
D009569_D001745 NONE oxide_5\NN\14818238|nitric|neuronal|in (r_compound) synthase_6\NN\0|NONE (r_pobj) of_2\IN\0|Increased|.|following (r_prep) expression_1\NN\4679549|NONE (l_prep) following_11\VBG\8180190|Increased|.|of (l_pobj) irritation_14\NN\14373582|NONE
D000171_D003556 NONE acrolein_13\NN\14584765|NONE (r_pobj) to_12\IN\0|which|is (r_prep) metabolized_11\VBN\0|)|( (r_relcl) cyp_7\NNP\0|NONE (r_appos) cyclophosphamide_5\NN\0|NONE (r_pobj) by_4\IN\0|was|cystitis (r_agent) induced_3\VBN\1627355|.|,|irritant|in (l_nsubjpass) cystitis_1\NN\14566129|by|was
D003520_D003556 CID cyclophosphamide_5\NN\0|NONE (r_pobj) by_4\IN\0|was|cystitis (r_agent) induced_3\VBN\1627355|.|,|irritant|in (l_nsubjpass) cystitis_1\NN\14566129|by|was
D003520_D003556 CID cyp_7\NNP\0|NONE (r_appos) cyclophosphamide_5\NN\0|NONE (r_pobj) by_4\IN\0|was|cystitis (r_agent) induced_3\VBN\1627355|.|,|irritant|in (l_nsubjpass) cystitis_1\NN\14566129|by|was
D009569_D014570 NONE oxide_13\NN\14818238|in|neuronal|)|(|NOS|nitric (r_compound) synthase_14\NN\0|NONE (r_pobj) of_10\IN\0|the (r_prep) expression_9\NN\4679549|NONE (r_pobj) in_7\IN\13603305|following (r_prep) alterations_6\NNS\7283608|to (l_prep) following_21\VBG\8180190|in (l_pobj) irritation_25\NN\14373582|NONE (l_prep) of_26\IN\0|acute (l_pobj) tract_29\NN\8574314|NONE
24753331
C083440_D064420 NONE s-23121_2\NN\0|and (r_conj) s-53482_0\NNS\0|.|herbicides (r_nsubj) are_3\VBP\13600404|NONE (l_attr) herbicides_7\NNS\14806838|.|S (l_conj) retardation_25\NN\7296428|phenylimide|teratogenicity|,|and|embryolethality|and|, (l_prep) in_26\IN\13603305|growth (l_pobj) rats_27\NNS\2329401|NONE (l_prep) in_28\IN\13603305|NONE (l_pobj) studies_33\NNS\635850|NONE (l_compound) toxicity_32\NN\13576101|conventional|oral
C083440_D006345 CID s-23121_2\NN\0|and (r_conj) s-53482_0\NNS\0|.|herbicides (r_nsubj) are_3\VBP\13600404|NONE (l_attr) herbicides_7\NNS\14806838|.|S (l_conj) teratogenicity_12\NN\0|phenylimide|retardation|,|and|embryolethality|and|, (l_conj) defects_17\NNS\14462666|)|(
C083440_D006345 CID s-23121_3\NN\0|NONE (r_pobj) of_2\IN\0|Dermal|at (r_prep) administration_1\NN\1133281|,|observed|but|in (r_nsubj) resulted_7\VBD\2633881|NONE (l_prep) in_8\IN\13603305|administration|,|observed|but (l_pobj) incidence_11\NN\13821570|NONE (l_prep) of_12\IN\0|increased|an (l_pobj) death_14\NN\7296428|NONE (l_conj) defect_18\NN\14462666|embryonic|and
C083440_D006345 CID s-23121_34\NN\0|NONE (r_pobj) to_33\IN\0|oral (r_prep) exposure_32\NN\5042871|it|was|as (r_dobj) following_30\VBG\8180190|was|not|.|growth (r_advcl) observed_26\VBN\2163746|administration|,|but|in (r_conj) resulted_7\VBD\2633881|NONE (l_prep) in_8\IN\13603305|administration|,|observed|but (l_pobj) incidence_11\NN\13821570|NONE (l_prep) of_12\IN\0|increased|an (l_pobj) death_14\NN\7296428|NONE (l_conj) defect_18\NN\14462666|embryonic|and
C106487_D064793 CID s-53482_0\NNS\0|.|herbicides (r_nsubj) are_3\VBP\13600404|NONE (l_attr) herbicides_7\NNS\14806838|.|S (l_conj) teratogenicity_12\NN\0|phenylimide|retardation|,|and|embryolethality|and|,
C106487_D064793 CID s-53482_5\NNS\0|,|Based|teratogenic|administered|. (r_nsubj) were_8\VBD\0|NONE (l_acomp) teratogenic_9\JJ\0|,|S|Based|administered|.
C083440_D020964 CID s-23121_2\NN\0|and (r_conj) s-53482_0\NNS\0|.|herbicides (r_nsubj) are_3\VBP\13600404|NONE (l_attr) herbicides_7\NNS\14806838|.|S (l_conj) embryolethality_10\NN\0|phenylimide|retardation|teratogenicity|,|and|and|,
C083440_D020964 CID s-23121_3\NN\0|NONE (r_pobj) of_2\IN\0|Dermal|at (r_prep) administration_1\NN\1133281|,|observed|but|in (r_nsubj) resulted_7\VBD\2633881|NONE (l_prep) in_8\IN\13603305|administration|,|observed|but (l_pobj) incidence_11\NN\13821570|NONE (l_prep) of_12\IN\0|increased|an (l_pobj) death_14\NN\7296428|NONE
C083440_D020964 CID s-23121_34\NN\0|NONE (r_pobj) to_33\IN\0|oral (r_prep) exposure_32\NN\5042871|it|was|as (r_dobj) following_30\VBG\8180190|was|not|.|growth (r_advcl) observed_26\VBN\2163746|administration|,|but|in (r_conj) resulted_7\VBD\2633881|NONE (l_prep) in_8\IN\13603305|administration|,|observed|but (l_pobj) incidence_11\NN\13821570|NONE (l_prep) of_12\IN\0|increased|an (l_pobj) death_14\NN\7296428|NONE
C106487_D006345 CID s-53482_0\NNS\0|.|herbicides (r_nsubj) are_3\VBP\13600404|NONE (l_attr) herbicides_7\NNS\14806838|.|S (l_conj) teratogenicity_12\NN\0|phenylimide|retardation|,|and|embryolethality|and|, (l_conj) defects_17\NNS\14462666|)|(
C106487_D005317 CID s-53482_0\NNS\0|.|herbicides (r_nsubj) are_3\VBP\13600404|NONE (l_attr) herbicides_7\NNS\14806838|.|S (l_conj) retardation_25\NN\7296428|phenylimide|teratogenicity|,|and|embryolethality|and|,
C106487_D020964 CID s-53482_0\NNS\0|.|herbicides (r_nsubj) are_3\VBP\13600404|NONE (l_attr) herbicides_7\NNS\14806838|.|S (l_conj) embryolethality_10\NN\0|phenylimide|retardation|teratogenicity|,|and|and|,
C083440_D005317 CID s-23121_2\NN\0|and (r_conj) s-53482_0\NNS\0|.|herbicides (r_nsubj) are_3\VBP\13600404|NONE (l_attr) herbicides_7\NNS\14806838|.|S (l_conj) retardation_25\NN\7296428|phenylimide|teratogenicity|,|and|embryolethality|and|,
C106487_D064420 NONE s-53482_0\NNS\0|.|herbicides (r_nsubj) are_3\VBP\13600404|NONE (l_attr) herbicides_7\NNS\14806838|.|S (l_conj) retardation_25\NN\7296428|phenylimide|teratogenicity|,|and|embryolethality|and|, (l_prep) in_26\IN\13603305|growth (l_pobj) rats_27\NNS\2329401|NONE (l_prep) in_28\IN\13603305|NONE (l_pobj) studies_33\NNS\635850|NONE (l_compound) toxicity_32\NN\13576101|conventional|oral
C106487_D064420 NONE s-53482_5\NNS\0|NONE (r_pobj) to_4\IN\0|Dermal|.|at|of (r_prep) exposure_1\NN\5042871|NONE (l_prep) at_6\IN\14622893|Dermal|.|to|of (l_pobj) patterns_10\NNS\5726345|NONE (l_prep) of_11\IN\0|produced|mg/kg (l_pobj) toxicity_13\NN\13576101|NONE
C083440_D064793 CID s-23121_2\NN\0|and (r_conj) s-53482_0\NNS\0|.|herbicides (r_nsubj) are_3\VBP\13600404|NONE (l_attr) herbicides_7\NNS\14806838|.|S (l_conj) teratogenicity_12\NN\0|phenylimide|retardation|,|and|embryolethality|and|,
C083440_D064793 CID s-23121_7\NN\0|and (r_conj) s-53482_5\NNS\0|,|Based|teratogenic|administered|. (r_nsubj) were_8\VBD\0|NONE (l_acomp) teratogenic_9\JJ\0|,|S|Based|administered|.
24209900
D007069_D008223 NONE ifosfamide_0\NNP\0|.|agent (r_nsubj) is_1\VBZ\0|NONE (l_attr) agent_4\NN\7347|.|Ifosfamide (l_amod) useful_5\JJ\0|an|alkylating (l_prep) in_6\IN\13603305|NONE (l_pobj) treatment_8\NN\654885|NONE (l_prep) of_9\IN\0|the (l_pobj) range_12\NN\5123416|NONE (l_prep) of_13\IN\0|wide|a (l_pobj) cancers_14\NNS\14239425|NONE (l_prep) including_15\VBG\0|NONE (l_pobj) sarcomas_16\NNS\14239918|NONE (l_conj) cancers_23\NNS\14239425|, (l_nmod) lymphoma_18\NN\14239918|gynecologic
D007069_D009369 NONE ifosfamide_0\NNP\0|.|agent (r_nsubj) is_1\VBZ\0|NONE (l_attr) agent_4\NN\7347|.|Ifosfamide (l_amod) useful_5\JJ\0|an|alkylating (l_prep) in_6\IN\13603305|NONE (l_pobj) treatment_8\NN\654885|NONE (l_prep) of_9\IN\0|the (l_pobj) range_12\NN\5123416|NONE (l_prep) of_13\IN\0|wide|a (l_pobj) cancers_14\NNS\14239425|NONE
D007069_D009369 NONE ifosfamide_0\NNP\0|.|agent (r_nsubj) is_1\VBZ\0|NONE (l_attr) agent_4\NN\7347|.|Ifosfamide (l_amod) useful_5\JJ\0|an|alkylating (l_prep) in_6\IN\13603305|NONE (l_pobj) treatment_8\NN\654885|NONE (l_prep) of_9\IN\0|the (l_pobj) range_12\NN\5123416|NONE (l_prep) of_13\IN\0|wide|a (l_pobj) cancers_14\NNS\14239425|NONE (l_prep) including_15\VBG\0|NONE (l_pobj) sarcomas_16\NNS\14239918|NONE (l_conj) cancers_23\NNS\14239425|,
D007069_D009369 NONE ifosfamide_29\RB\0|NONE (r_advmod) related_30\VBN\628491|acute (r_amod) encephalopathy_32\NN\14084880|who (r_dobj) developed_28\VBD\1753788|on|was|admitted|.|,|,|review (r_relcl) done_10\VBN\0|NONE (l_advcl) admitted_15\VBN\822367|on|was|.|,|,|developed|review (l_prep) to_16\IN\0|between (l_pobj) center_20\NNP\8497294|NONE (l_compound) cancer_19\NNP\14239425|Anderson|MD
D007069_D012509 NONE ifosfamide_0\NNP\0|.|agent (r_nsubj) is_1\VBZ\0|NONE (l_attr) agent_4\NN\7347|.|Ifosfamide (l_amod) useful_5\JJ\0|an|alkylating (l_prep) in_6\IN\13603305|NONE (l_pobj) treatment_8\NN\654885|NONE (l_prep) of_9\IN\0|the (l_pobj) range_12\NN\5123416|NONE (l_prep) of_13\IN\0|wide|a (l_pobj) cancers_14\NNS\14239425|NONE (l_prep) including_15\VBG\0|NONE (l_pobj) sarcomas_16\NNS\14239918|NONE
D007069_D001927 NONE ifosfamide_0\IN\0|need|related|.|: (r_nmod) encephalopathy_2\NN\14084880|NONE
D007069_D001927 NONE ifosfamide_16\NN\0|NONE (r_dobj) receiving_11\VBG\2210855|NONE (r_acl) patients_10\NNS\9898892|NONE (r_pobj) of_9\IN\0| (r_prep) %_8\NN\0|NONE (r_pobj) in_4\IN\13603305|been|has|Encephalopathy|. (r_prep) reported_3\VBN\831651|NONE (l_nsubjpass) encephalopathy_0\NNP\14084880|in|been|has|.
D007069_D001927 NONE ifosfamide_16\JJ\0|NONE (r_advmod) related_17\VBN\628491|NONE (r_amod) encephalopathy_18\NN\14084880|NONE
D007069_D001927 NONE ifosfamide_29\RB\0|NONE (r_advmod) related_30\VBN\628491|acute (r_amod) encephalopathy_32\NN\14084880|who
D007069_D001927 NONE ifosfamide_17\RB\0|NONE (r_advmod) receiving_16\VBG\2210855|within|(|:|)|symptoms|patients|after|. (r_advcl) experienced_4\VBD\2108377|NONE (l_dobj) symptoms_5\NNS\5823932|within|(|:|)|receiving|patients|after|. (l_prep) of_6\IN\0|NONE (l_pobj) encephalopathy_7\JJ\14084880|NONE
D007069_D001927 NONE ifosfamide_2\JJ\0|NONE (r_advmod) related_3\JJ\628491|NONE (r_amod) encephalopathy_4\JJ\14084880|NONE
D007069_D001927 NONE ifosfamide_9\RB\0|NONE (l_relcl) develop_11\VBP\1753788|NONE (l_dobj) features_12\NNS\5849040|who (l_prep) of_13\IN\0|NONE (l_pobj) encephalopathy_14\NN\14084880|NONE
24733133
C031942_D013921 NONE argatroban_2\NN\0|with|in (r_amod) thrombolysis_7\NN\13509528|NONE (l_prep) in_10\IN\13603305|with|argatroban (l_pobj) patient_13\NN\9898892|NONE (l_prep) with_14\IN\0|oncology|an (l_pobj) thrombocytopenia_18\NN\14189204|NONE
C031942_D013921 NONE argatroban_21\NN\0|(|CDT|directed|) (r_amod) thrombolysis_26\NN\13509528|NONE (r_pobj) with_20\IN\0|with|was (r_prep) treated_19\VBN\2376958|thrombocytopenia|who|and (r_conj) developed_7\VBD\1753788|oncology|an (l_dobj) thrombocytopenia_11\NN\14189204|treated|who|and
C031942_D013921 NONE argatroban_21\NN\0|(|CDT|directed|) (r_amod) thrombolysis_26\NN\13509528|NONE (r_pobj) with_20\IN\0|with|was (r_prep) treated_19\VBN\2376958|thrombocytopenia|who|and (r_conj) developed_7\VBD\1753788|oncology|an (l_dobj) thrombocytopenia_11\NN\14189204|treated|who|and (l_prep) with_12\IN\0|induced (l_pobj) thrombosis_13\NN\14100769|NONE (l_appos) hitt_15\NNP\0|NONE
C031942_D013921 NONE argatroban_18\NN\0|NONE (r_amod) with_17\IN\0|man|successfully|with|.|was (r_prep) treated_16\VBN\2376958|NONE (l_nsubjpass) man_4\NN\9605289|with|successfully|with|.|was (l_prep) to_12\IN\0|with|A|old (l_pobj) hitt_13\NNP\0|NONE
C031942_D004844 NONE argatroban_13\NN\0|NONE (r_amod) on_12\IN\0|.|was|patient (r_prep) restarted_11\VBN\1857717|,|epistaxis|day|and (r_conj) resolved_2\VBD\352826|NONE (l_nsubj) epistaxis_1\NN\14288235|,|day|restarted|and
D006493_D013921 CID heparin_15\NN\2718259| (r_npadvmod) induced_17\VBN\1627355|with (r_amod) thrombocytopenia_18\NN\14189204|NONE
D006493_D013921 CID heparin_8\NN\2718259| (r_npadvmod) induced_10\VBN\1627355|with (r_amod) thrombocytopenia_11\NN\14189204|treated|who|and
D006493_D013921 CID heparin_38\NN\2718259| (r_npadvmod) induced_40\VBN\1627355|NONE (r_amod) thrombocytopenia_41\NN\14189204|NONE
D006493_D013921 NONE heparin_8\NN\2718259| (r_npadvmod) induced_10\VBN\1627355|with (r_amod) thrombocytopenia_11\NN\14189204|treated|who|and (l_prep) with_12\IN\0|induced (l_pobj) thrombosis_13\NN\14100769|NONE (l_appos) hitt_15\NNP\0|NONE
D006493_D011655 CID heparin_38\NN\2718259| (r_npadvmod) induced_40\VBN\1627355|NONE (r_amod) thrombocytopenia_41\NN\14189204|NONE (r_pobj) to_37\IN\0|NONE (r_prep) secondary_36\JJ\8426461|pulmonary (r_amod) embolism_35\NN\15269513|(|DVT|)|bilateral|extensive|extremity|and|venous
D006493_D013927 NONE heparin_15\NN\2718259| (r_npadvmod) induced_17\VBN\1627355|with (r_amod) thrombocytopenia_18\NN\14189204|NONE (l_prep) with_19\IN\0|induced (l_pobj) thrombosis_20\NN\14100769|NONE
D006493_D013927 NONE heparin_8\NN\2718259| (r_npadvmod) induced_10\VBN\1627355|with (r_amod) thrombocytopenia_11\NN\14189204|treated|who|and (l_prep) with_12\IN\0|induced (l_pobj) thrombosis_13\NN\14100769|NONE
D006493_D013927 NONE heparin_8\NN\2718259| (r_npadvmod) induced_10\VBN\1627355|with (r_amod) thrombocytopenia_11\NN\14189204|treated|who|and (l_prep) with_12\IN\0|induced (l_pobj) thrombosis_13\NN\14100769|NONE (l_appos) hitt_15\NNP\0|NONE
D006493_D000686 NONE heparin_38\NN\2718259| (r_npadvmod) induced_40\VBN\1627355|NONE (r_amod) thrombocytopenia_41\NN\14189204|NONE (r_pobj) to_37\IN\0|NONE (r_prep) secondary_36\JJ\8426461|pulmonary (r_amod) embolism_35\NN\15269513|(|DVT|)|bilateral|extensive|extremity|and|venous (r_conj) thrombosis_29\NN\14100769|man|. (r_dobj) developed_21\VBD\1753788|NONE (l_nsubj) man_5\NN\9605289|thrombosis|. (l_prep) with_6\IN\0|A|old|Caucasian (l_pobj) amyloidosis_8\NN\14061805|NONE
D006493_D055499 NONE heparin_15\NN\2718259| (r_npadvmod) induced_17\VBN\1627355|with (r_amod) thrombocytopenia_18\NN\14189204|NONE (r_pobj) with_14\IN\0|oncology|an (r_prep) patient_13\NN\9898892|NONE (r_pobj) in_10\IN\13603305|with|argatroban (r_prep) thrombolysis_7\NN\13509528|NONE
D006493_D055499 NONE heparin_8\NN\2718259| (r_npadvmod) induced_10\VBN\1627355|with (r_amod) thrombocytopenia_11\NN\14189204|treated|who|and (r_dobj) developed_7\VBD\1753788|oncology|an (l_conj) treated_19\VBN\2376958|thrombocytopenia|who|and (l_prep) with_20\IN\0|with|was (l_pobj) thrombolysis_26\NN\13509528|NONE
C031942_D055499 NONE argatroban_2\NN\0|with|in (r_amod) thrombolysis_7\NN\13509528|NONE
C031942_D055499 NONE argatroban_21\NN\0|(|CDT|directed|) (r_amod) thrombolysis_26\NN\13509528|NONE
D006493_D056824 NONE heparin_38\NN\2718259| (r_npadvmod) induced_40\VBN\1627355|NONE (r_amod) thrombocytopenia_41\NN\14189204|NONE (r_pobj) to_37\IN\0|NONE (r_prep) secondary_36\JJ\8426461|pulmonary (r_amod) embolism_35\NN\15269513|(|DVT|)|bilateral|extensive|extremity|and|venous (r_conj) thrombosis_29\NN\14100769|man|.
D006493_D020246 CID heparin_38\NN\2718259| (r_npadvmod) induced_40\VBN\1627355|NONE (r_amod) thrombocytopenia_41\NN\14189204|NONE (r_pobj) to_37\IN\0|NONE (r_prep) secondary_36\JJ\8426461|pulmonary (r_amod) embolism_35\NN\15269513|(|DVT|)|bilateral|extensive|extremity|and|venous (r_conj) thrombosis_29\NN\14100769|man|. (l_appos) dvt_31\NNP\0|(|)|bilateral|extensive|extremity|and|embolism|venous
C031942_D013479 NONE argatroban_18\NN\0|NONE (r_amod) with_17\IN\0|man|successfully|with|.|was (r_prep) treated_16\VBN\2376958|NONE (l_nsubjpass) man_4\NN\9605289|with|successfully|with|.|was (l_prep) with_5\IN\0|A|old|to (l_pobj) amyloidosis_7\NN\14061805|NONE (l_conj) syndrome_10\NN\5870365|renal|and
C031942_D000686 NONE argatroban_18\NN\0|NONE (r_amod) with_17\IN\0|man|successfully|with|.|was (r_prep) treated_16\VBN\2376958|NONE (l_nsubjpass) man_4\NN\9605289|with|successfully|with|.|was (l_prep) with_5\IN\0|A|old|to (l_pobj) amyloidosis_7\NN\14061805|NONE
C031942_D013927 NONE argatroban_2\NN\0|with|in (r_amod) thrombolysis_7\NN\13509528|NONE (l_prep) in_10\IN\13603305|with|argatroban (l_pobj) patient_13\NN\9898892|NONE (l_prep) with_14\IN\0|oncology|an (l_pobj) thrombocytopenia_18\NN\14189204|NONE (l_prep) with_19\IN\0|induced (l_pobj) thrombosis_20\NN\14100769|NONE
C031942_D013927 NONE argatroban_21\NN\0|(|CDT|directed|) (r_amod) thrombolysis_26\NN\13509528|NONE (r_pobj) with_20\IN\0|with|was (r_prep) treated_19\VBN\2376958|thrombocytopenia|who|and (r_conj) developed_7\VBD\1753788|oncology|an (l_dobj) thrombocytopenia_11\NN\14189204|treated|who|and (l_prep) with_12\IN\0|induced (l_pobj) thrombosis_13\NN\14100769|NONE
C031942_D013927 NONE argatroban_21\NN\0|(|CDT|directed|) (r_amod) thrombolysis_26\NN\13509528|NONE (r_pobj) with_20\IN\0|with|was (r_prep) treated_19\VBN\2376958|thrombocytopenia|who|and (r_conj) developed_7\VBD\1753788|oncology|an (l_dobj) thrombocytopenia_11\NN\14189204|treated|who|and (l_prep) with_12\IN\0|induced (l_pobj) thrombosis_13\NN\14100769|NONE (l_appos) hitt_15\NNP\0|NONE
C031942_D013927 NONE argatroban_18\NN\0|NONE (r_amod) with_17\IN\0|man|successfully|with|.|was (r_prep) treated_16\VBN\2376958|NONE (l_nsubjpass) man_4\NN\9605289|with|successfully|with|.|was (l_prep) to_12\IN\0|with|A|old (l_pobj) hitt_13\NNP\0|NONE
24928523
C400082_D009101 NONE bortezomib_2\NNS\0|NONE (r_pobj) of_1\IN\0|thalidomide|as|. (r_prep) combination_0\NN\7951464|NONE (l_prep) as_11\IN\14622893|of|thalidomide|. (l_pobj) therapy_14\NN\657604|NONE (l_prep) after_15\IN\0|a|consolidation (l_pobj) transplantation_19\NN\671351|NONE (l_prep) for_20\IN\0|cell|autologous (l_pobj) myeloma_23\NN\14239425|NONE
C400082_D009101 NONE bortezomib_15\NNS\0|NONE (r_pobj) of_14\IN\0|combination (r_prep) regimen_13\NNS\5898568|NONE (r_pobj) of_11\IN\0|the|and|efficacy (r_prep) safety_8\NN\13920835|.|,|In|retrospectively|we|as (r_dobj) analyzed_6\VBD\0|NONE (l_prep) as_24\IN\14622893|.|,|In|retrospectively|safety|we (l_pobj) therapy_26\NN\657604|NONE (l_prep) in_27\IN\13603305|consolidation (l_pobj) patients_30\NNS\9898892|NONE (l_prep) with_31\IN\0|Japanese| (l_pobj) mm_34\NNP\13649268|NONE
D013792_D009101 NONE thalidomide_4\NN\4166841|of|as|. (r_conj) combination_0\NN\7951464|NONE (l_prep) as_11\IN\14622893|of|thalidomide|. (l_pobj) therapy_14\NN\657604|NONE (l_prep) after_15\IN\0|a|consolidation (l_pobj) transplantation_19\NN\671351|NONE (l_prep) for_20\IN\0|cell|autologous (l_pobj) myeloma_23\NN\14239425|NONE
D013792_D009101 NONE thalidomide_17\NN\4166841|, (r_conj) bortezomib_15\NNS\0|NONE (r_pobj) of_14\IN\0|combination (r_prep) regimen_13\NNS\5898568|NONE (r_pobj) of_11\IN\0|the|and|efficacy (r_prep) safety_8\NN\13920835|.|,|In|retrospectively|we|as (r_dobj) analyzed_6\VBD\0|NONE (l_prep) as_24\IN\14622893|.|,|In|retrospectively|safety|we (l_pobj) therapy_26\NN\657604|NONE (l_prep) in_27\IN\13603305|consolidation (l_pobj) patients_30\NNS\9898892|NONE (l_prep) with_31\IN\0|Japanese| (l_pobj) mm_34\NNP\13649268|NONE
D003907_D009101 NONE dexamethasone_7\NN\2721538|and|, (r_conj) thalidomide_4\NN\4166841|of|as|. (r_conj) combination_0\NN\7951464|NONE (l_prep) as_11\IN\14622893|of|thalidomide|. (l_pobj) therapy_14\NN\657604|NONE (l_prep) after_15\IN\0|a|consolidation (l_pobj) transplantation_19\NN\671351|NONE (l_prep) for_20\IN\0|cell|autologous (l_pobj) myeloma_23\NN\14239425|NONE
D003907_D009101 NONE dexamethasone_20\NN\2721538|,|and (r_conj) thalidomide_17\NN\4166841|, (r_conj) bortezomib_15\NNS\0|NONE (r_pobj) of_14\IN\0|combination (r_prep) regimen_13\NNS\5898568|NONE (r_pobj) of_11\IN\0|the|and|efficacy (r_prep) safety_8\NN\13920835|.|,|In|retrospectively|we|as (r_dobj) analyzed_6\VBD\0|NONE (l_prep) as_24\IN\14622893|.|,|In|retrospectively|safety|we (l_pobj) therapy_26\NN\657604|NONE (l_prep) in_27\IN\13603305|consolidation (l_pobj) patients_30\NNS\9898892|NONE (l_prep) with_31\IN\0|Japanese| (l_pobj) mm_34\NNP\13649268|NONE
2904523
D004837_D006973 CID adrenaline_2\NN\14807929| (r_compound) hypertension_4\NN\14057371|NONE
D004837_D006973 CID adrenaline_14\NN\14807929|hours (r_compound) infusion_15\NN\14589223|NONE (r_pobj) after_11\IN\0|hour|pressor (r_prep) effect_10\NN\34213|.|:|for (r_appos) support_0\NN\407535|NONE (l_prep) for_1\IN\0|effect|.|: (l_pobj) hypothesis_5\NN\7162194|NONE (l_compound) hypertension_4\NN\14057371|NONE
D004837_D006973 CID adrenaline_7\NN\14807929| (r_compound) hypertension_9\NN\14057371|the|in
24114426
D018817_D020920 CID ecstasy_26\NN\13985818|NONE (r_compound) users_27\NNS\7846|NONE (r_pobj) of_25\IN\0|current|the (r_prep) generation_24\NN\7942152|NONE (r_pobj) for_21\IN\0|the (r_prep) prognosis_20\NN\6748969|,|cause|Given|. (r_nsubj) is_28\VBZ\0|NONE (l_prep) given_0\VBN\5892096|prognosis|,|cause|. (l_pobj) record_2\NN\6643408|NONE (l_prep) of_3\IN\0|this (l_pobj) memory_5\NN\5926676|NONE (l_conj) levels_9\NNS\4916342|impaired|and (l_prep) of_10\IN\0|significant (l_pobj) depression_11\NN\14373582|NONE (l_conj) impulsiveness_13\NN\4661706|, (l_conj) disturbance_17\NN\407535|and|,
D018817_D003866 CID 3,4-methylenedioxymethamphetamine_15\NNP\0|ecstasy (r_pobj) of_14\IN\0|)|polydrug (r_prep) users_13\NNS\7846|and|in|.|impulsiveness|, (r_conj) depression_0\NN\14373582|NONE
D018817_D003866 CID mdma_17\NNP\3054098|NONE (r_nmod) ecstasy_19\NN\13985818|,methylenedioxymethamphetamine (r_pobj) of_14\IN\0|)|polydrug (r_prep) users_13\NNS\7846|and|in|.|impulsiveness|, (r_conj) depression_0\NN\14373582|NONE
D018817_D003866 CID ecstasy_19\NN\13985818|,methylenedioxymethamphetamine (r_pobj) of_14\IN\0|)|polydrug (r_prep) users_13\NNS\7846|and|in|.|impulsiveness|, (r_conj) depression_0\NN\14373582|NONE
D018817_D003866 CID ecstasy_26\NN\13985818|NONE (r_compound) users_27\NNS\7846|NONE (r_pobj) of_25\IN\0|current|the (r_prep) generation_24\NN\7942152|NONE (r_pobj) for_21\IN\0|the (r_prep) prognosis_20\NN\6748969|,|cause|Given|. (r_nsubj) is_28\VBZ\0|NONE (l_prep) given_0\VBN\5892096|prognosis|,|cause|. (l_pobj) record_2\NN\6643408|NONE (l_prep) of_3\IN\0|this (l_pobj) memory_5\NN\5926676|NONE (l_conj) levels_9\NNS\4916342|impaired|and (l_prep) of_10\IN\0|significant (l_pobj) depression_11\NN\14373582|NONE
D018817_D010554 CID 3,4-methylenedioxymethamphetamine_15\NNP\0|ecstasy (r_pobj) of_14\IN\0|)|polydrug (r_prep) users_13\NNS\7846|and|in|.|impulsiveness|, (r_conj) depression_0\NN\14373582|NONE (l_conj) impulsiveness_2\NN\4661706|and|users|in|.|,
D018817_D010554 CID mdma_17\NNP\3054098|NONE (r_nmod) ecstasy_19\NN\13985818|,methylenedioxymethamphetamine (r_pobj) of_14\IN\0|)|polydrug (r_prep) users_13\NNS\7846|and|in|.|impulsiveness|, (r_conj) depression_0\NN\14373582|NONE (l_conj) impulsiveness_2\NN\4661706|and|users|in|.|,
D018817_D010554 CID ecstasy_19\NN\13985818|,methylenedioxymethamphetamine (r_pobj) of_14\IN\0|)|polydrug (r_prep) users_13\NNS\7846|and|in|.|impulsiveness|, (r_conj) depression_0\NN\14373582|NONE (l_conj) impulsiveness_2\NN\4661706|and|users|in|.|,
D018817_D010554 CID ecstasy_26\NN\13985818|NONE (r_compound) users_27\NNS\7846|NONE (r_pobj) of_25\IN\0|current|the (r_prep) generation_24\NN\7942152|NONE (r_pobj) for_21\IN\0|the (r_prep) prognosis_20\NN\6748969|,|cause|Given|. (r_nsubj) is_28\VBZ\0|NONE (l_prep) given_0\VBN\5892096|prognosis|,|cause|. (l_pobj) record_2\NN\6643408|NONE (l_prep) of_3\IN\0|this (l_pobj) memory_5\NN\5926676|NONE (l_conj) levels_9\NNS\4916342|impaired|and (l_prep) of_10\IN\0|significant (l_pobj) depression_11\NN\14373582|NONE (l_conj) impulsiveness_13\NN\4661706|,
D018817_D008569 NONE ecstasy_26\NN\13985818|NONE (r_compound) users_27\NNS\7846|NONE (r_pobj) of_25\IN\0|current|the (r_prep) generation_24\NN\7942152|NONE (r_pobj) for_21\IN\0|the (r_prep) prognosis_20\NN\6748969|,|cause|Given|. (r_nsubj) is_28\VBZ\0|NONE (l_prep) given_0\VBN\5892096|prognosis|,|cause|. (l_pobj) record_2\NN\6643408|NONE (l_prep) of_3\IN\0|this (l_pobj) memory_5\NN\5926676|NONE
978847
D006145_D006973 NONE guanethidine_13\NN\0|NONE (r_pobj) of_12\IN\0|the|(|i.v.|(|)|,|mg|)|hexamethonium|intravenous (r_prep) injection_11\NN\320852|NONE (r_pobj) by_5\IN\0|potentiated|.|was|response|,|significantly|and (r_agent) reduced_4\VBN\441445|NONE (l_conj) potentiated_34\VBN\229605|.|was|response|,|significantly|by|and (l_advcl) propranolol_44\NN\0|,|,|by|conversely (l_conj) inhibited_51\VBD\2510337|mg|i.v.|while (l_dobj) enlargement_53\NN\363260|selectively (l_prep) of_54\IN\0|tachycardia|and|the (l_pobj) pressure_56\NN\11419404|NONE
D018738_D006973 NONE hexamethonium_19\NN\0|the|(|i.v.|(|)|of|,|mg|)|intravenous (r_conj) injection_11\NN\320852|NONE (r_pobj) by_5\IN\0|potentiated|.|was|response|,|significantly|and (r_agent) reduced_4\VBN\441445|NONE (l_conj) potentiated_34\VBN\229605|.|was|response|,|significantly|by|and (l_advcl) propranolol_44\NN\0|,|,|by|conversely (l_conj) inhibited_51\VBD\2510337|mg|i.v.|while (l_dobj) enlargement_53\NN\363260|selectively (l_prep) of_54\IN\0|tachycardia|and|the (l_pobj) pressure_56\NN\11419404|NONE
D002217_D006973 CID carbachol_62\NN\0|NONE (r_dobj) following_60\VBG\8180190|the (r_acl) tachycardia_59\NNS\14110674|of|and|the (r_conj) enlargement_53\NN\363260|selectively (l_prep) of_54\IN\0|tachycardia|and|the (l_pobj) pressure_56\NN\11419404|NONE
D011433_D013610 NONE propranolol_44\NN\0|,|,|by|conversely (l_conj) inhibited_51\VBD\2510337|mg|i.v.|while (l_dobj) enlargement_53\NN\363260|selectively (l_conj) tachycardia_59\NNS\14110674|of|and|the
D003891_D006973 CID desmethylimipramine_37\NN\0|NONE (r_pobj) by_35\IN\0|,|,|propranolol|conversely (r_agent) potentiated_34\VBN\229605|.|was|response|,|significantly|by|and (l_advcl) propranolol_44\NN\0|,|,|by|conversely (l_conj) inhibited_51\VBD\2510337|mg|i.v.|while (l_dobj) enlargement_53\NN\363260|selectively (l_prep) of_54\IN\0|tachycardia|and|the (l_pobj) pressure_56\NN\11419404|NONE
D010646_D006973 NONE phentolamine_25\NN\4537602|)|or|(|mg (r_conj) hexamethonium_19\NN\0|the|(|i.v.|(|)|of|,|mg|)|intravenous (r_conj) injection_11\NN\320852|NONE (r_pobj) by_5\IN\0|potentiated|.|was|response|,|significantly|and (r_agent) reduced_4\VBN\441445|NONE (l_conj) potentiated_34\VBN\229605|.|was|response|,|significantly|by|and (l_advcl) propranolol_44\NN\0|,|,|by|conversely (l_conj) inhibited_51\VBD\2510337|mg|i.v.|while (l_dobj) enlargement_53\NN\363260|selectively (l_prep) of_54\IN\0|tachycardia|and|the (l_pobj) pressure_56\NN\11419404|NONE
D011433_D006973 NONE propranolol_44\NN\0|,|,|by|conversely (l_conj) inhibited_51\VBD\2510337|mg|i.v.|while (l_dobj) enlargement_53\NN\363260|selectively (l_prep) of_54\IN\0|tachycardia|and|the (l_pobj) pressure_56\NN\11419404|NONE
D018738_D013610 NONE hexamethonium_19\NN\0|the|(|i.v.|(|)|of|,|mg|)|intravenous (r_conj) injection_11\NN\320852|NONE (r_pobj) by_5\IN\0|potentiated|.|was|response|,|significantly|and (r_agent) reduced_4\VBN\441445|NONE (l_conj) potentiated_34\VBN\229605|.|was|response|,|significantly|by|and (l_advcl) propranolol_44\NN\0|,|,|by|conversely (l_conj) inhibited_51\VBD\2510337|mg|i.v.|while (l_dobj) enlargement_53\NN\363260|selectively (l_conj) tachycardia_59\NNS\14110674|of|and|the
D003891_D013610 NONE desmethylimipramine_37\NN\0|NONE (r_pobj) by_35\IN\0|,|,|propranolol|conversely (r_agent) potentiated_34\VBN\229605|.|was|response|,|significantly|by|and (l_advcl) propranolol_44\NN\0|,|,|by|conversely (l_conj) inhibited_51\VBD\2510337|mg|i.v.|while (l_dobj) enlargement_53\NN\363260|selectively (l_conj) tachycardia_59\NNS\14110674|of|and|the
D006145_D013610 NONE guanethidine_13\NN\0|NONE (r_pobj) of_12\IN\0|the|(|i.v.|(|)|,|mg|)|hexamethonium|intravenous (r_prep) injection_11\NN\320852|NONE (r_pobj) by_5\IN\0|potentiated|.|was|response|,|significantly|and (r_agent) reduced_4\VBN\441445|NONE (l_conj) potentiated_34\VBN\229605|.|was|response|,|significantly|by|and (l_advcl) propranolol_44\NN\0|,|,|by|conversely (l_conj) inhibited_51\VBD\2510337|mg|i.v.|while (l_dobj) enlargement_53\NN\363260|selectively (l_conj) tachycardia_59\NNS\14110674|of|and|the
D010646_D013610 NONE phentolamine_25\NN\4537602|)|or|(|mg (r_conj) hexamethonium_19\NN\0|the|(|i.v.|(|)|of|,|mg|)|intravenous (r_conj) injection_11\NN\320852|NONE (r_pobj) by_5\IN\0|potentiated|.|was|response|,|significantly|and (r_agent) reduced_4\VBN\441445|NONE (l_conj) potentiated_34\VBN\229605|.|was|response|,|significantly|by|and (l_advcl) propranolol_44\NN\0|,|,|by|conversely (l_conj) inhibited_51\VBD\2510337|mg|i.v.|while (l_dobj) enlargement_53\NN\363260|selectively (l_conj) tachycardia_59\NNS\14110674|of|and|the
D002217_D013610 CID carbachol_62\NN\0|NONE (r_dobj) following_60\VBG\8180190|the (r_acl) tachycardia_59\NNS\14110674|of|and|the
8392553
D004837_D007511 NONE epinephrine_3\NN\14807929|chronic|week (r_compound) infusion_4\NN\14589223|NONE (r_pobj) with_0\IN\0|rats|observed|,|within|,|and (r_prep) died_10\VBD\146138|NONE (l_conj) observed_26\VBN\2163746|rats|With|,|within|,|and (l_nsubjpass) lesions_18\NNS\14204950|.|were
D004837_D007511 NONE epinephrine_4\RB\14807929| (r_npadvmod) induced_6\VBN\1627355|)|(|P (r_amod) death_7\NN\7296428|and|,|attenuated|Treatment|. (r_dobj) prevented_3\VBD\0|NONE (l_conj) attenuated_15\VBD\224901|and|,|death|Treatment|. (l_dobj) lesions_19\NNS\14204950|,|in
C056595_D006331 NONE clentiazem_3\NN\0|NONE (l_prep) against_4\IN\0|NONE (l_pobj) injury_9\NN\14052046|NONE
C056595_D006331 NONE clentiazem_3\NN\0|In|.|injury|,|,|through (r_npadvmod) attenuated_4\VBD\224901|NONE (l_dobj) injury_9\NN\14052046|In|.|clentiazem|,|,|through
D004837_D009202 CID epinephrine_13\NN\14807929| (r_npadvmod) induced_15\VBN\1627355|in (r_amod) cardiomyopathy_16\NN\14103288|NONE
C106746_D009202 NONE 1,5-benzothiazepine_8\CD\0|a|calcium (r_amod) antagonist_10\NN\7846|on|of|,|,|the (r_appos) effects_3\NNS\13245626|We|. (l_prep) on_12\IN\0|of|,|antagonist|,|the (l_pobj) cardiomyopathy_16\NN\14103288|NONE
C056595_D007511 NONE clentiazem_2\NN\0|NONE (r_pobj) with_1\IN\0|NONE (r_prep) treatment_0\NN\654885|and|,|attenuated|death|. (r_nsubj) prevented_3\VBD\0|NONE (l_conj) attenuated_15\VBD\224901|and|,|death|Treatment|. (l_dobj) lesions_19\NNS\14204950|,|in
C056595_D005355 NONE clentiazem_2\NN\0|NONE (r_pobj) with_1\IN\0|NONE (r_prep) treatment_0\NN\654885|and|,|attenuated|death|. (r_nsubj) prevented_3\VBD\0|NONE (l_conj) attenuated_15\VBD\224901|and|,|death|Treatment|. (l_dobj) lesions_19\NNS\14204950|,|in (l_conj) fibrosis_21\NN\14204950|the|ischemic|and|ventricular
C056595_D009202 NONE clentiazem_5\NN\0|NONE (r_pobj) of_4\IN\0|on|,|antagonist|,|the (r_prep) effects_3\NNS\13245626|We|. (l_prep) on_12\IN\0|of|,|antagonist|,|the (l_pobj) cardiomyopathy_16\NN\14103288|NONE
D004837_D005355 NONE epinephrine_3\NN\14807929|chronic|week (r_compound) infusion_4\NN\14589223|NONE (r_pobj) with_0\IN\0|rats|observed|,|within|,|and (r_prep) died_10\VBD\146138|NONE (l_conj) observed_26\VBN\2163746|rats|With|,|within|,|and (l_nsubjpass) lesions_18\NNS\14204950|.|were (l_conj) fibrosis_20\NN\14204950|severe|and|of|ischemic
D004837_D005355 NONE epinephrine_4\RB\14807929| (r_npadvmod) induced_6\VBN\1627355|)|(|P (r_amod) death_7\NN\7296428|and|,|attenuated|Treatment|. (r_dobj) prevented_3\VBD\0|NONE (l_conj) attenuated_15\VBD\224901|and|,|death|Treatment|. (l_dobj) lesions_19\NNS\14204950|,|in (l_conj) fibrosis_21\NN\14204950|the|ischemic|and|ventricular
D004837_D006331 NONE epinephrine_5\NN\14807929| (r_npadvmod) induced_7\VBN\1627355|cardiac|in (r_amod) injury_9\NN\14052046|NONE
D004837_D006331 NONE epinephrine_5\NN\14807929| (r_npadvmod) induced_7\VBN\1627355|cardiac (r_amod) injury_9\NN\14052046|In|.|clentiazem|,|,|through
D002118_D009202 NONE calcium_9\NN\14625458|a|,benzothiazepine (r_compound) antagonist_10\NN\7846|on|of|,|,|the (r_appos) effects_3\NNS\13245626|We|. (l_prep) on_12\IN\0|of|,|antagonist|,|the (l_pobj) cardiomyopathy_16\NN\14103288|NONE
7369302
D011803_D015845 CID sulfate_30\NN\15010703|NONE (r_pobj) of_28\IN\0|the (r_prep) use_27\NN\407535|NONE (r_pobj) after_25\IN\0|in (r_prep) developed_18\VBN\1753788|abnormal|evoked (r_acl) potentials_17\NNS\14481929|denervation|and|, (r_conj) supersensitivity_10\NN\0|a|transient|,|pupillary|tonic (r_conj) response_7\NN\11410625|NONE (l_amod) pupillary_6\JJ\0|a|supersensitivity|transient|,|tonic
D011803_D015845 CID quinine_16\NN\2721948|NONE (r_compound) toxicity_17\NN\13576101|NONE (r_pobj) in_15\IN\13603305|evoked|abnormal (r_prep) potentials_14\NNS\14481929|,|denervation|and (r_conj) supersensitivity_7\NN\0|,|A|pupillary|tonic|transient|,|to (r_conj) response_4\NN\11410625|not|have|been|,|.|previously (l_amod) pupillary_3\JJ\0|,|A|tonic|transient|supersensitivity|,|to
D011803_D001766 CID sulfate_30\NN\15010703|NONE (r_pobj) of_28\IN\0|the (r_prep) use_27\NN\407535|NONE (r_pobj) after_25\IN\0|in (r_prep) developed_18\VBN\1753788|abnormal|evoked (r_acl) potentials_17\NNS\14481929|denervation|and|, (r_conj) supersensitivity_10\NN\0|a|transient|,|pupillary|tonic (r_conj) response_7\NN\11410625|NONE (r_pobj) with_2\IN\0|.|Total (r_prep) blindness_1\NN\14552802|NONE
D011803_D000550 CID quinine_10\NN\2721948|NONE (r_compound) amblyopia_11\NN\14552802|NONE
D011803_D064420 NONE quinine_16\NN\2721948|NONE (r_compound) toxicity_17\NN\13576101|NONE
D011803_D009120 NONE sulfate_30\NN\15010703|NONE (l_prep) for_31\IN\0|quinine (l_pobj) cramps_33\NNS\14299637|NONE
3812624
D002220_D015835 CID carbamazepine_9\NN\0|NONE (r_pobj) with_8\IN\0|NONE (r_prep) associated_7\VBN\628491|Two|.|of (r_acl) cases_1\NNS\7283608|NONE (l_prep) of_2\IN\0|Two|.|associated (l_pobj) nystagmus_4\NN\337486|NONE (l_conj) oscillopsia_6\NN\0|downbeat|and
D002220_D009759 NONE carbamazepine_9\NN\0|NONE (r_pobj) with_8\IN\0|NONE (r_prep) associated_7\VBN\628491|Two|.|of (r_acl) cases_1\NNS\7283608|NONE (l_prep) of_2\IN\0|Two|.|associated (l_pobj) nystagmus_4\NN\337486|NONE
D002220_D009759 NONE carbamazepine_14\NN\0|NONE (r_compound) therapy_15\NN\657604|NONE (r_pobj) to_13\IN\0|NONE (r_prep) related_12\VBN\628491|reversible|downbeat (r_amod) nystagmus_11\NN\337486|NONE
D002220_D009759 NONE carbamazepine_11\NN\0|the (r_compound) levels_12\NNS\4916342|NONE (r_pobj) of_8\IN\0|NONE (r_prep) reduction_7\NN\351485|NONE (r_pobj) after_6\IN\0|nystagmus|. (r_prep) resolved_5\VBN\352826|NONE (l_nsubj) nystagmus_1\NN\337486|after|.
3798047
D008775_D006331 NONE mp_3\NNP\10249459|.|be|may|in (r_nsubjpass) contraindicated_6\VBN\872886|NONE (l_prep) in_7\IN\13603305|.|be|may|MP (l_pobj) patients_8\NNS\9898892|NONE (l_prep) with_9\IN\0|NONE (l_pobj) disease_12\NN\14061805|NONE
D008775_D001172 NONE methylprednisolone_13\NN\0|daily|who|for|) (r_dobj) received_8\VBD\2210855|consecutive||with (r_relcl) patients_3\NNS\9898892|NONE (l_prep) with_4\IN\0|received|consecutive| (l_pobj) arthritis_6\NN\14171682|NONE
D008775_D001172 NONE mp_15\NNP\10249459|(|)|( (r_nmod) therapy_17\NN\657604|intravenous|dose (r_appos) methylprednisolone_13\NN\0|daily|who|for|) (r_dobj) received_8\VBD\2210855|consecutive||with (r_relcl) patients_3\NNS\9898892|NONE (l_prep) with_4\IN\0|received|consecutive| (l_pobj) arthritis_6\NN\14171682|NONE
D008775_D001919 CID methylprednisolone_6\NN\0|dose|intravenous (r_compound) therapy_7\NN\657604|NONE (r_pobj) after_1\IN\0|. (r_prep) bradycardia_0\NNS\14110674|NONE
17721298
D016578_D003320 CID cocaine_6\NN\3492717|crack (r_compound) use_7\NN\407535|NONE (r_pobj) with_3\IN\0|NONE (r_prep) associated_2\VBN\628491|.|Corneal (r_acl) ulcers_1\NNS\14211294|NONE
D016578_D003320 CID cocaine_8\NN\3492717|crack (r_compound) use_9\NN\407535|NONE (r_pobj) with_6\IN\0|NONE (r_prep) associated_5\VBN\628491|corneal (r_acl) ulcers_4\NNS\14211294|NONE
D016578_D003320 CID cocaine_2\NN\3492717|crack (r_compound) use_3\NN\407535|with|can|.|be (r_nsubjpass) associated_6\VBN\628491|NONE (l_prep) with_7\IN\0|use|can|.|be (l_pobj) development_9\NN\248977|NONE (l_prep) of_10\IN\0|the (l_pobj) ulcers_12\NNS\14211294|NONE
1655018
D000728_D006528 CID androgen_8\JJ\14745635|NONE (r_pobj) with_7\IN\0|.|carcinoma (r_prep) treated_6\VBN\2376958|NONE (l_nsubj) carcinoma_1\NN\14239918|.|with
D000305_D006528 CID corticosteroid_10\NN\14745635|and (r_conj) androgen_8\JJ\14745635|NONE (r_pobj) with_7\IN\0|.|carcinoma (r_prep) treated_6\VBN\2376958|NONE (l_nsubj) carcinoma_1\NN\14239918|.|with
D000305_D010382 CID corticosteroid_22\NN\14745635| (r_npadvmod) treated_24\VBN\2376958|and (r_conj) androgen-_20\NN\0|Fanconi (r_amod) anemia_27\NN\14189204|NONE (r_pobj) with_19\IN\0|NONE (r_prep) patients_18\NNS\9898892|NONE (r_pobj) in_17\IN\13603305|can|neoplasms|that (r_prep) develop_16\VB\1753788|the|previous (l_nsubj) neoplasms_12\NNS\14234074|can|in|that (l_conj) peliosis_14\NN\14189204|metastasizing|and|hepatic
D000728_D010382 CID androgen-_20\NN\0|Fanconi (r_amod) anemia_27\NN\14189204|NONE (r_pobj) with_19\IN\0|NONE (r_prep) patients_18\NNS\9898892|NONE (r_pobj) in_17\IN\13603305|can|neoplasms|that (r_prep) develop_16\VB\1753788|the|previous (l_nsubj) neoplasms_12\NNS\14234074|can|in|that (l_conj) peliosis_14\NN\14189204|metastasizing|and|hepatic
D000305_D005199 NONE corticosteroid_10\NN\14745635|and (r_conj) androgen_8\JJ\14745635|NONE (r_pobj) with_7\IN\0|.|carcinoma (r_prep) treated_6\VBN\2376958|NONE (l_nsubj) carcinoma_1\NN\14239918|.|with (l_prep) in_2\IN\13603305|Hepatocellular (l_pobj) anemia_5\NN\14189204|NONE
D000305_D005199 NONE corticosteroids_27\NNS\14745635|, (r_conj) androgens_25\NNS\14745635|NONE (r_pobj) with_24\IN\0|was (r_prep) treated_23\VBN\2376958|who|and|was|have (r_conj) known_12\VBN\0|is|.|case (l_xcomp) have_14\VB\7846|who|and|was|treated (l_dobj) anemia_17\NN\14189204|to
D000305_D005199 NONE corticosteroid_22\NN\14745635| (r_npadvmod) treated_24\VBN\2376958|and (r_conj) androgen-_20\NN\0|Fanconi (r_amod) anemia_27\NN\14189204|NONE
D000728_D008113 NONE androgen-_20\NN\0|Fanconi (r_amod) anemia_27\NN\14189204|NONE (r_pobj) with_19\IN\0|NONE (r_prep) patients_18\NNS\9898892|NONE (r_pobj) in_17\IN\13603305|can|neoplasms|that (r_prep) develop_16\VB\1753788|the|previous (l_nsubj) neoplasms_12\NNS\14234074|can|in|that
D000305_D008113 NONE corticosteroid_22\NN\14745635| (r_npadvmod) treated_24\VBN\2376958|and (r_conj) androgen-_20\NN\0|Fanconi (r_amod) anemia_27\NN\14189204|NONE (r_pobj) with_19\IN\0|NONE (r_prep) patients_18\NNS\9898892|NONE (r_pobj) in_17\IN\13603305|can|neoplasms|that (r_prep) develop_16\VB\1753788|the|previous (l_nsubj) neoplasms_12\NNS\14234074|can|in|that
D000728_D005199 NONE androgen_8\JJ\14745635|NONE (r_pobj) with_7\IN\0|.|carcinoma (r_prep) treated_6\VBN\2376958|NONE (l_nsubj) carcinoma_1\NN\14239918|.|with (l_prep) in_2\IN\13603305|Hepatocellular (l_pobj) anemia_5\NN\14189204|NONE
D000728_D005199 NONE androgens_25\NNS\14745635|NONE (r_pobj) with_24\IN\0|was (r_prep) treated_23\VBN\2376958|who|and|was|have (r_conj) known_12\VBN\0|is|.|case (l_xcomp) have_14\VB\7846|who|and|was|treated (l_dobj) anemia_17\NN\14189204|to
D000728_D005199 NONE androgen-_20\NN\0|Fanconi (r_amod) anemia_27\NN\14189204|NONE
10975596
D007545_D013610 CID isoproterenol_20\NN\3740161| (r_npadvmod) induced_22\VBN\1627355|the (r_amod) tachycardia_23\NN\14110674|.|at|, (r_dobj) decreased_18\VBD\169651|dronedarone|,|tachycardia|and|significantly (r_conj) reduced_5\VBD\441445|NONE (l_dobj) tachycardia_10\NN\14110674|decreased|dronedarone|,|and|significantly
D007545_D013610 CID isoproterenol_20\NN\3740161| (r_npadvmod) induced_22\VBN\1627355|the (r_amod) tachycardia_23\NN\14110674|.|at|,
D000638_D009203 NONE amiodarone_7\NN\2715941|and (l_prep) with_10\IN\0|in (l_pobj) infarction_14\NN\14204950|NONE
D000638_D009203 NONE amiodarone_14\NN\2715941|NONE (r_pobj) to_13\IN\0|compound|structurally (r_prep) related_12\VBN\628491|,|hemodynamic|,|The|of (r_amod) effects_4\NNS\13245626|were|with|. (r_nsubjpass) compared_17\VBN\644583|NONE (l_prep) with_18\IN\0|effects|were|. (l_pobj) those_19\DT\0|NONE (l_prep) at_28\IN\14622893|of|,|after (l_conj) during_31\IN\0|and|both|rest (l_pobj) stimulation_33\NN\242808|NONE (l_prep) in_34\IN\13603305|sympathetic (l_pobj) dogs_36\NNS\2083346|NONE (l_prep) with_37\IN\0|conscious (l_pobj) infarction_41\NN\14204950|NONE
D000638_D009203 NONE amiodarone_21\NN\2715941|NONE (r_pobj) of_20\IN\0|,|after|at (r_prep) those_19\DT\0|NONE (l_prep) at_28\IN\14622893|of|,|after (l_conj) during_31\IN\0|and|both|rest (l_pobj) stimulation_33\NN\242808|NONE (l_prep) in_34\IN\13603305|sympathetic (l_pobj) dogs_36\NNS\2083346|NONE (l_prep) with_37\IN\0|conscious (l_pobj) infarction_41\NN\14204950|NONE
D000638_D013610 NONE amiodarone_3\NN\2715941|Both|and (r_conj) dronedarone_1\NN\0|decreased|,|tachycardia|and|significantly (r_nsubj) reduced_5\VBD\441445|NONE (l_dobj) tachycardia_10\NN\14110674|decreased|dronedarone|,|and|significantly
D000638_D013610 NONE amiodarone_3\NN\2715941|Both|and (r_conj) dronedarone_1\NN\0|decreased|,|tachycardia|and|significantly (r_nsubj) reduced_5\VBD\441445|NONE (l_conj) decreased_18\VBD\169651|dronedarone|,|tachycardia|and|significantly (l_dobj) tachycardia_23\NN\14110674|.|at|,
C118667_D001145 NONE dronedarone_2\NN\0|,|.|might|without|Consequently|suitable|, (r_nsubj) be_4\VB\14625458|NONE (l_acomp) suitable_6\JJ\0|,|.|might|without|Consequently|dronedarone|, (l_prep) for_7\IN\0|particularly (l_pobj) treatment_9\NN\654885|NONE (l_prep) of_12\IN\0|prevention|the|and (l_pobj) arrhythmias_15\NNS\14103288|NONE
C118667_D009203 NONE dronedarone_5\NN\0|NONE (l_conj) amiodarone_7\NN\2715941|and (l_prep) with_10\IN\0|in (l_pobj) infarction_14\NN\14204950|NONE
C118667_D009203 NONE dronedarone_6\NN\0|NONE (r_pobj) of_5\IN\0|,|hemodynamic|,|The|related (r_prep) effects_4\NNS\13245626|were|with|. (r_nsubjpass) compared_17\VBN\644583|NONE (l_prep) with_18\IN\0|effects|were|. (l_pobj) those_19\DT\0|NONE (l_prep) at_28\IN\14622893|of|,|after (l_conj) during_31\IN\0|and|both|rest (l_pobj) stimulation_33\NN\242808|NONE (l_prep) in_34\IN\13603305|sympathetic (l_pobj) dogs_36\NNS\2083346|NONE (l_prep) with_37\IN\0|conscious (l_pobj) infarction_41\NN\14204950|NONE
C118667_D013610 NONE dronedarone_1\NN\0|decreased|,|tachycardia|and|significantly (r_nsubj) reduced_5\VBD\441445|NONE (l_dobj) tachycardia_10\NN\14110674|decreased|dronedarone|,|and|significantly
C118667_D013610 NONE dronedarone_1\NN\0|decreased|,|tachycardia|and|significantly (r_nsubj) reduced_5\VBD\441445|NONE (l_conj) decreased_18\VBD\169651|dronedarone|,|tachycardia|and|significantly (l_dobj) tachycardia_23\NN\14110674|.|at|,
24618873
C002752_D012640 CID norpethidine_35\NN\0|,|,|its|neurotoxic (r_appos) metabolite_33\NN\20090|NONE (r_pobj) through_30\IN\0|system|(|CNS|)|resulting (r_prep) effects_29\NNS\13245626|,|may|.|In|pethidine (l_acl) resulting_37\VBG\2633881|system|(|CNS|)|through (l_prep) in_38\IN\13603305|NONE (l_pobj) irritability_39\NN\7552087|NONE (l_conj) attack_42\NN\955060|and (l_compound) seizure_41\NN\14081375|NONE
D008614_D012640 NONE pethidine_19\NN\0|,|effects|may|.|In (r_nsubj) cause_21\VB\7323922|NONE (l_dobj) effects_29\NNS\13245626|,|may|.|In|pethidine (l_acl) resulting_37\VBG\2633881|system|(|CNS|)|through (l_prep) in_38\IN\13603305|NONE (l_pobj) irritability_39\NN\7552087|NONE (l_conj) attack_42\NN\955060|and (l_compound) seizure_41\NN\14081375|NONE
D008614_D010146 NONE pethidine_0\NNP\0|opioid|. (r_nsubj) is_1\VBZ\0|NONE (l_attr) opioid_3\NN\0|Pethidine|. (l_relcl) gains_5\VBZ\13576355|an (l_prep) for_8\IN\0|popularity|that|through (l_pobj) control_12\NN\5190804|NONE (l_compound) pain_11\NN\14299637|the|effective
D008614_D010146 NONE pethidine_19\NN\0|,|effects|may|.|In (r_nsubj) cause_21\VB\7323922|NONE (l_prep) in_0\IN\13603305|,|effects|may|.|pethidine (l_conj) those_10\DT\0|,|and|patients (l_relcl) need_12\VBP\13920835|NONE (l_dobj) control_17\NN\5190804|who (l_compound) pain_16\NN\14299637|term
C002752_D001523 NONE norpethidine_35\NN\0|,|,|its|neurotoxic (r_appos) metabolite_33\NN\20090|NONE (r_pobj) through_30\IN\0|system|(|CNS|)|resulting (r_prep) effects_29\NNS\13245626|,|may|.|In|pethidine (l_acl) resulting_37\VBG\2633881|system|(|CNS|)|through (l_prep) in_38\IN\13603305|NONE (l_pobj) irritability_39\NN\7552087|NONE
D008614_D002526 NONE pethidine_9\NN\0|NONE (r_pobj) of_8\IN\0|rapid (r_prep) infusion_7\NN\14589223|NONE (r_pobj) by_5\IN\0|dysfunction|. (r_agent) induced_4\VBN\1627355|NONE (l_nsubj) dysfunction_3\NN\14204950|by|.
D008614_D020258 NONE pethidine_19\NN\0|,|effects|may|.|In (r_nsubj) cause_21\VB\7323922|NONE (l_dobj) effects_29\NNS\13245626|,|may|.|In|pethidine (l_prep) through_30\IN\0|system|(|CNS|)|resulting (l_pobj) metabolite_33\NN\20090|NONE (l_amod) neurotoxic_32\JJ\0|norpethidine|,|,|its
C002752_D017093 NONE norpethidine_35\NN\0|,|,|its|neurotoxic (r_appos) metabolite_33\NN\20090|NONE (r_pobj) through_30\IN\0|system|(|CNS|)|resulting (r_prep) effects_29\NNS\13245626|,|may|.|In|pethidine (r_dobj) cause_21\VB\7323922|NONE (l_prep) in_0\IN\13603305|,|effects|may|.|pethidine (l_pobj) patients_1\NNS\9898892|,|and|those (l_prep) with_2\IN\0|NONE (l_pobj) function_7\NN\13783581|NONE
D008614_D005128 NONE pethidine_9\NN\0|NONE (r_pobj) of_8\IN\0|rapid (r_prep) infusion_7\NN\14589223|NONE (r_pobj) by_5\IN\0|dysfunction|. (r_agent) induced_4\VBN\1627355|NONE (l_nsubj) dysfunction_3\NN\14204950|by|.
D008614_D051437 NONE pethidine_19\NN\0|,|effects|may|.|In (r_nsubj) cause_21\VB\7323922|NONE (l_prep) in_0\IN\13603305|,|effects|may|.|pethidine (l_pobj) patients_1\NNS\9898892|,|and|those (l_prep) with_2\IN\0|NONE (l_pobj) function_7\NN\13783581|NONE
D008614_D017093 NONE pethidine_19\NN\0|,|effects|may|.|In (r_nsubj) cause_21\VB\7323922|NONE (l_prep) in_0\IN\13603305|,|effects|may|.|pethidine (l_pobj) patients_1\NNS\9898892|,|and|those (l_prep) with_2\IN\0|NONE (l_pobj) function_7\NN\13783581|NONE
C002752_D020258 NONE norpethidine_35\NN\0|,|,|its|neurotoxic (r_appos) metabolite_33\NN\20090|NONE (l_amod) neurotoxic_32\JJ\0|norpethidine|,|,|its
C002752_D051437 NONE norpethidine_35\NN\0|,|,|its|neurotoxic (r_appos) metabolite_33\NN\20090|NONE (r_pobj) through_30\IN\0|system|(|CNS|)|resulting (r_prep) effects_29\NNS\13245626|,|may|.|In|pethidine (r_dobj) cause_21\VB\7323922|NONE (l_prep) in_0\IN\13603305|,|effects|may|.|pethidine (l_pobj) patients_1\NNS\9898892|,|and|those (l_prep) with_2\IN\0|NONE (l_pobj) function_7\NN\13783581|NONE
C002752_D010146 NONE norpethidine_35\NN\0|,|,|its|neurotoxic (r_appos) metabolite_33\NN\20090|NONE (r_pobj) through_30\IN\0|system|(|CNS|)|resulting (r_prep) effects_29\NNS\13245626|,|may|.|In|pethidine (r_dobj) cause_21\VB\7323922|NONE (l_prep) in_0\IN\13603305|,|effects|may|.|pethidine (l_conj) those_10\DT\0|,|and|patients (l_relcl) need_12\VBP\13920835|NONE (l_dobj) control_17\NN\5190804|who (l_compound) pain_16\NN\14299637|term
D008614_D001523 NONE pethidine_19\NN\0|,|effects|may|.|In (r_nsubj) cause_21\VB\7323922|NONE (l_dobj) effects_29\NNS\13245626|,|may|.|In|pethidine (l_acl) resulting_37\VBG\2633881|system|(|CNS|)|through (l_prep) in_38\IN\13603305|NONE (l_pobj) irritability_39\NN\7552087|NONE
7411769
D007213_D015210 NONE indomethacin_0\NNP\3828465| (r_npadvmod) induced_2\VBN\1627355|in|. (r_amod) hyperkalemia_3\NN\14299637|NONE (l_prep) in_4\IN\13603305|induced|. (l_pobj) patients_6\NNS\9898892|NONE (l_prep) with_7\IN\0|three (l_pobj) arthritis_9\NN\14171682|NONE
D007213_D015210 NONE indomethacin_23\NN\3828465|NONE (r_pobj) with_22\IN\0|of (r_prep) treatment_17\NN\654885|NONE (l_prep) of_18\IN\0|with (l_pobj) arthritis_21\NN\14171682|NONE
D007213_D051437 CID indomethacin_23\NN\3828465|NONE (r_pobj) with_22\IN\0|of (r_prep) treatment_17\NN\654885|NONE (r_pobj) after_16\IN\0|NONE (r_prep) developed_15\VBD\1753788|three|hyperkalemia (r_acl) patients_3\NNS\9898892|We|. (l_appos) hyperkalemia_11\NN\14299637|developed|three (l_conj) insufficiency_14\NN\14462946|and|threatening|,|severe|in
D007213_D006947 CID indomethacin_0\NNP\3828465| (r_npadvmod) induced_2\VBN\1627355|in|. (r_amod) hyperkalemia_3\NN\14299637|NONE
D007213_D006947 CID indomethacin_23\NN\3828465|NONE (r_pobj) with_22\IN\0|of (r_prep) treatment_17\NN\654885|NONE (r_pobj) after_16\IN\0|NONE (r_prep) developed_15\VBD\1753788|three|hyperkalemia (r_acl) patients_3\NNS\9898892|We|. (l_appos) hyperkalemia_11\NN\14299637|developed|three
D011188_D007674 NONE potassium_6\NN\14625458|NONE (r_compound) balance_7\NN\13934900|renal|in|and (r_conj) function_4\NN\13783581|NONE (r_pobj) to_2\IN\0|Careful (r_prep) attention_1\NN\5701944|,|,|prevent|will|in|. (r_nsubj) help_33\VB\407535|NONE (l_prep) in_21\IN\13603305|,|,|prevent|attention|will|. (l_pobj) patients_23\NNS\9898892|particularly (l_prep) with_24\IN\0|those (l_pobj) mellitus_26\NN\0|NONE (l_conj) disease_30\NN\14061805|diabetes|or
D007213_D007674 NONE indomethacin_11\NN\3828465|NONE (r_dobj) receiving_10\VBG\2210855|NONE (r_acl) patients_9\NNS\9898892|NONE (r_pobj) in_8\IN\13603305|renal|balance|and (r_prep) function_4\NN\13783581|NONE (r_pobj) to_2\IN\0|Careful (r_prep) attention_1\NN\5701944|,|,|prevent|will|in|. (r_nsubj) help_33\VB\407535|NONE (l_prep) in_21\IN\13603305|,|,|prevent|attention|will|. (l_pobj) patients_23\NNS\9898892|particularly (l_prep) with_24\IN\0|those (l_pobj) mellitus_26\NN\0|NONE (l_conj) disease_30\NN\14061805|diabetes|or
D011453_D006994 NONE prostaglandin_8\JJ\5414534|hypoaidosteronism|and (r_amod) synthesis_9\NN\13446390|NONE (l_conj) hypoaidosteronism_13\NN\0|prostaglandin|and
D011188_D003920 NONE potassium_6\NN\14625458|NONE (r_compound) balance_7\NN\13934900|renal|in|and (r_conj) function_4\NN\13783581|NONE (r_pobj) to_2\IN\0|Careful (r_prep) attention_1\NN\5701944|,|,|prevent|will|in|. (r_nsubj) help_33\VB\407535|NONE (l_prep) in_21\IN\13603305|,|,|prevent|attention|will|. (l_pobj) patients_23\NNS\9898892|particularly (l_prep) with_24\IN\0|those (l_pobj) mellitus_26\NN\0|NONE
D007213_D003920 NONE indomethacin_11\NN\3828465|NONE (r_dobj) receiving_10\VBG\2210855|NONE (r_acl) patients_9\NNS\9898892|NONE (r_pobj) in_8\IN\13603305|renal|balance|and (r_prep) function_4\NN\13783581|NONE (r_pobj) to_2\IN\0|Careful (r_prep) attention_1\NN\5701944|,|,|prevent|will|in|. (r_nsubj) help_33\VB\407535|NONE (l_prep) in_21\IN\13603305|,|,|prevent|attention|will|. (l_pobj) patients_23\NNS\9898892|particularly (l_prep) with_24\IN\0|those (l_pobj) mellitus_26\NN\0|NONE
9061777
D016202_D001930 NONE nmda_31\NNP\0|mediated|excitatory|an (r_compound) mechanism_35\NN\13446390|NONE (r_pobj) through_28\IN\0|brain (r_prep) damage_27\NN\7296428|elevation|,|may|indicate|.
D012601_D012640 NONE scopolamine_0\NNP\14712692|but|development|mg/kg|) (r_nsubj) prevented_11\VBN\0|.|not| (l_dobj) development_12\NN\248977|but|Scopolamine|mg/kg|) (l_prep) of_13\IN\0|NONE (l_pobj) seizure_18\NN\14081375|NONE
D012601_D012640 NONE scopolamine_0\NNP\14712692|.|augmented|,|seizure (r_nsubj) blocked_3\VBD\1476483|NONE (l_dobj) seizure_9\NN\14081375|.|augmented|,|Scopolamine
D012601_D012640 NONE scopolamine_0\NNP\14712692|.|augmented|,|seizure (r_nsubj) blocked_3\VBD\1476483|NONE (l_conj) augmented_13\VBD\153263|.|,|Scopolamine|seizure (l_dobj) seizure_16\NN\14081375|treatment
D016202_D013226 NONE nmda_31\NNP\0|mediated|excitatory|an (r_compound) mechanism_35\NN\13446390|NONE (r_pobj) through_28\IN\0|brain (r_prep) damage_27\NN\7296428|elevation|,|may|indicate|. (r_dobj) cause_25\VB\7323922|NONE (l_ccomp) indicate_2\VBP\952524|damage|elevation|,|may|. (l_ccomp) initiated_10\VBN\1617192|results (l_nsubjpass) status_4\NN\24720|is|that|by|and|propagated (l_acl) induced_6\VBN\1627355|NONE (l_advmod) epilepticus_5\NN\0|by
D010862_D001930 NONE pilocarpine_2\NN\14712692| (r_npadvmod) induced_4\VBN\1627355|electrographic (r_amod) seizure_6\NN\14081375|.|MK|protects|but (r_dobj) augments_1\VBZ\153263|NONE (l_conj) protects_8\VBZ\1127795|.|MK|seizure|but (l_prep) against_9\IN\0|NONE (l_pobj) damage_11\NN\7296428|NONE
D010862_D001930 NONE pilocarpine_10\NN\14712692|NONE (r_pobj) by_9\IN\0|the|brain (r_prep) damage_8\NN\7296428|MK
D010862_D001930 NONE pilocarpine_8\NN\14712692|NONE (r_pobj) by_7\IN\0|epilepticus (r_agent) induced_6\VBN\1627355|NONE (r_acl) status_4\NN\24720|is|that|by|and|propagated (r_nsubjpass) initiated_10\VBN\1617192|results (r_ccomp) indicate_2\VBP\952524|damage|elevation|,|may|. (r_ccomp) cause_25\VB\7323922|NONE (l_dobj) damage_27\NN\7296428|elevation|,|may|indicate|.
D010424_D001930 NONE pentobarbital_0\JJ\2792049|in|darker|.|,|though|cells|, (l_appos) scopolamine_2\NN\14712692|, (l_conj) protected_5\VBD\1127795|and (l_dobj) damage_8\NN\7296428|MK
D010862_D013226 CID pilocarpine_8\NN\14712692|NONE (r_pobj) by_7\IN\0|epilepticus (r_agent) induced_6\VBN\1627355|NONE (l_advmod) epilepticus_5\NN\0|by
D010424_D012640 NONE pentobarbital_6\NN\2792049|and|mg/kg (r_conj) scopolamine_0\NNP\14712692|but|development|mg/kg|) (r_nsubj) prevented_11\VBN\0|.|not| (l_dobj) development_12\NN\248977|but|Scopolamine|mg/kg|) (l_prep) of_13\IN\0|NONE (l_pobj) seizure_18\NN\14081375|NONE
D010424_D012640 NONE pentobarbital_2\NN\2792049|and (r_conj) scopolamine_0\NNP\14712692|.|augmented|,|seizure (r_nsubj) blocked_3\VBD\1476483|NONE (l_dobj) seizure_9\NN\14081375|.|augmented|,|Scopolamine
D010424_D012640 NONE pentobarbital_2\NN\2792049|and (r_conj) scopolamine_0\NNP\14712692|.|augmented|,|seizure (r_nsubj) blocked_3\VBD\1476483|NONE (l_conj) augmented_13\VBD\153263|.|,|Scopolamine|seizure (l_dobj) seizure_16\NN\14081375|treatment
D010862_D009410 CID pilocarpine_0\NNP\14712692|death|. (r_nsubj) produced_1\VBD\1617192|NONE (l_dobj) death_3\NN\7296428|.|Pilocarpine
D012601_D001930 NONE scopolamine_2\NN\14712692|, (l_conj) protected_5\VBD\1127795|and (l_dobj) damage_8\NN\7296428|MK
D010862_D012640 CID pilocarpine_2\NN\14712692| (r_npadvmod) induced_4\VBN\1627355|electrographic (r_amod) seizure_6\NN\14081375|.|MK|protects|but
D010862_D012640 CID pilocarpine_10\NN\14712692| (r_npadvmod) induced_12\VBN\1627355|seizure|the (r_amod) model_14\NN\5888929|MK (l_compound) seizure_13\NN\14081375|induced|the
D010862_D012640 CID pilocarpine_3\NN\14712692|NONE (r_pobj) of_2\IN\0|mg/kg|Intraperitoneal (r_prep) injection_1\NN\320852|seizure|. (r_nsubj) induced_8\VBN\1627355|NONE (l_dobj) seizure_12\NN\14081375|.|injection
D010862_D012640 CID pilocarpine_14\NN\14712692| (r_npadvmod) induced_16\VBN\1627355|behavioral (r_amod) seizure_18\NN\14081375|NONE
D010862_D012640 CID pilocarpine_10\NN\14712692| (r_npadvmod) treated_12\VBN\2376958|the (r_amod) group_13\NN\2137|NONE (r_pobj) in_8\IN\13603305|.|seizure (r_prep) appeared_7\VBD\2604760|NONE (l_nsubj) seizure_2\NN\14081375|in|.
D010862_D012640 CID pilocarpine_5\NN\14712692| (r_npadvmod) induced_7\VBN\1627355|the|electrographic (r_amod) seizure_9\NN\14081375|.|augmented|,|Scopolamine
D010862_D012640 CID pilocarpine_5\NN\14712692| (r_npadvmod) induced_7\VBN\1627355|the|electrographic (r_amod) seizure_9\NN\14081375|.|augmented|,|Scopolamine (r_dobj) blocked_3\VBD\1476483|NONE (l_conj) augmented_13\VBD\153263|.|,|Scopolamine|seizure (l_dobj) seizure_16\NN\14081375|treatment
D010862_D012640 CID pilocarpine_19\NN\14712692|NONE (r_pobj) by_18\IN\0|NONE (r_agent) induced_17\VBN\1627355|electrographic|the (r_acl) seizure_16\NN\14081375|treatment (r_dobj) augmented_13\VBD\153263|.|,|Scopolamine|seizure (r_conj) blocked_3\VBD\1476483|NONE (l_dobj) seizure_9\NN\14081375|.|augmented|,|Scopolamine
D010862_D012640 CID pilocarpine_19\NN\14712692|NONE (r_pobj) by_18\IN\0|NONE (r_agent) induced_17\VBN\1627355|electrographic|the (r_acl) seizure_16\NN\14081375|treatment
D016291_D001930 NONE mk-801_0\NNP\0|.|protects|seizure|but (r_punct) augments_1\VBZ\153263|NONE (l_conj) protects_8\VBZ\1127795|.|MK|seizure|but (l_prep) against_9\IN\0|NONE (l_pobj) damage_11\NN\7296428|NONE
D016291_D001930 NONE mk-801_4\NNP\0|damage (r_punct) protected_5\VBD\1127795|and (l_dobj) damage_8\NN\7296428|MK
D016291_D001930 NONE mk-801-treated_15\JJ\0|the (r_amod) group_16\NN\2137|NONE (r_pobj) in_13\IN\13603305|Pentobarbital|darker|.|,|though|cells|, (r_prep) appeared_23\VBD\2604760|NONE (l_nsubj) pentobarbital_0\JJ\2792049|in|darker|.|,|though|cells|, (l_appos) scopolamine_2\NN\14712692|, (l_conj) protected_5\VBD\1127795|and (l_dobj) damage_8\NN\7296428|MK
D016291_D012640 CID mk-801_0\NNP\0|.|protects|seizure|but (r_punct) augments_1\VBZ\153263|NONE (l_dobj) seizure_6\NN\14081375|.|MK|protects|but
D016291_D012640 CID mk-801_7\NNP\0|model (r_punct) on_8\IN\0|the|anticonvulsant|of (l_pobj) model_14\NN\5888929|MK (l_compound) seizure_13\NN\14081375|induced|the
D016291_D012640 CID mk-801_20\NNP\0|( (r_punct) 0.5_22\CD\0|NONE (r_nummod) mg/kg_23\NN\0|but|Scopolamine|development|) (r_conj) prevented_11\VBN\0|.|not| (l_dobj) development_12\NN\248977|but|Scopolamine|mg/kg|) (l_prep) of_13\IN\0|NONE (l_pobj) seizure_18\NN\14081375|NONE
D016291_D012640 CID mk-801_11\NNP\0|NONE (r_punct) treatment_12\NN\654885|seizure (r_nsubj) augmented_13\VBD\153263|.|,|Scopolamine|seizure (r_conj) blocked_3\VBD\1476483|NONE (l_dobj) seizure_9\NN\14081375|.|augmented|,|Scopolamine
D016291_D012640 CID mk-801_11\NNP\0|NONE (r_punct) treatment_12\NN\654885|seizure (r_nsubj) augmented_13\VBD\153263|.|,|Scopolamine|seizure (l_dobj) seizure_16\NN\14081375|treatment
24881749
D063325_D006816 NONE tiapride_10\NN\0|and|in (r_conj) tetrabenazine_8\NN\0|NONE (l_prep) in_11\IN\13603305|and|tiapride (l_pobj) patient_14\NN\9898892|NONE (l_prep) with_15\IN\0|a|Japanese (l_pobj) disease_18\NN\14061805|NONE
D063325_D006816 NONE tiapride_27\NN\0|NONE (r_pobj) with_26\IN\0|and|day|(|for|the|)|of|tetrabenazine (r_prep) initiation_22\NN\7450842|days (l_prep) for_42\IN\0|and|day|(|the|)|of|tetrabenazine|with (l_pobj) disease_45\NN\14061805|NONE
D063325_D001943 NONE tiapride_10\NN\0|and|in (r_conj) tetrabenazine_8\NN\0|NONE (l_prep) in_11\IN\13603305|and|tiapride (l_pobj) patient_14\NN\9898892|NONE (l_prep) with_15\IN\0|a|Japanese (l_pobj) disease_18\NN\14061805|NONE (l_prep) at_19\IN\14622893|Huntington (l_pobj) stage_22\NN\15113229|NONE (l_prep) of_23\IN\0|the|terminal (l_pobj) cancer_26\NN\14239425|NONE
D013747_D006816 NONE tetrabenazine_8\NN\0|NONE (l_prep) in_11\IN\13603305|and|tiapride (l_pobj) patient_14\NN\9898892|NONE (l_prep) with_15\IN\0|a|Japanese (l_pobj) disease_18\NN\14061805|NONE
D013747_D006816 NONE tetrabenazine_35\NN\0|and|day|(|for|the|)|of|with (r_conj) initiation_22\NN\7450842|days (l_prep) for_42\IN\0|and|day|(|the|)|of|tetrabenazine|with (l_pobj) disease_45\NN\14061805|NONE
D013747_D009459 CID tetrabenazine_8\NN\0|NONE (r_pobj) with_7\IN\0|.|syndrome|by (r_prep) induced_3\VBN\1627355|NONE (l_nsubj) syndrome_2\NN\5870365|with|.|by
D013747_D009459 CID tetrabenazine_35\NN\0|and|day|(|for|the|)|of|with (r_conj) initiation_22\NN\7450842|days (r_pobj) after_20\IN\0|that (r_prep) occurred_17\VBD\0|Japanese|with|an|old (r_relcl) woman_11\NN\9605289|NONE (l_prep) with_12\IN\0|Japanese|occurred|an|old (l_pobj) syndrome_15\NN\5870365|NONE
D013747_D009459 CID tetrabenazine_18\NN\0|NONE (r_pobj) with_17\IN\0|combination (r_prep) therapy_16\NN\657604|to (r_pobj) due_13\IN\5174653|of|the (r_prep) occurrence_8\NN\29378|not|previously|been|has|,|To|. (l_prep) of_9\IN\0|due|the (l_pobj) syndrome_12\NN\5870365|NONE
D013747_D001943 NONE tetrabenazine_8\NN\0|NONE (l_prep) in_11\IN\13603305|and|tiapride (l_pobj) patient_14\NN\9898892|NONE (l_prep) with_15\IN\0|a|Japanese (l_pobj) disease_18\NN\14061805|NONE (l_prep) at_19\IN\14622893|Huntington (l_pobj) stage_22\NN\15113229|NONE (l_prep) of_23\IN\0|the|terminal (l_pobj) cancer_26\NN\14239425|NONE
D063325_D009459 CID tiapride_10\NN\0|and|in (r_conj) tetrabenazine_8\NN\0|NONE (r_pobj) with_7\IN\0|.|syndrome|by (r_prep) induced_3\VBN\1627355|NONE (l_nsubj) syndrome_2\NN\5870365|with|.|by
D063325_D009459 CID tiapride_27\NN\0|NONE (r_pobj) with_26\IN\0|and|day|(|for|the|)|of|tetrabenazine (r_prep) initiation_22\NN\7450842|days (r_pobj) after_20\IN\0|that (r_prep) occurred_17\VBD\0|Japanese|with|an|old (r_relcl) woman_11\NN\9605289|NONE (l_prep) with_12\IN\0|Japanese|occurred|an|old (l_pobj) syndrome_15\NN\5870365|NONE
D063325_D009459 CID tiapride_20\NN\0|and (r_conj) tetrabenazine_18\NN\0|NONE (r_pobj) with_17\IN\0|combination (r_prep) therapy_16\NN\657604|to (r_pobj) due_13\IN\5174653|of|the (r_prep) occurrence_8\NN\29378|not|previously|been|has|,|To|. (l_prep) of_9\IN\0|due|the (l_pobj) syndrome_12\NN\5870365|NONE
3155884
D013311_D003920 CID streptozotocin_13\JJ\0|diabetic (r_nmod) rats_15\NNS\2329401|NONE (l_amod) diabetic_14\JJ\10595647|streptozotocin
D013311_D003920 CID streptozotocin_13\JJ\0|against (r_compound) diabetes_14\NNS\14075199|NONE
D013311_D003920 CID streptozotocin_10\JJ\0|that|resistance (r_nsubj) causes_13\VBZ\7323922|the (l_dobj) resistance_16\NN\37396|that|streptozotocin (l_conj) points_18\NNS\5868954|ISO|the|and (l_prep) towards_19\IN\0|NONE (l_pobj) effect_23\NN\34213|NONE (l_prep) on_24\IN\0|insulin|a|direct (l_pobj) sensitivity_27\NN\5651971|NONE (l_prep) in_28\IN\13603305|myocardial|catecholamine (l_pobj) rats_30\NNS\2329401|NONE (l_amod) diabetic_29\JJ\10595647|NONE
D013311_D066126 NONE streptozotocin_13\JJ\0|diabetic (r_nmod) rats_15\NNS\2329401|NONE (r_pobj) in_12\IN\13603305|the|of|cardiotoxic (r_prep) effect_9\NN\34213|NONE (l_amod) cardiotoxic_8\JJ\0|the|in|of
D013311_D066126 NONE streptozotocin_13\JJ\0|against (r_compound) diabetes_14\NNS\14075199|NONE (l_prep) against_15\IN\0|streptozotocin (l_pobj) effect_18\NN\34213|NONE (l_amod) cardiotoxic_17\JJ\0|of|the
D002395_D003920 NONE catecholamines_4\NNS\5407119|NONE (r_pobj) of_3\IN\0|myocardial|The (r_prep) content_2\NN\7951464|was|in|. (r_nsubjpass) estimated_6\VBN\637259|NONE (l_prep) in_7\IN\13603305|was|content|. (l_pobj) rats_12\NNS\2329401|NONE (l_amod) diabetic_11\JJ\10595647|these|day
D002395_D003920 NONE catecholamine_26\NN\5407119|myocardial|in (r_compound) sensitivity_27\NN\5651971|NONE (l_prep) in_28\IN\13603305|myocardial|catecholamine (l_pobj) rats_30\NNS\2329401|NONE (l_amod) diabetic_29\JJ\10595647|NONE
D005947_D005355 NONE glucose_52\NN\14710501|NONE (r_pobj) in_50\IN\13603305|the (r_prep) fall_49\NN\15236475|NONE (r_pobj) of_47\IN\0|the (r_prep) slope_46\NN\9287968|NONE (r_pobj) to_44\IN\0|a|significant|(|. (r_prep) correlation_33\NN\13841213|was|,|morphometrically|appeared|later (r_conj) analyzed_25\VBN\0|induced|after|ISO|subcutaneously|was|and|.|, (r_conj) given_13\VBN\5892096|NONE (l_conj) induced_18\VBD\1627355|after|ISO|analyzed|subcutaneously|was|and|.|, (l_dobj) fibrosis_19\NN\14204950|in|when|ISO
D007545_D005355 CID isoproterenol_4\NN\3740161|NONE (r_pobj) of_3\IN\0|morphometric|A (r_prep) study_2\NN\635850|fibrosis|. (r_nsubj) induced_5\VBN\1627355|NONE (l_dobj) fibrosis_7\NN\14204950|study|.
D007545_D005355 CID iso_11\NN\0|induced|after|analyzed|subcutaneously|was|and|.|, (r_nsubjpass) given_13\VBN\5892096|NONE (l_conj) induced_18\VBD\1627355|after|ISO|analyzed|subcutaneously|was|and|.|, (l_dobj) fibrosis_19\NN\14204950|in|when|ISO
D007545_D005355 CID iso_17\NN\0|in|when|fibrosis (r_nsubj) induced_18\VBD\1627355|after|ISO|analyzed|subcutaneously|was|and|.|, (l_dobj) fibrosis_19\NN\14204950|in|when|ISO
D007545_D003920 NONE isoproterenol_11\NN\3740161|NONE (r_pobj) of_10\IN\0|the|in|cardiotoxic (r_prep) effect_9\NN\34213|NONE (l_prep) in_12\IN\13603305|the|of|cardiotoxic (l_pobj) rats_15\NNS\2329401|NONE (l_amod) diabetic_14\JJ\10595647|streptozotocin
D007545_D003920 NONE isoproterenol_23\NN\3740161|NONE (r_pobj) of_22\IN\0|)|high|ISO|( (r_prep) doses_21\NNS\3740161|NONE (r_pobj) of_19\IN\0|cardiotoxic|the (r_prep) effect_18\NN\34213|NONE (r_pobj) against_15\IN\0|streptozotocin (r_prep) diabetes_14\NNS\14075199|NONE
D007545_D003920 NONE iso_25\NN\0|)|of|high|( (r_appos) doses_21\NNS\3740161|NONE (r_pobj) of_19\IN\0|cardiotoxic|the (r_prep) effect_18\NN\34213|NONE (r_pobj) against_15\IN\0|streptozotocin (r_prep) diabetes_14\NNS\14075199|NONE
D007545_D003920 NONE iso_15\NN\0|the|points|and (r_compound) resistance_16\NN\37396|that|streptozotocin (l_conj) points_18\NNS\5868954|ISO|the|and (l_prep) towards_19\IN\0|NONE (l_pobj) effect_23\NN\34213|NONE (l_prep) on_24\IN\0|insulin|a|direct (l_pobj) sensitivity_27\NN\5651971|NONE (l_prep) in_28\IN\13603305|myocardial|catecholamine (l_pobj) rats_30\NNS\2329401|NONE (l_amod) diabetic_29\JJ\10595647|NONE
D007545_D066126 NONE isoproterenol_11\NN\3740161|NONE (r_pobj) of_10\IN\0|the|in|cardiotoxic (r_prep) effect_9\NN\34213|NONE (l_amod) cardiotoxic_8\JJ\0|the|in|of
D007545_D066126 NONE isoproterenol_23\NN\3740161|NONE (r_pobj) of_22\IN\0|)|high|ISO|( (r_prep) doses_21\NNS\3740161|NONE (r_pobj) of_19\IN\0|cardiotoxic|the (r_prep) effect_18\NN\34213|NONE (l_amod) cardiotoxic_17\JJ\0|of|the
D007545_D066126 NONE iso_25\NN\0|)|of|high|( (r_appos) doses_21\NNS\3740161|NONE (r_pobj) of_19\IN\0|cardiotoxic|the (r_prep) effect_18\NN\34213|NONE (l_amod) cardiotoxic_17\JJ\0|of|the
25096313
D013256_D009422 NONE steroid_5\NN\14727670|at (r_compound) injection_6\NN\320852|NONE (r_pobj) after_4\IN\0|cutaneous|.|antebrachial|Lateral (r_prep) neuropathy_3\NN\14204950|NONE
D013256_D009422 NONE steroid_19\NN\14727670|a|in (r_compound) injection_20\NN\320852|NONE (r_pobj) after_17\IN\0|treat|that (r_prep) occurred_16\VBD\0|)|lateral|(|cutaneous|LACNP|antebrachial (r_relcl) neuropathy_11\NN\14204950|NONE
D013256_D010292 CID steroid_23\NN\14727670|before|in|a (r_compound) injection_24\NN\320852|NONE (r_pobj) after_21\IN\0|paresthesia|.|presented|;|had (r_prep) occurred_20\VBN\0|NONE (l_ccomp) presented_5\VBN\2137132|paresthesia|.|after|;|had (l_prep) with_6\IN\0|woman (l_pobj) sensation_8\NN\5708432|NONE (l_conj) paresthesia_10\NN\14299637|over|and|decreased
D013256_D010292 CID steroid_23\NN\14727670|before|in|a (r_compound) injection_24\NN\320852|NONE (r_pobj) after_21\IN\0|paresthesia|.|presented|;|had (r_prep) occurred_20\VBN\0|NONE (l_nsubj) paresthesia_18\NN\14299637|.|presented|after|;|had
D013256_D013716 NONE steroid_19\NN\14727670|a|in (r_compound) injection_20\NN\320852|NONE (r_pobj) after_17\IN\0|treat|that (r_prep) occurred_16\VBD\0|)|lateral|(|cutaneous|LACNP|antebrachial (l_advcl) treat_26\VB\7570720|that|after (l_dobj) epicondylitis_28\NN\14336539|in|to
D013256_D013716 NONE steroid_14\NN\14727670|a|for (r_compound) injection_15\NN\320852|NONE (l_prep) for_16\IN\0|steroid|a (l_pobj) treatment_18\NN\654885|NONE (l_prep) of_19\IN\0|the (l_pobj) epicondylitis_21\NN\14336539|NONE
24664478
C104457_D020258 NONE nelarabine_0\JJ\0|:|with (r_compound) neurotoxicity_1\NN\0|NONE
C104457_D020258 NONE nelarabine_1\JJ\0|in|Severe (r_compound) neurotoxicity_2\NN\0|.|is
C104457_D020258 NONE nelarabine_16\NN\0|NONE (r_pobj) by_15\IN\0|NONE (r_agent) caused_14\VBN\1617192|severe (r_acl) neurotoxicity_13\NN\0|NONE
24659727
D003520_D009503 CID ctx_22\NNP\0|NONE (r_pobj) of_19\IN\0|the|first (r_prep) treatment_18\NN\654885|NONE (r_pobj) after_15\IN\0|frequency (r_prep) neutropenia_14\NN\14196405|effect|.|was|Neutropenia|and|, (r_conj) was_1\VBD\0|NONE (l_nsubj) neutropenia_0\NNP\14196405|effect|.|neutropenia|was|and|,
D003520_D009503 CID ctx_22\NNP\0|NONE (r_pobj) of_19\IN\0|the|first (r_prep) treatment_18\NN\654885|NONE (r_pobj) after_15\IN\0|frequency (r_prep) neutropenia_14\NN\14196405|effect|.|was|Neutropenia|and|,
D008130_D064420 NONE lomustine_10\NN\2722458|NONE (r_pobj) of_9\IN\0|in|a (r_prep) protocol_8\NN\6652242|NONE (r_pobj) with_6\IN\0|NONE (r_prep) associated_5\VBN\628491|NONE (r_acl) toxicity_4\NN\13576101|.|study
D008130_D064420 NONE ccnu_12\NNP\0|cyclophosphamide|and|)|( (r_appos) lomustine_10\NN\2722458|NONE (r_pobj) of_9\IN\0|in|a (r_prep) protocol_8\NN\6652242|NONE (r_pobj) with_6\IN\0|NONE (r_prep) associated_5\VBN\628491|NONE (r_acl) toxicity_4\NN\13576101|.|study
D008130_D009503 CID ccnu_20\NNP\0|/ (r_nmod) ctx_22\NNP\0|NONE (r_pobj) of_19\IN\0|the|first (r_prep) treatment_18\NN\654885|NONE (r_pobj) after_15\IN\0|frequency (r_prep) neutropenia_14\NN\14196405|effect|.|was|Neutropenia|and|, (r_conj) was_1\VBD\0|NONE (l_nsubj) neutropenia_0\NNP\14196405|effect|.|neutropenia|was|and|,
D008130_D009503 CID ccnu_20\NNP\0|/ (r_nmod) ctx_22\NNP\0|NONE (r_pobj) of_19\IN\0|the|first (r_prep) treatment_18\NN\654885|NONE (r_pobj) after_15\IN\0|frequency (r_prep) neutropenia_14\NN\14196405|effect|.|was|Neutropenia|and|,
D008130_D008223 NONE lomustine_2\NN\2722458|NONE (l_prep) in_7\IN\13603305|in (l_pobj) dogs_8\NNS\2083346|NONE (l_prep) with_9\IN\0|NONE (l_pobj) lymphoma_10\NN\14239918|NONE
D008130_D008223 NONE lomustine_10\NN\2722458|NONE (r_pobj) of_9\IN\0|in|a (r_prep) protocol_8\NN\6652242|NONE (l_prep) in_19\IN\13603305|of|a (l_pobj) dogs_20\NNS\2083346|NONE (l_prep) with_21\IN\0|NONE (l_pobj) lymphoma_22\NN\14239918|NONE
D008130_D008223 NONE ccnu_12\NNP\0|cyclophosphamide|and|)|( (r_appos) lomustine_10\NN\2722458|NONE (r_pobj) of_9\IN\0|in|a (r_prep) protocol_8\NN\6652242|NONE (l_prep) in_19\IN\13603305|of|a (l_pobj) dogs_20\NNS\2083346|NONE (l_prep) with_21\IN\0|NONE (l_pobj) lymphoma_22\NN\14239918|NONE
D003520_D008223 NONE cyclophosphamide_6\NN\0|NONE (r_pobj) with_5\IN\0|NONE (r_prep) combination_4\NN\7951464|NONE (r_pobj) in_3\IN\13603305|in (r_prep) lomustine_2\NN\2722458|NONE (l_prep) in_7\IN\13603305|in (l_pobj) dogs_8\NNS\2083346|NONE (l_prep) with_9\IN\0|NONE (l_pobj) lymphoma_10\NN\14239918|NONE
D003520_D008223 NONE cyclophosphamide_15\NN\0|and|CCNU|)|( (r_conj) lomustine_10\NN\2722458|NONE (r_pobj) of_9\IN\0|in|a (r_prep) protocol_8\NN\6652242|NONE (l_prep) in_19\IN\13603305|of|a (l_pobj) dogs_20\NNS\2083346|NONE (l_prep) with_21\IN\0|NONE (l_pobj) lymphoma_22\NN\14239918|NONE
D003520_D008223 NONE ctx_17\NNP\0|)|( (r_appos) cyclophosphamide_15\NN\0|and|CCNU|)|( (r_conj) lomustine_10\NN\2722458|NONE (r_pobj) of_9\IN\0|in|a (r_prep) protocol_8\NN\6652242|NONE (l_prep) in_19\IN\13603305|of|a (l_pobj) dogs_20\NNS\2083346|NONE (l_prep) with_21\IN\0|NONE (l_pobj) lymphoma_22\NN\14239918|NONE
D003520_D064420 NONE cyclophosphamide_15\NN\0|and|CCNU|)|( (r_conj) lomustine_10\NN\2722458|NONE (r_pobj) of_9\IN\0|in|a (r_prep) protocol_8\NN\6652242|NONE (r_pobj) with_6\IN\0|NONE (r_prep) associated_5\VBN\628491|NONE (r_acl) toxicity_4\NN\13576101|.|study
D003520_D064420 NONE ctx_17\NNP\0|)|( (r_appos) cyclophosphamide_15\NN\0|and|CCNU|)|( (r_conj) lomustine_10\NN\2722458|NONE (r_pobj) of_9\IN\0|in|a (r_prep) protocol_8\NN\6652242|NONE (r_pobj) with_6\IN\0|NONE (r_prep) associated_5\VBN\628491|NONE (r_acl) toxicity_4\NN\13576101|.|study
15991002
D010433_D001008 CID pentylenetetrazole_18\NN\0|another|anxiogenic|,|,|in (r_appos) drug_16\NN\14778436|and (r_conj) caffeine_12\NN\14712692|NONE (r_pobj) by_11\IN\0|NONE (r_agent) induced_10\VBN\1627355|NONE (r_acl) anxiety_9\NN\14373582|NONE
D010433_D001008 CID pentylenetetrazole_11\NN\0||not (r_advmod) induced_13\VBN\1627355|NONE (r_amod) anxiety_14\NN\14373582|caffeine|Nicotine|but|.
D009538_D001008 NONE nicotine_7\NN\14712692|NONE (r_pobj) of_6\IN\0|the|on (r_prep) effects_5\NNS\13245626|study|. (l_prep) on_8\IN\0|the|of (l_pobj) anxiety_9\NN\14373582|NONE
D009538_D001008 NONE nicotine_0\NNP\14712692|caffeine|but|anxiety|. (r_nsubj) blocked_6\VBD\1476483|NONE (l_conj) anxiety_14\NN\14373582|caffeine|Nicotine|but|.
D009538_D001008 NONE nicotine_8\NN\14712692|NONE (r_pobj) of_7\IN\0|on|the|antagonistic (r_prep) effect_6\NN\34213|that|,|of|specific (l_prep) on_9\IN\0|the|of|antagonistic (l_pobj) anxiety_13\NN\14373582|NONE
D002110_D001008 CID caffeine_12\NN\14712692|NONE (r_pobj) by_11\IN\0|NONE (r_agent) induced_10\VBN\1627355|NONE (r_acl) anxiety_9\NN\14373582|NONE
D002110_D001008 CID caffeine-_8\NN\0|Nicotine|but|anxiety|. (r_dobj) blocked_6\VBD\1476483|NONE (l_conj) anxiety_14\NN\14373582|caffeine|Nicotine|but|.
D002110_D001008 CID caffeine_10\NN\14712692| (r_npadvmod) induced_12\VBN\1627355|NONE (r_amod) anxiety_13\NN\14373582|NONE
D002110_D001008 CID caffeine_17\NN\14712692|NONE (r_pobj) to_16\IN\0|NONE (r_prep) specific_15\JJ\5817396|that|,|of|effect (r_acomp) is_14\VBZ\0|results|. (l_nsubj) effect_6\NN\34213|that|,|of|specific (l_prep) on_9\IN\0|the|of|antagonistic (l_pobj) anxiety_13\NN\14373582|NONE
3987172
D010665_D006973 CID phenylpropanolamine_3\NN\2682038| (r_npadvmod) induced_5\VBN\1627355|NONE (r_amod) hypertension_6\NN\14057371|NONE
D010665_D006973 CID phenylpropanolamine_0\NNP\2682038|PPA|)|( (r_nmod) overdose_4\NN\84738|hypertension|can|. (r_nsubj) cause_6\VB\7323922|NONE (l_dobj) hypertension_8\NN\14057371|can|.|overdose
D010665_D006973 CID ppa_2\NNP\0|Phenylpropanolamine|)|( (r_nmod) overdose_4\NN\84738|hypertension|can|. (r_nsubj) cause_6\VB\7323922|NONE (l_dobj) hypertension_8\NN\14057371|can|.|overdose
D010665_D006973 CID ppa_12\NN\0| (r_npadvmod) induced_14\VBN\1627355|NONE (r_amod) hypertension_15\NN\14057371|NONE
D010665_D062787 NONE phenylpropanolamine_0\NNP\2682038|PPA|)|( (r_nmod) overdose_4\NN\84738|hypertension|can|.
D010665_D062787 NONE ppa_2\NNP\0|Phenylpropanolamine|)|( (r_nmod) overdose_4\NN\84738|hypertension|can|.
D011433_D006973 NONE propranolol_0\NNP\0|.|of (r_compound) antagonism_1\NN\24720|NONE (l_prep) of_2\IN\0|.|Propranolol (l_pobj) hypertension_6\NN\14057371|NONE
D011433_D006973 NONE propranolol_7\NN\0|NONE (l_prep) in_8\IN\13603305|NONE (l_pobj) treatment_10\NN\654885|NONE (l_prep) of_11\IN\0|the (l_pobj) hypertension_15\NN\14057371|NONE
D010665_D002543 NONE phenylpropanolamine_0\NNP\2682038|PPA|)|( (r_nmod) overdose_4\NN\84738|hypertension|can|. (r_nsubj) cause_6\VB\7323922|NONE (l_dobj) hypertension_8\NN\14057371|can|.|overdose (l_conj) hemorrhage_11\NN\14285662|severe|,
D010665_D002543 NONE ppa_2\NNP\0|Phenylpropanolamine|)|( (r_nmod) overdose_4\NN\84738|hypertension|can|. (r_nsubj) cause_6\VB\7323922|NONE (l_dobj) hypertension_8\NN\14057371|can|.|overdose (l_conj) hemorrhage_11\NN\14285662|severe|,
D010665_D020521 NONE ppa_10\NNP\0|)|%|from|that|ml|volume (r_nsubj) increased_11\VBD\169651|fraction|assessed|.|, (l_dobj) volume_14\NN\33615|)|%|PPA|from|that|ml (l_compound) stroke_13\NN\556313|the
20408947
D000082_D056486 CID acetaminophen_0\NNP\2707683| (r_npadvmod) induced_2\VBN\1627355|NONE (r_amod) hepatotoxicity_3\NN\0|.|cause
D000082_D008107 NONE acetaminophen_34\RB\2707683| (r_advmod) induced_36\VBN\1627355|n= (r_amod) alf_37\NNP\0|NONE (l_appos) n=36_39\NNP\0|induced (l_prep) with_41\IN\0|(|) (l_pobj) patients_47\NNS\9898892|NONE (l_acl) undergoing_48\VBG\109660|matched|age (l_dobj) lt_50\NN\0|NONE (l_prep) for_51\IN\0|emergent (l_pobj) alf_57\NNP\0|NONE (l_conj) lt_63\NN\0|(|and|induced|)|n= (l_prep) for_64\IN\0|elective (l_pobj) disease_67\NN\14061805|NONE
D000082_D008107 NONE acetaminophen_34\RB\2707683| (r_advmod) induced_36\VBN\1627355|n= (r_amod) alf_37\NNP\0|NONE (l_appos) n=36_39\NNP\0|induced (l_prep) with_41\IN\0|(|) (l_pobj) patients_47\NNS\9898892|NONE (l_acl) undergoing_48\VBG\109660|matched|age (l_dobj) lt_50\NN\0|NONE (l_prep) for_51\IN\0|emergent (l_pobj) alf_57\NNP\0|NONE (l_conj) lt_63\NN\0|(|and|induced|)|n= (l_prep) for_64\IN\0|elective (l_pobj) disease_67\NN\14061805|NONE (l_appos) cld_69\NNP\0|)|chronic|liver|(
D000082_D008107 NONE acetaminophen_54\RB\2707683|||non (r_advmod) induced_56\VBN\1627355|(|and|LT|)|n= (r_amod) alf_57\NNP\0|NONE (l_conj) lt_63\NN\0|(|and|induced|)|n= (l_prep) for_64\IN\0|elective (l_pobj) disease_67\NN\14061805|NONE
D000082_D008107 NONE acetaminophen_54\RB\2707683|||non (r_advmod) induced_56\VBN\1627355|(|and|LT|)|n= (r_amod) alf_57\NNP\0|NONE (l_conj) lt_63\NN\0|(|and|induced|)|n= (l_prep) for_64\IN\0|elective (l_pobj) disease_67\NN\14061805|NONE (l_appos) cld_69\NNP\0|)|chronic|liver|(
D000082_D008107 NONE acetaminophen_5\RB\2707683| (r_advmod) induced_7\VBN\1627355|Twenty|ALF|(|% (r_amod) patients_9\NNS\9898892|before|diagnosis (r_nsubj) had_10\VBD\0|P<.|;|.|attempt (l_prep) before_15\IN\0|patients|diagnosis (l_pobj) lt_16\NNP\0|NONE (l_appos) alf=0/35_23\NNP\0|NONE (l_appos) cld=2/34_25\NNP\0|induced|,|non
D000082_D008107 NONE acetaminophen_20\RB\2707683| (r_advmod) induced_22\VBN\1627355|CLD=/|,|non (r_amod) alf=0/35_23\NNP\0|NONE (l_appos) cld=2/34_25\NNP\0|induced|,|non
D000082_D008107 NONE acetaminophen_31\RB\2707683| (r_advmod) induced_33\VBN\1627355|year (r_amod) alf_34\NNP\0|the|ALF|;|( (r_appos) groups_29\NNS\2137|NONE (r_pobj) between_27\IN\0|survival|or|graft (r_prep) failure_24\NN\66216|CLD|,|in|no|significant (r_conj) differences_14\NNS\4723816|.|During|,|)|:|rank|there (l_conj) cld_57\NNP\0|,|in|failure|no|significant
D000082_D008107 NONE acetaminophen_47\RB\2707683| (r_advmod) induced_49\VBN\1627355| (r_acomp) non_45\AFX\0|%|; (r_nmod) alf_50\NNP\0|the|ALF|;|( (r_appos) groups_29\NNS\2137|NONE (r_pobj) between_27\IN\0|survival|or|graft (r_prep) failure_24\NN\66216|CLD|,|in|no|significant (r_conj) differences_14\NNS\4723816|.|During|,|)|:|rank|there (l_conj) cld_57\NNP\0|,|in|failure|no|significant
D000082_D008107 NONE acetaminophen_14\RB\2707683| (r_advmod) induced_16\VBN\1627355|NONE (r_amod) alf_17\NNP\0|NONE (r_pobj) for_13\IN\0|emergently (r_prep) transplanted_11\VBN\2013571|NONE (r_acl) patients_10\NNS\9898892|NONE (r_pobj) for_9\IN\0|NONE (r_prep) outcomes_8\NNS\7291312|Despite|comparable|,|. (r_nsubj) were_18\VBD\0|NONE (l_acomp) comparable_19\JJ\0|Despite|outcomes|,|. (l_prep) to_20\IN\0|NONE (l_pobj) those_21\DT\0|NONE (l_acl) transplanted_22\VBN\2013571|NONE (l_prep) for_32\IN\0|for (l_pobj) cld_33\NNP\0|electively
D000082_D008107 NONE acetaminophen_26\RB\2707683|non|| (r_advmod) induced_28\VBN\1627355|NONE (r_amod) alf_29\NNP\0|and (r_pobj) for_23\IN\0|for (r_prep) transplanted_22\VBN\2013571|NONE (l_prep) for_32\IN\0|for (l_pobj) cld_33\NNP\0|electively
D000082_D017114 CID acetaminophen_8\RB\2707683| (r_advmod) induced_10\VBN\1627355|liver|acute (r_amod) failure_13\NN\66216|NONE
D000082_D017114 CID acetaminophen_0\NNP\2707683| (r_npadvmod) induced_2\VBN\1627355|NONE (r_amod) hepatotoxicity_3\NN\0|.|cause (r_nsubj) is_4\VBZ\0|NONE (l_attr) cause_8\NN\7323922|.|hepatotoxicity (l_prep) of_9\IN\0|common|the (l_pobj) failure_12\NN\66216|NONE
D000082_D017114 CID acetaminophen_0\NNP\2707683| (r_npadvmod) induced_2\VBN\1627355|NONE (r_amod) hepatotoxicity_3\NN\0|.|cause (r_nsubj) is_4\VBZ\0|NONE (l_attr) cause_8\NN\7323922|.|hepatotoxicity (l_prep) of_9\IN\0|common|the (l_pobj) failure_12\NN\66216|NONE (l_appos) alf_14\NNP\0|liver|acute|(|in
D000082_D017114 CID acetaminophen_34\RB\2707683| (r_advmod) induced_36\VBN\1627355|n= (r_amod) alf_37\NNP\0|NONE
D000082_D017114 CID acetaminophen_34\RB\2707683| (r_advmod) induced_36\VBN\1627355|n= (r_amod) alf_37\NNP\0|NONE (l_appos) n=36_39\NNP\0|induced (l_prep) with_41\IN\0|(|) (l_pobj) patients_47\NNS\9898892|NONE (l_acl) undergoing_48\VBG\109660|matched|age (l_dobj) lt_50\NN\0|NONE (l_prep) for_51\IN\0|emergent (l_pobj) alf_57\NNP\0|NONE
D000082_D017114 CID acetaminophen_54\RB\2707683|||non (r_advmod) induced_56\VBN\1627355|(|and|LT|)|n= (r_amod) alf_57\NNP\0|NONE (r_pobj) for_51\IN\0|emergent (r_prep) lt_50\NN\0|NONE (r_dobj) undergoing_48\VBG\109660|matched|age (r_acl) patients_47\NNS\9898892|NONE (r_pobj) with_41\IN\0|(|) (r_prep) n=36_39\NNP\0|induced (r_appos) alf_37\NNP\0|NONE
D000082_D017114 CID acetaminophen_54\RB\2707683|||non (r_advmod) induced_56\VBN\1627355|(|and|LT|)|n= (r_amod) alf_57\NNP\0|NONE
D000082_D017114 CID acetaminophen_0\NNP\2707683| (r_npadvmod) induced_2\VBN\1627355|ALF|undergoing (r_amod) patients_4\NNS\9898892|.|severity (l_compound) alf_3\NNP\0|undergoing|induced
D000082_D017114 CID acetaminophen_5\RB\2707683| (r_advmod) induced_7\VBN\1627355|Twenty|ALF|(|% (r_amod) patients_9\NNS\9898892|before|diagnosis (l_compound) alf_8\NNP\0|induced|Twenty|(|%
D000082_D017114 CID acetaminophen_5\RB\2707683| (r_advmod) induced_7\VBN\1627355|Twenty|ALF|(|% (r_amod) patients_9\NNS\9898892|before|diagnosis (r_nsubj) had_10\VBD\0|P<.|;|.|attempt (l_prep) before_15\IN\0|patients|diagnosis (l_pobj) lt_16\NNP\0|NONE (l_appos) alf=0/35_23\NNP\0|NONE
D000082_D017114 CID acetaminophen_20\RB\2707683| (r_advmod) induced_22\VBN\1627355|CLD=/|,|non (r_amod) alf=0/35_23\NNP\0|NONE (r_appos) lt_16\NNP\0|NONE (r_pobj) before_15\IN\0|patients|diagnosis (r_prep) had_10\VBD\0|P<.|;|.|attempt (l_nsubj) patients_9\NNS\9898892|before|diagnosis (l_compound) alf_8\NNP\0|induced|Twenty|(|%
D000082_D017114 CID acetaminophen_20\RB\2707683| (r_advmod) induced_22\VBN\1627355|CLD=/|,|non (r_amod) alf=0/35_23\NNP\0|NONE
D000082_D017114 CID acetaminophen_31\RB\2707683| (r_advmod) induced_33\VBN\1627355|year (r_amod) alf_34\NNP\0|the|ALF|;|(
D000082_D017114 CID acetaminophen_31\RB\2707683| (r_advmod) induced_33\VBN\1627355|year (r_amod) alf_34\NNP\0|the|ALF|;|( (r_appos) groups_29\NNS\2137|NONE (l_appos) alf_50\NNP\0|the|ALF|;|(
D000082_D017114 CID acetaminophen_47\RB\2707683| (r_advmod) induced_49\VBN\1627355| (r_acomp) non_45\AFX\0|%|; (r_nmod) alf_50\NNP\0|the|ALF|;|( (r_appos) groups_29\NNS\2137|NONE (l_appos) alf_34\NNP\0|the|ALF|;|(
D000082_D017114 CID acetaminophen_47\RB\2707683| (r_advmod) induced_49\VBN\1627355| (r_acomp) non_45\AFX\0|%|; (r_nmod) alf_50\NNP\0|the|ALF|;|(
D000082_D017114 CID acetaminophen_1\RB\2707683| (r_advmod) induced_3\VBN\1627355|Two|ALF (r_amod) patients_5\NNS\9898892|.|LT (l_compound) alf_4\NNP\0|induced|Two
D000082_D017114 CID acetaminophen_14\RB\2707683| (r_advmod) induced_16\VBN\1627355|NONE (r_amod) alf_17\NNP\0|NONE
D000082_D017114 CID acetaminophen_14\RB\2707683| (r_advmod) induced_16\VBN\1627355|NONE (r_amod) alf_17\NNP\0|NONE (r_pobj) for_13\IN\0|emergently (r_prep) transplanted_11\VBN\2013571|NONE (r_acl) patients_10\NNS\9898892|NONE (r_pobj) for_9\IN\0|NONE (r_prep) outcomes_8\NNS\7291312|Despite|comparable|,|. (r_nsubj) were_18\VBD\0|NONE (l_acomp) comparable_19\JJ\0|Despite|outcomes|,|. (l_prep) to_20\IN\0|NONE (l_pobj) those_21\DT\0|NONE (l_acl) transplanted_22\VBN\2013571|NONE (l_prep) for_23\IN\0|for (l_pobj) alf_29\NNP\0|and
D000082_D017114 CID acetaminophen_26\RB\2707683|non|| (r_advmod) induced_28\VBN\1627355|NONE (r_amod) alf_29\NNP\0|and (r_pobj) for_23\IN\0|for (r_prep) transplanted_22\VBN\2013571|NONE (r_acl) those_21\DT\0|NONE (r_pobj) to_20\IN\0|NONE (r_prep) comparable_19\JJ\0|Despite|outcomes|,|. (r_acomp) were_18\VBD\0|NONE (l_nsubj) outcomes_8\NNS\7291312|Despite|comparable|,|. (l_prep) for_9\IN\0|NONE (l_pobj) patients_10\NNS\9898892|NONE (l_acl) transplanted_11\VBN\2013571|NONE (l_prep) for_13\IN\0|emergently (l_pobj) alf_17\NNP\0|NONE
D000082_D017114 CID acetaminophen_26\RB\2707683|non|| (r_advmod) induced_28\VBN\1627355|NONE (r_amod) alf_29\NNP\0|and
1423336
D010649_D007022 NONE phenylalanine_0\NNP\14605787|with (r_nsubj) competing_10\VBG\0|effects|.|, (r_advcl) reduced_22\VBD\441445|NONE (l_dobj) effects_27\NNS\13245626|.|competing|, (l_amod) hypotensive_24\JJ\10405694|of|the
D000596_D007022 NONE acid_6\NN\14818238|, (r_appos) phenylalanine_0\NNP\14605787|with (r_nsubj) competing_10\VBG\0|effects|.|, (r_advcl) reduced_22\VBD\441445|NONE (l_dobj) effects_27\NNS\13245626|.|competing|, (l_amod) hypotensive_24\JJ\10405694|of|the
D007980_D007022 CID levodopa_6\NN\14604959|NONE (r_pobj) of_5\IN\0|the|hypotensive (r_prep) effect_4\NN\34213|NONE (l_amod) hypotensive_3\JJ\10405694|of|the
D007980_D007022 CID levodopa_7\NN\14604959|NONE (r_pobj) of_6\IN\0|hypotensive|the (r_prep) effect_5\NN\34213|NONE (l_amod) hypotensive_4\JJ\10405694|of|the
D007980_D007022 CID levodopa_12\NN\14604959|NONE (r_pobj) with_11\IN\0|Phenylalanine (r_prep) competing_10\VBG\0|effects|.|, (r_advcl) reduced_22\VBD\441445|NONE (l_dobj) effects_27\NNS\13245626|.|competing|, (l_amod) hypotensive_24\JJ\10405694|of|the
D007980_D007022 CID levodopa_29\NN\14604959|NONE (r_pobj) of_28\IN\0|hypotensive|the (r_prep) effects_27\NNS\13245626|.|competing|, (l_amod) hypotensive_24\JJ\10405694|of|the
D007980_D007022 CID levodopa_3\NN\14604959|that|action (r_nsubj) has_4\VBZ\13888491|We|. (l_dobj) action_8\NN\30358|that|levodopa (l_amod) hypotensive_7\JJ\10405694|a|central|parallels
D007980_D010300 NONE levodopa_6\NN\14604959|NONE (l_prep) in_7\IN\13603305|NONE (l_pobj) patients_9\NNS\9898892|NONE (l_amod) parkinsonian_8\JJ\0|NONE
D007980_D010300 NONE levodopa_5\NN\14604959|NONE (r_pobj) of_3\IN\0|pressure (r_prep) effects_2\NNS\13245626|levodopa|were|in|. (r_nsubjpass) examined_7\VBN\0|NONE (l_prep) in_8\IN\13603305|levodopa|effects|were|. (l_pobj) patients_10\NNS\9898892|NONE (l_amod) parkinsonian_9\JJ\0|with
D007980_D010300 NONE levodopa_17\VB\14604959|effects|were|in|. (r_advcl) examined_7\VBN\0|NONE (l_prep) in_8\IN\13603305|levodopa|effects|were|. (l_pobj) patients_10\NNS\9898892|NONE (l_amod) parkinsonian_9\JJ\0|with
16906379
D008911_D011565 NONE minocycline_9\NN\4416530|been|with|who|for|had (r_dobj) taking_8\VBG\37396|old|.|A (l_prep) for_10\IN\0|been|with|who|minocycline|had (l_pobj) fever_14\NN\14299637|NONE (l_nmod) pustulosis_12\NN\0|developed|,|,|myalgias
D008911_D005334 NONE minocycline_9\NN\4416530|been|with|who|for|had (r_dobj) taking_8\VBG\37396|old|.|A (l_prep) for_10\IN\0|been|with|who|minocycline|had (l_pobj) fever_14\NN\14299637|NONE
D008911_D014657 NONE minocycline_0\NNP\4416530| (r_npadvmod) induced_2\VBN\1627355|fulfilling|. (r_amod) vasculitis_3\NN\14336539|NONE
D008911_D014657 NONE minocycline_10\NN\4416530| (r_npadvmod) induced_12\VBN\1627355|satisfying (r_amod) vasculitis_13\NN\14336539|NONE
D008911_D011115 NONE minocycline_9\NN\4416530|been|with|who|for|had (r_dobj) taking_8\VBG\37396|old|.|A (l_prep) for_10\IN\0|been|with|who|minocycline|had (l_pobj) fever_14\NN\14299637|NONE (l_conj) myalgias_16\NNS\14322699|developed|,|pustulosis|, (l_conj) polyneuropathy_18\VBP\0|,
D008911_D013733 NONE minocycline_9\NN\4416530|been|with|who|for|had (r_dobj) taking_8\VBG\37396|old|.|A (l_prep) for_10\IN\0|been|with|who|minocycline|had (l_pobj) fever_14\NN\14299637|NONE (l_conj) myalgias_16\NNS\14322699|developed|,|pustulosis|, (l_conj) polyneuropathy_18\VBP\0|, (l_conj) pain_22\NN\14299637|and|,
D008911_D010488 CID minocycline_0\NNP\4416530| (r_npadvmod) induced_2\VBN\1627355|fulfilling|. (r_amod) vasculitis_3\NN\14336539|NONE (l_acl) fulfilling_4\VBG\484166|induced|. (l_dobj) criteria_6\NNS\13577171|NONE (l_prep) of_7\IN\0|the (l_pobj) nodosa_9\NN\0|NONE
D008911_D063806 NONE minocycline_9\NN\4416530|been|with|who|for|had (r_dobj) taking_8\VBG\37396|old|.|A (l_prep) for_10\IN\0|been|with|who|minocycline|had (l_pobj) fever_14\NN\14299637|NONE (l_conj) myalgias_16\NNS\14322699|developed|,|pustulosis|,
12523489
D000661_D006948 NONE amphetamine_12\NN\3248958| (r_npadvmod) induced_14\VBN\1627355|NONE (r_amod) hyperactivity_15\NN\14052403|NONE (r_pobj) than_11\IN\0|more|hyperactivity|is|.|by (r_prep) influenced_6\VBN\137313|NONE (l_nsubjpass) hyperactivity_3\NN\14052403|more|than|is|.|by
D000661_D006948 NONE amphetamine_12\NN\3248958| (r_npadvmod) induced_14\VBN\1627355|NONE (r_amod) hyperactivity_15\NN\14052403|NONE
D000661_D006948 NONE amphetamine_12\NN\3248958| (r_npadvmod) induced_14\VBN\1627355|and| (r_conj) cocaine_9\NN\3492717|NONE (r_nmod) hyperactivity_15\NN\14052403|NONE
D000661_D006948 NONE amphetamine_7\NN\3248958| (r_npadvmod) induced_9\VBN\1627355|NONE (r_amod) hyperactivity_10\NN\14052403|but|.|,|Similarly|,|at|agonists
D000661_D006948 NONE amphetamine_7\NN\3248958| (r_npadvmod) induced_9\VBN\1627355|NONE (r_amod) hyperactivity_10\NN\14052403|but|.|,|Similarly|,|at|agonists (r_dobj) decreased_6\VBD\169651|NONE (l_conj) at_13\IN\14622893|but|.|,|Similarly|,|agonists|hyperactivity (l_pobj) doses_16\NNS\3740161|NONE (l_prep) than_17\IN\0|higher|the (l_pobj) those_18\DT\0|NONE (l_relcl) were_20\VBD\0|NONE (l_acomp) active_21\JJ\14779550|which (l_prep) in_22\IN\13603305|NONE (l_pobj) hyperactivity_26\NN\14052403|NONE
D000661_D006948 NONE amphetamine_17\NN\3248958| (r_npadvmod) induced_19\VBN\1627355|locomotor (r_amod) activity_21\NN\30358|and|indicate|cocaine|and|agonists|that (r_dobj) reduce_14\VBP\441445|results|have|. (l_conj) indicate_23\VBP\952524|and|cocaine|and|agonists|that|activity (l_ccomp) influenced_31\VBN\137313|NONE (l_nsubjpass) hyperactivity_28\NN\14052403|is|more|that|than|by
D000661_D006948 NONE amphetamine_17\NN\3248958| (r_npadvmod) induced_19\VBN\1627355|locomotor (r_amod) activity_21\NN\30358|and|indicate|cocaine|and|agonists|that (r_dobj) reduce_14\VBP\441445|results|have|. (l_conj) indicate_23\VBP\952524|and|cocaine|and|agonists|that|activity (l_ccomp) influenced_31\VBN\137313|NONE (l_prep) than_41\IN\0|is|more|that|hyperactivity|by (l_pobj) hyperactivity_45\NN\14052403|NONE
D000661_D006948 NONE amphetamine_42\NN\3248958| (r_npadvmod) induced_44\VBN\1627355|NONE (r_amod) hyperactivity_45\NN\14052403|NONE (r_pobj) than_41\IN\0|is|more|that|hyperactivity|by (r_prep) influenced_31\VBN\137313|NONE (l_nsubjpass) hyperactivity_28\NN\14052403|is|more|that|than|by
D000661_D006948 NONE amphetamine_42\NN\3248958| (r_npadvmod) induced_44\VBN\1627355|NONE (r_amod) hyperactivity_45\NN\14052403|NONE
D003042_D006948 NONE cocaine_0\NN\3492717| (r_npadvmod) induced_2\VBN\1627355|NONE (r_amod) hyperactivity_3\NN\14052403|more|than|is|.|by
D003042_D006948 NONE cocaine_0\NN\3492717| (r_npadvmod) induced_2\VBN\1627355|NONE (r_amod) hyperactivity_3\NN\14052403|more|than|is|.|by (r_nsubjpass) influenced_6\VBN\137313|NONE (l_prep) than_11\IN\0|more|hyperactivity|is|.|by (l_pobj) hyperactivity_15\NN\14052403|NONE
D003042_D006948 NONE cocaine_9\NN\3492717|NONE (r_nmod) hyperactivity_15\NN\14052403|NONE
D003042_D006948 NONE cocaine_23\NN\3492717| (r_npadvmod) induced_25\VBN\1627355|NONE (r_amod) hyperactivity_26\NN\14052403|NONE (r_pobj) in_22\IN\13603305|NONE (r_prep) active_21\JJ\14779550|which (r_acomp) were_20\VBD\0|NONE (r_relcl) those_18\DT\0|NONE (r_pobj) than_17\IN\0|higher|the (r_prep) doses_16\NNS\3740161|NONE (r_pobj) at_13\IN\14622893|but|.|,|Similarly|,|agonists|hyperactivity (r_conj) decreased_6\VBD\169651|NONE (l_dobj) hyperactivity_10\NN\14052403|but|.|,|Similarly|,|at|agonists
D003042_D006948 NONE cocaine_23\NN\3492717| (r_npadvmod) induced_25\VBN\1627355|NONE (r_amod) hyperactivity_26\NN\14052403|NONE
D003042_D006948 NONE cocaine-_15\JJ\0|and|indicate|and|agonists|that|activity (r_dobj) reduce_14\VBP\441445|results|have|. (l_conj) indicate_23\VBP\952524|and|cocaine|and|agonists|that|activity (l_ccomp) influenced_31\VBN\137313|NONE (l_nsubjpass) hyperactivity_28\NN\14052403|is|more|that|than|by
D003042_D006948 NONE cocaine-_15\JJ\0|and|indicate|and|agonists|that|activity (r_dobj) reduce_14\VBP\441445|results|have|. (l_conj) indicate_23\VBP\952524|and|cocaine|and|agonists|that|activity (l_ccomp) influenced_31\VBN\137313|NONE (l_prep) than_41\IN\0|is|more|that|hyperactivity|by (l_pobj) hyperactivity_45\NN\14052403|NONE
D003042_D006948 NONE cocaine_25\NN\3492717| (r_npadvmod) induced_27\VBN\1627355|NONE (r_amod) hyperactivity_28\NN\14052403|is|more|that|than|by
D003042_D006948 NONE cocaine_25\NN\3492717| (r_npadvmod) induced_27\VBN\1627355|NONE (r_amod) hyperactivity_28\NN\14052403|is|more|that|than|by (r_nsubjpass) influenced_31\VBN\137313|NONE (l_prep) than_41\IN\0|is|more|that|hyperactivity|by (l_pobj) hyperactivity_45\NN\14052403|NONE
D000241_D006948 NONE adenosine_8\NN\14964367|receptor (r_amod) agonists_10\NNS\0|NONE (r_pobj) by_7\IN\0|more|than|hyperactivity|is|. (r_agent) influenced_6\VBN\137313|NONE (l_nsubjpass) hyperactivity_3\NN\14052403|more|than|is|.|by
D000241_D006948 NONE adenosine_8\NN\14964367|receptor (r_amod) agonists_10\NNS\0|NONE (r_pobj) by_7\IN\0|more|than|hyperactivity|is|. (r_agent) influenced_6\VBN\137313|NONE (l_prep) than_11\IN\0|more|hyperactivity|is|.|by (l_pobj) hyperactivity_15\NN\14052403|NONE
D000241_D006948 NONE adenosine_3\NN\14964367|antagonists|and|receptor (r_amod) agonists_5\NNS\0|NONE (l_conj) antagonists_7\NNS\7846|and|adenosine|receptor (l_prep) on_8\IN\0|NONE (l_pobj) hyperactivity_15\NN\14052403|NONE
D000241_D006948 NONE adenosine_3\NN\14964367|receptor|all (r_amod) agonists_5\NNS\0|but|.|,|Similarly|,|at|hyperactivity (r_nsubj) decreased_6\VBD\169651|NONE (l_dobj) hyperactivity_10\NN\14052403|but|.|,|Similarly|,|at|agonists
D000241_D006948 NONE adenosine_3\NN\14964367|receptor|all (r_amod) agonists_5\NNS\0|but|.|,|Similarly|,|at|hyperactivity (r_nsubj) decreased_6\VBD\169651|NONE (l_conj) at_13\IN\14622893|but|.|,|Similarly|,|agonists|hyperactivity (l_pobj) doses_16\NNS\3740161|NONE (l_prep) than_17\IN\0|higher|the (l_pobj) those_18\DT\0|NONE (l_relcl) were_20\VBD\0|NONE (l_acomp) active_21\JJ\14779550|which (l_prep) in_22\IN\13603305|NONE (l_pobj) hyperactivity_26\NN\14052403|NONE
D000241_D006948 NONE adenosine_6\NN\14964367|A|)|all|(|receptor (r_amod) agonists_8\NNS\0|and|indicate|cocaine|and|that|activity (r_nsubj) reduce_14\VBP\441445|results|have|. (l_conj) indicate_23\VBP\952524|and|cocaine|and|agonists|that|activity (l_ccomp) influenced_31\VBN\137313|NONE (l_nsubjpass) hyperactivity_28\NN\14052403|is|more|that|than|by
D000241_D006948 NONE adenosine_6\NN\14964367|A|)|all|(|receptor (r_amod) agonists_8\NNS\0|and|indicate|cocaine|and|that|activity (r_nsubj) reduce_14\VBP\441445|results|have|. (l_conj) indicate_23\VBP\952524|and|cocaine|and|agonists|that|activity (l_ccomp) influenced_31\VBN\137313|NONE (l_prep) than_41\IN\0|is|more|that|hyperactivity|by (l_pobj) hyperactivity_45\NN\14052403|NONE
D000241_D006948 NONE adenosine_33\NN\14964367|receptor|(|)|receptors (r_amod) agonists_35\NNS\0|NONE (r_pobj) by_32\IN\0|is|more|that|than|hyperactivity (r_agent) influenced_31\VBN\137313|NONE (l_nsubjpass) hyperactivity_28\NN\14052403|is|more|that|than|by
D000241_D006948 NONE adenosine_33\NN\14964367|receptor|(|)|receptors (r_amod) agonists_35\NNS\0|NONE (r_pobj) by_32\IN\0|is|more|that|than|hyperactivity (r_agent) influenced_31\VBN\137313|NONE (l_prep) than_41\IN\0|is|more|that|hyperactivity|by (l_pobj) hyperactivity_45\NN\14052403|NONE
D000241_D004409 NONE adenosine_1\NN\14964367|All|receptor (r_amod) agonists_3\NNS\0|were|and|,|activity|significantly (r_nsubj) decreased_5\VBD\169651|NONE (l_dobj) activity_8\NN\30358|agonists|were|and|,|significantly
6453500
D004221_D056486 CID disulfiram_4\NN\3740161|NONE (r_pobj) by_3\IN\0|in|.|hepatitis (r_prep) induced_2\VBN\1627355|NONE (l_nsubj) hepatitis_1\NN\14127211|in|by|.
D004221_D056486 CID disulfiram_15\NN\3740161|NONE (r_pobj) with_14\IN\0|NONE (r_prep) treated_13\VBN\2376958|alcoholic|a (r_acl) woman_12\NN\9605289|NONE (r_pobj) in_7\IN\13603305|.|was|damage (r_prep) observed_6\VBN\2163746|NONE (l_nsubjpass) damage_4\NN\7296428|.|in|was
146391
D010672_D003875 CID diphenylhydantoin_13\NN\3550533|NONE (r_dobj) taking_12\VBG\37396|a (r_acl) patient_11\NN\9898892|NONE (r_pobj) in_9\IN\13603305|NONE (r_prep) lymphadenopathy_8\NN\14204950|and|toxic (r_conj) dermatitis_6\NN\14226056|.|cell|,|Pure
D010672_D012010 CID diphenylhydantoin_13\NN\3550533|NONE (r_dobj) taking_12\VBG\37396|a (r_acl) patient_11\NN\9898892|NONE (r_pobj) in_9\IN\13603305|NONE (r_prep) lymphadenopathy_8\NN\14204950|and|toxic (r_conj) dermatitis_6\NN\14226056|.|cell|,|Pure (r_conj) aplasia_3\NN\14365950|NONE
D010672_D012010 CID diphenylhydantoin_3\NN\3550533|for (r_dobj) taking_2\VBG\37396|A (r_acl) patient_1\NN\9898892|rash|. (r_nsubj) developed_7\VBD\1753788|NONE (l_dobj) rash_11\NN\14321469|patient|. (l_appos) aplasia_18\NN\14365950|,|generalized|a|skin
D010672_D012010 CID diphenylhydantoin_6\NN\3550533|NONE (r_compound) medication_7\NN\3247620|NONE (r_pobj) with_5\IN\0|NONE (r_prep) associated_4\VBN\628491|cell|Pure (r_acl) aplasia_3\NN\14365950|.|has|in|been
D010672_D012010 CID diphenylhydantoin_10\NN\3550533|NONE (r_pobj) of_9\IN\0|the|and|occurrence (r_prep) ingestion_8\NN\13440063|NONE (l_conj) occurrence_13\NN\29378|the|and|of (l_prep) of_14\IN\0|the (l_pobj) rash_17\NN\14321469|NONE (l_conj) lymphadenopathy_19\JJ\14204950|the|skin|, (l_conj) aplasia_24\NN\14365950|and
D010672_D005076 NONE diphenylhydantoin_3\NN\3550533|for (r_dobj) taking_2\VBG\37396|A (r_acl) patient_1\NN\9898892|rash|. (r_nsubj) developed_7\VBD\1753788|NONE (l_dobj) rash_11\NN\14321469|patient|.
D010672_D005076 NONE diphenylhydantoin_9\NN\3550533|NONE (r_compound) treatment_10\NN\654885|NONE (r_pobj) of_8\IN\0|a|known (r_prep) complication_7\NN\1073995|is|rash|. (r_attr) is_2\VBZ\0|NONE (l_nsubj) rash_1\NN\14321469|is|.|complication
D010672_D005076 NONE diphenylhydantoin_10\NN\3550533|NONE (r_pobj) of_9\IN\0|the|and|occurrence (r_prep) ingestion_8\NN\13440063|NONE (l_conj) occurrence_13\NN\29378|the|and|of (l_prep) of_14\IN\0|the (l_pobj) rash_17\NN\14321469|NONE
D010672_D008206 CID diphenylhydantoin_13\NN\3550533|NONE (r_dobj) taking_12\VBG\37396|a (r_acl) patient_11\NN\9898892|NONE (r_pobj) in_9\IN\13603305|NONE (r_prep) lymphadenopathy_8\NN\14204950|and|toxic
D010672_D008206 CID diphenylhydantoin_3\NN\3550533|for (r_dobj) taking_2\VBG\37396|A (r_acl) patient_1\NN\9898892|rash|. (r_nsubj) developed_7\VBD\1753788|NONE (l_dobj) rash_11\NN\14321469|patient|. (l_appos) aplasia_18\NN\14365950|,|generalized|a|skin (l_amod) lymphadenopathy_13\JJ\14204950|cell|pure
D010672_D008206 CID diphenylhydantoin_9\NN\3550533|NONE (r_compound) treatment_10\NN\654885|NONE (r_pobj) of_8\IN\0|a|known (r_prep) complication_7\NN\1073995|is|rash|. (r_attr) is_2\VBZ\0|NONE (l_advcl) is_12\VBZ\0|rash|.|complication (l_acomp) lymphadenopathy_16\NN\14204950|as
D010672_D008206 CID diphenylhydantoin_10\NN\3550533|NONE (r_pobj) of_9\IN\0|the|and|occurrence (r_prep) ingestion_8\NN\13440063|NONE (l_conj) occurrence_13\NN\29378|the|and|of (l_prep) of_14\IN\0|the (l_pobj) rash_17\NN\14321469|NONE (l_conj) lymphadenopathy_19\JJ\14204950|the|skin|,
6673474
D009599_D007022 CID nitroprusside_14\NN\0|NONE (r_amod) sodium_13\NN\14625458|NONE (r_pobj) under_12\IN\0|NONE (r_prep) dogs_11\NNS\2083346|NONE (r_pobj) in_10\IN\13603305|were|flow|.|and|trimetaphan (r_prep) studied_9\VBN\0|NONE (l_conj) trimetaphan_19\NN\0|were|flow|.|and|in (l_pobj) hypotension_24\NN\14057371|NONE
D009599_D007022 CID snp_16\NNP\11493266|NONE (r_appos) nitroprusside_14\NN\0|NONE (r_amod) sodium_13\NN\14625458|NONE (r_pobj) under_12\IN\0|NONE (r_prep) dogs_11\NNS\2083346|NONE (r_pobj) in_10\IN\13603305|were|flow|.|and|trimetaphan (r_prep) studied_9\VBN\0|NONE (l_conj) trimetaphan_19\NN\0|were|flow|.|and|in (l_pobj) hypotension_24\NN\14057371|NONE
D009599_D007022 CID nitroprusside_30\JJ\0|NONE (r_amod) hypotension_31\NN\14057371|that|be|decrease|safely|to|could (r_nsubjpass) used_35\VBN\0|could|Regarding|we|. (r_ccomp) confirm_28\VB\0|NONE (l_prep) regarding_0\VBG\689344|could|used|we|. (l_pobj) effects_2\NNS\13245626|NONE (l_prep) of_3\IN\0|the (l_pobj) hypotension_7\NN\14057371|NONE
D009599_D007022 CID nitroprusside_30\JJ\0|NONE (r_amod) hypotension_31\NN\14057371|that|be|decrease|safely|to|could
D009599_D007022 CID nitroprusside_30\JJ\0|NONE (r_amod) hypotension_31\NN\14057371|that|be|decrease|safely|to|could (r_nsubjpass) used_35\VBN\0|could|Regarding|we|. (l_advcl) decrease_42\NN\7296428|that|hypotension|be|safely|to|could (l_conj) decrease_54\NN\7296428|mean|pressure|,|from (l_dep) hypotension_47\NN\14057371|pressure|mean|trimetaphan
D009599_D007022 CID snp_6\NNP\11493266|NONE (r_compound) hypotension_7\NN\14057371|NONE
D014294_D007022 CID trimetaphan_19\NN\0|were|flow|.|and|in (l_pobj) hypotension_24\NN\14057371|NONE
D014294_D007022 CID tmp_21\NNP\0|%|)|(|deliberate|(|decrease (r_nmod) hypotension_24\NN\14057371|NONE
D014294_D007022 CID trimetaphan_46\NN\0|hypotension|pressure|mean (r_mark) decrease_54\NN\7296428|mean|pressure|,|from (r_conj) decrease_42\NN\7296428|that|hypotension|be|safely|to|could (r_advcl) used_35\VBN\0|could|Regarding|we|. (r_ccomp) confirm_28\VB\0|NONE (l_prep) regarding_0\VBG\689344|could|used|we|. (l_pobj) effects_2\NNS\13245626|NONE (l_prep) of_3\IN\0|the (l_pobj) hypotension_7\NN\14057371|NONE
D014294_D007022 CID trimetaphan_46\NN\0|hypotension|pressure|mean (r_mark) decrease_54\NN\7296428|mean|pressure|,|from (r_conj) decrease_42\NN\7296428|that|hypotension|be|safely|to|could (r_advcl) used_35\VBN\0|could|Regarding|we|. (l_nsubjpass) hypotension_31\NN\14057371|that|be|decrease|safely|to|could
D014294_D007022 CID trimetaphan_46\NN\0|hypotension|pressure|mean (r_mark) decrease_54\NN\7296428|mean|pressure|,|from (l_dep) hypotension_47\NN\14057371|pressure|mean|trimetaphan
20046642
D002330_D008569 CID bcnu_1\NNP\0|resulted|after|data|.|then (r_nsubj) revealed_16\VBD\2137132|NONE (l_ccomp) resulted_20\VBD\2633881|BCNU|after|data|.|then (l_prep) in_21\IN\13603305|administration|that|,|measured (l_pobj) deterioration_22\NN\14560612|NONE (l_prep) of_23\IN\0|NONE (l_pobj) learning_24\NN\5701944|NONE (l_conj) memory_29\NN\5926676|and
D002330_D008569 CID bcnu_18\NNP\0|NONE (r_compound) administration_19\NN\1133281|in|that|,|measured (r_nsubj) resulted_20\VBD\2633881|BCNU|after|data|.|then (l_prep) in_21\IN\13603305|administration|that|,|measured (l_pobj) deterioration_22\NN\14560612|NONE (l_prep) of_23\IN\0|NONE (l_pobj) learning_24\NN\5701944|NONE (l_conj) memory_29\NN\5926676|and
D008315_D064420 NONE mda_27\NNP\0|, (r_conj) tnfalpha_25\NNP\0|NONE (r_pobj) of_24\IN\0|the|increased (r_prep) levels_23\NNS\4916342|NONE (r_dobj) counteracted_20\VBD\2367363|inhibition|and|it|as (r_conj) prevented_13\VBD\0|induction|.|In|toxicity|, (r_advcl) halts_5\VBZ\14010148|NONE (l_dobj) toxicity_10\NN\13576101|induction|prevented|.|In|,
D005978_D064420 NONE gsh_17\NNP\0|NONE (r_compound) depletion_18\NN\351638|and|GR (r_conj) inhibition_15\NN\1068773|counteracted|and|it|as (r_dobj) prevented_13\VBD\0|induction|.|In|toxicity|, (r_advcl) halts_5\VBZ\14010148|NONE (l_dobj) toxicity_10\NN\13576101|induction|prevented|.|In|,
D005978_D007859 NONE glutathione_47\NN\0|hippocampal|activity|decreased (r_compound) reductase_48\NN\14732946|NONE (r_pobj) with_44\IN\0|NONE (r_prep) accompanied_43\VBN\0|,|as|by (r_conj) measured_35\VBN\697589|administration|in|that|, (r_advcl) resulted_20\VBD\2633881|BCNU|after|data|.|then (l_prep) in_21\IN\13603305|administration|that|,|measured (l_pobj) deterioration_22\NN\14560612|NONE (l_prep) of_23\IN\0|NONE (l_pobj) learning_24\NN\5701944|NONE (l_conj) memory_29\NN\5926676|and
D005978_D007859 NONE glutathione_55\NN\0|GSH|( (r_nmod) content_59\NN\7951464|and|)|GR|( (r_conj) activity_52\NN\30358|glutathione|hippocampal|decreased (r_appos) reductase_48\NN\14732946|NONE (r_pobj) with_44\IN\0|NONE (r_prep) accompanied_43\VBN\0|,|as|by (r_conj) measured_35\VBN\697589|administration|in|that|, (r_advcl) resulted_20\VBD\2633881|BCNU|after|data|.|then (l_prep) in_21\IN\13603305|administration|that|,|measured (l_pobj) deterioration_22\NN\14560612|NONE (l_prep) of_23\IN\0|NONE (l_pobj) learning_24\NN\5701944|NONE (l_conj) memory_29\NN\5926676|and
D005978_D007859 NONE gsh_57\NNP\0|glutathione|( (r_nmod) content_59\NN\7951464|and|)|GR|( (r_conj) activity_52\NN\30358|glutathione|hippocampal|decreased (r_appos) reductase_48\NN\14732946|NONE (r_pobj) with_44\IN\0|NONE (r_prep) accompanied_43\VBN\0|,|as|by (r_conj) measured_35\VBN\697589|administration|in|that|, (r_advcl) resulted_20\VBD\2633881|BCNU|after|data|.|then (l_prep) in_21\IN\13603305|administration|that|,|measured (l_pobj) deterioration_22\NN\14560612|NONE (l_prep) of_23\IN\0|NONE (l_pobj) learning_24\NN\5701944|NONE (l_conj) memory_29\NN\5926676|and
D002330_D009336 NONE bcnu_2\NNP\0|NONE (r_compound) administration_3\NN\1133281|,|Also|.|contents (r_nsubj) increased_4\VBD\169651|NONE (l_dobj) contents_22\NNS\6481320|,|Also|administration|. (l_nmod) factor_8\NN\7326557|activity|as|MDA|)|( (l_compound) necrosis_7\NN\11444117||alpha
D008315_D009369 NONE malondialdehyde_18\NN\0|and|hippocampal (r_conj) mt_16\NNP\14622893|,|TNFalpha (r_appos) alpha_10\NN\6828818||necrosis (r_appos) factor_8\NN\7326557|activity|as|MDA|)|( (l_compound) necrosis_7\NN\11444117||alpha (l_compound) tumor_6\NN\14234074|NONE
D008315_D009369 NONE mda_20\NNP\0|activity|as|)|(|factor (r_nmod) contents_22\NNS\6481320|,|Also|administration|. (l_nmod) factor_8\NN\7326557|activity|as|MDA|)|( (l_compound) necrosis_7\NN\11444117||alpha (l_compound) tumor_6\NN\14234074|NONE
D008315_D009336 NONE malondialdehyde_18\NN\0|and|hippocampal (r_conj) mt_16\NNP\14622893|,|TNFalpha (r_appos) alpha_10\NN\6828818||necrosis (r_appos) factor_8\NN\7326557|activity|as|MDA|)|( (l_compound) necrosis_7\NN\11444117||alpha
D008315_D009336 NONE mda_20\NNP\0|activity|as|)|(|factor (r_nmod) contents_22\NNS\6481320|,|Also|administration|. (l_nmod) factor_8\NN\7326557|activity|as|MDA|)|( (l_compound) necrosis_7\NN\11444117||alpha
D002330_D007859 CID bcnu_1\NNP\0|resulted|after|data|.|then (r_nsubj) revealed_16\VBD\2137132|NONE (l_ccomp) resulted_20\VBD\2633881|BCNU|after|data|.|then (l_prep) in_21\IN\13603305|administration|that|,|measured (l_pobj) deterioration_22\NN\14560612|NONE (l_prep) of_23\IN\0|NONE (l_pobj) learning_24\NN\5701944|NONE (l_conj) memory_29\NN\5926676|and
D002330_D007859 CID bcnu_18\NNP\0|NONE (r_compound) administration_19\NN\1133281|in|that|,|measured (r_nsubj) resulted_20\VBD\2633881|BCNU|after|data|.|then (l_prep) in_21\IN\13603305|administration|that|,|measured (l_pobj) deterioration_22\NN\14560612|NONE (l_prep) of_23\IN\0|NONE (l_pobj) learning_24\NN\5701944|NONE (l_conj) memory_29\NN\5926676|and
D008668_D003072 NONE mt_9\NNP\14622893|on (r_compound) induction_10\NN\7450842|NONE (l_prep) on_11\IN\0|MT (l_pobj) carmustine_12\NN\0|NONE (l_appos) dysfunction_17\NN\14204950|NONE
D008668_D064420 NONE mt_3\NNP\14622893|NONE (r_compound) induction_4\NN\7450842|prevented|.|In|toxicity|, (r_nsubj) halts_5\VBZ\14010148|NONE (l_dobj) toxicity_10\NN\13576101|induction|prevented|.|In|,
D008668_D009369 NONE mt_16\NNP\14622893|,|TNFalpha (r_appos) alpha_10\NN\6828818||necrosis (r_appos) factor_8\NN\7326557|activity|as|MDA|)|( (l_compound) necrosis_7\NN\11444117||alpha (l_compound) tumor_6\NN\14234074|NONE
D002330_D009369 NONE bcnu_2\NNP\0|NONE (r_compound) administration_3\NN\1133281|,|Also|.|contents (r_nsubj) increased_4\VBD\169651|NONE (l_dobj) contents_22\NNS\6481320|,|Also|administration|. (l_nmod) factor_8\NN\7326557|activity|as|MDA|)|( (l_compound) necrosis_7\NN\11444117||alpha (l_compound) tumor_6\NN\14234074|NONE
D008668_D009336 NONE mt_16\NNP\14622893|,|TNFalpha (r_appos) alpha_10\NN\6828818||necrosis (r_appos) factor_8\NN\7326557|activity|as|MDA|)|( (l_compound) necrosis_7\NN\11444117||alpha
D002330_D064420 NONE bcnu_6\NNP\0| (r_npadvmod) induced_8\VBN\1627355|hippocampal (r_amod) toxicity_10\NN\13576101|induction|prevented|.|In|,
D005978_D008569 NONE glutathione_47\NN\0|hippocampal|activity|decreased (r_compound) reductase_48\NN\14732946|NONE (r_pobj) with_44\IN\0|NONE (r_prep) accompanied_43\VBN\0|,|as|by (r_conj) measured_35\VBN\697589|administration|in|that|, (r_advcl) resulted_20\VBD\2633881|BCNU|after|data|.|then (l_prep) in_21\IN\13603305|administration|that|,|measured (l_pobj) deterioration_22\NN\14560612|NONE (l_prep) of_23\IN\0|NONE (l_pobj) learning_24\NN\5701944|NONE (l_conj) memory_29\NN\5926676|and
D005978_D008569 NONE glutathione_55\NN\0|GSH|( (r_nmod) content_59\NN\7951464|and|)|GR|( (r_conj) activity_52\NN\30358|glutathione|hippocampal|decreased (r_appos) reductase_48\NN\14732946|NONE (r_pobj) with_44\IN\0|NONE (r_prep) accompanied_43\VBN\0|,|as|by (r_conj) measured_35\VBN\697589|administration|in|that|, (r_advcl) resulted_20\VBD\2633881|BCNU|after|data|.|then (l_prep) in_21\IN\13603305|administration|that|,|measured (l_pobj) deterioration_22\NN\14560612|NONE (l_prep) of_23\IN\0|NONE (l_pobj) learning_24\NN\5701944|NONE (l_conj) memory_29\NN\5926676|and
D005978_D008569 NONE gsh_57\NNP\0|glutathione|( (r_nmod) content_59\NN\7951464|and|)|GR|( (r_conj) activity_52\NN\30358|glutathione|hippocampal|decreased (r_appos) reductase_48\NN\14732946|NONE (r_pobj) with_44\IN\0|NONE (r_prep) accompanied_43\VBN\0|,|as|by (r_conj) measured_35\VBN\697589|administration|in|that|, (r_advcl) resulted_20\VBD\2633881|BCNU|after|data|.|then (l_prep) in_21\IN\13603305|administration|that|,|measured (l_pobj) deterioration_22\NN\14560612|NONE (l_prep) of_23\IN\0|NONE (l_pobj) learning_24\NN\5701944|NONE (l_conj) memory_29\NN\5926676|and
D002330_D003072 CID carmustine_12\NN\0|NONE (l_appos) dysfunction_17\NN\14204950|NONE
D002330_D003072 CID bcnu)-induced_14\VBN\0|(|in|hippocampal|cognitive (r_amod) dysfunction_17\NN\14204950|NONE
24438483
D015742_D066126 NONE propofol_19\NN\0|NONE (r_pobj) of_18\IN\0|lipid|the (r_prep) content_17\NN\7951464|cardiotoxicity|may|. (r_nsubj) alleviate_21\VB\205885|been|has|and|increase|treatment|, (l_dobj) cardiotoxicity_25\NN\0|may|.|content
D015742_D066126 NONE propofol_11\NN\0|NONE (l_prep) in_12\IN\13603305|NONE (l_pobj) intralipid_13\NN\0|NONE (l_conj) emulsions_16\NNS\14588219|or (l_prep) on_17\IN\0|medialipid (l_pobj) cardiotoxicity_21\NN\0|NONE
D015742_D066126 NONE propofol_7\NN\0|.|We|induced|delayed (r_dobj) conclude_1\VBP\628491|NONE (l_conj) induced_25\VBN\1627355|.|We|propofol|delayed (l_dobj) effects_27\NNS\13245626| (l_amod) cardiotoxic_26\JJ\0|levels|as
D015742_D066126 NONE propofol_13\NN\0|NONE (r_pcomp) with_12\IN\0|NONE (r_prep) compared_11\VBN\644583|that|with|in|, (r_prep) propofol_7\NN\0|.|We|induced|delayed (r_dobj) conclude_1\VBP\628491|NONE (l_conj) induced_25\VBN\1627355|.|We|propofol|delayed (l_dobj) effects_27\NNS\13245626| (l_amod) cardiotoxic_26\JJ\0|levels|as
D002045_D066126 CID bupivacaine_12\NN\0|NONE (r_pobj) of_11\IN\0|lethal (r_prep) doses_10\NNS\3740161|to (r_dobj) increase_8\VB\13576355|alleviate|been|has|and|treatment|, (r_xcomp) shown_6\VBN\2137132|NONE (l_conj) alleviate_21\VB\205885|been|has|and|increase|treatment|, (l_dobj) cardiotoxicity_25\NN\0|may|.|content
D002045_D066126 CID bupivacaine_22\NN\0| (r_npadvmod) induced_24\VBN\1627355|NONE (r_amod) cardiotoxicity_25\NN\0|may|.|content
D002045_D066126 CID bupivacaine_18\NN\0| (r_npadvmod) induced_20\VBN\1627355|NONE (r_compound) cardiotoxicity_21\NN\0|NONE
D002045_D066126 CID bupivacaine_23\NN\0|NONE (r_pobj) of_22\IN\0|the (r_prep) onset_21\NN\7325190|, (r_dobj) delayed_19\VBD\439958|.|We|induced|propofol (r_conj) conclude_1\VBP\628491|NONE (l_conj) induced_25\VBN\1627355|.|We|propofol|delayed (l_dobj) effects_27\NNS\13245626| (l_amod) cardiotoxic_26\JJ\0|levels|as
D002045_D066126 CID bupivacaine_33\NN\0|NONE (r_compound) levels_34\NNS\4916342|as|cardiotoxic (r_conj) effects_27\NNS\13245626| (l_amod) cardiotoxic_26\JJ\0|levels|as
D002045_D002318 NONE bupivacaine_4\NN\0| (r_npadvmod) induced_6\VBN\1627355|cardiovascular (r_amod) depression_8\NN\14373582|NONE
D002045_D001145 NONE bupivacaine_37\NN\0|NONE (r_compound) consumption_38\NN\13440063|NONE (r_pobj) of_36\IN\0|total (r_prep) amount_35\NN\13329641|asystole (r_conj) time_30\NN\7308889|and|mean|arterial|, (r_conj) pressure_27\NN\11419404|respective|and|to (r_conj) times_9\NNS\15113229|We|,|to|time|. (r_npadvmod) recorded_1\VBD\2225492|NONE (l_prep) to_3\IN\0|We|,|times|time|. (l_pobj) occurrence_6\NN\29378|NONE (l_amod) dysrhythmia_5\NN\0|first
D002045_D006323 CID bupivacaine_37\NN\0|NONE (r_compound) consumption_38\NN\13440063|NONE (r_pobj) of_36\IN\0|total (r_prep) amount_35\NN\13329641|asystole (r_conj) time_30\NN\7308889|and|mean|arterial|, (l_relcl) asystole_32\NN\14204950|amount
D015742_D002318 NONE propofol_14\NN\0|NONE (r_pobj) of_13\IN\0|different|lipid (r_prep) formulations_12\NNS\14818238|treatment|. (r_dobj) using_9\VBG\418025|NONE (l_nsubj) treatment_2\NN\654885|formulations|. (l_prep) of_3\IN\0||Pre (l_pobj) depression_8\NN\14373582|NONE
6695685
D014700_D002637 NONE verapamil_8\NN\2938514|suppressed|neither|.|frequency|In|nor|, (r_nsubj) increased_10\VBD\169651|NONE (l_prep) in_0\IN\13603305|suppressed|neither|.|verapamil|frequency|nor|, (l_pobj) patients_1\NNS\9898892|NONE (l_prep) with_2\IN\0|NONE (l_pobj) syndromes_6\NNS\5870365|NONE (l_compound) pain_5\NN\14299637|chest|various
D014700_D001145 CID verapamil_5\NN\2938514|oral (r_compound) therapy_6\NN\657604|NONE (r_pobj) during_3\IN\0|Accelerated|.|junctional (r_prep) rhythms_2\NNS\15122011|NONE
D014700_D001145 CID verapamil_20\NN\2938514|NONE (r_dobj) receiving_18\VBG\2210855| (r_acl) patients_17\NNS\9898892|NONE (r_pobj) in_15\IN\13603305|rhythms (r_prep) accelerated_12\VBD\226566|frequency|and|study|. (l_dobj) rhythms_14\NNS\15122011|in
7176945
D013390_D010146 CID suxamethonium_2\NN\0|in|. (r_compound) pains_3\NNS\786195|NONE
D013390_D010146 CID scoline_8\JJ\0|NONE (r_amod) pain_9\NN\14299637|Contrary|in|,|.
D013390_D010146 CID scoline_9\JJ\0|NONE (r_amod) pain_10\NN\14299637|%|compared|.
D013390_D010146 CID scoline_20\JJ\0|NONE (r_amod) pain_21\NN\14299637|NONE
D013390_D010146 CID suxamethonium_16\NN\0|NONE (r_pobj) of_15\IN\0|salt|the (r_prep) preparation_14\NN\407535|the|nor|of|Neither|, (r_conj) type_2\NN\5839024|.|incidence (r_nsubj) affected_24\VBD\126264|NONE (l_dobj) incidence_26\NN\13821570|type|. (l_prep) of_27\IN\0|the (l_pobj) pain_29\NN\14299637|NONE
D013390_D010146 CID scoline_28\JJ\0|NONE (r_amod) pain_29\NN\14299637|NONE
D000530_D010146 NONE althesin_7\NNP\0|induction|(|) (r_appos) agent_5\NN\7347|NONE (r_pobj) of_3\IN\0|the|nor|Neither|,|preparation (r_prep) type_2\NN\5839024|.|incidence (r_nsubj) affected_24\VBD\126264|NONE (l_dobj) incidence_26\NN\13821570|type|. (l_prep) of_27\IN\0|the (l_pobj) pain_29\NN\14299637|NONE
D013390_D005207 CID scoline_20\JJ\0|NONE (r_amod) pain_21\NN\14299637|NONE (r_pobj) of_19\IN\0|the (r_prep) occurrence_18\NN\29378|did|not|abolition|. (r_dobj) influence_16\VB\5190804|NONE (l_nsubj) abolition_1\NN\209943|did|not|occurrence|. (l_prep) of_2\IN\0|dose|The (l_pobj) fasciculations_4\NNS\14361664|NONE
C084773_D005207 NONE fazadinium_12\NNP\0|NONE (r_pobj) of_11\IN\0|(|by|)|kg (r_prep) dose_10\NN\3740161|The|of (r_appos) abolition_1\NN\209943|did|not|occurrence|. (l_prep) of_2\IN\0|dose|The (l_pobj) fasciculations_4\NNS\14361664|NONE
D002712_D010146 NONE chloride_19\NN\14818238|NONE (r_oprd) used_17\VBN\0|NONE (r_acl) suxamethonium_16\NN\0|NONE (r_pobj) of_15\IN\0|salt|the (r_prep) preparation_14\NN\407535|the|nor|of|Neither|, (r_conj) type_2\NN\5839024|.|incidence (r_nsubj) affected_24\VBD\126264|NONE (l_dobj) incidence_26\NN\13821570|type|. (l_prep) of_27\IN\0|the (l_pobj) pain_29\NN\14299637|NONE
C084773_D010146 NONE fazadinium_12\NNP\0|NONE (r_pobj) of_11\IN\0|(|by|)|kg (r_prep) dose_10\NN\3740161|The|of (r_appos) abolition_1\NN\209943|did|not|occurrence|. (r_nsubj) influence_16\VB\5190804|NONE (l_dobj) occurrence_18\NN\29378|did|not|abolition|. (l_prep) of_19\IN\0|the (l_pobj) pain_21\NN\14299637|NONE
D001965_D010146 NONE bromide_21\NN\14904359|or|(|) (r_conj) chloride_19\NN\14818238|NONE (r_oprd) used_17\VBN\0|NONE (r_acl) suxamethonium_16\NN\0|NONE (r_pobj) of_15\IN\0|salt|the (r_prep) preparation_14\NN\407535|the|nor|of|Neither|, (r_conj) type_2\NN\5839024|.|incidence (r_nsubj) affected_24\VBD\126264|NONE (l_dobj) incidence_26\NN\13821570|type|. (l_prep) of_27\IN\0|the (l_pobj) pain_29\NN\14299637|NONE
D013874_D010146 NONE thiopentone_9\NNP\0|or (r_conj) althesin_7\NNP\0|induction|(|) (r_appos) agent_5\NN\7347|NONE (r_pobj) of_3\IN\0|the|nor|Neither|,|preparation (r_prep) type_2\NN\5839024|.|incidence (r_nsubj) affected_24\VBD\126264|NONE (l_dobj) incidence_26\NN\13821570|type|. (l_prep) of_27\IN\0|the (l_pobj) pain_29\NN\14299637|NONE
26033014
C051786_D008113 CID metolachlor_0\NNP\0|as|.|by|based|is (r_nsubjpass) classified_8\VBN\7249426|NONE (l_prep) based_20\VBN\0|as|.|by|is|Metolachlor (l_prep) on_21\IN\0|NONE (l_pobj) neoplasms_24\NNS\14234074|NONE
C051786_D008113 CID metolachlor_6\NN\0|among|liver (r_nmod) cancer_9\NN\14239425|NONE
C051786_D008113 CID metolachlor_6\NN\0|among|liver (r_nmod) cancer_9\NN\14239425|NONE (r_pobj) between_5\IN\0|an (r_prep) association_4\NN\8008335|NONE (r_pobj) of_2\IN\0|This (r_prep) suggestion_1\NN\5833840|finding|. (r_nsubj) is_13\VBZ\0|NONE (l_attr) finding_16\NN\43195|suggestion|. (l_conj) echoes_18\VBZ\5010627|a|and|novel (l_dobj) observation_19\NN\996969|in (l_prep) of_20\IN\0|NONE (l_pobj) neoplasms_23\NNS\14234074|NONE
C051786_D008113 CID metolachlor_21\JJ\0|from (r_amod) use_22\NN\407535|NONE (r_pobj) of_20\IN\0|differentiate (r_prep) effects_19\NNS\13245626|NONE (r_pobj) to_16\TO\0|follow||warrant (r_prep) up_15\NN\153263|both|liver|and (r_conj) cancer_7\NN\14239425|NONE
C051786_D009369 NONE metolachlor_3\JJ\0|in (r_amod) use_4\NN\407535|Cancer|and (r_conj) incidence_1\NN\13821570|An|:|. (l_compound) cancer_0\NN\14239425|use|and
C051786_D009369 NONE metolachlor_22\NN\0|ever (r_dobj) using_21\VBG\418025|% (r_xcomp) reported_19\VBD\831651|We|for|through|incidence|. (r_advcl) evaluated_1\VBD\670261|NONE (l_dobj) incidence_3\NN\13821570|We|for|through|.|reported (l_compound) cancer_2\NN\14239425|NONE
C051786_D009369 NONE metolachlor_11\JJ\0|NONE (r_amod) use_12\NN\407535|NONE (r_pobj) of_10\IN\0|days|incidence|(|)|two|and (r_prep) metrics_9\NNS\6169932|NONE (l_conj) incidence_25\NN\13821570|days|of|(|)|two|and (l_compound) cancer_24\NN\14239425|NONE
C051786_D009369 NONE metolachlor_5\JJ\0|and|incidence|, (r_amod) use_6\NN\407535|NONE (l_conj) incidence_8\NN\13821570|and|metolachlor|, (l_prep) of_9\IN\0|NONE (l_pobj) cancers_11\NNS\14239425|NONE
C051786_D009369 NONE metolachlor_5\JJ\0|and|incidence|, (r_amod) use_6\NN\407535|NONE (r_pobj) between_4\IN\0|no|with (r_prep) association_3\NN\8008335|We|. (l_prep) with_17\IN\0|no|between (l_pobj) lag_20\NN\1066163|NONE (l_conj) cancers_27\NNS\14239425|year|a|)|or
C051786_D008175 NONE metolachlor_12\JJ\0|in (r_amod) use_13\NN\407535|NONE (r_pobj) of_11\IN\0|high (r_prep) levels_10\NNS\4916342|NONE (r_pobj) at_8\IN\14622893|cancer|increased (r_prep) risk_7\NN\14541044|NONE (l_compound) cancer_6\NN\14239425|at|increased
C051786_D008223 NONE metolachlor_21\JJ\0|from (r_amod) use_22\NN\407535|NONE (r_pobj) of_20\IN\0|differentiate (r_prep) effects_19\NNS\13245626|NONE (r_pobj) to_16\TO\0|follow||warrant (r_prep) up_15\NN\153263|both|liver|and (l_compound) warrant_12\NN\6552984|follow||to (l_compound) lymphoma_11\NN\14239918|NONE
3895875
D008012_D009203 NONE lidocaine_1\NN\3681148|NONE (l_prep) in_2\IN\13603305|Prophylactic|. (l_pobj) phase_5\NN\15113229|NONE (l_prep) of_6\IN\0|early|the (l_pobj) infarction_9\NN\14204950|NONE
D008012_D009203 NONE lidocaine_25\NN\3681148|NONE (r_pobj) of_24\IN\0|blind|randomized|a (r_prep) trial_23\NN\786195|.|patients (r_dobj) entered_17\VBD\0|NONE (l_nsubj) patients_3\NNS\9898892|trial|. (l_prep) with_4\IN\0|two (l_pobj) infarction_7\NN\14204950|NONE
D008012_D009203 NONE lidocaine_3\NN\3681148|average|The|after (r_compound) level_4\NN\4916342|for|.|higher (l_prep) after_7\IN\0|average|The|lidocaine (l_pobj) administration_8\NN\1133281|minutes (l_prep) for_9\IN\0|NONE (l_pobj) patients_10\NNS\9898892|NONE (l_prep) without_11\IN\0|NONE (l_pobj) infarction_14\NN\14204950|NONE
D008012_D009203 NONE lidocaine_7\NN\3681148|NONE (r_pobj) of_6\IN\0|the (r_prep) administration_5\NN\1133281|We|not|in|.|prophylactically|can (r_dobj) advocate_3\VB\7846|NONE (l_prep) in_9\IN\13603305|We|not|.|administration|prophylactically|can (l_pobj) hours_12\NNS\15118228|NONE (l_prep) of_13\IN\0|early|the (l_pobj) infarction_16\NN\14204950|NONE
D008012_D007238 NONE lidocaine_3\NN\3681148|average|The|after (r_compound) level_4\NN\4916342|for|.|higher (r_nsubj) was_15\VBD\0|NONE (l_prep) for_20\IN\0|.|higher|level (l_pobj) patients_21\NNS\9898892|NONE (l_prep) with_22\IN\0|NONE (l_pobj) infarction_25\NN\14204950|NONE
D008012_D006323 NONE lidocaine_19\NN\3681148|the (r_compound) group_20\NN\2137|NONE (r_pobj) in_17\IN\13603305|significantly (r_prep) greater_16\JJR\0|During|,|incidence (r_acomp) was_14\VBD\0|,|died|in|hypotension|and|, (r_ccomp) occurred_23\VBD\0|NONE (l_conj) died_38\VBD\146138|was|,|in|hypotension|and|, (l_prep) from_39\IN\0|,|patients|had|. (l_pobj) asystole_40\NN\14204950|NONE
D008012_D006323 NONE lidocaine_33\NN\3681148|had|nine (r_dobj) received_32\VBN\2210855||, (r_relcl) patients_26\NNS\9898892|NONE (r_pobj) in_24\IN\13603305|was|,|died|hypotension|and|, (r_prep) occurred_23\VBD\0|NONE (l_conj) died_38\VBD\146138|was|,|in|hypotension|and|, (l_prep) from_39\IN\0|,|patients|had|. (l_pobj) asystole_40\NN\14204950|NONE
D008012_D006323 NONE lidocaine_47\NN\3681148|had|three (r_dobj) had_46\VBN\0|,|from|patients|. (r_conj) died_38\VBD\146138|was|,|in|hypotension|and|, (l_prep) from_39\IN\0|,|patients|had|. (l_pobj) asystole_40\NN\14204950|NONE
D008012_D017180 NONE lidocaine_0\NN\3681148|,|.|not|,|,|)|tachycardia|given|did|was (r_nsubj) prevent_17\VB\0|NONE (l_dobj) tachycardia_20\NN\14110674|,|.|not|,|,|Lidocaine|)|given|did|was
D008012_D017180 NONE lidocaine_45\NN\3681148|NONE (r_pobj) of_44\IN\0|the|. (r_prep) administration_43\NN\1133281|minutes (r_pobj) after_41\IN\0|although|reduction|there (r_prep) was_24\VBD\0|,|.|not|,|,|Lidocaine|)|tachycardia|given|did (r_advcl) prevent_17\VB\0|NONE (l_dobj) tachycardia_20\NN\14110674|,|.|not|,|,|Lidocaine|)|given|did|was
D008012_D001145 NONE lidocaine_0\NN\3681148|,|.|not|,|,|)|tachycardia|given|did|was (r_nsubj) prevent_17\VB\0|NONE (l_advcl) was_24\VBD\0|,|.|not|,|,|Lidocaine|)|tachycardia|given|did (l_attr) reduction_27\NN\351485|although|after|there (l_prep) in_28\IN\13603305|a|significant (l_pobj) number_30\NN\5107765|NONE (l_prep) of_31\IN\0|the (l_pobj) patients_32\NNS\9898892|NONE (l_prep) with_33\IN\0|NONE (l_pcomp) warning_34\VBG\7212190|NONE (l_dobj) arrhythmias_35\NNS\14103288|NONE
D008012_D001145 NONE lidocaine_45\NN\3681148|NONE (r_pobj) of_44\IN\0|the|. (r_prep) administration_43\NN\1133281|minutes (r_pobj) after_41\IN\0|although|reduction|there (r_prep) was_24\VBD\0|,|.|not|,|,|Lidocaine|)|tachycardia|given|did (l_attr) reduction_27\NN\351485|although|after|there (l_prep) in_28\IN\13603305|a|significant (l_pobj) number_30\NN\5107765|NONE (l_prep) of_31\IN\0|the (l_pobj) patients_32\NNS\9898892|NONE (l_prep) with_33\IN\0|NONE (l_pcomp) warning_34\VBG\7212190|NONE (l_dobj) arrhythmias_35\NNS\14103288|NONE
D008012_D007022 CID lidocaine_19\NN\3681148|the (r_compound) group_20\NN\2137|NONE (r_pobj) in_17\IN\13603305|significantly (r_prep) greater_16\JJR\0|During|,|incidence (r_acomp) was_14\VBD\0|,|died|in|hypotension|and|, (r_ccomp) occurred_23\VBD\0|NONE (l_nsubj) hypotension_22\NN\14057371|was|,|died|in|and|,
D008012_D007022 CID lidocaine_33\NN\3681148|had|nine (r_dobj) received_32\VBN\2210855||, (r_relcl) patients_26\NNS\9898892|NONE (r_pobj) in_24\IN\13603305|was|,|died|hypotension|and|, (r_prep) occurred_23\VBD\0|NONE (l_nsubj) hypotension_22\NN\14057371|was|,|died|in|and|,
D008012_D007022 CID lidocaine_47\NN\3681148|had|three (r_dobj) had_46\VBN\0|,|from|patients|. (r_conj) died_38\VBD\146138|was|,|in|hypotension|and|, (r_conj) occurred_23\VBD\0|NONE (l_nsubj) hypotension_22\NN\14057371|was|,|died|in|and|,
16880771
D004298_D020521 NONE dopamine_3\NN\14807737|NONE (r_compound) precursor_4\NN\14580897|the (r_compound) levodopa_5\NN\14604959|NONE (r_pobj) of_1\IN\0|NONE (r_prep) administration_0\NN\1133281|learning|. (r_nsubj) enhances_6\VBZ\227165|NONE (l_dobj) learning_7\VBG\5701944|Administration|. (l_prep) in_8\IN\13603305|NONE (l_pobj) subjects_10\NNS\6598915|NONE (l_conj) patients_13\NNS\9898892|healthy|and (l_compound) stroke_12\NN\556313|NONE
D004298_D020521 NONE dopamine_12\NN\14807737|by|learning (r_nsubj) enhances_13\VBZ\227165|critical|the (l_dobj) learning_15\NN\5701944|by|dopamine (l_prep) in_16\IN\13603305|associative (l_pobj) subjects_18\NNS\6598915|NONE (l_conj) patients_21\NNS\9898892|and|healthy (l_compound) stroke_20\NN\556313|NONE
D007980_D020521 NONE levodopa_5\NN\14604959|NONE (r_pobj) of_1\IN\0|NONE (r_prep) administration_0\NN\1133281|learning|. (r_nsubj) enhances_6\VBZ\227165|NONE (l_dobj) learning_7\VBG\5701944|Administration|. (l_prep) in_8\IN\13603305|NONE (l_pobj) subjects_10\NNS\6598915|NONE (l_conj) patients_13\NNS\9898892|healthy|and (l_compound) stroke_12\NN\556313|NONE
D004298_D007859 NONE dopamine_1\NN\14807737|The (r_compound) agonist_2\NN\0|significantly (r_nsubj) impaired_4\JJ\258857|compared|.|word (r_amod) learning_7\NN\5701944|NONE
7248895
D003520_D006869 NONE cyclophosphamide_23\NN\0|NONE (r_pobj) wtih_22\IN\0|being|for|for (r_prep) treated_18\VBN\2376958|NONE (r_pcomp) after_16\IN\0|woman|.|hematuria (r_prep) had_13\VBD\0|NONE (l_nsubj) woman_4\NN\9605289|.|after|hematuria (l_prep) with_5\IN\0|A|old (l_pobj) hydroureteronephrosis_7\NN\0|NONE
D003520_D006869 NONE cyclophosphamide_21\NN\0|NONE (r_pobj) to_20\IN\0|tract|urinary|upper (r_prep) epithelium_19\NN\5267548|NONE (r_pobj) of_15\IN\0|NONE (r_prep) exposure_14\NN\5042871|NONE (r_dobj) intensified_13\VBN\153263|that|and|stasis (r_conj) prolonged_11\VBN\317700|.|association (r_ccomp) suggests_8\VBZ\1010118|NONE (l_nsubj) association_1\NN\8008335|.|prolonged (l_prep) with_5\IN\0|The|of (l_pobj) hydroureteronephrosis_7\NN\0|NONE
D003520_D006417 CID cyclophosphamide_23\NN\0|NONE (r_pobj) wtih_22\IN\0|being|for|for (r_prep) treated_18\VBN\2376958|NONE (r_pcomp) after_16\IN\0|woman|.|hematuria (r_prep) had_13\VBD\0|NONE (l_dobj) hematuria_15\NN\14299637|woman|.|after
D003520_D020293 NONE cyclophosphamide_23\NN\0|NONE (r_pobj) wtih_22\IN\0|being|for|for (r_prep) treated_18\VBN\2376958|NONE (l_prep) for_24\IN\0|being|for|wtih (l_pobj) vasculitis_26\NN\14336539|NONE
D003520_D014571 NONE cyclophosphamide_4\NN\0|NONE (r_pobj) of_3\IN\0|cause|the (r_prep) ability_2\NN\4723816|Although|known (r_nsubj) is_18\VBZ\0|,|it (r_advcl) is_23\VBZ\0|widely|.|associated (r_auxpass) appreciated_26\VBN\892467|NONE (l_ccomp) associated_31\VBN\628491|widely|.|is (l_prep) with_32\IN\0|also|is|it|that (l_pobj) carcinoma_33\NN\14239918|NONE (l_prep) of_34\IN\0|NONE (l_pobj) tract_37\NN\8574314|NONE
D003520_D014571 NONE cyclophosphamide_11\JJ\0|for (r_compound) treatment_12\NN\654885|NONE (r_pobj) with_10\IN\0|NONE (r_prep) association_9\NN\8008335|NONE (r_pobj) in_8\IN\13603305|NONE (r_prep) reported_7\VBN\831651|urinary|tract|third|the (r_acl) cancer_6\NN\14239425|It|.
D003520_-1 NONE cyclophosphamide_8\NN\0|term (r_compound) treatment_9\NN\654885|NONE (r_pobj) for_4\IN\0|NONE (r_prep) candidates_3\NNS\10450303|who (r_attr) are_2\VBP\13600404|NONE (r_relcl) patients_0\NNS\9898892|be|routinely|for|should|. (r_nsubjpass) evaluated_13\VBN\670261|NONE (l_prep) for_14\IN\0|be|routinely|should|Patients|. (l_pobj) uropathy_16\NN\14204950|NONE
D003520_D010386 NONE cyclophosphamide_7\NN\0|NONE (r_compound) therapy_8\NN\657604|for (r_dobj) following_6\VBG\8180190|renal|the (r_prep) pelvis_5\NN\5578911|NONE
D003520_D010386 NONE cyclophosphamide_15\NN\0|NONE (r_compound) treatment_16\NN\654885|NONE (r_pobj) with_14\IN\0|NONE (r_prep) association_13\NN\8008335|NONE (r_pobj) in_12\IN\13603305|NONE (r_prep) reported_11\VBD\831651|renal|the (r_acl) pelvis_10\NN\5578911|NONE
D003520_D006470 NONE cyclophosphamide_4\NN\0|NONE (r_pobj) of_3\IN\0|cause|the (r_prep) ability_2\NN\4723816|Although|known (l_acl) cause_6\VB\7323922|of|the (l_dobj) cystitis_8\NN\14566129|to|and|urine
D003520_D002277 CID cyclophosphamide_4\NN\0|NONE (r_pobj) of_3\IN\0|cause|the (r_prep) ability_2\NN\4723816|Although|known (l_acl) cause_6\VB\7323922|of|the (l_conj) urine_10\NN\14853947|cystitis|to|and (l_dobj) abnormalities_12\NNS\14034177|NONE (l_amod) indistinguishable_13\JJ\0|cytologic (l_prep) from_14\IN\0|NONE (l_pobj) carcinoma_17\NN\14239918|NONE
D003520_D003556 NONE cyclophosphamide_4\NN\0|NONE (r_pobj) of_3\IN\0|cause|the (r_prep) ability_2\NN\4723816|Although|known (l_acl) cause_6\VB\7323922|of|the (l_dobj) cystitis_8\NN\14566129|to|and|urine
D003520_D009369 NONE cyclophosphamide_21\NN\0|NONE (r_pobj) to_20\IN\0|tract|urinary|upper (r_prep) epithelium_19\NN\5267548|NONE (r_pobj) of_15\IN\0|NONE (r_prep) exposure_14\NN\5042871|NONE (r_dobj) intensified_13\VBN\153263|that|and|stasis (r_conj) prolonged_11\VBN\317700|.|association (r_ccomp) suggests_8\VBZ\1010118|NONE (l_nsubj) association_1\NN\8008335|.|prolonged (l_prep) of_2\IN\0|The|with (l_pobj) tumor_4\NN\14234074|NONE
24345882
D008727_D054198 NONE methotrexate_20\JJ\2722166|a (r_compound) consequence_21\NN\34213|P|protocols|and|standard|:|)|( (r_appos) risk_3\NN\14541044|? (l_appos) protocols_14\NNS\6652242|P|consequence|and|standard|:|)|( (l_compound) leukemia_13\NN\14239918|ACCL|lymphoblastic|(|acute|)
D008727_D054198 NONE methotrexate_5\NN\2722166|in|MTX (r_nmod) neurotoxicity_9\NN\0|NONE (r_pobj) about_1\IN\0|NONE (r_prep) concerns_0\NNS\5682950|to|. (r_nsubj) led_13\VBD\3202760|NONE (l_prep) to_14\IN\0|Concerns|. (l_pobj) modifications_15\NNS\191142|NONE (l_prep) in_16\IN\13603305|NONE (l_pobj) therapy_21\NN\657604|NONE (l_conj) rescue_24\NN\45907|(|,|IT|intrathecal|) (l_conj) frequency_27\NN\15286249|,|leucovorin|and (l_prep) in_32\IN\13603305|of (l_pobj) children_33\NNS\9622049|NONE (l_prep) with_34\IN\0|NONE (l_pobj) leukemia_37\NN\14239918|NONE
D008727_D054198 NONE mtx_7\NNP\0|in|methotrexate (r_nmod) neurotoxicity_9\NN\0|NONE (r_pobj) about_1\IN\0|NONE (r_prep) concerns_0\NNS\5682950|to|. (r_nsubj) led_13\VBD\3202760|NONE (l_prep) to_14\IN\0|Concerns|. (l_pobj) modifications_15\NNS\191142|NONE (l_prep) in_16\IN\13603305|NONE (l_pobj) therapy_21\NN\657604|NONE (l_conj) rescue_24\NN\45907|(|,|IT|intrathecal|) (l_conj) frequency_27\NN\15286249|,|leucovorin|and (l_prep) in_32\IN\13603305|of (l_pobj) children_33\NNS\9622049|NONE (l_prep) with_34\IN\0|NONE (l_pobj) leukemia_37\NN\14239918|NONE
D008727_D054198 NONE mtx_30\NNP\0|systemic (r_compound) administration_31\NN\1133281|NONE (r_pobj) of_28\IN\0|in (r_prep) frequency_27\NN\15286249|,|leucovorin|and (l_prep) in_32\IN\13603305|of (l_pobj) children_33\NNS\9622049|NONE (l_prep) with_34\IN\0|NONE (l_pobj) leukemia_37\NN\14239918|NONE
D008727_D020258 NONE methotrexate_5\NN\2722166|in|MTX (r_nmod) neurotoxicity_9\NN\0|NONE
D008727_D020258 NONE mtx_7\NNP\0|in|methotrexate (r_nmod) neurotoxicity_9\NN\0|NONE
D008727_D020258 NONE mtx_30\NNP\0|systemic (r_compound) administration_31\NN\1133281|NONE (r_pobj) of_28\IN\0|in (r_prep) frequency_27\NN\15286249|,|leucovorin|and (r_conj) rescue_24\NN\45907|(|,|IT|intrathecal|) (r_conj) therapy_21\NN\657604|NONE (r_pobj) in_16\IN\13603305|NONE (r_prep) modifications_15\NNS\191142|NONE (r_pobj) to_14\IN\0|Concerns|. (r_prep) led_13\VBD\3202760|NONE (l_nsubj) concerns_0\NNS\5682950|to|. (l_prep) about_1\IN\0|NONE (l_pobj) neurotoxicity_9\NN\0|NONE
18945509
D005913_D003324 NONE glipizide_36\NN\2719105|NONE (r_pobj) with_35\IN\0|.|was|P=.|and|;|)|.fold|, (r_prep) 2-fold_27\JJ\0|associated|of|The|.|; (r_appos) hazard_1\NN\14541044|NONE (l_prep) of_2\IN\0|fold|associated|The|.|; (l_pcomp) developing_3\VBG\13541167|NONE (l_dobj) cad_4\NNP\10753546|NONE
D005913_D003324 NONE glipizide_9\NN\2719105|or (r_conj) glibenclamide_7\NN\0|NONE (r_pobj) with_6\IN\0| (r_prep) diabetes_5\NNS\14075199|treatment (r_dobj) initiating_0\VBG\1617192|.|with|is (r_csubjpass) associated_11\VBN\628491|NONE (l_prep) with_12\IN\0|.|is|Initiating (l_pobj) risk_14\NN\14541044|NONE (l_prep) of_15\IN\0|increased|in (l_pobj) cad_16\NNP\10753546|NONE
D005907_D003324 NONE gliclazide_20\VB\0|NONE (r_pobj) to_19\TO\0|NONE (r_prep) comparison_18\NN\635850|NONE (r_pobj) in_17\IN\13603305|of|increased (r_prep) risk_14\NN\14541044|NONE (l_prep) of_15\IN\0|increased|in (l_pobj) cad_16\NNP\10753546|NONE
-1_D003924 NONE sulphonylurea_8\JJ\0|of|initial (r_compound) treatment_9\NN\654885|NONE (l_prep) of_10\IN\0|initial|sulphonylurea (l_pobj) patients_11\NNS\9898892|NONE (l_prep) with_12\IN\0|NONE (l_pobj) diabetes_15\NNS\14075199|NONE
-1_D003924 NONE sulphonylureas_25\NNS\0|NONE (r_pobj) with_23\IN\0| (r_prep) diabetes_22\NNS\14075199|disease
C057619_D003924 NONE glimepiride_22\NN\0|or (r_conj) gliclazide_20\VB\0|NONE (r_pobj) to_19\TO\0|NONE (r_prep) comparison_18\NN\635850|NONE (r_pobj) in_17\IN\13603305|of|increased (r_prep) risk_14\NN\14541044|NONE (r_pobj) with_12\IN\0|.|is|Initiating (r_prep) associated_11\VBN\628491|NONE (l_csubjpass) initiating_0\VBG\1617192|.|with|is (l_dobj) diabetes_5\NNS\14075199|treatment
D005907_D003924 NONE gliclazide_20\VB\0|NONE (r_pobj) to_19\TO\0|NONE (r_prep) comparison_18\NN\635850|NONE (r_pobj) in_17\IN\13603305|of|increased (r_prep) risk_14\NN\14541044|NONE (r_pobj) with_12\IN\0|.|is|Initiating (r_prep) associated_11\VBN\628491|NONE (l_csubjpass) initiating_0\VBG\1617192|.|with|is (l_dobj) diabetes_5\NNS\14075199|treatment
-1_D003324 NONE sulphonylurea_8\JJ\0|of|initial (r_compound) treatment_9\NN\654885|NONE (r_pobj) with_6\IN\0|NONE (r_prep) associated_5\VBN\628491|artery|coronary (r_acl) disease_4\NN\14061805|NONE
-1_D003324 NONE sulphonylureas_25\NNS\0|NONE (r_pobj) with_23\IN\0| (r_prep) diabetes_22\NNS\14075199|disease (r_dobj) developing_8\VBG\13541167|NONE (l_dobj) disease_11\NN\14061805|diabetes
-1_D003324 NONE sulphonylureas_25\NNS\0|NONE (r_pobj) with_23\IN\0| (r_prep) diabetes_22\NNS\14075199|disease (r_dobj) developing_8\VBG\13541167|NONE (l_dobj) disease_11\NN\14061805|diabetes (l_appos) cad_13\NNP\10753546|artery|)|(|coronary|associated
D005905_D003324 CID glibenclamide_25\NN\0|NONE (r_pobj) with_24\IN\0|by (r_prep) increased_14\VBN\169651|initial (r_acl) treatment_13\NN\654885|NONE (r_pobj) with_11\IN\0|NONE (r_prep) associated_10\VBN\628491|fold|of|The|.|; (r_acl) hazard_1\NN\14541044|NONE (l_prep) of_2\IN\0|fold|associated|The|.|; (l_pcomp) developing_3\VBG\13541167|NONE (l_dobj) cad_4\NNP\10753546|NONE
D005905_D003324 CID glibenclamide_7\NN\0|NONE (r_pobj) with_6\IN\0| (r_prep) diabetes_5\NNS\14075199|treatment (r_dobj) initiating_0\VBG\1617192|.|with|is (r_csubjpass) associated_11\VBN\628491|NONE (l_prep) with_12\IN\0|.|is|Initiating (l_pobj) risk_14\NN\14541044|NONE (l_prep) of_15\IN\0|increased|in (l_pobj) cad_16\NNP\10753546|NONE
C057619_D003324 NONE glimepiride_22\NN\0|or (r_conj) gliclazide_20\VB\0|NONE (r_pobj) to_19\TO\0|NONE (r_prep) comparison_18\NN\635850|NONE (r_pobj) in_17\IN\13603305|of|increased (r_prep) risk_14\NN\14541044|NONE (l_prep) of_15\IN\0|increased|in (l_pobj) cad_16\NNP\10753546|NONE
D005913_D003924 NONE glipizide_9\NN\2719105|or (r_conj) glibenclamide_7\NN\0|NONE (r_pobj) with_6\IN\0| (r_prep) diabetes_5\NNS\14075199|treatment
D005905_D003924 NONE glibenclamide_7\NN\0|NONE (r_pobj) with_6\IN\0| (r_prep) diabetes_5\NNS\14075199|treatment
D008687_D003324 NONE metformin_53\NN\2719105|NONE (r_pobj) with_52\IN\0|NONE (r_prep) unchanged_51\JJ\0|NONE (r_acomp) was_50\VBD\0|.|P=.|and|;|)|.fold|,|with (r_conj) 2-fold_27\JJ\0|associated|of|The|.|; (r_appos) hazard_1\NN\14541044|NONE (l_prep) of_2\IN\0|fold|associated|The|.|; (l_pcomp) developing_3\VBG\13541167|NONE (l_dobj) cad_4\NNP\10753546|NONE
15627798
D005839_D005355 NONE gentamicin_3\NN\2716866|NONE (r_pobj) with_2\IN\0|NONE (r_prep) treated_1\VBN\2376958|NONE (r_acl) animals_0\NNS\4475|.|can|areas (r_nsubj) show_5\VB\429048|NONE (l_dobj) areas_7\NNS\8630985|.|can|Animals (l_prep) of_8\IN\0|residual|in (l_pobj) fibrosis_10\NN\14204950|NONE
D005839_D009395 CID gentamicin_12\NN\2716866|NONE (r_pobj) by_11\IN\0|NONE (r_agent) induced_10\VBN\1627355|tubulointerstitial (r_acl) nephritis_9\NN\14113228|.|Inhibition
D005839_D009395 CID gentamicin_15\NN\2716866|NONE (r_pobj) by_14\IN\0|NONE (r_agent) induced_13\VBN\1627355|that|nephritis|inhibition (r_advcl) attenuates_10\VBZ\224901|.|data (l_dobj) nephritis_12\NN\14113228|induced|that|inhibition
16731636
D007545_D006332 CID isoproterenol_1\NN\3740161| (r_npadvmod) induced_3\VBN\1627355|.|Enhanced|in|cardiac (r_amod) hypertrophy_5\NN\14365950|NONE
D007545_D006332 CID iso_4\NNP\0|NONE (r_compound) treatment_5\NN\654885|NONE (r_pobj) by_3\IN\0|hypertrophy (r_agent) induced_2\VBN\1627355|NONE (l_nsubj) hypertrophy_1\NN\14365950|by
6985498
D008733_D041881 NONE methoxyflurane_10\NN\0|developed (r_compound) anesthesia_11\NN\14034177|NONE (r_pobj) under_9\IN\0|for (r_prep) operated_5\VBN\2439501|A|old|. (l_prep) for_6\IN\0|under (l_pobj) cholecystitis_8\NN\14336539|NONE
D008733_D056486 CID methoxyflurane_8\NN\0|NONE (r_pobj) with_7\IN\0|NONE (r_prep) anesthesia_6\NN\14034177|NONE (r_pobj) after_5\IN\0|tubular|renal (r_prep) acidosis_4\NN\14204950|and|. (r_conj) hepatitis_0\NNP\14127211|NONE
D008733_D000141 CID methoxyflurane_8\NN\0|NONE (r_pobj) with_7\IN\0|NONE (r_prep) anesthesia_6\NN\14034177|NONE (r_pobj) after_5\IN\0|tubular|renal (r_prep) acidosis_4\NN\14204950|and|.
D008733_D000141 CID methoxyflurane_10\NN\0|developed (r_compound) anesthesia_11\NN\14034177|NONE (l_acl) developed_12\VBD\1753788|methoxyflurane (l_dobj) syndrome_17\NN\5870365|postoperatively (l_conj) acidosis_21\NN\14204950|a|insufficiency|and
D008733_D048550 NONE methoxyflurane_10\NN\0|developed (r_compound) anesthesia_11\NN\14034177|NONE (l_acl) developed_12\VBD\1753788|methoxyflurane (l_dobj) syndrome_17\NN\5870365|postoperatively
8819482
C082828_D023921 NONE cd-832_7\NNP\0|NONE (r_punct) ,_8\,\0|on|of|. (r_punct) effects_0\NNS\13245626|NONE (l_prep) on_9\IN\0|of|,|. (l_pobj) ischemia_14\NN\14195315|NONE (l_prep) in_15\IN\13603305|induced|myocardial (l_pobj) dogs_16\NNS\2083346|NONE (l_prep) with_17\IN\0|NONE (l_pobj) stenosis_20\NN\14204950|NONE
C082828_D023921 NONE cd-832_2\NNP\0|NONE (r_pobj) of_1\IN\0|on (r_prep) effects_0\NNS\13245626|ischemia|.|compared|in|were (r_nsubjpass) studied_10\VBN\0|NONE (l_prep) in_11\IN\13603305|Effects|ischemia|.|compared|were (l_pobj) dogs_12\NNS\2083346|NONE (l_prep) with_13\IN\0|NONE (l_pobj) stenosis_16\NN\14204950|NONE
D007545_D017202 CID isoproterenol_10\NN\3740161| (r_npadvmod) induced_12\VBN\1627355|in|myocardial (r_amod) ischemia_14\NN\14195315|NONE
D007545_D017202 CID isoproterenol_4\NN\3740161|NONE (r_pobj) on_3\IN\0|of (r_prep) effects_0\NNS\13245626|ischemia|.|compared|in|were (r_nsubjpass) studied_10\VBN\0|NONE (l_nsubjpass) ischemia_8\NN\14195315|Effects|.|compared|in|were
D007545_D017202 CID iso)-induced_6\VBN\0|myocardial (r_nmod) ischemia_8\NN\14195315|Effects|.|compared|in|were
D007545_D017202 CID iso_9\NN\0|with (r_compound) infusion_10\NN\14589223|NONE (r_pobj) during_8\IN\0|CD|that|and|ischemia|suggest (r_prep) improves_5\VBZ\126264|data|. (l_dobj) ischemia_7\NN\14195315|CD|that|during|and|suggest
D007545_D023921 NONE isoproterenol_10\NN\3740161| (r_npadvmod) induced_12\VBN\1627355|in|myocardial (r_amod) ischemia_14\NN\14195315|NONE (l_prep) in_15\IN\13603305|induced|myocardial (l_pobj) dogs_16\NNS\2083346|NONE (l_prep) with_17\IN\0|NONE (l_pobj) stenosis_20\NN\14204950|NONE
D007545_D023921 NONE isoproterenol_4\NN\3740161|NONE (r_pobj) on_3\IN\0|of (r_prep) effects_0\NNS\13245626|ischemia|.|compared|in|were (r_nsubjpass) studied_10\VBN\0|NONE (l_prep) in_11\IN\13603305|Effects|ischemia|.|compared|were (l_pobj) dogs_12\NNS\2083346|NONE (l_prep) with_13\IN\0|NONE (l_pobj) stenosis_16\NN\14204950|NONE
D007545_D023921 NONE iso)-induced_6\VBN\0|myocardial (r_nmod) ischemia_8\NN\14195315|Effects|.|compared|in|were (r_nsubjpass) studied_10\VBN\0|NONE (l_prep) in_11\IN\13603305|Effects|ischemia|.|compared|were (l_pobj) dogs_12\NNS\2083346|NONE (l_prep) with_13\IN\0|NONE (l_pobj) stenosis_16\NN\14204950|NONE
D007545_D023921 NONE iso_12\NNP\0|intracoronary (r_compound) infusion_13\NN\14589223|NONE (r_pobj) of_10\IN\0|min|min (r_prep) periods_9\NNS\13575869|rate|In|,|. (r_nsubj) increased_22\VBN\169651|NONE (l_prep) in_0\IN\13603305|rate|periods|,|. (l_pobj) presence_2\NN\13954253|NONE (l_prep) of_3\IN\0|the (l_pobj) stenosis_6\NN\14204950|NONE
D007545_D003251 NONE iso_3\NN\0|with (r_compound) infusion_4\NN\14589223|,|After|CD|doses|was (l_prep) with_5\IN\0|ISO (l_pobj) stenosis_6\NN\14204950|NONE
D007545_D003251 NONE iso_64\NN\0|with (r_compound) infusion_65\NN\14589223|NONE (l_prep) with_66\IN\0|ISO (l_pobj) stenosis_67\NN\14204950|NONE
D007545_D003251 NONE iso_60\NN\0|with (r_compound) infusion_61\NN\14589223|NONE (l_prep) with_62\IN\0|ISO (l_pobj) stenosis_63\NN\14204950|NONE
D007545_D003251 NONE iso_9\NN\0|with (r_compound) infusion_10\NN\14589223|NONE (l_prep) with_11\IN\0|ISO (l_pobj) stenosis_12\NN\14204950|NONE
D004110_D003251 NONE diltiazem_0\NNP\2938514|to|decrease|.|and|(|elevation|micrograms|also (r_nsubj) prevented_10\VBD\0|NONE (l_conj) elevation_40\NN\7445480|to|decrease|.|and|Diltiazem|(|micrograms|also (l_prep) from_41\IN\0|segment (l_prep) at_56\IN\14622893|mV|to (l_pobj) min_58\NN\15154774|NONE (l_prep) after_59\IN\0| (l_pobj) infusion_61\NN\14589223|NONE (l_prep) with_62\IN\0|ISO (l_pobj) stenosis_63\NN\14204950|NONE
D009543_D023921 NONE nifedipine_30\NN\2938514|NONE (r_pobj) for_29\IN\0|NONE (r_prep) those_28\DT\0|NONE (r_pobj) with_27\IN\0|were (r_prep) compared_26\VBN\644583|Effects|ischemia|.|in|were (r_prep) studied_10\VBN\0|NONE (l_prep) in_11\IN\13603305|Effects|ischemia|.|compared|were (l_pobj) dogs_12\NNS\2083346|NONE (l_prep) with_13\IN\0|NONE (l_pobj) stenosis_16\NN\14204950|NONE
C082828_D017202 NONE cd-832_7\NNP\0|NONE (r_punct) ,_8\,\0|on|of|. (r_punct) effects_0\NNS\13245626|NONE (l_prep) on_9\IN\0|of|,|. (l_pobj) ischemia_14\NN\14195315|NONE
C082828_D017202 NONE cd-832_2\NNP\0|NONE (r_pobj) of_1\IN\0|on (r_prep) effects_0\NNS\13245626|ischemia|.|compared|in|were (r_nsubjpass) studied_10\VBN\0|NONE (l_nsubjpass) ischemia_8\NN\14195315|Effects|.|compared|in|were
C082828_D017202 NONE cd-832_4\NNP\0|that|during|and|ischemia|suggest (r_nsubj) improves_5\VBZ\126264|data|. (l_dobj) ischemia_7\NN\14195315|CD|that|during|and|suggest
C082828_D017202 NONE cd-832_21\NNP\0|property|in|role|that (r_punct) plays_22\VBZ\7007684|NONE (r_ccomp) suggest_14\VBP\1010118|CD|that|during|and|ischemia (r_conj) improves_5\VBZ\126264|data|. (l_dobj) ischemia_7\NN\14195315|CD|that|during|and|suggest
C082828_D017202 NONE cd-832_31\NNP\0|NONE (r_pobj) of_30\IN\0|the|beneficial (r_prep) effects_29\NNS\13245626|NONE (r_pobj) in_26\IN\13603305|CD|property|role|that (r_prep) plays_22\VBZ\7007684|NONE (r_ccomp) suggest_14\VBP\1010118|CD|that|during|and|ischemia (r_conj) improves_5\VBZ\126264|data|. (l_dobj) ischemia_7\NN\14195315|CD|that|during|and|suggest
D009543_D017202 NONE nifedipine_30\NN\2938514|NONE (r_pobj) for_29\IN\0|NONE (r_prep) those_28\DT\0|NONE (r_pobj) with_27\IN\0|were (r_prep) compared_26\VBN\644583|Effects|ischemia|.|in|were (r_prep) studied_10\VBN\0|NONE (l_nsubjpass) ischemia_8\NN\14195315|Effects|.|compared|in|were
C082828_D003251 NONE cd-832_13\NNP\0|,|After|doses|was|infusion (r_punct) performed_8\VBN\0|NONE (l_nsubjpass) infusion_4\NN\14589223|,|After|CD|doses|was (l_prep) with_5\IN\0|ISO (l_pobj) stenosis_6\NN\14204950|NONE
C082828_D003251 NONE cd-832_5\NNP\0|and|decrease|In|elevation|.|, (r_nsubj) prevented_14\VBD\0|NONE (l_conj) elevation_44\NN\7445480|and|decrease|In|CD|.|, (l_prep) at_60\IN\14622893|from|to|segment (l_pobj) min_62\NN\15154774|NONE (l_prep) after_63\IN\0| (l_pobj) infusion_65\NN\14589223|NONE (l_prep) with_66\IN\0|ISO (l_pobj) stenosis_67\NN\14204950|NONE
C082828_D003251 NONE cd-832_4\NNP\0|that|during|and|ischemia|suggest (r_nsubj) improves_5\VBZ\126264|data|. (l_prep) during_8\IN\0|CD|that|and|ischemia|suggest (l_pobj) infusion_10\NN\14589223|NONE (l_prep) with_11\IN\0|ISO (l_pobj) stenosis_12\NN\14204950|NONE
C082828_D003251 NONE cd-832_21\NNP\0|property|in|role|that (r_punct) plays_22\VBZ\7007684|NONE (r_ccomp) suggest_14\VBP\1010118|CD|that|during|and|ischemia (r_conj) improves_5\VBZ\126264|data|. (l_prep) during_8\IN\0|CD|that|and|ischemia|suggest (l_pobj) infusion_10\NN\14589223|NONE (l_prep) with_11\IN\0|ISO (l_pobj) stenosis_12\NN\14204950|NONE
C082828_D003251 NONE cd-832_31\NNP\0|NONE (r_pobj) of_30\IN\0|the|beneficial (r_prep) effects_29\NNS\13245626|NONE (r_pobj) in_26\IN\13603305|CD|property|role|that (r_prep) plays_22\VBZ\7007684|NONE (r_ccomp) suggest_14\VBP\1010118|CD|that|during|and|ischemia (r_conj) improves_5\VBZ\126264|data|. (l_prep) during_8\IN\0|CD|that|and|ischemia|suggest (l_pobj) infusion_10\NN\14589223|NONE (l_prep) with_11\IN\0|ISO (l_pobj) stenosis_12\NN\14204950|NONE
D004110_D017202 NONE diltiazem_32\NN\2938514|or (r_conj) nifedipine_30\NN\2938514|NONE (r_pobj) for_29\IN\0|NONE (r_prep) those_28\DT\0|NONE (r_pobj) with_27\IN\0|were (r_prep) compared_26\VBN\644583|Effects|ischemia|.|in|were (r_prep) studied_10\VBN\0|NONE (l_nsubjpass) ischemia_8\NN\14195315|Effects|.|compared|in|were
D009543_D003251 NONE nifedipine_3\NN\2938514|NONE (r_pobj) to_2\IN\0|NONE (r_prep) contrast_1\NN\13854649|NONE (r_pobj) in_0\IN\13603305|and|decrease|CD|elevation|.|, (r_prep) prevented_14\VBD\0|NONE (l_conj) elevation_44\NN\7445480|and|decrease|In|CD|.|, (l_prep) at_60\IN\14622893|from|to|segment (l_pobj) min_62\NN\15154774|NONE (l_prep) after_63\IN\0| (l_pobj) infusion_65\NN\14589223|NONE (l_prep) with_66\IN\0|ISO (l_pobj) stenosis_67\NN\14204950|NONE
D002118_D023921 NONE calcium_4\NN\14625458|a|new|, (r_compound) antagonist_5\NN\7846|NONE (r_pobj) of_1\IN\0|on|,|. (r_prep) effects_0\NNS\13245626|NONE (l_prep) on_9\IN\0|of|,|. (l_pobj) ischemia_14\NN\14195315|NONE (l_prep) in_15\IN\13603305|induced|myocardial (l_pobj) dogs_16\NNS\2083346|NONE (l_prep) with_17\IN\0|NONE (l_pobj) stenosis_20\NN\14204950|NONE
D004110_D023921 NONE diltiazem_32\NN\2938514|or (r_conj) nifedipine_30\NN\2938514|NONE (r_pobj) for_29\IN\0|NONE (r_prep) those_28\DT\0|NONE (r_pobj) with_27\IN\0|were (r_prep) compared_26\VBN\644583|Effects|ischemia|.|in|were (r_prep) studied_10\VBN\0|NONE (l_prep) in_11\IN\13603305|Effects|ischemia|.|compared|were (l_pobj) dogs_12\NNS\2083346|NONE (l_prep) with_13\IN\0|NONE (l_pobj) stenosis_16\NN\14204950|NONE
D002118_D017202 NONE calcium_4\NN\14625458|a|new|, (r_compound) antagonist_5\NN\7846|NONE (r_pobj) of_1\IN\0|on|,|. (r_prep) effects_0\NNS\13245626|NONE (l_prep) on_9\IN\0|of|,|. (l_pobj) ischemia_14\NN\14195315|NONE
12165618
D019469_D015658 NONE indinavir_18\NNS\4013993|NONE (r_pobj) with_17\IN\0|NONE (r_prep) treated_16\VBN\2376958|infected (r_acl) children_15\NNS\9622049|.|leukocyturia|with|is (l_amod) 1-infected_14\VBN\0|treated
D019469_D015658 NONE indinavir_5\NNS\4013993| (r_npadvmod) related_7\VBN\628491|NONE (r_amod) nephrotoxicity_8\NN\0|in|to (r_dobj) monitor_4\VB\10676877|A|.|prospective (l_prep) in_9\IN\13603305|nephrotoxicity|to (l_pobj) cohort_11\NN\8184861|NONE (l_prep) of_12\IN\0|a (l_pobj) children_19\NNS\9622049|NONE (l_amod) 1-infected_18\VBN\0|treated|type
D019469_D015658 NONE indinavir_22\NNS\4013993|NONE (r_pobj) with_21\IN\0|NONE (r_prep) treated_20\VBN\2376958|type|infected (r_acl) children_19\NNS\9622049|NONE (l_amod) 1-infected_18\VBN\0|treated|type
D019469_-1 NONE indinavir_18\NNS\4013993|NONE (r_pobj) with_17\IN\0|NONE (r_prep) treated_16\VBN\2376958|infected (r_acl) children_15\NNS\9622049|.|leukocyturia|with|is (r_dobj) associated_4\VBN\628491|NONE (l_nsubjpass) leukocyturia_2\NN\0|.|with|children|is
D019469_-1 NONE indinavir_30\NNS\4013993|NONE (r_pobj) of_29\IN\0|a|serum|peak (r_prep) level_28\NN\4916342|/||mg|x|or|h (r_conj) l_21\NN\13616054|NONE (r_appos) >_17\XX\0|was|incidence|in (r_meta) found_8\VBN\13279262|NONE (l_nsubjpass) incidence_3\NN\13821570|was|in|> (l_prep) of_4\IN\0|higher|A|cumulative (l_pobj) leukocyturia_6\NN\0|NONE
D019469_-1 NONE indinavir_3\NNS\4013993|NONE (r_pobj) with_2\IN\0|Children (r_prep) treated_1\VBN\2376958|incidence|. (r_csubj) have_4\VBP\7846|NONE (l_dobj) incidence_8\NN\13821570|treated|. (l_prep) of_9\IN\0|a|high|cumulative (l_pobj) leukocyturia_12\NN\0|NONE
D019469_-1 NONE indinavir_0\NNP\4013993| (r_npadvmod) associated_2\VBN\628491|NONE (r_amod) nephrotoxicity_3\NN\0|in|be|,|closely|age|must (r_nsubjpass) monitored_6\VBN\2169352|NONE (l_prep) in_10\IN\13603305|be|,|nephrotoxicity|closely|age|must (l_pobj) children_11\NNS\9622049|especially (l_prep) with_12\IN\0|NONE (l_pobj) factors_14\NNS\7326557|NONE (l_prep) as_16\IN\14622893|risk (l_pobj) leukocyturia_19\NN\0|such
D019469_-1 NONE indinavir_32\NNS\4013993|NONE (r_pobj) of_31\IN\0|the (r_prep) curve_30\NN\13863771|NONE (r_pobj) under_28\IN\0|an (r_prep) area_27\NN\8630985|years|<|, (r_appos) age_21\NN\4916342|in|be|,|nephrotoxicity|closely|must (r_appos) monitored_6\VBN\2169352|NONE (l_prep) in_10\IN\13603305|be|,|nephrotoxicity|closely|age|must (l_pobj) children_11\NNS\9622049|especially (l_prep) with_12\IN\0|NONE (l_pobj) factors_14\NNS\7326557|NONE (l_prep) as_16\IN\14622893|risk (l_pobj) leukocyturia_19\NN\0|such
D003404_-1 NONE creatinine_15\NN\0|albumin (r_compound) ratio_16\NN\13815152|the (r_appos) urine_12\NN\14853947|by|and (r_pobj) in_10\IN\13603305|a|mild (r_prep) increase_9\NN\13576355|NONE (r_pobj) with_6\IN\0|frequently|.|was|leukocyturia (r_prep) associated_5\VBN\628491|NONE (l_nsubjpass) leukocyturia_2\NN\0|with|frequently|.|was
D003404_-1 NONE creatinine_9\JJ\0|serum|of (r_compound) levels_10\NNS\4916342|without|Children|.|frequently (r_dobj) had_7\VBD\0|NONE (l_nsubj) children_0\NNS\9622049|without|levels|.|frequently (l_prep) with_1\IN\0|NONE (l_pobj) leukocyturia_4\NN\0|NONE
D003404_-1 NONE creatinine_9\JJ\0|serum|of (r_compound) levels_10\NNS\4916342|without|Children|.|frequently (r_dobj) had_7\VBD\0|NONE (l_prep) without_19\IN\0|levels|Children|.|frequently (l_pobj) leukocyturia_22\NN\0|NONE
D003404_-1 NONE creatinine_4\NN\0|serum|the (r_compound) levels_5\NNS\4916342|Subsequently|,|,|returned (r_nsubj) decreased_6\VBD\169651|NONE (l_conj) returned_14\VBD\1835496|Subsequently|levels|,|, (l_conj) disappeared_21\VBD\0|,|to|ratios|and (l_nsubj) leukocyturia_20\NN\0|.|within
D003404_-1 NONE creatinine_12\NN\0|albumin|urine (r_compound) ratios_13\NNS\13815152|,|to|and|disappeared (r_nsubj) returned_14\VBD\1835496|Subsequently|levels|,|, (l_conj) disappeared_21\VBD\0|,|to|ratios|and (l_nsubj) leukocyturia_20\NN\0|.|within
D003404_-1 NONE creatinine_12\NN\0|serum|of (r_compound) levels_13\NNS\4916342|NONE (r_pobj) in_10\IN\13603305|above|an (r_prep) increase_9\NN\13576355|frequently|Children|. (r_dobj) had_7\VBD\0|NONE (l_nsubj) children_0\NNS\9622049|frequently|.|increase (l_prep) with_1\IN\0|NONE (l_pobj) leukocyturia_4\NN\0|NONE
D003404_D006417 NONE creatinine_15\NN\0|albumin (r_compound) ratio_16\NN\13815152|the (r_appos) urine_12\NN\14853947|by|and (r_pobj) in_10\IN\13603305|a|mild (l_conj) by_18\IN\0|and|urine (l_pobj) hematuria_20\NN\14299637|NONE
D019469_D007674 CID indinavir_18\NNS\4013993|NONE (r_pobj) with_17\IN\0|NONE (r_prep) treated_16\VBN\2376958|infected (r_acl) children_15\NNS\9622049|.|leukocyturia|with|is (r_dobj) associated_4\VBN\628491|NONE (l_prep) with_5\IN\0|.|leukocyturia|children|is (l_pobj) function_8\NN\13783581|NONE
D019469_D007674 CID indinavir_5\NNS\4013993| (r_npadvmod) related_7\VBN\628491|NONE (r_amod) nephrotoxicity_8\NN\0|in|to
D019469_D007674 CID indinavir_22\NNS\4013993|NONE (r_pobj) with_21\IN\0|NONE (r_prep) treated_20\VBN\2376958|type|infected (r_acl) children_19\NNS\9622049|NONE (r_pobj) of_12\IN\0|a (r_prep) cohort_11\NN\8184861|NONE (r_pobj) in_9\IN\13603305|nephrotoxicity|to (r_prep) monitor_4\VB\10676877|A|.|prospective (l_dobj) nephrotoxicity_8\NN\0|in|to
D019469_D007674 CID indinavir_4\NNS\4013993|was|In|.|of|, (r_nsubjpass) discontinued_6\VBN\0|NONE (l_prep) of_8\IN\0|was|In|.|,|indinavir (l_pobj) nephrotoxicity_9\NN\0|because
D019469_D007674 CID indinavir_0\NNP\4013993| (r_npadvmod) associated_2\VBN\628491|NONE (r_amod) nephrotoxicity_3\NN\0|in|be|,|closely|age|must
D019469_D007674 CID indinavir_32\NNS\4013993|NONE (r_pobj) of_31\IN\0|the (r_prep) curve_30\NN\13863771|NONE (r_pobj) under_28\IN\0|an (r_prep) area_27\NN\8630985|years|<|, (r_appos) age_21\NN\4916342|in|be|,|nephrotoxicity|closely|must (r_appos) monitored_6\VBN\2169352|NONE (l_nsubjpass) nephrotoxicity_3\NN\0|in|be|,|closely|age|must
16083708
D019980_D056486 CID clavulanate_2\NNP\0|out|.|as (r_nsubj) stands_3\VBZ\4359589|NONE (l_prep) as_5\IN\14622893|out|.|clavulanate (l_pobj) drug_9\NN\14778436|NONE (l_acl) related_10\VBN\628491|the|common (l_prep) to_11\IN\0|NONE (l_pobj) dili_12\NNP\0|NONE
D001663_D017114 NONE bilirubin_54\NN\14756039|CI|higher|plasma (r_compound) value_55\NN\5856066|)|,|P|and|< (r_conj) .009_47\CD\0|.|.|;|Factors|sex (r_appos) were_9\VBD\0|NONE (l_nsubj) factors_0\NNS\7326557|.|.|.|;|sex (l_acl) associated_1\VBN\628491|NONE (l_prep) with_2\IN\0|NONE (l_pobj) development_4\NN\248977|NONE (l_prep) of_5\IN\0|the (l_pobj) failure_8\NN\66216|NONE
23872883
D007545_D066126 CID isoproterenol_18\NN\3740161| (r_npadvmod) induced_20\VBN\1627355|in (r_amod) cardiotoxicity_21\NN\0|NONE
3833372
D013999_D006973 NONE maleate_23\NN\2718811|NONE (r_pobj) of_21\IN\0|mg||and (r_prep) mg_20\NN\13717155|NONE (r_dobj) containing_18\VBG\2632940|ratio|a|administered|, (r_acl) combination_17\NN\7951464|NONE (l_acl) administered_30\VBN\2436349|ratio|a|containing|, (l_prep) to_36\IN\0|daily|for (l_pobj) patients_38\NNS\9898892|NONE (l_amod) hypertensive_37\JJ\10405694|NONE
D006852_D006973 NONE hydrochlorothiazide_28\NN\4423288|NONE (r_pobj) of_27\IN\0| (r_prep) mg_26\NN\13717155|of||and (r_conj) mg_20\NN\13717155|NONE (r_dobj) containing_18\VBG\2632940|ratio|a|administered|, (r_acl) combination_17\NN\7951464|NONE (l_acl) administered_30\VBN\2436349|ratio|a|containing|, (l_prep) to_36\IN\0|daily|for (l_pobj) patients_38\NNS\9898892|NONE (l_amod) hypertensive_37\JJ\10405694|NONE
25041770
D017291_D012206 CID clarithromycin_9\NN\0|NONE (r_pobj) in_8\IN\13603305|simvastatin (r_prep) increment_7\NN\29677|NONE (r_pobj) with_3\IN\0|NONE (r_prep) association_2\NN\8008335|NONE (r_pobj) in_1\IN\13603305|. (r_prep) rhabdomyolysis_0\NNP\0|NONE
D017291_D012206 CID clarithromycin_17\NN\0|NONE (r_pobj) of_16\IN\0|the (r_prep) dose_15\NN\3740161|NONE (r_pobj) in_13\IN\13603305|an (r_prep) increase_12\NN\13576355|NONE (r_pobj) after_10\IN\0|only (r_prep) occurred_9\VBD\0|of|case|. (r_advcl) is_3\VBZ\0|NONE (l_prep) of_4\IN\0|occurred|case|. (l_pobj) interest_5\NN\5682570|NONE (l_prep) as_6\IN\14622893|NONE (l_pobj) rhabdomyolysis_7\NN\0|NONE
D019821_D012206 CID simvastatin_4\NN\3676175|in (r_nmod) increment_7\NN\29677|NONE (r_pobj) with_3\IN\0|NONE (r_prep) association_2\NN\8008335|NONE (r_pobj) in_1\IN\13603305|. (r_prep) rhabdomyolysis_0\NNP\0|NONE
D019821_D012206 CID statin_10\NN\3740161|NONE (r_pobj) with_9\IN\0|could|,|that|induced|be|warrant|elevation (r_prep) associated_8\VBN\628491|.|case (l_conj) induced_11\VBN\1627355|could|,|that|be|warrant|elevation|with (l_dobj) rhabdomyolysis_12\NN\0|NONE
11835460
D007980_D015835 CID levodopa_0\NNP\14604959|.||dyskinesias (r_npadvmod) induced_2\VBN\1627355|NONE (l_dobj) dyskinesias_4\NNS\14084880|.|Levodopa|
D007980_D015835 CID levodopa_0\NNP\14604959| (r_npadvmod) induced_2\VBN\1627355|ocular (r_amod) dyskinesias_4\NNS\14084880|.|uncommon
D007980_D015835 CID levodopa_17\NN\14604959|NONE (r_pobj) of_16\IN\0|the|peak (r_prep) effect_15\NN\34213|NONE (r_pobj) during_12\IN\0|We|,|and|on|hypothesize|. (r_prep) report_1\VBP\6470073|NONE (l_conj) hypothesize_20\VB\719734|We|,|during|and|on|. (l_ccomp) needed_31\VBN\0|NONE (l_prep) for_32\IN\0|that|denervation|is (l_pobj) appearance_34\NN\4723816|NONE (l_prep) of_35\IN\0|the (l_pobj) dyskinesias_41\NNS\14084880|NONE
D007980_D015835 CID levodopa_37\NN\14604959| (r_npadvmod) induce_39\VB\1627355|ocular|these (r_amod) dyskinesias_41\NNS\14084880|NONE
D007980_D010300 NONE levodopa_0\NNP\14604959|.||dyskinesias (r_npadvmod) induced_2\VBN\1627355|NONE (l_dobj) dyskinesias_4\NNS\14084880|.|Levodopa| (l_prep) in_5\IN\13603305|ocular (l_pobj) disease_8\NN\14061805|NONE
9759693
D018170_D017091 CID sumatriptan_3\JJ\0|NONE (r_amod) use_4\NN\407535|Ischemic|.|and (r_conj) colitis_1\NN\14336539|NONE
D018170_D017091 CID sumatriptan_18\NNP\0|NONE (r_pobj) with_17\IN\0|NONE (r_prep) treated_16\VBN\2376958|NONE (r_acl) migraine_15\NN\14326607|NONE (r_pobj) with_14\IN\0|NONE (r_prep) patients_13\NNS\9898892|NONE (r_pobj) in_12\IN\13603305|the|of (r_prep) development_4\NN\248977|NONE (l_prep) of_5\IN\0|the|in (l_pobj) cases_8\NNS\7283608|NONE (l_prep) of_9\IN\0|serious| (l_pobj) colitis_11\NN\14336539|NONE
D018170_D017202 NONE sumatriptan_16\JJ\0|NONE (r_compound) use_17\NN\407535|NONE (r_pobj) after_15\IN\0|NONE (r_prep) occurring_14\VBG\0|myocardial (r_acl) infarction_13\NN\14204950|myocardial|,|and (r_conj) ischemia_9\NN\14195315|coronary|,
D018170_D009203 NONE sumatriptan_16\JJ\0|NONE (r_compound) use_17\NN\407535|NONE (r_pobj) after_15\IN\0|NONE (r_prep) occurring_14\VBG\0|myocardial (r_acl) infarction_13\NN\14204950|myocardial|,|and
D018170_D008881 NONE sumatriptan_18\NNP\0|NONE (r_pobj) with_17\IN\0|NONE (r_prep) treated_16\VBN\2376958|NONE (r_acl) migraine_15\NN\14326607|NONE
D018170_D003329 NONE sumatriptan_16\JJ\0|NONE (r_compound) use_17\NN\407535|NONE (r_pobj) after_15\IN\0|NONE (r_prep) occurring_14\VBG\0|myocardial (r_acl) infarction_13\NN\14204950|myocardial|,|and (r_conj) ischemia_9\NN\14195315|coronary|, (r_conj) vasospasm_6\NN\0|NONE
9382023
D004280_D006973 CID dobutamine_3\NN\0|NONE (r_compound) stress_4\NN\7083732|NONE (r_compound) echocardiography_5\RB\177127|NONE (r_pobj) during_2\IN\0|Hypertensive|. (r_prep) response_1\NN\11410625|NONE (l_amod) hypertensive_0\JJ\10405694|during|.
D004280_D006973 CID dobutamine_2\NN\0|NONE (r_compound) stress_3\NN\7083732|NONE (r_compound) echocardiographic_4\JJ\0|, (r_amod) studies_5\NNS\635850|NONE (r_pobj) among_0\IN\0|,|or|a|,|hypertensive|defined (r_prep) response_9\NN\11410625|NONE (l_amod) hypertensive_8\JJ\10405694|,|or|a|,|Among|defined
D004280_D006973 CID dobutamine_20\NN\0|NONE (r_compound) infusion_21\NN\14589223|NONE (r_pobj) before_19\IN\0|BP (r_prep) had_12\VBD\0|.|often|history|Patients|and (r_conj) had_6\VBD\0|NONE (l_dobj) history_8\NN\15120823|.|had|often|Patients|and (l_prep) of_9\IN\0|a (l_pobj) hypertension_10\NN\14057371|NONE
9125676
D013015_D002311 NONE sotalol_32\NN\0|patients|prevent|. (r_dobj) received_26\VBD\2210855|NONE (l_nsubj) patients_4\NNS\9898892|prevent|.|sotalol (l_appos) 54_6\CD\0|with|consecutive|(|one (l_conj) 20_13\CD\13745420|and|,|with (l_prep) with_14\IN\0|) (l_pobj) cardiomyopathy_16\NN\14103288|NONE
D013015_D016171 CID sotalol_32\NN\0|d (r_pobj) with_27\IN\0|NONE (r_prep) treated_26\VBN\2376958|NONE (r_acl) patients_25\NNS\9898892|NONE (r_pobj) in_24\IN\13603305|torsades|de (r_prep) pointes_23\FW\831651|NONE (r_pobj) for_20\IN\0|risk|the|presumable (r_prep) factors_19\NNS\7326557|the|of|and|, (r_conj) incidence_9\NN\13821570|clinical|the|, (l_prep) of_10\IN\0|the|and|,|factors (l_pobj) pointes_13\FW\831651|NONE
D013015_D016171 CID sotalol_32\NN\0|d (r_pobj) with_27\IN\0|NONE (r_prep) treated_26\VBN\2376958|NONE (r_acl) patients_25\NNS\9898892|NONE (r_pobj) in_24\IN\13603305|torsades|de (r_prep) pointes_23\FW\831651|NONE
D013015_D016171 CID sotalol_21\NN\0|NONE (r_pobj) with_16\IN\0|initial|the|oral (r_prep) treatment_15\NN\654885|NONE (r_pobj) during_11\IN\0|patients|from|. (r_prep) had_6\VBD\0|NONE (l_prep) from_7\IN\0|patients|.|during (l_pobj) pointes_10\FW\831651|NONE
D013015_D016171 CID sotalol_10\NN\0|However|,|dose|,|.|lower|in (r_nsubj) was_11\VBD\0|NONE (l_prep) in_14\IN\13603305|However|sotalol|,|dose|,|.|lower (l_pobj) patients_15\NNS\9898892|NONE (l_prep) with_16\IN\0|NONE (l_pobj) pointes_19\FW\831651|NONE
D013015_D016171 CID sotalol_23\NN\0|NONE (r_pobj) with_18\IN\0|successful (r_prep) treatment_17\NN\654885|NONE (r_pobj) of_15\IN\0| (r_prep) years_14\NNS\15144371|NONE (r_pobj) after_12\IN\0|.|pointes|patient (r_prep) had_7\VBD\0|NONE (l_dobj) pointes_11\NNS\831651|.|patient|after
D013015_D016171 CID sotalol_17\NN\0|NONE (r_pobj) of_11\IN\0|low (r_prep) doses_10\NNS\3740161|even (r_pobj) with_8\IN\0|NONE (r_prep) treatment_6\NN\654885|NONE (r_pobj) during_5\IN\0|pointes|.|early (r_prep) occurred_3\VBD\0|NONE (l_nsubj) pointes_2\NNS\831651|during|.|early
D013015_D016171 CID sotalol_26\NN\0|d|.|might|subgroup|Pronounced|, (r_nsubj) identify_28\VB\699815|NONE (l_dobj) subgroup_30\NN\31264|sotalol|d|.|might|Pronounced|, (l_prep) of_31\IN\0|a (l_pobj) patients_32\NNS\9898892|NONE (l_prep) with_33\IN\0|NONE (l_pobj) risk_36\NN\14541044|NONE (l_prep) for_37\IN\0|an|increased (l_pobj) pointes_40\FW\831651|NONE
D013015_D016171 CID sotalol_11\NN\0|,|not|.|patients|did|parameters|at (r_nsubj) identify_14\VB\699815|NONE (l_prep) at_16\IN\14622893|,|not|.|sotalol|patients|did|parameters (l_pobj) risk_18\NN\14541044|NONE (l_prep) for_19\IN\0|increased (l_pobj) pointes_22\FW\831651|NONE
D013015_D014693 NONE sotalol_32\NN\0|patients|prevent|. (r_dobj) received_26\VBD\2210855|NONE (l_nsubj) patients_4\NNS\9898892|prevent|.|sotalol (l_prep) with_18\IN\0|consecutive|(|one| (l_pobj) tachycardia_22\NN\14110674|NONE (l_conj) fibrillation_25\NN\14361664|ventricular|or|sustained|inducible
D013015_D014693 NONE sotalol_8\NN\0|induction|in|, (r_nsubj) prevented_9\VBN\0|Those (l_dobj) induction_10\NN\7450842|in|,|sotalol (l_prep) of_11\IN\0|NONE (l_pobj) tachycardia_13\NN\14110674|NONE (l_conj) fibrillation_16\NN\14361664|ventricular|or
D013015_-1 NONE sotalol_11\NN\0|d (r_pobj) of_6\IN\0|the (r_prep) use_5\NN\407535|NONE (r_pobj) with_3\IN\0|NONE (r_prep) proarrhythmia_2\NN\0|and|.
D013015_D006331 NONE sotalol_23\NN\0|NONE (r_pobj) with_18\IN\0|successful (r_prep) treatment_17\NN\654885|NONE (r_pobj) of_15\IN\0| (r_prep) years_14\NNS\15144371|NONE (r_pobj) after_12\IN\0|.|pointes|patient (r_prep) had_7\VBD\0|NONE (l_nsubj) patient_2\NN\9898892|.|pointes|after (l_prep) with_3\IN\0|One|female (l_pobj) disease_6\NN\14061805|NONE
D013015_D003324 NONE sotalol_32\NN\0|patients|prevent|. (r_dobj) received_26\VBD\2210855|NONE (l_nsubj) patients_4\NNS\9898892|prevent|.|sotalol (l_appos) 54_6\CD\0|with|consecutive|(|one (l_prep) with_7\IN\0|and|,| (l_pobj) disease_10\NN\14061805|NONE
D013015_D017180 NONE sotalol_11\NN\0|d (l_prep) for_12\IN\0||,|l (l_pobj) tachyarrhythmias_15\NNS\0|NONE
D013015_D017180 NONE sotalol_32\NN\0|d (l_prep) for_33\IN\0||l|, (l_pobj) tachyarrhythmias_36\NNS\0|NONE
D013015_D017180 NONE sotalol_32\NN\0|patients|prevent|. (r_dobj) received_26\VBD\2210855|NONE (l_nsubj) patients_4\NNS\9898892|prevent|.|sotalol (l_prep) with_18\IN\0|consecutive|(|one| (l_pobj) tachycardia_22\NN\14110674|NONE
D013015_D017180 NONE sotalol_32\NN\0|patients|prevent|. (r_dobj) received_26\VBD\2210855|NONE (l_advcl) prevent_34\VB\0|patients|.|sotalol (l_dobj) induction_35\NN\7450842|to (l_prep) of_36\IN\0|NONE (l_pobj) tachyarrhythmia_39\NN\0|NONE
D013015_D017180 NONE sotalol_8\NN\0|induction|in|, (r_nsubj) prevented_9\VBN\0|Those (l_dobj) induction_10\NN\7450842|in|,|sotalol (l_prep) of_11\IN\0|NONE (l_pobj) tachycardia_13\NN\14110674|NONE
D013015_D017180 NONE sotalol_13\NN\0|,|in|inducible|d|;|tachyarrhythmia (r_dep) remained_25\VBD\2604760|;|by|Induction|was|and|tolerate (r_conj) prevented_6\VBN\0|NONE (l_nsubjpass) induction_0\NN\7450842|;|by|remained|was|and|tolerate (l_prep) of_1\IN\0|NONE (l_pobj) tachyarrhythmia_4\NN\0|NONE
D013015_D017180 NONE sotalol_13\NN\0|,|in|inducible|d|;|tachyarrhythmia (r_dep) remained_25\VBD\2604760|;|by|Induction|was|and|tolerate (l_nsubj) tachyarrhythmia_24\NN\0|,|sotalol|in|inducible|d|;
D013015_D017180 NONE sotalol_53\NN\0|d (r_pobj) of_48\IN\0| (r_prep) mg_47\NN\13717155|not|patients|did|daily|. (r_dobj) tolerate_44\VB\802318|;|by|Induction|remained|was|and (r_conj) prevented_6\VBN\0|NONE (l_nsubjpass) induction_0\NN\7450842|;|by|remained|was|and|tolerate (l_prep) of_1\IN\0|NONE (l_pobj) tachyarrhythmia_4\NN\0|NONE
D013015_D017180 NONE sotalol_53\NN\0|d (r_pobj) of_48\IN\0| (r_prep) mg_47\NN\13717155|not|patients|did|daily|. (r_dobj) tolerate_44\VB\802318|;|by|Induction|remained|was|and (r_conj) prevented_6\VBN\0|NONE (l_conj) remained_25\VBD\2604760|;|by|Induction|was|and|tolerate (l_nsubj) tachyarrhythmia_24\NN\0|,|sotalol|in|inducible|d|;
1735570
D014294_D007022 CID trimethaphan_1\RB\0| (r_npadvmod) induced_3\VBN\1627355|The (r_amod) hypotension_4\NN\14057371|was|.|by
D014294_D001919 NONE trimethaphan_1\RB\0| (r_npadvmod) induced_3\VBN\1627355|The (r_amod) hypotension_4\NN\14057371|was|.|by (r_nsubjpass) accompanied_6\VBN\0|NONE (l_agent) by_7\IN\0|was|.|hypotension (l_pobj) bradycardia_10\NN\14110674|NONE
D014294_D013610 CID trimethaphan_1\RB\0| (r_npadvmod) induced_3\VBN\1627355|The (r_amod) hypotension_4\NN\14057371|was|.|by (r_nsubjpass) accompanied_6\VBN\0|NONE (l_agent) by_7\IN\0|was|.|hypotension (l_pobj) bradycardia_10\NN\14110674|NONE (l_prep) in_11\IN\13603305|a|significant (l_pobj) rats_13\NNS\2329401|NONE (l_appos) beats_18\NNS\8289449|(||lesioned (l_conj) tachycardia_24\NN\14110674|per|+/||but|)
20169779
D007980_D001523 NONE levodopa_1\RB\14604959| (r_npadvmod) treated_3\VBN\2376958|The|lesioned (r_amod) marmoset_7\NN\2489589|as|.|was (r_nsubjpass) used_9\VBN\0|NONE (l_prep) as_10\IN\14622893|.|marmoset|was (l_pobj) model_12\NN\5888929|NONE (l_prep) of_13\IN\0|a (l_pobj) symptoms_15\NNS\5823932|NONE
D007980_D001523 NONE levodopa_7\NN\14604959| (r_npadvmod) induced_9\VBN\1627355|behaviors|motor|and (r_amod) fluctuations_11\NNS\7345593|NONE (l_conj) behaviors_16\NNS\407535|motor|induced|and
D007980_D001523 NONE levodopa_27\VB\14604959|NONE (r_pobj) to_26\IN\0|and|on|)|( (r_prep) prior_25\RB\10675876|analysis|,|blind (r_advmod) hoc_45\FW\0|for|were|Animals|on|. (r_prep) evaluated_2\VBN\670261|NONE (l_prep) for_3\IN\0|hoc|were|Animals|on|. (l_pobj) disability_5\NN\14547369|NONE (l_conj) dyskinesia_7\JJ\14084880|,|parkinsonian (l_conj) behaviors_20\NNS\407535|(|on|fluctuations|and|and|)
D007980_D001523 NONE levodopa_3\RB\14604959| (r_npadvmod) induced_5\VBN\1627355|like (r_amod) behaviors_9\NNS\407535|and|present|,|In|correlate
D007980_D001523 NONE levodopa_16\JJ\14604959|NONE (r_compound) treatment_17\NN\654885|NONE (r_pobj) of_15\IN\0|NONE (r_prep) 1_14\CD\13741022|NONE (r_nummod) day_13\NN\15154774|NONE (r_pobj) on_12\IN\0|NONE (r_prep) present_11\JJ\28270|and|,|In|behaviors|correlate (r_acomp) were_10\VBD\0|NONE (l_nsubj) behaviors_9\NNS\407535|and|present|,|In|correlate
D007980_D001523 NONE levodopa_14\NN\14604959|NONE (r_pobj) between_13\IN\0|than|an (r_prep) interaction_12\NN\37396|likely|that|therapy|disorders (r_attr) are_8\VBP\13600404|data|. (l_nsubj) disorders_5\NNS\14034177|likely|that|interaction|therapy
D015632_D001523 NONE mptp_4\NNP\0| (r_npadvmod) lesioned_6\VBN\0|The|treated (r_amod) marmoset_7\NN\2489589|as|.|was (r_nsubjpass) used_9\VBN\0|NONE (l_prep) as_10\IN\14622893|.|marmoset|was (l_pobj) model_12\NN\5888929|NONE (l_prep) of_13\IN\0|a (l_pobj) symptoms_15\NNS\5823932|NONE
D015632_D010302 NONE mptp_4\NNP\0|the|of|marmoset (r_nmod) model_6\NN\5888929|NONE (l_prep) of_7\IN\0|MPTP|the|marmoset (l_pobj) disease_10\NN\14061805|NONE
D015632_D010302 NONE mptp_4\NNP\0| (r_npadvmod) lesioned_6\VBN\0|The|treated (r_amod) marmoset_7\NN\2489589|as|.|was (r_nsubjpass) used_9\VBN\0|NONE (l_prep) as_10\IN\14622893|.|marmoset|was (l_pobj) model_12\NN\5888929|NONE (l_prep) of_13\IN\0|a (l_pobj) symptoms_15\NNS\5823932|NONE (l_prep) in_16\IN\13603305|neuropsychiatric (l_pobj) patients_18\NNS\9898892|NONE (l_compound) pd_17\NNP\14625458|NONE
D015632_D010302 NONE 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine_3\CD\0|)|were|for|.|Marmosets|s.c.|resulting|, (r_oprd) administered_2\VBN\2436349|NONE (l_advcl) resulting_13\VBG\2633881|)|were|methylphenyl,,,tetrahydropyridine|for|.|Marmosets|s.c.|, (l_prep) in_14\IN\13603305|NONE (l_pobj) parkinsonism_16\NN\14085708|NONE
D007980_D020734 NONE levodopa_27\VB\14604959|NONE (r_pobj) to_26\IN\0|and|on|)|( (r_prep) prior_25\RB\10675876|analysis|,|blind (r_advmod) hoc_45\FW\0|for|were|Animals|on|. (r_prep) evaluated_2\VBN\670261|NONE (l_prep) for_3\IN\0|hoc|were|Animals|on|. (l_pobj) disability_5\NN\14547369|NONE
D007980_D004409 CID levodopa_27\VB\14604959|NONE (r_pobj) to_26\IN\0|and|on|)|( (r_prep) prior_25\RB\10675876|analysis|,|blind (r_advmod) hoc_45\FW\0|for|were|Animals|on|. (r_prep) evaluated_2\VBN\670261|NONE (l_prep) for_3\IN\0|hoc|were|Animals|on|. (l_pobj) disability_5\NN\14547369|NONE (l_conj) dyskinesia_7\JJ\14084880|,|parkinsonian
D007980_D004409 CID levodopa_9\NN\14604959| (r_npadvmod) induced_11\VBN\1627355|dyskinesia|,|motor (r_amod) fluctuations_13\NNS\7345593|NONE (l_conj) dyskinesia_15\JJ\14084880|induced|,|motor
D007980_D004409 CID levodopa_27\NN\14604959|NONE (r_compound) therapy_28\NN\657604|NONE (r_pobj) of_26\IN\0|the (r_prep) duration_25\NN\15113229|NONE (r_pobj) with_23\IN\0|that (r_prep) correlated_22\VBD\2657219|in|a|progressive (r_relcl) increase_7\NN\13576355|anticipated|,|.|,|animals (l_prep) in_8\IN\13603305|correlated|a|progressive (l_pobj) fluctuations_13\NNS\7345593|NONE (l_conj) dyskinesia_15\JJ\14084880|induced|,|motor
D007980_D010302 NONE levodopa_1\RB\14604959| (r_npadvmod) treated_3\VBN\2376958|The|lesioned (r_amod) marmoset_7\NN\2489589|as|.|was (r_nsubjpass) used_9\VBN\0|NONE (l_prep) as_10\IN\14622893|.|marmoset|was (l_pobj) model_12\NN\5888929|NONE (l_prep) of_13\IN\0|a (l_pobj) symptoms_15\NNS\5823932|NONE (l_prep) in_16\IN\13603305|neuropsychiatric (l_pobj) patients_18\NNS\9898892|NONE (l_compound) pd_17\NNP\14625458|NONE
D007980_D010302 NONE levodopa_14\NN\14604959|NONE (r_pobj) between_13\IN\0|than|an (r_prep) interaction_12\NN\37396|likely|that|therapy|disorders (r_attr) are_8\VBP\13600404|data|. (l_nsubj) disorders_5\NNS\14034177|likely|that|interaction|therapy (l_prep) in_6\IN\13603305|neuropsychiatric (l_pobj) pd_7\NNP\14625458|NONE
24641119
D007654_-1 NONE ketoconazole_4\NN\0|NONE (r_pobj) by_3\IN\0|.|syndrome (r_prep) induced_2\VBN\1627355|NONE (l_nsubj) syndrome_1\NN\5870365|.|by
D007654_-1 NONE ketoconazole_21\NN\0|NONE (r_pobj) to_19\IN\0|prior (r_prep) sensitivity_18\NN\5651971|which (r_dobj) included_16\VBD\0|,|his (r_relcl) history_13\NN\15120823|NONE (r_pobj) on_11\IN\0|NONE (r_prep) based_10\VBN\0|baboon|induced (r_acl) syndrome_9\NN\5870365|NONE
D007654_-1 NONE ketoconazole_14\RB\0| (r_npadvmod) induced_16\VBN\1627355|in|baboon (r_amod) syndrome_18\NN\5870365|NONE
D007654_D003875 CID ketoconazole_20\RB\0|NONE (r_dobj) using_18\VBG\418025|NONE (r_pcomp) after_17\IN\0|.|patient|with (r_prep) presented_6\VBN\2137132|NONE (l_prep) with_7\IN\0|after|.|patient (l_pobj) eruption_10\NN\7307754|NONE
24840785
D002118_D011041 NONE ca(2_10\NNP\0|NONE (r_pobj) of_9\IN\0|the (r_prep) role_8\NN\719494|NONE (r_pobj) on_6\IN\0|NONE (r_prep) available_5\JJ\0|However|)|in|reports|.|+|, (r_acomp) are_4\VBP\13600404|NONE (l_prep) in_13\IN\13603305|However|)|available|reports|.|+|, (l_pobj) poisoning_15\NN\14034177|NONE
D002118_D011041 NONE ca(2_10\NNP\0|NONE (r_pobj) of_8\IN\0|the (r_prep) importance_7\NN\5138488|,|.|signaling|In|we|) (r_dobj) explored_5\VBD\789138|NONE (l_advcl) signaling_13\NN\33020|,|.|importance|In|we|) (l_prep) in_14\IN\13603305|in (l_pobj) poisoning_16\NN\14034177|NONE
D000157_D011041 CID aconitine_14\NN\0|NONE (r_compound) poisoning_15\NN\14034177|NONE
D000157_D011041 CID aconitine_15\NN\0|NONE (r_compound) poisoning_16\NN\14034177|NONE
D012964_D066126 NONE na(+_7\NN\0|voltage| (r_cc) dependent_6\JJ\9627906|) (r_nmod) channels_9\NNS\6251781|that|in|roles (r_nsubj) have_10\VBP\7846|evidence|. (l_prep) in_13\IN\13603305|channels|that|roles (l_pobj) cardiotoxicity_15\NN\0|NONE
D000157_D064420 NONE aconitine_4\NN\0|NONE (r_pobj) of_3\IN\0|on (r_prep) effects_2\NNS\13245626|To (r_dobj) investigate_1\VB\644583|assay|.|we|, (r_advcl) performed_10\VBD\0|NONE (l_dobj) assay_12\NN\5733583|.|we|investigate|, (l_compound) cytotoxicity_11\NN\13583478|level|as|in|,
D002118_D001145 NONE ca2_3\NN\0|and|apoptosis|arrhythmia|. (r_nsubj) causes_6\NNS\7323922|NONE (l_dobj) arrhythmia_7\NN\14103288|Ca|and|apoptosis|.
D002118_D001145 NONE ca(2_3\NNP\0|accelerated|caused|that|and (r_nsubj) lead_7\NN\5155821|.|We (l_conj) caused_18\VBD\1617192|accelerated|Ca(|that|and (l_dobj) arrhythmia_19\NN\14103288|in
D002118_D001145 NONE ca(2_9\NNP\0|causes|)|and (r_nmod) overload_12\NN\3679986|and|significantly|aconitine|promotes (l_conj) causes_14\VBZ\7323922|)|and|Ca( (l_dobj) arrhythmia_15\NN\14103288|NONE
D019344_D064420 NONE lactate_26\NN\14850483|NONE (r_compound) dehydrogenase_27\NN\0|measured|in (r_compound) level_28\NN\4916342|as|in|cytotoxicity|, (r_conj) assay_12\NN\5733583|.|we|investigate|, (l_compound) cytotoxicity_11\NN\13583478|level|as|in|,
D019344_D009202 NONE lactate_26\NN\14850483|NONE (r_compound) dehydrogenase_27\NN\0|measured|in (r_compound) level_28\NN\4916342|as|in|cytotoxicity|, (r_conj) assay_12\NN\5733583|.|we|investigate|, (r_dobj) performed_10\VBD\0|NONE (l_advcl) investigate_1\VB\644583|assay|.|we|, (l_dobj) effects_2\NNS\13245626|To (l_prep) on_5\IN\0|of (l_pobj) injury_7\NN\14052046|NONE
D000157_D001145 CID aconitine_0\NNP\0| (r_npadvmod) induced_2\VBN\1627355|+|overload (r_amod) ca2_3\NN\0|and|apoptosis|arrhythmia|. (r_nsubj) causes_6\NNS\7323922|NONE (l_dobj) arrhythmia_7\NN\14103288|Ca|and|apoptosis|.
D000157_D001145 CID aconitine_6\NN\0|and|significantly|promotes|overload (r_nsubj) aggravates_8\VBZ\126264|Hence|,|results|. (l_dobj) overload_12\NN\3679986|and|significantly|aconitine|promotes (l_conj) causes_14\VBZ\7323922|)|and|Ca( (l_dobj) arrhythmia_15\NN\14103288|NONE
D000157_D066126 CID aconitine_17\NN\0|NONE (r_pobj) of_16\IN\0|the (r_prep) cardiotoxicity_15\NN\0|NONE
D000157_D009202 NONE aconitine_4\NN\0|NONE (r_pobj) of_3\IN\0|on (r_prep) effects_2\NNS\13245626|To (l_prep) on_5\IN\0|of (l_pobj) injury_7\NN\14052046|NONE
D000157_D009202 NONE aconitine_4\NN\0|that|and|in|reduced (r_nsubj) resulted_5\VBD\2633881|.|results (l_prep) in_6\IN\13603305|that|aconitine|and|reduced (l_pobj) injury_8\NN\14052046|NONE
24975837
D014508_D058186 NONE urea_33\NN\14727670|and (r_conj) creatinine_31\NN\0|NONE (r_pobj) of_30\IN\0|serum (r_prep) levels_29\NNS\4916342|increase|, (r_dobj) augment_27\VBP\153263|,|drug|however|adopted|;|injury|can|,|.|due (r_conj) induce_14\VB\1627355|NONE (l_dobj) injury_17\NN\14052046|,|drug|however|adopted|;|augment|can|,|.|due
D002945_D007674 NONE cisplatin_15\NN\0|NONE (r_amod) therapy_16\NN\657604|NONE (r_pobj) by_14\IN\0|NONE (r_agent) induced_13\VBN\1627355|NONE (r_acl) nephrotoxicity_12\NN\0|NONE
D003404_D007683 NONE creatinine_31\NN\0|NONE (r_pobj) of_30\IN\0|serum (r_prep) levels_29\NNS\4916342|increase|, (r_dobj) augment_27\VBP\153263|,|drug|however|adopted|;|injury|can|,|.|due (l_conj) increase_35\VB\13576355|levels|, (l_dobj) score_40\NN\5736149|NONE (l_compound) necrosis_39\NN\11444117|and|acute|tubular|the|cytokines
D003404_D058186 NONE creatinine_31\NN\0|NONE (r_pobj) of_30\IN\0|serum (r_prep) levels_29\NNS\4916342|increase|, (r_dobj) augment_27\VBP\153263|,|drug|however|adopted|;|injury|can|,|.|due (r_conj) induce_14\VB\1627355|NONE (l_dobj) injury_17\NN\14052046|,|drug|however|adopted|;|augment|can|,|.|due
D002945_D058186 CID cisplatin_7\RB\0| (r_npadvmod) induced_9\VBN\1627355|acute|renal (r_amod) injury_12\NN\14052046|deletion|.
D002945_D058186 CID cisplatin_0\NNP\0|NONE (r_compound) treatment_1\NN\654885|has|in|been (r_nsubjpass) adopted_4\VBN\674607|,|drug|however|;|augment|injury|can|,|.|due (r_ccomp) induce_14\VB\1627355|NONE (l_dobj) injury_17\NN\14052046|,|drug|however|adopted|;|augment|can|,|.|due
D002945_D058186 CID cisplatin_10\NN\0| (r_advmod) induced_12\VBN\1627355|acute|kidney (r_amod) injury_15\NN\14052046|NONE
D002945_D058186 CID cisplatin_25\NN\0|NONE (r_pobj) with_24\IN\0|examine|were|.|mice (r_prep) challenged_23\VBN\869596|NONE (l_advcl) examine_1\VB\0|with|were|.|mice (l_dobj) role_3\NN\719494|To (l_prep) of_4\IN\0|the (l_pobj) kinin_6\NN\14744841|NONE (l_appos) receptor_8\NN\5225602|kinin|the|, (l_prep) in_9\IN\13603305|B (l_pobj) injury_15\NN\14052046|NONE
D002945_D058186 CID cisplatin_13\NN\0| (r_advmod) induced_15\VBN\1627355|kidney|acute (r_amod) injury_18\NN\14052046|NONE
D002945_D007683 CID cisplatin_0\NNP\0|NONE (r_compound) treatment_1\NN\654885|has|in|been (r_nsubjpass) adopted_4\VBN\674607|,|drug|however|;|augment|injury|can|,|.|due (r_ccomp) induce_14\VB\1627355|NONE (l_conj) augment_27\VBP\153263|,|drug|however|adopted|;|injury|can|,|.|due (l_conj) increase_35\VB\13576355|levels|, (l_dobj) score_40\NN\5736149|NONE (l_compound) necrosis_39\NN\11444117|and|acute|tubular|the|cytokines
D014508_D007683 NONE urea_33\NN\14727670|and (r_conj) creatinine_31\NN\0|NONE (r_pobj) of_30\IN\0|serum (r_prep) levels_29\NNS\4916342|increase|, (r_dobj) augment_27\VBP\153263|,|drug|however|adopted|;|injury|can|,|.|due (l_conj) increase_35\VB\13576355|levels|, (l_dobj) score_40\NN\5736149|NONE (l_compound) necrosis_39\NN\11444117|and|acute|tubular|the|cytokines
D002945_D009336 NONE cisplatin_13\NN\0| (r_advmod) induced_15\VBN\1627355|kidney|acute (r_amod) injury_18\NN\14052046|NONE (r_pobj) in_12\IN\13603305|kinin|is|by|that (r_prep) involved_11\VBN\2676054|Thus|data|,|. (l_prep) by_19\IN\0|kinin|is|in|that (l_pcomp) mediating_20\VBG\761713|NONE (l_dobj) process_23\NN\407535|resulting|, (l_amod) necrotic_22\JJ\0|expression|and|the
1556529
D015215_D056486 CID zidovudine_0\RB\3834836| (r_npadvmod) induced_2\VBN\1627355|. (r_amod) hepatitis_3\NN\14127211|NONE
D015215_D056486 CID zidovudine_7\NNP\3834836|NONE (r_pobj) by_6\IN\0|in (r_agent) induced_5\VBN\1627355|of|A (r_acl) case_1\NN\7283608|.|is (l_prep) of_2\IN\0|induced|A (l_pobj) hepatitis_4\NN\14127211|NONE
D015215_D000163 NONE zidovudine_7\NNP\3834836|NONE (r_pobj) by_6\IN\0|in (r_agent) induced_5\VBN\1627355|of|A (l_prep) in_8\IN\13603305|by (l_pobj) patient_13\NN\9898892|NONE (l_prep) with_14\IN\0|old|a (l_pobj) aids_15\NNP\13974317|NONE
8667442
D009853_D051437 NONE omeprazole_9\NN\14778019|)|, (r_conj) blockers_7\NNS\10101634|H|current|ulcer|( (r_conj) therapy_4\NN\657604|Although (r_pobj) with_1\IN\0|has|significantly|,|,|frequency (r_advcl) decreased_23\VBN\169651|.|hallmark|triad (r_ccomp) remains_37\VBZ\2684|NONE (l_nsubj) triad_28\NN\13741022|.|hallmark|decreased (l_prep) of_29\IN\0|the|classic (l_pobj) hypercalcemia_30\NN\14299637|NONE (l_conj) alkalosis_32\NN\14204950|, (l_conj) impairment_36\NN\7296428|and|,
D002118_D010437 NONE calcium_24\NN\14625458|NONE (r_pobj) of_23\IN\0|large (r_prep) amounts_22\NNS\13329641|NONE (r_pobj) with_20\IN\0|of|the (r_prep) treatment_15\NN\654885|NONE (l_prep) of_16\IN\0|the|with (l_pobj) disease_19\NN\14061805|NONE
D013392_D014456 NONE sucralfate_12\JJ\3740161|and|, (r_conj) omeprazole_9\NN\14778019|)|, (r_conj) blockers_7\NNS\10101634|H|current|ulcer|( (r_conj) therapy_4\NN\657604|Although (l_compound) ulcer_3\NN\14211294|blockers|H|current|(
D002118_D006934 CID calcium_24\NN\14625458|NONE (r_pobj) of_23\IN\0|large (r_prep) amounts_22\NNS\13329641|NONE (r_pobj) with_20\IN\0|of|the (r_prep) treatment_15\NN\654885|NONE (r_pobj) of_13\IN\0|the (r_prep) context_12\NN\6284777|NONE (r_pobj) in_10\IN\13603305|was|syndrome|ago|first|. (r_prep) described_6\VBN\1001294|NONE (l_nsubjpass) syndrome_3\NN\5870365|was|ago|first|.|in
D009853_D000471 NONE omeprazole_9\NN\14778019|)|, (r_conj) blockers_7\NNS\10101634|H|current|ulcer|( (r_conj) therapy_4\NN\657604|Although (r_pobj) with_1\IN\0|has|significantly|,|,|frequency (r_advcl) decreased_23\VBN\169651|.|hallmark|triad (r_ccomp) remains_37\VBZ\2684|NONE (l_nsubj) triad_28\NN\13741022|.|hallmark|decreased (l_prep) of_29\IN\0|the|classic (l_pobj) hypercalcemia_30\NN\14299637|NONE (l_conj) alkalosis_32\NN\14204950|,
D013392_D000471 NONE sucralfate_12\JJ\3740161|and|, (r_conj) omeprazole_9\NN\14778019|)|, (r_conj) blockers_7\NNS\10101634|H|current|ulcer|( (r_conj) therapy_4\NN\657604|Although (r_pobj) with_1\IN\0|has|significantly|,|,|frequency (r_advcl) decreased_23\VBN\169651|.|hallmark|triad (r_ccomp) remains_37\VBZ\2684|NONE (l_nsubj) triad_28\NN\13741022|.|hallmark|decreased (l_prep) of_29\IN\0|the|classic (l_pobj) hypercalcemia_30\NN\14299637|NONE (l_conj) alkalosis_32\NN\14204950|,
D002119_D007011 NONE carbonate_12\NN\15010703|NONE (r_pobj) with_10\IN\0|resulting|was|who (r_prep) treated_9\VBN\2376958|NONE (r_relcl) hypoparathyroidism_6\NN\14059928|NONE
D009853_D006934 NONE omeprazole_9\NN\14778019|)|, (r_conj) blockers_7\NNS\10101634|H|current|ulcer|( (r_conj) therapy_4\NN\657604|Although (r_pobj) with_1\IN\0|has|significantly|,|,|frequency (r_advcl) decreased_23\VBN\169651|.|hallmark|triad (l_nsubj) frequency_16\NN\15286249|has|significantly|,|with|, (l_prep) of_17\IN\0|the (l_pobj) syndrome_21\NN\5870365|NONE
D009853_D006934 NONE omeprazole_9\NN\14778019|)|, (r_conj) blockers_7\NNS\10101634|H|current|ulcer|( (r_conj) therapy_4\NN\657604|Although (r_pobj) with_1\IN\0|has|significantly|,|,|frequency (r_advcl) decreased_23\VBN\169651|.|hallmark|triad (r_ccomp) remains_37\VBZ\2684|NONE (l_nsubj) triad_28\NN\13741022|.|hallmark|decreased (l_prep) of_29\IN\0|the|classic (l_pobj) hypercalcemia_30\NN\14299637|NONE
C019248_D006934 NONE pamidronate_3\NN\0|.|This (l_advcl) presents_14\VBZ\28270|as|intravenous (l_nsubj) syndrome_13\NN\5870365|as|when
C019248_D006934 NONE pamidronate_3\NN\0|.|This (l_advcl) presents_14\VBZ\28270|as|intravenous (l_prep) as_15\IN\14622893|when|syndrome (l_pobj) emergency_17\NN\7417644|NONE
D002119_D006934 CID carbonate_12\NN\15010703|NONE (r_pobj) with_10\IN\0|resulting|was|who (r_prep) treated_9\VBN\2376958|NONE (l_advcl) resulting_15\VBG\2633881|was|with|who (l_prep) in_16\IN\13603305|NONE (l_pobj) admissions_18\NNS\49003|NONE (l_prep) for_22\IN\0|to|two (l_pobj) syndrome_26\NN\5870365|NONE
D002117_D006934 CID 1,25(oh)2d_6\CD\0|NONE (r_pobj) by_5\IN\0|in (r_agent) induced_4\VBN\1627355|alkali|. (r_acl) syndrome_3\NN\5870365|NONE
D002117_D006934 CID calcitriol_14\NN\0|calcium|and (r_conj) carbonate_12\NN\15010703|NONE (r_pobj) with_10\IN\0|resulting|was|who (r_prep) treated_9\VBN\2376958|NONE (l_advcl) resulting_15\VBG\2633881|was|with|who (l_prep) in_16\IN\13603305|NONE (l_pobj) admissions_18\NNS\49003|NONE (l_prep) for_22\IN\0|to|two (l_pobj) syndrome_26\NN\5870365|NONE
D000468_D006934 CID alkali_26\NN\14818238|and (r_conj) calcium_24\NN\14625458|NONE (r_pobj) of_23\IN\0|large (r_prep) amounts_22\NNS\13329641|NONE (r_pobj) with_20\IN\0|of|the (r_prep) treatment_15\NN\654885|NONE (r_pobj) of_13\IN\0|the (r_prep) context_12\NN\6284777|NONE (r_pobj) in_10\IN\13603305|was|syndrome|ago|first|. (r_prep) described_6\VBN\1001294|NONE (l_nsubjpass) syndrome_3\NN\5870365|was|ago|first|.|in
D013392_D006934 NONE sucralfate_12\JJ\3740161|and|, (r_conj) omeprazole_9\NN\14778019|)|, (r_conj) blockers_7\NNS\10101634|H|current|ulcer|( (r_conj) therapy_4\NN\657604|Although (r_pobj) with_1\IN\0|has|significantly|,|,|frequency (r_advcl) decreased_23\VBN\169651|.|hallmark|triad (l_nsubj) frequency_16\NN\15286249|has|significantly|,|with|, (l_prep) of_17\IN\0|the (l_pobj) syndrome_21\NN\5870365|NONE
D013392_D006934 NONE sucralfate_12\JJ\3740161|and|, (r_conj) omeprazole_9\NN\14778019|)|, (r_conj) blockers_7\NNS\10101634|H|current|ulcer|( (r_conj) therapy_4\NN\657604|Although (r_pobj) with_1\IN\0|has|significantly|,|,|frequency (r_advcl) decreased_23\VBN\169651|.|hallmark|triad (r_ccomp) remains_37\VBZ\2684|NONE (l_nsubj) triad_28\NN\13741022|.|hallmark|decreased (l_prep) of_29\IN\0|the|classic (l_pobj) hypercalcemia_30\NN\14299637|NONE
D009853_D014456 NONE omeprazole_9\NN\14778019|)|, (r_conj) blockers_7\NNS\10101634|H|current|ulcer|( (r_conj) therapy_4\NN\657604|Although (l_compound) ulcer_3\NN\14211294|blockers|H|current|(
D002117_D007011 NONE 1,25(oh)2d_6\CD\0|NONE (r_pobj) by_5\IN\0|in (r_agent) induced_4\VBN\1627355|alkali|. (l_prep) in_7\IN\13603305|by (l_pobj) patient_9\NN\9898892|NONE (l_prep) with_10\IN\0|a (l_pobj) hypoparathyroidism_11\NN\14059928|NONE
D002117_D007011 NONE calcitriol_14\NN\0|calcium|and (r_conj) carbonate_12\NN\15010703|NONE (r_pobj) with_10\IN\0|resulting|was|who (r_prep) treated_9\VBN\2376958|NONE (r_relcl) hypoparathyroidism_6\NN\14059928|NONE
D013392_D051437 NONE sucralfate_12\JJ\3740161|and|, (r_conj) omeprazole_9\NN\14778019|)|, (r_conj) blockers_7\NNS\10101634|H|current|ulcer|( (r_conj) therapy_4\NN\657604|Although (r_pobj) with_1\IN\0|has|significantly|,|,|frequency (r_advcl) decreased_23\VBN\169651|.|hallmark|triad (r_ccomp) remains_37\VBZ\2684|NONE (l_nsubj) triad_28\NN\13741022|.|hallmark|decreased (l_prep) of_29\IN\0|the|classic (l_pobj) hypercalcemia_30\NN\14299637|NONE (l_conj) alkalosis_32\NN\14204950|, (l_conj) impairment_36\NN\7296428|and|,
D000468_D010437 NONE alkali_26\NN\14818238|and (r_conj) calcium_24\NN\14625458|NONE (r_pobj) of_23\IN\0|large (r_prep) amounts_22\NNS\13329641|NONE (r_pobj) with_20\IN\0|of|the (r_prep) treatment_15\NN\654885|NONE (l_prep) of_16\IN\0|the|with (l_pobj) disease_19\NN\14061805|NONE
10986547
C076029_D015430 CID olanzapine_2\RB\0| (r_npadvmod) treated_4\VBN\2376958|NONE (r_amod) patients_5\NNS\9898892|However|,|.|mean (r_nsubj) had_6\VBD\0|NONE (l_dobj) mean_11\JJ\6021761|However|patients|,|. (l_appos) gain_17\NN\13576355|significant|a|greater|(
C076029_D001714 NONE olanzapine_2\NN\0|NONE (r_pobj) of_1\IN\0|.|in|study|: (r_prep) efficacy_0\NN\5199286|NONE (l_prep) in_3\IN\13603305|.|study|:|of (l_pobj) mania_6\NN\9180259|NONE
C076029_D001714 NONE olanzapine_7\NN\0|NONE (r_pobj) of_6\IN\0|for|the|safety|and (r_prep) efficacy_3\NN\5199286|We|. (l_prep) for_10\IN\0|the|safety|of|and (l_pobj) treatment_12\NN\654885|NONE (l_prep) of_13\IN\0|the (l_pobj) mania_16\NN\9180259|NONE
C076029_D001714 NONE olanzapine_22\NN\0|,|total|.|were (r_xcomp) randomized_20\VBN\278117|NONE (l_nsubjpass) total_1\NN\3553|,|.|were|olanzapine (l_prep) of_2\IN\0|A (l_pobj) patients_4\NNS\9898892|NONE (l_prep) with_5\IN\0| (l_pobj) diagnosis_10\NN\152018|NONE (l_prep) of_11\IN\0|IV|a (l_pobj) disorder_13\NN\14034177|NONE
C076029_D001714 NONE olanzapine_22\NN\0|,|total|.|were (r_xcomp) randomized_20\VBN\278117|NONE (l_nsubjpass) total_1\NN\3553|,|.|were|olanzapine (l_prep) of_2\IN\0|A (l_pobj) patients_4\NNS\9898892|NONE (l_prep) with_5\IN\0| (l_pobj) diagnosis_10\NN\152018|NONE (l_prep) of_11\IN\0|IV|a (l_pobj) disorder_13\NN\14034177|NONE (l_amod) manic_15\JJ\0|,|bipolar
C076029_D001714 NONE olanzapine_0\NNP\0|efficacy|.|tolerated|and (r_nsubj) demonstrated_1\VBD\2137132|NONE (l_dobj) efficacy_3\NN\5199286|Olanzapine|.|tolerated|and (l_prep) than_4\IN\0|greater (l_pobj) placebo_5\NN\3740161|NONE (l_prep) in_6\IN\13603305|NONE (l_pobj) treatment_8\NN\654885|NONE (l_prep) of_9\IN\0|the (l_pobj) mania_12\NN\9180259|NONE
C076029_D006970 CID olanzapine_2\RB\0| (r_npadvmod) treated_4\VBN\2376958|NONE (r_amod) patients_5\NNS\9898892|However|,|.|mean (r_nsubj) had_6\VBD\0|NONE (l_dobj) mean_11\JJ\6021761|However|patients|,|. (l_appos) gain_17\NN\13576355|significant|a|greater|( (l_conj) experienced_37\VBD\2108377|SD|and|+/|weight|)|than (l_dobj) somnolence_42\NN\14015731|also
17356399
D003561_D006212 CID cytarabine_35\NN\0|NONE (r_pobj) of_33\IN\0|the (r_prep) administration_32\NN\1133281|NONE (r_pobj) after_30\IN\0|diffuse|on|cerebral (r_prep) vasospasm_25\NN\0|NONE (r_pobj) with_22\IN\0|sided (r_prep) weakness_21\NN\14462666|visual|,|and (r_conj) hallucinations_15\NNS\14376855|,
C042705_D054198 NONE asparaginase_11\NN\2722458|NONE (r_pobj) including_8\VBG\0|NONE (r_prep) chemotherapy_7\NN\661091|for|.|after|encephalopathy (r_dobj) multiagent_6\JJ\0|NONE (l_prep) for_15\IN\0|.|after|chemotherapy|encephalopathy (l_pobj) treatment_17\NN\654885|NONE (l_prep) of_18\IN\0|the (l_pobj) leukemia_21\NN\14239918|NONE
C042705_D020803 NONE asparaginase_11\NN\2722458|NONE (r_pobj) including_8\VBG\0|NONE (r_prep) chemotherapy_7\NN\661091|for|.|after|encephalopathy (r_dobj) multiagent_6\JJ\0|NONE (l_nsubj) encephalopathy_1\JJ\14084880|for|.|after|chemotherapy
C042705_D020301 CID asparaginase_11\NN\2722458|NONE (r_pobj) including_8\VBG\0|NONE (r_prep) chemotherapy_7\NN\661091|for|.|after|encephalopathy (r_dobj) multiagent_6\JJ\0|NONE (l_nsubj) encephalopathy_1\JJ\14084880|for|.|after|chemotherapy (l_conj) vasospasm_4\NN\0|Acute|and
D003561_D018908 CID cytarabine_35\NN\0|NONE (r_pobj) of_33\IN\0|the (r_prep) administration_32\NN\1133281|NONE (r_pobj) after_30\IN\0|diffuse|on|cerebral (r_prep) vasospasm_25\NN\0|NONE (r_pobj) with_22\IN\0|sided (r_prep) weakness_21\NN\14462666|visual|,|and
D003561_D001037 CID cytarabine_35\NN\0|NONE (r_pobj) of_33\IN\0|the (r_prep) administration_32\NN\1133281|NONE (r_pobj) after_30\IN\0|diffuse|on|cerebral (r_prep) vasospasm_25\NN\0|NONE (r_pobj) with_22\IN\0|sided (r_prep) weakness_21\NN\14462666|visual|,|and (r_conj) hallucinations_15\NNS\14376855|, (r_conj) incontinence_12\NN\13473097|, (r_conj) aphasia_10\NN\14085708|behavioral|,
D003561_D020803 NONE cytarabine_14\NN\0|PEG||and (r_conj) asparaginase_11\NN\2722458|NONE (r_pobj) including_8\VBG\0|NONE (r_prep) chemotherapy_7\NN\661091|for|.|after|encephalopathy (r_dobj) multiagent_6\JJ\0|NONE (l_nsubj) encephalopathy_1\JJ\14084880|for|.|after|chemotherapy
D003561_D020803 NONE cytarabine_35\NN\0|NONE (r_pobj) of_33\IN\0|the (r_prep) administration_32\NN\1133281|NONE (r_pobj) after_30\IN\0|diffuse|on|cerebral (r_prep) vasospasm_25\NN\0|NONE (r_pobj) with_22\IN\0|sided (r_prep) weakness_21\NN\14462666|visual|,|and (r_conj) hallucinations_15\NNS\14376855|, (r_conj) incontinence_12\NN\13473097|, (r_conj) aphasia_10\NN\14085708|behavioral|, (r_conj) changes_8\NNS\7283608|NONE (r_pobj) by_6\IN\0|NONE (r_agent) evidenced_5\VBN\1015244|acute (r_acl) encephalopathy_4\NN\14084880|.|patient
D003561_D014549 CID cytarabine_35\NN\0|NONE (r_pobj) of_33\IN\0|the (r_prep) administration_32\NN\1133281|NONE (r_pobj) after_30\IN\0|diffuse|on|cerebral (r_prep) vasospasm_25\NN\0|NONE (r_pobj) with_22\IN\0|sided (r_prep) weakness_21\NN\14462666|visual|,|and (r_conj) hallucinations_15\NNS\14376855|, (r_conj) incontinence_12\NN\13473097|,
D003561_D020301 CID cytarabine_14\NN\0|PEG||and (r_conj) asparaginase_11\NN\2722458|NONE (r_pobj) including_8\VBG\0|NONE (r_prep) chemotherapy_7\NN\661091|for|.|after|encephalopathy (r_dobj) multiagent_6\JJ\0|NONE (l_nsubj) encephalopathy_1\JJ\14084880|for|.|after|chemotherapy (l_conj) vasospasm_4\NN\0|Acute|and
D003561_D020301 CID cytarabine_35\NN\0|NONE (r_pobj) of_33\IN\0|the (r_prep) administration_32\NN\1133281|NONE (r_pobj) after_30\IN\0|diffuse|on|cerebral (r_prep) vasospasm_25\NN\0|NONE
D003561_D054198 NONE cytarabine_14\NN\0|PEG||and (r_conj) asparaginase_11\NN\2722458|NONE (r_pobj) including_8\VBG\0|NONE (r_prep) chemotherapy_7\NN\661091|for|.|after|encephalopathy (r_dobj) multiagent_6\JJ\0|NONE (l_prep) for_15\IN\0|.|after|chemotherapy|encephalopathy (l_pobj) treatment_17\NN\654885|NONE (l_prep) of_18\IN\0|the (l_pobj) leukemia_21\NN\14239918|NONE
3533179
D003520_D007153 NONE cya_4\NNP\0|the (r_compound) cardiotoxicity_5\NN\0|,|prepared|that|and|with|calculated (r_nsubj) correlates_6\VBZ\5857459|.|We (l_conj) prepared_28\VBN\126264|,|that|and|with|cardiotoxicity|calculated (l_nsubjpass) patients_19\NNS\9898892|be|for|that|can|effectively (l_prep) with_20\IN\0|NONE (l_pobj) anemia_22\NN\14189204|NONE (l_conj) immunodeficiencies_24\NNS\13973990|aplastic|and
D003520_D007153 NONE cya_8\NNP\0|NONE (r_compound) dosage_9\NN\13576355|NONE (r_pobj) with_7\IN\0|,|prepared|that|and|cardiotoxicity|calculated (r_prep) correlates_6\VBZ\5857459|.|We (l_conj) prepared_28\VBN\126264|,|that|and|with|cardiotoxicity|calculated (l_nsubjpass) patients_19\NNS\9898892|be|for|that|can|effectively (l_prep) with_20\IN\0|NONE (l_pobj) anemia_22\NN\14189204|NONE (l_conj) immunodeficiencies_24\NNS\13973990|aplastic|and
D003520_D007153 NONE cya_35\NNP\0|a|of (r_compound) dose_36\NN\3740161|NONE (r_pobj) at_33\IN\14622893|marrow|with (r_prep) grafting_32\VBG\379422|NONE (r_pobj) for_29\IN\0|be|patients|that|can|effectively (r_prep) prepared_28\VBN\126264|,|that|and|with|cardiotoxicity|calculated (l_nsubjpass) patients_19\NNS\9898892|be|for|that|can|effectively (l_prep) with_20\IN\0|NONE (l_pobj) anemia_22\NN\14189204|NONE (l_conj) immunodeficiencies_24\NNS\13973990|aplastic|and
D003520_D007153 NONE cya_54\NNP\0|whose (r_compound) dosage_55\NN\13576355|based|is (r_nsubjpass) calculated_57\VBN\632627|NONE (r_relcl) patients_52\NNS\9898892|NONE (r_pobj) than_51\IN\0|NONE (r_prep) cardiotoxicity_50\NN\0|NONE (r_pobj) of_49\IN\0|a|lower (r_prep) incidence_48\NN\13821570|NONE (r_pobj) with_45\IN\0|marrow|at (r_prep) grafting_32\VBG\379422|NONE (r_pobj) for_29\IN\0|be|patients|that|can|effectively (r_prep) prepared_28\VBN\126264|,|that|and|with|cardiotoxicity|calculated (l_nsubjpass) patients_19\NNS\9898892|be|for|that|can|effectively (l_prep) with_20\IN\0|NONE (l_pobj) anemia_22\NN\14189204|NONE (l_conj) immunodeficiencies_24\NNS\13973990|aplastic|and
D003520_D014923 NONE cya_6\NNP\0|to (r_dobj) receive_5\VB\2210855|who (r_xcomp) were_3\VBD\0|Eighty (r_relcl) patients_1\NNS\9898892|total|for|.|syndrome|,|d (r_nsubj) underwent_21\VBD\109660|NONE (l_conj) syndrome_34\NN\5870365|total|for|.|patients|,|d
D003520_D016511 NONE cya_6\NNP\0|to (r_dobj) receive_5\VB\2210855|who (r_xcomp) were_3\VBD\0|Eighty (r_relcl) patients_1\NNS\9898892|total|for|.|syndrome|,|d (r_nsubj) underwent_21\VBD\109660|NONE (l_conj) syndrome_34\NN\5870365|total|for|.|patients|,|d (l_conj) syndrome_40\NN\5870365|,|Aldrich|or
D003520_D000741 NONE cya_6\NNP\0|to (r_dobj) receive_5\VB\2210855|who (r_xcomp) were_3\VBD\0|Eighty (r_relcl) patients_1\NNS\9898892|total|for|.|syndrome|,|d (r_nsubj) underwent_21\VBD\109660|NONE (l_dobj) total_23\NN\3553|for|.|syndrome|patients|,|d (l_prep) of_24\IN\0|a (l_pobj) transplants_26\NNS\5267548|NONE (l_prep) for_27\IN\0| (l_pobj) anemia_29\NN\14189204|NONE
D003520_D000741 NONE cya_4\NNP\0|the (r_compound) cardiotoxicity_5\NN\0|,|prepared|that|and|with|calculated (r_nsubj) correlates_6\VBZ\5857459|.|We (l_conj) prepared_28\VBN\126264|,|that|and|with|cardiotoxicity|calculated (l_nsubjpass) patients_19\NNS\9898892|be|for|that|can|effectively (l_prep) with_20\IN\0|NONE (l_pobj) anemia_22\NN\14189204|NONE
D003520_D000741 NONE cya_8\NNP\0|NONE (r_compound) dosage_9\NN\13576355|NONE (r_pobj) with_7\IN\0|,|prepared|that|and|cardiotoxicity|calculated (r_prep) correlates_6\VBZ\5857459|.|We (l_conj) prepared_28\VBN\126264|,|that|and|with|cardiotoxicity|calculated (l_nsubjpass) patients_19\NNS\9898892|be|for|that|can|effectively (l_prep) with_20\IN\0|NONE (l_pobj) anemia_22\NN\14189204|NONE
D003520_D000741 NONE cya_35\NNP\0|a|of (r_compound) dose_36\NN\3740161|NONE (r_pobj) at_33\IN\14622893|marrow|with (r_prep) grafting_32\VBG\379422|NONE (r_pobj) for_29\IN\0|be|patients|that|can|effectively (r_prep) prepared_28\VBN\126264|,|that|and|with|cardiotoxicity|calculated (l_nsubjpass) patients_19\NNS\9898892|be|for|that|can|effectively (l_prep) with_20\IN\0|NONE (l_pobj) anemia_22\NN\14189204|NONE
D003520_D000741 NONE cya_54\NNP\0|whose (r_compound) dosage_55\NN\13576355|based|is (r_nsubjpass) calculated_57\VBN\632627|NONE (r_relcl) patients_52\NNS\9898892|NONE (r_pobj) than_51\IN\0|NONE (r_prep) cardiotoxicity_50\NN\0|NONE (r_pobj) of_49\IN\0|a|lower (r_prep) incidence_48\NN\13821570|NONE (r_pobj) with_45\IN\0|marrow|at (r_prep) grafting_32\VBG\379422|NONE (r_pobj) for_29\IN\0|be|patients|that|can|effectively (r_prep) prepared_28\VBN\126264|,|that|and|with|cardiotoxicity|calculated (l_nsubjpass) patients_19\NNS\9898892|be|for|that|can|effectively (l_prep) with_20\IN\0|NONE (l_pobj) anemia_22\NN\14189204|NONE
D003520_D064420 NONE cya_19\NNP\0|NONE (r_pobj) of_18\IN\0|in|the (r_prep) dose_17\NN\3740161|.|determine|correlates|we|retrospectively|, (r_dobj) calculated_15\VBD\632627|NONE (l_advcl) correlates_5\VBZ\5857459|.|dose|determine|we|retrospectively|, (l_nsubj) toxicity_3\NN\13576101|with|Since|generally
D003520_D064420 NONE cya_32\NNP\0|NONE (r_compound) cardiotoxicity_33\NN\0|NONE (r_pobj) of_31\IN\0|the (r_prep) incidence_30\NN\13821570|with|whether (r_nsubj) correlated_34\VBN\2657219|to (r_ccomp) determine_27\VB\0|.|dose|correlates|we|retrospectively|, (r_advcl) calculated_15\VBD\632627|NONE (l_advcl) correlates_5\VBZ\5857459|.|dose|determine|we|retrospectively|, (l_nsubj) toxicity_3\NN\13576101|with|Since|generally
D003520_D066126 NONE cyclophosphamide_0\NNP\0|:|analysis|. (r_compound) cardiotoxicity_1\NN\0|NONE
D003520_D066126 NONE cya_5\NNP\0|NONE (r_pobj) of_4\IN\0|these|high (r_prep) doses_3\NNS\3740161|NONE (r_pobj) at_0\IN\14622893|may|cardiotoxicity|,|described|but|, (r_prep) occur_10\VB\0|NONE (l_nsubj) cardiotoxicity_8\NN\0|may|At|,|described|but|,
D003520_D066126 NONE cya_5\NNP\0|NONE (r_pobj) of_4\IN\0|these|high (r_prep) doses_3\NNS\3740161|NONE (r_pobj) at_0\IN\14622893|may|cardiotoxicity|,|described|but|, (r_prep) occur_10\VB\0|NONE (l_conj) described_25\VBN\1001294|may|cardiotoxicity|At|,|but|, (l_nsubjpass) factors_15\NNS\7326557|not|been|have|. (l_prep) for_16\IN\0|definitive|risk (l_pobj) development_18\NN\248977|NONE (l_prep) of_19\IN\0|the (l_pobj) cardiotoxicity_21\NN\0|NONE
D003520_D066126 NONE cya_19\NNP\0|NONE (r_pobj) of_18\IN\0|in|the (r_prep) dose_17\NN\3740161|.|determine|correlates|we|retrospectively|, (r_dobj) calculated_15\VBD\632627|NONE (l_advcl) determine_27\VB\0|.|dose|correlates|we|retrospectively|, (l_ccomp) correlated_34\VBN\2657219|to (l_nsubj) incidence_30\NN\13821570|with|whether (l_prep) of_31\IN\0|the (l_pobj) cardiotoxicity_33\NN\0|NONE
D003520_D066126 NONE cya_32\NNP\0|NONE (r_compound) cardiotoxicity_33\NN\0|NONE
D003520_D066126 NONE cya_14\NNP\0|NONE (r_compound) cardiotoxicity_15\NN\0|NONE
D003520_D066126 NONE cya_26\NNP\0|NONE (r_pobj) of_25\IN\0| (r_prep) doses_24\NNS\3740161|NONE (r_dobj) receiving_20\VBG\2210855|NONE (r_pcomp) of_19\IN\0|ten (r_prep) days_18\NNS\15140892|NONE (r_pobj) within_16\IN\0|symptoms|patients|. (r_prep) had_8\VBD\0|NONE (l_dobj) symptoms_9\NNS\5823932|within|patients|. (l_amod) consistent_12\JJ\0|and|signs (l_prep) with_13\IN\0|NONE (l_pobj) cardiotoxicity_15\NN\0|NONE
D003520_D066126 NONE cya_8\NNP\0|NONE (r_pobj) to_7\IN\0|be|to (r_prep) related_6\VBN\628491|that|was (r_xcomp) thought_3\VBN\5809192|NONE (r_relcl) cardiotoxicity_0\NN\0|.|in
D003520_D066126 NONE cya_4\NNP\0|the (r_compound) cardiotoxicity_5\NN\0|,|prepared|that|and|with|calculated
D003520_D066126 NONE cya_4\NNP\0|the (r_compound) cardiotoxicity_5\NN\0|,|prepared|that|and|with|calculated (r_nsubj) correlates_6\VBZ\5857459|.|We (l_conj) prepared_28\VBN\126264|,|that|and|with|cardiotoxicity|calculated (l_prep) for_29\IN\0|be|patients|that|can|effectively (l_pobj) grafting_32\VBG\379422|NONE (l_prep) with_45\IN\0|marrow|at (l_pobj) incidence_48\NN\13821570|NONE (l_prep) of_49\IN\0|a|lower (l_pobj) cardiotoxicity_50\NN\0|NONE
D003520_D066126 NONE cya_8\NNP\0|NONE (r_compound) dosage_9\NN\13576355|NONE (r_pobj) with_7\IN\0|,|prepared|that|and|cardiotoxicity|calculated (r_prep) correlates_6\VBZ\5857459|.|We (l_nsubj) cardiotoxicity_5\NN\0|,|prepared|that|and|with|calculated
D003520_D066126 NONE cya_8\NNP\0|NONE (r_compound) dosage_9\NN\13576355|NONE (r_pobj) with_7\IN\0|,|prepared|that|and|cardiotoxicity|calculated (r_prep) correlates_6\VBZ\5857459|.|We (l_conj) prepared_28\VBN\126264|,|that|and|with|cardiotoxicity|calculated (l_prep) for_29\IN\0|be|patients|that|can|effectively (l_pobj) grafting_32\VBG\379422|NONE (l_prep) with_45\IN\0|marrow|at (l_pobj) incidence_48\NN\13821570|NONE (l_prep) of_49\IN\0|a|lower (l_pobj) cardiotoxicity_50\NN\0|NONE
D003520_D066126 NONE cya_35\NNP\0|a|of (r_compound) dose_36\NN\3740161|NONE (r_pobj) at_33\IN\14622893|marrow|with (r_prep) grafting_32\VBG\379422|NONE (r_pobj) for_29\IN\0|be|patients|that|can|effectively (r_prep) prepared_28\VBN\126264|,|that|and|with|cardiotoxicity|calculated (r_conj) correlates_6\VBZ\5857459|.|We (l_nsubj) cardiotoxicity_5\NN\0|,|prepared|that|and|with|calculated
D003520_D066126 NONE cya_35\NNP\0|a|of (r_compound) dose_36\NN\3740161|NONE (r_pobj) at_33\IN\14622893|marrow|with (r_prep) grafting_32\VBG\379422|NONE (l_prep) with_45\IN\0|marrow|at (l_pobj) incidence_48\NN\13821570|NONE (l_prep) of_49\IN\0|a|lower (l_pobj) cardiotoxicity_50\NN\0|NONE
D003520_D066126 NONE cya_54\NNP\0|whose (r_compound) dosage_55\NN\13576355|based|is (r_nsubjpass) calculated_57\VBN\632627|NONE (r_relcl) patients_52\NNS\9898892|NONE (r_pobj) than_51\IN\0|NONE (r_prep) cardiotoxicity_50\NN\0|NONE (r_pobj) of_49\IN\0|a|lower (r_prep) incidence_48\NN\13821570|NONE (r_pobj) with_45\IN\0|marrow|at (r_prep) grafting_32\VBG\379422|NONE (r_pobj) for_29\IN\0|be|patients|that|can|effectively (r_prep) prepared_28\VBN\126264|,|that|and|with|cardiotoxicity|calculated (r_conj) correlates_6\VBZ\5857459|.|We (l_nsubj) cardiotoxicity_5\NN\0|,|prepared|that|and|with|calculated
D003520_D066126 NONE cya_54\NNP\0|whose (r_compound) dosage_55\NN\13576355|based|is (r_nsubjpass) calculated_57\VBN\632627|NONE (r_relcl) patients_52\NNS\9898892|NONE (r_pobj) than_51\IN\0|NONE (r_prep) cardiotoxicity_50\NN\0|NONE
20589632
D014295_D000743 CID trimethoprim_0\NNP\0| (r_npadvmod) induced_2\VBN\1627355|.|in|immune|hemolytic (r_amod) anemia_5\NN\14189204|NONE
15018178
D015662_D000743 CID sulfomethoxazole_24\NN\0|NONE (r_pobj) by_21\IN\0|NONE (r_agent) induced_20\VBN\1627355|anemia|installing|a|hemolytic (r_acl) crisis_19\NN\14411243|who (l_compound) anemia_18\NN\14189204|induced|installing|a|hemolytic
D015662_D002534 NONE sulfomethoxazole_24\NN\0|NONE (r_pobj) by_21\IN\0|NONE (r_agent) induced_20\VBN\1627355|anemia|installing|a|hemolytic (r_acl) crisis_19\NN\14411243|who (r_dobj) had_13\VBD\0|a|old (r_relcl) girl_11\NN\10787470|NONE (r_pobj) of_6\IN\0|imaging (r_prep) findings_5\NNS\7951464|We|resulting|.|, (r_dobj) present_1\VBP\28270|NONE (l_advcl) resulting_26\VBG\2633881|We|findings|.|, (l_prep) in_27\IN\13603305|NONE (l_pobj) anoxia_29\NN\14041256|NONE
23666265
D003520_D010146 CID cyp_7\NNP\0|NONE (r_pobj) of_6\IN\0|the (r_prep) administration_5\NN\1133281|NONE (r_pobj) following_3\VBG\8180190|pain|Spontaneous (r_prep) behaviors_2\NNS\407535|.|were (l_compound) pain_1\NN\14299637|following|Spontaneous
D003520_D010146 CID cyclophosphamide_0\NNP\0|NONE (r_compound) treatment_1\NN\654885|.|scores (r_nsubj) increased_2\VBD\169651|NONE (l_dobj) scores_7\NNS\13757724|.|treatment (l_compound) behaviors_6\NNS\407535|NONE (l_compound) pain_5\NN\14299637|spontaneous|the
D003520_D003556 CID cyclophosphamide_10\NN\0| (r_npadvmod) induced_12\VBN\1627355|in (r_amod) cystitis_13\NN\14566129|NONE
D003520_D003556 CID cyclophosphamide_17\NN\0|NONE (r_pobj) on_16\IN\0|PX|cystitis|( (r_prep) antagonists_15\NNS\7846|NONE (l_appos) cystitis_20\NN\14566129|PX|(|on
D003520_D003556 CID cyp)-induced_19\VBN\0|in (r_amod) cystitis_20\NN\14566129|PX|(|on
D003520_D003556 CID cyp_1\NNP\0| (r_npadvmod) induced_3\VBN\1627355|expression|,|increased (r_amod) cystitis_4\NN\14566129|.
9578276
15366550
D008094_D018500 CID lithium_0\NN\14625458|changed|is|,|and|in (r_nsubjpass) implicated_2\VBN\2677097|NONE (l_prep) in_3\IN\13603305|changed|Lithium|is|,|and (l_pobj) di_8\NNP\0|NONE
D008094_D018500 CID lithium_0\NN\14625458|changed|is|,|and|in (r_nsubjpass) implicated_2\VBN\2677097|NONE (l_conj) changed_27\VBD\0|Lithium|is|,|and|in (l_advcl) focus_29\VB\5704266|,|treatment|.|received (l_prep) on_30\IN\0|to (l_pobj) di_32\NNP\0|NONE
D008094_D018500 CID lithium_17\NN\14625458|because|patient|had|not|since (r_dobj) received_16\VBN\2210855|focus|,|treatment|. (r_advcl) changed_27\VBD\0|Lithium|is|,|and|in (r_conj) implicated_2\VBN\2677097|NONE (l_prep) in_3\IN\13603305|changed|Lithium|is|,|and (l_pobj) di_8\NNP\0|NONE
D008094_D018500 CID lithium_17\NN\14625458|because|patient|had|not|since (r_dobj) received_16\VBN\2210855|focus|,|treatment|. (r_advcl) changed_27\VBD\0|Lithium|is|,|and|in (l_advcl) focus_29\VB\5704266|,|treatment|.|received (l_prep) on_30\IN\0|to (l_pobj) di_32\NNP\0|NONE
D008094_D018500 CID lithium_32\NN\14625458| (r_npadvmod) induced_34\VBN\1627355|nephrogenic|his (r_amod) di_36\NNP\0||developed|self|and|been
D008094_D018500 CID lithium_32\NN\14625458| (r_npadvmod) induced_34\VBN\1627355|nephrogenic|his (r_amod) di_36\NNP\0||developed|self|and|been (r_dobj) treating_30\VBG\2376958|team|By|,|. (l_conj) developed_38\VBN\1753788||DI|self|and|been (l_dobj) di_40\NNP\0|brain
D008094_D001930 NONE lithium_32\NN\14625458| (r_npadvmod) induced_34\VBN\1627355|nephrogenic|his (r_amod) di_36\NNP\0||developed|self|and|been (r_dobj) treating_30\VBG\2376958|team|By|,|. (l_conj) developed_38\VBN\1753788||DI|self|and|been (l_advcl) brain_43\NN\5462674|DI (l_dobj) trauma_44\NN\14052046|to
D008094_D059606 NONE lithium_24\NN\14625458|standing (r_compound) use_25\NN\407535|and (r_conj) polydipsia_19\NN\14040660|NONE
10713017
D005277_D006976 CID fenfluramines_9\NNS\0|However|.|association|,|of|,|compared (r_nsubj) had_10\VBD\0|NONE (l_dobj) association_14\NN\8008335|However|.|,|of|,|fenfluramines|compared (l_prep) with_15\IN\0|significant|preferential|a (l_pobj) pph_16\NNP\0|NONE
D005277_D006976 CID fenfluramines_22\NNS\0|NONE (r_pobj) for_21\IN\0|the (r_prep) specificity_20\NN\4762633|and|with|the (r_conj) association_4\NN\8008335|NONE (l_prep) with_5\IN\0|and|specificity|the (l_pobj) pph_6\NNP\0|NONE
D005277_D006976 CID fenfluramines_22\NNS\0|NONE (r_pobj) for_21\IN\0|the (r_prep) specificity_20\NN\4762633|and|with|the (r_conj) association_4\NN\8008335|NONE (r_pobj) of_2\IN\0|The (r_prep) magnitude_1\NN\4916342|consistent|. (r_nsubj) are_23\VBP\13600404|NONE (l_acomp) consistent_24\JJ\0|magnitude|. (l_prep) with_25\IN\0|NONE (l_pobj) studies_27\NNS\635850|NONE (l_acl) indicating_28\VBG\952524|previous (l_ccomp) related_33\VBN\628491|NONE (l_prep) to_34\IN\0|causally|fenfluramines|are|that (l_pobj) pph_35\NNP\0|NONE
D005277_D006976 CID fenfluramines_30\NNS\0|to|causally|are|that (r_nsubjpass) related_33\VBN\628491|NONE (r_ccomp) indicating_28\VBG\952524|previous (r_acl) studies_27\NNS\635850|NONE (r_pobj) with_25\IN\0|NONE (r_prep) consistent_24\JJ\0|magnitude|. (r_acomp) are_23\VBP\13600404|NONE (l_nsubj) magnitude_1\NN\4916342|consistent|. (l_prep) of_2\IN\0|The (l_pobj) association_4\NN\8008335|NONE (l_prep) with_5\IN\0|and|specificity|the (l_pobj) pph_6\NNP\0|NONE
D005277_D006976 CID fenfluramines_30\NNS\0|to|causally|are|that (r_nsubjpass) related_33\VBN\628491|NONE (l_prep) to_34\IN\0|causally|fenfluramines|are|that (l_pobj) pph_35\NNP\0|NONE
2818777
D010672_D056486 NONE phenytoin_0\NNP\3550533|.|injury (r_nsubj) induced_1\VBD\1627355|NONE (l_dobj) injury_4\NN\14052046|.|Phenytoin
D010672_D017093 CID phenytoin_10\NN\3550533|NONE (r_compound) administration_11\NN\1133281|NONE (r_pobj) after_9\IN\0|.|A|developed|old|female|fatal|hepatic (r_prep) failure_8\NN\66216|NONE
25986755
D003404_D005355 NONE creatinine_26\NN\0|NONE (r_nmod) protein_29\NN\14944888|NONE (r_pobj) of_24\IN\0|elevated (r_prep) levels_23\NNS\4916342|NONE (r_pobj) by_21\IN\0|NONE (r_agent) accompanied_20\VBN\0|kidneys|glomerulosclerosis|that (r_advcl) exhibited_12\VBD\2632167|results|. (l_dobj) glomerulosclerosis_13\NN\0|kidneys|accompanied|that (l_conj) fibrosis_18\NN\14204950|as
D003404_D005921 NONE creatinine_26\NN\0|NONE (r_nmod) protein_29\NN\14944888|NONE (r_pobj) of_24\IN\0|elevated (r_prep) levels_23\NNS\4916342|NONE (r_pobj) by_21\IN\0|NONE (r_agent) accompanied_20\VBN\0|kidneys|glomerulosclerosis|that (r_advcl) exhibited_12\VBD\2632167|results|. (l_dobj) glomerulosclerosis_13\NN\0|kidneys|accompanied|that
D002110_D005317 CID caffeine_7\NN\14712692|PCE (r_compound) exposure_8\NN\5042871|that|could|retardation (r_nsubj) induce_13\VB\1627355|.|has|study (l_dobj) retardation_16\NN\7296428|that|could|exposure
D002110_D005317 CID caffeine_7\NN\14712692|PCE (r_compound) exposure_8\NN\5042871|that|could|retardation (r_nsubj) induce_13\VB\1627355|.|has|study (l_dobj) retardation_16\NN\7296428|that|could|exposure (l_appos) iugr_18\NNP\0|intrauterine|growth
D002110_D005921 NONE caffeine_18\NN\14712692|NONE (r_compound) exposure_19\NN\5042871|NONE (r_pobj) by_16\IN\0|NONE (r_agent) induced_15\VBN\1627355|adult (r_acl) offspring_14\NN\10235549|NONE (r_pobj) in_12\IN\13603305|.|origin|programming (r_prep) mediates_6\VBZ\761713|NONE (l_dobj) origin_9\NN\8620061|.|programming|in (l_prep) of_10\IN\0|the|developmental (l_pobj) glomerulosclerosis_11\NN\0|NONE
2217015
D008528_D051437 CID acid_1\NN\14818238|neutropenia||. (r_npadvmod) induced_3\VBN\1627355|NONE (l_dobj) neutropenia_4\NN\14196405|acid||. (l_conj) failure_7\NN\66216|and|with|in
D008528_D051437 CID acid_3\NN\14818238| (r_npadvmod) induced_5\VBN\1627355|occurring|oliguric|and|renal|mefenamic (r_amod) failure_10\NN\66216|We|.
D008528_D009503 CID acid_1\NN\14818238|neutropenia||. (r_npadvmod) induced_3\VBN\1627355|NONE (l_dobj) neutropenia_4\NN\14196405|acid||.
D008528_D009503 CID acid_3\NN\14818238| (r_npadvmod) induced_5\VBN\1627355|occurring|oliguric|and|renal|mefenamic (r_amod) failure_10\NN\66216|We|. (l_conj) occurring_14\VBG\0|oliguric|and|induced|renal|mefenamic (l_compound) neutropenia_13\NN\14196405|simultaneously|in
D008528_D007037 NONE acid_1\NN\14818238|neutropenia||. (r_npadvmod) induced_3\VBN\1627355|NONE (l_dobj) neutropenia_4\NN\14196405|acid||. (l_prep) with_11\IN\0|and|failure|in (l_pobj) hypothyroidism_12\NN\14059928|NONE
D008528_D007037 NONE acid_10\NN\14818238|in|to|corrected|not (r_dobj) use_8\VB\407535|However|prudent|,|it|.|would (l_prep) in_11\IN\13603305|acid|to|corrected|not (l_pobj) patients_13\NNS\9898892|NONE (l_amod) hypothyroid_12\JJ\0|NONE
D008528_D007037 NONE acid_10\NN\14818238|in|to|corrected|not (r_dobj) use_8\VB\407535|However|prudent|,|it|.|would (l_advcl) corrected_19\VBN\138508|acid|in|to|not (l_nsubjpass) hypothyroidism_16\NN\14059928|has|been|until
15609701
D013015_D002311 NONE sotalol_0\NNP\0||spasm|.|in (r_npadvmod) induced_2\VBN\1627355|NONE (l_prep) in_5\IN\13603305||Sotalol|spasm|. (l_pobj) patient_7\NN\9898892|NONE (l_prep) with_8\IN\0|a (l_pobj) cardiomyopathy_10\NN\14103288|NONE
C076259_D017180 NONE hydrochloride_5\NN\14817592|NONE (r_pobj) of_3\IN\0|the (r_prep) administration_2\NN\1133281|.|After|was|,|VT (r_nsubjpass) terminated_10\VBN\126264|NONE (l_nsubjpass) vt_8\NNP\0|.|After|was|administration|,
D013015_D003329 CID sotalol_0\NNP\0||spasm|.|in (r_npadvmod) induced_2\VBN\1627355|NONE (l_dobj) spasm_4\NN\14299637||Sotalol|.|in
D013015_D003329 CID sotalol_15\NN\0|NONE (r_pobj) of_14\IN\0|blocking|the|selective (r_prep) properties_13\NNS\32613|NONE (r_pobj) by_5\IN\0|vasospasm|may|be|. (r_agent) induced_4\VBN\1627355|NONE (l_nsubjpass) vasospasm_1\NN\0|may|be|.|by
D013015_D017180 NONE sotalol_0\NNP\0||spasm|.|in (r_npadvmod) induced_2\VBN\1627355|NONE (l_prep) in_5\IN\13603305||Sotalol|spasm|. (l_pobj) patient_7\NN\9898892|NONE (l_prep) with_8\IN\0|a (l_pobj) cardiomyopathy_10\NN\14103288|NONE (l_acl) associated_11\VBN\628491|dilated (l_prep) with_12\IN\0|NONE (l_pobj) tachycardia_15\NN\14110674|NONE
D013015_D017180 NONE sotalol_6\NN\0|An|class|,|III|alternate (r_appos) agent_4\NN\7347|,|effective|.|also (r_nsubj) was_8\VBD\0|NONE (l_acomp) effective_10\JJ\0|,|agent|.|also (l_prep) for_11\IN\0|NONE (l_pobj) prevention_13\NN\1073995|NONE (l_prep) of_14\IN\0|the (l_pobj) vt_15\NNP\0|NONE
23433219
D008694_D000987 CID methamphetamine_39\NN\2704153|heavy (r_compound) uses_40\NNS\407535|personality|(|and|antisocial|OR=. (r_conj) disorder_28\NN\14034177|major|,|(|,|disorder|depressive|OR=.|morbid
D008694_D000987 CID methamphetamine_46\NN\2704153| (r_npadvmod) induced_48\VBN\1627355|lifetime (r_amod) psychosis_49\NN\14380140|NONE (r_pobj) with_44\IN\0|were|significantly|adjusted|disorder|. (r_prep) associated_43\VBN\628491|NONE (l_nsubjpass) disorder_5\NN\14034177|were|significantly|adjusted|with|. (l_appos) disorder_28\NN\14034177|major|,|(|,|disorder|depressive|OR=.|morbid
D008694_D000987 CID methamphetamine_15\NN\2704153|heavy (r_compound) use_16\NN\407535|antisocial|,|and (r_conj) personality_11\NN\24264|affective|,|morbid
D008694_D019964 NONE methamphetamine_15\NN\2704153|heavy (r_compound) use_16\NN\407535|antisocial|,|and (r_conj) personality_11\NN\24264|affective|,|morbid (r_conj) disorder_8\NN\14034177|NONE
D008694_D011605 CID methamphetamine_6\NN\2704153|in (r_compound) psychosis_7\NN\14380140|NONE
D008694_D011605 CID methamphetamine_9\NN\2704153| (r_npadvmod) dependent_11\JJ\9627906|in (r_amod) patients_12\NNS\9898892|NONE (r_pobj) in_8\IN\13603305|methamphetamine (r_prep) psychosis_7\NN\14380140|NONE
D008694_D011605 CID methamphetamine_14\NN\2704153| (r_npadvmod) induced_16\VBN\1627355|current (r_amod) psychosis_17\NN\14380140|and|in
D008694_D011605 CID methamphetamine_21\NN\2704153|NONE (r_compound) dependence_22\NN\24720|NONE (r_pobj) with_20\IN\0|NONE (r_prep) patients_19\NNS\9898892|NONE (r_pobj) in_18\IN\13603305|and|psychosis (r_prep) lifetime_11\NN\15113229|NONE (l_conj) psychosis_17\NN\14380140|and|in
D008694_D011605 CID methamphetamine_8\NN\2704153|NONE (r_punct) -_9\HYPH\0|morbidity (r_punct) induced_10\VBN\1627355|NONE (r_amod) psychosis_11\NN\14380140|NONE
D008694_D011605 CID methamphetamine_5\NN\2704153|NONE (r_pobj) of_4\IN\0|the (r_prep) diagnosis_3\NN\152018|NONE (r_pobj) with_1\IN\0|NONE (r_prep) patients_0\NNS\9898892|using|were (r_nsubjpass) interviewed_12\VBN\964694|NONE (l_advcl) using_13\VBG\418025|Patients|were (l_prep) for_22\IN\0|Interview (l_pobj) psychosis_26\NN\14380140|NONE
D008694_D011605 CID methamphetamine_23\NN\2704153| (r_npadvmod) induced_25\VBN\1627355|and|Axis (r_amod) psychosis_26\NN\14380140|NONE
D008694_D011605 CID methamphetamine_39\NN\2704153|heavy (r_compound) uses_40\NNS\407535|personality|(|and|antisocial|OR=. (r_conj) disorder_28\NN\14034177|major|,|(|,|disorder|depressive|OR=.|morbid (r_appos) disorder_5\NN\14034177|were|significantly|adjusted|with|. (r_nsubjpass) associated_43\VBN\628491|NONE (l_prep) with_44\IN\0|were|significantly|adjusted|disorder|. (l_pobj) psychosis_49\NN\14380140|NONE
D008694_D011605 CID methamphetamine_46\NN\2704153| (r_npadvmod) induced_48\VBN\1627355|lifetime (r_amod) psychosis_49\NN\14380140|NONE
D008694_D011605 CID methamphetamine_10\NN\2704153|NONE (r_compound) dependence_11\NN\24720|NONE (r_pobj) with_9\IN\0|NONE (r_prep) patients_8\NNS\9898892|NONE (r_pobj) in_7\IN\13603305|of|a|high (r_prep) risk_4\NN\14541044|There|. (l_prep) of_5\IN\0|a|high|in (l_pobj) psychosis_6\NN\14380140|NONE
D008694_D011605 CID methamphetamine_7\NN\2704153|NONE (r_compound) dependence_8\NN\24720|NONE (r_pobj) of_6\IN\0|all (r_prep) cases_5\NNS\7283608|that|be|should|for (r_nsubjpass) screened_11\VBN\2533282|.|It|is (l_prep) for_12\IN\0|cases|that|be|should (l_pobj) symptoms_14\NNS\5823932|NONE
D008694_D003866 NONE methamphetamine_39\NN\2704153|heavy (r_compound) uses_40\NNS\407535|personality|(|and|antisocial|OR=. (r_conj) disorder_28\NN\14034177|major|,|(|,|disorder|depressive|OR=.|morbid (r_appos) disorder_5\NN\14034177|were|significantly|adjusted|with|.
D008694_D003866 NONE methamphetamine_46\NN\2704153| (r_npadvmod) induced_48\VBN\1627355|lifetime (r_amod) psychosis_49\NN\14380140|NONE (r_pobj) with_44\IN\0|were|significantly|adjusted|disorder|. (r_prep) associated_43\VBN\628491|NONE (l_nsubjpass) disorder_5\NN\14034177|were|significantly|adjusted|with|.
D008694_D001714 CID methamphetamine_39\NN\2704153|heavy (r_compound) uses_40\NNS\407535|personality|(|and|antisocial|OR=. (r_conj) disorder_28\NN\14034177|major|,|(|,|disorder|depressive|OR=.|morbid (r_appos) disorder_5\NN\14034177|were|significantly|adjusted|with|. (l_appos) disorder_16\NN\14034177|major|,|(|,|depressive|OR=.|disorder|morbid
D008694_D001714 CID methamphetamine_46\NN\2704153| (r_npadvmod) induced_48\VBN\1627355|lifetime (r_amod) psychosis_49\NN\14380140|NONE (r_pobj) with_44\IN\0|were|significantly|adjusted|disorder|. (r_prep) associated_43\VBN\628491|NONE (l_nsubjpass) disorder_5\NN\14034177|were|significantly|adjusted|with|. (l_appos) disorder_16\NN\14034177|major|,|(|,|depressive|OR=.|disorder|morbid
16112787
C048498_-1 NONE erdosteine_33\NN\0|the (r_amod) groups_34\NNS\2137|and|the (r_conj) control_30\NN\5190804|NONE (r_pobj) of_28\IN\0|NONE (r_prep) those_27\DT\0|NONE (r_pobj) than_26\IN\0|NONE (r_prep) more_25\JJR\0|a|significant|,|vacuolization|of (r_amod) dilatation_4\NN\14034177|There|. (l_conj) vacuolization_12\NN\13920835|a|significant|,|of|more (l_conj) atrophy_14\NN\14299637|cell|in|epithelial|extensive|, (l_conj) desquamation_16\NN\11418750|,
D014640_D009336 NONE vcm_21\NNP\0| (r_npadvmod) treated_23\VBN\2376958|NONE (r_amod) rats_24\NNS\2329401|NONE (r_pobj) in_20\IN\13603305|cell|epithelial|atrophy|extensive|, (r_prep) vacuolization_12\NN\13920835|a|significant|,|of|more (l_conj) atrophy_14\NN\14299637|cell|in|epithelial|extensive|, (l_conj) desquamation_16\NN\11418750|, (l_conj) necrosis_19\NN\11444117|,|and
D014640_D007674 CID vancomycin_12\NNP\2716866| (r_npadvmod) induced_14\VBN\1627355|protection|: (r_amod) nephrotoxicity_15\NN\0|NONE
D014640_D007674 CID vancomycin_8\NNP\2716866|oxidative|(|promotes|and|VCM)induced (r_det) stress_12\NN\7083732|to|investigate (r_dobj) examine_7\VB\0|.|aims (l_advcl) investigate_25\VB\644583|stress|to (l_dobj) role_27\NN\719494|to (l_appos) agent_33\NN\7347|,|of|the (l_prep) on_41\IN\0|an|,|expectorant|,|has (l_pobj) tissue_43\NN\5220461|NONE (l_prep) against_44\IN\0|kidney (l_pobj) impairment_51\NN\7296428|NONE
D014640_D007674 CID vcm)-induced_10\VBN\0|oxidative|(|promotes|and|vancomycin (r_amod) stress_12\NN\7083732|to|investigate (r_dobj) examine_7\VB\0|.|aims (l_advcl) investigate_25\VB\644583|stress|to (l_dobj) role_27\NN\719494|to (l_appos) agent_33\NN\7347|,|of|the (l_prep) on_41\IN\0|an|,|expectorant|,|has (l_pobj) tissue_43\NN\5220461|NONE (l_prep) against_44\IN\0|kidney (l_pobj) impairment_51\NN\7296428|NONE
D014640_D007674 CID vcm_47\NN\0| (r_npadvmod) induced_49\VBN\1627355|possible|in|the|renal (r_amod) impairment_51\NN\7296428|NONE
D014640_D007674 CID vcm_0\NN\0|NONE (r_compound) administration_1\NN\1133281|decreased|.|but|rats|to|malondialdehyde (r_nsubj) control_3\VB\5190804|NONE (l_dobj) malondialdehyde_8\NN\0|decreased|.|but|administration|rats|to (l_appos) excretion_33\NN\13466586|(|increased|renal|MDA (l_nmod) glucosaminidase_22\NN\0|NONE (l_appos) nag_24\NN\9631463|beta|d||(||urinary|) (l_appos) marker_27\NN\21939|, (l_prep) of_28\IN\0|a (l_pobj) injury_31\NN\14052046|NONE
D014640_D007674 CID vcm_5\NNP\0| (r_npadvmod) induced_7\VBN\1627355|NONE (r_amod) nephrotoxicity_8\NN\0|NONE
D014640_D007674 CID vcm_13\NNP\0| (r_npadvmod) induced_15\VBN\1627355|the (r_amod) nephrotoxicity_16\NN\0|NONE
D014640_D007674 CID vcm_13\NNP\0| (r_npadvmod) induced_15\VBN\1627355|the (r_amod) nephrotoxicity_16\NN\0|NONE (r_pobj) in_11\IN\13603305|an|and|modulation|important (r_prep) role_10\NN\719494|damage|that (r_dobj) plays_7\VBZ\7007684|reduces|It|is|. (r_ccomp) concluded_2\VBN\628491|NONE (l_conj) reduces_25\VBZ\441445|It|is|plays|. (l_dobj) damage_31\NN\7296428|NONE
D014640_D007674 CID vcm_27\NNP\0| (r_npadvmod) induced_29\VBN\1627355|the|kidney|at (r_amod) damage_31\NN\7296428|NONE (r_dobj) reduces_25\VBZ\441445|It|is|plays|. (r_conj) concluded_2\VBN\628491|NONE (l_ccomp) plays_7\VBZ\7007684|reduces|It|is|. (l_dobj) role_10\NN\719494|damage|that (l_prep) in_11\IN\13603305|an|and|modulation|important (l_pobj) nephrotoxicity_16\NN\0|NONE
D014640_D007674 CID vcm_27\NNP\0| (r_npadvmod) induced_29\VBN\1627355|the|kidney|at (r_amod) damage_31\NN\7296428|NONE
C048498_D007674 NONE erdosteine_19\NN\0|NONE (r_pobj) by_18\IN\0|NONE (r_prep) protection_17\NN\407535|induced|: (r_appos) nephrotoxicity_15\NN\0|NONE
C048498_D007674 NONE erdosteine_29\NN\0|NONE (r_pobj) of_28\IN\0|,|agent|the (r_prep) role_27\NN\719494|to (l_appos) agent_33\NN\7347|,|of|the (l_prep) on_41\IN\0|an|,|expectorant|,|has (l_pobj) tissue_43\NN\5220461|NONE (l_prep) against_44\IN\0|kidney (l_pobj) impairment_51\NN\7296428|NONE
C048498_D007674 NONE erdosteine_0\NNP\0|.|protection (r_nsubj) showed_1\VBD\2137132|NONE (l_dobj) protection_3\NN\407535|Erdosteine|. (l_prep) against_4\IN\0|histopathological (l_pobj) nephrotoxicity_8\NN\0|NONE
C048498_D007674 NONE erdosteine_24\NN\0|NONE (r_pobj) with_23\IN\0|of|the (r_prep) modulation_19\NN\7044917|an|in|and|important (r_conj) role_10\NN\719494|damage|that (l_prep) in_11\IN\13603305|an|and|modulation|important (l_pobj) nephrotoxicity_16\NN\0|NONE
C048498_D007674 NONE erdosteine_24\NN\0|NONE (r_pobj) with_23\IN\0|of|the (r_prep) modulation_19\NN\7044917|an|in|and|important (r_conj) role_10\NN\719494|damage|that (r_dobj) plays_7\VBZ\7007684|reduces|It|is|. (r_ccomp) concluded_2\VBN\628491|NONE (l_conj) reduces_25\VBZ\441445|It|is|plays|. (l_dobj) damage_31\NN\7296428|NONE
C048498_D009336 NONE erdosteine_33\NN\0|the (r_amod) groups_34\NNS\2137|and|the (r_conj) control_30\NN\5190804|NONE (r_pobj) of_28\IN\0|NONE (r_prep) those_27\DT\0|NONE (r_pobj) than_26\IN\0|NONE (r_prep) more_25\JJR\0|a|significant|,|vacuolization|of (r_amod) dilatation_4\NN\14034177|There|. (l_conj) vacuolization_12\NN\13920835|a|significant|,|of|more (l_conj) atrophy_14\NN\14299637|cell|in|epithelial|extensive|, (l_conj) desquamation_16\NN\11418750|, (l_conj) necrosis_19\NN\11444117|,|and
D014640_-1 NONE vcm_21\NNP\0| (r_npadvmod) treated_23\VBN\2376958|NONE (r_amod) rats_24\NNS\2329401|NONE (r_pobj) in_20\IN\13603305|cell|epithelial|atrophy|extensive|, (r_prep) vacuolization_12\NN\13920835|a|significant|,|of|more (l_conj) atrophy_14\NN\14299637|cell|in|epithelial|extensive|, (l_conj) desquamation_16\NN\11418750|,
D010100_D007674 NONE oxygen_18\NN\14622893|ROS|)|(|reactive (r_compound) species_19\NNS\7992450|NONE (r_pobj) of_16\IN\0|NONE (r_prep) production_15\NN\30358|that (r_dobj) promotes_14\VBZ\2556126|oxidative|(|and|VCM)induced|vancomycin (r_relcl) stress_12\NN\7083732|to|investigate (r_dobj) examine_7\VB\0|.|aims (l_advcl) investigate_25\VB\644583|stress|to (l_dobj) role_27\NN\719494|to (l_appos) agent_33\NN\7347|,|of|the (l_prep) on_41\IN\0|an|,|expectorant|,|has (l_pobj) tissue_43\NN\5220461|NONE (l_prep) against_44\IN\0|kidney (l_pobj) impairment_51\NN\7296428|NONE
D008315_D007674 NONE malondialdehyde_8\NN\0|decreased|.|but|administration|rats|to (l_appos) excretion_33\NN\13466586|(|increased|renal|MDA (l_nmod) glucosaminidase_22\NN\0|NONE (l_appos) nag_24\NN\9631463|beta|d||(||urinary|) (l_appos) marker_27\NN\21939|, (l_prep) of_28\IN\0|a (l_pobj) injury_31\NN\14052046|NONE
D008315_D007674 NONE mda_10\NNP\0|(|excretion|increased|renal (r_appos) malondialdehyde_8\NN\0|decreased|.|but|administration|rats|to (l_appos) excretion_33\NN\13466586|(|increased|renal|MDA (l_nmod) glucosaminidase_22\NN\0|NONE (l_appos) nag_24\NN\9631463|beta|d||(||urinary|) (l_appos) marker_27\NN\21939|, (l_prep) of_28\IN\0|a (l_pobj) injury_31\NN\14052046|NONE
D013481_D007674 NONE superoxide_36\NN\14971519|and|activities|SOD|(|) (r_amod) dismutase_37\NN\0|NONE (r_dobj) decreased_35\VBD\169651|.|but|administration|rats|to|malondialdehyde (r_conj) control_3\VB\5190804|NONE (l_dobj) malondialdehyde_8\NN\0|decreased|.|but|administration|rats|to (l_appos) excretion_33\NN\13466586|(|increased|renal|MDA (l_nmod) glucosaminidase_22\NN\0|NONE (l_appos) nag_24\NN\9631463|beta|d||(||urinary|) (l_appos) marker_27\NN\21939|, (l_prep) of_28\IN\0|a (l_pobj) injury_31\NN\14052046|NONE
D014640_D001284 NONE vcm_21\NNP\0| (r_npadvmod) treated_23\VBN\2376958|NONE (r_amod) rats_24\NNS\2329401|NONE (r_pobj) in_20\IN\13603305|cell|epithelial|atrophy|extensive|, (r_prep) vacuolization_12\NN\13920835|a|significant|,|of|more (l_conj) atrophy_14\NN\14299637|cell|in|epithelial|extensive|,
C048498_D001284 NONE erdosteine_33\NN\0|the (r_amod) groups_34\NNS\2137|and|the (r_conj) control_30\NN\5190804|NONE (r_pobj) of_28\IN\0|NONE (r_prep) those_27\DT\0|NONE (r_pobj) than_26\IN\0|NONE (r_prep) more_25\JJR\0|a|significant|,|vacuolization|of (r_amod) dilatation_4\NN\14034177|There|. (l_conj) vacuolization_12\NN\13920835|a|significant|,|of|more (l_conj) atrophy_14\NN\14299637|cell|in|epithelial|extensive|,
11439380
D013792_D011471 NONE thalidomide_0\NNP\4166841|.|in (r_compound) neuropathy_1\NN\14204950|NONE (l_prep) in_2\IN\13603305|Thalidomide|. (l_pobj) patients_3\NNS\9898892|NONE (l_acl) treated_4\VBN\2376958|NONE (l_prep) for_5\IN\0|NONE (l_pobj) cancer_8\NN\14239425|NONE
D013792_D011471 NONE thalidomide_19\NN\4166841|NONE (r_pobj) of_17\IN\0|an|label (r_prep) trial_16\NN\786195|NONE (r_pobj) in_11\IN\13603305|with|seven (r_prep) men_3\NNS\8208016|.|to|examinations (l_prep) with_4\IN\0|in|seven (l_pobj) cancer_10\NN\14239425|NONE
D013792_D009422 NONE thalidomide_0\NNP\4166841|.|in (r_compound) neuropathy_1\NN\14204950|NONE
D013792_D009422 NONE thalidomide_3\NN\4166841| (r_npadvmod) induced_5\VBN\1627355|using (r_amod) neuropathy_6\NN\14204950|We|.|prospectively
D013792_D009422 NONE thalidomide_8\NN\4166841|NONE (r_pobj) of_7\IN\0|a|common|in (r_prep) complication_6\NN\1073995|thus|may|.|Neuropathy (r_attr) be_3\VB\14625458|NONE (l_nsubj) neuropathy_0\NNP\14204950|thus|may|.|complication
D000728_D011471 NONE androgen_6\JJ\14745635| (r_npadvmod) independent_8\JJ\9619824|metastatic|prostate (r_amod) cancer_10\NN\14239425|NONE
24842192
D000667_D009203 NONE amp_20\NNP\13633375| (r_npadvmod) activated_22\VBN\1641914|AMPK|protein (r_amod) kinase_24\NN\14732946|NONE (r_pobj) of_19\IN\0|NONE (r_prep) activation_18\NN\13561719|to (r_pobj) due_16\JJ\5174653|.|effect|treatment (r_prep) has_4\VBZ\13888491|NONE (l_dobj) effect_7\NN\34213|due|.|treatment (l_prep) in_8\IN\13603305|a|by|protective (l_pobj) infarction_10\NN\14204950|NONE
D007545_D009369 NONE isoproterenol_3\NN\3740161| (r_npadvmod) induced_5\VBN\1627355|in (r_amod) elevation_6\NN\7445480|.|,|myeloid|markedly|Metfromin (r_dobj) lowered_2\VBD\1850315|NONE (l_advcl) myeloid_14\NN\0|.|,|elevation|markedly|Metfromin (l_dobj) protein_16\NN\14944888|in (l_appos) factor_24\NN\7326557|MyD||,|differentiation|) (l_compound) necrosis_23\NN\11444117|interleukin||alpha|,|and (l_compound) tumor_22\NN\14234074|NONE
D007545_D009203 CID isoproterenol_0\NNP\3740161|was|.|subcutaneously|induce|on (r_nsubjpass) injected_7\VBN\81072|NONE (l_advcl) induce_16\VB\1627355|was|.|subcutaneously|Isoproterenol|on (l_dobj) infarction_19\NN\14204950|to
D008687_D018487 NONE metformin_3\NN\2719105|NONE (r_pobj) with_2\IN\0|Chronic (r_prep) treatment_1\NN\654885|and|left|.|attenuates|receptor (r_nsubj) suppresses_4\VBZ\2510337|NONE (l_conj) left_13\VBN\8621598|treatment|and|.|attenuates|receptor (l_dobj) dysfunction_15\NN\14204950|NONE
D008687_D018487 NONE metformin_18\NN\2719105|NONE (r_pobj) of_17\IN\0|/| (r_prep) kg_16\NNS\13717155|NONE (r_pobj) with_11\IN\0|NONE (r_prep) treated_10\VBN\2376958|the (r_acl) groups_9\NNS\2137|NONE (r_pobj) in_7\IN\13603305|dysfunction|lower|. (r_prep) was_4\VBD\0|NONE (l_nsubj) dysfunction_3\NN\14204950|in|lower|.
D008687_D006331 NONE metformin_13\NN\2719105|TLR|following|)|( (l_prep) on_14\IN\0|with|,|In|effect (l_pobj) dysfunction_16\NN\14204950|NONE
D008687_D009203 NONE metformin_3\NN\2719105|NONE (r_pobj) with_2\IN\0|Chronic (r_prep) treatment_1\NN\654885|and|left|.|attenuates|receptor (r_nsubj) suppresses_4\VBZ\2510337|NONE (l_conj) left_13\VBN\8621598|treatment|and|.|attenuates|receptor (l_dobj) dysfunction_15\NN\14204950|NONE (l_prep) following_16\VBG\8180190|ventricular (l_pobj) infarction_18\NN\14204950|NONE
D008687_D009203 NONE metformin_3\NN\2719105|NONE (r_pobj) with_2\IN\0|Acute (r_prep) treatment_1\NN\654885|due|.|effect (r_nsubj) has_4\VBZ\13888491|NONE (l_dobj) effect_7\NN\34213|due|.|treatment (l_prep) in_8\IN\13603305|a|by|protective (l_pobj) infarction_10\NN\14204950|NONE
D008687_D009203 NONE metformin_13\NN\2719105|TLR|following|)|( (r_nmod) activities_26\NNS\30358|.|were (l_acl) following_27\VBG\8180190|TLR|metformin|)|( (l_pobj) infarction_29\NN\14204950|NONE
D008687_D009203 NONE metformin_5\NN\2719105|suppresses|.|and|dysfunction (r_nsubj) reduces_6\VBZ\441445|NONE (l_dobj) dysfunction_12\NN\14204950|suppresses|.|and|metformin (l_nmod) infarction_10\NN\14204950|myocardial|cardiac
D007545_D009336 NONE isoproterenol_3\NN\3740161| (r_npadvmod) induced_5\VBN\1627355|in (r_amod) elevation_6\NN\7445480|.|,|myeloid|markedly|Metfromin (r_dobj) lowered_2\VBD\1850315|NONE (l_advcl) myeloid_14\NN\0|.|,|elevation|markedly|Metfromin (l_dobj) protein_16\NN\14944888|in (l_appos) factor_24\NN\7326557|MyD||,|differentiation|) (l_compound) necrosis_23\NN\11444117|interleukin||alpha|,|and
9646784
D006493_D013923 CID heparin_0\NNP\2718259| (r_npadvmod) induced_2\VBN\1627355|.|thromboembolism|, (r_amod) thrombocytopenia_3\NN\14189204|NONE (l_conj) thromboembolism_6\NN\14100769|.|induced|,
D006493_D013923 CID heparin_13\JJ\2718259|NONE (r_compound) therapy_14\NN\657604|NONE (r_pobj) of_12\IN\0|other|side (r_prep) effects_11\NNS\13245626|,|and|paradoxical (r_conj) thromboembolism_6\NN\14100769|.|induced|,
D006493_D000505 CID heparin_4\JJ\2718259|including (r_compound) therapy_5\NN\657604|NONE (l_prep) including_6\VBG\0|heparin (l_pobj) thrombocytopenia_10\NN\14189204|NONE (l_conj) osteoporosis_15\NN\14204950|induced|, (l_conj) eosinophilia_17\NN\14299637|associated|, (l_conj) reactions_20\NNS\13446390|, (l_conj) reactions_23\NNS\13446390|skin|, (l_amod) other_24\JJ\0|allergic (l_prep) than_25\IN\0|NONE (l_pobj) thrombocytopenia_26\JJ\14189204|NONE (l_conj) alopecia_28\NN\14457041|and
D006493_D000505 CID heparin_7\NN\2718259| (r_npadvmod) induced_9\VBN\1627355|osteoporosis|, (r_amod) thrombocytopenia_10\NN\14189204|NONE (l_conj) osteoporosis_15\NN\14204950|induced|, (l_conj) eosinophilia_17\NN\14299637|associated|, (l_conj) reactions_20\NNS\13446390|, (l_conj) reactions_23\NNS\13446390|skin|, (l_amod) other_24\JJ\0|allergic (l_prep) than_25\IN\0|NONE (l_pobj) thrombocytopenia_26\JJ\14189204|NONE (l_conj) alopecia_28\NN\14457041|and
D006493_D000505 CID heparin_12\NN\2718259| (r_npadvmod) associated_14\VBN\628491|eosinophilia|, (r_amod) osteoporosis_15\NN\14204950|induced|, (l_conj) eosinophilia_17\NN\14299637|associated|, (l_conj) reactions_20\NNS\13446390|, (l_conj) reactions_23\NNS\13446390|skin|, (l_amod) other_24\JJ\0|allergic (l_prep) than_25\IN\0|NONE (l_pobj) thrombocytopenia_26\JJ\14189204|NONE (l_conj) alopecia_28\NN\14457041|and
D006493_D010024 CID heparin_4\JJ\2718259|including (r_compound) therapy_5\NN\657604|NONE (l_prep) including_6\VBG\0|heparin (l_pobj) thrombocytopenia_10\NN\14189204|NONE (l_conj) osteoporosis_15\NN\14204950|induced|,
D006493_D010024 CID heparin_7\NN\2718259| (r_npadvmod) induced_9\VBN\1627355|osteoporosis|, (r_amod) thrombocytopenia_10\NN\14189204|NONE (l_conj) osteoporosis_15\NN\14204950|induced|,
D006493_D010024 CID heparin_12\NN\2718259| (r_npadvmod) associated_14\VBN\628491|eosinophilia|, (r_amod) osteoporosis_15\NN\14204950|induced|,
D006493_D012871 CID heparin_4\JJ\2718259|including (r_compound) therapy_5\NN\657604|NONE (l_prep) including_6\VBG\0|heparin (l_pobj) thrombocytopenia_10\NN\14189204|NONE (l_conj) osteoporosis_15\NN\14204950|induced|, (l_conj) eosinophilia_17\NN\14299637|associated|, (l_conj) reactions_20\NNS\13446390|,
D006493_D012871 CID heparin_7\NN\2718259| (r_npadvmod) induced_9\VBN\1627355|osteoporosis|, (r_amod) thrombocytopenia_10\NN\14189204|NONE (l_conj) osteoporosis_15\NN\14204950|induced|, (l_conj) eosinophilia_17\NN\14299637|associated|, (l_conj) reactions_20\NNS\13446390|,
D006493_D012871 CID heparin_12\NN\2718259| (r_npadvmod) associated_14\VBN\628491|eosinophilia|, (r_amod) osteoporosis_15\NN\14204950|induced|, (l_conj) eosinophilia_17\NN\14299637|associated|, (l_conj) reactions_20\NNS\13446390|,
D006493_D013921 CID heparin_0\NNP\2718259| (r_npadvmod) induced_2\VBN\1627355|.|thromboembolism|, (r_amod) thrombocytopenia_3\NN\14189204|NONE
D006493_D013921 CID heparin_13\JJ\2718259|NONE (r_compound) therapy_14\NN\657604|NONE (r_pobj) of_12\IN\0|other|side (r_prep) effects_11\NNS\13245626|,|and|paradoxical (r_conj) thromboembolism_6\NN\14100769|.|induced|, (r_conj) thrombocytopenia_3\NN\14189204|NONE
D006493_D013921 CID heparin_4\JJ\2718259|including (r_compound) therapy_5\NN\657604|NONE (l_prep) including_6\VBG\0|heparin (l_pobj) thrombocytopenia_10\NN\14189204|NONE
D006493_D013921 CID heparin_4\JJ\2718259|including (r_compound) therapy_5\NN\657604|NONE (l_prep) including_6\VBG\0|heparin (l_pobj) thrombocytopenia_10\NN\14189204|NONE (l_conj) osteoporosis_15\NN\14204950|induced|, (l_conj) eosinophilia_17\NN\14299637|associated|, (l_conj) reactions_20\NNS\13446390|, (l_conj) reactions_23\NNS\13446390|skin|, (l_amod) other_24\JJ\0|allergic (l_prep) than_25\IN\0|NONE (l_pobj) thrombocytopenia_26\JJ\14189204|NONE
D006493_D013921 CID heparin_7\NN\2718259| (r_npadvmod) induced_9\VBN\1627355|osteoporosis|, (r_amod) thrombocytopenia_10\NN\14189204|NONE
D006493_D013921 CID heparin_7\NN\2718259| (r_npadvmod) induced_9\VBN\1627355|osteoporosis|, (r_amod) thrombocytopenia_10\NN\14189204|NONE (l_conj) osteoporosis_15\NN\14204950|induced|, (l_conj) eosinophilia_17\NN\14299637|associated|, (l_conj) reactions_20\NNS\13446390|, (l_conj) reactions_23\NNS\13446390|skin|, (l_amod) other_24\JJ\0|allergic (l_prep) than_25\IN\0|NONE (l_pobj) thrombocytopenia_26\JJ\14189204|NONE
D006493_D013921 CID heparin_12\NN\2718259| (r_npadvmod) associated_14\VBN\628491|eosinophilia|, (r_amod) osteoporosis_15\NN\14204950|induced|, (r_conj) thrombocytopenia_10\NN\14189204|NONE
D006493_D013921 CID heparin_12\NN\2718259| (r_npadvmod) associated_14\VBN\628491|eosinophilia|, (r_amod) osteoporosis_15\NN\14204950|induced|, (l_conj) eosinophilia_17\NN\14299637|associated|, (l_conj) reactions_20\NNS\13446390|, (l_conj) reactions_23\NNS\13446390|skin|, (l_amod) other_24\JJ\0|allergic (l_prep) than_25\IN\0|NONE (l_pobj) thrombocytopenia_26\JJ\14189204|NONE
D006493_D004342 CID heparin_4\JJ\2718259|including (r_compound) therapy_5\NN\657604|NONE (l_prep) including_6\VBG\0|heparin (l_pobj) thrombocytopenia_10\NN\14189204|NONE (l_conj) osteoporosis_15\NN\14204950|induced|, (l_conj) eosinophilia_17\NN\14299637|associated|, (l_conj) reactions_20\NNS\13446390|, (l_conj) reactions_23\NNS\13446390|skin|,
D006493_D004342 CID heparin_7\NN\2718259| (r_npadvmod) induced_9\VBN\1627355|osteoporosis|, (r_amod) thrombocytopenia_10\NN\14189204|NONE (l_conj) osteoporosis_15\NN\14204950|induced|, (l_conj) eosinophilia_17\NN\14299637|associated|, (l_conj) reactions_20\NNS\13446390|, (l_conj) reactions_23\NNS\13446390|skin|,
D006493_D004342 CID heparin_12\NN\2718259| (r_npadvmod) associated_14\VBN\628491|eosinophilia|, (r_amod) osteoporosis_15\NN\14204950|induced|, (l_conj) eosinophilia_17\NN\14299637|associated|, (l_conj) reactions_20\NNS\13446390|, (l_conj) reactions_23\NNS\13446390|skin|,
D006493_D004802 CID heparin_4\JJ\2718259|including (r_compound) therapy_5\NN\657604|NONE (l_prep) including_6\VBG\0|heparin (l_pobj) thrombocytopenia_10\NN\14189204|NONE (l_conj) osteoporosis_15\NN\14204950|induced|, (l_conj) eosinophilia_17\NN\14299637|associated|,
D006493_D004802 CID heparin_7\NN\2718259| (r_npadvmod) induced_9\VBN\1627355|osteoporosis|, (r_amod) thrombocytopenia_10\NN\14189204|NONE (l_conj) osteoporosis_15\NN\14204950|induced|, (l_conj) eosinophilia_17\NN\14299637|associated|,
D006493_D004802 CID heparin_12\NN\2718259| (r_npadvmod) associated_14\VBN\628491|eosinophilia|, (r_amod) osteoporosis_15\NN\14204950|induced|, (l_conj) eosinophilia_17\NN\14299637|associated|,
24582773
C069541_D011595 CID quetiapine_11\NN\0|high|add||in (r_amod) doses_10\NNS\3740161|NONE (r_pobj) by_4\IN\0|agitation|. (r_prep) induced_3\VBN\1627355|NONE (l_nsubj) agitation_2\NN\14373582|.|by
C069541_D011595 CID quetiapine_9\NN\0|NONE (r_pobj) of_8\IN\0|the|)|(|gradual|day (r_prep) introduction_7\NN\235435|NONE (r_pobj) following_4\VBG\8180190|the| (r_prep) h_3\NN\14622893|NONE (r_pobj) within_0\IN\0|,|patient|contrasting|,|agitation|without|. (r_prep) presented_21\VBD\2137132|NONE (l_dobj) agitation_23\NN\14373582|,|patient|Within|contrasting|,|without|.
C069541_D011595 CID quetiapine_7\NN\0|NONE (r_pobj) of_6\IN\0|later|,|the|gradual|,|led (r_prep) reintroduction_5\NN\7217349|The|and (l_relcl) led_13\VBD\3202760|of|later|,|the|gradual|, (l_prep) to_14\IN\0|which (l_pobj) agitation_17\NN\14373582|NONE
C069541_D011595 CID quetiapine_7\NN\0|NONE (r_pobj) of_6\IN\0|later|,|the|gradual|,|led (r_prep) reintroduction_5\NN\7217349|The|and (r_conj) withdrawal_1\NN\7206096|us|attribute|. (r_nsubj) enabled_19\VBD\126264|NONE (l_xcomp) attribute_22\VB\5835747|withdrawal|us|. (l_dobj) agitation_24\NN\14373582|to|to
C069541_D011595 CID quetiapine_27\NN\0|specifically (r_pobj) to_26\IN\0|to|agitation (r_prep) attribute_22\VB\5835747|withdrawal|us|. (r_xcomp) enabled_19\VBD\126264|NONE (l_nsubj) withdrawal_1\NN\7206096|us|attribute|. (l_conj) reintroduction_5\NN\7217349|The|and (l_relcl) led_13\VBD\3202760|of|later|,|the|gradual|, (l_prep) to_14\IN\0|which (l_pobj) agitation_17\NN\14373582|NONE
C069541_D011595 CID quetiapine_27\NN\0|specifically (r_pobj) to_26\IN\0|to|agitation (r_prep) attribute_22\VB\5835747|withdrawal|us|. (l_dobj) agitation_24\NN\14373582|to|to
D008094_D011618 NONE lithium_41\NN\14625458|day|and (r_conj) zuclopenthixol_33\NN\0|,|generation (r_appos) antipsychotics_31\NNS\4470232|NONE (r_pobj) of_27\IN\0|a (r_prep) combination_26\NN\7951464|NONE (r_pobj) by_24\IN\0|serum (r_agent) treated_23\VBN\2376958|of|,|the|since (r_acl) case_3\NN\7283608|We|. (l_prep) of_4\IN\0|,|treated|the|since (l_pobj) suffering_10\NN\14322699|NONE (l_prep) from_11\IN\0|a|old|patient (l_pobj) disorder_15\NN\14034177|NONE
D008094_D011618 NONE lithium=0.85_50\NN\0|)|l|( (r_punct) serum_49\NN\5397468|by (r_parataxis) treated_23\VBN\2376958|of|,|the|since (r_acl) case_3\NN\7283608|We|. (l_prep) of_4\IN\0|,|treated|the|since (l_pobj) suffering_10\NN\14322699|NONE (l_prep) from_11\IN\0|a|old|patient (l_pobj) disorder_15\NN\14034177|NONE
C069541_D010554 NONE quetiapine_9\NN\0|NONE (r_pobj) of_8\IN\0|the|)|(|gradual|day (r_prep) introduction_7\NN\235435|NONE (r_pobj) following_4\VBG\8180190|the| (r_prep) h_3\NN\14622893|NONE (r_pobj) within_0\IN\0|,|patient|contrasting|,|agitation|without|. (r_prep) presented_21\VBD\2137132|NONE (l_advcl) contrasting_29\VBG\650353|,|patient|Within|,|agitation|without|. (l_prep) with_30\IN\0|NONE (l_pobj) absence_32\NN\14449405|NONE (l_prep) of_33\IN\0|the (l_pobj) history_35\NN\15120823|NONE (l_prep) of_36\IN\0|a (l_pobj) aggressiveness_37\NN\4835724|NONE
C069541_D010554 NONE quetiapine_9\NN\0|NONE (r_pobj) of_8\IN\0|the|)|(|gradual|day (r_prep) introduction_7\NN\235435|NONE (r_pobj) following_4\VBG\8180190|the| (r_prep) h_3\NN\14622893|NONE (r_pobj) within_0\IN\0|,|patient|contrasting|,|agitation|without|. (r_prep) presented_21\VBD\2137132|NONE (l_advcl) contrasting_29\VBG\650353|,|patient|Within|,|agitation|without|. (l_prep) with_30\IN\0|NONE (l_pobj) absence_32\NN\14449405|NONE (l_prep) of_33\IN\0|the (l_pobj) history_35\NN\15120823|NONE (l_prep) of_36\IN\0|a (l_pobj) aggressiveness_37\NN\4835724|NONE (l_conj) disorder_40\NN\14034177|or
C069541_D011618 NONE quetiapine_11\NN\0|high|add||in (r_amod) doses_10\NNS\3740161|NONE (l_prep) in_12\IN\13603305|high|add||quetiapine (l_pobj) disorder_16\NN\14034177|NONE
D003006_D011618 NONE zuclopenthixol_33\NN\0|,|generation (r_appos) antipsychotics_31\NNS\4470232|NONE (r_pobj) of_27\IN\0|a (r_prep) combination_26\NN\7951464|NONE (r_pobj) by_24\IN\0|serum (r_agent) treated_23\VBN\2376958|of|,|the|since (r_acl) case_3\NN\7283608|We|. (l_prep) of_4\IN\0|,|treated|the|since (l_pobj) suffering_10\NN\14322699|NONE (l_prep) from_11\IN\0|a|old|patient (l_pobj) disorder_15\NN\14034177|NONE
24459006
D015725_D013921 CID fluconazole_0\NNP\0|.|agranulocytosis (r_nsubj) associated_1\VBD\628491|NONE (l_dobj) agranulocytosis_2\NN\14189204|Fluconazole|. (l_conj) thrombocytopenia_4\NN\14189204|and
D015725_D013921 CID fluconazole_6\NN\0|NONE (r_pobj) of_5\IN\0|a|second (r_prep) case_4\NN\7283608|We|agranulocytosis|. (r_dobj) describe_1\VBP\1001294|NONE (l_dobj) agranulocytosis_8\NN\14189204|We|case|. (l_prep) with_9\IN\0|associated (l_pobj) thrombocytopenia_10\NN\14189204|NONE
D015725_D013921 CID fluconazole_21\NN\0|NONE (r_pobj) with_20\IN\0|NONE (r_prep) therapy_19\NN\657604|NONE (r_pobj) of_18\IN\0|a (r_prep) result_17\NN\34213|NONE (r_pobj) as_15\IN\14622893|agranulocytosis|that (r_prep) occurred_14\VBD\0|the (l_nsubj) agranulocytosis_11\NN\14189204|as|that (l_conj) thrombocytopenia_13\NN\14189204|patient|and
D015725_D001855 NONE fluconazole_13\NN\0|NONE (r_pobj) of_12\IN\0|and|the|abatement (r_prep) initiation_11\NN\7450842|NONE (r_pobj) to_9\IN\0|temporal|of|the (r_prep) relationship_4\NN\31921|particular|. (l_prep) of_5\IN\0|to|temporal|the (l_pobj) suppression_8\NN\13489037|NONE
D015725_D000380 CID fluconazole_0\NNP\0|.|agranulocytosis (r_nsubj) associated_1\VBD\628491|NONE (l_dobj) agranulocytosis_2\NN\14189204|Fluconazole|.
D015725_D000380 CID fluconazole_6\NN\0|NONE (r_pobj) of_5\IN\0|a|second (r_prep) case_4\NN\7283608|We|agranulocytosis|. (r_dobj) describe_1\VBP\1001294|NONE (l_dobj) agranulocytosis_8\NN\14189204|We|case|.
D015725_D000380 CID fluconazole_21\NN\0|NONE (r_pobj) with_20\IN\0|NONE (r_prep) therapy_19\NN\657604|NONE (r_pobj) of_18\IN\0|a (r_prep) result_17\NN\34213|NONE (r_pobj) as_15\IN\14622893|agranulocytosis|that (r_prep) occurred_14\VBD\0|the (l_nsubj) agranulocytosis_11\NN\14189204|as|that
24234943
C086816_D001008 CID desvenlafaxine_3\NN\0|included|and|medications|, (r_dobj) included_2\VBD\0|NONE (l_conj) included_7\VBD\0|and|medications|,|desvenlafaxine (l_dobj) nausea_8\NN\14299637|symptoms|. (l_conj) anxiety_10\NN\14373582|,
C086816_D007177 CID desvenlafaxine_8\NN\0|NONE (r_pobj) with_7\IN\0|NONE (r_prep) associated_6\VBN\628491|hormone|antidiuretic|inappropriate (r_acl) secretion_5\NN\13526110|NONE (l_compound) hormone_4\NN\5404728|antidiuretic|associated|inappropriate
C086816_D007177 CID desvenlafaxine_18\NN\0|NONE (r_pobj) with_17\IN\0|NONE (r_prep) associated_16\VBN\628491|)|hormone|inappropriate|SIADH|( (r_acl) secretion_15\NN\13526110|NONE (l_nmod) hormone_11\NN\5404728|)|inappropriate|SIADH|(|associated
C086816_D007177 CID desvenlafaxine_18\NN\0|NONE (r_pobj) with_17\IN\0|NONE (r_prep) associated_16\VBN\628491|)|hormone|inappropriate|SIADH|( (r_acl) secretion_15\NN\13526110|NONE (l_nmod) siadh_13\NNP\0|)|hormone|inappropriate|(|associated
C086816_D009325 CID desvenlafaxine_3\NN\0|included|and|medications|, (r_dobj) included_2\VBD\0|NONE (l_conj) included_7\VBD\0|and|medications|,|desvenlafaxine (l_dobj) nausea_8\NN\14299637|symptoms|.
C086816_D003221 CID desvenlafaxine_3\NN\0|included|and|medications|, (r_dobj) included_2\VBD\0|NONE (l_conj) included_7\VBD\0|and|medications|,|desvenlafaxine (l_dobj) nausea_8\NN\14299637|symptoms|. (l_conj) anxiety_10\NN\14373582|, (l_conj) confusion_12\NN\13972797|and
C086816_D007010 CID desvenlafaxine_5\NN\0|might|hyponatremia|that (r_nsubj) cause_7\VB\7323922|report|. (l_dobj) hyponatremia_10\NN\14299637|might|desvenlafaxine|that
D012964_D007177 NONE sodium_2\NN\14625458|L (r_nsubj) was_6\VBD\0|osmolality|mosmol|.|, (r_ccomp) was_14\VBD\0|NONE (l_attr) mosmol_16\NN\0|osmolality|was|.|, (l_amod) consistent_34\JJ\0|,|,|/|kg|osmolality| (l_prep) with_35\IN\0|NONE (l_pobj) diagnosis_37\NN\152018|NONE (l_prep) of_38\IN\0|a (l_pobj) siadh_39\NNP\0|NONE
D012964_D007177 NONE sodium_28\NN\14625458|and|L|/|mosmol (r_conj) kg_25\NNS\13717155|urine (r_appos) osmolality_21\NN\0|,|,|/|kg|consistent| (r_appos) mosmol_16\NN\0|osmolality|was|.|, (l_amod) consistent_34\JJ\0|,|,|/|kg|osmolality| (l_prep) with_35\IN\0|NONE (l_pobj) diagnosis_37\NN\152018|NONE (l_prep) of_38\IN\0|a (l_pobj) siadh_39\NNP\0|NONE
8829135
D001058_D000647 CID apomorphine_5\NN\3786417| (r_npadvmod) induced_7\VBN\1627355|of (r_amod) amnesia_8\NN\5669934|Nefiracetam
D001058_D000647 CID apomorphine_2\NN\3786417|NONE (r_pobj) given_0\VBN\5892096|retention|given (r_prep) inhibits_3\VBZ\2510337|,|.|ability|we (r_ccomp) evaluated_24\VBD\670261|NONE (l_dobj) ability_26\NN\4723816|,|.|inhibits|we (l_acl) attenuate_30\VB\224901|the|of (l_dobj) amnesia_31\NN\5669934|to
D001058_D000647 CID apomorphine_13\NN\3786417|NONE (r_pobj) by_12\IN\0|at (r_agent) induced_11\VBN\1627355|the (r_acl) amnesia_10\NN\5669934|However|was|administration|,|completely|and
D011760_D007859 NONE pyrrolidone_4\NN\0|a|attenuates|novel (r_compound) derivative_5\NN\5802185|.|Nefiracetam (l_relcl) attenuates_7\VBZ\224901|a|novel|pyrrolidone (l_dobj) learning_11\NN\5701944|which (l_conj) deficits_17\NNS\5113133|induced|and
C058876_D007859 NONE nefiracetam_0\NNP\0|.|derivative (r_nsubj) is_1\VBZ\0|NONE (l_attr) derivative_5\NN\5802185|.|Nefiracetam (l_relcl) attenuates_7\VBZ\224901|a|novel|pyrrolidone (l_dobj) learning_11\NN\5701944|which (l_conj) deficits_17\NNS\5113133|induced|and
D012601_D007859 CID scopolamine_8\NN\14712692| (r_npadvmod) induced_10\VBN\1627355|deficits|and (r_amod) learning_11\NN\5701944|which (l_conj) deficits_17\NNS\5113133|induced|and
C058876_D000647 NONE nefiracetam_0\NNP\0|amnesia (r_nsubj) reverses_4\VBZ\13854649|emergence|.|: (l_dobj) amnesia_8\NN\5669934|Nefiracetam
C058876_D000647 NONE dm-9384_2\NNP\0|(|) (r_appos) nefiracetam_0\NNP\0|amnesia (r_nsubj) reverses_4\VBZ\13854649|emergence|.|: (l_dobj) amnesia_8\NN\5669934|Nefiracetam
C058876_D000647 NONE nefiracetam_28\NN\0|NONE (r_pobj) of_27\IN\0|attenuate|the (r_prep) ability_26\NN\4723816|,|.|inhibits|we (l_acl) attenuate_30\VB\224901|the|of (l_dobj) amnesia_31\NN\5669934|to
C058876_D000647 NONE nefiracetam_4\NN\0|NONE (r_pobj) of_3\IN\0|during (r_prep) administration_2\NN\1133281|However|was|amnesia|,|completely|and (r_nsubj) reversed_8\VBD\109660|NONE (l_dobj) amnesia_10\NN\5669934|However|was|administration|,|completely|and
24709919
C035054_D006930 NONE ginsenosides_15\NNS\0|NONE (l_prep) on_23\IN\0|components|,|,|Re (l_pobj) oih_24\NNP\0|NONE
C035054_D006930 NONE ginsenosides_6\NNS\0|However|prevent|,|. (r_nsubj) failed_7\VBD\0|NONE (l_xcomp) prevent_9\VB\0|However|ginsenosides|,|. (l_dobj) oih_10\NNP\0|in|to
C035054_D006930 NONE rg1_2\NNP\0|tendency|.|,|Furthermore (r_nsubj) showed_3\VBD\2137132|NONE (l_dobj) tendency_5\NN\6193203|.|,|Rg|Furthermore (l_acl) aggravate_7\VB\126264|a (l_dobj) oih_8\NNP\0|in|to
C035054_D006930 NONE rg1_10\NN\0|the|but|Re (r_conj) ginsenoside_5\NN\0|that|,|toward|may (r_nsubj) contribute_15\VB\126264|data|. (l_prep) toward_16\IN\0|ginsenoside|that|,|may (l_pobj) reversal_17\NN\199130|NONE (l_prep) of_18\IN\0|NONE (l_pobj) oih_19\NNP\0|NONE
D009020_D006930 CID morphine_9\NN\2707683|NONE (r_pobj) of_8\IN\0|subcutaneous (r_prep) administration_7\NN\1133281|NONE (r_pobj) after_5\IN\0|was|OIH|in|for|. (r_prep) achieved_2\VBN\2524171|NONE (l_nsubjpass) oih_0\NNP\0|was|in|after|for|.
D036145_D006930 NONE ginsenosides_2\NNS\0|NONE (l_prep) on_3\IN\0|NONE (l_pobj) hyperalgesia_7\NN\0|NONE
C049864_D006930 NONE ginsenosides_15\NNS\0|NONE (l_prep) on_23\IN\0|components|,|,|Re (l_pobj) oih_24\NNP\0|NONE
C049864_D006930 NONE re_0\IN\14625458|NONE (l_appos) mg/kg_3\NNS\0|.|( (l_dobj) oih_6\NNP\0||in
C049864_D006930 NONE re_6\IN\14625458|the|but|Rg (r_prep) ginsenoside_5\NN\0|that|,|toward|may (r_nsubj) contribute_15\VB\126264|data|. (l_prep) toward_16\IN\0|ginsenoside|that|,|may (l_pobj) reversal_17\NN\199130|NONE (l_prep) of_18\IN\0|NONE (l_pobj) oih_19\NNP\0|NONE
D019342_D006930 NONE acid_16\NN\14818238||writhing (r_npadvmod) induced_18\VBN\1627355|the (r_advcl) acetic_15\JJ\0|the|sensitivity|both|and (r_conj) test_12\NN\5798043|NONE (r_pobj) in_7\IN\13603305||OIH (r_prep) mg/kg_3\NNS\0|.|( (l_dobj) oih_6\NNP\0||in
D019342_D006930 NONE acid_12\NN\14818238|the||acetic (r_npadvmod) induced_14\VBN\1627355|NONE (r_amod) writhing_15\VBG\1831531|NONE (r_compound) test_16\NN\5798043|NONE (r_pobj) in_9\IN\13603305|OIH|to (r_prep) aggravate_7\VB\126264|a (l_dobj) oih_8\NNP\0|in|to
C442759_D006930 NONE ginsenosides_15\NNS\0|NONE (l_prep) on_23\IN\0|components|,|,|Re (l_pobj) oih_24\NNP\0|NONE
C442759_D006930 NONE ginsenosides_6\NNS\0|However|prevent|,|. (r_nsubj) failed_7\VBD\0|NONE (l_xcomp) prevent_9\VB\0|However|ginsenosides|,|. (l_dobj) oih_10\NNP\0|in|to
C442759_D006930 NONE rb1_12\NN\0|not|or (r_conj) rg1_10\NN\0|the|but|Re (r_conj) ginsenoside_5\NN\0|that|,|toward|may (r_nsubj) contribute_15\VB\126264|data|. (l_prep) toward_16\IN\0|ginsenoside|that|,|may (l_pobj) reversal_17\NN\199130|NONE (l_prep) of_18\IN\0|NONE (l_pobj) oih_19\NNP\0|NONE
689020
D005280_D014202 CID hydrobromide_6\NN\0|NONE (r_compound) infusion_7\NN\14589223|NONE (r_pobj) of_3\IN\0|the (r_prep) end_2\NN\8568978|NONE (r_pobj) after_0\IN\0|.|amplitudes|,|faster (r_prep) decreased_11\VBD\169651|NONE (l_nsubj) amplitudes_10\NNS\7444668|.|After|,|faster (l_compound) tremor_9\NN\345926|NONE
D012312_D014202 CID hcl_19\NN\0|NONE (r_compound) infusion_20\NN\14589223|NONE (r_pobj) following_16\VBG\8180190|NONE (r_acl) those_15\DT\0|NONE (r_pobj) than_14\IN\0|significantly (r_prep) faster_13\RBR\0|.|After|amplitudes|, (r_advmod) decreased_11\VBD\169651|NONE (l_nsubj) amplitudes_10\NNS\7444668|.|After|,|faster (l_compound) tremor_9\NN\345926|NONE
19392810
D003932_D012206 CID heroin_7\NN\3492717| (r_npadvmod) dependent_9\JJ\9627906|a (r_amod) male_10\NN\15388|NONE (r_pobj) in_5\IN\13603305|.|Rhabdomyolysis|under|ischemic (r_prep) stroke_4\NN\556313|NONE (l_nmod) rhabdomyolysis_0\NNP\0|.|under|in|ischemic
D003932_D012206 CID heroin_14\NN\3492717|NONE (r_pobj) after_12\IN\0|with|man|. (r_prep) presented_5\VBN\2137132|NONE (l_prep) with_6\IN\0|man|.|after (l_pobj) rhabdomyolysis_7\NN\0|NONE
D003932_D012206 CID heroin_4\NN\3492717|and (r_conj) methadone_2\NN\3808564|simultaneously (r_dobj) using_1\VBG\418025|NONE (r_acl) those_0\DT\0|.|risk|may (r_nsubj) increase_7\VB\13576355|NONE (l_dobj) risk_8\NN\14541044|.|Those|may (l_prep) of_9\IN\0|NONE (l_pobj) rhabdomyolysis_10\NN\0|NONE
D003932_D012206 CID heroin_2\NN\3492717| (r_npadvmod) related_4\VBN\628491|stroke|and (r_amod) rhabdomyolysis_5\NN\0|NONE
D003932_D012206 CID heroin_9\NN\3492717|NONE (r_compound) abusers_10\NNS\9633969|NONE (r_pobj) in_8\IN\13603305|NONE (r_prep) stroke_7\NN\556313|and|related (r_conj) rhabdomyolysis_5\NN\0|NONE
D003932_D002544 NONE heroin_7\NN\3492717| (r_npadvmod) dependent_9\JJ\9627906|a (r_amod) male_10\NN\15388|NONE (r_pobj) in_5\IN\13603305|.|Rhabdomyolysis|under|ischemic (r_prep) stroke_4\NN\556313|NONE
D003932_D002544 NONE heroin_14\NN\3492717|NONE (r_pobj) after_12\IN\0|with|man|. (r_prep) presented_5\VBN\2137132|NONE (l_prep) with_6\IN\0|man|.|after (l_pobj) rhabdomyolysis_7\NN\0|NONE (l_conj) stroke_11\NN\556313|and
D003932_D002544 NONE heroin_4\NN\3492717|and (r_conj) methadone_2\NN\3808564|simultaneously (r_dobj) using_1\VBG\418025|NONE (r_acl) those_0\DT\0|.|risk|may (r_nsubj) increase_7\VB\13576355|NONE (l_dobj) risk_8\NN\14541044|.|Those|may (l_prep) of_9\IN\0|NONE (l_pobj) rhabdomyolysis_10\NN\0|NONE (l_conj) stroke_13\NN\556313|and
D008691_D012206 CID methadone_12\NN\3808564|maintenance (r_compound) therapy_14\NN\657604|NONE (r_pobj) under_11\IN\0|.|Rhabdomyolysis|in|ischemic (r_prep) stroke_4\NN\556313|NONE (l_nmod) rhabdomyolysis_0\NNP\0|.|under|in|ischemic
D008691_D012206 CID methadone_2\NN\3808564|simultaneously (r_dobj) using_1\VBG\418025|NONE (r_acl) those_0\DT\0|.|risk|may (r_nsubj) increase_7\VB\13576355|NONE (l_dobj) risk_8\NN\14541044|.|Those|may (l_prep) of_9\IN\0|NONE (l_pobj) rhabdomyolysis_10\NN\0|NONE
D003932_D020521 CID heroin_2\NN\3492717| (r_npadvmod) related_4\VBN\628491|stroke|and (r_amod) rhabdomyolysis_5\NN\0|NONE (l_conj) stroke_7\NN\556313|and|related
D003932_D020521 CID heroin_9\NN\3492717|NONE (r_compound) abusers_10\NNS\9633969|NONE (r_pobj) in_8\IN\13603305|NONE (r_prep) stroke_7\NN\556313|and|related
D008691_D002544 NONE methadone_12\NN\3808564|maintenance (r_compound) therapy_14\NN\657604|NONE (r_pobj) under_11\IN\0|.|Rhabdomyolysis|in|ischemic (r_prep) stroke_4\NN\556313|NONE
D008691_D002544 NONE methadone_2\NN\3808564|simultaneously (r_dobj) using_1\VBG\418025|NONE (r_acl) those_0\DT\0|.|risk|may (r_nsubj) increase_7\VB\13576355|NONE (l_dobj) risk_8\NN\14541044|.|Those|may (l_prep) of_9\IN\0|NONE (l_pobj) rhabdomyolysis_10\NN\0|NONE (l_conj) stroke_13\NN\556313|and
24451297
C065180_D056486 CID fluvastatin_10\NNP\3676175|NONE (r_compound) therapy_11\NNP\657604|NONE (r_pobj) after_9\IN\0| (r_prep) hours_8\NNS\15118228|NONE (r_pobj) within_6\IN\0|Liver|.|Induced|Acute (r_prep) injury_5\NN\14052046|NONE
C065180_D056486 CID fluvastatin_19\NN\3676175|NONE (r_pobj) with_18\IN\0|NONE (r_prep) treatment_17\NN\654885|NONE (r_dobj) beginning_16\VBG\7283608|hours (r_pcomp) after_15\IN\0|which (r_prep) appeared_12\VBD\2604760|,|liver (r_relcl) damage_9\NN\7296428|NONE
D019161_D056486 NONE statins_1\NNS\3740161|Although|generally|drugs (r_nsubj) are_2\VBP\13600404|been|cases|have|.|, (r_advcl) reported_23\VBN\831651|NONE (l_nsubjpass) cases_10\NNS\7283608|been|are|have|.|, (l_prep) of_11\IN\0|associated|recent (l_pobj) injury_16\NN\14052046|NONE
15229250
D008694_D006984 NONE ma_3\NNP\10332385|NONE (r_compound) abusers_4\NNS\9633969|.|On|.|volumes|, (r_nsubj) had_5\VBD\0|NONE (l_dobj) 0.05_29\CD\0|.|On|abusers|volumes|, (l_conj) hypertrophy_36\NN\14365950|.|;|)|,|;|right|and|<|p
D008694_D008659 NONE ma_7\NNP\10332385|have|who (r_dobj) used_6\VBN\0|human (r_relcl) subjects_3\NNS\6598915|NONE (r_pobj) of_1\IN\0|NONE (r_prep) studies_0\NNS\635850|.|deficits|have|chronically (r_nsubj) revealed_10\VBN\2137132|NONE (l_dobj) deficits_11\NNS\5113133|.|have|chronically|Studies (l_prep) in_12\IN\13603305|NONE (l_pobj) systems_16\NNS\3575240|NONE (l_conj) abnormalities_20\NNS\14034177|dopaminergic|and
D008694_D008569 CID methamphetamine_7\NN\2704153|chronic (r_compound) abuse_8\NN\418025|pattern|that (r_nsubj) causes_9\VBZ\7323922|maps|. (l_dobj) pattern_12\NN\5726345|abuse|that (l_prep) of_13\IN\0|selective|a (l_pobj) deterioration_15\NN\14560612|NONE (l_relcl) contributes_17\VBZ\126264|cerebral (l_prep) to_18\IN\0|that (l_pobj) performance_21\NN\6619065|NONE
D008694_D003072 NONE ma_26\NNP\10332385|in|chronic (r_compound) abuse_27\NN\418025|NONE (r_pobj) with_24\IN\0|NONE (r_prep) associated_23\VBN\628491|structural|brain (r_acl) alterations_22\NNS\7283608|NONE (r_pobj) of_19\IN\0|the (r_prep) pattern_18\NN\5726345|related|we|and|.|,|Using (r_dobj) determined_16\VBD\0|NONE (l_conj) related_32\VBD\628491|we|and|.|,|pattern|Using (l_prep) to_35\IN\0|deficits (l_pobj) impairment_37\NN\7296428|NONE
D008694_D001930 CID methamphetamine_20\NN\2704153|NONE (r_pobj) with_18\IN\0|NONE (r_prep) associated_17\VBN\628491|human|the (r_acl) brain_16\NN\5462674|NONE
D008694_D001930 CID ma_22\NNP\10332385|(|) (r_nmod) abuse_24\NN\418025|chronic (r_appos) methamphetamine_20\NN\2704153|NONE (r_pobj) with_18\IN\0|NONE (r_prep) associated_17\VBN\628491|human|the (r_acl) brain_16\NN\5462674|NONE
D008694_D001930 CID ma_34\NNP\10332385|who (r_dobj) used_33\VBD\0|human| (r_relcl) subjects_31\NNS\6598915|NONE (r_pobj) in_28\IN\13603305|NONE (r_prep) ventricles_27\NNS\5303402|and|white|,
D008694_D001930 CID ma_10\NNP\10332385|NONE (r_compound) abuse_11\NN\418025|NONE (r_pobj) of_9\IN\0|the (r_prep) symptoms_8\NNS\5823932|NONE (r_pobj) for_6\IN\0|NONE (r_prep) account_5\VB\6647206|.|providing|,|may|substrates (r_xcomp) help_4\VB\407535|NONE (l_advcl) providing_13\VBG\2199590|.|,|account|may|substrates (l_dobj) targets_15\NNS\7258332|NONE (l_prep) for_16\IN\0|therapeutic (l_pobj) injury_21\NN\14052046|NONE
16867246
D002746_D012559 NONE chlorpromazine_5\NN\3713736| (r_npadvmod) induced_7\VBN\1627355|and|DRD (r_conj) polymorphisms_3\NNS\11418750|in|extrapyramidal (r_nmod) syndrome_9\NN\5870365|NONE (l_prep) in_10\IN\13603305|polymorphisms|extrapyramidal (l_pobj) patients_13\NNS\9898892|NONE (l_amod) schizophrenic_12\JJ\10490141|Chinese
D002746_D012559 NONE chlorpromazine_11\NN\3713736| (r_npadvmod) induced_13\VBN\1627355|in (r_amod) eps_14\NNP\0|NONE (l_prep) in_15\IN\13603305|induced (l_pobj) patients_17\NNS\9898892|NONE (l_amod) schizophrenic_16\JJ\10490141|NONE
D002746_D012559 NONE chlorpromazine_38\NN\3713736|NONE (r_pobj) with_37\IN\0|,|after|TaqIB|.|rs (r_prep) treated_36\VBN\2376958|NONE (l_nsubj) rs6275_6\ADD\0|,|after|TaqIB|.|with (l_prep) in_12\IN\13603305|rs|SerCys|)|,|, (l_pobj) gene_15\NN\8459252|NONE (l_prep) in_16\IN\13603305|DRD|the (l_pobj) inpatients_19\NNS\10405694|NONE (l_amod) schizophrenic_18\JJ\10490141|(|according||
D002746_D012559 NONE chlorpromazine_30\NN\3713736|NONE (r_pobj) by_29\IN\0|NONE (r_agent) induced_28\VBN\1627355|the|variable|adverse (r_acl) effect_27\NN\34213|NONE (r_pobj) in_22\IN\13603305|variation|that|in|,|role (r_prep) plays_18\VBZ\7007684|the (l_prep) in_34\IN\13603305|variation|in|that|,|role (l_pobj) patients_36\NNS\9898892|least (l_prep) with_37\IN\0|Chinese (l_pobj) schizophrenia_38\NN\14398067|NONE
D002746_D001480 CID chlorpromazine_5\NN\3713736| (r_npadvmod) induced_7\VBN\1627355|and|DRD (r_conj) polymorphisms_3\NNS\11418750|in|extrapyramidal (r_nmod) syndrome_9\NN\5870365|NONE
D002746_D001480 CID chlorpromazine_11\NN\3713736| (r_npadvmod) induced_13\VBN\1627355|in (r_amod) eps_14\NNP\0|NONE
D002746_D001480 CID chlorpromazine_38\NN\3713736|NONE (r_pobj) with_37\IN\0|,|after|TaqIB|.|rs (r_prep) treated_36\VBN\2376958|NONE (l_nsubj) rs6275_6\ADD\0|,|after|TaqIB|.|with (l_prep) in_12\IN\13603305|rs|SerCys|)|,|, (l_pobj) gene_15\NN\8459252|NONE (l_prep) in_16\IN\13603305|DRD|the (l_pobj) inpatients_19\NNS\10405694|NONE (l_appos) 59_21\CD\0|schizophrenic|(|according| (l_prep) with_22\IN\0||and (l_pobj) eps_23\NNP\0|NONE
D002746_D001480 CID chlorpromazine_38\NN\3713736|NONE (r_pobj) with_37\IN\0|,|after|TaqIB|.|rs (r_prep) treated_36\VBN\2376958|NONE (l_nsubj) rs6275_6\ADD\0|,|after|TaqIB|.|with (l_prep) in_12\IN\13603305|rs|SerCys|)|,|, (l_pobj) gene_15\NN\8459252|NONE (l_prep) in_16\IN\13603305|DRD|the (l_pobj) inpatients_19\NNS\10405694|NONE (l_appos) 59_21\CD\0|schizophrenic|(|according| (l_conj) 87_25\CD\0|and|with (l_prep) without_26\IN\0|NONE (l_pobj) eps_27\NNP\0|NONE
611664
D009638_D004342 NONE norepinephrine_27\NN\14807929|NONE (r_pobj) of_25\IN\0|the|pressor (r_prep) effects_24\NNS\13245626|NONE (r_pobj) to_21\IN\0|NONE (r_prep) hypersensitivity_20\NN\14531772|had
D002395_D004342 NONE catecholamines_6\NNS\5407119|They|marked|.|and (r_dobj) exhibited_2\VBD\2632167|NONE (l_conj) marked_19\VBN\1296462|They|catecholamines|.|and (l_dobj) hypersensitivity_20\NN\14531772|had
D011433_D006973 CID propranolol_9\NN\0|NONE (r_pobj) by_8\IN\0|hypertension|,|In|and|was|had (r_agent) induced_7\VBN\1627355|NONE (l_nsubjpass) hypertension_5\NN\14057371|,|by|In|and|was|had
D011433_C544351 NONE propranolol_2\NN\0|NONE (l_prep) in_3\IN\13603305|NONE (l_pobj) treatment_5\NN\654885|NONE (l_prep) of_6\IN\0|the (l_pobj) hypotension_9\NN\14057371|NONE
D011433_C544351 NONE propranolol_4\NN\0|that|drug (r_nsubj) is_5\VBZ\0|.|studies (l_attr) drug_8\NN\14778436|that|propranolol (l_prep) in_9\IN\13603305|useful|a (l_pobj) patients_11\NNS\9898892|NONE (l_prep) with_12\IN\0|selected (l_pobj) hypotension_16\NN\14057371|NONE
20513036
C542870_D010243 NONE botox_3\JJ\14587688|for (r_compound) injection_4\NN\320852|NONE (r_pobj) after_2\IN\0|.|Abductor (r_prep) paralysis_1\NN\14557898|NONE
C542870_D010243 NONE botox_10\NNP\14587688|complication|,|for (r_compound) injections_11\NNS\320852|NONE (r_pobj) following_9\VBG\8180190|.|cases|Here|we (r_prep) report_2\VBP\6470073|NONE (l_dobj) cases_4\NNS\7283608|.|following|Here|we (l_prep) of_5\IN\0|multiple (l_pobj) paralysis_8\NN\14557898|NONE
C542870_D010243 NONE botox_12\NNP\14587688|dose|paralytic|, (r_compound) dose_13\NN\3740161|, (r_conj) sex_9\NN\13440063|, (r_conj) age_7\NN\4916342|bilateral|,|abductor (r_conj) paralysis_5\NN\14557898|NONE
C542870_D010243 NONE botox_12\NNP\14587688|dose|paralytic|, (r_compound) dose_13\NN\3740161|, (l_conj) dose_17\NN\3740161|paralytic|Botox|, (l_conj) paralysis_22\NN\14557898|and|prior|course|,|Botox
C542870_D010243 NONE botox_16\NNP\14587688|and|prior|course|,|paralysis (r_compound) dose_17\NN\3740161|paralytic|Botox|, (r_conj) dose_13\NN\3740161|, (r_conj) sex_9\NN\13440063|, (r_conj) age_7\NN\4916342|bilateral|,|abductor (r_conj) paralysis_5\NN\14557898|NONE
C542870_D010243 NONE botox_16\NNP\14587688|and|prior|course|,|paralysis (r_compound) dose_17\NN\3740161|paralytic|Botox|, (l_conj) paralysis_22\NN\14557898|and|prior|course|,|Botox
C542870_D010243 NONE botox_6\NNP\14587688|for (r_compound) injection_7\NN\320852|NONE (r_pobj) after_5\IN\0|of|The (r_prep) incidence_1\NN\13821570|%|. (l_prep) of_2\IN\0|after|The (l_pobj) paralysis_4\NN\14557898|NONE
C542870_D010243 NONE botox_8\NNP\14587688|for (r_compound) injections_9\NNS\320852|NONE (r_pobj) of_7\IN\0|a|rare (r_prep) complication_6\NN\1073995|paralysis|causing|.|, (r_attr) is_3\VBZ\0|NONE (l_nsubj) paralysis_2\NN\14557898|complication|causing|.|,
C542870_D010243 NONE botox_8\NNP\14587688|NONE (r_pobj) of_7\IN\0|around (r_prep) diffusion_6\NN\13518963|.|mechanism (r_attr) is_5\VBZ\0|NONE (l_nsubj) mechanism_2\NN\13446390|diffusion|. (l_prep) of_3\IN\0|likely|The (l_pobj) paralysis_4\NN\14557898|NONE
C542870_D055154 NONE botox_5\NNP\14587688|NONE (r_compound) injections_6\NNS\320852|that|for (r_dobj) received_4\VBD\2210855|NONE (l_prep) for_7\IN\0|injections|that (l_pobj) dysphonia_9\NN\14400677|NONE
C542870_D014826 CID botox_3\JJ\14587688|for (r_compound) injection_4\NN\320852|NONE (l_prep) for_5\IN\0|botox (l_pobj) dysphonia_8\NN\14400677|NONE
C542870_D014826 CID botox_3\NNP\14587688|Botulinum|(|injections|) (r_appos) toxin_1\NN\15032376|.|standard (r_nsubj) are_10\VBP\13600404|NONE (l_attr) standard_13\NN\13577171|.|toxin (l_prep) for_16\IN\0|of|the|current (l_pobj) dysphonia_19\NN\14400677|NONE
C542870_D014826 CID botox_3\NNP\14587688|Botulinum|(|injections|) (r_appos) toxin_1\NN\15032376|.|standard (r_nsubj) are_10\VBP\13600404|NONE (l_attr) standard_13\NN\13577171|.|toxin (l_prep) for_16\IN\0|of|the|current (l_pobj) dysphonia_19\NN\14400677|NONE (l_appos) adsd_21\NNP\0|adductor|spasmodic|)|(
C542870_D014826 CID botox_10\NNP\14587688|complication|,|for (r_compound) injections_11\NNS\320852|NONE (l_prep) for_12\IN\0|complication|Botox|, (l_pobj) adsd_13\NNP\0|NONE
C542870_D014826 CID botox_7\NNP\14587688|NONE (r_dobj) receiving_6\VBG\2210855| (r_acl) patients_5\NNS\9898892|NONE (r_pobj) of_3\IN\0|a (r_prep) database_2\NN\6634376|NONE (r_pobj) from_0\IN\0|been|patients|with|had|,|. (r_prep) diagnosed_13\VBN\644583|NONE (l_prep) with_14\IN\0|been|patients|had|,|.|From (l_pobj) adsd_15\NNP\0|NONE
C542870_D014826 CID botox_6\NNP\14587688|for (r_compound) injection_7\NN\320852|NONE (l_prep) for_8\IN\0|Botox (l_pobj) adsd_9\NNP\0|NONE
C542870_D014826 CID botox_8\NNP\14587688|for (r_compound) injections_9\NNS\320852|NONE (l_prep) for_10\IN\0|Botox (l_pobj) adsd_11\NNP\0|NONE
2614930
D009543_D009422 NONE nifedipine_0\NNP\2938514|.|bradycardia|in (r_nsubj) induced_1\VBD\1627355|NONE (l_prep) in_3\IN\13603305|.|bradycardia|Nifedipine (l_pobj) patient_5\NN\9898892|NONE (l_prep) with_6\IN\0|a (l_pobj) neuropathy_8\NN\14204950|NONE
D009543_D013610 CID nifedipine_10\NN\2938514|in|that|tachycardia (r_nsubj) induces_11\VBZ\1627355|established|the (l_dobj) tachycardia_12\VBG\14110674|nifedipine|in|that
D009543_D001919 CID nifedipine_0\NNP\2938514|.|bradycardia|in (r_nsubj) induced_1\VBD\1627355|NONE (l_dobj) bradycardia_2\NNP\14110674|.|Nifedipine|in
D009543_D001282 NONE nifedipine_21\NN\2938514|to|down|which (r_advcl) slowed_14\VBD\151689|of|ventricular|a (r_relcl) rate_10\NN\13815152|NONE (r_pobj) at_7\IN\14622893|to|flutter (r_prep) have_4\VB\7846|was|He|. (l_dobj) flutter_6\NN\331950|at|to
24614773
D014635_D020325 NONE valproate_25\NN\0|on|been|had (l_prep) for_26\IN\0|NONE (l_pobj) migraine_29\NN\14326607|NONE
D014635_D010291 NONE valproate_25\NN\0|on|been|had (r_conj) started_23\VBN\0|patient|,|and|In|,|.|number (r_conj) had_7\VBD\0|NONE (l_dobj) number_9\NN\5107765|patient|,|and|started|In|,|. (l_prep) of_10\IN\0|a (l_pobj) admissions_11\NNS\49003|NONE (l_prep) with_12\IN\0|NONE (l_pobj) hemiparesis_15\NN\0|NONE
D014635_D001927 NONE valproate_4\VBP\0|Normoammonemic|:|? (r_acl) encephalopathy_1\NN\14084880|NONE
D014635_D001927 NONE valproate_4\NN\0| (r_npadvmod) induced_6\VBN\1627355|and|encephalitis (r_amod) encephalopathy_7\JJ\14084880|NONE
D016202_D004660 NONE nmda_9\NNP\0|associated (r_nmod) encephalitis_13\NN\14336539|and|induced
D016202_D001927 NONE aspartate_20\NNP\0|receptor|titre|low (r_nmod) antibodies_25\NNS\14728724|and|, (r_conj) encephalopathy_9\JJ\14084880|NONE
D016202_D001927 NONE nmda_22\NNP\0|)|( (r_nmod) receptor_24\NN\5225602|aspartate|titre|low (r_compound) antibodies_25\NNS\14728724|and|, (r_conj) encephalopathy_9\JJ\14084880|NONE
D016202_D001927 NONE nmda_9\NNP\0|associated (r_nmod) encephalitis_13\NN\14336539|and|induced (r_conj) encephalopathy_7\JJ\14084880|NONE
D014635_D004660 NONE valproate_4\NN\0| (r_npadvmod) induced_6\VBN\1627355|and|encephalitis (r_amod) encephalopathy_7\JJ\14084880|NONE (l_conj) encephalitis_13\NN\14336539|and|induced
17042797
D010862_D013226 CID pilocarpine_14\NN\14712692| (r_npadvmod) induced_16\VBN\1627355|epilepticus (r_amod) status_17\NN\24720|NONE (l_acl) epilepticus_18\NN\0|induced
D010862_D013226 CID pilocarpine_22\NN\14712692| (r_npadvmod) induced_24\VBN\1627355|NONE (r_amod) status_25\NN\24720|NONE (r_nsubj) epilepticus_26\NN\0|NONE
D010862_D004833 CID pilocarpine_16\NN\14712692|of|the (r_amod) model_17\NN\5888929|NONE (l_prep) of_18\IN\0|pilocarpine|the (l_pobj) epilepsy_21\NN\14085708|NONE
7378868
D010197_D014313 NONE pancuronium_21\NN\0|NONE (r_pobj) with_20\IN\0|NONE (r_prep) pretreatment_19\NN\0|NONE (r_pobj) despite_18\IN\7501545|in (r_prep) suxamethonium_12\NN\0|NONE (r_pobj) after_11\IN\0|that|rigidity|may (r_prep) occur_10\VB\0|.|case (l_nsubj) rigidity_6\NN\5023233|that|after|may
D013390_D063806 CID suxamethonium_0\NN\0| (r_npadvmod) induced_2\VBN\1627355|myalgia|associated|jaw|and (r_amod) stiffness_4\NN\5023233|.|case|: (l_conj) myalgia_6\NN\14322699|associated|jaw|induced|and
D013390_D063806 CID suxamethonium_12\NN\0|NONE (r_pobj) after_11\IN\0|that|rigidity|may (r_prep) occur_10\VB\0|.|case (l_nsubj) rigidity_6\NN\5023233|that|after|may (l_conj) myalgia_8\NN\14322699|prolonged|and|jaw
D013390_D014313 CID suxamethonium_0\NN\0| (r_npadvmod) induced_2\VBN\1627355|myalgia|associated|jaw|and (r_amod) stiffness_4\NN\5023233|.|case|:
D013390_D014313 CID suxamethonium_12\NN\0|NONE (r_pobj) after_11\IN\0|that|rigidity|may (r_prep) occur_10\VB\0|.|case (l_nsubj) rigidity_6\NN\5023233|that|after|may
D010197_D063806 NONE pancuronium_21\NN\0|NONE (r_pobj) with_20\IN\0|NONE (r_prep) pretreatment_19\NN\0|NONE (r_pobj) despite_18\IN\7501545|in (r_prep) suxamethonium_12\NN\0|NONE (r_pobj) after_11\IN\0|that|rigidity|may (r_prep) occur_10\VB\0|.|case (l_nsubj) rigidity_6\NN\5023233|that|after|may (l_conj) myalgia_8\NN\14322699|prolonged|and|jaw
9869655
D004997_D002780 CID ethinylestradiol_6\NNP\0|with|is|that (l_appos) cholestasis_10\NN\14052403||alpha
D004997_D002780 CID ee)-induced_8\VBN\0|in|intrahepatic|( (r_nmod) cholestasis_10\NN\14052403||alpha
D001647_D002780 NONE salt_24\NN\14818238|BS (r_nmod) synthesis_28\NN\13446390|NONE (r_pobj) of_22\IN\0|the|neutral (r_prep) pathway_21\NN\5483677|NONE (r_pobj) of_18\IN\0|selective (r_prep) inhibition_17\NN\1068773|NONE (r_pobj) with_15\IN\0|is|that|ethinylestradiol (r_prep) associated_14\VBN\628491|.|study (l_nsubjpass) ethinylestradiol_6\NNP\0|with|is|that (l_appos) cholestasis_10\NN\14052403||alpha
D001647_D002780 NONE bs_26\NN\6698252|salt (r_nmod) synthesis_28\NN\13446390|NONE (r_pobj) of_22\IN\0|the|neutral (r_prep) pathway_21\NN\5483677|NONE (r_pobj) of_18\IN\0|selective (r_prep) inhibition_17\NN\1068773|NONE (r_pobj) with_15\IN\0|is|that|ethinylestradiol (r_prep) associated_14\VBN\628491|.|study (l_nsubjpass) ethinylestradiol_6\NNP\0|with|is|that (l_appos) cholestasis_10\NN\14052403||alpha
11366874
D019888_D001145 NONE viracept_0\NNP\4013993|heartbeat|. (r_amod) warning_4\NN\7212190|NONE (l_compound) heartbeat_3\NN\7296190|.|Viracept
D019888_D001145 NONE viracept_11\NNP\4013993|that|may|beat (r_nsubj) cause_13\VB\7323922|.|group (l_ccomp) beat_17\VBD\8616311|that|may|Viracept
D019888_D001919 CID viracept_11\NNP\4013993|that|may|beat (r_nsubj) cause_13\VB\7323922|.|group (l_ccomp) beat_17\VBD\8616311|that|may|Viracept (l_advcl) known_19\VBN\0|,|,|in|heart (l_prep) as_20\IN\14622893|NONE (l_pobj) bradycardia_21\NNP\14110674|NONE
D019888_D001919 CID viracept_11\NNP\4013993|who (r_attr) was_10\VBD\0|male|a|old (r_relcl) patient_8\NN\9898892|NONE (r_pobj) in_2\IN\13603305|.|Bradycardia (r_prep) occurred_1\VBD\0|NONE (l_nsubj) bradycardia_0\NNS\14110674|.|in
11423811
D003042_D002637 CID cocaine_17\NN\3492717| (r_npadvmod) associated_19\VBN\628491|chest (r_amod) pain_21\NN\14299637|NONE
D003042_D002637 CID cocaine_9\NN\3492717|NONE (r_compound) use_10\NN\407535|NONE (r_pobj) of_8\IN\0|the (r_prep) setting_7\NN\8567235|NONE (r_pobj) in_5\IN\13603305|Chest (r_prep) pain_4\NN\14299637|dilemma
D003042_D002637 CID cocaine_13\NN\3492717|NONE (r_compound) use_14\NN\407535|NONE (r_pobj) of_12\IN\0|the (r_prep) setting_11\NN\8567235|NONE (r_pobj) in_9\IN\13603305|NONE (r_prep) dobutamine_8\NN\0|NONE (r_pobj) of_7\IN\0|NONE (r_prep) administration_6\NN\1133281|NONE (r_pobj) regarding_5\VBG\689344|theoretical|the (r_prep) concern_4\NN\5682950|of (r_pobj) because_0\IN\0|,|.|we|study (r_prep) conducted_17\VBD\2436349|NONE (l_dobj) study_20\NN\635850|Because|,|.|we (l_relcl) assess_22\VB\5220461|pilot|a (l_dobj) safety_24\NN\13920835|to (l_prep) in_27\IN\13603305|the|of (l_pobj) patients_30\NNS\9898892|NONE (l_prep) with_31\IN\0|department (l_pobj) pain_36\NN\14299637|NONE
D003042_D002637 CID cocaine_32\NN\3492717| (r_npadvmod) associated_34\VBN\628491|chest (r_amod) pain_36\NN\14299637|NONE
D003042_D002637 CID cocaine_9\NN\3492717|within|if|had|they|preceding|had|and (r_dobj) used_8\VBN\0|eligible|.|Patients (l_advcl) preceding_13\VBG\0|within|if|had|they|had|cocaine|and (l_dobj) onset_15\NN\7325190|NONE (l_prep) of_16\IN\0|the (l_pobj) pain_18\NN\14299637|NONE
D003042_D002637 CID cocaine_13\NN\3492717| (r_npadvmod) related_15\VBN\628491|chest (r_amod) pain_17\NN\14299637|NONE
D004280_D002637 NONE dobutamine_8\NN\0|echocardiography (r_compound) stress_9\NN\7083732|NONE (l_dobj) echocardiography_10\RB\177127|dobutamine (l_prep) in_11\IN\13603305|NONE (l_pobj) evaluation_15\NN\874067|NONE (l_prep) of_16\IN\0|department|the (l_pobj) pain_21\NN\14299637|NONE
D004280_D002637 NONE dobutamine_8\NN\0|NONE (r_pobj) of_7\IN\0|NONE (r_prep) administration_6\NN\1133281|NONE (r_pobj) regarding_5\VBG\689344|theoretical|the (r_prep) concern_4\NN\5682950|of (r_pobj) because_0\IN\0|,|.|we|study (r_prep) conducted_17\VBD\2436349|NONE (l_dobj) study_20\NN\635850|Because|,|.|we (l_relcl) assess_22\VB\5220461|pilot|a (l_dobj) safety_24\NN\13920835|to (l_prep) in_27\IN\13603305|the|of (l_pobj) patients_30\NNS\9898892|NONE (l_prep) with_31\IN\0|department (l_pobj) pain_36\NN\14299637|NONE
D004280_D002637 NONE dobutamine_7\NN\0|to|when|was (r_nsubjpass) administered_9\VBN\2436349|response|was|. (l_prep) to_10\IN\0|when|was|dobutamine (l_pobj) patients_11\NNS\9898892|NONE (l_prep) with_12\IN\0|NONE (l_pobj) pain_17\NN\14299637|NONE
D004280_D007511 NONE dobutamine_0\NNP\0|echocardiography (r_nsubj) stress_1\NN\7083732|test|. (r_nsubj) is_6\VBZ\0|NONE (l_attr) test_12\NN\5798043|stress|. (l_prep) for_13\IN\0|a|available (l_pcomp) evaluating_14\VBG\670261|NONE (l_dobj) ischemia_16\NN\14195315|NONE
D003042_D064420 NONE cocaine_5\NN\3492717|continuing (r_compound) toxicity_6\NN\13576101|NONE
17255138
D000082_D006471 NONE acetaminophen_24\RB\2707683|NS||and (r_conj) nsaids_22\NNPS\2721538|COX|, (r_conj) inhibitors_18\NNS\20090|NONE (r_dobj) using_16\VBG\418025|elderly (r_acl) patients_15\NNS\9898892|NONE (r_pobj) among_13\IN\0|NONE (r_prep) bleeding_12\VBG\14285662|the|of
D009288_D006471 CID naproxen_7\NN\3828465|,|carry|Among|. (r_nsubj) seemed_8\VBD\2604760|NONE (l_xcomp) carry_10\VB\315986|,|Among|naproxen|. (l_dobj) risk_13\NN\14541044|to (l_prep) for_14\IN\0|the|highest (l_pobj) bleeding_18\NN\14285662|NONE
C105934_D064420 NONE celecoxib_6\NN\3124700|NONE (r_pobj) of_5\IN\0|The|GI (r_prep) toxicity_4\NN\13576101|seemed|.|and|similar
D007052_D009203 NONE ibuprofen_66\NNP\3828465|.|and (r_conj) diclofenac_58\NN\0|.|, (r_conj) naproxen_50\NN\3828465|,|.|,|(|)|celecoxib|. (r_appos) rofecoxib_34\XX\3124700|:|group|Among|,|. (r_nsubj) were_32\VBD\0|NONE (l_nsubj) group_31\NN\2137|:|rofecoxib|Among|,|. (l_nmod) ratios_10\NNS\13815152|NONE (l_appos) interval_15\NN\33615|the|adjusted|hazard|) (l_prep) of_17\IN\0|)|(|%|confidence (l_pobj) hospitalization_18\NN\15113229|NONE (l_prep) for_19\IN\0|NONE (l_pobj) gi_22\NNP\13634615|NONE (l_nmod) ami_20\NNP\0|with|vs|/
D052246_D006471 NONE inhibitors_18\NNS\20090|NONE (r_dobj) using_16\VBG\418025|elderly (r_acl) patients_15\NNS\9898892|NONE (r_pobj) among_13\IN\0|NONE (r_prep) bleeding_12\VBG\14285662|the|of
D000082_D064420 NONE acetaminophen_12\RB\2707683|NONE (r_pobj) of_11\IN\0|NONE (r_prep) that_10\DT\0|NONE (r_pobj) to_9\IN\0|NONE (r_prep) similar_8\JJ\0|seemed|.|and|toxicity (r_acomp) was_7\VBD\0|NONE (l_nsubj) toxicity_4\NN\13576101|seemed|.|and|similar
D001241_D006471 NONE aspirin_5\NN\2707683|NONE (r_pobj) of_4\IN\0|non| (r_prep) users_3\NNS\7846|NONE (r_punct) ,_6\,\0|carry|Among|naproxen|. (r_punct) seemed_8\VBD\2604760|NONE (l_xcomp) carry_10\VB\315986|,|Among|naproxen|. (l_dobj) risk_13\NN\14541044|to (l_prep) for_14\IN\0|the|highest (l_pobj) bleeding_18\NN\14285662|NONE
D001241_D009203 NONE aspirin_5\NN\2707683|NONE (r_pobj) of_4\IN\0|non| (r_prep) users_3\NNS\7846|NONE (r_punct) ,_6\,\0|:|rofecoxib|group|Among|. (r_punct) were_32\VBD\0|NONE (l_nsubj) group_31\NN\2137|:|rofecoxib|Among|,|. (l_nmod) ratios_10\NNS\13815152|NONE (l_appos) interval_15\NN\33615|the|adjusted|hazard|) (l_prep) of_17\IN\0|)|(|%|confidence (l_pobj) hospitalization_18\NN\15113229|NONE (l_prep) for_19\IN\0|NONE (l_pobj) gi_22\NNP\13634615|NONE (l_nmod) ami_20\NNP\0|with|vs|/
D001241_D009203 NONE aspirin_29\NN\2707683|( (r_pobj) with_27\IN\0|AMI|vs|/ (r_parataxis) gi_22\NNP\13634615|NONE (l_nmod) ami_20\NNP\0|with|vs|/
D001241_D009203 NONE aspirin_5\NN\2707683|NONE (r_pobj) of_4\IN\0|non| (r_prep) users_3\NNS\7846|NONE (r_punct) ,_6\,\0|carry|Among|naproxen|. (r_punct) seemed_8\VBD\2604760|NONE (l_xcomp) carry_10\VB\315986|,|Among|naproxen|. (l_dobj) risk_13\NN\14541044|to (l_prep) for_14\IN\0|the|highest (l_pobj) bleeding_18\NN\14285662|NONE (l_compound) gi_17\NNP\13634615|NONE (l_nmod) ami_15\NNP\0|/
C116926_D009203 CID rofecoxib_34\XX\3124700|:|group|Among|,|. (r_nsubj) were_32\VBD\0|NONE (l_nsubj) group_31\NN\2137|:|rofecoxib|Among|,|. (l_nmod) ratios_10\NNS\13815152|NONE (l_appos) interval_15\NN\33615|the|adjusted|hazard|) (l_prep) of_17\IN\0|)|(|%|confidence (l_pobj) hospitalization_18\NN\15113229|NONE (l_prep) for_19\IN\0|NONE (l_pobj) gi_22\NNP\13634615|NONE (l_nmod) ami_20\NNP\0|with|vs|/
C116926_D009203 CID rofecoxib_21\NN\3124700|NONE (r_pobj) of_20\IN\0|NONE (r_prep) those_19\DT\0|NONE (r_pobj) than_18\IN\0|NONE (r_prep) better_17\JJR\5142180|to (r_acomp) be_16\VB\14625458|NONE (r_xcomp) seemed_14\VBD\2604760|.|and|similar|toxicity (r_conj) was_7\VBD\0|NONE (l_nsubj) toxicity_4\NN\13576101|seemed|.|and|similar (l_compound) gi_3\NNP\13634615|of|The (l_nmod) ami_1\NNP\0|/
D009288_D009203 CID naproxen_50\NN\3828465|,|.|,|(|)|celecoxib|. (r_appos) rofecoxib_34\XX\3124700|:|group|Among|,|. (r_nsubj) were_32\VBD\0|NONE (l_nsubj) group_31\NN\2137|:|rofecoxib|Among|,|. (l_nmod) ratios_10\NNS\13815152|NONE (l_appos) interval_15\NN\33615|the|adjusted|hazard|) (l_prep) of_17\IN\0|)|(|%|confidence (l_pobj) hospitalization_18\NN\15113229|NONE (l_prep) for_19\IN\0|NONE (l_pobj) gi_22\NNP\13634615|NONE (l_nmod) ami_20\NNP\0|with|vs|/
D009288_D009203 CID naproxen_7\NN\3828465|,|carry|Among|. (r_nsubj) seemed_8\VBD\2604760|NONE (l_xcomp) carry_10\VB\315986|,|Among|naproxen|. (l_dobj) risk_13\NN\14541044|to (l_prep) for_14\IN\0|the|highest (l_pobj) bleeding_18\NN\14285662|NONE (l_compound) gi_17\NNP\13634615|NONE (l_nmod) ami_15\NNP\0|/
C116926_D064420 NONE rofecoxib_21\NN\3124700|NONE (r_pobj) of_20\IN\0|NONE (r_prep) those_19\DT\0|NONE (r_pobj) than_18\IN\0|NONE (r_prep) better_17\JJR\5142180|to (r_acomp) be_16\VB\14625458|NONE (r_xcomp) seemed_14\VBD\2604760|.|and|similar|toxicity (r_conj) was_7\VBD\0|NONE (l_nsubj) toxicity_4\NN\13576101|seemed|.|and|similar
C105934_D009203 NONE celecoxib_42\NN\3124700|,|.|,|(|)|naproxen|. (r_conj) rofecoxib_34\XX\3124700|:|group|Among|,|. (r_nsubj) were_32\VBD\0|NONE (l_nsubj) group_31\NN\2137|:|rofecoxib|Among|,|. (l_nmod) ratios_10\NNS\13815152|NONE (l_appos) interval_15\NN\33615|the|adjusted|hazard|) (l_prep) of_17\IN\0|)|(|%|confidence (l_pobj) hospitalization_18\NN\15113229|NONE (l_prep) for_19\IN\0|NONE (l_pobj) gi_22\NNP\13634615|NONE (l_nmod) ami_20\NNP\0|with|vs|/
C105934_D009203 NONE celecoxib_6\NN\3124700|NONE (r_pobj) of_5\IN\0|The|GI (r_prep) toxicity_4\NN\13576101|seemed|.|and|similar (l_compound) gi_3\NNP\13634615|of|The (l_nmod) ami_1\NNP\0|/
D000082_D009203 NONE acetaminophen_24\RB\2707683|NS||and (r_conj) nsaids_22\NNPS\2721538|COX|, (r_conj) inhibitors_18\NNS\20090|NONE (r_dobj) using_16\VBG\418025|elderly (r_acl) patients_15\NNS\9898892|NONE (r_pobj) among_13\IN\0|NONE (r_prep) bleeding_12\VBG\14285662|the|of (r_acl) risks_5\NNS\14541044|to (l_prep) of_6\IN\0|the|bleeding (l_pobj) hospitalization_7\NN\15113229|NONE (l_prep) for_8\IN\0|NONE (l_pobj) ami_9\NNP\0|NONE
D000082_D009203 NONE acetaminophen_25\NN\2707683|NONE (r_pobj) vs_23\IN\13634784|with|AMI|/ (r_prep) gi_22\NNP\13634615|NONE (l_nmod) ami_20\NNP\0|with|vs|/
D000082_D009203 NONE acetaminophen_12\RB\2707683|NONE (r_pobj) of_11\IN\0|NONE (r_prep) that_10\DT\0|NONE (r_pobj) to_9\IN\0|NONE (r_prep) similar_8\JJ\0|seemed|.|and|toxicity (r_acomp) was_7\VBD\0|NONE (l_nsubj) toxicity_4\NN\13576101|seemed|.|and|similar (l_compound) gi_3\NNP\13634615|of|The (l_nmod) ami_1\NNP\0|/
D052246_D009203 CID inhibitors_11\NNS\20090|NONE (r_pobj) with_9\IN\0|(|acute|)|AMI|myocardial (r_prep) infarction_5\NN\14204950|NONE
D052246_D009203 CID inhibitors_11\NNS\20090|NONE (r_pobj) with_9\IN\0|(|acute|)|AMI|myocardial (r_prep) infarction_5\NN\14204950|NONE (l_appos) ami_7\NNP\0|(|acute|)|myocardial|with
D052246_D009203 CID inhibitors_18\NNS\20090|NONE (r_dobj) using_16\VBG\418025|elderly (r_acl) patients_15\NNS\9898892|NONE (r_pobj) among_13\IN\0|NONE (r_prep) bleeding_12\VBG\14285662|the|of (r_acl) risks_5\NNS\14541044|to (l_prep) of_6\IN\0|the|bleeding (l_pobj) hospitalization_7\NN\15113229|NONE (l_prep) for_8\IN\0|NONE (l_pobj) ami_9\NNP\0|NONE
D000894_D009203 CID drugs_34\NNS\14778436|NONE (r_pobj) with_21\IN\0|NONE (r_prep) compared_20\VBN\644583|risk|.|benefit|may (r_prep) offset_13\VB\15180528|NONE (l_nsubj) risk_1\NN\14541044|compared|.|benefit|may (l_prep) of_2\IN\0|The (l_pobj) infarction_5\NN\14204950|NONE
D000894_D009203 CID drugs_34\NNS\14778436|NONE (r_pobj) with_21\IN\0|NONE (r_prep) compared_20\VBN\644583|risk|.|benefit|may (r_prep) offset_13\VB\15180528|NONE (l_nsubj) risk_1\NN\14541044|compared|.|benefit|may (l_prep) of_2\IN\0|The (l_pobj) infarction_5\NN\14204950|NONE (l_appos) ami_7\NNP\0|(|acute|)|myocardial|with
D004008_D009203 NONE diclofenac_58\NN\0|.|, (r_conj) naproxen_50\NN\3828465|,|.|,|(|)|celecoxib|. (r_appos) rofecoxib_34\XX\3124700|:|group|Among|,|. (r_nsubj) were_32\VBD\0|NONE (l_nsubj) group_31\NN\2137|:|rofecoxib|Among|,|. (l_nmod) ratios_10\NNS\13815152|NONE (l_appos) interval_15\NN\33615|the|adjusted|hazard|) (l_prep) of_17\IN\0|)|(|%|confidence (l_pobj) hospitalization_18\NN\15113229|NONE (l_prep) for_19\IN\0|NONE (l_pobj) gi_22\NNP\13634615|NONE (l_nmod) ami_20\NNP\0|with|vs|/
15953230
C012052_D062787 NONE amisulpride_3\JJ\0|NONE (r_amod) overdose_4\NN\84738|NONE
C012052_D011041 NONE amisulpride_14\NN\0|NONE (r_pobj) of_13\IN\0|,|respectively|. (r_prep) g_12\NN\13717155||and|deliberate|with|self (r_conj) poisoning_6\NN\14034177|NONE
D002125_D008133 NONE gluconate_11\VBN\0|NONE (r_pobj) of_8\IN\0|NONE (r_prep) administration_7\NN\1133281|NONE (r_pobj) to_6\IN\0|to (r_prep) respond_5\VB\2367363|.|prolongation (r_xcomp) appeared_3\VBD\2604760|NONE (l_nsubj) prolongation_2\NN\1017987|.|respond
C012052_D008133 CID amisulpride_3\JJ\0|NONE (r_amod) overdose_4\NN\84738|NONE (r_pobj) of_2\IN\0|:|.|Two|cause (r_prep) cases_1\NNS\7283608|NONE (l_appos) cause_7\NN\7323922|:|of|.|Two (l_prep) for_8\IN\0|a (l_pobj) syndrome_11\NN\5870365|NONE
12498738
C043211_D009202 NONE carvedilol_0\NNP\2832168|against|. (r_nsubj) protects_1\VBZ\1127795|NONE (l_prep) against_2\IN\0|.|Carvedilol (l_pobj) cardiomyopathy_7\NN\14103288|NONE
C043211_D009202 NONE carvedilol_7\NN\2832168|NONE (r_pobj) by_6\IN\0|this (r_prep) protection_5\NN\407535|that|in|advantage|may (r_nsubj) afford_18\VB\2267060|It|is|. (l_prep) in_22\IN\13603305|that|advantage|protection|may (l_pcomp) minimizing_23\VBG\441445|NONE (l_dobj) dysfunction_29\NN\14204950|NONE (l_conj) cardiomyopathy_31\NN\14103288|the|limiting|mitochondrial|and|accompanies
C043211_D028361 NONE carvedilol_7\NN\2832168|NONE (r_pobj) by_6\IN\0|this (r_prep) protection_5\NN\407535|that|in|advantage|may (r_nsubj) afford_18\VB\2267060|It|is|. (l_prep) in_22\IN\13603305|that|advantage|protection|may (l_pcomp) minimizing_23\VBG\441445|NONE (l_dobj) dysfunction_29\NN\14204950|NONE
D004317_D028361 NONE doxorubicin_37\NN\2716866|term (r_compound) therapy_38\NN\657604|in|that (r_dobj) accompanies_33\VBZ\0|the|limiting|mitochondrial|and|cardiomyopathy (r_relcl) dysfunction_29\NN\14204950|NONE
D004317_D064420 NONE doxorubicin_37\JJ\2716866|subchronic (r_compound) toxicity_38\NN\13576101|NONE
D004317_D009202 CID doxorubicin_3\RB\2716866| (r_npadvmod) induced_5\VBN\1627355|mitochondrial (r_amod) cardiomyopathy_7\NN\14103288|NONE
D004317_D009202 CID doxorubicin_18\NN\2716866|NONE (r_pobj) by_17\IN\0|NONE (r_agent) caused_16\VBN\1617192|cumulative|the|limiting (r_acl) cardiomyopathy_15\NN\14103288|to
D004317_D009202 CID doxorubicin_37\NN\2716866|term (r_compound) therapy_38\NN\657604|in|that (r_dobj) accompanies_33\VBZ\0|the|limiting|mitochondrial|and|cardiomyopathy (r_relcl) dysfunction_29\NN\14204950|NONE (l_conj) cardiomyopathy_31\NN\14103288|the|limiting|mitochondrial|and|accompanies
C043211_D009369 NONE carvedilol_7\NN\2832168|NONE (r_pobj) by_6\IN\0|this (r_prep) protection_5\NN\407535|that|in|advantage|may (r_nsubj) afford_18\VB\2267060|It|is|. (l_prep) in_22\IN\13603305|that|advantage|protection|may (l_pcomp) minimizing_23\VBG\441445|NONE (l_dobj) dysfunction_29\NN\14204950|NONE (l_relcl) accompanies_33\VBZ\0|the|limiting|mitochondrial|and|cardiomyopathy (l_prep) in_39\IN\13603305|therapy|that (l_pobj) patients_41\NNS\9898892|NONE (l_compound) cancer_40\NN\14239425|NONE
D004317_D009369 NONE doxorubicin_37\NN\2716866|term (r_compound) therapy_38\NN\657604|in|that (r_dobj) accompanies_33\VBZ\0|the|limiting|mitochondrial|and|cardiomyopathy (l_prep) in_39\IN\13603305|therapy|that (l_pobj) patients_41\NNS\9898892|NONE (l_compound) cancer_40\NN\14239425|NONE
C043211_D064420 NONE carvedilol_11\NN\2832168|against (r_nsubj) protects_25\VBZ\1127795|the (l_prep) against_26\IN\0|carvedilol (l_pobj) dysfunction_33\NN\14204950|NONE (l_acl) associated_34\VBN\628491|the|cardiac|bioenergetic|mitochondrial (l_prep) with_35\IN\0|NONE (l_pobj) toxicity_38\NN\13576101|NONE
19515070
D019343_D064420 NONE citrate_6\NN\14850483|unsafe|regional|in (r_compound) anticoagulation_7\NN\657604|carries|.|anticoagulation (r_attr) is_2\VBZ\0|NONE (l_conj) carries_15\VBZ\315986|.|anticoagulation|anticoagulation (l_dobj) risk_17\NN\14541044|NONE (l_prep) of_18\IN\0|the (l_pobj) toxicity_20\NN\13576101|NONE
D019343_D064420 NONE citrate_19\JJ\14850483|NONE (r_compound) toxicity_20\NN\13576101|NONE
D019343_D064420 NONE citrate_10\JJ\14850483|NONE (r_compound) toxicity_11\NN\13576101|NONE
D000082_D017114 CID acetaminophen_11\RB\2707683| (r_advmod) induced_13\VBN\1627355|with|fulminant|liver (r_amod) failure_16\NN\66216|NONE
D019343_D017114 NONE citrate_30\NN\14850483|NONE (r_compound) dialysate_31\NN\0|NONE (r_pobj) with_29\IN\0|during (r_prep) anticoagulated_28\VBN\0|liver (r_acl) transplantation_27\NN\671351|NONE (r_pobj) during_25\IN\0|support|who (r_prep) underwent_21\VBD\109660|associated (r_relcl) aki_19\NNP\0|NONE (r_pobj) with_17\IN\0|induced|fulminant|liver (r_prep) failure_16\NN\66216|NONE
D019343_D017114 NONE citrate_0\NNP\14850483|NONE (r_compound) dialysate_1\NN\0|.|alternative (r_nsubj) is_2\VBZ\0|NONE (l_attr) alternative_5\NN\5788149|.|dialysate (l_prep) for_6\IN\0|a|safe (l_pobj) support_8\NN\407535|NONE (l_prep) in_12\IN\13603305|of|intradialytic (l_pobj) failure_15\NN\66216|NONE
D000082_D058186 CID acetaminophen_11\RB\2707683| (r_advmod) induced_13\VBN\1627355|with|fulminant|liver (r_amod) failure_16\NN\66216|NONE (l_prep) with_17\IN\0|induced|fulminant|liver (l_pobj) aki_19\NNP\0|NONE
D019343_D058186 NONE citrate_30\NN\14850483|NONE (r_compound) dialysate_31\NN\0|NONE (r_pobj) with_29\IN\0|during (r_prep) anticoagulated_28\VBN\0|liver (r_acl) transplantation_27\NN\671351|NONE (r_pobj) during_25\IN\0|support|who (r_prep) underwent_21\VBD\109660|associated (r_relcl) aki_19\NNP\0|NONE
9889429
D009543_D005885 CID nifedipine_10\NN\2938514|and|cyclosporin (r_conj) a_8\NN\13649268|NONE (r_pobj) with_6\IN\0|combined (r_prep) therapy_5\NN\657604|NONE (r_pobj) during_3\IN\0|The|adverse (r_prep) events_2\NNS\23100|increase|. (r_nsubj) included_11\VBD\0|NONE (l_dobj) increase_13\NN\13576355|events|. (l_prep) in_19\IN\13603305|an|in|in (l_pobj) 9_20\CD\13741022|NONE (l_prep) of_21\IN\0|NONE (l_pobj) patients_24\NNS\9898892|NONE (l_prep) of_27\IN\0||the|development|and (l_pobj) hyperplasia_29\NN\14365950|NONE
D009543_D005885 CID nifedipine_7\NN\2938514|for|useful|but|,|monitored (r_nsubj) is_8\VBZ\0|findings|. (l_conj) monitored_29\VBN\2169352|for|nifedipine|useful|but|, (l_prep) for_30\IN\0|should|patients|be|that (l_pobj) hyperplasia_32\NN\14365950|NONE
D016572_D011565 NONE a_15\NNP\13649268| (r_npadvmod) induced_17\VBN\1627355|in (r_amod) hypertension_18\NN\14057371|NONE (l_prep) in_19\IN\13603305|induced (l_pobj) patients_20\NNS\9898892|NONE (l_prep) with_21\IN\0|NONE (l_pobj) psoriasis_22\NN\14219661|NONE
D016572_D011565 NONE a_10\NNP\13649268|NONE (r_det) therapy_11\NN\657604|cyclosporin (r_pobj) of_8\IN\0|the (r_prep) course_7\NN\883297|NONE (r_pobj) during_5\IN\0|with|psoriatic|Thirteen (r_prep) patients_2\NNS\9898892|study|with|.|were|for|nifedipine|,|, (l_amod) psoriatic_1\JJ\0|with|Thirteen|during
D016572_D011565 NONE a_21\NN\13649268|NONE (r_pobj) with_19\IN\0|term (r_prep) treatment_18\NN\654885|NONE (r_pobj) under_14\IN\0|hypertensive|psoriatic (r_prep) patients_13\NNS\9898892|NONE (l_amod) psoriatic_12\JJ\0|under|hypertensive
D016572_D006973 CID a_15\NNP\13649268| (r_npadvmod) induced_17\VBN\1627355|in (r_amod) hypertension_18\NN\14057371|NONE
D016572_D006973 CID a_10\NNP\13649268|NONE (r_det) therapy_11\NN\657604|cyclosporin (r_pobj) of_8\IN\0|the (r_prep) course_7\NN\883297|NONE (r_pobj) during_5\IN\0|with|psoriatic|Thirteen (r_prep) patients_2\NNS\9898892|study|with|.|were|for|nifedipine|,|, (l_prep) with_3\IN\0|psoriatic|Thirteen|during (l_pobj) hypertension_4\NN\14057371|NONE
D016572_D006973 CID a_13\NNP\13649268|NONE (r_det) therapy_14\NN\657604|NONE (r_dobj) cyclosporin_12\NN\0|NONE (r_pcomp) before_11\IN\0|.|state|Seven|had (r_prep) exhibited_6\VBN\2632167|NONE (l_dobj) state_10\NN\8491826|.|Seven|before|had (l_amod) hypertensive_9\JJ\10405694|a|subclinical
D016572_D006973 CID a_21\NN\13649268|NONE (r_pobj) with_19\IN\0|term (r_prep) treatment_18\NN\654885|NONE (r_pobj) under_14\IN\0|hypertensive|psoriatic (r_prep) patients_13\NNS\9898892|NONE (l_amod) hypertensive_11\JJ\10405694|under|psoriatic
D001806_D005885 NONE nitrogen_17\NN\14622893|urea (r_compound) levels_18\NNS\4916342|NONE (r_pobj) in_14\IN\13603305|in|an|in (r_prep) increase_13\NN\13576355|events|. (l_prep) in_19\IN\13603305|an|in|in (l_pobj) 9_20\CD\13741022|NONE (l_prep) of_21\IN\0|NONE (l_pobj) patients_24\NNS\9898892|NONE (l_prep) of_27\IN\0||the|development|and (l_pobj) hyperplasia_29\NN\14365950|NONE
D002118_D011565 NONE calcium_19\NN\14625458|NONE (r_compound) channel_20\NN\6251781|a (r_compound) blocker_21\NN\10101634|NONE (r_pobj) with_17\IN\0|study|patients|.|were|for|nifedipine|,|, (r_prep) treated_13\VBN\2376958|NONE (l_nsubjpass) patients_2\NNS\9898892|study|with|.|were|for|nifedipine|,|, (l_amod) psoriatic_1\JJ\0|with|Thirteen|during
D009543_D011565 NONE nifedipine_8\JJ\2938514|for|release (r_amod) tablets_12\NNS\4233405|NONE (l_prep) for_13\IN\0|release|nifedipine (l_pobj) cyclosporin_14\NN\0|NONE (l_dobj) hypertension_18\NN\14057371|NONE (l_prep) in_19\IN\13603305|induced (l_pobj) patients_20\NNS\9898892|NONE (l_prep) with_21\IN\0|NONE (l_pobj) psoriasis_22\NN\14219661|NONE
D009543_D011565 NONE nifedipine_26\NN\2938514|study|patients|with|.|were|for|,|, (r_dobj) treated_13\VBN\2376958|NONE (l_nsubjpass) patients_2\NNS\9898892|study|with|.|were|for|nifedipine|,|, (l_amod) psoriatic_1\JJ\0|with|Thirteen|during
D009543_D011565 NONE nifedipine_7\NN\2938514|for|useful|but|,|monitored (r_nsubj) is_8\VBZ\0|findings|. (l_prep) for_10\IN\0|nifedipine|useful|but|,|monitored (l_pobj) patients_13\NNS\9898892|NONE (l_amod) psoriatic_12\JJ\0|under|hypertensive
D009543_D006973 NONE nifedipine_8\JJ\2938514|for|release (r_amod) tablets_12\NNS\4233405|NONE (l_prep) for_13\IN\0|release|nifedipine (l_pobj) cyclosporin_14\NN\0|NONE (l_dobj) hypertension_18\NN\14057371|NONE
D009543_D006973 NONE nifedipine_26\NN\2938514|study|patients|with|.|were|for|,|, (r_dobj) treated_13\VBN\2376958|NONE (l_nsubjpass) patients_2\NNS\9898892|study|with|.|were|for|nifedipine|,|, (l_prep) with_3\IN\0|psoriatic|Thirteen|during (l_pobj) hypertension_4\NN\14057371|NONE
D009543_D006973 NONE nifedipine_7\NN\2938514|for|useful|but|,|monitored (r_nsubj) is_8\VBZ\0|findings|. (l_prep) for_10\IN\0|nifedipine|useful|but|,|monitored (l_pobj) patients_13\NNS\9898892|NONE (l_amod) hypertensive_11\JJ\10405694|under|psoriatic
D002118_D006973 NONE calcium_19\NN\14625458|NONE (r_compound) channel_20\NN\6251781|a (r_compound) blocker_21\NN\10101634|NONE (r_pobj) with_17\IN\0|study|patients|.|were|for|nifedipine|,|, (r_prep) treated_13\VBN\2376958|NONE (l_nsubjpass) patients_2\NNS\9898892|study|with|.|were|for|nifedipine|,|, (l_prep) with_3\IN\0|psoriatic|Thirteen|during (l_pobj) hypertension_4\NN\14057371|NONE
D016572_D005885 CID a_8\NN\13649268|NONE (r_pobj) with_6\IN\0|combined (r_prep) therapy_5\NN\657604|NONE (r_pobj) during_3\IN\0|The|adverse (r_prep) events_2\NNS\23100|increase|. (r_nsubj) included_11\VBD\0|NONE (l_dobj) increase_13\NN\13576355|events|. (l_prep) in_19\IN\13603305|an|in|in (l_pobj) 9_20\CD\13741022|NONE (l_prep) of_21\IN\0|NONE (l_pobj) patients_24\NNS\9898892|NONE (l_prep) of_27\IN\0||the|development|and (l_pobj) hyperplasia_29\NN\14365950|NONE
D016572_D005885 CID a_21\NN\13649268|NONE (r_pobj) with_19\IN\0|term (r_prep) treatment_18\NN\654885|NONE (r_pobj) under_14\IN\0|hypertensive|psoriatic (r_prep) patients_13\NNS\9898892|NONE (r_pobj) for_10\IN\0|nifedipine|useful|but|,|monitored (r_prep) is_8\VBZ\0|findings|. (l_conj) monitored_29\VBN\2169352|for|nifedipine|useful|but|, (l_prep) for_30\IN\0|should|patients|be|that (l_pobj) hyperplasia_32\NN\14365950|NONE
17554526
D003042_D001925 CID cocaine_6\NN\3492717|regular (r_compound) users_7\NNS\7846|NONE (r_pobj) in_3\IN\13603305|Impaired|fear|. (r_prep) recognition_2\NN\13932421|NONE
D003042_D001925 CID cocaine_21\NN\3492717|NONE (r_pobj) of_20\IN\0|the|subacute (r_prep) effects_19\NNS\13245626|NONE (r_pobj) by_16\IN\0|deficit|were|.|can|,|be|not (r_agent) explained_15\VBN\831651|NONE (l_nsubjpass) deficit_2\NN\5113133|were|.|can|,|be|not|by (l_prep) in_3\IN\13603305|selective|The (l_pobj) accuracy_6\NN\4723816|fear (l_compound) recognition_5\NN\13932421|manifested
D018817_D001925 NONE ecstasy_24\NN\13985818|,|or (r_conj) cocaine_21\NN\3492717|NONE (r_pobj) of_20\IN\0|the|subacute (r_prep) effects_19\NNS\13245626|NONE (r_pobj) by_16\IN\0|deficit|were|.|can|,|be|not (r_agent) explained_15\VBN\831651|NONE (l_nsubjpass) deficit_2\NN\5113133|were|.|can|,|be|not|by (l_prep) in_3\IN\13603305|selective|The (l_pobj) accuracy_6\NN\4723816|fear (l_compound) recognition_5\NN\13932421|manifested
920167
D014859_-1 NONE warfarin_3\RB\2718259| (r_npadvmod) induced_5\VBN\1627355|with (r_amod) embryopathy_6\JJ\0|.|baby (l_prep) with_7\IN\0|induced (l_pobj) hypoplasia_9\NN\14365950|NONE
D014859_-1 NONE warfarin_19\NN\2718259|NONE (r_pobj) with_18\IN\0|during (r_prep) treated_17\VBN\2376958|NONE (r_acl) mothers_16\NNS\10399491|NONE (r_pobj) to_15\IN\0|NONE (r_prep) born_14\VBN\0| (r_acl) infants_13\NNS\9918248|NONE (r_pobj) in_11\IN\13603305|hypoplasia|now|is|been|has|,|and (r_prep) reported_10\VBN\831651|NONE (l_nsubjpass) hypoplasia_1\NN\14365950|in|now|is|been|has|,|and
D014859_D005315 NONE warfarin_3\RB\2718259| (r_npadvmod) induced_5\VBN\1627355|with (r_amod) embryopathy_6\JJ\0|.|baby
D014859_D002806 CID warfarin_3\RB\2718259| (r_npadvmod) induced_5\VBN\1627355|with (r_amod) embryopathy_6\JJ\0|.|baby (l_prep) with_7\IN\0|induced (l_pobj) hypoplasia_9\NN\14365950|NONE (l_conj) epiphyses_12\NNS\5275651|and|nasal
D014859_D002806 CID warfarin_3\RB\2718259| (r_npadvmod) induced_5\VBN\1627355|with (r_amod) embryopathy_6\JJ\0|.|baby (l_prep) with_7\IN\0|induced (l_pobj) hypoplasia_9\NN\14365950|NONE (l_conj) epiphyses_12\NNS\5275651|and|nasal (l_appos) punctata_15\NN\0|)|(|stippled
D014859_D002806 CID warfarin_19\NN\2718259|NONE (r_pobj) with_18\IN\0|during (r_prep) treated_17\VBN\2376958|NONE (r_acl) mothers_16\NNS\10399491|NONE (r_pobj) to_15\IN\0|NONE (r_prep) born_14\VBN\0| (r_acl) infants_13\NNS\9918248|NONE (r_pobj) in_11\IN\13603305|hypoplasia|now|is|been|has|,|and (r_prep) reported_10\VBN\831651|NONE (l_nsubjpass) hypoplasia_1\NN\14365950|in|now|is|been|has|,|and (l_prep) with_2\IN\0|Nasal (l_conj) without_4\IN\0|or (l_pobj) epiphyses_6\NNS\5275651|NONE
25054547
C049430_C537417 CID mivacurium_16\NN\0|or (r_conj) suxamethonium_14\NN\0|)|(|muscle (r_appos) relaxants_12\NNS\3247620|NONE (r_pobj) of_10\IN\0|the|in (r_prep) use_9\NN\407535|NONE (r_pobj) after_7\IN\0|by|is|.|deficiency (r_prep) characterized_3\VBN\609683|NONE (l_nsubjpass) deficiency_1\NN\14449126|after|by|is|.
D013390_C537417 CID suxamethonium_14\NN\0|)|(|muscle (r_appos) relaxants_12\NNS\3247620|NONE (r_pobj) of_10\IN\0|the|in (r_prep) use_9\NN\407535|NONE (r_pobj) after_7\IN\0|by|is|.|deficiency (r_prep) characterized_3\VBN\609683|NONE (l_nsubjpass) deficiency_1\NN\14449126|after|by|is|.
D013390_D001049 CID suxamethonium_25\NN\0|NONE (r_pobj) with_24\IN\0|prolonged (r_prep) apnea_23\NN\14299637|of|and
D013390_D001049 CID suxamethonium_14\NN\0|)|(|muscle (r_appos) relaxants_12\NNS\3247620|NONE (r_pobj) of_10\IN\0|the|in (r_prep) use_9\NN\407535|NONE (r_pobj) after_7\IN\0|by|is|.|deficiency (r_prep) characterized_3\VBN\609683|NONE (l_agent) by_4\IN\0|after|is|.|deficiency (l_pobj) apnea_6\NN\14299637|NONE
C049430_D001049 CID mivacurium_16\NN\0|or (r_conj) suxamethonium_14\NN\0|)|(|muscle (r_appos) relaxants_12\NNS\3247620|NONE (r_pobj) of_10\IN\0|the|in (r_prep) use_9\NN\407535|NONE (r_pobj) after_7\IN\0|by|is|.|deficiency (r_prep) characterized_3\VBN\609683|NONE (l_agent) by_4\IN\0|after|is|.|deficiency (l_pobj) apnea_6\NN\14299637|NONE
10677406
D004280_D017202 NONE dobutamine_13\NN\0|NONE (r_pobj) after_11\IN\0|ischaemia (r_mark) induced_16\VBN\1627355|in|.|dysfunction (l_dobj) ischaemia_18\NN\14195315|after
D004280_D003324 NONE dobutamine_13\NN\0|NONE (r_pobj) after_11\IN\0|ischaemia (r_mark) induced_16\VBN\1627355|in|.|dysfunction (r_advcl) occurs_4\VBZ\0|NONE (l_prep) in_5\IN\13603305|induced|.|dysfunction (l_pobj) patients_6\NNS\9898892|NONE (l_prep) with_7\IN\0|NONE (l_pobj) disease_10\NN\14061805|NONE
D004280_D003324 NONE dobutamine_7\NN\0|in|,|results|.|In|,|presumed (r_nsubj) induced_8\VBN\1627355|NONE (l_prep) in_0\IN\13603305|in|,|results|.|,|presumed|dobutamine (l_pobj) patients_1\NNS\9898892|NONE (l_prep) with_2\IN\0|NONE (l_pobj) disease_5\NN\14061805|NONE
D004280_D003324 NONE dobutamine_0\NNP\0|ischaemia (r_nsubj) induced_1\VBD\1627355|therefore|could|.|be|study (r_csubjpass) used_6\VBN\0|NONE (l_xcomp) study_8\VB\635850|therefore|could|.|be|induced (l_prep) in_15\IN\13603305|pathophysiology|to|further (l_pobj) patients_16\NNS\9898892|NONE (l_prep) with_17\IN\0|NONE (l_pobj) disease_20\NN\14061805|NONE
D004280_D007511 NONE dobutamine_17\NN\0|and (r_conj) exercise_15\NN\621627|NONE (r_pobj) after_14\IN\0|randomised|crossover|of|A (r_prep) study_3\NN\635850|.|ischaemia (r_nsubj) induced_18\VBN\1627355|NONE (l_dobj) ischaemia_19\NN\14195315|.|study
D004280_D007511 NONE dobutamine_7\NN\0|in|,|results|.|In|,|presumed (r_nsubj) induced_8\VBN\1627355|NONE (l_dobj) results_10\NNS\34213|in|,|.|In|,|presumed|dobutamine (l_compound) ischaemia_9\NN\14195315|NONE
D004280_D007511 NONE dobutamine_0\NNP\0|ischaemia (r_nsubj) induced_1\VBD\1627355|therefore|could|.|be|study (l_dobj) ischaemia_2\NN\14195315|Dobutamine
D004280_D018487 CID dobutamine_13\NN\0|NONE (r_pobj) after_11\IN\0|ischaemia (r_mark) induced_16\VBN\1627355|in|.|dysfunction (r_advcl) occurs_4\VBZ\0|NONE (l_nsubj) dysfunction_3\NN\14204950|induced|in|.
D004280_D018487 CID dobutamine_7\NN\0|in|,|results|.|In|,|presumed (r_nsubj) induced_8\VBN\1627355|NONE (l_prep) in_11\IN\13603305|,|results|.|In|,|presumed|dobutamine (l_pobj) dysfunction_16\NN\14204950|NONE
D004280_D017682 CID dobutamine_7\NN\0|in|,|results|.|In|,|presumed (r_nsubj) induced_8\VBN\1627355|NONE (l_conj) presumed_18\VBN\719734|in|,|results|.|In|,|dobutamine (l_xcomp) be_20\VB\14625458|NONE (l_acomp) similar_24\JJ\0|to (l_amod) stunning_22\JJ\269140|to|myocardial
1361574
D007538_D012640 CID isoniazid_22\NN\2716205|NONE (r_pobj) by_21\IN\0|NONE (r_agent) induced_20\VBN\1627355|the (r_acl) convulsions_19\NNS\14081375|.|mg/kg|increase|Moreover|and|,|markedly
D002243_D012640 NONE carboline_8\NN\0|NONE (r_pobj) of_4\IN\0|. (r_prep) mg/kg_3\NNS\0|convulsions|.|increase|Moreover|and|,|markedly (r_nsubj) reduced_9\VBD\441445|NONE (l_conj) convulsions_19\NNS\14081375|.|mg/kg|increase|Moreover|and|,|markedly
C037476_D012640 NONE 35s]tbps_15\NNP\0|[ (r_nummod) binding_16\NN\4688246|NONE (r_pobj) of_13\IN\0|the (r_prep) increase_12\NN\13576355|convulsions|.|mg/kg|Moreover|and|,|markedly (r_dobj) reduced_9\VBD\441445|NONE (l_conj) convulsions_19\NNS\14081375|.|mg/kg|increase|Moreover|and|,|markedly
6687006
D000661_D020258 NONE amphetamine_3\NN\3248958|NONE (r_compound) hyperactivity_4\NN\14052403|NONE (r_pobj) of_2\IN\0|The|induced (r_prep) reduction_1\NN\351485|by|.|was (r_nsubjpass) blocked_9\VBN\1476483|NONE (l_agent) by_10\IN\0|.|reduction|was (l_pobj) pretreatment_11\NN\0|NONE (l_prep) with_12\IN\0|NONE (l_pobj) agent_18\NN\7347|NONE (l_relcl) prevents_23\VBZ\0|,|desipramine|the|uptake|,|blocking (l_dobj) action_26\NN\30358|which (l_amod) neurotoxic_25\JJ\0|of|the
D003913_D006948 CID amphetamine_6\NN\3248958|NONE (r_pobj) by_3\IN\0|NONE (r_agent) induced_2\VBN\1627355|The|) (r_acl) hyperactivity_1\NN\14052403|.|was|by|significantly
C012102_D019956 NONE dsp4_17\NNP\0|NONE (r_pobj) with_16\IN\0|NONE (r_prep) pretreatment_15\NN\0|NONE (r_pobj) by_14\IN\0|However|,|not|rearings|.|were (r_agent) blocked_13\VBN\1476483|NONE (l_nsubjpass) rearings_4\NNS\4921754|However|,|not|by|.|were (l_conj) stereotypies_10\NNS\0|the|and|increased
D009638_D020258 NONE noradrenaline_14\NN\14807929| (r_amod) uptake_16\NN\13440063|,|desipramine|the|,|prevents|blocking (r_compound) agent_18\NN\7347|NONE (l_relcl) prevents_23\VBZ\0|,|desipramine|the|uptake|,|blocking (l_dobj) action_26\NN\30358|which (l_amod) neurotoxic_25\JJ\0|of|the
D000661_D006948 NONE amphetamine_3\NN\3248958|NONE (r_compound) hyperactivity_4\NN\14052403|NONE
C012102_D020258 NONE dsp4_7\NNP\0|NONE (r_pobj) by_6\IN\0|NONE (r_agent) induced_5\VBN\1627355|of|The (r_acl) reduction_1\NN\351485|by|.|was (r_nsubjpass) blocked_9\VBN\1476483|NONE (l_agent) by_10\IN\0|.|reduction|was (l_pobj) pretreatment_11\NN\0|NONE (l_prep) with_12\IN\0|NONE (l_pobj) agent_18\NN\7347|NONE (l_relcl) prevents_23\VBZ\0|,|desipramine|the|uptake|,|blocking (l_dobj) action_26\NN\30358|which (l_amod) neurotoxic_25\JJ\0|of|the
C012102_D020258 NONE dsp4_28\NNP\0|NONE (r_pobj) of_27\IN\0|the|neurotoxic (r_prep) action_26\NN\30358|which (l_amod) neurotoxic_25\JJ\0|of|the
D003891_D006948 NONE desipramine_20\NN\4482543|,|the|uptake|,|prevents|blocking (r_appos) agent_18\NN\7347|NONE (r_pobj) with_12\IN\0|NONE (r_prep) pretreatment_11\NN\0|NONE (r_pobj) by_10\IN\0|.|reduction|was (r_agent) blocked_9\VBN\1476483|NONE (l_nsubjpass) reduction_1\NN\351485|by|.|was (l_prep) of_2\IN\0|The|induced (l_pobj) hyperactivity_4\NN\14052403|NONE
D003891_D020258 NONE desipramine_20\NN\4482543|,|the|uptake|,|prevents|blocking (r_appos) agent_18\NN\7347|NONE (l_relcl) prevents_23\VBZ\0|,|desipramine|the|uptake|,|blocking (l_dobj) action_26\NN\30358|which (l_amod) neurotoxic_25\JJ\0|of|the
C012102_D006948 NONE dsp4_17\NNP\0|NONE (r_compound) pretreatment_18\NN\0|NONE (r_pobj) by_16\IN\0|.|was|hyperactivity|significantly (r_agent) reduced_15\VBN\441445|NONE (l_nsubjpass) hyperactivity_1\NN\14052403|.|was|by|significantly
C012102_D006948 NONE dsp4_7\NNP\0|NONE (r_pobj) by_6\IN\0|NONE (r_agent) induced_5\VBN\1627355|of|The (r_acl) reduction_1\NN\351485|by|.|was (l_prep) of_2\IN\0|The|induced (l_pobj) hyperactivity_4\NN\14052403|NONE
C012102_D006948 NONE dsp4_28\NNP\0|NONE (r_pobj) of_27\IN\0|the|neurotoxic (r_prep) action_26\NN\30358|which (r_dobj) prevents_23\VBZ\0|,|desipramine|the|uptake|,|blocking (r_relcl) agent_18\NN\7347|NONE (r_pobj) with_12\IN\0|NONE (r_prep) pretreatment_11\NN\0|NONE (r_pobj) by_10\IN\0|.|reduction|was (r_agent) blocked_9\VBN\1476483|NONE (l_nsubjpass) reduction_1\NN\351485|by|.|was (l_prep) of_2\IN\0|The|induced (l_pobj) hyperactivity_4\NN\14052403|NONE
D009638_D006948 NONE noradrenaline_14\NN\14807929| (r_amod) uptake_16\NN\13440063|,|desipramine|the|,|prevents|blocking (r_compound) agent_18\NN\7347|NONE (r_pobj) with_12\IN\0|NONE (r_prep) pretreatment_11\NN\0|NONE (r_pobj) by_10\IN\0|.|reduction|was (r_agent) blocked_9\VBN\1476483|NONE (l_nsubjpass) reduction_1\NN\351485|by|.|was (l_prep) of_2\IN\0|The|induced (l_pobj) hyperactivity_4\NN\14052403|NONE
D000661_D019956 NONE amphetamine_7\NN\3248958| (r_npadvmod) induced_9\VBN\1627355|the (r_amod) stereotypies_10\NNS\0|the|and|increased
10770468
D008094_D001714 NONE lithium_8\NN\14625458|developed (r_compound) therapy_9\NN\657604|NONE (r_dobj) receiving_6\VBG\2210855|a|bipolar (r_acl) patient_5\NN\9898892|NONE (l_amod) bipolar_4\JJ\0|a|receiving
D008094_D001714 NONE lithium_8\NN\14625458|developed (r_compound) therapy_9\NN\657604|NONE (r_dobj) receiving_6\VBG\2210855|a|bipolar (r_acl) patient_5\NN\9898892|NONE (r_pobj) in_2\IN\13603305|Recent (r_prep) findings_1\NNS\7951464|authors|conduct|. (r_nsubj) prompted_16\VBD\1645601|NONE (l_xcomp) conduct_20\VB\407535|authors|findings|. (l_dobj) study_23\NN\635850|to (l_prep) of_24\IN\0|a|retrospective|with (l_pobj) patients_26\NNS\9898892|NONE (l_amod) bipolar_25\JJ\0|NONE
D008094_D001714 NONE lithium_28\NN\14625458| (r_npadvmod) associated_30\VBN\628491|NONE (r_amod) hypercalcemia_31\NN\14299637|NONE (r_pobj) with_27\IN\0|a|retrospective|of (r_prep) study_23\NN\635850|to (r_dobj) conduct_20\VB\407535|authors|findings|. (r_xcomp) prompted_16\VBD\1645601|NONE (l_nsubj) findings_1\NNS\7951464|authors|conduct|. (l_prep) in_2\IN\13603305|Recent (l_pobj) patient_5\NN\9898892|NONE (l_amod) bipolar_4\JJ\0|a|receiving
D008094_D001714 NONE lithium_28\NN\14625458| (r_npadvmod) associated_30\VBN\628491|NONE (r_amod) hypercalcemia_31\NN\14299637|NONE (r_pobj) with_27\IN\0|a|retrospective|of (r_prep) study_23\NN\635850|to (l_prep) of_24\IN\0|a|retrospective|with (l_pobj) patients_26\NNS\9898892|NONE (l_amod) bipolar_25\JJ\0|NONE
D008094_D001714 NONE lithium_18\NN\14625458| (r_npadvmod) treated_20\VBN\2376958|normocalcemic|bipolar|comparable|age (r_amod) patients_23\NNS\9898892|which (l_amod) bipolar_21\JJ\0|normocalcemic|comparable|treated|age
D008094_D001714 NONE lithium_18\NN\14625458| (r_npadvmod) treated_20\VBN\2376958|normocalcemic|bipolar|comparable|age (r_amod) patients_23\NNS\9898892|which (r_dobj) included_12\VBD\0|,|,|C|:|group|and (r_relcl) c1_9\NN\0|Thus|,|groups|were|. (l_conj) c2_27\NNP\0|,|,|included|:|group|and (l_relcl) included_30\VBD\0|,|group (l_dobj) patients_33\NNS\9898892|which (l_amod) bipolar_31\JJ\0|treated|normocalcemic
D008094_D001714 NONE lithium_11\NN\14625458| (r_npadvmod) associated_13\VBN\628491|NONE (r_amod) hypercalcemia_14\NN\14299637|NONE (r_pobj) with_10\IN\0|medical|and|patients (r_prep) diseases_6\NNS\14061805|NONE (l_conj) patients_9\NNS\9898892|medical|with|and (l_amod) bipolar_8\JJ\0|NONE
D008094_D006934 CID lithium_8\NN\14625458|developed (r_compound) therapy_9\NN\657604|NONE (l_relcl) developed_11\VBD\1753788|lithium (l_dobj) hypercalcemia_12\NN\14299637|who
D008094_D006934 CID lithium_8\NN\14625458|developed (r_compound) therapy_9\NN\657604|NONE (r_dobj) receiving_6\VBG\2210855|a|bipolar (r_acl) patient_5\NN\9898892|NONE (r_pobj) in_2\IN\13603305|Recent (r_prep) findings_1\NNS\7951464|authors|conduct|. (r_nsubj) prompted_16\VBD\1645601|NONE (l_xcomp) conduct_20\VB\407535|authors|findings|. (l_dobj) study_23\NN\635850|to (l_prep) with_27\IN\0|a|retrospective|of (l_pobj) hypercalcemia_31\NN\14299637|NONE
D008094_D006934 CID lithium_28\NN\14625458| (r_npadvmod) associated_30\VBN\628491|NONE (r_amod) hypercalcemia_31\NN\14299637|NONE (r_pobj) with_27\IN\0|a|retrospective|of (r_prep) study_23\NN\635850|to (r_dobj) conduct_20\VB\407535|authors|findings|. (r_xcomp) prompted_16\VBD\1645601|NONE (l_nsubj) findings_1\NNS\7951464|authors|conduct|. (l_prep) in_2\IN\13603305|Recent (l_pobj) patient_5\NN\9898892|NONE (l_acl) receiving_6\VBG\2210855|a|bipolar (l_dobj) therapy_9\NN\657604|NONE (l_relcl) developed_11\VBD\1753788|lithium (l_dobj) hypercalcemia_12\NN\14299637|who
D008094_D006934 CID lithium_28\NN\14625458| (r_npadvmod) associated_30\VBN\628491|NONE (r_amod) hypercalcemia_31\NN\14299637|NONE
D008094_D006934 CID lithium_17\NN\14625458| (r_npadvmod) treated_19\VBN\2376958||with|and|patients (r_amod) patients_20\NNS\9898892|authors|After|.|, (r_dobj) identified_13\VBD\699815|NONE (l_prep) after_0\IN\0|patients|authors|.|, (l_pcomp) eliminating_1\VBG\1619929|NONE (l_dobj) hypercalcemias_3\NNS\14299637|NONE
D008094_D006934 CID lithium_17\NN\14625458| (r_npadvmod) treated_19\VBN\2376958||with|and|patients (r_amod) patients_20\NNS\9898892|authors|After|.|, (l_prep) with_21\IN\0||treated|and|patients (l_pobj) hypercalcemias_22\NNS\14299637|NONE
D008094_D006934 CID lithium_17\NN\14625458| (r_npadvmod) treated_19\VBN\2376958||with|and|patients (r_amod) patients_20\NNS\9898892|authors|After|.|, (l_conj) patients_36\NNS\9898892||treated|with|and (l_prep) with_37\IN\0| (l_pobj) hypercalcemia_41\NN\14299637|NONE
D008094_D006934 CID lithium_38\NN\14625458| (r_npadvmod) associated_40\VBN\628491|(|)|B (r_amod) hypercalcemia_41\NN\14299637|NONE (r_pobj) with_37\IN\0| (r_prep) patients_36\NNS\9898892||treated|with|and (r_conj) patients_20\NNS\9898892|authors|After|.|, (r_dobj) identified_13\VBD\699815|NONE (l_prep) after_0\IN\0|patients|authors|.|, (l_pcomp) eliminating_1\VBG\1619929|NONE (l_dobj) hypercalcemias_3\NNS\14299637|NONE
D008094_D006934 CID lithium_38\NN\14625458| (r_npadvmod) associated_40\VBN\628491|(|)|B (r_amod) hypercalcemia_41\NN\14299637|NONE (r_pobj) with_37\IN\0| (r_prep) patients_36\NNS\9898892||treated|with|and (r_conj) patients_20\NNS\9898892|authors|After|.|, (l_prep) with_21\IN\0||treated|and|patients (l_pobj) hypercalcemias_22\NNS\14299637|NONE
D008094_D006934 CID lithium_38\NN\14625458| (r_npadvmod) associated_40\VBN\628491|(|)|B (r_amod) hypercalcemia_41\NN\14299637|NONE
D008094_D006934 CID lithium_11\NN\14625458| (r_npadvmod) associated_13\VBN\628491|NONE (r_amod) hypercalcemia_14\NN\14299637|NONE (r_pobj) with_10\IN\0|medical|and|patients (r_prep) diseases_6\NNS\14061805|NONE (r_pobj) from_4\IN\0|NONE (r_prep) resulting_3\VBG\2633881|NONE (r_acl) hypercalcemia_2\NN\14299637|NONE
D008094_D006934 CID lithium_11\NN\14625458| (r_npadvmod) associated_13\VBN\628491|NONE (r_amod) hypercalcemia_14\NN\14299637|NONE
D008094_D001919 NONE lithium_8\NN\14625458|developed (r_compound) therapy_9\NN\657604|NONE (l_relcl) developed_11\VBD\1753788|lithium (l_dobj) hypercalcemia_12\NN\14299637|who (l_conj) bradyarrhythmia_15\NN\0|and
D008094_D001919 NONE lithium_28\NN\14625458| (r_npadvmod) associated_30\VBN\628491|NONE (r_amod) hypercalcemia_31\NN\14299637|NONE (r_pobj) with_27\IN\0|a|retrospective|of (r_prep) study_23\NN\635850|to (r_dobj) conduct_20\VB\407535|authors|findings|. (r_xcomp) prompted_16\VBD\1645601|NONE (l_nsubj) findings_1\NNS\7951464|authors|conduct|. (l_prep) in_2\IN\13603305|Recent (l_pobj) patient_5\NN\9898892|NONE (l_acl) receiving_6\VBG\2210855|a|bipolar (l_dobj) therapy_9\NN\657604|NONE (l_relcl) developed_11\VBD\1753788|lithium (l_dobj) hypercalcemia_12\NN\14299637|who (l_conj) bradyarrhythmia_15\NN\0|and
D008094_D009369 NONE lithium_17\NN\14625458| (r_npadvmod) treated_19\VBN\2376958||with|and|patients (r_amod) patients_20\NNS\9898892|authors|After|.|, (l_prep) with_21\IN\0||treated|and|patients (l_pobj) hypercalcemias_22\NNS\14299637|NONE (l_acl) related_23\VBN\628491|NONE (l_prep) to_24\IN\0|NONE (l_pobj) malignancies_25\NNS\14070360|NONE
D008094_D009369 NONE lithium_38\NN\14625458| (r_npadvmod) associated_40\VBN\628491|(|)|B (r_amod) hypercalcemia_41\NN\14299637|NONE (r_pobj) with_37\IN\0| (r_prep) patients_36\NNS\9898892||treated|with|and (r_conj) patients_20\NNS\9898892|authors|After|.|, (l_prep) with_21\IN\0||treated|and|patients (l_pobj) hypercalcemias_22\NNS\14299637|NONE (l_acl) related_23\VBN\628491|NONE (l_prep) to_24\IN\0|NONE (l_pobj) malignancies_25\NNS\14070360|NONE
18025637
D005473_D012170 CID fluoxetine_5\NN\4169152|.|Branch|and|vein (r_conj) occlusion_3\NN\14081375|NONE
D005473_D012170 CID fluoxetine_9\NN\4169152| (r_advmod) induced_11\VBN\1627355|secondary (r_amod) hypertension_13\NN\14057371|NONE (r_pobj) with_8\IN\0|NONE (r_prep) associated_7\VBN\628491|branch|vein (r_acl) occlusion_6\NN\14081375|NONE
D005473_D006973 CID fluoxetine_9\NN\4169152| (r_advmod) induced_11\VBN\1627355|secondary (r_amod) hypertension_13\NN\14057371|NONE
D012701_D006973 NONE serotonin_6\NN\14807737|reuptake|inhibitor|selective (r_compound) therapy_9\NN\657604|NONE (r_pobj) of_4\IN\0|infrequent|an (r_prep) complication_3\NN\1073995|NONE (r_pobj) although_0\IN\0|important|.|are|,|it (r_prep) is_12\VBZ\0|NONE (l_ccomp) are_16\VBP\13600404|Although|important|.|,|it (l_acomp) aware_17\JJ\0|ophthalmologists|that (l_ccomp) cause_22\VB\7323922|NONE (l_dobj) hypertension_23\NN\14057371|that|can|agents|prescribed
16309808
D004298_D012148 NONE dopamine_14\NN\14807737|levodopa (r_compound) agonists_15\NNS\0|NONE (r_pobj) by_11\IN\0|For|,|,|be|.|dramatically|can|symptoms|induce (r_agent) improved_10\VBN\126264|NONE (l_nsubjpass) symptoms_4\NNS\5823932|For|,|,|be|.|dramatically|can|by|induce (l_prep) of_5\IN\0|the (l_pobj) rls_6\NNP\0|NONE
D004298_D012148 NONE dopamine_14\NN\14807737|levodopa (r_compound) agonists_15\NNS\0|NONE (r_pobj) by_11\IN\0|For|,|,|be|.|dramatically|can|symptoms|induce (r_agent) improved_10\VBN\126264|NONE (l_advcl) induce_24\VB\1627355|For|,|,|be|.|dramatically|can|symptoms|by (l_conj) aggravate_26\VB\126264|or|antagonists|whereas|can (l_dobj) symptoms_28\NNS\5823932|NONE (l_compound) rls_27\NNP\0|NONE
D004298_D012148 NONE dopamine_19\NN\14807737|receptor (r_compound) antagonists_22\NNS\7846|or|aggravate|whereas|can (r_nsubj) induce_24\VB\1627355|For|,|,|be|.|dramatically|can|symptoms|by (r_advcl) improved_10\VBN\126264|NONE (l_nsubjpass) symptoms_4\NNS\5823932|For|,|,|be|.|dramatically|can|by|induce (l_prep) of_5\IN\0|the (l_pobj) rls_6\NNP\0|NONE
D004298_D012148 NONE dopamine_19\NN\14807737|receptor (r_compound) antagonists_22\NNS\7846|or|aggravate|whereas|can (r_nsubj) induce_24\VB\1627355|For|,|,|be|.|dramatically|can|symptoms|by (l_conj) aggravate_26\VB\126264|or|antagonists|whereas|can (l_dobj) symptoms_28\NNS\5823932|NONE (l_compound) rls_27\NNP\0|NONE
D004298_D012148 NONE dopamine_15\NN\14807737|receptor|D|a (r_compound) antagonist_18\NN\7846|, (r_appos) domperidone_11\NN\0|aggravate|also|can|whether|or|, (r_nsubj) induce_22\VB\1627355|NONE (l_conj) aggravate_24\VBP\126264|domperidone|also|can|whether|or|, (l_dobj) symptoms_25\NNS\5823932|NONE (l_prep) of_26\IN\0|NONE (l_pobj) rls_27\NNP\0|NONE
D004298_D012148 NONE dopamine_24\NN\14807737|receptor|concomitant (r_compound) antagonists_27\NNS\7846|NONE (r_dobj) receiving_22\VBG\2210855|especially (r_acl) those_21\DT\0|the|associated|, (r_appos) possibility_8\NN\5944958|NONE (l_acl) associated_13\VBN\628491|the|those|, (l_prep) with_14\IN\0|that|can|mirtazapine|be|in (l_pobj) rls_15\NNP\0|NONE
D007980_D012148 NONE levodopa_12\NN\14604959|dopamine (r_nmod) agonists_15\NNS\0|NONE (r_pobj) by_11\IN\0|For|,|,|be|.|dramatically|can|symptoms|induce (r_agent) improved_10\VBN\126264|NONE (l_nsubjpass) symptoms_4\NNS\5823932|For|,|,|be|.|dramatically|can|by|induce (l_prep) of_5\IN\0|the (l_pobj) rls_6\NNP\0|NONE
D007980_D012148 NONE levodopa_12\NN\14604959|dopamine (r_nmod) agonists_15\NNS\0|NONE (r_pobj) by_11\IN\0|For|,|,|be|.|dramatically|can|symptoms|induce (r_agent) improved_10\VBN\126264|NONE (l_advcl) induce_24\VB\1627355|For|,|,|be|.|dramatically|can|symptoms|by (l_conj) aggravate_26\VB\126264|or|antagonists|whereas|can (l_dobj) symptoms_28\NNS\5823932|NONE (l_compound) rls_27\NNP\0|NONE
D004294_D012148 NONE domperidone_1\NN\0|?|Does|syndrome (r_nsubj) potentiate_2\VB\229605|NONE (l_dobj) syndrome_8\NN\5870365|?|domperidone|Does
D004294_D012148 NONE domperidone_11\NN\0|aggravate|also|can|whether|or|, (r_nsubj) induce_22\VB\1627355|NONE (l_conj) aggravate_24\VBP\126264|domperidone|also|can|whether|or|, (l_dobj) symptoms_25\NNS\5823932|NONE (l_prep) of_26\IN\0|NONE (l_pobj) rls_27\NNP\0|NONE
D004294_D012148 NONE domperidone_21\NN\0|his (r_compound) therapy_22\NN\657604|NONE (r_pobj) to_19\IN\0|been|had (r_prep) added_18\VBN\156601|comorbid|.|here|authors (r_ccomp) report_2\VBP\6470073|NONE (l_dobj) comorbid_7\JJ\0|added|.|here|authors (l_prep) with_8\IN\0|a|depressed|patient (l_pobj) dyspepsia_10\NN\14299637|NONE (l_relcl) developed_12\VBD\1753788|postprandial (l_dobj) rls_13\NNP\0|who|after
D004294_D012148 NONE domperione_24\NN\0|NONE (r_pobj) of_23\IN\0|a|potentiating (r_prep) effect_22\NN\34213|did|relationship|not|. (r_dobj) support_19\VB\407535|NONE (l_nsubj) relationship_3\NN\31921|did|not|.|effect (l_prep) between_4\IN\0|temporal|Such|a (l_pobj) use_6\NN\407535|NONE (l_conj) symptoms_11\NNS\5823932|the|and|of (l_prep) of_12\IN\0|in|the (l_pobj) rls_13\NNP\0|NONE
D004294_D012148 NONE domperione_24\NN\0|NONE (l_prep) on_25\IN\0|NONE (l_pobj) rls_29\NNP\0|NONE
D004294_D004415 NONE domperidone_21\NN\0|his (r_compound) therapy_22\NN\657604|NONE (r_pobj) to_19\IN\0|been|had (r_prep) added_18\VBN\156601|comorbid|.|here|authors (r_ccomp) report_2\VBP\6470073|NONE (l_dobj) comorbid_7\JJ\0|added|.|here|authors (l_prep) with_8\IN\0|a|depressed|patient (l_pobj) dyspepsia_10\NN\14299637|NONE
C035133_D004415 NONE mirtazapine_15\RB\0|NONE (r_pobj) after_14\IN\0|who|RLS (r_prep) developed_12\VBD\1753788|postprandial (r_relcl) dyspepsia_10\NN\14299637|NONE
C035133_D012148 CID mirtazapine_3\RB\0| (r_advmod) associated_5\VBN\628491|legs (r_amod) syndrome_8\NN\5870365|?|domperidone|Does
C035133_D012148 CID mirtazapine_0\NNP\0|with|.|been|in|has (r_nsubjpass) associated_15\VBN\628491|NONE (l_prep) with_16\IN\0|Mirtazapine|.|been|in|has (l_pobj) rls_17\NNP\0|NONE
C035133_D012148 CID mirtazapine_15\RB\0|NONE (r_pobj) after_14\IN\0|who|RLS (r_prep) developed_12\VBD\1753788|postprandial (l_dobj) rls_13\NNP\0|who|after
C035133_D012148 CID mirtazapine_15\NN\0|NONE (r_pobj) with_14\IN\0|had|only|been|he|after (r_prep) treated_13\VBN\2376958|symptoms|to (r_advcl) have_4\VB\7846|and|patient|resolved|, (l_dobj) symptoms_5\NNS\5823932|treated|to (l_prep) of_6\IN\0|NONE (l_pobj) rls_7\NNP\0|NONE
C035133_D012148 CID mirtazapine_15\NN\0|NONE (r_pobj) with_14\IN\0|had|only|been|he|after (r_prep) treated_13\VBN\2376958|symptoms|to (r_advcl) have_4\VB\7846|and|patient|resolved|, (r_xcomp) started_2\VBD\0|NONE (l_conj) resolved_21\VBD\352826|and|patient|,|have (l_nsubj) symptoms_20\NNS\5823932|.|completely|upon (l_compound) rls_19\NNP\0|his
C035133_D012148 CID mirtazapine_27\NN\0|NONE (r_pobj) of_25\IN\0|NONE (r_prep) discontinuation_24\NN\209943|NONE (r_pobj) upon_23\IN\0|.|symptoms|completely (r_prep) resolved_21\VBD\352826|and|patient|,|have (r_conj) started_2\VBD\0|NONE (l_xcomp) have_4\VB\7846|and|patient|resolved|, (l_dobj) symptoms_5\NNS\5823932|treated|to (l_prep) of_6\IN\0|NONE (l_pobj) rls_7\NNP\0|NONE
C035133_D012148 CID mirtazapine_27\NN\0|NONE (r_pobj) of_25\IN\0|NONE (r_prep) discontinuation_24\NN\209943|NONE (r_pobj) upon_23\IN\0|.|symptoms|completely (r_prep) resolved_21\VBD\352826|and|patient|,|have (l_nsubj) symptoms_20\NNS\5823932|.|completely|upon (l_compound) rls_19\NNP\0|his
C035133_D012148 CID mirtazapine_8\NN\0|NONE (r_pobj) of_7\IN\0|the|and|symptoms (r_prep) use_6\NN\407535|NONE (l_conj) symptoms_11\NNS\5823932|the|and|of (l_prep) of_12\IN\0|in|the (l_pobj) rls_13\NNP\0|NONE
C035133_D012148 CID mirtazapine_8\NN\0|NONE (r_pobj) of_7\IN\0|the|and|symptoms (r_prep) use_6\NN\407535|NONE (r_pobj) between_4\IN\0|temporal|Such|a (r_prep) relationship_3\NN\31921|did|not|.|effect (r_nsubj) support_19\VB\407535|NONE (l_dobj) effect_22\NN\34213|did|relationship|not|. (l_prep) of_23\IN\0|a|potentiating (l_pobj) domperione_24\NN\0|NONE (l_prep) on_25\IN\0|NONE (l_pobj) rls_29\NNP\0|NONE
C035133_D012148 CID mirtazapine_26\RB\0| (r_npadvmod) associated_28\VBN\628491|NONE (r_amod) rls_29\NNP\0|NONE (r_pobj) on_25\IN\0|NONE (r_prep) domperione_24\NN\0|NONE (r_pobj) of_23\IN\0|a|potentiating (r_prep) effect_22\NN\34213|did|relationship|not|. (r_dobj) support_19\VB\407535|NONE (l_nsubj) relationship_3\NN\31921|did|not|.|effect (l_prep) between_4\IN\0|temporal|Such|a (l_pobj) use_6\NN\407535|NONE (l_conj) symptoms_11\NNS\5823932|the|and|of (l_prep) of_12\IN\0|in|the (l_pobj) rls_13\NNP\0|NONE
C035133_D012148 CID mirtazapine_26\RB\0| (r_npadvmod) associated_28\VBN\628491|NONE (r_amod) rls_29\NNP\0|NONE
C035133_D012148 CID mirtazapine_10\NN\0|that|can|with|be|in (r_nsubjpass) associated_13\VBN\628491|the|those|, (l_prep) with_14\IN\0|that|can|mirtazapine|be|in (l_pobj) rls_15\NNP\0|NONE
3832950
D002998_D013036 NONE clonazepam_23\NN\0|NONE (r_pobj) with_22\IN\0|patients|.|were (r_prep) treated_21\VBN\2376958|NONE (l_nsubjpass) patients_1\NNS\9898892|.|were|with (l_prep) with_12\IN\0|(|Sixty|)|range (l_pobj) types_14\NNS\5839024|NONE (l_prep) than_17\IN\0|of|other (l_pobj) spasms_19\NNS\14299637|NONE
D002998_D004827 NONE clonazepam_0\NNP\0|.|for|in (r_compound) monotherapy_1\NN\0|NONE (l_prep) for_2\IN\0|Clonazepam|.|in (l_pobj) epilepsy_3\NN\14085708|NONE
D002998_D004827 NONE clonazepam_23\NN\0|NONE (r_pobj) with_22\IN\0|patients|.|were (r_prep) treated_21\VBN\2376958|NONE (l_nsubjpass) patients_1\NNS\9898892|.|were|with (l_prep) with_12\IN\0|(|Sixty|)|range (l_pobj) types_14\NNS\5839024|NONE (l_prep) of_15\IN\0|than|other (l_pobj) epilepsy_16\NN\14085708|NONE
4010471
D004229_D012640 NONE dithiothreitol_15\NN\0|NONE (r_pobj) with_14\IN\0|NONE (r_prep) treatment_13\NN\654885|NONE (r_pobj) by_12\IN\0|.|sites|were|equally (r_agent) affected_11\VBN\126264|NONE (l_nsubjpass) sites_2\NNS\8673395|.|by|were|equally (l_prep) from_3\IN\0|binding|The (l_pobj) mice_8\NNS\2329401|NONE (l_amod) sensitive_5\JJ\10488309|NONE (l_npadvmod) seizure_4\NN\14081375|and|resistant
D009538_D012640 CID nicotine_2\NN\14712692| (r_npadvmod) induced_4\VBN\1627355|receptors|and (r_amod) seizures_5\NNS\14081375|NONE
D009538_D012640 CID nicotine_15\NN\14712692| (r_npadvmod) induced_17\VBN\1627355|concentration|and (r_amod) seizures_18\NNS\14081375|NONE
D009538_D012640 CID nicotine_7\NN\14712692|NONE (r_pobj) of_6\IN\0|convulsant|the (r_prep) effects_5\NNS\13245626|NONE (r_pobj) to_2\IN\0|NONE (r_prep) sensitive_1\JJ\10488309|NONE (r_amod) mice_0\NNS\2329401|.|binding (r_nsubj) had_8\VBD\0|NONE (l_dobj) binding_13\NN\4688246|Mice|. (l_prep) than_17\IN\0|bungarotoxin|in|greater (l_pobj) mice_20\NNS\2329401|NONE (l_nmod) seizure_18\NN\14081375|insensitive
7644931
D017239_D006402 CID paclitaxel_14\NN\0|/ (r_nmod) carboplatin_16\NN\0|the (r_compound) combination_17\NN\7951464|be|could|.|weeks (r_nsubjpass) dosed_20\VBN\515154|and|,|not|did|add|Carboplatin (r_conj) appear_3\VB\2604760|NONE (l_xcomp) add_5\VB\14304060|and|,|dosed|not|did|Carboplatin (l_prep) to_6\IN\0|to (l_pobj) toxicities_9\NNS\13576101|NONE
D017239_D064420 NONE paclitaxel_14\NN\0|NONE (r_pobj) of_13\IN\0|alone|I (r_prep) trial_12\NN\786195|Toxicities|.|were|with (r_dobj) compared_2\VBN\644583|NONE (l_nsubjpass) toxicities_0\NNS\13576101|trial|.|were|with
D017239_D002289 NONE paclitaxel_0\NNP\0|was|with|.|in (r_nsubjpass) combined_18\VBN\2630189|NONE (l_prep) in_21\IN\13603305|Paclitaxel|was|with|. (l_pobj) phase_23\NN\15113229|NONE (l_acl) directed_28\VBN\746718|a (l_prep) to_29\IN\0|study (l_pobj) patients_30\NNS\9898892|NONE (l_prep) with_31\IN\0|NONE (l_pobj) cancer_37\NN\14239425|NONE
D017239_D002289 NONE taxol_2\NNP\0|Company (r_appos) paclitaxel_0\NNP\0|was|with|.|in (r_nsubjpass) combined_18\VBN\2630189|NONE (l_prep) in_21\IN\13603305|Paclitaxel|was|with|. (l_pobj) phase_23\NN\15113229|NONE (l_acl) directed_28\VBN\746718|a (l_prep) to_29\IN\0|study (l_pobj) patients_30\NNS\9898892|NONE (l_prep) with_31\IN\0|NONE (l_pobj) cancer_37\NN\14239425|NONE
D016190_D002289 NONE carboplatin_20\NN\0|NONE (r_pobj) with_19\IN\0|Paclitaxel|was|.|in (r_prep) combined_18\VBN\2630189|NONE (l_prep) in_21\IN\13603305|Paclitaxel|was|with|. (l_pobj) phase_23\NN\15113229|NONE (l_acl) directed_28\VBN\746718|a (l_prep) to_29\IN\0|study (l_pobj) patients_30\NNS\9898892|NONE (l_prep) with_31\IN\0|NONE (l_pobj) cancer_37\NN\14239425|NONE
D016190_D006402 NONE carboplatin_0\NNP\0|and|,|dosed|not|did|add (r_nsubj) appear_3\VB\2604760|NONE (l_xcomp) add_5\VB\14304060|and|,|dosed|not|did|Carboplatin (l_prep) to_6\IN\0|to (l_pobj) toxicities_9\NNS\13576101|NONE
D016190_D006402 NONE carboplatin_16\NN\0|the (r_compound) combination_17\NN\7951464|be|could|.|weeks (r_nsubjpass) dosed_20\VBN\515154|and|,|not|did|add|Carboplatin (r_conj) appear_3\VB\2604760|NONE (l_xcomp) add_5\VB\14304060|and|,|dosed|not|did|Carboplatin (l_prep) to_6\IN\0|to (l_pobj) toxicities_9\NNS\13576101|NONE
1280054
D014750_D007049 CID vincristine_0\NNP\3917455|.|,|intrathecally|to|was|accidentally|producing (r_nsubjpass) given_3\VBN\5892096|NONE (l_advcl) producing_11\VBG\1617192|.|,|intrathecally|to|was|accidentally|Vincristine (l_dobj) dysfunction_15\NN\14204950|NONE
D014750_D001927 CID vincristine_5\NN\3917455|intrathecal (r_compound) administration_6\NN\1133281|to (r_pobj) due_2\IN\5174653|.|Fatal (r_prep) myeloencephalopathy_1\NN\0|NONE
D014750_D001927 CID vincristine_0\NNP\3917455|.|,|intrathecally|to|was|accidentally|producing (r_nsubjpass) given_3\VBN\5892096|NONE (l_advcl) producing_11\VBG\1617192|.|,|intrathecally|to|was|accidentally|Vincristine (l_dobj) dysfunction_15\NN\14204950|NONE (l_acl) followed_16\VBN\1835496|sensory (l_agent) by_17\IN\0|NONE (l_pobj) encephalopathy_18\JJ\14084880|NONE
D014750_D007938 NONE vincristine_0\NNP\3917455|.|,|intrathecally|to|was|accidentally|producing (r_nsubjpass) given_3\VBN\5892096|NONE (l_dative) to_5\IN\0|.|,|intrathecally|was|accidentally|Vincristine|producing (l_pobj) child_7\NN\9622049|NONE (l_prep) with_8\IN\0|a (l_pobj) leukaemia_9\NN\14239918|NONE
895432
D007545_D009203 CID isoproterenol_7\NN\3740161| (r_npadvmod) induced_9\VBN\1627355|myocardial (r_amod) infarction_11\NN\14204950|NONE
D007545_D009203 CID isoproterenol_8\NN\3740161| (r_npadvmod) induced_10\VBN\1627355|myocardial (r_amod) infarction_12\NN\14204950|NONE
D007545_D007238 NONE isoproterenol_16\NN\3740161|NONE (r_pobj) of_15\IN\0|large (r_prep) dosages_14\NNS\13576355|NONE (r_pobj) of_12\IN\0|the (r_prep) effects_11\NNS\13245626|NONE (r_pobj) with_9\IN\0|NONE (r_prep) associated_8\VBN\628491|the (r_acl) mortality_7\NN\5054863|but|exercise|had|that (r_dobj) reduced_5\VBD\441445|.|results (l_conj) had_18\VBD\0|but|exercise|mortality|that (l_prep) on_20\IN\0|little (l_pobj) severity_22\NN\5036394|NONE (l_prep) of_23\IN\0|the (l_pobj) infarction_25\NN\14204950|NONE
19815465
D020888_D014786 CID vigabatrin_8\NN\0|NONE (r_pobj) to_7\TO\0|NONE (r_prep) specific_6\JJ\5817396|not|.|defects (r_acomp) are_4\VBP\13600404|NONE (l_nsubj) defects_3\NNS\14462666|not|.|specific
D020888_D014786 CID vigabatrin_11\NN\0|NONE (r_pobj) with_7\IN\0|NONE (r_prep) associated_6\VBN\628491|visual|the (r_acl) defects_5\NNS\14462666|.|study
D020888_D014786 CID vgb_13\NNP\0|the|(|antiepileptic|drug|) (r_appos) vigabatrin_11\NN\0|NONE (r_pobj) with_7\IN\0|NONE (r_prep) associated_6\VBN\628491|visual|the (r_acl) defects_5\NNS\14462666|.|study
D020888_D004827 NONE vgb_24\NNP\0|NONE (r_pobj) to_23\IN\0|no|current (r_prep) exposure_22\NN\5042871|)|(|antiepileptic|drug (r_appos) therapy_14\NN\657604|NONE (r_pobj) of_11\IN\0|the (r_prep) basis_10\NN\13790712|NONE (r_pobj) on_8\IN\0|people|.|were (r_prep) grouped_7\VBN\654625|NONE (l_nsubjpass) people_3\NNS\31264|.|were|on (l_prep) with_4\IN\0|four (l_pobj) epilepsy_5\NN\14085708|NONE
D020888_D012164 CID vgb_19\NNP\0|NONE (r_pobj) with_18\IN\0|NONE (r_prep) associated_17\VBN\628491|retinal (r_acl) toxicity_16\NN\13576101|reliably|to
16565833
C522803_D066126 NONE monoher_7\NN\0|NONE (r_pobj) between_6\IN\0|time|the (r_prep) interval_5\NN\33615|NONE (r_pobj) of_2\IN\0|and|.|The|administration (r_prep) influence_1\NN\5190804|NONE (l_conj) administration_10\NN\1133281|and|.|of|The (l_prep) on_11\IN\0|doxorubicin (l_pobj) protection_13\NN\407535|NONE (l_prep) against_14\IN\0|the (l_pobj) cardiotoxicity_18\NN\0|NONE
C522803_D066126 NONE monohydroxyethylrutoside_3\NN\0|.|cardioprotection (r_nsubj) showed_7\VBD\2137132|NONE (l_dobj) cardioprotection_8\NN\0|.|monohydroxyethylrutoside (l_prep) against_9\IN\0|NONE (l_pobj) cardiotoxicity_13\NN\0|NONE
C522803_D066126 NONE monoher_5\NN\0|flavonoid|semisynthetic|The|)|( (r_appos) monohydroxyethylrutoside_3\NN\0|.|cardioprotection (r_nsubj) showed_7\VBD\2137132|NONE (l_dobj) cardioprotection_8\NN\0|.|monohydroxyethylrutoside (l_prep) against_9\IN\0|NONE (l_pobj) cardiotoxicity_13\NN\0|NONE
D004317_D066126 NONE doxorubicin_9\NN\2716866|on (r_compound) administration_10\NN\1133281|and|.|of|The (l_prep) on_11\IN\0|doxorubicin (l_pobj) protection_13\NN\407535|NONE (l_prep) against_14\IN\0|the (l_pobj) cardiotoxicity_18\NN\0|NONE
D004317_D066126 NONE doxorubicin_15\NN\2716866| (r_npadvmod) induced_17\VBN\1627355|in (r_amod) cardiotoxicity_18\NN\0|NONE
D004317_D066126 NONE doxorubicin_9\NN\2716866|.|be (l_prep) despite_0\IN\7501545|anthracyclin|DOX|, (l_pobj) cardiotoxicity_5\NN\0|NONE
D004317_D066126 NONE dox_11\NNP\0|anthracyclin|Despite|, (r_appos) doxorubicin_9\NN\2716866|.|be (l_prep) despite_0\IN\7501545|anthracyclin|DOX|, (l_pobj) cardiotoxicity_5\NN\0|NONE
D004317_D066126 NONE dox_10\NNP\0| (r_npadvmod) induced_12\VBN\1627355|through (r_amod) cardiotoxicity_13\NN\0|NONE
D007501_D066126 NONE iron_19\NN\14625458|NONE (r_compound) chelating_20\VBG\2621395|scavenging (r_compound) properties_21\NNS\32613|NONE (r_pobj) through_14\IN\0|induced (r_prep) cardiotoxicity_13\NN\0|NONE
D004317_D006331 NONE dox_0\NNP\0| (r_npadvmod) induced_2\VBN\1627355|cardiac (r_amod) damage_4\NN\7296428|from|presumably|.
D004317_D006331 NONE dox_14\NNP\0|NONE (r_pobj) by_13\IN\0|free (r_prep) radicals_12\NNS\9465459|NONE (r_pobj) of_10\IN\0|the (r_prep) formation_9\NN\7938773|NONE (r_pobj) from_7\IN\0|presumably|damage|. (r_prep) results_6\VBZ\34213|NONE (l_nsubj) damage_4\NN\7296428|from|presumably|.
D004317_D006331 NONE dox_6\NNP\0|NONE (r_pobj) with_5\IN\0|alone (r_prep) treatment_4\NN\654885|that|damage (r_nsubj) induced_8\VBD\1627355|.|evaluation (l_dobj) damage_11\NN\7296428|that|treatment
D005419_D066126 NONE flavonoid_2\NN\14983143|semisynthetic|monoHER|The|)|( (r_compound) monohydroxyethylrutoside_3\NN\0|.|cardioprotection (r_nsubj) showed_7\VBD\2137132|NONE (l_dobj) cardioprotection_8\NN\0|.|monohydroxyethylrutoside (l_prep) against_9\IN\0|NONE (l_pobj) cardiotoxicity_13\NN\0|NONE
20682692
D013311_D003920 NONE streptozotocin_28\JJ\0|(|STZ)induced (r_nmod) diabetes_31\NNS\14075199|NONE
D013311_D003920 NONE stz)-induced_30\VBN\0|(|streptozotocin (r_amod) diabetes_31\NNS\14075199|NONE
D013311_D003928 CID streptozotocin_15\NNS\0| (r_npadvmod) induced_17\VBN\1627355|diabetic (r_amod) nephropathy_19\NN\14573196|NONE
D013311_D003928 CID stz_22\NNP\0| (r_npadvmod) induced_24\VBN\1627355|in|diabetic (r_amod) nephropathy_26\NN\14573196|NONE
D013311_D003928 CID stz_20\NNP\0| (r_npadvmod) induced_22\VBN\1627355|diabetic (r_amod) nephropathy_24\NN\14573196|NONE
D000804_D003928 NONE angiotensin_13\NN\4522421|the (r_compound) system_14\NN\3575240|NONE (r_pobj) of_9\IN\0|in|early (r_prep) blockade_8\NN\952963|that|,|not|did|suggesting|progression (r_nsubj) retard_25\VB\10599354|trial|. (l_advcl) suggesting_31\VBG\1010118|that|blockade|,|not|did|progression (l_ccomp) involved_37\VBN\2676054|NONE (l_prep) in_38\IN\13603305|)|mechanism(s|are|that (l_pobj) pathogenesis_40\NN\13533470|NONE (l_prep) of_41\IN\0|the (l_pobj) nephropathy_44\NN\14573196|NONE
D000804_D003928 NONE angiotensin_13\NN\4522421|the (r_compound) system_14\NN\3575240|NONE (r_pobj) of_9\IN\0|in|early (r_prep) blockade_8\NN\952963|that|,|not|did|suggesting|progression (r_nsubj) retard_25\VB\10599354|trial|. (l_advcl) suggesting_31\VBG\1010118|that|blockade|,|not|did|progression (l_ccomp) involved_37\VBN\2676054|NONE (l_prep) in_38\IN\13603305|)|mechanism(s|are|that (l_pobj) pathogenesis_40\NN\13533470|NONE (l_prep) of_41\IN\0|the (l_pobj) nephropathy_44\NN\14573196|NONE (l_appos) nephropathy_47\NN\14573196|early|(|diabetic|)
D013311_D005355 NONE streptozotocin_28\JJ\0|(|STZ)induced (r_nmod) diabetes_31\NNS\14075199|NONE (r_pobj) with_27\IN\0|NONE (r_prep) mice_26\NNS\2329401|NONE (r_pobj) in_25\IN\13603305|early|the|of|of (r_prep) development_17\NN\248977|NONE (l_prep) of_18\IN\0|in|early|the|of (l_pobj) fibrosis_21\NN\14204950|NONE
D013311_D005355 NONE stz)-induced_30\VBN\0|(|streptozotocin (r_amod) diabetes_31\NNS\14075199|NONE (r_pobj) with_27\IN\0|NONE (r_prep) mice_26\NNS\2329401|NONE (r_pobj) in_25\IN\13603305|early|the|of|of (r_prep) development_17\NN\248977|NONE (l_prep) of_18\IN\0|in|early|the|of (l_pobj) fibrosis_21\NN\14204950|NONE
D000804_D007674 NONE angiotensin_13\NN\4522421|the (r_compound) system_14\NN\3575240|NONE (r_pobj) of_9\IN\0|in|early (r_prep) blockade_8\NN\952963|that|,|not|did|suggesting|progression (r_nsubj) retard_25\VB\10599354|trial|. (l_dobj) progression_27\NN\8457976|that|blockade|,|not|did|suggesting (l_prep) of_28\IN\0|the (l_pobj) nephropathy_29\NN\14573196|NONE
D000804_D003922 NONE angiotensin_13\NN\4522421|the (r_compound) system_14\NN\3575240|NONE (r_pobj) of_9\IN\0|in|early (r_prep) blockade_8\NN\952963|that|,|not|did|suggesting|progression (l_prep) in_15\IN\13603305|of|early (l_pobj) patients_16\NNS\9898892|NONE (l_prep) with_17\IN\0|NONE (l_pobj) diabetes_20\NNS\14075199|NONE
18189308
D014443_D003556 NONE tyrosine_9\NN\14601829|(|)|Trks|kinase (r_det) receptors_11\NNS\5225602|NONE (r_pobj) of_8\IN\0|the|regulation|and (r_prep) expression_5\NN\4679549|studies|in|.|have (r_dobj) examined_3\VBN\0|NONE (l_prep) in_15\IN\13603305|studies|expression|.|have (l_pobj) reflexes_17\NNS\859001|NONE (l_prep) with_18\IN\0|micturition (l_pobj) inflammation_21\NN\14299637|NONE
D003520_D003556 CID cyclophosphamide_12\NN\0| (r_npadvmod) induced_14\VBN\1627355|NONE (r_amod) cystitis_15\NN\14566129|NONE
D003520_D003556 CID cyclophosphamide_27\NN\0|NONE (r_pobj) by_26\IN\0|NONE (r_agent) induced_25\VBN\1627355|various|of (r_acl) durations_21\NNS\15113229|NONE (l_prep) of_22\IN\0|various|induced (l_pobj) inflammation_24\NN\14299637|NONE
D003520_D003556 CID cyp_29\NNP\0|NONE (r_appos) cyclophosphamide_27\NN\0|NONE (r_pobj) by_26\IN\0|NONE (r_agent) induced_25\VBN\1627355|various|of (r_acl) durations_21\NNS\15113229|NONE (l_prep) of_22\IN\0|various|induced (l_pobj) inflammation_24\NN\14299637|NONE
D003520_D003556 CID cyp_0\NNP\0| (r_npadvmod) induced_2\VBN\1627355|NONE (r_amod) cystitis_3\NN\14566129|(|expression|.
D003520_D003556 CID cyp_27\NNP\0| (r_npadvmod) induced_29\VBN\1627355|)|acute|( (r_amod) cystitis_30\NN\14566129|NONE
D003520_D003556 CID cyp_7\NNP\0||intermediate (r_npadvmod) induced_9\VBN\1627355|NONE (r_amod) cystitis_10\NN\14566129|NONE
9428298
D000420_D001249 NONE albuterol_2\NN\2905612|NONE (l_prep) in_3\IN\13603305|nebulized|:|.|study (l_pobj) exacerbations_5\NNS\374224|NONE (l_prep) of_6\IN\0|severe|in (l_pobj) asthma_7\NN\14145095|NONE
D000420_D001249 NONE albuterol_25\NN\2905612|(|)|nebulized (r_nmod) cna_27\NNP\0|who|versus (r_dobj) received_22\VBD\2210855|severe|of (r_relcl) exacerbations_18\NNS\374224|NONE (l_prep) of_19\IN\0|severe|received (l_pobj) asthma_20\NN\14145095|NONE
D000420_D001249 NONE albuterol_31\NN\2905612|(|intermittent|INA|) (r_nmod) treatments_35\NNS\654885|NONE (r_pobj) versus_29\IN\0|who|CNA (r_prep) received_22\VBD\2210855|severe|of (r_relcl) exacerbations_18\NNS\374224|NONE (l_prep) of_19\IN\0|severe|received (l_pobj) asthma_20\NN\14145095|NONE
16369751
C032348_D002637 NONE fbal_34\NNP\0|serum|of (r_compound) concentration_35\NN\4916342|NONE (r_pobj) with_30\IN\0|concomitantly|pain|during (r_prep) occurred_28\VBD\0|intravenous|,|a|of|continuous (l_nsubj) pain_22\NN\14299637|concomitantly|with|during
C032348_D002037 NONE fbal_34\NNP\0|serum|of (r_compound) concentration_35\NN\4916342|NONE (r_pobj) with_30\IN\0|concomitantly|pain|during (r_prep) occurred_28\VBD\0|intravenous|,|a|of|continuous (l_nsubj) pain_22\NN\14299637|concomitantly|with|during (l_prep) with_23\IN\0|precordial (l_pobj) block_27\NN\21939|NONE
C032348_D066126 NONE alanine_10\NN\14601829|NONE (r_pobj) by_3\IN\0|NONE (r_agent) induced_2\VBN\1627355|.|Fluorouracil (r_acl) cardiotoxicity_1\NN\0|NONE
C032348_D066126 NONE alanine_30\NN\14601829|NONE (r_pobj) of_23\IN\0|serum|a|high (r_prep) level_22\NN\4916342|)|in|(|was (r_nsubjpass) observed_35\VBN\2163746|induced|, (r_relcl) cardiotoxicity_15\NN\0|NONE
C032348_D066126 NONE fbal_32\NNP\0|NONE (r_preconj) (_31\-LRB-\0|)|in|level|was (r_punct) observed_35\VBN\2163746|induced|, (r_relcl) cardiotoxicity_15\NN\0|NONE
C032348_D066126 NONE fbal_16\NNP\0|to|that|is (r_nsubjpass) related_18\VBN\628491|.|,|experience (l_prep) to_19\IN\0|FBAL|that|is (l_pobj) cardiotoxicity_23\NN\0|NONE
D005472_D002037 CID 5-fu_11\CD\0|NONE (r_pobj) of_10\IN\0|intravenous|,|occurred|a|continuous (r_prep) infusion_9\NN\14589223|,|After|.|patient (l_relcl) occurred_28\VBD\0|intravenous|,|a|of|continuous (l_nsubj) pain_22\NN\14299637|concomitantly|with|during (l_prep) with_23\IN\0|precordial (l_pobj) block_27\NN\21939|NONE
D005472_D009369 NONE 5-fu_1\CD\0|)|(|for|. (r_nummod) treatment_3\NN\654885|NONE (l_prep) for_4\IN\0|)|(|.|FU (l_pobj) malignancies_5\NNS\14070360|NONE
D005472_D066126 NONE 5-fluorouracil_0\CD\0|.|induced (r_punct) cardiotoxicity_1\NN\0|NONE
D005472_D066126 NONE 5-fluorouracil_7\CD\0|complication|Cardiotoxicity (r_punct) is_1\VBZ\0|NONE (l_nsubj) cardiotoxicity_0\NNP\0|complication|fluorouracil
D005472_D066126 NONE 5-fu_12\CD\0| (r_npadvmod) induced_14\VBN\1627355|observed|, (r_amod) cardiotoxicity_15\NN\0|NONE
D005472_D066126 NONE 5-fu_14\CD\0| (r_npadvmod) induced_16\VBN\1627355|NONE (r_compound) cardiotoxicity_17\NN\0|NONE
D005472_D066126 NONE 5-fu_22\CD\0|NONE (r_pobj) of_21\IN\0|the (r_prep) administration_20\NN\1133281|,|considered|was|. (r_nsubjpass) abandoned_24\VBN\2222318|NONE (l_advcl) considered_8\VBN\689344|,|administration|was|. (l_xcomp) been_11\VBN\0|As|pain|was (l_acomp) due_12\JJ\5174653|have|to (l_prep) to_13\IN\0|NONE (l_pobj) cardiotoxicity_17\NN\0|NONE
D005472_D066126 NONE 5-fu_20\CD\0| (r_npadvmod) induced_22\VBN\1627355|NONE (r_compound) cardiotoxicity_23\NN\0|NONE
D005472_D066126 NONE 5-fu_8\CD\0| (r_npadvmod) induced_10\VBN\1627355|NONE (r_amod) cardiotoxicity_11\NN\0|NONE
D005472_D002637 CID 5-fu_11\CD\0|NONE (r_pobj) of_10\IN\0|intravenous|,|occurred|a|continuous (r_prep) infusion_9\NN\14589223|,|After|.|patient (l_relcl) occurred_28\VBD\0|intravenous|,|a|of|continuous (l_nsubj) pain_22\NN\14299637|concomitantly|with|during
D005472_D002637 CID 5-fu_14\CD\0|NONE (r_pobj) of_13\IN\0|the (r_prep) discontinuation_12\NN\209943|NONE (r_pobj) after_10\IN\0|.|spontaneously|pain (r_prep) disappeared_8\VBD\0|NONE (l_nsubj) pain_3\NN\14299637|after|.|spontaneously
D005472_D002637 CID 5-fu_14\CD\0| (r_npadvmod) induced_16\VBN\1627355|NONE (r_compound) cardiotoxicity_17\NN\0|NONE (r_pobj) to_13\IN\0|NONE (r_prep) due_12\JJ\5174653|have|to (r_acomp) been_11\VBN\0|As|pain|was (r_xcomp) considered_8\VBN\689344|,|administration|was|. (l_nsubjpass) pain_3\NN\14299637|As|was|been
D005472_D002637 CID 5-fu_22\CD\0|NONE (r_pobj) of_21\IN\0|the (r_prep) administration_20\NN\1133281|,|considered|was|. (r_nsubjpass) abandoned_24\VBN\2222318|NONE (l_advcl) considered_8\VBN\689344|,|administration|was|. (l_nsubjpass) pain_3\NN\14299637|As|was|been
3708328
D005680_D012640 NONE acid_16\NN\14818238|NONE (r_pobj) of_11\IN\0|the (r_prep) activity_10\NN\30358|NONE (r_dobj) manipulating_8\VBG\2536557|NONE (r_pcomp) of_7\IN\0|the|inhibition (r_prep) effects_6\NNS\13245626|,|were|In|.|, (l_appos) inhibition_20\NN\1068773|of|the (l_prep) on_25\IN\0|(|within|GABA)mediated|synaptic (l_pobj) seizures_26\NNS\14081375|NONE
D005680_D012640 NONE gaba)-mediated_18\VBN\0|(|within|on|synaptic (r_amod) inhibition_20\NN\1068773|of|the (l_prep) on_25\IN\0|(|within|GABA)mediated|synaptic (l_pobj) seizures_26\NNS\14081375|NONE
D005680_D012640 NONE gaba_17\NNP\14601829| (r_npadvmod) synthesizing_19\VBG\193486|decarboxylase|,|,|into|the (r_amod) enzyme_20\NN\14723628|NONE (r_pobj) of_15\IN\0|NONE (r_prep) activity_14\NN\30358|NONE (r_pobj) of_13\IN\0|an (r_prep) inhibitor_12\NN\20090|,| (r_appos) micrograms_9\NNS\13717155|,|of (r_conj) microinjections_4\NNS\0|NONE (r_pobj) with_3\IN\0|NONE (r_prep) pretreated_2\VBN\0|NONE (r_acl) animals_1\NNS\4475|NONE (r_pobj) in_0\IN\13603305|.|doses|in (r_prep) resulted_52\VBD\2633881|NONE (l_prep) in_53\IN\13603305|.|doses|In (l_pobj) seizures_57\NNS\14081375|NONE
D005680_D012640 NONE gaba_20\NNP\14601829| (r_npadvmod) mediated_22\VBN\761713|synaptic|the|within (r_amod) inhibition_24\NN\1068773|NONE (r_pobj) of_18\IN\0|the (r_prep) regulation_17\NN\6652242|NONE (r_pobj) to_15\IN\0|is|that|threshold (r_prep) subjected_14\VBN\137313|.|results (l_nsubjpass) threshold_5\NN\15265518|to|is|that (l_prep) for_6\IN\0|the (l_pobj) seizures_10\NNS\14081375|NONE
D007538_D013226 NONE isoniazid_6\NN\2716205|NONE (r_pobj) of_5\IN\0|micrograms|, (r_prep) microinjections_4\NNS\0|NONE (r_pobj) with_3\IN\0|NONE (r_prep) pretreated_2\VBN\0|NONE (r_acl) animals_1\NNS\4475|NONE (r_pobj) in_0\IN\13603305|.|doses|in (r_prep) resulted_52\VBD\2633881|NONE (l_prep) in_53\IN\13603305|.|doses|In (l_pobj) seizures_57\NNS\14081375|NONE (l_conj) epilepticus_60\NN\0|motor|severe|limbic|and
D010862_D013226 NONE pilocarpine_45\NN\14712692|NONE (r_pobj) of_44\IN\0|,|mg/kg|,||convulsant (r_prep) doses_43\NNS\3740161|.|In|in (r_nsubj) resulted_52\VBD\2633881|NONE (l_prep) in_53\IN\13603305|.|doses|In (l_pobj) seizures_57\NNS\14081375|NONE (l_conj) epilepticus_60\NN\0|motor|severe|limbic|and
D020888_D012640 NONE gaba_17\NNP\14601829|or (r_conj) isoniazid_11\NN\2716205|NONE (r_pobj) of_10\IN\0|into (r_prep) microinjection_9\NN\0|NONE (r_pobj) after_8\IN\0|NONE (r_prep) rats_7\NNS\2329401|NONE (r_pobj) in_6\IN\13603305|by (r_prep) produced_3\VBN\1617192|NONE (r_acl) seizures_2\NNS\14081375|NONE
D020888_D012640 NONE acid_6\NN\14818238|,|,|into|,|micrograms (r_appos) d_1\NNP\15089472|mg/kg|,|.|(|,|bilaterally|,|appearance (r_nsubj) suppressed_18\VBD\2510337|NONE (l_dobj) appearance_20\NN\4723816|mg/kg|,|.|(|,|bilaterally|D|, (l_prep) of_21\IN\0|the (l_pobj) seizures_25\NNS\14081375|NONE
D020888_D012640 NONE gaba_6\NNP\14601829|NONE (r_pobj) of_1\IN\0|into (r_prep) microinjections_0\NNS\0|.|prevent|,|mg/kg|bilaterally|,|, (r_nsubj) failed_18\VBD\0|NONE (l_xcomp) prevent_20\VB\0|.|,|mg/kg|bilaterally|Microinjections|,|, (l_dobj) development_22\NN\248977|to (l_prep) of_23\IN\0|the (l_pobj) convulsions_24\NNS\14081375|NONE
D018698_D012640 NONE acid_25\NN\14818238|glutamic (r_compound) decarboxylase_26\NN\14732946|,|synthesizing|,|into|the (r_appos) enzyme_20\NN\14723628|NONE (r_pobj) of_15\IN\0|NONE (r_prep) activity_14\NN\30358|NONE (r_pobj) of_13\IN\0|an (r_prep) inhibitor_12\NN\20090|,| (r_appos) micrograms_9\NNS\13717155|,|of (r_conj) microinjections_4\NNS\0|NONE (r_pobj) with_3\IN\0|NONE (r_prep) pretreated_2\VBN\0|NONE (r_acl) animals_1\NNS\4475|NONE (r_pobj) in_0\IN\13603305|.|doses|in (r_prep) resulted_52\VBD\2633881|NONE (l_prep) in_53\IN\13603305|.|doses|In (l_pobj) seizures_57\NNS\14081375|NONE
D010862_D012640 CID pilocarpine_5\NN\14712692|NONE (r_pobj) by_4\IN\0|in (r_agent) produced_3\VBN\1617192|NONE (r_acl) seizures_2\NNS\14081375|NONE
D010862_D012640 CID pilocarpine_0\NNP\14712692|and|,|.|provides|sequelae|,|given (r_nsubj) reproduces_7\VBZ\1621555|NONE (l_conj) provides_16\VBZ\2199590|and|,|Pilocarpine|.|sequelae|,|given (l_dobj) model_20\NN\5888929|NONE (l_prep) for_21\IN\0|relevant|a|animal (l_pcomp) studying_22\VBG\5808794|NONE (l_dobj) mechanisms_23\NNS\13446390|NONE (l_prep) of_24\IN\0|NONE (l_pobj) buildup_25\NN\372013|NONE (l_prep) of_26\IN\0|NONE (l_pobj) activity_28\NN\30358|NONE (l_amod) convulsive_27\JJ\0|pathways|and|operative
D010862_D012640 CID pilocarpine_0\NNP\14712692|and|,|.|provides|sequelae|,|given (r_nsubj) reproduces_7\VBZ\1621555|NONE (l_conj) provides_16\VBZ\2199590|and|,|Pilocarpine|.|sequelae|,|given (l_dobj) model_20\NN\5888929|NONE (l_prep) for_21\IN\0|relevant|a|animal (l_pcomp) studying_22\VBG\5808794|NONE (l_dobj) mechanisms_23\NNS\13446390|NONE (l_prep) of_24\IN\0|NONE (l_pobj) buildup_25\NN\372013|NONE (l_prep) of_26\IN\0|NONE (l_pobj) activity_28\NN\30358|NONE (l_amod) operative_31\JJ\9777353|pathways|and|convulsive (l_prep) in_32\IN\13603305|NONE (l_pobj) generalization_34\NN\5764197|NONE (l_prep) of_37\IN\0|the|propagation|and (l_pobj) seizures_38\NNS\14081375|NONE
D010862_D012640 CID pilocarpine_29\NN\14712692|NONE (r_pobj) by_28\IN\0|in (r_agent) produced_27\VBN\1617192|NONE (r_acl) seizures_26\NNS\14081375|NONE
D010862_D012640 CID pilocarpine_45\NN\14712692|NONE (r_pobj) of_44\IN\0|,|mg/kg|,||convulsant (r_prep) doses_43\NNS\3740161|.|In|in (r_nsubj) resulted_52\VBD\2633881|NONE (l_prep) in_53\IN\13603305|.|doses|In (l_pobj) seizures_57\NNS\14081375|NONE
D010862_D012640 CID pilocarpine_12\NN\14712692| (r_npadvmod) induced_14\VBN\1627355|NONE (r_amod) convulsions_15\NNS\14081375|NONE
D010862_D012640 CID pilocarpine_36\NN\14712692|NONE (r_pobj) with_35\IN\0|in|which|typically|is (r_prep) observed_34\VBN\2163746|hippocampal|,|,|the|thalamus (r_relcl) formation_17\NN\7938773|NONE (r_pobj) to_14\IN\0|related (r_prep) damage_13\NN\7296428|analysis|. (l_amod) related_12\VBN\628491|to (l_npadvmod) seizure_10\NN\14081375|
D010862_D012640 CID pilocarpine_11\NN\14712692|NONE (r_pobj) by_10\IN\0|NONE (r_agent) produced_9\VBN\1617192|,|mg/kg (r_acl) seizures_8\NNS\14081375|.|not|did|injections
D010862_D012640 CID pilocarpine_28\NN\14712692|NONE (r_pobj) by_27\IN\0|NONE (r_agent) produced_26\VBN\1617192|electrographic (r_acl) seizures_25\NNS\14081375|NONE
D010862_D012640 CID pilocarpine_27\NN\14712692|NONE (r_pobj) by_26\IN\0|NONE (r_agent) produced_25\VBN\1617192|NONE (r_acl) convulsions_24\NNS\14081375|NONE
D010862_D012640 CID pilocarpine_7\NN\14712692| (r_npadvmod) induced_9\VBN\1627355|in (r_amod) seizures_10\NNS\14081375|NONE
D010862_D004833 NONE pilocarpine_0\NNP\14712692|and|,|.|provides|sequelae|,|given (r_nsubj) reproduces_7\VBZ\1621555|NONE (l_dobj) sequelae_10\NNS\14501726|and|,|Pilocarpine|.|provides|,|given (l_prep) of_11\IN\0|the|neuropathological (l_pobj) epilepsy_14\NN\14085708|NONE
D007538_D012640 NONE isoniazid_11\NN\2716205|NONE (r_pobj) of_10\IN\0|into (r_prep) microinjection_9\NN\0|NONE (r_pobj) after_8\IN\0|NONE (r_prep) rats_7\NNS\2329401|NONE (r_pobj) in_6\IN\13603305|by (r_prep) produced_3\VBN\1617192|NONE (r_acl) seizures_2\NNS\14081375|NONE
D007538_D012640 NONE isoniazid_6\NN\2716205|NONE (r_pobj) of_5\IN\0|micrograms|, (r_prep) microinjections_4\NNS\0|NONE (r_pobj) with_3\IN\0|NONE (r_prep) pretreated_2\VBN\0|NONE (r_acl) animals_1\NNS\4475|NONE (r_pobj) in_0\IN\13603305|.|doses|in (r_prep) resulted_52\VBD\2633881|NONE (l_prep) in_53\IN\13603305|.|doses|In (l_pobj) seizures_57\NNS\14081375|NONE
D007538_D012640 NONE isoniazid_4\NN\2716205|NONE (r_pobj) of_3\IN\0|Bilateral|intrastriatal (r_prep) injections_2\NNS\320852|.|not|did|seizures (r_nsubj) augment_7\VB\153263|NONE (l_dobj) seizures_8\NNS\14081375|.|not|did|injections
D018698_D013226 NONE acid_25\NN\14818238|glutamic (r_compound) decarboxylase_26\NN\14732946|,|synthesizing|,|into|the (r_appos) enzyme_20\NN\14723628|NONE (r_pobj) of_15\IN\0|NONE (r_prep) activity_14\NN\30358|NONE (r_pobj) of_13\IN\0|an (r_prep) inhibitor_12\NN\20090|,| (r_appos) micrograms_9\NNS\13717155|,|of (r_conj) microinjections_4\NNS\0|NONE (r_pobj) with_3\IN\0|NONE (r_prep) pretreated_2\VBN\0|NONE (r_acl) animals_1\NNS\4475|NONE (r_pobj) in_0\IN\13603305|.|doses|in (r_prep) resulted_52\VBD\2633881|NONE (l_prep) in_53\IN\13603305|.|doses|In (l_pobj) seizures_57\NNS\14081375|NONE (l_conj) epilepticus_60\NN\0|motor|severe|limbic|and
D005680_D013226 NONE gaba_17\NNP\14601829| (r_npadvmod) synthesizing_19\VBG\193486|decarboxylase|,|,|into|the (r_amod) enzyme_20\NN\14723628|NONE (r_pobj) of_15\IN\0|NONE (r_prep) activity_14\NN\30358|NONE (r_pobj) of_13\IN\0|an (r_prep) inhibitor_12\NN\20090|,| (r_appos) micrograms_9\NNS\13717155|,|of (r_conj) microinjections_4\NNS\0|NONE (r_pobj) with_3\IN\0|NONE (r_prep) pretreated_2\VBN\0|NONE (r_acl) animals_1\NNS\4475|NONE (r_pobj) in_0\IN\13603305|.|doses|in (r_prep) resulted_52\VBD\2633881|NONE (l_prep) in_53\IN\13603305|.|doses|In (l_pobj) seizures_57\NNS\14081375|NONE (l_conj) epilepticus_60\NN\0|motor|severe|limbic|and
4082466
D009020_D012640 CID morphine_0\NNP\2707683| (r_npadvmod) induced_2\VBN\1627355|.|in (r_amod) seizures_3\NNS\14081375|NONE
D009020_D012640 CID sulfate_12\NN\15010703|NONE (r_pobj) of_9\IN\0|the (r_prep) course_8\NN\883297|NONE (r_pobj) during_6\IN\0|neonates|.|from (r_prep) suffered_2\VBD\2110220|NONE (l_prep) from_3\IN\0|neonates|.|during (l_pobj) seizures_5\NNS\14081375|NONE
D009020_D012640 CID morphine_18\NN\2707683|NONE (r_pobj) of_17\IN\0|NONE (r_prep) cessation_16\NN\7365849|hours (r_pobj) after_15\IN\0|reoccur|convulsions|and|. (r_prep) stopped_11\VBD\0|reasons|and|were|out (r_conj) ruled_6\VBN\2441022|NONE (l_nsubjpass) reasons_2\NNS\9178821|and|were|stopped|out (l_prep) for_3\IN\0|Other|known (l_pobj) seizures_4\NNS\14081375|NONE
D009020_D012640 CID morphine_18\NN\2707683|NONE (r_pobj) of_17\IN\0|NONE (r_prep) cessation_16\NN\7365849|hours (r_pobj) after_15\IN\0|reoccur|convulsions|and|. (r_prep) stopped_11\VBD\0|reasons|and|were|out (l_nsubj) convulsions_10\NNS\14081375|after|reoccur|and|.
2933998
D017265_D014202 CID procaterol_8\NN\0|NONE (r_pobj) of_7\IN\0|Both|asthmatic (r_prep) effects_6\NNS\13245626|related|. (l_amod) asthmatic_3\JJ\7846|of|Both (l_conj) tremorgenic_5\JJ\0||and
D013726_D001249 NONE terbutaline_2\NN\0|and|. (l_prep) in_3\IN\13603305|NONE (l_pobj) asthma_5\NN\14145095|NONE
D017265_D001249 NONE procaterol_0\NNP\0|NONE (l_conj) terbutaline_2\NN\0|and|. (l_prep) in_3\IN\13603305|NONE (l_pobj) asthma_5\NN\14145095|NONE
D017265_D001249 NONE procaterol_0\NNP\0|in|was|. (r_nsubjpass) studied_9\VBN\0|NONE (l_prep) in_10\IN\13603305|was|.|Procaterol (l_pobj) trial_23\NN\786195|NONE (l_prep) in_24\IN\13603305|controlled|blind|,|cross|a|, (l_pobj) patients_25\NNS\9898892|NONE (l_prep) with_26\IN\0|NONE (l_pobj) asthma_28\NN\14145095|NONE
D017265_D001249 NONE procaterol_8\NN\0|NONE (r_pobj) of_7\IN\0|Both|asthmatic (r_prep) effects_6\NNS\13245626|related|. (l_amod) asthmatic_3\JJ\7846|of|Both
24778426
D008353_D007674 NONE mannitol_22\NN\3214670|NONE (r_pobj) without_21\IN\0|and (r_conj) with_19\IN\0|NONE (r_prep) cisplatin_18\NN\0|agent (r_dobj) receiving_14\VBG\2210855|cancer (r_acl) patients_13\NNS\9898892|NONE (r_pobj) in_11\IN\13603305|induced (r_prep) nephrotoxicity_10\NN\0|NONE
D008353_D007674 NONE mannitol_5\NN\3214670|not|who|did (r_dobj) receive_4\VB\2210855|NONE (r_relcl) patients_0\NNS\9898892|.|likely|ratio (r_nsubj) were_6\VBD\0|NONE (l_acomp) likely_8\JJ\0|.|Patients|ratio (l_xcomp) develop_10\VB\1753788|more (l_dobj) nephrotoxicity_11\NN\0|to
D008353_D007674 NONE mannitol_4\NNS\3214670|NONE (r_pobj) of_3\IN\0|limited (r_prep) quantities_2\NNS\2137|When|available (r_nsubj) are_5\VBP\13600404|should|.|to|,|preferentially|it|be (r_advcl) given_12\VBN\5892096|NONE (l_dative) to_13\IN\0|should|.|,|preferentially|it|be|are (l_pobj) patients_14\NNS\9898892|NONE (l_prep) at_15\IN\14622893|NONE (l_pobj) risk_18\NN\14541044|NONE (l_prep) of_19\IN\0|high (l_pobj) nephrotoxicity_20\NN\0|NONE
D008353_D007674 NONE mannitol_38\NN\3214670|NONE (r_pobj) of_37\IN\0|the (r_prep) addition_36\NN\3081021|NONE (r_pobj) from_34\IN\0|would (r_prep) benefit_33\VB\13278375|weeks|and|at (r_conj) are_24\VBP\13600404|that|patients (l_prep) at_25\IN\14622893|weeks|and|benefit (l_pobj) risk_28\NN\14541044|NONE (l_prep) of_29\IN\0|the|greatest (l_pobj) nephrotoxicity_30\NN\0|NONE
D002945_D007674 NONE cisplatin_6\JJ\0|NONE (r_amod) use_7\NN\407535|NONE (r_pobj) of_5\IN\0|the|major (r_prep) complications_4\NNS\1073995|NONE (r_pobj) of_1\IN\0|NONE (r_prep) one_0\CD\13741022|nephrotoxicity|. (r_nsubj) is_8\VBZ\0|NONE (l_attr) nephrotoxicity_12\NN\0|One|.
D002945_D007674 NONE cisplatin_7\NN\0| (r_advmod) induced_9\VBN\1627355|in (r_amod) nephrotoxicity_10\NN\0|NONE
D002945_D007674 NONE cisplatin_18\NN\0|agent (r_dobj) receiving_14\VBG\2210855|cancer (r_acl) patients_13\NNS\9898892|NONE (r_pobj) in_11\IN\13603305|induced (r_prep) nephrotoxicity_10\NN\0|NONE
D002945_D007674 NONE cisplatin_16\NN\0|analysis|. (l_advcl) are_24\VBP\13600404|that|patients (l_prep) at_25\IN\14622893|weeks|and|benefit (l_pobj) risk_28\NN\14541044|NONE (l_prep) of_29\IN\0|the|greatest (l_pobj) nephrotoxicity_30\NN\0|NONE
D008353_D064420 NONE mannitol_13\NN\3214670|NONE (r_pobj) of_12\IN\0|as|the (r_prep) use_11\NN\407535|NONE (r_pobj) including_9\VBG\0|,|to|toxicity (r_prep) prevent_5\VB\0|many (l_dobj) toxicity_7\NN\13576101|,|to|including
D002945_D009369 NONE cisplatin_7\NN\0| (r_advmod) induced_9\VBN\1627355|in (r_amod) nephrotoxicity_10\NN\0|NONE (l_prep) in_11\IN\13603305|induced (l_pobj) patients_13\NNS\9898892|NONE (l_compound) cancer_12\NN\14239425|receiving
D002945_D009369 NONE cisplatin_18\NN\0|agent (r_dobj) receiving_14\VBG\2210855|cancer (r_acl) patients_13\NNS\9898892|NONE (l_compound) cancer_12\NN\14239425|receiving
D002945_D009369 NONE cisplatin_11\NN\0|as (r_dobj) receiving_7\VBG\2210855|cancer (r_acl) patients_6\NNS\9898892|NONE (l_compound) cancer_5\NN\14239425|receiving
D002945_D009369 NONE cisplatin_10\NN\0|who (r_dobj) received_6\VBD\2210855| (r_relcl) patients_4\NNS\9898892|:|We (r_dobj) evaluated_2\VBD\670261|.|as|%|;|cancer (r_ccomp) had_16\VBD\0|NONE (l_prep) as_21\IN\14622893|.|evaluated|%|;|cancer (l_pobj) malignancy_24\NN\14070360|NONE
D002945_D006973 NONE cisplatin_16\NN\0|analysis|. (l_advcl) are_24\VBP\13600404|that|patients (l_nsubj) weeks_19\NNS\15113229|and|benefit|at (l_conj) those_21\DT\0|every|and| (l_prep) with_22\IN\0|NONE (l_pobj) hypertension_23\NN\14057371|NONE
D002945_D006258 NONE cisplatin_10\NN\0|who (r_dobj) received_6\VBD\2210855| (r_relcl) patients_4\NNS\9898892|:|We (r_dobj) evaluated_2\VBD\670261|.|as|%|;|cancer (r_ccomp) had_16\VBD\0|NONE (l_dobj) cancer_20\NN\14239425|.|as|evaluated|%|;
D008353_D009369 NONE mannitol_22\NN\3214670|NONE (r_pobj) without_21\IN\0|and (r_conj) with_19\IN\0|NONE (r_prep) cisplatin_18\NN\0|agent (r_dobj) receiving_14\VBG\2210855|cancer (r_acl) patients_13\NNS\9898892|NONE (l_compound) cancer_12\NN\14239425|receiving
D008353_D006973 NONE mannitol_38\NN\3214670|NONE (r_pobj) of_37\IN\0|the (r_prep) addition_36\NN\3081021|NONE (r_pobj) from_34\IN\0|would (r_prep) benefit_33\VB\13278375|weeks|and|at (r_conj) are_24\VBP\13600404|that|patients (l_nsubj) weeks_19\NNS\15113229|and|benefit|at (l_conj) those_21\DT\0|every|and| (l_prep) with_22\IN\0|NONE (l_pobj) hypertension_23\NN\14057371|NONE
20447294
C401121_D003929 NONE cnsb002_9\NNP\0|and (r_conj) morphine_7\NN\2707683|NONE (r_pobj) of_6\IN\0|nonsedating (r_prep) doses_5\NNS\3740161|NONE (r_pobj) for_3\IN\0|response|given (r_prep) curves_2\VBZ\13863771|were|for (r_nsubjpass) constructed_18\VBN\1617192|induced|paw|and|:|.|streptozotocin|neuropathy (r_ccomp) inflammation_38\NN\14299637|NONE (l_appos) neuropathy_44\NN\14204950|induced|paw|and|:|.|streptozotocin|constructed
C401121_D007249 NONE cnsb002_9\NNP\0|and (r_conj) morphine_7\NN\2707683|NONE (r_pobj) of_6\IN\0|nonsedating (r_prep) doses_5\NNS\3740161|NONE (r_pobj) for_3\IN\0|response|given (r_prep) curves_2\VBZ\13863771|were|for (r_nsubjpass) constructed_18\VBN\1617192|induced|paw|and|:|.|streptozotocin|neuropathy (r_ccomp) inflammation_38\NN\14299637|NONE
D013311_D007249 NONE streptozotocin_40\JJ\0|induced|paw|and|:|.|neuropathy|constructed (r_conj) inflammation_38\NN\14299637|NONE
D013311_D007249 NONE stz)-induced_42\VBN\0|(|diabetic (r_amod) neuropathy_44\NN\14204950|induced|paw|and|:|.|streptozotocin|constructed (r_appos) inflammation_38\NN\14299637|NONE
C401121_D006930 NONE cnsb002_45\NNP\0|NONE (r_pobj) for_44\IN\0|neuropathy|the|induced (r_prep) model_43\NN\5888929|NONE (r_pobj) in_37\IN\13603305|,|)|SEM|.|(|.|and|) (r_prep) 7.54_14\CD\0|doses|. (r_attr) were_13\VBD\0|NONE (l_nsubj) doses_1\NNS\3740161|.|. (l_acl) calculated_2\VBN\632627|(|)|ED|The (l_advcl) cause_4\VB\7323922|NONE (l_dobj) reversal_7\NN\199130|to (l_prep) of_8\IN\0|% (l_pobj) hyperalgesia_9\NN\0|NONE
C401121_D006930 NONE cnsb002_15\NNP\0|administration (r_pobj) with_14\IN\0|to|.|reversal|and (r_punct) from_16\IN\0|was|antinociception|. (l_conj) reversal_26\NN\199130|to|.|and|with (l_prep) of_27\IN\0|respectively|%|,|P|(|in (l_pobj) hyperalgesia_28\NN\0|NONE
C401121_D010146 NONE cnsb002_9\NNP\0|and (r_conj) morphine_7\NN\2707683|NONE (r_pobj) of_6\IN\0|nonsedating (r_prep) doses_5\NNS\3740161|NONE (r_pobj) for_3\IN\0|response|given (r_prep) curves_2\VBZ\13863771|were|for (r_nsubjpass) constructed_18\VBN\1617192|induced|paw|and|:|.|streptozotocin|neuropathy (l_prep) for_19\IN\0|were|curves (l_pobj) effect_21\NN\34213|NONE (l_acl) using_22\VBG\418025|antihyperalgesic (l_prep) in_28\IN\13603305|withdrawal (l_pobj) models_32\NNS\5888929|NONE (l_compound) pain_31\NN\14299637|rat|two
C401121_D009437 NONE cnsb002_12\NNP\0|novel|a|,|channel (r_appos) blocker_10\NN\10101634|and (r_conj) morphine_4\NN\2707683|NONE (r_pobj) between_3\IN\0|NONE (r_prep) synergy_2\NN\13518963|NONE (r_pobj) of_1\IN\0|.|in|, (r_prep) studies_0\NNS\635850|NONE (l_prep) in_14\IN\13603305|.|of|, (l_pobj) models_16\NNS\5888929|NONE (l_prep) of_17\IN\0|rat (l_pobj) pain_21\NN\14299637|NONE
C401121_D009437 NONE cnsb002_9\NNP\0|NONE (l_appos) blocker_14\NN\10101634|, (l_prep) with_15\IN\0|channel|a (l_conj) in_21\IN\13603305|properties|and (l_pobj) combinations_22\NNS\7951464|NONE (l_prep) in_25\IN\13603305|with (l_pobj) models_27\NNS\5888929|NONE (l_prep) of_28\IN\0|rat (l_pobj) pain_32\NN\14299637|NONE
D002351_D010146 NONE carrageenan_34\NN\14898470| (r_npadvmod) induced_36\VBN\1627355|paw|and|:|.|streptozotocin|neuropathy|constructed (r_amod) inflammation_38\NN\14299637|NONE (l_ccomp) constructed_18\VBN\1617192|induced|paw|and|:|.|streptozotocin|neuropathy (l_prep) for_19\IN\0|were|curves (l_pobj) effect_21\NN\34213|NONE (l_acl) using_22\VBG\418025|antihyperalgesic (l_prep) in_28\IN\13603305|withdrawal (l_pobj) models_32\NNS\5888929|NONE (l_compound) pain_31\NN\14299637|rat|two
D013311_D009422 NONE stz_39\NNP\0| (r_npadvmod) induced_41\VBN\1627355|neuropathy|for|the (r_amod) model_43\NN\5888929|NONE (l_compound) neuropathy_42\NN\14204950|for|the|induced
D009020_D010146 NONE morphine_7\NN\2707683|NONE (r_pobj) of_6\IN\0|nonsedating (r_prep) doses_5\NNS\3740161|NONE (r_pobj) for_3\IN\0|response|given (r_prep) curves_2\VBZ\13863771|were|for (r_nsubjpass) constructed_18\VBN\1617192|induced|paw|and|:|.|streptozotocin|neuropathy (l_prep) for_19\IN\0|were|curves (l_pobj) effect_21\NN\34213|NONE (l_acl) using_22\VBG\418025|antihyperalgesic (l_prep) in_28\IN\13603305|withdrawal (l_pobj) models_32\NNS\5888929|NONE (l_compound) pain_31\NN\14299637|rat|two
D002351_D006930 CID carrageenan_25\NN\14898470|the (r_compound) model_26\NN\5888929|NONE (r_pobj) in_23\IN\13603305|.|.|.|.|and|and (r_prep) 4.83_19\CD\0|,|)|SEM|.|(|in|and|) (r_conj) 7.54_14\CD\0|doses|. (r_attr) were_13\VBD\0|NONE (l_nsubj) doses_1\NNS\3740161|.|. (l_acl) calculated_2\VBN\632627|(|)|ED|The (l_advcl) cause_4\VB\7323922|NONE (l_dobj) reversal_7\NN\199130|to (l_prep) of_8\IN\0|% (l_pobj) hyperalgesia_9\NN\0|NONE
D009020_D009437 NONE morphine_4\NN\2707683|NONE (r_pobj) between_3\IN\0|NONE (r_prep) synergy_2\NN\13518963|NONE (r_pobj) of_1\IN\0|.|in|, (r_prep) studies_0\NNS\635850|NONE (l_prep) in_14\IN\13603305|.|of|, (l_pobj) models_16\NNS\5888929|NONE (l_prep) of_17\IN\0|rat (l_pobj) pain_21\NN\14299637|NONE
D009020_D009437 NONE morphine_24\NN\2707683|NONE (r_pobj) with_23\IN\0|in (r_prep) combinations_22\NNS\7951464|NONE (l_prep) in_25\IN\13603305|with (l_pobj) models_27\NNS\5888929|NONE (l_prep) of_28\IN\0|rat (l_pobj) pain_32\NN\14299637|NONE
D002351_D003929 NONE carrageenan_34\NN\14898470| (r_npadvmod) induced_36\VBN\1627355|paw|and|:|.|streptozotocin|neuropathy|constructed (r_amod) inflammation_38\NN\14299637|NONE (l_appos) neuropathy_44\NN\14204950|induced|paw|and|:|.|streptozotocin|constructed
D013311_D006930 CID stz_39\NNP\0| (r_npadvmod) induced_41\VBN\1627355|neuropathy|for|the (r_amod) model_43\NN\5888929|NONE (r_pobj) in_37\IN\13603305|,|)|SEM|.|(|.|and|) (r_prep) 7.54_14\CD\0|doses|. (r_attr) were_13\VBD\0|NONE (l_nsubj) doses_1\NNS\3740161|.|. (l_acl) calculated_2\VBN\632627|(|)|ED|The (l_advcl) cause_4\VB\7323922|NONE (l_dobj) reversal_7\NN\199130|to (l_prep) of_8\IN\0|% (l_pobj) hyperalgesia_9\NN\0|NONE
D002351_D009422 NONE carrageenan_25\NN\14898470|the (r_compound) model_26\NN\5888929|NONE (r_pobj) in_23\IN\13603305|.|.|.|.|and|and (r_prep) 4.83_19\CD\0|,|)|SEM|.|(|in|and|) (r_conj) 7.54_14\CD\0|doses|. (l_prep) in_37\IN\13603305|,|)|SEM|.|(|.|and|) (l_pobj) model_43\NN\5888929|NONE (l_compound) neuropathy_42\NN\14204950|for|the|induced
D002351_D009422 NONE carrageenan_29\NN\14898470|the (r_compound) model_30\NN\5888929|NONE (r_pobj) in_27\IN\13603305|.|nonsedating|maximum|the (r_prep) dose_21\NN\3740161|NONE (r_pobj) than_17\IN\0|and|. (r_prep) less_16\JJR\14187378|.|values (l_conj) 1.37_32\CD\0|than|and (l_prep) in_36\IN\13603305|. (l_pobj) model_39\NN\5888929|SEM (l_compound) neuropathy_38\NN\14204950|the
C401121_D009422 NONE cnsb002_45\NNP\0|NONE (r_pobj) for_44\IN\0|neuropathy|the|induced (r_prep) model_43\NN\5888929|NONE (l_compound) neuropathy_42\NN\14204950|for|the|induced
C401121_D009422 NONE cnsb002_10\NNP\0|NONE (r_pobj) with_9\IN\0|NONE (r_prep) combination_8\NN\7951464|NONE (r_pobj) in_7\IN\13603305|when|mg/kg (r_prep) given_6\VBN\5892096|for|ED|The (r_advcl) values_2\NNS\5941423|.|less (r_nsubj) were_15\VBD\0|NONE (l_acomp) less_16\JJR\14187378|.|values (l_conj) 1.37_32\CD\0|than|and (l_prep) in_36\IN\13603305|. (l_pobj) model_39\NN\5888929|SEM (l_compound) neuropathy_38\NN\14204950|the
C401121_D009422 NONE cnsb002_15\NNP\0|administration (r_pobj) with_14\IN\0|to|.|reversal|and (r_punct) from_16\IN\0|was|antinociception|. (l_conj) reversal_26\NN\199130|to|.|and|with (l_prep) in_29\IN\13603305|respectively|%|,|P|(|of (l_pobj) models_34\NNS\5888929|NONE (l_amod) inflammatory_31\JJ\0|the (l_conj) neuropathic_33\JJ\0|and
D013311_D003929 CID streptozotocin_40\JJ\0|induced|paw|and|:|.|neuropathy|constructed (r_conj) inflammation_38\NN\14299637|NONE (l_appos) neuropathy_44\NN\14204950|induced|paw|and|:|.|streptozotocin|constructed
D013311_D003929 CID stz)-induced_42\VBN\0|(|diabetic (r_amod) neuropathy_44\NN\14204950|induced|paw|and|:|.|streptozotocin|constructed
D009020_D006930 NONE morphine_47\NN\2707683|and (r_conj) cnsb002_45\NNP\0|NONE (r_pobj) for_44\IN\0|neuropathy|the|induced (r_prep) model_43\NN\5888929|NONE (r_pobj) in_37\IN\13603305|,|)|SEM|.|(|.|and|) (r_prep) 7.54_14\CD\0|doses|. (r_attr) were_13\VBD\0|NONE (l_nsubj) doses_1\NNS\3740161|.|. (l_acl) calculated_2\VBN\632627|(|)|ED|The (l_advcl) cause_4\VB\7323922|NONE (l_dobj) reversal_7\NN\199130|to (l_prep) of_8\IN\0|% (l_pobj) hyperalgesia_9\NN\0|NONE
D009020_D006930 NONE morphine_3\NN\2707683|NONE (r_pobj) after_2\IN\0|mg/kg|The|(|) (r_prep) antinociception_1\NN\0|was|from|. (r_nsubjpass) increased_9\VBN\169651|NONE (l_prep) from_16\IN\0|was|antinociception|. (l_conj) reversal_26\NN\199130|to|.|and|with (l_prep) of_27\IN\0|respectively|%|,|P|(|in (l_pobj) hyperalgesia_28\NN\0|NONE
D013311_D010146 NONE streptozotocin_40\JJ\0|induced|paw|and|:|.|neuropathy|constructed (r_conj) inflammation_38\NN\14299637|NONE (l_ccomp) constructed_18\VBN\1617192|induced|paw|and|:|.|streptozotocin|neuropathy (l_prep) for_19\IN\0|were|curves (l_pobj) effect_21\NN\34213|NONE (l_acl) using_22\VBG\418025|antihyperalgesic (l_prep) in_28\IN\13603305|withdrawal (l_pobj) models_32\NNS\5888929|NONE (l_compound) pain_31\NN\14299637|rat|two
D013311_D010146 NONE stz)-induced_42\VBN\0|(|diabetic (r_amod) neuropathy_44\NN\14204950|induced|paw|and|:|.|streptozotocin|constructed (r_appos) inflammation_38\NN\14299637|NONE (l_ccomp) constructed_18\VBN\1617192|induced|paw|and|:|.|streptozotocin|neuropathy (l_prep) for_19\IN\0|were|curves (l_pobj) effect_21\NN\34213|NONE (l_acl) using_22\VBG\418025|antihyperalgesic (l_prep) in_28\IN\13603305|withdrawal (l_pobj) models_32\NNS\5888929|NONE (l_compound) pain_31\NN\14299637|rat|two
D012964_D009437 NONE sodium_8\NN\14625458|NONE (r_compound) channel_9\NN\6251781|novel|a|CNSB|, (r_compound) blocker_10\NN\10101634|and (r_conj) morphine_4\NN\2707683|NONE (r_pobj) between_3\IN\0|NONE (r_prep) synergy_2\NN\13518963|NONE (r_pobj) of_1\IN\0|.|in|, (r_prep) studies_0\NNS\635850|NONE (l_prep) in_14\IN\13603305|.|of|, (l_pobj) models_16\NNS\5888929|NONE (l_prep) of_17\IN\0|rat (l_pobj) pain_21\NN\14299637|NONE
D012964_D009437 NONE sodium_12\NN\14625458|NONE (r_compound) channel_13\NN\6251781|a|with (r_compound) blocker_14\NN\10101634|, (l_prep) with_15\IN\0|channel|a (l_conj) in_21\IN\13603305|properties|and (l_pobj) combinations_22\NNS\7951464|NONE (l_prep) in_25\IN\13603305|with (l_pobj) models_27\NNS\5888929|NONE (l_prep) of_28\IN\0|rat (l_pobj) pain_32\NN\14299637|NONE
D009020_D009422 NONE morphine_47\NN\2707683|and (r_conj) cnsb002_45\NNP\0|NONE (r_pobj) for_44\IN\0|neuropathy|the|induced (r_prep) model_43\NN\5888929|NONE (l_compound) neuropathy_42\NN\14204950|for|the|induced
D009020_D009422 NONE morphine_4\NN\2707683|NONE (r_pobj) for_3\IN\0|given|ED|The (r_prep) values_2\NNS\5941423|.|less (r_nsubj) were_15\VBD\0|NONE (l_acomp) less_16\JJR\14187378|.|values (l_conj) 1.37_32\CD\0|than|and (l_prep) in_36\IN\13603305|. (l_pobj) model_39\NN\5888929|SEM (l_compound) neuropathy_38\NN\14204950|the
D009020_D009422 NONE morphine_3\NN\2707683|NONE (r_pobj) after_2\IN\0|mg/kg|The|(|) (r_prep) antinociception_1\NN\0|was|from|. (r_nsubjpass) increased_9\VBN\169651|NONE (l_prep) from_16\IN\0|was|antinociception|. (l_conj) reversal_26\NN\199130|to|.|and|with (l_prep) in_29\IN\13603305|respectively|%|,|P|(|of (l_pobj) models_34\NNS\5888929|NONE (l_amod) inflammatory_31\JJ\0|the (l_conj) neuropathic_33\JJ\0|and
D009020_D007249 NONE morphine_7\NN\2707683|NONE (r_pobj) of_6\IN\0|nonsedating (r_prep) doses_5\NNS\3740161|NONE (r_pobj) for_3\IN\0|response|given (r_prep) curves_2\VBZ\13863771|were|for (r_nsubjpass) constructed_18\VBN\1617192|induced|paw|and|:|.|streptozotocin|neuropathy (r_ccomp) inflammation_38\NN\14299637|NONE
D009020_D003929 NONE morphine_7\NN\2707683|NONE (r_pobj) of_6\IN\0|nonsedating (r_prep) doses_5\NNS\3740161|NONE (r_pobj) for_3\IN\0|response|given (r_prep) curves_2\VBZ\13863771|were|for (r_nsubjpass) constructed_18\VBN\1617192|induced|paw|and|:|.|streptozotocin|neuropathy (r_ccomp) inflammation_38\NN\14299637|NONE (l_appos) neuropathy_44\NN\14204950|induced|paw|and|:|.|streptozotocin|constructed
D002351_D007249 CID carrageenan_34\NN\14898470| (r_npadvmod) induced_36\VBN\1627355|paw|and|:|.|streptozotocin|neuropathy|constructed (r_amod) inflammation_38\NN\14299637|NONE
22836123
D016559_D012595 CID tacrolimus_13\NN\0|in (r_compound) use_14\NN\407535|NONE (l_prep) in_15\IN\13603305|tacrolimus (l_pobj) patients_16\NNS\9898892|NONE (l_prep) with_17\IN\0|NONE (l_pobj) ssc_18\NNS\0|NONE
D016572_D012595 NONE cyclosporine_11\NN\0|NONE (l_prep) in_12\IN\13603305|NONE (l_pobj) patients_13\NNS\9898892|NONE (l_prep) with_14\IN\0|NONE (l_pobj) ssc_15\NNS\0|NONE
D000305_D007674 NONE corticosteroid_4\NN\14745635|high|dose (r_compound) use_5\NN\407535|NONE (r_pobj) to_1\IN\0|NONE (r_prep) moderate_0\JJ\9605289|is|.|as (r_nsubjpass) recognized_7\VBN\686447|NONE (l_prep) as_8\IN\14622893|is|Moderate|. (l_pobj) factor_12\NN\7326557|NONE (l_prep) for_13\IN\0|risk|major|a (l_pobj) src_14\NNP\0|NONE
D000305_D007674 NONE corticosteroids_14\NNS\14745635|and (r_conj) tacrolimus_12\NNS\0|NONE (r_pobj) by_11\IN\0|NONE (r_agent) induced_10\VBN\1627355|with|a (r_acl) patient_7\NN\9898892|In|,|we|. (l_prep) with_8\IN\0|induced|a (l_pobj) src_9\NNP\0|NONE
D016572_D057049 CID cyclosporine_11\NN\0|NONE (r_pobj) by_10\IN\0|NONE (r_agent) precipitated_9\VBN\1642924|thrombotic (r_acl) microangiopathy_8\NN\0|NONE
D011239_D007674 NONE prednisolone_10\NN\2721538|and (r_conj) tacrolimus_8\NN\0|NONE (r_pobj) by_7\IN\0|crisis (r_agent) induced_6\VBN\1627355|.|case|a|: (l_nsubj) crisis_5\NN\14411243|by
D016559_D007674 NONE tacrolimus_8\NN\0|NONE (r_pobj) by_7\IN\0|crisis (r_agent) induced_6\VBN\1627355|.|case|a|: (l_nsubj) crisis_5\NN\14411243|by
D016559_D007674 NONE tacrolimus_12\NNS\0|NONE (r_pobj) by_11\IN\0|NONE (r_agent) induced_10\VBN\1627355|with|a (r_acl) patient_7\NN\9898892|In|,|we|. (l_prep) with_8\IN\0|induced|a (l_pobj) src_9\NNP\0|NONE
12559315
D007213_D008415 CID indomethacin_0\NNP\3828465|.|in (r_nsubj) resulted_1\VBD\2633881|NONE (l_prep) in_2\IN\13603305|.|Indomethacin (l_pobj) findings_4\NNS\7951464|NONE (l_amod) typical_5\JJ\0|histopathologic (l_prep) of_6\IN\0|NONE (l_pobj) cystitis_8\NN\14566129|NONE (l_prep) as_11\IN\14622893|,|interstitial (l_pobj) epithelium_14\NN\5267548|such (l_conj) mastocytosis_17\NN\0|leaky|bladder|and
D007213_D018856 CID indomethacin_0\NNP\3828465|.|in (r_nsubj) resulted_1\VBD\2633881|NONE (l_prep) in_2\IN\13603305|.|Indomethacin (l_pobj) findings_4\NNS\7951464|NONE (l_amod) typical_5\JJ\0|histopathologic (l_prep) of_6\IN\0|NONE (l_pobj) cystitis_8\NN\14566129|NONE
753803
D008696_D009135 NONE dianabol_29\NNP\0|(|)|anabolizing|one (r_appos) agent_27\NN\7347|NONE (r_pobj) of_24\IN\0|the|at|beneficial (r_prep) effects_23\NNS\13245626|to (r_dobj) investigate_20\VB\644583|results|authors|have|E. (r_xcomp) encouraged_16\VBN\2556126|NONE (l_nsubj) results_2\NNS\34213|investigate|authors|have|E. (l_acl) obtained_3\VBN\2210855|The|encouraging (l_prep) in_4\IN\13603305|by (l_pobj) departments_7\NNS\8220714|NONE (l_prep) in_8\IN\13603305|various|authoratative (l_pobj) patients_10\NNS\9898892|NONE (l_amod) myopathic_9\JJ\0|NONE
D008696_D009135 NONE dianabol_29\NNP\0|(|)|anabolizing|one (r_appos) agent_27\NN\7347|NONE (r_pobj) of_24\IN\0|the|at|beneficial (r_prep) effects_23\NNS\13245626|to (l_prep) at_33\IN\14622893|the|of|beneficial (l_pobj) doses_35\NNS\3740161|NONE (l_prep) in_36\IN\13603305|high (l_pobj) rats_37\NNS\2329401|NONE (l_acl) rendered_38\VBN\120316|NONE (l_oprd) myopathic_39\JJ\0|by
D014810_D009136 CID e._15\NNP\0|NONE (r_pobj) in_13\IN\13603305|NONE (r_prep) lacking_12\VBG\0|a (r_acl) diet_11\NN\7560652|it (r_dobj) giving_8\VBG\1085793|NONE (r_pcomp) by_7\IN\0|myodystrophy|authors (r_prep) induced_2\VBD\1627355|NONE (l_dobj) myodystrophy_3\NN\0|by|authors
-1_D009135 NONE ciba_31\NNP\0|, (r_appos) dianabol_29\NNP\0|(|)|anabolizing|one (r_appos) agent_27\NN\7347|NONE (r_pobj) of_24\IN\0|the|at|beneficial (r_prep) effects_23\NNS\13245626|to (r_dobj) investigate_20\VB\644583|results|authors|have|E. (r_xcomp) encouraged_16\VBN\2556126|NONE (l_nsubj) results_2\NNS\34213|investigate|authors|have|E. (l_acl) obtained_3\VBN\2210855|The|encouraging (l_prep) in_4\IN\13603305|by (l_pobj) departments_7\NNS\8220714|NONE (l_prep) in_8\IN\13603305|various|authoratative (l_pobj) patients_10\NNS\9898892|NONE (l_amod) myopathic_9\JJ\0|NONE
-1_D009135 NONE ciba_31\NNP\0|, (r_appos) dianabol_29\NNP\0|(|)|anabolizing|one (r_appos) agent_27\NN\7347|NONE (r_pobj) of_24\IN\0|the|at|beneficial (r_prep) effects_23\NNS\13245626|to (l_prep) at_33\IN\14622893|the|of|beneficial (l_pobj) doses_35\NNS\3740161|NONE (l_prep) in_36\IN\13603305|high (l_pobj) rats_37\NNS\2329401|NONE (l_acl) rendered_38\VBN\120316|NONE (l_oprd) myopathic_39\JJ\0|by
D013256_D009135 NONE steroids_14\NNS\14727670|NONE (r_dobj) using_12\VBG\418025|NONE (r_pcomp) by_11\IN\0|in (r_prep) obtained_3\VBN\2210855|The|encouraging (l_prep) in_4\IN\13603305|by (l_pobj) departments_7\NNS\8220714|NONE (l_prep) in_8\IN\13603305|various|authoratative (l_pobj) patients_10\NNS\9898892|NONE (l_amod) myopathic_9\JJ\0|NONE
D013256_D009135 NONE steroids_14\NNS\14727670|NONE (r_dobj) using_12\VBG\418025|NONE (r_pcomp) by_11\IN\0|in (r_prep) obtained_3\VBN\2210855|The|encouraging (r_acl) results_2\NNS\34213|investigate|authors|have|E. (r_nsubj) encouraged_16\VBN\2556126|NONE (l_xcomp) investigate_20\VB\644583|results|authors|have|E. (l_dobj) effects_23\NNS\13245626|to (l_prep) at_33\IN\14622893|the|of|beneficial (l_pobj) doses_35\NNS\3740161|NONE (l_prep) in_36\IN\13603305|high (l_pobj) rats_37\NNS\2329401|NONE (l_acl) rendered_38\VBN\120316|NONE (l_oprd) myopathic_39\JJ\0|by
D013256_D009135 NONE steroids_11\NNS\14727670|NONE (r_pobj) of_8\IN\0|in|undoubted|the (r_prep) efficacy_7\NN\5199286|NONE (l_prep) in_12\IN\13603305|undoubted|the|of (l_pobj) disease_15\NN\14061805|NONE
D014810_D009135 NONE e_6\NNS\14724645|NONE (r_pobj) of_4\IN\0|induced (r_prep) lack_3\NN\14449126|to (r_pobj) due_1\IN\5174653|NONE (r_amod) myopathy_0\NNP\14204950|with|much|.|anatomically
D014810_D009135 NONE e_6\NNS\14724645|NONE (l_conj) myopathy_8\NNS\14204950|and|vitamin
D014810_D009135 NONE e._46\NNP\0|results|investigate|authors|have (r_punct) encouraged_16\VBN\2556126|NONE (l_nsubj) results_2\NNS\34213|investigate|authors|have|E. (l_acl) obtained_3\VBN\2210855|The|encouraging (l_prep) in_4\IN\13603305|by (l_pobj) departments_7\NNS\8220714|NONE (l_prep) in_8\IN\13603305|various|authoratative (l_pobj) patients_10\NNS\9898892|NONE (l_amod) myopathic_9\JJ\0|NONE
D014810_D009135 NONE e._46\NNP\0|results|investigate|authors|have (r_punct) encouraged_16\VBN\2556126|NONE (l_xcomp) investigate_20\VB\644583|results|authors|have|E. (l_dobj) effects_23\NNS\13245626|to (l_prep) at_33\IN\14622893|the|of|beneficial (l_pobj) doses_35\NNS\3740161|NONE (l_prep) in_36\IN\13603305|high (l_pobj) rats_37\NNS\2329401|NONE (l_acl) rendered_38\VBN\120316|NONE (l_oprd) myopathic_39\JJ\0|by
D014810_D009135 NONE e_91\NN\14724645|NONE (r_pobj) of_89\IN\0|but|the|something (r_prep) lack_88\NN\14449126|because|finally|agent|certainly|not (r_attr) is_84\VBZ\0|often|;|and|because|at|injury (r_conj) occurs_58\VBZ\0|reservations|.|;|they (r_advcl) have_19\VBP\7846|by|,|but|authors (r_conj) conclude_2\VBP\628491|NONE (l_prep) by_3\IN\0|have|,|but|authors (l_pcomp) affirming_4\VBG\0|NONE (l_dobj) efficacy_7\NN\5199286|NONE (l_prep) in_12\IN\13603305|undoubted|the|of (l_pobj) disease_15\NN\14061805|NONE
1760851
D004317_D066126 CID doxorubicin_3\NN\2716866|NONE (r_pobj) of_2\IN\0|Reduced|and|.|:|study (r_prep) cardiotoxicity_1\NN\0|NONE
D004317_D066126 CID doxorubicin_18\NN\2716866|NONE (r_pobj) of_15\IN\0|the|late (r_prep) cardiotoxicity_14\NN\0|acute|and|general|the
D004317_D066126 CID dox_20\NNP\0|mg/kg (r_appos) doxorubicin_18\NN\2716866|NONE (r_pobj) of_15\IN\0|the|late (r_prep) cardiotoxicity_14\NN\0|acute|and|general|the
D004317_D066126 CID dox_21\NNP\0|that (r_dobj) received_18\VBD\2210855|NONE (r_relcl) animals_16\NNS\4475|only (r_pobj) in_15\IN\13603305|deaths|Throughout|,|were (r_prep) observed_13\VBN\2163746|in|investigations|.|,|changes|; (l_nsubjpass) deaths_8\NNS\7296428|in|Throughout|,|were (l_acl) related_9\VBN\628491|NONE (l_prep) to_10\IN\0|NONE (l_pobj) cardiotoxicity_11\NN\0|NONE
D004317_D066126 CID dox_21\NNP\0|that (r_dobj) received_18\VBD\2210855|NONE (r_relcl) animals_16\NNS\4475|only (r_pobj) in_15\IN\13603305|deaths|Throughout|,|were (r_prep) observed_13\VBN\2163746|in|investigations|.|,|changes|; (r_ccomp) revealed_38\VBD\2137132|NONE (l_dobj) changes_40\NNS\7283608|in|investigations|.|,|;|observed (l_relcl) were_45\VBD\0|marked|in (l_acomp) consistent_46\JJ\0|that (l_prep) with_47\IN\0|NONE (l_pobj) cardiotoxicity_51\NN\0|NONE
D004317_D066126 CID dox_30\NNP\0|HPMA|and (r_conj) copolymer_27\NN\14994328|NONE (r_pobj) of_25\IN\0|the (r_prep) mixture_24\NN\19613|free|or (r_conj) dox_21\NNP\0|that (r_dobj) received_18\VBD\2210855|NONE (r_relcl) animals_16\NNS\4475|only (r_pobj) in_15\IN\13603305|deaths|Throughout|,|were (r_prep) observed_13\VBN\2163746|in|investigations|.|,|changes|; (l_nsubjpass) deaths_8\NNS\7296428|in|Throughout|,|were (l_acl) related_9\VBN\628491|NONE (l_prep) to_10\IN\0|NONE (l_pobj) cardiotoxicity_11\NN\0|NONE
D004317_D066126 CID dox_30\NNP\0|HPMA|and (r_conj) copolymer_27\NN\14994328|NONE (r_pobj) of_25\IN\0|the (r_prep) mixture_24\NN\19613|free|or (r_conj) dox_21\NNP\0|that (r_dobj) received_18\VBD\2210855|NONE (r_relcl) animals_16\NNS\4475|only (r_pobj) in_15\IN\13603305|deaths|Throughout|,|were (r_prep) observed_13\VBN\2163746|in|investigations|.|,|changes|; (r_ccomp) revealed_38\VBD\2137132|NONE (l_dobj) changes_40\NNS\7283608|in|investigations|.|,|;|observed (l_relcl) were_45\VBD\0|marked|in (l_acomp) consistent_46\JJ\0|that (l_prep) with_47\IN\0|NONE (l_pobj) cardiotoxicity_51\NN\0|NONE
D004317_D066126 CID dox_48\NNP\0| (r_npadvmod) induced_50\VBN\1627355|NONE (r_amod) cardiotoxicity_51\NN\0|NONE (r_pobj) with_47\IN\0|NONE (r_prep) consistent_46\JJ\0|that (r_acomp) were_45\VBD\0|marked|in (r_relcl) changes_40\NNS\7283608|in|investigations|.|,|;|observed (r_dobj) revealed_38\VBD\2137132|NONE (l_ccomp) observed_13\VBN\2163746|in|investigations|.|,|changes|; (l_nsubjpass) deaths_8\NNS\7296428|in|Throughout|,|were (l_acl) related_9\VBN\628491|NONE (l_prep) to_10\IN\0|NONE (l_pobj) cardiotoxicity_11\NN\0|NONE
D004317_D066126 CID dox_48\NNP\0| (r_npadvmod) induced_50\VBN\1627355|NONE (r_amod) cardiotoxicity_51\NN\0|NONE
C032976_D064420 NONE n-(2-hydroxypropyl)methacrylamide_33\NN\0|copolymer|three (r_nmod) conjugates_38\NNS\14589223|NONE (r_pobj) of_31\IN\0|the (r_prep) form_30\NN\6286395|NONE (r_pobj) in_28\IN\13603305|or|drug|either (r_conj) as_24\IN\14622893|NONE (r_prep) given_22\VBN\5892096|was|evaluate|model|. (r_prep) used_4\VBN\0|NONE (l_xcomp) evaluate_6\VB\670261|was|model|.|given (l_dobj) toxicity_10\NN\13576101|to
C032976_D064420 NONE hpma_35\NNP\0|)|( (r_nmod) copolymer_37\NN\14994328|N(hydroxypropyl)methacrylamide|three (r_compound) conjugates_38\NNS\14589223|NONE (r_pobj) of_31\IN\0|the (r_prep) form_30\NN\6286395|NONE (r_pobj) in_28\IN\13603305|or|drug|either (r_conj) as_24\IN\14622893|NONE (r_prep) given_22\VBN\5892096|was|evaluate|model|. (r_prep) used_4\VBN\0|NONE (l_xcomp) evaluate_6\VB\670261|was|model|.|given (l_dobj) toxicity_10\NN\13576101|to
D004317_D064420 NONE doxorubicin_18\NN\2716866|NONE (r_pobj) of_15\IN\0|the|late (r_prep) cardiotoxicity_14\NN\0|acute|and|general|the (r_conj) toxicity_10\NN\13576101|to
D004317_D064420 NONE dox_20\NNP\0|mg/kg (r_appos) doxorubicin_18\NN\2716866|NONE (r_pobj) of_15\IN\0|the|late (r_prep) cardiotoxicity_14\NN\0|acute|and|general|the (r_conj) toxicity_10\NN\13576101|to
C032976_D066126 NONE n-(2-hydroxypropyl)methacrylamide_9\JJ\0|NONE (r_compound) conjugates_10\NNS\14589223|NONE (r_pobj) of_8\IN\0|the (r_prep) form_7\NN\6286395|NONE (r_pobj) in_5\IN\13603305|NONE (r_prep) given_4\VBN\5892096|NONE (r_acl) doxorubicin_3\NN\2716866|NONE (r_pobj) of_2\IN\0|Reduced|and|.|:|study (r_prep) cardiotoxicity_1\NN\0|NONE
C032976_D066126 NONE n-(2-hydroxypropyl)methacrylamide_33\NN\0|copolymer|three (r_nmod) conjugates_38\NNS\14589223|NONE (r_pobj) of_31\IN\0|the (r_prep) form_30\NN\6286395|NONE (r_pobj) in_28\IN\13603305|or|drug|either (r_conj) as_24\IN\14622893|NONE (r_prep) given_22\VBN\5892096|was|evaluate|model|. (r_prep) used_4\VBN\0|NONE (l_xcomp) evaluate_6\VB\670261|was|model|.|given (l_dobj) toxicity_10\NN\13576101|to (l_conj) cardiotoxicity_14\NN\0|acute|and|general|the
C032976_D066126 NONE hpma_35\NNP\0|)|( (r_nmod) copolymer_37\NN\14994328|N(hydroxypropyl)methacrylamide|three (r_compound) conjugates_38\NNS\14589223|NONE (r_pobj) of_31\IN\0|the (r_prep) form_30\NN\6286395|NONE (r_pobj) in_28\IN\13603305|or|drug|either (r_conj) as_24\IN\14622893|NONE (r_prep) given_22\VBN\5892096|was|evaluate|model|. (r_prep) used_4\VBN\0|NONE (l_xcomp) evaluate_6\VB\670261|was|model|.|given (l_dobj) toxicity_10\NN\13576101|to (l_conj) cardiotoxicity_14\NN\0|acute|and|general|the
C032976_D066126 NONE hpma_26\NNP\0|DOX|and (r_compound) copolymer_27\NN\14994328|NONE (r_pobj) of_25\IN\0|the (r_prep) mixture_24\NN\19613|free|or (r_conj) dox_21\NNP\0|that (r_dobj) received_18\VBD\2210855|NONE (r_relcl) animals_16\NNS\4475|only (r_pobj) in_15\IN\13603305|deaths|Throughout|,|were (r_prep) observed_13\VBN\2163746|in|investigations|.|,|changes|; (l_nsubjpass) deaths_8\NNS\7296428|in|Throughout|,|were (l_acl) related_9\VBN\628491|NONE (l_prep) to_10\IN\0|NONE (l_pobj) cardiotoxicity_11\NN\0|NONE
C032976_D066126 NONE hpma_26\NNP\0|DOX|and (r_compound) copolymer_27\NN\14994328|NONE (r_pobj) of_25\IN\0|the (r_prep) mixture_24\NN\19613|free|or (r_conj) dox_21\NNP\0|that (r_dobj) received_18\VBD\2210855|NONE (r_relcl) animals_16\NNS\4475|only (r_pobj) in_15\IN\13603305|deaths|Throughout|,|were (r_prep) observed_13\VBN\2163746|in|investigations|.|,|changes|; (r_ccomp) revealed_38\VBD\2137132|NONE (l_dobj) changes_40\NNS\7283608|in|investigations|.|,|;|observed (l_relcl) were_45\VBD\0|marked|in (l_acomp) consistent_46\JJ\0|that (l_prep) with_47\IN\0|NONE (l_pobj) cardiotoxicity_51\NN\0|NONE
17879217
D012293_D014376 NONE rifampicin_9\NNS\0|NONE (r_compound) therapy_10\NN\657604|NONE (r_pobj) of_8\IN\0|in (r_prep) complication_7\NN\1073995|NONE (l_prep) in_11\IN\13603305|of (l_pobj) patients_12\NNS\9898892|NONE (l_acl) receiving_13\VBG\2210855|NONE (l_dobj) treatment_14\NN\654885|NONE (l_prep) for_15\IN\0|NONE (l_pobj) tuberculosis_16\NN\14127211|NONE
D012293_D058186 CID rifampicin_25\NNS\0|NONE (r_pobj) with_24\IN\0|while|being (r_prep) treated_23\VBN\2376958|,|and|failure|who|review (r_advcl) developed_11\VBD\1753788|Staphylococcal (l_dobj) failure_14\NN\66216|,|and|treated|who|review
D012293_D058186 CID rifampicin_35\NNS\0|NONE (r_compound) therapy_36\NN\657604|NONE (r_pobj) of_34\IN\0|this (r_prep) complication_33\NN\1073995|NONE (r_pobj) regarding_31\VBG\689344|literature (r_prep) review_28\VB\5733583|,|and|treated|failure|who (r_conj) developed_11\VBD\1753788|Staphylococcal (l_dobj) failure_14\NN\66216|,|and|treated|who|review
D012293_D013203 NONE rifampicin_0\NNS\0| (r_npadvmod) associated_2\VBN\628491|necrotizing|in|. (r_amod) glomerulonephritis_5\NN\14113798|NONE (l_prep) in_6\IN\13603305|necrotizing|associated|. (l_pobj) endocarditis_8\NN\14338942|NONE
D012293_D013203 NONE rifampicin_20\NNS\0|NONE (l_prep) for_21\IN\0|NONE (l_pobj) infections_23\NNS\14052046|NONE
D012293_D013203 NONE rifampicin_25\NNS\0|NONE (r_pobj) with_24\IN\0|while|being (r_prep) treated_23\VBN\2376958|,|and|failure|who|review (r_advcl) developed_11\VBD\1753788|Staphylococcal (r_relcl) ie_9\NNP\0|NONE
D012293_D013203 NONE rifampicin_35\NNS\0|NONE (r_compound) therapy_36\NN\657604|NONE (r_pobj) of_34\IN\0|this (r_prep) complication_33\NN\1073995|NONE (r_pobj) regarding_31\VBG\689344|literature (r_prep) review_28\VB\5733583|,|and|treated|failure|who (r_conj) developed_11\VBD\1753788|Staphylococcal (r_relcl) ie_9\NNP\0|NONE
D012293_D005921 CID rifampicin_0\NNS\0| (r_npadvmod) associated_2\VBN\628491|necrotizing|in|. (r_amod) glomerulonephritis_5\NN\14113798|NONE
D012293_D005921 CID rifampicin_9\NNS\0|NONE (r_compound) therapy_10\NN\657604|NONE (r_pobj) of_8\IN\0|in (r_prep) complication_7\NN\1073995|NONE (r_pobj) as_6\IN\14622893|.|been|has|glomerulonephritis (r_prep) reported_5\VBN\831651|NONE (l_nsubjpass) glomerulonephritis_2\NN\14113798|.|as|been|has
D012293_D005921 CID rifampicin_25\NNS\0|NONE (r_pobj) with_24\IN\0|while|being (r_prep) treated_23\VBN\2376958|,|and|failure|who|review (r_advcl) developed_11\VBD\1753788|Staphylococcal (l_dobj) failure_14\NN\66216|,|and|treated|who|review (l_amod) secondary_15\JJ\8426461|renal|acute (l_prep) to_16\IN\0|NONE (l_pobj) glomerulonephritis_20\NN\14113798|NONE
D012293_D005921 CID rifampicin_35\NNS\0|NONE (r_compound) therapy_36\NN\657604|NONE (r_pobj) of_34\IN\0|this (r_prep) complication_33\NN\1073995|NONE (r_pobj) regarding_31\VBG\689344|literature (r_prep) review_28\VB\5733583|,|and|treated|failure|who (r_conj) developed_11\VBD\1753788|Staphylococcal (l_dobj) failure_14\NN\66216|,|and|treated|who|review (l_amod) secondary_15\JJ\8426461|renal|acute (l_prep) to_16\IN\0|NONE (l_pobj) glomerulonephritis_20\NN\14113798|NONE
D012293_D007239 NONE rifampicin_20\NNS\0|NONE (r_pobj) of_19\IN\0|the (r_prep) use_18\NN\407535|NONE (r_pobj) in_16\IN\13603305|an (r_prep) increase_15\NN\13576355|NONE (r_pobj) to_13\IN\0|Changing|.|has (r_prep) led_12\VBN\3202760|NONE (l_csubj) changing_0\VBG\0|.|has|to (l_dobj) epidemiology_1\NN\6043075|NONE (l_prep) of_2\IN\0|NONE (l_pobj) infections_3\NNS\14052046|NONE
D012293_D004696 NONE rifampicin_0\NNS\0| (r_npadvmod) associated_2\VBN\628491|necrotizing|in|. (r_amod) glomerulonephritis_5\NN\14113798|NONE (l_prep) in_6\IN\13603305|necrotizing|associated|. (l_pobj) endocarditis_8\NN\14338942|NONE
D012293_D004696 NONE rifampicin_20\NNS\0|NONE (r_pobj) of_19\IN\0|the (r_prep) use_18\NN\407535|NONE (r_pobj) in_16\IN\13603305|an (r_prep) increase_15\NN\13576355|NONE (r_pobj) to_13\IN\0|Changing|.|has (r_prep) led_12\VBN\3202760|NONE (l_csubj) changing_0\VBG\0|.|has|to (l_dobj) epidemiology_1\NN\6043075|NONE (l_prep) of_2\IN\0|NONE (l_pobj) infections_3\NNS\14052046|NONE (l_prep) as_5\IN\14622893|NONE (l_pobj) endocarditis_7\NN\14338942|such
D012293_D004696 NONE rifampicin_20\NNS\0|NONE (r_pobj) of_19\IN\0|the (r_prep) use_18\NN\407535|NONE (r_pobj) in_16\IN\13603305|an (r_prep) increase_15\NN\13576355|NONE (r_pobj) to_13\IN\0|Changing|.|has (r_prep) led_12\VBN\3202760|NONE (l_csubj) changing_0\VBG\0|.|has|to (l_dobj) epidemiology_1\NN\6043075|NONE (l_prep) of_2\IN\0|NONE (l_pobj) infections_3\NNS\14052046|NONE (l_prep) as_5\IN\14622893|NONE (l_pobj) endocarditis_7\NN\14338942|such (l_appos) ie_9\NNP\0|infective|)|(
D012293_D004696 NONE rifampicin_25\NNS\0|NONE (r_pobj) with_24\IN\0|while|being (r_prep) treated_23\VBN\2376958|,|and|failure|who|review (r_advcl) developed_11\VBD\1753788|Staphylococcal (r_relcl) ie_9\NNP\0|NONE
D012293_D004696 NONE rifampicin_35\NNS\0|NONE (r_compound) therapy_36\NN\657604|NONE (r_pobj) of_34\IN\0|this (r_prep) complication_33\NN\1073995|NONE (r_pobj) regarding_31\VBG\689344|literature (r_prep) review_28\VB\5733583|,|and|treated|failure|who (r_conj) developed_11\VBD\1753788|Staphylococcal (r_relcl) ie_9\NNP\0|NONE
8957205
D000324_D006935 NONE corticotropin_1\NN\5407119| (r_npadvmod) releasing_3\VBG\0|Human|and (r_amod) hormone_4\NN\5404728|releasing (r_nmod) hormone_9\NN\5404728|.|response (r_nsubj) modulate_10\VBP\1724459|NONE (l_dobj) response_14\NN\11410625|.|hormone (l_amod) hypercapnic_12\JJ\0|the|ventilatory|in
D013972_D006935 NONE thyrotropin_6\NN\5407119| (r_npadvmod) releasing_8\VBG\0|hormone (r_amod) hormone_9\NN\5404728|.|response (r_nsubj) modulate_10\VBP\1724459|NONE (l_dobj) response_14\NN\11410625|.|hormone (l_amod) hypercapnic_12\JJ\0|the|ventilatory|in
24816962
D008795_D001927 CID metronidazole_0\NNP\2723292| (r_npadvmod) induced_2\VBN\1627355|.|:|scenario (r_amod) encephalopathy_3\NN\14084880|NONE
D008795_D001927 CID metronidazole_13\NN\2723292|prolonged (r_compound) intake_14\NN\13440063|NONE (r_pobj) following_11\VBG\8180190|of|patient|where|a|developed (r_prep) features_8\NNS\5849040|a (l_prep) of_9\IN\0|following|patient|where|a|developed (l_pobj) encephalopathy_10\JJ\14084880|NONE
D008795_D064420 NONE metronidazole_3\JJ\2723292|NONE (r_amod) toxicity_4\NN\13576101|NONE
12950111
D006024_D006261 CID glycopyrrolate_17\NN\0||)|( (r_appos) patients_13\NNS\9898892|NONE (r_pobj) in_11\IN\13603305|a|sore (r_prep) throat_10\NN\5548726|,|dry|a|headache|and (r_conj) mouth_6\NN\5610008|.|effects (l_appos) headache_22\NN\5829480|,|dry|a|throat|and
D006024_D006261 CID glycopyrrolate_29\NN\0|a|light|in (r_parataxis) headache_22\NN\5829480|,|dry|a|throat|and
D006024_D010612 CID glycopyrrolate_17\NN\0||)|( (r_appos) patients_13\NNS\9898892|NONE (r_pobj) in_11\IN\13603305|a|sore (r_prep) throat_10\NN\5548726|,|dry|a|headache|and
D006024_D010612 CID glycopyrrolate_29\NN\0|a|light|in (r_parataxis) headache_22\NN\5829480|,|dry|a|throat|and (r_appos) mouth_6\NN\5610008|.|effects (l_conj) throat_10\NN\5548726|,|dry|a|headache|and
D006024_D014987 NONE glycopyrrolate_17\NN\0||)|( (r_appos) patients_13\NNS\9898892|NONE (r_pobj) in_11\IN\13603305|a|sore (r_prep) throat_10\NN\5548726|,|dry|a|headache|and (r_conj) mouth_6\NN\5610008|.|effects
D006024_D014987 NONE glycopyrrolate_29\NN\0|a|light|in (r_parataxis) headache_22\NN\5829480|,|dry|a|throat|and (r_appos) mouth_6\NN\5610008|.|effects
D006024_D013547 NONE glycopyrrolate_7\NN\0|NONE (r_pobj) with_5\IN\0|gustatory|compensatory (r_prep) hyperhidrosis_4\NN\13535261|NONE
D006024_D013547 NONE glycopyrrolate_3\NN\0|NONE (r_dobj) applying_1\VBG\0|NONE (r_pcomp) after_0\IN\0|,|excellent|.|sweating|effect (r_prep) was_8\VBD\0|NONE (l_parataxis) sweating_12\NN\13440063|,|excellent|.|After|effect
D006024_D013547 NONE glycopyrrolate_3\NN\0|NONE (r_dobj) applying_1\VBG\0|NONE (r_pcomp) after_0\IN\0|,|excellent|.|sweating|effect (r_prep) was_8\VBD\0|NONE (l_parataxis) sweating_12\NN\13440063|,|excellent|.|After|effect (l_conj) sweating_32\NN\13440063|no|in|(|and|after|)|,
D006024_D013547 NONE glycopyrrolate_5\JJ\0|a (r_compound) pad_6\NN\14974264|NONE (r_pobj) of_3\IN\0|topical|The|method (r_prep) application_2\NN\947128|tolerated|.|be (l_appos) method_20\NN\5616786|of|topical|The (l_prep) to_25\TO\0|,|convenient|of|in|a|with (l_pobj) symptoms_27\NNS\5823932|NONE (l_prep) of_28\IN\0|severe (l_pobj) hyperhidrosis_30\NN\13535261|NONE
20024739
D000431_D003866 CID alcohol_5\NN\7881800|and|depression (r_compound) consumption_6\NN\13440063|NONE (l_conj) depression_8\NN\14373582|and|alcohol
D000431_D003866 CID alcohol_39\NN\7881800|NONE (r_compound) use_40\NN\407535|at|and|,|semiannually|. (r_compound) assessment_41\NN\5732756|participants|examination|using|and|,|( (r_conj) had_2\VBD\0|NONE (l_dobj) examination_4\NN\633864|participants|using|assessment|and|,|( (l_appos) measurement_19\NN\407535|extraction|physical|, (l_prep) of_20\IN\0|NONE (l_pobj) symptoms_22\NNS\5823932|NONE (l_compound) depression_21\NN\14373582|NONE
D000431_D003866 CID alcohol_39\NN\7881800|NONE (r_compound) use_40\NN\407535|at|and|,|semiannually|. (r_compound) assessment_41\NN\5732756|participants|examination|using|and|,|( (r_conj) had_2\VBD\0|NONE (l_advcl) using_24\VBG\418025|participants|examination|assessment|and|,|( (l_dobj) center_29\NNP\8497294|) (l_prep) for_30\IN\0|report|the (l_pobj) scale_35\NNP\7260623|NONE (l_compound) depression_34\NNP\14373582|Epidemiological
D000431_D003866 CID alcohol_3\NN\7881800|depression|and (r_compound) consumption_4\NN\13440063|NONE (l_conj) depression_6\NN\14373582|and|alcohol
D000431_D003866 CID alcohol_4\NN\7881800|NONE (r_compound) consumption_5\NN\13440063|that|association (r_nsubj) has_6\VBZ\13888491|.|findings (l_dobj) association_9\NN\8008335|consumption|that (l_prep) with_10\IN\0|direct|a (l_pobj) depression_11\NN\14373582|NONE
D000431_D015658 NONE alcohol_3\NN\7881800|with (r_compound) use_4\NN\407535|NONE (l_prep) with_5\IN\0|alcohol (l_pobj) progression_8\NN\8457976|NONE (l_compound) disease_7\NN\14061805|health|and
D000431_D015658 NONE alcohol_5\NN\7881800|and|depression (r_compound) consumption_6\NN\13440063|NONE (r_pobj) of_4\IN\0|the (r_prep) association_3\NN\8008335|We|,|.|and|effects (r_dobj) evaluated_1\VBD\670261|NONE (l_conj) effects_12\NNS\13245626|We|,|.|association|and (l_prep) on_13\IN\0|their (l_pobj) progression_16\NN\8457976|NONE (l_compound) disease_15\NN\14061805|among
24717468
D015742_D007022 CID propofol_16\NN\0|who|dexmedetomidine|or (r_conj) receive_13\VBP\2210855|neurocritical|care (r_relcl) patients_11\NNS\9898892|NONE (r_pobj) in_8\IN\13603305|similar (r_prep) prevalence_7\NN\4764412|NONE (r_pobj) at_5\IN\14622893|.|hypotension (r_prep) occur_4\VBP\0|NONE (l_nsubj) hypotension_1\NN\14057371|.|at
D020927_D001919 CID dexmedetomidine_14\NN\0|who|propofol|or (r_dobj) receive_13\VBP\2210855|neurocritical|care (r_relcl) patients_11\NNS\9898892|NONE (r_pobj) in_8\IN\13603305|similar (r_prep) prevalence_7\NN\4764412|NONE (r_pobj) at_5\IN\14622893|.|hypotension (r_prep) occur_4\VBP\0|NONE (l_nsubj) hypotension_1\NN\14057371|.|at (l_conj) bradycardia_3\NN\14110674|and|Severe
D015742_D001919 CID propofol_16\NN\0|who|dexmedetomidine|or (r_conj) receive_13\VBP\2210855|neurocritical|care (r_relcl) patients_11\NNS\9898892|NONE (r_pobj) in_8\IN\13603305|similar (r_prep) prevalence_7\NN\4764412|NONE (r_pobj) at_5\IN\14622893|.|hypotension (r_prep) occur_4\VBP\0|NONE (l_nsubj) hypotension_1\NN\14057371|.|at (l_conj) bradycardia_3\NN\14110674|and|Severe
D020927_D007022 CID dexmedetomidine_14\NN\0|who|propofol|or (r_dobj) receive_13\VBP\2210855|neurocritical|care (r_relcl) patients_11\NNS\9898892|NONE (r_pobj) in_8\IN\13603305|similar (r_prep) prevalence_7\NN\4764412|NONE (r_pobj) at_5\IN\14622893|.|hypotension (r_prep) occur_4\VBP\0|NONE (l_nsubj) hypotension_1\NN\14057371|.|at
8985298
D019259_D006509 NONE lamivudine_0\NNP\3834836|effective|. (r_nsubj) is_1\VBZ\0|NONE (l_acomp) effective_2\JJ\0|Lamivudine|. (l_prep) in_3\IN\13603305|NONE (l_pcomp) suppressing_4\VBG\2510337|NONE (l_dobj) dna_8\NN\14994328|NONE (l_compound) virus_7\NN\9312843|in|:|trial (l_compound) b_6\NNP\1355326|NONE
D019259_D006509 NONE lamivudine_0\NNP\3834836|analogue|. (r_nsubj) is_1\VBZ\0|NONE (l_attr) analogue_6\NN\4743605|Lamivudine|. (l_relcl) has_8\VBZ\13888491|novel|a|','dideoxy|cytosine (l_dobj) effects_11\NNS\13245626|that|in (l_prep) on_12\IN\0|potent|inhibitory (l_pobj) replication_16\NN\1019524|NONE (l_compound) virus_15\NN\9312843|NONE (l_compound) b_14\NN\1355326|NONE
D019259_D006509 NONE cytosine_5\NN\14999913|novel|a|','dideoxy|has (r_compound) analogue_6\NN\4743605|Lamivudine|. (l_relcl) has_8\VBZ\13888491|novel|a|','dideoxy|cytosine (l_dobj) effects_11\NNS\13245626|that|in (l_prep) on_12\IN\0|potent|inhibitory (l_pobj) replication_16\NN\1019524|NONE (l_compound) virus_15\NN\9312843|NONE (l_compound) b_14\NN\1355326|NONE
D019259_D006509 NONE lamivudine_4\NN\3834836|NONE (r_dobj) receiving_3\VBG\2210855|All| (r_acl) patients_2\NNS\9898892|)|.|decrease|compared (r_nsubj) had_5\VBD\0|NONE (l_dobj) decrease_7\NN\7296428|)|patients|.|compared (l_prep) in_8\IN\13603305|a (l_pobj) virus_11\NN\9312843|NONE (l_compound) b_10\NN\1355326|P|values|(|(
D006514_D006509 CID antigen_14\NN\20090|B|Chinese (r_compound) carriers_15\NNS\9629752|NONE (r_pobj) in_9\IN\13603305|:|trial|virus (r_prep) dna_8\NN\14994328|NONE (l_compound) virus_7\NN\9312843|in|:|trial (l_compound) b_6\NNP\1355326|NONE
24927617
D019821_D012206 CID simvastatin_12\NN\3676175|and|with (r_conj) treated_8\VBN\2376958|infected (r_acl) patient_7\NN\9898892|.|in (r_appos) rhabdomyolysis_0\NNP\0|NONE
D019821_D009135 CID simvastatin_0\NNP\3676175|NONE (r_compound) plasma_1\NN\5398023|NONE (r_compound) concentration_2\NN\4916342|times|in|induced|. (r_nsubj) increased_3\VBD\169651|NONE (l_advcl) induced_11\VBD\1627355|times|in|concentration|. (l_ccomp) related_15\VBN\628491|NONE (l_nsubjpass) toxicity_13\NN\13576101|is|to
D019821_D009135 CID statin_10\NN\3740161|this|and (r_conj) patient_8\NN\9898892|NONE (r_pobj) in_6\IN\13603305|times|concentration|induced|. (r_prep) increased_3\VBD\169651|NONE (l_advcl) induced_11\VBD\1627355|times|in|concentration|. (l_ccomp) related_15\VBN\628491|NONE (l_nsubjpass) toxicity_13\NN\13576101|is|to
D019821_D009135 CID statin_21\NN\3740161|NONE (r_pobj) of_19\IN\0|the (r_prep) concentration_18\NN\4916342|NONE (r_pobj) to_16\IN\0|toxicity|is (r_prep) related_15\VBN\628491|NONE (l_nsubjpass) toxicity_13\NN\13576101|is|to
D019821_D064420 NONE simvastatin_2\NN\3676175|admission (l_conj) discontinued_8\VBN\0|and (l_advcl) suspected_19\VBN\916909|were|.|drugs (l_nsubjpass) toxicity_10\NN\13576101|was|because
D019821_D006526 NONE simvastatin_12\NN\3676175|and|with (r_conj) treated_8\VBN\2376958|infected (r_acl) patient_7\NN\9898892|.|in (l_amod) infected_6\VBN\2316868|treated
C486464_D012206 CID telaprevir_10\NNS\0|NONE (r_pobj) with_9\IN\0|and|simvastatin (r_prep) treated_8\VBN\2376958|infected (r_acl) patient_7\NN\9898892|.|in (r_appos) rhabdomyolysis_0\NNP\0|NONE
C417083_D006526 NONE interferon_18\NN\2725367|NONE (r_dobj) pegylated_17\VBN\0|with|man|.|therapy|, (r_conj) received_11\VBD\2210855|NONE (l_nsubj) man_3\NN\9605289|with|.|pegylated|therapy|, (l_prep) with_4\IN\0|year|old|A (l_pobj) infection_10\NN\14052046|NONE
D012254_D006526 NONE ribavirin_15\RB\2725367|NONE (r_pobj) with_14\IN\0|man|.|pegylated|therapy|, (r_prep) received_11\VBD\2210855|NONE (l_nsubj) man_3\NN\9605289|with|.|pegylated|therapy|, (l_prep) with_4\IN\0|year|old|A (l_pobj) infection_10\NN\14052046|NONE
C486464_D006526 NONE telaprevir_10\NNS\0|NONE (r_pobj) with_9\IN\0|and|simvastatin (r_prep) treated_8\VBN\2376958|infected (r_acl) patient_7\NN\9898892|.|in (l_amod) infected_6\VBN\2316868|treated
C486464_D006526 NONE telaprevir_20\NNS\0|and (r_conj) interferon_18\NN\2725367|NONE (r_dobj) pegylated_17\VBN\0|with|man|.|therapy|, (r_conj) received_11\VBD\2210855|NONE (l_nsubj) man_3\NN\9605289|with|.|pegylated|therapy|, (l_prep) with_4\IN\0|year|old|A (l_pobj) infection_10\NN\14052046|NONE
11474137
D000617_D006311 NONE aminoglycoside_7\NN\0| (r_npadvmod) induced_9\VBN\1627355|NONE (r_amod) ototoxicity_10\NN\0|NONE
D000617_D006311 NONE aminoglycoside_7\NN\0| (r_npadvmod) induced_9\VBN\1627355|NONE (r_amod) ototoxicity_10\NN\0|NONE (r_pobj) in_6\IN\13603305|reactive|oxygen (r_prep) species_5\NNS\7992450|NONE (r_pobj) of_2\IN\0|The (r_prep) participation_1\NN\1080366|has|.|been|from (r_nsubjpass) deduced_13\VBN\634472|NONE (l_prep) from_14\IN\0|has|.|participation|been (l_pobj) observations_15\NNS\996969|NONE (l_acl) catalyze_21\VBP\146138|NONE (l_conj) attenuate_32\VBP\224901|complexes|that|and|formation (l_dobj) ototoxicity_33\NN\0|antioxidants|that
D000617_D006311 NONE aminoglycoside_17\NN\0| (r_compound) iron_19\NN\14625458|NONE (r_compound) complexes_20\NNS\5869584|attenuate|that|and|formation (r_nsubj) catalyze_21\VBP\146138|NONE (r_acl) observations_15\NNS\996969|NONE (r_pobj) from_14\IN\0|has|.|participation|been (r_prep) deduced_13\VBN\634472|NONE (l_nsubjpass) participation_1\NN\1080366|has|.|been|from (l_prep) of_2\IN\0|The (l_pobj) species_5\NNS\7992450|NONE (l_prep) in_6\IN\13603305|reactive|oxygen (l_pobj) ototoxicity_10\NN\0|NONE
D000617_D006311 NONE aminoglycoside_17\NN\0| (r_compound) iron_19\NN\14625458|NONE (r_compound) complexes_20\NNS\5869584|attenuate|that|and|formation (r_nsubj) catalyze_21\VBP\146138|NONE (l_conj) attenuate_32\VBP\224901|complexes|that|and|formation (l_dobj) ototoxicity_33\NN\0|antioxidants|that
D000617_D006311 NONE aminoglycoside_18\NN\0| (r_npadvmod) induced_20\VBN\1627355|NONE (r_amod) ototoxicity_21\NN\0|NONE
D003300_D034381 NONE copper_2\NN\14821043|/||zinc (r_npadvmod) superoxide_6\NN\14971519|NONE (r_amod) dismutase_7\NN\0|NONE (r_pobj) of_1\IN\0|NONE (r_prep) overexpression_0\NN\0|from|. (r_nsubj) protects_8\VBZ\1127795|NONE (l_prep) from_9\IN\0|Overexpression|. (l_pobj) loss_14\NN\13252973|NONE
D007612_D034381 CID kanamycin_10\NN\2716866| (r_npadvmod) induced_12\VBN\1627355|hearing (r_amod) loss_14\NN\13252973|NONE
D015032_D006311 NONE zn_8\NNP\14625458| (r_compound) superoxide_10\NN\14971519|)|Cu|/|SOD|( (r_amod) dismutase_11\NN\0|NONE (r_pobj) of_5\IN\0|that (r_prep) overexpression_4\NN\0|from|should|mice (r_nsubj) protect_18\VB\1127795|We|.|therefore (l_prep) from_21\IN\0|should|overexpression|mice (l_pobj) ototoxicity_22\NN\0|NONE
D003300_D006311 NONE cu_6\NNP\14821043|superoxide|)|/|SOD|( (r_nmod) dismutase_11\NN\0|NONE (r_pobj) of_5\IN\0|that (r_prep) overexpression_4\NN\0|from|should|mice (r_nsubj) protect_18\VB\1127795|We|.|therefore (l_prep) from_21\IN\0|should|overexpression|mice (l_pobj) ototoxicity_22\NN\0|NONE
D013481_D034381 NONE superoxide_6\NN\14971519|NONE (r_amod) dismutase_7\NN\0|NONE (r_pobj) of_1\IN\0|NONE (r_prep) overexpression_0\NN\0|from|. (r_nsubj) protects_8\VBZ\1127795|NONE (l_prep) from_9\IN\0|Overexpression|. (l_pobj) loss_14\NN\13252973|NONE
D015032_D034381 NONE zinc_4\NN\14625458|copper|/| (r_npadvmod) superoxide_6\NN\14971519|NONE (r_amod) dismutase_7\NN\0|NONE (r_pobj) of_1\IN\0|NONE (r_prep) overexpression_0\NN\0|from|. (r_nsubj) protects_8\VBZ\1127795|NONE (l_prep) from_9\IN\0|Overexpression|. (l_pobj) loss_14\NN\13252973|NONE
D010100_D006311 NONE oxygen_4\NN\14622893|reactive|in (r_compound) species_5\NNS\7992450|NONE (l_prep) in_6\IN\13603305|reactive|oxygen (l_pobj) ototoxicity_10\NN\0|NONE
D010100_D006311 NONE oxygen_4\NN\14622893|reactive|in (r_compound) species_5\NNS\7992450|NONE (r_pobj) of_2\IN\0|The (r_prep) participation_1\NN\1080366|has|.|been|from (r_nsubjpass) deduced_13\VBN\634472|NONE (l_prep) from_14\IN\0|has|.|participation|been (l_pobj) observations_15\NNS\996969|NONE (l_acl) catalyze_21\VBP\146138|NONE (l_conj) attenuate_32\VBP\224901|complexes|that|and|formation (l_dobj) ototoxicity_33\NN\0|antioxidants|that
D013481_D006311 NONE superoxide_25\JJ\14971519|in (r_amod) radicals_26\NNS\9465459|NONE (r_pobj) of_24\IN\0|the (r_prep) formation_23\NN\7938773|complexes|attenuate|that|and (r_dobj) catalyze_21\VBP\146138|NONE (r_acl) observations_15\NNS\996969|NONE (r_pobj) from_14\IN\0|has|.|participation|been (r_prep) deduced_13\VBN\634472|NONE (l_nsubjpass) participation_1\NN\1080366|has|.|been|from (l_prep) of_2\IN\0|The (l_pobj) species_5\NNS\7992450|NONE (l_prep) in_6\IN\13603305|reactive|oxygen (l_pobj) ototoxicity_10\NN\0|NONE
D013481_D006311 NONE superoxide_25\JJ\14971519|in (r_amod) radicals_26\NNS\9465459|NONE (r_pobj) of_24\IN\0|the (r_prep) formation_23\NN\7938773|complexes|attenuate|that|and (r_dobj) catalyze_21\VBP\146138|NONE (l_conj) attenuate_32\VBP\224901|complexes|that|and|formation (l_dobj) ototoxicity_33\NN\0|antioxidants|that
D013481_D006311 NONE superoxide_10\NN\14971519|)|Cu|/|SOD|( (r_amod) dismutase_11\NN\0|NONE (r_pobj) of_5\IN\0|that (r_prep) overexpression_4\NN\0|from|should|mice (r_nsubj) protect_18\VB\1127795|We|.|therefore (l_prep) from_21\IN\0|should|overexpression|mice (l_pobj) ototoxicity_22\NN\0|NONE
D013481_D006311 NONE superoxide_5\NN\14971519|NONE (r_amod) dismutase_6\NN\0|NONE (r_pobj) of_4\IN\0|NONE (r_prep) overexpression_3\NN\0|NONE (r_pobj) by_2\IN\0|The (r_prep) protection_1\NN\407535|.|hypothesis (r_nsubj) supports_7\VBZ\407535|NONE (l_dobj) hypothesis_9\NN\7162194|.|protection (l_acl) plays_13\VBZ\7007684|the (l_dobj) role_16\NN\719494|that|stress (l_prep) in_17\IN\13603305|significant|a (l_pobj) ototoxicity_21\NN\0|NONE
D007501_D006311 NONE iron_19\NN\14625458|NONE (r_compound) complexes_20\NNS\5869584|attenuate|that|and|formation (r_nsubj) catalyze_21\VBP\146138|NONE (r_acl) observations_15\NNS\996969|NONE (r_pobj) from_14\IN\0|has|.|participation|been (r_prep) deduced_13\VBN\634472|NONE (l_nsubjpass) participation_1\NN\1080366|has|.|been|from (l_prep) of_2\IN\0|The (l_pobj) species_5\NNS\7992450|NONE (l_prep) in_6\IN\13603305|reactive|oxygen (l_pobj) ototoxicity_10\NN\0|NONE
D007501_D006311 NONE iron_19\NN\14625458|NONE (r_compound) complexes_20\NNS\5869584|attenuate|that|and|formation (r_nsubj) catalyze_21\VBP\146138|NONE (l_conj) attenuate_32\VBP\224901|complexes|that|and|formation (l_dobj) ototoxicity_33\NN\0|antioxidants|that
24897009
D004977_D011115 CID ethambutol_0\NNP\0|is|cause|and|polyneuropathy (r_nsubjpass) known_2\VBN\0|NONE (l_conj) polyneuropathy_13\NN\0|Ethambutol|is|cause|and
D004977_D064420 NONE ethambutol_15\VB\0|.|case|vulnerability (l_dobj) toxicity_16\NN\13576101|to
D004977_D009901 CID ethambutol_0\NNP\0|is|cause|and|polyneuropathy (r_nsubjpass) known_2\VBN\0|NONE (l_xcomp) cause_4\VB\7323922|Ethambutol|is|and|polyneuropathy (l_dobj) neuropathy_6\NN\14204950|to
D004977_D010292 CID ethambutol_32\NN\0|NONE (r_pobj) of_31\IN\0|a|supratherapeutic (r_prep) dose_30\NN\3740161|NONE (r_pobj) to_27\IN\0|NONE (r_prep) exposure_26\NN\5042871|NONE (r_pobj) of_25\IN\0| (r_prep) weeks_24\NNS\15113229|NONE (r_pobj) after_22\IN\0|who|loss (r_prep) developed_17\VBD\1753788|old|a (l_dobj) loss_19\NN\13252973|after|who (l_conj) paresthesias_21\NNS\14299637|visual|and
D004977_D014786 CID ethambutol_32\NN\0|NONE (r_pobj) of_31\IN\0|a|supratherapeutic (r_prep) dose_30\NN\3740161|NONE (r_pobj) to_27\IN\0|NONE (r_prep) exposure_26\NN\5042871|NONE (r_pobj) of_25\IN\0| (r_prep) weeks_24\NNS\15113229|NONE (r_pobj) after_22\IN\0|who|loss (r_prep) developed_17\VBD\1753788|old|a (l_dobj) loss_19\NN\13252973|after|who
D004977_D010523 NONE ethambutol_6\NN\0|NONE (r_amod) overtreatment_7\NN\0|to (r_pobj) due_4\IN\5174653|and|neuropathy|. (r_prep) optochiasmatic_0\JJ\0|NONE (l_conj) neuropathy_3\NN\14204950|and|.|due
25071004
C039726_D000740 NONE artesunate_6\NN\0|NONE (r_pobj) with_4\IN\0|NONE (r_prep) treatment_3\NN\654885|NONE (r_pobj) after_2\IN\0|issue|:|.|anemia (r_prep) delayed_0\JJ\439958|NONE (l_dobj) anemia_1\NN\14189204|issue|:|after|.
C039726_D008288 NONE artesunate_12\NN\0|NONE (r_pobj) with_10\IN\0|NONE (r_prep) treatment_9\NN\654885|NONE (r_pobj) after_8\IN\0|been|Organization|have|,|Cases (r_prep) described_7\VBN\1001294|NONE (l_appos) organization_18\NNP\7950920|been|have|,|after|Cases (l_parataxis) who)-recommended_20\VBN\0|current|Health|the|World (l_dobj) drug_24\NN\14778436|.|( (l_prep) for_25\IN\0|line (l_pobj) treatment_27\NN\654885|NONE (l_prep) of_28\IN\0|the (l_pobj) malaria_30\NN\14178913|NONE
C039726_D008288 NONE artesunate_36\NN\0|NONE (l_prep) for_37\IN\0|injectable (l_pobj) malaria_39\NN\14178913|NONE
C039726_D000743 CID artesunate_12\NN\0|NONE (r_pobj) with_10\IN\0|NONE (r_prep) treatment_9\NN\654885|NONE (r_pobj) after_8\IN\0|been|Organization|have|,|Cases (r_prep) described_7\VBN\1001294|NONE (l_nsubjpass) cases_0\NNS\7283608|been|Organization|have|,|after (l_prep) of_1\IN\0|NONE (l_pobj) anemia_4\NN\14189204|NONE
19914299
D005473_D008569 NONE fluoxetine_0\NNP\4169152|.|deficits|fluorouracil (r_nsubj) improves_1\VBZ\126264|NONE (l_dobj) deficits_4\NNS\5113133|Fluoxetine|.|fluorouracil
D005472_D008569 CID 5-fluorouracil_10\CD\0|Fluoxetine|.|deficits (r_punct) improves_1\VBZ\126264|NONE (l_dobj) deficits_4\NNS\5113133|Fluoxetine|.|fluorouracil
11745287
D004317_D002294 NONE doxorubicin_7\NN\2716866|in (r_dobj) liposomal_6\JJ\0|.|II|and|of (l_prep) in_8\IN\13603305|doxorubicin (l_pobj) patients_9\NNS\9898892|NONE (l_prep) with_10\IN\0|NONE (l_pobj) carcinoma_14\NN\14239918|NONE (l_prep) of_15\IN\0|cell|recurrent (l_pobj) cervix_17\NN\5225090|NONE
D004317_D002294 NONE doxorubicin_18\NN\2716866|combination|; (r_dobj) liposomal_17\JJ\0|was|days|intravenously|.|to|dose|determine (r_ccomp) administered_32\VBN\2436349|NONE (l_prep) to_37\IN\0|was|days|intravenously|.|dose|liposomal|determine (l_pobj) patients_39\NNS\9898892|NONE (l_prep) with_40\IN\0| (l_pobj) carcinoma_45\NN\14239918|NONE
D004317_D002294 NONE doxil_20\NNS\0|NONE (r_appos) doxorubicin_18\NN\2716866|combination|; (r_dobj) liposomal_17\JJ\0|was|days|intravenously|.|to|dose|determine (r_ccomp) administered_32\VBN\2436349|NONE (l_prep) to_37\IN\0|was|days|intravenously|.|dose|liposomal|determine (l_pobj) patients_39\NNS\9898892|NONE (l_prep) with_40\IN\0| (l_pobj) carcinoma_45\NN\14239918|NONE
D004317_D064420 NONE doxorubicin_18\NN\2716866|combination|; (r_dobj) liposomal_17\JJ\0|was|days|intravenously|.|to|dose|determine (r_ccomp) administered_32\VBN\2436349|NONE (l_advcl) determine_47\VB\0|was|days|intravenously|.|to|dose|liposomal (l_dobj) activity_49\NN\30358|to (l_conj) profile_52\NN\6999802|antitumor|and (l_compound) toxicity_51\NN\13576101|NONE
D004317_D064420 NONE doxil_20\NNS\0|NONE (r_appos) doxorubicin_18\NN\2716866|combination|; (r_dobj) liposomal_17\JJ\0|was|days|intravenously|.|to|dose|determine (r_ccomp) administered_32\VBN\2436349|NONE (l_advcl) determine_47\VB\0|was|days|intravenously|.|to|dose|liposomal (l_dobj) activity_49\NN\30358|to (l_conj) profile_52\NN\6999802|antitumor|and (l_compound) toxicity_51\NN\13576101|NONE
D016190_D064420 NONE carboplatin_3\NN\0|(|under (r_nmod) area_5\NN\8630985|NONE (r_pobj) of_2\IN\0|The (r_prep) combination_1\NN\7951464|doxorubicin|; (r_nsubj) liposomal_17\JJ\0|was|days|intravenously|.|to|dose|determine (r_ccomp) administered_32\VBN\2436349|NONE (l_advcl) determine_47\VB\0|was|days|intravenously|.|to|dose|liposomal (l_dobj) activity_49\NN\30358|to (l_conj) profile_52\NN\6999802|antitumor|and (l_compound) toxicity_51\NN\13576101|NONE
D016190_D002294 NONE carboplatin_4\NN\0|NONE (r_pobj) of_3\IN\0|liposomal|.|II|and (r_prep) study_2\NN\635850|NONE (l_conj) liposomal_6\JJ\0|.|II|and|of (l_prep) in_8\IN\13603305|doxorubicin (l_pobj) patients_9\NNS\9898892|NONE (l_prep) with_10\IN\0|NONE (l_pobj) carcinoma_14\NN\14239918|NONE (l_prep) of_15\IN\0|cell|recurrent (l_pobj) cervix_17\NN\5225090|NONE
D016190_D002294 NONE carboplatin_3\NN\0|(|under (r_nmod) area_5\NN\8630985|NONE (r_pobj) of_2\IN\0|The (r_prep) combination_1\NN\7951464|doxorubicin|; (r_nsubj) liposomal_17\JJ\0|was|days|intravenously|.|to|dose|determine (r_ccomp) administered_32\VBN\2436349|NONE (l_prep) to_37\IN\0|was|days|intravenously|.|dose|liposomal|determine (l_pobj) patients_39\NNS\9898892|NONE (l_prep) with_40\IN\0| (l_pobj) carcinoma_45\NN\14239918|NONE
D016190_D002583 NONE carboplatin_4\NN\0|NONE (r_pobj) of_3\IN\0|liposomal|.|II|and (r_prep) study_2\NN\635850|NONE (l_conj) liposomal_6\JJ\0|.|II|and|of (l_prep) in_8\IN\13603305|doxorubicin (l_pobj) patients_9\NNS\9898892|NONE (l_prep) with_10\IN\0|NONE (l_pobj) carcinoma_14\NN\14239918|NONE (l_prep) of_15\IN\0|cell|recurrent (l_pobj) cervix_17\NN\5225090|NONE
D016190_D002583 NONE carboplatin_6\NN\0|NONE (r_pobj) of_5\IN\0|the (r_prep) combination_4\NN\7951464|NONE (r_pobj) of_2\IN\0|The (r_prep) activity_1\NN\30358|was|.|in (r_nsubjpass) tested_11\VBN\670261|NONE (l_prep) in_12\IN\13603305|was|.|activity (l_pobj) study_16\NN\635850|NONE (l_prep) of_17\IN\0|II|a (l_pobj) patients_18\NNS\9898892|NONE (l_prep) with_19\IN\0|NONE (l_pobj) carcinoma_22\NN\14239918|NONE
D016190_D002583 NONE carboplatin_3\NN\0|(|under (r_nmod) area_5\NN\8630985|NONE (r_pobj) of_2\IN\0|The (r_prep) combination_1\NN\7951464|doxorubicin|; (r_nsubj) liposomal_17\JJ\0|was|days|intravenously|.|to|dose|determine (r_ccomp) administered_32\VBN\2436349|NONE (l_prep) to_37\IN\0|was|days|intravenously|.|dose|liposomal|determine (l_pobj) patients_39\NNS\9898892|NONE (l_prep) with_40\IN\0| (l_pobj) carcinoma_45\NN\14239918|NONE
D016190_D002583 NONE carboplatin_3\NN\0|doxorubicin (r_pobj) of_2\IN\0|The (r_prep) combination_1\NN\7951464|activity|. (r_nsubj) has_7\VBZ\13888491|NONE (l_dobj) activity_9\NN\30358|combination|. (l_prep) in_10\IN\13603305|modest (l_pobj) patients_11\NNS\9898892|NONE (l_prep) with_12\IN\0|NONE (l_pobj) carcinoma_15\NN\14239918|NONE
D004317_D002583 NONE doxorubicin_7\NN\2716866|in (r_dobj) liposomal_6\JJ\0|.|II|and|of (l_prep) in_8\IN\13603305|doxorubicin (l_pobj) patients_9\NNS\9898892|NONE (l_prep) with_10\IN\0|NONE (l_pobj) carcinoma_14\NN\14239918|NONE (l_prep) of_15\IN\0|cell|recurrent (l_pobj) cervix_17\NN\5225090|NONE
D004317_D002583 NONE doxorubicin_9\NN\2716866|and (r_conj) carboplatin_6\NN\0|NONE (r_pobj) of_5\IN\0|the (r_prep) combination_4\NN\7951464|NONE (r_pobj) of_2\IN\0|The (r_prep) activity_1\NN\30358|was|.|in (r_nsubjpass) tested_11\VBN\670261|NONE (l_prep) in_12\IN\13603305|was|.|activity (l_pobj) study_16\NN\635850|NONE (l_prep) of_17\IN\0|II|a (l_pobj) patients_18\NNS\9898892|NONE (l_prep) with_19\IN\0|NONE (l_pobj) carcinoma_22\NN\14239918|NONE
D004317_D002583 NONE doxorubicin_18\NN\2716866|combination|; (r_dobj) liposomal_17\JJ\0|was|days|intravenously|.|to|dose|determine (r_ccomp) administered_32\VBN\2436349|NONE (l_prep) to_37\IN\0|was|days|intravenously|.|dose|liposomal|determine (l_pobj) patients_39\NNS\9898892|NONE (l_prep) with_40\IN\0| (l_pobj) carcinoma_45\NN\14239918|NONE
D004317_D002583 NONE doxil_20\NNS\0|NONE (r_appos) doxorubicin_18\NN\2716866|combination|; (r_dobj) liposomal_17\JJ\0|was|days|intravenously|.|to|dose|determine (r_ccomp) administered_32\VBN\2436349|NONE (l_prep) to_37\IN\0|was|days|intravenously|.|dose|liposomal|determine (l_pobj) patients_39\NNS\9898892|NONE (l_prep) with_40\IN\0| (l_pobj) carcinoma_45\NN\14239918|NONE
D004317_D002583 NONE doxorubicin_6\NN\2716866|carboplatin (r_pobj) of_2\IN\0|The (r_prep) combination_1\NN\7951464|activity|. (r_nsubj) has_7\VBZ\13888491|NONE (l_dobj) activity_9\NN\30358|combination|. (l_prep) in_10\IN\13603305|modest (l_pobj) patients_11\NNS\9898892|NONE (l_prep) with_12\IN\0|NONE (l_pobj) carcinoma_15\NN\14239918|NONE
10510854
D006220_D002375 CID haloperidol_9\NN\3713736|NONE (r_pobj) by_8\IN\0|NONE (r_agent) induced_7\VBN\1627355|high|a|of|indicating (r_acl) reversal_4\NN\199130|e|. (l_prep) of_5\IN\0|high|a|induced|indicating (l_pobj) catalepsy_6\NN\14023236|NONE
1943082
D005978_D015427 NONE glutathione_8\NN\0|NONE (r_pobj) in_4\IN\13603305|following|no (r_prep) change_3\NN\7283608|.|There (l_prep) following_9\VBG\8180190|in|no (l_pobj) injury_14\NN\14052046|NONE
D005978_D007511 NONE glutathione_8\NN\0|NONE (r_pobj) in_4\IN\13603305|following|no (r_prep) change_3\NN\7283608|.|There (l_prep) following_9\VBG\8180190|in|no (l_pobj) injury_14\NN\14052046|NONE (l_compound) reperfusion_13\NN\0|intestinal (l_compound) ischemia_11\NN\14195315|
3074291
C017590_D014839 NONE oxitropium_6\NN\0|NONE (r_pobj) of_5\IN\0|side (r_prep) effects_4\NNS\13245626|compared|.|subject|, (r_dobj) reported_2\VBN\831651|NONE (l_advcl) compared_9\VBN\644583|.|effects|subject|, (l_prep) to_10\IN\0|as (l_pobj) subjects_12\NNS\6598915|NONE (l_acl) reporting_13\VBG\6681177|three (l_dobj) nausea_14\NN\14299637|after (l_conj) vomiting_16\VBG\116687|,
D013806_D009325 CID theophylline_20\NN\2905612|NONE (r_pobj) after_19\IN\0|nausea (r_prep) reporting_13\VBG\6681177|three (l_dobj) nausea_14\NN\14299637|after
C017590_D009325 NONE oxitropium_6\NN\0|NONE (r_pobj) of_5\IN\0|side (r_prep) effects_4\NNS\13245626|compared|.|subject|, (r_dobj) reported_2\VBN\831651|NONE (l_advcl) compared_9\VBN\644583|.|effects|subject|, (l_prep) to_10\IN\0|as (l_pobj) subjects_12\NNS\6598915|NONE (l_acl) reporting_13\VBG\6681177|three (l_dobj) nausea_14\NN\14299637|after
D013806_D001249 NONE theophylline_12\NN\2905612|NONE (l_prep) on_13\IN\0|release (l_pobj) asthma_15\NN\14145095|NONE
D013806_D001249 NONE theophylline_18\NN\2905612|upon|a|release (r_amod) preparation_19\NN\407535|NONE (l_prep) upon_20\IN\0|a|theophylline|release (l_pobj) asthma_22\NN\14145095|NONE
D013806_D001249 NONE theophylline_8\NN\2905612|NONE (r_pobj) to_7\IN\0|in|valuable|a (r_prep) alternative_6\NN\5788149|to (l_prep) in_9\IN\13603305|to|valuable|a (l_pobj) asthma_11\NN\14145095|NONE
C017590_D001249 NONE bromide_6\NN\14904359|NONE (r_pobj) of_4\IN\0|the (r_prep) effect_3\NN\34213|NONE (r_pobj) of_1\IN\0|.|and|of (r_prep) comparison_0\NN\635850|NONE (l_conj) of_8\IN\0|.|and|of (l_pobj) theophylline_12\NN\2905612|NONE (l_prep) on_13\IN\0|release (l_pobj) asthma_15\NN\14145095|NONE
C017590_D001249 NONE bromide_10\NN\14904359|a|,|inhaled|antimuscarinic|new (r_appos) drug_7\NN\14778436|and|of (r_pobj) of_2\IN\0|The (l_conj) of_13\IN\0|and|drug (l_pobj) preparation_19\NN\407535|NONE (l_prep) upon_20\IN\0|a|theophylline|release (l_pobj) asthma_22\NN\14145095|NONE
C017590_D001249 NONE oxitropium_0\NNP\0|is|be|.|, (r_nsubj) proves_1\VBZ\9759069|NONE (l_xcomp) be_3\VB\14625458|is|.|Oxitropium|, (l_attr) alternative_6\NN\5788149|to (l_prep) in_9\IN\13603305|to|valuable|a (l_pobj) asthma_11\NN\14145095|NONE
D013806_D014202 CID theophylline_20\NN\2905612|NONE (r_pobj) after_19\IN\0|nausea (r_prep) reporting_13\VBG\6681177|three (l_dobj) nausea_14\NN\14299637|after (l_conj) vomiting_16\VBG\116687|, (l_conj) tremors_18\NNS\345926|and
C017590_D014202 NONE oxitropium_6\NN\0|NONE (r_pobj) of_5\IN\0|side (r_prep) effects_4\NNS\13245626|compared|.|subject|, (r_dobj) reported_2\VBN\831651|NONE (l_advcl) compared_9\VBN\644583|.|effects|subject|, (l_prep) to_10\IN\0|as (l_pobj) subjects_12\NNS\6598915|NONE (l_acl) reporting_13\VBG\6681177|three (l_dobj) nausea_14\NN\14299637|after (l_conj) vomiting_16\VBG\116687|, (l_conj) tremors_18\NNS\345926|and
D013806_D014839 CID theophylline_20\NN\2905612|NONE (r_pobj) after_19\IN\0|nausea (r_prep) reporting_13\VBG\6681177|three (l_dobj) nausea_14\NN\14299637|after (l_conj) vomiting_16\VBG\116687|,
19263707
D002231_D014657 NONE carbimazole_12\NN\0|who (r_dobj) developed_9\VBD\1753788|Graves (r_relcl) disease_7\NN\14061805|NONE (r_pobj) with_4\IN\0|a (r_prep) patient_3\NN\9898892|vasculitis (r_nsubj) induced_13\VBD\1627355|We|. (l_dobj) vasculitis_14\NN\14336539|patient
D002231_D014657 NONE carbimazole_12\NN\0|this|.|To (l_acl) induced_13\VBD\1627355|first|the|ANCA|positive (l_dobj) case_15\NN\7283608|NONE (l_compound) vasculitis_14\JJ\14336539|reported
D002231_D006980 NONE carbimazole_6\NN\0|NONE (r_pobj) like_5\IN\5839024|,|thyroid (r_prep) drugs_3\NNS\14778436|are|commonly|.|for (r_nsubjpass) prescribed_14\VBN\748282|NONE (l_prep) for_15\IN\0|drugs|are|commonly|. (l_pobj) treatment_17\NN\654885|NONE (l_prep) of_18\IN\0|the (l_pobj) hyperthyroidism_19\NN\14059928|NONE
D013956_D006980 NONE drugs_3\NNS\14778436|are|commonly|.|for (r_nsubjpass) prescribed_14\VBN\748282|NONE (l_prep) for_15\IN\0|drugs|are|commonly|. (l_pobj) treatment_17\NN\654885|NONE (l_prep) of_18\IN\0|the (l_pobj) hyperthyroidism_19\NN\14059928|NONE
D002231_D056648 CID carbimazole_0\NNS\0|.|vasculitis (r_nsubj) induced_1\VBD\1627355|NONE (l_dobj) vasculitis_4\NN\14336539|Carbimazole|.
D002231_D006111 NONE carbimazole_12\NN\0|who (r_dobj) developed_9\VBD\1753788|Graves (r_relcl) disease_7\NN\14061805|NONE
D013956_D056648 CID antithyroidmedications_15\NNS\0|NONE (r_pobj) of_14\IN\0|threatening|adverse|a (r_prep) effect_13\NN\34213|.|antibody (r_attr) is_6\VBZ\0|NONE (l_nsubj) antibody_2\NN\14728724|.|effect (l_appos) vasculitis_5\NN\14336539|cytoplasmic|Antineutrophil
D011441_D006980 NONE propylthiouracil_8\NN\14727670|PTU|and (r_conj) carbimazole_6\NN\0|NONE (r_pobj) like_5\IN\5839024|,|thyroid (r_prep) drugs_3\NNS\14778436|are|commonly|.|for (r_nsubjpass) prescribed_14\VBN\748282|NONE (l_prep) for_15\IN\0|drugs|are|commonly|. (l_pobj) treatment_17\NN\654885|NONE (l_prep) of_18\IN\0|the (l_pobj) hyperthyroidism_19\NN\14059928|NONE
D011441_D006980 NONE ptu_10\NNP\0|propylthiouracil|and (r_appos) carbimazole_6\NN\0|NONE (r_pobj) like_5\IN\5839024|,|thyroid (r_prep) drugs_3\NNS\14778436|are|commonly|.|for (r_nsubjpass) prescribed_14\VBN\748282|NONE (l_prep) for_15\IN\0|drugs|are|commonly|. (l_pobj) treatment_17\NN\654885|NONE (l_prep) of_18\IN\0|the (l_pobj) hyperthyroidism_19\NN\14059928|NONE
816141
D002512_D007674 NONE cephalothin_13\JJ\2996840|NONE (r_compound) therapy_14\NN\657604|while (r_dobj) receiving_12\VBG\2210855|anemia|patient|. (r_advcl) developed_5\VBD\1753788|NONE (l_nsubj) patient_1\NN\9898892|anemia|receiving|. (l_prep) with_2\IN\0|A (l_pobj) disease_4\NN\14061805|NONE
D002512_D000743 CID cephalothin_0\NNP\2996840| (r_npadvmod) induced_2\VBN\1627355|immune|.|hemolytic (r_amod) anemia_5\NN\14189204|NONE
D002512_D000743 CID cephalothin_13\JJ\2996840|NONE (r_compound) therapy_14\NN\657604|while (r_dobj) receiving_12\VBG\2210855|anemia|patient|. (r_advcl) developed_5\VBD\1753788|NONE (l_dobj) anemia_10\NN\14189204|patient|receiving|.
10960401
D009020_D009759 CID morphine_10\NN\2707683|NONE (r_pobj) of_9\IN\0|intravenous|controlled (r_prep) administration_8\NN\1133281|NONE (r_pobj) with_3\IN\0|NONE (r_prep) associated_2\VBN\628491|.|Downbeat (r_acl) nystagmus_1\NN\337486|NONE
D009020_D009759 CID morphine_23\NN\2707683|NONE (r_pobj) of_17\IN\0|large|a (r_prep) dose_16\NN\3740161|while (r_dobj) receiving_12\VBG\2210855|who|dizziness|with (r_advcl) developed_6\VBD\1753788|a (l_prep) with_8\IN\0|who|receiving|dizziness (l_pobj) nystagmus_10\NN\337486|NONE
D009020_D004244 CID morphine_23\NN\2707683|NONE (r_pobj) of_17\IN\0|large|a (r_prep) dose_16\NN\3740161|while (r_dobj) receiving_12\VBG\2210855|who|dizziness|with (r_advcl) developed_6\VBD\1753788|a (l_dobj) dizziness_7\NN\14299637|who|receiving|with
891494
D010672_D012640 NONE phenytoin_3\NNP\3550533|)|with|DPH|( (r_nmod) encephalopathy_7\JJ\14084880|NONE (l_prep) with_8\IN\0|phenytoin|)|DPH|( (l_pobj) seizures_10\NNS\14081375|NONE
D010672_D012640 NONE dph_5\NNP\6702458|phenytoin|)|with|( (r_nmod) encephalopathy_7\JJ\14084880|NONE (l_prep) with_8\IN\0|phenytoin|)|DPH|( (l_pobj) seizures_10\NNS\14081375|NONE
D010672_D012640 NONE dph_8\NNP\6702458|NONE (r_compound) treatment_9\NN\654885|NONE (r_dobj) starting_7\VBG\457382|a (r_acl) patient_6\NN\9898892|increase (r_pobj) in_4\IN\13603305|should|to|physician|are|that|,|, (l_pobj) increase_12\NN\13576355|patient (l_prep) in_13\IN\13603305|an|with|,|unexpected (l_pobj) seizures_14\NNS\14081375|NONE
D010672_D012640 NONE dph_34\NNP\6702458|from (r_dobj) eliminating_33\VBG\1619929|NONE (r_pcomp) for_32\IN\0|possible|the (r_prep) need_31\NN\13920835|NONE (r_pobj) to_28\IN\0|should|physician|are|that|in|,|, (r_prep) alert_25\VB\14031108|.|authors (l_prep) in_4\IN\13603305|should|to|physician|are|that|,|, (l_pobj) increase_12\NN\13576355|patient (l_prep) in_13\IN\13603305|an|with|,|unexpected (l_pobj) seizures_14\NNS\14081375|NONE
D010672_D005076 NONE dph_6\NNP\6702458|NONE (r_pobj) of_4\IN\0|the (r_prep) concentration_3\NN\4916342|In|normal (r_nsubj) was_7\VBD\0|patient|,|during|rash (r_ccomp) presented_12\VBD\2137132|protidogram|,|normal|had|and|, (l_dobj) rash_16\JJ\14321469|patient|,|during|was
D010672_D005076 NONE dph_18\NNP\6702458|NONE (r_compound) treatment_19\NN\654885|NONE (r_pobj) during_17\IN\0|patient|,|was|rash (r_prep) presented_12\VBD\2137132|protidogram|,|normal|had|and|, (l_dobj) rash_16\JJ\14321469|patient|,|during|was
D010672_D005076 NONE dph_29\NNP\6702458|an|intradermic (r_compound) injection_30\NN\320852|effect|. (r_nsubj) had_31\VBD\0|protidogram|,|normal|and|presented|, (r_conj) was_23\VBD\0|NONE (l_ccomp) presented_12\VBD\2137132|protidogram|,|normal|had|and|, (l_dobj) rash_16\JJ\14321469|patient|,|during|was
D010672_D001927 CID phenytoin_0\NNP\3550533|as|report|:|. (r_compound) encephalopathy_1\NNP\14084880|NONE
D010672_D001927 CID phenytoin_3\NNP\3550533|)|with|DPH|( (r_nmod) encephalopathy_7\JJ\14084880|NONE
D010672_D001927 CID dph_5\NNP\6702458|phenytoin|)|with|( (r_nmod) encephalopathy_7\JJ\14084880|NONE
11915580
D009569_D004412 NONE no_19\JJ\7204911|an (r_det) donor_20\NN\9608709|glyceryl|,|,|(|GTN|) (r_appos) trinitrate_13\NN\0|NONE (r_pobj) of_11\IN\0|the (r_prep) efficacy_10\NN\5199286|to|in (r_dobj) determine_8\VB\0|.|aim (l_prep) in_22\IN\13603305|to|efficacy (l_pobj) resolution_24\NN\6470073|NONE (l_prep) of_25\IN\0|the|in (l_pobj) dysmenorrhea_27\NN\14322699|NONE
D005996_D006261 CID gtn_5\NNP\0|not|but (r_pobj) by_4\IN\0|.|was|significantly|by|Headache (r_agent) increased_3\VBN\169651|NONE (l_nsubjpass) headache_0\NNP\5829480|.|was|significantly|by|by
D005996_D006261 CID gtn_4\NNP\0|NONE (r_dobj) using_3\VBG\418025|became|patients|. (r_xcomp) stopped_2\VBD\0|NONE (l_advcl) became_13\VBD\146138|patients|using|. (l_nsubj) headache_6\NN\5829480|intolerable|because
D004008_D006261 NONE dcf_9\NNP\0|NONE (r_pobj) by_8\IN\0|.|was|significantly|Headache|by (r_prep) increased_3\VBN\169651|NONE (l_nsubjpass) headache_0\NNP\5829480|.|was|significantly|by|by
D004008_D004412 NONE diclofenac_6\NN\0|NONE (r_pobj) with_5\IN\0|for|glyceryl (r_prep) trinitrate_4\NN\0|NONE (l_prep) for_7\IN\0|glyceryl|with (l_pobj) treatment_9\NN\654885|NONE (l_prep) of_10\IN\0|the (l_pobj) dysmenorrhea_12\NN\14322699|NONE
D004008_D004412 NONE diclofenac_31\NNP\0|NONE (r_pobj) with_30\IN\0|NONE (r_prep) comparison_29\NN\635850|NONE (r_pobj) in_28\IN\13603305|of|the (r_prep) resolution_24\NN\6470073|NONE (l_prep) of_25\IN\0|the|in (l_pobj) dysmenorrhea_27\NN\14322699|NONE
D004008_D004412 NONE dcf_33\NNP\0|NONE (r_appos) diclofenac_31\NNP\0|NONE (r_pobj) with_30\IN\0|NONE (r_prep) comparison_29\NN\635850|NONE (r_pobj) in_28\IN\13603305|of|the (r_prep) resolution_24\NN\6470073|NONE (l_prep) of_25\IN\0|the|in (l_pobj) dysmenorrhea_27\NN\14322699|NONE
D004008_D004412 NONE dcf_14\NNP\0|NONE (r_pobj) with_13\IN\0|in (r_prep) comparison_12\NN\635850|NONE (l_prep) in_15\IN\13603305|with (l_pobj) treatment_17\NN\654885|NONE (l_prep) of_18\IN\0|the (l_pobj) dysmenorrhea_20\NN\14322699|NONE
D005996_D004412 NONE trinitrate_4\NN\0|NONE (l_prep) for_7\IN\0|glyceryl|with (l_pobj) treatment_9\NN\654885|NONE (l_prep) of_10\IN\0|the (l_pobj) dysmenorrhea_12\NN\14322699|NONE
D005996_D004412 NONE trinitrate_13\NN\0|NONE (r_pobj) of_11\IN\0|the (r_prep) efficacy_10\NN\5199286|to|in (r_dobj) determine_8\VB\0|.|aim (l_prep) in_22\IN\13603305|to|efficacy (l_pobj) resolution_24\NN\6470073|NONE (l_prep) of_25\IN\0|the|in (l_pobj) dysmenorrhea_27\NN\14322699|NONE
D005996_D004412 NONE gtn_15\NNP\0|glyceryl|donor|,|,|(|) (r_appos) trinitrate_13\NN\0|NONE (r_pobj) of_11\IN\0|the (r_prep) efficacy_10\NN\5199286|to|in (r_dobj) determine_8\VB\0|.|aim (l_prep) in_22\IN\13603305|to|efficacy (l_pobj) resolution_24\NN\6470073|NONE (l_prep) of_25\IN\0|the|in (l_pobj) dysmenorrhea_27\NN\14322699|NONE
D005996_D004412 NONE gtn_4\NNP\0|that|efficacy|by (r_nsubj) has_5\VBZ\13888491|findings|. (l_prep) by_11\IN\0|GTN|that|efficacy (l_pobj) comparison_12\NN\635850|NONE (l_prep) in_15\IN\13603305|with (l_pobj) treatment_17\NN\654885|NONE (l_prep) of_18\IN\0|the (l_pobj) dysmenorrhea_20\NN\14322699|NONE
D011453_D004412 NONE prostaglandins_16\NNS\5414534|NONE (r_pobj) of_14\IN\0|a (r_prep) hypersecretion_13\NN\13553916|NONE (r_pobj) by_11\IN\0|NONE (r_agent) caused_10\VBN\1617192|uterine|painful (r_acl) contractility_9\NN\5200169|NONE (r_pobj) by_6\IN\0|NONE (r_agent) characterized_5\VBN\609683|a (r_acl) syndrome_4\NN\5870365|dysmenorrhea|.|are (r_attr) is_2\VBZ\0|NONE (l_nsubj) dysmenorrhea_1\NN\14322699|.|syndrome|are
D004008_D017699 NONE dcf_2\NNP\0|However|,|remained|.|,|be (r_nsubj) continued_3\VBD\2367363|NONE (l_xcomp) be_5\VB\14625458|However|,|DCF|remained|.|, (l_acomp) effective_6\JJ\0|to (l_prep) in_7\IN\13603305|NONE (l_pcomp) reducing_8\VBG\13447361|NONE (l_dobj) pain_10\NN\14299637|for
D005996_D017699 NONE gtn_16\NNP\0|NONE (r_compound) scores_17\NNS\13757724|(|:|whereas|stable|GTN|after|and|higher|after (r_nsubj) remained_18\VBD\2604760|However|,|DCF|.|,|be (r_advcl) continued_3\VBD\2367363|NONE (l_xcomp) be_5\VB\14625458|However|,|DCF|remained|.|, (l_acomp) effective_6\JJ\0|to (l_prep) in_7\IN\13603305|NONE (l_pcomp) reducing_8\VBG\13447361|NONE (l_dobj) pain_10\NN\14299637|for
D005996_D017699 NONE gtn_38\NNP\0|(|:|whereas|stable|after|scores|and|higher|after (r_npadvmod) remained_18\VBD\2604760|However|,|DCF|.|,|be (r_advcl) continued_3\VBD\2367363|NONE (l_xcomp) be_5\VB\14625458|However|,|DCF|remained|.|, (l_acomp) effective_6\JJ\0|to (l_prep) in_7\IN\13603305|NONE (l_pcomp) reducing_8\VBG\13447361|NONE (l_dobj) pain_10\NN\14299637|for
D005996_D017699 NONE gtn_54\NNP\0|.|,|after|;|;|.|.|.|DFC|DFC|:|+/|. (r_appos) gtn_38\NNP\0|(|:|whereas|stable|after|scores|and|higher|after (r_npadvmod) remained_18\VBD\2604760|However|,|DCF|.|,|be (r_advcl) continued_3\VBD\2367363|NONE (l_xcomp) be_5\VB\14625458|However|,|DCF|remained|.|, (l_acomp) effective_6\JJ\0|to (l_prep) in_7\IN\13603305|NONE (l_pcomp) reducing_8\VBG\13447361|NONE (l_dobj) pain_10\NN\14299637|for
24190587
D018817_D008107 NONE ecstasy_0\NNP\13985818|.|drug (r_nsubj) is_4\VBZ\0|NONE (l_attr) drug_7\NN\14778436|.|Ecstasy (l_relcl) associated_11\VBN\628491|psychostimulant|a (l_prep) with_12\IN\0|is|increasingly|which (l_pobj) dysfunction_14\NN\14204950|NONE
D018817_D008107 NONE mdma_2\NNP\3054098|NONE (r_appos) ecstasy_0\NNP\13985818|.|drug (r_nsubj) is_4\VBZ\0|NONE (l_attr) drug_7\NN\14778436|.|Ecstasy (l_relcl) associated_11\VBN\628491|psychostimulant|a (l_prep) with_12\IN\0|is|increasingly|which (l_pobj) dysfunction_14\NN\14204950|NONE
D018817_D003866 CID ecstasy_14\NN\13985818| (r_npadvmod) polydrug_16\NN\0|recreational (r_compound) users_17\NNS\7846|NONE (r_pobj) in_12\IN\13603305|previous (r_prep) observations_11\NNS\996969|NONE (r_pobj) with_9\IN\0|NONE (r_prep) line_8\NN\8426461|NONE (r_pobj) in_7\IN\13603305|.|increases (r_prep) are_6\VBP\13600404|NONE (l_nsubj) increases_1\NNS\13576355|.|in (l_prep) in_2\IN\13603305|The (l_pobj) anxiety_3\NN\14373582|NONE (l_conj) depression_5\NN\14373582|and
D018817_D001008 NONE ecstasy_14\NN\13985818| (r_npadvmod) polydrug_16\NN\0|recreational (r_compound) users_17\NNS\7846|NONE (r_pobj) in_12\IN\13603305|previous (r_prep) observations_11\NNS\996969|NONE (r_pobj) with_9\IN\0|NONE (r_prep) line_8\NN\8426461|NONE (r_pobj) in_7\IN\13603305|.|increases (r_prep) are_6\VBP\13600404|NONE (l_nsubj) increases_1\NNS\13576355|.|in (l_prep) in_2\IN\13603305|The (l_pobj) anxiety_3\NN\14373582|NONE
35781
D010423_D002375 NONE pentazocine_18\NN\2707683|and (r_conj) fentanyl_16\NN\2707683|, (r_conj) codeine_14\NN\2707683|, (r_conj) morphine_12\NN\2707683|NONE (r_pobj) by_11\IN\0|NONE (r_agent) induced_10\VBN\1627355|NONE (r_acl) analgesia_9\NN\14034177|NONE (r_pobj) on_8\IN\0|NONE (r_prep) xylometazoline_7\NN\0|and|, (r_conj) naphazoline_5\NN\3809939|, (r_conj) clonidine_3\NN\2721160|on|and (r_pobj) of_2\IN\0|The (l_conj) on_21\IN\0|clonidine|and (l_pobj) effect_23\NN\34213|NONE (l_amod) cataleptic_22\JJ\10490141|of
D003000_D002375 CID clonidine_3\NN\2721160|on|and (r_pobj) of_2\IN\0|The (l_conj) on_21\IN\0|clonidine|and (l_pobj) effect_23\NN\34213|NONE (l_amod) cataleptic_22\JJ\10490141|of
D003000_D002375 CID clonidine_5\NN\2721160|NONE (r_pobj) by_4\IN\0|and|decreased|catalepsy|was|. (r_agent) increased_3\VBN\169651|NONE (l_nsubjpass) catalepsy_1\NN\14023236|and|decreased|by|was|.
D009638_D002375 NONE na_8\NNP\14625458|central (r_compound) receptors_9\NNS\5225602|NONE (r_dobj) stimulating_6\VBG\137313|three (r_acl) drugs_5\NNS\14778436|that|enhanced|affect|and (r_nsubj) failed_10\VBD\0|was|It|. (l_conj) enhanced_22\VBD\227165|that|affect|drugs|and (l_dobj) catalepsy_23\NN\14023236|they
D003061_D002375 CID codeine_14\NN\2707683|, (r_conj) morphine_12\NN\2707683|NONE (r_pobj) by_11\IN\0|NONE (r_agent) induced_10\VBN\1627355|NONE (r_acl) analgesia_9\NN\14034177|NONE (r_pobj) on_8\IN\0|NONE (r_prep) xylometazoline_7\NN\0|and|, (r_conj) naphazoline_5\NN\3809939|, (r_conj) clonidine_3\NN\2721160|on|and (r_pobj) of_2\IN\0|The (l_conj) on_21\IN\0|clonidine|and (l_pobj) effect_23\NN\34213|NONE (l_amod) cataleptic_22\JJ\10490141|of
D003061_D002375 CID codine_27\NN\0|, (r_conj) morphine_25\NN\2707683|NONE (r_pobj) of_24\IN\0|cataleptic (r_prep) effect_23\NN\34213|NONE (l_amod) cataleptic_22\JJ\10490141|of
D003061_D002375 CID codeine_0\NNP\2707683|NONE (r_compound) catalepsy_1\NN\14023236|and|decreased|by|was|.
C009695_D002375 CID xylometazoline_7\NN\0|and|, (r_conj) naphazoline_5\NN\3809939|, (r_conj) clonidine_3\NN\2721160|on|and (r_pobj) of_2\IN\0|The (l_conj) on_21\IN\0|clonidine|and (l_pobj) effect_23\NN\34213|NONE (l_amod) cataleptic_22\JJ\10490141|of
C009695_D002375 CID xylometazoline_11\NN\0|and (r_conj) naphazoline_9\NN\3809939|NONE (r_pobj) by_8\IN\0|NONE (r_prep) decreased_7\VBD\169651|and|catalepsy|by|was|. (r_conj) increased_3\VBN\169651|NONE (l_nsubjpass) catalepsy_1\NN\14023236|and|decreased|by|was|.
D009020_D002375 CID morphine_12\NN\2707683|NONE (r_pobj) by_11\IN\0|NONE (r_agent) induced_10\VBN\1627355|NONE (r_acl) analgesia_9\NN\14034177|NONE (r_pobj) on_8\IN\0|NONE (r_prep) xylometazoline_7\NN\0|and|, (r_conj) naphazoline_5\NN\3809939|, (r_conj) clonidine_3\NN\2721160|on|and (r_pobj) of_2\IN\0|The (l_conj) on_21\IN\0|clonidine|and (l_pobj) effect_23\NN\34213|NONE (l_amod) cataleptic_22\JJ\10490141|of
D009020_D002375 CID morphine_25\NN\2707683|NONE (r_pobj) of_24\IN\0|cataleptic (r_prep) effect_23\NN\34213|NONE (l_amod) cataleptic_22\JJ\10490141|of
D009020_D002375 CID morphine_26\NN\2707683|NONE (r_pobj) by_25\IN\0|NONE (r_agent) induced_24\VBN\1627355|NONE (r_acl) catalepsy_23\NN\14023236|they
D009278_D002375 CID naphazoline_5\NN\3809939|, (r_conj) clonidine_3\NN\2721160|on|and (r_pobj) of_2\IN\0|The (l_conj) on_21\IN\0|clonidine|and (l_pobj) effect_23\NN\34213|NONE (l_amod) cataleptic_22\JJ\10490141|of
D009278_D002375 CID naphazoline_9\NN\3809939|NONE (r_pobj) by_8\IN\0|NONE (r_prep) decreased_7\VBD\169651|and|catalepsy|by|was|. (r_conj) increased_3\VBN\169651|NONE (l_nsubjpass) catalepsy_1\NN\14023236|and|decreased|by|was|.
D005283_D002375 CID fentanyl_16\NN\2707683|, (r_conj) codeine_14\NN\2707683|, (r_conj) morphine_12\NN\2707683|NONE (r_pobj) by_11\IN\0|NONE (r_agent) induced_10\VBN\1627355|NONE (r_acl) analgesia_9\NN\14034177|NONE (r_pobj) on_8\IN\0|NONE (r_prep) xylometazoline_7\NN\0|and|, (r_conj) naphazoline_5\NN\3809939|, (r_conj) clonidine_3\NN\2721160|on|and (r_pobj) of_2\IN\0|The (l_conj) on_21\IN\0|clonidine|and (l_pobj) effect_23\NN\34213|NONE (l_amod) cataleptic_22\JJ\10490141|of
D005283_D002375 CID fentanyl_29\NN\2707683|and (r_conj) codine_27\NN\0|, (r_conj) morphine_25\NN\2707683|NONE (r_pobj) of_24\IN\0|cataleptic (r_prep) effect_23\NN\34213|NONE (l_amod) cataleptic_22\JJ\10490141|of
D005283_D002375 CID fentanyl_28\NN\2707683|and (r_conj) morphine_26\NN\2707683|NONE (r_pobj) by_25\IN\0|NONE (r_agent) induced_24\VBN\1627355|NONE (r_acl) catalepsy_23\NN\14023236|they
6310832
D016572_D016470 NONE cyclosporine_3\NN\0|NONE (r_pobj) on_2\IN\0|Renal (r_prep) patients_1\NNS\9898892|.|bacteremias (r_nsubj) had_4\VBD\0|NONE (l_dobj) bacteremias_7\NNS\14204950|.|patients
D001379_D013203 NONE aza_0\NNP\0|NONE (r_compound) patients_1\NNS\9898892|occurred|and|infections|, (r_nsubj) had_2\VBD\0|NONE (l_dobj) infections_6\NNS\14052046|occurred|patients|and|,
D016572_D003586 NONE cyclosporine_2\JJ\0|the (r_compound) patients_3\NNS\9898892|NONE (r_pobj) of_0\IN\0| (r_prep) %_6\NN\0|,|symptoms|. (r_nsubj) had_7\VBD\0|NONE (l_dobj) symptoms_8\NNS\5823932|,|%|. (l_acl) related_9\VBN\628491|NONE (l_prep) to_10\IN\0|NONE (l_pobj) infection_12\NN\14052046|NONE
D016572_D007239 CID cyclosporine_12\NN\0|NONE (r_pobj) on_11\IN\0|transplant (r_prep) recipients_10\NNS\9764201|and|, (r_conj) heart_5\NN\5919034|, (r_conj) kidney_3\NN\5333259|NONE (r_pobj) in_2\IN\13603305|Early|. (r_prep) infections_1\NNS\14052046|NONE
D016572_D007239 CID cyclosporine_27\NN\0|the|randomized (r_compound) patients_28\NNS\9898892|NONE (r_pobj) than_24\IN\0|patients|.|infections (r_prep) had_4\VBD\0|NONE (l_dobj) infections_7\NNS\14052046|patients|.|than
D016572_D007239 CID cyclosporine_27\NN\0|the|randomized (r_compound) patients_28\NNS\9898892|NONE (r_pobj) than_24\IN\0|patients|.|infections (r_prep) had_4\VBD\0|NONE (l_dobj) infections_7\NNS\14052046|patients|.|than (l_appos) p_9\NN\14622893|(|(|overall|)|P (l_conj) infections_17\NNS\14052046|)|.|and
D016572_D007239 CID cyclosporine_8\JJ\0|renal (r_nmod) patients_10\NNS\9898892|NONE (r_pobj) than_7\IN\0|infections|more|but (r_prep) infections_6\NNS\14052046|patients|.
D016572_D007239 CID cyclosporine_8\JJ\0|renal (r_nmod) patients_10\NNS\9898892|NONE (r_pobj) than_7\IN\0|infections|more|but (r_prep) infections_6\NNS\14052046|patients|. (l_conj) infections_13\NNS\14052046|than|more|but
D016572_D007239 CID cyclosporine_10\NN\0|NONE (r_pobj) on_9\IN\0|transplant|renal (r_prep) patients_8\NNS\9898892|NONE (r_pobj) in_5\IN\13603305|infectious|no (r_prep) deaths_4\NNS\7296428|There|played|but|, (r_attr) were_1\VBD\0|NONE (l_conj) played_16\VBD\1072262|There|but|deaths|, (l_nsubj) infection_15\NN\14052046|out|.|in|role|out
D016572_D007239 CID cyclosporine_6\NN\0| (r_npadvmod) treated_8\VBN\2376958|renal (r_amod) patients_10\NNS\9898892|NONE (r_pobj) in_5\IN\13603305|infections|than|common|. (r_prep) were_2\VBD\0|NONE (l_nsubj) infections_1\NNS\14052046|than|in|common|.
D016572_D020031 NONE cyclosporine_14\NN\0|studied| (r_compound) patients_15\NNS\9898892|NONE (r_pobj) of_12\IN\0| (r_prep) %_11\NN\0|NONE (r_pobj) in_9\IN\13603305|was|.|evidence (r_prep) found_8\VBN\13279262|NONE (l_nsubjpass) evidence_1\NN\5816287|was|.|in (l_prep) for_2\IN\0|Serological (l_pobj) infection_6\NN\14052046|NONE
D001379_D009181 NONE aza_0\NNP\0|NONE (r_compound) patients_1\NNS\9898892|occurred|and|infections|, (r_nsubj) had_2\VBD\0|NONE (l_conj) occurred_23\VBD\0|patients|and|infections|, (l_nsubj) infections_22\NNS\14052046|in|.
D001379_D007239 CID aza_2\NNP\0|The|randomized (r_compound) patients_3\NNS\9898892|.|infections|than (r_nsubj) had_4\VBD\0|NONE (l_dobj) infections_7\NNS\14052046|patients|.|than
D001379_D007239 CID aza_2\NNP\0|The|randomized (r_compound) patients_3\NNS\9898892|.|infections|than (r_nsubj) had_4\VBD\0|NONE (l_dobj) infections_7\NNS\14052046|patients|.|than (l_appos) p_9\NN\14622893|(|(|overall|)|P (l_conj) infections_17\NNS\14052046|)|.|and
D001379_D007239 CID aza_16\NNP\0|the|renal (r_nmod) patients_18\NNS\9898892|NONE (r_pobj) than_14\IN\0|fewer (r_prep) infections_13\NNS\14052046|than|more|but (r_conj) infections_6\NNS\14052046|patients|.
D001379_D007239 CID aza_16\NNP\0|the|renal (r_nmod) patients_18\NNS\9898892|NONE (r_pobj) than_14\IN\0|fewer (r_prep) infections_13\NNS\14052046|than|more|but
D001379_D007239 CID aza_12\NNP\0|or (r_conj) cyclosporine_10\NN\0|NONE (r_pobj) on_9\IN\0|transplant|renal (r_prep) patients_8\NNS\9898892|NONE (r_pobj) in_5\IN\13603305|infectious|no (r_prep) deaths_4\NNS\7296428|There|played|but|, (r_attr) were_1\VBD\0|NONE (l_conj) played_16\VBD\1072262|There|but|deaths|, (l_nsubj) infection_15\NN\14052046|out|.|in|role|out
D001379_D007239 CID aza_13\NNP\0| (r_npadvmod) treated_15\VBN\2376958|(|)|P (r_amod) patients_16\NNS\9898892|NONE (r_pobj) in_12\IN\13603305|NONE (r_prep) than_11\IN\0|infections|in|common|. (r_prep) were_2\VBD\0|NONE (l_nsubj) infections_1\NNS\14052046|than|in|common|.
8096565
D018170_D003027 NONE sumatriptan_15\NNP\0|NONE (r_pobj) of_14\IN\0|NONE (r_prep) administration_13\NN\1133281|NONE (r_pobj) after_12\IN\0|acute|subcutaneously|myocardial|an|for (r_prep) infarction_11\NN\14204950|NONE (l_prep) for_19\IN\0|acute|subcutaneously|myocardial|an|after (l_pobj) headache_21\NN\5829480|NONE
D018170_D009203 CID sumatriptan_4\NNP\0|NONE (r_pobj) with_3\IN\0|Transmural|myocardial|. (r_prep) infarction_2\NN\14204950|NONE
D018170_D009203 CID sumatriptan_15\NNP\0|NONE (r_pobj) of_14\IN\0|NONE (r_prep) administration_13\NN\1133281|NONE (r_pobj) after_12\IN\0|acute|subcutaneously|myocardial|an|for (r_prep) infarction_11\NN\14204950|NONE
16876986
D010862_D012640 CID pilocarpine_6\NN\14712692| (r_npadvmod) induced_8\VBN\1627355|in|subsequent (r_amod) seizures_9\NNS\14081375|NONE
D010862_D012640 CID pilocarpine_6\NN\14712692|in (r_amod) injections_7\NNS\320852|NONE (r_pobj) by_5\IN\0|were|.|,|Thereafter|seizures (r_agent) induced_4\VBN\1627355|NONE (l_nsubjpass) seizures_2\NNS\14081375|were|.|,|by|Thereafter
946593
D008727_D002493 NONE methothexate_34\NN\0|cerebrospinal|elevated|;|related|presence (r_compound) concentration_35\NN\4916342|,|cerebrospinal|abnormal|and|related|leakage|; (r_appos) dynamics_15\NNS\6100236|The|following (l_acl) related_16\VBN\628491|,|cerebrospinal|abnormal|and|leakage|;|concentration (l_prep) to_17\IN\0|NONE (l_pobj) presence_19\NN\13954253|NONE (l_prep) of_20\IN\0|the (l_pobj) leukemia_24\NN\14239918|NONE
D008727_D002493 NONE methotrexate_46\NN\2722166|high|based (r_compound) doses_47\NNS\3740161|NONE (r_pobj) to_43\TO\0|and|to (r_conj) related_36\VBN\628491|cerebrospinal|elevated|methothexate|;|presence (r_acl) concentration_35\NN\4916342|,|cerebrospinal|abnormal|and|related|leakage|; (r_appos) dynamics_15\NNS\6100236|The|following (l_acl) related_16\VBN\628491|,|cerebrospinal|abnormal|and|leakage|;|concentration (l_prep) to_17\IN\0|NONE (l_pobj) presence_19\NN\13954253|NONE (l_prep) of_20\IN\0|the (l_pobj) leukemia_24\NN\14239918|NONE
D008727_D002493 NONE methotrexate_68\NN\2722166|diluents|available|and (r_compound) preparations_69\NNS\407535|NONE (r_pobj) in_65\IN\13603305|of|and|;|the|use (r_prep) presence_61\NN\13954253|cerebrospinal|elevated|methothexate|;|related (r_conj) concentration_35\NN\4916342|,|cerebrospinal|abnormal|and|related|leakage|; (r_appos) dynamics_15\NNS\6100236|The|following (l_acl) related_16\VBN\628491|,|cerebrospinal|abnormal|and|leakage|;|concentration (l_prep) to_17\IN\0|NONE (l_pobj) presence_19\NN\13954253|NONE (l_prep) of_20\IN\0|the (l_pobj) leukemia_24\NN\14239918|NONE
D008727_D002493 NONE methotrexate_77\NN\2722166|of (r_compound) diluents_78\NNS\14778436|NONE (r_pobj) of_76\IN\0|the (r_prep) use_75\NN\407535|in|of|and|;|the (r_conj) presence_61\NN\13954253|cerebrospinal|elevated|methothexate|;|related (r_conj) concentration_35\NN\4916342|,|cerebrospinal|abnormal|and|related|leakage|; (r_appos) dynamics_15\NNS\6100236|The|following (l_acl) related_16\VBN\628491|,|cerebrospinal|abnormal|and|leakage|;|concentration (l_prep) to_17\IN\0|NONE (l_pobj) presence_19\NN\13954253|NONE (l_prep) of_20\IN\0|the (l_pobj) leukemia_24\NN\14239918|NONE
D008727_D002493 NONE methotrexate_12\NNP\2722166|NONE (r_pobj) of_11\IN\0|lower (r_prep) doses_10\NNS\3740161|in|in|, (r_dobj) employing_8\VBG\0|NONE (l_prep) in_13\IN\13603305|doses|in|, (l_pobj) presence_15\NN\13954253|NONE (l_prep) of_16\IN\0|the (l_pobj) leukemia_20\NN\14239918|NONE
D008727_D020258 NONE methothexate_34\NN\0|cerebrospinal|elevated|;|related|presence (r_compound) concentration_35\NN\4916342|,|cerebrospinal|abnormal|and|related|leakage|; (l_conj) presence_61\NN\13954253|cerebrospinal|elevated|methothexate|;|related (l_prep) of_62\IN\0|in|and|;|the|use (l_pobj) preservatives_64\NNS\14818238|NONE (l_amod) neurotoxic_63\JJ\0|NONE
D008727_D020258 NONE methotrexate_46\NN\2722166|high|based (r_compound) doses_47\NNS\3740161|NONE (r_pobj) to_43\TO\0|and|to (r_conj) related_36\VBN\628491|cerebrospinal|elevated|methothexate|;|presence (r_acl) concentration_35\NN\4916342|,|cerebrospinal|abnormal|and|related|leakage|; (l_conj) presence_61\NN\13954253|cerebrospinal|elevated|methothexate|;|related (l_prep) of_62\IN\0|in|and|;|the|use (l_pobj) preservatives_64\NNS\14818238|NONE (l_amod) neurotoxic_63\JJ\0|NONE
D008727_D020258 NONE methotrexate_68\NN\2722166|diluents|available|and (r_compound) preparations_69\NNS\407535|NONE (r_pobj) in_65\IN\13603305|of|and|;|the|use (r_prep) presence_61\NN\13954253|cerebrospinal|elevated|methothexate|;|related (l_prep) of_62\IN\0|in|and|;|the|use (l_pobj) preservatives_64\NNS\14818238|NONE (l_amod) neurotoxic_63\JJ\0|NONE
D008727_D020258 NONE methotrexate_77\NN\2722166|of (r_compound) diluents_78\NNS\14778436|NONE (r_pobj) of_76\IN\0|the (r_prep) use_75\NN\407535|in|of|and|;|the (r_conj) presence_61\NN\13954253|cerebrospinal|elevated|methothexate|;|related (l_prep) of_62\IN\0|in|and|;|the|use (l_pobj) preservatives_64\NNS\14818238|NONE (l_amod) neurotoxic_63\JJ\0|NONE
D008727_D020258 NONE methotrexate_12\NNP\2722166|NONE (r_pobj) of_11\IN\0|lower (r_prep) doses_10\NNS\3740161|in|in|, (r_dobj) employing_8\VBG\0|NONE (r_pcomp) by_7\IN\0|incidence|be|.|may (r_prep) reduced_6\VBN\441445|NONE (l_nsubjpass) incidence_1\NN\13821570|by|be|.|may (l_prep) of_2\IN\0|The (l_pobj) neurotoxicity_3\NN\0|NONE
D008727_D020258 NONE methotrexate_5\NNP\2722166|cerebruspinal (r_compound) levels_6\NNS\4916342|NONE (r_pobj) of_2\IN\0|Periodic (r_prep) monitoring_1\NN\879759|may|.|predictive (r_nsubj) be_8\VB\14625458|NONE (l_acomp) predictive_9\JJ\0|monitoring|may|. (l_prep) of_10\IN\0|NONE (l_pobj) development_12\NN\248977|NONE (l_prep) of_13\IN\0|the (l_pobj) neurotoxicity_15\NN\0|NONE
D008727_D064420 NONE methotrexate_3\NNP\2722166|deficiency|, (r_compound) contaminants_4\NNS\14580897|NONE (r_pobj) of_2\IN\0|in|The (r_prep) role_1\NN\719494|.|unclear (l_prep) in_13\IN\13603305|The|of (l_pobj) pathogenesis_15\NN\13533470|NONE (l_prep) of_16\IN\0|the (l_pobj) toxicity_19\NN\13576101|NONE
D008727_D064420 NONE methotrexate_18\NNP\2722166|intrathecal (r_compound) toxicity_19\NN\13576101|NONE
D008727_D010264 CID methotrexate_3\NN\2722166|NONE (r_dobj) following_1\VBG\8180190|report (r_prep) paraplegia_0\NNP\14558226|NONE
D008727_D010264 CID methotrexate_10\NNP\2722166|NONE (r_pobj) of_9\IN\0|the|intrathecal (r_prep) instillation_8\NN\320852|NONE (r_pobj) following_5\VBG\8180190|paraplegia|who (r_prep) developed_3\VBD\1753788|A (l_dobj) paraplegia_4\NNS\14558226|following|who
D008727_C536409 NONE methotrexate_3\NNP\2722166|deficiency|, (r_compound) contaminants_4\NNS\14580897|NONE (l_conj) deficiency_8\NN\14449126|,|methotrexate
D008727_C536409 NONE methotrexate_18\NNP\2722166|intrathecal (r_compound) toxicity_19\NN\13576101|NONE (r_pobj) of_16\IN\0|the (r_prep) pathogenesis_15\NN\13533470|NONE (r_pobj) in_13\IN\13603305|The|of (r_prep) role_1\NN\719494|.|unclear (l_prep) of_2\IN\0|in|The (l_pobj) contaminants_4\NNS\14580897|NONE (l_conj) deficiency_8\NN\14449126|,|methotrexate
16034922
D004967_D020521 CID oestrogen_3\NN\14745635|term (r_compound) ht_6\NNP\0|risk|significantly|also|. (r_nsubj) increased_9\VBD\169651|NONE (l_dobj) risk_11\NN\14541044|significantly|HT|also|. (l_prep) of_12\IN\0|the (l_pobj) disease_16\NN\14061805|NONE (l_nmod) stroke_13\NN\556313|NONE
D004967_D005705 CID oestrogen_3\NN\14745635|term (r_compound) ht_6\NNP\0|risk|significantly|also|. (r_nsubj) increased_9\VBD\169651|NONE (l_dobj) risk_11\NN\14541044|significantly|HT|also|. (l_prep) of_12\IN\0|the (l_pobj) disease_16\NN\14061805|NONE
17445520
D002110_D003865 NONE caffeine_51\NN\14712692|NONE (r_compound) challenge_52\NN\13927383|oral|an (r_compound) test_53\NN\5798043|NONE (r_pobj) by_48\IN\0|panic (r_prep) attacks_47\NNS\955060|NONE (r_pobj) of_45\IN\0|the (r_prep) induction_44\NN\7450842|NONE (r_pobj) to_42\IN\0|similar|a (r_prep) way_41\NN\4916342|NONE (r_pobj) in_38\IN\13603305|if|patients (r_prep) respond_37\VBP\2367363|to (l_nsubj) patients_6\NNS\9898892|if|in (l_prep) with_7\IN\0|NONE (l_pobj) disorder_9\NN\14034177|NONE (l_conj) patients_14\NNS\9898892|(|panic|and|)|PD (l_prep) with_15\IN\0|NONE (l_pobj) depression_17\NN\14373582|NONE
D002110_D003865 NONE caffeine_51\NN\14712692|NONE (r_compound) challenge_52\NN\13927383|oral|an (r_compound) test_53\NN\5798043|NONE (r_pobj) by_48\IN\0|panic (r_prep) attacks_47\NNS\955060|NONE (r_pobj) of_45\IN\0|the (r_prep) induction_44\NN\7450842|NONE (r_pobj) to_42\IN\0|similar|a (r_prep) way_41\NN\4916342|NONE (r_pobj) in_38\IN\13603305|if|patients (r_prep) respond_37\VBP\2367363|to (l_nsubj) patients_6\NNS\9898892|if|in (l_prep) with_7\IN\0|NONE (l_pobj) disorder_9\NN\14034177|NONE (l_conj) patients_14\NNS\9898892|(|panic|and|)|PD (l_prep) with_15\IN\0|NONE (l_pobj) depression_17\NN\14373582|NONE (l_prep) with_18\IN\0|major (l_pobj) attacks_20\NNS\955060|NONE (l_appos) mdp_22\NNP\0|(|)|panic|)|Diagnostic|(
D002110_D003865 NONE caffeine_56\NN\14712692|)|chi()(|the|mg|challenge|)|,|P|.|( (r_compound) test_58\NN\5798043|NONE (r_pobj) after_53\IN\0|total|attack|. (r_prep) had_49\VBD\0|NONE (l_nsubj) total_1\NN\3553|after|attack|. (l_prep) of_2\IN\0|A (l_pobj) %_4\NN\0|NONE (l_prep) of_22\IN\0|%|,|(|n|and|,|of|of|)||)|%|)|.|,|% (l_pobj) patients_23\NNS\9898892|NONE (l_prep) with_24\IN\0|NONE (l_pobj) mdp_25\NNP\0|NONE
D002110_D003865 NONE caffeine_56\NN\14712692|)|chi()(|the|mg|challenge|)|,|P|.|( (r_compound) test_58\NN\5798043|NONE (r_pobj) after_53\IN\0|total|attack|. (r_prep) had_49\VBD\0|NONE (l_nsubj) total_1\NN\3553|after|attack|. (l_prep) of_2\IN\0|A (l_pobj) %_4\NN\0|NONE (l_prep) of_34\IN\0|%|,|(|n|and|,|of|)||)|%|of|)|.|,|% (l_pobj) patients_35\NNS\9898892|NONE (l_prep) with_36\IN\0|NONE (l_pobj) md_37\NNP\14622893|NONE
D002110_D003865 NONE caffeine_10\NN\14712692|NONE (r_pobj) to_9\IN\0|more|were (r_prep) sensitive_8\JJ\10488309|.|patients (r_acomp) were_6\VBD\0|NONE (l_nsubj) patients_1\NNS\9898892|sensitive|. (l_prep) with_2\IN\0|The (l_pobj) pd_3\NNP\14625458|NONE (l_conj) mdp_5\NNP\0|and
D002110_D003865 NONE caffeine_10\NN\14712692|NONE (r_pobj) to_9\IN\0|more|were (r_prep) sensitive_8\JJ\10488309|.|patients (l_advcl) were_12\VBD\0|to|more (l_nsubj) patients_13\NNS\9898892|than (l_prep) with_14\IN\0|NONE (l_pobj) md_15\NNP\14622893|NONE
D002110_D003865 NONE caffeine_26\NN\14712692|NONE (r_compound) challenge_27\NN\13927383|an|oral (r_compound) test_28\NN\5798043|NONE (r_pobj) to_23\IN\0|NONE (r_prep) hyperreactivity_22\NN\0|that|there|matter|association|and|,|associated (r_conj) is_5\VBZ\0|.|data (l_advcl) associated_15\VBN\628491|that|there|matter|association|and|,|hyperreactivity (l_prep) with_16\IN\0|if (l_pobj) pd_17\NNP\14625458|NONE (l_conj) mdp_19\NNP\0|or
D002110_D003866 NONE caffeine_0\NN\14712692|.|in|challenge (r_amod) test_2\NN\5798043|NONE (l_prep) in_3\IN\13603305|.|Caffeine|challenge (l_pobj) disorder_5\NN\14034177|NONE (l_conj) depression_7\NN\14373582|and|panic
D002110_D001008 NONE caffeine_17\NN\14712692|applied|,|In|.|were|in (r_nsubjpass) administered_28\VBN\2436349|NONE (l_prep) in_29\IN\13603305|applied|,|In|caffeine|.|were (l_pobj) scales_35\NNS\7260623|NONE (l_nmod) form_32\NN\6286395|a (l_conj) anxiety_34\NN\14373582|and|coffee
D002110_D001008 NONE caffeine_20\NN\14712692| (r_npadvmod) free_22\JJ\7942152|)|(|placebo|a (r_amod) solution_26\NN\14586258|and|mg (r_conj) caffeine_17\NN\14712692|applied|,|In|.|were|in (r_nsubjpass) administered_28\VBN\2436349|NONE (l_prep) in_29\IN\13603305|applied|,|In|caffeine|.|were (l_pobj) scales_35\NNS\7260623|NONE (l_nmod) form_32\NN\6286395|a (l_conj) anxiety_34\NN\14373582|and|coffee
D002110_D016584 CID caffeine_0\NN\14712692|.|in|challenge (r_amod) test_2\NN\5798043|NONE (l_prep) in_3\IN\13603305|.|Caffeine|challenge (l_pobj) disorder_5\NN\14034177|NONE
D002110_D016584 CID caffeine_0\NN\14712692|.|in|challenge (r_amod) test_2\NN\5798043|NONE (l_prep) in_3\IN\13603305|.|Caffeine|challenge (l_pobj) disorder_5\NN\14034177|NONE (l_conj) depression_7\NN\14373582|and|panic (l_prep) with_8\IN\0|NONE (l_pobj) attacks_10\NNS\955060|NONE
D002110_D016584 CID caffeine_51\NN\14712692|NONE (r_compound) challenge_52\NN\13927383|oral|an (r_compound) test_53\NN\5798043|NONE (r_pobj) by_48\IN\0|panic (r_prep) attacks_47\NNS\955060|NONE (r_pobj) of_45\IN\0|the (r_prep) induction_44\NN\7450842|NONE (r_pobj) to_42\IN\0|similar|a (r_prep) way_41\NN\4916342|NONE (r_pobj) in_38\IN\13603305|if|patients (r_prep) respond_37\VBP\2367363|to (l_nsubj) patients_6\NNS\9898892|if|in (l_prep) with_7\IN\0|NONE (l_pobj) disorder_9\NN\14034177|NONE
D002110_D016584 CID caffeine_51\NN\14712692|NONE (r_compound) challenge_52\NN\13927383|oral|an (r_compound) test_53\NN\5798043|NONE (r_pobj) by_48\IN\0|panic (r_prep) attacks_47\NNS\955060|NONE (r_pobj) of_45\IN\0|the (r_prep) induction_44\NN\7450842|NONE (r_pobj) to_42\IN\0|similar|a (r_prep) way_41\NN\4916342|NONE (r_pobj) in_38\IN\13603305|if|patients (r_prep) respond_37\VBP\2367363|to (l_nsubj) patients_6\NNS\9898892|if|in (l_prep) with_7\IN\0|NONE (l_pobj) disorder_9\NN\14034177|NONE (l_appos) pd_11\NNP\14625458|(|panic|and|patients|)
D002110_D016584 CID caffeine_51\NN\14712692|NONE (r_compound) challenge_52\NN\13927383|oral|an (r_compound) test_53\NN\5798043|NONE (r_pobj) by_48\IN\0|panic (r_prep) attacks_47\NNS\955060|NONE (r_pobj) of_45\IN\0|the (r_prep) induction_44\NN\7450842|NONE (r_pobj) to_42\IN\0|similar|a (r_prep) way_41\NN\4916342|NONE (r_pobj) in_38\IN\13603305|if|patients (r_prep) respond_37\VBP\2367363|to (l_nsubj) patients_6\NNS\9898892|if|in (l_prep) with_7\IN\0|NONE (l_pobj) disorder_9\NN\14034177|NONE (l_conj) patients_14\NNS\9898892|(|panic|and|)|PD (l_prep) with_15\IN\0|NONE (l_pobj) depression_17\NN\14373582|NONE (l_prep) with_18\IN\0|major (l_pobj) attacks_20\NNS\955060|NONE
D002110_D016584 CID caffeine_51\NN\14712692|NONE (r_compound) challenge_52\NN\13927383|oral|an (r_compound) test_53\NN\5798043|NONE (r_pobj) by_48\IN\0|panic (r_prep) attacks_47\NNS\955060|NONE
D002110_D016584 CID caffeine_56\NN\14712692|)|chi()(|the|mg|challenge|)|,|P|.|( (r_compound) test_58\NN\5798043|NONE (r_pobj) after_53\IN\0|total|attack|. (r_prep) had_49\VBD\0|NONE (l_nsubj) total_1\NN\3553|after|attack|. (l_prep) of_2\IN\0|A (l_pobj) %_4\NN\0|NONE (l_prep) of_10\IN\0|%|,|(|n|and|,|of|)||)|%|of|)|.|,|% (l_pobj) patients_11\NNS\9898892|NONE (l_prep) with_12\IN\0|NONE (l_pobj) pd_13\NNP\14625458|NONE
D002110_D016584 CID caffeine_56\NN\14712692|)|chi()(|the|mg|challenge|)|,|P|.|( (r_compound) test_58\NN\5798043|NONE (r_pobj) after_53\IN\0|total|attack|. (r_prep) had_49\VBD\0|NONE (l_dobj) attack_52\NN\955060|total|after|.
D002110_D016584 CID caffeine_10\NN\14712692|NONE (r_pobj) to_9\IN\0|more|were (r_prep) sensitive_8\JJ\10488309|.|patients (r_acomp) were_6\VBD\0|NONE (l_nsubj) patients_1\NNS\9898892|sensitive|. (l_prep) with_2\IN\0|The (l_pobj) pd_3\NNP\14625458|NONE
D002110_D016584 CID caffeine_7\NN\14712692| (r_npadvmod) free_9\JJ\7942152|solution|the (r_amod) intake_11\NN\13440063|NONE (r_pobj) after_5\IN\0|attack|.|was (r_prep) observed_4\VBN\2163746|NONE (l_nsubjpass) attack_2\NN\955060|.|was|after
D002110_D016584 CID caffeine_26\NN\14712692|NONE (r_compound) challenge_27\NN\13927383|an|oral (r_compound) test_28\NN\5798043|NONE (r_pobj) to_23\IN\0|NONE (r_prep) hyperreactivity_22\NN\0|that|there|matter|association|and|,|associated (r_conj) is_5\VBZ\0|.|data (l_attr) association_7\NN\8008335|that|there|matter|and|,|hyperreactivity|associated (l_prep) between_8\IN\0|an|, (l_pobj) attacks_10\NNS\955060|NONE
D002110_D016584 CID caffeine_26\NN\14712692|NONE (r_compound) challenge_27\NN\13927383|an|oral (r_compound) test_28\NN\5798043|NONE (r_pobj) to_23\IN\0|NONE (r_prep) hyperreactivity_22\NN\0|that|there|matter|association|and|,|associated (r_conj) is_5\VBZ\0|.|data (l_advcl) associated_15\VBN\628491|that|there|matter|association|and|,|hyperreactivity (l_prep) with_16\IN\0|if (l_pobj) pd_17\NNP\14625458|NONE
D002110_D016584 NONE caffeine_51\NN\14712692|NONE (r_compound) challenge_52\NN\13927383|oral|an (r_compound) test_53\NN\5798043|NONE (r_pobj) by_48\IN\0|panic (r_prep) attacks_47\NNS\955060|NONE (r_pobj) of_45\IN\0|the (r_prep) induction_44\NN\7450842|NONE (r_pobj) to_42\IN\0|similar|a (r_prep) way_41\NN\4916342|NONE (r_pobj) in_38\IN\13603305|if|patients (r_prep) respond_37\VBP\2367363|to (l_nsubj) patients_6\NNS\9898892|if|in (l_prep) with_7\IN\0|NONE (l_pobj) disorder_9\NN\14034177|NONE (l_conj) patients_14\NNS\9898892|(|panic|and|)|PD (l_prep) with_15\IN\0|NONE (l_pobj) depression_17\NN\14373582|NONE (l_prep) with_18\IN\0|major (l_pobj) attacks_20\NNS\955060|NONE (l_appos) mdp_22\NNP\0|(|)|panic|)|Diagnostic|(
D002110_D016584 NONE caffeine_56\NN\14712692|)|chi()(|the|mg|challenge|)|,|P|.|( (r_compound) test_58\NN\5798043|NONE (r_pobj) after_53\IN\0|total|attack|. (r_prep) had_49\VBD\0|NONE (l_nsubj) total_1\NN\3553|after|attack|. (l_prep) of_2\IN\0|A (l_pobj) %_4\NN\0|NONE (l_prep) of_22\IN\0|%|,|(|n|and|,|of|of|)||)|%|)|.|,|% (l_pobj) patients_23\NNS\9898892|NONE (l_prep) with_24\IN\0|NONE (l_pobj) mdp_25\NNP\0|NONE
D002110_D016584 NONE caffeine_10\NN\14712692|NONE (r_pobj) to_9\IN\0|more|were (r_prep) sensitive_8\JJ\10488309|.|patients (r_acomp) were_6\VBD\0|NONE (l_nsubj) patients_1\NNS\9898892|sensitive|. (l_prep) with_2\IN\0|The (l_pobj) pd_3\NNP\14625458|NONE (l_conj) mdp_5\NNP\0|and
D002110_D016584 NONE caffeine_26\NN\14712692|NONE (r_compound) challenge_27\NN\13927383|an|oral (r_compound) test_28\NN\5798043|NONE (r_pobj) to_23\IN\0|NONE (r_prep) hyperreactivity_22\NN\0|that|there|matter|association|and|,|associated (r_conj) is_5\VBZ\0|.|data (l_advcl) associated_15\VBN\628491|that|there|matter|association|and|,|hyperreactivity (l_prep) with_16\IN\0|if (l_pobj) pd_17\NNP\14625458|NONE (l_conj) mdp_19\NNP\0|or
D002110_D001523 NONE caffeine_51\NN\14712692|NONE (r_compound) challenge_52\NN\13927383|oral|an (r_compound) test_53\NN\5798043|NONE (r_pobj) by_48\IN\0|panic (r_prep) attacks_47\NNS\955060|NONE (r_pobj) of_45\IN\0|the (r_prep) induction_44\NN\7450842|NONE (r_pobj) to_42\IN\0|similar|a (r_prep) way_41\NN\4916342|NONE (r_pobj) in_38\IN\13603305|if|patients (r_prep) respond_37\VBP\2367363|to (l_nsubj) patients_6\NNS\9898892|if|in (l_prep) with_7\IN\0|NONE (l_pobj) disorder_9\NN\14034177|NONE (l_conj) patients_14\NNS\9898892|(|panic|and|)|PD (l_prep) with_15\IN\0|NONE (l_pobj) depression_17\NN\14373582|NONE (l_prep) with_18\IN\0|major (l_pobj) attacks_20\NNS\955060|NONE (l_appos) diagnostic_25\NNP\0|MDP|(|)|panic|)|( (l_conj) manual_28\NNP\6421301|criteria|,|and (l_prep) of_29\IN\0|Statistical (l_pobj) disorders_31\NNP\14034177|NONE
10462057
D017330_D000741 CID remoxipride_4\NN\0|and|in|cells (r_compound) metabolites_5\NNS\20090|NONE (r_pobj) by_3\IN\0|NONE (r_agent) apoptosis_2\NN\11486178|NONE (r_pobj) of_1\IN\0|:|.|relevance (r_prep) induction_0\NN\7450842|NONE (l_appos) relevance_17\NN\13791389|:|.|of (l_prep) to_18\IN\0|potential (l_pobj) anemia_23\NN\14189204|NONE
D017330_D000741 CID remoxipride_19\NN\0| (r_npadvmod) induced_21\VBN\1627355|aplastic (r_amod) anemia_23\NN\14189204|NONE
D017330_D000741 CID remoxipride_4\NN\0|been|with|.|has (r_nsubjpass) associated_14\VBN\628491|NONE (l_prep) with_15\IN\0|been|remoxipride|.|has (l_pobj) anemia_18\NN\14189204|NONE
D017330_D000741 CID amide_10\NN\14727670|agent|]|,|[|( (r_appos) remoxipride_4\NN\0|been|with|.|has (r_nsubjpass) associated_14\VBN\628491|NONE (l_prep) with_15\IN\0|been|remoxipride|.|has (l_pobj) anemia_18\NN\14189204|NONE
D017330_D000741 CID remoxipride_3\NN\0|and|apoptosis|via|may|that|anemia (r_nsubj) induce_7\VB\1627355|contribute|We|. (l_dobj) anemia_9\NN\14189204|and|apoptosis|via|may|that|remoxipride
D017330_D000741 CID remoxipride_3\NN\0|and|apoptosis|via|may|that|anemia (r_nsubj) induce_7\VB\1627355|contribute|We|. (r_ccomp) propose_1\VBP\1010118|NONE (l_conj) contribute_31\VB\126264|We|induce|. (l_prep) to_32\IN\0|may (l_pobj) anemia_38\NN\14189204|NONE
D017330_D000741 CID remoxipride_44\NN\0|NONE (r_pobj) with_43\IN\0|has|been|that (r_prep) associated_42\VBN\628491|aplastic|underlying|acquired|mechanism (r_relcl) anemia_38\NN\14189204|NONE (r_pobj) to_32\IN\0|may (r_prep) contribute_31\VB\126264|We|induce|. (r_conj) propose_1\VBP\1010118|NONE (l_ccomp) induce_7\VB\1627355|contribute|We|. (l_dobj) anemia_9\NN\14189204|and|apoptosis|via|may|that|remoxipride
D017330_D000741 CID remoxipride_44\NN\0|NONE (r_pobj) with_43\IN\0|has|been|that (r_prep) associated_42\VBN\628491|aplastic|underlying|acquired|mechanism (r_relcl) anemia_38\NN\14189204|NONE
C084325_D009336 NONE ncq436_8\NNP\0|NONE (r_pobj) with_7\IN\0|NONE (r_prep) treated_6\VBN\2376958|NONE (r_acl) cells_5\NNS\3080309|NONE (r_pobj) in_4\IN\13603305|necrosis|had|was|but (r_prep) observed_3\VBN\2163746|NONE (l_nsubjpass) necrosis_1\NN\11444117|in|had|was|but
C084325_D009336 NONE ncq436_8\NNP\0|NONE (r_pobj) with_7\IN\0|NONE (r_prep) treated_6\VBN\2376958|NONE (r_acl) cells_5\NNS\3080309|NONE (r_pobj) in_4\IN\13603305|necrosis|had|was|but (r_prep) observed_3\VBN\2163746|NONE (l_conj) had_11\VBD\0|in|necrosis|was|but (l_advcl) inducing_20\VBG\42311|,|NCQ|effect|. (l_advmod) apoptosis_21\NN\11486178|NONE (l_prep) at_22\IN\14622893|NONE (l_pobj) concentrations_24\NNS\4916342|NONE (l_conj) necrosis_26\NN\11444117|and|at|lower
C112341_D009336 NONE ncq344_10\NNP\0|,|effect|inducing|. (r_nsubj) had_11\VBD\0|in|necrosis|was|but (r_conj) observed_3\VBN\2163746|NONE (l_nsubjpass) necrosis_1\NN\11444117|in|had|was|but
C112341_D009336 NONE ncq344_10\NNP\0|,|effect|inducing|. (r_nsubj) had_11\VBD\0|in|necrosis|was|but (l_advcl) inducing_20\VBG\42311|,|NCQ|effect|. (l_advmod) apoptosis_21\NN\11486178|NONE (l_prep) at_22\IN\14622893|NONE (l_pobj) concentrations_24\NNS\4916342|NONE (l_conj) necrosis_26\NN\11444117|and|at|lower
D001554_D000741 CID benzene_5\NN\14767996|and (r_conj) remoxipride_3\NN\0|and|apoptosis|via|may|that|anemia (r_nsubj) induce_7\VB\1627355|contribute|We|. (l_dobj) anemia_9\NN\14189204|and|apoptosis|via|may|that|remoxipride
D001554_D000741 CID benzene_5\NN\14767996|and (r_conj) remoxipride_3\NN\0|and|apoptosis|via|may|that|anemia (r_nsubj) induce_7\VB\1627355|contribute|We|. (r_ccomp) propose_1\VBP\1010118|NONE (l_conj) contribute_31\VB\126264|We|induce|. (l_prep) to_32\IN\0|may (l_pobj) anemia_38\NN\14189204|NONE
C084325_D000741 NONE ncq436_21\NNP\0|NONE (r_pobj) of_20\IN\0|the|induce (r_prep) ability_19\NN\4723816|in|that (r_nsubj) apoptosis_26\NN\11486178|and|via|may|that|remoxipride|anemia (r_conj) induce_7\VB\1627355|contribute|We|. (l_dobj) anemia_9\NN\14189204|and|apoptosis|via|may|that|remoxipride
C084325_D000741 NONE ncq436_21\NNP\0|NONE (r_pobj) of_20\IN\0|the|induce (r_prep) ability_19\NN\4723816|in|that (r_nsubj) apoptosis_26\NN\11486178|and|via|may|that|remoxipride|anemia (r_conj) induce_7\VB\1627355|contribute|We|. (r_ccomp) propose_1\VBP\1010118|NONE (l_conj) contribute_31\VB\126264|We|induce|. (l_prep) to_32\IN\0|may (l_pobj) anemia_38\NN\14189204|NONE
C112341_D000741 NONE ncq344_23\NNP\0|and (r_conj) ncq436_21\NNP\0|NONE (r_pobj) of_20\IN\0|the|induce (r_prep) ability_19\NN\4723816|in|that (r_nsubj) apoptosis_26\NN\11486178|and|via|may|that|remoxipride|anemia (r_conj) induce_7\VB\1627355|contribute|We|. (l_dobj) anemia_9\NN\14189204|and|apoptosis|via|may|that|remoxipride
C112341_D000741 NONE ncq344_23\NNP\0|and (r_conj) ncq436_21\NNP\0|NONE (r_pobj) of_20\IN\0|the|induce (r_prep) ability_19\NN\4723816|in|that (r_nsubj) apoptosis_26\NN\11486178|and|via|may|that|remoxipride|anemia (r_conj) induce_7\VB\1627355|contribute|We|. (r_ccomp) propose_1\VBP\1010118|NONE (l_conj) contribute_31\VB\126264|We|induce|. (l_prep) to_32\IN\0|may (l_pobj) anemia_38\NN\14189204|NONE
6627074
D013390_D020879 NONE succinylcholine_15\NN\3800001|NONE (r_pobj) of_14\IN\0|the (r_prep) administration_13\NN\1133281|NONE (r_pobj) following_11\VBG\8180190|neuromuscular|prolonged (r_prep) blockade_10\NN\952963|to
D013390_D001049 CID succinylcholine_0\NN\3800001|attempted|.|: (r_compound) apnoea_1\NN\0|NONE
D013390_D001049 CID succinylcholine_14\NN\3800001|NONE (r_compound) apnoea_15\NN\0|NONE
3323599
D011479_D064420 NONE ps_9\NNP\6763273|NONE (r_pobj) of_8\IN\0|the (r_prep) administration_7\NN\1133281|and|that|produces|toxicity (r_nsubj) enhances_10\VBZ\227165|Therefore|,|.|it|is (l_dobj) toxicity_12\NN\13576101|and|administration|that|produces
D011692_D007676 CID amns_14\NNP\0|NONE (r_pobj) of_13\IN\0|the|on (r_prep) toxicity_12\NN\13576101|and|administration|that|produces (r_dobj) enhances_10\VBZ\227165|Therefore|,|.|it|is (l_conj) produces_20\VBZ\7555863|and|administration|that|toxicity (l_dobj) fsgs_22\NNS\0|readily (l_prep) in_23\IN\13603305|progressive (l_pobj) rats_24\NNS\2329401|NONE (l_acl) resulting_25\VBG\2633881|NONE (l_prep) in_26\IN\13603305|NONE (l_pobj) disease_32\NN\14061805|NONE
D011692_D064420 NONE amns_14\NNP\0|NONE (r_pobj) of_13\IN\0|the|on (r_prep) toxicity_12\NN\13576101|and|administration|that|produces
D011479_D007676 NONE ps_9\NNP\6763273|NONE (r_pobj) of_8\IN\0|the (r_prep) administration_7\NN\1133281|and|that|produces|toxicity (r_nsubj) enhances_10\VBZ\227165|Therefore|,|.|it|is (l_conj) produces_20\VBZ\7555863|and|administration|that|toxicity (l_dobj) fsgs_22\NNS\0|readily (l_prep) in_23\IN\13603305|progressive (l_pobj) rats_24\NNS\2329401|NONE (l_acl) resulting_25\VBG\2633881|NONE (l_prep) in_26\IN\13603305|NONE (l_pobj) disease_32\NN\14061805|NONE
D011692_D009401 NONE aminonucleoside_3\JJ\0|NONE (r_amod) nephrosis_4\NN\14304060|NONE
D011692_D005923 CID aminonucleoside_22\NN\0|NONE (r_pobj) of_19\IN\0|combined|the (r_prep) administration_18\NN\1133281|NONE (r_pobj) by_15\IN\0|model|was|in|. (r_agent) developed_12\VBN\1753788|NONE (l_nsubjpass) model_2\NN\5888929|was|by|in|. (l_prep) of_3\IN\0|FSGS|experimental|(|An|) (l_pobj) sclerosis_7\NN\14204950|NONE
D011692_D005923 CID aminonucleoside_22\NN\0|NONE (r_pobj) of_19\IN\0|combined|the (r_prep) administration_18\NN\1133281|NONE (r_pobj) by_15\IN\0|model|was|in|. (r_agent) developed_12\VBN\1753788|NONE (l_nsubjpass) model_2\NN\5888929|was|by|in|. (l_appos) fsgs_9\NNP\0|of|experimental|(|An|)
D011692_D005923 CID amns_24\NNP\0|puromycin| (r_appos) aminonucleoside_22\NN\0|NONE (r_pobj) of_19\IN\0|combined|the (r_prep) administration_18\NN\1133281|NONE (r_pobj) by_15\IN\0|model|was|in|. (r_agent) developed_12\VBN\1753788|NONE (l_nsubjpass) model_2\NN\5888929|was|by|in|. (l_prep) of_3\IN\0|FSGS|experimental|(|An|) (l_pobj) sclerosis_7\NN\14204950|NONE
D011692_D005923 CID amns_24\NNP\0|puromycin| (r_appos) aminonucleoside_22\NN\0|NONE (r_pobj) of_19\IN\0|combined|the (r_prep) administration_18\NN\1133281|NONE (r_pobj) by_15\IN\0|model|was|in|. (r_agent) developed_12\VBN\1753788|NONE (l_nsubjpass) model_2\NN\5888929|was|by|in|. (l_appos) fsgs_9\NNP\0|of|experimental|(|An|)
D011692_D005923 CID amns_14\NNP\0|NONE (r_pobj) of_13\IN\0|the|on (r_prep) toxicity_12\NN\13576101|and|administration|that|produces (r_dobj) enhances_10\VBZ\227165|Therefore|,|.|it|is (l_conj) produces_20\VBZ\7555863|and|administration|that|toxicity (l_dobj) fsgs_22\NNS\0|readily
D011479_D005923 NONE sulfate_28\NN\15010703|) (r_dobj) protamine_27\NN\14736972|)|and|( (r_conj) amns_24\NNP\0|puromycin| (r_appos) aminonucleoside_22\NN\0|NONE (r_pobj) of_19\IN\0|combined|the (r_prep) administration_18\NN\1133281|NONE (r_pobj) by_15\IN\0|model|was|in|. (r_agent) developed_12\VBN\1753788|NONE (l_nsubjpass) model_2\NN\5888929|was|by|in|. (l_prep) of_3\IN\0|FSGS|experimental|(|An|) (l_pobj) sclerosis_7\NN\14204950|NONE
D011479_D005923 NONE sulfate_28\NN\15010703|) (r_dobj) protamine_27\NN\14736972|)|and|( (r_conj) amns_24\NNP\0|puromycin| (r_appos) aminonucleoside_22\NN\0|NONE (r_pobj) of_19\IN\0|combined|the (r_prep) administration_18\NN\1133281|NONE (r_pobj) by_15\IN\0|model|was|in|. (r_agent) developed_12\VBN\1753788|NONE (l_nsubjpass) model_2\NN\5888929|was|by|in|. (l_appos) fsgs_9\NNP\0|of|experimental|(|An|)
D011479_D005923 NONE ps_30\NNP\6763273|NONE (r_appos) sulfate_28\NN\15010703|) (r_dobj) protamine_27\NN\14736972|)|and|( (r_conj) amns_24\NNP\0|puromycin| (r_appos) aminonucleoside_22\NN\0|NONE (r_pobj) of_19\IN\0|combined|the (r_prep) administration_18\NN\1133281|NONE (r_pobj) by_15\IN\0|model|was|in|. (r_agent) developed_12\VBN\1753788|NONE (l_nsubjpass) model_2\NN\5888929|was|by|in|. (l_prep) of_3\IN\0|FSGS|experimental|(|An|) (l_pobj) sclerosis_7\NN\14204950|NONE
D011479_D005923 NONE ps_30\NNP\6763273|NONE (r_appos) sulfate_28\NN\15010703|) (r_dobj) protamine_27\NN\14736972|)|and|( (r_conj) amns_24\NNP\0|puromycin| (r_appos) aminonucleoside_22\NN\0|NONE (r_pobj) of_19\IN\0|combined|the (r_prep) administration_18\NN\1133281|NONE (r_pobj) by_15\IN\0|model|was|in|. (r_agent) developed_12\VBN\1753788|NONE (l_nsubjpass) model_2\NN\5888929|was|by|in|. (l_appos) fsgs_9\NNP\0|of|experimental|(|An|)
D011479_D005923 NONE ps_9\NNP\6763273|NONE (r_pobj) of_8\IN\0|the (r_prep) administration_7\NN\1133281|and|that|produces|toxicity (r_nsubj) enhances_10\VBZ\227165|Therefore|,|.|it|is (l_conj) produces_20\VBZ\7555863|and|administration|that|toxicity (l_dobj) fsgs_22\NNS\0|readily
24658375
D014212_D009220 CID acid_4\NN\14818238| (r_npadvmod) induced_6\VBN\1627355|.|inflammatory|retinoic|trans|in (r_amod) myositis_8\NN\14336539|NONE
D014212_D009220 CID atra_6\NNP\0| (r_npadvmod) induced_8\VBN\1627355|NONE (r_amod) myositis_9\NN\14336539|NONE
D014212_D015473 NONE acid_4\NN\14818238| (r_npadvmod) induced_6\VBN\1627355|.|inflammatory|retinoic|trans|in (r_amod) myositis_8\NN\14336539|NONE (l_prep) in_9\IN\13603305|induced|.|inflammatory|retinoic|trans (l_pobj) patient_11\NN\9898892|NONE (l_prep) with_12\IN\0|a (l_pobj) leukemia_15\NN\14239918|NONE
D014212_D015473 NONE acid_4\NN\14818238|is|with|. (l_appos) component_10\NN\5867413|,|trans|ATRA|,|retinoic (l_prep) for_14\IN\0|a|of (l_pobj) leukemia_17\NN\14239918|NONE
D014212_D015473 NONE acid_4\NN\14818238|is|with|. (l_appos) component_10\NN\5867413|,|trans|ATRA|,|retinoic (l_prep) for_14\IN\0|a|of (l_pobj) leukemia_17\NN\14239918|NONE (l_appos) apl_19\NNP\0|promyelocytic|(|)|acute
D014212_D015473 NONE atra_6\NNP\0|,|trans|component|,|retinoic (r_appos) acid_4\NN\14818238|is|with|. (l_appos) component_10\NN\5867413|,|trans|ATRA|,|retinoic (l_prep) for_14\IN\0|a|of (l_pobj) leukemia_17\NN\14239918|NONE
D014212_D015473 NONE atra_6\NNP\0|,|trans|component|,|retinoic (r_appos) acid_4\NN\14818238|is|with|. (l_appos) component_10\NN\5867413|,|trans|ATRA|,|retinoic (l_prep) for_14\IN\0|a|of (l_pobj) leukemia_17\NN\14239918|NONE (l_appos) apl_19\NNP\0|promyelocytic|(|)|acute
12535818
D000638_D001919 CID amiodarone_0\NN\2715941|NONE (l_conj) risk_3\NN\14541044|and|. (l_prep) of_4\IN\0|requiring|the (l_pobj) bradyarrhythmia_5\JJ\0|NONE
D000638_D001919 CID amiodarone_14\NN\2715941|NONE (r_pobj) of_13\IN\0|the (r_prep) use_12\NN\407535|risk|)|whether (r_nsubj) increases_23\VBZ\13576355|to (l_dobj) risk_25\NN\14541044|use|)|whether (l_prep) of_26\IN\0|the|requiring (l_pobj) bradyarrhythmia_27\NNS\0|NONE
D000638_D001919 CID amiodarone_5\NN\2715941|NONE (r_compound) therapy_6\NN\657604|NONE (r_pobj) during_4\IN\0|severe (r_prep) bradyarrhythmia_3\NN\0|NONE
D000638_D001919 CID amiodarone_7\NN\2715941|NONE (r_pobj) of_6\IN\0|the|and|MI (r_prep) use_5\NN\407535|risk|that (r_nsubj) increases_17\VBZ\13576355|study|. (l_dobj) risk_19\NN\14541044|that|use (l_prep) of_20\IN\0|requiring|the (l_pobj) bradyarrhythmia_21\NNS\0|NONE
D000638_D001145 NONE amiodarone_5\NN\2715941|NONE (r_compound) therapy_6\NN\657604|NONE (r_pobj) during_4\IN\0|severe (r_prep) bradyarrhythmia_3\NN\0|NONE (r_pobj) of_1\IN\0|NONE (r_prep) reports_0\NNS\6470073|.|infrequent (r_nsubj) are_7\VBP\13600404|NONE (l_acomp) infrequent_8\JJ\0|.|Reports (l_conj) limited_10\VBN\4019101|and (l_prep) to_11\IN\0|NONE (l_pobj) studies_12\NNS\635850|NONE (l_acl) assessing_13\VBG\670261|NONE (l_dobj) use_17\NN\407535|NONE (l_prep) in_18\IN\13603305|therapy (l_pobj) management_20\NN\1123598|NONE (l_prep) of_21\IN\0|the (l_pobj) patients_22\NNS\9898892|NONE (l_prep) with_23\IN\0|NONE (l_pobj) arrhythmias_25\NNS\14103288|NONE
D000638_D009203 NONE amiodarone_0\NN\2715941|NONE (l_conj) risk_3\NN\14541044|and|. (l_acl) requiring_6\VBG\0|of|the (l_dobj) pacemaker_8\NN\5925366|NONE (l_prep) in_9\IN\13603305|permanent (l_pobj) patients_11\NNS\9898892|NONE (l_prep) with_12\IN\0|elderly (l_pobj) fibrillation_14\NN\14361664|NONE (l_conj) infarction_18\NN\14204950|and|atrial
D000638_D009203 NONE amiodarone_7\NN\2715941|NONE (r_pobj) of_6\IN\0|the|and|MI (r_prep) use_5\NN\407535|risk|that (l_conj) mi_16\NNP\14207561|of|the|and
D000638_D001281 NONE amiodarone_0\NN\2715941|NONE (l_conj) risk_3\NN\14541044|and|. (l_acl) requiring_6\VBG\0|of|the (l_dobj) pacemaker_8\NN\5925366|NONE (l_prep) in_9\IN\13603305|permanent (l_pobj) patients_11\NNS\9898892|NONE (l_prep) with_12\IN\0|elderly (l_pobj) fibrillation_14\NN\14361664|NONE
D000638_D001281 NONE amiodarone_14\NN\2715941|NONE (l_prep) in_15\IN\13603305|NONE (l_pobj) patients_16\NNS\9898892|NONE (l_prep) with_17\IN\0|NONE (l_pobj) fibrillation_19\NN\14361664|NONE
D000638_D001281 NONE amiodarone_14\NN\2715941|NONE (l_prep) in_15\IN\13603305|NONE (l_pobj) patients_16\NNS\9898892|NONE (l_prep) with_17\IN\0|NONE (l_pobj) fibrillation_19\NN\14361664|NONE (l_appos) af_21\NNP\0|atrial|(
D000638_D001281 NONE amiodarone_7\NN\2715941|NONE (l_prep) in_8\IN\13603305|NONE (l_pobj) patients_10\NNS\9898892|NONE (l_prep) with_11\IN\0|elderly (l_pobj) af_12\NNP\0|NONE
2429800
D014403_D007022 CID tubocurarine_5\NN\14712692| (r_advmod) induced_7\VBN\1627355|d|in (r_amod) hypotension_8\NN\14057371|Histamine|and|.
D006632_D007022 NONE histamine_0\NN\14739004|and|.|hypotension (r_amod) antagonists_1\NNS\7846|NONE (l_conj) hypotension_8\NN\14057371|Histamine|and|.
2765447
D019793_D012640 NONE fluorescein_3\NN\14598383|intravenous (r_amod) angiography_4\NN\904623|NONE (r_dobj) following_1\VBG\8180190|. (r_prep) convulsion_0\NNP\14081375|NONE
D019793_D004830 CID fluorescein_6\NN\14598383|for|in|intravenous (r_amod) injection_7\NN\320852|seizures|. (r_dobj) followed_4\VBD\1835496|NONE (l_nsubj) seizures_3\NNS\14081375|injection|.
3685052
D004986_D007035 NONE ether_1\NN\14840755|hypothermia (r_nsubj) produced_2\VBD\1617192|.|unclear|;|however|,|relationship (l_dobj) hypothermia_3\NN\14034177|ether
D004986_D007035 NONE ether_1\NN\14840755|hypothermia (r_nsubj) produced_2\VBD\1617192|.|unclear|;|however|,|relationship (r_ccomp) was_23\VBD\0|NONE (l_nsubj) relationship_17\NN\31921|.|unclear|;|produced|however|, (l_prep) of_18\IN\0|the|to (l_pobj) hypothermia_19\NN\14034177|NONE
D009270_D012640 NONE naloxone_1\NN\3808977|mg/kg|)|( (r_nmod) challenge_6\NN\13927383|also|in|ineffective|. (r_nsubj) was_7\VBD\0|NONE (l_prep) in_10\IN\13603305|also|ineffective|challenge|. (l_pcomp) altering_11\VBG\692130|NONE (l_dobj) thresholds_14\NNS\15265518|NONE (l_compound) seizure_13\NN\14081375|of|the
D005481_D012640 NONE flurothyl_0\JJ\0|seizure|in (r_compound) thresholds_2\NNS\15265518|.|neonatally|evaluation|:|with (l_compound) seizure_1\NN\14081375|in|Flurothyl
D005481_D012640 NONE flurothyl_0\JJ\0|seizure|in (r_compound) thresholds_2\NNS\15265518|.|neonatally|evaluation|:|with (r_nsubj) treated_5\VBD\2376958|NONE (l_dobj) evaluation_18\NN\874067|.|neonatally|thresholds|:|with (l_prep) of_19\IN\0|NONE (l_pobj) parameters_21\NNS\5858936|NONE (l_prep) in_22\IN\13603305|experimental (l_pobj) testing_25\NN\639556|NONE (l_compound) seizure_24\NN\14081375|flurothyl
D005481_D012640 NONE flurothyl_23\JJ\0|seizure (r_compound) testing_25\NN\639556|NONE (r_pobj) in_22\IN\13603305|experimental (r_prep) parameters_21\NNS\5858936|NONE (r_pobj) of_19\IN\0|NONE (r_prep) evaluation_18\NN\874067|.|neonatally|thresholds|:|with (r_dobj) treated_5\VBD\2376958|NONE (l_nsubj) thresholds_2\NNS\15265518|.|neonatally|evaluation|:|with (l_compound) seizure_1\NN\14081375|in|Flurothyl
D005481_D012640 NONE flurothyl_23\JJ\0|seizure (r_compound) testing_25\NN\639556|NONE (l_compound) seizure_24\NN\14081375|flurothyl
D005481_D012640 NONE flurothyl_1\JJ\0|ether|screening|A (r_nmod) technique_5\NN\5660268|.|was|)|evaluate (l_compound) screening_4\NN\6887726|ether|flurothyl|A (l_compound) seizure_3\NN\14081375|NONE
D005481_D012640 NONE flurothyl_1\JJ\0|ether|screening|A (r_nmod) technique_5\NN\5660268|.|was|)|evaluate (r_nsubjpass) used_7\VBN\0|NONE (l_xcomp) evaluate_9\VB\670261|.|was|technique|) (l_dobj) susceptibility_11\NN\13920835|to (l_compound) seizure_10\NN\14081375|in|received
D005481_D012640 NONE flurothyl_0\NNP\0|NONE (r_compound) ether_1\NN\14840755|hypothermia (r_nsubj) produced_2\VBD\1617192|.|unclear|;|however|,|relationship (r_ccomp) was_23\VBD\0|NONE (l_nsubj) relationship_17\NN\31921|.|unclear|;|produced|however|, (l_prep) to_20\IN\0|of|the (l_pobj) induction_22\NN\7450842|NONE (l_compound) seizure_21\NN\14081375|NONE
D005481_D012640 NONE flurothyl_11\JJ\0|NONE (r_compound) exposure_12\NN\5042871|NONE (r_pobj) of_10\IN\0|the (r_prep) duration_9\NN\15113229|NONE (r_pobj) with_7\IN\0|was|which (r_prep) correlated_6\VBN\2657219|NONE (r_relcl) hypothermia_3\NN\14034177|ether (r_dobj) produced_2\VBD\1617192|.|unclear|;|however|,|relationship (r_ccomp) was_23\VBD\0|NONE (l_nsubj) relationship_17\NN\31921|.|unclear|;|produced|however|, (l_prep) to_20\IN\0|of|the (l_pobj) induction_22\NN\7450842|NONE (l_compound) seizure_21\NN\14081375|NONE
D005481_D012640 NONE flurothyl_0\JJ\0|seizure (r_compound) testing_2\NN\639556|be|. (l_compound) seizure_1\NN\14081375|Flurothyl
D005481_D012640 NONE flurothyl_0\JJ\0|seizure (r_compound) testing_2\NN\639556|be|. (r_nsubj) proved_3\VBD\2604760|NONE (l_xcomp) be_5\VB\14625458|testing|. (l_attr) technique_10\NN\5660268|to (l_relcl) evaluate_14\VB\670261|a|rapid (l_dobj) susceptibility_16\NN\13920835|to|with (l_compound) seizure_15\NN\14081375|NONE
D005481_D007035 CID flurothyl_0\NNP\0|NONE (r_compound) ether_1\NN\14840755|hypothermia (r_nsubj) produced_2\VBD\1617192|.|unclear|;|however|,|relationship (l_dobj) hypothermia_3\NN\14034177|ether
D005481_D007035 CID flurothyl_0\NNP\0|NONE (r_compound) ether_1\NN\14840755|hypothermia (r_nsubj) produced_2\VBD\1617192|.|unclear|;|however|,|relationship (r_ccomp) was_23\VBD\0|NONE (l_nsubj) relationship_17\NN\31921|.|unclear|;|produced|however|, (l_prep) of_18\IN\0|the|to (l_pobj) hypothermia_19\NN\14034177|NONE
D005481_D007035 CID flurothyl_11\JJ\0|NONE (r_compound) exposure_12\NN\5042871|NONE (r_pobj) of_10\IN\0|the (r_prep) duration_9\NN\15113229|NONE (r_pobj) with_7\IN\0|was|which (r_prep) correlated_6\VBN\2657219|NONE (r_relcl) hypothermia_3\NN\14034177|ether
D005481_D007035 CID flurothyl_11\JJ\0|NONE (r_compound) exposure_12\NN\5042871|NONE (r_pobj) of_10\IN\0|the (r_prep) duration_9\NN\15113229|NONE (r_pobj) with_7\IN\0|was|which (r_prep) correlated_6\VBN\2657219|NONE (r_relcl) hypothermia_3\NN\14034177|ether (r_dobj) produced_2\VBD\1617192|.|unclear|;|however|,|relationship (r_ccomp) was_23\VBD\0|NONE (l_nsubj) relationship_17\NN\31921|.|unclear|;|produced|however|, (l_prep) of_18\IN\0|the|to (l_pobj) hypothermia_19\NN\14034177|NONE
D012970_D012640 NONE glutamate_13\NN\15010703|NONE (r_pobj) of_11\IN\0|a|single (r_prep) injection_10\NN\320852|NONE (r_pobj) with_7\IN\0|.|neonatally|thresholds|evaluation|: (r_prep) treated_5\VBD\2376958|NONE (l_nsubj) thresholds_2\NNS\15265518|.|neonatally|evaluation|:|with (l_compound) seizure_1\NN\14081375|in|Flurothyl
D012970_D012640 NONE glutamate_13\NN\15010703|NONE (r_pobj) of_11\IN\0|a|single (r_prep) injection_10\NN\320852|NONE (r_pobj) with_7\IN\0|.|neonatally|thresholds|evaluation|: (r_prep) treated_5\VBD\2376958|NONE (l_dobj) evaluation_18\NN\874067|.|neonatally|thresholds|:|with (l_prep) of_19\IN\0|NONE (l_pobj) parameters_21\NNS\5858936|NONE (l_prep) in_22\IN\13603305|experimental (l_pobj) testing_25\NN\639556|NONE (l_compound) seizure_24\NN\14081375|flurothyl
D012970_D012640 NONE msg_15\NNP\7809368|monosodium (r_appos) glutamate_13\NN\15010703|NONE (r_pobj) of_11\IN\0|a|single (r_prep) injection_10\NN\320852|NONE (r_pobj) with_7\IN\0|.|neonatally|thresholds|evaluation|: (r_prep) treated_5\VBD\2376958|NONE (l_nsubj) thresholds_2\NNS\15265518|.|neonatally|evaluation|:|with (l_compound) seizure_1\NN\14081375|in|Flurothyl
D012970_D012640 NONE msg_15\NNP\7809368|monosodium (r_appos) glutamate_13\NN\15010703|NONE (r_pobj) of_11\IN\0|a|single (r_prep) injection_10\NN\320852|NONE (r_pobj) with_7\IN\0|.|neonatally|thresholds|evaluation|: (r_prep) treated_5\VBD\2376958|NONE (l_dobj) evaluation_18\NN\874067|.|neonatally|thresholds|:|with (l_prep) of_19\IN\0|NONE (l_pobj) parameters_21\NNS\5858936|NONE (l_prep) in_22\IN\13603305|experimental (l_pobj) testing_25\NN\639556|NONE (l_compound) seizure_24\NN\14081375|flurothyl
D012970_D012640 NONE glutamate_1\NN\15010703|(|)|MSG|to (r_nmod) administration_5\NN\1133281|convulsions|.|in (r_nsubj) produces_9\VBZ\7555863|NONE (l_dobj) convulsions_10\NNS\14081375|.|administration|in
D012970_D012640 NONE msg_3\NNP\7809368|(|)|glutamate|to (r_nmod) administration_5\NN\1133281|convulsions|.|in (r_nsubj) produces_9\VBZ\7555863|NONE (l_dobj) convulsions_10\NNS\14081375|.|administration|in
D012970_D012640 NONE msg_10\NNP\7809368|NONE (r_pobj) of_9\IN\0|neonatal (r_prep) administration_8\NN\1133281|if|alterations (r_nsubj) produced_11\VBD\1617192|to (l_dobj) alterations_13\NNS\7283608|if|administration (l_prep) in_14\IN\13603305|permanent (l_pobj) susceptibility_16\NN\13920835|NONE (l_compound) seizure_15\NN\14081375|NONE
D012970_D012640 NONE msg_20\NNP\7809368|NONE (r_pobj) of_19\IN\0|g|neonatal (r_prep) injections_18\NNS\320852|that (r_dobj) received_16\VBD\2210855|seizure|in (r_relcl) susceptibility_11\NN\13920835|to (r_dobj) evaluate_9\VB\670261|.|was|technique|) (r_xcomp) used_7\VBN\0|NONE (l_nsubjpass) technique_5\NN\5660268|.|was|)|evaluate (l_compound) screening_4\NN\6887726|ether|flurothyl|A (l_compound) seizure_3\NN\14081375|NONE
D012970_D012640 NONE msg_20\NNP\7809368|NONE (r_pobj) of_19\IN\0|g|neonatal (r_prep) injections_18\NNS\320852|that (r_dobj) received_16\VBD\2210855|seizure|in (r_relcl) susceptibility_11\NN\13920835|to (l_compound) seizure_10\NN\14081375|in|received
D012970_D012640 NONE msg_0\NNP\7809368|NONE (r_compound) treatment_1\NN\654885|alter|.|in|but (r_nsubj) resulted_2\VBD\2633881|NONE (l_conj) alter_13\VB\0|treatment|.|in|but (l_dobj) threshold_15\NN\15265518|did|not (l_compound) seizure_14\NN\14081375|NONE
D012970_D012640 NONE msg_19\NNP\7809368| (r_npadvmod) treated_21\VBN\2376958|NONE (r_amod) mice_22\NNS\2329401|NONE (r_pobj) of_18\IN\0|either (r_prep) control_17\NN\5190804|NONE (r_pobj) of_15\IN\0|seizure|the (r_prep) thresholds_14\NNS\15265518|NONE (l_compound) seizure_13\NN\14081375|of|the
D004986_D012640 NONE ether_2\NN\14840755|flurothyl|screening|A (r_compound) technique_5\NN\5660268|.|was|)|evaluate (l_compound) screening_4\NN\6887726|ether|flurothyl|A (l_compound) seizure_3\NN\14081375|NONE
D004986_D012640 NONE ether_2\NN\14840755|flurothyl|screening|A (r_compound) technique_5\NN\5660268|.|was|)|evaluate (r_nsubjpass) used_7\VBN\0|NONE (l_xcomp) evaluate_9\VB\670261|.|was|technique|) (l_dobj) susceptibility_11\NN\13920835|to (l_compound) seizure_10\NN\14081375|in|received
D004986_D012640 NONE ether_1\NN\14840755|hypothermia (r_nsubj) produced_2\VBD\1617192|.|unclear|;|however|,|relationship (r_ccomp) was_23\VBD\0|NONE (l_nsubj) relationship_17\NN\31921|.|unclear|;|produced|however|, (l_prep) to_20\IN\0|of|the (l_pobj) induction_22\NN\7450842|NONE (l_compound) seizure_21\NN\14081375|NONE
1360900
D005680_D012640 NONE acid_34\NN\14818238|NONE (r_pobj) of_30\IN\0|the (r_prep) synthesis_29\NN\13446390|NONE (r_dobj) suppressed_27\VBD\2510337|turnover|but|)|.|injection (r_conj) accelerated_16\VBD\226566|NONE (l_nsubj) injection_1\NN\320852|turnover|but|)|.|suppressed (l_prep) of_2\IN\0|Intracerebroventricular|mouse (l_pobj) acid_4\NN\14818238|NONE (l_appos) dose_9\NN\3740161|ethacrynic (l_amod) convulsive_8\JJ\0|%|(
D012701_D012640 NONE 5-hydroxytryptamine_22\CD\14807737|NONE (r_pobj) of_21\IN\0|/|synthesis|the (r_prep) turnover_20\NN\13819207|but|)|.|injection|suppressed (r_dobj) accelerated_16\VBD\226566|NONE (l_nsubj) injection_1\NN\320852|turnover|but|)|.|suppressed (l_prep) of_2\IN\0|Intracerebroventricular|mouse (l_pobj) acid_4\NN\14818238|NONE (l_appos) dose_9\NN\3740161|ethacrynic (l_amod) convulsive_8\JJ\0|%|(
D012701_D012640 NONE 5-ht_24\CD\0|NONE (r_appos) 5-hydroxytryptamine_22\CD\14807737|NONE (r_pobj) of_21\IN\0|/|synthesis|the (r_prep) turnover_20\NN\13819207|but|)|.|injection|suppressed (r_dobj) accelerated_16\VBD\226566|NONE (l_nsubj) injection_1\NN\320852|turnover|but|)|.|suppressed (l_prep) of_2\IN\0|Intracerebroventricular|mouse (l_pobj) acid_4\NN\14818238|NONE (l_appos) dose_9\NN\3740161|ethacrynic (l_amod) convulsive_8\JJ\0|%|(
D004976_D012640 CID acid_1\NN\14818238| (r_npadvmod) induced_3\VBN\1627355|neurotransmitters|.|in|Ethacrynic|and (r_amod) convulsions_4\NNS\14081375|NONE
D004976_D012640 CID acid_4\NN\14818238|NONE (l_appos) dose_9\NN\3740161|ethacrynic (l_amod) convulsive_8\JJ\0|%|(
D004976_D012640 CID acid_2\NN\14818238| (r_npadvmod) induced_4\VBN\1627355|ethacrynic (r_amod) convulsions_5\NNS\14081375|NONE
D000109_D012640 NONE acetylcholine_36\NN\14807558|aminobutyric|and (r_conj) acid_34\NN\14818238|NONE (r_pobj) of_30\IN\0|the (r_prep) synthesis_29\NN\13446390|NONE (r_dobj) suppressed_27\VBD\2510337|turnover|but|)|.|injection (r_conj) accelerated_16\VBD\226566|NONE (l_nsubj) injection_1\NN\320852|turnover|but|)|.|suppressed (l_prep) of_2\IN\0|Intracerebroventricular|mouse (l_pobj) acid_4\NN\14818238|NONE (l_appos) dose_9\NN\3740161|ethacrynic (l_amod) convulsive_8\JJ\0|%|(
11026989
D014331_D015878 CID tropicamide_6\NN\0|NONE (r_pobj) with_5\IN\0|pupil (r_prep) dilation_4\NN\7138085|NONE
D014331_D015878 CID tropicamide_28\NN\0|guttae (r_advmod) using_26\VBG\418025|pupil (r_acl) dilation_25\NN\7138085|NONE
24729111
D000638_D007035 CID amiodarone_20\NN\2715941|NONE (r_compound) therapy_21\NN\657604|NONE (r_pobj) of_19\IN\0|for (r_prep) initiation_18\NN\7450842|weeks (r_pobj) after_17\IN\0|bradycardia|to (r_prep) have_8\VB\7846|.|man|was (l_dobj) bradycardia_9\VBN\14110674|after|to (l_conj) hypothermia_11\NN\14034177|,
D000638_D003128 CID amiodarone_0\NN\2715941| (r_npadvmod) induced_2\VBN\1627355|NONE (r_amod) myxoedema_3\NN\14121276|. (r_compound) coma_4\NN\5678932|NONE
D000638_D003128 CID amiodarone_5\NN\2715941| (r_npadvmod) induced_7\VBN\1627355|NONE (r_amod) myxoedema_8\NN\14121276|in (r_compound) coma_9\NN\5678932|NONE
D000638_D003128 CID amiodarone_9\NN\2715941| (r_npadvmod) induced_11\VBN\1627355|NONE (r_amod) myxoedema_12\NN\14121276|with (r_compound) coma_13\NN\5678932|NONE
D000638_D012131 CID amiodarone_20\NN\2715941|NONE (r_compound) therapy_21\NN\657604|NONE (r_pobj) of_19\IN\0|for (r_prep) initiation_18\NN\7450842|weeks (r_pobj) after_17\IN\0|bradycardia|to (r_prep) have_8\VB\7846|.|man|was (l_dobj) bradycardia_9\VBN\14110674|after|to (l_conj) hypothermia_11\NN\14034177|, (l_conj) failure_14\NN\66216|and
D000638_D013959 NONE amiodarone_9\NN\2715941| (r_npadvmod) induced_11\VBN\1627355|NONE (r_amod) myxoedema_12\NN\14121276|with (r_compound) coma_13\NN\5678932|NONE (l_prep) with_14\IN\0|myxoedema (l_pobj) history_16\NN\15120823|NONE (l_amod) significant_17\JJ\0|a (l_prep) for_18\IN\0|NONE (l_pobj) disease_21\NN\14061805|NONE
D000638_D001919 CID amiodarone_20\NN\2715941|NONE (r_compound) therapy_21\NN\657604|NONE (r_pobj) of_19\IN\0|for (r_prep) initiation_18\NN\7450842|weeks (r_pobj) after_17\IN\0|bradycardia|to (r_prep) have_8\VB\7846|.|man|was (l_dobj) bradycardia_9\VBN\14110674|after|to
D000638_D001281 NONE amiodarone_20\NN\2715941|NONE (r_compound) therapy_21\NN\657604|NONE (r_pobj) of_19\IN\0|for (r_prep) initiation_18\NN\7450842|weeks (l_prep) for_22\IN\0|of (l_pobj) fibrillation_24\NN\14361664|NONE
D000638_D007037 CID amiodarone_0\NN\2715941| (r_npadvmod) induced_2\VBN\1627355|NONE (r_amod) myxoedema_3\NN\14121276|. (r_compound) coma_4\NN\5678932|NONE
D000638_D007037 CID amiodarone_5\NN\2715941| (r_npadvmod) induced_7\VBN\1627355|NONE (r_amod) myxoedema_8\NN\14121276|in (r_compound) coma_9\NN\5678932|NONE
D000638_D007037 CID amiodarone_9\NN\2715941| (r_npadvmod) induced_11\VBN\1627355|NONE (r_amod) myxoedema_12\NN\14121276|with (r_compound) coma_13\NN\5678932|NONE
15282950
D007545_D009202 CID isoproterenol_11\NN\3740161|NONE (r_pobj) by_10\IN\0|NONE (r_agent) induced_9\VBN\1627355|against|.|effect (r_advcl) chebula_4\NN\0|NONE (l_prep) against_5\IN\0|induced|.|effect (l_pobj) injury_8\NN\14052046|NONE
D007545_D009202 CID isoproterenol_18\NN\3740161|NONE (r_pobj) in_17\IN\13603305|.|induced|effect|was|body (r_prep) examined_16\VBN\0|NONE (l_conj) induced_25\VBN\1627355|.|effect|in|was|body (l_dobj) damage_27\NN\7296428|NONE
D010936_D009202 NONE chebula_4\NN\0|NONE (l_prep) against_5\IN\0|induced|.|effect (l_pobj) injury_8\NN\14052046|NONE
D010936_D009202 NONE fruits_8\NNS\11675842|NONE (r_pobj) of_5\IN\0|ethanolic (r_prep) extract_4\NN\14589223|NONE (r_pobj) of_2\IN\0|Cardioprotective (r_prep) effect_1\NN\34213|.|induced|in|was|body (r_nsubjpass) examined_16\VBN\0|NONE (l_conj) induced_25\VBN\1627355|.|effect|in|was|body (l_dobj) damage_27\NN\7296428|NONE
11105626
D015474_D065817 CID isotretinoin_21\VB\0|NONE (r_pobj) to_20\IN\0|within (r_prep) exposure_19\NN\5042871|to (r_pobj) due_17\IN\5174653|.|We|infant (r_prep) report_1\VBP\6470073|NONE (l_dobj) infant_4\NN\9918248|.|We|due (l_prep) with_5\IN\0|newborn|a (l_pobj) anomalies_8\NNS\14501726|NONE (l_appos) anotia_10\NN\0|)|(|congenital|multiple
D015474_D004310 CID isotretinoin_21\VB\0|NONE (r_pobj) to_20\IN\0|within (r_prep) exposure_19\NN\5042871|to (r_pobj) due_17\IN\5174653|.|We|infant (r_prep) report_1\VBP\6470073|NONE (l_dobj) infant_4\NN\9918248|.|We|due (l_prep) with_5\IN\0|newborn|a (l_pobj) anomalies_8\NNS\14501726|NONE (l_appos) anotia_10\NN\0|)|(|congenital|multiple (l_conj) malformation_15\NN\14213199|and
1420650
D003024_D020258 NONE clozapine_29\NN\3713736|or (r_conj) lithium_27\NN\14625458|NONE (r_pobj) as_26\IN\14622893|certain (r_prep) drugs_25\NNS\14778436|are|if|in (r_nsubjpass) used_31\VBN\0|We|be|.|, (r_advcl) consider_1\VBP\689344|NONE (l_ccomp) be_4\VB\14625458|We|.|used|, (l_attr) sign_8\NN\6643763|asterixis|to (l_prep) of_9\IN\0|an|overlooked (l_pobj) neurotoxicity_10\NN\0|NONE
D002220_D020820 NONE carbamazepine_3\NN\0|NONE (r_compound) therapy_4\NN\657604|NONE (r_pobj) by_2\IN\0|.|Asterixis (r_agent) induced_1\VBN\1627355|NONE (l_nsubj) asterixis_0\NNS\0|by|.
D002220_D020820 NONE carbamazepine_24\NN\0|to (r_dobj) adding_23\VBG\156601|either (r_pcomp) by_22\IN\0|was|asterixis|in (r_prep) triggered_20\VBN\1641914|,|different|psychotropic (l_nsubjpass) asterixis_18\NNS\0|was|by|in
D002220_D020820 NONE cbz_26\NNP\0|)|( (r_appos) carbamazepine_24\NN\0|to (r_dobj) adding_23\VBG\156601|either (r_pcomp) by_22\IN\0|was|asterixis|in (r_prep) triggered_20\VBN\1641914|,|different|psychotropic (l_nsubjpass) asterixis_18\NNS\0|was|by|in
D002220_D020820 NONE cbz_35\NN\0|NONE (r_pobj) with_34\IN\0|NONE (r_prep) combination_33\NN\7951464|NONE (r_pobj) in_32\IN\13603305|are|if|drugs (r_prep) used_31\VBN\0|We|be|.|, (r_advcl) consider_1\VBP\689344|NONE (l_ccomp) be_4\VB\14625458|We|.|used|, (l_nsubj) asterixis_2\NNS\0|sign|to
D008094_D020820 CID lithium_27\NN\14625458|NONE (r_pobj) as_26\IN\14622893|certain (r_prep) drugs_25\NNS\14778436|are|if|in (r_nsubjpass) used_31\VBN\0|We|be|.|, (r_advcl) consider_1\VBP\689344|NONE (l_ccomp) be_4\VB\14625458|We|.|used|, (l_nsubj) asterixis_2\NNS\0|sign|to
D002220_D020258 NONE cbz_35\NN\0|NONE (r_pobj) with_34\IN\0|NONE (r_prep) combination_33\NN\7951464|NONE (r_pobj) in_32\IN\13603305|are|if|drugs (r_prep) used_31\VBN\0|We|be|.|, (r_advcl) consider_1\VBP\689344|NONE (l_ccomp) be_4\VB\14625458|We|.|used|, (l_attr) sign_8\NN\6643763|asterixis|to (l_prep) of_9\IN\0|an|overlooked (l_pobj) neurotoxicity_10\NN\0|NONE
D003024_D020820 CID clozapine_29\NN\3713736|or (r_conj) lithium_27\NN\14625458|NONE (r_pobj) as_26\IN\14622893|certain (r_prep) drugs_25\NNS\14778436|are|if|in (r_nsubjpass) used_31\VBN\0|We|be|.|, (r_advcl) consider_1\VBP\689344|NONE (l_ccomp) be_4\VB\14625458|We|.|used|, (l_nsubj) asterixis_2\NNS\0|sign|to
D008094_D020258 NONE lithium_27\NN\14625458|NONE (r_pobj) as_26\IN\14622893|certain (r_prep) drugs_25\NNS\14778436|are|if|in (r_nsubjpass) used_31\VBN\0|We|be|.|, (r_advcl) consider_1\VBP\689344|NONE (l_ccomp) be_4\VB\14625458|We|.|used|, (l_attr) sign_8\NN\6643763|asterixis|to (l_prep) of_9\IN\0|an|overlooked (l_pobj) neurotoxicity_10\NN\0|NONE
3746148
D004176_D003324 NONE dipyridamole_14\NN\0|NONE (r_compound) infusion_15\NN\14589223|NONE (r_pobj) after_13\IN\0|invasive|by|of|. (r_prep) detection_3\NN\5708432|NONE (l_prep) of_4\IN\0|after|invasive|by|. (l_pobj) disease_7\NN\14061805|NONE
D004176_D003324 NONE dipyridamole_3\NN\0|NONE (r_compound) infusion_4\NN\14589223|NONE (r_pobj) after_2\IN\0|Electrocardiographic|min (r_prep) changes_1\NNS\7283608|.|and|compared|were|in (r_nsubjpass) studied_13\VBN\0|NONE (l_prep) in_14\IN\13603305|changes|.|and|compared|were (l_pobj) patients_16\NNS\9898892|NONE (l_prep) with_17\IN\0| (l_pobj) disease_20\NN\14061805|NONE
D004176_D003324 NONE dipyridamole_4\NN\0|ECG|the (r_compound) test_6\NN\5798043|useful|that (r_nsubj) is_7\VBZ\0|We|. (l_acomp) useful_9\JJ\0|test|that (l_prep) as_10\IN\14622893|as (l_pobj) test_14\NN\5798043|NONE (l_prep) for_15\IN\0|the|ECG (l_pobj) assessment_17\NN\5732756|NONE (l_prep) of_18\IN\0|the (l_pobj) disease_21\NN\14061805|NONE
D004176_D009203 NONE dipyridamole_1\NN\0|NONE (r_pobj) after_0\IN\0|was|mV|depression|,|.|in (r_prep) observed_15\VBN\2163746|NONE (l_prep) in_16\IN\13603305|was|After|mV|depression|,|. (l_pobj) %_18\NN\0|NONE (l_prep) of_19\IN\0||,|% (l_pobj) group_24\NN\2137|NONE (l_compound) mi_23\NNP\14207561|the
D004176_D017202 CID dipyridamole_5\NN\0| (r_npadvmod) induced_7\VBN\1627355|the|myocardial (r_amod) ischemia_9\NN\14195315|that|by|is
D004176_D003866 NONE dipyridamole_1\NN\0|NONE (r_pobj) after_0\IN\0|was|mV|depression|,|.|in (r_prep) observed_15\VBN\2163746|NONE (l_nsubjpass) depression_7\NN\14373582|was|After|mV|,|.|in
D004176_D007511 NONE dipyridamole_1\NN\0|NONE (r_pobj) after_0\IN\0|was|mV|depression|,|.|in (r_prep) observed_15\VBN\2163746|NONE (l_nsubjpass) depression_7\NN\14373582|was|After|mV|,|.|in (l_amod) ischemic_3\JJ\0|segment
D004176_D056989 NONE dipyridamole_1\NN\0|NONE (r_pobj) after_0\IN\0|was|mV|depression|,|.|in (r_prep) observed_15\VBN\2163746|NONE (l_prep) in_16\IN\13603305|was|After|mV|depression|,|. (l_pobj) %_18\NN\0|NONE (l_appos) %_27\NN\0|of||, (l_appos) %_36\NN\0|,|of| (l_prep) of_37\IN\0|and|%| (l_pobj) group_42\NN\2137|NONE (l_compound) mi_41\NNP\14207561|the
D004176_D056988 NONE dipyridamole_1\NN\0|NONE (r_pobj) after_0\IN\0|was|mV|depression|,|.|in (r_prep) observed_15\VBN\2163746|NONE (l_prep) in_16\IN\13603305|was|After|mV|depression|,|. (l_pobj) %_18\NN\0|NONE (l_appos) %_27\NN\0|of||, (l_prep) of_28\IN\0|,|%| (l_pobj) group_33\NN\2137|NONE (l_compound) mi_32\NNP\14207561|the
24055495
D005690_D003072 CID galactose_4\NN\15062778|term (r_compound) treatment_5\NN\654885|deficits|. (r_nsubj) prevents_6\VBZ\0|NONE (l_dobj) deficits_8\NNS\5113133|treatment|.
D005690_D003072 CID galactose_9\NN\15062778|NONE (l_appos) treatment_18\NN\654885|continuous|daily|oral (l_prep) on_19\IN\0|kg|(|)|in (l_pobj) deficits_21\NNS\5113133|NONE
D005690_D003072 CID galactose_4\NN\15062778|oral (r_compound) treatment_5\NN\654885|NONE (r_pobj) of_2\IN\0|One (r_prep) month_1\NN\15113229|prevented|after|immediately|.|, (r_nsubj) initiated_6\VBD\1617192|NONE (l_conj) prevented_16\VBN\0|after|month|immediately|.|, (l_dobj) development_17\NN\248977|successfully (l_prep) of_18\IN\0|NONE (l_pobj) deficits_26\NNS\5113133|NONE
D005690_D003072 CID galactose_1\NN\15062778|Oral (r_compound) exposure_2\NN\5042871|effects|and|be|.|might (r_nsubj) have_4\VB\7846|NONE (l_conj) be_14\VB\14625458|effects|and|.|might|exposure (l_acomp) worth_15\JJ\13576355|could (l_xcomp) investigating_16\VBG\575741|NONE (l_prep) for_17\IN\0|NONE (l_pobj) improvement_18\NN\7359599|NONE (l_prep) of_19\IN\0|NONE (l_pobj) deficits_21\NNS\5113133|NONE
D005690_D008569 NONE galactose_5\NN\15062778|NONE (r_pobj) of_4\IN\0|Exclusively|daily|parenteral (r_prep) injections_3\NNS\320852|,|tested|used|and|but|deterioration (r_nsubj) induce_6\VBP\1627355|NONE (l_dobj) deterioration_8\NN\14560612|,|tested|used|and|but|injections
D005690_D008569 NONE galactose_25\NN\15062778|on|oral (r_compound) treatment_26\NN\654885|NONE (r_pobj) of_23\IN\0|the (r_prep) effects_22\NNS\13245626|.|have|never|been (r_nsubjpass) tested_33\VBN\670261|,|used|and|but|injections|deterioration (r_conj) induce_6\VBP\1627355|NONE (l_dobj) deterioration_8\NN\14560612|,|tested|used|and|but|injections
D005947_D000544 CID glucose_33\NN\14710501|and|metabolism|decreased|via (r_compound) transport_34\NN\3575240|NONE (r_pobj) by_31\IN\0|NONE (r_agent) followed_30\VBN\1835496|of (r_acl) dysfunction_20\NN\14204950|NONE (r_pobj) with_19\IN\0|that|is|dementia (r_prep) associated_18\VBN\628491|has|research|. (l_nsubjpass) dementia_7\NN\14395018|that|with|is (l_prep) of_8\IN\0|NONE (l_pobj) type_16\NN\5839024|NONE (l_nmod) disease_12\NN\14061805|(|)|sAD
D005947_D000544 CID glucose_36\NN\14710501|transporter (r_compound) glut4_38\NNPS\0|NONE (r_pobj) via_35\IN\0|and|glucose|metabolism|decreased (r_prep) transport_34\NN\3575240|NONE (r_pobj) by_31\IN\0|NONE (r_agent) followed_30\VBN\1835496|of (r_acl) dysfunction_20\NN\14204950|NONE (r_pobj) with_19\IN\0|that|is|dementia (r_prep) associated_18\VBN\628491|has|research|. (l_nsubjpass) dementia_7\NN\14395018|that|with|is (l_prep) of_8\IN\0|NONE (l_pobj) type_16\NN\5839024|NONE (l_nmod) disease_12\NN\14061805|(|)|sAD
D005947_D000544 CID glucose_41\NN\14710501|in|decreased (r_compound) metabolism_42\NN\13526110|and|glucose|decreased|via (r_conj) transport_34\NN\3575240|NONE (r_pobj) by_31\IN\0|NONE (r_agent) followed_30\VBN\1835496|of (r_acl) dysfunction_20\NN\14204950|NONE (r_pobj) with_19\IN\0|that|is|dementia (r_prep) associated_18\VBN\628491|has|research|. (l_nsubjpass) dementia_7\NN\14395018|that|with|is (l_prep) of_8\IN\0|NONE (l_pobj) type_16\NN\5839024|NONE (l_nmod) disease_12\NN\14061805|(|)|sAD
D013311_D003072 CID streptozotocin_16\NNS\0|NONE (r_pobj) with_15\IN\0|intracerebroventricularly (r_prep) treated_13\VBD\2376958|cognitive|in (r_acl) deficits_8\NNS\5113133|treatment|.
D013311_D003072 CID streptozotocin_23\NNS\0| (r_npadvmod) induced_25\VBN\1627355|)|icv|rat|(|of|,|tested (r_amod) model_32\NN\5888929|NONE (r_pobj) in_22\IN\13603305|on|kg|(|) (r_prep) treatment_18\NN\654885|continuous|daily|oral (l_prep) on_19\IN\0|kg|(|)|in (l_pobj) deficits_21\NNS\5113133|NONE
D013311_D003072 CID stz_27\NNP\0| (r_nmod) icv_29\NN\0|)|induced|rat|(|of|,|tested (r_nmod) model_32\NN\5888929|NONE (r_pobj) in_22\IN\13603305|on|kg|(|) (r_prep) treatment_18\NN\654885|continuous|daily|oral (l_prep) on_19\IN\0|kg|(|)|in (l_pobj) deficits_21\NNS\5113133|NONE
D013311_D003072 CID stz_10\NNP\0| (r_compound) icv_12\NN\0|the (r_compound) administration_13\NN\1133281|NONE (r_pobj) after_8\IN\0|prevented|month|immediately|.|, (r_prep) initiated_6\VBD\1617192|NONE (l_conj) prevented_16\VBN\0|after|month|immediately|.|, (l_dobj) development_17\NN\248977|successfully (l_prep) of_18\IN\0|NONE (l_pobj) deficits_26\NNS\5113133|NONE
D013311_D003072 CID stz_20\NNP\0| (r_compound) icv_22\NN\0| (r_npadvmod) induced_24\VBN\1627355|cognitive|the (r_amod) deficits_26\NNS\5113133|NONE
D005947_D003704 NONE glucose_33\NN\14710501|and|metabolism|decreased|via (r_compound) transport_34\NN\3575240|NONE (r_pobj) by_31\IN\0|NONE (r_agent) followed_30\VBN\1835496|of (r_acl) dysfunction_20\NN\14204950|NONE (r_pobj) with_19\IN\0|that|is|dementia (r_prep) associated_18\VBN\628491|has|research|. (l_nsubjpass) dementia_7\NN\14395018|that|with|is
D005947_D003704 NONE glucose_36\NN\14710501|transporter (r_compound) glut4_38\NNPS\0|NONE (r_pobj) via_35\IN\0|and|glucose|metabolism|decreased (r_prep) transport_34\NN\3575240|NONE (r_pobj) by_31\IN\0|NONE (r_agent) followed_30\VBN\1835496|of (r_acl) dysfunction_20\NN\14204950|NONE (r_pobj) with_19\IN\0|that|is|dementia (r_prep) associated_18\VBN\628491|has|research|. (l_nsubjpass) dementia_7\NN\14395018|that|with|is
D005947_D003704 NONE glucose_41\NN\14710501|in|decreased (r_compound) metabolism_42\NN\13526110|and|glucose|decreased|via (r_conj) transport_34\NN\3575240|NONE (r_pobj) by_31\IN\0|NONE (r_agent) followed_30\VBN\1835496|of (r_acl) dysfunction_20\NN\14204950|NONE (r_pobj) with_19\IN\0|that|is|dementia (r_prep) associated_18\VBN\628491|has|research|. (l_nsubjpass) dementia_7\NN\14395018|that|with|is
D005690_D000544 NONE galactose_1\NN\15062778|Oral (r_compound) exposure_2\NN\5042871|effects|and|be|.|might (r_nsubj) have_4\VB\7846|NONE (l_conj) be_14\VB\14625458|effects|and|.|might|exposure (l_acomp) worth_15\JJ\13576355|could (l_xcomp) investigating_16\VBG\575741|NONE (l_prep) for_17\IN\0|NONE (l_pobj) improvement_18\NN\7359599|NONE (l_prep) of_19\IN\0|NONE (l_pobj) deficits_21\NNS\5113133|NONE (l_acl) associated_22\VBN\628491|cognitive (l_prep) with_23\IN\0|NONE (l_pobj) hypometabolism_25\NN\0|NONE (l_prep) in_26\IN\13603305|glucose (l_pobj) ad_27\NN\7247071|NONE
D005690_D018149 NONE galactose_1\NN\15062778|Oral (r_compound) exposure_2\NN\5042871|effects|and|be|.|might (r_nsubj) have_4\VB\7846|NONE (l_conj) be_14\VB\14625458|effects|and|.|might|exposure (l_acomp) worth_15\JJ\13576355|could (l_xcomp) investigating_16\VBG\575741|NONE (l_prep) for_17\IN\0|NONE (l_pobj) improvement_18\NN\7359599|NONE (l_prep) of_19\IN\0|NONE (l_pobj) deficits_21\NNS\5113133|NONE (l_acl) associated_22\VBN\628491|cognitive (l_prep) with_23\IN\0|NONE (l_pobj) hypometabolism_25\NN\0|NONE
24220752
D003287_D009369 NONE contrast_2\NN\13854649| (r_npadvmod) induced_4\VBN\1627355|NONE (r_amod) nephropathy_5\NN\14573196|NONE (r_pobj) of_1\IN\0|.|in (r_prep) incidence_0\NN\13821570|NONE (l_prep) in_6\IN\13603305|.|of (l_pobj) patients_8\NNS\9898892|NONE (l_prep) with_9\IN\0|hospitalised (l_pobj) cancer_10\NN\14239425|NONE
D003287_D009369 NONE contrast_10\NN\13854649| (r_npadvmod) induced_12\VBN\1627355|CIN|(|) (r_amod) nephropathy_13\NN\14573196|NONE (r_pobj) to_9\IN\0|in (r_prep) related_8\VBN\628491|possible (l_prep) in_17\IN\13603305|to (l_pobj) patients_19\NNS\9898892|NONE (l_prep) with_20\IN\0|hospitalised (l_pobj) cancer_21\NN\14239425|NONE
C051890_D006973 NONE irinotecan_9\NN\0|NONE (r_pobj) with_6\IN\0|NONE (r_prep) treatment_5\NN\654885|more|in|and (r_pobj) after_4\IN\0|.|CIN (l_conj) in_16\IN\13603305|more|treatment|and (l_pobj) patients_17\NNS\9898892|NONE (l_prep) with_18\IN\0|NONE (l_pobj) hypertension_19\NN\14057371|NONE
C051890_D006973 NONE irinotecan_7\NN\0|NONE (r_pobj) of_4\IN\0|the (r_prep) combination_3\NN\7951464|and (r_conj) hypertension_0\NN\14057371|factors|.|may
-1_D006973 NONE bevacizumab_7\NN\0|P|/|( (r_amod) irinotecan_9\NN\0|NONE (r_pobj) with_6\IN\0|NONE (r_prep) treatment_5\NN\654885|more|in|and (r_pobj) after_4\IN\0|.|CIN (l_conj) in_16\IN\13603305|more|treatment|and (l_pobj) patients_17\NNS\9898892|NONE (l_prep) with_18\IN\0|NONE (l_pobj) hypertension_19\NN\14057371|NONE
-1_D006973 NONE bevacizumab_5\NN\0|/ (r_amod) irinotecan_7\NN\0|NONE (r_pobj) of_4\IN\0|the (r_prep) combination_3\NN\7951464|and (r_conj) hypertension_0\NN\14057371|factors|.|may
-1_D006973 NONE bevacizumab_4\NN\0|NONE (r_pobj) with_3\IN\0|NONE (r_prep) treatment_2\NN\654885|and (r_conj) hypertension_0\NN\14057371|.|be
D003287_D007674 CID contrast_2\NN\13854649| (r_npadvmod) induced_4\VBN\1627355|NONE (r_amod) nephropathy_5\NN\14573196|NONE
D003287_D007674 CID contrast_10\NN\13854649| (r_npadvmod) induced_12\VBN\1627355|CIN|(|) (r_amod) nephropathy_13\NN\14573196|NONE
D003287_D007674 CID contrast_0\RB\13854649| (r_npadvmod) induced_2\VBN\1627355|is (r_amod) nephropathy_3\NN\14573196|NONE
17069550
D005702_D019958 NONE galantamine_5\NN\0|and|.|appeared|tolerated|In|, (r_nsubj) was_6\VBD\0|NONE (l_conj) appeared_11\VBD\2604760|and|.|tolerated|In|,|galantamine (l_xcomp) be_13\VB\14625458|NONE (l_acomp) beneficial_14\JJ\0|to (l_prep) for_15\IN\0|NONE (l_pobj) treatment_17\NN\654885|NONE (l_prep) of_18\IN\0|the (l_pcomp) interfering_19\VBG\2451370|NONE (l_dobj) behaviors_20\NNS\407535|NONE (l_prep) in_21\IN\13603305|NONE (l_pobj) children_22\NNS\9622049|NONE (l_prep) with_23\IN\0|NONE (l_pobj) autism_24\NN\14304060|NONE (l_appos) aggression_27\NN\4657876|, (l_conj) dyscontrol_30\NN\0|particularly|, (l_conj) inattention_33\NN\5701944|behavioral|,|and
D005702_D001523 NONE galantamine_5\NN\0|and|.|appeared|tolerated|In|, (r_nsubj) was_6\VBD\0|NONE (l_conj) appeared_11\VBD\2604760|and|.|tolerated|In|,|galantamine (l_xcomp) be_13\VB\14625458|NONE (l_acomp) beneficial_14\JJ\0|to (l_prep) for_15\IN\0|NONE (l_pobj) treatment_17\NN\654885|NONE (l_prep) of_18\IN\0|the (l_pcomp) interfering_19\VBG\2451370|NONE (l_dobj) behaviors_20\NNS\407535|NONE (l_prep) in_21\IN\13603305|NONE (l_pobj) children_22\NNS\9622049|NONE (l_prep) with_23\IN\0|NONE (l_pobj) autism_24\NN\14304060|NONE (l_appos) aggression_27\NN\4657876|,
D005702_D001321 NONE galantamine_8\NN\0|NONE (r_pobj) of_7\IN\0|,|A|label|in|prospective|. (r_prep) trial_6\NN\786195|NONE (l_prep) in_9\IN\13603305|,|A|label|of|prospective|. (l_pobj) disorder_11\NN\14034177|NONE
D005702_D001321 NONE galantamine_11\NN\0|NONE (r_pobj) of_10\IN\0|in|the (r_prep) use_9\NN\407535|to (l_prep) in_21\IN\13603305|the|of (l_pobj) treatment_23\NN\654885|NONE (l_prep) of_24\IN\0|the (l_pcomp) interfering_25\VBG\2451370|NONE (l_dobj) behaviors_26\NNS\407535|NONE (l_prep) in_27\IN\13603305|NONE (l_pobj) children_28\NNS\9622049|NONE (l_prep) with_29\IN\0|NONE (l_pobj) autism_30\NN\14304060|NONE
D005702_D001321 NONE galantamine_26\NN\0|NONE (r_pobj) of_25\IN\0|,|week|a|label (r_prep) trial_24\NN\786195|NONE (r_pobj) in_17\IN\13603305|.|children (r_prep) participated_16\VBD\2367363|NONE (l_nsubj) children_4\NNS\9622049|in|. (l_prep) with_5\IN\0|)|free|Thirteen (l_pobj) autism_6\NN\14304060|NONE
D005702_D001321 NONE galantamine_5\NN\0|and|.|appeared|tolerated|In|, (r_nsubj) was_6\VBD\0|NONE (l_conj) appeared_11\VBD\2604760|and|.|tolerated|In|,|galantamine (l_xcomp) be_13\VB\14625458|NONE (l_acomp) beneficial_14\JJ\0|to (l_prep) for_15\IN\0|NONE (l_pobj) treatment_17\NN\654885|NONE (l_prep) of_18\IN\0|the (l_pcomp) interfering_19\VBG\2451370|NONE (l_dobj) behaviors_20\NNS\407535|NONE (l_prep) in_21\IN\13603305|NONE (l_pobj) children_22\NNS\9622049|NONE (l_prep) with_23\IN\0|NONE (l_pobj) autism_24\NN\14304060|NONE
D005702_D006261 CID galantamine_2\NN\0|,|,|.|Overall|with|tolerated (r_nsubj) was_3\VBD\0|NONE (l_prep) with_8\IN\0|,|,|.|Overall|galantamine|tolerated (l_pobj) effects_12\NNS\13245626|NONE (l_advmod) apart_13\RB\0|no|significant|adverse (l_prep) from_14\IN\0|NONE (l_pobj) headaches_15\NNS\5829480|NONE
D005702_D002653 NONE galantamine_5\NN\0|and|.|appeared|tolerated|In|, (r_nsubj) was_6\VBD\0|NONE (l_conj) appeared_11\VBD\2604760|and|.|tolerated|In|,|galantamine (l_xcomp) be_13\VB\14625458|NONE (l_acomp) beneficial_14\JJ\0|to (l_prep) for_15\IN\0|NONE (l_pobj) treatment_17\NN\654885|NONE (l_prep) of_18\IN\0|the (l_pcomp) interfering_19\VBG\2451370|NONE (l_dobj) behaviors_20\NNS\407535|NONE (l_prep) in_21\IN\13603305|NONE (l_pobj) children_22\NNS\9622049|NONE (l_prep) with_23\IN\0|NONE (l_pobj) autism_24\NN\14304060|NONE (l_appos) aggression_27\NN\4657876|, (l_conj) dyscontrol_30\NN\0|particularly|,
20595935
D014700_-1 NONE verapamil_7\NN\2938514|NONE (r_pobj) to_6\IN\0|NONE (r_prep) unresponsiveness_5\NN\4723816|that|as (r_nsubj) defined_8\VBN\2604760|analysis|discriminated|,|. (r_ccomp) revealed_3\VBD\2137132|NONE (l_conj) discriminated_15\VBD\650353|analysis|,|defined|. (l_npadvmod) sensitivity_22\NN\5651971|respectively|effect (l_acl) associated_46\VBN\628491|%|:|(|,|) (l_prep) with_47\IN\0|NONE (l_pobj) pseudoprolactinoma_48\NN\0|NONE
D018967_D006966 CID risperidone_25\NN\0| (r_npadvmod) induced_27\VBN\1627355|PRL|. (r_amod) hyperprolactinemia_28\NN\0|PRL|,|)|:|%|(|,|,|in|N.|and|but
D018967_D006966 CID risperidone_50\NN\0| (r_npadvmod) induced_52\VBN\1627355|NONE (r_amod) hyperprolactinemia_53\NN\0|or
D014700_D015175 NONE verapamil_12\NN\2938514|NONE (r_pobj) of_11\IN\0|in|diagnostic|the (r_prep) value_10\NN\5856066|we|.|Here|, (l_prep) in_13\IN\13603305|of|diagnostic|the (l_pobj) population_15\NN\7942152|NONE (l_relcl) screened_19\VBN\2533282|a (l_prep) for_20\IN\0|who|all|were (l_pobj) macroprolactinemia_21\NN\0|NONE
D014700_D015175 NONE verapamil_1\NNP\2938514|levels|in|significantly|:|macroprolactinoma (r_nsubj) increased_3\VBD\169651|NONE (l_advcl) macroprolactinoma_19\NN\0|levels|in|significantly|Verapamil|:
D014700_D015175 NONE verapamil_1\NNP\2938514|levels|in|significantly|:|macroprolactinoma (r_nsubj) increased_3\VBD\169651|NONE (l_advcl) macroprolactinoma_19\NN\0|levels|in|significantly|Verapamil|: (l_appos) prl_24\NN\0|NONE (l_conj) microprolactinoma_30\NN\0|(|:|,|%|)|,|N.|,|macroprolactinemia
D014700_D015175 NONE verapamil_1\NNP\2938514|levels|in|significantly|:|macroprolactinoma (r_nsubj) increased_3\VBD\169651|NONE (l_advcl) macroprolactinoma_19\NN\0|levels|in|significantly|Verapamil|: (l_appos) prl_24\NN\0|NONE (l_appos) macroprolactinemia_41\JJ\0|(|:|,|%|)|,|N.|,|microprolactinoma
D018967_-1 NONE risperidone_25\NN\0| (r_npadvmod) induced_27\VBN\1627355|PRL|. (r_amod) hyperprolactinemia_28\NN\0|PRL|,|)|:|%|(|,|,|in|N.|and|but (r_conj) prl_4\NN\0|NONE (l_conj) in_12\IN\13603305|hyperprolactinemia|PRL|,|)|:|%|(|,|,|N.|and|but (l_pobj) pseudoprolactinoma_13\NN\0|not
D018967_-1 NONE risperidone_50\NN\0| (r_npadvmod) induced_52\VBN\1627355|NONE (r_amod) hyperprolactinemia_53\NN\0|or (r_conj) pseudoprolactinoma_48\NN\0|NONE
D014700_D006966 NONE verapamil_0\NNP\2938514|stimulation|in|loss|:|. (r_compound) test_2\NN\5798043|NONE (l_prep) in_3\IN\13603305|stimulation|Verapamil|loss|:|. (l_pobj) hyperprolactinemia_4\NN\0|NONE
D014700_D006966 NONE verapamil_0\NNP\2938514|stimulation (r_compound) test_2\NN\5798043|,|previously|but|was|with|.|as (r_nsubjpass) investigated_5\VBN\644583|NONE (l_prep) as_6\IN\14622893|,|previously|but|test|was|with|. (l_pobj) tool_8\NN\3563967|NONE (l_prep) for_9\IN\0|a (l_pobj) diagnosis_11\NN\152018|NONE (l_prep) of_12\IN\0|differential (l_pobj) hyperprolactinemia_13\NN\0|NONE
D014700_D006966 NONE verapamil_3\NN\2938514|NONE (r_pobj) to_2\IN\0|with|in|Prolactin (r_prep) responses_1\NNS\11410625|in|.|were (l_prep) with_16\IN\0|in|Prolactin|to (l_pobj) hyperprolactinemia_17\NN\0|NONE
D014700_D006966 NONE verapamil_7\NN\2938514|NONE (r_pobj) to_6\IN\0|NONE (r_prep) unresponsiveness_5\NN\4723816|that|as (r_nsubj) defined_8\VBN\2604760|analysis|discriminated|,|. (r_ccomp) revealed_3\VBD\2137132|NONE (l_conj) discriminated_15\VBD\650353|analysis|,|defined|. (l_npadvmod) sensitivity_22\NN\5651971|respectively|effect (l_acl) associated_46\VBN\628491|%|:|(|,|) (l_prep) with_47\IN\0|NONE (l_pobj) pseudoprolactinoma_48\NN\0|NONE (l_conj) hyperprolactinemia_53\NN\0|or
D014700_D006966 NONE verapamil_0\NNP\2938514|NONE (r_compound) responsiveness_1\NN\5652926|.|finding|not (r_nsubj) is_2\VBZ\0|NONE (l_attr) finding_6\NN\43195|.|not|responsiveness (l_prep) for_7\IN\0|a|reliable (l_pobj) diagnosis_10\NN\152018|NONE (l_prep) of_11\IN\0|the|differential (l_pobj) hyperprolactinemia_12\NN\0|NONE
D014700_D006966 NONE verapamil_2\NN\2938514|NONE (r_compound) unresponsiveness_3\NN\4723816|However|effect|,|. (r_nsubj) discriminates_4\VBZ\650353|NONE (l_dobj) effect_6\NN\34213|However|,|.|unresponsiveness (l_parataxis) inhibited_13\JJ\2510337|stalk (l_prep) from_17\IN\0|functionally|anatomically|,|(|tonus|i.e.|) (l_pobj) causes_19\NNS\7323922|NONE (l_prep) of_20\IN\0|with|other (l_pobj) hyperprolactinemia_21\NN\0|NONE
3339945
D013806_D020258 NONE theophylline_0\NNP\2905612|in|. (r_amod) neurotoxicity_1\NN\0|NONE
D013806_D020258 NONE theophylline_12\NN\2905612|NONE (r_pobj) of_11\IN\0|the (r_prep) neurotoxicity_10\NN\0|is|whether|in
D013806_D020258 NONE theophylline_15\NN\2905612|NONE (r_pobj) to_14\IN\0|in|neurotoxic|the (r_prep) response_13\NN\11410625|NONE (l_amod) neurotoxic_12\JJ\0|in|to|the
D000628_D012640 CID aminophylline_21\NN\2905612|NONE (r_pobj) of_20\IN\0|NONE (r_prep) infusions_19\NNS\14589223|.|until|rats (r_dobj) received_18\VBD\2210855|NONE (l_prep) until_22\IN\0|.|rats|infusions (l_pobj) onset_23\NN\7325190|NONE (l_prep) of_24\IN\0|NONE (l_pobj) seizures_26\NNS\14081375|NONE
6893265
D011441_D056486 CID propylthiouracil_0\NNP\14727670| (r_npadvmod) induced_2\VBN\1627355|.|hepatic (r_amod) damage_4\NN\7296428|NONE
D011441_D056486 CID propylthiouracil_3\NN\14727670| (r_npadvmod) induced_5\VBN\1627355|liver (r_amod) damage_7\NN\7296428|NONE
16810074
D018738_D006973 NONE hexamethonium_5\NN\0|NONE (r_pobj) with_4\IN\0|ganglionic (r_prep) blockade_3\NN\952963|.|,|Similarly|fall|compared (r_nsubj) caused_6\VBD\1617192|NONE (l_dobj) fall_10\NN\15236475|.|,|Similarly|compared|blockade (l_prep) in_11\IN\13603305|greater|a (l_pobj) rats_14\NNS\2329401|NONE (l_amod) hypertensive_13\JJ\10405694|Hg|LNNA|(|)
D019335_D006973 NONE arginine_21\NN\14605787|)|LNNA|through (r_nmod) hypertension_25\NN\14057371|NONE
D019335_D006973 NONE lnna_23\NNP\0|arginine|)|through (r_nmod) hypertension_25\NN\14057371|NONE
D019335_D006973 NONE lnna_17\NNP\0|NONE (r_compound) hypertension_18\NN\14057371|NONE
D019335_D006973 NONE lnna_25\NNP\0|weeks (r_pobj) after_24\IN\0|was|,|an|pressure|not|in|in|.|at (r_prep) elevated_15\VBN\4048568|NONE (l_prep) in_16\IN\13603305|was|,|after|an|pressure|not|in|.|at (l_pobj) hypertension_18\NN\14057371|NONE
D019335_D006973 NONE lnna_12\NNS\0|Hg|hypertensive|(|) (r_nmod) rats_14\NNS\2329401|NONE (l_amod) hypertensive_13\JJ\10405694|Hg|LNNA|(|)
D009569_D006973 CID oxide_6\NN\14818238|NO|)|( (r_nmod) deficiency_10\NN\14449126|NONE (r_pobj) by_4\IN\0|Mechanisms (r_agent) induced_3\VBN\1627355|on|:|. (l_nsubj) mechanisms_0\NNS\13446390|by (l_prep) of_1\IN\0|NONE (l_pobj) hypertension_2\NN\14057371|NONE
D009569_D006973 CID no_8\NNP\7204911|)|(|oxide (r_intj) deficiency_10\NN\14449126|NONE (r_pobj) by_4\IN\0|Mechanisms (r_agent) induced_3\VBN\1627355|on|:|. (l_nsubj) mechanisms_0\NNS\13446390|by (l_prep) of_1\IN\0|NONE (l_pobj) hypertension_2\NN\14057371|NONE
D009569_D006973 CID oxide_7\NN\14818238|NONE (l_prep) in_11\IN\13603305|NO|nitric|endothelial|(|derived (l_pobj) hypertension_12\NN\14057371|NONE
D009569_D006973 CID no_9\NNP\7204911|nitric|endothelial|(|in|derived (r_appos) oxide_7\NN\14818238|NONE (l_prep) in_11\IN\13603305|NO|nitric|endothelial|(|derived (l_pobj) hypertension_12\NN\14057371|NONE
D009569_D006973 CID no_7\UH\7204911|NONE (r_pobj) of_6\IN\0|the (r_prep) removal_5\NN\383606|NONE (r_pobj) by_3\IN\0|NONE (r_agent) created_2\VBN\0|Experimental (r_acl) hypertension_1\NN\14057371|.|mechanisms|,|,|decreased|however
D009569_D006973 CID no_5\DT\7204911|NONE (r_det) deficiency_6\NN\14449126|in|while|stress (r_nsubj) increases_7\VBZ\13576355|,|that|contribution|not|does|impact (r_advcl) make_26\VB\5839024|data|. (l_dobj) contribution_29\NN\786195|,|that|increases|not|does|impact (l_prep) to_30\IN\0|major|a (l_pobj) form_32\NN\6286395|NONE (l_prep) of_33\IN\0|this (l_pobj) hypertension_34\NN\14057371|NONE
D009569_D018754 NONE oxide_7\NN\14818238|NONE (r_pobj) of_1\IN\0|NONE (r_prep) loss_0\NN\13252973|.|hallmark (r_nsubj) is_13\VBZ\0|NONE (l_attr) hallmark_15\NN\4731497|.|Loss (l_prep) of_16\IN\0|a (l_pobj) dysfunction_18\NN\14204950|NONE
D009569_D018754 NONE no_9\NNP\7204911|nitric|endothelial|(|in|derived (r_appos) oxide_7\NN\14818238|NONE (r_pobj) of_1\IN\0|NONE (r_prep) loss_0\NN\13252973|.|hallmark (r_nsubj) is_13\VBZ\0|NONE (l_attr) hallmark_15\NN\4731497|.|Loss (l_prep) of_16\IN\0|a (l_pobj) dysfunction_18\NN\14204950|NONE
1563460
D014859_D020758 CID coumadin_4\NN\2718259|anticoagulant (r_amod) therapy_6\NN\657604|NONE (r_pobj) to_3\IN\0|report|:|.|secondary|Thoracic (r_prep) hematomyelia_1\NNS\0|NONE
6529939
D011433_D019955 NONE propranolol_6\NN\0|being (r_pcomp) for_5\IN\0|NONE (l_pcomp) being_7\VBG\24720|propranolol (l_attr) cause_9\NN\7323922|NONE (l_prep) of_10\IN\0|the (l_pobj) disorder_13\NN\14034177|NONE
D011433_D000787 NONE propranolol_28\NN\0|NONE (r_pobj) with_25\IN\0|NONE (r_prep) angina_24\NN\14171682|NONE
D011433_D001146 CID propranolol_9\NN\0|NONE (r_pobj) by_8\IN\0|NONE (r_agent) induced_7\VBN\1627355|rhythm|. (r_xcomp) alternating_0\VBG\123170|NONE (l_dobj) rhythm_2\NN\15122011|induced|.
D011433_D001146 CID propranolol_28\NN\0|NONE (r_pobj) with_25\IN\0|NONE (r_prep) angina_24\NN\14171682|NONE (r_pobj) for_23\IN\0|NONE (r_prep) treatment_22\NN\654885|NONE (r_pobj) under_21\IN\0|was|block|in|,|Alternating|. (r_prep) observed_13\VBN\2163746|NONE (l_advcl) alternating_0\VBG\123170|under|was|block|in|,|. (l_dobj) rhythm_2\NN\15122011|NONE
D011433_D012848 CID propranolol_9\NN\0|NONE (r_pobj) by_8\IN\0|NONE (r_agent) induced_7\VBN\1627355|rhythm|. (r_xcomp) alternating_0\VBG\123170|NONE (l_dobj) rhythm_2\NN\15122011|induced|. (l_conj) block_6\NN\21939|sinus|and
D011433_D012848 CID propranolol_28\NN\0|NONE (r_pobj) with_25\IN\0|NONE (r_prep) angina_24\NN\14171682|NONE (r_pobj) for_23\IN\0|NONE (r_prep) treatment_22\NN\654885|NONE (r_pobj) under_21\IN\0|was|block|in|,|Alternating|. (r_prep) observed_13\VBN\2163746|NONE (l_nsubjpass) block_11\NN\21939|under|was|in|,|Alternating|.
D011433_D012848 CID propranolol_8\NN\0|NONE (r_pobj) of_7\IN\0|and|the (r_prep) withdrawal_6\NN\7206096|NONE (r_pobj) with_4\IN\0|rhythm (r_prep) disappeared_3\VBD\0|block|restarted|was|. (r_ccomp) seen_22\VBN\2106506|NONE (l_nsubjpass) block_20\NN\21939|restarted|was|disappeared|.
24812279
D004317_D066126 NONE doxorubicin_2\NNP\2716866|but|associated|therapeutic|, (r_nsubj) is_6\VBZ\0|.|: (l_conj) associated_16\VBN\628491|but|therapeutic|Doxorubicin|, (l_prep) with_17\IN\0|is (l_pobj) cardiotoxicity_24\NN\0|NONE
D004317_D066126 NONE dox_4\NNP\0|) (r_appos) doxorubicin_2\NNP\2716866|but|associated|therapeutic|, (r_nsubj) is_6\VBZ\0|.|: (l_conj) associated_16\VBN\628491|but|therapeutic|Doxorubicin|, (l_prep) with_17\IN\0|is (l_pobj) cardiotoxicity_24\NN\0|NONE
D004317_D066126 NONE dox_13\NNP\0|stage (r_compound) cardiotoxicity_14\NN\0|NONE
D004317_D006333 CID dox_5\NNP\0| (r_npadvmod) induced_7\VBN\1627355|heart (r_amod) failure_9\NN\66216|NONE
D004317_D009369 NONE doxorubicin_2\NNP\2716866|but|associated|therapeutic|, (r_nsubj) is_6\VBZ\0|.|: (l_attr) therapeutic_12\NN\3740161|but|associated|Doxorubicin|, (l_compound) cancer_11\NN\14239425|effective|an
D004317_D009369 NONE dox_4\NNP\0|) (r_appos) doxorubicin_2\NNP\2716866|but|associated|therapeutic|, (r_nsubj) is_6\VBZ\0|.|: (l_attr) therapeutic_12\NN\3740161|but|associated|Doxorubicin|, (l_compound) cancer_11\NN\14239425|effective|an
D018943_D066126 NONE anthracycline_6\NN\0|stage (r_amod) cardiotoxicity_7\NN\0|.|inhibition
3538855
D000617_D008107 NONE aminoglycoside_13\NN\0|therapy (r_compound) levels_14\NNS\4916342|NONE (r_pobj) of_9\IN\0|,|gender|disease|the (r_prep) duration_8\NN\15113229|that|all|risk (l_appos) disease_17\NN\14061805|,|of|gender|the
D000617_D058186 NONE aminoglycosides_3\NNS\0|NONE (r_pobj) of_2\IN\0|in|Clinical (r_prep) trials_1\NNS\786195|ranges|. (r_nsubj) indicate_8\VBP\952524|NONE (l_ccomp) ranges_20\VBZ\5123416|trials|. (l_nsubj) risk_12\NN\14541044|and|that|from|is (l_prep) for_13\IN\0|the|relative (l_pcomp) developing_14\VBG\13541167|NONE (l_dobj) failure_17\NN\66216|during
D000617_D007674 CID aminoglycoside_5\NN\0|NONE (r_compound) nephrotoxicity_6\NN\0|NONE
D000617_D007674 CID aminoglycoside_3\NN\0|NONE (r_pobj) of_2\IN\0|The (r_prep) epidemiology_1\NN\6043075| (r_nsubj) induced_5\VBN\1627355|NONE (r_amod) nephrotoxicity_6\NN\0|fully|is|not|.
D000617_D007674 CID aminoglycosides_7\NNS\0|studies|.|cause (r_dobj) indicate_6\VBP\952524|NONE (l_conj) cause_8\VBP\7323922|studies|.|aminoglycosides (l_conj) cause_22\VB\7323922|,|but|damage (l_dobj) dysfunction_26\NN\14204950|ever|rarely|,|,
D000617_D007674 CID aminoglycoside_13\NN\0|therapy (r_compound) levels_14\NNS\4916342|NONE (r_pobj) of_9\IN\0|,|gender|disease|the (r_prep) duration_8\NN\15113229|that|all|risk (r_nsubj) increase_34\VBP\13576355|analysis|. (l_dobj) risk_36\NN\14541044|that|all|duration (l_prep) for_37\IN\0|the (l_pobj) nephrotoxicity_38\NN\0|NONE
D000617_D007674 CID aminoglycoside_13\NN\0| (r_npadvmod) induced_15\VBN\1627355|NONE (r_amod) nephrotoxicity_16\NN\0|NONE
D003404_D007674 NONE creatinine_25\NN\0|high|,|possibly|and|estimated|initial (r_compound) clearance_26\NN\5089947|,|advanced (r_conj) age_20\NN\4916342|,|liver (r_conj) disease_17\NN\14061805|,|of|gender|the (r_appos) duration_8\NN\15113229|that|all|risk (r_nsubj) increase_34\VBP\13576355|analysis|. (l_dobj) risk_36\NN\14541044|that|all|duration (l_prep) for_37\IN\0|the (l_pobj) nephrotoxicity_38\NN\0|NONE
D003404_D008107 NONE creatinine_25\NN\0|high|,|possibly|and|estimated|initial (r_compound) clearance_26\NN\5089947|,|advanced (r_conj) age_20\NN\4916342|,|liver (r_conj) disease_17\NN\14061805|,|of|gender|the
15817013
D014859_D001281 NONE warfarin_8\NN\2718259|NONE (r_pobj) on_7\IN\0|atrial (r_prep) fibrillation_6\NN\14361664|NONE
D014859_D001281 NONE warfarin_22\NN\2718259|NONE (r_pobj) on_18\IN\0|atrial (r_prep) fibrillation_17\NN\14361664|NONE
D014859_D001281 NONE warfarin_32\NN\2718259|NONE (r_pobj) on_31\IN\0|atrial (r_prep) fibrillation_30\NN\14361664|NONE
D014859_D006470 CID warfarin_8\NN\2718259|NONE (r_pobj) on_7\IN\0|atrial (r_prep) fibrillation_6\NN\14361664|NONE (r_pobj) in_4\IN\13603305|over (r_prep) 75_3\CD\0|NONE (r_dobj) aged_1\VBN\7943480|rate|:|. (r_acl) people_0\NNS\31264|NONE (l_appos) rate_11\NN\13815152|:|aged|. (l_prep) of_12\IN\0|the (l_pobj) hemorrhage_14\NN\14285662|NONE
D014859_D006470 CID warfarin_22\NN\2718259|NONE (r_pobj) on_18\IN\0|atrial (r_prep) fibrillation_17\NN\14361664|NONE (r_pobj) with_15\IN\0| (r_prep) aged_11\VBN\7943480|admitted (r_acl) people_10\NNS\31264|NONE (r_pobj) in_9\IN\13603305|NONE (r_prep) stroke_8\NN\556313|and|major (r_conj) hemorrhage_6\NN\14285662|NONE
D014859_D006470 CID warfarin_9\JJ\2718259|NONE (r_compound) use_10\NN\407535|,|and (r_conj) strokes_6\NNS\556313|bleeding|major|, (r_conj) episodes_4\NNS\7283608|NONE (l_compound) bleeding_3\VBG\14285662|strokes|major|,
D014859_D006470 CID warfarin_31\NN\2718259|NONE (r_pobj) on_30\IN\0|stroke|the (r_prep) rate_29\NN\13815152|low|, (r_nsubj) was_32\VBD\0|.|demonstrating|,|in (r_ccomp) resulted_18\VBD\2633881|rate|excluding|but|,|high|in (r_conj) was_5\VBD\0|NONE (l_nsubj) rate_1\NN\13815152|excluding|but|,|high|in|resulted (l_prep) of_2\IN\0|The (l_pobj) hemorrhage_4\NN\14285662|NONE
D014859_D006470 CID warfarin_38\JJ\2718259|NONE (r_compound) treatment_39\NN\654885|effective (r_nsubj) is_40\VBZ\0|NONE (r_ccomp) demonstrating_35\VBG\2137132|was|.|,|in (r_advcl) resulted_18\VBD\2633881|rate|excluding|but|,|high|in (r_conj) was_5\VBD\0|NONE (l_nsubj) rate_1\NN\13815152|excluding|but|,|high|in|resulted (l_prep) of_2\IN\0|The (l_pobj) hemorrhage_4\NN\14285662|NONE
D014859_D020521 NONE warfarin_8\NN\2718259|NONE (r_pobj) on_7\IN\0|atrial (r_prep) fibrillation_6\NN\14361664|NONE (r_pobj) in_4\IN\13603305|over (r_prep) 75_3\CD\0|NONE (r_dobj) aged_1\VBN\7943480|rate|:|. (r_acl) people_0\NNS\31264|NONE (l_appos) rate_11\NN\13815152|:|aged|. (l_prep) of_12\IN\0|the (l_pobj) hemorrhage_14\NN\14285662|NONE (l_conj) stroke_16\NN\556313|and|major
D014859_D020521 NONE warfarin_22\NN\2718259|NONE (r_pobj) on_18\IN\0|atrial (r_prep) fibrillation_17\NN\14361664|NONE (r_pobj) with_15\IN\0| (r_prep) aged_11\VBN\7943480|admitted (r_acl) people_10\NNS\31264|NONE (r_pobj) in_9\IN\13603305|NONE (r_prep) stroke_8\NN\556313|and|major
D014859_D020521 NONE warfarin_9\JJ\2718259|NONE (r_compound) use_10\NN\407535|,|and (r_conj) strokes_6\NNS\556313|bleeding|major|,
D014859_D020521 NONE warfarin_7\NN\2718259|NONE (r_pobj) of_6\IN\0|NONE (r_prep) initiation_5\NN\7450842|NONE (r_pobj) after_4\IN\0|annual|The|stroke (r_prep) rate_3\NN\13815152|%|. (l_compound) stroke_2\NN\556313|annual|after|The
D014859_D020521 NONE warfarin_31\NN\2718259|NONE (r_pobj) on_30\IN\0|stroke|the (r_prep) rate_29\NN\13815152|low|, (l_compound) stroke_28\NN\556313|the|on
D014859_D020521 NONE warfarin_38\JJ\2718259|NONE (r_compound) treatment_39\NN\654885|effective (r_nsubj) is_40\VBZ\0|NONE (r_ccomp) demonstrating_35\VBG\2137132|was|.|,|in (r_advcl) resulted_18\VBD\2633881|rate|excluding|but|,|high|in (l_ccomp) was_32\VBD\0|.|demonstrating|,|in (l_nsubj) rate_29\NN\13815152|low|, (l_compound) stroke_28\NN\556313|the|on
19178808
D015742_D006470 NONE propofol_54\NN\0| (r_compound) remifentanil_56\NN\0|NONE (r_compound) total_57\JJ\3553|TIVA|i.v.|(|) (r_amod) anesthesia_59\NN\14034177|NONE (r_pobj) by_53\IN\0|NONE (r_agent) induced_52\VBN\1627355|controlled|hypotension (r_acl) anesthesia_51\NN\14034177|NONE (r_dobj) maintaining_48\VBG\0|NONE (r_pcomp) in_47\IN\13603305|airway|versus (r_prep) using_32\VBG\418025|during|to|conditions (r_advcl) compare_7\VB\4744814|purpose|. (l_dobj) conditions_9\NNS\14512817|using|during|to (l_prep) including_11\VBG\0|surgical|,|, (l_pobj) amount_13\NN\13329641|NONE (l_prep) of_14\IN\0|the (l_pobj) bleeding_16\NN\14285662|NONE
C071741_D006470 NONE remifentanil_56\NN\0|NONE (r_compound) total_57\JJ\3553|TIVA|i.v.|(|) (r_amod) anesthesia_59\NN\14034177|NONE (r_pobj) by_53\IN\0|NONE (r_agent) induced_52\VBN\1627355|controlled|hypotension (r_acl) anesthesia_51\NN\14034177|NONE (r_dobj) maintaining_48\VBG\0|NONE (r_pcomp) in_47\IN\13603305|airway|versus (r_prep) using_32\VBG\418025|during|to|conditions (r_advcl) compare_7\VB\4744814|purpose|. (l_dobj) conditions_9\NNS\14512817|using|during|to (l_prep) including_11\VBG\0|surgical|,|, (l_pobj) amount_13\NN\13329641|NONE (l_prep) of_14\IN\0|the (l_pobj) bleeding_16\NN\14285662|NONE
D015742_D007022 CID propofol_54\NN\0| (r_compound) remifentanil_56\NN\0|NONE (r_compound) total_57\JJ\3553|TIVA|i.v.|(|) (r_amod) anesthesia_59\NN\14034177|NONE (r_pobj) by_53\IN\0|NONE (r_agent) induced_52\VBN\1627355|controlled|hypotension (r_acl) anesthesia_51\NN\14034177|NONE (l_compound) hypotension_50\NN\14057371|induced|controlled
D015742_D007022 CID propofol_19\JJ\0|remifentanil|| (r_compound) tiva_23\NNP\0|NONE (r_pobj) by_18\IN\0|NONE (r_agent) caused_17\VBN\1617192|controlled|hypotension (r_acl) anesthesia_16\NN\14034177|NONE (l_compound) hypotension_15\NN\14057371|controlled|caused
C071741_D007022 CID remifentanil_56\NN\0|NONE (r_compound) total_57\JJ\3553|TIVA|i.v.|(|) (r_amod) anesthesia_59\NN\14034177|NONE (r_pobj) by_53\IN\0|NONE (r_agent) induced_52\VBN\1627355|controlled|hypotension (r_acl) anesthesia_51\NN\14034177|NONE (l_compound) hypotension_50\NN\14057371|induced|controlled
C071741_D007022 CID remifentanil_21\NN\0|||propofol (r_compound) tiva_23\NNP\0|NONE (r_pobj) by_18\IN\0|NONE (r_agent) caused_17\VBN\1617192|controlled|hypotension (r_acl) anesthesia_16\NN\14034177|NONE (l_compound) hypotension_15\NN\14057371|controlled|caused
C071741_D007022 CID remifentanil_15\NN\0|NONE (r_compound) infusion_16\NN\14589223|NONE (r_pobj) of_14\IN\0|lower (r_prep) rates_13\NNS\13308999|and (r_dobj) using_11\VBG\418025|mask (r_xcomp) using_8\VBG\418025|shorter|a (r_acl) period_7\NN\13575869|NONE (r_pobj) within_4\IN\0|.|dose|hypotension|was (r_prep) achieved_3\VBN\2524171|NONE (l_nsubjpass) hypotension_1\NN\14057371|.|within|dose|was
C071741_D007022 CID remifentanil_22\NN\0|NONE (r_pobj) of_21\IN\0|lower|total (r_prep) dose_20\NN\3740161|.|within|hypotension|was (r_dobj) achieved_3\VBN\2524171|NONE (l_nsubjpass) hypotension_1\NN\14057371|.|within|dose|was
C071741_D007022 CID remifentanil_39\NN\0|NONE (r_pobj) of_38\IN\0|low (r_prep) doses_37\NNS\3740161|NONE (r_pobj) with_35\IN\0|convenient|induced|in|during (r_prep) hypotension_34\NN\14057371|NONE (r_pobj) for_31\IN\0|NONE (r_prep) allowed_30\VBN\0|FRLMA|management|and|during (r_conj) using_9\VBG\418025|,|results|In|. (l_prep) during_11\IN\0|FRLMA|management|allowed|and (l_pobj) anesthesia_14\NN\14034177|NONE (l_compound) hypotension_13\NN\14057371|controlled|provided
C071741_D007022 CID remifentanil_39\NN\0|NONE (r_pobj) of_38\IN\0|low (r_prep) doses_37\NNS\3740161|NONE (r_pobj) with_35\IN\0|convenient|induced|in|during (r_prep) hypotension_34\NN\14057371|NONE
7121659
D012293_D006461 CID rifampicin_18\NNS\0|NONE (r_pobj) of_17\IN\0|the (r_prep) reintroduction_16\NN\7217349|NONE (r_pobj) by_14\IN\0|NONE (r_agent) induced_13\VBN\1627355||with| (r_acl) patients_1\NNS\9898892|are|. (l_appos) 3_7\CD\13741022|with||induced (l_prep) with_8\IN\0|(|) (l_pobj) thrombopenia_9\NN\14189204|NONE (l_conj) hemolysis_11\NN\13509528|and
D012293_D013921 CID rifampicin_18\NNS\0|NONE (r_pobj) of_17\IN\0|the (r_prep) reintroduction_16\NN\7217349|NONE (r_pobj) by_14\IN\0|NONE (r_agent) induced_13\VBN\1627355||with| (r_acl) patients_1\NNS\9898892|are|. (l_appos) 3_7\CD\13741022|with||induced (l_prep) with_8\IN\0|(|) (l_pobj) thrombopenia_9\NN\14189204|NONE
D012293_D058186 NONE rifampicin_18\NNS\0|NONE (r_pobj) of_17\IN\0|the (r_prep) reintroduction_16\NN\7217349|NONE (r_pobj) by_14\IN\0|NONE (r_agent) induced_13\VBN\1627355||with| (r_acl) patients_1\NNS\9898892|are|. (l_prep) with_2\IN\0|||induced (l_pobj) failure_5\NN\66216|NONE
D012293_D051437 NONE rifampicin_4\NN\0| (r_npadvmod) associated_6\VBN\628491|renal|acute (r_amod) failure_8\NN\66216|NONE
12644816
D013792_D019337 NONE thalidomide_4\NN\4166841|NONE (r_pobj) of_3\IN\0|The|antiangiogenic (r_prep) effects_2\NNS\13245626|.|in|have|been (r_nsubjpass) assessed_7\VBN\670261|NONE (l_prep) in_8\IN\13603305|effects|.|have|been (l_pobj) trials_10\NNS\786195|NONE (l_prep) in_11\IN\13603305|clinical (l_pobj) patients_12\NNS\9898892|NONE (l_prep) with_13\IN\0|NONE (l_pobj) malignancies_18\NNS\14070360|NONE
D013792_D011471 NONE thalidomide_11\NN\4166841|NONE (l_prep) in_12\IN\13603305|dose (l_pobj) cancer_17\NN\14239425|NONE
D013792_D011471 NONE thalidomide_8\NN\4166841|for|daily (r_dobj) using_7\VBG\418025|an|label (l_prep) for_13\IN\0|daily|thalidomide (l_pobj) months_17\NNS\15113229|NONE (l_prep) in_18\IN\13603305| (l_pobj) men_20\NNS\8208016|NONE (l_prep) with_21\IN\0| (l_pobj) cancer_26\NN\14239425|NONE
D013792_D010523 CID thalidomide_9\NN\4166841|NONE (r_pobj) on_8\IN\0|who|months (r_prep) completed_5\VBD\352826|seven|the (r_relcl) men_3\NNS\8208016|NONE (r_pobj) in_0\IN\13603305|.|but|,|in|in|evidence|was (r_prep) found_17\VBN\13279262|NONE (l_nsubjpass) evidence_12\NN\5816287|.|but|,|in|In|in|was (l_prep) of_13\IN\0|subclinical (l_pobj) neuropathy_15\NN\14204950|NONE
D013792_D010523 CID thalidomide_4\NN\4166841|may|option|,|that (r_nsubj) be_6\VB\14625458|findings|.|provided (r_ccomp) indicate_2\VBP\952524|NONE (l_ccomp) provided_19\VBD\2199590|findings|.|be (l_dobj) maintained_25\VBN\0|NONE (l_prep) for_26\IN\0|up|is (l_pobj) development_27\NN\248977|NONE (l_prep) of_28\IN\0|NONE (l_pobj) neuropathy_30\NN\14204950|NONE
D000728_D011471 NONE androgen_13\JJ\14745635| (r_npadvmod) independent_15\JJ\9619824|prostate (r_amod) cancer_17\NN\14239425|NONE
D000728_D011471 NONE androgen_22\JJ\14745635| (r_npadvmod) independent_24\JJ\9619824|prostate (r_amod) cancer_26\NN\14239425|NONE
3990093
D011692_D009401 NONE aminonucleoside_8\JJ\0|NONE (r_amod) nephrosis_9\NN\14304060|NONE
D011692_D009401 NONE pan_7\NNP\3101986|NONE (r_compound) nephrosis_8\NN\14304060|NONE
D011692_D007674 NONE aminonucleoside_8\JJ\0|NONE (r_amod) nephrosis_9\NN\14304060|NONE (r_pobj) with_7\IN\0|NONE (r_prep) rats_6\NNS\2329401|NONE (r_pobj) in_5\IN\13603305|glomerular (r_prep) sclerosis_4\NN\14204950|and|Mesangial|.
D011692_D007674 NONE aminonucleoside_16\NN\0|)|(|PAN (r_nmod) model_20\NN\5888929|.|relationship|in|was (r_advcl) studied_12\VBN\0|NONE (l_nsubjpass) relationship_2\NN\31921|.|model|in|was (l_prep) between_3\IN\0|possible|The (l_pobj) dysfunction_5\NN\14204950|NONE
D011692_D007674 NONE aminonucleoside_16\NN\0|)|(|PAN (r_nmod) model_20\NN\5888929|.|relationship|in|was (r_advcl) studied_12\VBN\0|NONE (l_nsubjpass) relationship_2\NN\31921|.|model|in|was (l_prep) between_3\IN\0|possible|The (l_pobj) dysfunction_5\NN\14204950|NONE (l_prep) of_8\IN\0|mesangial|and|development (l_pobj) sclerosis_10\NN\14204950|NONE
D011692_D007674 NONE pan_18\NNP\3101986|)|(|aminonucleoside (r_nmod) model_20\NN\5888929|.|relationship|in|was (r_advcl) studied_12\VBN\0|NONE (l_nsubjpass) relationship_2\NN\31921|.|model|in|was (l_prep) between_3\IN\0|possible|The (l_pobj) dysfunction_5\NN\14204950|NONE
D011692_D007674 NONE pan_18\NNP\3101986|)|(|aminonucleoside (r_nmod) model_20\NN\5888929|.|relationship|in|was (r_advcl) studied_12\VBN\0|NONE (l_nsubjpass) relationship_2\NN\31921|.|model|in|was (l_prep) between_3\IN\0|possible|The (l_pobj) dysfunction_5\NN\14204950|NONE (l_prep) of_8\IN\0|mesangial|and|development (l_pobj) sclerosis_10\NN\14204950|NONE
D011692_D007674 NONE pan_16\NNP\3101986|NONE (r_compound) rats_17\NNS\2329401|NONE (r_pobj) of_15\IN\0|the (r_prep) glomeruli_14\NN\5425910|NONE (r_pobj) of_12\IN\0|+/|.|. (r_prep) %_11\NN\0|NONE (r_pobj) in_7\IN\13603305|At|was|sclerosis|;|were (r_prep) found_6\VBN\13279262|NONE (l_nsubjpass) sclerosis_4\NN\14204950|At|was|in|;|were
D011692_D007674 NONE pan_7\NNP\3101986|NONE (r_compound) nephrosis_8\NN\14304060|NONE (r_pobj) in_6\IN\13603305|remnant|kidney|the (r_prep) model_5\NN\5888929|NONE (r_pobj) to_1\IN\0|NONE (r_prep) similar_0\JJ\0|may|.|be|development|"|to (r_nsubjpass) related_16\VBN\628491|NONE (l_nsubjpass) development_10\NN\248977|may|Similar|.|be|"|to (l_prep) of_11\IN\0|the (l_pobj) sclerosis_13\NN\14204950|NONE
D011692_D011507 CID pan_4\NNP\3101986|the (r_compound) rats_5\NNS\2329401|NONE (r_nsubj) were_6\VBD\0|severely|given|After|,|and|hr (r_auxpass) proteinuric_8\JJ\0|NONE
D002244_D011507 NONE carbon_23\NN\14622893|.|rats|intravenously|were (r_dobj) given_21\VBN\5892096|were|severely|After|,|and|hr (r_conj) proteinuric_8\JJ\0|NONE
D011692_D012598 NONE pan_12\NNP\3101986|chronic (r_compound) treatment_13\NN\654885|NONE (r_pobj) during_10\IN\0|Since|not|did|clearance (r_prep) change_9\VB\7283608|,|we|.|caused (r_advcl) conclude_16\VBP\628491|NONE (l_ccomp) caused_26\VBN\1617192|,|we|.|change (l_agent) by_27\IN\0|that|is|localization (l_pobj) uptake_31\NN\13440063|NONE (l_prep) after_33\IN\0|an|increased|CC (l_pobj) injection_34\NN\320852|shortly (l_prep) in_35\IN\13603305|NONE (l_pobj) areas_38\NNS\8630985|NONE (l_relcl) develop_42\VB\1753788|vulnerable|apparent (l_nsubj) sclerosis_40\NN\14204950|where|subsequently|will
17346443
D003300_D001523 NONE copper_10\NN\14821043|hepatic (r_compound) metabolism_11\NN\13526110|NONE (r_pobj) of_8\IN\0|with|an|recessive|autosomal (r_prep) disorder_7\NN\14034177|.|disease (l_prep) with_12\IN\0|an|recessive|autosomal|of (l_pobj) accumulation_15\NN\13497135|NONE (l_prep) in_18\IN\13603305|toxicity|consequent|copper|and (l_pobj) tissues_20\NNS\5220461|NONE (l_conj) disorders_28\NNS\14034177|many|and
D003300_D001523 NONE copper_14\NN\14821043|toxicity|consequent|and|in (r_compound) accumulation_15\NN\13497135|NONE (l_prep) in_18\IN\13603305|toxicity|consequent|copper|and (l_pobj) tissues_20\NNS\5220461|NONE (l_conj) disorders_28\NNS\14034177|many|and
D010396_D017512 CID penicillamine_0\NN\3740161| (r_npadvmod) related_2\VBN\628491|utility|in|and|.|lichenoid (r_amod) dermatitis_4\NN\14226056|NONE
D010396_D017512 CID penicillamine_9\NN\3740161|and|During|,|after|,|permitted|was (r_nsubjpass) interrupted_11\VBN\362348|NONE (l_prep) after_12\IN\0|and|During|penicillamine|,|,|permitted|was (l_pobj) appearance_14\NN\4723816|NONE (l_prep) of_15\IN\0|the (l_pobj) dermatitis_18\NN\14226056|NONE
D010396_D006527 NONE penicillamine_0\NN\3740161| (r_npadvmod) related_2\VBN\628491|utility|in|and|.|lichenoid (r_amod) dermatitis_4\NN\14226056|NONE (l_prep) in_10\IN\13603305|utility|related|and|.|lichenoid (l_pobj) patient_14\JJ\9898892|NONE (l_compound) disease_13\NN\14061805|a|with
D010396_D006527 NONE penicillamine_20\NN\3740161| (r_npadvmod) related_22\VBN\628491|side (r_amod) effects_24\NNS\13245626|in (r_nsubj) appeared_25\VBD\2604760|for|effective|an (r_relcl) treatment_11\NN\654885|.|therapy|In (l_prep) for_12\IN\0|effective|an|appeared (l_pobj) patient_17\NN\9898892|NONE (l_compound) disease_16\NN\14061805|Wilson
D010396_D006527 NONE penicillamine_6\NN\3740161| (r_npadvmod) treated_8\VBN\2376958|disease|Wilson (r_amod) patients_9\NNS\9898892|NONE (l_nmod) disease_5\NN\14061805|treated|Wilson
D019345_D001008 NONE acetate_9\NN\15010703|NONE (r_pobj) of_7\IN\0|NONE (r_prep) utility_6\NN\8186047|in|related|and|.|lichenoid (r_conj) dermatitis_4\NN\14226056|NONE (l_prep) in_10\IN\13603305|utility|related|and|.|lichenoid (l_pobj) patient_14\JJ\9898892|NONE (l_prep) with_15\IN\0|a|disease (l_pobj) presentation_17\NN\1027379|NONE (l_conj) anxiety_19\NN\14373582|,|hepatic
D010396_D012871 NONE penicillamine_6\NN\3740161| (r_npadvmod) treated_8\VBN\2376958|disease|Wilson (r_amod) patients_9\NNS\9898892|NONE (r_pobj) of_2\IN\0|NONE (r_prep) most_1\JJS\0|Since|not|do|develop (r_nsubj) seem_12\VB\2604760|conceivable|,|could|it|involved|. (l_xcomp) develop_14\VB\1753788|Since|not|do|most (l_dobj) lesion_17\NN\14204950|to
D010396_D001008 NONE penicillamine_0\NN\3740161| (r_npadvmod) related_2\VBN\628491|utility|in|and|.|lichenoid (r_amod) dermatitis_4\NN\14226056|NONE (l_prep) in_10\IN\13603305|utility|related|and|.|lichenoid (l_pobj) patient_14\JJ\9898892|NONE (l_prep) with_15\IN\0|a|disease (l_pobj) presentation_17\NN\1027379|NONE (l_conj) anxiety_19\NN\14373582|,|hepatic
D003300_D056486 NONE copper_10\NN\14821043|hepatic (r_compound) metabolism_11\NN\13526110|NONE (r_pobj) of_8\IN\0|with|an|recessive|autosomal (r_prep) disorder_7\NN\14034177|.|disease (l_prep) with_12\IN\0|an|recessive|autosomal|of (l_pobj) accumulation_15\NN\13497135|NONE (l_prep) in_18\IN\13603305|toxicity|consequent|copper|and (l_pobj) tissues_20\NNS\5220461|NONE (l_conj) disorders_28\NNS\14034177|many|and
D003300_D056486 NONE copper_14\NN\14821043|toxicity|consequent|and|in (r_compound) accumulation_15\NN\13497135|NONE (l_prep) in_18\IN\13603305|toxicity|consequent|copper|and (l_pobj) tissues_20\NNS\5220461|NONE (l_conj) disorders_28\NNS\14034177|many|and
D003300_D006527 NONE copper_10\NN\14821043|hepatic (r_compound) metabolism_11\NN\13526110|NONE (r_pobj) of_8\IN\0|with|an|recessive|autosomal (r_prep) disorder_7\NN\14034177|.|disease (r_attr) is_3\VBZ\0|NONE (l_nsubj) disease_2\NN\14061805|.|disorder
D003300_D006527 NONE copper_14\NN\14821043|toxicity|consequent|and|in (r_compound) accumulation_15\NN\13497135|NONE (r_pobj) with_12\IN\0|an|recessive|autosomal|of (r_prep) disorder_7\NN\14034177|.|disease (r_attr) is_3\VBZ\0|NONE (l_nsubj) disease_2\NN\14061805|.|disorder
D003300_D009422 NONE copper_10\NN\14821043|hepatic (r_compound) metabolism_11\NN\13526110|NONE (r_pobj) of_8\IN\0|with|an|recessive|autosomal (r_prep) disorder_7\NN\14034177|.|disease (l_prep) with_12\IN\0|an|recessive|autosomal|of (l_pobj) accumulation_15\NN\13497135|NONE (l_prep) in_18\IN\13603305|toxicity|consequent|copper|and (l_pobj) tissues_20\NNS\5220461|NONE (l_conj) disorders_28\NNS\14034177|many|and
D003300_D009422 NONE copper_14\NN\14821043|toxicity|consequent|and|in (r_compound) accumulation_15\NN\13497135|NONE (l_prep) in_18\IN\13603305|toxicity|consequent|copper|and (l_pobj) tissues_20\NNS\5220461|NONE (l_conj) disorders_28\NNS\14034177|many|and
D019345_D017512 NONE acetate_9\NN\15010703|NONE (r_pobj) of_7\IN\0|NONE (r_prep) utility_6\NN\8186047|in|related|and|.|lichenoid (r_conj) dermatitis_4\NN\14226056|NONE
D019345_D017512 NONE acetate_22\NN\15010703|.|continue (r_nsubj) permitted_23\VBD\797697|and|During|penicillamine|,|after|,|was (r_conj) interrupted_11\VBN\362348|NONE (l_prep) after_12\IN\0|and|During|penicillamine|,|,|permitted|was (l_pobj) appearance_14\NN\4723816|NONE (l_prep) of_15\IN\0|the (l_pobj) dermatitis_18\NN\14226056|NONE
D019345_D006527 NONE acetate_9\NN\15010703|NONE (r_pobj) of_7\IN\0|NONE (r_prep) utility_6\NN\8186047|in|related|and|.|lichenoid (r_conj) dermatitis_4\NN\14226056|NONE (l_prep) in_10\IN\13603305|utility|related|and|.|lichenoid (l_pobj) patient_14\JJ\9898892|NONE (l_compound) disease_13\NN\14061805|a|with
D019345_D006527 NONE acetate_7\NN\15010703|NONE (r_pobj) with_5\IN\0|the (r_prep) therapy_4\NN\657604|.|In|treatment (r_nsubj) represented_8\VBD\2664769|NONE (l_dobj) treatment_11\NN\654885|.|therapy|In (l_prep) for_12\IN\0|effective|an|appeared (l_pobj) patient_17\NN\9898892|NONE (l_compound) disease_16\NN\14061805|Wilson
D019345_D006527 NONE acetate_5\NN\15010703|NONE (r_pobj) of_2\IN\0|The (r_prep) safety_1\NN\13920835|avoid (r_nsubj) allowed_6\VBD\0|observation|;|in|. (r_ccomp) is_18\VBZ\0|NONE (l_prep) in_19\IN\13603305|allowed|observation|;|. (l_pobj) line_20\NN\8426461|NONE (l_prep) with_21\IN\0|NONE (l_pobj) evidence_24\NN\5816287|NONE (l_prep) on_25\IN\0|growing|the (l_pobj) efficacy_27\NN\5199286|NONE (l_prep) of_28\IN\0|the (l_pobj) drug_30\NN\14778436|NONE (l_prep) in_31\IN\13603305|the (l_pobj) treatment_33\NN\654885|NONE (l_prep) of_34\IN\0|the (l_pobj) disease_37\NN\14061805|NONE
D003300_D064420 NONE copper_10\NN\14821043|hepatic (r_compound) metabolism_11\NN\13526110|NONE (r_pobj) of_8\IN\0|with|an|recessive|autosomal (r_prep) disorder_7\NN\14034177|.|disease (l_prep) with_12\IN\0|an|recessive|autosomal|of (l_pobj) accumulation_15\NN\13497135|NONE (l_conj) toxicity_17\NN\13576101|consequent|copper|and|in
D003300_D064420 NONE copper_14\NN\14821043|toxicity|consequent|and|in (r_compound) accumulation_15\NN\13497135|NONE (l_conj) toxicity_17\NN\13576101|consequent|copper|and|in
3975902
C024986_D004342 NONE chloride_11\NN\14818238|chronic (r_compound) ingestion_12\NN\13440063|NONE (r_pobj) by_8\IN\0|.|dysfunction (r_agent) induced_7\VBN\1627355|NONE (l_nsubj) dysfunction_1\NN\14204950|.|by (l_conj) hypersensitivity_3\NN\14531772|and|pentobarbital|Cardiovascular
D001464_D006973 NONE barium_0\NN\14625458| (r_npadvmod) supplemented_2\VBN\182406|hooded|Evans (r_amod) rats_7\NNS\2329401|were|.|by (r_nsubjpass) characterized_9\VBN\609683|NONE (l_agent) by_10\IN\0|were|.|rats (l_pobj) hypertension_13\NN\14057371|NONE
D001464_D006973 NONE barium_21\NN\14625458|NONE (r_pobj) of_20\IN\0|treatment| (r_prep) month_19\NN\15113229|NONE (r_pobj) after_17\IN\0|that|evident (r_prep) was_15\VBD\0|persistent|a (r_relcl) hypertension_13\NN\14057371|NONE
D001464_D009202 NONE barium_37\NN\14625458|chronic (r_compound) exposure_38\NN\5042871|NONE (r_pobj) by_35\IN\0|NONE (r_agent) induced_34\VBN\1627355|a|undescribed|cardiomyopathic (r_acl) disorder_33\NN\14034177|NONE
D001464_D002318 NONE barium_18\NN\14625458| (r_npadvmod) induced_20\VBN\1627355|significant|other|within (r_amod) disturbances_21\NNS\407535|Analysis|. (l_prep) within_22\IN\0|significant|induced|other (l_pobj) system_25\NN\3575240|NONE
D001464_D008659 NONE barium_37\NN\14625458|chronic (r_compound) exposure_38\NN\5042871|NONE (r_pobj) by_35\IN\0|NONE (r_agent) induced_34\VBN\1627355|a|undescribed|cardiomyopathic (r_acl) disorder_33\NN\14034177|NONE (r_pobj) of_28\IN\0|the (r_prep) existence_27\NN\24720|.|contractility|Overall|, (r_dobj) suggest_25\VBP\1010118|NONE (l_nsubj) contractility_5\NN\5200169|.|Overall|,|existence (l_conj) disturbances_13\NNS\407535|characteristics|pentobarbital|and|cardiac|the|altered|,
D010424_D004342 NONE pentobarbital_6\NN\2792049|hypersensitivity|and|Cardiovascular (r_amod) dysfunction_1\NN\14204950|.|by (l_conj) hypersensitivity_3\NN\14531772|and|pentobarbital|Cardiovascular
D010424_D004342 NONE pentobarbital_18\NN\2792049|demonstrated|a|of|to (r_amod) hypersensitivity_11\NN\14531772|.|aspect
D010424_D004342 NONE pentobarbital_24\NN\2792049|characteristics|and|disturbances|cardiac|the|altered|, (r_appos) contractility_5\NN\5200169|.|Overall|,|existence (l_conj) disturbances_13\NNS\407535|characteristics|pentobarbital|and|cardiac|the|altered|, (l_conj) hypersensitivity_17\NN\14531772|,|metabolic|and|the|myocardial
D010424_D002318 NONE pentobarbital_6\NN\2792049|hypersensitivity|and|Cardiovascular (r_amod) dysfunction_1\NN\14204950|.|by
D010424_D008659 NONE pentobarbital_24\NN\2792049|characteristics|and|disturbances|cardiac|the|altered|, (r_appos) contractility_5\NN\5200169|.|Overall|,|existence (l_conj) disturbances_13\NNS\407535|characteristics|pentobarbital|and|cardiac|the|altered|,
D010424_D009202 NONE pentobarbital_24\NN\2792049|characteristics|and|disturbances|cardiac|the|altered|, (r_appos) contractility_5\NN\5200169|.|Overall|,|existence (r_nsubj) suggest_25\VBP\1010118|NONE (l_dobj) existence_27\NN\24720|.|contractility|Overall|, (l_prep) of_28\IN\0|the (l_pobj) disorder_33\NN\14034177|NONE
D001464_D004342 NONE barium_6\NN\14625458|the (r_compound) effect_7\NN\34213|NONE (r_pobj) of_4\IN\0|distinctive|The (r_prep) aspect_3\NN\5849789|.|hypersensitivity (r_nsubj) was_8\VBD\0|NONE (l_attr) hypersensitivity_11\NN\14531772|.|aspect
D001464_D004342 NONE barium_37\NN\14625458|chronic (r_compound) exposure_38\NN\5042871|NONE (r_pobj) by_35\IN\0|NONE (r_agent) induced_34\VBN\1627355|a|undescribed|cardiomyopathic (r_acl) disorder_33\NN\14034177|NONE (r_pobj) of_28\IN\0|the (r_prep) existence_27\NN\24720|.|contractility|Overall|, (r_dobj) suggest_25\VBP\1010118|NONE (l_nsubj) contractility_5\NN\5200169|.|Overall|,|existence (l_conj) disturbances_13\NNS\407535|characteristics|pentobarbital|and|cardiac|the|altered|, (l_conj) hypersensitivity_17\NN\14531772|,|metabolic|and|the|myocardial
C024986_D002318 NONE chloride_11\NN\14818238|chronic (r_compound) ingestion_12\NN\13440063|NONE (r_pobj) by_8\IN\0|.|dysfunction (r_agent) induced_7\VBN\1627355|NONE (l_nsubj) dysfunction_1\NN\14204950|.|by
17379047
C081489_D006973 NONE valsartan_2\JJ\2712393|hydrochlorothiazide|combination (r_nmod) therapy_6\NN\657604|NONE (r_pobj) of_1\IN\0|.|at|study|: (r_prep) comparison_0\NN\635850|NONE (l_appos) study_24\NN\635850|.|at|of|: (l_acl) followed_25\VBN\1835496|controlled|a|blind|, (l_agent) by_26\IN\0|NONE (l_pobj) therapy_31\NN\657604|NONE (l_prep) in_32\IN\13603305|combination|term (l_pobj) adults_34\NNS\7846|NONE (l_amod) hypertensive_33\JJ\10405694|NONE
C081489_C562386 NONE valsartan_10\JJ\2712393|NONE (l_appos) hctz)-monotherapy_17\NN\0|(|VAL (l_conj) combinations_22\NNS\7951464|and (l_prep) in_23\IN\13603305|dose (l_pobj) patients_24\NNS\9898892|NONE (l_prep) with_25\IN\0|NONE (l_pobj) hypertension_27\NN\14057371|NONE
C081489_C562386 NONE val_12\NNP\0|(|HCTZ)monotherapy (r_appos) valsartan_10\JJ\2712393|NONE (l_appos) hctz)-monotherapy_17\NN\0|(|VAL (l_conj) combinations_22\NNS\7951464|and (l_prep) in_23\IN\13603305|dose (l_pobj) patients_24\NNS\9898892|NONE (l_prep) with_25\IN\0|NONE (l_pobj) hypertension_27\NN\14057371|NONE
C081489_C562386 NONE val_34\NNP\0|:||treatment (r_appos) groups_32\NNS\2137|NONE (r_pobj) to_27\IN\0|Patients|.|sitting|were|mean (r_prep) randomized_26\VBN\278117|NONE (l_nsubjpass) patients_0\NNS\9898892|.|sitting|to|were|mean (l_prep) with_1\IN\0|NONE (l_pobj) hypertension_3\NN\14057371|NONE
C081489_C562386 NONE val_46\NNP\0|,|/.|/.|placebo|or|;|/ (r_nmod) hctz_48\NNP\0||HCTZ|;|;|mg (r_appos) val_34\NNP\0|:||treatment (r_appos) groups_32\NNS\2137|NONE (r_pobj) to_27\IN\0|Patients|.|sitting|were|mean (r_prep) randomized_26\VBN\278117|NONE (l_nsubjpass) patients_0\NNS\9898892|.|sitting|to|were|mean (l_prep) with_1\IN\0|NONE (l_pobj) hypertension_3\NN\14057371|NONE
D006852_D007008 CID hctz_9\NNP\0|(|)|% (r_compound) combinations_10\NNS\7951464|NONE (r_pobj) with_6\IN\0|than (r_prep) lower_5\JJR\2831724|incidence|. (r_acomp) was_4\VBD\0|NONE (l_nsubj) incidence_1\NN\13821570|lower|. (l_prep) of_2\IN\0|The (l_pobj) hypokalemia_3\NN\14299637|NONE
D006852_D007008 CID hctz_17\NNP\0|(|)|% (r_compound) monotherapies_18\NNS\0|NONE (r_pobj) with_16\IN\0|NONE (r_prep) than_15\IN\0|with (r_prep) lower_5\JJR\2831724|incidence|. (r_acomp) was_4\VBD\0|NONE (l_nsubj) incidence_1\NN\13821570|lower|. (l_prep) of_2\IN\0|The (l_pobj) hypokalemia_3\NN\14299637|NONE
D006852_D007008 CID hctz_10\NNP\0|NONE (r_pobj) with_7\IN\0|combination (r_prep) therapies_6\NNS\657604|were|.|with|,|tolerated|In|, (r_nsubjpass) associated_12\VBN\628491|NONE (l_conj) tolerated_25\VBN\802318|were|.|therapies|with|,|In|, (l_conj) associated_29\VBN\628491|were|and|well|, (l_prep) with_30\IN\0|were (l_pobj) hypokalemia_32\NN\14299637|NONE
D006852_D007008 CID hctz_34\NNP\0|NONE (r_pobj) than_33\IN\0|less (r_prep) hypokalemia_32\NN\14299637|NONE
D006852_D006973 NONE hydrochlorothiazide_4\JJ\4423288|valsartan|combination (r_compound) therapy_6\NN\657604|NONE (r_pobj) of_1\IN\0|.|at|study|: (r_prep) comparison_0\NN\635850|NONE (l_appos) study_24\NN\635850|.|at|of|: (l_acl) followed_25\VBN\1835496|controlled|a|blind|, (l_agent) by_26\IN\0|NONE (l_pobj) therapy_31\NN\657604|NONE (l_prep) in_32\IN\13603305|combination|term (l_pobj) adults_34\NNS\7846|NONE (l_amod) hypertensive_33\JJ\10405694|NONE
C081489_D007008 NONE val_7\NNP\0|/ (r_nmod) hctz_9\NNP\0|(|)|% (r_compound) combinations_10\NNS\7951464|NONE (r_pobj) with_6\IN\0|than (r_prep) lower_5\JJR\2831724|incidence|. (r_acomp) was_4\VBD\0|NONE (l_nsubj) incidence_1\NN\13821570|lower|. (l_prep) of_2\IN\0|The (l_pobj) hypokalemia_3\NN\14299637|NONE
C081489_D007008 NONE val_8\NNP\0|/ (r_nmod) hctz_10\NNP\0|NONE (r_pobj) with_7\IN\0|combination (r_prep) therapies_6\NNS\657604|were|.|with|,|tolerated|In|, (r_nsubjpass) associated_12\VBN\628491|NONE (l_conj) tolerated_25\VBN\802318|were|.|therapies|with|,|In|, (l_conj) associated_29\VBN\628491|were|and|well|, (l_prep) with_30\IN\0|were (l_pobj) hypokalemia_32\NN\14299637|NONE
D006852_C562386 NONE hydrochlorothiazide_15\NN\4423288|)|or|( (r_conj) val_12\NNP\0|(|HCTZ)monotherapy (r_appos) valsartan_10\JJ\2712393|NONE (l_appos) hctz)-monotherapy_17\NN\0|(|VAL (l_conj) combinations_22\NNS\7951464|and (l_prep) in_23\IN\13603305|dose (l_pobj) patients_24\NNS\9898892|NONE (l_prep) with_25\IN\0|NONE (l_pobj) hypertension_27\NN\14057371|NONE
D006852_C562386 NONE hctz)-monotherapy_17\NN\0|(|VAL (l_conj) combinations_22\NNS\7951464|and (l_prep) in_23\IN\13603305|dose (l_pobj) patients_24\NNS\9898892|NONE (l_prep) with_25\IN\0|NONE (l_pobj) hypertension_27\NN\14057371|NONE
D006852_C562386 NONE hctz_40\NNP\0||;|HCTZ|;|mg (r_appos) val_34\NNP\0|:||treatment (r_appos) groups_32\NNS\2137|NONE (r_pobj) to_27\IN\0|Patients|.|sitting|were|mean (r_prep) randomized_26\VBN\278117|NONE (l_nsubjpass) patients_0\NNS\9898892|.|sitting|to|were|mean (l_prep) with_1\IN\0|NONE (l_pobj) hypertension_3\NN\14057371|NONE
D006852_C562386 NONE hctz_48\NNP\0||HCTZ|;|;|mg (r_appos) val_34\NNP\0|:||treatment (r_appos) groups_32\NNS\2137|NONE (r_pobj) to_27\IN\0|Patients|.|sitting|were|mean (r_prep) randomized_26\VBN\278117|NONE (l_nsubjpass) patients_0\NNS\9898892|.|sitting|to|were|mean (l_prep) with_1\IN\0|NONE (l_pobj) hypertension_3\NN\14057371|NONE
24068571
D015742_D003693 NONE propofol_19\NN\0|NONE (r_pcomp) to_18\IN\0|df (r_prep) compared_17\VBN\644583|with|was|significantly|.|use (r_prep) associated_6\VBN\628491|NONE (l_prep) with_7\IN\0|was|significantly|compared|.|use (l_pobj) risk_14\NN\14541044|NONE (l_prep) for_15\IN\0|higher|an (l_pobj) delirium_16\NN\14391660|NONE
D013874_D003693 CID thiopentone_3\NN\0|NONE (r_pobj) of_2\IN\0|The (r_prep) use_1\NN\407535|with|was|significantly|compared|. (r_nsubjpass) associated_6\VBN\628491|NONE (l_prep) with_7\IN\0|was|significantly|compared|.|use (l_pobj) risk_14\NN\14541044|NONE (l_prep) for_15\IN\0|higher|an (l_pobj) delirium_16\NN\14391660|NONE
10933650
C059765_D007683 CID amb_11\VBN\0| (r_dep) treated_13\VBN\2376958|D (r_amod) rats_14\NNS\2329401|NONE (r_pobj) in_8\IN\13603305|tubular (r_prep) necrosis_7\NN\11444117|but|.|examination|change
D000666_D064420 NONE b_7\NN\1355326|nanosphere (r_dobj) incorporating_5\VBG\1461328|a (r_acl) lipid_3\NN\14944888|effective|.|and|,|,|has|NS (r_nsubj) is_9\VBZ\0|NONE (l_conj) has_15\VBZ\13888491|effective|.|and|,|,|lipid|NS (l_dobj) toxicity_17\NN\13576101|NONE
D000666_D064420 NONE fungizone_9\NNP\0|sodium|( (r_nmod) deoxycholate_15\NN\0|NONE (r_pobj) of_8\IN\0|NONE (r_prep) that_7\DT\0|NS (r_pobj) with_6\IN\0|NONE (r_punct) ;_16\:\0|in|AmB|following|by|and|cultures (r_punct) using_23\VBG\418025|toxicity|We|. (r_advcl) compared_1\VBD\644583|NONE (l_dobj) toxicity_3\NN\13576101|using|We|.
D000666_D064420 NONE b_44\NNP\1355326|NONE (r_pobj) of_42\IN\0|pharmacokinetic (r_prep) study_41\NN\635850|the|and (r_conj) kidney_38\NN\5333259|NONE (r_pobj) of_36\IN\0|histopathological (r_prep) study_35\NN\635850|biochemical|, (r_appos) analysis_32\NN\633864|NONE (r_pobj) by_30\IN\0|in|AmB|following|and|cultures|; (r_prep) using_23\VBG\418025|toxicity|We|. (r_advcl) compared_1\VBD\644583|NONE (l_dobj) toxicity_3\NN\13576101|using|We|.
C059765_D064420 NONE deoxycholate_15\NN\0|NONE (r_pobj) of_8\IN\0|NONE (r_prep) that_7\DT\0|NS (r_pobj) with_6\IN\0|NONE (r_punct) ;_16\:\0|in|AmB|following|by|and|cultures (r_punct) using_23\VBG\418025|toxicity|We|. (r_advcl) compared_1\VBD\644583|NONE (l_dobj) toxicity_3\NN\13576101|using|We|.
C059765_D064420 NONE amb_19\NNP\0|in|following|by|and|cultures|; (r_nsubj) using_23\VBG\418025|toxicity|We|. (r_advcl) compared_1\VBD\644583|NONE (l_dobj) toxicity_3\NN\13576101|using|We|.
D000666_D007674 NONE b._13\NNP\0|by|of (r_appos) attenuation_0\NN\7427337|NONE (l_prep) of_1\IN\0|by|B. (l_pobj) nephrotoxicity_2\NN\0|NONE
D000666_D007674 NONE b_12\NNP\1355326|NONE (r_pobj) of_10\IN\0|into (r_prep) incorporation_9\NN\1237415|NS|nephrotoxicity|that (r_nsubj) attenuates_18\VBZ\224901|in (l_dobj) nephrotoxicity_20\NN\0|NS|that|incorporation
D000666_D007674 NONE b._23\NNP\0|NONE (r_pobj) of_21\IN\0|the (r_prep) nephrotoxicity_20\NN\0|NS|that|incorporation
9881641
D019806_D007022 CID levcromakalim_14\RB\0| (r_npadvmod) produced_16\VBN\1617192|in|a (r_amod) decrease_17\NN\7296428|which (r_dobj) abolished_12\VBD\0|, (r_relcl) glibenclamide_9\NN\0|NONE (r_pobj) by_8\IN\0|.|Hypotension|was|significantly (r_agent) attenuated_7\VBN\224901|NONE (l_nsubjpass) hypotension_0\NN\14057371|.|was|significantly|by
C040442_D007022 CID helodermin_6\NN\0|NONE (r_pobj) by_5\IN\0|NONE (r_agent) produced_4\VBN\1617192|sensitive|. (r_acl) hypotension_3\NN\14057371|NONE
C040442_D007022 CID helodermin_0\NNP\0|hypotension|. (r_nsubj) produced_1\VBD\1617192|NONE (l_dobj) hypotension_2\NN\14057371|Helodermin|.
C040442_D007022 CID helodermin_4\NN\0| (r_npadvmod) induced_6\VBN\1627355|NONE (r_amod) hypotension_7\NN\14057371|not|did|Oxyhemoglobin|shortened|.|,
C040442_D007022 CID helodermin_4\NN\0| (r_npadvmod) induced_6\VBN\1627355|NONE (r_amod) hypotension_7\NN\14057371|not|did|Oxyhemoglobin|shortened|.|, (r_dobj) affect_3\VB\26192|NONE (l_advcl) shortened_11\VBD\429060|hypotension|not|did|Oxyhemoglobin|.|, (l_dobj) duration_13\NN\15113229|whereas|it (l_prep) of_14\IN\0|the (l_pobj) acetylcholine_15\NN\14807558|NONE (l_appos) hypotension_18\NN\14057371|NONE
C040442_D007022 CID helodermin_4\NN\0| (r_npadvmod) produced_6\VBN\1617192|NONE (r_amod) hypotension_7\NN\14057371|that|attributable
D011188_D007022 NONE k+_18\NNP\0|exist|sensitive|,|channels (r_amod) channels_19\NNS\6251781|NONE (r_pobj) of_14\IN\0|the (r_prep) activation_13\NN\13561719|NONE (r_pobj) to_11\IN\0|partly (r_prep) attributable_10\JJ\0|that|hypotension (r_acomp) is_8\VBZ\0|findings|. (l_nsubj) hypotension_7\NN\14057371|that|attributable
D011188_D007022 NONE k(atp_21\NNP\0|)|)|( (r_nmod) channels_23\NNS\6251781|exist|sensitive|,|K+ (r_appos) channels_19\NNS\6251781|NONE (r_pobj) of_14\IN\0|the (r_prep) activation_13\NN\13561719|NONE (r_pobj) to_11\IN\0|partly (r_prep) attributable_10\JJ\0|that|hypotension (r_acomp) is_8\VBZ\0|findings|. (l_nsubj) hypotension_7\NN\14057371|that|attributable
D005905_D007022 NONE glibenclamide_0\NN\0| (r_npadvmod) sensitive_2\JJ\10488309|.|produced (r_amod) hypotension_3\NN\14057371|NONE
D005905_D007022 NONE glibenclamide_9\NN\0|NONE (r_pobj) by_8\IN\0|.|Hypotension|was|significantly (r_agent) attenuated_7\VBN\224901|NONE (l_nsubjpass) hypotension_0\NN\14057371|.|was|significantly|by
D005905_D007022 NONE glibenclamide_15\NN\0| (r_npadvmod) sensitive_17\JJ\10488309|exist|,|channels|K+ (r_amod) channels_19\NNS\6251781|NONE (r_pobj) of_14\IN\0|the (r_prep) activation_13\NN\13561719|NONE (r_pobj) to_11\IN\0|partly (r_prep) attributable_10\JJ\0|that|hypotension (r_acomp) is_8\VBZ\0|findings|. (l_nsubj) hypotension_7\NN\14057371|that|attributable
D000109_D007022 CID acetylcholine_15\NN\14807558|NONE (r_pobj) of_14\IN\0|the (r_prep) duration_13\NN\15113229|whereas|it (r_dobj) shortened_11\VBD\429060|hypotension|not|did|Oxyhemoglobin|.|, (r_advcl) affect_3\VB\26192|NONE (l_dobj) hypotension_7\NN\14057371|not|did|Oxyhemoglobin|shortened|.|,
D000109_D007022 CID acetylcholine_15\NN\14807558|NONE (l_appos) hypotension_18\NN\14057371|NONE
D000109_D007022 CID ach)-produced_17\JJ\0|( (r_amod) hypotension_18\NN\14057371|NONE (r_appos) acetylcholine_15\NN\14807558|NONE (r_pobj) of_14\IN\0|the (r_prep) duration_13\NN\15113229|whereas|it (r_dobj) shortened_11\VBD\429060|hypotension|not|did|Oxyhemoglobin|.|, (r_advcl) affect_3\VB\26192|NONE (l_dobj) hypotension_7\NN\14057371|not|did|Oxyhemoglobin|shortened|.|,
D000109_D007022 CID ach)-produced_17\JJ\0|( (r_amod) hypotension_18\NN\14057371|NONE
D009569_D007022 NONE oxide_7\NN\14818238|NONE (r_dobj) relaxing_5\VBG\146138|endothelium| (r_xcomp) derived_4\VBN\634472|( (r_acl) edrf_0\NN\0|play|.|does|not (r_nsubj) seem_10\VB\2604760|NONE (l_xcomp) play_12\VB\7007684|EDRF|.|does|not (l_dobj) role_15\NN\719494|to (l_prep) in_16\IN\13603305|important|an (l_pobj) hypotension_21\NN\14057371|NONE
D000255_D007022 NONE k(atp_21\NNP\0|)|)|( (r_nmod) channels_23\NNS\6251781|exist|sensitive|,|K+ (r_appos) channels_19\NNS\6251781|NONE (r_pobj) of_14\IN\0|the (r_prep) activation_13\NN\13561719|NONE (r_pobj) to_11\IN\0|partly (r_prep) attributable_10\JJ\0|that|hypotension (r_acomp) is_8\VBZ\0|findings|. (l_nsubj) hypotension_7\NN\14057371|that|attributable
1158089
D013752_D003866 NONE tetracycline_23\NN\2716205|NONE (r_pobj) of_22\IN\0|accumulation|and (r_prep) dose_21\NN\3740161|NONE (l_conj) accumulation_26\NN\13497135|and|of (l_prep) of_27\IN\0|by|both (l_pobj) triglyceride_28\NN\14885088|NONE (l_prep) in_29\IN\13603305|NONE (l_pobj) liver_31\NN\5298729|NONE (l_conj) depression_33\NN\14373582|of|the|and
D013752_D003866 NONE tetracycline_19\NN\2716205|NONE (r_pobj) of_18\IN\0|on|the (r_prep) effects_17\NNS\13245626|NONE (l_prep) on_20\IN\0|of|the (l_pobj) depression_21\NN\14373582|NONE
D019301_D003866 NONE acid_5\NN\14818238|NONE (r_pobj) of_2\IN\0|as (r_prep) provision_1\NN\6755568|NONE (r_pobj) with_0\IN\0|,|relationship|between|was|. (r_prep) observed_19\VBN\2163746|NONE (l_prep) between_20\IN\0|,|relationship|With|was|. (l_pobj) dose_21\NN\3740161|NONE (l_conj) accumulation_26\NN\13497135|and|of (l_prep) of_27\IN\0|by|both (l_pobj) triglyceride_28\NN\14885088|NONE (l_prep) in_29\IN\13603305|NONE (l_pobj) liver_31\NN\5298729|NONE (l_conj) depression_33\NN\14373582|of|the|and
D013752_D005234 CID tetracycline_4\NN\2716205|NONE (r_pobj) by_3\IN\0|in (r_agent) induced_2\VBN\1627355|Fatty|. (r_acl) liver_1\NN\5298729|NONE
D013752_D005234 CID tetracycline_18\NN\2716205|NONE (r_pobj) by_17\IN\0|NONE (r_agent) induced_16\VBN\1627355|response|mechanisms|, (r_acl) relationships_3\NNS\31921|in|were|. (l_conj) mechanisms_6\NNS\13446390|response|induced|, (l_conj) differences_10\NNS\4723816|biochemical|and|, (l_prep) in_11\IN\13603305|sex (l_pobj) liver_15\NN\5298729|NONE
D013752_D005234 CID tetracycline_37\NN\2716205|NONE (r_pobj) to_36\IN\0|NONE (r_prep) response_35\NN\11410625|NONE (r_pobj) in_34\IN\13603305|of|the (r_prep) production_26\NN\30358|NONE (l_prep) of_27\IN\0|the|in (l_pobj) liver_33\NN\5298729|NONE
D014280_D005234 NONE triglyceride_4\NN\14885088|NONE (r_pobj) of_3\IN\0|hepatic|Depressed (r_prep) secretion_2\NN\13526110|indicating|.|%|, (r_nsubj) accounted_5\VBD\2604760|NONE (l_advcl) indicating_17\VBG\952524|.|secretion|%|, (l_ccomp) involved_23\VBN\2676054|NONE (l_prep) in_24\IN\13603305|mechanisms|must|be|that (l_pobj) production_26\NN\30358|NONE (l_prep) of_27\IN\0|the|in (l_pobj) liver_33\NN\5298729|NONE
D014280_D005234 NONE triglyceride_15\NN\14885088|NONE (r_pobj) of_12\IN\0| (r_prep) %_11\NN\0|indicating|.|secretion|, (r_dobj) accounted_5\VBD\2604760|NONE (l_advcl) indicating_17\VBG\952524|.|secretion|%|, (l_ccomp) involved_23\VBN\2676054|NONE (l_prep) in_24\IN\13603305|mechanisms|must|be|that (l_pobj) production_26\NN\30358|NONE (l_prep) of_27\IN\0|the|in (l_pobj) liver_33\NN\5298729|NONE
D014280_D005234 NONE triglyceride_29\NN\14885088| (r_npadvmod) rich_31\JJ\7942152|fatty|the (r_amod) liver_33\NN\5298729|NONE
D014280_D003866 NONE triglyceride_28\NN\14885088|NONE (l_prep) in_29\IN\13603305|NONE (l_pobj) liver_31\NN\5298729|NONE (l_conj) depression_33\NN\14373582|of|the|and
D014280_D003866 NONE triglyceride_37\NN\14885088|NONE (r_pobj) of_36\IN\0|NONE (r_prep) output_35\NN\4007894|NONE (r_pobj) of_34\IN\0|the|depression|and (r_prep) liver_31\NN\5298729|NONE (l_conj) depression_33\NN\14373582|of|the|and
D014280_D003866 NONE triglyceride_25\NN\14885088|NONE (r_pobj) of_24\IN\0|NONE (r_prep) output_23\NN\4007894|NONE (r_pobj) of_22\IN\0|under (r_prep) depression_21\NN\14373582|NONE
1289188
D003676_D058186 NONE desferrioxamine_6\NN\0|intravenous (r_compound) therapy_7\NN\657604|NONE (r_pobj) during_4\IN\0|NONE (r_prep) occurring_3\VBG\0|recovery|.|:|Acute|renal (r_acl) failure_2\NN\66216|NONE
D003676_D058186 NONE desferrioxamine_24\NN\0|NONE (r_pobj) by_23\IN\0|NONE (r_agent) caused_22\VBN\1617192|renal|progressive|acute (r_acl) failure_21\NN\66216|NONE
D003676_D013789 NONE desferrioxamine_11\NN\0|.|because|was|patient (r_dobj) undergoing_8\VBG\109660|NONE (l_nsubj) patient_1\NN\9898892|.|because|was|desferrioxamine (l_prep) with_2\IN\0|A (l_pobj) thalassemia_6\NN\14165544|NONE
D003676_D013789 NONE dfx_13\NNP\0|by|)|( (r_nmod) treatment_15\NN\654885|home|intravenous (r_appos) desferrioxamine_11\NN\0|.|because|was|patient (r_dobj) undergoing_8\VBG\109660|NONE (l_nsubj) patient_1\NN\9898892|.|because|was|desferrioxamine (l_prep) with_2\IN\0|A (l_pobj) thalassemia_6\NN\14165544|NONE
24309294
D012844_D000647 NONE cck-8_5\NNP\0|reversed|amnesia|and|decreases|that|significantly (r_punct) alleviated_7\VBN\205885|We|previously|.|have (l_dobj) amnesia_11\NN\5669934|reversed|and|CCK|decreases|that|significantly
D009020_D000647 CID morphine_8\NN\2707683| (r_npadvmod) induced_10\VBN\1627355|NONE (r_amod) amnesia_11\NN\5669934|reversed|and|CCK|decreases|that|significantly
D009020_D000647 CID morphine_25\NN\2707683| (r_npadvmod) treated_27\VBN\2376958|NONE (r_amod) animals_28\NNS\4475|NONE (r_pobj) in_24\IN\13603305|CA|of|the (r_prep) region_20\NN\27167|NONE (r_pobj) in_17\IN\13603305|NONE (r_prep) decreases_16\VBZ\7296428|reversed|amnesia|and|CCK|that|significantly (r_conj) alleviated_7\VBN\205885|We|previously|.|have (l_dobj) amnesia_11\NN\5669934|reversed|and|CCK|decreases|that|significantly
D009020_D008569 NONE morphine_10\NN\2707683|NONE (r_pobj) of_9\IN\0|through|the|on (r_prep) effect_8\NN\34213|that|suggest|CCK|and (r_dobj) attenuates_6\VBZ\224901|.|results (l_conj) suggest_18\VBP\1010118|that|CCK|effect|and (l_dobj) function_21\NN\13783581|NONE (l_prep) on_24\IN\0|an|of|ameliorative (l_pobj) impairment_29\NN\7296428|CCK
D009020_D008569 NONE morphine_25\NN\2707683| (r_npadvmod) induced_27\VBN\1627355|memory (r_amod) impairment_29\NN\7296428|CCK
D012844_D008569 NONE cck-8_5\NNP\0|that|suggest|effect|and (r_nsubj) attenuates_6\VBZ\224901|.|results (l_conj) suggest_18\VBP\1010118|that|CCK|effect|and (l_dobj) function_21\NN\13783581|NONE (l_prep) on_24\IN\0|an|of|ameliorative (l_pobj) impairment_29\NN\7296428|CCK
D012844_D008569 NONE cck-8_23\NNP\0|impairment (r_punct) on_24\IN\0|an|of|ameliorative (l_pobj) impairment_29\NN\7296428|CCK
15630069
D018967_D011618 NONE risperidone_25\NN\0|,|or (r_conj) olanzapine_22\NN\0|either|, (r_conj) clozapine_20\NN\3713736|NONE (r_pobj) with_18\IN\0|NONE (r_prep) treated_17\VBN\2376958|and|by (r_conj) matched_11\VBN\2664769|nonobese|with|,|six|, (r_acl) subjects_4\NNS\6598915|.|in|were (l_prep) with_5\IN\0|nonobese|,|matched|six|, (l_pobj) schizophrenia_6\NN\14398067|NONE (l_conj) disorder_9\NN\14034177|or
D003024_D012559 NONE clozapine_20\NN\3713736|NONE (r_pobj) with_18\IN\0|NONE (r_prep) treated_17\VBN\2376958|and|by (r_conj) matched_11\VBN\2664769|nonobese|with|,|six|, (r_acl) subjects_4\NNS\6598915|.|in|were (l_prep) with_5\IN\0|nonobese|,|matched|six|, (l_pobj) schizophrenia_6\NN\14398067|NONE
D005947_D012559 NONE glucose_0\NN\14710501|:|test|.|in (r_nsubj) metabolism_1\NN\13526110|NONE (l_prep) in_2\IN\13603305|:|test|.|Glucose (l_pobj) patients_3\NNS\9898892|NONE (l_prep) with_4\IN\0|NONE (l_pobj) schizophrenia_5\NN\14398067|NONE
D005947_D012559 NONE glucose_16\NN\14710501|NONE (r_compound) tolerance_17\NN\5032565|intravenous|analysis|sampled|and|a (r_compound) test_18\NN\5798043|:|.|in|Glucose (r_appos) metabolism_1\NN\13526110|NONE (l_prep) in_2\IN\13603305|:|test|.|Glucose (l_pobj) patients_3\NNS\9898892|NONE (l_prep) with_4\IN\0|NONE (l_pobj) schizophrenia_5\NN\14398067|NONE
D005947_D012559 NONE glucose_32\NN\14710501|NONE (r_compound) metabolism_33\NN\13526110|are|or|increasing|agents|directly|whether (r_dobj) affecting_31\VBG\126264|it|unclear|increasing|,|. (r_ccomp) remains_24\VBZ\2684|NONE (l_advcl) increasing_11\VBG\169651|it|unclear|affecting|,|. (l_prep) in_12\IN\13603305|incidence|While|may|be (l_pobj) patients_13\NNS\9898892|NONE (l_prep) with_14\IN\0|NONE (l_pobj) schizophrenia_15\NN\14398067|NONE
D005947_D012559 NONE glucose_18\NN\14710501|NONE (r_compound) tolerance_19\NN\5032565|and|analysis|sampled|a|intravenous (r_compound) test_20\NN\5798043|NONE (r_dobj) using_13\VBG\418025|NONE (r_advcl) evaluated_12\VBD\670261|NONE (r_acl) schizophrenia_11\NN\14398067|NONE
C076029_D012559 NONE olanzapine_22\NN\0|either|, (r_conj) clozapine_20\NN\3713736|NONE (r_pobj) with_18\IN\0|NONE (r_prep) treated_17\VBN\2376958|and|by (r_conj) matched_11\VBN\2664769|nonobese|with|,|six|, (r_acl) subjects_4\NNS\6598915|.|in|were (l_prep) with_5\IN\0|nonobese|,|matched|six|, (l_pobj) schizophrenia_6\NN\14398067|NONE
D003024_D007333 CID clozapine_20\NN\3713736|<|olanzapine|(|)|< (r_nmod) risperidone_24\NNP\0|)|,|with (r_appos) p<.001_17\NNP\0|There|=|;|difference (r_appos) was_1\VBD\0|NONE (l_attr) difference_4\NN\4723816|There|=|;|P<. (l_prep) in_5\IN\13603305|significant|among|a (l_pobj) index_8\NN\13850304|NONE (l_compound) sensitivity_7\NN\5651971|NONE
D003024_D007333 CID clozapine_20\NN\3713736|<|olanzapine|(|)|< (r_nmod) risperidone_24\NNP\0|)|,|with (r_appos) p<.001_17\NNP\0|There|=|;|difference (l_prep) with_27\IN\0|risperidone|)|, (l_pobj) subjects_28\NNS\6598915|NONE (l_acl) exhibiting_34\VBG\2632167|received (l_dobj) resistance_37\NN\37396|compared
D003024_D007333 CID clozapine_31\NN\3713736|who (r_dobj) received_30\VBD\2210855|exhibiting (r_relcl) subjects_28\NNS\6598915|NONE (r_pobj) with_27\IN\0|risperidone|)|, (r_prep) p<.001_17\NNP\0|There|=|;|difference (r_appos) was_1\VBD\0|NONE (l_attr) difference_4\NN\4723816|There|=|;|P<. (l_prep) in_5\IN\13603305|significant|among|a (l_pobj) index_8\NN\13850304|NONE (l_compound) sensitivity_7\NN\5651971|NONE
D003024_D007333 CID clozapine_31\NN\3713736|who (r_dobj) received_30\VBD\2210855|exhibiting (r_relcl) subjects_28\NNS\6598915|NONE (l_acl) exhibiting_34\VBG\2632167|received (l_dobj) resistance_37\NN\37396|compared
D003024_D007333 CID clozapine_47\NN\3713736|NONE (r_appos) risperidone_45\NN\0|NONE (r_pobj) with_44\IN\0|who|were (r_prep) treated_43\VBN\2376958|NONE (r_relcl) subjects_40\NNS\6598915|NONE (r_pobj) with_39\IN\0|NONE (r_prep) compared_38\VBN\644583|resistance (r_prep) exhibiting_34\VBG\2632167|received (r_acl) subjects_28\NNS\6598915|NONE (r_pobj) with_27\IN\0|risperidone|)|, (r_prep) p<.001_17\NNP\0|There|=|;|difference (r_appos) was_1\VBD\0|NONE (l_attr) difference_4\NN\4723816|There|=|;|P<. (l_prep) in_5\IN\13603305|significant|among|a (l_pobj) index_8\NN\13850304|NONE (l_compound) sensitivity_7\NN\5651971|NONE
D003024_D007333 CID clozapine_47\NN\3713736|NONE (r_appos) risperidone_45\NN\0|NONE (r_pobj) with_44\IN\0|who|were (r_prep) treated_43\VBN\2376958|NONE (r_relcl) subjects_40\NNS\6598915|NONE (r_pobj) with_39\IN\0|NONE (r_prep) compared_38\VBN\644583|resistance (r_prep) exhibiting_34\VBG\2632167|received (l_dobj) resistance_37\NN\37396|compared
D003024_D007333 CID clozapine-_2\NN\0|treated (r_nmod) groups_7\NNS\2137|resistance|compared|. (r_nsubj) displayed_8\VBD\2137132|NONE (l_dobj) resistance_11\NN\37396|groups|compared|.
D003024_D007333 CID clozapine_2\NN\3713736|and|olanzapine (r_dobj) taking_1\VBG\37396|NONE (r_acl) patients_0\NNS\9898892|must|be|.|for (r_nsubjpass) examined_7\VBN\0|NONE (l_prep) for_8\IN\0|must|be|Patients|. (l_pobj) resistance_10\NN\37396|NONE
C076029_D007333 CID olanzapine_22\RB\0|<|clozapine|(|)|< (r_nmod) risperidone_24\NNP\0|)|,|with (r_appos) p<.001_17\NNP\0|There|=|;|difference (r_appos) was_1\VBD\0|NONE (l_attr) difference_4\NN\4723816|There|=|;|P<. (l_prep) in_5\IN\13603305|significant|among|a (l_pobj) index_8\NN\13850304|NONE (l_compound) sensitivity_7\NN\5651971|NONE
C076029_D007333 CID olanzapine_22\RB\0|<|clozapine|(|)|< (r_nmod) risperidone_24\NNP\0|)|,|with (r_appos) p<.001_17\NNP\0|There|=|;|difference (l_prep) with_27\IN\0|risperidone|)|, (l_pobj) subjects_28\NNS\6598915|NONE (l_acl) exhibiting_34\VBG\2632167|received (l_dobj) resistance_37\NN\37396|compared
C076029_D007333 CID olanzapine_33\RB\0|and (r_conj) clozapine_31\NN\3713736|who (r_dobj) received_30\VBD\2210855|exhibiting (r_relcl) subjects_28\NNS\6598915|NONE (r_pobj) with_27\IN\0|risperidone|)|, (r_prep) p<.001_17\NNP\0|There|=|;|difference (r_appos) was_1\VBD\0|NONE (l_attr) difference_4\NN\4723816|There|=|;|P<. (l_prep) in_5\IN\13603305|significant|among|a (l_pobj) index_8\NN\13850304|NONE (l_compound) sensitivity_7\NN\5651971|NONE
C076029_D007333 CID olanzapine_33\RB\0|and (r_conj) clozapine_31\NN\3713736|who (r_dobj) received_30\VBD\2210855|exhibiting (r_relcl) subjects_28\NNS\6598915|NONE (l_acl) exhibiting_34\VBG\2632167|received (l_dobj) resistance_37\NN\37396|compared
C076029_D007333 CID olanzapine_4\RB\0| (r_npadvmod) treated_6\VBN\2376958|clozapine (r_amod) groups_7\NNS\2137|resistance|compared|. (r_nsubj) displayed_8\VBD\2137132|NONE (l_dobj) resistance_11\NN\37396|groups|compared|.
C076029_D007333 CID olanzapine_4\NN\0|clozapine|and (r_conj) taking_1\VBG\37396|NONE (r_acl) patients_0\NNS\9898892|must|be|.|for (r_nsubjpass) examined_7\VBN\0|NONE (l_prep) for_8\IN\0|must|be|Patients|. (l_pobj) resistance_10\NN\37396|NONE
D005947_D007333 NONE glucose_6\NN\14710501|fasting|index|,|and (r_dobj) fasting_4\VBG\1068773|.|MAIN|:|OUTCOME (l_conj) index_15\NN\13850304|fasting|,|glucose|and (l_compound) sensitivity_14\NN\5651971|,|assessment
D005947_D007333 NONE glucose_6\NN\14710501|fasting|index|,|and (r_dobj) fasting_4\VBG\1068773|.|MAIN|:|OUTCOME (l_conj) index_15\NN\13850304|fasting|,|glucose|and (l_conj) assessment_19\NN\5732756|sensitivity|, (l_prep) of_20\IN\0|model|,|and|effectiveness (l_pobj) resistance_22\NN\37396|NONE
D005947_D007333 NONE glucose_25\NN\14710501|NONE (r_compound) effectiveness_26\NN\5190804|model|,|and|of (r_conj) assessment_19\NN\5732756|sensitivity|, (r_conj) index_15\NN\13850304|fasting|,|glucose|and (l_compound) sensitivity_14\NN\5651971|,|assessment
D005947_D007333 NONE glucose_25\NN\14710501|NONE (r_compound) effectiveness_26\NN\5190804|model|,|and|of (r_conj) assessment_19\NN\5732756|sensitivity|, (l_prep) of_20\IN\0|model|,|and|effectiveness (l_pobj) resistance_22\NN\37396|NONE
D005947_D007333 NONE glucose_15\NN\14710501|NONE (r_compound) effectiveness_16\NN\5190804|NONE (r_pobj) of_14\IN\0|NONE (r_prep) impairment_13\NN\7296428|significant|insulin|and (r_conj) resistance_11\NN\37396|groups|compared|.
D018967_D012559 NONE risperidone_25\NN\0|,|or (r_conj) olanzapine_22\NN\0|either|, (r_conj) clozapine_20\NN\3713736|NONE (r_pobj) with_18\IN\0|NONE (r_prep) treated_17\VBN\2376958|and|by (r_conj) matched_11\VBN\2664769|nonobese|with|,|six|, (r_acl) subjects_4\NNS\6598915|.|in|were (l_prep) with_5\IN\0|nonobese|,|matched|six|, (l_pobj) schizophrenia_6\NN\14398067|NONE
D005947_D003920 NONE glucose_32\NN\14710501|NONE (r_compound) metabolism_33\NN\13526110|are|or|increasing|agents|directly|whether (r_dobj) affecting_31\VBG\126264|it|unclear|increasing|,|. (r_ccomp) remains_24\VBZ\2684|NONE (l_advcl) increasing_11\VBG\169651|it|unclear|affecting|,|. (l_nsubj) incidence_2\NN\13821570|in|While|may|be (l_prep) of_3\IN\0|the (l_pobj) mellitus_8\NN\0|NONE
D005947_D003920 NONE glucose_32\NN\14710501|NONE (r_compound) metabolism_33\NN\13526110|are|or|increasing|agents|directly|whether (r_dobj) affecting_31\VBG\126264|it|unclear|increasing|,|. (l_conj) increasing_36\VBG\169651|are|metabolism|or|agents|directly|whether (l_dobj) factors_39\NNS\7326557|simply (l_prep) for_40\IN\0|known|risk (l_pobj) diabetes_41\NNS\14075199|NONE
C076029_D011618 NONE olanzapine_22\NN\0|either|, (r_conj) clozapine_20\NN\3713736|NONE (r_pobj) with_18\IN\0|NONE (r_prep) treated_17\VBN\2376958|and|by (r_conj) matched_11\VBN\2664769|nonobese|with|,|six|, (r_acl) subjects_4\NNS\6598915|.|in|were (l_prep) with_5\IN\0|nonobese|,|matched|six|, (l_pobj) schizophrenia_6\NN\14398067|NONE (l_conj) disorder_9\NN\14034177|or
D018967_D007333 NONE risperidone_24\NNP\0|)|,|with (r_appos) p<.001_17\NNP\0|There|=|;|difference (r_appos) was_1\VBD\0|NONE (l_attr) difference_4\NN\4723816|There|=|;|P<. (l_prep) in_5\IN\13603305|significant|among|a (l_pobj) index_8\NN\13850304|NONE (l_compound) sensitivity_7\NN\5651971|NONE
D018967_D007333 NONE risperidone_24\NNP\0|)|,|with (r_appos) p<.001_17\NNP\0|There|=|;|difference (l_prep) with_27\IN\0|risperidone|)|, (l_pobj) subjects_28\NNS\6598915|NONE (l_acl) exhibiting_34\VBG\2632167|received (l_dobj) resistance_37\NN\37396|compared
D018967_D007333 NONE risperidone_45\NN\0|NONE (r_pobj) with_44\IN\0|who|were (r_prep) treated_43\VBN\2376958|NONE (r_relcl) subjects_40\NNS\6598915|NONE (r_pobj) with_39\IN\0|NONE (r_prep) compared_38\VBN\644583|resistance (r_prep) exhibiting_34\VBG\2632167|received (r_acl) subjects_28\NNS\6598915|NONE (r_pobj) with_27\IN\0|risperidone|)|, (r_prep) p<.001_17\NNP\0|There|=|;|difference (r_appos) was_1\VBD\0|NONE (l_attr) difference_4\NN\4723816|There|=|;|P<. (l_prep) in_5\IN\13603305|significant|among|a (l_pobj) index_8\NN\13850304|NONE (l_compound) sensitivity_7\NN\5651971|NONE
D018967_D007333 NONE risperidone_45\NN\0|NONE (r_pobj) with_44\IN\0|who|were (r_prep) treated_43\VBN\2376958|NONE (r_relcl) subjects_40\NNS\6598915|NONE (r_pobj) with_39\IN\0|NONE (r_prep) compared_38\VBN\644583|resistance (r_prep) exhibiting_34\VBG\2632167|received (l_dobj) resistance_37\NN\37396|compared
D018967_D007333 NONE risperidone_49\NN\0|NONE (r_pobj) vs_48\IN\13634784|)|( (r_prep) clozapine_47\NN\3713736|NONE (r_appos) risperidone_45\NN\0|NONE (r_pobj) with_44\IN\0|who|were (r_prep) treated_43\VBN\2376958|NONE (r_relcl) subjects_40\NNS\6598915|NONE (r_pobj) with_39\IN\0|NONE (r_prep) compared_38\VBN\644583|resistance (r_prep) exhibiting_34\VBG\2632167|received (r_acl) subjects_28\NNS\6598915|NONE (r_pobj) with_27\IN\0|risperidone|)|, (r_prep) p<.001_17\NNP\0|There|=|;|difference (r_appos) was_1\VBD\0|NONE (l_attr) difference_4\NN\4723816|There|=|;|P<. (l_prep) in_5\IN\13603305|significant|among|a (l_pobj) index_8\NN\13850304|NONE (l_compound) sensitivity_7\NN\5651971|NONE
D018967_D007333 NONE risperidone_49\NN\0|NONE (r_pobj) vs_48\IN\13634784|)|( (r_prep) clozapine_47\NN\3713736|NONE (r_appos) risperidone_45\NN\0|NONE (r_pobj) with_44\IN\0|who|were (r_prep) treated_43\VBN\2376958|NONE (r_relcl) subjects_40\NNS\6598915|NONE (r_pobj) with_39\IN\0|NONE (r_prep) compared_38\VBN\644583|resistance (r_prep) exhibiting_34\VBG\2632167|received (l_dobj) resistance_37\NN\37396|compared
D018967_D007333 NONE risperidone_19\NN\0| (r_npadvmod) treated_21\VBN\2376958|NONE (r_amod) subjects_22\NNS\6598915|NONE (r_pobj) with_18\IN\0|NONE (r_prep) compared_17\VBN\644583|groups|resistance|. (r_prep) displayed_8\VBD\2137132|NONE (l_dobj) resistance_11\NN\37396|groups|compared|.
D003024_D011618 NONE clozapine_20\NN\3713736|NONE (r_pobj) with_18\IN\0|NONE (r_prep) treated_17\VBN\2376958|and|by (r_conj) matched_11\VBN\2664769|nonobese|with|,|six|, (r_acl) subjects_4\NNS\6598915|.|in|were (l_prep) with_5\IN\0|nonobese|,|matched|six|, (l_pobj) schizophrenia_6\NN\14398067|NONE (l_conj) disorder_9\NN\14034177|or
19841052
D016578_D006679 CID cocaine_13\NN\3492717|crack (r_pobj) of_11\IN\0|daily (r_prep) smokers_10\NNS\9612848|NONE (r_pobj) among_8\IN\0|HIV (r_prep) seroconversion_7\NN\0|NONE
D016578_D006679 CID cocaine_22\NN\3492717|NONE (r_dobj) crack_21\VB\9379111|NONE (r_pcomp) of_20\IN\0|daily (r_prep) smokers_19\NNS\9612848|who (r_attr) were_17\VBD\0|NONE (r_relcl) participants_15\NNS\9816771|NONE (r_pobj) among_14\IN\0|HIV (r_prep) seroconversion_13\NN\0|NONE
D016578_D006679 CID cocaine_3\NN\3492717|crack (r_pobj) of_1\IN\0|NONE (r_prep) smoking_0\NN\831191|was|.|be (r_nsubjpass) found_5\VBN\13279262|NONE (l_xcomp) be_7\VB\14625458|was|.|Smoking (l_attr) factor_11\NN\7326557|to (l_prep) for_12\IN\0|an|risk|independent (l_pobj) seroconversion_14\NN\0|NONE
D016578_D015658 NONE cocaine_3\NN\3492717|as (r_dobj) crack_2\VB\9379111|NONE (l_prep) as_4\IN\14622893|cocaine (l_pobj) factor_7\NN\7326557|NONE (l_prep) for_8\IN\0|a|risk (l_pobj) infection_10\NN\14052046|NONE
D016578_D015658 NONE cocaine_10\NN\3492717|smoking|that (r_dobj) crack_9\VBP\9379111|has|possible|the (r_relcl) role_6\NN\719494|NONE (l_acl) has_11\VBZ\13888491|possible|crack|the (l_prep) on_12\IN\0|NONE (l_pobj) incidence_14\NN\13821570|NONE (l_prep) of_15\IN\0|the (l_pobj) infection_17\NN\14052046|NONE
D016578_D015658 NONE cocaine_6\NN\3492717|NONE (r_pobj) of_4\IN\0|increasing|the (r_prep) use_3\NN\407535|NONE (r_pobj) given_0\VBN\5892096|we|,|examine|. (r_prep) sought_9\VBD\1825237|NONE (l_xcomp) examine_11\VB\0|we|,|.|Given (l_ccomp) become_19\VBN\146138|to (l_attr) factor_22\NN\7326557|has|use|whether (l_prep) for_23\IN\0|risk|a (l_pobj) infection_25\NN\14052046|NONE
851038
D011188_D007008 NONE potassium_11\NN\14625458|NONE (r_pobj) of_10\IN\0|renal|the (r_prep) excretion_9\NN\13466586|NONE (r_pobj) on_6\IN\0|L| (r_prep) dopa_5\NN\14601829|NONE (r_pobj) of_2\IN\0|The (r_prep) influence_1\NN\5190804|.|in|was (r_nsubjpass) studied_13\VBN\0|NONE (l_prep) in_14\IN\13603305|.|was|influence (l_pobj) patients_16\NNS\9898892|in|and (l_prep) with_17\IN\0| (l_pobj) hypokalemia_18\NN\14299637|NONE
D011188_D007008 NONE potassium_38\NN\14625458|NONE (r_pobj) of_37\IN\0|plasma (r_prep) concentration_36\NN\4916342|,|filtration|glomerular (r_conj) rate_33\NN\13815152|renal|,|plasma (r_conj) flow_29\NN\7311115|NONE (r_pobj) of_26\IN\0|NONE (r_prep) determination_25\NN\43195|NONE (r_pobj) by_24\IN\0|normokalemic| (r_prep) patients_23\NNS\9898892|NONE (r_pobj) in_20\IN\13603305|and|patients (r_conj) in_14\IN\13603305|.|was|influence (l_pobj) patients_16\NNS\9898892|in|and (l_prep) with_17\IN\0| (l_pobj) hypokalemia_18\NN\14299637|NONE
D011188_D007008 NONE potassium_47\NN\14625458|NONE (r_pobj) of_46\IN\0|urinary (r_prep) excretion_45\NN\13466586|and|as|sodium (r_conj) potassium_38\NN\14625458|NONE (r_pobj) of_37\IN\0|plasma (r_prep) concentration_36\NN\4916342|,|filtration|glomerular (r_conj) rate_33\NN\13815152|renal|,|plasma (r_conj) flow_29\NN\7311115|NONE (r_pobj) of_26\IN\0|NONE (r_prep) determination_25\NN\43195|NONE (r_pobj) by_24\IN\0|normokalemic| (r_prep) patients_23\NNS\9898892|NONE (r_pobj) in_20\IN\13603305|and|patients (r_conj) in_14\IN\13603305|.|was|influence (l_pobj) patients_16\NNS\9898892|in|and (l_prep) with_17\IN\0| (l_pobj) hypokalemia_18\NN\14299637|NONE
D000450_D007008 NONE aldosterone_51\NN\14751863|and (r_conj) sodium_49\NN\14625458|, (r_conj) potassium_47\NN\14625458|NONE (r_pobj) of_46\IN\0|urinary (r_prep) excretion_45\NN\13466586|and|as|sodium (r_conj) potassium_38\NN\14625458|NONE (r_pobj) of_37\IN\0|plasma (r_prep) concentration_36\NN\4916342|,|filtration|glomerular (r_conj) rate_33\NN\13815152|renal|,|plasma (r_conj) flow_29\NN\7311115|NONE (r_pobj) of_26\IN\0|NONE (r_prep) determination_25\NN\43195|NONE (r_pobj) by_24\IN\0|normokalemic| (r_prep) patients_23\NNS\9898892|NONE (r_pobj) in_20\IN\13603305|and|patients (r_conj) in_14\IN\13603305|.|was|influence (l_pobj) patients_16\NNS\9898892|in|and (l_prep) with_17\IN\0| (l_pobj) hypokalemia_18\NN\14299637|NONE
D012964_D007008 NONE sodium_40\NN\14625458|excretion|and|as (r_conj) potassium_38\NN\14625458|NONE (r_pobj) of_37\IN\0|plasma (r_prep) concentration_36\NN\4916342|,|filtration|glomerular (r_conj) rate_33\NN\13815152|renal|,|plasma (r_conj) flow_29\NN\7311115|NONE (r_pobj) of_26\IN\0|NONE (r_prep) determination_25\NN\43195|NONE (r_pobj) by_24\IN\0|normokalemic| (r_prep) patients_23\NNS\9898892|NONE (r_pobj) in_20\IN\13603305|and|patients (r_conj) in_14\IN\13603305|.|was|influence (l_pobj) patients_16\NNS\9898892|in|and (l_prep) with_17\IN\0| (l_pobj) hypokalemia_18\NN\14299637|NONE
D012964_D007008 NONE sodium_49\NN\14625458|, (r_conj) potassium_47\NN\14625458|NONE (r_pobj) of_46\IN\0|urinary (r_prep) excretion_45\NN\13466586|and|as|sodium (r_conj) potassium_38\NN\14625458|NONE (r_pobj) of_37\IN\0|plasma (r_prep) concentration_36\NN\4916342|,|filtration|glomerular (r_conj) rate_33\NN\13815152|renal|,|plasma (r_conj) flow_29\NN\7311115|NONE (r_pobj) of_26\IN\0|NONE (r_prep) determination_25\NN\43195|NONE (r_pobj) by_24\IN\0|normokalemic| (r_prep) patients_23\NNS\9898892|NONE (r_pobj) in_20\IN\13603305|and|patients (r_conj) in_14\IN\13603305|.|was|influence (l_pobj) patients_16\NNS\9898892|in|and (l_prep) with_17\IN\0| (l_pobj) hypokalemia_18\NN\14299637|NONE
D007980_D007008 CID dopa_11\NN\14601829| (r_npadvmod) treated_13\VBN\2376958|some|parkinsonian (r_amod) patients_15\NNS\9898892|NONE (r_pobj) in_7\IN\13603305|Hypokalemia|was|. (r_prep) observed_6\VBN\2163746|NONE (l_nsubjpass) hypokalemia_0\NNP\14299637|in|was|.
D007980_D007008 CID dopa_5\NN\14601829|NONE (r_pobj) of_2\IN\0|The (r_prep) influence_1\NN\5190804|.|in|was (r_nsubjpass) studied_13\VBN\0|NONE (l_prep) in_14\IN\13603305|.|was|influence (l_pobj) patients_16\NNS\9898892|in|and (l_prep) with_17\IN\0| (l_pobj) hypokalemia_18\NN\14299637|NONE
D007980_D010300 NONE dopa_5\NN\14601829|in (r_compound) treatment_6\NN\654885|NONE (l_prep) in_7\IN\13603305|dopa (l_pobj) patients_9\NNS\9898892|NONE (l_amod) parkinsonian_8\JJ\0|NONE
D007980_D010300 NONE dopa_11\NN\14601829| (r_npadvmod) treated_13\VBN\2376958|some|parkinsonian (r_amod) patients_15\NNS\9898892|NONE (l_amod) parkinsonian_14\JJ\0|treated|some
20129423
D002220_D004802 CID carbamazepine_1\NN\0|.|hypersensitivity (r_nsubj) induced_2\VBD\1627355|NONE (l_dobj) hypersensitivity_6\NN\14531772|.|carbamazepine (l_amod) eosinophilic_4\JJ\0|myocarditis|fulminant|(|)|emphasis
D002220_D009205 CID carbamazepine_1\NN\0|.|hypersensitivity (r_nsubj) induced_2\VBD\1627355|NONE (l_dobj) hypersensitivity_6\NN\14531772|.|carbamazepine (l_amod) myocarditis_8\NN\14338942|fulminant|eosinophilic|(|)|emphasis
D002220_D009205 CID carbamazepine_10\NN\0|NONE (r_pobj) of_9\IN\0|rare|side (r_prep) effect_8\NN\34213|.|,|is|although|myocarditis|fatal (r_nsubj) necrotizing_12\VBG\0|NONE (l_oprd) myocarditis_17\NN\14338942|.|,|is|although|fatal|effect
D002220_D009205 CID carbamazepine_11\NN\0|NONE (r_pobj) of_10\IN\0|NONE (r_prep) administration_9\NN\1133281|NONE (r_pobj) to_8\IN\0|myocarditis (r_prep) secondary_7\JJ\8426461|NONE (l_advmod) myocarditis_6\NN\14338942|to
D002220_D009205 CID carbamazepine_12\NN\0|NONE (r_pobj) of_10\IN\0|second|the|induced (r_prep) case_9\NN\7283608|this|To|. (l_acl) induced_13\VBN\1627355|second|of|the (l_dobj) myocarditis_14\NN\14338942|NONE
D002220_D004342 CID carbamazepine_1\NN\0|.|hypersensitivity (r_nsubj) induced_2\VBD\1627355|NONE (l_dobj) hypersensitivity_6\NN\14531772|.|carbamazepine
D002220_D004342 CID carbamazepine_1\NN\0|.|hypersensitivity (r_nsubj) induced_2\VBD\1627355|NONE (l_dobj) hypersensitivity_6\NN\14531772|.|carbamazepine (l_appos) emphasis_10\NN\14434681|myocarditis|fulminant|eosinophilic|(|) (l_prep) on_11\IN\0|NONE (l_pobj) characteristics_15\NNS\5849040|NONE (l_prep) of_20\IN\0|,|anatomical|mechanisms (l_pobj) hypersensitivity_22\NN\14531772|NONE
D002220_D004342 CID carbamazepine_10\NN\0|NONE (r_pobj) of_9\IN\0|rare|side (r_prep) effect_8\NN\34213|.|,|is|although|myocarditis|fatal (r_nsubj) necrotizing_12\VBG\0|NONE (l_oprd) myocarditis_17\NN\14338942|.|,|is|although|fatal|effect (l_nmod) hypersensitivity_15\NN\14531772|eosinophilic
D002220_D004342 CID carbamazepine_11\NN\0|NONE (r_pobj) of_10\IN\0|NONE (r_prep) administration_9\NN\1133281|NONE (r_pobj) to_8\IN\0|myocarditis (r_prep) secondary_7\JJ\8426461|NONE (r_amod) hypersensitivity_5\NN\14531772|NONE
10327032
D000644_D001424 NONE ammonium_2\NN\14743582|onset|Higher|and (r_compound) levels_3\NNS\4916342|in|.|and|in|were (r_nsubjpass) seen_11\VBN\2106506|NONE (l_prep) in_12\IN\13603305|levels|.|and|in|were (l_pobj) patients_14\NNS\9898892|NONE (l_prep) with_15\IN\0| (l_pobj) infections_17\NNS\14052046|NONE
D005472_D007239 NONE 5-fluorouracil_13\CD\0|complication (r_punct) with_14\IN\0|who|infusion (l_pobj) complication_16\NN\1073995|fluorouracil (l_prep) of_17\IN\0|the (l_pobj) dehydration_18\NN\14536438|NONE (l_conj) infection_20\NN\14052046|and
D005472_D009369 NONE 5-fluorouracil_13\CD\0|complication (r_punct) with_14\IN\0|who|infusion (r_prep) received_9\VBD\2210855|cancer (r_relcl) patients_7\NNS\9898892|NONE (l_compound) cancer_6\NN\14239425|received
D005472_D009369 NONE 5-fluorouracil_21\CD\0|( (r_punct) 5-fu_23\CD\0|NONE (r_pobj) of_20\IN\0|continuous (r_prep) infusion_19\NN\14589223|NONE (r_pobj) to_17\IN\0|NONE (r_prep) related_16\VBN\628491|hyperammonemic|transient (r_acl) encephalopathy_15\NN\14084880|NONE (r_pobj) of_12\IN\0| (r_prep) episodes_11\NNS\7283608|who (r_dobj) had_9\VBD\0|)||cancer (r_relcl) patients_7\NNS\9898892|,|From|.|were (l_compound) cancer_6\NN\14239425|had|)|
D005472_D009369 NONE 5-fu_23\CD\0|NONE (r_pobj) of_20\IN\0|continuous (r_prep) infusion_19\NN\14589223|NONE (r_pobj) to_17\IN\0|NONE (r_prep) related_16\VBN\628491|hyperammonemic|transient (r_acl) encephalopathy_15\NN\14084880|NONE (r_pobj) of_12\IN\0| (r_prep) episodes_11\NNS\7283608|who (r_dobj) had_9\VBD\0|)||cancer (r_relcl) patients_7\NNS\9898892|,|From|.|were (l_compound) cancer_6\NN\14239425|had|)|
D005472_D003681 NONE 5-fluorouracil_13\CD\0|complication (r_punct) with_14\IN\0|who|infusion (l_pobj) complication_16\NN\1073995|fluorouracil (l_prep) of_17\IN\0|the (l_pobj) dehydration_18\NN\14536438|NONE
D000644_D022124 NONE ammonium_2\NN\14743582|onset|Higher|and (r_compound) levels_3\NNS\4916342|in|.|and|in|were (l_conj) onset_7\NN\7325190|ammonium|Higher|and (l_prep) of_8\IN\0|rapid (l_pobj) hyperammonemia_9\NN\0|NONE
D005472_D022124 CID 5-fluorouracil_13\CD\0|complication (r_punct) with_14\IN\0|who|infusion (r_prep) received_9\VBD\2210855|cancer (r_relcl) patients_7\NNS\9898892|NONE (r_pobj) in_5\IN\13603305|transient|hyperammonemic (r_prep) encephalopathy_4\NN\14084880|NONE
D005472_D022124 CID 5-fluorouracil_21\CD\0|( (r_punct) 5-fu_23\CD\0|NONE (r_pobj) of_20\IN\0|continuous (r_prep) infusion_19\NN\14589223|NONE (r_pobj) to_17\IN\0|NONE (r_prep) related_16\VBN\628491|hyperammonemic|transient (r_acl) encephalopathy_15\NN\14084880|NONE
D005472_D022124 CID 5-fu_23\CD\0|NONE (r_pobj) of_20\IN\0|continuous (r_prep) infusion_19\NN\14589223|NONE (r_pobj) to_17\IN\0|NONE (r_prep) related_16\VBN\628491|hyperammonemic|transient (r_acl) encephalopathy_15\NN\14084880|NONE
D005472_D022124 CID 5-fu_42\CD\0|NONE (r_pobj) of_41\IN\0|(|high|m|)|daily (r_prep) doses_32\NNS\3740161|respectively (r_dobj) receiving_29\VBG\2210855|nine (r_acl) patients_28\NNS\9898892|) (r_pobj) in_26\IN\13603305|in|levels|.|and|were (r_prep) seen_11\VBN\2106506|NONE (l_nsubjpass) levels_3\NNS\4916342|in|.|and|in|were (l_conj) onset_7\NN\7325190|ammonium|Higher|and (l_prep) of_8\IN\0|rapid (l_pobj) hyperammonemia_9\NN\0|NONE
D005472_D022124 CID 5-fu_13\CD\0|NONE (r_pobj) of_12\IN\0|continuous (r_prep) infusion_11\NN\14589223|NONE (r_dobj) receiving_9\VBG\2210855|NONE (r_acl) patients_8\NNS\9898892|NONE (r_pobj) in_7\IN\13603305|.|In|encephalopathy|,|can (r_prep) occur_6\VB\0|NONE (l_nsubj) encephalopathy_4\NN\14084880|.|In|,|can|in
D005472_D001424 NONE 5-fu_42\CD\0|NONE (r_pobj) of_41\IN\0|(|high|m|)|daily (r_prep) doses_32\NNS\3740161|respectively (r_dobj) receiving_29\VBG\2210855|nine (r_acl) patients_28\NNS\9898892|) (r_pobj) in_26\IN\13603305|in|levels|.|and|were (r_prep) seen_11\VBN\2106506|NONE (l_prep) in_12\IN\13603305|levels|.|and|in|were (l_pobj) patients_14\NNS\9898892|NONE (l_prep) with_15\IN\0| (l_pobj) infections_17\NNS\14052046|NONE
D005472_D001927 CID 5-fluorouracil_13\CD\0|complication (r_punct) with_14\IN\0|who|infusion (r_prep) received_9\VBD\2210855|cancer (r_relcl) patients_7\NNS\9898892|NONE (r_pobj) in_5\IN\13603305|transient|hyperammonemic (r_prep) encephalopathy_4\NN\14084880|NONE
D005472_D001927 CID 5-fluorouracil_21\CD\0|( (r_punct) 5-fu_23\CD\0|NONE (r_pobj) of_20\IN\0|continuous (r_prep) infusion_19\NN\14589223|NONE (r_pobj) to_17\IN\0|NONE (r_prep) related_16\VBN\628491|hyperammonemic|transient (r_acl) encephalopathy_15\NN\14084880|NONE
D005472_D001927 CID 5-fu_23\CD\0|NONE (r_pobj) of_20\IN\0|continuous (r_prep) infusion_19\NN\14589223|NONE (r_pobj) to_17\IN\0|NONE (r_prep) related_16\VBN\628491|hyperammonemic|transient (r_acl) encephalopathy_15\NN\14084880|NONE
D005472_D001927 CID 5-fu_13\CD\0|NONE (r_pobj) of_12\IN\0|continuous (r_prep) infusion_11\NN\14589223|NONE (r_dobj) receiving_9\VBG\2210855|NONE (r_acl) patients_8\NNS\9898892|NONE (r_pobj) in_7\IN\13603305|.|In|encephalopathy|,|can (r_prep) occur_6\VB\0|NONE (l_nsubj) encephalopathy_4\NN\14084880|.|In|,|can|in
3109094
D015080_D001745 NONE mesna_20\NN\0|NONE (r_pobj) by_19\IN\0|their (r_prep) prevention_18\NN\1073995|and|of|induced|the (r_conj) lesions_8\NNS\14204950|NONE (l_prep) of_9\IN\0|and|prevention|induced|the (l_pobj) bladder_12\NN\5515670|NONE
D003520_D004487 NONE cyclophosphamide_2\NN\0| (r_npadvmod) induced_4\VBN\1627355|developed (r_amod) cystitis_5\NN\14566129|is|edema|.|by (r_nsubjpass) characterized_7\VBN\609683|NONE (l_dobj) edema_18\NN\14315192|is|.|by|cystitis
D003520_D003556 NONE cyclophosphamide_2\NN\0| (r_npadvmod) induced_4\VBN\1627355|developed (r_amod) cystitis_5\NN\14566129|is|edema|.|by
D003520_D001745 CID cyclophosphamide_5\NN\0| (r_npadvmod) induced_7\VBN\1627355|and|prevention|of|the (r_amod) lesions_8\NNS\14204950|NONE (l_prep) of_9\IN\0|and|prevention|induced|the (l_pobj) bladder_12\NN\5515670|NONE
D003520_D009336 NONE cyclophosphamide_2\NN\0| (r_npadvmod) induced_4\VBN\1627355|developed (r_amod) cystitis_5\NN\14566129|is|edema|.|by (r_nsubjpass) characterized_7\VBN\609683|NONE (l_dobj) edema_18\NN\14315192|is|.|by|cystitis (l_acl) owing_19\VBG\0|,|submucosal|severe (l_prep) to_20\IN\0|NONE (l_pobj) damage_21\NN\7296428|NONE (l_prep) to_22\IN\0|NONE (l_pobj) bed_25\NN\2821943|NONE (l_conj) necroses_29\NNS\93775|the|and|microvascular
11380496
D011441_D019226 CID ptu_36\NNP\0|NONE (r_compound) therapy_37\NN\657604|NONE (r_dobj) stopping_35\VBG\3323703|weeks (r_pcomp) after_34\IN\0|decreased|,|and|symptoms (r_prep) resolved_31\VBD\352826|she|fever|,|but (r_conj) developed_18\VBD\1753788|,|In|to|and|titre (l_dobj) fever_21\NN\14299637|she|resolved|,|but (l_conj) ulcers_24\NNS\14211294|higher|,|a
D011441_D019226 CID ptu_56\NNP\0|NONE (r_dobj) discontinuing_55\VBG\0|NONE (r_pcomp) after_54\IN\0|by|titre|to|. (r_prep) decreased_45\VBD\169651|,|after|and|symptoms (r_conj) resolved_31\VBD\352826|she|fever|,|but (r_conj) developed_18\VBD\1753788|,|In|to|and|titre (l_dobj) fever_21\NN\14299637|she|resolved|,|but (l_conj) ulcers_24\NNS\14211294|higher|,|a
D011441_D018771 CID ptu_36\NNP\0|NONE (r_compound) therapy_37\NN\657604|NONE (r_dobj) stopping_35\VBG\3323703|weeks (r_pcomp) after_34\IN\0|decreased|,|and|symptoms (r_prep) resolved_31\VBD\352826|she|fever|,|but (r_conj) developed_18\VBD\1753788|,|In|to|and|titre (l_dobj) fever_21\NN\14299637|she|resolved|,|but (l_conj) ulcers_24\NNS\14211294|higher|,|a (l_conj) polyarthralgia_26\NN\0|oral|and
D011441_D018771 CID ptu_56\NNP\0|NONE (r_dobj) discontinuing_55\VBG\0|NONE (r_pcomp) after_54\IN\0|by|titre|to|. (r_prep) decreased_45\VBD\169651|,|after|and|symptoms (r_conj) resolved_31\VBD\352826|she|fever|,|but (r_conj) developed_18\VBD\1753788|,|In|to|and|titre (l_dobj) fever_21\NN\14299637|she|resolved|,|but (l_conj) ulcers_24\NNS\14211294|higher|,|a (l_conj) polyarthralgia_26\NN\0|oral|and
D011441_D005334 CID ptu_36\NNP\0|NONE (r_compound) therapy_37\NN\657604|NONE (r_dobj) stopping_35\VBG\3323703|weeks (r_pcomp) after_34\IN\0|decreased|,|and|symptoms (r_prep) resolved_31\VBD\352826|she|fever|,|but (r_conj) developed_18\VBD\1753788|,|In|to|and|titre (l_dobj) fever_21\NN\14299637|she|resolved|,|but
D011441_D005334 CID ptu_56\NNP\0|NONE (r_dobj) discontinuing_55\VBG\0|NONE (r_pcomp) after_54\IN\0|by|titre|to|. (r_prep) decreased_45\VBD\169651|,|after|and|symptoms (r_conj) resolved_31\VBD\352826|she|fever|,|but (r_conj) developed_18\VBD\1753788|,|In|to|and|titre (l_dobj) fever_21\NN\14299637|she|resolved|,|but
D011441_D006111 NONE propylthiouracil_21\NN\14727670|NONE (r_pobj) with_20\IN\0|NONE (r_prep) treated_19\VBN\2376958|disease|Graves (r_acl) patients_18\NNS\9898892|NONE (l_compound) disease_17\NN\14061805|treated|Graves
D011441_D006111 NONE propylthiouracil_22\NN\14727670|NONE (r_pobj) with_21\IN\0|were|who (r_prep) treated_20\VBN\2376958|Graves (r_relcl) disease_17\NN\14061805|NONE
D011441_D006111 NONE ptu_24\NNP\0|NONE (r_appos) propylthiouracil_22\NN\14727670|NONE (r_pobj) with_21\IN\0|were|who (r_prep) treated_20\VBN\2376958|Graves (r_relcl) disease_17\NN\14061805|NONE
D011441_D006111 NONE ptu_21\NNP\0|NONE (r_compound) therapy_22\NN\657604|NONE (r_pobj) during_20\IN\0|the|of (r_prep) appearance_13\NN\4723816|NONE (r_pobj) between_11\IN\0|the|temporal (r_prep) relationship_10\NN\31921|NONE (r_pobj) on_7\IN\0|no (r_prep) studies_6\NNS\635850|there|,|,|on|Nevertheless|or|.|have (r_attr) been_4\VBN\0|NONE (l_conj) on_25\IN\0|there|,|,|Nevertheless|or|studies|.|have (l_pobj) anca_31\NNP\0|incidence| (l_prep) in_32\IN\13603305|NONE (l_pobj) patients_37\NNS\9898892|NONE (l_compound) disease_36\NN\14061805|Graves
D011441_D006111 NONE ptu_27\NNP\0|NONE (r_compound) therapy_28\NN\657604|NONE (r_dobj) starting_26\VBG\457382|NONE (r_pcomp) after_25\IN\0|development|the (r_prep) vasculitis_24\NN\14336539|NONE (r_pobj) for_21\IN\0|We|due|.|patients|and|, (r_conj) investigated_1\VBD\644583|NONE (l_prep) due_7\IN\5174653|We|.|patients|and|,|for (l_pobj) disease_11\NN\14061805|to
D011441_D014652 NONE ptu_24\NNP\0|continued (r_compound) therapy_25\NN\657604|NONE (r_pobj) despite_22\IN\7501545|respectively|,|,|titres|but|developed|,|In|transiently|to|, (r_prep) increased_11\VBD\169651|NONE (l_conj) developed_31\VBD\1753788|respectively|despite|,|,|titres|but|,|In|transiently|to|, (l_nsubj) disorders_30\NNS\14034177|.
D011441_D014657 NONE propylthiouracil_22\NN\14727670|NONE (r_pobj) with_21\IN\0|were|who (r_prep) treated_20\VBN\2376958|Graves (r_relcl) disease_17\NN\14061805|NONE (r_pobj) with_14\IN\0|NONE (r_prep) patients_13\NNS\9898892|NONE (r_pobj) in_12\IN\13603305|been|has|vasculitis|. (r_prep) reported_11\VBN\831651|NONE (l_nsubjpass) vasculitis_8\NN\14336539|been|has|in|.
D011441_D014657 NONE ptu_24\NNP\0|NONE (r_appos) propylthiouracil_22\NN\14727670|NONE (r_pobj) with_21\IN\0|were|who (r_prep) treated_20\VBN\2376958|Graves (r_relcl) disease_17\NN\14061805|NONE (r_pobj) with_14\IN\0|NONE (r_prep) patients_13\NNS\9898892|NONE (r_pobj) in_12\IN\13603305|been|has|vasculitis|. (r_prep) reported_11\VBN\831651|NONE (l_nsubjpass) vasculitis_8\NN\14336539|been|has|in|.
D011441_D014657 NONE ptu_21\NNP\0|NONE (r_compound) therapy_22\NN\657604|NONE (r_pobj) during_20\IN\0|the|of (r_prep) appearance_13\NN\4723816|NONE (l_prep) of_14\IN\0|the|during (l_pobj) mpo_15\NNP\0|NONE (l_appos) anca_17\NNP\0| (l_conj) vasculitis_19\NN\14336539|and
D011441_D014657 NONE ptu_27\NNP\0|NONE (r_compound) therapy_28\NN\657604|NONE (r_dobj) starting_26\VBG\457382|NONE (r_pcomp) after_25\IN\0|development|the (r_prep) vasculitis_24\NN\14336539|NONE
D011441_D006980 NONE ptu_27\NNP\0|NONE (r_compound) therapy_28\NN\657604|NONE (r_dobj) starting_26\VBG\457382|NONE (r_pcomp) after_25\IN\0|development|the (r_prep) vasculitis_24\NN\14336539|NONE (r_pobj) for_21\IN\0|We|due|.|patients|and|, (r_conj) investigated_1\VBD\644583|NONE (l_dobj) patients_4\NNS\9898892|We|due|.|and|,|for (l_prep) with_5\IN\0||untreated (l_pobj) hyperthyroidism_6\NN\14059928|NONE
11176729
D017706_D006333 NONE lisinopril_15\NN\2673637|NONE (l_prep) in_16\IN\13603305|dose (l_pobj) chf_17\NNP\0|NONE
D000806_D006947 NONE inhibitor_8\NN\20090|previously|not (r_dobj) receiving_5\VBG\2210855| (r_acl) patients_2\NNS\9898892|NONE (r_pobj) of_0\IN\0|to|be|or|,|could|not|because|doses|.|because (r_prep) titrated_18\VBN\489837|NONE (l_conj) because_38\IN\0|to|be|or|,|could|not|Of|doses|.|because (l_pobj) dysfunction_41\NN\14204950|of (l_conj) hyperkalemia_43\NN\14299637|or|(|)|renal|%
D000806_D007022 NONE inhibitor_8\NN\20090|previously|not (r_dobj) receiving_5\VBG\2210855| (r_acl) patients_2\NNS\9898892|NONE (r_pobj) of_0\IN\0|to|be|or|,|could|not|because|doses|.|because (r_prep) titrated_18\VBN\489837|NONE (l_prep) because_26\IN\0|to|be|or|,|could|not|Of|because|doses|. (l_pobj) symptoms_28\NNS\5823932|of (l_acl) related_30\VBD\628491|NONE (l_prep) to_31\IN\0|possibly (l_pobj) hypotension_32\NN\14057371|NONE
D000806_D006333 NONE inhibitors_9\NNS\20090|NONE (r_pobj) of_4\IN\0|high (r_prep) doses_3\NNS\3740161|NONE (r_pobj) of_1\IN\0|in|results|.|: (r_prep) toleration_0\NN\4637923|NONE (l_prep) in_10\IN\13603305|of|results|.|: (l_pobj) patients_11\NNS\9898892|NONE (l_prep) with_12\IN\0|NONE (l_pobj) failure_15\NN\66216|NONE
D000806_D006333 NONE inhibitors_9\NNS\20090|NONE (r_pobj) with_1\IN\0|NONE (r_prep) treatment_0\NN\654885|receiving|mortality|,|but (r_nsubj) reduces_10\VBZ\441445|NONE (l_dobj) mortality_11\NN\5054863|receiving|Treatment|,|but (l_prep) in_14\IN\13603305|morbidity|and (l_pobj) patients_15\NNS\9898892|NONE (l_prep) with_16\IN\0|NONE (l_pobj) failure_19\NN\66216|NONE
D000806_D006333 NONE inhibitors_9\NNS\20090|NONE (r_pobj) with_1\IN\0|NONE (r_prep) treatment_0\NN\654885|receiving|mortality|,|but (r_nsubj) reduces_10\VBZ\441445|NONE (l_dobj) mortality_11\NN\5054863|receiving|Treatment|,|but (l_prep) in_14\IN\13603305|morbidity|and (l_pobj) patients_15\NNS\9898892|NONE (l_prep) with_16\IN\0|NONE (l_pobj) failure_19\NN\66216|NONE (l_appos) chf_21\NNP\0|heart|chronic
D000806_D006333 NONE inhibitor_5\NN\20090|ACE|in (r_compound) therapy_6\NN\657604|can|maintained|be|and|successfully|to|,|that|warranted|and (l_prep) in_7\IN\13603305|inhibitor|ACE (l_pobj) patients_9\NNS\9898892|NONE (l_prep) with_10\IN\0|most (l_pobj) chf_11\NNP\0|NONE
D000806_D007674 NONE inhibitor_8\NN\20090|previously|not (r_dobj) receiving_5\VBG\2210855| (r_acl) patients_2\NNS\9898892|NONE (r_pobj) of_0\IN\0|to|be|or|,|could|not|because|doses|.|because (r_prep) titrated_18\VBN\489837|NONE (l_conj) because_38\IN\0|to|be|or|,|could|not|Of|doses|.|because (l_pobj) dysfunction_41\NN\14204950|of
2383364
C048279_D010146 CID chp_6\NNP\0|ratings|and (r_compound) concentration_7\NN\4916342|NONE (l_conj) ratings_11\NNS\5733583|and|CHP (l_prep) of_12\IN\0|on|patients (l_pobj) pain_13\NN\14299637|NONE
C048279_D010146 CID chp_4\NNP\0|cent|The|. (r_compound) cream_5\NN\8386555|closest|in (r_nsubj) was_6\VBD\0|;|however|statistically|none|,|from|. (l_prep) in_10\IN\13603305|cream|closest (l_pobj) tolerance_12\NN\5032565|NONE (l_compound) pain_11\NN\14299637|NONE
C048279_D002056 NONE diphosphanilate_6\NN\0|NONE (r_pobj) of_3\IN\0|agent|tolerance|:|. (r_prep) study_2\NN\635850|NONE (l_appos) agent_11\NN\7347|of|tolerance|:|. (l_prep) for_12\IN\0|new|a|topical (l_pobj) burns_13\NNS\0|NONE
C048279_D002056 NONE phosphanilate_1\NN\0|has|as|but|,|been|reported (r_nsubjpass) evaluated_16\VBN\670261|NONE (l_prep) as_17\IN\14622893|has|but|,|been|reported|phosphanilate (l_pobj) wound_21\NN\14285662|NONE (l_compound) burn_20\NN\14322699|dressing|topical|a
C048279_D002056 NONE chp_3\NNP\0|,|agent|,|Chlorhexidine (r_appos) phosphanilate_1\NN\0|has|as|but|,|been|reported (r_nsubjpass) evaluated_16\VBN\670261|NONE (l_prep) as_17\IN\14622893|has|but|,|been|reported|phosphanilate (l_pobj) wound_21\NN\14285662|NONE (l_compound) burn_20\NN\14322699|dressing|topical|a
C048279_D002056 NONE chp_10\NNP\0|four|different (r_compound) concentrations_11\NNS\4916342|NONE (r_pobj) of_7\IN\0|NONE (r_prep) each_6\DT\0|NONE (r_pobj) with_5\IN\0|vehicle|was|,|,|site|.|from (r_prep) treated_4\VBN\2376958|NONE (l_nsubjpass) site_2\NN\8673395|vehicle|was|,|,|.|from|with (l_compound) burn_1\NN\14322699|One
C048279_D002056 NONE chp_10\NNP\0|four|different (r_compound) concentrations_11\NNS\4916342|NONE (r_pobj) of_7\IN\0|NONE (r_prep) each_6\DT\0|NONE (r_pobj) with_5\IN\0|vehicle|was|,|,|site|.|from (r_prep) treated_4\VBN\2376958|NONE (l_dobj) vehicle_23\NN\3100490|was|,|,|site|.|from|with (l_conj) cream_34\NN\8386555|their|and|, (l_appos) agent_38\NN\7347||)|,|sulphadiazine|(|AgSD (l_acl) used_40\VBN\0|an|antimicrobial (l_prep) for_41\IN\0|frequently (l_pobj) treatment_43\NN\654885|NONE (l_prep) of_44\IN\0|topical (l_pobj) wounds_46\NNS\14285662|NONE (l_compound) burn_45\NN\14322699|NONE
D012837_D010146 NONE agsd_9\NNP\0|NONE (r_pobj) to_8\IN\0|NONE (r_prep) closest_7\JJS\0|cream|in (r_acomp) was_6\VBD\0|;|however|statistically|none|,|from|. (l_prep) in_10\IN\13603305|cream|closest (l_pobj) tolerance_12\NN\5032565|NONE (l_compound) pain_11\NN\14299637|NONE
D012837_D010146 NONE agsd_23\NNP\0|from|or (r_pobj) from_22\IN\0|;|however|statistically|none|was|,|. (r_prep) differed_20\VBD\0|NONE (l_ccomp) was_6\VBD\0|;|however|statistically|none|,|from|. (l_prep) in_10\IN\13603305|cream|closest (l_pobj) tolerance_12\NN\5032565|NONE (l_compound) pain_11\NN\14299637|NONE
D012837_D002056 NONE sulphadiazine_30\NN\0||)|,|agent|(|AgSD (r_nmod) cream_34\NN\8386555|their|and|, (r_conj) vehicle_23\NN\3100490|was|,|,|site|.|from|with (r_dobj) treated_4\VBN\2376958|NONE (l_nsubjpass) site_2\NN\8673395|vehicle|was|,|,|.|from|with (l_compound) burn_1\NN\14322699|One
D012837_D002056 NONE sulphadiazine_30\NN\0||)|,|agent|(|AgSD (r_nmod) cream_34\NN\8386555|their|and|, (l_appos) agent_38\NN\7347||)|,|sulphadiazine|(|AgSD (l_acl) used_40\VBN\0|an|antimicrobial (l_prep) for_41\IN\0|frequently (l_pobj) treatment_43\NN\654885|NONE (l_prep) of_44\IN\0|topical (l_pobj) wounds_46\NNS\14285662|NONE (l_compound) burn_45\NN\14322699|NONE
D012837_D002056 NONE agsd_32\NNP\0||)|,|agent|sulphadiazine|( (r_nmod) cream_34\NN\8386555|their|and|, (r_conj) vehicle_23\NN\3100490|was|,|,|site|.|from|with (r_dobj) treated_4\VBN\2376958|NONE (l_nsubjpass) site_2\NN\8673395|vehicle|was|,|,|.|from|with (l_compound) burn_1\NN\14322699|One
D012837_D002056 NONE agsd_32\NNP\0||)|,|agent|sulphadiazine|( (r_nmod) cream_34\NN\8386555|their|and|, (l_appos) agent_38\NN\7347||)|,|sulphadiazine|(|AgSD (l_acl) used_40\VBN\0|an|antimicrobial (l_prep) for_41\IN\0|frequently (l_pobj) treatment_43\NN\654885|NONE (l_prep) of_44\IN\0|topical (l_pobj) wounds_46\NNS\14285662|NONE (l_compound) burn_45\NN\14322699|NONE
9725303
D019469_D015658 NONE indinavir_17\NNS\4013993|NONE (r_dobj) receiving_16\VBG\2210855|six|infected (r_acl) patients_15\NNS\9898892|NONE (l_amod) infected_14\VBN\2316868|six|receiving
D019469_D015658 NONE indinavir_25\NNS\4013993|NONE (r_compound) therapy_26\NN\657604|who (r_dobj) receive_24\VBP\2210855|with (r_relcl) patients_19\NNS\9898892|NONE (l_prep) with_20\IN\0|receive (l_pobj) infection_22\NN\14052046|NONE
D019469_D014514 CID indinavir_17\NNS\4013993|NONE (r_dobj) receiving_16\VBG\2210855|six|infected (r_acl) patients_15\NNS\9898892|NONE (r_pobj) in_10\IN\13603305|,|.|features|inhibitor|We|: (r_prep) describe_2\VBP\1001294|NONE (l_dobj) features_6\NNS\5849040|,|.|in|inhibitor|We|: (l_prep) of_7\IN\0|CT|unique|the (l_pobj) calculi_9\NNS\9416076|NONE
D019469_D014514 NONE indinavir_25\NNS\4013993|NONE (r_compound) therapy_26\NN\657604|who (r_dobj) receive_24\VBP\2210855|with (r_relcl) patients_19\NNS\9898892|NONE (r_pobj) in_18\IN\13603305|or|obstruction|ureteric (r_prep) stones_15\NNS\19128|NONE (l_conj) obstruction_17\NN\4341686|or|in|ureteric
D019469_D052878 NONE indinavir_17\NNS\4013993|NONE (r_dobj) receiving_16\VBG\2210855|six|infected (r_acl) patients_15\NNS\9898892|NONE (r_pobj) in_10\IN\13603305|,|.|features|inhibitor|We|: (r_prep) describe_2\VBP\1001294|NONE (l_dobj) inhibitor_25\NN\20090|,|.|features|in|We|: (l_relcl) associated_29\VBN\628491|,|the|protease|used (l_prep) with_30\IN\0|which|is (l_pobj) incidence_33\NN\13821570|NONE (l_prep) of_34\IN\0|an|increased (l_pobj) urolithiasis_35\NN\0|NONE
D019469_D014517 NONE indinavir_11\NNS\4013993|NONE (r_compound) therapy_12\NN\657604|NONE (r_dobj) undergoing_10\VBG\109660|with (r_acl) patients_7\NNS\9898892|NONE (r_pobj) in_6\IN\13603305|obstruction (r_prep) causing_3\VBG\30358|crystal|. (l_dobj) obstruction_5\NN\4341686|in
D019469_D014517 NONE indinavir_5\JJ\4013993|precipitated (r_compound) crystals_6\NNS\15046900|NONE (r_pobj) by_3\IN\0|NONE (r_agent) caused_2\VBN\1617192|Ureteric (r_acl) obstruction_1\NN\4341686|difficult|.|may
D019469_D014517 NONE indinavir_25\NNS\4013993|NONE (r_compound) therapy_26\NN\657604|who (r_dobj) receive_24\VBP\2210855|with (r_relcl) patients_19\NNS\9898892|NONE (r_pobj) in_18\IN\13603305|or|obstruction|ureteric (r_prep) stones_15\NNS\19128|NONE (l_conj) obstruction_17\NN\4341686|or|in|ureteric
10401555
D012601_D008569 CID scopolamine_13\NN\14712692|NONE (r_pobj) by_12\IN\0|in (r_agent) induced_11\VBN\1627355|learning (r_acl) impairment_10\NN\7296428|NONE
D012601_D008569 CID scopolamine_23\NN\14712692|NONE (r_pobj) by_22\IN\0|NONE (r_agent) induced_21\VBN\1627355|of (r_acl) impairment_16\NN\7296428|whether|could|using|FQ (l_prep) of_17\IN\0|induced (l_pobj) learning_18\NN\5701944|NONE (l_conj) memory_20\NN\5926676|and
D012601_D007859 CID scopolamine_13\NN\14712692|NONE (r_pobj) by_12\IN\0|in (r_agent) induced_11\VBN\1627355|learning (r_acl) impairment_10\NN\7296428|NONE
D012601_D007859 CID scopolamine_23\NN\14712692|NONE (r_pobj) by_22\IN\0|NONE (r_agent) induced_21\VBN\1627355|of (r_acl) impairment_16\NN\7296428|whether|could|using|FQ (l_prep) of_17\IN\0|induced (l_pobj) learning_18\NN\5701944|NONE (l_conj) memory_20\NN\5926676|and
C111148_D006930 NONE nocistatin_5\NN\0|,|On|recently|from|.|is (r_advmod) isolated_8\VBN\2512305|NONE (l_prep) from_9\IN\0|,|On|nocistatin|recently|.|is (l_pobj) precursor_12\NN\14580897|NONE (l_prep) as_13\IN\14622893|the|same (l_pobj) allodynia_20\NN\0|nociceptin
C111148_D006930 NONE nocistatin_5\NN\0|,|On|recently|from|.|is (r_advmod) isolated_8\VBN\2512305|NONE (l_prep) from_9\IN\0|,|On|nocistatin|recently|.|is (l_pobj) precursor_12\NN\14580897|NONE (l_prep) as_13\IN\14622893|the|same (l_pobj) allodynia_20\NN\0|nociceptin (l_conj) hyperalgesia_22\NN\0|induced|and
C096012_D007859 NONE nociceptin_0\NNP\0|/ (r_nmod) orphanin_2\NN\0|and|.|nocistatin (r_compound) fq_3\NNP\0|NONE (l_conj) nocistatin_5\NNS\0|orphanin|and|. (l_prep) on_6\IN\0|NONE (l_pobj) impairment_10\NN\7296428|NONE
C096012_D007859 NONE fq_3\NNP\0|NONE (l_conj) nocistatin_5\NNS\0|orphanin|and|. (l_prep) on_6\IN\0|NONE (l_pobj) impairment_10\NN\7296428|NONE
C096012_D007859 NONE nociceptin_8\NN\0|/ (r_nmod) orphanin_10\VB\0|and|nocistatin (r_compound) fq_11\NNP\0|whether|could|impairment|using (r_nsubj) modulate_15\VB\1724459|to (l_dobj) impairment_16\NN\7296428|whether|could|using|FQ (l_prep) of_17\IN\0|induced (l_pobj) learning_18\NN\5701944|NONE (l_conj) memory_20\NN\5926676|and
C096012_D007859 NONE fq_11\NNP\0|whether|could|impairment|using (r_nsubj) modulate_15\VB\1724459|to (l_dobj) impairment_16\NN\7296428|whether|could|using|FQ (l_prep) of_17\IN\0|induced (l_pobj) learning_18\NN\5701944|NONE (l_conj) memory_20\NN\5926676|and
C111148_D007859 NONE nocistatin_5\NNS\0|orphanin|and|. (l_prep) on_6\IN\0|NONE (l_pobj) impairment_10\NN\7296428|NONE
C111148_D007859 NONE nocistatin_13\NN\0|and|orphanin (r_conj) fq_11\NNP\0|whether|could|impairment|using (r_nsubj) modulate_15\VB\1724459|to (l_dobj) impairment_16\NN\7296428|whether|could|using|FQ (l_prep) of_17\IN\0|induced (l_pobj) learning_18\NN\5701944|NONE (l_conj) memory_20\NN\5926676|and
C096012_D008569 NONE nociceptin_0\NNP\0|/ (r_nmod) orphanin_2\NN\0|and|.|nocistatin (r_compound) fq_3\NNP\0|NONE (l_conj) nocistatin_5\NNS\0|orphanin|and|. (l_prep) on_6\IN\0|NONE (l_pobj) impairment_10\NN\7296428|NONE
C096012_D008569 NONE fq_3\NNP\0|NONE (l_conj) nocistatin_5\NNS\0|orphanin|and|. (l_prep) on_6\IN\0|NONE (l_pobj) impairment_10\NN\7296428|NONE
C096012_D008569 NONE nociceptin_8\NN\0|/ (r_nmod) orphanin_10\VB\0|and|nocistatin (r_compound) fq_11\NNP\0|whether|could|impairment|using (r_nsubj) modulate_15\VB\1724459|to (l_dobj) impairment_16\NN\7296428|whether|could|using|FQ (l_prep) of_17\IN\0|induced (l_pobj) learning_18\NN\5701944|NONE (l_conj) memory_20\NN\5926676|and
C096012_D008569 NONE fq_11\NNP\0|whether|could|impairment|using (r_nsubj) modulate_15\VB\1724459|to (l_dobj) impairment_16\NN\7296428|whether|could|using|FQ (l_prep) of_17\IN\0|induced (l_pobj) learning_18\NN\5701944|NONE (l_conj) memory_20\NN\5926676|and
C111148_D008569 NONE nocistatin_5\NNS\0|orphanin|and|. (l_prep) on_6\IN\0|NONE (l_pobj) impairment_10\NN\7296428|NONE
C111148_D008569 NONE nocistatin_13\NN\0|and|orphanin (r_conj) fq_11\NNP\0|whether|could|impairment|using (r_nsubj) modulate_15\VB\1724459|to (l_dobj) impairment_16\NN\7296428|whether|could|using|FQ (l_prep) of_17\IN\0|induced (l_pobj) learning_18\NN\5701944|NONE (l_conj) memory_20\NN\5926676|and
C096012_D006930 NONE nociceptin_14\NN\0|allodynia (r_amod) as_13\IN\14622893|the|same (l_pobj) allodynia_20\NN\0|nociceptin
C096012_D006930 NONE nociceptin_14\NN\0|allodynia (r_amod) as_13\IN\14622893|the|same (l_pobj) allodynia_20\NN\0|nociceptin (l_conj) hyperalgesia_22\NN\0|induced|and
C096012_D006930 NONE nociceptin_17\RB\0| (r_advmod) induced_19\VBN\1627355|hyperalgesia|and (r_amod) allodynia_20\NN\0|nociceptin
C096012_D006930 NONE nociceptin_17\RB\0| (r_advmod) induced_19\VBN\1627355|hyperalgesia|and (r_amod) allodynia_20\NN\0|nociceptin (l_conj) hyperalgesia_22\NN\0|induced|and
3323259
D009553_D008881 NONE nimodipine_6\RB\0|in|potentially (r_nsubj) useful_8\JJ\0|.|Selectivity (l_prep) in_9\IN\13603305|nimodipine|potentially (l_pobj) treatment_11\NN\654885|NONE (l_prep) of_12\IN\0|the (l_pobj) hemorrhage_14\NN\14285662|NONE (l_conj) headache_17\NN\5829480|,|subarachnoid
C038806_D006973 NONE dihydropyridine_3\NN\0|for|As|the|first (r_advmod) available_4\JJ\0|angina|,|.|nifedipine (r_advcl) controls_13\NNS\5190804|NONE (l_dobj) angina_14\NN\14171682|,|available|.|nifedipine (l_conj) hypertension_16\NN\14057371|with|and
D015737_D000787 NONE nisoldipine_5\NN\0|NONE (r_pobj) of_4\IN\0|vasodilating|The|coronary (r_prep) properties_3\NNS\32613|to|have|. (r_nsubj) led_7\VBN\3202760|NONE (l_prep) to_8\IN\0|properties|have|. (l_pobj) investigation_10\NN\5797597|NONE (l_prep) for_14\IN\0|of|the (l_pobj) use_15\NN\407535|NONE (l_prep) in_16\IN\13603305|NONE (l_pobj) angina_17\NN\14171682|NONE
D009543_D000787 NONE nifedipine_12\NN\2938514|angina|,|available|. (r_amod) controls_13\NNS\5190804|NONE (l_dobj) angina_14\NN\14171682|,|available|.|nifedipine
C038806_D005483 NONE dihydropyridine_4\JJ\0|NONE (r_compound) calcium_5\NN\14625458|the (r_compound) channel_6\NN\6251781|NONE (r_compound) blockers_7\NNS\10101634|,|with|,|In|are|usually|well|. (r_nsubjpass) tolerated_11\VBN\802318|NONE (l_prep) with_13\IN\0|,|,|In|are|usually|well|blockers|. (l_pobj) headache_14\NN\5829480|being (l_conj) flushing_17\NN\281101|,
C038806_D004244 NONE dihydropyridine_4\JJ\0|NONE (r_compound) calcium_5\NN\14625458|the (r_compound) channel_6\NN\6251781|NONE (r_compound) blockers_7\NNS\10101634|,|with|,|In|are|usually|well|. (r_nsubjpass) tolerated_11\VBN\802318|NONE (l_prep) with_13\IN\0|,|,|In|are|usually|well|blockers|. (l_pobj) headache_14\NN\5829480|being (l_conj) flushing_17\NN\281101|, (l_conj) palpitations_19\NNS\14299637|facial|, (l_conj) edema_21\NN\14315192|, (l_conj) nausea_23\NN\14299637|, (l_conj) anorexia_25\NN\14055623|, (l_conj) dizziness_28\NN\14299637|,|and
D009553_D013345 NONE nimodipine_6\RB\0|in|potentially (r_nsubj) useful_8\JJ\0|.|Selectivity (l_prep) in_9\IN\13603305|nimodipine|potentially (l_pobj) treatment_11\NN\654885|NONE (l_prep) of_12\IN\0|the (l_pobj) hemorrhage_14\NN\14285662|NONE
D002121_D004487 CID blockers_7\NNS\10101634|,|with|,|In|are|usually|well|. (r_nsubjpass) tolerated_11\VBN\802318|NONE (l_prep) with_13\IN\0|,|,|In|are|usually|well|blockers|. (l_pobj) headache_14\NN\5829480|being (l_conj) flushing_17\NN\281101|, (l_conj) palpitations_19\NNS\14299637|facial|, (l_conj) edema_21\NN\14315192|,
D002121_D005483 CID blockers_7\NNS\10101634|,|with|,|In|are|usually|well|. (r_nsubjpass) tolerated_11\VBN\802318|NONE (l_prep) with_13\IN\0|,|,|In|are|usually|well|blockers|. (l_pobj) headache_14\NN\5829480|being (l_conj) flushing_17\NN\281101|,
D009553_D003704 NONE nimodipine_6\RB\0|in|potentially (r_nsubj) useful_8\JJ\0|.|Selectivity (l_prep) in_9\IN\13603305|nimodipine|potentially (l_pobj) treatment_11\NN\654885|NONE (l_prep) of_12\IN\0|the (l_pobj) hemorrhage_14\NN\14285662|NONE (l_conj) headache_17\NN\5829480|,|subarachnoid (l_conj) dementia_19\NN\14395018|,|migraine
C038806_D006261 NONE dihydropyridine_4\JJ\0|NONE (r_compound) calcium_5\NN\14625458|the (r_compound) channel_6\NN\6251781|NONE (r_compound) blockers_7\NNS\10101634|,|with|,|In|are|usually|well|. (r_nsubjpass) tolerated_11\VBN\802318|NONE (l_prep) with_13\IN\0|,|,|In|are|usually|well|blockers|. (l_pobj) headache_14\NN\5829480|being
D009568_D006973 NONE nitrendipine_7\NN\0|NONE (r_pobj) with_6\IN\0|daily|possible|Once (r_prep) dosage_4\NN\13576355|schedule|. (r_nsubj) offers_10\VBZ\7160883|NONE (l_dobj) schedule_14\NN\5898568|dosage|. (l_relcl) encourages_17\VBZ\2556126|administration|convenient|,|a (l_dobj) compliance_19\NN\1202904|which (l_prep) in_20\IN\13603305|patient (l_pobj) therapy_24\NN\657604|NONE (l_prep) of_25\IN\0|term (l_pobj) hypertension_26\NN\14057371|NONE
D002121_D006261 CID blockers_7\NNS\10101634|,|with|,|In|are|usually|well|. (r_nsubjpass) tolerated_11\VBN\802318|NONE (l_prep) with_13\IN\0|,|,|In|are|usually|well|blockers|. (l_pobj) headache_14\NN\5829480|being
C038806_D000855 NONE dihydropyridine_4\JJ\0|NONE (r_compound) calcium_5\NN\14625458|the (r_compound) channel_6\NN\6251781|NONE (r_compound) blockers_7\NNS\10101634|,|with|,|In|are|usually|well|. (r_nsubjpass) tolerated_11\VBN\802318|NONE (l_prep) with_13\IN\0|,|,|In|are|usually|well|blockers|. (l_pobj) headache_14\NN\5829480|being (l_conj) flushing_17\NN\281101|, (l_conj) palpitations_19\NNS\14299637|facial|, (l_conj) edema_21\NN\14315192|, (l_conj) nausea_23\NN\14299637|, (l_conj) anorexia_25\NN\14055623|,
D015737_D006973 NONE nisoldipine_9\NN\0|and (r_conj) nitrendipine_7\NN\0|NONE (r_pobj) with_6\IN\0|daily|possible|Once (r_prep) dosage_4\NN\13576355|schedule|. (r_nsubj) offers_10\VBZ\7160883|NONE (l_dobj) schedule_14\NN\5898568|dosage|. (l_relcl) encourages_17\VBZ\2556126|administration|convenient|,|a (l_dobj) compliance_19\NN\1202904|which (l_prep) in_20\IN\13603305|patient (l_pobj) therapy_24\NN\657604|NONE (l_prep) of_25\IN\0|term (l_pobj) hypertension_26\NN\14057371|NONE
D009553_D020521 NONE nimodipine_6\RB\0|in|potentially (r_nsubj) useful_8\JJ\0|.|Selectivity (l_prep) in_9\IN\13603305|nimodipine|potentially (l_pobj) treatment_11\NN\654885|NONE (l_prep) of_12\IN\0|the (l_pobj) hemorrhage_14\NN\14285662|NONE (l_conj) headache_17\NN\5829480|,|subarachnoid (l_conj) dementia_19\NN\14395018|,|migraine (l_conj) stroke_22\NN\556313|,|and
D002121_D000855 CID blockers_7\NNS\10101634|,|with|,|In|are|usually|well|. (r_nsubjpass) tolerated_11\VBN\802318|NONE (l_prep) with_13\IN\0|,|,|In|are|usually|well|blockers|. (l_pobj) headache_14\NN\5829480|being (l_conj) flushing_17\NN\281101|, (l_conj) palpitations_19\NNS\14299637|facial|, (l_conj) edema_21\NN\14315192|, (l_conj) nausea_23\NN\14299637|, (l_conj) anorexia_25\NN\14055623|,
D002121_-1 NONE blockers_7\NNS\10101634|,|with|,|In|are|usually|well|. (r_nsubjpass) tolerated_11\VBN\802318|NONE (l_prep) with_13\IN\0|,|,|In|are|usually|well|blockers|. (l_pobj) headache_14\NN\5829480|being (l_conj) flushing_17\NN\281101|, (l_conj) palpitations_19\NNS\14299637|facial|,
D009543_D006973 NONE nifedipine_12\NN\2938514|angina|,|available|. (r_amod) controls_13\NNS\5190804|NONE (l_dobj) angina_14\NN\14171682|,|available|.|nifedipine (l_conj) hypertension_16\NN\14057371|with|and
D002121_D009325 CID blockers_7\NNS\10101634|,|with|,|In|are|usually|well|. (r_nsubjpass) tolerated_11\VBN\802318|NONE (l_prep) with_13\IN\0|,|,|In|are|usually|well|blockers|. (l_pobj) headache_14\NN\5829480|being (l_conj) flushing_17\NN\281101|, (l_conj) palpitations_19\NNS\14299637|facial|, (l_conj) edema_21\NN\14315192|, (l_conj) nausea_23\NN\14299637|,
C038806_-1 NONE dihydropyridine_4\JJ\0|NONE (r_compound) calcium_5\NN\14625458|the (r_compound) channel_6\NN\6251781|NONE (r_compound) blockers_7\NNS\10101634|,|with|,|In|are|usually|well|. (r_nsubjpass) tolerated_11\VBN\802318|NONE (l_prep) with_13\IN\0|,|,|In|are|usually|well|blockers|. (l_pobj) headache_14\NN\5829480|being (l_conj) flushing_17\NN\281101|, (l_conj) palpitations_19\NNS\14299637|facial|,
C038806_D009325 NONE dihydropyridine_4\JJ\0|NONE (r_compound) calcium_5\NN\14625458|the (r_compound) channel_6\NN\6251781|NONE (r_compound) blockers_7\NNS\10101634|,|with|,|In|are|usually|well|. (r_nsubjpass) tolerated_11\VBN\802318|NONE (l_prep) with_13\IN\0|,|,|In|are|usually|well|blockers|. (l_pobj) headache_14\NN\5829480|being (l_conj) flushing_17\NN\281101|, (l_conj) palpitations_19\NNS\14299637|facial|, (l_conj) edema_21\NN\14315192|, (l_conj) nausea_23\NN\14299637|,
D002121_D004244 CID blockers_7\NNS\10101634|,|with|,|In|are|usually|well|. (r_nsubjpass) tolerated_11\VBN\802318|NONE (l_prep) with_13\IN\0|,|,|In|are|usually|well|blockers|. (l_pobj) headache_14\NN\5829480|being (l_conj) flushing_17\NN\281101|, (l_conj) palpitations_19\NNS\14299637|facial|, (l_conj) edema_21\NN\14315192|, (l_conj) nausea_23\NN\14299637|, (l_conj) anorexia_25\NN\14055623|, (l_conj) dizziness_28\NN\14299637|,|and
D002118_D002318 NONE calcium_6\NN\14625458|NONE (r_pobj) of_5\IN\0|the|in (r_prep) importance_4\NN\5138488|NONE (l_prep) in_7\IN\13603305|the|of (l_pobj) pathogenesis_9\NN\13533470|NONE (l_prep) of_10\IN\0|the (l_pobj) disease_12\NN\14061805|NONE
D002118_D002318 NONE calcium_6\NN\14625458|NONE (r_pobj) of_5\IN\0|the|in (r_prep) importance_4\NN\5138488|NONE (r_pobj) of_2\IN\0|Increasing (r_prep) recognition_1\NN\13932421|into|has|.|research (r_nsubj) stimulated_14\VBN\137313|NONE (l_prep) into_16\IN\0|has|recognition|.|research (l_pobj) use_18\NN\407535|NONE (l_acl) blocking_22\VBG\562280|the|of (l_prep) for_24\IN\0|agents (l_pobj) treatment_25\NN\654885|NONE (l_prep) of_26\IN\0|NONE (l_pobj) variety_28\NN\7951464|NONE (l_prep) of_29\IN\0|a (l_pobj) diseases_31\NNS\14061805|NONE
C038806_D004487 NONE dihydropyridine_4\JJ\0|NONE (r_compound) calcium_5\NN\14625458|the (r_compound) channel_6\NN\6251781|NONE (r_compound) blockers_7\NNS\10101634|,|with|,|In|are|usually|well|. (r_nsubjpass) tolerated_11\VBN\802318|NONE (l_prep) with_13\IN\0|,|,|In|are|usually|well|blockers|. (l_pobj) headache_14\NN\5829480|being (l_conj) flushing_17\NN\281101|, (l_conj) palpitations_19\NNS\14299637|facial|, (l_conj) edema_21\NN\14315192|,
C038806_D000787 NONE dihydropyridine_3\NN\0|for|As|the|first (r_advmod) available_4\JJ\0|angina|,|.|nifedipine (r_advcl) controls_13\NNS\5190804|NONE (l_dobj) angina_14\NN\14171682|,|available|.|nifedipine
D002121_D002318 NONE agents_23\NNS\7347|for (r_dobj) blocking_22\VBG\562280|the|of (r_acl) use_18\NN\407535|NONE (r_pobj) into_16\IN\0|has|recognition|.|research (r_prep) stimulated_14\VBN\137313|NONE (l_nsubj) recognition_1\NN\13932421|into|has|.|research (l_prep) of_2\IN\0|Increasing (l_pobj) importance_4\NN\5138488|NONE (l_prep) in_7\IN\13603305|the|of (l_pobj) pathogenesis_9\NN\13533470|NONE (l_prep) of_10\IN\0|the (l_pobj) disease_12\NN\14061805|NONE
D002121_D002318 NONE agents_23\NNS\7347|for (r_dobj) blocking_22\VBG\562280|the|of (l_prep) for_24\IN\0|agents (l_pobj) treatment_25\NN\654885|NONE (l_prep) of_26\IN\0|NONE (l_pobj) variety_28\NN\7951464|NONE (l_prep) of_29\IN\0|a (l_pobj) diseases_31\NNS\14061805|NONE
2884595
D006632_D001927 NONE histamine_2\NN\14739004|H (r_compound) receptors_4\NNS\5225602|NONE (r_pobj) of_1\IN\0|NONE (r_prep) blockade_0\NN\952963|.|mortality|may (r_nsubj) reduce_6\VB\441445|NONE (l_dobj) mortality_7\NN\5054863|.|Blockade|may (l_prep) in_8\IN\13603305|NONE (l_pobj) encephalopathy_13\NN\14084880|NONE
D006632_D014917 NONE histamine_2\NN\14739004|H (r_compound) receptors_4\NNS\5225602|NONE (r_pobj) of_1\IN\0|NONE (r_prep) blockade_0\NN\952963|.|mortality|may (r_nsubj) reduce_6\VB\441445|NONE (l_dobj) mortality_7\NN\5054863|.|Blockade|may (l_prep) in_8\IN\13603305|NONE (l_pobj) encephalopathy_13\NN\14084880|NONE (l_compound) pertussis_9\NN\14127211|in|induced
2710809
D009116_D001919 NONE muscarine_25\NN\0|NONE (r_compound) receptors_26\NNS\5225602|NONE (r_pobj) on_24\IN\0|related|of|a|dual (r_prep) effect_18\NN\34213|NONE (r_pobj) to_12\IN\0|and|speed (r_conj) to_6\IN\0|.|is|Bradycardia (r_prep) attributed_5\VBN\670261|NONE (l_nsubjpass) bradycardia_0\NNS\14110674|.|to|is
D001285_D001919 NONE atropine_20\NN\14712692| (r_npadvmod) like_22\JJ\5839024|NONE (r_amod) drugs_23\NNS\14778436|NONE (r_pobj) of_19\IN\0|related|a|dual|on (r_prep) effect_18\NN\34213|NONE (r_pobj) to_12\IN\0|and|speed (r_conj) to_6\IN\0|.|is|Bradycardia (r_prep) attributed_5\VBN\670261|NONE (l_nsubjpass) bradycardia_0\NNS\14110674|.|to|is
C036432_D014277 NONE lactate_21\NN\14850483|NONE (r_pobj) of_17\IN\0|intravenous (r_prep) application_16\NN\947128|.|to|In|, (r_nsubj) led_22\VBD\3202760|NONE (l_prep) in_0\IN\13603305|application|.|to|, (l_pobj) patient_6\NN\9898892|NONE (l_acl) suffering_7\NN\14322699|old|male|a (l_prep) from_8\IN\0|NONE (l_pobj) neuralgia_13\NN\14322699|NONE
C036432_D006562 NONE lactate_21\NN\14850483|NONE (r_pobj) of_17\IN\0|intravenous (r_prep) application_16\NN\947128|.|to|In|, (r_nsubj) led_22\VBD\3202760|NONE (l_prep) in_0\IN\13603305|application|.|to|, (l_pobj) patient_6\NN\9898892|NONE (l_acl) suffering_7\NN\14322699|old|male|a (l_prep) from_8\IN\0|NONE (l_pobj) neuralgia_13\NN\14322699|NONE (l_nmod) postzosteric_11\JJ\0|severe|a|trigeminal
C036432_D004401 NONE lactate_21\NN\14850483|NONE (r_pobj) of_17\IN\0|intravenous (r_prep) application_16\NN\947128|.|to|In|, (r_nsubj) led_22\VBD\3202760|NONE (l_prep) to_23\IN\0|application|.|In|, (l_pobj) reaction_29\NN\13446390|NONE (l_acl) characterized_30\VBN\609683|a|paradoxical|lasting (l_agent) by_31\IN\0|NONE (l_pobj) bradycardia_33\NN\14110674|NONE (l_conj) dysarthria_35\NN\14400677|,|considerable
C036432_D001919 NONE lactate_21\NN\14850483|NONE (r_pobj) of_17\IN\0|intravenous (r_prep) application_16\NN\947128|.|to|In|, (r_nsubj) led_22\VBD\3202760|NONE (l_prep) to_23\IN\0|application|.|In|, (l_pobj) reaction_29\NN\13446390|NONE (l_acl) characterized_30\VBN\609683|a|paradoxical|lasting (l_agent) by_31\IN\0|NONE (l_pobj) bradycardia_33\NN\14110674|NONE
C036432_D003680 NONE lactate_21\NN\14850483|NONE (r_pobj) of_17\IN\0|intravenous (r_prep) application_16\NN\947128|.|to|In|, (r_nsubj) led_22\VBD\3202760|NONE (l_prep) to_23\IN\0|application|.|In|, (l_pobj) reaction_29\NN\13446390|NONE (l_acl) characterized_30\VBN\609683|a|paradoxical|lasting (l_agent) by_31\IN\0|NONE (l_pobj) bradycardia_33\NN\14110674|NONE (l_conj) dysarthria_35\NN\14400677|,|considerable (l_conj) dysphagia_38\NN\14052403|and|,
D001712_D001919 CID biperiden_3\VBN\0|NONE (l_nsubj) bradycardia_0\NNS\14110674|.
D001712_D001919 CID biperiden_3\VBN\0|NONE (r_pobj) by_2\IN\0|NONE (r_agent) induced_1\VBN\1627355|NONE (r_acl) bradycardia_0\NNS\14110674|.|to|is
12865514
D007980_D009127 NONE levodopa_29\RB\14604959| (r_npadvmod) induced_31\VBN\1627355|NONE (r_amod) dyskinesias_32\NNS\14084880|and|, (r_conj) rigidity_26\NN\5023233|particularly|,
D007980_D018476 NONE levodopa_29\RB\14604959| (r_npadvmod) induced_31\VBN\1627355|NONE (r_amod) dyskinesias_32\NNS\14084880|and|, (r_conj) rigidity_26\NN\5023233|particularly|, (r_conj) bradykinesia_24\JJ\0|Stages|,|)|and
D007980_D004409 CID levodopa_29\RB\14604959| (r_npadvmod) induced_31\VBN\1627355|NONE (r_amod) dyskinesias_32\NNS\14084880|and|,
D007980_D004409 CID levodopa_4\JJ\14604959|the (r_compound) dose_5\NN\3740161|NONE (r_pobj) in_2\IN\13603305|The (r_prep) reduction_1\NN\351485|useful|. (r_nsubj) is_6\VBZ\0|NONE (l_acomp) useful_7\JJ\0|.|reduction (l_prep) in_8\IN\13603305|NONE (l_pcomp) controlling_9\VBG\0|NONE (l_dobj) dyskinesias_13\NNS\14084880|NONE
D007980_D010300 NONE levodopa_29\RB\14604959| (r_npadvmod) induced_31\VBN\1627355|NONE (r_amod) dyskinesias_32\NNS\14084880|and|, (r_conj) rigidity_26\NN\5023233|particularly|, (r_conj) bradykinesia_24\JJ\0|Stages|,|)|and (r_conj) scale_19\NN\7260623|suffering|three (r_appos) patients_3\NNS\9898892|implantation|. (l_acl) suffering_4\VBG\14322699|scale|three (l_prep) from_5\IN\0|NONE (l_pobj) disease_9\NN\14061805|NONE
16323982
D004967_D050171 NONE estrogen_47\NN\14745635|NONE (r_pobj) by_46\IN\0|NONE (r_agent) caused_45\VBN\1617192|the|hyperglyceridemic|known (r_acl) effect_44\NN\34213|NONE
D004967_D003324 NONE estrogen_47\NN\14745635|NONE (r_pobj) by_46\IN\0|NONE (r_agent) caused_45\VBN\1617192|the|hyperglyceridemic|known (r_acl) effect_44\NN\34213|NONE (r_pobj) than_38\IN\0|I (r_prep) other_37\JJ\0|arteriosclerosis|is|through|,|. (r_conj) mediated_17\VBN\761713|NONE (l_nsubjpass) arteriosclerosis_2\NN\14110411|other|is|through|,|.
D002784_D003324 NONE cholesterol_22\NN\15058310|NONE (r_pobj) in_20\IN\13603305|NONE (r_prep) changes_19\NNS\7283608|NONE (r_pobj) through_18\IN\0|other|arteriosclerosis|is|,|. (r_prep) mediated_17\VBN\761713|NONE (l_nsubjpass) arteriosclerosis_2\NN\14110411|other|is|through|,|.
D002784_D050171 NONE cholesterol_22\NN\15058310|NONE (r_pobj) in_20\IN\13603305|NONE (r_prep) changes_19\NNS\7283608|NONE (r_pobj) through_18\IN\0|other|arteriosclerosis|is|,|. (r_prep) mediated_17\VBN\761713|NONE (l_conj) other_37\JJ\0|arteriosclerosis|is|through|,|. (l_prep) than_38\IN\0|I (l_pobj) effect_44\NN\34213|NONE
D017373_D050171 CID cpa_14\NN\9761403|prolonged (r_compound) therapy_15\NN\657604|NONE (r_pobj) by_12\IN\0|as (r_agent) caused_11\VBN\1617192|Ischaemic|coronary|with (r_advcl) arteriosclerosis_2\NN\14110411|other|is|through|,|. (r_nsubjpass) mediated_17\VBN\761713|NONE (l_conj) other_37\JJ\0|arteriosclerosis|is|through|,|. (l_prep) than_38\IN\0|I (l_pobj) effect_44\NN\34213|NONE
D017373_D003324 CID cpa_14\NN\9761403|prolonged (r_compound) therapy_15\NN\657604|NONE (r_pobj) by_12\IN\0|as (r_agent) caused_11\VBN\1617192|Ischaemic|coronary|with (r_advcl) arteriosclerosis_2\NN\14110411|other|is|through|,|.
D017373_D003327 NONE cpa_7\NN\9761403|NONE (r_compound) treatment_8\NN\654885|NONE (r_pobj) on_6\IN\0|. (r_prep) years_5\NNS\15144371|NONE (r_pobj) of_3\IN\0|a (r_prep) period_2\NN\13575869|NONE (r_pobj) after_0\IN\0|patients|affected|.|were|, (r_prep) found_18\VBN\13279262|NONE (l_xcomp) affected_21\VBN\126264|patients|After|.|were|, (l_agent) by_22\IN\0|be|to (l_pobj) disease_25\NN\14061805|NONE
16723784
D015764_D001282 NONE bepridil_6\NN\0|NONE (r_amod) administration_7\NN\1133281|NONE (r_pobj) during_5\IN\0|adverse|for (r_prep) effects_4\NNS\13245626|NONE (l_prep) for_8\IN\0|during|adverse (l_pobj) fibrillation_10\NN\14361664|NONE (l_conj) flutter_12\JJ\331950|and|atrial
D015764_D001282 NONE hydrochloride_1\NN\14817592|attention|Bepridil|has|.|as (r_nsubj) attracted_6\VBN\1448100|NONE (l_prep) as_8\IN\14622893|attention|Bepridil|has|.|hydrochloride (l_pobj) drug_11\NN\14778436|NONE (l_prep) for_12\IN\0|an|effective (l_pobj) fibrillation_14\NN\14361664|NONE (l_conj) flutter_20\NN\331950|AF|atrial|(
D015764_D001282 NONE hydrochloride_1\NN\14817592|attention|Bepridil|has|.|as (r_nsubj) attracted_6\VBN\1448100|NONE (l_prep) as_8\IN\14622893|attention|Bepridil|has|.|hydrochloride (l_pobj) drug_11\NN\14778436|NONE (l_prep) for_12\IN\0|an|effective (l_pobj) fibrillation_14\NN\14361664|NONE (l_conj) flutter_20\NN\331950|AF|atrial|( (l_appos) afl_22\NNP\8303504|(|)|atrial
D015764_D001282 NONE bpd_3\NNP\0|NONE (r_appos) hydrochloride_1\NN\14817592|attention|Bepridil|has|.|as (r_nsubj) attracted_6\VBN\1448100|NONE (l_prep) as_8\IN\14622893|attention|Bepridil|has|.|hydrochloride (l_pobj) drug_11\NN\14778436|NONE (l_prep) for_12\IN\0|an|effective (l_pobj) fibrillation_14\NN\14361664|NONE (l_conj) flutter_20\NN\331950|AF|atrial|(
D015764_D001282 NONE bpd_3\NNP\0|NONE (r_appos) hydrochloride_1\NN\14817592|attention|Bepridil|has|.|as (r_nsubj) attracted_6\VBN\1448100|NONE (l_prep) as_8\IN\14622893|attention|Bepridil|has|.|hydrochloride (l_pobj) drug_11\NN\14778436|NONE (l_prep) for_12\IN\0|an|effective (l_pobj) fibrillation_14\NN\14361664|NONE (l_conj) flutter_20\NN\331950|AF|atrial|( (l_appos) afl_22\NNP\8303504|(|)|atrial
D015764_D001282 NONE bpd_0\NNP\0|was|.|to (r_nsubjpass) administered_2\VBN\2436349|NONE (l_prep) to_3\IN\0|was|.|Bpd (l_pobj) patients_5\NNS\9898892|NONE (l_acl) comprising_14\VBG\2604760||(|males|) (l_dobj) cases_20\NNS\7283608|NONE (l_compound) afl_19\NNP\8303504|AF||
D015764_D001281 NONE bepridil_6\NN\0|NONE (r_amod) administration_7\NN\1133281|NONE (r_pobj) during_5\IN\0|adverse|for (r_prep) effects_4\NNS\13245626|NONE (l_prep) for_8\IN\0|during|adverse (l_pobj) fibrillation_10\NN\14361664|NONE (l_conj) flutter_12\JJ\331950|and|atrial
D015764_D001281 NONE hydrochloride_1\NN\14817592|attention|Bepridil|has|.|as (r_nsubj) attracted_6\VBN\1448100|NONE (l_prep) as_8\IN\14622893|attention|Bepridil|has|.|hydrochloride (l_pobj) drug_11\NN\14778436|NONE (l_prep) for_12\IN\0|an|effective (l_pobj) fibrillation_14\NN\14361664|NONE
D015764_D001281 NONE hydrochloride_1\NN\14817592|attention|Bepridil|has|.|as (r_nsubj) attracted_6\VBN\1448100|NONE (l_prep) as_8\IN\14622893|attention|Bepridil|has|.|hydrochloride (l_pobj) drug_11\NN\14778436|NONE (l_prep) for_12\IN\0|an|effective (l_pobj) fibrillation_14\NN\14361664|NONE (l_appos) af_16\NNP\0|atrial|(|flutter
D015764_D001281 NONE bpd_3\NNP\0|NONE (r_appos) hydrochloride_1\NN\14817592|attention|Bepridil|has|.|as (r_nsubj) attracted_6\VBN\1448100|NONE (l_prep) as_8\IN\14622893|attention|Bepridil|has|.|hydrochloride (l_pobj) drug_11\NN\14778436|NONE (l_prep) for_12\IN\0|an|effective (l_pobj) fibrillation_14\NN\14361664|NONE
D015764_D001281 NONE bpd_3\NNP\0|NONE (r_appos) hydrochloride_1\NN\14817592|attention|Bepridil|has|.|as (r_nsubj) attracted_6\VBN\1448100|NONE (l_prep) as_8\IN\14622893|attention|Bepridil|has|.|hydrochloride (l_pobj) drug_11\NN\14778436|NONE (l_prep) for_12\IN\0|an|effective (l_pobj) fibrillation_14\NN\14361664|NONE (l_appos) af_16\NNP\0|atrial|(|flutter
D015764_D001281 NONE bpd_0\NNP\0|was|.|to (r_nsubjpass) administered_2\VBN\2436349|NONE (l_prep) to_3\IN\0|was|.|Bpd (l_pobj) patients_5\NNS\9898892|NONE (l_acl) comprising_14\VBG\2604760||(|males|) (l_dobj) cases_20\NNS\7283608|NONE (l_nmod) af_16\NNP\0||AFL|
15321332
D004329_D001008 CID droperidol_9\NN\0|to (r_pobj) due_5\IN\5174653|of|A|. (r_prep) case_1\NN\7283608|NONE (l_prep) of_2\IN\0|A|.|due (l_pobj) anxiety_4\NN\14373582|NONE
D004329_D001008 CID droperidol_3\NN\0| (r_npadvmod) induced_5\VBN\1627355|psychological (r_amod) disturbance_7\NN\407535|NONE
19920070
D010634_D006529 CID phenobarbital_21\JJ\2792049|NONE (r_amod) administration_22\NN\1133281|NONE (r_pobj) after_20\IN\0|NONE (r_prep) hepatomegaly_19\NN\14501726|of|specific|and|.
6806735
D006585_D005767 NONE hmm_0\UH\0|gastrointestinal (r_compound) toxicity_2\NN\13576101|.|discontinuation
C034868_D010051 NONE cpdd_20\NNP\0|NONE (r_appos) cisplatinum_18\NN\0|NONE (r_pobj) of_17\IN\0|a (r_prep) combination_16\NN\7951464|NONE (r_pobj) with_14\IN\0|were|During|patients|,|m|,|. (r_prep) treated_13\VBN\2376958|NONE (l_nsubjpass) patients_8\NNS\9898892|were|During|,|with|m|,|. (l_prep) with_9\IN\0| (l_pobj) cancer_11\NN\14239425|NONE
D006585_D010051 NONE hexamethylmelamine_16\NN\0|and (r_conj) cyclophosphamide_14\NN\0|,|platinum|, (r_conj) adriamycin_12\NNS\0|NONE (r_pobj) of_7\IN\0|a (r_prep) combination_6\NN\7951464|NONE (r_pobj) with_4\IN\0|.|of (r_prep) treatment_0\NN\654885|NONE (l_prep) of_1\IN\0|.|with (l_pobj) cancer_3\NN\14239425|NONE
D006585_D010051 NONE hexamethylmelamine_47\NN\0|and|,|on|mg||,|adriamycin|,|;|/|m (r_conj) m2_26\NN\13357178|were|During|patients|,|with|,|. (r_npadvmod) treated_13\VBN\2376958|NONE (l_nsubjpass) patients_8\NNS\9898892|were|During|,|with|m|,|. (l_prep) with_9\IN\0| (l_pobj) cancer_11\NN\14239425|NONE
D006585_D010051 NONE hmm_49\NNP\0|,|daily|for|, (r_appos) hexamethylmelamine_47\NN\0|and|,|on|mg||,|adriamycin|,|;|/|m (r_conj) m2_26\NN\13357178|were|During|patients|,|with|,|. (r_npadvmod) treated_13\VBN\2376958|NONE (l_nsubjpass) patients_8\NNS\9898892|were|During|,|with|m|,|. (l_prep) with_9\IN\0| (l_pobj) cancer_11\NN\14239425|NONE
D004317_D010051 NONE adriamycin_12\NNS\0|NONE (r_pobj) of_7\IN\0|a (r_prep) combination_6\NN\7951464|NONE (r_pobj) with_4\IN\0|.|of (r_prep) treatment_0\NN\654885|NONE (l_prep) of_1\IN\0|.|with (l_pobj) cancer_3\NN\14239425|NONE
D004317_D010051 NONE adriamycin_28\NNS\0|and|,|on|mg||,|,|;|/|hexamethylmelamine|m (r_amod) m2_26\NN\13357178|were|During|patients|,|with|,|. (r_npadvmod) treated_13\VBN\2376958|NONE (l_nsubjpass) patients_8\NNS\9898892|were|During|,|with|m|,|. (l_prep) with_9\IN\0| (l_pobj) cancer_11\NN\14239425|NONE
D003520_D010051 NONE cyclophosphamide_14\NN\0|,|platinum|, (r_conj) adriamycin_12\NNS\0|NONE (r_pobj) of_7\IN\0|a (r_prep) combination_6\NN\7951464|NONE (r_pobj) with_4\IN\0|.|of (r_prep) treatment_0\NN\654885|NONE (l_prep) of_1\IN\0|.|with (l_pobj) cancer_3\NN\14239425|NONE
D003520_D010051 NONE cyclophosphamide_35\NN\0||mg|/|, (r_conj) m2_33\NN\13357178|, (r_conj) adriamycin_28\NNS\0|and|,|on|mg||,|,|;|/|hexamethylmelamine|m (r_amod) m2_26\NN\13357178|were|During|patients|,|with|,|. (r_npadvmod) treated_13\VBN\2376958|NONE (l_nsubjpass) patients_8\NNS\9898892|were|During|,|with|m|,|. (l_prep) with_9\IN\0| (l_pobj) cancer_11\NN\14239425|NONE
D002945_D010051 NONE platinum_10\NN\14627081|,|,|cyclophosphamide (r_nmod) adriamycin_12\NNS\0|NONE (r_pobj) of_7\IN\0|a (r_prep) combination_6\NN\7951464|NONE (r_pobj) with_4\IN\0|.|of (r_prep) treatment_0\NN\654885|NONE (l_prep) of_1\IN\0|.|with (l_pobj) cancer_3\NN\14239425|NONE
D002945_D010051 NONE cisplatinum_18\NN\0|NONE (r_pobj) of_17\IN\0|a (r_prep) combination_16\NN\7951464|NONE (r_pobj) with_14\IN\0|were|During|patients|,|m|,|. (r_prep) treated_13\VBN\2376958|NONE (l_nsubjpass) patients_8\NNS\9898892|were|During|,|with|m|,|. (l_prep) with_9\IN\0| (l_pobj) cancer_11\NN\14239425|NONE
24275640
D004317_D066126 CID doxorubicin_12\NN\2716866|NONE (r_pobj) of_11\IN\0|single (r_prep) doses_10\NNS\3740161|NONE (r_pobj) with_6\IN\0|NONE (r_prep) treatment_5\NN\654885|NONE (r_pobj) after_4\IN\0|NONE (r_prep) cardiotoxicity_3\NN\0|NONE
D004317_D066126 CID doxorubicin_3\NN\2716866|NONE (r_pobj) of_2\IN\0|The (r_prep) mechanism_1\NN\13446390|cardiotoxicity|.|controversial (r_nsubj) remains_7\VBZ\2684|NONE (l_nsubj) cardiotoxicity_6\NN\0|.|controversial|mechanism
D004317_D066126 CID dox)-induced_5\JJ\0|( (r_amod) cardiotoxicity_6\NN\0|.|controversial|mechanism
D004317_D066126 CID dox_17\NNP\0|NONE (r_pobj) of_16\IN\0|a|single (r_prep) dose_15\NN\3740161|NONE (r_pobj) by_12\IN\0|only (r_agent) induced_11\VBN\1627355|acute (r_acl) cardiotoxicity_10\NN\0|NONE
D004317_D006331 NONE dox_3\NNP\0|NONE (r_pobj) of_2\IN\0|Single (r_prep) dose_1\NN\3740161|.|with|was (r_nsubjpass) associated_5\VBN\628491|NONE (l_prep) with_6\IN\0|dose|.|was (l_pobj) disarrangement_9\NN\14499262|NONE
D004317_D009336 CID dox_3\NNP\0|NONE (r_pobj) of_2\IN\0|Single (r_prep) dose_1\NN\3740161|.|with|was (r_nsubjpass) associated_5\VBN\628491|NONE (l_prep) with_6\IN\0|dose|.|was (l_pobj) disarrangement_9\NN\14499262|NONE (l_conj) necrosis_11\NN\11444117|cardiac|increased|,
3409843
D002220_D004827 NONE carbamazepine_8\NN\0|in (r_compound) treatment_9\NN\654885|to (l_prep) in_10\IN\13603305|carbamazepine (l_pobj) woman_13\NN\9605289|NONE (l_amod) epileptic_12\JJ\10595647|an
D002220_D001855 NONE carbamazepine_9\NN\0|NONE (r_pobj) to_8\IN\0|NONE (r_pcomp) due_7\IN\5174653|of (r_prep) concerns_1\NNS\5682950|NONE (l_prep) of_2\IN\0|due (l_pobj) toxicity_6\NN\13576101|NONE
D002220_D000741 CID carbamazepine_8\NN\0|NONE (r_pobj) with_7\IN\0|NONE (r_prep) treated_6\VBN\2376958|a (r_acl) patient_5\NN\9898892|NONE (r_pobj) in_3\IN\13603305|.|Fatal|aplastic (r_prep) anemia_2\NN\14189204|NONE
D002220_D000741 CID carbamazepine_8\NN\0|in (r_compound) treatment_9\NN\654885|to (r_pobj) due_6\IN\5174653|of|A (r_amod) case_1\NN\7283608|.|is (l_prep) of_2\IN\0|due|A (l_pobj) anemia_5\NN\14189204|NONE
2021990
D002927_D007022 CID cimetidine_15\NN\14778019|NONE (r_pobj) by_13\IN\0|NONE (r_agent) caused_12\VBN\1617192|NONE (r_acl) hypotension_11\NN\14057371|NONE
D002927_D007022 CID cimetidine_22\NN\14778019|NONE (r_pobj) of_21\IN\0|the|vasodilating (r_prep) activity_20\NN\30358|,|is|through|,|since|in (r_nsubjpass) mediated_24\VBN\761713|,|antagonist|useful|that|may (r_advcl) be_7\VB\14625458|We|. (l_acomp) useful_8\JJ\0|,|antagonist|that|may|mediated (l_prep) in_9\IN\13603305|NONE (l_pcomp) preventing_10\VBG\0|NONE (l_dobj) hypotension_11\NN\14057371|NONE
8996419
D003276_D020246 NONE ocs_11\NNS\0|NONE (r_pobj) of_9\IN\0|NONE (r_prep) use_8\NN\407535|NONE (r_pobj) with_7\IN\0|NONE (r_prep) associated_6\VBN\628491||the|of (r_acl) cases_3\NNS\7283608|NONE (r_pobj) of_0\IN\0|.|and||five|,|as|were (r_prep) recorded_15\VBN\2225492|NONE (l_prep) as_16\IN\14622893|.|and||five|Of|,|were (l_pobj) thrombosis_20\NN\14100769|NONE
D003276_D020246 NONE ocs_11\NNS\0|NONE (r_pobj) of_9\IN\0|NONE (r_prep) use_8\NN\407535|NONE (r_pobj) with_7\IN\0|NONE (r_prep) associated_6\VBN\628491||the|of (r_acl) cases_3\NNS\7283608|NONE (r_pobj) of_0\IN\0|.|and||five|,|as|were (r_prep) recorded_15\VBN\2225492|NONE (l_conj) five_28\CD\13741022|.|and||Of|,|as|were (l_prep) as_29\IN\14622893|NONE (l_pobj) thrombosis_31\NN\14100769|NONE
D011372_D054556 NONE progestagen_15\NN\0|NONE (r_nmod) ocs_18\NNS\0|NONE (r_pobj) of_14\IN\0|NONE (r_prep) users_13\NNS\7846|two (r_attr) were_12\VBD\0|, (r_relcl) vte_7\NNP\0|NONE
C033273_D054556 NONE gestodene_35\NN\0|NONE (r_dobj) containing_29\VBG\2632940|higher|incidence|that (r_advcl) was_18\VBD\0|.|studies (l_nsubj) incidence_11\NN\13821570|higher|containing|that (l_prep) of_12\IN\0|the (l_pobj) thromboembolism_14\NN\14100769|NONE
C033273_D054556 NONE gestodene_35\NN\0|NONE (r_dobj) containing_29\VBG\2632940|higher|incidence|that (r_advcl) was_18\VBD\0|.|studies (l_nsubj) incidence_11\NN\13821570|higher|containing|that (l_prep) of_12\IN\0|the (l_pobj) thromboembolism_14\NN\14100769|NONE (l_appos) vte_16\NNP\0|(|venous|)
C033273_D054556 NONE gestodene_26\NN\0|NONE (r_pobj) of_25\IN\0|with (r_prep) users_24\NNS\7846|NONE (r_pobj) in_23\IN\13603305|NONE (r_prep) than_22\IN\0|.|higher|in|risk|Among|, (r_prep) was_12\VBD\0|NONE (l_nsubj) risk_9\NN\14541044|than|.|higher|in|Among|, (l_prep) of_10\IN\0|the (l_pobj) vte_11\NNP\0|NONE
D004997_D054556 NONE ethinyloestradiol_21\NN\0|NONE (r_pobj) with_18\IN\0|of (r_prep) users_15\NNS\7846|NONE (r_pobj) in_14\IN\13603305|than|.|higher|risk|Among|, (r_prep) was_12\VBD\0|NONE (l_nsubj) risk_9\NN\14541044|than|.|higher|in|Among|, (l_prep) of_10\IN\0|the (l_pobj) vte_11\NNP\0|NONE
D004997_D054556 NONE ethinyloestradiol_32\NN\0|NONE (r_pobj) with_29\IN\0|of (r_prep) users_24\NNS\7846|NONE (r_pobj) in_23\IN\13603305|NONE (r_prep) than_22\IN\0|.|higher|in|risk|Among|, (r_prep) was_12\VBD\0|NONE (l_nsubj) risk_9\NN\14541044|than|.|higher|in|Among|, (l_prep) of_10\IN\0|the (l_pobj) vte_11\NNP\0|NONE
D004997_D054556 NONE ethinyloestradiol_27\NN\0|plus (r_appos) desogestrel_23\NN\0|NONE (r_pobj) for_22\IN\0|.|) (r_prep) 3.49_16\CD\0|for|ratios|With|.|, (r_attr) were_15\VBD\0|NONE (l_nsubj) ratios_12\NNS\13815152|for|With|.|.|, (l_prep) for_13\IN\0|the|odds (l_pobj) vte_14\NNP\0|NONE
D003276_D054556 CID contraceptives_13\NNS\3183080|NONE (r_pobj) with_10\IN\0|NONE (r_prep) associated_9\VBN\628491|venous (r_acl) thromboembolism_8\NN\14100769|NONE
D003276_D054556 CID contraceptives_25\NNS\3183080|who (r_dobj) used_23\VBD\0|NONE (r_relcl) women_21\NNS\9605289|NONE (r_pobj) in_20\IN\13603305|NONE (r_prep) higher_19\JJR\0|incidence|containing|that (r_acomp) was_18\VBD\0|.|studies (l_nsubj) incidence_11\NN\13821570|higher|containing|that (l_prep) of_12\IN\0|the (l_pobj) thromboembolism_14\NN\14100769|NONE
D003276_D054556 CID contraceptives_25\NNS\3183080|who (r_dobj) used_23\VBD\0|NONE (r_relcl) women_21\NNS\9605289|NONE (r_pobj) in_20\IN\13603305|NONE (r_prep) higher_19\JJR\0|incidence|containing|that (r_acomp) was_18\VBD\0|.|studies (l_nsubj) incidence_11\NN\13821570|higher|containing|that (l_prep) of_12\IN\0|the (l_pobj) thromboembolism_14\NN\14100769|NONE (l_appos) vte_16\NNP\0|(|venous|)
D003276_D054556 CID ocs_27\NNP\0|oral|(|) (r_appos) contraceptives_25\NNS\3183080|who (r_dobj) used_23\VBD\0|NONE (r_relcl) women_21\NNS\9605289|NONE (r_pobj) in_20\IN\13603305|NONE (r_prep) higher_19\JJR\0|incidence|containing|that (r_acomp) was_18\VBD\0|.|studies (l_nsubj) incidence_11\NN\13821570|higher|containing|that (l_prep) of_12\IN\0|the (l_pobj) thromboembolism_14\NN\14100769|NONE
D003276_D054556 CID ocs_27\NNP\0|oral|(|) (r_appos) contraceptives_25\NNS\3183080|who (r_dobj) used_23\VBD\0|NONE (r_relcl) women_21\NNS\9605289|NONE (r_pobj) in_20\IN\13603305|NONE (r_prep) higher_19\JJR\0|incidence|containing|that (r_acomp) was_18\VBD\0|.|studies (l_nsubj) incidence_11\NN\13821570|higher|containing|that (l_prep) of_12\IN\0|the (l_pobj) thromboembolism_14\NN\14100769|NONE (l_appos) vte_16\NNP\0|(|venous|)
D003276_D054556 CID ocs_42\NNS\0|NONE (r_pobj) of_41\IN\0|NONE (r_prep) users_40\NNS\7846|NONE (r_pobj) in_39\IN\13603305|NONE (r_prep) than_38\IN\0|desogestrel|progestagens|the|generation|or (r_prep) gestodene_35\NN\0|NONE (r_dobj) containing_29\VBG\2632940|higher|incidence|that (r_advcl) was_18\VBD\0|.|studies (l_nsubj) incidence_11\NN\13821570|higher|containing|that (l_prep) of_12\IN\0|the (l_pobj) thromboembolism_14\NN\14100769|NONE
D003276_D054556 CID ocs_42\NNS\0|NONE (r_pobj) of_41\IN\0|NONE (r_prep) users_40\NNS\7846|NONE (r_pobj) in_39\IN\13603305|NONE (r_prep) than_38\IN\0|desogestrel|progestagens|the|generation|or (r_prep) gestodene_35\NN\0|NONE (r_dobj) containing_29\VBG\2632940|higher|incidence|that (r_advcl) was_18\VBD\0|.|studies (l_nsubj) incidence_11\NN\13821570|higher|containing|that (l_prep) of_12\IN\0|the (l_pobj) thromboembolism_14\NN\14100769|NONE (l_appos) vte_16\NNP\0|(|venous|)
D003276_D054556 CID oc_17\NNP\0|and (r_conj) vte_15\NNP\0|with
D003276_D054556 CID oc_17\NNP\0|the|main (r_compound) preparations_18\NNS\407535|NONE (r_pobj) of_14\IN\0|NONE (r_prep) users_13\NNS\7846|NONE (r_pobj) in_12\IN\13603305|incidence (r_prep) compare_8\VB\4744814|and|to (l_dobj) incidence_9\NN\13821570|in (l_prep) of_10\IN\0|NONE (l_pobj) vte_11\NNP\0|NONE
D003276_D054556 CID oc_17\NNP\0|the|main (r_compound) preparations_18\NNS\407535|NONE (r_pobj) of_14\IN\0|NONE (r_prep) users_13\NNS\7846|NONE (r_pobj) in_12\IN\13603305|incidence (r_prep) compare_8\VB\4744814|and|to (r_conj) estimate_6\VB\5802185|a|cohort (r_relcl) analysis_4\NN\633864|study|We|.|,|and (r_dobj) did_1\VBD\0|NONE (l_conj) study_26\NN\635850|We|.|,|and|analysis (l_acl) calculate_28\VB\632627|nested|a|,|after|control (l_dobj) ratios_31\NNS\13815152|to (l_prep) of_32\IN\0|associated|odds|the (l_pobj) vte_33\NNP\0|NONE
D003276_D054556 CID oc_41\NNP\0|NONE (r_pobj) of_40\IN\0|different (r_prep) types_39\NNS\5839024|NONE (r_pobj) of_37\IN\0|NONE (r_prep) use_36\NN\407535|NONE (r_pobj) with_35\IN\0|NONE (r_prep) associated_34\VBN\628491|odds|of|the (r_acl) ratios_31\NNS\13815152|to (r_dobj) calculate_28\VB\632627|nested|a|,|after|control (r_acl) study_26\NN\635850|We|.|,|and|analysis (r_conj) did_1\VBD\0|NONE (l_dobj) analysis_4\NN\633864|study|We|.|,|and (l_relcl) estimate_6\VB\5802185|a|cohort (l_conj) compare_8\VB\4744814|and|to (l_dobj) incidence_9\NN\13821570|in (l_prep) of_10\IN\0|NONE (l_pobj) vte_11\NNP\0|NONE
D003276_D054556 CID oc_41\NNP\0|NONE (r_pobj) of_40\IN\0|different (r_prep) types_39\NNS\5839024|NONE (r_pobj) of_37\IN\0|NONE (r_prep) use_36\NN\407535|NONE (r_pobj) with_35\IN\0|NONE (r_prep) associated_34\VBN\628491|odds|of|the (r_acl) ratios_31\NNS\13815152|to (l_prep) of_32\IN\0|associated|odds|the (l_pobj) vte_33\NNP\0|NONE
D003276_D054556 CID ocs_18\NNS\0|NONE (r_pobj) of_14\IN\0|NONE (r_prep) users_13\NNS\7846|two (r_attr) were_12\VBD\0|, (r_relcl) vte_7\NNP\0|NONE
D003276_D054556 CID ocs_11\NNS\0|NONE (r_pobj) of_9\IN\0|NONE (r_prep) use_8\NN\407535|NONE (r_pobj) with_7\IN\0|NONE (r_prep) associated_6\VBN\628491||the|of (r_acl) cases_3\NNS\7283608|NONE (l_prep) of_4\IN\0||the|associated (l_pobj) vte_5\NNP\0|NONE
D003276_D054556 CID oc_17\NNP\0|NONE (r_pobj) of_15\IN\0|current (r_prep) users_14\NNS\7846|NONE (r_pobj) in_12\IN\13603305|,|. (r_prep) 4.10_11\CD\0|.|rate (r_attr) was_10\VBD\0|NONE (l_nsubj) rate_2\NN\13815152|.|. (l_prep) of_3\IN\0|per|The|crude (l_pobj) vte_4\NNP\0|NONE
D003276_D054556 CID ocs_26\NNS\0|NONE (r_pobj) of_22\IN\0|NONE (r_prep) users_21\NNS\7846|NONE (r_pobj) in_20\IN\13603305|.|,|and (r_prep) 3.10_19\CD\0|,|in (r_appos) 4.10_11\CD\0|.|rate (r_attr) was_10\VBD\0|NONE (l_nsubj) rate_2\NN\13815152|.|. (l_prep) of_3\IN\0|per|The|crude (l_pobj) vte_4\NNP\0|NONE
D003276_D054556 CID ocs_21\NNS\0|NONE (r_pobj) to_17\IN\0|generation (r_prep) relative_16\JJ\7846|NONE (r_pobj) of_12\IN\0|NONE (r_prep) users_11\NNS\7846|NONE (r_pobj) in_10\IN\13603305|the|of|rate (r_prep) ratio_7\NN\13815152|.|%|After|, (l_prep) of_8\IN\0|the|in|rate (l_pobj) vte_9\NNP\0|NONE
D003276_D054556 CID ocs_21\NNS\0|NONE (r_pobj) of_13\IN\0|NONE (r_prep) users_12\NNS\7846|NONE (r_pobj) between_11\IN\0|of|the (r_prep) risk_8\NN\14541044|NONE (l_prep) of_9\IN\0|the|between (l_pobj) vte_10\NNP\0|NONE
D003276_D054556 CID ocs_5\NNS\0|NONE (r_pobj) with_0\IN\0|for|ratios|.|.|, (r_prep) were_15\VBD\0|NONE (l_nsubj) ratios_12\NNS\13815152|for|With|.|.|, (l_prep) for_13\IN\0|the|odds (l_pobj) vte_14\NNP\0|NONE
D017135_D054556 NONE desogestrel_37\NN\0|progestagens|the|generation|or|than (r_conj) gestodene_35\NN\0|NONE (r_dobj) containing_29\VBG\2632940|higher|incidence|that (r_advcl) was_18\VBD\0|.|studies (l_nsubj) incidence_11\NN\13821570|higher|containing|that (l_prep) of_12\IN\0|the (l_pobj) thromboembolism_14\NN\14100769|NONE
D017135_D054556 NONE desogestrel_37\NN\0|progestagens|the|generation|or|than (r_conj) gestodene_35\NN\0|NONE (r_dobj) containing_29\VBG\2632940|higher|incidence|that (r_advcl) was_18\VBD\0|.|studies (l_nsubj) incidence_11\NN\13821570|higher|containing|that (l_prep) of_12\IN\0|the (l_pobj) thromboembolism_14\NN\14100769|NONE (l_appos) vte_16\NNP\0|(|venous|)
D017135_D054556 NONE desogestrel_17\NN\0|NONE (r_pobj) of_16\IN\0|with (r_prep) users_15\NNS\7846|NONE (r_pobj) in_14\IN\13603305|than|.|higher|risk|Among|, (r_prep) was_12\VBD\0|NONE (l_nsubj) risk_9\NN\14541044|than|.|higher|in|Among|, (l_prep) of_10\IN\0|the (l_pobj) vte_11\NNP\0|NONE
D017135_D054556 NONE desogestrel_28\NN\0|or (r_conj) gestodene_26\NN\0|NONE (r_pobj) of_25\IN\0|with (r_prep) users_24\NNS\7846|NONE (r_pobj) in_23\IN\13603305|NONE (r_prep) than_22\IN\0|.|higher|in|risk|Among|, (r_prep) was_12\VBD\0|NONE (l_nsubj) risk_9\NN\14541044|than|.|higher|in|Among|, (l_prep) of_10\IN\0|the (l_pobj) vte_11\NNP\0|NONE
D017135_D054556 NONE desogestrel_23\NN\0|NONE (r_pobj) for_22\IN\0|.|) (r_prep) 3.49_16\CD\0|for|ratios|With|.|, (r_attr) were_15\VBD\0|NONE (l_nsubj) ratios_12\NNS\13815152|for|With|.|.|, (l_prep) for_13\IN\0|the|odds (l_pobj) vte_14\NNP\0|NONE
D011374_D054556 NONE progestagens_34\NNS\0|desogestrel|the|generation|or|than (r_compound) gestodene_35\NN\0|NONE (r_dobj) containing_29\VBG\2632940|higher|incidence|that (r_advcl) was_18\VBD\0|.|studies (l_nsubj) incidence_11\NN\13821570|higher|containing|that (l_prep) of_12\IN\0|the (l_pobj) thromboembolism_14\NN\14100769|NONE
D011374_D054556 NONE progestagens_34\NNS\0|desogestrel|the|generation|or|than (r_compound) gestodene_35\NN\0|NONE (r_dobj) containing_29\VBG\2632940|higher|incidence|that (r_advcl) was_18\VBD\0|.|studies (l_nsubj) incidence_11\NN\13821570|higher|containing|that (l_prep) of_12\IN\0|the (l_pobj) thromboembolism_14\NN\14100769|NONE (l_appos) vte_16\NNP\0|(|venous|)
D011374_D054556 NONE progestagens_47\NNS\0|NONE (r_dobj) containing_43\VBG\2632940|NONE (r_acl) ocs_42\NNS\0|NONE (r_pobj) of_41\IN\0|NONE (r_prep) users_40\NNS\7846|NONE (r_pobj) in_39\IN\13603305|NONE (r_prep) than_38\IN\0|desogestrel|progestagens|the|generation|or (r_prep) gestodene_35\NN\0|NONE (r_dobj) containing_29\VBG\2632940|higher|incidence|that (r_advcl) was_18\VBD\0|.|studies (l_nsubj) incidence_11\NN\13821570|higher|containing|that (l_prep) of_12\IN\0|the (l_pobj) thromboembolism_14\NN\14100769|NONE
D011374_D054556 NONE progestagens_47\NNS\0|NONE (r_dobj) containing_43\VBG\2632940|NONE (r_acl) ocs_42\NNS\0|NONE (r_pobj) of_41\IN\0|NONE (r_prep) users_40\NNS\7846|NONE (r_pobj) in_39\IN\13603305|NONE (r_prep) than_38\IN\0|desogestrel|progestagens|the|generation|or (r_prep) gestodene_35\NN\0|NONE (r_dobj) containing_29\VBG\2632940|higher|incidence|that (r_advcl) was_18\VBD\0|.|studies (l_nsubj) incidence_11\NN\13821570|higher|containing|that (l_prep) of_12\IN\0|the (l_pobj) thromboembolism_14\NN\14100769|NONE (l_appos) vte_16\NNP\0|(|venous|)
D011374_D054556 NONE progestagens_6\NNS\0|NONE (r_pobj) of_2\IN\0|NONE (r_prep) users_1\NNS\7846|NONE (r_pobj) among_0\IN\0|than|.|higher|in|risk|, (r_prep) was_12\VBD\0|NONE (l_nsubj) risk_9\NN\14541044|than|.|higher|in|Among|, (l_prep) of_10\IN\0|the (l_pobj) vte_11\NNP\0|NONE
D011374_D054556 NONE progestagens_41\NNS\0|NONE (r_pobj) for_35\IN\0|ratios|With|.|.|, (r_prep) were_15\VBD\0|NONE (l_nsubj) ratios_12\NNS\13815152|for|With|.|.|, (l_prep) for_13\IN\0|the|odds (l_pobj) vte_14\NNP\0|NONE
D003276_D013927 NONE ocs_11\NNS\0|NONE (r_pobj) of_9\IN\0|NONE (r_prep) use_8\NN\407535|NONE (r_pobj) with_7\IN\0|NONE (r_prep) associated_6\VBN\628491||the|of (r_acl) cases_3\NNS\7283608|NONE (r_pobj) of_0\IN\0|.|and||five|,|as|were (r_prep) recorded_15\VBN\2225492|NONE (l_prep) as_16\IN\14622893|.|and||five|Of|,|were (l_pobj) thrombosis_20\NN\14100769|NONE (l_appos) 35_22\CD\0|,|vein|, (l_prep) as_23\IN\14622893|NONE (l_pobj) thrombosis_25\NN\14100769|NONE
18422462
D018119_D010523 CID t_21\NN\14999913|d (r_compound) therapy_22\NN\657604|with|and|rash (r_conj) developing_17\VBG\13541167|NONE (l_prep) with_23\IN\0|and|rash|therapy (l_pcomp) developing_24\VBG\13541167|. (l_dobj) neuropathy_26\NN\14204950|NONE
D000409_D000740 NONE alanine_32\NN\14601829|NONE (r_compound) aminotransferase_33\FW\15077571|NONE (r_pobj) with_31\IN\0|(|clinical (r_prep) jaundice_30\NN\14299637|> (r_appos) hepatitis_27\NN\14127211|upper|CD|)|of||in (r_nsubj) limits_38\NNS\5123416|in|anemia|and|.|was (r_conj) observed_12\VBN\2163746|NONE (l_nsubjpass) anemia_2\NN\14189204|in|and|limits|.|was
D019829_D005076 CID nvp_11\NNP\0|NONE (r_compound) therapy_12\NN\657604|.|,|was|with|Among|significantly (r_nsubjpass) associated_15\VBN\628491|NONE (l_prep) with_16\IN\0|.|therapy|,|was|Among|significantly (l_pcomp) developing_17\VBG\13541167|NONE (l_dobj) rash_18\NN\14321469|with|and|therapy
D019829_D010523 NONE nvp_11\NNP\0|NONE (r_compound) therapy_12\NN\657604|.|,|was|with|Among|significantly (r_nsubjpass) associated_15\VBN\628491|NONE (l_prep) with_16\IN\0|.|therapy|,|was|Among|significantly (l_pcomp) developing_17\VBG\13541167|NONE (l_prep) with_23\IN\0|and|rash|therapy (l_pcomp) developing_24\VBG\13541167|. (l_dobj) neuropathy_26\NN\14204950|NONE
D018119_D005076 NONE t_21\NN\14999913|d (r_compound) therapy_22\NN\657604|with|and|rash (r_conj) developing_17\VBG\13541167|NONE (l_dobj) rash_18\NN\14321469|with|and|therapy
D000409_D007565 NONE alanine_32\NN\14601829|NONE (r_compound) aminotransferase_33\FW\15077571|NONE (r_pobj) with_31\IN\0|(|clinical (r_prep) jaundice_30\NN\14299637|>
D000409_D056486 NONE alanine_32\NN\14601829|NONE (r_compound) aminotransferase_33\FW\15077571|NONE (r_pobj) with_31\IN\0|(|clinical (r_prep) jaundice_30\NN\14299637|> (r_appos) hepatitis_27\NN\14127211|upper|CD|)|of||in
18450790
D013792_D008178 NONE thalidomide_30\NN\4166841|NONE (r_pobj) with_29\IN\0|and|use|.|CLE|( (r_prep) treated_28\VBN\2376958|measure|aims|amplitude (r_parataxis) were_4\VBD\0|NONE (l_punct) amplitude_17\VBP\7444668|measure|aims|treated (l_prep) in_18\IN\13603305|NONE (l_pobj) patients_19\NNS\9898892|NONE (l_prep) with_20\IN\0|NONE (l_pobj) erythematosus_24\NN\0|NONE
D013792_D008178 NONE thalidomide_30\NN\4166841|NONE (r_pobj) with_29\IN\0|and|use|.|CLE|( (r_prep) treated_28\VBN\2376958|measure|aims|amplitude (l_nsubj) cle_26\NNP\0|and|use|with|.|(
D013792_D008178 NONE thalidomide_41\NN\4166841|NONE (r_pobj) of_40\IN\0|neurotoxic|the (r_prep) potential_39\NN\14481929|to (r_dobj) identify_36\VB\699815|findings (r_xcomp) use_32\VB\407535|and|with|.|CLE|( (r_conj) treated_28\VBN\2376958|measure|aims|amplitude (r_parataxis) were_4\VBD\0|NONE (l_punct) amplitude_17\VBP\7444668|measure|aims|treated (l_prep) in_18\IN\13603305|NONE (l_pobj) patients_19\NNS\9898892|NONE (l_prep) with_20\IN\0|NONE (l_pobj) erythematosus_24\NN\0|NONE
D013792_D008178 NONE thalidomide_41\NN\4166841|NONE (r_pobj) of_40\IN\0|neurotoxic|the (r_prep) potential_39\NN\14481929|to (r_dobj) identify_36\VB\699815|findings (r_xcomp) use_32\VB\407535|and|with|.|CLE|( (r_conj) treated_28\VBN\2376958|measure|aims|amplitude (l_nsubj) cle_26\NNP\0|and|use|with|.|(
D013792_D008178 NONE thalidomide_17\NN\4166841|and (r_pobj) with_16\IN\0|NONE (r_prep) treatment_15\NN\654885|NONE (r_pobj) during_14\IN\0|in|Clinical (r_prep) data_7\NNS\7951464|months|.|were|discontinuation|after|PATIENTS (l_prep) in_8\IN\13603305|during|Clinical (l_pobj) patients_11\NNS\9898892|NONE (l_prep) with_12\IN\0|female| (l_pobj) cle_13\NNP\0|NONE
D013792_D010523 CID thalidomide_0\NNP\4166841|NONE (l_conj) neurotoxicity_3\NN\0|and|.|study|:
D013792_D010523 CID thalidomide_17\NN\4166841|NONE (r_pobj) of_16\IN\0|different (r_prep) doses_15\NNS\3740161|NONE (r_pobj) with_13\IN\0|NONE (r_prep) treated_12\VBN\2376958|NONE (r_acl) patients_11\NNS\9898892|NONE (r_pobj) in_10\IN\13603305|high|a|of (r_prep) incidence_5\NN\13821570|.|studies (l_prep) of_6\IN\0|high|in|a (l_pobj) neuropathy_9\NN\14204950|NONE
D013792_D020258 NONE thalidomide_30\NN\4166841|NONE (r_pobj) with_29\IN\0|and|use|.|CLE|( (r_prep) treated_28\VBN\2376958|measure|aims|amplitude (l_conj) use_32\VB\407535|and|with|.|CLE|( (l_xcomp) identify_36\VB\699815|findings (l_dobj) potential_39\NN\14481929|to (l_amod) neurotoxic_38\JJ\0|the|of
D013792_D020258 NONE thalidomide_41\NN\4166841|NONE (r_pobj) of_40\IN\0|neurotoxic|the (r_prep) potential_39\NN\14481929|to (l_amod) neurotoxic_38\JJ\0|the|of
D013792_D020258 NONE thalidomide_10\NN\4166841|NONE (r_pobj) of_9\IN\0|neurotoxic|subclinical (r_prep) potential_8\NN\14481929|NONE (l_amod) neurotoxic_7\JJ\0|of|subclinical
24894748
D008790_D003324 NONE metoprolol_8\NN\2832168|course|day|.|was (l_prep) for_13\IN\0|day|man (l_pobj) disease_17\NN\14061805|NONE
C041359_D003221 NONE terbinafine_5\NN\2720201|NONE (r_compound) therapy_6\NN\657604|NONE (r_pobj) of_4\IN\0|th|the (r_prep) day_3\NN\15154774|NONE (r_pobj) on_0\IN\0|for|.|,|was|to|he (r_prep) brought_10\VBN\1449974|NONE (l_prep) for_15\IN\0|.|,|was|On|to|he (l_pobj) decrease_17\NN\7296428|NONE (l_prep) of_18\IN\0|a (l_pobj) status_22\NN\24720|NONE (l_conj) confusion_24\NN\13972797|health|global|,|his
C041359_D014009 NONE terbinafine_25\NN\2720201|NONE (r_pobj) of_23\IN\0|day|a (r_prep) course_22\NN\883297|metoprolol|day|.|was (r_dobj) prescribed_19\VBN\748282|NONE (l_npadvmod) day_29\NN\15154774|course|metoprolol|.|was (l_prep) for_30\IN\0|mg||/ (l_pobj) onychomycosis_31\NN\0|NONE
C041359_D001919 CID terbinafine_3\NN\2720201|A (r_compound) combination_4\NN\7951464|bradycardia|. (r_nsubj) induced_5\VBN\1627355|NONE (l_dobj) bradycardia_6\NN\14110674|combination|.
C041359_D064420 NONE terbinafine_29\NN\2720201|and (r_conj) metoprolol_27\NN\2832168|NONE (r_pobj) between_26\IN\0|drug|the (r_prep) interaction_25\NN\37396|sinus|and (r_conj) bradycardia_21\NNP\14110674|NONE (r_pobj) between_16\IN\0|a|probable (r_prep) relationship_15\NN\31921|score|. (r_dobj) indicates_12\VBZ\952524|NONE (l_nsubj) score_1\NN\5736149|relationship|. (l_prep) on_4\IN\0|A|of (l_pobj) scale_11\NN\7260623|NONE (l_compound) probability_10\NN\33615|the|Naranjo (l_compound) reaction_9\NN\13446390|NONE
D008790_D064420 NONE metoprolol_27\NN\2832168|NONE (r_pobj) between_26\IN\0|drug|the (r_prep) interaction_25\NN\37396|sinus|and (r_conj) bradycardia_21\NNP\14110674|NONE (r_pobj) between_16\IN\0|a|probable (r_prep) relationship_15\NN\31921|score|. (r_dobj) indicates_12\VBZ\952524|NONE (l_nsubj) score_1\NN\5736149|relationship|. (l_prep) on_4\IN\0|A|of (l_pobj) scale_11\NN\7260623|NONE (l_compound) probability_10\NN\33615|the|Naranjo (l_compound) reaction_9\NN\13446390|NONE
D008790_D001919 CID metoprolol_1\NN\2832168|NONE (r_compound) terbinafine_3\NN\2720201|A (r_compound) combination_4\NN\7951464|bradycardia|. (r_nsubj) induced_5\VBN\1627355|NONE (l_dobj) bradycardia_6\NN\14110674|combination|.
D008790_D012804 NONE metoprolol_7\NN\2832168|NONE (r_pobj) by_6\IN\0|.|report (r_agent) induced_5\VBN\1627355|NONE (l_advcl) report_1\VB\6470073|.|by (l_dobj) bradycardia_4\NN\14110674|To|sinus
D008790_D012804 NONE metoprolol_27\NN\2832168|NONE (r_pobj) between_26\IN\0|drug|the (r_prep) interaction_25\NN\37396|sinus|and (r_conj) bradycardia_21\NNP\14110674|NONE
D008790_D012804 NONE metoprolol_10\NN\2832168|NONE (r_poss) clearance_12\NN\5089947|,|leading|terbinafine|By|,|had|. (r_dobj) decreased_9\VBN\169651|NONE (l_advcl) leading_14\VBG\4339291|,|terbinafine|By|clearance|,|had|. (l_prep) in_15\IN\13603305|NONE (l_pobj) accumulation_17\NN\13497135|NONE (l_relcl) resulted_20\VBN\2633881|metoprolol (l_prep) in_21\IN\13603305|has|which (l_pobj) bradycardia_25\NN\14110674|NONE
D008790_D012804 NONE metoprolol_16\NN\2832168|resulted (r_compound) accumulation_17\NN\13497135|NONE (l_relcl) resulted_20\VBN\2633881|metoprolol (l_prep) in_21\IN\13603305|has|which (l_pobj) bradycardia_25\NN\14110674|NONE
D008790_D014009 NONE metoprolol_8\NN\2832168|course|day|.|was (r_nsubjpass) prescribed_19\VBN\748282|NONE (l_npadvmod) day_29\NN\15154774|course|metoprolol|.|was (l_prep) for_30\IN\0|mg||/ (l_pobj) onychomycosis_31\NN\0|NONE
C041359_D003324 NONE terbinafine_25\NN\2720201|NONE (r_pobj) of_23\IN\0|day|a (r_prep) course_22\NN\883297|metoprolol|day|.|was (r_dobj) prescribed_19\VBN\748282|NONE (l_nsubjpass) metoprolol_8\NN\2832168|course|day|.|was (l_prep) for_13\IN\0|day|man (l_pobj) disease_17\NN\14061805|NONE
C041359_D012804 NONE terbinafine_9\NN\2720201|and|management|drug (r_compound) interaction_13\NN\37396|and (r_conj) metoprolol_7\NN\2832168|NONE (r_pobj) by_6\IN\0|.|report (r_agent) induced_5\VBN\1627355|NONE (l_advcl) report_1\VB\6470073|.|by (l_dobj) bradycardia_4\NN\14110674|To|sinus
C041359_D012804 NONE terbinafine_29\NN\2720201|and (r_conj) metoprolol_27\NN\2832168|NONE (r_pobj) between_26\IN\0|drug|the (r_prep) interaction_25\NN\37396|sinus|and (r_conj) bradycardia_21\NNP\14110674|NONE
C041359_D012804 NONE terbinafine_7\NN\2720201|,|leading|By|clearance|,|had|. (r_nsubj) decreased_9\VBN\169651|NONE (l_advcl) leading_14\VBG\4339291|,|terbinafine|By|clearance|,|had|. (l_prep) in_15\IN\13603305|NONE (l_pobj) accumulation_17\NN\13497135|NONE (l_relcl) resulted_20\VBN\2633881|metoprolol (l_prep) in_21\IN\13603305|has|which (l_pobj) bradycardia_25\NN\14110674|NONE
19715529
12051122
D014750_D007010 CID vincristine_14\NNP\3917455|NONE (r_pobj) of_13\IN\0|the (r_prep) use_12\NN\407535|NONE (r_pobj) with_10\IN\0|NONE (r_prep) reported_9\VBN\831651|inappropriate|diuretic| (r_acl) hormone_8\NN\5404728|NONE (r_pobj) of_3\IN\0|NONE (r_prep) syndrome_2\NN\5870365|and|? (r_conj) hyponatremia_0\NNP\14299637|NONE
D014750_D007010 CID vincristine_32\NN\3917455| (r_npadvmod) treated_34\VBN\2376958|NONE (r_amod) patients_35\NNS\9898892|NONE (r_pobj) among_31\IN\0|(|) (r_prep) siadh_29\NNP\0||diuretic (r_appos) hormone_27\NN\5404728|NONE (r_pobj) of_23\IN\0|inappropriate (r_prep) secretion_22\NN\13526110|NONE (r_pobj) of_20\IN\0|NONE (r_prep) syndrome_19\NN\5870365|and/or (r_conj) hyponatremia_17\NN\14299637|NONE
D014750_D007010 CID vincristine_33\NN\3917455|NONE (r_pobj) of_32\IN\0|the (r_prep) use_31\NN\407535|NONE (r_pobj) during_29\IN\0|been|that|had (r_prep) reported_28\VBN\831651|and|database|the|Eli (r_relcl) lilly_4\NNP\0|We|as|. (l_conj) database_11\NN\6634376|and|the|Eli|reported (l_prep) for_12\IN\0|event|Company|computerized (l_pobj) cases_15\NNS\7283608|NONE (l_prep) of_16\IN\0|all|reported (l_pobj) hyponatremia_17\NN\14299637|NONE
D014750_D007010 CID vincristine_11\NN\3917455|NONE (r_compound) use_12\NN\407535|NONE (r_pobj) with_10\IN\0|NONE (r_prep) associated_9\VBD\628491|A|of (r_acl) total_1\NN\3553|were|. (l_prep) of_2\IN\0|A|associated (l_pobj) cases_4\NNS\7283608|NONE (l_prep) of_5\IN\0| (l_pobj) hyponatremia_6\NN\14299637|NONE
D014750_D007010 CID vincristine_17\NN\3917455|NONE (r_compound) use_18\NN\407535|NONE (r_pobj) with_16\IN\0|NONE (r_prep) associated_15\VBD\628491|increased|of (r_acl) risk_10\NN\14541044|NONE (l_prep) of_11\IN\0|increased|associated (l_pobj) hyponatremia_12\NN\14299637|NONE
D014750_D007177 CID vincristine_14\NNP\3917455|NONE (r_pobj) of_13\IN\0|the (r_prep) use_12\NN\407535|NONE (r_pobj) with_10\IN\0|NONE (r_prep) reported_9\VBN\831651|inappropriate|diuretic| (r_acl) hormone_8\NN\5404728|NONE
D014750_D007177 CID vincristine_32\NN\3917455| (r_npadvmod) treated_34\VBN\2376958|NONE (r_amod) patients_35\NNS\9898892|NONE (r_pobj) among_31\IN\0|(|) (r_prep) siadh_29\NNP\0||diuretic (r_appos) hormone_27\NN\5404728|NONE
D014750_D007177 CID vincristine_32\NN\3917455| (r_npadvmod) treated_34\VBN\2376958|NONE (r_amod) patients_35\NNS\9898892|NONE (r_pobj) among_31\IN\0|(|) (r_prep) siadh_29\NNP\0||diuretic
D014750_D007177 CID vincristine_33\NN\3917455|NONE (r_pobj) of_32\IN\0|the (r_prep) use_31\NN\407535|NONE (r_pobj) during_29\IN\0|been|that|had (r_prep) reported_28\VBN\831651|and|database|the|Eli (r_relcl) lilly_4\NNP\0|We|as|. (l_conj) database_11\NN\6634376|and|the|Eli|reported (l_prep) for_12\IN\0|event|Company|computerized (l_pobj) cases_15\NNS\7283608|NONE (l_prep) of_16\IN\0|all|reported (l_pobj) hyponatremia_17\NN\14299637|NONE (l_conj) siadh_19\NNP\0|and/or
D014750_D007177 CID vincristine_11\NN\3917455|NONE (r_compound) use_12\NN\407535|NONE (r_pobj) with_10\IN\0|NONE (r_prep) associated_9\VBD\628491|A|of (r_acl) total_1\NN\3553|were|. (l_prep) of_2\IN\0|A|associated (l_pobj) cases_4\NNS\7283608|NONE (l_prep) of_5\IN\0| (l_pobj) hyponatremia_6\NN\14299637|NONE (l_conj) siadh_8\NNP\0|and/or
D014750_D007177 CID vincristine_17\NN\3917455|NONE (r_compound) use_18\NN\407535|NONE (r_pobj) with_16\IN\0|NONE (r_prep) associated_15\VBD\628491|increased|of (r_acl) risk_10\NN\14541044|NONE (l_prep) of_11\IN\0|increased|associated (l_pobj) hyponatremia_12\NN\14299637|NONE (l_conj) siadh_14\NNP\0|and/or
D014750_D007177 CID vincristine_9\NN\3917455|NONE (r_pobj) with_8\IN\0|NONE (r_prep) associated_7\VBN\628491|overall|reported|of|the (r_acl) rate_4\NN\13815152|Although|low (l_prep) of_5\IN\0|overall|reported|the|associated (l_pobj) siadh_6\NNP\0|NONE
15605432
D010100_D066126 NONE oxygen_12\NN\14622893|be|if (r_nsubj) reported_19\VBD\831651|to (r_ccomp) determine_8\VB\0|.|resulted|purpose|adriamycin (r_xcomp) was_6\VBD\0|NONE (l_conj) resulted_29\VBD\2633881|determine|.|purpose|adriamycin (l_nsubj) cardiotoxicity_27\NN\0|determine|actually|and|in|,
D004317_D066126 NONE adriamycin_24\NNS\0|determine|.|resulted|purpose (r_acomp) was_6\VBD\0|NONE (l_conj) resulted_29\VBD\2633881|determine|.|purpose|adriamycin (l_nsubj) cardiotoxicity_27\NN\0|determine|actually|and|in|,
D004317_D066126 NONE adr)-induced_26\JJ\0|( (r_compound) cardiotoxicity_27\NN\0|determine|actually|and|in|,
D004317_D028361 CID adriamycin_6\NNS\0| (r_npadvmod) induced_8\VBN\1627355|mitochondrial|cardiac (r_amod) injury_11\NN\14052046|NONE
D004317_D028361 CID adr_3\NNP\0|adducts|at (r_nsubj) induced_4\VBD\1627355|.|data (l_prep) at_11\IN\14622893|adducts|ADR (l_pobj) point_15\NN\5868954|NONE (l_prep) as_16\IN\14622893|time|the|same (l_pcomp) appeared_21\VBD\2604760|NONE (l_nsubj) injury_19\NN\14052046|initially|when
D009584_D066126 NONE ros)/nitrogen_14\NN\0|(|)|(|RNS (r_compound) species_15\NNS\7992450|reactive|elevated (r_appos) oxygen_12\NN\14622893|be|if (r_nsubj) reported_19\VBD\831651|to (r_ccomp) determine_8\VB\0|.|resulted|purpose|adriamycin (r_xcomp) was_6\VBD\0|NONE (l_conj) resulted_29\VBD\2633881|determine|.|purpose|adriamycin (l_nsubj) cardiotoxicity_27\NN\0|determine|actually|and|in|,
C027576_D028361 NONE 4hne_5\CD\0| (r_compound) protein_7\NN\14944888|in (r_compound) adducts_8\NNS\14818238|ADR|at (r_dobj) induced_4\VBD\1627355|.|data (l_prep) at_11\IN\14622893|adducts|ADR (l_pobj) point_15\NN\5868954|NONE (l_prep) as_16\IN\14622893|time|the|same (l_pcomp) appeared_21\VBD\2604760|NONE (l_nsubj) injury_19\NN\14052046|initially|when
8184922
D007545_D006332 CID isoproterenol_17\NN\3740161| (r_npadvmod) induced_19\VBN\1627355|cardiac (r_amod) hypertrophy_21\NN\14365950|NONE
20959502
D017576_D008581 NONE daptomycin_7\NN\0|NONE (l_prep) in_8\IN\13603305|dose (l_pobj) meningitis_12\NN\14127211|NONE
D017576_D008581 NONE daptomycin_23\NN\0|NONE (r_pobj) with_19\IN\0|NONE (r_prep) treated_18\VBD\2376958|suspected|MSSA (r_acl) meningitis_17\NN\14127211|NONE
D017576_D008581 NONE daptomycin_4\JJ\0|.|and|initiated|was|Nafcillin (r_conj) discontinued_2\VBN\0|NONE (l_conj) initiated_9\VBN\1617192|.|and|daptomycin|was|Nafcillin (l_prep) for_10\IN\0|was|and|continued (l_pobj) meningitis_12\NN\14127211|NONE
D017576_D016470 NONE daptomycin_23\NN\0|NONE (r_pobj) with_19\IN\0|NONE (r_prep) treated_18\VBD\2376958|suspected|MSSA (r_acl) meningitis_17\NN\14127211|NONE (r_pobj) with_14\IN\0|MSSA|)|( (r_prep) bacteremia_13\XX\14204950|sensitive|Staphylococcus
D017576_D016470 NONE daptomycin_0\NNP\0|.|in|was|nephritis (r_nsubjpass) initiated_2\VBN\1617192|NONE (l_dobj) nephritis_14\NN\14113228|Daptomycin|.|in|was (l_conj) relapsing_16\VBG\66636|and|acute|interstitial|induced (l_dobj) bacteremia_17\NN\14204950|NONE
D017576_D016470 NONE daptomycin_3\NN\0|may|option|. (r_nsubj) be_5\VB\14625458|NONE (l_attr) option_8\NN\6480506|daptomycin|may|. (l_prep) for_9\IN\0|an|alternative (l_pobj) bacteremia_11\VBG\14204950|NONE
D009254_D016470 NONE nafcillin_9\NN\3910417| (r_npadvmod) induced_11\VBN\1627355|and|acute|interstitial|relapsing (r_amod) nephritis_14\NN\14113228|Daptomycin|.|in|was (l_conj) relapsing_16\VBG\66636|and|acute|interstitial|induced (l_dobj) bacteremia_17\NN\14204950|NONE
D008712_D016470 NONE methicillin_5\NN\3910033| (r_npadvmod) sensitive_7\JJ\10488309|bacteremia|Staphylococcus (r_amod) aureus_9\NNP\0|NONE (l_appos) bacteremia_13\XX\14204950|sensitive|Staphylococcus
D009254_D008581 NONE nafcillin_0\NNP\3910417|.|and|initiated|daptomycin|was (r_nsubjpass) discontinued_2\VBN\0|NONE (l_conj) initiated_9\VBN\1617192|.|and|daptomycin|was|Nafcillin (l_prep) for_10\IN\0|was|and|continued (l_pobj) meningitis_12\NN\14127211|NONE
D008712_D008581 NONE methicillin_5\NN\3910033| (r_npadvmod) sensitive_7\JJ\10488309|bacteremia|Staphylococcus (r_amod) aureus_9\NNP\0|NONE (l_appos) bacteremia_13\XX\14204950|sensitive|Staphylococcus (l_prep) with_14\IN\0|MSSA|)|( (l_pobj) meningitis_17\NN\14127211|NONE
D003404_D058186 NONE creatinine_12\JJ\0|(|renal|acute|, (r_appos) failure_9\NN\66216|)|from
D017576_D009395 NONE daptomycin_0\NNP\0|.|in|was|nephritis (r_nsubjpass) initiated_2\VBN\1617192|NONE (l_dobj) nephritis_14\NN\14113228|Daptomycin|.|in|was
D009254_D009395 CID nafcillin_9\NN\3910417| (r_npadvmod) induced_11\VBN\1627355|and|acute|interstitial|relapsing (r_amod) nephritis_14\NN\14113228|Daptomycin|.|in|was
89511
D004967_D004714 NONE oestrogen_4\NN\14745635|dose|Cyclical|with (r_compound) therapy_5\NN\657604|does|not|.|increase (r_nsubj) seem_15\VB\2604760|NONE (l_xcomp) increase_17\VB\13576355|does|not|.|therapy (l_dobj) risk_19\NN\14541044|to (l_prep) of_20\IN\0|the (l_pobj) hyperplasia_22\NN\14365950|NONE
D004967_D009369 NONE oestrogen_16\NN\14745635|difficulty|inappropriate|unopposed|and (r_compound) therapy_17\NN\657604|NONE (l_conj) difficulty_20\NN\621627|inappropriate|unopposed|and|oestrogen (l_prep) in_21\IN\13603305|the (l_pcomp) distinguishing_22\VBG\618878|NONE (l_prep) from_25\IN\0|hyperplasia (l_pobj) malignancy_26\NN\14070360|NONE
D004967_D014591 NONE oestrogen_10\NN\14745635|NONE (r_compound) therapy_11\NN\657604|NONE (r_dobj) receiving_9\VBG\2210855|climacteric (r_acl) women_8\NNS\9605289|NONE (r_pobj) in_6\IN\13603305|.|and|of|treatment (r_prep) prevention_0\NN\1073995|NONE (l_prep) of_3\IN\0|.|in|and|treatment (l_pobj) disease_5\NN\14061805|NONE
D004967_D014591 NONE oestrogen_16\NN\14745635|NONE (r_compound) therapy_17\NN\657604|NONE (r_dobj) receiving_15\VBG\2210855||climacteric (r_acl) women_14\NNS\9605289|NONE (r_pobj) among_11\IN\0|in|regimens|.|are (r_prep) described_4\VBN\1001294|NONE (l_prep) in_5\IN\13603305|among|regimens|.|are (l_pobj) patients_7\NNS\9898892|NONE (l_prep) with_8\IN\0| (l_pobj) disease_10\NN\14061805|NONE
D011372_D004714 NONE progestagen_12\NN\0|NONE (r_pobj) of_11\IN\0| (r_prep) days_10\NNS\15140892|NONE (r_pobj) with_6\IN\0|oestrogen|dose|Cyclical (r_prep) therapy_5\NN\657604|does|not|.|increase (r_nsubj) seem_15\VB\2604760|NONE (l_xcomp) increase_17\VB\13576355|does|not|.|therapy (l_dobj) risk_19\NN\14541044|to (l_prep) of_20\IN\0|the (l_pobj) hyperplasia_22\NN\14365950|NONE
D004967_D002277 NONE oestrogen_4\NN\14745635|dose|Cyclical|with (r_compound) therapy_5\NN\657604|does|not|.|increase (r_nsubj) seem_15\VB\2604760|NONE (l_xcomp) increase_17\VB\13576355|does|not|.|therapy (l_dobj) risk_19\NN\14541044|to (l_prep) of_20\IN\0|the (l_pobj) hyperplasia_22\NN\14365950|NONE (l_conj) carcinoma_24\NN\14239918|or|endometrial
D009640_D006965 NONE norethisterone_8\NN\0| (r_amod) mg_7\NN\13717155|NONE (r_pobj) of_5\IN\0| (r_prep) days_4\NNS\15140892|NONE (r_pobj) of_2\IN\0|Two (r_prep) courses_1\NNS\883297|reversion||.|and (r_nsubj) caused_10\VBN\1617192|NONE (l_dobj) reversion_11\NN\13286801||courses|.|and (l_prep) in_14\IN\13603305|to (l_pobj) cases_17\NNS\7283608|NONE (l_prep) of_18\IN\0||all (l_pobj) hyperplasia_20\NN\14365950|NONE
D009640_D006965 NONE norethisterone_8\NN\0| (r_amod) mg_7\NN\13717155|NONE (r_pobj) of_5\IN\0| (r_prep) days_4\NNS\15140892|NONE (r_pobj) of_2\IN\0|Two (r_prep) courses_1\NNS\883297|reversion||.|and (r_nsubj) caused_10\VBN\1617192|NONE (l_conj) 6_22\CD\13741022|reversion|courses|.|and (l_prep) of_23\IN\0|NONE (l_pobj) cases_26\NNS\7283608|NONE (l_prep) of_27\IN\0|the| (l_pobj) hyperplasia_29\NN\14365950|NONE
D004967_D006965 CID oestrogen_6\NN\14745635|unopposed (r_compound) therapy_7\NN\657604|NONE (r_pobj) with_4\IN\0|without|.|hyperplasia|was (r_prep) associated_3\VBN\628491|NONE (l_nsubjpass) hyperplasia_1\NN\14365950|without|with|.|was
D004967_D006965 CID oestrogen_16\NN\14745635|difficulty|inappropriate|unopposed|and (r_compound) therapy_17\NN\657604|NONE (l_conj) difficulty_20\NN\621627|inappropriate|unopposed|and|oestrogen (l_prep) in_21\IN\13603305|the (l_pcomp) distinguishing_22\VBG\618878|NONE (l_dobj) hyperplasia_24\NN\14365950|from
D004967_D016889 NONE oestrogen_16\NN\14745635|difficulty|inappropriate|unopposed|and (r_compound) therapy_17\NN\657604|NONE (r_pobj) of_11\IN\0|the (r_prep) problems_10\NNS\14408086|.|referred (r_dobj) demonstrated_8\VBD\2137132|NONE (l_csubj) referred_5\VBD\730052|.|problems (l_nsubj) cases_1\NNS\7283608|from (l_prep) of_2\IN\0| (l_pobj) carcinoma_4\NN\14239918|NONE
D011372_D006965 NONE progestagen_9\NN\0|NONE (r_pobj) without_8\IN\0|with|.|hyperplasia|was (r_prep) associated_3\VBN\628491|NONE (l_nsubjpass) hyperplasia_1\NN\14365950|without|with|.|was
D011372_D002277 NONE progestagen_12\NN\0|NONE (r_pobj) of_11\IN\0| (r_prep) days_10\NNS\15140892|NONE (r_pobj) with_6\IN\0|oestrogen|dose|Cyclical (r_prep) therapy_5\NN\657604|does|not|.|increase (r_nsubj) seem_15\VB\2604760|NONE (l_xcomp) increase_17\VB\13576355|does|not|.|therapy (l_dobj) risk_19\NN\14541044|to (l_prep) of_20\IN\0|the (l_pobj) hyperplasia_22\NN\14365950|NONE (l_conj) carcinoma_24\NN\14239918|or|endometrial
8748050
D000639_D003866 NONE amitriptyline_12\NN\4482543|NONE (r_compound) therapy_13\NN\657604|NONE (r_pobj) of_11\IN\0|the (r_prep) course_10\NN\883297|NONE (r_pobj) in_8\IN\13603305|NONE (r_prep) developed_7\VBN\1753788|NONE (r_acl) encephalopathy_6\NN\14084880|NONE (r_pobj) of_5\IN\0|a (r_prep) case_4\NN\7283608|report|,|.|during (r_dobj) describes_2\VBZ\1001294|NONE (l_prep) during_15\IN\0|report|,|.|case (l_pobj) remission_17\NN\7368256|NONE (l_prep) of_18\IN\0|a (l_pobj) depression_20\NN\14373582|NONE
D000639_D020230 NONE amitriptyline_2\NN\4482543|NONE (r_compound) therapy_3\NN\657604|NONE (r_pobj) during_1\IN\0|NONE (r_prep) encephalopathy_0\VBG\14084880|:|?|syndrome (r_nsubj) are_5\VBP\13600404|NONE (l_attr) syndrome_8\NN\5870365|:|?|Encephalopathy (l_conj) disorders_13\NNS\14034177|and|malignant|neuroleptic (l_compound) syndrome_11\NN\5870365|spectrum|serotonin
D000639_D001927 CID amitriptyline_2\NN\4482543|NONE (r_compound) therapy_3\NN\657604|NONE (r_pobj) during_1\IN\0|NONE (r_prep) encephalopathy_0\VBG\14084880|:|?|syndrome
D000639_D001927 CID amitriptyline_12\NN\4482543|NONE (r_compound) therapy_13\NN\657604|NONE (r_pobj) of_11\IN\0|the (r_prep) course_10\NN\883297|NONE (r_pobj) in_8\IN\13603305|NONE (r_prep) developed_7\VBN\1753788|NONE (r_acl) encephalopathy_6\NN\14084880|NONE
D000639_D009459 NONE amitriptyline_2\NN\4482543|NONE (r_compound) therapy_3\NN\657604|NONE (r_pobj) during_1\IN\0|NONE (r_prep) encephalopathy_0\VBG\14084880|:|?|syndrome (r_nsubj) are_5\VBP\13600404|NONE (l_attr) syndrome_8\NN\5870365|:|?|Encephalopathy
24535067
D005045_D009069 NONE etomidate_19\NN\0|during|according (r_advcl) graded_9\VBN\670261|which|were|and (r_conj) observed_7\VBN\2163746|.|,|movements|are (r_advcl) evaluated_3\VBN\670261|NONE (l_nsubjpass) movements_1\NNS\191142|.|,|observed|are
D008874_D009207 NONE midazolam_13\NN\2830852|, (r_appos) fentanyl_11\NN\2707683|induced|:|:|is (r_appos) myoclonus_5\NN\14360459|NONE
D008874_D009207 NONE midazolam_15\NN\2830852|, (r_conj) fentanyl_13\NN\2707683|NONE (r_pobj) of_12\IN\0|combination|the (r_prep) effectiveness_11\NN\5190804|to (l_conj) combination_19\NN\7951464|the|of (l_relcl) prevent_25\VB\0|a|of (l_dobj) myoclonus_29\NN\14360459|to
D008874_D009207 NONE midazolam_23\NN\2830852|and (r_conj) fentanyl_21\NN\2707683|NONE (r_pobj) of_20\IN\0|prevent|a (r_prep) combination_19\NN\7951464|the|of (l_relcl) prevent_25\VB\0|a|of (l_dobj) myoclonus_29\NN\14360459|to
D008874_D009207 NONE midazolam_11\NN\2830852|and (r_conj) fentanyl_9\NN\2707683|NONE (r_pobj) of_8\IN\0|or|combination (r_prep) fentanyl_5\NN\2707683|NONE (r_pobj) with_4\IN\0|NONE (r_prep) pretreatment_3\NN\0|that|effective (r_nsubj) was_12\VBD\0|We|. (l_acomp) effective_13\JJ\0|that|pretreatment (l_prep) in_14\IN\13603305|NONE (l_pcomp) preventing_15\VBG\0|NONE (l_dobj) myoclonus_19\NN\14360459|NONE
D005045_D009207 CID etomidate_2\NN\0| (r_npadvmod) induced_4\VBN\1627355|:|:|Fentanyl|is (r_amod) myoclonus_5\NN\14360459|NONE
D005045_D009207 CID etomidate_26\NN\0| (r_npadvmod) induced_28\VBN\1627355|NONE (r_amod) myoclonus_29\NN\14360459|to
D005045_D009207 CID etomidate_16\NN\0| (r_npadvmod) induced_18\VBN\1627355|NONE (r_amod) myoclonus_19\NN\14360459|NONE
D005045_D010146 NONE etomidate_6\NN\0|NONE (r_xcomp) due_4\IN\5174653|The|of (r_prep) severity_1\NN\5036394|pressure|, (l_prep) of_2\IN\0|The|due (l_pobj) pain_3\NN\14299637|NONE
D005283_D009207 NONE fentanyl_11\NN\2707683|induced|:|:|is (r_appos) myoclonus_5\NN\14360459|NONE
D005283_D009207 NONE fentanyl_13\NN\2707683|NONE (r_pobj) of_12\IN\0|combination|the (r_prep) effectiveness_11\NN\5190804|to (l_conj) combination_19\NN\7951464|the|of (l_relcl) prevent_25\VB\0|a|of (l_dobj) myoclonus_29\NN\14360459|to
D005283_D009207 NONE fentanyl_21\NN\2707683|NONE (r_pobj) of_20\IN\0|prevent|a (r_prep) combination_19\NN\7951464|the|of (l_relcl) prevent_25\VB\0|a|of (l_dobj) myoclonus_29\NN\14360459|to
D005283_D009207 NONE fentanyl_5\NN\2707683|NONE (r_pobj) with_4\IN\0|NONE (r_prep) pretreatment_3\NN\0|that|effective (r_nsubj) was_12\VBD\0|We|. (l_acomp) effective_13\JJ\0|that|pretreatment (l_prep) in_14\IN\13603305|NONE (l_pcomp) preventing_15\VBG\0|NONE (l_dobj) myoclonus_19\NN\14360459|NONE
D005283_D009207 NONE fentanyl_9\NN\2707683|NONE (r_pobj) of_8\IN\0|or|combination (r_prep) fentanyl_5\NN\2707683|NONE (r_pobj) with_4\IN\0|NONE (r_prep) pretreatment_3\NN\0|that|effective (r_nsubj) was_12\VBD\0|We|. (l_acomp) effective_13\JJ\0|that|pretreatment (l_prep) in_14\IN\13603305|NONE (l_pcomp) preventing_15\VBG\0|NONE (l_dobj) myoclonus_19\NN\14360459|NONE
24802403
D010433_D003072 CID pentylenetetrazole_23\NN\0| (r_npadvmod) induced_25\VBN\1627355|kindling (r_amod) animals_27\NNS\4475|NONE (r_pobj) in_22\IN\13603305|NONE (r_prep) observed_21\VBN\2163746|ameliorative|on|of|the (r_acl) effects_8\NNS\13245626|to (l_prep) on_11\IN\0|ameliorative|observed|of|the (l_pobj) seizures_12\NNS\14081375|NONE (l_conj) impairment_15\NN\7296428|,
D008687_D012640 NONE metformin_0\NNP\2719105|against|. (r_nsubj) protects_1\VBZ\1127795|NONE (l_prep) against_2\IN\0|Metformin|. (l_pobj) seizures_3\NNS\14081375|NONE
D008687_D012640 NONE metformin_10\NN\2719105|NONE (r_pobj) of_9\IN\0|ameliorative|observed|on|the (r_prep) effects_8\NNS\13245626|to (l_prep) on_11\IN\0|ameliorative|observed|of|the (l_pobj) seizures_12\NNS\14081375|NONE
D008687_D012640 NONE metformin_6\NN\2719105|that|may|agent (r_nsubj) be_8\VB\14625458|Thus|.|study (l_attr) agent_11\NN\7347|that|metformin|may (l_prep) for_12\IN\0|potential|a (l_pobj) treatment_14\NN\654885|NONE (l_conj) medicine_22\NN\6045562|the|of|as (l_acl) induced_26\VBN\1627355|protective|a|against (l_agent) by_27\IN\0|NONE (l_pobj) seizures_28\NNS\14081375|NONE
D008687_D003072 NONE metformin_10\NN\2719105|NONE (r_pobj) of_9\IN\0|ameliorative|observed|on|the (r_prep) effects_8\NNS\13245626|to (l_prep) on_11\IN\0|ameliorative|observed|of|the (l_pobj) seizures_12\NNS\14081375|NONE (l_conj) impairment_15\NN\7296428|,
D008687_D003072 NONE metformin_3\NN\2719105|progression|,|ameliorated|that (r_nsubj) suppressed_4\VBD\2510337|We|. (l_conj) ameliorated_10\VBD\126264|metformin|progression|,|that (l_dobj) impairment_13\NN\7296428|and|decreased
D008687_D003072 NONE metformin_6\NN\2719105|that|may|agent (r_nsubj) be_8\VB\14625458|Thus|.|study (l_attr) agent_11\NN\7347|that|metformin|may (l_prep) for_12\IN\0|potential|a (l_pobj) treatment_14\NN\654885|NONE (l_conj) medicine_22\NN\6045562|the|of|as (l_prep) against_23\IN\0|induced|protective|a (l_pobj) impairment_25\NN\7296428|NONE
D010433_D008569 CID pentylenetetrazole_14\NN\0| (r_npadvmod) induced_16\VBN\1627355|in (r_amod) kindling_17\NN\15101361|NONE (r_pobj) by_13\IN\0|NONE (r_agent) induced_12\VBN\1627355|damage|and (r_acl) impairments_8\NNS\7296428|,|learning
D008687_D007859 NONE metformin_0\NNP\2719105|against|. (r_nsubj) protects_1\VBZ\1127795|NONE (l_prep) against_2\IN\0|Metformin|. (l_pobj) seizures_3\NNS\14081375|NONE (l_conj) impairments_8\NNS\7296428|,|learning
D010433_D007859 CID pentylenetetrazole_14\NN\0| (r_npadvmod) induced_16\VBN\1627355|in (r_amod) kindling_17\NN\15101361|NONE (r_pobj) by_13\IN\0|NONE (r_agent) induced_12\VBN\1627355|damage|and (r_acl) impairments_8\NNS\7296428|,|learning
D008687_D008569 NONE metformin_0\NNP\2719105|against|. (r_nsubj) protects_1\VBZ\1127795|NONE (l_prep) against_2\IN\0|Metformin|. (l_pobj) seizures_3\NNS\14081375|NONE (l_conj) impairments_8\NNS\7296428|,|learning
D010433_D012640 CID pentylenetetrazole_14\NN\0| (r_npadvmod) induced_16\VBN\1627355|in (r_amod) kindling_17\NN\15101361|NONE (r_pobj) by_13\IN\0|NONE (r_agent) induced_12\VBN\1627355|damage|and (r_acl) impairments_8\NNS\7296428|,|learning (r_conj) seizures_3\NNS\14081375|NONE
D010433_D012640 CID pentylenetetrazole_23\NN\0| (r_npadvmod) induced_25\VBN\1627355|kindling (r_amod) animals_27\NNS\4475|NONE (r_pobj) in_22\IN\13603305|NONE (r_prep) observed_21\VBN\2163746|ameliorative|on|of|the (r_acl) effects_8\NNS\13245626|to (l_prep) on_11\IN\0|ameliorative|observed|of|the (l_pobj) seizures_12\NNS\14081375|NONE
D008687_D004827 NONE metformin_6\NN\2719105|that|may|agent (r_nsubj) be_8\VB\14625458|Thus|.|study (l_attr) agent_11\NN\7347|that|metformin|may (l_prep) for_12\IN\0|potential|a (l_pobj) treatment_14\NN\654885|NONE (l_prep) of_15\IN\0|the|as|medicine (l_pobj) epilepsy_16\NN\14085708|NONE
25006369
D013390_D005207 CID succinylcholine_11\NN\3800001|NONE (r_compound) administration_12\NN\1133281|NONE (r_pobj) following_10\VBG\8180190|to|fasciculation (r_prep) decrease_6\VB\7296428|precurarizing|.|Optimal|of (l_dobj) fasciculation_7\NN\14361664|to|following
D013390_D005207 CID succinylcholine_0\NNP\3800001|commonly|.|effects (r_nsubj) produces_2\VBZ\7555863|NONE (l_dobj) effects_5\NNS\13245626|commonly|Succinylcholine|. (l_prep) including_7\VBG\0|adverse|,|frequent (l_pobj) fasciculation_9\NN\14361664|NONE
D013390_D005207 CID succinylcholine_11\NN\3800001| (r_npadvmod) induced_13\VBN\1627355|and|myalgia (r_amod) fasciculation_14\NN\14361664|to
D013390_D005207 CID succinylcholine_30\NN\3800001|NONE (r_pobj) by_29\IN\0|NONE (r_agent) produced_28\VBN\1617192|NONE (r_acl) onset_27\NN\7325190|NONE (r_pobj) of_26\IN\0|the (r_prep) speed_25\NN\15286249|NONE (r_pobj) on_23\IN\0|NONE (r_prep) rocuronium_22\NN\0|NONE (r_pobj) of_21\IN\0|the (r_prep) influence_20\NN\5190804|NONE (r_dobj) evaluated_18\VBD\670261|dose|.|study|and|prevent (r_conj) identified_3\VBD\699815|NONE (l_advcl) prevent_10\VB\0|evaluated|dose|.|study|and (l_dobj) fasciculation_14\NN\14361664|to
D013390_D005207 CID succinylcholine_3\NN\3800001|and|,|patients|.|assessed (r_dobj) received_2\VBD\2210855|NONE (l_conj) assessed_15\VBN\670261|and|,|patients|.|succinylcholine (l_dobj) incidence_17\NN\13821570|were|assessed|, (l_prep) of_20\IN\0|severity|the|and (l_pobj) fasciculations_21\NNS\14361664|NONE
D013390_D063806 CID succinylcholine_11\NN\3800001|NONE (r_compound) administration_12\NN\1133281|NONE (r_pobj) following_10\VBG\8180190|to|fasciculation (r_prep) decrease_6\VB\7296428|precurarizing|.|Optimal|of (l_dobj) fasciculation_7\NN\14361664|to|following (l_conj) myalgia_9\NN\14322699|and
D013390_D063806 CID succinylcholine_0\NNP\3800001|commonly|.|effects (r_nsubj) produces_2\VBZ\7555863|NONE (l_dobj) effects_5\NNS\13245626|commonly|Succinylcholine|. (l_prep) including_7\VBG\0|adverse|,|frequent (l_pobj) fasciculation_9\NN\14361664|NONE (l_conj) myalgia_11\NN\14322699|muscle|and
D013390_D063806 CID succinylcholine_11\NN\3800001| (r_npadvmod) induced_13\VBN\1627355|and|myalgia (r_amod) fasciculation_14\NN\14361664|to (l_conj) myalgia_16\NN\14322699|induced|and
D013390_D063806 CID succinylcholine_30\NN\3800001|NONE (r_pobj) by_29\IN\0|NONE (r_agent) produced_28\VBN\1617192|NONE (r_acl) onset_27\NN\7325190|NONE (r_pobj) of_26\IN\0|the (r_prep) speed_25\NN\15286249|NONE (r_pobj) on_23\IN\0|NONE (r_prep) rocuronium_22\NN\0|NONE (r_pobj) of_21\IN\0|the (r_prep) influence_20\NN\5190804|NONE (r_dobj) evaluated_18\VBD\670261|dose|.|study|and|prevent (r_conj) identified_3\VBD\699815|NONE (l_advcl) prevent_10\VB\0|evaluated|dose|.|study|and (l_dobj) fasciculation_14\NN\14361664|to (l_conj) myalgia_16\NN\14322699|induced|and
D013390_D063806 CID succinylcholine_3\NN\3800001|and|,|patients|.|assessed (r_dobj) received_2\VBD\2210855|NONE (l_conj) assessed_15\VBN\670261|and|,|patients|.|succinylcholine (l_advcl) assessed_26\VBN\670261|were|incidence|, (l_nsubjpass) myalgia_24\NN\14322699|was|at|while
C061870_D063806 NONE rocuronium_4\NN\0|NONE (r_pobj) of_3\IN\0|precurarizing|.|decrease|Optimal (r_prep) dose_2\NN\3740161|NONE (l_acl) decrease_6\VB\7296428|precurarizing|.|Optimal|of (l_dobj) fasciculation_7\NN\14361664|to|following (l_conj) myalgia_9\NN\14322699|and
C061870_D063806 NONE rocuronium_8\NN\0|NONE (r_pobj) of_7\IN\0|the|optimal (r_prep) dose_6\NN\3740161|evaluated|.|study|and|prevent (r_dobj) identified_3\VBD\699815|NONE (l_advcl) prevent_10\VB\0|evaluated|dose|.|study|and (l_dobj) fasciculation_14\NN\14361664|to (l_conj) myalgia_16\NN\14322699|induced|and
C061870_D063806 NONE rocuronium_22\NN\0|NONE (r_pobj) of_21\IN\0|the (r_prep) influence_20\NN\5190804|NONE (r_dobj) evaluated_18\VBD\670261|dose|.|study|and|prevent (r_conj) identified_3\VBD\699815|NONE (l_advcl) prevent_10\VB\0|evaluated|dose|.|study|and (l_dobj) fasciculation_14\NN\14361664|to (l_conj) myalgia_16\NN\14322699|induced|and
C061870_D063806 NONE rocuronium_15\NN\0|NONE (r_pobj) of_14\IN\0|NONE (r_prep) dose_13\NN\3740161|NONE (r_dobj) precurarizing_12\VBG\0|NONE (r_pcomp) of_11\IN\0|the (r_prep) amount_10\NN\13329641|NONE (r_dobj) increasing_8\VBG\169651|NONE (r_pcomp) to_7\IN\0|NONE (r_prep) according_6\VBG\2657219|to (r_prep) decrease_5\VB\7296428|but|Those|,|was (r_xcomp) tend_3\VBP\2604760|NONE (l_nsubj) those_0\DT\0|but|,|decrease|was (l_prep) of_1\IN\0|NONE (l_pobj) myalgia_2\NN\14322699|NONE
C061870_D063806 NONE rocuronium_4\NN\0|NONE (r_pobj) with_1\IN\0|NONE (r_prep) precurarization_0\NN\0|dose|and|.|precurarization|, (r_nsubj) was_5\VBD\0|NONE (l_attr) dose_8\NN\3740161|Precurarization|and|.|precurarization|, (l_acl) considering_9\VBG\689344|the|optimal (l_dobj) reduction_11\NN\351485|NONE (l_prep) in_12\IN\13603305|the (l_pobj) incidence_14\NN\13821570|NONE (l_prep) of_17\IN\0|the|and|severity (l_pobj) fasciculation_18\NN\14361664|NONE (l_conj) myalgia_20\NN\14322699|and
C061870_D005207 NONE rocuronium_4\NN\0|NONE (r_pobj) of_3\IN\0|precurarizing|.|decrease|Optimal (r_prep) dose_2\NN\3740161|NONE (l_acl) decrease_6\VB\7296428|precurarizing|.|Optimal|of (l_dobj) fasciculation_7\NN\14361664|to|following
C061870_D005207 NONE rocuronium_8\NN\0|NONE (r_pobj) of_7\IN\0|the|optimal (r_prep) dose_6\NN\3740161|evaluated|.|study|and|prevent (r_dobj) identified_3\VBD\699815|NONE (l_advcl) prevent_10\VB\0|evaluated|dose|.|study|and (l_dobj) fasciculation_14\NN\14361664|to
C061870_D005207 NONE rocuronium_22\NN\0|NONE (r_pobj) of_21\IN\0|the (r_prep) influence_20\NN\5190804|NONE (r_dobj) evaluated_18\VBD\670261|dose|.|study|and|prevent (r_conj) identified_3\VBD\699815|NONE (l_advcl) prevent_10\VB\0|evaluated|dose|.|study|and (l_dobj) fasciculation_14\NN\14361664|to
C061870_D005207 NONE rocuronium_19\NN\0|NONE (r_pobj) of_18\IN\0|NONE (r_prep) dose_17\NN\3740161|NONE (r_dobj) precurarizing_16\VBG\0|NONE (r_pcomp) of_15\IN\0|)|the|P|( (r_prep) amount_14\NN\13329641|NONE (r_dobj) increasing_12\VBG\169651|NONE (r_pcomp) with_11\IN\0|significantly (r_prep) less_10\JJR\14187378|.|incidence (r_acomp) was_8\VBD\0|NONE (l_nsubj) incidence_1\NN\13821570|.|less (l_prep) of_4\IN\0|The|severity|and (l_pobj) fasciculation_7\NN\14361664|NONE
C061870_D005207 NONE rocuronium_4\NN\0|NONE (r_pobj) with_1\IN\0|NONE (r_prep) precurarization_0\NN\0|dose|and|.|precurarization|, (r_nsubj) was_5\VBD\0|NONE (l_attr) dose_8\NN\3740161|Precurarization|and|.|precurarization|, (l_acl) considering_9\VBG\689344|the|optimal (l_dobj) reduction_11\NN\351485|NONE (l_prep) in_12\IN\13603305|the (l_pobj) incidence_14\NN\13821570|NONE (l_prep) of_17\IN\0|the|and|severity (l_pobj) fasciculation_18\NN\14361664|NONE
8188982
D009599_D007022 CID nitroprusside_42\NN\0|(|phenylephrine|hypertension|SN)induced (r_amod) hypotension_45\NN\14057371|NONE
D009599_D007022 CID sn)-induced_44\JJ\0|(|phenylephrine|hypertension|nitroprusside (r_amod) hypotension_45\NN\14057371|NONE
D009599_D007022 CID sn_13\NNP\14625458| (r_npadvmod) induced_15\VBN\1627355|NONE (r_amod) hypotension_16\NN\14057371|NONE
D001127_D006973 CID avp_4\NNP\0|NONE (r_pobj) of_3\IN\0|cardiovascular|Central|in|. (r_prep) effects_2\NNS\13245626|NONE (l_prep) in_7\IN\13603305|cardiovascular|Central|of|. (l_pobj) rats_12\NNS\2329401|NONE (l_amod) hypertensive_11\JJ\10405694|normotensive
D001127_D006973 CID vasopressin_13\NN\5407119|NONE (r_pobj) of_10\IN\0|NONE (r_prep) influence_9\NN\5190804|to|on|and|of|rats|and (r_dobj) compare_8\VB\4744814|purpose|. (l_conj) rats_51\NNS\2329401|to|on|influence|and|of|and (l_amod) hypertensive_47\JJ\10405694|SHR|(|)
D001127_D006973 CID avp_15\NNP\0|arginine|central|(|) (r_appos) vasopressin_13\NN\5407119|NONE (r_pobj) of_10\IN\0|NONE (r_prep) influence_9\NN\5190804|to|on|and|of|rats|and (r_dobj) compare_8\VB\4744814|purpose|. (l_conj) rats_51\NNS\2329401|to|on|influence|and|of|and (l_amod) hypertensive_47\JJ\10405694|SHR|(|)
D010656_D007022 NONE phenylephrine_36\NN\2682038|(|hypertension|nitroprusside|SN)induced (r_nmod) hypotension_45\NN\14057371|NONE
D010656_D007022 NONE phe)-induced_38\VBN\0|sodium|and|( (r_amod) hypertension_39\NN\14057371|(|phenylephrine|nitroprusside|SN)induced (r_nmod) hypotension_45\NN\14057371|NONE
D010656_D006973 CID phenylephrine_36\NN\2682038|(|hypertension|nitroprusside|SN)induced (r_nmod) hypotension_45\NN\14057371|NONE (l_nmod) hypertension_39\NN\14057371|(|phenylephrine|nitroprusside|SN)induced
D010656_D006973 CID phe)-induced_38\VBN\0|sodium|and|( (r_amod) hypertension_39\NN\14057371|(|phenylephrine|nitroprusside|SN)induced
D009599_D006973 NONE nitroprusside_42\NN\0|(|phenylephrine|hypertension|SN)induced (r_amod) hypotension_45\NN\14057371|NONE (l_nmod) hypertension_39\NN\14057371|(|phenylephrine|nitroprusside|SN)induced
D009599_D006973 NONE sn)-induced_44\JJ\0|(|phenylephrine|hypertension|nitroprusside (r_amod) hypotension_45\NN\14057371|NONE (l_nmod) hypertension_39\NN\14057371|(|phenylephrine|nitroprusside|SN)induced
D001127_D007022 NONE avp_11\NNP\0|NONE (r_pobj) of_10\IN\0|LV (r_prep) administration_9\NN\1133281|NONE (r_pobj) after_7\IN\0|CCB|was|in|during|. (r_prep) reduced_2\VBN\441445|NONE (l_prep) during_12\IN\0|CCB|was|in|after|. (l_pobj) hypotension_16\NN\14057371|NONE
23892921
C467567_D009101 NONE lenalidomide_12\NN\0|NONE (r_pobj) of_11\IN\0|the|safety|and (r_prep) efficacy_8\NN\5199286|NONE (r_pobj) on_6\IN\0|in|study|.|world|:|"|" (r_prep) data_5\NNS\7951464|NONE (l_prep) in_15\IN\13603305|study|.|world|:|"|on|" (l_pobj) patients_16\NNS\9898892|NONE (l_prep) with_17\IN\0|NONE (l_pobj) myeloma_22\NN\14239425|NONE
C467567_D009101 NONE lenalidomide_12\NN\0|NONE (r_pobj) of_11\IN\0|the|safety|and (r_prep) efficacy_8\NN\5199286|NONE (r_pobj) on_6\IN\0|in|study|.|world|:|"|" (r_prep) data_5\NNS\7951464|NONE (l_appos) study_34\NN\635850|in|.|world|:|"|on|" (l_prep) of_35\IN\0|a (l_pobj) group_40\NNP\2137|NONE (l_compound) myeloma_38\NNP\14239425|the|Greek|Study
C467567_D009101 NONE lenalidomide_0\NNP\0|is|,|standard|but (r_nsubj) is_6\VBZ\0|NONE (l_attr) standard_8\NN\13577171|is|Lenalidomide|,|but (l_prep) for_11\IN\0|of|a (l_pobj) myeloma_16\NN\14239425|NONE
C467567_D009101 NONE lenalidomide_0\NNP\0|is|,|standard|but (r_nsubj) is_6\VBZ\0|NONE (l_attr) standard_8\NN\13577171|is|Lenalidomide|,|but (l_prep) for_11\IN\0|of|a (l_pobj) myeloma_16\NN\14239425|NONE (l_appos) rrmm_18\NNP\0|multiple|refractory|relapsed
C467567_D009101 NONE rd_4\NNP\0|NONE (r_appos) dexamethasone_2\NN\2721538|and (r_conj) lenalidomide_0\NNP\0|is|,|standard|but (r_nsubj) is_6\VBZ\0|NONE (l_attr) standard_8\NN\13577171|is|Lenalidomide|,|but (l_prep) for_11\IN\0|of|a (l_pobj) myeloma_16\NN\14239425|NONE
C467567_D009101 NONE rd_4\NNP\0|NONE (r_appos) dexamethasone_2\NN\2721538|and (r_conj) lenalidomide_0\NNP\0|is|,|standard|but (r_nsubj) is_6\VBZ\0|NONE (l_attr) standard_8\NN\13577171|is|Lenalidomide|,|but (l_prep) for_11\IN\0|of|a (l_pobj) myeloma_16\NN\14239425|NONE (l_appos) rrmm_18\NNP\0|multiple|refractory|relapsed
C467567_D009101 NONE rd_7\NNP\0|who|in (r_dobj) received_6\VBD\2210855||RRMM (r_relcl) patients_4\NNS\9898892|We|. (l_compound) rrmm_3\NNP\0|received|
C467567_D009101 NONE rd_4\NNP\0|that|in|effective (r_nsubj) is_5\VBZ\0|study (l_acomp) effective_6\JJ\0|that|in|RD (l_conj) safe_8\JJ\4340750|and (l_prep) in_9\IN\13603305|NONE (l_pobj) rrmm_10\NNP\0|NONE
D003907_D009101 NONE dexamethasone_14\NN\2721538|and (r_conj) lenalidomide_12\NN\0|NONE (r_pobj) of_11\IN\0|the|safety|and (r_prep) efficacy_8\NN\5199286|NONE (r_pobj) on_6\IN\0|in|study|.|world|:|"|" (r_prep) data_5\NNS\7951464|NONE (l_prep) in_15\IN\13603305|study|.|world|:|"|on|" (l_pobj) patients_16\NNS\9898892|NONE (l_prep) with_17\IN\0|NONE (l_pobj) myeloma_22\NN\14239425|NONE
D003907_D009101 NONE dexamethasone_14\NN\2721538|and (r_conj) lenalidomide_12\NN\0|NONE (r_pobj) of_11\IN\0|the|safety|and (r_prep) efficacy_8\NN\5199286|NONE (r_pobj) on_6\IN\0|in|study|.|world|:|"|" (r_prep) data_5\NNS\7951464|NONE (l_appos) study_34\NN\635850|in|.|world|:|"|on|" (l_prep) of_35\IN\0|a (l_pobj) group_40\NNP\2137|NONE (l_compound) myeloma_38\NNP\14239425|the|Greek|Study
D003907_D009101 NONE dexamethasone_2\NN\2721538|and (r_conj) lenalidomide_0\NNP\0|is|,|standard|but (r_nsubj) is_6\VBZ\0|NONE (l_attr) standard_8\NN\13577171|is|Lenalidomide|,|but (l_prep) for_11\IN\0|of|a (l_pobj) myeloma_16\NN\14239425|NONE
D003907_D009101 NONE dexamethasone_2\NN\2721538|and (r_conj) lenalidomide_0\NNP\0|is|,|standard|but (r_nsubj) is_6\VBZ\0|NONE (l_attr) standard_8\NN\13577171|is|Lenalidomide|,|but (l_prep) for_11\IN\0|of|a (l_pobj) myeloma_16\NN\14239425|NONE (l_appos) rrmm_18\NNP\0|multiple|refractory|relapsed
D003907_D009101 NONE rd_4\NNP\0|NONE (r_appos) dexamethasone_2\NN\2721538|and (r_conj) lenalidomide_0\NNP\0|is|,|standard|but (r_nsubj) is_6\VBZ\0|NONE (l_attr) standard_8\NN\13577171|is|Lenalidomide|,|but (l_prep) for_11\IN\0|of|a (l_pobj) myeloma_16\NN\14239425|NONE
D003907_D009101 NONE rd_4\NNP\0|NONE (r_appos) dexamethasone_2\NN\2721538|and (r_conj) lenalidomide_0\NNP\0|is|,|standard|but (r_nsubj) is_6\VBZ\0|NONE (l_attr) standard_8\NN\13577171|is|Lenalidomide|,|but (l_prep) for_11\IN\0|of|a (l_pobj) myeloma_16\NN\14239425|NONE (l_appos) rrmm_18\NNP\0|multiple|refractory|relapsed
D003907_D009101 NONE rd_7\NNP\0|who|in (r_dobj) received_6\VBD\2210855||RRMM (r_relcl) patients_4\NNS\9898892|We|. (l_compound) rrmm_3\NNP\0|received|
D003907_D009101 NONE rd_4\NNP\0|that|in|effective (r_nsubj) is_5\VBZ\0|study (l_acomp) effective_6\JJ\0|that|in|RD (l_conj) safe_8\JJ\4340750|and (l_prep) in_9\IN\13603305|NONE (l_pobj) rrmm_10\NNP\0|NONE
12359538
D003042_D009336 NONE cocaine_19\NN\3492717| (r_npadvmod) associated_21\VBN\628491|chest|MI|and (r_amod) pain_23\NN\14299637|NONE (r_pobj) with_18\IN\0|NONE (r_prep) patients_17\NNS\9898892|NONE (r_pobj) in_16\IN\13603305|NONE (r_prep) necrosis_15\NN\11444117|NONE
D003042_D002637 NONE cocaine_7\NN\3492717| (r_npadvmod) associated_9\VBN\628491|chest (r_amod) pain_11\NN\14299637|NONE
D003042_D002637 NONE cocaine_24\NN\3492717| (r_npadvmod) associated_26\VBN\628491|chest (r_amod) pain_28\NN\14299637|NONE
D003042_D002637 NONE cocaine_10\NN\3492717|NONE (r_compound) chest_11\NN\5220461|NONE (r_compound) pain_12\NN\14299637|NONE
D003042_D002637 NONE cocaine_19\NN\3492717| (r_npadvmod) associated_21\VBN\628491|chest|MI|and (r_amod) pain_23\NN\14299637|NONE
D003042_D009203 CID cocaine_24\NN\3492717| (r_npadvmod) associated_26\VBN\628491|chest (r_amod) pain_28\NN\14299637|NONE (r_pobj) with_23\IN\0|NONE (r_prep) patients_22\NNS\9898892|NONE (r_pobj) in_21\IN\13603305|NONE (r_prep) difficult_20\JJ\0|.|abnormalities|diagnosis (r_ccomp) make_11\VBP\5839024|NONE (l_dobj) diagnosis_13\NN\152018|.|difficult|abnormalities (l_prep) of_14\IN\0|accurate (l_pobj) infarction_16\NN\14204950|NONE
D003042_D009203 CID cocaine_24\NN\3492717| (r_npadvmod) associated_26\VBN\628491|chest (r_amod) pain_28\NN\14299637|NONE (r_pobj) with_23\IN\0|NONE (r_prep) patients_22\NNS\9898892|NONE (r_pobj) in_21\IN\13603305|NONE (r_prep) difficult_20\JJ\0|.|abnormalities|diagnosis (r_ccomp) make_11\VBP\5839024|NONE (l_dobj) diagnosis_13\NN\152018|.|difficult|abnormalities (l_prep) of_14\IN\0|accurate (l_pobj) infarction_16\NN\14204950|NONE (l_appos) mi_18\NNP\14207561|)|myocardial|(
D003042_D009203 CID cocaine_10\NN\3492717|NONE (r_compound) chest_11\NN\5220461|NONE (r_compound) pain_12\NN\14299637|NONE (r_pobj) with_9\IN\0|NONE (r_prep) patients_8\NNS\9898892|NONE (r_pobj) in_7\IN\13603305|admitted|troponin (r_prep) positivity_6\NN\13856574|NONE (l_acl) admitted_13\VBD\822367|in|troponin (l_prep) for_14\IN\0|NONE (l_pobj) exclusion_15\NN\13927383|NONE (l_prep) of_16\IN\0|NONE (l_pobj) mi_17\NNP\14207561|NONE
D003042_D009203 CID cocaine_10\NN\3492717|NONE (r_compound) use_11\NN\407535|NONE (r_pobj) after_9\IN\0|for (r_prep) admitted_5\VBN\822367|NONE (l_prep) for_6\IN\0|after (l_pobj) mi_8\NNP\14207561|NONE
D003042_D009203 CID cocaine_19\NN\3492717| (r_npadvmod) associated_21\VBN\628491|chest|MI|and (r_amod) pain_23\NN\14299637|NONE (l_conj) mi_26\NNP\14207561|chest|associated|and
D003042_D009202 NONE cocaine_24\NN\3492717| (r_npadvmod) associated_26\VBN\628491|chest (r_amod) pain_28\NN\14299637|NONE (r_pobj) with_23\IN\0|NONE (r_prep) patients_22\NNS\9898892|NONE (r_pobj) in_21\IN\13603305|NONE (r_prep) difficult_20\JJ\0|.|abnormalities|diagnosis (r_ccomp) make_11\VBP\5839024|NONE (l_nsubj) abnormalities_2\NNS\14034177|.|difficult|diagnosis (l_acl) associated_7\VBN\628491|and|elevations|electrocardiogram|Baseline (l_prep) with_8\IN\0|not (l_pobj) necrosis_10\NN\11444117|NONE
25080425
D001622_D017202 NONE betaine_11\NN\14712692|NONE (r_pobj) of_10\IN\0|induced|cardioprotective|the|on (r_prep) effects_9\NNS\13245626|to (l_prep) on_12\IN\0|induced|of|cardioprotective|the (l_pobj) ischemia_15\NN\14195315|NONE
D001622_D017202 NONE betaine_7\NN\14712692|NONE (r_compound) pretreatment_8\NN\0|NONE (r_nsubj) attenuated_9\VBD\224901|induced|that|myocardial|via|acute (r_amod) ischemia_15\NN\14195315|,|results|.|In
D001622_D020257 NONE betaine_3\NN\14712692|NONE (r_pobj) of_2\IN\0|mg/kg|Oral (r_prep) administration_1\NN\1133281|and|significantly|.|level|prevented (r_nsubj) reduced_11\VBD\441445|NONE (l_conj) prevented_22\VBN\0|and|significantly|administration|.|level (l_dobj) remodeling_25\NN\126264|NONE
D007545_D009202 NONE isoproterenol_15\NN\3740161| (r_npadvmod) induced_17\VBN\1627355|acute|myocardial|in (r_amod) injury_20\NN\14052046|Regulation|.
D001622_D009202 NONE betaine_13\NN\14712692|NONE (r_pobj) by_12\IN\0|of (r_prep) regulation_0\NN\6652242|.|injury (r_nsubj) attenuates_14\VBZ\224901|NONE (l_dobj) injury_20\NN\14052046|Regulation|.
D001622_D009202 NONE betaine_4\NN\14712692|NONE (l_prep) on_5\IN\0|NONE (l_pobj) damage_7\NN\7296428|NONE
D007545_D017202 CID isoproterenol_12\NN\3740161|NONE (r_pobj) of_11\IN\0|(|mg/kg|subcutaneous|) (r_prep) injection_10\NN\320852|NONE (r_pobj) by_8\IN\0|in|was|.|injury|for|, (r_agent) induced_5\VBN\1627355|NONE (l_nsubjpass) injury_3\NN\14052046|in|was|.|for|by|,
D007545_D017202 CID isoproterenol_10\NN\3740161| (r_npadvmod) induced_12\VBN\1627355|that|myocardial|via|attenuated|acute (r_amod) ischemia_15\NN\14195315|,|results|.|In
15614572
D006220_D009062 NONE haloperidol_19\NN\3713736|NONE (r_pobj) by_18\IN\0|NONE (r_agent) induced_17\VBN\1627355|NONE (r_acl) catalepsy_16\NN\14023236|NONE (r_pobj) on_15\IN\0|was|.|,|on|effect|,|in (r_prep) studied_47\VBN\0|NONE (l_nsubjpass) effect_1\NN\34213|was|.|on|,|on|,|in (l_prep) of_2\IN\0|The (l_pobj) pretreatment_3\NN\0|NONE (l_prep) on_6\IN\0|with (l_pobj) stereotypies_13\NNS\0|NONE
D001058_D002375 CID apomorphine_9\NN\3786417|and (r_conj) dexamphetamine-_7\FW\0| (r_npadvmod) induced_11\VBN\1627355|oral (r_amod) stereotypies_13\NNS\0|NONE (r_pobj) on_6\IN\0|with (r_prep) pretreatment_3\NN\0|NONE (r_pobj) of_2\IN\0|The (r_prep) effect_1\NN\34213|was|.|on|,|on|,|in (r_nsubjpass) studied_47\VBN\0|NONE (l_prep) on_15\IN\0|was|.|,|on|effect|,|in (l_pobj) catalepsy_16\NN\14023236|NONE
D001058_D002375 CID apomorphine_21\NN\3786417|and|mg/kg (r_conj) haloperidol_19\NN\3713736|NONE (r_pobj) by_18\IN\0|NONE (r_agent) induced_17\VBN\1627355|NONE (r_acl) catalepsy_16\NN\14023236|NONE
D001058_D002375 CID apomorphine_16\NN\3786417|not|did|catalepsy (r_dobj) antagonize_15\VB\1787955|Trazodone|did|catalepsy|not|,|.|and (r_conj) induce_9\VB\1627355|NONE (l_dobj) catalepsy_10\NN\14023236|Trazodone|did|not|,|.|antagonize|and
D001058_D002375 CID apomorphine_16\NN\3786417|not|did|catalepsy (r_dobj) antagonize_15\VB\1787955|Trazodone|did|catalepsy|not|,|.|and (l_dobj) catalepsy_31\NN\14023236|not|did|apomorphine
D001058_D002375 CID apomorphine_25\NN\3786417|and|)|mg/kg|( (r_conj) stereotypy_23\NN\0|kg)induced (r_nmod) catalepsy_31\NN\14023236|not|did|apomorphine (r_dobj) antagonize_15\VB\1787955|Trazodone|did|catalepsy|not|,|.|and (r_conj) induce_9\VB\1627355|NONE (l_dobj) catalepsy_10\NN\14023236|Trazodone|did|not|,|.|antagonize|and
D001058_D002375 CID apomorphine_25\NN\3786417|and|)|mg/kg|( (r_conj) stereotypy_23\NN\0|kg)induced (r_nmod) catalepsy_31\NN\14023236|not|did|apomorphine
D001058_D002375 CID apomorphine_13\NN\3786417|NONE (r_dobj) antagonized_12\VBN\1787955|i.p.|,|Trazodone|mg/kg|catalepsy|and|. (r_conj) induced_9\VBN\1627355|NONE (l_dobj) catalepsy_10\NN\14023236|i.p.|,|Trazodone|mg/kg|and|.|antagonized
D001058_D009062 NONE apomorphine_9\NN\3786417|and (r_conj) dexamphetamine-_7\FW\0| (r_npadvmod) induced_11\VBN\1627355|oral (r_amod) stereotypies_13\NNS\0|NONE
D001058_D009062 NONE apomorphine_21\NN\3786417|and|mg/kg (r_conj) haloperidol_19\NN\3713736|NONE (r_pobj) by_18\IN\0|NONE (r_agent) induced_17\VBN\1627355|NONE (r_acl) catalepsy_16\NN\14023236|NONE (r_pobj) on_15\IN\0|was|.|,|on|effect|,|in (r_prep) studied_47\VBN\0|NONE (l_nsubjpass) effect_1\NN\34213|was|.|on|,|on|,|in (l_prep) of_2\IN\0|The (l_pobj) pretreatment_3\NN\0|NONE (l_prep) on_6\IN\0|with (l_pobj) stereotypies_13\NNS\0|NONE
D014196_D002375 NONE trazodone_5\NN\3829085|NONE (r_pobj) with_4\IN\0|on (r_prep) pretreatment_3\NN\0|NONE (r_pobj) of_2\IN\0|The (r_prep) effect_1\NN\34213|was|.|on|,|on|,|in (r_nsubjpass) studied_47\VBN\0|NONE (l_prep) on_15\IN\0|was|.|,|on|effect|,|in (l_pobj) catalepsy_16\NN\14023236|NONE
D014196_D002375 NONE trazodone_4\NN\3829085|catalepsy|in|whether (r_nsubj) induces_5\VBZ\1627355|We|.|also (l_dobj) catalepsy_6\NN\14023236|in|trazodone|whether
D014196_D002375 NONE trazodone_0\NNP\3829085|did|catalepsy|not|,|.|antagonize|and (r_nsubj) induce_9\VB\1627355|NONE (l_dobj) catalepsy_10\NN\14023236|Trazodone|did|not|,|.|antagonize|and
D014196_D002375 NONE trazodone_0\NNP\3829085|did|catalepsy|not|,|.|antagonize|and (r_nsubj) induce_9\VB\1627355|NONE (l_conj) antagonize_15\VB\1787955|Trazodone|did|catalepsy|not|,|.|and (l_dobj) catalepsy_31\NN\14023236|not|did|apomorphine
D014196_D002375 NONE trazodone_11\NNP\3829085|dexamphetamine|i.p.|enhanced|, (r_nmod) stereotypy_14\NN\0| (r_pobj) with_3\IN\0|However|,|and|antagonized|,|. (r_prep) pretreatment_2\NN\0|NONE (l_conj) antagonized_17\VBD\1787955|However|,|and|with|,|. (l_dobj) catalepsy_19\NN\14023236|NONE
D014196_D002375 NONE trazodone_0\NNP\3829085|i.p.|,|mg/kg|catalepsy|and|.|antagonized (r_nsubj) induced_9\VBN\1627355|NONE (l_dobj) catalepsy_10\NN\14023236|i.p.|,|Trazodone|mg/kg|and|.|antagonized
D014196_D002375 NONE trazodone_3\NNP\3829085|that|neurons|,|and|potentiates|, (r_nsubj) releases_20\VBZ\3748886|We|. (l_conj) potentiates_34\VBZ\229605|trazodone|that|neurons|,|and|, (l_conj) antagonizes_38\VBZ\1787955|stereotypy|thereby|and (l_dobj) catalepsy_40\NN\14023236|NONE
D014196_D009062 NONE trazodone_5\NN\3829085|NONE (r_pobj) with_4\IN\0|on (r_prep) pretreatment_3\NN\0|NONE (l_prep) on_6\IN\0|with (l_pobj) stereotypies_13\NNS\0|NONE
D012701_D002375 NONE 5-ht_16\CD\0|NONE (r_compound) 2c_17\NNP\0|the (r_compound) receptors_18\NNS\5225602|NONE (r_dobj) blocking_14\VBG\562280|NONE (r_pcomp) by_13\IN\0|mg/kg|, (r_prep) trazodone_3\NNP\3829085|that|neurons|,|and|potentiates|, (r_nsubj) releases_20\VBZ\3748886|We|. (l_conj) potentiates_34\VBZ\229605|trazodone|that|neurons|,|and|, (l_conj) antagonizes_38\VBZ\1787955|stereotypy|thereby|and (l_dobj) catalepsy_40\NN\14023236|NONE
D012701_D002375 NONE 5-ht_30\CD\0|NONE (r_pobj) by_29\IN\0|NONE (r_agent) caused_28\VBN\1617192|tonic (r_acl) inhibition_27\NN\1068773|NONE (r_pobj) from_25\IN\0|nigrostriatal|DAergic|the (r_prep) neurons_24\NNS\5430628|trazodone|that|,|and|potentiates|, (r_dobj) releases_20\VBZ\3748886|We|. (l_conj) potentiates_34\VBZ\229605|trazodone|that|neurons|,|and|, (l_conj) antagonizes_38\VBZ\1787955|stereotypy|thereby|and (l_dobj) catalepsy_40\NN\14023236|NONE
D003913_D009062 NONE dexamphetamine-_7\FW\0| (r_npadvmod) induced_11\VBN\1627355|oral (r_amod) stereotypies_13\NNS\0|NONE
D006220_D002375 CID haloperidol_19\NN\3713736|NONE (r_pobj) by_18\IN\0|NONE (r_agent) induced_17\VBN\1627355|NONE (r_acl) catalepsy_16\NN\14023236|NONE
D006220_D002375 CID haloperidol_18\NN\3713736|behavior|, (r_det) catalepsy_19\NN\14023236|NONE
D006220_D002375 CID haloperidol_39\NN\3713736|NONE (r_det) catalepsy_40\NN\14023236|NONE
D004874_D002375 NONE ergometrine_30\NN\0| (r_advmod) induced_32\VBN\1627355|(|)|erections|and|shake|WDS (r_amod) behavior_39\NN\407535|NONE (r_pobj) on_29\IN\0|was|.|on|,|effect|,|in (r_prep) studied_47\VBN\0|NONE (l_prep) on_15\IN\0|was|.|,|on|effect|,|in (l_pobj) catalepsy_16\NN\14023236|NONE
D004874_D002375 NONE ergometrine_21\NN\0| (r_advmod) induced_23\VBN\1627355|erections|and|WDS (r_amod) behavior_25\NN\407535|haloperidol|, (r_conj) catalepsy_19\NN\14023236|NONE
D003913_D002375 NONE dexamphetamine-_7\FW\0| (r_npadvmod) induced_11\VBN\1627355|oral (r_amod) stereotypies_13\NNS\0|NONE (r_pobj) on_6\IN\0|with (r_prep) pretreatment_3\NN\0|NONE (r_pobj) of_2\IN\0|The (r_prep) effect_1\NN\34213|was|.|on|,|on|,|in (r_nsubjpass) studied_47\VBN\0|NONE (l_prep) on_15\IN\0|was|.|,|on|effect|,|in (l_pobj) catalepsy_16\NN\14023236|NONE
D003913_D002375 NONE dexamphetamine_13\NN\0|trazodone|i.p.|enhanced|, (r_compound) stereotypy_14\NN\0| (r_pobj) with_3\IN\0|However|,|and|antagonized|,|. (r_prep) pretreatment_2\NN\0|NONE (l_conj) antagonized_17\VBD\1787955|However|,|and|with|,|. (l_dobj) catalepsy_19\NN\14023236|NONE
D003913_D002375 NONE dexamphetamine_15\NN\0|NONE (r_compound) stereotypies_16\NNS\0|and (r_conj) apomorphine_13\NN\3786417|NONE (r_dobj) antagonized_12\VBN\1787955|i.p.|,|Trazodone|mg/kg|catalepsy|and|. (r_conj) induced_9\VBN\1627355|NONE (l_dobj) catalepsy_10\NN\14023236|i.p.|,|Trazodone|mg/kg|and|.|antagonized
D003913_D002375 NONE dexamphetamine_35\NN\0|NONE (r_compound) stereotypy_36\NN\0|thereby|antagonizes|and (r_dobj) potentiates_34\VBZ\229605|trazodone|that|neurons|,|and|, (l_conj) antagonizes_38\VBZ\1787955|stereotypy|thereby|and (l_dobj) catalepsy_40\NN\14023236|NONE
D004874_D009062 NONE ergometrine_30\NN\0| (r_advmod) induced_32\VBN\1627355|(|)|erections|and|shake|WDS (r_amod) behavior_39\NN\407535|NONE (r_pobj) on_29\IN\0|was|.|on|,|effect|,|in (r_prep) studied_47\VBN\0|NONE (l_nsubjpass) effect_1\NN\34213|was|.|on|,|on|,|in (l_prep) of_2\IN\0|The (l_pobj) pretreatment_3\NN\0|NONE (l_prep) on_6\IN\0|with (l_pobj) stereotypies_13\NNS\0|NONE
D005473_D009062 NONE fluoxetine_41\NN\4169152| (r_advmod) induced_43\VBN\1627355|penile (r_amod) erections_45\NNS\14037619|(|)|induced|and|shake|WDS (r_conj) behavior_39\NN\407535|NONE (r_pobj) on_29\IN\0|was|.|on|,|effect|,|in (r_prep) studied_47\VBN\0|NONE (l_nsubjpass) effect_1\NN\34213|was|.|on|,|on|,|in (l_prep) of_2\IN\0|The (l_pobj) pretreatment_3\NN\0|NONE (l_prep) on_6\IN\0|with (l_pobj) stereotypies_13\NNS\0|NONE
D005473_D002375 NONE fluoxetine_41\NN\4169152| (r_advmod) induced_43\VBN\1627355|penile (r_amod) erections_45\NNS\14037619|(|)|induced|and|shake|WDS (r_conj) behavior_39\NN\407535|NONE (r_pobj) on_29\IN\0|was|.|on|,|effect|,|in (r_prep) studied_47\VBN\0|NONE (l_prep) on_15\IN\0|was|.|,|on|effect|,|in (l_pobj) catalepsy_16\NN\14023236|NONE
D005473_D002375 NONE fluoxetine_27\NN\4169152| (r_advmod) induced_29\VBN\1627355|penile (r_amod) erections_31\NNS\14037619|and|induced|WDS (r_conj) behavior_25\NN\407535|haloperidol|, (r_conj) catalepsy_19\NN\14023236|NONE
11425091
D003042_D006470 NONE cocaine_1\NN\3492717|NONE (r_compound) exposure_2\NN\5042871|has|with|been|. (r_nsubjpass) linked_5\VBN\628491|NONE (l_prep) with_6\IN\0|has|exposure|been|. (l_pobj) hemorrhage_8\NN\14285662|NONE
D003042_D019970 NONE cocaine_5\NN\3492717| (r_npadvmod) exposed_7\VBN\2110927|the (r_amod) group_8\NN\2137|NONE (r_pobj) to_3\IN\0|was|.|were|Infants (r_prep) assigned_2\VBN\2475922|NONE (l_advcl) was_11\VBD\0|.|were|to|Infants (l_attr) history_14\NN\15120823|if|there|were (l_prep) of_15\IN\0|a|or|maternal (l_pobj) abuse_17\NN\418025|NONE
D003042_D003560 CID cocaine_1\NN\3492717|NONE (r_compound) exposure_2\NN\5042871|has|with|been|. (r_nsubjpass) linked_5\VBN\628491|NONE (l_prep) with_6\IN\0|has|exposure|been|. (l_pobj) hemorrhage_8\NN\14285662|NONE (l_conj) formation_11\NN\7938773|subependymal|and (l_prep) of_12\IN\0|are|the (l_pobj) cysts_13\NNS\14204950|NONE
D003042_D003560 CID cocaine_6\NN\3492717|NONE (r_compound) exposure_7\NN\5042871|if|incidence (r_nsubj) increases_8\VBZ\13576355|to (l_dobj) incidence_10\NN\13821570|exposure|if (l_prep) of_11\IN\0|the (l_pobj) cysts_13\NNS\14204950|NONE
D003042_D003560 CID cocaine_9\NN\3492717|NONE (r_pobj) to_8\IN\0|prenatally (r_prep) exposed_7\VBN\2110927|NONE (r_acl) infants_6\NNS\9918248|NONE (r_pobj) in_5\IN\13603305|subependymal (r_prep) cysts_4\NNS\14204950|NONE
D003042_D003560 CID cocaine_16\NN\3492717|NONE (r_pobj) to_15\IN\0|who|were (r_prep) exposed_14\VBN\2110927|preterm (r_relcl) infants_11\NNS\9918248|NONE (r_pobj) in_9\IN\13603305|subependymal|cyst (r_prep) formation_8\NN\7938773|NONE (l_compound) cyst_7\NN\14204950|subependymal|in
D003042_D007235 CID cocaine_1\NN\3492717|.|in|findings|and (r_compound) exposure_2\NN\5042871|NONE (l_prep) in_7\IN\13603305|.|findings|cocaine|and (l_pobj) infants_9\NNS\9918248|NONE
D003042_D007235 CID cocaine_6\NN\3492717|NONE (r_compound) exposure_7\NN\5042871|if|incidence (r_nsubj) increases_8\VBZ\13576355|to (l_dobj) incidence_10\NN\13821570|exposure|if (l_prep) of_11\IN\0|the (l_pobj) cysts_13\NNS\14204950|NONE (l_prep) in_14\IN\13603305|subependymal (l_pobj) infants_16\NNS\9918248|NONE
D003042_D007235 CID cocaine_16\NN\3492717|NONE (r_pobj) to_15\IN\0|who|were (r_prep) exposed_14\VBN\2110927|preterm (r_relcl) infants_11\NNS\9918248|NONE
D003042_D001927 CID cocaine_6\NN\3492717|NONE (r_compound) exposure_7\NN\5042871|if|incidence (r_nsubj) increases_8\VBZ\13576355|to (l_dobj) incidence_10\NN\13821570|exposure|if (l_prep) of_11\IN\0|the (l_pobj) cysts_13\NNS\14204950|NONE
D003042_D001927 CID cocaine_9\NN\3492717|NONE (r_pobj) to_8\IN\0|prenatally (r_prep) exposed_7\VBN\2110927|NONE (r_acl) infants_6\NNS\9918248|NONE (r_pobj) in_5\IN\13603305|subependymal (r_prep) cysts_4\NNS\14204950|NONE
D003042_D001927 CID cocaine_16\NN\3492717|NONE (r_pobj) to_15\IN\0|who|were (r_prep) exposed_14\VBN\2110927|preterm (r_relcl) infants_11\NNS\9918248|NONE (r_pobj) in_9\IN\13603305|subependymal|cyst (r_prep) formation_8\NN\7938773|NONE (l_compound) cyst_7\NN\14204950|subependymal|in
17954033
D019259_D006509 NONE lamivudine_20\NN\3834836| (r_npadvmod) untreated_22\VBN\0|B|chronic (r_amod) patients_26\NNS\9898892|NONE (r_pobj) in_19\IN\13603305|natural|genome (r_prep) variability_18\NN\4733640|NONE (r_pobj) as_15\IN\14622893|that|mutants (r_prep) occur_14\VBP\0|.|studies (l_nsubj) mutants_7\NNS\4475|that|as (l_appos) virus_12\NN\9312843|(|)|the|motif (l_compound) b_11\NNP\1355326|resistant
D019259_D019694 NONE lamivudine_6\NN\3834836| (r_npadvmod) untreated_8\VBN\0|with|Iranian (r_amod) patients_10\NNS\9898892|NONE (l_prep) with_11\IN\0|untreated|Iranian (l_pobj) infection_16\NN\14052046|NONE
D019259_D019694 NONE lamivudine_0\NNP\3834836|for|is|. (r_nsubjpass) used_2\VBN\0|NONE (l_prep) for_3\IN\0|is|Lamivudine|. (l_pobj) treatment_5\NN\654885|NONE (l_prep) of_6\IN\0|the (l_pobj) patients_10\NNS\9898892|NONE (l_compound) b_9\NNP\1355326|chronic
D019259_D019694 NONE lamivudine_20\NN\3834836| (r_npadvmod) untreated_22\VBN\0|B|chronic (r_amod) patients_26\NNS\9898892|NONE (l_compound) b_25\NNP\1355326|chronic|untreated
D019259_D019694 NONE lamivudine_14\NN\3834836| (r_npadvmod) untreated_16\VBN\0|chronic|in|B (r_amod) patients_20\NNS\9898892|NONE (l_compound) b_19\NNP\1355326|chronic|untreated|in
D019259_D019694 NONE lamivudine_14\NN\3834836|NONE (r_pobj) with_13\IN\0|who|had|not|been (r_prep) treated_12\VBN\2376958|chronic||B (r_relcl) patients_7\NNS\9898892|NONE (l_compound) b_6\NNP\1355326|chronic|treated|
D019259_D019694 NONE lamivudine_9\NN\3834836| (r_npadvmod) untreated_11\VBN\0|with (r_amod) patients_12\NNS\9898892|NONE (l_prep) with_13\IN\0|untreated (l_pobj) b_16\NNP\1355326|NONE
D019259_D019694 NONE lamivudine_9\NN\3834836| (r_npadvmod) untreated_11\VBN\0|with (r_amod) patients_12\NNS\9898892|NONE (r_pobj) in_8\IN\13603305|YMDD|motif (r_prep) mutants_7\NNS\4475|NONE (r_pobj) of_4\IN\0|natural|the (r_prep) occurrence_3\NN\29378|been|Although|has (r_nsubjpass) reported_19\VBN\831651|not|were|mutants|in|,|. (r_advcl) detected_25\VBN\2163746|NONE (l_prep) in_26\IN\13603305|not|reported|were|mutants|,|. (l_pobj) patients_34\NNS\9898892|NONE (l_compound) b_33\NNP\1355326|Iranian|untreated|chronic
D019259_D019694 NONE lamivudine_28\NN\3834836| (r_npadvmod) untreated_30\VBN\0|B|Iranian|chronic (r_amod) patients_34\NNS\9898892|NONE (r_pobj) in_26\IN\13603305|not|reported|were|mutants|,|. (r_prep) detected_25\VBN\2163746|NONE (l_advcl) reported_19\VBN\831651|not|were|mutants|in|,|. (l_nsubjpass) occurrence_3\NN\29378|been|Although|has (l_prep) of_4\IN\0|natural|the (l_pobj) mutants_7\NNS\4475|NONE (l_prep) in_8\IN\13603305|YMDD|motif (l_pobj) patients_12\NNS\9898892|NONE (l_prep) with_13\IN\0|untreated (l_pobj) b_16\NNP\1355326|NONE
D019259_D019694 NONE lamivudine_28\NN\3834836| (r_npadvmod) untreated_30\VBN\0|B|Iranian|chronic (r_amod) patients_34\NNS\9898892|NONE (l_compound) b_33\NNP\1355326|Iranian|untreated|chronic
2484903
D008713_D047508 CID methimazole_13\NN\0| (r_npadvmod) associated_15\VBN\628491|hepatocellular|fatal (r_amod) necrosis_17\NN\11444117|NONE
D008713_D056486 NONE methimazole_13\NN\0| (r_npadvmod) associated_15\VBN\628491|hepatocellular|fatal (r_amod) necrosis_17\NN\11444117|NONE (r_pobj) of_11\IN\0|one|case|and (r_prep) case_10\NN\7283608|of|,|Two (r_appos) cases_1\NNS\7283608|.|are (l_prep) of_2\IN\0|case|,|Two (l_pobj) hepatitis_7\NN\14127211|NONE
D011441_D047508 NONE propylthiouracil_3\NN\14727670| (r_npadvmod) associated_5\VBN\628491|acute (r_amod) hepatitis_7\NN\14127211|NONE (r_pobj) of_2\IN\0|case|,|Two (r_prep) cases_1\NNS\7283608|.|are (l_appos) case_10\NN\7283608|of|,|Two (l_prep) of_11\IN\0|one|case|and (l_pobj) necrosis_17\NN\11444117|NONE
D011441_D047508 NONE propylthiouracil_22\NN\14727670| (r_npadvmod) associated_24\VBN\628491|like (r_amod) syndrome_28\NN\5870365|NONE (r_pobj) of_21\IN\0|one (r_prep) case_20\NN\7283608|one|of|and (r_conj) case_10\NN\7283608|of|,|Two (l_prep) of_11\IN\0|one|case|and (l_pobj) necrosis_17\NN\11444117|NONE
D011441_D056486 CID propylthiouracil_3\NN\14727670| (r_npadvmod) associated_5\VBN\628491|acute (r_amod) hepatitis_7\NN\14127211|NONE
D011441_D056486 CID propylthiouracil_22\NN\14727670| (r_npadvmod) associated_24\VBN\628491|like (r_amod) syndrome_28\NN\5870365|NONE (r_pobj) of_21\IN\0|one (r_prep) case_20\NN\7283608|one|of|and (r_conj) case_10\NN\7283608|of|,|Two (r_appos) cases_1\NNS\7283608|.|are (l_prep) of_2\IN\0|case|,|Two (l_pobj) hepatitis_7\NN\14127211|NONE
D011441_D008180 CID propylthiouracil_3\NN\14727670| (r_npadvmod) associated_5\VBN\628491|acute (r_amod) hepatitis_7\NN\14127211|NONE (r_pobj) of_2\IN\0|case|,|Two (r_prep) cases_1\NNS\7283608|.|are (l_appos) case_10\NN\7283608|of|,|Two (l_conj) case_20\NN\7283608|one|of|and (l_prep) of_21\IN\0|one (l_pobj) syndrome_28\NN\5870365|NONE
D011441_D008180 CID propylthiouracil_22\NN\14727670| (r_npadvmod) associated_24\VBN\628491|like (r_amod) syndrome_28\NN\5870365|NONE
D008713_D008180 NONE methimazole_13\NN\0| (r_npadvmod) associated_15\VBN\628491|hepatocellular|fatal (r_amod) necrosis_17\NN\11444117|NONE (r_pobj) of_11\IN\0|one|case|and (r_prep) case_10\NN\7283608|of|,|Two (l_conj) case_20\NN\7283608|one|of|and (l_prep) of_21\IN\0|one (l_pobj) syndrome_28\NN\5870365|NONE
17484470
D011433_D008944 NONE propranolol_6\NN\0|NONE (r_pobj) by_5\IN\0|failure|was (r_agent) induced_4\VBN\1627355|;|absence|was|by|. (r_ccomp) confirmed_21\VBN\0|NONE (l_nsubjpass) absence_17\NN\14449405|;|induced|was|by|. (l_prep) of_18\IN\0|an (l_pobj) mr_19\NNP\6339416|NONE
D011433_D006333 CID propranolol_6\NN\0|NONE (r_pobj) by_5\IN\0|failure|was (r_agent) induced_4\VBN\1627355|;|absence|was|by|. (l_nsubjpass) failure_2\NN\66216|by|was
23535177
D007980_D004409 CID levodopa_19\RB\14604959| (r_npadvmod) induced_21\VBN\1627355|)|LIDs|( (r_amod) dyskinesias_22\NNS\14084880|Parkinson|and|)|(|PD
D007980_D004409 CID levodopa_19\RB\14604959| (r_npadvmod) induced_21\VBN\1627355|)|LIDs|( (r_amod) dyskinesias_22\NNS\14084880|Parkinson|and|)|(|PD (l_appos) lids_24\NNPS\5313679|)|induced|(
D007980_D010300 NONE levodopa_19\RB\14604959| (r_npadvmod) induced_21\VBN\1627355|)|LIDs|( (r_amod) dyskinesias_22\NNS\14084880|Parkinson|and|)|(|PD (r_conj) disease_14\NN\14061805|NONE
D007980_D010300 NONE levodopa_19\RB\14604959| (r_npadvmod) induced_21\VBN\1627355|)|LIDs|( (r_amod) dyskinesias_22\NNS\14084880|Parkinson|and|)|(|PD (r_conj) disease_14\NN\14061805|NONE (l_appos) pd_16\NNP\14625458|Parkinson|and|)|(|dyskinesias
6585590
D004317_D066126 NONE doxorubicin_8\NN\2716866|NONE (r_pobj) of_7\IN\0|NONE (r_prep) nephrotoxicity_6\NN\0|in|,|and (r_conj) cardiotoxicity_3\NN\0|,|Antitumor|.
D004317_D066126 NONE doxorubicin_9\NN\2716866|NONE (r_pobj) by_8\IN\0|NONE (r_agent) induced_7\VBN\1627355|NONE (r_acl) nephrotoxicity_6\NN\0|and|, (r_conj) cardiotoxicity_3\NN\0|Antitumor|,
D004317_D066126 NONE doxorubicin_17\NN\2716866|mg|/ (r_nmod) kg_19\NNS\13717155|NONE (r_pobj) of_14\IN\0|a (r_prep) dose_13\NN\3740161|NONE (r_pobj) at_11\IN\14622893|scored|.|was|only (r_prep) observed_10\VBN\2163746|NONE (l_ccomp) scored_4\VBD\1111028|at|.|was|only (l_nsubj) evidence_1\NN\5816287|as (l_prep) of_2\IN\0|Histologic (l_pobj) cardiotoxicity_3\NN\0|NONE
D004317_D000419 CID doxorubicin_14\NN\2716866|mg|/ (r_nmod) kg_16\NNS\13717155|NONE (r_pobj) of_11\IN\0|resulted|a|, (r_prep) dose_10\NN\3740161|NONE (l_relcl) resulted_19\VBD\2633881|of|a|, (l_prep) in_20\IN\13603305|which (l_pobj) albuminuria_21\NN\14299637|NONE
D004317_D009369 NONE doxorubicin_18\NN\2716866|NONE (r_pobj) of_17\IN\0|iv (r_prep) injections_16\NNS\320852|NONE (r_pobj) with_14\IN\0|on|Animals|followed|)|,|.|were|body (r_prep) treated_13\VBN\2376958|NONE (l_nsubjpass) animals_0\NNS\4475|with|on|followed|)|,|.|were|body (l_prep) with_1\IN\0|+/|,|) (l_pobj) tumor_3\NN\14234074|NONE
D004317_D009369 NONE doxorubicin_7\NN\2716866|mg|/ (r_nmod) kg_9\NNS\13717155|NONE (r_pobj) with_4\IN\0|was|regression|. (r_prep) observed_3\VBN\2163746|NONE (l_nsubjpass) regression_1\NN\14501726|was|.|with (l_compound) tumor_0\NN\14234074|NONE
D004317_D009369 NONE doxorubicin_10\NN\2716866|/|mg (r_nmod) kg_12\NNS\13717155|NONE (r_pobj) with_7\IN\0|was|disappearance|. (r_prep) induced_6\VBN\1627355|NONE (l_nsubjpass) disappearance_1\NN\42757|was|with|. (l_prep) of_2\IN\0|Complete (l_pobj) tumor_4\NN\14234074|NONE
D004317_D007674 NONE doxorubicin_8\NN\2716866|NONE (r_pobj) of_7\IN\0|NONE (r_prep) nephrotoxicity_6\NN\0|in|,|and
D004317_D007674 NONE doxorubicin_9\NN\2716866|NONE (r_pobj) by_8\IN\0|NONE (r_agent) induced_7\VBN\1627355|NONE (r_acl) nephrotoxicity_6\NN\0|and|,
D004317_D007674 NONE doxorubicin_14\NN\2716866|mg|/ (r_nmod) kg_16\NNS\13717155|NONE (r_pobj) of_11\IN\0|resulted|a|, (r_prep) dose_10\NN\3740161|NONE (r_pobj) above_8\IN\6392001|evidence|was|. (r_prep) seen_7\VBN\2106506|NONE (l_nsubjpass) evidence_2\NN\5816287|above|was|. (l_prep) of_3\IN\0|microscopic|Light (l_pobj) damage_5\NN\7296428|NONE
D004317_-1 NONE doxorubicin_8\NN\2716866|NONE (r_pobj) of_7\IN\0|NONE (r_prep) nephrotoxicity_6\NN\0|in|,|and (r_conj) cardiotoxicity_3\NN\0|,|Antitumor|. (l_prep) in_9\IN\13603305|nephrotoxicity|,|and (l_pobj) rat_21\NN\2329401|NONE (l_amod) bearing_15\VBG\13795489|the|WSL|solid|IgM (l_compound) immunocytoma_13\NN\0|
D004317_-1 NONE doxorubicin_9\NN\2716866|NONE (r_pobj) by_8\IN\0|NONE (r_agent) induced_7\VBN\1627355|NONE (r_acl) nephrotoxicity_6\NN\0|and|, (r_conj) cardiotoxicity_3\NN\0|Antitumor|, (r_conj) activity_1\NN\30358|bearing|in|.|were (r_nsubjpass) studied_11\VBN\0|NONE (l_advcl) bearing_21\VBG\13795489|activity|in|.|were (l_dobj) immunocytoma_26\NN\0|each
2650911
D004958_D009369 NONE estradiol_10\NN\14749794|NONE (r_pobj) of_7\IN\0|in|the|vivo (r_prep) injection_6\NN\320852|NONE (r_pobj) following_2\VBG\8180190|was|over|Radiolabelling|,|, (r_prep) increased_13\VBN\169651|concentration|analysis|;|. (l_prep) over_15\IN\5867413|was|Radiolabelling|following|,|, (l_pobj) nuclei_17\NNS\5445668|only (l_prep) of_18\IN\0|the (l_pobj) cells_20\NNS\3080309|NONE (l_compound) tumor_19\NN\14234074|NONE
D004054_D002292 CID diethylstilbesterol_9\NN\15058023|NONE (r_pobj) of_8\IN\0|NONE (r_prep) nuclei_7\NNS\5445668|NONE (r_pobj) in_6\IN\13603305|binding|estrogen (r_prep) sites_5\NNS\8673395|NONE (r_pobj) of_2\IN\0|Autoradiographic (r_prep) evidence_1\NN\5816287|.|carcinomas (r_nsubj) induced_10\VBN\1627355|NONE (l_dobj) carcinomas_13\NNS\14239918|.|evidence
D004054_D002292 CID diethylstilbesterol_13\NN\15058023|NONE (r_pobj) in_7\IN\13603305|NONE (r_prep) autoradiography_6\NN\13545382|NONE (r_pobj) by_5\IN\0|induced|.|were|sites (r_agent) demonstrated_4\VBN\2137132|NONE (l_conj) induced_14\VBD\1627355|.|were|sites|by (l_dobj) carcinomas_16\NNS\14239918|in
D004967_D002292 NONE estrogen_3\NN\14745635|binding|in (r_nmod) sites_5\NNS\8673395|NONE (r_pobj) of_2\IN\0|Autoradiographic (r_prep) evidence_1\NN\5816287|.|carcinomas (r_nsubj) induced_10\VBN\1627355|NONE (l_dobj) carcinomas_13\NNS\14239918|.|evidence
D004967_D002292 NONE estrogen_0\NN\14745635|binding (r_nmod) sites_2\NNS\8673395|induced|.|were|by (r_nsubjpass) demonstrated_4\VBN\2137132|NONE (l_conj) induced_14\VBD\1627355|.|were|sites|by (l_dobj) carcinomas_16\NNS\14239918|in
D004967_D002292 NONE estrogen_13\NN\14745635|NONE (r_pobj) of_12\IN\0|vivo (r_prep) binding_11\NN\4688246|NONE (r_pobj) in_9\IN\13603305|the (r_prep) preferential_8\NN\0|to (r_dobj) documenting_6\VBG\1000214|the|first|induced|published (r_acl) report_5\NN\6470073|.|This (l_acl) induced_20\VBD\1627355|the|documenting|first|published (l_dobj) carcinomas_23\NNS\14239918|NONE
D004967_D002292 NONE estrogen_19\NN\14745635|NONE (r_pobj) in_18\IN\13603305|NONE (r_prep) cells_17\NNS\3080309|NONE (r_pobj) of_16\IN\0|NONE (r_prep) nuclei_15\NNS\5445668|NONE (r_pobj) to_14\IN\0|preferential (r_prep) documenting_6\VBG\1000214|the|first|induced|published (r_acl) report_5\NN\6470073|.|This (l_acl) induced_20\VBD\1627355|the|documenting|first|published (l_dobj) carcinomas_23\NNS\14239918|NONE
D012834_D009369 NONE silver_33\NN\14821043|reduced|over|than (r_compound) grains_34\NNS\14585519|NONE (r_pobj) of_31\IN\0|a|higher|.times (r_prep) concentration_30\NN\4916342|increased|analysis|;|. (r_dobj) revealed_24\VBD\2137132|NONE (l_ccomp) increased_13\VBN\169651|concentration|analysis|;|. (l_prep) over_15\IN\5867413|was|Radiolabelling|following|,|, (l_pobj) nuclei_17\NNS\5445668|only (l_prep) of_18\IN\0|the (l_pobj) cells_20\NNS\3080309|NONE (l_compound) tumor_19\NN\14234074|NONE
17297207
D011803_D007565 NONE quinine_25\NN\2721948|NONE (r_compound) infusion_26\NN\14589223|was (r_nsubjpass) reported_28\VBN\831651|while (r_ccomp) getting_24\VBG\30358|there|that|case|) (r_advcl) was_5\VBD\0|was|It|. (l_attr) case_7\NN\7283608|there|that|getting|) (l_prep) of_8\IN\0|contraction|a (l_pobj) patient_11\NN\9898892|NONE (l_prep) with_12\IN\0|severe|malaria (l_pobj) jaundice_13\NN\14299637|NONE
D011803_D007565 NONE quinine_11\NN\2721948|in (r_compound) infusion_12\NN\14589223|% (r_dobj) got_10\VBD\0|.|as|was|and|Patient (r_conj) diagnosed_3\VBN\644583|NONE (l_prep) as_4\IN\14622893|.|got|was|and|Patient (l_pobj) malaria_6\NN\14178913|NONE (l_prep) with_7\IN\0|severe (l_pobj) jaundice_8\NN\14299637|NONE
D011803_D016778 NONE quinine_0\NN\2721948| (r_npadvmod) induced_2\VBN\1627355|in|. (r_amod) arrhythmia_3\NN\14103288|NONE (l_prep) in_4\IN\13603305|.|induced (l_pobj) patient_6\NN\9898892|NONE (l_prep) with_7\IN\0|a (l_pobj) malaria_9\NN\14178913|NONE
D011803_D016778 NONE quinine_25\NN\2721948|NONE (r_compound) infusion_26\NN\14589223|was (r_nsubjpass) reported_28\VBN\831651|while (r_ccomp) getting_24\VBG\30358|there|that|case|) (r_advcl) was_5\VBD\0|was|It|. (l_attr) case_7\NN\7283608|there|that|getting|) (l_prep) of_8\IN\0|contraction|a (l_pobj) patient_11\NN\9898892|NONE (l_compound) malaria_10\NN\14178913|severe|with
D011803_D016778 NONE quinine_11\NN\2721948|in (r_compound) infusion_12\NN\14589223|% (r_dobj) got_10\VBD\0|.|as|was|and|Patient (r_conj) diagnosed_3\VBN\644583|NONE (l_prep) as_4\IN\14622893|.|got|was|and|Patient (l_pobj) malaria_6\NN\14178913|NONE
D011803_D001145 NONE quinine_0\NN\2721948| (r_npadvmod) induced_2\VBN\1627355|in|. (r_amod) arrhythmia_3\NN\14103288|NONE
D011803_D001145 NONE quinine_25\NN\2721948|NONE (r_compound) infusion_26\NN\14589223|was (r_nsubjpass) reported_28\VBN\831651|while (r_ccomp) getting_24\VBG\30358|there|that|case|) (r_advcl) was_5\VBD\0|was|It|. (l_attr) case_7\NN\7283608|there|that|getting|) (l_prep) of_8\IN\0|contraction|a (l_pobj) patient_11\NN\9898892|NONE (l_prep) with_12\IN\0|severe|malaria (l_pobj) jaundice_13\NN\14299637|NONE (l_relcl) presented_15\VBD\2137132|NONE (l_prep) with_16\IN\0|who (l_pobj) arrhythmia_17\NN\14103288|NONE
D011803_D001145 NONE quinine_0\NN\2721948|arrhythmic|alkaloid|.|,|,|,|like (r_nsubj) is_5\VBZ\0|NONE (l_attr) alkaloid_8\NN\14727670|arrhythmic|.|,|,|Quinine|,|like (l_relcl) has_10\VBZ\13888491|a|chincona (l_dobj) property_14\NN\32613|that (l_amod) arrhythmic_13\JJ\0|NONE
D011803_D001145 NONE quinine_0\NN\2721948|arrhythmic|alkaloid|.|,|,|,|like (r_nsubj) is_5\VBZ\0|NONE (l_advcl) arrhythmic_21\JJ\0|alkaloid|.|,|,|Quinine|,|like
D011803_D001145 NONE quinine_0\NN\2721948|arrhythmic|alkaloid|.|,|,|,|like (r_nsubj) is_5\VBZ\0|NONE (l_advcl) arrhythmic_21\JJ\0|alkaloid|.|,|,|Quinine|,|like (l_ccomp) cause_24\VB\7323922|although|also||it (l_dobj) arrhythmias_26\NNS\14103288|can|that
D011803_D001145 NONE quinine_0\NN\2721948|arrhythmic|alkaloid|.|,|,|,|like (r_nsubj) is_5\VBZ\0|NONE (l_advcl) arrhythmic_21\JJ\0|alkaloid|.|,|,|Quinine|,|like (l_ccomp) cause_24\VB\7323922|although|also||it (l_dobj) arrhythmias_26\NNS\14103288|can|that (l_prep) including_28\VBG\0|,|various (l_pobj) arrhythmia_30\NN\14103288|NONE
D011803_D001145 NONE quinine_3\NN\2721948|NONE (r_pobj) of_1\IN\0|NONE (r_prep) administration_0\NN\1133281|with|be|must|and|carefully|because|. (r_nsubjpass) done_6\VBN\0|NONE (l_prep) because_12\IN\0|with|Administration|be|must|and|carefully|. (l_pobj) effect_18\NN\34213|of (l_amod) arrhythmic_17\JJ\0|its|in|,
D011803_-1 NONE quinine_4\NN\2721948|NONE (r_compound) infusion_5\NN\14589223|NONE (r_pobj) of_3\IN\0| (r_prep) hours_2\NNS\15118228|NONE (r_pobj) after_0\IN\0|patient|showed|palpitation (r_prep) felt_8\VBD\3309808|NONE (l_dobj) palpitation_9\NN\14299637|After|patient|showed
D011803_D014839 NONE quinine_3\NN\2721948|NONE (r_pobj) of_1\IN\0|NONE (r_prep) administration_0\NN\1133281|with|be|must|and|carefully|because|. (r_nsubjpass) done_6\VBN\0|NONE (l_prep) because_12\IN\0|with|Administration|be|must|and|carefully|. (l_pobj) effect_18\NN\34213|of (l_prep) in_21\IN\13603305|its|arrhythmic|, (l_pobj) patients_23\NNS\9898892|especially (l_relcl) have_25\VBP\7846|older (l_dobj) diseases_27\NNS\14061805|who (l_conj) patients_29\NNS\9898892|or|heart (l_prep) with_30\IN\0|NONE (l_pobj) disorder_32\NN\14034177|NONE (l_relcl) occurs_38\VBZ\0|)|electrolyte|(|hypokalemia (l_advcl) vomiting_41\NN\116687|which|frequently|due
D011803_D008288 NONE quinine_3\NN\2721948|NONE (r_pobj) of_1\IN\0|NONE (r_prep) administration_0\NN\1133281|with|be|must|and|carefully|because|. (r_nsubjpass) done_6\VBN\0|NONE (l_prep) because_12\IN\0|with|Administration|be|must|and|carefully|. (l_pobj) effect_18\NN\34213|of (l_prep) in_21\IN\13603305|its|arrhythmic|, (l_pobj) patients_23\NNS\9898892|especially (l_relcl) have_25\VBP\7846|older (l_dobj) diseases_27\NNS\14061805|who (l_conj) patients_29\NNS\9898892|or|heart (l_prep) with_30\IN\0|NONE (l_pobj) disorder_32\NN\14034177|NONE (l_relcl) occurs_38\VBZ\0|)|electrolyte|(|hypokalemia (l_advcl) vomiting_41\NN\116687|which|frequently|due (l_conj) diarrhea_44\NN\14299637|or|and (l_prep) in_45\IN\13603305|NONE (l_pobj) cases_47\NNS\7283608|NONE (l_compound) malaria_46\NN\14178913|NONE
D005947_D007565 NONE dextrose_14\NN\14884120|NONE (r_pobj) in_13\IN\13603305|quinine (r_prep) infusion_12\NN\14589223|% (r_dobj) got_10\VBD\0|.|as|was|and|Patient (r_conj) diagnosed_3\VBN\644583|NONE (l_prep) as_4\IN\14622893|.|got|was|and|Patient (l_pobj) malaria_6\NN\14178913|NONE (l_prep) with_7\IN\0|severe (l_pobj) jaundice_8\NN\14299637|NONE
D011802_D018879 NONE quinidine_3\NN\2715941|NONE (r_pobj) like_2\IN\5839024|arrhythmic|alkaloid|.|,|,|Quinine|, (r_prep) is_5\VBZ\0|NONE (l_advcl) arrhythmic_21\JJ\0|alkaloid|.|,|,|Quinine|,|like (l_ccomp) cause_24\VB\7323922|although|also||it (l_dobj) arrhythmias_26\NNS\14103288|can|that (l_prep) including_28\VBG\0|,|various (l_pobj) arrhythmia_30\NN\14103288|NONE (l_prep) as_32\IN\14622893|severe (l_pobj) pvc_34\NN\15088440|such
D011803_D018879 CID quinine_25\NN\2721948|NONE (r_compound) infusion_26\NN\14589223|was (r_nsubjpass) reported_28\VBN\831651|while (r_ccomp) getting_24\VBG\30358|there|that|case|) (r_advcl) was_5\VBD\0|was|It|. (l_attr) case_7\NN\7283608|there|that|getting|) (l_appos) contraction_21\NN\358931|a|of
D011803_D018879 CID quinine_4\NN\2721948|NONE (r_compound) infusion_5\NN\14589223|NONE (r_pobj) of_3\IN\0| (r_prep) hours_2\NNS\15118228|NONE (r_pobj) after_0\IN\0|patient|showed|palpitation (r_prep) felt_8\VBD\3309808|NONE (l_parataxis) showed_16\VBD\2137132|After|patient|palpitation (l_dobj) contraction_19\NN\358931|(|.|wave|recording
D011803_D018879 CID quinine_4\NN\2721948|NONE (r_compound) infusion_5\NN\14589223|NONE (r_pobj) of_3\IN\0| (r_prep) hours_2\NNS\15118228|NONE (r_pobj) after_0\IN\0|patient|showed|palpitation (r_prep) felt_8\VBD\3309808|NONE (l_parataxis) showed_16\VBD\2137132|After|patient|palpitation (l_dobj) contraction_19\NN\358931|(|.|wave|recording (l_appos) pvc_21\NN\15088440|>|ventricular|premature
D011803_D018879 CID quinine_0\NN\2721948|arrhythmic|alkaloid|.|,|,|,|like (r_nsubj) is_5\VBZ\0|NONE (l_advcl) arrhythmic_21\JJ\0|alkaloid|.|,|,|Quinine|,|like (l_ccomp) cause_24\VB\7323922|although|also||it (l_dobj) arrhythmias_26\NNS\14103288|can|that (l_prep) including_28\VBG\0|,|various (l_pobj) arrhythmia_30\NN\14103288|NONE (l_prep) as_32\IN\14622893|severe (l_pobj) pvc_34\NN\15088440|such
D005947_D016778 NONE dextrose_14\NN\14884120|NONE (r_pobj) in_13\IN\13603305|quinine (r_prep) infusion_12\NN\14589223|% (r_dobj) got_10\VBD\0|.|as|was|and|Patient (r_conj) diagnosed_3\VBN\644583|NONE (l_prep) as_4\IN\14622893|.|got|was|and|Patient (l_pobj) malaria_6\NN\14178913|NONE
D011803_D006331 NONE quinine_3\NN\2721948|NONE (r_pobj) of_1\IN\0|NONE (r_prep) administration_0\NN\1133281|with|be|must|and|carefully|because|. (r_nsubjpass) done_6\VBN\0|NONE (l_prep) because_12\IN\0|with|Administration|be|must|and|carefully|. (l_pobj) effect_18\NN\34213|of (l_prep) in_21\IN\13603305|its|arrhythmic|, (l_pobj) patients_23\NNS\9898892|especially (l_relcl) have_25\VBP\7846|older (l_dobj) diseases_27\NNS\14061805|who
D011803_D007008 NONE quinine_3\NN\2721948|NONE (r_pobj) of_1\IN\0|NONE (r_prep) administration_0\NN\1133281|with|be|must|and|carefully|because|. (r_nsubjpass) done_6\VBN\0|NONE (l_prep) because_12\IN\0|with|Administration|be|must|and|carefully|. (l_pobj) effect_18\NN\34213|of (l_prep) in_21\IN\13603305|its|arrhythmic|, (l_pobj) patients_23\NNS\9898892|especially (l_relcl) have_25\VBP\7846|older (l_dobj) diseases_27\NNS\14061805|who (l_conj) patients_29\NNS\9898892|or|heart (l_prep) with_30\IN\0|NONE (l_pobj) disorder_32\NN\14034177|NONE (l_appos) hypokalemia_34\NN\14299637|)|electrolyte|occurs|(
D011803_D003967 NONE quinine_3\NN\2721948|NONE (r_pobj) of_1\IN\0|NONE (r_prep) administration_0\NN\1133281|with|be|must|and|carefully|because|. (r_nsubjpass) done_6\VBN\0|NONE (l_prep) because_12\IN\0|with|Administration|be|must|and|carefully|. (l_pobj) effect_18\NN\34213|of (l_prep) in_21\IN\13603305|its|arrhythmic|, (l_pobj) patients_23\NNS\9898892|especially (l_relcl) have_25\VBP\7846|older (l_dobj) diseases_27\NNS\14061805|who (l_conj) patients_29\NNS\9898892|or|heart (l_prep) with_30\IN\0|NONE (l_pobj) disorder_32\NN\14034177|NONE (l_relcl) occurs_38\VBZ\0|)|electrolyte|(|hypokalemia (l_advcl) vomiting_41\NN\116687|which|frequently|due (l_conj) diarrhea_44\NN\14299637|or|and
D011803_D014883 NONE quinine_3\NN\2721948|NONE (r_pobj) of_1\IN\0|NONE (r_prep) administration_0\NN\1133281|with|be|must|and|carefully|because|. (r_nsubjpass) done_6\VBN\0|NONE (l_prep) because_12\IN\0|with|Administration|be|must|and|carefully|. (l_pobj) effect_18\NN\34213|of (l_prep) in_21\IN\13603305|its|arrhythmic|, (l_pobj) patients_23\NNS\9898892|especially (l_relcl) have_25\VBP\7846|older (l_dobj) diseases_27\NNS\14061805|who (l_conj) patients_29\NNS\9898892|or|heart (l_prep) with_30\IN\0|NONE (l_pobj) disorder_32\NN\14034177|NONE
D011803_D012848 NONE quinine_4\NN\2721948|NONE (r_compound) infusion_5\NN\14589223|NONE (r_pobj) of_3\IN\0| (r_prep) hours_2\NNS\15118228|NONE (r_pobj) after_0\IN\0|patient|showed|palpitation (r_prep) felt_8\VBD\3309808|NONE (l_parataxis) showed_16\VBD\2137132|After|patient|palpitation (l_ccomp) wave_39\VBP\7309781|(|contraction|.|recording (l_nmod) block_35\NN\21939|U|positive|,
D011188_D018879 NONE potassium_29\NN\14625458|NONE (r_compound) level_30\NN\4916342|meq/|,|reduced (r_nsubj) was_31\VBD\0|NONE (l_ccomp) reduced_12\VBN\441445|meq/|,|level (l_nsubj) frequency_9\NN\15286249|,|was|felt|to (l_prep) of_10\IN\0|the (l_pobj) pvc_11\NNP\15088440|NONE
D011802_D001145 NONE quinidine_3\NN\2715941|NONE (r_pobj) like_2\IN\5839024|arrhythmic|alkaloid|.|,|,|Quinine|, (r_prep) is_5\VBZ\0|NONE (l_attr) alkaloid_8\NN\14727670|arrhythmic|.|,|,|Quinine|,|like (l_relcl) has_10\VBZ\13888491|a|chincona (l_dobj) property_14\NN\32613|that (l_amod) arrhythmic_13\JJ\0|NONE
D011802_D001145 NONE quinidine_3\NN\2715941|NONE (r_pobj) like_2\IN\5839024|arrhythmic|alkaloid|.|,|,|Quinine|, (r_prep) is_5\VBZ\0|NONE (l_advcl) arrhythmic_21\JJ\0|alkaloid|.|,|,|Quinine|,|like
D011802_D001145 NONE quinidine_3\NN\2715941|NONE (r_pobj) like_2\IN\5839024|arrhythmic|alkaloid|.|,|,|Quinine|, (r_prep) is_5\VBZ\0|NONE (l_advcl) arrhythmic_21\JJ\0|alkaloid|.|,|,|Quinine|,|like (l_ccomp) cause_24\VB\7323922|although|also||it (l_dobj) arrhythmias_26\NNS\14103288|can|that
D011802_D001145 NONE quinidine_3\NN\2715941|NONE (r_pobj) like_2\IN\5839024|arrhythmic|alkaloid|.|,|,|Quinine|, (r_prep) is_5\VBZ\0|NONE (l_advcl) arrhythmic_21\JJ\0|alkaloid|.|,|,|Quinine|,|like (l_ccomp) cause_24\VB\7323922|although|also||it (l_dobj) arrhythmias_26\NNS\14103288|can|that (l_prep) including_28\VBG\0|,|various (l_pobj) arrhythmia_30\NN\14103288|NONE
3084231
D014635_D022124 CID acid_25\NN\14818238|NONE (r_pobj) of_23\IN\0|toxic (r_prep) effect_22\NN\34213|central|CNS|nervous|;|(|effect|a|direct|) (r_appos) system_17\NN\3575240|.|mechanisms|: (l_appos) effect_30\NN\34213|central|CNS|nervous|;|(|effect|a|direct|) (l_conj) effect_41\NN\34213|;|and|secondary|epileptogenic|paradoxical|a (l_acl) mediated_42\VBN\761713|indirect|toxic|CNS|an (l_prep) through_43\IN\0|NONE (l_pobj) hyperammonemia_48\NN\0|NONE
D014635_D022124 CID acid_45\NN\14818238| (r_npadvmod) induced_47\VBN\1627355|valproic (r_amod) hyperammonemia_48\NN\0|NONE
D014635_D003704 CID acid_2\NN\14818238| (r_npadvmod) induced_4\VBN\1627355|Reversible|:|valproic|.|report (r_amod) dementia_5\NN\14395018|NONE
D014635_D003704 CID acid_2\NN\14818238| (r_npadvmod) induced_4\VBN\1627355|valproic|Reversible (r_amod) dementia_5\NN\14395018|.|in|was
D014635_D004827 NONE acid_2\NN\14818238| (r_npadvmod) induced_4\VBN\1627355|valproic|Reversible (r_amod) dementia_5\NN\14395018|.|in|was (r_nsubjpass) documented_7\VBN\1000214|NONE (l_prep) in_8\IN\13603305|.|dementia|was (l_pobj) man_13\NN\9605289|NONE (l_prep) with_14\IN\0|a|had|old (l_pobj) epilepsy_15\NN\14085708|NONE
2083961
D012293_D014839 NONE rifampicin_0\NNP\0|thrice|was|as|and|developed (r_nsubjpass) administered_2\VBN\2436349|NONE (l_conj) developed_17\VBD\1753788|thrice|was|as|Rifampicin|and (l_dobj) effects_20\NNS\13245626|time|.|he (l_prep) like_21\IN\5839024|untoward|side (l_pobj) nausea_22\NN\14299637|NONE (l_conj) vomiting_24\NN\116687|,
D012293_D005334 NONE rifampicin_0\NNP\0|thrice|was|as|and|developed (r_nsubjpass) administered_2\VBN\2436349|NONE (l_conj) developed_17\VBD\1753788|thrice|was|as|Rifampicin|and (l_dobj) effects_20\NNS\13245626|time|.|he (l_prep) like_21\IN\5839024|untoward|side (l_pobj) nausea_22\NN\14299637|NONE (l_conj) vomiting_24\NN\116687|, (l_conj) fever_26\NN\14299637|and
D012293_D058186 CID rifampicin_5\NNS\0|to (r_pobj) due_3\IN\5174653|Acute|renal|. (r_prep) failure_2\NN\66216|NONE
D012293_D009325 NONE rifampicin_0\NNP\0|thrice|was|as|and|developed (r_nsubjpass) administered_2\VBN\2436349|NONE (l_conj) developed_17\VBD\1753788|thrice|was|as|Rifampicin|and (l_dobj) effects_20\NNS\13245626|time|.|he (l_prep) like_21\IN\5839024|untoward|side (l_pobj) nausea_22\NN\14299637|NONE
23949582
D007069_D030342 NONE ifo_3\NNP\0|NONE (r_poss) genotoxicity_5\NN\0|.|,|Mesna|acts|significantly
D015080_D030342 NONE mesna_0\NNP\0|.|,|genotoxicity|acts|significantly (r_nsubj) reduces_2\VBZ\441445|NONE (l_dobj) genotoxicity_5\NN\0|.|,|Mesna|acts|significantly
19154241
D008094_D006934 CID lithium_6\NN\14625458| (r_npadvmod) treated_8\VBN\2376958|had|a (r_amod) patient_9\NN\9898892|NONE (l_relcl) had_11\VBD\0|treated|a (l_dobj) hypercalcemia_13\NN\14299637|who|understand
D008094_D006934 CID lithium_6\NN\14625458| (r_npadvmod) treated_8\VBN\2376958|NONE (r_amod) patients_9\NNS\9898892|NONE (r_pobj) of_5\IN\0| (r_prep) %_4\NN\0|hypercalcemic|. (r_nsubj) become_10\VBP\146138|NONE (l_acomp) hypercalcemic_11\JJ\0|%|.
D008094_D049950 NONE lithium_16\NN\14625458|term (r_compound) therapy_17\NN\657604|NONE (r_pobj) of_12\IN\0|side|rare|a (r_prep) effect_11\NN\34213|hyperparathyroidism|. (r_attr) is_2\VBZ\0|NONE (l_nsubj) hyperparathyroidism_1\NN\14059928|effect|.
D008094_D006961 CID lithium_3\NN\14625458|leading (r_compound) therapy_4\NN\657604|case|:|a|. (l_acl) leading_5\VBG\4339291|lithium (l_prep) to_6\IN\0|NONE (l_pobj) hyperparathyroidism_7\NN\14059928|NONE
8318674
D003561_D011654 CID c_10\NN\13714184|NONE (r_pobj) after_4\IN\0|.|shock|;|and|role|Pulmonary (r_prep) edema_1\NN\14315192|NONE
D003561_D012128 NONE c_29\NNP\13714184|that|with|be|may (r_nsubjpass) associated_32\VBN\628491|we|.|,|thought (r_ccomp) hypothesize_22\VBP\719734|NONE (l_advcl) thought_5\VBN\5809192|we|associated|.|, (l_xcomp) involved_8\VBN\2676054|As|are|TNF (l_prep) in_9\IN\13603305|be|to (l_pobj) development_11\NN\248977|NONE (l_prep) of_12\IN\0|the (l_pobj) shock_14\NN\7510495|NONE (l_conj) syndrome_19\NN\5870365|septic|and
D003561_D012769 CID c_10\NN\13714184|NONE (r_pobj) after_4\IN\0|.|shock|;|and|role|Pulmonary (r_prep) edema_1\NN\14315192|NONE (l_conj) shock_3\NN\7510495|after|.|;|and|role|Pulmonary
D003561_D012769 CID c_29\NNP\13714184|that|with|be|may (r_nsubjpass) associated_32\VBN\628491|we|.|,|thought (r_ccomp) hypothesize_22\VBP\719734|NONE (l_advcl) thought_5\VBN\5809192|we|associated|.|, (l_xcomp) involved_8\VBN\2676054|As|are|TNF (l_prep) in_9\IN\13603305|be|to (l_pobj) development_11\NN\248977|NONE (l_prep) of_12\IN\0|the (l_pobj) shock_14\NN\7510495|NONE
D003561_D008223 NONE c_10\NN\13714184|NONE (l_prep) for_11\IN\0||aracytine|dose (l_pobj) lymphoma_12\NN\14239918|NONE
D003561_D008223 NONE c_13\NNP\13714184|NONE (r_pobj) with_7\IN\0|in|for (r_prep) treated_6\VBN\2376958|consecutive| (l_prep) for_14\IN\0|in|with (l_pobj) lymphomas_15\NNS\14239918|NONE
19338378
C031942_D013921 NONE argatroban_9\JJ\0|in (r_amod) therapy_10\NN\657604|NONE (l_prep) in_11\IN\13603305|argatroban (l_pobj) thrombocytopenia_15\NN\14189204|NONE
C031942_D013921 NONE argatroban_0\NNP\0|for|and|.|inhibitor (r_nsubj) is_1\VBZ\0|NONE (l_attr) inhibitor_8\NN\20090|for|and|.|Argatroban (l_acl) used_9\VBN\0|a|direct|,|metabolized|thrombin (l_prep) in_16\IN\13603305|for (l_pobj) thrombocytopenia_20\NN\14189204|NONE
C031942_D013921 NONE argatroban_0\NNP\0|for|and|.|inhibitor (r_nsubj) is_1\VBZ\0|NONE (l_attr) inhibitor_8\NN\20090|for|and|.|Argatroban (l_acl) used_9\VBN\0|a|direct|,|metabolized|thrombin (l_prep) in_16\IN\13603305|for (l_pobj) thrombocytopenia_20\NN\14189204|NONE (l_appos) hit_22\NNP\36762|induced|)|(
C031942_D013921 NONE argatroban_0\NNP\0|for|and|.|inhibitor (r_nsubj) is_1\VBZ\0|NONE (l_conj) for_25\IN\0|and|.|Argatroban|inhibitor (l_pobj) patients_26\NNS\9898892|NONE (l_prep) with_27\IN\0|undergoing (l_conj) at_29\IN\14622893|or (l_pobj) risk_30\NN\14541044|NONE (l_prep) of_31\IN\0|NONE (l_pobj) hit_32\NNP\36762|NONE
C031942_D013921 NONE argatroban_11\JJ\0|in (r_amod) therapy_12\NN\657604|NONE (l_prep) in_13\IN\13603305|argatroban (l_pobj) hit_14\NNP\36762|NONE
C031942_D013921 NONE argatroban_5\JJ\0|recommended|in (r_amod) dose_6\NN\3740161|(|min (l_prep) in_7\IN\13603305|recommended|argatroban (l_pobj) hit_8\NNP\36762|NONE
C031942_D013921 NONE argatroban_6\JJ\0|in|including|, (r_amod) therapy_7\NN\657604|NONE (l_prep) in_8\IN\13603305|argatroban|including|, (l_pobj) hit_9\NNP\36762|NONE
C031942_D013921 NONE argatroban_6\JJ\0|in|including|, (r_amod) therapy_7\NN\657604|NONE (r_pobj) with_5\IN\0|Improved|of (r_prep) familiarity_1\NN\5816287|.|may|reduction|, (r_nsubj) facilitate_20\VB\2547586|NONE (l_dobj) reduction_21\NN\351485|familiarity|.|may|, (l_prep) of_22\IN\0|NONE (l_pobj) harm_23\NN\14052046|NONE (l_acl) associated_24\VBN\628491|NONE (l_prep) with_25\IN\0|NONE (l_pobj) thromboses_30\NNS\146138|NONE (l_nmod) hit_26\NNP\36762|(|treatment|or|)|fewer
C031942_D013921 NONE argatroban_38\JJ\0|fewer|medication (r_amod) errors_40\NNS\66216|)|(|its (r_appos) treatment_34\NN\654885|(|or|)|HIT|fewer (r_conj) thromboses_30\NNS\146138|NONE (r_pobj) with_25\IN\0|NONE (r_prep) associated_24\VBN\628491|NONE (r_acl) harm_23\NN\14052046|NONE (r_pobj) of_22\IN\0|NONE (r_prep) reduction_21\NN\351485|familiarity|.|may|, (r_dobj) facilitate_20\VB\2547586|NONE (l_nsubj) familiarity_1\NN\5816287|.|may|reduction|, (l_prep) with_5\IN\0|Improved|of (l_pobj) therapy_7\NN\657604|NONE (l_prep) in_8\IN\13603305|argatroban|including|, (l_pobj) hit_9\NNP\36762|NONE
C031942_D013921 NONE argatroban_38\JJ\0|fewer|medication (r_amod) errors_40\NNS\66216|)|(|its (r_appos) treatment_34\NN\654885|(|or|)|HIT|fewer (r_conj) thromboses_30\NNS\146138|NONE (l_nmod) hit_26\NNP\36762|(|treatment|or|)|fewer
D006493_D013927 NONE heparin_17\NN\2718259| (r_npadvmod) induced_19\VBN\1627355|HIT|)|( (r_amod) thrombocytopenia_20\NN\14189204|NONE (r_pobj) in_16\IN\13603305|for (r_prep) used_9\VBN\0|a|direct|,|metabolized|thrombin (l_prep) for_10\IN\0|in (l_pobj) prophylaxis_11\NN\1077350|NONE (l_conj) treatment_13\NN\654885|or (l_prep) of_14\IN\0|NONE (l_pobj) thrombosis_15\NN\14100769|NONE
C031942_D006470 CID argatroban_3\NN\0|NONE (r_amod) with_2\IN\0|NONE (r_prep) bleeding_1\VBG\14285662|NONE
C031942_D008107 NONE argatroban_5\JJ\0|recommended|in (r_amod) dose_6\NN\3740161|(|min (r_nsubj) is_9\VBZ\0|NONE (l_attr) min_15\NN\15154774|dose|( (l_acl) reduced_17\VBN\441445|/|)|adjusted|(||microg|kg|, (l_prep) in_18\IN\13603305|NONE (l_pobj) patients_19\NNS\9898892|NONE (l_prep) with_20\IN\0|NONE (l_pobj) impairment_22\NN\7296428|and|in
D006493_D013921 NONE heparin_12\NN\2718259| (r_npadvmod) induced_14\VBN\1627355|NONE (r_amod) thrombocytopenia_15\NN\14189204|NONE
D006493_D013921 NONE heparin_17\NN\2718259| (r_npadvmod) induced_19\VBN\1627355|HIT|)|( (r_amod) thrombocytopenia_20\NN\14189204|NONE
D006493_D013921 NONE heparin_17\NN\2718259| (r_npadvmod) induced_19\VBN\1627355|HIT|)|( (r_amod) thrombocytopenia_20\NN\14189204|NONE (l_appos) hit_22\NNP\36762|induced|)|(
D006493_D013921 NONE heparin_17\NN\2718259| (r_npadvmod) induced_19\VBN\1627355|HIT|)|( (r_amod) thrombocytopenia_20\NN\14189204|NONE (r_pobj) in_16\IN\13603305|for (r_prep) used_9\VBN\0|a|direct|,|metabolized|thrombin (r_acl) inhibitor_8\NN\20090|for|and|.|Argatroban (r_attr) is_1\VBZ\0|NONE (l_conj) for_25\IN\0|and|.|Argatroban|inhibitor (l_pobj) patients_26\NNS\9898892|NONE (l_prep) with_27\IN\0|undergoing (l_conj) at_29\IN\14622893|or (l_pobj) risk_30\NN\14541044|NONE (l_prep) of_31\IN\0|NONE (l_pobj) hit_32\NNP\36762|NONE
C031942_D009765 NONE argatroban_3\NN\0|has|For|been|in|,|not (r_advmod) investigated_7\VBN\644583|be|;|unnecessary|,|adjustment|and (r_ccomp) is_15\VBZ\0|NONE (l_acomp) unnecessary_16\JJ\0|be|;|,|adjustment|investigated|and (l_prep) for_17\IN\0|NONE (l_pobj) age_19\NN\4916342|NONE (l_conj) sex_21\NN\13440063|,|adult (l_conj) ethnicity_25\NN\4723816|, (l_conj) obesity_27\NN\4999401|/|race|or
C031942_D013927 NONE argatroban_0\NNP\0|for|and|.|inhibitor (r_nsubj) is_1\VBZ\0|NONE (l_attr) inhibitor_8\NN\20090|for|and|.|Argatroban (l_acl) used_9\VBN\0|a|direct|,|metabolized|thrombin (l_prep) for_10\IN\0|in (l_pobj) prophylaxis_11\NN\1077350|NONE (l_conj) treatment_13\NN\654885|or (l_prep) of_14\IN\0|NONE (l_pobj) thrombosis_15\NN\14100769|NONE
12948256
D004977_D014388 NONE ethambutol_10\NN\0|NONE (l_prep) for_11\IN\0|NONE (l_pobj) tuberculosis_12\NN\14127211|NONE (l_prep) of_13\IN\0|NONE (l_pobj) node_18\NN\13870805|NONE
D004977_D014397 NONE ethambutol_10\NN\0|NONE (l_prep) for_11\IN\0|NONE (l_pobj) tuberculosis_12\NN\14127211|NONE (l_prep) of_13\IN\0|NONE (l_pobj) node_18\NN\13870805|NONE
D004977_D009901 CID ethambutol_0\NNP\0|. (r_nmod) neuropathy_3\NN\14204950|NONE
D004977_D009901 CID ethambutol_5\NN\0|NONE (r_amod) neuropathy_8\NN\14204950|NONE
D004977_D009901 CID ethambutol_10\NN\0|NONE (r_pobj) with_9\IN\0|being (r_prep) treated_8\VBN\2376958|NONE (r_pcomp) after_6\IN\0|who|neuropathy (r_prep) developed_3\VBD\1753788|Thirteen (l_dobj) neuropathy_5\NN\14204950|who|after
D004977_D009901 CID ethambutol_19\NN\0|NONE (r_amod) therapy_20\NN\657604|at (r_dobj) starting_18\VBG\457382|NONE (r_pcomp) after_17\IN\0|patients|.|:|neuropathy|) (r_prep) had_3\VBD\0|NONE (l_dobj) neuropathy_5\NN\14204950|patients|.|:|after|)
D004977_D009901 CID ethambutol_11\NN\0|NONE (r_amod) therapy_12\NN\657604|NONE (r_pobj) with_10\IN\0|NONE (r_prep) patients_9\NNS\9898892|NONE (r_pobj) in_8\IN\13603305|.|recognition|be|should (r_prep) considered_7\VBN\689344|NONE (l_nsubjpass) recognition_1\NN\13932421|.|in|be|should (l_prep) of_2\IN\0|Early (l_pobj) neuropathy_4\NN\14204950|NONE
8312343
D004317_D002311 NONE doxorubicin_49\NN\2716866|,|with|)|and|)|%|disease|(|,|heart|cardiomyopathy|(|%|congenital|, (r_conj) disease_13\NN\14061805|for (r_appos) indications_0\NNS\33020|,|cardiomyopathy|. (r_nsubj) were_3\VBD\0|NONE (l_attr) cardiomyopathy_5\NN\14103288|,|Indications|.
D004317_D006349 NONE doxorubicin_49\NN\2716866|,|with|)|and|)|%|disease|(|,|heart|cardiomyopathy|(|%|congenital|, (r_conj) disease_13\NN\14061805|for (l_appos) disease_42\NN\14061805|,|doxorubicin|with|)|and|)|%|(|,|heart|cardiomyopathy|(|%|congenital|,
D004317_D009202 CID doxorubicin_49\NN\2716866|,|with|)|and|)|%|disease|(|,|heart|cardiomyopathy|(|%|congenital|, (l_appos) cardiomyopathy_50\NN\14103288|%
D004317_D006331 NONE doxorubicin_49\NN\2716866|,|with|)|and|)|%|disease|(|,|heart|cardiomyopathy|(|%|congenital|, (r_conj) disease_13\NN\14061805|for
D004317_D002312 NONE doxorubicin_49\NN\2716866|,|with|)|and|)|%|disease|(|,|heart|cardiomyopathy|(|%|congenital|, (r_conj) disease_13\NN\14061805|for (l_conj) cardiomyopathy_34\NN\14103288|,|doxorubicin|with|)|and|)|%|disease|(|,|heart|(|%|congenital|,
D015774_D003586 NONE ganciclovir_6\NN\0|NONE (r_pobj) with_5\IN\0|were|.|infections|successfully (r_prep) treated_3\VBN\2376958|NONE (l_nsubjpass) infections_1\NNS\14052046|were|with|.|successfully
11401944
C086123_D016171 NONE azimilide_34\NN\0|dl|and| (r_conj) sotalol_32\NN\0|NONE (r_pobj) by_29\IN\0|NONE (r_agent) induced_28\VBN\1627355|QT (r_acl) prolongation_27\NN\1017987|NONE (r_pobj) with_25\IN\0|to|pointes (r_prep) initiate_18\VB\9632274|a (l_dobj) pointes_21\FW\831651|with|to
C086123_D016171 NONE azimilide_34\NN\0|dl|and| (r_conj) sotalol_32\NN\0|NONE (r_pobj) by_29\IN\0|NONE (r_agent) induced_28\VBN\1627355|QT (r_acl) prolongation_27\NN\1017987|NONE (r_pobj) with_25\IN\0|to|pointes (r_prep) initiate_18\VB\9632274|a (l_dobj) pointes_21\FW\831651|with|to (l_appos) tdp_23\NN\0|de|torsade|)|(
D013015_D016171 CID sotalol_32\NN\0|NONE (r_pobj) by_29\IN\0|NONE (r_agent) induced_28\VBN\1627355|QT (r_acl) prolongation_27\NN\1017987|NONE (r_pobj) with_25\IN\0|to|pointes (r_prep) initiate_18\VB\9632274|a (l_dobj) pointes_21\FW\831651|with|to
D013015_D016171 CID sotalol_32\NN\0|NONE (r_pobj) by_29\IN\0|NONE (r_agent) induced_28\VBN\1627355|QT (r_acl) prolongation_27\NN\1017987|NONE (r_pobj) with_25\IN\0|to|pointes (r_prep) initiate_18\VB\9632274|a (l_dobj) pointes_21\FW\831651|with|to (l_appos) tdp_23\NN\0|de|torsade|)|(
D013015_D016171 CID sotalol_7\NN\0|NONE (r_pobj) by_4\IN\0|in|An (r_prep) increase_1\NN\13576355|.|propagation (r_nsubj) facilitated_8\VBN\2547586|NONE (l_dobj) propagation_10\NN\6253140|.|increase (l_relcl) initiated_14\VBD\1617192|transmural|of (l_dobj) episodes_16\NNS\7283608|in|that (l_prep) of_17\IN\0|multiple (l_pobj) tdp_19\NN\0|NONE
C086123_D008133 NONE azimilide_34\NN\0|dl|and| (r_conj) sotalol_32\NN\0|NONE (r_pobj) by_29\IN\0|NONE (r_agent) induced_28\VBN\1627355|QT (r_acl) prolongation_27\NN\1017987|NONE
C086123_D008133 NONE azimilide_6\NN\0|both|dl||and (r_conj) sotalol_4\NNS\0|Although|rarely|EADs (r_nsubj) induced_8\VBD\1627355|,|,|.|in|EADs|pronounced|they (r_advcl) produced_16\VBD\1617192|NONE (l_relcl) pronounced_25\VBN\0|,|,|.|in|EADs|induced|they (l_ccomp) seen_29\VBN\2106506|more|in (l_nsubjpass) prolongation_27\NN\1017987|was
D013015_D008133 CID sotalol_32\NN\0|NONE (r_pobj) by_29\IN\0|NONE (r_agent) induced_28\VBN\1627355|QT (r_acl) prolongation_27\NN\1017987|NONE
D013015_D008133 CID sotalol_2\NNP\0|,|in|leading|.|preferentially|duration (r_nsubj) prolonged_4\VBD\317700|NONE (l_advcl) leading_26\VBG\4339291|,|Sotalol|in|.|preferentially|duration (l_prep) to_27\IN\0|NONE (l_pobj) prolongation_29\NN\1017987|NONE
D013015_D008133 CID sotalol_4\NNS\0|Although|rarely|EADs (r_nsubj) induced_8\VBD\1627355|,|,|.|in|EADs|pronounced|they (r_advcl) produced_16\VBD\1617192|NONE (l_relcl) pronounced_25\VBN\0|,|,|.|in|EADs|induced|they (l_ccomp) seen_29\VBN\2106506|more|in (l_nsubjpass) prolongation_27\NN\1017987|was
6517710
D011796_D013927 NONE hydrochloride_8\NN\14817592|ppm (r_appos) quinacrine_7\NN\2721948|percent|in|simultaneously (r_dobj) given_4\VBN\5892096|have|.|,|thrombosis (r_csubj) had_18\VBD\0|NONE (l_dobj) thrombosis_19\NN\14100769|have|.|,|given
D012977_D003328 NONE nitrite_13\NN\14621446|and (r_conj) hydrochloride_8\NN\14817592|ppm (r_appos) quinacrine_7\NN\2721948|percent|in|simultaneously (r_dobj) given_4\VBN\5892096|have|.|,|thrombosis (r_csubj) had_18\VBD\0|NONE (l_advcl) have_36\VB\7846|.|,|thrombosis|given (l_dobj) thrombosis_38\NN\14100769|did|while|not|rats
D011796_D003328 CID hydrochloride_10\NN\14817592|NONE (r_dobj) ingesting_8\VBG\0|F (r_acl) rats_7\NNS\2329401|NONE (r_pobj) of_5\IN\0|the (r_prep) heart_4\NN\5919034|NONE (r_dobj) involving_2\VBG\2676054|.|Atrial (r_acl) thrombosis_1\NN\14100769|NONE
D011796_D003328 CID hydrochloride_6\NN\14817592|ppm|in (r_appos) quinacrine_5\NN\2721948|NONE (r_pobj) with_2\IN\0|.|developed|Rats (r_prep) treated_1\VBD\2376958|NONE (l_conj) developed_11\VBD\1753788|with|.|Rats (l_dobj) incidence_14\NN\13821570|all (l_prep) of_15\IN\0|a|high (l_pobj) thrombosis_18\NN\14100769|NONE
D011796_D003328 CID hydrochloride_8\NN\14817592|ppm (r_appos) quinacrine_7\NN\2721948|percent|in|simultaneously (r_dobj) given_4\VBN\5892096|have|.|,|thrombosis (r_csubj) had_18\VBD\0|NONE (l_advcl) have_36\VB\7846|.|,|thrombosis|given (l_dobj) thrombosis_38\NN\14100769|did|while|not|rats
D012977_D013927 NONE nitrite_13\NN\14621446|and (r_conj) hydrochloride_8\NN\14817592|ppm (r_appos) quinacrine_7\NN\2721948|percent|in|simultaneously (r_dobj) given_4\VBN\5892096|have|.|,|thrombosis (r_csubj) had_18\VBD\0|NONE (l_dobj) thrombosis_19\NN\14100769|have|.|,|given
7661171
D007213_D005355 NONE indomethacin_8\NN\3828465| (r_npadvmod) induced_10\VBN\1627355|in|renal (r_amod) dysfunction_12\NN\14204950|NONE (l_prep) in_13\IN\13603305|renal|induced (l_pobj) cirrhosis_16\NN\14116321|NONE
D007213_D005355 NONE indomethacin_12\NN\3828465| (r_npadvmod) induced_14\VBN\1627355|in|renal|the (r_amod) dysfunction_16\NN\14204950|to|acutely (l_prep) in_17\IN\13603305|induced|renal|the (l_pobj) patients_21\NNS\9898892|NONE (l_amod) cirrhotic_20\JJ\0|compensated
D007213_D005355 NONE indomethacin_31\NN\3828465|NONE (r_pobj) of_30\IN\0|doses|and| (r_prep) mg_29\NN\13717155|NONE (r_pobj) of_27\IN\0|oral|an (r_prep) combination_26\NN\7951464|NONE (r_pobj) after_23\IN\0|and (r_conj) before_21\RB\0|in|Parameters|were|by|. (r_prep) assessed_11\VBN\670261|NONE (l_prep) in_15\IN\13603305|Parameters|were|by|before|. (l_pobj) patients_20\NNS\9898892|NONE (l_amod) cirrhotic_19\JJ\0|compensated|
D007213_D005355 NONE indomethacin_17\NN\3828465|NONE (r_pobj) of_16\IN\0|the|adverse (r_prep) effects_15\NNS\13245626|to (r_dobj) prevent_12\VB\0|of|this|apparent (r_acl) ability_5\NN\4723816|However|with|is|,|until (r_nsubjpass) confirmed_22\VBN\0|prudent|would|.|it|,|avoid (r_advcl) be_30\VB\14625458|NONE (l_xcomp) avoid_33\VB\0|prudent|confirmed|would|.|it|, (l_dobj) therapy_38\NN\657604|to (l_prep) in_39\IN\13603305|inflammatory|nonsteroidal (l_pobj) patients_40\NNS\9898892|NONE (l_prep) with_41\IN\0|NONE (l_pobj) cirrhosis_42\NN\14116321|NONE
D016595_D005355 NONE misoprostol_6\NN\0|NONE (r_pobj) of_5\IN\0|dependent|.|The|on (r_prep) effect_4\NN\34213|NONE (l_prep) on_7\IN\0|dependent|of|.|The (l_pobj) dysfunction_12\NN\14204950|NONE (l_prep) in_13\IN\13603305|renal|induced (l_pobj) cirrhosis_16\NN\14116321|NONE
D016595_D005355 NONE misoprostol_0\NNP\0|.|counteract|has|been (r_nsubjpass) shown_7\VBN\2137132|NONE (l_xcomp) counteract_10\VB\2367363|.|has|Misoprostol|been (l_dobj) dysfunction_16\NN\14204950|to|acutely (l_prep) in_17\IN\13603305|induced|renal|the (l_pobj) patients_21\NNS\9898892|NONE (l_amod) cirrhotic_20\JJ\0|compensated
D016595_D005355 NONE misoprostol_36\NN\0|NONE (r_pobj) of_35\IN\0|various (r_prep) doses_34\NNS\3740161|and||of (r_conj) mg_29\NN\13717155|NONE (r_pobj) of_27\IN\0|oral|an (r_prep) combination_26\NN\7951464|NONE (r_pobj) after_23\IN\0|and (r_conj) before_21\RB\0|in|Parameters|were|by|. (r_prep) assessed_11\VBN\670261|NONE (l_prep) in_15\IN\13603305|Parameters|were|by|before|. (l_pobj) patients_20\NNS\9898892|NONE (l_amod) cirrhotic_19\JJ\0|compensated|
D016595_D005355 NONE misoprostol_10\NNP\0|NONE (r_pobj) of_9\IN\0| (r_prep) micrograms_8\NNS\13717155|NONE (r_pobj) of_6\IN\0|this|apparent|prevent (r_prep) ability_5\NN\4723816|However|with|is|,|until (r_nsubjpass) confirmed_22\VBN\0|prudent|would|.|it|,|avoid (r_advcl) be_30\VB\14625458|NONE (l_xcomp) avoid_33\VB\0|prudent|confirmed|would|.|it|, (l_dobj) therapy_38\NN\657604|to (l_prep) in_39\IN\13603305|inflammatory|nonsteroidal (l_pobj) patients_40\NNS\9898892|NONE (l_prep) with_41\IN\0|NONE (l_pobj) cirrhosis_42\NN\14116321|NONE
D016595_D007674 NONE misoprostol_6\NN\0|NONE (r_pobj) of_5\IN\0|dependent|.|The|on (r_prep) effect_4\NN\34213|NONE (l_prep) on_7\IN\0|dependent|of|.|The (l_pobj) dysfunction_12\NN\14204950|NONE
D016595_D007674 NONE misoprostol_0\NNP\0|.|counteract|has|been (r_nsubjpass) shown_7\VBN\2137132|NONE (l_xcomp) counteract_10\VB\2367363|.|has|Misoprostol|been (l_dobj) dysfunction_16\NN\14204950|to|acutely
D012964_D005355 NONE sodium_6\NN\14625458|and|renal (r_conj) hemodynamics_3\NNS\6080522|NONE (r_pobj) of_1\IN\0|handling (r_prep) parameters_0\NNS\5858936|in|were|by|before|. (r_nsubjpass) assessed_11\VBN\670261|NONE (l_prep) in_15\IN\13603305|Parameters|were|by|before|. (l_pobj) patients_20\NNS\9898892|NONE (l_amod) cirrhotic_19\JJ\0|compensated|
D007213_D007674 CID indomethacin_8\NN\3828465| (r_npadvmod) induced_10\VBN\1627355|in|renal (r_amod) dysfunction_12\NN\14204950|NONE
D007213_D007674 CID indomethacin_12\NN\3828465| (r_npadvmod) induced_14\VBN\1627355|in|renal|the (r_amod) dysfunction_16\NN\14204950|to|acutely
11385188
D003042_D009202 CID cocaine_18\NN\3492717|young|chronic|asymptomatic (r_compound) users_19\NNS\7846|NONE (r_pobj) in_14\IN\13603305|% (r_prep) common_9\JJ\8673395|that|disease (r_acomp) is_8\VBZ\0|We|. (l_nsubj) disease_7\NN\14061805|that|common
D003042_D003324 CID cocaine_18\NN\3492717|young|chronic|asymptomatic (r_compound) users_19\NNS\7846|NONE (r_pobj) in_14\IN\13603305|% (r_prep) common_9\JJ\8673395|that|disease (r_acomp) is_8\VBZ\0|We|. (l_nsubj) disease_7\NN\14061805|that|common
D003042_D006331 NONE cocaine_7\NN\3492717|chronic|asymptomatic (r_compound) users_8\NNS\7846|NONE (r_pobj) in_4\IN\13603305|.|of (r_prep) prevalence_0\NN\4764412|NONE (l_prep) of_1\IN\0|.|in (l_pobj) disease_3\NN\14061805|NONE
D003042_D006331 NONE cocaine_12\NN\3492717|asymptomatic|chronic|young (r_compound) users_13\NNS\7846|NONE (r_pobj) in_7\IN\13603305|heart (r_prep) disease_6\NN\14061805|NONE
D003042_D006331 NONE cocaine_16\NN\3492717|controls||and (r_compound) users_17\NNS\7846|the|of|, (r_conj) prevalence_3\NN\4764412|To (l_prep) of_4\IN\0|the|users|, (l_pobj) disease_6\NN\14061805|NONE
24091473
C476513_D066126 NONE levobupivacaine_9\NN\0| (r_npadvmod) induced_11\VBN\1627355|in|cardiac (r_amod) toxicity_13\NN\13576101|NONE
D004837_D066126 NONE epinephrine_4\NN\14807929|, (l_conj) both_7\DT\0|,|or (l_prep) in_8\IN\13603305|NONE (l_pobj) toxicity_13\NN\13576101|NONE
D004837_D064420 NONE epinephrine_8\NN\14807929|lipid|, (r_conj) emulsion_6\NN\14588219|NONE (r_pobj) of_4\IN\0|optimal|The|dosing (r_prep) regimens_3\NNS\5898568|are|not|in|yet|. (r_nsubjpass) determined_15\VBN\0|NONE (l_prep) in_16\IN\13603305|are|not|yet|regimens|. (l_pobj) neonates_17\NNS\9827683|NONE (l_prep) in_18\IN\13603305|NONE (l_pobj) cases_19\NNS\7283608|NONE (l_prep) of_20\IN\0|NONE (l_pobj) toxicity_24\NN\13576101|NONE
C476513_D002318 CID levobupivacaine_3\PRP\0|piglets|.|occurred (r_dobj) received_2\VBD\2210855|NONE (l_advcl) occurred_7\VBD\0|piglets|.|levobupivacaine (l_nsubj) collapse_6\NN\14061805|until
16911931
D019259_D006509 NONE lamivudine_7\NN\3834836|NONE (r_pobj) with_6\IN\0|after (r_prep) combined_5\VBN\2630189|B|Intramuscular|immune|. (r_acl) globulin_4\NN\14736972|NONE (l_compound) b_2\NNP\1355326|Intramuscular|combined|immune|.
D019259_D006509 NONE lamivudine_7\NN\3834836|NONE (l_prep) in_8\IN\13603305|NONE (l_pobj) prevention_9\NN\1073995|NONE (l_prep) of_10\IN\0|NONE (l_pobj) recurrence_13\NN\7342049|NONE (l_compound) b_12\NNP\1355326|NONE
D019259_D006509 NONE lamivudine_9\NN\3834836|)|and (r_conj) hbig_6\NNP\0|Combined|after|immune|B|( (r_appos) globulin_4\NN\14736972|significantly|.|survival|has (l_compound) b_2\NNP\1355326|Combined|after|immune|(|HBIg
D019259_D006509 NONE lamivudine_9\NN\3834836|)|and (l_prep) in_10\IN\13603305|NONE (l_pobj) prophylaxis_11\NN\1077350|NONE (l_prep) of_12\IN\0|NONE (l_pobj) recurrence_14\NN\7342049|NONE (l_prep) of_15\IN\0|the (l_pobj) b_17\NNP\1355326|NONE
D006514_D006509 NONE hbsag_27\JJ\0|positive (r_nmod) patients_29\NNS\9898892|NONE (r_pobj) of_26\IN\0|the (r_prep) survival_25\NN\13961642|significantly|.|globulin|has (r_dobj) improved_23\VBN\126264|NONE (l_nsubj) globulin_4\NN\14736972|significantly|.|survival|has (l_compound) b_2\NNP\1355326|Combined|after|immune|(|HBIg
D006514_D006509 NONE hbsag_27\JJ\0|positive (r_nmod) patients_29\NNS\9898892|NONE (r_pobj) of_26\IN\0|the (r_prep) survival_25\NN\13961642|significantly|.|globulin|has (r_dobj) improved_23\VBN\126264|NONE (l_nsubj) globulin_4\NN\14736972|significantly|.|survival|has (l_appos) hbig_6\NNP\0|Combined|after|immune|B|( (l_conj) lamivudine_9\NN\3834836|)|and (l_prep) in_10\IN\13603305|NONE (l_pobj) prophylaxis_11\NN\1077350|NONE (l_prep) of_12\IN\0|NONE (l_pobj) recurrence_14\NN\7342049|NONE (l_prep) of_15\IN\0|the (l_pobj) b_17\NNP\1355326|NONE
20034406
D010862_D013226 CID pilocarpine_12\NN\14712692| (r_npadvmod) induced_14\VBN\1627355|epilepticus (r_amod) status_15\NN\24720|NONE (l_amod) epilepticus_16\NN\0|induced
D010862_D013226 CID pilocarpine_17\NN\14712692|NONE (r_amod) injection_18\NN\320852|NONE (r_pobj) by_16\IN\0|NONE (r_agent) induced_15\VBN\1627355|status|(|epilepticus|) (r_acl) se_13\NNP\14724645|NONE (l_nmod) epilepticus_11\NN\0|status|(|induced|)
D010862_D013226 CID pilocarpine_17\NN\14712692|NONE (r_amod) injection_18\NN\320852|NONE (r_pobj) by_16\IN\0|NONE (r_agent) induced_15\VBN\1627355|status|(|epilepticus|) (r_acl) se_13\NNP\14724645|NONE
D010862_D013226 CID pilocarpine_4\NN\14712692|NONE (r_amod) injection_5\NN\320852|NONE (r_pobj) by_3\IN\0|SE|was|. (r_agent) induced_2\VBN\1627355|NONE (l_nsubjpass) se_0\NNP\14724645|by|was|.
D010862_D013226 CID pilocarpine_15\NN\14712692| (r_npadvmod) induced_17\VBN\1627355|NONE (r_amod) se_18\NNP\14724645|NONE
6985297
D015764_D001919 CID bepridil_6\NN\0|NONE (r_pcomp) by_5\IN\0|Studies|. (r_prep) induced_4\VBN\1627355|NONE (l_nsubj) studies_0\NNS\635850|by|. (l_prep) on_1\IN\0|NONE (l_pobj) bradycardia_3\NN\14110674|NONE
D015764_D001919 CID bepridil_0\NN\0|compound|bradycardia|,|, (r_advmod) induced_13\VBD\1627355|,|.|were|mechanisms|in (l_dobj) bradycardia_15\NNS\14110674|Bepridil|compound|,|,
D015764_D013610 NONE bepridil_0\NN\0|compound|bradycardia|,|, (r_advmod) induced_13\VBD\1627355|,|.|were|mechanisms|in (l_dobj) bradycardia_15\NNS\14110674|Bepridil|compound|,|, (l_conj) effect_24\NN\34213|and|persistent (l_amod) tachycardial_23\JJ\0|a
D015764_D000787 NONE bepridil_0\NN\0|compound|bradycardia|,|, (r_advmod) induced_13\VBD\1627355|,|.|were|mechanisms|in (l_nsubj) compound_5\NN\5869584|Bepridil|bradycardia|,|, (l_prep) for_6\IN\0|active|a|novel (l_pobj) treatment_8\NN\654885|NONE (l_prep) of_9\IN\0|prophylactic (l_pobj) attacks_11\NNS\955060|NONE
7949506
D013148_D006929 NONE spironolactone_16\CD\2721160|woman|and|.|was|d|with (r_conj) treated_8\VBN\2376958|NONE (l_nsubjpass) woman_4\NN\9605289|and|.|was|d|with|spironolactone (l_prep) with_5\IN\0|A|old (l_pobj) hyperaldosteronism_6\NN\14059928|NONE
D003000_D007022 CID clonidine_10\NN\2721160|NONE (r_pobj) between_9\IN\0|adverse|possible|resulting|a (r_prep) interaction_8\NN\37396|NONE (l_acl) resulting_13\VBG\2633881|adverse|possible|between|a (l_prep) in_14\IN\13603305|NONE (l_pobj) block_19\NN\21939|NONE (l_prep) in_20\IN\13603305|atrioventricular|)|AV|( (l_pobj) patients_22\NNS\9898892|NONE (l_conj) hypotension_25\NN\14057371|both|and
D003000_D007022 CID clonidine_8\NN\2721160|NONE (r_pobj) of_7\IN\0|a|bid|minimal (r_prep) dose_6\NN\3740161|NONE (r_pobj) of_3\IN\0|the (r_prep) addition_2\NN\3081021|NONE (r_pobj) after_0\IN\0|block|she|, (r_prep) developed_16\VBD\1753788|NONE (l_dobj) block_19\NN\21939|she|After|, (l_conj) hypotension_22\NN\14057371|,|AV|and|resolved|complete
D003000_D054537 CID clonidine_10\NN\2721160|NONE (r_pobj) between_9\IN\0|adverse|possible|resulting|a (r_prep) interaction_8\NN\37396|NONE (l_acl) resulting_13\VBG\2633881|adverse|possible|between|a (l_prep) in_14\IN\13603305|NONE (l_pobj) block_19\NN\21939|NONE
D003000_D054537 CID clonidine_8\NN\2721160|NONE (r_pobj) of_7\IN\0|a|bid|minimal (r_prep) dose_6\NN\3740161|NONE (r_pobj) of_3\IN\0|the (r_prep) addition_2\NN\3081021|NONE (r_pobj) after_0\IN\0|block|she|, (r_prep) developed_16\VBD\1753788|NONE (l_dobj) block_19\NN\21939|she|After|,
D003000_D054537 CID clonidine_4\JJ\2721160|NONE (r_pobj) of_3\IN\0|the (r_prep) addition_2\NN\3081021|bid (r_pobj) after_0\IN\0|.|she|block (r_prep) developed_9\VBD\1753788|NONE (l_dobj) block_12\NN\21939|After|.|she
D014700_D054537 CID verapamil_12\NN\2938514|and (r_conj) clonidine_10\NN\2721160|NONE (r_pobj) between_9\IN\0|adverse|possible|resulting|a (r_prep) interaction_8\NN\37396|NONE (l_acl) resulting_13\VBG\2633881|adverse|possible|between|a (l_prep) in_14\IN\13603305|NONE (l_pobj) block_19\NN\21939|NONE
D014700_D007022 CID verapamil_12\NN\2938514|and (r_conj) clonidine_10\NN\2721160|NONE (r_pobj) between_9\IN\0|adverse|possible|resulting|a (r_prep) interaction_8\NN\37396|NONE (l_acl) resulting_13\VBG\2633881|adverse|possible|between|a (l_prep) in_14\IN\13603305|NONE (l_pobj) block_19\NN\21939|NONE (l_prep) in_20\IN\13603305|atrioventricular|)|AV|( (l_pobj) patients_22\NNS\9898892|NONE (l_conj) hypotension_25\NN\14057371|both|and
D014700_D006929 NONE verapamil_10\NN\2938514|NONE (r_pobj) with_9\IN\0|woman|and|.|was|d|spironolactone (r_prep) treated_8\VBN\2376958|NONE (l_nsubjpass) woman_4\NN\9605289|and|.|was|d|with|spironolactone (l_prep) with_5\IN\0|A|old (l_pobj) hyperaldosteronism_6\NN\14059928|NONE
11135381
D008729_D014550 NONE methoxamine_2\NN\0|NONE (l_prep) on_3\IN\0|NONE (l_pobj) pressure_6\NN\11419404|NONE (l_prep) with_9\IN\0|in|maximum|urethral (l_pobj) incontinence_12\NN\13473097|NONE
D008729_D014550 NONE methoxamine_6\NN\0|NONE (r_pobj) of_4\IN\0|incremental|(|saline|) (r_prep) doses_3\NNS\3740161|Half (r_dobj) log_1\NN\15098161|.|were|measuring|to (r_csubjpass) administered_13\VBN\2436349|NONE (l_prep) to_14\IN\0|log|.|were|measuring (l_pobj) group_16\NN\2137|NONE (l_prep) with_19\IN\0|of|a (l_pobj) incontinence_22\NN\13473097|NONE
D008729_D006973 CID methoxamine_0\NNP\0|but|increases|caused|. (r_nsubj) evoked_1\VBD\1617192|NONE (l_conj) caused_13\VBD\1617192|Methoxamine|but|increases|. (l_dobj) rise_16\NN\7324673|NONE (l_prep) in_17\IN\13603305|a|and|fall|significant (l_pobj) pressure_20\NN\11419404|NONE
3191389
D010862_D013226 CID pilocarpine_4\NN\14712692|.|followed|in (r_nsubj) induces_5\VBZ\1627355|NONE (l_prep) in_6\IN\13603305|.|pilocarpine|followed (l_pobj) seizures_8\NNS\14081375|NONE (l_conj) epilepticus_11\NN\0|and|rats
D007213_D012640 NONE indomethacin_24\NN\3828465|, (r_conj) phenylbutazone_22\NN\2721538|sodium|, (r_appos) salicylate_20\NN\3828465|steroidal|inflammatory||,|, (r_conj) drugs_17\NNS\14778436|NONE (r_pobj) of_9\IN\0|on|the (r_prep) effect_8\NN\34213|to (l_prep) on_31\IN\0|the|of (l_pobj) seizures_32\NNS\14081375|NONE
D007213_D012640 NONE indomethacin_0\NNP\3828465|.|modulate (r_nsubj) failed_15\VBD\0|NONE (l_xcomp) modulate_17\VB\1724459|.|Indomethacin (l_dobj) seizures_18\NNS\14081375|to
D012980_D012640 CID salicylate_20\NN\3828465|steroidal|inflammatory||,|, (r_conj) drugs_17\NNS\14778436|NONE (r_pobj) of_9\IN\0|on|the (r_prep) effect_8\NN\34213|to (l_prep) on_31\IN\0|the|of (l_pobj) seizures_32\NNS\14081375|NONE
D010862_D001930 NONE pilocarpine_24\NN\14712692|NONE (r_pobj) by_23\IN\0|NONE (r_agent) induced_22\VBN\1627355|brain|related (r_acl) damage_21\NN\7296428|NONE
D010862_D012640 CID pilocarpine_14\NN\14712692|NONE (r_pobj) by_13\IN\0|in (r_agent) produced_12\VBN\1617192|NONE (r_acl) seizures_11\NNS\14081375|NONE
D010862_D012640 CID pilocarpine_4\NN\14712692|.|followed|in (r_nsubj) induces_5\VBZ\1627355|NONE (l_prep) in_6\IN\13603305|.|pilocarpine|followed (l_pobj) seizures_8\NNS\14081375|NONE
D010862_D012640 CID pilocarpine_35\NN\14712692|NONE (r_pobj) by_34\IN\0|NONE (r_agent) produced_33\VBN\1617192|NONE (r_acl) seizures_32\NNS\14081375|NONE
D010862_D012640 CID pilocarpine_21\NN\14712692|NONE (r_pobj) by_20\IN\0|NONE (r_agent) produced_19\VBN\1617192|NONE (r_acl) seizures_18\NNS\14081375|to
D010862_D012640 CID pilocarpine_24\NN\14712692|NONE (r_pobj) by_23\IN\0|NONE (r_agent) induced_22\VBN\1627355|brain|related (r_acl) damage_21\NN\7296428|NONE (r_pobj) from_16\IN\0|rats|mg/kg|and|, (r_prep) seizures_12\NNS\14081375|acid|.
D010862_D012640 CID pilocarpine_24\NN\14712692|NONE (r_pobj) by_23\IN\0|NONE (r_agent) induced_22\VBN\1627355|brain|related (r_acl) damage_21\NN\7296428|NONE (l_amod) related_19\VBN\628491|induced|brain (l_npadvmod) seizure_17\NN\14081375|
D010862_D012640 CID pilocarpine_16\NN\14712692| (r_npadvmod) induced_18\VBN\1627355|NONE (r_amod) seizures_19\NNS\14081375|NONE
D008528_D012640 NONE acid_29\NN\14818238|and (r_conj) ibuprofen_26\NNP\3828465|, (r_conj) indomethacin_24\NN\3828465|, (r_conj) phenylbutazone_22\NN\2721538|sodium|, (r_appos) salicylate_20\NN\3828465|steroidal|inflammatory||,|, (r_conj) drugs_17\NNS\14778436|NONE (r_pobj) of_9\IN\0|on|the (r_prep) effect_8\NN\34213|to (l_prep) on_31\IN\0|the|of (l_pobj) seizures_32\NNS\14081375|NONE
D008528_D012640 NONE acid_1\NN\14818238|.|seizures (r_nsubj) prevented_11\VBN\0|NONE (l_dobj) seizures_12\NNS\14081375|acid|.
D008528_D012640 NONE acid_1\NN\14818238|.|seizures (r_nsubj) prevented_11\VBN\0|NONE (l_dobj) seizures_12\NNS\14081375|acid|. (l_prep) from_16\IN\0|rats|mg/kg|and|, (l_pobj) damage_21\NN\7296428|NONE (l_amod) related_19\VBN\628491|induced|brain (l_npadvmod) seizure_17\NN\14081375|
D007052_D012640 NONE ibuprofen_26\NNP\3828465|, (r_conj) indomethacin_24\NN\3828465|, (r_conj) phenylbutazone_22\NN\2721538|sodium|, (r_appos) salicylate_20\NN\3828465|steroidal|inflammatory||,|, (r_conj) drugs_17\NNS\14778436|NONE (r_pobj) of_9\IN\0|on|the (r_prep) effect_8\NN\34213|to (l_prep) on_31\IN\0|the|of (l_pobj) seizures_32\NNS\14081375|NONE
D007052_D012640 NONE ibuprofen_8\NNP\3828465|and|,| (r_conj) mg/kg_5\NN\0|,|,|mg/kg|, (r_conj) indomethacin_0\NNP\3828465|.|modulate (r_nsubj) failed_15\VBD\0|NONE (l_xcomp) modulate_17\VB\1724459|.|Indomethacin (l_dobj) seizures_18\NNS\14081375|to
D008528_D001930 NONE acid_1\NN\14818238|.|seizures (r_nsubj) prevented_11\VBN\0|NONE (l_dobj) seizures_12\NNS\14081375|acid|. (l_prep) from_16\IN\0|rats|mg/kg|and|, (l_pobj) damage_21\NN\7296428|NONE
D010653_D012640 CID phenylbutazone_22\NN\2721538|sodium|, (r_appos) salicylate_20\NN\3828465|steroidal|inflammatory||,|, (r_conj) drugs_17\NNS\14778436|NONE (r_pobj) of_9\IN\0|on|the (r_prep) effect_8\NN\34213|to (l_prep) on_31\IN\0|the|of (l_pobj) seizures_32\NNS\14081375|NONE
7147232
D009599_D007022 CID nitroprusside_10\NN\0|NONE (l_nsubj) effects_1\NNS\13245626|.|on (l_prep) of_2\IN\0|induced|Cardiovascular (l_pobj) hypotension_3\NN\14057371|NONE
D009599_D007022 CID nitroprusside_7\NN\0|.|induce|are|to (r_nsubjpass) administered_12\VBN\2436349|NONE (l_advcl) induce_16\VB\1627355|nitroprusside|.|are|to (l_conj) control_18\VB\5190804|to|and (l_dobj) hypotension_19\NN\14057371|NONE
D009599_D007022 CID snp_9\NNP\11493266|triphosphate (r_appos) nitroprusside_7\NN\0|.|induce|are|to (r_nsubjpass) administered_12\VBN\2436349|NONE (l_advcl) induce_16\VB\1627355|nitroprusside|.|are|to (l_conj) control_18\VB\5190804|to|and (l_dobj) hypotension_19\NN\14057371|NONE
D009599_D007022 CID snp_4\NNP\11493266|similar (r_nmod) decreases_6\NNS\7296428|NONE (r_pobj) by_3\IN\0|NONE (r_agent) produced_2\VBN\1617192|NONE (r_acl) hypotension_1\NN\14057371|NONE
D010100_D007022 NONE oxygen_66\NN\14622893|.|and|)|,|body|rate|( (r_compound) consumption_67\NN\13440063|peripheral|product|,|total|)|,|.|( (r_conj) resistance_46\NN\37396|accompanied|pressure|,|pressure|, (r_dobj) left_31\VBD\8621598|normal|variables|stopped|within|;|. (l_ccomp) accompanied_5\VBN\0|pressure|,|pressure|resistance|, (l_nsubjpass) hypotension_0\NN\14057371|by|was
D010100_D007022 NONE oxygen_65\NN\14622893|content|)|.|between (r_compound) difference_67\NN\4723816|,|.|and|)|(|pressure (r_conj) product_56\NN\3076708|total|.|peripheral|increased|,|(|,|) (r_conj) resistance_46\NN\37396|During|p|,|.|were|in (r_appos) observed_8\VBN\2163746|NONE (l_prep) during_0\IN\0|resistance|p|,|.|were|in (l_pobj) hypotension_1\NN\14057371|NONE
D000255_D007022 CID triphosphate_7\NN\0|NONE (r_pobj) by_5\IN\0|NONE (r_agent) induced_4\VBN\1627355|of|Cardiovascular (r_acl) effects_1\NNS\13245626|.|on (l_prep) of_2\IN\0|induced|Cardiovascular (l_pobj) hypotension_3\NN\14057371|NONE
D000255_D007022 CID triphosphate_1\NN\0|SNP (r_nsubj) nitroprusside_7\NN\0|.|induce|are|to (r_nsubjpass) administered_12\VBN\2436349|NONE (l_advcl) induce_16\VB\1627355|nitroprusside|.|are|to (l_conj) control_18\VB\5190804|to|and (l_dobj) hypotension_19\NN\14057371|NONE
D000255_D007022 CID atp_3\NNP\14964590|sodium|Adenosine|(|)|and (r_appos) triphosphate_1\NN\0|SNP (r_nsubj) nitroprusside_7\NN\0|.|induce|are|to (r_nsubjpass) administered_12\VBN\2436349|NONE (l_advcl) induce_16\VB\1627355|nitroprusside|.|are|to (l_conj) control_18\VB\5190804|to|and (l_dobj) hypotension_19\NN\14057371|NONE
D000255_D007022 CID atp_3\NNP\14964590|NONE (r_pobj) by_2\IN\0|NONE (r_agent) induced_1\VBN\1627355|NONE (r_acl) hypotension_0\NN\14057371|by|was
D000255_D007022 CID atp_94\NNP\14964590|was|after (r_nsubjpass) stopped_96\VBN\0|normal|left|variables|within|;|. (r_advcl) returned_88\VBD\1835496|NONE (l_ccomp) left_31\VBD\8621598|normal|variables|stopped|within|;|. (l_ccomp) accompanied_5\VBN\0|pressure|,|pressure|resistance|, (l_nsubjpass) hypotension_0\NN\14057371|by|was
24665854
D014635_D022124 CID valproate_0\NNP\0|.||encephalopathy (r_npadvmod) induced_2\VBN\1627355|NONE (l_dobj) encephalopathy_4\NN\14084880|.||Valproate (l_det) hyperammonemic_3\JJ\0|in
D014635_D022124 CID valproate_0\NNP\0| (r_npadvmod) induced_2\VBN\1627355|hyperammonemic (r_amod) encephalopathy_4\NN\14084880|.|effect (l_det) hyperammonemic_3\JJ\0|induced
D014635_D022124 CID valproate_12\NN\0|NONE (r_amod) treatment_13\NN\654885|NONE (r_pobj) of_11\IN\0|an|uncommon (r_prep) effect_10\NN\34213|.|encephalopathy (r_attr) is_5\VBZ\0|NONE (l_nsubj) encephalopathy_4\NN\14084880|.|effect (l_det) hyperammonemic_3\JJ\0|induced
D014635_D022124 CID valproate_21\NN\0|of|the (l_conj) revealed_26\VBN\2137132|and|due (l_dobj) consciousness_28\NN\5669934|after (l_prep) with_29\IN\0|impaired (l_pobj) hyperammonemia_30\NN\0|NONE
D014635_D003244 CID valproate_21\NN\0|of|the (l_conj) revealed_26\VBN\2137132|and|due (l_dobj) consciousness_28\NN\5669934|after
D014635_D001927 NONE valproate_0\NNP\0|.||encephalopathy (r_npadvmod) induced_2\VBN\1627355|NONE (l_dobj) encephalopathy_4\NN\14084880|.||Valproate
D014635_D001927 NONE valproate_0\NNP\0| (r_npadvmod) induced_2\VBN\1627355|hyperammonemic (r_amod) encephalopathy_4\NN\14084880|.|effect
D014635_D001927 NONE valproate_12\NN\0|NONE (r_amod) treatment_13\NN\654885|NONE (r_pobj) of_11\IN\0|an|uncommon (r_prep) effect_10\NN\34213|.|encephalopathy (r_attr) is_5\VBZ\0|NONE (l_nsubj) encephalopathy_4\NN\14084880|.|effect
D014635_D004827 NONE valproate_21\NN\0|of|the (l_prep) due_22\JJ\5174653|and|revealed (l_prep) to_23\IN\0|NONE (l_pobj) epilepsy_24\NN\14085708|NONE
8603459
D004317_D066126 CID doxorubicin_0\NNP\2716866| (r_npadvmod) induced_2\VBN\1627355|.|monitored (r_amod) cardiotoxicity_3\NN\0|NONE
D004317_D066126 CID doxorubicin_11\RB\2716866| (r_npadvmod) induced_13\VBN\1627355|NONE (r_amod) cardiotoxicity_14\NN\0|to
D004317_D066126 CID doxorubicin_13\NN\2716866| (r_npadvmod) induced_15\VBN\1627355|NONE (r_amod) cardiotoxicity_16\NN\0|NONE
D064730_D064420 NONE icrf-187_16\NNP\0|NONE (r_pobj) of_15\IN\0|the (r_prep) protection_14\NN\407535|,|.|exerted|was|using|) (r_nsubjpass) determined_18\VBN\0|NONE (l_advcl) exerted_3\VBD\1158872|protection|,|.|was|using|) (l_dobj) toxicity_5\NN\13576101|As|schedule
D064730_D064420 NONE icrf-187_16\NNP\0|NONE (r_pobj) of_15\IN\0|the (r_prep) protection_14\NN\407535|,|.|exerted|was|using|) (r_nsubjpass) determined_18\VBN\0|NONE (l_xcomp) using_19\VBG\418025|protection|,|.|exerted|was|) (l_dobj) schedule_22\NN\5898568|NONE (l_prep) with_23\IN\0|dose|a (l_pobj) toxicity_26\NN\13576101|NONE
D004317_D064420 NONE doxorubicin_34\NN\2716866|(|doses|lower|general (r_punct) toxicity_26\NN\13576101|NONE (r_pobj) with_23\IN\0|dose|a (r_prep) schedule_22\NN\5898568|NONE (r_dobj) using_19\VBG\418025|protection|,|.|exerted|was|) (r_xcomp) determined_18\VBN\0|NONE (l_advcl) exerted_3\VBD\1158872|protection|,|.|was|using|) (l_dobj) toxicity_5\NN\13576101|As|schedule
D004317_D064420 NONE doxorubicin_34\NN\2716866|(|doses|lower|general (r_punct) toxicity_26\NN\13576101|NONE
D064730_D066126 NONE icrf-187_24\NNP\0|NONE (r_pobj) by_23\IN\0|NONE (r_agent) provided_22\VBN\2199590|the (r_acl) protection_21\NN\407535|NONE (r_pobj) by_19\IN\0|testing|as (r_agent) demonstrated_18\VBN\2137132|that (l_nsubj) testing_9\NN\639556|as|by (l_prep) of_10\IN\0|the (l_pobj) protectors_11\NNS\10466918|NONE (l_prep) against_12\IN\0|NONE (l_pobj) cardiotoxicity_16\NN\0|NONE
D004317_D006984 NONE doxorubicin_5\RB\2716866| (r_npadvmod) treated_7\VBN\2376958|NONE (r_amod) animals_8\NNS\4475|NONE (r_pobj) of_4\IN\0|the (r_prep) hearts_3\NNS\496167|NONE (r_dobj) sacrifice_1\NN\30358|NONE (r_pcomp) after_0\IN\0|and|were|were (r_prep) enlarged_10\VBN\153263|NONE (l_conj) were_14\VBD\0|After|and|were (l_acomp) hypertrophic_15\JJ\0|.|atria
21195121
D005680_D012640 NONE gaba(a_8\NNP\0|) (r_nmod) receptors_10\NNS\5225602|NONE (r_pobj) of_7\IN\0|the (r_prep) blockage_6\NN\14034177|mainly|convulsions (r_dobj) trough_4\VB\9366017|It|. (l_nsubj) convulsions_2\NNS\14081375|mainly|blockage
D009569_D004827 NONE oxide_1\NN\14818238|observed|,|in|due|role|and (r_nsubj) has_9\VBZ\13888491|NONE (l_conj) observed_39\VBN\2163746|oxide|,|in|due|role|and (l_prep) in_40\IN\13603305|NAME|. (l_pobj) models_43\NNS\5888929|NONE (l_compound) epilepsy_42\NN\14085708|different
D009569_D004827 NONE no_3\NNP\7204911|,|(|)|,|Nitric|neurotransmitter (r_intj) oxide_1\NN\14818238|observed|,|in|due|role|and (r_nsubj) has_9\VBZ\13888491|NONE (l_conj) observed_39\VBN\2163746|oxide|,|in|due|role|and (l_prep) in_40\IN\13603305|NAME|. (l_pobj) models_43\NNS\5888929|NONE (l_compound) epilepsy_42\NN\14085708|different
D009569_D004827 NONE no_25\DT\7204911|NOS (r_det) syntheses_26\NNS\13446390|NONE (r_pobj) of_24\IN\0|arginine (r_prep) precursor_23\NN\14580897|NONE (r_pobj) of_18\IN\0|opposite (r_prep) effects_17\NNS\13245626|to (r_pobj) due_14\IN\5174653|oxide|observed|,|in|role|and (r_prep) has_9\VBZ\13888491|NONE (l_conj) observed_39\VBN\2163746|oxide|,|in|due|role|and (l_prep) in_40\IN\13603305|NAME|. (l_pobj) models_43\NNS\5888929|NONE (l_compound) epilepsy_42\NN\14085708|different
D009569_D004827 NONE no_12\DT\7204911|NONE (r_pobj) of_11\IN\0|on|the (r_prep) effects_10\NNS\13245626|to (l_prep) on_13\IN\0|of|the (l_pobj) characteristics_18\NNS\5849040|NONE (l_prep) of_19\IN\0|in|the|behavioral (l_pobj) epilepsy_23\NN\14085708|NONE
D001556_D004827 NONE lindane_20\NN\14919948| (r_npadvmod) induced_22\VBN\1627355|NONE (r_amod) epilepsy_23\NN\14085708|NONE
D009569_D012640 NONE oxide_4\NN\14818238|NONE (r_pobj) of_2\IN\0|in|induced|.|The (r_prep) role_1\NN\719494|NONE (l_prep) in_5\IN\13603305|induced|.|The|of (l_pobj) convulsions_6\NNS\14081375|NONE
D009569_D012640 NONE no_6\DT\7204911|that|role (r_nsubj) plays_7\VBZ\7007684|the (l_dobj) role_9\NN\719494|that|NO (l_prep) in_13\IN\13603305|of|a (l_pobj) model_15\NN\5888929|NONE (l_prep) of_16\IN\0|rat (l_pobj) seizures_18\NNS\14081375|NONE
D019331_D012640 NONE name_8\NNP\6284225|NONE (r_pobj) with_5\IN\0|mg/kg (r_prep) pretreatment_4\NN\0|following|On|incidence|,|. (r_nsubj) decreased_19\VBD\169651|NONE (l_npadvmod) incidence_21\NN\13821570|following|On|,|.|pretreatment (l_compound) convulsion_20\NN\14081375|severity|time|and|and
D019331_D012640 NONE name_8\NNP\6284225|NONE (r_pobj) with_5\IN\0|mg/kg (r_prep) pretreatment_4\NN\0|following|On|incidence|,|. (r_nsubj) decreased_19\VBD\169651|NONE (l_npadvmod) incidence_21\NN\13821570|following|On|,|.|pretreatment (l_conj) time_27\NN\7308889|severity|convulsion|and|and (l_prep) to_28\IN\0|prolonged|latency (l_pobj) convulsion_29\NN\14081375|NONE
D019331_D012640 NONE name_8\NNP\6284225|NONE (r_pobj) with_5\IN\0|mg/kg (r_prep) pretreatment_4\NN\0|following|On|incidence|,|. (r_nsubj) decreased_19\VBD\169651|NONE (l_prep) following_30\VBG\8180190|On|incidence|,|.|pretreatment (l_pobj) injection_31\NN\320852|NONE (l_prep) with_32\IN\0|NONE (l_pobj) dose_35\NN\3740161|NONE (l_amod) convulsive_34\JJ\0|a|(|)|of|mg/kg
D001120_D012640 NONE arginine_5\NN\14605787|NONE (r_pobj) of_2\IN\0|in|)|mg/kg|i.p.|The|, (r_prep) administration_1\NN\1133281|shortened|and|incidence|significantly|. (r_nsubj) increased_22\VBD\169651|NONE (l_dobj) incidence_24\NN\13821570|shortened|and|administration|significantly|. (l_compound) convulsion_23\NN\14081375|and|severity
D001120_D012640 NONE arginine_5\NN\14605787|NONE (r_pobj) of_2\IN\0|in|)|mg/kg|i.p.|The|, (r_prep) administration_1\NN\1133281|shortened|and|incidence|significantly|. (r_nsubj) increased_22\VBD\169651|NONE (l_conj) shortened_28\VBN\429060|and|administration|incidence|significantly|. (l_prep) to_31\IN\0|time (l_pobj) convulsion_33\NN\14081375|NONE
D001556_D012640 CID lindane_9\NN\14919948|NONE (r_pobj) by_8\IN\0|NONE (r_agent) induced_7\VBN\1627355|in|.|The|of (r_acl) role_1\NN\719494|NONE (l_prep) in_5\IN\13603305|induced|.|The|of (l_pobj) convulsions_6\NNS\14081375|NONE
D001556_D012640 CID lindane_37\NN\14919948|mg/kg|lower (r_compound) dose_38\NN\3740161|NONE (r_pobj) by_35\IN\0|NONE (r_agent) elicited_34\VBN\1617192|first (r_acl) convulsion_33\NN\14081375|NONE (r_pobj) to_31\IN\0|time (r_prep) shortened_28\VBN\429060|and|administration|incidence|significantly|. (r_conj) increased_22\VBD\169651|NONE (l_dobj) incidence_24\NN\13821570|shortened|and|administration|significantly|. (l_compound) convulsion_23\NN\14081375|and|severity
D001556_D012640 CID lindane_37\NN\14919948|mg/kg|lower (r_compound) dose_38\NN\3740161|NONE (r_pobj) by_35\IN\0|NONE (r_agent) elicited_34\VBN\1617192|first (r_acl) convulsion_33\NN\14081375|NONE
D001556_D012640 CID lindane_37\NN\14919948|NONE (r_pobj) of_36\IN\0|a|(|)|convulsive|mg/kg (r_prep) dose_35\NN\3740161|NONE (r_pobj) with_32\IN\0|NONE (r_prep) injection_31\NN\320852|NONE (r_pobj) following_30\VBG\8180190|On|incidence|,|.|pretreatment (r_prep) decreased_19\VBD\169651|NONE (l_npadvmod) incidence_21\NN\13821570|following|On|,|.|pretreatment (l_compound) convulsion_20\NN\14081375|severity|time|and|and
D001556_D012640 CID lindane_37\NN\14919948|NONE (r_pobj) of_36\IN\0|a|(|)|convulsive|mg/kg (r_prep) dose_35\NN\3740161|NONE (r_pobj) with_32\IN\0|NONE (r_prep) injection_31\NN\320852|NONE (r_pobj) following_30\VBG\8180190|On|incidence|,|.|pretreatment (r_prep) decreased_19\VBD\169651|NONE (l_npadvmod) incidence_21\NN\13821570|following|On|,|.|pretreatment (l_conj) time_27\NN\7308889|severity|convulsion|and|and (l_prep) to_28\IN\0|prolonged|latency (l_pobj) convulsion_29\NN\14081375|NONE
D001556_D012640 CID lindane_37\NN\14919948|NONE (r_pobj) of_36\IN\0|a|(|)|convulsive|mg/kg (r_prep) dose_35\NN\3740161|NONE (l_amod) convulsive_34\JJ\0|a|(|)|of|mg/kg
D001556_D012640 CID lindane_17\NN\14919948|NONE (r_compound) seizures_18\NNS\14081375|NONE
D019331_D004827 NONE name_34\NNP\6284225|.|in (r_nsubj) observed_39\VBN\2163746|oxide|,|in|due|role|and (l_prep) in_40\IN\13603305|NAME|. (l_pobj) models_43\NNS\5888929|NONE (l_compound) epilepsy_42\NN\14085708|different
D001120_D004827 NONE arginine_21\NN\14605787|of (r_nmod) precursor_23\NN\14580897|NONE (r_pobj) of_18\IN\0|opposite (r_prep) effects_17\NNS\13245626|to (r_pobj) due_14\IN\5174653|oxide|observed|,|in|role|and (r_prep) has_9\VBZ\13888491|NONE (l_conj) observed_39\VBN\2163746|oxide|,|in|due|role|and (l_prep) in_40\IN\13603305|NAME|. (l_pobj) models_43\NNS\5888929|NONE (l_compound) epilepsy_42\NN\14085708|different
3864191
D012459_D007674 NONE salicylate_0\NNP\3828465|role|.|:|in (r_compound) nephropathy_1\NN\14573196|NONE
D011453_D007674 NONE prostaglandins_10\NNS\5414534|NONE (r_pobj) of_9\IN\0|potential (r_prep) role_8\NN\719494|Salicylate|.|:|in (r_appos) nephropathy_1\NN\14573196|NONE
D011453_D007674 NONE prostaglandins_6\NNS\5414534|NONE (r_pobj) of_5\IN\0|the|potential|in (r_prep) role_4\NN\719494|We|. (l_prep) in_7\IN\13603305|of|the|potential (l_pobj) development_9\NN\248977|NONE (l_prep) of_10\IN\0|the|in (l_pobj) nephropathy_12\NN\14573196|NONE
D011453_D007674 NONE prostaglandin_4\NN\5414534|renal (r_amod) synthesis_5\NN\13446390|NONE (r_pobj) in_2\IN\13603305|The (r_prep) changes_1\NNS\7283608|were|by|. (r_nsubjpass) accompanied_7\VBN\0|NONE (l_agent) by_8\IN\0|changes|were|. (l_pobj) evidence_9\NN\5816287|NONE (l_prep) of_10\IN\0|rats|but (l_pobj) damage_12\NN\7296428|NONE
D011453_D007674 NONE prostaglandin_5\NN\5414534|enhanced (r_amod) synthesis_6\NN\13446390|lead|,|to|and|that (r_nsubj) contributes_7\VBZ\126264|.|results (l_conj) lead_24\VB\5155821|,|synthesis|to|and|that (l_prep) to_25\IN\0|that|may|inhibition (l_pobj) lesions_29\NNS\14204950|NONE (l_conj) deterioration_31\NN\14560612|medullary|renal|pathological|and (l_prep) of_32\IN\0|NONE (l_pobj) function_34\NN\13783581|NONE
D011453_D007674 NONE prostaglandin_21\JJ\5414534|NONE (r_amod) synthesis_22\NN\13446390|NONE (r_pobj) of_20\IN\0|NONE (r_prep) inhibition_19\NN\1068773|to|that|may (r_nsubj) lead_24\VB\5155821|,|synthesis|to|and|that (l_prep) to_25\IN\0|that|may|inhibition (l_pobj) lesions_29\NNS\14204950|NONE (l_conj) deterioration_31\NN\14560612|medullary|renal|pathological|and (l_prep) of_32\IN\0|NONE (l_pobj) function_34\NN\13783581|NONE
D011453_D006417 NONE prostaglandin_4\NN\5414534|renal (r_amod) synthesis_5\NN\13446390|NONE (r_pobj) in_2\IN\13603305|The (r_prep) changes_1\NNS\7283608|were|by|. (r_nsubjpass) accompanied_7\VBN\0|NONE (l_agent) by_8\IN\0|changes|were|. (l_pobj) evidence_9\NN\5816287|NONE (l_conj) rats_21\NNS\2329401|of|but (l_conj) incidence_27\NN\13821570|creatinine|;|:|evidenced|jJ (l_prep) of_30\IN\0|increased|p|severity|and (l_pobj) hematuria_31\NN\14299637|NONE
D003404_D007674 NONE creatinine_41\NN\0|;|:|incidence|evidenced|jJ (r_conj) rats_21\NNS\2329401|of|but (r_conj) evidence_9\NN\5816287|NONE (l_prep) of_10\IN\0|rats|but (l_pobj) damage_12\NN\7296428|NONE
D001241_D006417 NONE aspirin_14\NN\2707683| (r_npadvmod) treated_16\VBN\2376958|NONE (r_amod) jj_17\UH\0|NONE (r_pobj) in_13\IN\13603305|renal (r_prep) damage_12\NN\7296428|NONE (r_pobj) of_10\IN\0|rats|but (r_prep) evidence_9\NN\5816287|NONE (l_conj) rats_21\NNS\2329401|of|but (l_conj) incidence_27\NN\13821570|creatinine|;|:|evidenced|jJ (l_prep) of_30\IN\0|increased|p|severity|and (l_pobj) hematuria_31\NN\14299637|NONE
D001241_D006417 NONE aspirin_69\NN\2707683| (r_npadvmod) treated_71\VBN\2376958|NONE (r_amod) jj_72\NNP\0|or|treated|either (r_conj) jj_67\NNS\0|NONE (r_pobj) to_62\IN\0|NONE (r_prep) compared_61\VBN\644583|.|) (r_prep) p_57\XX\14622893|(|in (r_appos) increase_50\VB\13576355|and|increased|;|.|)|serum|( (r_conj) creatinine_41\NN\0|;|:|incidence|evidenced|jJ (r_conj) rats_21\NNS\2329401|of|but (l_conj) incidence_27\NN\13821570|creatinine|;|:|evidenced|jJ (l_prep) of_30\IN\0|increased|p|severity|and (l_pobj) hematuria_31\NN\14299637|NONE
D001663_D006932 NONE bilirubin_18\NN\14756039|in|marked (r_amod) deposition_19\NN\13424865|NONE (r_pobj) to_16\IN\0|NONE (r_prep) leading_15\VBG\4339291|rats|hyperbilirubinemia|.|, (r_advcl) have_4\VBP\7846|NONE (l_dobj) hyperbilirubinemia_6\NN\14204950|rats|.|leading|,
-1_D006932 NONE glucuronyl_12\NN\0|NONE (r_compound) transferase_13\NN\14732946|NONE (r_pobj) of_11\IN\0|the (r_prep) absence_10\NN\14449405|to (r_pobj) due_7\IN\5174653|unconjugated (r_amod) hyperbilirubinemia_6\NN\14204950|rats|.|leading|,
D001241_D007674 CID aspirin_14\NN\2707683| (r_npadvmod) treated_16\VBN\2376958|NONE (r_amod) jj_17\UH\0|NONE (r_pobj) in_13\IN\13603305|renal (r_prep) damage_12\NN\7296428|NONE
D001241_D007674 CID aspirin_69\NN\2707683| (r_npadvmod) treated_71\VBN\2376958|NONE (r_amod) jj_72\NNP\0|or|treated|either (r_conj) jj_67\NNS\0|NONE (r_pobj) to_62\IN\0|NONE (r_prep) compared_61\VBN\644583|.|) (r_prep) p_57\XX\14622893|(|in (r_appos) increase_50\VB\13576355|and|increased|;|.|)|serum|( (r_conj) creatinine_41\NN\0|;|:|incidence|evidenced|jJ (r_conj) rats_21\NNS\2329401|of|but (r_conj) evidence_9\NN\5816287|NONE (l_prep) of_10\IN\0|rats|but (l_pobj) damage_12\NN\7296428|NONE
D003404_D006417 NONE creatinine_41\NN\0|;|:|incidence|evidenced|jJ (r_conj) rats_21\NNS\2329401|of|but (l_conj) incidence_27\NN\13821570|creatinine|;|:|evidenced|jJ (l_prep) of_30\IN\0|increased|p|severity|and (l_pobj) hematuria_31\NN\14299637|NONE
D011453_D058186 NONE prostaglandin_5\NN\5414534|enhanced (r_amod) synthesis_6\NN\13446390|lead|,|to|and|that (r_nsubj) contributes_7\VBZ\126264|.|results (l_conj) lead_24\VB\5155821|,|synthesis|to|and|that (l_prep) to_25\IN\0|that|may|inhibition (l_pobj) lesions_29\NNS\14204950|NONE
D011453_D058186 NONE prostaglandin_21\JJ\5414534|NONE (r_amod) synthesis_22\NN\13446390|NONE (r_pobj) of_20\IN\0|NONE (r_prep) inhibition_19\NN\1068773|to|that|may (r_nsubj) lead_24\VB\5155821|,|synthesis|to|and|that (l_prep) to_25\IN\0|that|may|inhibition (l_pobj) lesions_29\NNS\14204950|NONE
15815446
C009591_D001930 NONE chloride_18\NN\14818238|NONE (r_dobj) using_16\VBG\418025|tissue (r_advcl) staining_14\VBG\275424|NONE (r_pcomp) by_13\IN\0|,|was|for|A (r_prep) evaluated_12\VBN\670261|by|.|was (l_prep) for_3\IN\0|,|by|was|A (l_pobj) rats_5\NNS\2329401|NONE (l_prep) in_6\IN\13603305|eight (l_pobj) injury_10\NN\14052046|NONE
D010656_D001930 NONE phenylephrine_17\NN\2682038| (r_npadvmod) induced_19\VBN\1627355|on (r_amod) hypertension_20\NN\14057371|NONE (l_prep) on_21\IN\0|induced (l_pobj) injury_24\NN\14052046|NONE
D010656_D006973 CID phenylephrine_8\NN\2682038| (r_npadvmod) induced_10\VBN\1627355|NONE (r_amod) hypertension_11\NN\14057371|NONE
D010656_D006973 CID phenylephrine_17\NN\2682038| (r_npadvmod) induced_19\VBN\1627355|on (r_amod) hypertension_20\NN\14057371|NONE (r_pobj) of_16\IN\0|the (r_prep) effect_15\NN\34213|After|, (r_nsubj) was_31\VBD\0|. (l_prep) after_0\IN\0|effect|, (l_pobj) min_2\NN\15154774|NONE (l_prep) of_3\IN\0| (l_pobj) occlusion_8\NN\14081375|NONE (l_prep) in_9\IN\13603305|cerebral|artery|temporary|middle (l_pobj) rats_12\NNS\2329401|NONE (l_amod) hypertensive_11\JJ\10405694|NONE
D010656_D006973 CID phenylephrine_17\NN\2682038| (r_npadvmod) induced_19\VBN\1627355|on (r_amod) hypertension_20\NN\14057371|NONE
D005070_D006973 NONE blue_1\NNP\4959672|greater|. (r_nsubj) was_9\VBD\0|NONE (l_acomp) greater_10\JJR\0|Blue|. (l_prep) in_11\IN\13603305|NONE (l_pobj) group_14\NN\2137|NONE (l_nummod) 90/htn_13\CD\0|)|.|(|)|(|the|versus|was|+/|,
D005070_D006973 NONE blue_1\NNP\4959672|greater|. (r_nsubj) was_9\VBD\0|NONE (l_acomp) greater_10\JJR\0|Blue|. (l_prep) in_11\IN\13603305|NONE (l_pobj) group_14\NN\2137|NONE (l_relcl) was_31\VBD\0|)|.|(|)|(|the|versus|/HTN|+/|, (l_acomp) greater_34\JJR\0|in|which (l_prep) than_35\IN\0|NONE (l_pobj) group_38\NN\2137|NONE (l_compound) 15/htn_37\CD\0|)|the|+/|(
D010656_D002545 NONE phenylephrine_8\NN\2682038| (r_npadvmod) induced_10\VBN\1627355|NONE (r_amod) hypertension_11\NN\14057371|NONE (r_pobj) of_7\IN\0|during (r_prep) effect_6\NN\34213|.|:|cerebral|in|Focal (r_appos) ischemia_2\NN\14195315|NONE
D010656_D020244 NONE phenylephrine_17\NN\2682038| (r_npadvmod) induced_19\VBN\1627355|on (r_amod) hypertension_20\NN\14057371|NONE (r_pobj) of_16\IN\0|the (r_prep) effect_15\NN\34213|After|, (r_nsubj) was_31\VBD\0|. (l_prep) after_0\IN\0|effect|, (l_pobj) min_2\NN\15154774|NONE (l_prep) of_3\IN\0| (l_pobj) occlusion_8\NN\14081375|NONE
C009591_D004487 NONE chloride_18\NN\14818238|NONE (l_conj) edema_20\NN\14315192|,,triphenyltetrazolium|and
15276093
C451780_D050171 NONE lovastatin_5\NN\3676175|NONE (r_appos) niacin_0\NNP\15090742|.|product (r_nsubj) is_6\VBZ\0|NONE (l_attr) product_10\NN\3076708|.|Niacin (l_acl) approved_11\VBN\803325|a|new|combination (l_prep) for_12\IN\0|NONE (l_pobj) treatment_13\NN\654885|NONE (l_prep) of_14\IN\0|NONE (l_pobj) hypercholesterolemia_16\NN\14299637|NONE (l_conj) dyslipidemia_19\NN\0|and|primary
C451780_D050171 NONE lovastatin_30\NN\3676175|niacin|and (r_conj) dyslipidemia_23\NN\0|NONE
C451780_D006937 NONE lovastatin_5\NN\3676175|NONE (r_appos) niacin_0\NNP\15090742|.|product (r_nsubj) is_6\VBZ\0|NONE (l_attr) product_10\NN\3076708|.|Niacin (l_acl) approved_11\VBN\803325|a|new|combination (l_prep) for_12\IN\0|NONE (l_pobj) treatment_13\NN\654885|NONE (l_prep) of_14\IN\0|NONE (l_pobj) hypercholesterolemia_16\NN\14299637|NONE
D003401_D009135 NONE creatine_3\NN\14601829|NONE (r_compound) phosphokinase_4\NN\0|NONE (r_pobj) of_2\IN\0|to|An (r_prep) increase_1\NN\13576355|,|in|and|limit|observed (r_nsubj) occurred_14\VBD\0|NONE (l_conj) observed_30\VBN\2163746|,|increase|in|and|limit (l_nsubjpass) cases_23\NNS\7283608|were|. (l_prep) of_24\IN\0|no (l_pobj) myopathy_28\NNS\14204950|NONE
7479194
D014295_D064420 NONE trimethoprim_14\NN\0||trimethoprim|, (r_conj) sulfamethoxazole_12\NN\4352070|NONE (r_pobj) of_9\IN\0|large|A|.|based|up|for (r_prep) study_8\NN\635850|NONE (l_prep) for_18\IN\0|large|A|.|of|based|up (l_pobj) toxicity_22\NN\13576101|NONE
D002506_D007674 NONE cephalexin_34\NN\2996840|,|trimethoprim|,|,|and (r_conj) prescribed_27\VBD\748282|.|estimate|We|study (r_conj) conducted_1\VBD\2436349|NONE (l_advcl) estimate_37\VB\5802185|.|prescribed|We|study (l_dobj) risk_39\NN\14541044|to (l_prep) of_40\IN\0|the (l_pobj) liver_42\NN\5298729|NONE (l_conj) blood_44\NN\5397468|serious|, (l_conj) skin_46\NN\5237755|, (l_conj) disorders_50\NNS\14034177|and|,
D015662_D008107 CID smz_15\NNP\0|(|) (r_nmod) 5.2/100,000_17\CD\0|NONE (r_dobj) prescribed_12\VBN\748282|NONE (r_acl) persons_11\NNS\7347|NONE (r_pobj) for_10\IN\0|NONE (r_prep) similar_9\JJ\0|and|trimethoprim|risk (r_acomp) was_8\VBD\0|NONE (l_nsubj) risk_1\NN\14541044|and|trimethoprim|similar (l_prep) of_2\IN\0|The (l_pobj) disease_7\NN\14061805|NONE
D015662_D008107 NONE sulfamethoxazole_19\NN\4352070||)|(|TMP (r_compound) smz_23\NNP\0|who|were (r_dobj) prescribed_16\VBN\748282|, (r_relcl) people_13\NNS\31264|NONE (r_pobj) of_11\IN\0|day|follow|a|based (r_prep) study_10\NN\635850|.|prescribed|estimate|We (r_dobj) conducted_1\VBD\2436349|NONE (l_advcl) estimate_37\VB\5802185|.|prescribed|We|study (l_dobj) risk_39\NN\14541044|to (l_prep) of_40\IN\0|the (l_pobj) liver_42\NN\5298729|NONE (l_conj) blood_44\NN\5397468|serious|, (l_conj) skin_46\NN\5237755|, (l_conj) disorders_50\NNS\14034177|and|,
D015662_D008107 NONE smz_23\NNP\0|who|were (r_dobj) prescribed_16\VBN\748282|, (r_relcl) people_13\NNS\31264|NONE (r_pobj) of_11\IN\0|day|follow|a|based (r_prep) study_10\NN\635850|.|prescribed|estimate|We (r_dobj) conducted_1\VBD\2436349|NONE (l_advcl) estimate_37\VB\5802185|.|prescribed|We|study (l_dobj) risk_39\NN\14541044|to (l_prep) of_40\IN\0|the (l_pobj) liver_42\NN\5298729|NONE (l_conj) blood_44\NN\5397468|serious|, (l_conj) skin_46\NN\5237755|, (l_conj) disorders_50\NNS\14034177|and|,
D002506_D012871 NONE cephalexin_34\NN\2996840|,|trimethoprim|,|,|and (r_conj) prescribed_27\VBD\748282|.|estimate|We|study (r_conj) conducted_1\VBD\2436349|NONE (l_advcl) estimate_37\VB\5802185|.|prescribed|We|study (l_dobj) risk_39\NN\14541044|to (l_prep) of_40\IN\0|the (l_pobj) liver_42\NN\5298729|NONE (l_conj) blood_44\NN\5397468|serious|, (l_conj) skin_46\NN\5237755|, (l_conj) disorders_50\NNS\14034177|and|,
D014295_D012871 NONE trimethoprim_28\NN\0|,|cephalexin|,|,|and (r_dobj) prescribed_27\VBD\748282|.|estimate|We|study (r_conj) conducted_1\VBD\2436349|NONE (l_advcl) estimate_37\VB\5802185|.|prescribed|We|study (l_dobj) risk_39\NN\14541044|to (l_prep) of_40\IN\0|the (l_pobj) liver_42\NN\5298729|NONE (l_conj) blood_44\NN\5397468|serious|, (l_conj) skin_46\NN\5237755|, (l_conj) disorders_50\NNS\14034177|and|,
D015662_D004892 NONE smz_15\NNP\0|NONE (r_pobj) to_12\IN\0|one|was (r_prep) exposed_11\VBN\2110927|,|blood|of|; (r_relcl) disorders_5\NNS\14034177|patients (l_prep) of_17\IN\0|,|blood|exposed|; (l_pobj) seven_18\CD\13741022|NONE (l_prep) with_19\IN\0|NONE (l_pobj) multiforme_21\NNS\0|NONE
D015662_D004892 NONE smz_34\NNP\0|NONE (r_pobj) to_31\IN\0|were|experienced|.|four|, (r_prep) exposed_30\VBN\2110927|NONE (l_ccomp) experienced_3\VBD\2108377|were|.|four|,|to (l_dobj) disorders_5\NNS\14034177|patients (l_prep) of_17\IN\0|,|blood|exposed|; (l_pobj) seven_18\CD\13741022|NONE (l_prep) with_19\IN\0|NONE (l_pobj) multiforme_21\NNS\0|NONE
D014295_D008107 CID trimethoprim_22\NN\0|and|risk|similar (r_conj) was_8\VBD\0|NONE (l_nsubj) risk_1\NN\14541044|and|trimethoprim|similar (l_prep) of_2\IN\0|The (l_pobj) disease_7\NN\14061805|NONE
D014295_D008107 NONE trimethoprim_28\NN\0|,|cephalexin|,|,|and (r_dobj) prescribed_27\VBD\748282|.|estimate|We|study (r_conj) conducted_1\VBD\2436349|NONE (l_advcl) estimate_37\VB\5802185|.|prescribed|We|study (l_dobj) risk_39\NN\14541044|to (l_prep) of_40\IN\0|the (l_pobj) liver_42\NN\5298729|NONE (l_conj) blood_44\NN\5397468|serious|, (l_conj) skin_46\NN\5237755|, (l_conj) disorders_50\NNS\14034177|and|,
D015662_D064420 NONE sulfamethoxazole_12\NN\4352070|NONE (r_pobj) of_9\IN\0|large|A|.|based|up|for (r_prep) study_8\NN\635850|NONE (l_prep) for_18\IN\0|large|A|.|of|based|up (l_pobj) toxicity_22\NN\13576101|NONE
D014295_D007674 NONE trimethoprim_28\NN\0|,|cephalexin|,|,|and (r_dobj) prescribed_27\VBD\748282|.|estimate|We|study (r_conj) conducted_1\VBD\2436349|NONE (l_advcl) estimate_37\VB\5802185|.|prescribed|We|study (l_dobj) risk_39\NN\14541044|to (l_prep) of_40\IN\0|the (l_pobj) liver_42\NN\5298729|NONE (l_conj) blood_44\NN\5397468|serious|, (l_conj) skin_46\NN\5237755|, (l_conj) disorders_50\NNS\14034177|and|,
D015662_D007674 NONE sulfamethoxazole_19\NN\4352070||)|(|TMP (r_compound) smz_23\NNP\0|who|were (r_dobj) prescribed_16\VBN\748282|, (r_relcl) people_13\NNS\31264|NONE (r_pobj) of_11\IN\0|day|follow|a|based (r_prep) study_10\NN\635850|.|prescribed|estimate|We (r_dobj) conducted_1\VBD\2436349|NONE (l_advcl) estimate_37\VB\5802185|.|prescribed|We|study (l_dobj) risk_39\NN\14541044|to (l_prep) of_40\IN\0|the (l_pobj) liver_42\NN\5298729|NONE (l_conj) blood_44\NN\5397468|serious|, (l_conj) skin_46\NN\5237755|, (l_conj) disorders_50\NNS\14034177|and|,
D015662_D007674 NONE smz_23\NNP\0|who|were (r_dobj) prescribed_16\VBN\748282|, (r_relcl) people_13\NNS\31264|NONE (r_pobj) of_11\IN\0|day|follow|a|based (r_prep) study_10\NN\635850|.|prescribed|estimate|We (r_dobj) conducted_1\VBD\2436349|NONE (l_advcl) estimate_37\VB\5802185|.|prescribed|We|study (l_dobj) risk_39\NN\14541044|to (l_prep) of_40\IN\0|the (l_pobj) liver_42\NN\5298729|NONE (l_conj) blood_44\NN\5397468|serious|, (l_conj) skin_46\NN\5237755|, (l_conj) disorders_50\NNS\14034177|and|,
D015662_D013262 CID smz_15\NNP\0|NONE (r_pobj) to_12\IN\0|one|was (r_prep) exposed_11\VBN\2110927|,|blood|of|; (r_relcl) disorders_5\NNS\14034177|patients (l_prep) of_17\IN\0|,|blood|exposed|; (l_pobj) seven_18\CD\13741022|NONE (l_prep) with_19\IN\0|NONE (l_pobj) multiforme_21\NNS\0|NONE (l_conj) syndrome_26\NN\5870365|erythema|and
D015662_D013262 CID smz_34\NNP\0|NONE (r_pobj) to_31\IN\0|were|experienced|.|four|, (r_prep) exposed_30\VBN\2110927|NONE (l_ccomp) experienced_3\VBD\2108377|were|.|four|,|to (l_dobj) disorders_5\NNS\14034177|patients (l_prep) of_17\IN\0|,|blood|exposed|; (l_pobj) seven_18\CD\13741022|NONE (l_prep) with_19\IN\0|NONE (l_pobj) multiforme_21\NNS\0|NONE (l_conj) syndrome_26\NN\5870365|erythema|and
D002506_D008107 NONE cephalexin_34\NN\2996840|,|trimethoprim|,|,|and (r_conj) prescribed_27\VBD\748282|.|estimate|We|study (r_conj) conducted_1\VBD\2436349|NONE (l_advcl) estimate_37\VB\5802185|.|prescribed|We|study (l_dobj) risk_39\NN\14541044|to (l_prep) of_40\IN\0|the (l_pobj) liver_42\NN\5298729|NONE (l_conj) blood_44\NN\5397468|serious|, (l_conj) skin_46\NN\5237755|, (l_conj) disorders_50\NNS\14034177|and|,
D002506_D006402 NONE cephalexin_34\NN\2996840|,|trimethoprim|,|,|and (r_conj) prescribed_27\VBD\748282|.|estimate|We|study (r_conj) conducted_1\VBD\2436349|NONE (l_advcl) estimate_37\VB\5802185|.|prescribed|We|study (l_dobj) risk_39\NN\14541044|to (l_prep) of_40\IN\0|the (l_pobj) liver_42\NN\5298729|NONE (l_conj) blood_44\NN\5397468|serious|, (l_conj) skin_46\NN\5237755|, (l_conj) disorders_50\NNS\14034177|and|,
D015662_D012871 NONE sulfamethoxazole_19\NN\4352070||)|(|TMP (r_compound) smz_23\NNP\0|who|were (r_dobj) prescribed_16\VBN\748282|, (r_relcl) people_13\NNS\31264|NONE (r_pobj) of_11\IN\0|day|follow|a|based (r_prep) study_10\NN\635850|.|prescribed|estimate|We (r_dobj) conducted_1\VBD\2436349|NONE (l_advcl) estimate_37\VB\5802185|.|prescribed|We|study (l_dobj) risk_39\NN\14541044|to (l_prep) of_40\IN\0|the (l_pobj) liver_42\NN\5298729|NONE (l_conj) blood_44\NN\5397468|serious|, (l_conj) skin_46\NN\5237755|, (l_conj) disorders_50\NNS\14034177|and|,
D015662_D012871 NONE smz_23\NNP\0|who|were (r_dobj) prescribed_16\VBN\748282|, (r_relcl) people_13\NNS\31264|NONE (r_pobj) of_11\IN\0|day|follow|a|based (r_prep) study_10\NN\635850|.|prescribed|estimate|We (r_dobj) conducted_1\VBD\2436349|NONE (l_advcl) estimate_37\VB\5802185|.|prescribed|We|study (l_dobj) risk_39\NN\14541044|to (l_prep) of_40\IN\0|the (l_pobj) liver_42\NN\5298729|NONE (l_conj) blood_44\NN\5397468|serious|, (l_conj) skin_46\NN\5237755|, (l_conj) disorders_50\NNS\14034177|and|,
D002506_D013262 CID cephalexin_13\NN\2996840|who (r_dobj) took_12\VBD\2367363|a (r_relcl) patient_10\NN\9898892|NONE (r_pobj) in_8\IN\13603305|case|. (r_prep) occurred_7\VBD\0|NONE (l_nsubj) case_2\NN\7283608|.|in (l_prep) of_3\IN\0|one|The (l_pobj) necrolysis_6\NN\13509528|NONE
D002506_D064420 NONE cephalexin_17\NN\2996840|and|, (r_conj) trimethoprim_14\NN\0||trimethoprim|, (r_conj) sulfamethoxazole_12\NN\4352070|NONE (r_pobj) of_9\IN\0|large|A|.|based|up|for (r_prep) study_8\NN\635850|NONE (l_prep) for_18\IN\0|large|A|.|of|based|up (l_pobj) toxicity_22\NN\13576101|NONE
D014295_D006402 NONE trimethoprim_28\NN\0|,|cephalexin|,|,|and (r_dobj) prescribed_27\VBD\748282|.|estimate|We|study (r_conj) conducted_1\VBD\2436349|NONE (l_advcl) estimate_37\VB\5802185|.|prescribed|We|study (l_dobj) risk_39\NN\14541044|to (l_prep) of_40\IN\0|the (l_pobj) liver_42\NN\5298729|NONE (l_conj) blood_44\NN\5397468|serious|, (l_conj) skin_46\NN\5237755|, (l_conj) disorders_50\NNS\14034177|and|,
D015662_D006402 NONE sulfamethoxazole_19\NN\4352070||)|(|TMP (r_compound) smz_23\NNP\0|who|were (r_dobj) prescribed_16\VBN\748282|, (r_relcl) people_13\NNS\31264|NONE (r_pobj) of_11\IN\0|day|follow|a|based (r_prep) study_10\NN\635850|.|prescribed|estimate|We (r_dobj) conducted_1\VBD\2436349|NONE (l_advcl) estimate_37\VB\5802185|.|prescribed|We|study (l_dobj) risk_39\NN\14541044|to (l_prep) of_40\IN\0|the (l_pobj) liver_42\NN\5298729|NONE (l_conj) blood_44\NN\5397468|serious|, (l_conj) skin_46\NN\5237755|, (l_conj) disorders_50\NNS\14034177|and|,
D015662_D006402 NONE smz_23\NNP\0|who|were (r_dobj) prescribed_16\VBN\748282|, (r_relcl) people_13\NNS\31264|NONE (r_pobj) of_11\IN\0|day|follow|a|based (r_prep) study_10\NN\635850|.|prescribed|estimate|We (r_dobj) conducted_1\VBD\2436349|NONE (l_advcl) estimate_37\VB\5802185|.|prescribed|We|study (l_dobj) risk_39\NN\14541044|to (l_prep) of_40\IN\0|the (l_pobj) liver_42\NN\5298729|NONE (l_conj) blood_44\NN\5397468|serious|, (l_conj) skin_46\NN\5237755|, (l_conj) disorders_50\NNS\14034177|and|,
8511251
D003042_D017202 CID cocaine_0\NN\3492717|ischemia|. (r_nsubj) induced_1\VBD\1627355|NONE (l_dobj) ischemia_3\NN\14195315|Cocaine|.
D003042_D017202 CID cocaine_9\NN\3492717|NONE (r_pobj) by_8\IN\0|NONE (r_agent) induced_7\VBN\1627355|of|a (r_acl) case_3\NN\7283608|.|We (l_prep) of_4\IN\0|induced|a (l_pobj) ischemia_6\NN\14195315|NONE
D005996_D007511 NONE nitroglycerin_11\NN\15015501|NONE (r_pobj) by_10\IN\0|was (r_agent) reversed_9\VBN\109660|by|probably|.|ischemia (r_conj) induced_3\VBN\1627355|NONE (l_nsubj) ischemia_1\NN\14195315|by|reversed|probably|.
D002118_D007511 NONE calcium_13\NN\14625458|NONE (r_npadvmod) blocking_14\VBG\562280|NONE (r_amod) agents_15\NNS\7347|and (r_conj) nitroglycerin_11\NN\15015501|NONE (r_pobj) by_10\IN\0|was (r_agent) reversed_9\VBN\109660|by|probably|.|ischemia (r_conj) induced_3\VBN\1627355|NONE (l_nsubj) ischemia_1\NN\14195315|by|reversed|probably|.
D002118_D003329 NONE calcium_13\NN\14625458|NONE (r_npadvmod) blocking_14\VBG\562280|NONE (r_amod) agents_15\NNS\7347|and (r_conj) nitroglycerin_11\NN\15015501|NONE (r_pobj) by_10\IN\0|was (r_agent) reversed_9\VBN\109660|by|probably|.|ischemia (r_conj) induced_3\VBN\1627355|NONE (l_agent) by_4\IN\0|reversed|probably|.|ischemia (l_pobj) spasm_7\NN\14299637|NONE
D005996_D003329 NONE nitroglycerin_11\NN\15015501|NONE (r_pobj) by_10\IN\0|was (r_agent) reversed_9\VBN\109660|by|probably|.|ischemia (r_conj) induced_3\VBN\1627355|NONE (l_agent) by_4\IN\0|reversed|probably|.|ischemia (l_pobj) spasm_7\NN\14299637|NONE
19447152
D012964_D001714 NONE na(+)/k(+)-atpase_10\NNP\0|a (r_compound) inhibitor_11\NN\20090|(|ICV|in|(|)|)|of (r_appos) administration_5\NN\1133281|The (r_appos) intracerebroventricular_1\JJ\0|been|.|has|mimic (r_nsubjpass) suggested_17\VBN\1010118|NONE (l_xcomp) mimic_19\VB\10200365|been|.|has|intracerebroventricular (l_dobj) symptoms_21\NNS\5823932|to (l_prep) of_22\IN\0|some (l_pobj) mania_25\NN\9180259|NONE
D010042_D009069 NONE ouabain_4\NN\0|hyperlocomotion|that (r_nsubj) induced_10\VBN\1627355|remained|findings|and|, (l_dobj) hyperlocomotion_11\NN\0|ouabain|that
D011188_D001714 NONE na(+)/k(+)-atpase_10\NNP\0|a (r_compound) inhibitor_11\NN\20090|(|ICV|in|(|)|)|of (r_appos) administration_5\NN\1133281|The (r_appos) intracerebroventricular_1\JJ\0|been|.|has|mimic (r_nsubjpass) suggested_17\VBN\1010118|NONE (l_xcomp) mimic_19\VB\10200365|been|.|has|intracerebroventricular (l_dobj) symptoms_21\NNS\5823932|to (l_prep) of_22\IN\0|some (l_pobj) mania_25\NN\9180259|NONE
D010042_D001714 CID ouabain_6\NN\0|NONE (r_pobj) by_5\IN\0|model|Evidence|.|: (r_prep) induced_4\VBN\1627355|NONE (l_nsubj) model_1\NN\5888929|by|Evidence|.|: (l_prep) of_2\IN\0|Animal (l_pobj) mania_3\NN\9180259|NONE
D010042_D001714 CID ouabain_7\NN\0|NONE (r_pobj) of_6\IN\0|(|ICV|in|(|inhibitor|)|) (r_prep) administration_5\NN\1133281|The (r_appos) intracerebroventricular_1\JJ\0|been|.|has|mimic (r_nsubjpass) suggested_17\VBN\1010118|NONE (l_xcomp) mimic_19\VB\10200365|been|.|has|intracerebroventricular (l_dobj) symptoms_21\NNS\5823932|to (l_prep) of_22\IN\0|some (l_pobj) mania_25\NN\9180259|NONE
D010042_D001714 CID ouabain_3\NN\0| (r_npadvmod) induced_5\VBN\1627355|mania (r_amod) behavior_9\NN\407535|,|.|In|model|may (l_nmod) mania_6\NN\9180259|induced
D010042_D001714 CID ouabain_3\NN\0| (r_npadvmod) induced_5\VBN\1627355|mania (r_amod) behavior_9\NN\407535|,|.|In|model|may (r_nsubj) provide_11\VB\2199590|NONE (l_dobj) model_15\NN\5888929|,|.|In|may|behavior (l_relcl) test_17\VB\5798043|animal|a|useful (l_dobj) hypothesis_19\NN\7162194|to (l_prep) of_20\IN\0|the (l_pobj) involvement_22\NN\1080366|NONE (l_prep) of_23\IN\0|the (l_pobj) stress_25\NN\7083732|NONE (l_prep) in_26\IN\13603305|oxidative (l_pobj) disorder_28\NN\14034177|NONE
733189
C000873_D015356 CID acetate_24\NN\15010703|NONE (r_pobj) with_22\IN\0|in|tissue|head (r_prep) injection_21\NN\320852|NONE (r_dobj) following_14\VBG\8180190|NONE (r_prep) blindness_13\NN\14552802|NONE (r_pobj) with_12\IN\0|choriocapillaris (r_prep) occlusions_11\NNS\14081375|bilateral|and|retinal
D010406_D015356 NONE penicillin_33\NN\2716866|,|or (r_conj) epinephrine_30\NN\14807929|, (r_conj) lidocaine_28\NN\3681148|NONE (r_pobj) with_27\IN\0|NONE (r_prep) combination_26\NN\7951464|NONE (r_pobj) in_25\IN\13603305|with|tissue|head (r_prep) injection_21\NN\320852|NONE (r_dobj) following_14\VBG\8180190|NONE (r_prep) blindness_13\NN\14552802|NONE (r_pobj) with_12\IN\0|choriocapillaris (r_prep) occlusions_11\NNS\14081375|bilateral|and|retinal
D004837_D015356 NONE epinephrine_30\NN\14807929|, (r_conj) lidocaine_28\NN\3681148|NONE (r_pobj) with_27\IN\0|NONE (r_prep) combination_26\NN\7951464|NONE (r_pobj) in_25\IN\13603305|with|tissue|head (r_prep) injection_21\NN\320852|NONE (r_dobj) following_14\VBG\8180190|NONE (r_prep) blindness_13\NN\14552802|NONE (r_pobj) with_12\IN\0|choriocapillaris (r_prep) occlusions_11\NNS\14081375|bilateral|and|retinal
D004837_D001766 NONE epinephrine_30\NN\14807929|, (r_conj) lidocaine_28\NN\3681148|NONE (r_pobj) with_27\IN\0|NONE (r_prep) combination_26\NN\7951464|NONE (r_pobj) in_25\IN\13603305|with|tissue|head (r_prep) injection_21\NN\320852|NONE (r_dobj) following_14\VBG\8180190|NONE (r_prep) blindness_13\NN\14552802|NONE
D008012_D015356 NONE lidocaine_28\NN\3681148|NONE (r_pobj) with_27\IN\0|NONE (r_prep) combination_26\NN\7951464|NONE (r_pobj) in_25\IN\13603305|with|tissue|head (r_prep) injection_21\NN\320852|NONE (r_dobj) following_14\VBG\8180190|NONE (r_prep) blindness_13\NN\14552802|NONE (r_pobj) with_12\IN\0|choriocapillaris (r_prep) occlusions_11\NNS\14081375|bilateral|and|retinal
D008012_D001766 NONE lidocaine_28\NN\3681148|NONE (r_pobj) with_27\IN\0|NONE (r_prep) combination_26\NN\7951464|NONE (r_pobj) in_25\IN\13603305|with|tissue|head (r_prep) injection_21\NN\320852|NONE (r_dobj) following_14\VBG\8180190|NONE (r_prep) blindness_13\NN\14552802|NONE
D010406_D001766 NONE penicillin_33\NN\2716866|,|or (r_conj) epinephrine_30\NN\14807929|, (r_conj) lidocaine_28\NN\3681148|NONE (r_pobj) with_27\IN\0|NONE (r_prep) combination_26\NN\7951464|NONE (r_pobj) in_25\IN\13603305|with|tissue|head (r_prep) injection_21\NN\320852|NONE (r_dobj) following_14\VBG\8180190|NONE (r_prep) blindness_13\NN\14552802|NONE
D000305_D015356 NONE corticosteroid_13\NN\14745635|in|acting (r_compound) suspensions_14\NNS\14586258|NONE (r_pobj) of_9\IN\0|the (r_prep) injection_8\NN\320852|NONE (r_pobj) following_6\VBG\8180190|.|retinal|studies|Bilateral|and|occlusion|: (r_prep) artery_2\NN\5417975|NONE (l_conj) occlusion_5\NN\14081375|.|following|retinal|studies|Bilateral|and|:
C000873_D001766 NONE acetate_24\NN\15010703|NONE (r_pobj) with_22\IN\0|in|tissue|head (r_prep) injection_21\NN\320852|NONE (r_dobj) following_14\VBG\8180190|NONE (r_prep) blindness_13\NN\14552802|NONE
20566328
C476756_D006331 NONE mitoq._15\NNP\0|NONE (r_pobj) by_11\IN\0|NONE (r_prep) prevention_10\NN\1073995|Mitochondrial (r_appos) impairment_1\NN\7296428|to|: (r_nsubj) contributes_2\VBZ\126264|NONE (l_prep) to_3\IN\0|:|impairment (l_pobj) dysfunction_8\NN\14204950|NONE
C476756_D006331 NONE mitoq_0\NNP\0|was|.|prevent (r_nsubjpass) shown_9\VBN\2137132|NONE (l_xcomp) prevent_12\VB\0|was|.|MitoQ (l_dobj) abnormalities_15\NNS\14034177|completely|to (l_conj) dysfunction_20\NN\14204950|as|mitochondrial|these
C476756_-1 NONE mitoq_0\NNP\0|was|.|prevent (r_nsubjpass) shown_9\VBN\2137132|NONE (l_xcomp) prevent_12\VB\0|was|.|MitoQ (l_dobj) abnormalities_15\NNS\14034177|completely|to (l_conj) dysfunction_20\NN\14204950|as|mitochondrial|these (l_acl) characterized_21\VBN\609683|cardiac (l_agent) by_23\IN\0|here (l_pobj) dysfunction_26\NN\14204950|NONE
D003042_D028361 NONE cocaine_4\NN\3492717| (r_npadvmod) induced_6\VBN\1627355|cardiac (r_amod) dysfunction_8\NN\14204950|NONE (r_pobj) to_3\IN\0|:|impairment (r_prep) contributes_2\VBZ\126264|NONE (l_nsubj) impairment_1\NN\7296428|to|:
D003042_D028361 NONE cocaine_15\NN\3492717|NONE (r_pobj) to_14\IN\0|term (r_prep) exposure_13\NN\5042871|NONE (r_pobj) after_9\IN\0|effect|not|,|suggesting|detectable|. (r_prep) was_6\VBD\0|NONE (l_advcl) suggesting_17\VBG\1010118|after|effect|not|,|detectable|. (l_ccomp) were_22\VBD\0|NONE (l_nsubj) abnormalities_21\NNS\14034177|event|that
D003042_D028361 NONE cocaine_35\NN\3492717|NONE (r_pobj) to_34\IN\0|the|pathological (r_prep) response_33\NN\11410625|NONE (r_pobj) in_30\IN\13603305|a|late|a|primary (r_prep) event_29\NN\23100|abnormalities|that (r_attr) were_22\VBD\0|NONE (l_nsubj) abnormalities_21\NNS\14034177|event|that
D003042_D028361 NONE cocaine_11\NN\3492717| (r_npadvmod) induced_13\VBN\1627355|cardiac (r_amod) dysfunction_15\NN\14204950|due|that|may (r_nsubj) be_17\VB\14625458|NONE (l_acomp) due_18\JJ\5174653|dysfunction|that|may (l_prep) to_19\IN\0|NONE (l_pobj) defect_22\NN\14462666|NONE
D003042_D006331 CID cocaine_4\NN\3492717| (r_npadvmod) induced_6\VBN\1627355|cardiac (r_amod) dysfunction_8\NN\14204950|NONE
D003042_D006331 CID cocaine_18\NN\3492717| (r_npadvmod) induced_20\VBN\1627355|cardiac (r_amod) dysfunction_22\NN\14204950|NONE
D003042_D006331 CID cocaine_11\NN\3492717| (r_npadvmod) induced_13\VBN\1627355|cardiac (r_amod) dysfunction_15\NN\14204950|due|that|may
C476756_D028361 NONE mitoq._15\NNP\0|NONE (r_pobj) by_11\IN\0|NONE (r_prep) prevention_10\NN\1073995|Mitochondrial (r_appos) impairment_1\NN\7296428|to|:
C476756_D028361 NONE mitoq_0\NNP\0|was|.|prevent (r_nsubjpass) shown_9\VBN\2137132|NONE (l_xcomp) prevent_12\VB\0|was|.|MitoQ (l_dobj) abnormalities_15\NNS\14034177|completely|to
8308951
D014859_D001778 NONE warfarin_7\RB\2718259| (r_npadvmod) induced_9\VBN\1627355|NONE (r_amod) coagulopathy_10\NN\0|to
D014859_D001778 NONE warfarin_3\JJ\2718259|NONE (r_pobj) of_2\IN\0|Percutaneous|causing (r_prep) absorption_1\NN\13558490|in|,|.|is|times|, (l_acl) causing_4\VBG\30358|Percutaneous|of (l_dobj) coagulopathy_5\NN\0|NONE
D014859_D002543 CID warfarin_3\VB\2718259| (r_npadvmod) like_5\JJ\5839024|NONE (r_amod) anticoagulant_6\NN\3740161|NONE (r_pobj) to_2\IN\0|.|report|Cutaneous|:|causing (r_prep) exposure_1\NN\5042871|NONE (l_acl) causing_7\VBG\30358|.|report|to|Cutaneous|: (l_dobj) hemorrhage_10\NN\14285662|NONE
D010894_D001778 NONE piroxicam_5\NN\3828465|NONE (r_pobj) with_4\IN\0|An|took|adverse|,|drug (r_prep) interaction_3\NN\37396|coagulopathy|.|,|may|have (r_nsubj) exacerbated_14\VBN\126264|NONE (l_dobj) coagulopathy_16\NN\0|.|interaction|,|may|have
D014859_D006406 NONE warfarin_7\RB\2718259| (r_npadvmod) induced_9\VBN\1627355|NONE (r_amod) coagulopathy_10\NN\0|to (r_pobj) due_5\IN\5174653|A|of (r_prep) case_1\NN\7283608|is|. (l_prep) of_2\IN\0|due|A (l_pobj) hematoma_4\NN\14317720|NONE
2718706
D006221_D007022 CID halothane_6\NN\3570838|NONE (r_pobj) with_5\IN\0|NONE (r_prep) labetalol_4\NN\2721160|NONE (r_pobj) by_3\IN\0|NONE (r_agent) induced_2\VBN\1627355|.|Deliberate (r_acl) hypotension_1\NN\14057371|NONE
D006221_D007022 CID halothane_25\NN\3570838|inhalation|(|) (r_appos) anaesthetics_23\NNS\3247620|NONE (r_pobj) with_21\IN\0|NONE (r_prep) combination_20\NN\7951464|NONE (r_pobj) in_19\IN\13603305|hypotensive|a (r_prep) agent_18\NN\7347|NONE (l_amod) hypotensive_17\JJ\10405694|in|a
D006221_D007022 CID h_2\NN\14622893|concentration|The|during|mean (r_compound) concentration_3\NN\4916342|+/|, (l_prep) during_4\IN\0|H|concentration|The|mean (l_pobj) hypotension_5\NN\14057371|NONE
D004737_D007022 CID enflurane_8\NN\3299929|, (r_conj) halothane_6\NN\3570838|NONE (r_pobj) with_5\IN\0|NONE (r_prep) labetalol_4\NN\2721160|NONE (r_pobj) by_3\IN\0|NONE (r_agent) induced_2\VBN\1627355|.|Deliberate (r_acl) hypotension_1\NN\14057371|NONE
D004737_D007022 CID enflurane_27\NN\3299929|, (r_conj) halothane_25\NN\3570838|inhalation|(|) (r_appos) anaesthetics_23\NNS\3247620|NONE (r_pobj) with_21\IN\0|NONE (r_prep) combination_20\NN\7951464|NONE (r_pobj) in_19\IN\13603305|hypotensive|a (r_prep) agent_18\NN\7347|NONE (l_amod) hypotensive_17\JJ\10405694|in|a
D004737_D007022 CID e_18\NN\14724645|the|mean|mean|.|and|,|+/ (r_compound) concentration_19\NN\4916342|H|The|during|mean (r_appos) concentration_3\NN\4916342|+/|, (l_prep) during_4\IN\0|H|concentration|The|mean (l_pobj) hypotension_5\NN\14057371|NONE
D003404_D007022 NONE creatinine_5\NN\0|the|serum (r_compound) concentration_6\NN\4916342|returned|significantly|in|During|.|,|and|before (r_nsubj) rose_7\VBD\13112664|NONE (l_prep) during_0\IN\0|returned|significantly|in|.|,|concentration|and|before (l_pobj) hypotension_1\NN\14057371|NONE
D003404_D007022 NONE creatinine_5\NN\0|the|serum (r_compound) concentration_6\NN\4916342|returned|significantly|in|During|.|,|and|before (r_nsubj) rose_7\VBD\13112664|NONE (l_prep) before_15\IN\0|returned|significantly|in|During|.|,|concentration|and (l_pobj) hypotension_16\NN\14057371|NONE
D007741_D007022 CID labetalol_4\NN\2721160|NONE (r_pobj) by_3\IN\0|NONE (r_agent) induced_2\VBN\1627355|.|Deliberate (r_acl) hypotension_1\NN\14057371|NONE
D007741_D007022 CID labetalol_4\NN\2721160|as (r_dobj) using_3\VBG\418025|NONE (l_prep) as_15\IN\14622893|labetalol (l_pobj) agent_18\NN\7347|NONE (l_amod) hypotensive_17\JJ\10405694|in|a
D007741_D007022 CID labetalol_4\NN\2721160|hypotension|that (r_nsubj) induces_5\VBZ\1627355|.|results (l_dobj) hypotension_8\NN\14057371|that|labetalol
D007741_D006973 NONE labetalol_4\NN\2721160|hypotension|that (r_nsubj) induces_5\VBZ\1627355|.|results (l_dobj) hypotension_8\NN\14057371|that|labetalol (l_conj) hypertension_14\NN\14057371|and|adjustable|without
D007741_D013610 NONE labetalol_4\NN\2721160|hypotension|that (r_nsubj) induces_5\VBZ\1627355|.|results (l_dobj) hypotension_8\NN\14057371|that|labetalol (l_prep) without_9\IN\0|and|adjustable|hypertension (l_pobj) tachycardia_11\NNS\14110674|NONE
D007530_D007022 CID isoflurane_10\RB\3570838|or (r_conj) enflurane_8\NN\3299929|, (r_conj) halothane_6\NN\3570838|NONE (r_pobj) with_5\IN\0|NONE (r_prep) labetalol_4\NN\2721160|NONE (r_pobj) by_3\IN\0|NONE (r_agent) induced_2\VBN\1627355|.|Deliberate (r_acl) hypotension_1\NN\14057371|NONE
D007530_D007022 CID isoflurane_29\RB\3570838|or (r_conj) enflurane_27\NN\3299929|, (r_conj) halothane_25\NN\3570838|inhalation|(|) (r_appos) anaesthetics_23\NNS\3247620|NONE (r_pobj) with_21\IN\0|NONE (r_prep) combination_20\NN\7951464|NONE (r_pobj) in_19\IN\13603305|hypotensive|a (r_prep) agent_18\NN\7347|NONE (l_amod) hypotensive_17\JJ\10405694|in|a
D007530_D007022 CID isoflurane_31\JJ\3570838|the (r_amod) group_32\NN\2137|NONE (r_pobj) except_29\IN\807461|to|postoperatively|, (r_prep) returned_18\VBD\1835496|significantly|in|During|.|,|concentration|and|before (r_conj) rose_7\VBD\13112664|NONE (l_prep) during_0\IN\0|returned|significantly|in|.|,|concentration|and|before (l_pobj) hypotension_1\NN\14057371|NONE
D007530_D007022 CID isoflurane_31\JJ\3570838|the (r_amod) group_32\NN\2137|NONE (r_pobj) except_29\IN\807461|to|postoperatively|, (r_prep) returned_18\VBD\1835496|significantly|in|During|.|,|concentration|and|before (r_conj) rose_7\VBD\13112664|NONE (l_prep) before_15\IN\0|returned|significantly|in|During|.|,|concentration|and (l_pobj) hypotension_16\NN\14057371|NONE
2400986
D002998_D002493 NONE clonazepam_33\NN\0|NONE (r_pobj) with_32\IN\0|m (r_prep) busulfan_31\NNS\0|NONE (r_pobj) under_26\IN\0|in|gas|mass|without|spectrometry|a (r_prep) assay_11\NN\5733583|NONE (l_prep) without_21\IN\0|in|gas|mass|under|spectrometry|a (l_pobj) disease_25\NN\14061805|NONE
D002066_D002493 NONE busulfan_0\NNS\0|NONE (r_compound) levels_1\NNS\4916342|by|was|were (r_nsubjpass) measured_3\VBN\697589|NONE (l_agent) by_4\IN\0|was|levels|were (l_pobj) assay_11\NN\5733583|NONE (l_prep) without_21\IN\0|in|gas|mass|under|spectrometry|a (l_pobj) disease_25\NN\14061805|NONE
D002066_D002493 NONE busulfan_31\NNS\0|NONE (r_pobj) under_26\IN\0|in|gas|mass|without|spectrometry|a (r_prep) assay_11\NN\5733583|NONE (l_prep) without_21\IN\0|in|gas|mass|under|spectrometry|a (l_pobj) disease_25\NN\14061805|NONE
D002066_D002493 NONE busulfan_35\NNS\0|:|fluid|plasma|cerebrospinal (r_amod) ratio_40\NN\13815152|.|. (r_nsubj) was_41\VBD\0|by|levels|were (r_conj) measured_3\VBN\697589|NONE (l_agent) by_4\IN\0|was|levels|were (l_pobj) assay_11\NN\5733583|NONE (l_prep) without_21\IN\0|in|gas|mass|under|spectrometry|a (l_pobj) disease_25\NN\14061805|NONE
D002998_D020258 NONE clonazepam_16\NN\0|NONE (r_pobj) by_15\IN\0|efficiently (r_agent) prevented_14\VBN\0|and|dependent|that|neurotoxicity (r_conj) is_6\VBZ\0|.|study (l_nsubj) neurotoxicity_5\NN\0|and|dependent|that|prevented
D002066_D001932 NONE busulfan_20\NNS\0|before (r_dobj) receiving_16\VBG\2210855|of|a|retrospective (r_acl) study_5\NN\635850|We|here|excluded|, (r_dobj) report_1\VBP\6470073|NONE (l_conj) excluded_35\VBD\471711|We|study|here|, (l_nsubj) tumors_34\NNS\14234074|.
D002066_D012640 CID busulfan_23\NNS\0|the (r_amod) course_24\NN\883297|NONE (r_pobj) of_21\IN\0||within|the|or (r_prep) days_20\NNS\15140892|NONE (r_pobj) during_17\IN\0|given|;|.|seizures|% (r_prep) developed_15\VBN\1753788|NONE (l_dobj) seizures_16\NNS\14081375|given|;|during|.|%
D002998_D009461 NONE clonazepam_18\NN\0|NONE (r_pobj) of_17\IN\0|continuous|i.v. (r_prep) infusion_16\NN\14589223|NONE (r_pobj) with_13\IN\0|busulfan|total|a (r_prep) dose_12\NN\3740161|were|patients (r_dobj) given_5\VBN\5892096|;|.|symptoms|none (r_ccomp) had_21\VBD\0|NONE (l_dobj) symptoms_24\NNS\5823932|;|.|given|none
D002066_D020258 NONE busulfan_8\NNS\0|NONE (r_pobj) of_4\IN\0|.|study|dependent|: (r_prep) neurotoxicity_3\NN\0|NONE
D002066_D020258 NONE busulfan_0\NNPS\0|is|be|,|but|remains (r_nsubjpass) known_2\VBN\0|NONE (l_xcomp) be_4\VB\14625458|Busulfan|is|,|but|remains (l_acomp) neurotoxic_5\JJ\0|to
D002066_D020258 NONE busulfan_0\NNPS\0|is|be|,|but|remains (r_nsubjpass) known_2\VBN\0|NONE (l_conj) remains_15\VBZ\2684|Busulfan|is|be|,|but (l_nsubj) neurotoxicity_14\NN\0|.|characterized
D002066_D020258 NONE busulfan_3\NNS\0|total|the (r_compound) dose_4\NN\3740161|was|When|into (r_nsubjpass) taken_6\VBN\2367363|there|.|difference|, (r_advcl) was_11\VBD\0|NONE (l_attr) difference_14\NN\4723816|there|.|taken|, (l_prep) in_15\IN\13603305|patients|significant|a|and (l_pobj) terms_16\NNS\13945919|NONE (l_prep) of_17\IN\0|NONE (l_pobj) incidence_19\JJ\13821570|NONE (l_compound) neurotoxicity_18\NN\0|among
D002066_D020258 NONE busulfan_4\NNS\0|NONE (r_amod) neurotoxicity_5\NN\0|and|dependent|that|prevented
D002066_D020258 NONE busulfan_1\NNS\0|,|A|calculated|resulting|, (r_compound) dose_2\NN\3740161|was|.|by|,|close|observed (r_nsubjpass) followed_21\VBN\1835496|NONE (l_agent) by_22\IN\0|was|.|dose|,|close|observed (l_pobj) neurotoxicity_24\NN\0|NONE
D002066_D020258 NONE busulfan_1\NNS\0|,|A|calculated|resulting|, (r_compound) dose_2\NN\3740161|was|.|by|,|close|observed (r_nsubjpass) followed_21\VBN\1835496|NONE (l_advmod) close_26\JJ\15266911|was|.|dose|by|,|observed (l_prep) to_27\IN\0|NONE (l_pobj) incidence_29\NN\13821570|NONE (l_compound) neurotoxicity_28\NN\0|NONE
D002066_D009461 NONE busulfan_10\NNS\0|with|total|a (r_nmod) dose_12\NN\3740161|were|patients (r_dobj) given_5\VBN\5892096|;|.|symptoms|none (r_ccomp) had_21\VBD\0|NONE (l_dobj) symptoms_24\NNS\5823932|;|.|given|none
D002066_D009369 NONE busulfan_20\NNS\0|before (r_dobj) receiving_16\VBG\2210855|of|a|retrospective (l_prep) before_24\IN\0|busulfan (l_pobj) transplantation_27\NN\671351|NONE (l_prep) for_28\IN\0|bone|marrow (l_pobj) tumors_31\NNS\14234074|NONE
9782254
D007980_D009127 NONE dopa_28\NNP\14601829|L|| (r_npadvmod) induced_30\VBN\1627355|NONE (r_amod) dyskinesias_31\NNS\14084880|and|, (r_conj) rigidity_23\NN\5023233|,
D007980_D018476 NONE dopa_28\NNP\14601829|L|| (r_npadvmod) induced_30\VBN\1627355|NONE (r_amod) dyskinesias_31\NNS\14084880|and|, (r_conj) rigidity_23\NN\5023233|, (r_conj) bradykinesia_21\NN\0|NONE
D007980_D004409 CID dopa_28\NNP\14601829|L|| (r_npadvmod) induced_30\VBN\1627355|NONE (r_amod) dyskinesias_31\NNS\14084880|and|,
D007980_D010300 NONE dopa_28\NNP\14601829|L|| (r_npadvmod) induced_30\VBN\1627355|NONE (r_amod) dyskinesias_31\NNS\14084880|and|, (r_conj) rigidity_23\NN\5023233|, (r_conj) bradykinesia_21\NN\0|NONE (r_pobj) of_20\IN\0|NONE (r_prep) treatment_19\NN\654885|NONE (r_pobj) for_18\IN\0|.|patients|between|pallidotomy (r_prep) underwent_8\VBD\109660|NONE (l_nsubj) patients_1\NNS\9898892|for|.|between|pallidotomy (l_prep) with_2\IN\0| (l_pobj) disease_7\NN\14061805|NONE
25907210
D010755_D009369 NONE organophosphate_10\NN\14919948|insecticide|in|the (r_amod) diazinon_12\NN\0|NONE (r_pobj) to_8\IN\0|NONE (r_prep) exposed_7\VBN\2110927|pesticide (r_acl) applicators_6\NNS\3183080|NONE (r_pobj) among_4\IN\0|solid (r_prep) tumours_3\NNS\14234074|NONE
D010755_D009369 NONE organophosphate_4\NN\14919948|with|common|a (r_compound) insecticide_5\NN\14980215|,|, (r_appos) diazinon_0\NNP\0|was|previously|with (r_nsubjpass) associated_12\VBN\628491|.|have|studies|risk (r_ccomp) examined_32\VBN\0|NONE (l_dobj) risk_37\NN\14541044|.|associated|have|studies (l_compound) cancer_36\NN\14239425|associated
D010755_D008175 NONE organophosphate_4\NN\14919948|with|common|a (r_compound) insecticide_5\NN\14980215|,|, (r_appos) diazinon_0\NNP\0|was|previously|with (r_nsubjpass) associated_12\VBN\628491|.|have|studies|risk (l_prep) with_13\IN\0|was|Diazinon|previously (l_pobj) cancer_15\NN\14239425|NONE
D003976_D009369 NONE diazinon_12\NN\0|NONE (r_pobj) to_8\IN\0|NONE (r_prep) exposed_7\VBN\2110927|pesticide (r_acl) applicators_6\NNS\3183080|NONE (r_pobj) among_4\IN\0|solid (r_prep) tumours_3\NNS\14234074|NONE
D003976_D009369 NONE diazinon_0\NNP\0|was|previously|with (r_nsubjpass) associated_12\VBN\628491|.|have|studies|risk (r_ccomp) examined_32\VBN\0|NONE (l_dobj) risk_37\NN\14541044|.|associated|have|studies (l_compound) cancer_36\NN\14239425|associated
D003976_D009369 NONE diazinon_33\NN\0| (r_npadvmod) associated_35\VBN\628491|cancer (r_amod) risk_37\NN\14541044|.|associated|have|studies (l_compound) cancer_36\NN\14239425|associated
D003976_D009369 NONE diazinon_3\NN\0|and|updated|information (r_compound) exposure_4\NN\5042871|We|.|evaluate (l_conj) information_8\NN\6598915|and|diazinon|updated (l_compound) cancer_6\NN\14239425|incidence
D003976_D009369 NONE diazinon_3\NN\0|and|updated|information (r_compound) exposure_4\NN\5042871|We|.|evaluate (r_dobj) used_1\VBD\0|NONE (l_xcomp) evaluate_10\VB\670261|We|.|exposure (l_dobj) risk_13\NN\14541044|to|in (l_compound) tumour_12\NN\14234074|solid
D003976_D009369 NONE diazinon_10\NN\0|at (r_compound) use_11\NN\407535|applicators (r_dobj) reported_8\VBD\831651|.|through|incidence|;|)|was (r_ccomp) assessed_32\VBN\670261|NONE (l_nsubjpass) incidence_30\NN\13821570|reported|.|through|;|)|was (l_compound) cancer_29\NN\14239425|NONE
D003976_D008175 CID diazinon_0\NNP\0|was|previously|with (r_nsubjpass) associated_12\VBN\628491|.|have|studies|risk (l_prep) with_13\IN\0|was|Diazinon|previously (l_pobj) cancer_15\NN\14239425|NONE
D003976_D008175 CID diazinon_33\NN\0| (r_npadvmod) associated_35\VBN\628491|cancer (r_amod) risk_37\NN\14541044|.|associated|have|studies (r_dobj) examined_32\VBN\0|NONE (l_ccomp) associated_12\VBN\628491|.|have|studies|risk (l_prep) with_13\IN\0|was|Diazinon|previously (l_pobj) cancer_15\NN\14239425|NONE
D003976_D008175 CID diazinon_34\NN\0|NONE (r_compound) use_35\NN\407535|NONE (r_pobj) of_33\IN\0|;|IW|(|RR=. (r_prep) days_32\NNS\15140892|)|and (r_conj) ptrend=0.02_28\LS\0|.|;|%|to|% (r_appos) ci_23\NNP\13635336|:|risks|.|;|We (r_npadvmod) observed_2\VBD\2163746|NONE (l_dobj) risks_6\NNS\14541044|CI|:|.|;|We (l_compound) cancer_5\NN\14239425|(|N=|among|elevated|)
D003976_D008175 CID diazinon_4\NNS\0|NONE (r_pobj) of_3\IN\0|Our|updated (r_prep) evaluation_2\NN\874067|.|evidence (r_nsubj) provides_5\VBZ\2199590|NONE (l_dobj) evidence_7\NN\5816287|.|evaluation (l_prep) of_8\IN\0|additional (l_pobj) association_10\NN\8008335|NONE (l_prep) with_11\IN\0|an (l_pobj) risk_14\NN\14541044|NONE (l_compound) cancer_13\NN\14239425|NONE
2173761
D018727_D013610 NONE blockade_25\VBP\952963|NONE (l_conj) tachycardia_30\NN\14110674|beta|combined|but|prior|receptors
D020110_D007022 CID pinacidil_13\NN\0|and (r_conj) cromakalim_11\NN\0|NONE (r_pobj) by_10\IN\0|NONE (r_agent) induced_9\VBN\1627355|of (r_acl) vasodilation_0\NN\365995|by|were|abolished|not|. (l_prep) of_1\IN\0|induced (l_pobj) vessels_6\NNS\5246511|NONE (l_conj) hypotension_8\NN\14057371|coronary|large|and
D019806_D007022 CID cromakalim_11\NN\0|NONE (r_pobj) by_10\IN\0|NONE (r_agent) induced_9\VBN\1627355|of (r_acl) vasodilation_0\NN\365995|by|were|abolished|not|. (l_prep) of_1\IN\0|induced (l_pobj) vessels_6\NNS\5246511|NONE (l_conj) hypotension_8\NN\14057371|coronary|large|and
D000319_D013610 NONE blockade_25\VBP\952963|NONE (l_conj) tachycardia_30\NN\14110674|beta|combined|but|prior|receptors
D018727_D007022 NONE blockade_25\VBP\952963|NONE (r_pobj) by_17\IN\0|were|abolished|not|.|Vasodilation (r_agent) affected_16\VBN\126264|NONE (l_nsubjpass) vasodilation_0\NN\365995|by|were|abolished|not|. (l_prep) of_1\IN\0|induced (l_pobj) vessels_6\NNS\5246511|NONE (l_conj) hypotension_8\NN\14057371|coronary|large|and
D019806_D013610 CID cromakalim_11\NN\0|NONE (r_pobj) by_10\IN\0|NONE (r_agent) induced_9\VBN\1627355|of (r_acl) vasodilation_0\NN\365995|by|were|abolished|not|. (r_nsubjpass) affected_16\VBN\126264|NONE (l_agent) by_17\IN\0|were|abolished|not|.|Vasodilation (l_pobj) blockade_25\VBP\952963|NONE (l_conj) tachycardia_30\NN\14110674|beta|combined|but|prior|receptors
D020110_D013610 CID pinacidil_13\NN\0|and (r_conj) cromakalim_11\NN\0|NONE (r_pobj) by_10\IN\0|NONE (r_agent) induced_9\VBN\1627355|of (r_acl) vasodilation_0\NN\365995|by|were|abolished|not|. (r_nsubjpass) affected_16\VBN\126264|NONE (l_agent) by_17\IN\0|were|abolished|not|.|Vasodilation (l_pobj) blockade_25\VBP\952963|NONE (l_conj) tachycardia_30\NN\14110674|beta|combined|but|prior|receptors
D000319_D007022 NONE blockade_25\VBP\952963|NONE (r_pobj) by_17\IN\0|were|abolished|not|.|Vasodilation (r_agent) affected_16\VBN\126264|NONE (l_nsubjpass) vasodilation_0\NN\365995|by|were|abolished|not|. (l_prep) of_1\IN\0|induced (l_pobj) vessels_6\NNS\5246511|NONE (l_conj) hypotension_8\NN\14057371|coronary|large|and
10390729
D011803_D006948 NONE quinine-_33\JJ\0| (r_npadvmod) sensitive_37\JJ\10488309|NONE (r_amod) k(+)-channels_38\NNPS\0|NONE (r_pobj) to_31\IN\0|be|to (r_prep) connected_30\VBN\0|whereas|hyperactivity (r_xcomp) seems_27\VBZ\2604760|blockade|that|not|sufficient (l_nsubj) hyperactivity_26\NN\14052403|whereas|connected
D011803_D009069 NONE quinine-_33\JJ\0| (r_npadvmod) sensitive_37\JJ\10488309|NONE (r_amod) k(+)-channels_38\NNPS\0|NONE (r_pobj) to_31\IN\0|be|to (r_prep) connected_30\VBN\0|whereas|hyperactivity (r_xcomp) seems_27\VBZ\2604760|blockade|that|not|sufficient (r_advcl) is_13\VBZ\0|It|is|.|also (l_acomp) sufficient_15\JJ\0|blockade|that|seems|not (l_xcomp) prevent_17\VB\0|NONE (l_dobj) hypoactivity_21\NN\0|to
D009020_D006948 CID morphine_18\NN\2707683| (r_npadvmod) induced_20\VBN\1627355|NONE (r_amod) hypoactivity_21\NN\0|neither|prevented|In|,|but (r_dobj) affected_17\VBD\126264|NONE (l_conj) prevented_27\VBD\0|neither|hypoactivity|In|,|but (l_dobj) hyperactivity_32\NN\14052403|blockers|.
D009020_D006948 CID morphine_28\NN\2707683| (r_npadvmod) induced_30\VBN\1627355|secondary (r_amod) hyperactivity_32\NN\14052403|blockers|.
D009020_D006948 CID morphine_18\NN\2707683| (r_npadvmod) induced_20\VBN\1627355|NONE (r_amod) hypoactivity_21\NN\0|to (r_dobj) prevent_17\VB\0|NONE (r_xcomp) sufficient_15\JJ\0|blockade|that|seems|not (r_acomp) is_13\VBZ\0|It|is|.|also (l_advcl) seems_27\VBZ\2604760|blockade|that|not|sufficient (l_nsubj) hyperactivity_26\NN\14052403|whereas|connected
D009020_D006948 CID morphine_23\NN\2707683| (r_npadvmod) induced_25\VBN\1627355|NONE (r_amod) hyperactivity_26\NN\14052403|whereas|connected
D009020_D009069 NONE morphine_18\NN\2707683| (r_npadvmod) induced_20\VBN\1627355|NONE (r_amod) hypoactivity_21\NN\0|neither|prevented|In|,|but
D009020_D009069 NONE morphine_28\NN\2707683| (r_npadvmod) induced_30\VBN\1627355|secondary (r_amod) hyperactivity_32\NN\14052403|blockers|. (r_dobj) prevented_27\VBD\0|neither|hypoactivity|In|,|but (r_conj) affected_17\VBD\126264|NONE (l_dobj) hypoactivity_21\NN\0|neither|prevented|In|,|but
D009020_D009069 NONE morphine_18\NN\2707683| (r_npadvmod) induced_20\VBN\1627355|NONE (r_amod) hypoactivity_21\NN\0|to
D009020_D009069 NONE morphine_23\NN\2707683| (r_npadvmod) induced_25\VBN\1627355|NONE (r_amod) hyperactivity_26\NN\14052403|whereas|connected (r_nsubj) seems_27\VBZ\2604760|blockade|that|not|sufficient (r_advcl) is_13\VBZ\0|It|is|.|also (l_acomp) sufficient_15\JJ\0|blockade|that|seems|not (l_xcomp) prevent_17\VB\0|NONE (l_dobj) hypoactivity_21\NN\0|to
D011188_D006948 NONE k(+)-channel_15\NNP\0|the (r_compound) blockers_16\NNS\10101634|NONE (r_pobj) of_13\IN\0|NONE (r_prep) neither_12\DT\0|prevented|hypoactivity|In|,|but (r_nsubj) affected_17\VBD\126264|NONE (l_conj) prevented_27\VBD\0|neither|hypoactivity|In|,|but (l_dobj) hyperactivity_32\NN\14052403|blockers|.
D011188_D006948 NONE k(+)-channel_25\NNP\0|both (r_compound) blockers_26\NNS\10101634|.|hyperactivity (r_nsubj) prevented_27\VBD\0|neither|hypoactivity|In|,|but (l_dobj) hyperactivity_32\NN\14052403|blockers|.
D011188_D006948 NONE k(+)-channels_8\NNPS\0|NONE (r_pobj) of_7\IN\0|the (r_prep) blockade_6\NN\952963|that|seems|not|sufficient (r_nsubj) is_13\VBZ\0|It|is|.|also (l_advcl) seems_27\VBZ\2604760|blockade|that|not|sufficient (l_nsubj) hyperactivity_26\NN\14052403|whereas|connected
D011188_D006948 NONE k(+)-channels_38\NNPS\0|NONE (r_pobj) to_31\IN\0|be|to (r_prep) connected_30\VBN\0|whereas|hyperactivity (r_xcomp) seems_27\VBZ\2604760|blockade|that|not|sufficient (l_nsubj) hyperactivity_26\NN\14052403|whereas|connected
D015761_D006948 NONE 4-aminopyridine_35\CD\0|NONE (r_punct) -_36\HYPH\0|quinine (r_punct) sensitive_37\JJ\10488309|NONE (r_amod) k(+)-channels_38\NNPS\0|NONE (r_pobj) to_31\IN\0|be|to (r_prep) connected_30\VBN\0|whereas|hyperactivity (r_xcomp) seems_27\VBZ\2604760|blockade|that|not|sufficient (l_nsubj) hyperactivity_26\NN\14052403|whereas|connected
D011188_D009069 NONE k(+)-channel_15\NNP\0|the (r_compound) blockers_16\NNS\10101634|NONE (r_pobj) of_13\IN\0|NONE (r_prep) neither_12\DT\0|prevented|hypoactivity|In|,|but (r_nsubj) affected_17\VBD\126264|NONE (l_dobj) hypoactivity_21\NN\0|neither|prevented|In|,|but
D011188_D009069 NONE k(+)-channel_25\NNP\0|both (r_compound) blockers_26\NNS\10101634|.|hyperactivity (r_nsubj) prevented_27\VBD\0|neither|hypoactivity|In|,|but (r_conj) affected_17\VBD\126264|NONE (l_dobj) hypoactivity_21\NN\0|neither|prevented|In|,|but
D011188_D009069 NONE k(+)-channels_8\NNPS\0|NONE (r_pobj) of_7\IN\0|the (r_prep) blockade_6\NN\952963|that|seems|not|sufficient (r_nsubj) is_13\VBZ\0|It|is|.|also (l_acomp) sufficient_15\JJ\0|blockade|that|seems|not (l_xcomp) prevent_17\VB\0|NONE (l_dobj) hypoactivity_21\NN\0|to
D011188_D009069 NONE k(+)-channels_38\NNPS\0|NONE (r_pobj) to_31\IN\0|be|to (r_prep) connected_30\VBN\0|whereas|hyperactivity (r_xcomp) seems_27\VBZ\2604760|blockade|that|not|sufficient (r_advcl) is_13\VBZ\0|It|is|.|also (l_acomp) sufficient_15\JJ\0|blockade|that|seems|not (l_xcomp) prevent_17\VB\0|NONE (l_dobj) hypoactivity_21\NN\0|to
D015761_D009069 NONE 4-aminopyridine_35\CD\0|NONE (r_punct) -_36\HYPH\0|quinine (r_punct) sensitive_37\JJ\10488309|NONE (r_amod) k(+)-channels_38\NNPS\0|NONE (r_pobj) to_31\IN\0|be|to (r_prep) connected_30\VBN\0|whereas|hyperactivity (r_xcomp) seems_27\VBZ\2604760|blockade|that|not|sufficient (r_advcl) is_13\VBZ\0|It|is|.|also (l_acomp) sufficient_15\JJ\0|blockade|that|seems|not (l_xcomp) prevent_17\VB\0|NONE (l_dobj) hypoactivity_21\NN\0|to
25119790
D003474_D007674 NONE curcumin_0\NN\0|nephrotoxicity (r_nsubj) prevents_1\VBZ\0|NONE (l_dobj) nephrotoxicity_5\NN\0|Curcumin
D003474_D007674 NONE curcumin_8\NN\0|NONE (r_pobj) of_4\IN\0|against|The|potential|protective (r_prep) effect_3\NN\34213|.|was (l_prep) against_20\IN\0|of|The|potential|protective (l_pobj) injury_23\NN\14052046|NONE
D003474_D007674 NONE curcumin_4\NN\0|that|able (r_nsubj) is_5\VBZ\0|It|.|is (l_acomp) able_6\JJ\0|that|curcumin (l_xcomp) attenuate_8\VB\224901|NONE (l_prep) in_9\IN\13603305|to (l_pobj) nephropathy_14\NN\14573196|and|in
D005947_D007674 NONE glucose_20\NN\14710501|,|total (r_conj) protein_18\NN\14944888|NONE (r_pobj) of_16\IN\0|urinary|the (r_prep) excretion_15\NN\13466586|NONE (r_pobj) in_12\IN\13603305|in|and (r_conj) increase_6\NN\13576355|,|determined|injury (r_dobj) included_5\VBD\0|NONE (l_nsubj) injury_4\NN\14052046|,|determined|increase
D005947_D007674 NONE glucose_20\NN\14710501|,|total (r_conj) protein_18\NN\14944888|NONE (r_pobj) of_16\IN\0|urinary|the (r_prep) excretion_15\NN\13466586|NONE (r_pobj) in_12\IN\13603305|in|and (r_conj) increase_6\NN\13576355|,|determined|injury (r_dobj) included_5\VBD\0|NONE (l_conj) determined_75\VBN\0|,|injury|increase (l_nsubjpass) upregulation_45\NN\0|was|by|. (l_prep) of_46\IN\0|decrease (l_pobj) molecule_49\NN\9465459|NONE (l_compound) injury_48\NN\14052046|kidney
D005947_D009336 NONE glucose_20\NN\14710501|,|total (r_conj) protein_18\NN\14944888|NONE (r_pobj) of_16\IN\0|urinary|the (r_prep) excretion_15\NN\13466586|NONE (r_pobj) in_12\IN\13603305|in|and (r_conj) increase_6\NN\13576355|,|determined|injury (r_dobj) included_5\VBD\0|NONE (l_conj) determined_75\VBN\0|,|injury|increase (l_nsubjpass) upregulation_45\NN\0|was|by|. (l_parataxis) decrease_53\NN\7296428|of (l_prep) besides_61\IN\0|KIM)|,|apoptosis|(|and|in (l_prep) of_62\IN\0|NONE (l_pobj) necrosis_63\NN\11444117|NONE
C030272_D011507 CID maleate_12\NN\2718811|NONE (r_pobj) of_11\IN\0|a|single|in (r_prep) injection_10\NN\320852|NONE (r_pobj) by_7\IN\0|proteinuria|.|were (r_agent) induced_6\VBN\1627355|NONE (l_nsubjpass) proteinuria_1\NN\14299637|by|.|were
D010100_D007674 NONE oxygen_16\NN\14622893|and|mitochondrial|of|activity (r_compound) consumption_17\NN\13440063|,|oxidative (r_conj) stress_13\NN\7083732|,|hemodynamic (r_conj) alterations_10\NNS\7283608|NONE (r_pobj) to_8\IN\0|NONE (r_prep) relation_7\NN\2137|induced|: (r_appos) nephrotoxicity_5\NN\0|Curcumin
D012964_D009336 NONE sodium_22\NN\14625458|, (r_conj) glucose_20\NN\14710501|,|total (r_conj) protein_18\NN\14944888|NONE (r_pobj) of_16\IN\0|urinary|the (r_prep) excretion_15\NN\13466586|NONE (r_pobj) in_12\IN\13603305|in|and (r_conj) increase_6\NN\13576355|,|determined|injury (r_dobj) included_5\VBD\0|NONE (l_conj) determined_75\VBN\0|,|injury|increase (l_nsubjpass) upregulation_45\NN\0|was|by|. (l_parataxis) decrease_53\NN\7296428|of (l_prep) besides_61\IN\0|KIM)|,|apoptosis|(|and|in (l_prep) of_62\IN\0|NONE (l_pobj) necrosis_63\NN\11444117|NONE
C030272_D007674 CID maleate_2\NN\2718811| (r_npadvmod) induced_4\VBN\1627355|:|relation (r_amod) nephrotoxicity_5\NN\0|Curcumin
C030272_D007674 CID maleate_26\NN\2718811|NONE (r_pobj) by_25\IN\0|NONE (r_agent) induced_24\VBN\1627355|renal|the (r_acl) injury_23\NN\14052046|NONE
C030272_D007674 CID maleate_0\NNP\2718811| (r_npadvmod) induced_2\VBN\1627355|renal (r_amod) injury_4\NN\14052046|,|determined|increase
C030272_D007674 CID maleate_0\NNP\2718811| (r_npadvmod) induced_2\VBN\1627355|renal (r_amod) injury_4\NN\14052046|,|determined|increase (r_nsubj) included_5\VBD\0|NONE (l_conj) determined_75\VBN\0|,|injury|increase (l_nsubjpass) upregulation_45\NN\0|was|by|. (l_prep) of_46\IN\0|decrease (l_pobj) molecule_49\NN\9465459|NONE (l_compound) injury_48\NN\14052046|kidney
C030272_D007674 CID maleate_11\NN\2718811| (r_npadvmod) induced_13\VBN\1627355|vivo (r_amod) nephropathy_14\NN\14573196|and|in
C030272_D009336 CID maleate_0\NNP\2718811| (r_npadvmod) induced_2\VBN\1627355|renal (r_amod) injury_4\NN\14052046|,|determined|increase (r_nsubj) included_5\VBD\0|NONE (l_conj) determined_75\VBN\0|,|injury|increase (l_nsubjpass) upregulation_45\NN\0|was|by|. (l_parataxis) decrease_53\NN\7296428|of (l_prep) besides_61\IN\0|KIM)|,|apoptosis|(|and|in (l_prep) of_62\IN\0|NONE (l_pobj) necrosis_63\NN\11444117|NONE
D012964_D007674 NONE sodium_22\NN\14625458|, (r_conj) glucose_20\NN\14710501|,|total (r_conj) protein_18\NN\14944888|NONE (r_pobj) of_16\IN\0|urinary|the (r_prep) excretion_15\NN\13466586|NONE (r_pobj) in_12\IN\13603305|in|and (r_conj) increase_6\NN\13576355|,|determined|injury (r_dobj) included_5\VBD\0|NONE (l_nsubj) injury_4\NN\14052046|,|determined|increase
D012964_D007674 NONE sodium_22\NN\14625458|, (r_conj) glucose_20\NN\14710501|,|total (r_conj) protein_18\NN\14944888|NONE (r_pobj) of_16\IN\0|urinary|the (r_prep) excretion_15\NN\13466586|NONE (r_pobj) in_12\IN\13603305|in|and (r_conj) increase_6\NN\13576355|,|determined|injury (r_dobj) included_5\VBD\0|NONE (l_conj) determined_75\VBN\0|,|injury|increase (l_nsubjpass) upregulation_45\NN\0|was|by|. (l_prep) of_46\IN\0|decrease (l_pobj) molecule_49\NN\9465459|NONE (l_compound) injury_48\NN\14052046|kidney
24434397
D014148_D051437 NONE acid_1\NN\14818238|induced|in|.|generalized (r_compound) seizure_6\NN\14081375|NONE (l_prep) in_7\IN\13603305|acid|induced|.|generalized (l_pobj) failure_9\NN\66216|NONE
D014148_D012640 NONE acid_1\NN\14818238|induced|in|.|generalized (r_compound) seizure_6\NN\14081375|NONE
D014148_D012640 NONE tna_14\NNP\0|NONE (r_pobj) of_13\IN\0|an (r_prep) overdose_12\NN\84738|to (r_attr) be_10\VB\14625458|Thus|,|cause|was|. (r_xcomp) believed_8\VBN\686447|NONE (l_nsubjpass) cause_4\NN\7323922|Thus|be|,|was|. (l_prep) of_5\IN\0|precipitating|the (l_pobj) convulsions_6\NNS\14081375|NONE
D014148_D004830 CID tna_7\NNP\0|NONE (r_pobj) of_6\IN\0|sixth|the (r_prep) dose_5\NN\3740161|hours (r_pobj) after_2\IN\0|,|episode|.|she (r_prep) had_10\VBD\0|NONE (l_dobj) episode_12\NN\7283608|,|.|she|after (l_prep) of_13\IN\0|an (l_pobj) convulsions_17\NNS\14081375|NONE
D014148_D062787 NONE tna_14\NNP\0|NONE (r_pobj) of_13\IN\0|an (r_prep) overdose_12\NN\84738|to
D014148_D006470 NONE acid_1\NN\14818238|hourly|to|.|control|was (r_nsubjpass) administered_9\VBN\2436349|NONE (l_advcl) control_13\VB\5190804|hourly|to|.|acid|was (l_xcomp) bleeding_14\NN\14285662|to
D014148_D006470 NONE tna_3\NNP\0|Tranexamic|g (r_appos) acid_1\NN\14818238|hourly|to|.|control|was (r_nsubjpass) administered_9\VBN\2436349|NONE (l_advcl) control_13\VB\5190804|hourly|to|.|acid|was (l_xcomp) bleeding_14\NN\14285662|to
8135424
D003975_D012640 CID diazepam_9\NN\2830852|mixed (r_compound) intoxications_10\NNS\14034177|NONE (r_pobj) in_5\IN\13603305|and|death (r_prep) seizures_2\NNS\14081375|.|Flumazenil
D003975_D012640 CID diazepam_17\NN\2830852|combined (r_compound) intoxications_18\NNS\14034177|NONE (r_pobj) of_13\IN\0|a (r_prep) model_12\NN\5888929|NONE (r_pobj) in_10\IN\13603305|incidence (r_prep) increase_5\VB\13576355|can|.|seizures|and|Flumazenil (r_conj) unmask_2\VB\853195|NONE (l_dobj) seizures_3\NNS\14081375|can|.|increase|and|Flumazenil
D005442_D012640 CID flumazenil_0\NNP\0|.|seizures (r_nsubj) induces_1\VBZ\1627355|NONE (l_dobj) seizures_2\NNS\14081375|.|Flumazenil
D005442_D012640 CID flumazenil_8\JJ\0|of (r_appos) administration_3\NN\1133281|may|seizures (r_nsubj) unmask_10\VB\853195|.|STUDY|: (l_dobj) seizures_11\NNS\14081375|may|Administration
D005442_D012640 CID flumazenil_0\NNP\0|can|.|seizures|increase|and (r_nsubj) unmask_2\VB\853195|NONE (l_dobj) seizures_3\NNS\14081375|can|.|increase|and|Flumazenil
D003042_D012640 CID cocaine_7\NN\3492717| (r_compound) diazepam_9\NN\2830852|mixed (r_compound) intoxications_10\NNS\14034177|NONE (r_pobj) in_5\IN\13603305|and|death (r_prep) seizures_2\NNS\14081375|.|Flumazenil
D003042_D012640 CID cocaine_14\NN\3492717| (r_compound) benzodiazepine_16\NN\3771443|mixed (r_amod) intoxication_17\NN\14034177|NONE (r_pobj) in_12\IN\13603305|NONE (r_prep) seizures_11\NNS\14081375|may|Administration
D003042_D012640 CID cocaine_15\NN\3492717| (r_compound) diazepam_17\NN\2830852|combined (r_compound) intoxications_18\NNS\14034177|NONE (r_pobj) of_13\IN\0|a (r_prep) model_12\NN\5888929|NONE (r_pobj) in_10\IN\13603305|incidence (r_prep) increase_5\VB\13576355|can|.|seizures|and|Flumazenil (r_conj) unmask_2\VB\853195|NONE (l_dobj) seizures_3\NNS\14081375|can|.|increase|and|Flumazenil
D001569_D012640 NONE benzodiazepine_6\JJ\3771443|the (r_amod) antagonist_7\NN\7846|NONE (r_pobj) of_4\IN\0|flumazenil (r_prep) administration_3\NN\1133281|may|seizures (r_nsubj) unmask_10\VB\853195|.|STUDY|: (l_dobj) seizures_11\NNS\14081375|may|Administration
D001569_D012640 NONE benzodiazepine_16\NN\3771443|mixed (r_amod) intoxication_17\NN\14034177|NONE (r_pobj) in_12\IN\13603305|NONE (r_prep) seizures_11\NNS\14081375|may|Administration
24333387
D013311_D020258 NONE streptozotocin_12\NNP\0|NONE (r_pobj) in_11\IN\13603305|the|key (r_prep) events_10\NNS\23100|impairment (r_nsubj) induced_16\VBN\1627355|neurotoxicity|:|Glial|.|and (r_acl) activation_1\NN\13561719|NONE (l_conj) neurotoxicity_6\NN\0|induced|:|Glial|.|and
D013311_D020258 NONE stz_0\NNP\0|NONE (r_compound) treatment_1\NN\654885|and|expression|remains|CaMKIIa|PSD (r_nsubj) showed_2\VBD\2137132|NONE (l_conj) remains_25\VBZ\2684|and|expression|CaMKIIa|treatment|PSD (l_nsubj) neurotoxicity_31\NN\0|,|while|,|.|expression
D013311_D020258 NONE stz_0\NNP\0|activation|. (r_nsubj) induced_1\VBN\1627355|NONE (l_dobj) activation_3\NN\13561719|STZ|. (l_conj) death_7\NN\7296428|,|glial (l_conj) post_9\VB\8621598|and|apoptotic|cell (l_dobj) neurotoxicity_11\NN\0|NONE
D013311_D020258 NONE stz_16\NNP\0|NONE (r_pobj) in_15\IN\13603305|the|induced|key (r_prep) factors_14\NNS\7326557|that|activation (r_attr) are_11\VBP\13600404|clearly|study|. (l_nsubj) activation_6\NN\13561719|that|factors (l_conj) post_8\VB\8621598|glial|and (l_dobj) neurotoxicity_10\NN\0|NONE
D013311_D007249 CID stz_0\NN\0|.|expression (r_nsubj) causes_1\VBZ\7323922|NONE (l_dobj) expression_3\NN\4679549|STZ|. (l_prep) of_4\IN\0|increased (l_pobj) gfap_5\NNP\0|NONE (l_appos) activation_14\NN\13561719|CDb|,| (l_conj) neuroinflammation_16\NN\0|indicating|and|glial|a
D002118_D064420 NONE ca(2_11\NNP\0|, (r_conj) nitrite_9\NN\14621446|, (r_appos) ros_7\NNP\6894544|NONE (r_pobj) of_6\IN\0|the (r_prep) level_5\NN\4916342|significantly|and|STZ|reduced|)|also|. (r_dobj) increased_3\VBD\169651|NONE (l_conj) reduced_15\VBD\441445|significantly|and|STZ|)|also|.|level (l_dobj) activity_18\NN\30358|NONE (l_prep) in_19\IN\13603305|mitochondrial|the (l_pobj) preparation_21\NN\407535|NONE (l_acl) illustrating_22\VBG\955601|synaptosomal (l_dobj) generation_25\NN\7942152|NONE (l_conj) excitotoxicity_27\NN\0|radical|free|and
D013311_D064420 NONE streptozotocin_15\NNP\0|NONE (r_pobj) in_13\IN\13603305|toxicity|glial|and (r_prep) activation_8\NN\13561719|NONE (l_conj) toxicity_12\NN\13576101|glial|and|in
D013311_D064420 NONE stz_17\NNP\0|ICV (r_appos) streptozotocin_15\NNP\0|NONE (r_pobj) in_13\IN\13603305|toxicity|glial|and (r_prep) activation_8\NN\13561719|NONE (l_conj) toxicity_12\NN\13576101|glial|and|in
D013311_D064420 NONE stz_0\NNP\0|significantly|and|reduced|)|also|.|level (r_nsubj) increased_3\VBD\169651|NONE (l_conj) reduced_15\VBD\441445|significantly|and|STZ|)|also|.|level (l_dobj) activity_18\NN\30358|NONE (l_prep) in_19\IN\13603305|mitochondrial|the (l_pobj) preparation_21\NN\407535|NONE (l_acl) illustrating_22\VBG\955601|synaptosomal (l_dobj) generation_25\NN\7942152|NONE (l_conj) excitotoxicity_27\NN\0|radical|free|and
D009573_D064420 NONE nitrite_9\NN\14621446|, (r_appos) ros_7\NNP\6894544|NONE (r_pobj) of_6\IN\0|the (r_prep) level_5\NN\4916342|significantly|and|STZ|reduced|)|also|. (r_dobj) increased_3\VBD\169651|NONE (l_conj) reduced_15\VBD\441445|significantly|and|STZ|)|also|.|level (l_dobj) activity_18\NN\30358|NONE (l_prep) in_19\IN\13603305|mitochondrial|the (l_pobj) preparation_21\NN\407535|NONE (l_acl) illustrating_22\VBG\955601|synaptosomal (l_dobj) generation_25\NN\7942152|NONE (l_conj) excitotoxicity_27\NN\0|radical|free|and
D013311_D008569 CID streptozotocin_12\NNP\0|NONE (r_pobj) in_11\IN\13603305|the|key (r_prep) events_10\NNS\23100|impairment (r_nsubj) induced_16\VBN\1627355|neurotoxicity|:|Glial|.|and (l_dobj) impairment_18\NN\7296428|events
D013311_D008569 CID streptozotocin_15\NNP\0|NONE (r_pobj) in_13\IN\13603305|toxicity|glial|and (r_prep) activation_8\NN\13561719|NONE (r_pobj) of_6\IN\0|the (r_prep) role_5\NN\719494|the|present (r_dobj) study_3\NN\635850|NONE (r_pobj) in_0\IN\13603305|.|explored (r_prep) induced_19\VBN\1627355|NONE (l_ccomp) explored_24\VBN\789138|.|In (l_nsubjpass) rats_22\NNS\2329401|was (l_amod) impaired_21\VBN\258857|NONE
D013311_D008569 CID stz_17\NNP\0|ICV (r_appos) streptozotocin_15\NNP\0|NONE (r_pobj) in_13\IN\13603305|toxicity|glial|and (r_prep) activation_8\NN\13561719|NONE (r_pobj) of_6\IN\0|the (r_prep) role_5\NN\719494|the|present (r_dobj) study_3\NN\635850|NONE (r_pobj) in_0\IN\13603305|.|explored (r_prep) induced_19\VBN\1627355|NONE (l_ccomp) explored_24\VBN\789138|.|In (l_nsubjpass) rats_22\NNS\2329401|was (l_amod) impaired_21\VBN\258857|NONE
D013311_D008569 CID stz_21\NNP\0|days (r_pobj) after_20\IN\0|:|in|was|.|In|deficit (r_prep) found_9\VBN\13279262|NONE (l_nsubjpass) deficit_7\NN\5113133|:|in|was|.|In|after
D013311_D008569 CID stz_16\NNP\0|NONE (r_pobj) in_15\IN\13603305|the|induced|key (r_prep) factors_14\NNS\7326557|that|activation (l_acl) induced_17\VBN\1627355|the|in|key (l_dobj) impairment_19\NN\7296428|NONE
24587916
D006861_D015431 NONE h2o2_11\NNP\0|significantly|and|increased (r_dobj) reduced_7\VBD\441445|LF|.|loss|and (r_conj) prevented_1\VBD\0|NONE (l_dobj) loss_4\NN\13252973|LF|.|reduced|and
D003907_D006973 CID dexamethasone_6\NN\2721538| (r_npadvmod) induced_8\VBN\1627355|in (r_amod) hypertension_9\NN\14057371|NONE
D003907_D006973 CID dexamethasone-_0\NNP\0|.|associated (r_nsubj) induced_4\VBN\1627355|NONE (l_ccomp) associated_7\VBN\628491|.|Dexamethasone (l_nsubjpass) hypertension_5\NN\14057371|is|with
D003907_D006973 CID dex-_2\NNP\0|NONE (r_appos) dexamethasone-_0\NNP\0|.|associated (r_nsubj) induced_4\VBN\1627355|NONE (l_ccomp) associated_7\VBN\628491|.|Dexamethasone (l_nsubjpass) hypertension_5\NN\14057371|is|with
D003907_D006973 CID dex_19\NNP\0|NONE (r_compound) administration_20\NN\1133281|NONE (r_pobj) upon_18\IN\0|oxidative|and|hypertension (r_prep) stress_15\NN\7083732|NONE (l_conj) hypertension_17\NN\14057371|oxidative|and|upon
D003907_D006973 CID dex_0\NNP\0| (r_npadvmod) induced_2\VBN\1627355|. (r_amod) hypertension_3\NN\14057371|NONE
D003907_D006973 CID dex_18\NNP\0| (r_npadvmod) induced_20\VBN\1627355|NONE (r_amod) hypertension_21\NN\14057371|NONE
23952588
D007980_D004409 CID levodopa_5\NN\14604959| (r_npadvmod) induced_7\VBN\1627355|with|among (r_amod) dyskinesia_8\NN\14084880|NONE
D007980_D004409 CID levodopa_2\NN\14604959|pulsatile|Chronic|for (r_compound) therapy_3\NN\657604|to|. (r_nsubj) leads_11\VBZ\5155821|NONE (l_prep) to_12\IN\0|therapy|. (l_pobj) development_14\NN\248977|NONE (l_prep) of_15\IN\0|the (l_pobj) fluctuations_17\NNS\7345593|NONE (l_conj) dyskinesia_19\NN\14084880|and|motor
D007980_D004409 CID levodopa_7\NN\14604959| (r_npadvmod) induced_9\VBN\1627355|among (r_amod) dyskinesia_10\NN\14084880|NONE
D007980_D004409 CID levodopa_13\NN\14604959|of|median (r_compound) therapy_14\NN\657604|NONE (r_pobj) with_11\IN\0|in (r_prep) present_2\JJ\28270|Dyskinesia|. (r_acomp) was_1\VBD\0|NONE (l_nsubj) dyskinesia_0\NNP\14084880|.|present
D007980_D004409 CID levodopa_16\NN\14604959|NONE (r_compound) therapy_17\NN\657604|NONE (r_pobj) of_15\IN\0|duration|.|dose|longer|,|, (r_prep) duration_14\NN\15113229|,|.|Patients|age (r_dobj) had_3\VBD\0|NONE (l_nsubj) patients_0\NNS\9898892|,|.|duration|age (l_prep) with_1\IN\0|NONE (l_pobj) dyskinesia_2\JJ\14084880|NONE
D007980_D004409 CID levodopa_16\NN\14604959|NONE (r_compound) therapy_17\NN\657604|NONE (r_pobj) of_15\IN\0|duration|.|dose|longer|,|, (r_prep) duration_14\NN\15113229|,|.|Patients|age (l_appos) dose_37\NN\3740161|duration|.|of|longer|,|, (l_conj) scores_48\NNS\13757724|and|.|total|higher|levodopa|, (l_appos) p_50\NN\14622893|(|total|higher|UPDRS (l_prep) than_54\IN\0|)|. (l_pobj) patients_55\NNS\9898892|NONE (l_prep) without_56\IN\0|NONE (l_pobj) dyskinesia_57\JJ\14084880|NONE
D007980_D004409 CID levodopa_36\NN\14604959|and|.|total|higher|scores|, (r_compound) dose_37\NN\3740161|duration|.|of|longer|,|, (r_appos) duration_14\NN\15113229|,|.|Patients|age (r_dobj) had_3\VBD\0|NONE (l_nsubj) patients_0\NNS\9898892|,|.|duration|age (l_prep) with_1\IN\0|NONE (l_pobj) dyskinesia_2\JJ\14084880|NONE
D007980_D004409 CID levodopa_36\NN\14604959|and|.|total|higher|scores|, (r_compound) dose_37\NN\3740161|duration|.|of|longer|,|, (l_conj) scores_48\NNS\13757724|and|.|total|higher|levodopa|, (l_appos) p_50\NN\14622893|(|total|higher|UPDRS (l_prep) than_54\IN\0|)|. (l_pobj) patients_55\NNS\9898892|NONE (l_prep) without_56\IN\0|NONE (l_pobj) dyskinesia_57\JJ\14084880|NONE
D007980_D004409 CID levodopa_9\NN\14604959|,|age (r_compound) therapy_10\NN\657604|NONE (r_pobj) of_8\IN\0|NONE (r_prep) duration_7\NN\15113229|predictors|. (r_attr) were_6\VBD\0|NONE (l_nsubj) predictors_3\NNS\10756433|duration|. (l_prep) of_4\IN\0|three|The|significant (l_pobj) dyskinesia_5\JJ\14084880|NONE
D007980_D004409 CID levodopa_18\NN\14604959|total|daily (r_compound) dose_19\NN\3740161|onset|,|and (r_conj) age_13\NN\4916342|,|levodopa (r_conj) therapy_10\NN\657604|NONE (r_pobj) of_8\IN\0|NONE (r_prep) duration_7\NN\15113229|predictors|. (r_attr) were_6\VBD\0|NONE (l_nsubj) predictors_3\NNS\10756433|duration|. (l_prep) of_4\IN\0|three|The|significant (l_pobj) dyskinesia_5\JJ\14084880|NONE
D007980_D004409 CID levodopa_3\NN\14604959| (r_npadvmod) induced_5\VBN\1627355|NONE (r_amod) dyskinesia_6\NN\14084880|NONE
D007980_D010300 NONE levodopa_5\NN\14604959| (r_npadvmod) induced_7\VBN\1627355|with|among (r_amod) dyskinesia_8\NN\14084880|NONE (l_prep) with_12\IN\0|induced|among (l_pobj) disease_15\NN\14061805|NONE
D007980_D010300 NONE levodopa_2\NN\14604959|pulsatile|Chronic|for (r_compound) therapy_3\NN\657604|to|. (l_prep) for_4\IN\0|pulsatile|levodopa|Chronic (l_pobj) disease_7\NN\14061805|NONE
D007980_D010300 NONE levodopa_2\NN\14604959|pulsatile|Chronic|for (r_compound) therapy_3\NN\657604|to|. (l_prep) for_4\IN\0|pulsatile|levodopa|Chronic (l_pobj) disease_7\NN\14061805|NONE (l_appos) pd_9\NNP\14625458|(|Parkinson|)
D007980_D010300 NONE levodopa_7\NN\14604959| (r_npadvmod) induced_9\VBN\1627355|among (r_amod) dyskinesia_10\NN\14084880|NONE (l_prep) among_11\IN\0|induced (l_pobj) patients_14\NNS\9898892|NONE (l_prep) with_15\IN\0|multiethnic|Malaysian (l_pobj) pd_16\NNP\14625458|NONE
D007980_D010300 NONE levodopa_14\NN\14604959|uninterrupted (r_compound) therapy_15\NN\657604|NONE (r_pobj) on_12\IN\0||with (r_prep) patients_9\NNS\9898892|for (l_prep) with_10\IN\0|on| (l_pobj) pd_11\NNP\14625458|NONE
24588023
D014148_D012640 CID acid_4\NN\14818238|NONE (l_conj) seizures_7\NNS\14081375|tranexamic|and (l_amod) convulsive_6\JJ\0|NONE
D014148_D012640 CID acid_4\NN\14818238|NONE (l_conj) seizures_7\NNS\14081375|tranexamic|and
D014148_D012640 CID acid_37\NN\14818238|NONE (r_pobj) of_30\IN\0|NONE (r_prep) duration_29\NN\15113229|circulatory|deep|,|hypothermic (r_conj) arrest_27\NN\88481|heart|,|congestive (r_conj) failure_22\NN\66216|of|, (r_conj) calcification_15\NN\13446390|cardiac|, (r_conj) surgery_13\NN\6045562|NONE (r_dobj) redo_11\VB\1621555|age|predictors|. (r_conj) included_5\VBD\0|NONE (l_nsubj) predictors_1\NNS\10756433|age|redo|. (l_prep) of_2\IN\0|Independent (l_pobj) seizures_4\NNS\14081375|NONE
D014148_D012640 CID acid_9\NN\14818238|)|,|tested|.|predictor (r_nsubj) was_10\VBD\0|NONE (l_attr) predictor_14\NN\10756433|)|,|acid|tested|. (l_prep) of_15\IN\0|strong|a|independent|. (l_pobj) seizures_16\NNS\14081375|NONE
D014148_D012640 CID acid_2\NN\14818238|As|factor (r_nsubj) is_3\VBZ\0|be|administration|,|against|should|. (r_advcl) weighed_22\VBN\2704349|NONE (l_prep) against_23\IN\0|be|administration|,|is|should|. (l_pobj) risk_25\NN\14541044|NONE (l_prep) of_26\IN\0|the (l_pobj) seizures_28\NNS\14081375|NONE
D014148_D007035 NONE acid_37\NN\14818238|NONE (r_pobj) of_30\IN\0|NONE (r_prep) duration_29\NN\15113229|circulatory|deep|,|hypothermic (r_conj) arrest_27\NN\88481|heart|,|congestive (l_amod) hypothermic_25\JJ\0|duration|circulatory|deep|,
D014148_D006333 NONE acid_37\NN\14818238|NONE (r_pobj) of_30\IN\0|NONE (r_prep) duration_29\NN\15113229|circulatory|deep|,|hypothermic (r_conj) arrest_27\NN\88481|heart|,|congestive (r_conj) failure_22\NN\66216|of|,
24040781
D016559_D011507 NONE tacrolimus_31\NN\0|NONE (r_pobj) from_30\IN\0|NONE (r_prep) conversion_29\NN\7359599|NONE (r_pobj) after_28\IN\0|proteinuria|who (r_prep) developed_26\VBD\1753788|undetermined (l_dobj) proteinuria_27\NN\14299637|after|who
D020123_D011507 NONE rapamycin_13\NNS\0|i|)|( (r_amod) inhibitors_14\NNS\20090|NONE (r_pobj) of_12\IN\0|mammalian (r_prep) target_11\NN\7258332|NONE (r_pobj) with_9\IN\0|NONE (r_prep) treated_8\VBN\2376958|in|an|expected (r_acl) complication_4\NN\1073995|.|Proteinuria (r_attr) is_1\VBZ\0|NONE (l_nsubj) proteinuria_0\NNP\14299637|.|complication
D016559_D000686 NONE tacrolimus_31\NN\0|NONE (r_pobj) from_30\IN\0|NONE (r_prep) conversion_29\NN\7359599|NONE (r_pobj) after_28\IN\0|proteinuria|who (r_prep) developed_26\VBD\1753788|undetermined (r_relcl) significance_24\NN\5168261|NONE (r_pobj) of_22\IN\0|transplant|monoclonal (r_prep) gammapathy_21\JJ\0|NONE (r_pobj) with_16\IN\0|transplant|a (r_prep) patient_15\NN\9898892|NONE (r_pobj) in_10\IN\13603305|the|unexpected|of (r_prep) diagnosis_7\NN\152018|In|.|we (l_prep) of_8\IN\0|in|the|unexpected (l_pobj) amyloidosis_9\NN\14061805|NONE
C107135_D011507 CID everolimus_13\NN\0|NONE (r_pobj) with_12\IN\0|NONE (r_prep) treated_11\VBN\2376958|:|An|.|unexpected|in|amyloidosis (r_acl) diagnosis_2\NN\152018|NONE (l_prep) in_3\IN\13603305|:|An|.|unexpected|treated|amyloidosis (l_pobj) patient_8\NN\9898892|NONE (l_prep) with_9\IN\0|a|transplant (l_pobj) proteinuria_10\NN\14299637|NONE
C107135_D011507 CID everolimus_33\NN\0|NONE (r_pobj) to_32\IN\0|NONE (r_prep) tacrolimus_31\NN\0|NONE (r_pobj) from_30\IN\0|NONE (r_prep) conversion_29\NN\7359599|NONE (r_pobj) after_28\IN\0|proteinuria|who (r_prep) developed_26\VBD\1753788|undetermined (l_dobj) proteinuria_27\NN\14299637|after|who
C107135_D000686 CID everolimus_13\NN\0|NONE (r_pobj) with_12\IN\0|NONE (r_prep) treated_11\VBN\2376958|:|An|.|unexpected|in|amyloidosis (r_acl) diagnosis_2\NN\152018|NONE (l_appos) amyloidosis_16\NN\14061805|:|An|.|unexpected|in|treated (l_compound) al_15\NNP\14625458|NONE
C107135_D000686 CID everolimus_13\NN\0|NONE (r_pobj) with_12\IN\0|NONE (r_prep) treated_11\VBN\2376958|:|An|.|unexpected|in|amyloidosis (r_acl) diagnosis_2\NN\152018|NONE (l_appos) amyloidosis_16\NN\14061805|:|An|.|unexpected|in|treated
C107135_D000686 CID everolimus_33\NN\0|NONE (r_pobj) to_32\IN\0|NONE (r_prep) tacrolimus_31\NN\0|NONE (r_pobj) from_30\IN\0|NONE (r_prep) conversion_29\NN\7359599|NONE (r_pobj) after_28\IN\0|proteinuria|who (r_prep) developed_26\VBD\1753788|undetermined (r_relcl) significance_24\NN\5168261|NONE (r_pobj) of_22\IN\0|transplant|monoclonal (r_prep) gammapathy_21\JJ\0|NONE (r_pobj) with_16\IN\0|transplant|a (r_prep) patient_15\NN\9898892|NONE (r_pobj) in_10\IN\13603305|the|unexpected|of (r_prep) diagnosis_7\NN\152018|In|.|we (l_prep) of_8\IN\0|in|the|unexpected (l_pobj) amyloidosis_9\NN\14061805|NONE
6728873
D002110_D012640 CID caffeine_28\NN\14712692|in|under|various (r_compound) doses_29\NNS\3740161|NONE (r_pobj) at_26\IN\14622893|characteristics|were|. (r_prep) scored_25\VBN\1111028|NONE (l_nsubjpass) characteristics_2\NNS\5849040|were|at|. (l_acl) righting_7\VBG\126264|phenotypic||activity|Five| (l_dobj) ability_8\NN\4723816|NONE (l_conj) induction_12\NN\7450842|, (l_compound) seizure_11\NN\14081375|,|lethality
-1_D064420 NONE alkylxanthines_8\NNS\0|NONE (r_pobj) of_7\IN\0|behavioral|in|toxicity (r_prep) testing_6\NN\639556|misleading|may|that (l_compound) toxicity_5\NN\13576101|behavioral|in|of
3375885
D005438_D006947 NONE fludrocortisone_9\NN\0|NONE (r_pobj) by_8\IN\0|NONE (r_agent) reversed_7\VBN\109660|Hyperkalemia|and|.|by (r_conj) induced_1\VBN\1627355|NONE (l_nsubj) hyperkalemia_0\NNP\14299637|reversed|and|.|by
D005438_D006947 NONE fludrocortisone_13\NN\0|,|was|.|correcting|,|was (r_nsubjpass) added_15\VBN\156601|NONE (l_advcl) correcting_17\VBG\138508|,|was|fludrocortisone|.|,|was (l_dobj) hyperkalemia_19\NN\14299637|allowing|and
D011453_D007674 NONE prostaglandin_17\JJ\5414534|synthetase (r_amod) inhibitors_19\NNS\20090|NONE (r_pobj) with_16\IN\0|to|acidosis (r_prep) type_11\VB\5839024|that|disease|patient (r_advcl) predisposed_7\VBD\680841|NONE (l_nsubj) disease_6\NN\14061805|that|type|patient
D008528_D006947 NONE acid_14\NN\14818238|caused|mefenamic (r_compound) nephropathy_15\NN\14573196|NONE (l_relcl) caused_23\VBN\1617192|acid|mefenamic (l_nsubjpass) hyperkalemia_18\NN\14299637|in|,|by|were|without
D008528_D006994 NONE acid_14\NN\14818238|caused|mefenamic (r_compound) nephropathy_15\NN\14573196|NONE (l_relcl) caused_23\VBN\1617192|acid|mefenamic (l_nsubjpass) hyperkalemia_18\NN\14299637|in|,|by|were|without (l_conj) hypoaldosteronism_21\NN\0|inappropriate|and
D008528_D007674 CID acid_14\NN\14818238|caused|mefenamic (r_compound) nephropathy_15\NN\14573196|NONE
D009288_D001172 NONE naproxen_28\NN\3828465|both|and (r_conj) indomethacin_26\NN\3828465|NONE (r_pobj) by_24\IN\0|in|,|hyperkalemia|were|without (r_agent) caused_23\VBN\1617192|acid|mefenamic (r_relcl) nephropathy_15\NN\14573196|NONE (r_pobj) of_12\IN\0|a (r_prep) history_11\NN\15120823|rheumatoid|severe|and (r_conj) arthritis_8\NN\14171682|NONE
D011453_D006994 NONE prostaglandin_17\JJ\5414534|synthetase (r_amod) inhibitors_19\NNS\20090|NONE (r_pobj) with_16\IN\0|to|acidosis (r_prep) type_11\VB\5839024|that|disease|patient (l_dobj) acidosis_15\NN\14204950|to|with
D009288_D006947 CID naproxen_5\NN\3828465|and (r_conj) indomethacin_3\NN\3828465|NONE (r_pobj) by_2\IN\0|reversed|Hyperkalemia|and|. (r_prep) induced_1\VBN\1627355|NONE (l_nsubj) hyperkalemia_0\NNP\14299637|reversed|and|.|by
D009288_D006947 CID naproxen_28\NN\3828465|both|and (r_conj) indomethacin_26\NN\3828465|NONE (r_pobj) by_24\IN\0|in|,|hyperkalemia|were|without (r_agent) caused_23\VBN\1617192|acid|mefenamic (l_nsubjpass) hyperkalemia_18\NN\14299637|in|,|by|were|without
D007213_D006947 CID indomethacin_3\NN\3828465|NONE (r_pobj) by_2\IN\0|reversed|Hyperkalemia|and|. (r_prep) induced_1\VBN\1627355|NONE (l_nsubj) hyperkalemia_0\NNP\14299637|reversed|and|.|by
D007213_D006947 CID indomethacin_26\NN\3828465|NONE (r_pobj) by_24\IN\0|in|,|hyperkalemia|were|without (r_agent) caused_23\VBN\1617192|acid|mefenamic (l_nsubjpass) hyperkalemia_18\NN\14299637|in|,|by|were|without
D007213_D006947 CID indomethacin_22\NN\3828465|NONE (r_compound) therapy_23\NN\657604|safely|to|be (r_nsubjpass) continued_26\VBN\2367363|NONE (r_ccomp) allowing_21\VBG\0|hyperkalemia|and (r_conj) correcting_17\VBG\138508|,|was|fludrocortisone|.|,|was (l_dobj) hyperkalemia_19\NN\14299637|allowing|and
D007213_D007674 NONE indomethacin_26\NN\3828465|NONE (r_pobj) by_24\IN\0|in|,|hyperkalemia|were|without (r_agent) caused_23\VBN\1617192|acid|mefenamic (r_relcl) nephropathy_15\NN\14573196|NONE
D009288_D007674 NONE naproxen_28\NN\3828465|both|and (r_conj) indomethacin_26\NN\3828465|NONE (r_pobj) by_24\IN\0|in|,|hyperkalemia|were|without (r_agent) caused_23\VBN\1617192|acid|mefenamic (r_relcl) nephropathy_15\NN\14573196|NONE
D008528_D001172 NONE acid_14\NN\14818238|caused|mefenamic (r_compound) nephropathy_15\NN\14573196|NONE (r_pobj) of_12\IN\0|a (r_prep) history_11\NN\15120823|rheumatoid|severe|and (r_conj) arthritis_8\NN\14171682|NONE
D007213_D001172 NONE indomethacin_26\NN\3828465|NONE (r_pobj) by_24\IN\0|in|,|hyperkalemia|were|without (r_agent) caused_23\VBN\1617192|acid|mefenamic (r_relcl) nephropathy_15\NN\14573196|NONE (r_pobj) of_12\IN\0|a (r_prep) history_11\NN\15120823|rheumatoid|severe|and (r_conj) arthritis_8\NN\14171682|NONE
D007213_D006994 CID indomethacin_26\NN\3828465|NONE (r_pobj) by_24\IN\0|in|,|hyperkalemia|were|without (r_agent) caused_23\VBN\1617192|acid|mefenamic (l_nsubjpass) hyperkalemia_18\NN\14299637|in|,|by|were|without (l_conj) hypoaldosteronism_21\NN\0|inappropriate|and
D009288_D006994 CID naproxen_28\NN\3828465|both|and (r_conj) indomethacin_26\NN\3828465|NONE (r_pobj) by_24\IN\0|in|,|hyperkalemia|were|without (r_agent) caused_23\VBN\1617192|acid|mefenamic (l_nsubjpass) hyperkalemia_18\NN\14299637|in|,|by|were|without (l_conj) hypoaldosteronism_21\NN\0|inappropriate|and
9538487
D008094_D001714 NONE lithium_15\NN\14625458|NONE (r_pobj) with_14\IN\0|NONE (r_prep) treated_13\VBN\2376958|manic (r_acl) depression_12\NN\14373582|NONE
D005947_D018500 NONE glucose_11\NN\14710501|normal (r_compound) concentrations_12\NNS\4916342|NONE (r_pobj) despite_8\IN\7501545|he|After|,|polyuric (r_prep) remained_6\VBD\2604760|insipidus|testing|,|likely|;|. (r_ccomp) indicated_17\VBD\952524|NONE (l_dobj) insipidus_20\NN\0|testing|remained|,|likely|;|.
D005947_-1 NONE glucose_11\NN\14710501|normal (r_compound) concentrations_12\NNS\4916342|NONE (r_pobj) despite_8\IN\7501545|he|After|,|polyuric (r_prep) remained_6\VBD\2604760|insipidus|testing|,|likely|;|. (l_prep) after_0\IN\0|he|,|polyuric|despite (l_pobj) recovery_1\NN\7357388|NONE (l_prep) from_2\IN\0|NONE (l_pobj) hyperglycaemia_3\NN\14299637|NONE
D008094_D006944 CID lithium_5\NN\14625458| (r_npadvmod) induced_7\VBN\1627355|diabetes (r_amod) insipidus_10\NN\0|NONE (r_pobj) by_4\IN\0|.|coma (r_agent) precipitated_3\VBD\1642924|NONE (l_nsubj) coma_2\NN\5678932|by|.
D008094_D006944 CID lithium_15\NN\14625458|NONE (r_pobj) with_14\IN\0|NONE (r_prep) treated_13\VBN\2376958|manic (r_acl) depression_12\NN\14373582|NONE (r_pobj) of_10\IN\0|a|year (r_prep) history_9\NN\15120823|NONE (r_pobj) with_6\IN\0|coma|man|.|,|with|,|was|, (r_prep) admitted_18\VBN\822367|NONE (l_npadvmod) coma_23\NN\5678932|man|with|.|,|with|,|was|,
D008094_-1 NONE lithium_25\NN\14625458| (r_npadvmod) induced_27\VBN\1627355|to (r_acomp) be_24\VB\14625458|NONE (r_xcomp) likely_22\JJ\0|insipidus|testing|remained|,|;|. (r_amod) indicated_17\VBD\952524|NONE (l_ccomp) remained_6\VBD\2604760|insipidus|testing|,|likely|;|. (l_prep) after_0\IN\0|he|,|polyuric|despite (l_pobj) recovery_1\NN\7357388|NONE (l_prep) from_2\IN\0|NONE (l_pobj) hyperglycaemia_3\NN\14299637|NONE
D008094_D011141 CID lithium_25\NN\14625458| (r_npadvmod) induced_27\VBN\1627355|to (r_acomp) be_24\VB\14625458|NONE (r_xcomp) likely_22\JJ\0|insipidus|testing|remained|,|;|. (r_amod) indicated_17\VBD\952524|NONE (l_ccomp) remained_6\VBD\2604760|insipidus|testing|,|likely|;|. (l_acomp) polyuric_7\JJ\0|he|After|,|despite
D008094_D018500 CID lithium_5\NN\14625458| (r_npadvmod) induced_7\VBN\1627355|diabetes (r_amod) insipidus_10\NN\0|NONE
D008094_D018500 CID lithium_25\NN\14625458| (r_npadvmod) induced_27\VBN\1627355|to (r_acomp) be_24\VB\14625458|NONE (r_xcomp) likely_22\JJ\0|insipidus|testing|remained|,|;|. (r_amod) indicated_17\VBD\952524|NONE (l_dobj) insipidus_20\NN\0|testing|remained|,|likely|;|.
D005947_D011141 NONE glucose_20\NN\14710501|NONE (r_pobj) for_19\IN\0|NONE (r_prep) negative_18\JJ\7204401|during|urinalysis|had (r_acomp) been_17\VBN\0|year|of|,|a (r_relcl) history_6\NN\15120823|.|He (l_prep) of_7\IN\0|year|,|been|a (l_pobj) polyuria_8\NN\14113228|NONE
D005947_D011141 NONE glucose_11\NN\14710501|normal (r_compound) concentrations_12\NNS\4916342|NONE (r_pobj) despite_8\IN\7501545|he|After|,|polyuric (r_prep) remained_6\VBD\2604760|insipidus|testing|,|likely|;|. (l_acomp) polyuric_7\JJ\0|he|After|,|despite
D005947_D059606 NONE glucose_20\NN\14710501|NONE (r_pobj) for_19\IN\0|NONE (r_prep) negative_18\JJ\7204401|during|urinalysis|had (r_acomp) been_17\VBN\0|year|of|,|a (r_relcl) history_6\NN\15120823|.|He (l_prep) of_7\IN\0|year|,|been|a (l_pobj) polyuria_8\NN\14113228|NONE (l_conj) polydipsia_10\NN\14040660|and
2239937
D002119_D006934 CID carbonate_8\NN\15010703|calcium (r_compound) therapy_9\NN\657604|NONE (r_pobj) on_6\IN\0|hemodialysis (r_prep) patients_5\NNS\9898892|NONE (r_pobj) in_3\IN\13603305|NONE (r_prep) hypercalcemia_2\NN\14299637|NONE
D002119_D006934 CID carbonate_15\NN\15010703|NONE (r_pobj) to_13\IN\0|as (r_prep) switching_12\VBG\191142|NONE (r_pcomp) after_11\IN\0|patients|.|hypercalcemic (r_prep) became_9\VBD\146138|NONE (l_acomp) hypercalcemic_10\JJ\0|patients|after|.
D010710_D006934 NONE phosphate_19\NN\15010703|their|principal (r_compound) binder_20\NN\3496892|NONE (r_pobj) as_16\IN\14622893|to (r_prep) switching_12\VBG\191142|NONE (r_pcomp) after_11\IN\0|patients|.|hypercalcemic (r_prep) became_9\VBD\146138|NONE (l_acomp) hypercalcemic_10\JJ\0|patients|after|.
D002118_D007674 NONE calcium_17\NN\14625458|rate|intestinal|and (r_compound) reabsorption_18\NN\13526110|NONE (r_pobj) of_15\IN\0|indirect|in (r_prep) parameters_14\NNS\5858936|risk|,|associated (r_appos) factors_5\NNS\7326557|to (r_dobj) identify_3\VB\699815|NONE (r_acl) order_1\NN\7168131|NONE (r_pobj) in_0\IN\13603305|were|.|with (r_prep) compared_28\VBN\644583|NONE (l_prep) with_29\IN\0|were|.|In (l_pobj) results_30\NNS\34213|NONE (l_prep) in_31\IN\13603305|NONE (l_pobj) patients_34\NNS\9898892|NONE (l_acl) matched_35\VBN\2664769||eucalcemic (l_prep) for_36\IN\0|NONE (l_pobj) age_37\NN\4916342|NONE (l_conj) sex_39\NN\13440063|, (l_conj) length_41\NN\5093581|, (l_conj) etiology_48\NN\7326557|and|on|,|of (l_prep) of_49\IN\0|NONE (l_pobj) disease_51\NN\14061805|NONE
D002118_D006934 NONE calcium_17\NN\14625458|rate|intestinal|and (r_compound) reabsorption_18\NN\13526110|NONE (r_pobj) of_15\IN\0|indirect|in (r_prep) parameters_14\NNS\5858936|risk|,|associated (r_appos) factors_5\NNS\7326557|to (l_acl) associated_6\VBN\628491|risk|parameters|, (l_prep) with_7\IN\0|NONE (l_pobj) development_9\NN\248977|NONE (l_prep) of_10\IN\0|the (l_pobj) hypercalcemia_11\NN\14299637|NONE
D002118_D006934 NONE calcium_8\NN\14625458|of|peak (r_compound) values_9\NNS\5941423|NONE (r_pobj) with_6\IN\0|hypercalcemic (r_prep) episodes_5\NNS\7283608|NONE (l_amod) hypercalcemic_4\JJ\0|with
D002118_D006934 NONE calcium_8\NN\14625458|of|peak (r_compound) values_9\NNS\5941423|NONE (r_pobj) with_6\IN\0|hypercalcemic (r_prep) episodes_5\NNS\7283608|NONE (r_dobj) experiencing_3\VBG\2108377|NONE (r_pcomp) to_2\IN\0|NONE (r_prep) addition_1\NN\3081021|NONE (r_pobj) in_0\IN\13603305|patients|,|increase|. (r_prep) exhibited_31\VBD\2632167|NONE (l_nsubj) patients_26\NNS\9898892|,|In|increase|. (l_prep) in_27\IN\13603305|NONE (l_pobj) group_30\NN\2137|NONE (l_amod) hypercalcemic_29\NN\0|the
D002118_D006934 NONE calcium_38\NN\14625458|mean|the (r_compound) concentration_39\NN\4916342|NONE (r_pobj) in_35\IN\13603305|a|,|compared|obtained|significant (r_prep) increase_34\NN\13576355|patients|,|In|. (r_dobj) exhibited_31\VBD\2632167|NONE (l_prep) in_0\IN\13603305|patients|,|increase|. (l_pobj) addition_1\NN\3081021|NONE (l_prep) to_2\IN\0|NONE (l_pcomp) experiencing_3\VBG\2108377|NONE (l_dobj) episodes_5\NNS\7283608|NONE (l_amod) hypercalcemic_4\JJ\0|with
D002118_D006934 NONE calcium_38\NN\14625458|mean|the (r_compound) concentration_39\NN\4916342|NONE (r_pobj) in_35\IN\13603305|a|,|compared|obtained|significant (r_prep) increase_34\NN\13576355|patients|,|In|. (r_dobj) exhibited_31\VBD\2632167|NONE (l_nsubj) patients_26\NNS\9898892|,|In|increase|. (l_prep) in_27\IN\13603305|NONE (l_pobj) group_30\NN\2137|NONE (l_amod) hypercalcemic_29\NN\0|the
2625524
D000661_D012640 CID amphetamine_4\NN\3248958| (r_npadvmod) induced_6\VBN\1627355|NONE (r_amod) seizures_7\NNS\14081375|to
D000661_D012640 CID amphetamine_18\NN\3248958|dose (r_compound) exposure_19\NN\5042871|NONE (r_pobj) from_14\IN\0|NONE (r_prep) death_13\NN\7296428|NONE (r_pobj) against_12\IN\0|dopamine|haloperidol|the (r_prep) blocker_10\NN\10101634|NONE (r_pobj) for_6\IN\0|protective|a|without (r_prep) role_5\NN\719494|.|data (l_prep) without_20\IN\0|protective|for|a (l_pcomp) reducing_21\VBG\13447361|NONE (l_dobj) incidence_23\NN\13821570|NONE (l_prep) of_24\IN\0|the (l_pobj) seizures_25\NNS\14081375|NONE
D006220_D012640 NONE haloperidol_0\NNP\3713736|lower|prevent|,|but|. (r_nsubj) failed_1\VBD\0|NONE (l_xcomp) prevent_3\VB\0|lower|Haloperidol|,|but|. (l_dobj) seizures_7\NNS\14081375|to
D006220_D012640 NONE haloperidol_0\NN\3713736|incidence|at|but|,|reach (r_nsubj) decreased_1\VBD\169651|NONE (l_dobj) incidence_3\NN\13821570|at|but|Haloperidol|,|reach (l_prep) of_4\IN\0|the (l_pobj) seizures_8\NNS\14081375|NONE
D006220_D012640 NONE haloperidol_11\NN\3713736|dopamine|against|the (r_appos) blocker_10\NN\10101634|NONE (r_pobj) for_6\IN\0|protective|a|without (r_prep) role_5\NN\719494|.|data (l_prep) without_20\IN\0|protective|for|a (l_pcomp) reducing_21\VBG\13447361|NONE (l_dobj) incidence_23\NN\13821570|NONE (l_prep) of_24\IN\0|the (l_pobj) seizures_25\NNS\14081375|NONE
D006220_D012640 NONE haloperidol_3\NN\3713736|ability|In|.|, (r_nsubj) demonstrated_4\VBD\2137132|NONE (l_dobj) ability_6\NN\4723816|In|.|,|haloperidol (l_acl) reduce_8\VB\441445|an (l_dobj) seizures_12\NNS\14081375|to|without
D004298_D012640 NONE dopamine_9\NN\14807737|haloperidol|against|the (r_compound) blocker_10\NN\10101634|NONE (r_pobj) for_6\IN\0|protective|a|without (r_prep) role_5\NN\719494|.|data (l_prep) without_20\IN\0|protective|for|a (l_pcomp) reducing_21\VBG\13447361|NONE (l_dobj) incidence_23\NN\13821570|NONE (l_prep) of_24\IN\0|the (l_pobj) seizures_25\NNS\14081375|NONE
D003042_D012640 CID cocaine_5\NN\3492717| (r_npadvmod) induced_7\VBN\1627355|NONE (r_amod) seizures_8\NNS\14081375|NONE
D003042_D012640 CID cocaine_9\NN\3492717| (r_npadvmod) induced_11\VBN\1627355|NONE (r_amod) seizures_12\NNS\14081375|to|without
11299446
C027429_D010302 CID veralipride_7\NN\0|NONE (r_pobj) of_6\IN\0|the (r_prep) use_5\NN\407535|NONE (r_pobj) after_3\IN\0|of (r_prep) worsening_0\VBG\13457378|.|case|: (l_prep) of_1\IN\0|after (l_pobj) parkinsonism_2\NN\14085708|NONE
C027429_D010302 CID veralipride_27\NN\0|NONE (r_pobj) with_26\IN\0|related (r_prep) symptoms_25\NNS\5823932|of (r_appos) therapy_21\NN\657604|NONE (r_pobj) following_20\VBG\8180190|has|worsening|who (r_prep) shown_12\VBN\2137132|Parkinson|stable (r_relcl) disease_9\NN\14061805|NONE
3831029
C037293_D001145 NONE denopamine_8\NN\0|NONE (r_pobj) of_7\IN\0|these (r_prep) doses_6\NNS\3740161|NONE (r_pobj) by_4\IN\0|arrhythmias|were|. (r_agent) induced_3\VBN\1627355|NONE (l_nsubjpass) arrhythmias_1\NNS\14103288|were|.|by
C037293_D006333 NONE denopamine_2\NN\0|NONE (r_pobj) by_1\IN\0|of|. (r_prep) improvement_0\NN\7359599|NONE (l_prep) of_6\IN\0|.|by (l_pobj) failure_11\NN\66216|)
C037293_D006333 NONE ta-064_4\NNP\0|NONE (r_punct) )_5\-RRB-\0|failure (r_punct) of_6\IN\0|.|by (l_pobj) failure_11\NN\66216|)
C037293_D006333 NONE denopamine_3\NN\0|NONE (r_pobj) of_2\IN\0|,|agonist|The|, (r_prep) efficacy_1\NN\5199286|in|.|was|in (r_nsubjpass) assessed_17\VBN\670261|NONE (l_prep) in_12\IN\13603305|efficacy|.|was|in (l_pcomp) improving_13\VBG\126264|NONE (l_dobj) failure_15\NN\66216|NONE
C037293_D006333 NONE denopamine_6\NN\0|NONE (r_pobj) of_5\IN\0|clinical|in (r_prep) trials_4\NNS\786195|results|. (l_prep) in_7\IN\13603305|clinical|of (l_pobj) treatment_9\NN\654885|NONE (l_prep) of_10\IN\0|the (l_pobj) failure_12\NN\66216|NONE
D010424_D006333 CID pentobarbital_7\NN\2792049| (r_npadvmod) induced_9\VBN\1627355|in|cardiac (r_amod) failure_11\NN\66216|)
2974281
D007545_D006332 CID isoproterenol_8\NN\3740161| (r_npadvmod) induced_10\VBN\1627355|rat|in|heart (r_amod) hypertrophy_13\NN\14365950|NONE
D007545_D006332 CID isoproterenol_9\NN\3740161| (r_npadvmod) induced_11\VBN\1627355|in|heart (r_amod) hypertrophy_13\NN\14365950|NONE
D007545_D006332 CID isoproterenol_24\NN\3740161|to|from (r_dobj) prevent_23\VB\0|/|potency (l_prep) from_25\IN\0|isoproterenol|to (l_pcomp) producing_26\VBG\1617192|NONE (l_dobj) hypertrophy_28\NN\14365950|NONE
D009952_D006332 NONE ornithine_7\NN\14601829|NONE (r_compound) decarboxylase_8\NN\14732946|the|increased|with (r_compound) activity_9\NN\30358|to (l_prep) with_10\IN\0|decarboxylase|the|increased (l_pobj) blockers_14\NNS\10101634|NONE (l_prep) in_15\IN\13603305|both||beta (l_pobj) hearts_17\NNS\496167|NONE
D011433_D006332 NONE propranolol_3\NN\0|NONE (r_pobj) of_2\IN\0|.|Subacute|on (r_prep) effects_1\NNS\13245626|NONE (l_prep) on_7\IN\0|of|.|Subacute (l_pobj) hypertrophy_13\NN\14365950|NONE
D011433_D006332 NONE propranolol_15\NN\0|any (l_conj) have_19\VBP\7846|that|blockers|and (l_advcl) prevent_23\VB\0|/|potency (l_prep) from_25\IN\0|isoproterenol|to (l_pcomp) producing_26\VBG\1617192|NONE (l_dobj) hypertrophy_28\NN\14365950|NONE
D011433_D006984 NONE propranolol_1\NN\0|could|changes|. (r_csubj) stop_6\VB\7291312|NONE (l_dobj) changes_8\NNS\7283608|could|.|propranolol (l_prep) in_9\IN\13603305|the (l_pobj) pattern_14\NN\5726345|myosin (l_prep) of_15\IN\0|isoenzyme (l_pobj) heart_19\NN\5919034|NONE (l_amod) hypertrophied_17\JJ\230746|the|rat
24100257
C089750_D054549 CID zolmitriptan_10\NNP\0|NONE (r_pobj) to_9\IN\0|NONE (r_prep) secondary_8\JJ\8426461|)|.|ballooning (r_amod) syndrome_6\NN\5870365|Takotsubo|(|or (r_conj) syndrome_1\NN\5870365|NONE
C089750_D054549 CID zolmitriptan_10\NNP\0|NONE (r_pobj) to_9\IN\0|NONE (r_prep) secondary_8\JJ\8426461|)|.|ballooning (r_amod) syndrome_6\NN\5870365|Takotsubo|(|or
C089750_D054549 CID zolmitriptan_12\NN\0|secondary|artery (r_advcl) vasospasm_9\NN\0|NONE (r_pobj) of_6\IN\0|multiple (r_prep) cases_5\NNS\7283608|search|but|,|associated (r_dobj) revealed_3\VBD\2137132|NONE (l_conj) associated_20\VBN\628491|search|but|,|cases (l_prep) with_21\IN\0|none|were|. (l_pobj) ts_22\NNP\14999913|NONE
C089750_D008881 NONE zolmitriptan_9\NN\0|patient|that|had|sparingly (r_dobj) took_8\VBD\2367363|history|.|retrospectively (l_advcl) had_14\VBD\0|patient|that|zolmitriptan|sparingly (l_dobj) migraines_15\NNS\14326607|when|she|only
C089750_D008881 NONE zolmitriptan_8\JJ\0|daily|before|But|for||.|because|she|was|, (r_dobj) taking_7\VBG\37396|NONE (l_prep) because_17\IN\0|daily|before|But|zolmitriptan|for||.|she|was|, (l_pobj) headache_22\NN\5829480|of
C089750_D003329 CID zolmitriptan_12\NN\0|secondary|artery (r_advcl) vasospasm_9\NN\0|NONE
15987266
D010862_D013226 CID pilocarpine_46\NN\14712692|NONE (r_pobj) by_45\IN\0|epilepticus (r_agent) induced_44\VBN\1627355|of|(|densitometry|the (l_amod) epilepticus_43\NN\0|by
D010862_D013226 CID pilo_48\NNP\0|NONE (r_appos) pilocarpine_46\NN\14712692|NONE (r_pobj) by_45\IN\0|epilepticus (r_agent) induced_44\VBN\1627355|of|(|densitometry|the (l_amod) epilepticus_43\NN\0|by
D003513_D013226 NONE cycloheximide_56\NN\0|not (r_pobj) with_55\IN\0|CHX|or|previously (r_conj) injected_52\VBN\81072|investigate|,|,|we|intensity|. (r_conj) assessed_13\VBD\670261|NONE (l_dobj) intensity_15\NN\5090441|investigate|,|,|we|injected|. (l_acl) induced_44\VBN\1627355|of|(|densitometry|the (l_amod) epilepticus_43\NN\0|by
D003513_D013226 NONE chx_58\NNP\0|or|with|previously (r_appos) injected_52\VBN\81072|investigate|,|,|we|intensity|. (r_conj) assessed_13\VBD\670261|NONE (l_dobj) intensity_15\NN\5090441|investigate|,|,|we|injected|. (l_acl) induced_44\VBN\1627355|of|(|densitometry|the (l_amod) epilepticus_43\NN\0|by
D003513_D004827 NONE cycloheximide_16\NN\0|NONE (r_pobj) with_15\IN\0|expression|. (r_prep) treated_14\VBN\2376958|NONE (l_nsubj) expression_5\NN\4679549|.|with (l_prep) in_6\IN\13603305||protein (l_pobj) layer_9\NN\21939|NONE (l_prep) of_10\IN\0|molecular|hippocampal (l_pobj) rats_13\NNS\2329401|NONE (l_amod) epileptic_12\JJ\10595647|chronic
19728177
D000082_D001929 CID acetaminophen_27\NN\2707683|NONE (r_pobj) from_26\IN\0|care|and|a|in (r_prep) facility_17\NN\21939|NONE (r_pobj) in_13\IN\13603305|.|edema|based|from (r_prep) observations_3\NNS\996969|NONE (l_conj) edema_31\NN\14315192|.|in|based|from
D000082_D001929 CID acetaminophen_5\NN\2707683|NONE (l_conj) edema_8\NN\14315192|and
D000082_D001929 CID acetaminophen_8\NN\2707683|NONE (r_compound) overdose_9\NN\84738|NONE (r_pobj) from_7\IN\0|cerebral (r_prep) edema_6\NN\14315192|and
D000082_D062787 NONE acetaminophen_8\NN\2707683|NONE (r_compound) overdose_9\NN\84738|NONE
D000082_D017114 CID acetaminophen_27\NN\2707683|NONE (r_pobj) from_26\IN\0|care|and|a|in (r_prep) facility_17\NN\21939|NONE (l_prep) in_18\IN\13603305|care|and|from|a (l_pobj) female_23\NN\15388|NONE (l_prep) with_24\IN\0|a|old (l_pobj) fhf_25\NNP\0|NONE
D000082_D017114 CID acetaminophen_5\NN\2707683|NONE (r_pobj) from_4\IN\0|.|FHF|evaluation (r_prep) confirmed_2\VBN\0|NONE (l_dobj) fhf_3\NNP\0|.|evaluation|from
D000082_D017114 CID acetaminophen_8\NN\2707683|NONE (r_compound) overdose_9\NN\84738|NONE (r_pobj) from_7\IN\0|cerebral (r_prep) edema_6\NN\14315192|and (r_conj) fhf_3\NNP\0|NONE
D000082_D007035 NONE acetaminophen_8\NN\2707683|NONE (r_compound) overdose_9\NN\84738|NONE (r_pobj) from_7\IN\0|cerebral (r_prep) edema_6\NN\14315192|and (r_conj) fhf_3\NNP\0|NONE (r_pobj) with_2\IN\0|NONE (r_prep) patients_1\NNS\9898892|NONE (r_pobj) in_0\IN\13603305|hypothermia|potentially|be|could|.|,|as (r_prep) used_17\VBN\0|NONE (l_nsubjpass) hypothermia_13\NN\14034177|potentially|be|could|.|In|,|as
D000082_D064420 NONE acetaminophen_16\NN\2707683|NONE (r_pobj) from_15\IN\0|ingested|presumed (r_prep) toxicity_14\NN\13576101|NONE
19531695
D005424_D064420 NONE flecainide_5\JJ\2715941|with|is|when (r_nsubjpass) prescribed_7\VBN\748282|toxicity|may|Because (r_advcl) occur_3\VB\0|with|be|.|should|closely (l_nsubj) toxicity_1\NN\13576101|may|Because|prescribed
D005424_D064420 NONE flecainide_16\JJ\2715941|plasma (r_amod) concentrations_18\NNS\4916342|and|,|inhibitors (r_conj) paroxetine_9\NN\0|NONE (r_pobj) with_8\IN\0|is|when|flecainide (r_prep) prescribed_7\VBN\748282|toxicity|may|Because (r_advcl) occur_3\VB\0|with|be|.|should|closely (l_nsubj) toxicity_1\NN\13576101|may|Because|prescribed
D017374_D003693 CID paroxetine_18\NN\0|NONE (r_pobj) with_17\IN\0|drug|pharmacokinetic|a (r_prep) interaction_16\NN\37396|NONE (r_pobj) of_12\IN\0|the (r_prep) role_11\NN\719494|:|.|in (r_appos) delirium_0\NN\14391660|NONE
D017374_D003693 CID paroxetine_16\NN\0|NONE (r_pobj) with_15\IN\0|drug|pharmacokinetic|a (r_prep) interaction_14\NN\37396|NONE (r_pobj) with_10\IN\0|NONE (r_prep) associated_9\VBN\628491|induced (r_acl) delirium_8\NN\14391660|NONE
D017374_D003693 CID paroxetine_24\NN\0|and|a|,|CYPD (l_appos) inhibitor_28\NN\20090|, (l_conj) reports_35\NNS\6470073|,|as|CYPD|a (l_prep) of_36\IN\0|case| (l_pobj) delirium_40\NN\14391660|NONE
D017374_D003693 CID paroxetine_33\NN\0|and (r_conj) flecainide_31\NN\2715941|NONE (r_pobj) between_30\IN\0|a|possible|drug|pharmacokinetic (r_prep) interaction_29\NN\37396|was|Scale|.|; (r_dobj) indicates_24\VBZ\952524|NONE (l_ccomp) was_8\VBD\0|Scale|.|interaction|; (l_attr) cause_11\NN\7323922|According|flecainide|, (l_prep) of_12\IN\0|the|probable (l_pobj) delirium_16\NN\14391660|NONE
D012964_D003693 NONE sodium_8\NN\14625458|NONE (r_compound) channels_9\NNS\6251781|NONE (r_pobj) with_7\IN\0|that (r_prep) interact_6\VBP\2367363|Flecainide (r_relcl) agents_4\NNS\7347|.|may|delirium (r_nsubj) cause_11\VB\7323922|NONE (l_dobj) delirium_12\NN\14391660|.|may|agents
D005424_D001281 NONE flecainide_0\NNP\2715941|prior|.|been|had (r_nsubjpass) started_3\VBN\0|NONE (l_advmod) prior_6\RB\10675876|.|Flecainide|been|had (l_prep) for_7\IN\0|weeks (l_pobj) fibrillation_9\NN\14361664|NONE
D017374_D064420 NONE paroxetine_9\NN\0|NONE (r_pobj) with_8\IN\0|is|when|flecainide (r_prep) prescribed_7\VBN\748282|toxicity|may|Because (r_advcl) occur_3\VB\0|with|be|.|should|closely (l_nsubj) toxicity_1\NN\13576101|may|Because|prescribed
D005424_D003693 CID flecainide_6\JJ\2715941|toxic|plasma (r_amod) concentrations_8\NNS\4916342|NONE (r_pobj) with_4\IN\0|a (r_prep) patient_3\NN\9898892|NONE (r_pobj) in_1\IN\13603305|role|:|. (r_prep) delirium_0\NN\14391660|NONE
D005424_D003693 CID flecainide_5\RB\2715941| (r_advmod) induced_7\VBN\1627355|associated (r_amod) delirium_8\NN\14391660|NONE
D005424_D003693 CID flecainide_0\NNP\2715941|interact (r_amod) agents_4\NNS\7347|.|may|delirium (r_nsubj) cause_11\VB\7323922|NONE (l_dobj) delirium_12\NN\14391660|.|may|agents
D005424_D003693 CID flecainide_17\NN\2715941|NONE (r_pobj) between_16\IN\0|the (r_prep) interaction_15\NN\37396|NONE (r_pobj) on_13\IN\0|,|pharmacokinetic|substrate (r_prep) study_12\NN\635850|.|search|one (l_conj) substrate_21\NN\19613|,|pharmacokinetic|on (l_conj) paroxetine_24\NN\0|and|a|,|CYPD (l_appos) inhibitor_28\NN\20090|, (l_conj) reports_35\NNS\6470073|,|as|CYPD|a (l_prep) of_36\IN\0|case| (l_pobj) delirium_40\NN\14391660|NONE
D005424_D003693 CID flecainide_37\RB\2715941| (r_advmod) induced_39\VBN\1627355|NONE (r_amod) delirium_40\NN\14391660|NONE
D005424_D003693 CID flecainide_7\NN\2715941|According|,|cause (r_advmod) was_8\VBD\0|Scale|.|interaction|; (l_attr) cause_11\NN\7323922|According|flecainide|, (l_prep) of_12\IN\0|the|probable (l_pobj) delirium_16\NN\14391660|NONE
D005424_D003693 CID flecainide_31\NN\2715941|NONE (r_pobj) between_30\IN\0|a|possible|drug|pharmacokinetic (r_prep) interaction_29\NN\37396|was|Scale|.|; (r_dobj) indicates_24\VBZ\952524|NONE (l_ccomp) was_8\VBD\0|Scale|.|interaction|; (l_attr) cause_11\NN\7323922|According|flecainide|, (l_prep) of_12\IN\0|the|probable (l_pobj) delirium_16\NN\14391660|NONE
D005424_D003693 CID flecainide_1\JJ\2715941|plasma|Supratherapeutic (r_amod) concentrations_3\NNS\4916342|may|delirium|. (r_nsubj) cause_5\VB\7323922|NONE (l_dobj) delirium_6\NN\14391660|may|.|concentrations
6631522
D004317_D066126 CID doxorubicin_23\NN\2716866|NONE (r_compound) cardiotoxicity_24\NN\0|NONE
C013102_D066126 NONE ha_16\NNP\13888491|not|factor|changes|I|that (r_nsubj) are_17\VBP\13600404|findings|. (l_attr) factor_21\NN\7326557|not|changes|HA|I|that (l_prep) in_22\IN\13603305|the|initiating (l_pobj) cardiotoxicity_24\NN\0|NONE
25951420
D052638_D010300 CID matter_9\NN\5670710|and (r_conj) ozone_5\NN\14877585|NONE (r_pobj) of_4\IN\0|NONE (r_prep) associations_3\NNS\8008335|with|study|. (r_dobj) describes_2\VBZ\1001294|NONE (l_prep) with_10\IN\0|study|associations|. (l_pobj) disease_13\NN\14061805|NONE
D052638_D010300 CID matter_28\NN\5670710|to|and|) (r_conj) 0.98_21\CD\0|;|.|=|odds|:|CI (r_appos) ratio_13\NN\13815152|(|positive|of (r_appos) associations_4\NNS\8008335|:|.|We (l_prep) of_5\IN\0|(|ratio|positive (l_pobj) disease_8\NN\14061805|NONE
D010126_D010300 CID ozone_2\NN\14877585|NONE (r_pobj) of_1\IN\0|With|. (r_prep) associations_0\NNS\8008335|NONE (l_prep) with_6\IN\0|of|. (l_pobj) disease_9\NNP\14061805|NONE
D010126_D010300 CID ozone_5\NN\14877585|NONE (r_pobj) of_4\IN\0|NONE (r_prep) associations_3\NNS\8008335|with|study|. (r_dobj) describes_2\VBZ\1001294|NONE (l_prep) with_10\IN\0|study|associations|. (l_pobj) disease_13\NN\14061805|NONE
D010126_D010300 CID ozone_10\NN\14877585|NONE (r_pobj) with_9\IN\0|Parkinson (r_prep) disease_8\NN\14061805|NONE
11395263
D000431_D009203 NONE ethanol_5\NN\14708720|the|of (r_compound) extract_6\NN\14589223|NONE (r_pobj) of_3\IN\0|rhizomes|The|on|cardioprotective (r_prep) effect_2\NN\34213|has|.|been (l_prep) on_16\IN\0|rhizomes|The|of|cardioprotective (l_pobj) infarction_21\NN\14204950|NONE
D007545_D009203 CID isoproterenol_17\NN\3740161| (r_npadvmod) induced_19\VBN\1627355|in|myocardial (r_amod) infarction_21\NN\14204950|NONE
D007545_D009203 CID isoproterenol_9\NN\3740161| (r_npadvmod) induced_11\VBN\1627355|myocardial|the (r_amod) infarction_13\NN\14204950|maintained|and|.|day(|significantly
2907577
D003404_D009336 NONE creatinine_10\NN\0|plasma|analysis|,|)|(|and|biochemical (r_conj) urea_8\NN\14727670|NONE (l_conj) analysis_16\NN\633864|plasma|,|)|(|creatinine|and|biochemical (l_conj) degree_31\NN\4916342|and|functional|and|clearances|indices|urine|( (l_prep) of_32\IN\0|)|morphological|( (l_pobj) necrosis_33\NN\11444117|NONE
D014508_D009336 NONE urea_8\NN\14727670|NONE (l_conj) analysis_16\NN\633864|plasma|,|)|(|creatinine|and|biochemical (l_conj) degree_31\NN\4916342|and|functional|and|clearances|indices|urine|( (l_prep) of_32\IN\0|)|morphological|( (l_pobj) necrosis_33\NN\11444117|NONE
D000241_D058186 NONE adenosine_0\NNP\14964367|NONE (r_amod) antagonists_1\NNS\7846|.|have|be|been|previously (r_nsubjpass) shown_5\VBN\2137132|NONE (l_xcomp) be_7\VB\14625458|.|have|been|antagonists|previously (l_prep) in_10\IN\13603305|to|of (l_pobj) models_15\NNS\5888929|NONE (l_prep) of_16\IN\0|ischaemic|some (l_pobj) failure_19\NN\66216|NONE
D000241_D058186 NONE adenosine_0\NNP\14964367|NONE (r_amod) antagonists_1\NNS\7846|.|have|be|been|previously (r_nsubjpass) shown_5\VBN\2137132|NONE (l_xcomp) be_7\VB\14625458|.|have|been|antagonists|previously (l_prep) in_10\IN\13603305|to|of (l_pobj) models_15\NNS\5888929|NONE (l_prep) of_16\IN\0|ischaemic|some (l_pobj) failure_19\NN\66216|NONE (l_appos) arf_21\NNP\0|acute|renal|)|(
D000241_D058186 NONE adenosine_14\NN\14964367|theophylline|, (r_amod) antagonists_15\NNS\7846|NONE (r_pobj) as_13\IN\14622893|different (r_prep) potencies_12\NNS\5196375|NONE (r_pobj) with_10\IN\0|three (r_prep) alkylxanthines_9\NNS\0|NONE (r_pobj) of_7\IN\0|the (r_prep) effects_6\NNS\13245626|.|,|,|In|were|in|) (r_nsubjpass) examined_23\VBN\0|NONE (l_prep) in_24\IN\13603305|.|effects|,|,|In|were|) (l_pobj) rats_25\NNS\2329401|NONE (l_acl) developing_26\VBG\13541167|NONE (l_dobj) failure_29\NN\66216|after
D000241_D058186 NONE adenosine_18\NN\14964367|little|role|that|, (r_nsubj) plays_19\VBZ\7007684|NONE (l_dobj) role_26\NN\719494|little|adenosine|that|, (l_prep) in_27\IN\13603305|pathophysiological|any|, (l_pobj) arf_31\NN\0|NONE
D010130_D009336 NONE acid_25\NN\14818238|H]inulin|) (r_compound) clearances_26\NNS\5089947|and|functional|and|indices|urine|degree|( (r_conj) analysis_16\NN\633864|plasma|,|)|(|creatinine|and|biochemical (l_conj) degree_31\NN\4916342|and|functional|and|clearances|indices|urine|( (l_prep) of_32\IN\0|)|morphological|( (l_pobj) necrosis_33\NN\11444117|NONE
D005839_D058186 CID gentamicin_4\NN\2716866| (r_npadvmod) induced_6\VBN\1627355|acute|renal|in (r_amod) failure_9\NN\66216|NONE
D005839_D058186 CID gentamicin_35\NN\2716866|NONE (r_pobj) of_34\IN\0|kg|(||daily (r_prep) injections_33\NNS\320852|NONE (r_pobj) after_30\IN\0|failure (r_prep) developing_26\VBG\13541167|NONE (l_dobj) failure_29\NN\66216|after
D005839_D058186 CID gentamicin_28\NN\2716866| (r_npadvmod) induced_30\VBN\1627355|NONE (r_amod) arf_31\NN\0|NONE
D000241_D007674 NONE adenosine_0\NNP\14964367|NONE (r_amod) antagonists_1\NNS\7846|.|have|be|been|previously (r_nsubjpass) shown_5\VBN\2137132|NONE (l_xcomp) be_7\VB\14625458|.|have|been|antagonists|previously (l_prep) in_10\IN\13603305|to|of (l_pobj) models_15\NNS\5888929|NONE (l_amod) ischaemic_12\JJ\0|of|some (l_conj) nephrotoxic_14\JJ\0|and
D013806_D058186 NONE theophylline_18\NN\2905612|adenosine|, (r_amod) antagonists_15\NNS\7846|NONE (r_pobj) as_13\IN\14622893|different (r_prep) potencies_12\NNS\5196375|NONE (r_pobj) with_10\IN\0|three (r_prep) alkylxanthines_9\NNS\0|NONE (r_pobj) of_7\IN\0|the (r_prep) effects_6\NNS\13245626|.|,|,|In|were|in|) (r_nsubjpass) examined_23\VBN\0|NONE (l_prep) in_24\IN\13603305|.|effects|,|,|In|were|) (l_pobj) rats_25\NNS\2329401|NONE (l_acl) developing_26\VBG\13541167|NONE (l_dobj) failure_29\NN\66216|after
C028322_D058186 NONE 8-phenyltheophylline_16\NN\0|NONE (r_punct) ,_17\,\0|adenosine|theophylline (r_punct) antagonists_15\NNS\7846|NONE (r_pobj) as_13\IN\14622893|different (r_prep) potencies_12\NNS\5196375|NONE (r_pobj) with_10\IN\0|three (r_prep) alkylxanthines_9\NNS\0|NONE (r_pobj) of_7\IN\0|the (r_prep) effects_6\NNS\13245626|.|,|,|In|were|in|) (r_nsubjpass) examined_23\VBN\0|NONE (l_prep) in_24\IN\13603305|.|effects|,|,|In|were|) (l_pobj) rats_25\NNS\2329401|NONE (l_acl) developing_26\VBG\13541167|NONE (l_dobj) failure_29\NN\66216|after
D000241_D007511 NONE adenosine_0\NNP\14964367|NONE (r_amod) antagonists_1\NNS\7846|.|have|be|been|previously (r_nsubjpass) shown_5\VBN\2137132|NONE (l_xcomp) be_7\VB\14625458|.|have|been|antagonists|previously (l_prep) in_10\IN\13603305|to|of (l_pobj) models_15\NNS\5888929|NONE (l_amod) ischaemic_12\JJ\0|of|some
-1_D058186 NONE alkylxanthines_2\NNS\0|NONE (l_prep) on_3\IN\0|NONE (l_pobj) failure_9\NN\66216|NONE
-1_D058186 NONE alkylxanthines_9\NNS\0|NONE (r_pobj) of_7\IN\0|the (r_prep) effects_6\NNS\13245626|.|,|,|In|were|in|) (r_nsubjpass) examined_23\VBN\0|NONE (l_prep) in_24\IN\13603305|.|effects|,|,|In|were|) (l_pobj) rats_25\NNS\2329401|NONE (l_acl) developing_26\VBG\13541167|NONE (l_dobj) failure_29\NN\66216|after
-1_D058186 NONE alkylxanthines_10\NNS\0|NONE (r_pobj) with_8\IN\0|.|lack|indicates (r_prep) noted_7\VBN\1009240|NONE (l_ccomp) indicates_16\VBZ\952524|.|lack|with (l_ccomp) plays_19\VBZ\7007684|NONE (l_dobj) role_26\NN\719494|little|adenosine|that|, (l_prep) in_27\IN\13603305|pathophysiological|any|, (l_pobj) arf_31\NN\0|NONE
C034347_D058186 NONE enprofylline_20\NN\0|and (r_conj) theophylline_18\NN\2905612|adenosine|, (r_amod) antagonists_15\NNS\7846|NONE (r_pobj) as_13\IN\14622893|different (r_prep) potencies_12\NNS\5196375|NONE (r_pobj) with_10\IN\0|three (r_prep) alkylxanthines_9\NNS\0|NONE (r_pobj) of_7\IN\0|the (r_prep) effects_6\NNS\13245626|.|,|,|In|were|in|) (r_nsubjpass) examined_23\VBN\0|NONE (l_prep) in_24\IN\13603305|.|effects|,|,|In|were|) (l_pobj) rats_25\NNS\2329401|NONE (l_acl) developing_26\VBG\13541167|NONE (l_dobj) failure_29\NN\66216|after
2983630
D000241_D009421 NONE adenosine_4\NN\14964367|an|receptor (r_amod) antagonist_6\NN\7846|caffeine|Because (r_attr) is_2\VBZ\0|.|have|,|results (r_advcl) suggest_10\VBP\1010118|NONE (l_ccomp) have_17\VB\7846|.|,|results|is (l_dobj) abnormalities_18\NNS\14034177|that|patients|may (l_prep) in_19\IN\13603305|NONE (l_pobj) systems_21\NNS\3575240|NONE
D000241_D009421 NONE adenosine_23\NN\14964367|NONE (r_dobj) involving_22\VBG\2676054|neuronal (r_acl) systems_21\NNS\3575240|NONE
D008734_D000379 NONE 3-methoxy-4-hydroxyphenethyleneglycol_24\CD\0|NONE (r_pobj) of_23\IN\0|and|levels|blood (r_prep) pressure_19\NN\11419404|somatic|, (r_conj) symptoms_16\NNS\5823932|behavioral|, (r_conj) ratings_13\NNS\5733583|NONE (r_pobj) on_11\IN\0|of|(|)|The|mg/kg (r_prep) effects_1\NNS\13245626|meeting|in|were|. (r_nsubjpass) determined_31\VBN\0|NONE (l_advcl) meeting_39\VBG\7975026|in|were|.|effects (l_dobj) criteria_43\NNS\13577171|patients (l_prep) for_44\IN\0|III (l_pobj) agoraphobia_45\NN\14381416|NONE
D008734_D000379 NONE mhpg_26\RB\0|and|)|cortisol|( (r_appos) 3-methoxy-4-hydroxyphenethyleneglycol_24\CD\0|NONE (r_pobj) of_23\IN\0|and|levels|blood (r_prep) pressure_19\NN\11419404|somatic|, (r_conj) symptoms_16\NNS\5823932|behavioral|, (r_conj) ratings_13\NNS\5733583|NONE (r_pobj) on_11\IN\0|of|(|)|The|mg/kg (r_prep) effects_1\NNS\13245626|meeting|in|were|. (r_nsubjpass) determined_31\VBN\0|NONE (l_advcl) meeting_39\VBG\7975026|in|were|.|effects (l_dobj) criteria_43\NNS\13577171|patients (l_prep) for_44\IN\0|III (l_pobj) agoraphobia_45\NN\14381416|NONE
D006854_D016584 NONE cortisol_29\NN\14751417|MHPG|and|)|( (r_conj) 3-methoxy-4-hydroxyphenethyleneglycol_24\CD\0|NONE (r_pobj) of_23\IN\0|and|levels|blood (r_prep) pressure_19\NN\11419404|somatic|, (r_conj) symptoms_16\NNS\5823932|behavioral|, (r_conj) ratings_13\NNS\5733583|NONE (r_pobj) on_11\IN\0|of|(|)|The|mg/kg (r_prep) effects_1\NNS\13245626|meeting|in|were|. (r_nsubjpass) determined_31\VBN\0|NONE (l_advcl) meeting_39\VBG\7975026|in|were|.|effects (l_dobj) criteria_43\NNS\13577171|patients (l_prep) for_44\IN\0|III (l_pobj) agoraphobia_45\NN\14381416|NONE (l_prep) with_46\IN\0|NONE (l_pobj) attacks_48\NNS\955060|NONE
D006854_D016584 NONE cortisol_29\NN\14751417|MHPG|and|)|( (r_conj) 3-methoxy-4-hydroxyphenethyleneglycol_24\CD\0|NONE (r_pobj) of_23\IN\0|and|levels|blood (r_prep) pressure_19\NN\11419404|somatic|, (r_conj) symptoms_16\NNS\5823932|behavioral|, (r_conj) ratings_13\NNS\5733583|NONE (r_pobj) on_11\IN\0|of|(|)|The|mg/kg (r_prep) effects_1\NNS\13245626|meeting|in|were|. (r_nsubjpass) determined_31\VBN\0|NONE (l_advcl) meeting_39\VBG\7975026|in|were|.|effects (l_dobj) criteria_43\NNS\13577171|patients (l_prep) for_44\IN\0|III (l_pobj) agoraphobia_45\NN\14381416|NONE (l_prep) with_46\IN\0|NONE (l_pobj) attacks_48\NNS\955060|NONE (l_conj) disorder_51\NN\14034177|or|panic
D002110_D009421 NONE caffeine_1\NN\14712692|antagonist|Because (r_nsubj) is_2\VBZ\0|.|have|,|results (r_advcl) suggest_10\VBP\1010118|NONE (l_ccomp) have_17\VB\7846|.|,|results|is (l_dobj) abnormalities_18\NNS\14034177|that|patients|may (l_prep) in_19\IN\13603305|NONE (l_pobj) systems_21\NNS\3575240|NONE
D002110_D009325 CID caffeine_0\NN\14712692|increases|.|compared (r_nsubj) produced_1\VBD\1617192|NONE (l_dobj) increases_4\NNS\13576355|Caffeine|.|compared (l_prep) in_5\IN\13603305|greater (l_pobj) anxiety_9\NN\14373582|NONE (l_conj) nervousness_11\NN\7523905|in|,|rated (l_conj) fear_13\NN\7480068|, (l_conj) nausea_15\NN\14299637|,
D002110_D001008 CID caffeine_0\NN\14712692|increases|.|compared (r_nsubj) produced_1\VBD\1617192|NONE (l_dobj) increases_4\NNS\13576355|Caffeine|.|compared (l_prep) in_5\IN\13603305|greater (l_pobj) anxiety_9\NN\14373582|NONE
D002110_D001008 CID caffeine_8\NN\14712692| (r_npadvmod) containing_10\VBG\2632940|and|beverages (r_amod) foods_11\NNS\20090|NONE (r_dobj) avoiding_7\VBG\0|NONE (r_pcomp) by_6\IN\0|may|Patients|. (r_prep) benefit_5\VB\13278375|NONE (l_nsubj) patients_0\NNS\9898892|may|by|. (l_prep) with_1\IN\0|NONE (l_pobj) disorders_3\NNS\14034177|NONE
D000241_D016584 NONE adenosine_4\NN\14964367|an|receptor (r_amod) antagonist_6\NN\7846|caffeine|Because (r_attr) is_2\VBZ\0|.|have|,|results (r_advcl) suggest_10\VBP\1010118|NONE (l_ccomp) have_17\VB\7846|.|,|results|is (l_nsubj) patients_15\NNS\9898892|that|may|abnormalities (l_compound) disorder_14\NN\14034177|some
D000241_D016584 NONE adenosine_23\NN\14964367|NONE (r_dobj) involving_22\VBG\2676054|neuronal (r_acl) systems_21\NNS\3575240|NONE (r_pobj) in_19\IN\13603305|NONE (r_prep) abnormalities_18\NNS\14034177|that|patients|may (r_dobj) have_17\VB\7846|.|,|results|is (l_nsubj) patients_15\NNS\9898892|that|may|abnormalities (l_compound) disorder_14\NN\14034177|some
D006854_D000379 NONE cortisol_29\NN\14751417|MHPG|and|)|( (r_conj) 3-methoxy-4-hydroxyphenethyleneglycol_24\CD\0|NONE (r_pobj) of_23\IN\0|and|levels|blood (r_prep) pressure_19\NN\11419404|somatic|, (r_conj) symptoms_16\NNS\5823932|behavioral|, (r_conj) ratings_13\NNS\5733583|NONE (r_pobj) on_11\IN\0|of|(|)|The|mg/kg (r_prep) effects_1\NNS\13245626|meeting|in|were|. (r_nsubjpass) determined_31\VBN\0|NONE (l_advcl) meeting_39\VBG\7975026|in|were|.|effects (l_dobj) criteria_43\NNS\13577171|patients (l_prep) for_44\IN\0|III (l_pobj) agoraphobia_45\NN\14381416|NONE
D008734_D016584 NONE 3-methoxy-4-hydroxyphenethyleneglycol_24\CD\0|NONE (r_pobj) of_23\IN\0|and|levels|blood (r_prep) pressure_19\NN\11419404|somatic|, (r_conj) symptoms_16\NNS\5823932|behavioral|, (r_conj) ratings_13\NNS\5733583|NONE (r_pobj) on_11\IN\0|of|(|)|The|mg/kg (r_prep) effects_1\NNS\13245626|meeting|in|were|. (r_nsubjpass) determined_31\VBN\0|NONE (l_advcl) meeting_39\VBG\7975026|in|were|.|effects (l_dobj) criteria_43\NNS\13577171|patients (l_prep) for_44\IN\0|III (l_pobj) agoraphobia_45\NN\14381416|NONE (l_prep) with_46\IN\0|NONE (l_pobj) attacks_48\NNS\955060|NONE
D008734_D016584 NONE 3-methoxy-4-hydroxyphenethyleneglycol_24\CD\0|NONE (r_pobj) of_23\IN\0|and|levels|blood (r_prep) pressure_19\NN\11419404|somatic|, (r_conj) symptoms_16\NNS\5823932|behavioral|, (r_conj) ratings_13\NNS\5733583|NONE (r_pobj) on_11\IN\0|of|(|)|The|mg/kg (r_prep) effects_1\NNS\13245626|meeting|in|were|. (r_nsubjpass) determined_31\VBN\0|NONE (l_advcl) meeting_39\VBG\7975026|in|were|.|effects (l_dobj) criteria_43\NNS\13577171|patients (l_prep) for_44\IN\0|III (l_pobj) agoraphobia_45\NN\14381416|NONE (l_prep) with_46\IN\0|NONE (l_pobj) attacks_48\NNS\955060|NONE (l_conj) disorder_51\NN\14034177|or|panic
D008734_D016584 NONE mhpg_26\RB\0|and|)|cortisol|( (r_appos) 3-methoxy-4-hydroxyphenethyleneglycol_24\CD\0|NONE (r_pobj) of_23\IN\0|and|levels|blood (r_prep) pressure_19\NN\11419404|somatic|, (r_conj) symptoms_16\NNS\5823932|behavioral|, (r_conj) ratings_13\NNS\5733583|NONE (r_pobj) on_11\IN\0|of|(|)|The|mg/kg (r_prep) effects_1\NNS\13245626|meeting|in|were|. (r_nsubjpass) determined_31\VBN\0|NONE (l_advcl) meeting_39\VBG\7975026|in|were|.|effects (l_dobj) criteria_43\NNS\13577171|patients (l_prep) for_44\IN\0|III (l_pobj) agoraphobia_45\NN\14381416|NONE (l_prep) with_46\IN\0|NONE (l_pobj) attacks_48\NNS\955060|NONE
D008734_D016584 NONE mhpg_26\RB\0|and|)|cortisol|( (r_appos) 3-methoxy-4-hydroxyphenethyleneglycol_24\CD\0|NONE (r_pobj) of_23\IN\0|and|levels|blood (r_prep) pressure_19\NN\11419404|somatic|, (r_conj) symptoms_16\NNS\5823932|behavioral|, (r_conj) ratings_13\NNS\5733583|NONE (r_pobj) on_11\IN\0|of|(|)|The|mg/kg (r_prep) effects_1\NNS\13245626|meeting|in|were|. (r_nsubjpass) determined_31\VBN\0|NONE (l_advcl) meeting_39\VBG\7975026|in|were|.|effects (l_dobj) criteria_43\NNS\13577171|patients (l_prep) for_44\IN\0|III (l_pobj) agoraphobia_45\NN\14381416|NONE (l_prep) with_46\IN\0|NONE (l_pobj) attacks_48\NNS\955060|NONE (l_conj) disorder_51\NN\14034177|or|panic
D002110_-1 NONE caffeine_0\NN\14712692|increases|.|compared (r_nsubj) produced_1\VBD\1617192|NONE (l_dobj) increases_4\NNS\13576355|Caffeine|.|compared (l_prep) in_5\IN\13603305|greater (l_pobj) anxiety_9\NN\14373582|NONE (l_conj) nervousness_11\NN\7523905|in|,|rated (l_conj) fear_13\NN\7480068|, (l_conj) nausea_15\NN\14299637|, (l_conj) palpitations_17\NNS\14299637|,
D002110_D011595 NONE caffeine_0\NN\14712692|increases|.|compared (r_nsubj) produced_1\VBD\1617192|NONE (l_dobj) increases_4\NNS\13576355|Caffeine|.|compared (l_prep) in_5\IN\13603305|greater (l_pobj) anxiety_9\NN\14373582|NONE (l_conj) nervousness_11\NN\7523905|in|,|rated (l_conj) fear_13\NN\7480068|, (l_conj) nausea_15\NN\14299637|, (l_conj) palpitations_17\NNS\14299637|, (l_conj) restlessness_19\NN\4773351|,
D002110_D014202 CID caffeine_0\NN\14712692|increases|.|compared (r_nsubj) produced_1\VBD\1617192|NONE (l_dobj) increases_4\NNS\13576355|Caffeine|.|compared (l_prep) in_5\IN\13603305|greater (l_pobj) anxiety_9\NN\14373582|NONE (l_conj) nervousness_11\NN\7523905|in|,|rated (l_conj) fear_13\NN\7480068|, (l_conj) nausea_15\NN\14299637|, (l_conj) palpitations_17\NNS\14299637|, (l_conj) restlessness_19\NN\4773351|, (l_conj) tremors_22\NNS\345926|,|and
D002110_D016584 NONE caffeine_4\NN\14712692|NONE (r_pobj) of_3\IN\0|Increased|.|in|anxiogenic (r_prep) effects_2\NNS\13245626|NONE (l_prep) in_5\IN\13603305|Increased|.|anxiogenic|of (l_pobj) disorders_7\NNS\14034177|NONE
D002110_D016584 NONE caffeine_6\NN\14712692|NONE (r_pobj) of_5\IN\0|oral (r_prep) administration_4\NN\1133281|NONE (r_pobj) of_2\IN\0|(|)|on|The|mg/kg (r_prep) effects_1\NNS\13245626|meeting|in|were|. (r_nsubjpass) determined_31\VBN\0|NONE (l_advcl) meeting_39\VBG\7975026|in|were|.|effects (l_dobj) criteria_43\NNS\13577171|patients (l_prep) for_44\IN\0|III (l_pobj) agoraphobia_45\NN\14381416|NONE (l_prep) with_46\IN\0|NONE (l_pobj) attacks_48\NNS\955060|NONE
D002110_D016584 NONE caffeine_6\NN\14712692|NONE (r_pobj) of_5\IN\0|oral (r_prep) administration_4\NN\1133281|NONE (r_pobj) of_2\IN\0|(|)|on|The|mg/kg (r_prep) effects_1\NNS\13245626|meeting|in|were|. (r_nsubjpass) determined_31\VBN\0|NONE (l_advcl) meeting_39\VBG\7975026|in|were|.|effects (l_dobj) criteria_43\NNS\13577171|patients (l_prep) for_44\IN\0|III (l_pobj) agoraphobia_45\NN\14381416|NONE (l_prep) with_46\IN\0|NONE (l_pobj) attacks_48\NNS\955060|NONE (l_conj) disorder_51\NN\14034177|or|panic
D002110_D016584 NONE caffeine_13\NN\14712692|NONE (r_pobj) of_12\IN\0|behavioral|the (r_prep) effects_11\NNS\13245626|that|similar (r_nsubj) were_14\VBD\0|percent|. (l_acomp) similar_15\JJ\0|that|effects (l_prep) to_16\IN\0|NONE (l_pobj) those_17\DT\0|NONE (l_acl) experienced_18\VBN\2108377|NONE (l_prep) during_19\IN\0|NONE (l_pobj) attacks_21\NNS\955060|NONE
D002110_D016584 NONE caffeine_1\NN\14712692|antagonist|Because (r_nsubj) is_2\VBZ\0|.|have|,|results (r_advcl) suggest_10\VBP\1010118|NONE (l_ccomp) have_17\VB\7846|.|,|results|is (l_nsubj) patients_15\NNS\9898892|that|may|abnormalities (l_compound) disorder_14\NN\14034177|some
D002110_D000379 NONE caffeine_6\NN\14712692|NONE (r_pobj) of_5\IN\0|oral (r_prep) administration_4\NN\1133281|NONE (r_pobj) of_2\IN\0|(|)|on|The|mg/kg (r_prep) effects_1\NNS\13245626|meeting|in|were|. (r_nsubjpass) determined_31\VBN\0|NONE (l_advcl) meeting_39\VBG\7975026|in|were|.|effects (l_dobj) criteria_43\NNS\13577171|patients (l_prep) for_44\IN\0|III (l_pobj) agoraphobia_45\NN\14381416|NONE
9128918
D004298_D006966 NONE dopamine_5\NN\14807737|NONE (r_compound) neurons_6\NNS\5430628|NONE (r_pobj) in_4\IN\13603305|NONE (r_prep) changes_3\NNS\7283608|.|Chronic|and (r_conj) hyperprolactinemia_1\NN\0|NONE
D004298_D006966 NONE dopamine_9\NN\14807737|a|and|technique|,|receptor (r_compound) antagonist_11\NN\7846|, (r_appos) haloperidol_6\NN\3713736|NONE (r_pobj) with_5\IN\0|NONE (r_prep) treatment_4\NN\654885|NONE (r_pobj) by_3\IN\0|Hyperprolactinemia|used|.|was (r_agent) induced_2\VBN\1627355|NONE (l_nsubjpass) hyperprolactinemia_0\NNP\0|by|used|.|was
D004298_D006966 NONE dopamine_6\NN\14807737|)|(|in|DA (r_nmod) concentrations_10\NNS\4916342|,|.|After|over|by (r_nsubj) increased_18\VBN\169651|NONE (l_prep) after_0\IN\0|,|concentrations|.|over|by (l_pobj) months_2\NNS\15113229|NONE (l_prep) of_3\IN\0| (l_pobj) hyperprolactinemia_4\NN\0|NONE
D004298_D006966 NONE da_8\NNP\10484858|)|(|in|dopamine (r_nmod) concentrations_10\NNS\4916342|,|.|After|over|by (r_nsubj) increased_18\VBN\169651|NONE (l_prep) after_0\IN\0|,|concentrations|.|over|by (l_pobj) months_2\NNS\15113229|NONE (l_prep) of_3\IN\0| (l_pobj) hyperprolactinemia_4\NN\0|NONE
D004298_D006966 NONE da_10\NNP\10484858|in (r_compound) concentrations_11\NNS\4916342|NONE (r_pobj) in_9\IN\13603305|a|over|% (r_prep) increase_8\NN\13576355|months|. (r_dobj) produced_4\VBD\1617192|NONE (l_nsubj) months_1\NNS\15113229|increase|. (l_prep) of_2\IN\0|Nine (l_pobj) hyperprolactinemia_3\NN\0|NONE
D004298_D006966 NONE da_2\NNP\10484858|NONE (r_compound) response_3\NN\11410625|However|was|.|,|followed (r_nsubjpass) lost_5\VBN\7942152|NONE (l_advcl) followed_15\VBN\1835496|However|was|.|,|response (l_nsubjpass) hyperprolactinemia_13\NN\0|was|if|by
D004298_D006966 NONE da_8\NNP\10484858|NONE (r_pobj) of_7\IN\0|the (r_prep) levels_6\NNS\4916342|NONE (r_pobj) in_4\IN\13603305|no (r_prep) change_3\NN\7283608|.|There|putamen|, (r_attr) was_1\VBD\0|NONE (l_attr) putamen_39\NNS\5497363|.|There|change|, (l_prep) except_57\IN\807461|,|nigra|CP|caudate|, (l_prep) for_58\IN\0|NONE (l_pobj) decrease_60\NN\7296428|NONE (l_prep) after_70\IN\0|and|in|in|a|increase (l_pobj) 6-months_71\IN\0|NONE (l_prep) of_72\IN\0|NONE (l_pobj) hyperprolactinemia_73\NN\0|NONE
D004298_D006966 NONE da_8\NNP\10484858|NONE (r_pobj) of_7\IN\0|the (r_prep) levels_6\NNS\4916342|NONE (r_pobj) in_4\IN\13603305|no (r_prep) change_3\NN\7283608|.|There|putamen|, (r_attr) was_1\VBD\0|NONE (l_attr) putamen_39\NNS\5497363|.|There|change|, (l_prep) except_57\IN\807461|,|nigra|CP|caudate|, (l_prep) for_58\IN\0|NONE (l_pobj) decrease_60\NN\7296428|NONE (l_conj) increase_76\NN\13576355|and|in|in|after|a (l_prep) after_83\IN\0|in|in|an (l_pobj) 9-months_84\JJ\0|NONE (l_prep) of_85\IN\0|NONE (l_pobj) hyperprolactinemia_86\NN\0|NONE
D004298_D006966 NONE da_78\NNP\10484858|NONE (r_compound) concentrations_79\NNS\4916342|NONE (r_pobj) in_77\IN\13603305|in|after|an (r_prep) increase_76\NN\13576355|and|in|in|after|a (r_conj) decrease_60\NN\7296428|NONE (l_prep) after_70\IN\0|and|in|in|a|increase (l_pobj) 6-months_71\IN\0|NONE (l_prep) of_72\IN\0|NONE (l_pobj) hyperprolactinemia_73\NN\0|NONE
D004298_D006966 NONE da_78\NNP\10484858|NONE (r_compound) concentrations_79\NNS\4916342|NONE (r_pobj) in_77\IN\13603305|in|after|an (r_prep) increase_76\NN\13576355|and|in|in|after|a (l_prep) after_83\IN\0|in|in|an (l_pobj) 9-months_84\JJ\0|NONE (l_prep) of_85\IN\0|NONE (l_pobj) hyperprolactinemia_86\NN\0|NONE
D009638_D006966 NONE norepinephrine_10\NN\14807929|serotonin|, (r_appos) da_8\NNP\10484858|NONE (r_pobj) of_7\IN\0|the (r_prep) levels_6\NNS\4916342|NONE (r_pobj) in_4\IN\13603305|no (r_prep) change_3\NN\7283608|.|There|putamen|, (r_attr) was_1\VBD\0|NONE (l_attr) putamen_39\NNS\5497363|.|There|change|, (l_prep) except_57\IN\807461|,|nigra|CP|caudate|, (l_prep) for_58\IN\0|NONE (l_pobj) decrease_60\NN\7296428|NONE (l_prep) after_70\IN\0|and|in|in|a|increase (l_pobj) 6-months_71\IN\0|NONE (l_prep) of_72\IN\0|NONE (l_pobj) hyperprolactinemia_73\NN\0|NONE
D009638_D006966 NONE norepinephrine_10\NN\14807929|serotonin|, (r_appos) da_8\NNP\10484858|NONE (r_pobj) of_7\IN\0|the (r_prep) levels_6\NNS\4916342|NONE (r_pobj) in_4\IN\13603305|no (r_prep) change_3\NN\7283608|.|There|putamen|, (r_attr) was_1\VBD\0|NONE (l_attr) putamen_39\NNS\5497363|.|There|change|, (l_prep) except_57\IN\807461|,|nigra|CP|caudate|, (l_prep) for_58\IN\0|NONE (l_pobj) decrease_60\NN\7296428|NONE (l_conj) increase_76\NN\13576355|and|in|in|after|a (l_prep) after_83\IN\0|in|in|an (l_pobj) 9-months_84\JJ\0|NONE (l_prep) of_85\IN\0|NONE (l_pobj) hyperprolactinemia_86\NN\0|NONE
D009638_D006966 NONE ne_12\NNP\14622893|NONE (r_appos) norepinephrine_10\NN\14807929|serotonin|, (r_appos) da_8\NNP\10484858|NONE (r_pobj) of_7\IN\0|the (r_prep) levels_6\NNS\4916342|NONE (r_pobj) in_4\IN\13603305|no (r_prep) change_3\NN\7283608|.|There|putamen|, (r_attr) was_1\VBD\0|NONE (l_attr) putamen_39\NNS\5497363|.|There|change|, (l_prep) except_57\IN\807461|,|nigra|CP|caudate|, (l_prep) for_58\IN\0|NONE (l_pobj) decrease_60\NN\7296428|NONE (l_prep) after_70\IN\0|and|in|in|a|increase (l_pobj) 6-months_71\IN\0|NONE (l_prep) of_72\IN\0|NONE (l_pobj) hyperprolactinemia_73\NN\0|NONE
D009638_D006966 NONE ne_12\NNP\14622893|NONE (r_appos) norepinephrine_10\NN\14807929|serotonin|, (r_appos) da_8\NNP\10484858|NONE (r_pobj) of_7\IN\0|the (r_prep) levels_6\NNS\4916342|NONE (r_pobj) in_4\IN\13603305|no (r_prep) change_3\NN\7283608|.|There|putamen|, (r_attr) was_1\VBD\0|NONE (l_attr) putamen_39\NNS\5497363|.|There|change|, (l_prep) except_57\IN\807461|,|nigra|CP|caudate|, (l_prep) for_58\IN\0|NONE (l_pobj) decrease_60\NN\7296428|NONE (l_conj) increase_76\NN\13576355|and|in|in|after|a (l_prep) after_83\IN\0|in|in|an (l_pobj) 9-months_84\JJ\0|NONE (l_prep) of_85\IN\0|NONE (l_pobj) hyperprolactinemia_86\NN\0|NONE
D006220_D006966 CID haloperidol_6\NN\3713736|NONE (r_pobj) with_5\IN\0|NONE (r_prep) treatment_4\NN\654885|NONE (r_pobj) by_3\IN\0|Hyperprolactinemia|used|.|was (r_agent) induced_2\VBN\1627355|NONE (l_nsubjpass) hyperprolactinemia_0\NNP\0|by|used|.|was
D006220_D006966 CID haloperidol_10\NN\3713736| (r_npadvmod) induced_12\VBN\1627355|long|a (r_amod) hyperprolactinemia_13\NN\0|was|if|by
D006897_D006966 NONE acid_63\NN\14818238|NONE (r_pobj) in_61\IN\13603305|and|in|after|a|increase (r_prep) decrease_60\NN\7296428|NONE (l_prep) after_70\IN\0|and|in|in|a|increase (l_pobj) 6-months_71\IN\0|NONE (l_prep) of_72\IN\0|NONE (l_pobj) hyperprolactinemia_73\NN\0|NONE
D006897_D006966 NONE acid_63\NN\14818238|NONE (r_pobj) in_61\IN\13603305|and|in|after|a|increase (r_prep) decrease_60\NN\7296428|NONE (l_conj) increase_76\NN\13576355|and|in|in|after|a (l_prep) after_83\IN\0|in|in|an (l_pobj) 9-months_84\JJ\0|NONE (l_prep) of_85\IN\0|NONE (l_pobj) hyperprolactinemia_86\NN\0|NONE
D006897_D006966 NONE 5-hiaa_65\CD\0|(|hydroxyindoleacetic|) (r_appos) acid_63\NN\14818238|NONE (r_pobj) in_61\IN\13603305|and|in|after|a|increase (r_prep) decrease_60\NN\7296428|NONE (l_prep) after_70\IN\0|and|in|in|a|increase (l_pobj) 6-months_71\IN\0|NONE (l_prep) of_72\IN\0|NONE (l_pobj) hyperprolactinemia_73\NN\0|NONE
D006897_D006966 NONE 5-hiaa_65\CD\0|(|hydroxyindoleacetic|) (r_appos) acid_63\NN\14818238|NONE (r_pobj) in_61\IN\13603305|and|in|after|a|increase (r_prep) decrease_60\NN\7296428|NONE (l_conj) increase_76\NN\13576355|and|in|in|after|a (l_prep) after_83\IN\0|in|in|an (l_pobj) 9-months_84\JJ\0|NONE (l_prep) of_85\IN\0|NONE (l_pobj) hyperprolactinemia_86\NN\0|NONE
D012701_D006966 NONE serotonin_15\NN\14807737|norepinephrine|, (r_appos) da_8\NNP\10484858|NONE (r_pobj) of_7\IN\0|the (r_prep) levels_6\NNS\4916342|NONE (r_pobj) in_4\IN\13603305|no (r_prep) change_3\NN\7283608|.|There|putamen|, (r_attr) was_1\VBD\0|NONE (l_attr) putamen_39\NNS\5497363|.|There|change|, (l_prep) except_57\IN\807461|,|nigra|CP|caudate|, (l_prep) for_58\IN\0|NONE (l_pobj) decrease_60\NN\7296428|NONE (l_prep) after_70\IN\0|and|in|in|a|increase (l_pobj) 6-months_71\IN\0|NONE (l_prep) of_72\IN\0|NONE (l_pobj) hyperprolactinemia_73\NN\0|NONE
D012701_D006966 NONE serotonin_15\NN\14807737|norepinephrine|, (r_appos) da_8\NNP\10484858|NONE (r_pobj) of_7\IN\0|the (r_prep) levels_6\NNS\4916342|NONE (r_pobj) in_4\IN\13603305|no (r_prep) change_3\NN\7283608|.|There|putamen|, (r_attr) was_1\VBD\0|NONE (l_attr) putamen_39\NNS\5497363|.|There|change|, (l_prep) except_57\IN\807461|,|nigra|CP|caudate|, (l_prep) for_58\IN\0|NONE (l_pobj) decrease_60\NN\7296428|NONE (l_conj) increase_76\NN\13576355|and|in|in|after|a (l_prep) after_83\IN\0|in|in|an (l_pobj) 9-months_84\JJ\0|NONE (l_prep) of_85\IN\0|NONE (l_pobj) hyperprolactinemia_86\NN\0|NONE
D012701_D006966 NONE 5-ht_17\CD\0|)|or|,|metabolites|( (r_appos) serotonin_15\NN\14807737|norepinephrine|, (r_appos) da_8\NNP\10484858|NONE (r_pobj) of_7\IN\0|the (r_prep) levels_6\NNS\4916342|NONE (r_pobj) in_4\IN\13603305|no (r_prep) change_3\NN\7283608|.|There|putamen|, (r_attr) was_1\VBD\0|NONE (l_attr) putamen_39\NNS\5497363|.|There|change|, (l_prep) except_57\IN\807461|,|nigra|CP|caudate|, (l_prep) for_58\IN\0|NONE (l_pobj) decrease_60\NN\7296428|NONE (l_prep) after_70\IN\0|and|in|in|a|increase (l_pobj) 6-months_71\IN\0|NONE (l_prep) of_72\IN\0|NONE (l_pobj) hyperprolactinemia_73\NN\0|NONE
D012701_D006966 NONE 5-ht_17\CD\0|)|or|,|metabolites|( (r_appos) serotonin_15\NN\14807737|norepinephrine|, (r_appos) da_8\NNP\10484858|NONE (r_pobj) of_7\IN\0|the (r_prep) levels_6\NNS\4916342|NONE (r_pobj) in_4\IN\13603305|no (r_prep) change_3\NN\7283608|.|There|putamen|, (r_attr) was_1\VBD\0|NONE (l_attr) putamen_39\NNS\5497363|.|There|change|, (l_prep) except_57\IN\807461|,|nigra|CP|caudate|, (l_prep) for_58\IN\0|NONE (l_pobj) decrease_60\NN\7296428|NONE (l_conj) increase_76\NN\13576355|and|in|in|after|a (l_prep) after_83\IN\0|in|in|an (l_pobj) 9-months_84\JJ\0|NONE (l_prep) of_85\IN\0|NONE (l_pobj) hyperprolactinemia_86\NN\0|NONE
11936424
D011692_D006984 NONE aminonucleoside_43\NN\0|)|( (r_nmod) pan_45\NNP\3101986|glomerulosclerosis|in (r_npadvmod) prevented_38\VBN\0|whether|administration|hypertrophy|and (r_conj) inhibited_34\VBD\2510337|to (l_dobj) hypertrophy_36\NN\14365950|prevented|whether|administration|and
D011692_D006984 NONE pan_45\NNP\3101986|glomerulosclerosis|in (r_npadvmod) prevented_38\VBN\0|whether|administration|hypertrophy|and (r_conj) inhibited_34\VBD\2510337|to (l_dobj) hypertrophy_36\NN\14365950|prevented|whether|administration|and
C055603_D009404 NONE temocapril_13\NN\0|NONE (r_pobj) of_12\IN\0|chronic|,|angiotensin (r_prep) administration_11\NN\1133281|prevented|whether|hypertrophy|and (r_nsubj) inhibited_34\VBD\2510337|to (r_ccomp) determine_8\VB\0|induced|.|purpose (r_xcomp) was_6\VBD\0|NONE (l_conj) induced_48\VBN\1627355|.|purpose|determine (l_dobj) rats_50\NNS\2329401| (l_amod) nephrotic_49\JJ\0|NONE
C055603_D011507 NONE temocapril_13\NN\0|NONE (r_pobj) of_12\IN\0|chronic|,|angiotensin (r_prep) administration_11\NN\1133281|prevented|whether|hypertrophy|and (l_appos) angiotensin_23\NN\4522421|chronic|,|of (l_acl) reduced_31\VBN\441445|group|,|a|converting|, (l_dobj) proteinuria_32\NN\14299637|NONE
C055603_D011507 NONE temocapril_0\NNP\0|,|did|at|proteinuria|not|lower|but (r_nsubj) attenuate_3\VB\224901|NONE (l_dobj) proteinuria_4\NN\14299637|,|Temocapril|did|at|not|lower|but
C055603_D005921 NONE temocapril_13\NN\0|NONE (r_pobj) of_12\IN\0|chronic|,|angiotensin (r_prep) administration_11\NN\1133281|prevented|whether|hypertrophy|and (r_nsubj) inhibited_34\VBD\2510337|to (l_conj) prevented_38\VBN\0|whether|administration|hypertrophy|and (l_dobj) glomerulosclerosis_39\NN\0|in|PAN
D000809_D011507 NONE angiotensin_23\NN\4522421|chronic|,|of (l_acl) reduced_31\VBN\441445|group|,|a|converting|, (l_dobj) proteinuria_32\NN\14299637|NONE
D000809_D006984 NONE angiotensin_23\NN\4522421|chronic|,|of (r_appos) administration_11\NN\1133281|prevented|whether|hypertrophy|and (r_nsubj) inhibited_34\VBD\2510337|to (l_dobj) hypertrophy_36\NN\14365950|prevented|whether|administration|and
D011692_D009401 CID aminonucleoside_21\JJ\0|puromycin (r_amod) nephrosis_22\NN\14304060|NONE
D011692_D009401 CID pan_6\NNP\3101986|NONE (r_pobj) of_5\IN\0|in (r_prep) injection_4\NN\320852|NONE (r_pobj) by_3\IN\0|Nephrosis|.|was (r_agent) induced_2\VBN\1627355|NONE (l_nsubjpass) nephrosis_0\NNP\14304060|by|.|was
D011692_D009401 CID pan_15\NNP\3101986|neprotic (r_compound) rats_17\NNS\2329401|NONE (l_amod) neprotic_16\JJ\0|PAN
D000809_D009404 NONE angiotensin_23\NN\4522421|chronic|,|of (r_appos) administration_11\NN\1133281|prevented|whether|hypertrophy|and (r_nsubj) inhibited_34\VBD\2510337|to (r_ccomp) determine_8\VB\0|induced|.|purpose (r_xcomp) was_6\VBD\0|NONE (l_conj) induced_48\VBN\1627355|.|purpose|determine (l_dobj) rats_50\NNS\2329401| (l_amod) nephrotic_49\JJ\0|NONE
D000809_D007674 NONE angiotensin_10\NN\4522421|,|, (r_appos) temocapril_0\NNP\0|injury|. (r_nsubj) modulates_15\VBZ\1724459|NONE (l_dobj) injury_17\NN\14052046|.|Temocapril
C055603_D006984 NONE temocapril_13\NN\0|NONE (r_pobj) of_12\IN\0|chronic|,|angiotensin (r_prep) administration_11\NN\1133281|prevented|whether|hypertrophy|and (r_nsubj) inhibited_34\VBD\2510337|to (l_dobj) hypertrophy_36\NN\14365950|prevented|whether|administration|and
D000809_D005921 NONE angiotensin_23\NN\4522421|chronic|,|of (r_appos) administration_11\NN\1133281|prevented|whether|hypertrophy|and (r_nsubj) inhibited_34\VBD\2510337|to (l_conj) prevented_38\VBN\0|whether|administration|hypertrophy|and (l_dobj) glomerulosclerosis_39\NN\0|in|PAN
D011692_D007674 NONE aminonucleoside_21\JJ\0|puromycin (r_amod) nephrosis_22\NN\14304060|NONE (r_pobj) in_18\IN\13603305|glomerular (r_prep) injury_17\NN\14052046|.|Temocapril
D011692_D011507 CID aminonucleoside_43\NN\0|)|( (r_nmod) pan_45\NNP\3101986|glomerulosclerosis|in (r_npadvmod) prevented_38\VBN\0|whether|administration|hypertrophy|and (r_conj) inhibited_34\VBD\2510337|to (l_nsubj) administration_11\NN\1133281|prevented|whether|hypertrophy|and (l_appos) angiotensin_23\NN\4522421|chronic|,|of (l_acl) reduced_31\VBN\441445|group|,|a|converting|, (l_dobj) proteinuria_32\NN\14299637|NONE
D011692_D011507 CID pan_45\NNP\3101986|glomerulosclerosis|in (r_npadvmod) prevented_38\VBN\0|whether|administration|hypertrophy|and (r_conj) inhibited_34\VBD\2510337|to (l_nsubj) administration_11\NN\1133281|prevented|whether|hypertrophy|and (l_appos) angiotensin_23\NN\4522421|chronic|,|of (l_acl) reduced_31\VBN\441445|group|,|a|converting|, (l_dobj) proteinuria_32\NN\14299637|NONE
C055603_D009401 NONE temocapril_0\NNP\0|injury|. (r_nsubj) modulates_15\VBZ\1724459|NONE (l_dobj) injury_17\NN\14052046|.|Temocapril (l_prep) in_18\IN\13603305|glomerular (l_pobj) nephrosis_22\NN\14304060|NONE
C055603_D009401 NONE temocapril_3\NN\0|that|effective (r_nsubj) was_4\VBD\0|.|It (l_acomp) effective_5\JJ\0|temocapril|that (l_prep) in_6\IN\13603305|NONE (l_pcomp) retarding_7\VBG\438495|NONE (l_conj) protected_11\VBD\1127795|progression|and (l_dobj) function_13\NN\13783581|NONE (l_prep) in_14\IN\13603305|renal (l_pobj) rats_17\NNS\2329401|NONE (l_amod) neprotic_16\JJ\0|PAN
D011692_D009404 NONE aminonucleoside_43\NN\0|)|( (r_nmod) pan_45\NNP\3101986|glomerulosclerosis|in (r_npadvmod) prevented_38\VBN\0|whether|administration|hypertrophy|and (r_conj) inhibited_34\VBD\2510337|to (r_ccomp) determine_8\VB\0|induced|.|purpose (r_xcomp) was_6\VBD\0|NONE (l_conj) induced_48\VBN\1627355|.|purpose|determine (l_dobj) rats_50\NNS\2329401| (l_amod) nephrotic_49\JJ\0|NONE
D011692_D009404 NONE pan_45\NNP\3101986|glomerulosclerosis|in (r_npadvmod) prevented_38\VBN\0|whether|administration|hypertrophy|and (r_conj) inhibited_34\VBD\2510337|to (r_ccomp) determine_8\VB\0|induced|.|purpose (r_xcomp) was_6\VBD\0|NONE (l_conj) induced_48\VBN\1627355|.|purpose|determine (l_dobj) rats_50\NNS\2329401| (l_amod) nephrotic_49\JJ\0|NONE
C055603_D007674 NONE temocapril_0\NNP\0|injury|. (r_nsubj) modulates_15\VBZ\1724459|NONE (l_dobj) injury_17\NN\14052046|.|Temocapril
D011692_D005921 NONE aminonucleoside_43\NN\0|)|( (r_nmod) pan_45\NNP\3101986|glomerulosclerosis|in (r_npadvmod) prevented_38\VBN\0|whether|administration|hypertrophy|and (l_dobj) glomerulosclerosis_39\NN\0|in|PAN
D011692_D005921 NONE pan_45\NNP\3101986|glomerulosclerosis|in (r_npadvmod) prevented_38\VBN\0|whether|administration|hypertrophy|and (l_dobj) glomerulosclerosis_39\NN\0|in|PAN
D011692_D005921 NONE pan_26\NNP\3101986|the (r_compound) group_27\NN\2137|NONE (r_pobj) in_24\IN\13603305| (r_prep) weeks_23\NNS\15113229|NONE (r_pobj) at_19\IN\14622893|index|.|at|% (r_prep) was_6\VBD\0|NONE (l_nsubj) index_2\NN\13850304|at|.|at|% (l_compound) glomerulosclerosis_1\NN\0|(|The|GSI|)
D000809_D009401 NONE angiotensin_10\NN\4522421|,|, (r_appos) temocapril_0\NNP\0|injury|. (r_nsubj) modulates_15\VBZ\1724459|NONE (l_dobj) injury_17\NN\14052046|.|Temocapril (l_prep) in_18\IN\13603305|glomerular (l_pobj) nephrosis_22\NN\14304060|NONE
24923469
7492040
D008012_D014693 NONE lidocaine_5\NN\3681148|who|in (r_dobj) received_4\VBD\2210855| (r_relcl) patients_2\NNS\9898892|,|patient (r_nsubj) died_17\VBD\146138|.|;|bradydysrhythmias (r_ccomp) exhibited_19\VBN\2632167|NONE (l_dobj) bradydysrhythmias_20\NNS\0|died|.|; (l_conj) tachycardia_23\NN\14110674|or|;|seizures|, (l_conj) fibrillation_27\NN\14361664|or|,|ventricular
D008012_D014693 NONE lidocaine_35\NN\3681148|NONE (r_pobj) of_34\IN\0|interval (r_prep) administration_33\NN\1133281|NONE (r_pobj) after_32\IN\0|experienced (r_prep) seizures_31\NNS\14081375|or|tachycardia|;|, (r_conj) bradydysrhythmias_20\NNS\0|died|.|; (l_conj) tachycardia_23\NN\14110674|or|;|seizures|, (l_conj) fibrillation_27\NN\14361664|or|,|ventricular
D003042_D017180 NONE cocaine_10\NN\3492717| (r_npadvmod) associated_12\VBN\628491|NONE (r_amod) mi_13\NNP\14207561|NONE (r_pobj) of_9\IN\0|the (r_prep) setting_8\NN\8567235|NONE (r_pobj) in_6\IN\13603305|who|lidocaine (r_prep) received_4\VBD\2210855| (r_relcl) patients_2\NNS\9898892|,|patient (r_nsubj) died_17\VBD\146138|.|;|bradydysrhythmias (r_ccomp) exhibited_19\VBN\2632167|NONE (l_dobj) bradydysrhythmias_20\NNS\0|died|.|; (l_conj) tachycardia_23\NN\14110674|or|;|seizures|,
D008012_D009203 NONE lidocaine_3\NN\3681148|NONE (r_pobj) of_2\IN\0|Clinical|in|. (r_prep) safety_1\NN\13920835|NONE (l_prep) in_4\IN\13603305|Clinical|.|of (l_pobj) patients_5\NNS\9898892|NONE (l_prep) with_6\IN\0|NONE (l_pobj) infarction_11\NN\14204950|NONE
D008012_D009203 NONE lidocaine_8\NN\3681148|NONE (r_pobj) of_7\IN\0|the|in (r_prep) safety_6\NN\13920835|To (l_prep) in_9\IN\13603305|of|the (l_pobj) setting_11\NN\8567235|NONE (l_prep) of_12\IN\0|the (l_pobj) infarction_17\NN\14204950|NONE
D008012_D009203 NONE lidocaine_8\NN\3681148|NONE (r_pobj) of_7\IN\0|the|in (r_prep) safety_6\NN\13920835|To (l_prep) in_9\IN\13603305|of|the (l_pobj) setting_11\NN\8567235|NONE (l_prep) of_12\IN\0|the (l_pobj) infarction_17\NN\14204950|NONE (l_appos) mi_19\NNP\14207561|myocardial|)|induced|(
D008012_D009203 NONE lidocaine_10\NN\3681148|who|in (r_dobj) received_9\VBD\2210855|with (r_relcl) patients_2\NNS\9898892|:|. (l_prep) with_3\IN\0|received (l_pobj) mi_7\NNP\14207561|NONE
D008012_D009203 NONE lidocaine_5\NN\3681148|who|in (r_dobj) received_4\VBD\2210855| (l_prep) in_6\IN\13603305|who|lidocaine (l_pobj) setting_8\NN\8567235|NONE (l_prep) of_9\IN\0|the (l_pobj) mi_13\NNP\14207561|NONE
D008012_D009203 NONE lidocaine_35\NN\3681148|NONE (r_pobj) of_34\IN\0|interval (r_prep) administration_33\NN\1133281|NONE (r_pobj) after_32\IN\0|experienced (r_prep) seizures_31\NNS\14081375|or|tachycardia|;|, (r_conj) bradydysrhythmias_20\NNS\0|died|.|; (r_dobj) exhibited_19\VBN\2632167|NONE (l_ccomp) died_17\VBD\146138|.|;|bradydysrhythmias (l_nsubj) patients_2\NNS\9898892|,|patient (l_relcl) received_4\VBD\2210855| (l_prep) in_6\IN\13603305|who|lidocaine (l_pobj) setting_8\NN\8567235|NONE (l_prep) of_9\IN\0|the (l_pobj) mi_13\NNP\14207561|NONE
D008012_D009203 NONE lidocaine_4\NN\3681148|may|toxicity|that (r_nsubj) enhance_6\VB\227165|theoretical (r_acl) concerns_2\NNS\5682950|NONE (r_pobj) despite_0\IN\7501545|use|,|not|.|was|with (r_prep) associated_23\VBN\628491|NONE (l_nsubjpass) use_11\NN\407535|,|Despite|not|.|was|with (l_prep) in_14\IN\13603305|the|of (l_pobj) patients_15\NNS\9898892|NONE (l_prep) with_16\IN\0|NONE (l_pobj) mi_20\NNP\14207561|NONE
D008012_D009203 NONE lidocaine_13\NN\3681148|NONE (r_pobj) of_12\IN\0|the|in (r_prep) use_11\NN\407535|,|Despite|not|.|was|with (l_prep) in_14\IN\13603305|the|of (l_pobj) patients_15\NNS\9898892|NONE (l_prep) with_16\IN\0|NONE (l_pobj) mi_20\NNP\14207561|NONE
D003042_D009203 CID cocaine_7\NN\3492717| (r_npadvmod) associated_9\VBN\628491|myocardial (r_amod) infarction_11\NN\14204950|NONE
D003042_D009203 CID cocaine_13\NN\3492717| (r_npadvmod) induced_15\VBN\1627355|myocardial|MI|)|( (r_amod) infarction_17\NN\14204950|NONE
D003042_D009203 CID cocaine_13\NN\3492717| (r_npadvmod) induced_15\VBN\1627355|myocardial|MI|)|( (r_amod) infarction_17\NN\14204950|NONE (l_appos) mi_19\NNP\14207561|myocardial|)|induced|(
D003042_D009203 CID cocaine_4\NN\3492717| (r_npadvmod) associated_6\VBN\628491|NONE (r_amod) mi_7\NNP\14207561|NONE
D003042_D009203 CID cocaine_10\NN\3492717| (r_npadvmod) associated_12\VBN\628491|NONE (r_amod) mi_13\NNP\14207561|NONE
D003042_D009203 CID cocaine_7\NN\3492717|NONE (r_compound) toxicity_8\NN\13576101|may|that|lidocaine (r_dobj) enhance_6\VB\227165|theoretical (r_acl) concerns_2\NNS\5682950|NONE (r_pobj) despite_0\IN\7501545|use|,|not|.|was|with (r_prep) associated_23\VBN\628491|NONE (l_nsubjpass) use_11\NN\407535|,|Despite|not|.|was|with (l_prep) in_14\IN\13603305|the|of (l_pobj) patients_15\NNS\9898892|NONE (l_prep) with_16\IN\0|NONE (l_pobj) mi_20\NNP\14207561|NONE
D003042_D009203 CID cocaine_17\NN\3492717| (r_npadvmod) associated_19\VBN\628491|NONE (r_amod) mi_20\NNP\14207561|NONE
D008012_D017180 NONE lidocaine_5\NN\3681148|who|in (r_dobj) received_4\VBD\2210855| (r_relcl) patients_2\NNS\9898892|,|patient (r_nsubj) died_17\VBD\146138|.|;|bradydysrhythmias (r_ccomp) exhibited_19\VBN\2632167|NONE (l_dobj) bradydysrhythmias_20\NNS\0|died|.|; (l_conj) tachycardia_23\NN\14110674|or|;|seizures|,
D008012_D017180 NONE lidocaine_35\NN\3681148|NONE (r_pobj) of_34\IN\0|interval (r_prep) administration_33\NN\1133281|NONE (r_pobj) after_32\IN\0|experienced (r_prep) seizures_31\NNS\14081375|or|tachycardia|;|, (r_conj) bradydysrhythmias_20\NNS\0|died|.|; (l_conj) tachycardia_23\NN\14110674|or|;|seizures|,
D003042_D012640 NONE cocaine_10\NN\3492717| (r_npadvmod) associated_12\VBN\628491|NONE (r_amod) mi_13\NNP\14207561|NONE (r_pobj) of_9\IN\0|the (r_prep) setting_8\NN\8567235|NONE (r_pobj) in_6\IN\13603305|who|lidocaine (r_prep) received_4\VBD\2210855| (r_relcl) patients_2\NNS\9898892|,|patient (r_nsubj) died_17\VBD\146138|.|;|bradydysrhythmias (r_ccomp) exhibited_19\VBN\2632167|NONE (l_dobj) bradydysrhythmias_20\NNS\0|died|.|; (l_conj) seizures_31\NNS\14081375|or|tachycardia|;|,
D008012_D002493 NONE lidocaine_4\NN\3681148|may|toxicity|that (r_nsubj) enhance_6\VB\227165|theoretical (r_acl) concerns_2\NNS\5682950|NONE (r_pobj) despite_0\IN\7501545|use|,|not|.|was|with (r_prep) associated_23\VBN\628491|NONE (l_prep) with_24\IN\0|use|,|Despite|not|.|was (l_pobj) toxicity_31\NN\13576101|NONE
D008012_D002493 NONE lidocaine_13\NN\3681148|NONE (r_pobj) of_12\IN\0|the|in (r_prep) use_11\NN\407535|,|Despite|not|.|was|with (r_nsubjpass) associated_23\VBN\628491|NONE (l_prep) with_24\IN\0|use|,|Despite|not|.|was (l_pobj) toxicity_31\NN\13576101|NONE
D008012_D012640 NONE lidocaine_5\NN\3681148|who|in (r_dobj) received_4\VBD\2210855| (r_relcl) patients_2\NNS\9898892|,|patient (r_nsubj) died_17\VBD\146138|.|;|bradydysrhythmias (r_ccomp) exhibited_19\VBN\2632167|NONE (l_dobj) bradydysrhythmias_20\NNS\0|died|.|; (l_conj) seizures_31\NNS\14081375|or|tachycardia|;|,
D008012_D012640 NONE lidocaine_35\NN\3681148|NONE (r_pobj) of_34\IN\0|interval (r_prep) administration_33\NN\1133281|NONE (r_pobj) after_32\IN\0|experienced (r_prep) seizures_31\NNS\14081375|or|tachycardia|;|,
D008012_D064420 NONE lidocaine_4\NN\3681148|may|toxicity|that (r_nsubj) enhance_6\VB\227165|theoretical (l_dobj) toxicity_8\NN\13576101|may|that|lidocaine
D008012_D064420 NONE lidocaine_13\NN\3681148|NONE (r_pobj) of_12\IN\0|the|in (r_prep) use_11\NN\407535|,|Despite|not|.|was|with (r_nsubjpass) associated_23\VBN\628491|NONE (l_prep) despite_0\IN\7501545|use|,|not|.|was|with (l_pobj) concerns_2\NNS\5682950|NONE (l_acl) enhance_6\VB\227165|theoretical (l_dobj) toxicity_8\NN\13576101|may|that|lidocaine
D003042_D002493 NONE cocaine_7\NN\3492717|NONE (r_compound) toxicity_8\NN\13576101|may|that|lidocaine (r_dobj) enhance_6\VB\227165|theoretical (r_acl) concerns_2\NNS\5682950|NONE (r_pobj) despite_0\IN\7501545|use|,|not|.|was|with (r_prep) associated_23\VBN\628491|NONE (l_prep) with_24\IN\0|use|,|Despite|not|.|was (l_pobj) toxicity_31\NN\13576101|NONE
D003042_D002493 NONE cocaine_17\NN\3492717| (r_npadvmod) associated_19\VBN\628491|NONE (r_amod) mi_20\NNP\14207561|NONE (r_pobj) with_16\IN\0|NONE (r_prep) patients_15\NNS\9898892|NONE (r_pobj) in_14\IN\13603305|the|of (r_prep) use_11\NN\407535|,|Despite|not|.|was|with (r_nsubjpass) associated_23\VBN\628491|NONE (l_prep) with_24\IN\0|use|,|Despite|not|.|was (l_pobj) toxicity_31\NN\13576101|NONE
D003042_D014693 NONE cocaine_10\NN\3492717| (r_npadvmod) associated_12\VBN\628491|NONE (r_amod) mi_13\NNP\14207561|NONE (r_pobj) of_9\IN\0|the (r_prep) setting_8\NN\8567235|NONE (r_pobj) in_6\IN\13603305|who|lidocaine (r_prep) received_4\VBD\2210855| (r_relcl) patients_2\NNS\9898892|,|patient (r_nsubj) died_17\VBD\146138|.|;|bradydysrhythmias (r_ccomp) exhibited_19\VBN\2632167|NONE (l_dobj) bradydysrhythmias_20\NNS\0|died|.|; (l_conj) tachycardia_23\NN\14110674|or|;|seizures|, (l_conj) fibrillation_27\NN\14361664|or|,|ventricular
D008012_D002318 NONE lidocaine_4\NN\3681148|may|toxicity|that (r_nsubj) enhance_6\VB\227165|theoretical (r_acl) concerns_2\NNS\5682950|NONE (r_pobj) despite_0\IN\7501545|use|,|not|.|was|with (r_prep) associated_23\VBN\628491|NONE (l_prep) with_24\IN\0|use|,|Despite|not|.|was (l_pobj) toxicity_31\NN\13576101|NONE
D008012_D002318 NONE lidocaine_13\NN\3681148|NONE (r_pobj) of_12\IN\0|the|in (r_prep) use_11\NN\407535|,|Despite|not|.|was|with (r_nsubjpass) associated_23\VBN\628491|NONE (l_prep) with_24\IN\0|use|,|Despite|not|.|was (l_pobj) toxicity_31\NN\13576101|NONE
D008012_D001919 NONE lidocaine_5\NN\3681148|who|in (r_dobj) received_4\VBD\2210855| (r_relcl) patients_2\NNS\9898892|,|patient (r_nsubj) died_17\VBD\146138|.|;|bradydysrhythmias (r_ccomp) exhibited_19\VBN\2632167|NONE (l_dobj) bradydysrhythmias_20\NNS\0|died|.|;
D008012_D001919 NONE lidocaine_35\NN\3681148|NONE (r_pobj) of_34\IN\0|interval (r_prep) administration_33\NN\1133281|NONE (r_pobj) after_32\IN\0|experienced (r_prep) seizures_31\NNS\14081375|or|tachycardia|;|, (r_conj) bradydysrhythmias_20\NNS\0|died|.|;
D003042_D002318 NONE cocaine_7\NN\3492717|NONE (r_compound) toxicity_8\NN\13576101|may|that|lidocaine (r_dobj) enhance_6\VB\227165|theoretical (r_acl) concerns_2\NNS\5682950|NONE (r_pobj) despite_0\IN\7501545|use|,|not|.|was|with (r_prep) associated_23\VBN\628491|NONE (l_prep) with_24\IN\0|use|,|Despite|not|.|was (l_pobj) toxicity_31\NN\13576101|NONE
D003042_D002318 NONE cocaine_17\NN\3492717| (r_npadvmod) associated_19\VBN\628491|NONE (r_amod) mi_20\NNP\14207561|NONE (r_pobj) with_16\IN\0|NONE (r_prep) patients_15\NNS\9898892|NONE (r_pobj) in_14\IN\13603305|the|of (r_prep) use_11\NN\407535|,|Despite|not|.|was|with (r_nsubjpass) associated_23\VBN\628491|NONE (l_prep) with_24\IN\0|use|,|Despite|not|.|was (l_pobj) toxicity_31\NN\13576101|NONE
D003042_D064420 NONE cocaine_7\NN\3492717|NONE (r_compound) toxicity_8\NN\13576101|may|that|lidocaine
D003042_D064420 NONE cocaine_17\NN\3492717| (r_npadvmod) associated_19\VBN\628491|NONE (r_amod) mi_20\NNP\14207561|NONE (r_pobj) with_16\IN\0|NONE (r_prep) patients_15\NNS\9898892|NONE (r_pobj) in_14\IN\13603305|the|of (r_prep) use_11\NN\407535|,|Despite|not|.|was|with (r_nsubjpass) associated_23\VBN\628491|NONE (l_prep) despite_0\IN\7501545|use|,|not|.|was|with (l_pobj) concerns_2\NNS\5682950|NONE (l_acl) enhance_6\VB\227165|theoretical (l_dobj) toxicity_8\NN\13576101|may|that|lidocaine
D003042_D001919 NONE cocaine_10\NN\3492717| (r_npadvmod) associated_12\VBN\628491|NONE (r_amod) mi_13\NNP\14207561|NONE (r_pobj) of_9\IN\0|the (r_prep) setting_8\NN\8567235|NONE (r_pobj) in_6\IN\13603305|who|lidocaine (r_prep) received_4\VBD\2210855| (r_relcl) patients_2\NNS\9898892|,|patient (r_nsubj) died_17\VBD\146138|.|;|bradydysrhythmias (r_ccomp) exhibited_19\VBN\2632167|NONE (l_dobj) bradydysrhythmias_20\NNS\0|died|.|;
17035713
-1_D007674 NONE sulfhydryl_3\NN\0|a (r_amod) reagent_4\NN\14779550|NONE (r_pobj) as_1\IN\14622893|.|role|: (r_prep) chloroacetaldehyde_0\NNP\0|NONE (l_appos) role_7\NN\719494|.|as|: (l_prep) of_8\IN\0|the (l_pobj) groups_11\NNS\2137|NONE (l_prep) in_12\IN\13603305|thiol|critical (l_pobj) nephropathy_14\NN\14573196|NONE
C004656_D009369 NONE chloroacetaldehyde_0\NNP\0|.|metabolite (r_nsubj) is_4\VBZ\0|NONE (l_attr) metabolite_6\NN\20090|.|Chloroacetaldehyde (l_conj) responsible_17\JJ\0|a|of|and (l_prep) for_18\IN\0|putatively (l_pobj) damage_20\NN\7296428|NONE (l_prep) following_21\VBG\8180190|renal (l_pobj) therapy_25\NN\657604|with (l_compound) tumor_24\NN\14234074|NONE
C004656_D009369 NONE caa_2\NNP\0|)|( (r_appos) chloroacetaldehyde_0\NNP\0|.|metabolite (r_nsubj) is_4\VBZ\0|NONE (l_attr) metabolite_6\NN\20090|.|Chloroacetaldehyde (l_conj) responsible_17\JJ\0|a|of|and (l_prep) for_18\IN\0|putatively (l_pobj) damage_20\NN\7296428|NONE (l_prep) following_21\VBG\8180190|renal (l_pobj) therapy_25\NN\657604|with (l_compound) tumor_24\NN\14234074|NONE
C004656_D064420 NONE caa_2\NNP\0|NONE (r_pobj) of_1\IN\0|NONE (r_prep) toxicity_0\NN\13576101|by|trypan|was|.
C004656_D064420 NONE caa_2\NNP\0|Thus|.|,|directly|mediating|,|with (r_nsubj) reacts_4\VBZ\2367363|NONE (l_advcl) mediating_14\VBG\761713|Thus|.|,|directly|CAA|,|with (l_dobj) toxicity_16\NN\13576101|NONE
D007069_D007674 CID ifosfamide_13\JJ\0|NONE (r_amod) nephropathy_14\NN\14573196|NONE
D007069_D007674 CID ifosfamide_11\NN\0|NONE (r_pobj) of_7\IN\0|a|responsible|and (r_prep) metabolite_6\NN\20090|.|Chloroacetaldehyde (l_conj) responsible_17\JJ\0|a|of|and (l_prep) for_18\IN\0|putatively (l_pobj) damage_20\NN\7296428|NONE
D007069_D007674 CID ifo_13\NN\0|the|agent|)|( (r_appos) ifosfamide_11\NN\0|NONE (r_pobj) of_7\IN\0|a|responsible|and (r_prep) metabolite_6\NN\20090|.|Chloroacetaldehyde (l_conj) responsible_17\JJ\0|a|of|and (l_prep) for_18\IN\0|putatively (l_pobj) damage_20\NN\7296428|NONE
D007069_D007674 CID ifo_27\NN\0|NONE (r_pobj) with_26\IN\0|therapy (r_prep) following_21\VBG\8180190|renal (r_prep) damage_20\NN\7296428|NONE
D007069_D007674 CID ifo_10\NN\0|NONE (r_compound) nephropathy_11\NN\14573196|in|to
D014343_D064420 NONE blue_16\JJ\4959672|NONE (r_amod) exclusion_17\NN\13927383|and|activity (r_compound) assay_18\NN\5733583|NONE (r_dobj) trypan_15\NN\0|by|was|Toxicity|. (r_advcl) determined_4\VBN\0|NONE (l_nsubjpass) toxicity_0\NN\13576101|by|trypan|was|.
D007069_D009369 NONE ifosfamide_11\NN\0|NONE (r_pobj) of_7\IN\0|a|responsible|and (r_prep) metabolite_6\NN\20090|.|Chloroacetaldehyde (l_conj) responsible_17\JJ\0|a|of|and (l_prep) for_18\IN\0|putatively (l_pobj) damage_20\NN\7296428|NONE (l_prep) following_21\VBG\8180190|renal (l_pobj) therapy_25\NN\657604|with (l_compound) tumor_24\NN\14234074|NONE
D007069_D009369 NONE ifo_13\NN\0|the|agent|)|( (r_appos) ifosfamide_11\NN\0|NONE (r_pobj) of_7\IN\0|a|responsible|and (r_prep) metabolite_6\NN\20090|.|Chloroacetaldehyde (l_conj) responsible_17\JJ\0|a|of|and (l_prep) for_18\IN\0|putatively (l_pobj) damage_20\NN\7296428|NONE (l_prep) following_21\VBG\8180190|renal (l_pobj) therapy_25\NN\657604|with (l_compound) tumor_24\NN\14234074|NONE
D007069_D009369 NONE ifo_27\NN\0|NONE (r_pobj) with_26\IN\0|therapy (r_prep) following_21\VBG\8180190|renal (l_pobj) therapy_25\NN\657604|with (l_compound) tumor_24\NN\14234074|NONE
D013438_D064420 NONE thiols_12\NNS\0|NONE (r_pobj) with_5\IN\0|Thus|.|,|directly|CAA|mediating|, (r_prep) reacts_4\VBZ\2367363|NONE (l_advcl) mediating_14\VBG\761713|Thus|.|,|directly|CAA|,|with (l_dobj) toxicity_16\NN\13576101|NONE
C004656_D009336 NONE caa_0\NNP\0|.|number|induced|, (r_nsubj) reduced_1\VBD\441445|NONE (l_conj) induced_8\VBD\1627355|CAA|.|number|, (l_dobj) loss_10\NN\13252973|NONE (l_conj) increase_17\NN\13576355|a|in|and (l_prep) in_18\IN\13603305|an (l_pobj) markers_20\NNS\21939|NONE (l_compound) necrosis_19\NN\11444117|NONE
C004656_D009336 NONE caa_7\NNP\0|NONE (r_pobj) of_6\IN\0|the|with (r_prep) reaction_5\NN\13446390|which (r_dobj) slowed_3\VBD\151689|,|, (r_relcl) acidification_0\NN\13518963|effects|.|also|could (r_nsubj) attenuate_14\VB\224901|NONE (l_dobj) effects_15\NNS\13245626|Acidification|.|also|could (l_prep) on_18\IN\0|of (l_pobj) markers_20\NNS\21939|NONE (l_compound) necrosis_19\NN\11444117|depletion|,
C004656_D009336 NONE caa_17\NNP\0|NONE (r_pobj) of_16\IN\0|on (r_prep) effects_15\NNS\13245626|Acidification|.|also|could (l_prep) on_18\IN\0|of (l_pobj) markers_20\NNS\21939|NONE (l_compound) necrosis_19\NN\11444117|depletion|,
D003545_D009336 NONE cysteine_25\NN\14601829|NONE (r_compound) protease_26\NN\14732946|in (r_compound) inhibition_27\NN\1068773|thiol|and (r_conj) depletion_23\NN\351638|,|necrosis (r_conj) markers_20\NNS\21939|NONE (l_compound) necrosis_19\NN\11444117|depletion|,
C004656_D007674 NONE chloroacetaldehyde_0\NNP\0|NONE (l_appos) role_7\NN\719494|.|as|: (l_prep) of_8\IN\0|the (l_pobj) groups_11\NNS\2137|NONE (l_prep) in_12\IN\13603305|thiol|critical (l_pobj) nephropathy_14\NN\14573196|NONE
C004656_D007674 NONE chloroacetaldehyde_0\NNP\0|.|metabolite (r_nsubj) is_4\VBZ\0|NONE (l_attr) metabolite_6\NN\20090|.|Chloroacetaldehyde (l_conj) responsible_17\JJ\0|a|of|and (l_prep) for_18\IN\0|putatively (l_pobj) damage_20\NN\7296428|NONE
C004656_D007674 NONE caa_2\NNP\0|)|( (r_appos) chloroacetaldehyde_0\NNP\0|.|metabolite (r_nsubj) is_4\VBZ\0|NONE (l_attr) metabolite_6\NN\20090|.|Chloroacetaldehyde (l_conj) responsible_17\JJ\0|a|of|and (l_prep) for_18\IN\0|putatively (l_pobj) damage_20\NN\7296428|NONE
D013438_D009336 NONE thiols_14\NNS\0|NONE (r_pobj) in_11\IN\13603305|a|increase|and (r_prep) loss_10\NN\13252973|NONE (l_conj) increase_17\NN\13576355|a|in|and (l_prep) in_18\IN\13603305|an (l_pobj) markers_20\NNS\21939|NONE (l_compound) necrosis_19\NN\11444117|NONE
D013438_D009336 NONE thiol_9\JJ\0|NONE (r_compound) donors_10\NNS\9608709|NONE (r_pobj) with_8\IN\0|the|of (r_prep) reaction_5\NN\13446390|which (r_dobj) slowed_3\VBD\151689|,|, (r_relcl) acidification_0\NN\13518963|effects|.|also|could (r_nsubj) attenuate_14\VB\224901|NONE (l_dobj) effects_15\NNS\13245626|Acidification|.|also|could (l_prep) on_18\IN\0|of (l_pobj) markers_20\NNS\21939|NONE (l_compound) necrosis_19\NN\11444117|depletion|,
D013438_D009336 NONE thiol_22\JJ\0|inhibition|and (r_compound) depletion_23\NN\351638|,|necrosis (r_conj) markers_20\NNS\21939|NONE (l_compound) necrosis_19\NN\11444117|depletion|,
D013438_D007674 NONE thiol_10\JJ\0|in|critical (r_compound) groups_11\NNS\2137|NONE (l_prep) in_12\IN\13603305|thiol|critical (l_pobj) nephropathy_14\NN\14573196|NONE
9831002
D008774_D009459 CID methylphenidate_4\NN\4320126|and|.|malignant|Neuroleptic (r_conj) syndrome_2\NN\5870365|NONE
D008774_D009459 CID methylphenidate_13\NN\4320126|NONE (r_pobj) by_12\IN\0|.|presented|probably (r_agent) caused_11\VBN\1617192|NONE (l_nsubj) presented_5\VBN\2137132|.|by|probably (l_prep) with_6\IN\0|female (l_pobj) syndrome_9\NN\5870365|NONE
D008774_D009459 CID methylphenidate_13\NN\4320126|NONE (r_pobj) by_12\IN\0|probably (r_agent) caused_11\VBN\1617192|first|the|with|reported (r_acl) patient_5\JJ\9898892|.|This (l_prep) with_6\IN\0|first|the|reported|caused (l_pobj) syndrome_9\NN\5870365|NONE
24072398
D012701_D003866 NONE serotonin_38\NN\14807737|and|tyrosine (r_conj) hydroxylase_36\NN\0|and|HVA|, (r_conj) dopac_31\NNP\0|by|, (r_conj) indicated_21\VBN\952524|by|.|observed|profile|was|,|, (r_advcl) accompanied_9\VBN\0|NONE (l_nsubjpass) profile_4\NN\6999802|by|.|observed|was|,|,|indicated (l_amod) like_3\JJ\5839024|induced|This (l_npadvmod) depressive_1\JJ\10595647|
D015102_D003866 NONE dopac_31\NNP\0|by|, (r_conj) indicated_21\VBN\952524|by|.|observed|profile|was|,|, (r_advcl) accompanied_9\VBN\0|NONE (l_nsubjpass) profile_4\NN\6999802|by|.|observed|was|,|,|indicated (l_amod) like_3\JJ\5839024|induced|This (l_npadvmod) depressive_1\JJ\10595647|
D008694_D003866 CID methamphetamine_5\NN\2704153|NONE (r_pobj) of_4\IN\0|single|A|neurotoxic (r_prep) dose_3\NN\3740161|.|behaviour (r_nsubj) induces_6\VBZ\1627355|NONE (l_dobj) behaviour_14\NN\14006945|.|dose (l_amod) like_13\JJ\5839024|in|a|lasting (l_amod) depressive_11\JJ\10595647|
D008694_D003866 CID methamphetamine_0\NN\2704153|leads|.|disruption (r_nsubj) triggers_4\VBZ\3659292|NONE (l_conj) leads_14\VBZ\5155821|.|Methamphetamine|disruption (l_prep) to_15\IN\0|abuse (l_pobj) states_18\NNS\8491826|NONE (l_prep) including_19\VBG\0|negative|emotional (l_pobj) symptoms_21\NNS\5823932|NONE
D008694_D003866 CID meth_2\NNP\2704153|(|) (r_appos) methamphetamine_0\NN\2704153|leads|.|disruption (r_nsubj) triggers_4\VBZ\3659292|NONE (l_conj) leads_14\VBZ\5155821|.|Methamphetamine|disruption (l_prep) to_15\IN\0|abuse (l_pobj) states_18\NNS\8491826|NONE (l_prep) including_19\VBG\0|negative|emotional (l_pobj) symptoms_21\NNS\5823932|NONE
D008694_D003866 CID meth_12\NNP\2704153|NONE (r_compound) abuse_13\NN\418025|to (r_nsubj) leads_14\VBZ\5155821|.|Methamphetamine|disruption (l_prep) to_15\IN\0|abuse (l_pobj) states_18\NNS\8491826|NONE (l_prep) including_19\VBG\0|negative|emotional (l_pobj) symptoms_21\NNS\5823932|NONE
D008694_D003866 CID meth_12\NNP\2704153|NONE (r_pobj) of_11\IN\0|acute|toxic|the (r_prep) dosage_10\NN\13576355|also|if|phenotype (r_nsubj) causes_14\VBZ\7323922|However|.|it|currently|,|unknown (l_dobj) phenotype_20\NN\4933544|also|if|dosage (l_amod) depressive_19\JJ\10595647|deficits|and|a|lasting
D008694_D003866 CID meth_23\NNP\2704153|a|high|single|mg/kg (r_compound) dose_24\NN\3740161|NONE (r_pobj) following_19\VBG\8180190|Thus|.|,|we|at|behaviour|now (r_prep) assessed_4\VBD\670261|NONE (l_dobj) behaviour_9\NN\14006945|Thus|.|,|we|at|following|now (l_amod) like_8\JJ\5839024|the|in (l_npadvmod) depressive_6\JJ\10595647|
D008694_D003866 CID meth_7\NNP\2704153|NONE (r_pobj) by_6\IN\0|NONE (r_agent) induced_5\VBN\1627355|This|like (r_acl) profile_4\NN\6999802|by|.|observed|was|,|,|indicated (l_amod) like_3\JJ\5839024|induced|This (l_npadvmod) depressive_1\JJ\10595647|
D008694_D003866 CID meth_13\NNP\2704153|NONE (r_pobj) of_12\IN\0|a|high|single (r_prep) dose_11\NN\3740161|that|behaviour (r_nsubj) induces_14\VBZ\1627355|findings|.|for (l_dobj) behaviour_21\NN\14006945|that|dose (l_amod) like_20\JJ\5839024|in|lasting (l_amod) depressive_18\JJ\10595647|
D006719_D003866 NONE hva_33\NNP\0|hydroxylase|and|, (r_conj) dopac_31\NNP\0|by|, (r_conj) indicated_21\VBN\952524|by|.|observed|profile|was|,|, (r_advcl) accompanied_9\VBN\0|NONE (l_nsubjpass) profile_4\NN\6999802|by|.|observed|was|,|,|indicated (l_amod) like_3\JJ\5839024|induced|This (l_npadvmod) depressive_1\JJ\10595647|
D014443_D003866 NONE tyrosine_35\JJ\14601829|and|serotonin (r_compound) hydroxylase_36\NN\0|and|HVA|, (r_conj) dopac_31\NNP\0|by|, (r_conj) indicated_21\VBN\952524|by|.|observed|profile|was|,|, (r_advcl) accompanied_9\VBN\0|NONE (l_nsubjpass) profile_4\NN\6999802|by|.|observed|was|,|,|indicated (l_amod) like_3\JJ\5839024|induced|This (l_npadvmod) depressive_1\JJ\10595647|
D008694_D020258 NONE methamphetamine_5\NN\2704153|NONE (r_pobj) of_4\IN\0|single|A|neurotoxic (r_prep) dose_3\NN\3740161|.|behaviour (l_amod) neurotoxic_2\JJ\0|single|of|A
D004298_D003866 NONE dopamine_29\NN\14807737|NONE (r_pobj) of_28\IN\0|the (r_prep) levels_27\NNS\4916342|NONE (r_pobj) in_25\IN\13603305|a (r_prep) reduction_24\NN\351485|NONE (r_pobj) by_22\IN\0|,|DOPAC (r_agent) indicated_21\VBN\952524|by|.|observed|profile|was|,|, (r_advcl) accompanied_9\VBN\0|NONE (l_nsubjpass) profile_4\NN\6999802|by|.|observed|was|,|,|indicated (l_amod) like_3\JJ\5839024|induced|This (l_npadvmod) depressive_1\JJ\10595647|
18801087
D000638_D009369 NONE amiodarone_11\NN\2715941| (r_npadvmod) related_13\VBN\628491|pulmonary|and|neoplasm|an (r_amod) lesion_15\NN\14204950|NONE (l_conj) neoplasm_18\NN\14234074|pulmonary|and|an|related
D000638_D009369 NONE amiodarone_36\NN\2715941|NONE (r_compound) treatment_37\NN\654885|NONE (r_pobj) of_35\IN\0|another|possible (r_prep) complication_34\NN\1073995|might|glomerulonephritis|that (r_attr) be_31\VB\14625458|NONE (r_ccomp) suggests_26\VBZ\1010118|possibility|and|case|.|, (r_conj) highlights_3\VBZ\13809920|NONE (l_dobj) possibility_5\NN\5944958|suggests|and|case|.|, (l_acl) be_20\VB\14625458|the (l_nsubj) diagnosis_8\NN\152018|radiologically|difficult|can|that (l_prep) between_9\IN\0|differential (l_pobj) lesion_15\NN\14204950|NONE (l_conj) neoplasm_18\NN\14234074|pulmonary|and|an|related
D000638_D001145 NONE amiodarone_0\NN\2715941|but|drug|,|reported (r_nsubj) is_1\VBZ\0|NONE (l_attr) drug_6\NN\14778436|Amiodarone|but|,|reported (l_amod) arrhythmic_5\JJ\0|for|an
D000638_D055370 CID amiodarone_0\NN\2715941| (r_npadvmod) related_2\VBN\628491|.|pulmonary|pitfall|in|and|:|glomerulonephritis (r_amod) mass_4\NN\13575869|NONE
D000638_D055370 CID amiodarone_36\NN\2715941|NONE (r_pobj) with_35\IN\0|for (r_prep) treatment_34\NN\654885|NONE (r_pobj) after_33\IN\0|who|mass (r_prep) developed_15\VBD\1753788|a (l_dobj) mass_18\NN\13575869|after|who
D000638_D055370 CID amiodarone_47\NN\2715941| (r_npadvmod) related_49\VBN\628491|an (r_amod) lesion_50\NN\14204950|it|that (r_attr) was_45\VBD\0|NONE (r_ccomp) indicating_42\VBG\952524|was|lesion|.|histologically|of|, (r_advcl) composed_22\VBN\2620587|mass|was|but|be|highly|, (r_conj) suspected_5\VBN\916909|NONE (l_nsubjpass) mass_2\NN\13575869|was|but|be|highly|,|composed
D000638_D055370 CID amiodarone_11\NN\2715941| (r_npadvmod) related_13\VBN\628491|pulmonary|and|neoplasm|an (r_amod) lesion_15\NN\14204950|NONE
D000638_D055370 CID amiodarone_36\NN\2715941|NONE (r_compound) treatment_37\NN\654885|NONE (r_pobj) of_35\IN\0|another|possible (r_prep) complication_34\NN\1073995|might|glomerulonephritis|that (r_attr) be_31\VB\14625458|NONE (r_ccomp) suggests_26\VBZ\1010118|possibility|and|case|.|, (r_conj) highlights_3\VBZ\13809920|NONE (l_dobj) possibility_5\NN\5944958|suggests|and|case|.|, (l_acl) be_20\VB\14625458|the (l_nsubj) diagnosis_8\NN\152018|radiologically|difficult|can|that (l_prep) between_9\IN\0|differential (l_pobj) lesion_15\NN\14204950|NONE
D000638_D013610 NONE amiodarone_0\NN\2715941|but|drug|,|reported (r_nsubj) is_1\VBZ\0|NONE (l_attr) drug_6\NN\14778436|Amiodarone|but|,|reported (l_prep) for_7\IN\0|arrhythmic|an (l_pobj) tachycardia_11\NN\14110674|NONE
D000638_D015433 CID amiodarone_0\NN\2715941| (r_npadvmod) related_2\VBN\628491|.|pulmonary|pitfall|in|and|:|glomerulonephritis (r_amod) mass_4\NN\13575869|NONE (l_conj) glomerulonephritis_8\NN\14113798|.|pulmonary|related|pitfall|in|and|:
D000638_D015433 CID amiodarone_11\NN\2715941| (r_npadvmod) related_13\VBN\628491|pulmonary|and|neoplasm|an (r_amod) lesion_15\NN\14204950|NONE (r_pobj) between_9\IN\0|differential (r_prep) diagnosis_8\NN\152018|radiologically|difficult|can|that (r_nsubj) be_20\VB\14625458|the (r_acl) possibility_5\NN\5944958|suggests|and|case|.|, (r_dobj) highlights_3\VBZ\13809920|NONE (l_conj) suggests_26\VBZ\1010118|possibility|and|case|.|, (l_ccomp) be_31\VB\14625458|NONE (l_nsubj) glomerulonephritis_29\NN\14113798|might|that|complication
D000638_D015433 CID amiodarone_36\NN\2715941|NONE (r_compound) treatment_37\NN\654885|NONE (r_pobj) of_35\IN\0|another|possible (r_prep) complication_34\NN\1073995|might|glomerulonephritis|that (r_attr) be_31\VB\14625458|NONE (l_nsubj) glomerulonephritis_29\NN\14113798|might|that|complication
D000638_D008175 NONE amiodarone_47\NN\2715941| (r_npadvmod) related_49\VBN\628491|an (r_amod) lesion_50\NN\14204950|it|that (r_attr) was_45\VBD\0|NONE (r_ccomp) indicating_42\VBG\952524|was|lesion|.|histologically|of|, (r_advcl) composed_22\VBN\2620587|mass|was|but|be|highly|, (r_conj) suspected_5\VBN\916909|NONE (l_xcomp) be_7\VB\14625458|mass|was|but|highly|,|composed (l_attr) cancer_9\NN\14239425|to
D000638_D006349 NONE amiodarone_0\NN\2715941| (r_npadvmod) related_2\VBN\628491|.|pulmonary|pitfall|in|and|:|glomerulonephritis (r_amod) mass_4\NN\13575869|NONE (l_prep) in_9\IN\13603305|.|pulmonary|related|pitfall|and|:|glomerulonephritis (l_pobj) patient_11\NN\9898892|NONE (l_prep) with_12\IN\0|a (l_pobj) disease_15\NN\14061805|NONE
D000638_D006349 NONE amiodarone_36\NN\2715941|NONE (r_pobj) with_35\IN\0|for (r_prep) treatment_34\NN\654885|NONE (r_pobj) after_33\IN\0|who|mass (r_prep) developed_15\VBD\1753788|a (r_relcl) patient_13\NN\9898892|NONE (r_pobj) in_11\IN\13603305|is|herein|. (r_prep) reported_0\VBN\831651|NONE (l_auxpass) is_2\VBZ\0|herein|in|. (l_attr) case_5\NN\7283608|, (l_prep) of_6\IN\0|an|autopsy (l_pobj) disease_9\NN\14061805|NONE
D000638_D011507 NONE amiodarone_36\NN\2715941|NONE (r_pobj) with_35\IN\0|for (r_prep) treatment_34\NN\654885|NONE (r_pobj) after_33\IN\0|who|mass (r_prep) developed_15\VBD\1753788|a (l_dobj) mass_18\NN\13575869|after|who (l_appos) cm_21\NNS\13649268|(|)|lung|a|day|( (l_conj) proteinuria_26\NN\14299637|in|and|)|.
20927253
D004164_D010024 NONE bisphosphonates_13\NNS\0|.|are|,|inhibit (r_nsubjpass) used_16\VBN\0|by|,|is|and|Osteoporosis (r_conj) caused_2\VBN\1617192|NONE (l_nsubjpass) osteoporosis_0\NN\14204950|by|,|is|and|used
D004164_D010024 NONE bisphosphonate_11\NN\0| (r_npadvmod) related_13\VBN\628491|NONE (r_amod) pain_14\NN\14299637|be|should|also|before (r_nsubjpass) considered_18\VBN\689344|can|pain|patients|that|and (r_conj) report_7\VB\6470073|We|. (l_nsubj) patients_3\NNS\9898892|can|considered|pain|that|and (l_prep) with_4\IN\0|NONE (l_pobj) osteoporosis_5\NN\14204950|NONE
D004164_D010024 NONE bisphosphonate_11\NN\0| (r_npadvmod) related_13\VBN\628491|NONE (r_amod) pain_14\NN\14299637|be|should|also|before (r_nsubjpass) considered_18\VBN\689344|can|pain|patients|that|and (l_prep) before_19\IN\0|be|should|also|pain (l_pcomp) ascribing_20\VBG\670261|NONE (l_prep) to_23\IN\0|complaint (l_pobj) osteoporosis_24\NN\14204950|NONE
D019386_D010146 CID alendronate_6\NN\3740161|NONE (r_pobj) of_5\IN\0|NONE (r_prep) administration_4\NN\1133281|NONE (r_pobj) after_3\IN\0|.|skeletal|Diffuse (r_prep) pain_2\NN\14299637|NONE
D019386_D010146 CID alendronate_20\NN\3740161|NONE (r_pobj) of_19\IN\0|three|consecutive (r_prep) administration_18\NN\1133281|NONE (r_pobj) after_15\IN\0|to|with (r_prep) admitted_4\VBN\822367|a (l_prep) with_11\IN\0|to|after (l_pobj) pain_14\NN\14299637|NONE
D004164_D010146 NONE bisphosphonate_11\NN\0| (r_npadvmod) related_13\VBN\628491|NONE (r_amod) pain_14\NN\14299637|be|should|also|before (r_nsubjpass) considered_18\VBN\689344|can|pain|patients|that|and (r_conj) report_7\VB\6470073|We|. (l_dobj) pain_8\NN\14299637|can|considered|patients|that|and
D004164_D010146 NONE bisphosphonate_11\NN\0| (r_npadvmod) related_13\VBN\628491|NONE (r_amod) pain_14\NN\14299637|be|should|also|before
D019386_D010024 NONE alendronate_0\NNP\3740161|.|effective (r_nsubj) is_5\VBZ\0|NONE (l_acomp) effective_6\JJ\0|.|Alendronate (l_prep) for_7\IN\0|NONE (l_pobj) treatment_10\NN\654885|NONE (l_prep) of_13\IN\0|the|both|prevention|and (l_pobj) osteoporosis_14\NN\14204950|NONE
-1_D010024 NONE biphosphonate_3\NN\0|,|, (r_appos) alendronate_0\NNP\3740161|.|effective (r_nsubj) is_5\VBZ\0|NONE (l_acomp) effective_6\JJ\0|.|Alendronate (l_prep) for_7\IN\0|NONE (l_pobj) treatment_10\NN\654885|NONE (l_prep) of_13\IN\0|the|both|prevention|and (l_pobj) osteoporosis_14\NN\14204950|NONE
24902786
D013629_D008569 CID tamoxifen_6\NN\2714883|or (r_conj) letrozole_4\NN\0|,|of (r_conj) administration_0\NN\1133281|memory|attenuated|.|and|significantly|, (r_nsubj) impaired_8\VBD\258857|NONE (l_dobj) memory_10\NN\5926676|attenuated|Administration|.|and|significantly|,
D013629_D008569 CID tamoxifen_6\NN\2714883|or (r_conj) letrozole_4\NN\0|,|of (r_conj) administration_0\NN\1133281|memory|attenuated|.|and|significantly|, (r_nsubj) impaired_8\VBD\258857|NONE (l_conj) attenuated_17\VBD\224901|memory|Administration|.|and|significantly|, (l_dobj) replacement_20\NN\196485|significantly (l_prep) in_21\IN\13603305|the|testosterone (l_pcomp) improving_22\VBG\126264|NONE (l_dobj) impairment_29\NN\7296428|NONE
D013739_D008569 NONE testosterone_0\NN\14747587|.|impairment (r_nsubj) ameliorates_1\VBZ\126264|NONE (l_dobj) impairment_6\NN\7296428|Testosterone|.
D013739_D008569 NONE testosterone_7\NN\14747587|NONE (r_pobj) of_6\IN\0|the|on (r_prep) effects_5\NNS\13245626|To (l_prep) on_8\IN\0|the|of (l_pobj) impairment_13\NN\7296428|NONE
D013739_D008569 NONE testosterone_19\NN\14747587|the|in (r_compound) replacement_20\NN\196485|significantly (r_dobj) attenuated_17\VBD\224901|memory|Administration|.|and|significantly|, (r_conj) impaired_8\VBD\258857|NONE (l_dobj) memory_10\NN\5926676|attenuated|Administration|.|and|significantly|,
D013739_D008569 NONE testosterone_19\NN\14747587|the|in (r_compound) replacement_20\NN\196485|significantly (l_prep) in_21\IN\13603305|the|testosterone (l_pcomp) improving_22\VBG\126264|NONE (l_dobj) impairment_29\NN\7296428|NONE
D013739_D008569 NONE testosterone_0\NN\14747587|NONE (r_compound) administration_1\NN\1133281|.|impairment (r_nsubj) ameliorates_2\VBZ\126264|NONE (l_dobj) impairment_9\NN\7296428|administration|.
C067431_D008569 CID letrozole_4\NN\0|,|of (r_conj) administration_0\NN\1133281|memory|attenuated|.|and|significantly|, (r_nsubj) impaired_8\VBD\258857|NONE (l_dobj) memory_10\NN\5926676|attenuated|Administration|.|and|significantly|,
C067431_D008569 CID letrozole_4\NN\0|,|of (r_conj) administration_0\NN\1133281|memory|attenuated|.|and|significantly|, (r_nsubj) impaired_8\VBD\258857|NONE (l_conj) attenuated_17\VBD\224901|memory|Administration|.|and|significantly|, (l_dobj) replacement_20\NN\196485|significantly (l_prep) in_21\IN\13603305|the|testosterone (l_pcomp) improving_22\VBG\126264|NONE (l_dobj) impairment_29\NN\7296428|NONE
D005485_D008569 CID flutamide_2\NN\0|NONE (r_pobj) of_1\IN\0|,|letrozole (r_prep) administration_0\NN\1133281|memory|attenuated|.|and|significantly|, (r_nsubj) impaired_8\VBD\258857|NONE (l_dobj) memory_10\NN\5926676|attenuated|Administration|.|and|significantly|,
D005485_D008569 CID flutamide_2\NN\0|NONE (r_pobj) of_1\IN\0|,|letrozole (r_prep) administration_0\NN\1133281|memory|attenuated|.|and|significantly|, (r_nsubj) impaired_8\VBD\258857|NONE (l_conj) attenuated_17\VBD\224901|memory|Administration|.|and|significantly|, (l_dobj) replacement_20\NN\196485|significantly (l_prep) in_21\IN\13603305|the|testosterone (l_pcomp) improving_22\VBG\126264|NONE (l_dobj) impairment_29\NN\7296428|NONE
D013311_D008569 CID streptozotocin_2\RB\0| (r_npadvmod) induced_4\VBN\1627355|in|memory (r_amod) impairment_6\NN\7296428|Testosterone|.
D013311_D008569 CID streptozotocin_9\JJ\0|memory|in|( (r_nmod) impairment_13\NN\7296428|NONE
D013311_D008569 CID stz)-induced_11\VBN\0|NONE (r_amod) memory_12\NN\5926676|streptozotocin|in|( (r_compound) impairment_13\NN\7296428|NONE
D013311_D008569 CID stz-_23\NNP\0|memory (r_nmod) impairment_29\NN\7296428|NONE (r_dobj) improving_22\VBG\126264|NONE (r_pcomp) in_21\IN\13603305|the|testosterone (r_prep) replacement_20\NN\196485|significantly (r_dobj) attenuated_17\VBD\224901|memory|Administration|.|and|significantly|, (r_conj) impaired_8\VBD\258857|NONE (l_dobj) memory_10\NN\5926676|attenuated|Administration|.|and|significantly|,
D013311_D008569 CID stz-_23\NNP\0|memory (r_nmod) impairment_29\NN\7296428|NONE
D013311_D008569 CID stz-_3\NNP\0|memory|induced|in (r_nmod) impairment_9\NN\7296428|administration|.
8160791
D006152_D007674 NONE monophosphate_7\NN\0|)|and|(|increase|cGMP (r_nmod) excretion_11\NN\13466586|A|significant|in (r_appos) reduction_2\NN\351485|in|.|also|were (r_nsubjpass) observed_25\VBN\2163746|NONE (l_prep) in_26\IN\13603305|reduction|.|also|were (l_pobj) nephropathy_30\NN\14573196|NONE
D006152_D007674 NONE cgmp_9\NN\0|)|and|(|increase|monophosphate (r_nmod) excretion_11\NN\13466586|A|significant|in (r_appos) reduction_2\NN\351485|in|.|also|were (r_nsubjpass) observed_25\VBN\2163746|NONE (l_prep) in_26\IN\13603305|reduction|.|also|were (l_pobj) nephropathy_30\NN\14573196|NONE
D005839_D007674 CID gentamicin_9\NN\2716866| (r_npadvmod) mediated_11\VBN\761713|NONE (r_amod) nephropathy_12\NN\14573196|NONE
D005839_D007674 CID gentamicin_16\NN\2716866|GM)mediated|( (r_nmod) nephropathy_19\NN\14573196|NONE
D005839_D007674 CID gm)-mediated_18\JJ\0|(|gentamicin (r_amod) nephropathy_19\NN\14573196|NONE
D005839_D007674 CID gm_2\NNP\13717155|NONE (r_pobj) of_1\IN\0|for|at (r_prep) administration_0\NN\1133281|damage|.|reduction (r_nsubj) induced_12\VBD\1627355|NONE (l_dobj) damage_34\NN\7296428|.|Administration|reduction
D005839_D007674 CID gm_27\NNP\13717155| (r_npadvmod) mediated_29\VBN\761713|NONE (r_amod) nephropathy_30\NN\14573196|NONE
D005839_D007674 CID gm_14\NNP\13717155| (r_npadvmod) mediated_16\VBN\761713|,||) (r_amod) nephropathy_17\NN\14573196|NONE
D005839_D007674 CID gm_43\NNP\13717155| (r_npadvmod) induced_45\VBN\1627355|renal (r_amod) vasoconstriction_47\NN\1149911|NONE (r_pobj) in_42\IN\13603305|critical|a (r_prep) role_41\NN\719494|NONE (r_dobj) play_38\VBP\7007684|SOD|differ|that||effects (r_conj) have_10\VBP\7846|results|. (l_dobj) effects_12\NNS\13245626|SOD|play|differ|that| (l_prep) on_13\IN\0|protective (l_pobj) nephropathy_17\NN\14573196|NONE
D013481_D007674 NONE superoxide_36\JJ\14971519|NONE (r_amod) anions_37\NNS\9315159|DMTU|,|and|and| (r_conj) sod_29\NNP\9335240|NONE (r_pobj) for_28\IN\0|mechanisms (r_prep) differ_27\VBP\0|SOD|play|that||effects (r_conj) have_10\VBP\7846|results|. (l_dobj) effects_12\NNS\13245626|SOD|play|differ|that| (l_prep) on_13\IN\0|protective (l_pobj) nephropathy_17\NN\14573196|NONE
C038983_D007674 NONE dmtu_3\NNP\0|,|but|affect|significantly|In|damage|, (r_nsubj) reduced_5\VBD\441445|NONE (l_dobj) damage_8\NN\7296428|,|but|affect|significantly|DMTU|In|,
C038983_D007674 NONE dmtu_9\NNP\0|both|and (r_conj) sod_7\NNP\9335240|play|differ|that||effects (r_nsubj) have_10\VBP\7846|results|. (l_dobj) effects_12\NNS\13245626|SOD|play|differ|that| (l_prep) on_13\IN\0|protective (l_pobj) nephropathy_17\NN\14573196|NONE
C038983_D007674 NONE dmtu_31\NNP\0|,|and|anions|and| (r_conj) sod_29\NNP\9335240|NONE (r_pobj) for_28\IN\0|mechanisms (r_prep) differ_27\VBP\0|SOD|play|that||effects (r_conj) have_10\VBP\7846|results|. (l_dobj) effects_12\NNS\13245626|SOD|play|differ|that| (l_prep) on_13\IN\0|protective (l_pobj) nephropathy_17\NN\14573196|NONE
8701013
D015738_D014456 NONE famotidine_0\NNP\3522239|and|showing|.|antagonist (r_nsubj) is_1\VBZ\0|NONE (l_attr) antagonist_5\NN\7846|and|showing|.|Famotidine (l_acl) used_6\VBD\0|a|Hreceptor|histamine (l_prep) in_7\IN\13603305|NONE (l_pobj) settings_9\NNS\8567235|NONE (l_prep) for_10\IN\0|inpatient (l_pobj) prevention_11\NN\1073995|NONE (l_prep) of_12\IN\0|NONE (l_pobj) ulcers_14\NNS\14211294|NONE
D015738_D003693 CID famotidine_0\NN\3522239| (r_npadvmod) associated_2\VBN\628491|. (r_amod) delirium_3\NN\14391660|NONE
D015738_D003693 CID famotidine_25\NN\3522239|NONE (r_pobj) with_24\IN\0|been|cases|have|,|.|shown (r_prep) associated_23\VBN\628491|NONE (l_advcl) shown_9\VBN\2137132|been|with|cases|have|,|. (l_dobj) propensity_11\NN\7498854|Although|all|have (l_acl) cause_13\VB\7323922|the (l_dobj) delirium_14\NN\14391660|to
D015738_D003693 CID famotidine_7\NN\3522239| (r_npadvmod) associated_9\VBN\628491|in (r_amod) delirium_10\NN\14391660|NONE
D015738_D003693 CID famotidine_20\NN\3522239|NONE (r_pobj) of_19\IN\0|NONE (r_prep) removal_18\NN\383606|NONE (r_pobj) upon_17\IN\0|completely|who (r_prep) cleared_15\VBD\126264|hospitalized (r_relcl) patients_13\NNS\9898892|NONE (r_pobj) in_11\IN\13603305|associated (r_prep) delirium_10\NN\14391660|NONE
24684312
D018698_D010146 NONE glutamate_3\NN\15010703|NONE (r_pobj) of_2\IN\0|Intradermal (r_prep) injections_1\NNS\320852|attractive|mimic|. (r_nsubj) are_6\VBP\13600404|NONE (l_acomp) attractive_7\JJ\0|mimic|injections|. (l_xcomp) use_9\VB\407535|NONE (l_prep) in_10\IN\13603305|to (l_pobj) models_14\NNS\5888929|NONE (l_compound) pain_13\NN\14299637|human|experimental
D002211_D013001 NONE capsaicin_5\NN\15032661|and (r_conj) glutamate_3\NN\15010703|NONE (r_pobj) of_2\IN\0|Intradermal (r_prep) injections_1\NNS\320852|attractive|mimic|. (r_nsubj) are_6\VBP\13600404|NONE (l_advcl) mimic_19\VBP\10200365|attractive|injections|. (l_dobj) aspects_21\NNS\5849789|because|hyperalgesia (l_prep) of_22\IN\0|isolated (l_pobj) disorders_25\NNS\14034177|NONE
D002211_D010146 NONE capsaicin_5\NN\15032661|and (r_conj) glutamate_3\NN\15010703|NONE (r_pobj) of_2\IN\0|Intradermal (r_prep) injections_1\NNS\320852|attractive|mimic|. (r_nsubj) are_6\VBP\13600404|NONE (l_acomp) attractive_7\JJ\0|mimic|injections|. (l_xcomp) use_9\VB\407535|NONE (l_prep) in_10\IN\13603305|to (l_pobj) models_14\NNS\5888929|NONE (l_compound) pain_13\NN\14299637|human|experimental
D018698_D006930 NONE glutamate_1\NN\15010703|NONE (l_appos) variability_9\NN\4733640|:|Intradermal|and|injections|. (l_prep) of_10\IN\0|intra (l_pobj) hyperalgesia_12\NN\0|NONE
D018698_D006930 NONE glutamate_1\NN\15010703|NONE (l_appos) variability_9\NN\4733640|:|Intradermal|and|injections|. (l_prep) of_10\IN\0|intra (l_pobj) hyperalgesia_12\NN\0|NONE (l_conj) allodynia_14\NN\0|provoked|and
D018698_D006930 NONE glutamate_3\NN\15010703|NONE (r_pobj) of_2\IN\0|Intradermal (r_prep) injections_1\NNS\320852|attractive|mimic|. (r_nsubj) are_6\VBP\13600404|NONE (l_advcl) mimic_19\VBP\10200365|attractive|injections|. (l_nsubj) hyperalgesia_16\NN\0|aspects|because
D018698_D006930 NONE glutamate_3\NN\15010703|NONE (r_pobj) of_2\IN\0|Intradermal (r_prep) injections_1\NNS\320852|attractive|mimic|. (r_nsubj) are_6\VBP\13600404|NONE (l_advcl) mimic_19\VBP\10200365|attractive|injections|. (l_nsubj) hyperalgesia_16\NN\0|aspects|because (l_conj) allodynia_18\NN\0|and
D018698_D006930 NONE glutamate_32\NN\15010703|NONE (r_compound) injection_33\NN\320852|NONE (r_pobj) after_31\IN\0|)|P|(|and||g (r_prep) gauges_21\VBZ\3733925|Frey (r_pobj) to_18\IN\0|)|scale|VAS|( (r_prep) response_17\NN\11410625|NONE (r_pobj) in_9\IN\13603305|marked|a (r_prep) increase_8\NN\13576355|NONE (r_pobj) as_5\IN\14622893|.|hyperalgesia|was (r_prep) observed_4\VBN\2163746|NONE (l_nsubjpass) hyperalgesia_2\NN\0|.|was|as
D018698_D006930 NONE glutamate_3\NN\15010703|NONE (r_nmod) yield_6\NN\913705|hyperalgesic|,|suited|and (r_nmod) responses_11\NNS\11410625|, (l_amod) hyperalgesic_8\JJ\0|,|suited|and|yield
D018698_D006930 NONE glutamate_3\NN\15010703|NONE (r_nmod) yield_6\NN\913705|hyperalgesic|,|suited|and (r_nmod) responses_11\NNS\11410625|, (l_amod) hyperalgesic_8\JJ\0|,|suited|and|yield (l_conj) allodynic_10\JJ\0|reproducible|and
D002211_D006930 CID capsaicin_3\NN\15032661|NONE (r_compound) injections_4\NNS\320852|:|Intradermal|variability|and|. (r_conj) glutamate_1\NN\15010703|NONE (l_appos) variability_9\NN\4733640|:|Intradermal|and|injections|. (l_prep) of_10\IN\0|intra (l_pobj) hyperalgesia_12\NN\0|NONE
D002211_D006930 CID capsaicin_3\NN\15032661|NONE (r_compound) injections_4\NNS\320852|:|Intradermal|variability|and|. (r_conj) glutamate_1\NN\15010703|NONE (l_appos) variability_9\NN\4733640|:|Intradermal|and|injections|. (l_prep) of_10\IN\0|intra (l_pobj) hyperalgesia_12\NN\0|NONE (l_conj) allodynia_14\NN\0|provoked|and
D002211_D006930 CID capsaicin_5\NN\15032661|and (r_conj) glutamate_3\NN\15010703|NONE (r_pobj) of_2\IN\0|Intradermal (r_prep) injections_1\NNS\320852|attractive|mimic|. (r_nsubj) are_6\VBP\13600404|NONE (l_advcl) mimic_19\VBP\10200365|attractive|injections|. (l_nsubj) hyperalgesia_16\NN\0|aspects|because
D002211_D006930 CID capsaicin_5\NN\15032661|and (r_conj) glutamate_3\NN\15010703|NONE (r_pobj) of_2\IN\0|Intradermal (r_prep) injections_1\NNS\320852|attractive|mimic|. (r_nsubj) are_6\VBP\13600404|NONE (l_advcl) mimic_19\VBP\10200365|attractive|injections|. (l_nsubj) hyperalgesia_16\NN\0|aspects|because (l_conj) allodynia_18\NN\0|and
D002211_D006930 CID capsaicin_1\NN\15032661|NONE (r_pobj) for_0\IN\0|was|with|hyperalgesia|,|. (r_prep) detected_7\VBN\2163746|NONE (l_nsubjpass) hyperalgesia_5\NN\0|was|with|For|,|.
D002211_D006930 CID capsaicin_0\NN\15032661|NONE (r_compound) injection_1\NN\320852|.|>|reproducible|allodynia|and (r_nsubj) was_2\VBD\0|NONE (l_acomp) reproducible_3\JJ\0|.|injection|>|allodynia|and (l_prep) for_4\IN\0|NONE (l_pobj) hyperalgesia_6\NN\0|NONE
D002211_D006930 CID capsaicin_0\NN\15032661|NONE (r_compound) injection_1\NN\320852|.|>|reproducible|allodynia|and (r_nsubj) was_2\VBD\0|NONE (l_attr) allodynia_13\NN\0|.|injection|>|reproducible|and
D002211_D006930 CID capsaicin_5\NN\15032661|and (r_conj) glutamate_3\NN\15010703|NONE (r_nmod) yield_6\NN\913705|hyperalgesic|,|suited|and (r_nmod) responses_11\NNS\11410625|, (l_amod) hyperalgesic_8\JJ\0|,|suited|and|yield
D002211_D006930 CID capsaicin_5\NN\15032661|and (r_conj) glutamate_3\NN\15010703|NONE (r_nmod) yield_6\NN\913705|hyperalgesic|,|suited|and (r_nmod) responses_11\NNS\11410625|, (l_amod) hyperalgesic_8\JJ\0|,|suited|and|yield (l_conj) allodynic_10\JJ\0|reproducible|and
D018698_D013001 NONE glutamate_3\NN\15010703|NONE (r_pobj) of_2\IN\0|Intradermal (r_prep) injections_1\NNS\320852|attractive|mimic|. (r_nsubj) are_6\VBP\13600404|NONE (l_advcl) mimic_19\VBP\10200365|attractive|injections|. (l_dobj) aspects_21\NNS\5849789|because|hyperalgesia (l_prep) of_22\IN\0|isolated (l_pobj) disorders_25\NNS\14034177|NONE
3925479
D001285_D002375 NONE atropine_5\NN\14712692|NONE (r_preconj) ,_4\,\0|,|blocker|catalepsy|. (r_punct) disrupted_7\VBD\362348|NONE (l_dobj) catalepsy_11\NN\14023236|,|,|blocker|.
D006220_D002375 CID haloperidol_6\NN\3713736| (r_npadvmod) induced_8\VBN\1627355|NONE (r_amod) catalepsy_9\NN\14023236|NONE
D006220_D002375 CID haloperidol_19\NN\3713736|,|dopaminergic|the (r_appos) blocker_17\NN\10101634|NONE (r_pobj) by_14\IN\0|was|that (r_agent) induced_13\VBN\1627355|the (r_relcl) catalepsy_10\NN\14023236|NONE
D006220_D002375 CID haloperidol_8\NN\3713736| (r_npadvmod) induced_10\VBN\1627355|NONE (r_amod) catalepsy_11\NN\14023236|,|,|blocker|.
D006220_D002375 CID haloperidol_19\NN\3713736|NONE (r_pobj) by_18\IN\0|that|usually|is (r_agent) induced_17\VBN\1627355|the (r_relcl) catalepsy_13\NN\14023236|.|,|injection
D006220_D002375 CID haloperidol_15\NN\3713736|such (r_pobj) as_14\IN\14622893|NONE (r_prep) neuroleptics_12\NNS\4470232|NONE (r_pobj) by_11\IN\0|that|is (r_agent) produced_10\VBN\1617192|the (r_relcl) catalepsy_7\NN\14023236|is|that|by|actually
D014150_D002375 NONE neuroleptic_25\RB\4470232| (r_amod) induced_27\VBN\1627355|NONE (r_amod) catalepsy_28\NN\14023236|NONE (r_pobj) of_24\IN\0|full (r_prep) expression_23\NN\4679549|NONE (r_pobj) for_21\IN\0|to|intact (r_prep) be_19\VB\14625458|that|mechanisms (r_xcomp) need_17\VBP\13920835|that|activation|and|catalepsy (r_conj) promotes_11\VBZ\2556126|previous (l_dobj) catalepsy_12\NN\14023236|that|need|activation|and
D014150_D002375 NONE neuroleptic_25\RB\4470232| (r_amod) induced_27\VBN\1627355|NONE (r_amod) catalepsy_28\NN\14023236|NONE
D014150_D002375 NONE neuroleptics_12\NNS\4470232|NONE (r_pobj) by_11\IN\0|that|is (r_agent) produced_10\VBN\1617192|the (r_relcl) catalepsy_7\NN\14023236|is|that|by|actually
D000109_D002375 NONE acetylcholine_4\NN\14807558| (r_compound) synthesis_6\NN\13446390|,|an|hemicholinium (r_compound) inhibitor_7\NN\20090|NONE (r_pobj) of_2\IN\0|Intracranial (r_prep) injection_1\NN\320852|.|catalepsy|, (r_nsubj) prevented_11\VBD\0|NONE (l_dobj) catalepsy_13\NN\14023236|.|,|injection
D010862_D002375 CID pilocarpine_6\NN\14712692|Large|of|,|, (r_appos) doses_1\NNS\3740161|catalepsy|blocked|.|could (r_nsubj) induce_9\VB\1627355|NONE (l_dobj) catalepsy_10\NN\14023236|blocked|.|doses|could
D010862_D002375 CID pilocarpine_3\NN\14712692|NONE (r_pobj) of_2\IN\0|Low (r_prep) doses_1\NNS\3740161|.|enhancement (r_nsubj) caused_4\VBD\1617192|NONE (l_dobj) enhancement_7\NN\248977|doses|. (l_prep) of_8\IN\0|pronounced|a (l_pobj) catalepsy_10\NN\14023236|NONE
D006426_D002375 NONE hemicholinium_9\NN\0|synthesis|,|an (r_appos) inhibitor_7\NN\20090|NONE (r_pobj) of_2\IN\0|Intracranial (r_prep) injection_1\NN\320852|.|catalepsy|, (r_nsubj) prevented_11\VBD\0|NONE (l_dobj) catalepsy_13\NN\14023236|.|,|injection
25084821
C069541_D008107 NONE quetiapine_23\NN\0|NONE (r_pobj) to_22\IN\0|adverse (r_prep) reaction_21\NN\13446390|NONE (r_pobj) for_19\IN\0|diagnostic|a (r_prep) marker_18\NN\21939|fever|may|. (r_attr) be_15\VB\14625458|one|dysfunction|and|,|may (r_conj) be_3\VB\14625458|NONE (l_nsubj) dysfunction_1\NN\14204950|one|and|be|,|may
C069541_D007970 CID quetiapine_7\NN\0|NONE (r_pobj) with_6\IN\0|being (r_prep) treated_5\VBN\2376958|NONE (r_pcomp) after_3\IN\0|leucopenia|.|She (r_prep) developed_1\VBD\1753788|NONE (l_dobj) leucopenia_2\JJ\14189204|.|She|after
C069541_D006528 NONE quetiapine_0\NNP\0|neutropenia||.|in (r_npadvmod) induced_2\VBN\1627355|NONE (l_prep) in_4\IN\13603305|neutropenia||.|Quetiapine (l_pobj) patient_7\NN\9898892|NONE (l_prep) with_8\IN\0|a|bipolar (l_pobj) carcinoma_10\NN\14239918|NONE
C069541_D006528 NONE quetiapine_14\NN\0|NONE (r_pobj) with_13\IN\0|NONE (r_prep) treatment_12\NN\654885|NONE (r_pobj) after_11\IN\0|that|neutropenia (r_prep) developed_9\VBD\1753788|with|a (r_relcl) patient_4\NN\9898892|NONE (l_prep) with_5\IN\0|a|developed (l_pobj) carcinoma_7\NN\14239918|NONE
C069541_D005334 CID quetiapine_23\NN\0|NONE (r_pobj) to_22\IN\0|adverse (r_prep) reaction_21\NN\13446390|NONE (r_pobj) for_19\IN\0|diagnostic|a (r_prep) marker_18\NN\21939|fever|may|. (r_attr) be_15\VB\14625458|one|dysfunction|and|,|may (l_nsubj) fever_13\NN\14299637|marker|may|.
C069541_D001714 NONE quetiapine_0\NNP\0|neutropenia||.|in (r_npadvmod) induced_2\VBN\1627355|NONE (l_prep) in_4\IN\13603305|neutropenia||.|Quetiapine (l_pobj) patient_7\NN\9898892|NONE (l_amod) bipolar_6\JJ\0|a|with
C069541_D009503 CID quetiapine_0\NNP\0|neutropenia||.|in (r_npadvmod) induced_2\VBN\1627355|NONE (l_dobj) neutropenia_3\NN\14196405||.|Quetiapine|in
C069541_D009503 CID quetiapine_1\NNP\0|has|.|derivative|: (r_nsubj) is_2\VBZ\0|NONE (l_advcl) has_12\VBZ\13888491|.|Quetiapine|derivative|: (l_dobj) risk_15\NN\14541044|which (l_prep) of_16\IN\0|highest|the (l_pcomp) causing_17\VBG\30358|NONE (l_dobj) dyscrasias_19\NNS\14052046|NONE (l_appos) neutropenia_22\NN\14196405|blood|,
C069541_D009503 CID quetiapine_14\NN\0|NONE (r_pobj) with_13\IN\0|NONE (r_prep) treatment_12\NN\654885|NONE (r_pobj) after_11\IN\0|that|neutropenia (r_prep) developed_9\VBD\1753788|with|a (l_dobj) neutropenia_10\NN\14196405|after|that
C069541_D009503 CID quetiapine_9\NN\0|NONE (r_pobj) of_8\IN\0|a|side|common (r_prep) effect_7\NN\34213|Although|not|neutropenia (r_attr) is_2\VBZ\0|cautious|.|should|,|physicians (l_nsubj) neutropenia_1\NN\14196405|Although|not|effect
D003024_D009503 NONE clozapine_9\NN\3713736|NONE (r_pobj) to_8\IN\0|NONE (r_prep) similar_7\JJ\0|dibenzothiazepine|,|,|a (r_amod) derivative_5\JJ\5802185|has|.|Quetiapine|: (r_attr) is_2\VBZ\0|NONE (l_advcl) has_12\VBZ\13888491|.|Quetiapine|derivative|: (l_dobj) risk_15\NN\14541044|which (l_prep) of_16\IN\0|highest|the (l_pcomp) causing_17\VBG\30358|NONE (l_dobj) dyscrasias_19\NNS\14052046|NONE (l_appos) neutropenia_22\NN\14196405|blood|,
D003024_D006402 NONE clozapine_9\NN\3713736|NONE (r_pobj) to_8\IN\0|NONE (r_prep) similar_7\JJ\0|dibenzothiazepine|,|,|a (r_amod) derivative_5\JJ\5802185|has|.|Quetiapine|: (r_attr) is_2\VBZ\0|NONE (l_advcl) has_12\VBZ\13888491|.|Quetiapine|derivative|: (l_dobj) risk_15\NN\14541044|which (l_prep) of_16\IN\0|highest|the (l_pcomp) causing_17\VBG\30358|NONE (l_dobj) dyscrasias_19\NNS\14052046|NONE
C069541_D006402 NONE quetiapine_1\NNP\0|has|.|derivative|: (r_nsubj) is_2\VBZ\0|NONE (l_advcl) has_12\VBZ\13888491|.|Quetiapine|derivative|: (l_dobj) risk_15\NN\14541044|which (l_prep) of_16\IN\0|highest|the (l_pcomp) causing_17\VBG\30358|NONE (l_dobj) dyscrasias_19\NNS\14052046|NONE
18341442
C026098_C562694 NONE levetiracetam_0\NNP\0|NONE (l_advcl) phenobarbital_5\JJ\2792049|as|. (l_dobj) treatment_6\NN\654885|to (l_prep) in_7\IN\13603305|NONE (l_pobj) cats_8\NNS\2120997|NONE (l_prep) with_9\IN\0|NONE (l_pobj) epilepsy_12\NN\14085708|NONE
C026098_C562694 NONE levetiracetam_10\NN\0|NONE (l_advcl) phenobarbital_16\JJ\2792049|assess|.|administered (l_dobj) treatment_17\NN\654885|to (l_prep) in_18\IN\13603305|NONE (l_pobj) cats_19\NNS\2120997|NONE (l_prep) with_20\IN\0|NONE (l_pobj) epilepsy_25\NN\14085708|NONE
C026098_C562694 NONE levetiracetam_3\NN\0|is|and|well|be|that|in (r_nsubjpass) tolerated_6\VBN\802318|.|Results (l_conj) be_11\VB\14625458|is|and|well|that|in|levetiracetam (l_acomp) useful_12\JJ\0|may (l_prep) as_13\IN\14622893|NONE (l_pobj) adjunct_15\NN\9312645|NONE (l_relcl) phenobarbital_17\JJ\2792049|an (l_dobj) treatment_18\NN\654885|to (l_prep) in_19\IN\13603305|NONE (l_pobj) cats_20\NNS\2120997|NONE (l_prep) with_21\IN\0|NONE (l_pobj) epilepsy_23\NN\14085708|NONE
C026098_D012640 NONE levetiracetam_7\NN\0|NONE (r_amod) treatment_8\NN\654885|NONE (r_pobj) of_6\IN\0|NONE (r_prep) initiation_5\NN\7450842|and|frequencies|were|,|recorded (r_nsubjpass) compared_10\VBN\644583|NONE (l_nsubjpass) frequencies_1\NNS\15286249|and|were|,|recorded|initiation (l_compound) seizure_0\NN\14081375|before
C026098_D012640 NONE levetiracetam_7\NN\0|NONE (r_pcomp) with_6\IN\0|NONE (r_prep) treatment_5\NN\654885|NONE (r_pobj) to_4\IN\0|NONE (r_prep) prior_3\RB\10675876|and|higher|classified|,|after|frequency (r_advmod) was_14\VBD\0|NONE (l_nsubj) frequency_2\NN\15286249|and|prior|higher|classified|,|after (l_compound) seizure_1\NN\14081375|Median
C026098_D012640 NONE levetiracetam_7\NN\0|NONE (l_appos) seizures_10\NNS\14081375|)|(
C026098_D012640 NONE levetiracetam_7\NN\0|NONE (r_pcomp) with_6\IN\0|NONE (r_prep) treatment_5\NN\654885|NONE (r_pobj) to_4\IN\0|NONE (r_prep) prior_3\RB\10675876|and|higher|classified|,|after|frequency (r_advmod) was_14\VBD\0|NONE (l_acomp) higher_16\JJR\0|and|prior|classified|,|after|frequency (l_prep) than_17\IN\0|significantly (l_pobj) frequency_20\NN\15286249|NONE (l_compound) seizure_19\NN\14081375|median
C026098_D012640 NONE levetiracetam_7\NN\0|NONE (r_pcomp) with_6\IN\0|NONE (r_prep) treatment_5\NN\654885|NONE (r_pobj) to_4\IN\0|NONE (r_prep) prior_3\RB\10675876|and|higher|classified|,|after|frequency (r_advmod) was_14\VBD\0|NONE (l_prep) after_21\IN\0|and|prior|higher|classified|,|frequency (l_pobj) initiation_22\NN\7450842|NONE (l_prep) of_23\IN\0|NONE (l_pobj) treatment_25\NN\654885|NONE (l_appos) seizures_28\NNS\14081375|levetiracetam
C026098_D012640 NONE levetiracetam_7\NN\0|NONE (r_pcomp) with_6\IN\0|NONE (r_prep) treatment_5\NN\654885|NONE (r_pobj) to_4\IN\0|NONE (r_prep) prior_3\RB\10675876|and|higher|classified|,|after|frequency (r_advmod) was_14\VBD\0|NONE (l_conj) classified_39\VBN\7249426|and|prior|higher|,|after|frequency (l_prep) as_40\IN\14622893|.|were|cats (l_pcomp) responded_42\VBN\2367363|NONE (l_attr) reduction_49\NN\351485|having|levetiracetam (l_prep) in_50\IN\13603305|)|,|ie|( (l_pobj) frequency_52\NN\15286249|NONE (l_compound) seizure_51\NN\14081375|of
C026098_D012640 NONE levetiracetam_24\NN\0|seizures (r_amod) treatment_25\NN\654885|NONE (r_pobj) of_23\IN\0|NONE (r_prep) initiation_22\NN\7450842|NONE (r_pobj) after_21\IN\0|and|prior|higher|classified|,|frequency (r_prep) was_14\VBD\0|NONE (l_nsubj) frequency_2\NN\15286249|and|prior|higher|classified|,|after (l_compound) seizure_1\NN\14081375|Median
C026098_D012640 NONE levetiracetam_24\NN\0|seizures (r_amod) treatment_25\NN\654885|NONE (r_pobj) of_23\IN\0|NONE (r_prep) initiation_22\NN\7450842|NONE (r_pobj) after_21\IN\0|and|prior|higher|classified|,|frequency (r_prep) was_14\VBD\0|NONE (l_advmod) prior_3\RB\10675876|and|higher|classified|,|after|frequency (l_prep) to_4\IN\0|NONE (l_pobj) treatment_5\NN\654885|NONE (l_prep) with_6\IN\0|NONE (l_pcomp) levetiracetam_7\NN\0|NONE (l_appos) seizures_10\NNS\14081375|)|(
C026098_D012640 NONE levetiracetam_24\NN\0|seizures (r_amod) treatment_25\NN\654885|NONE (r_pobj) of_23\IN\0|NONE (r_prep) initiation_22\NN\7450842|NONE (r_pobj) after_21\IN\0|and|prior|higher|classified|,|frequency (r_prep) was_14\VBD\0|NONE (l_acomp) higher_16\JJR\0|and|prior|classified|,|after|frequency (l_prep) than_17\IN\0|significantly (l_pobj) frequency_20\NN\15286249|NONE (l_compound) seizure_19\NN\14081375|median
C026098_D012640 NONE levetiracetam_24\NN\0|seizures (r_amod) treatment_25\NN\654885|NONE (l_appos) seizures_28\NNS\14081375|levetiracetam
C026098_D012640 NONE levetiracetam_24\NN\0|seizures (r_amod) treatment_25\NN\654885|NONE (r_pobj) of_23\IN\0|NONE (r_prep) initiation_22\NN\7450842|NONE (r_pobj) after_21\IN\0|and|prior|higher|classified|,|frequency (r_prep) was_14\VBD\0|NONE (l_conj) classified_39\VBN\7249426|and|prior|higher|,|after|frequency (l_prep) as_40\IN\14622893|.|were|cats (l_pcomp) responded_42\VBN\2367363|NONE (l_attr) reduction_49\NN\351485|having|levetiracetam (l_prep) in_50\IN\13603305|)|,|ie|( (l_pobj) frequency_52\NN\15286249|NONE (l_compound) seizure_51\NN\14081375|of
C026098_D012640 NONE levetiracetam_44\VB\0|reduction|having (r_xcomp) responded_42\VBN\2367363|NONE (r_pcomp) as_40\IN\14622893|.|were|cats (r_prep) classified_39\VBN\7249426|and|prior|higher|,|after|frequency (r_conj) was_14\VBD\0|NONE (l_nsubj) frequency_2\NN\15286249|and|prior|higher|classified|,|after (l_compound) seizure_1\NN\14081375|Median
C026098_D012640 NONE levetiracetam_44\VB\0|reduction|having (r_xcomp) responded_42\VBN\2367363|NONE (r_pcomp) as_40\IN\14622893|.|were|cats (r_prep) classified_39\VBN\7249426|and|prior|higher|,|after|frequency (r_conj) was_14\VBD\0|NONE (l_advmod) prior_3\RB\10675876|and|higher|classified|,|after|frequency (l_prep) to_4\IN\0|NONE (l_pobj) treatment_5\NN\654885|NONE (l_prep) with_6\IN\0|NONE (l_pcomp) levetiracetam_7\NN\0|NONE (l_appos) seizures_10\NNS\14081375|)|(
C026098_D012640 NONE levetiracetam_44\VB\0|reduction|having (r_xcomp) responded_42\VBN\2367363|NONE (r_pcomp) as_40\IN\14622893|.|were|cats (r_prep) classified_39\VBN\7249426|and|prior|higher|,|after|frequency (r_conj) was_14\VBD\0|NONE (l_acomp) higher_16\JJR\0|and|prior|classified|,|after|frequency (l_prep) than_17\IN\0|significantly (l_pobj) frequency_20\NN\15286249|NONE (l_compound) seizure_19\NN\14081375|median
C026098_D012640 NONE levetiracetam_44\VB\0|reduction|having (r_xcomp) responded_42\VBN\2367363|NONE (r_pcomp) as_40\IN\14622893|.|were|cats (r_prep) classified_39\VBN\7249426|and|prior|higher|,|after|frequency (r_conj) was_14\VBD\0|NONE (l_prep) after_21\IN\0|and|prior|higher|classified|,|frequency (l_pobj) initiation_22\NN\7450842|NONE (l_prep) of_23\IN\0|NONE (l_pobj) treatment_25\NN\654885|NONE (l_appos) seizures_28\NNS\14081375|levetiracetam
C026098_D012640 NONE levetiracetam_44\VB\0|reduction|having (r_xcomp) responded_42\VBN\2367363|NONE (l_attr) reduction_49\NN\351485|having|levetiracetam (l_prep) in_50\IN\13603305|)|,|ie|( (l_pobj) frequency_52\NN\15286249|NONE (l_compound) seizure_51\NN\14081375|of
D010634_C562694 NONE phenobarbital_5\JJ\2792049|as|. (l_dobj) treatment_6\NN\654885|to (l_prep) in_7\IN\13603305|NONE (l_pobj) cats_8\NNS\2120997|NONE (l_prep) with_9\IN\0|NONE (l_pobj) epilepsy_12\NN\14085708|NONE
D010634_C562694 NONE phenobarbital_16\JJ\2792049|assess|.|administered (l_dobj) treatment_17\NN\654885|to (l_prep) in_18\IN\13603305|NONE (l_pobj) cats_19\NNS\2120997|NONE (l_prep) with_20\IN\0|NONE (l_pobj) epilepsy_25\NN\14085708|NONE
D010634_C562694 NONE phenobarbital_12\JJ\2792049|NONE (r_pobj) with_11\IN\0|that|poorly|had|or|was (r_prep) controlled_10\VBN\0|idiopathic (r_relcl) epilepsy_6\NN\14085708|to
D010634_C562694 NONE phenobarbital_22\NN\2792049|NONE (r_pobj) with_21\IN\0|when (r_prep) treated_20\VBN\2376958|effects|that (r_advcl) had_15\VBD\0|that|poorly|or|with|was (r_conj) controlled_10\VBN\0|idiopathic (r_relcl) epilepsy_6\NN\14085708|to
D010634_C562694 NONE phenobarbital_17\JJ\2792049|an (l_dobj) treatment_18\NN\654885|to (l_prep) in_19\IN\13603305|NONE (l_pobj) cats_20\NNS\2120997|NONE (l_prep) with_21\IN\0|NONE (l_pobj) epilepsy_23\NN\14085708|NONE
24341598
D012965_D007674 NONE chloride_6\NN\14818238|NONE (r_pobj) of_3\IN\0|with (r_prep) effects_2\NNS\13245626|NONE (l_prep) with_7\IN\0|of (l_pobj) diltiazem_8\NN\2938514|NONE (l_prep) in_9\IN\13603305|NONE (l_pobj) prevention_10\NN\1073995|NONE (l_prep) of_11\IN\0|NONE (l_pobj) nephropathy_15\NN\14573196|NONE
D003287_D058186 CID contrast_25\NN\13854649|NONE (r_amod) material_26\NN\19613|(|was|%|)|after (r_nsubjpass) injected_28\VBN\81072|,|on|patients|.|failure|Among (r_advcl) developed_13\VBD\1753788|NONE (l_dobj) failure_16\NN\66216|,|on|patients|.|injected|Among
D003287_D058186 CID contrast_25\NN\13854649|NONE (r_amod) material_26\NN\19613|(|was|%|)|after (r_nsubjpass) injected_28\VBN\81072|,|on|patients|.|failure|Among (r_advcl) developed_13\VBD\1753788|NONE (l_dobj) failure_16\NN\66216|,|on|patients|.|injected|Among (l_appos) arf_18\NNP\0|(|)|renal|acute
D004110_D007674 NONE diltiazem_8\NN\2938514|NONE (l_prep) in_9\IN\13603305|NONE (l_pobj) prevention_10\NN\1073995|NONE (l_prep) of_11\IN\0|NONE (l_pobj) nephropathy_15\NN\14573196|NONE
D003287_D007674 NONE contrast_12\NN\13854649| (r_npadvmod) induced_14\VBN\1627355|NONE (r_amod) nephropathy_15\NN\14573196|NONE
D003287_D007674 NONE contrast_0\RB\13854649| (r_npadvmod) induced_2\VBN\1627355|CIN (r_amod) nephropathy_3\NN\14573196|.|morbidity|significantly
17028363
D004008_D058186 CID diclofenac_20\NN\0|inflammatory|steroidal|,|a (r_appos) drug_18\NN\14778436|NONE (r_pobj) of_10\IN\0|concomitant|the (r_prep) intake_9\NN\13440063|NONE (r_pobj) by_6\IN\0|injury|.|probably|was (r_agent) aggravated_5\VBN\126264|NONE (l_nsubjpass) injury_2\NN\14052046|.|probably|was|by
D000880_D058186 NONE anthraquinones_11\NNS\0|NONE (r_dobj) containing_10\VBG\2632940|slimming (r_acl) pills_9\NNS\4424218|NONE (r_pobj) of_7\IN\0|prolonged (r_prep) intake_6\NN\13440063|NONE (r_pobj) with_4\IN\0|NONE (r_prep) associated_3\VBN\628491|.|Acute|renal (r_acl) failure_2\NN\66216|NONE
D000880_D058186 NONE anthraquinone_24\NN\0|NONE (r_compound) derivatives_25\NNS\5802185|that (r_dobj) contained_23\VBD\2632940|Chinese|a|,|herbal|slimming|proprietary (r_relcl) pill_21\NN\4424218|NONE (r_pobj) of_15\IN\0|prolonged|extracted (r_prep) use_14\NN\407535|NONE (r_pobj) following_12\VBG\8180190|who|failure (r_prep) developed_8\VBD\1753788|a|old (l_dobj) failure_11\NN\66216|who|following
D000880_D058186 NONE anthraquinone_9\NN\0| (r_npadvmod) containing_11\VBG\2632940|herbal|injury|an|and (r_amod) agent_13\NN\7347|NONE (l_conj) injury_16\NN\14052046|herbal|an|and|containing
D000880_D051437 NONE anthraquinone_9\NN\0| (r_npadvmod) containing_11\VBG\2632940|herbal|injury|an|and (r_amod) agent_13\NN\7347|NONE (r_pobj) of_7\IN\0|the (r_prep) use_6\NN\407535|NONE (r_pobj) between_4\IN\0|causal|a (r_prep) relationship_3\NN\31921|Although|proven (r_nsubj) remains_17\VBZ\2684|nephropathy|be|.|in|,|should (r_advcl) considered_29\VBN\689344|NONE (l_prep) in_30\IN\13603305|nephropathy|remains|be|.|,|should (l_pobj) patients_31\NNS\9898892|NONE (l_relcl) present_33\VBP\28270|NONE (l_prep) with_34\IN\0|who (l_pobj) failure_37\NN\66216|NONE
D034341_D007674 NONE acids_16\NNS\14818238|NONE (r_pobj) of_14\IN\0|the (r_prep) use_13\NN\407535|usually (r_dobj) involving_11\VBG\2676054|,|been|Nephropathy|has|previously|. (r_advcl) reported_8\VBN\831651|NONE (l_nsubjpass) nephropathy_0\NNP\14573196|,|been|has|previously|involving|.
D004365_D007674 NONE herbs_4\NNS\13083586|NONE (r_pobj) by_2\IN\0|NONE (r_agent) caused_1\VBN\1617192|NONE (r_acl) nephropathy_0\NNP\14573196|,|been|has|previously|involving|.
D004365_D058186 CID herbal_19\JJ\7933274|Chinese|a|,|slimming|contained|proprietary (r_amod) pill_21\NN\4424218|NONE (r_pobj) of_15\IN\0|prolonged|extracted (r_prep) use_14\NN\407535|NONE (r_pobj) following_12\VBG\8180190|who|failure (r_prep) developed_8\VBD\1753788|a|old (l_dobj) failure_11\NN\66216|who|following
D000880_D007674 NONE anthraquinone_9\NN\0| (r_npadvmod) containing_11\VBG\2632940|herbal|injury|an|and (r_amod) agent_13\NN\7347|NONE (r_pobj) of_7\IN\0|the (r_prep) use_6\NN\407535|NONE (r_pobj) between_4\IN\0|causal|a (r_prep) relationship_3\NN\31921|Although|proven (r_nsubj) remains_17\VBZ\2684|nephropathy|be|.|in|,|should (r_advcl) considered_29\VBN\689344|NONE (l_nsubjpass) nephropathy_26\NN\14573196|remains|be|.|in|,|should
24911645
D005680_D012640 NONE acid_36\NN\14818238|amino (r_appos) acid_31\NN\14818238|NONE (r_pobj) on_29\IN\0|its (r_prep) effects_28\NNS\13245626|and|anticonvulsant|their (r_conj) activity_25\NN\30358|to (r_dobj) determine_22\VB\0|effects|to (r_advcl) evaluate_5\VB\670261|NONE (l_dobj) effects_8\NNS\13245626|determine|to (l_prep) at_9\IN\14622893|GFC|the (l_pobj) doses_10\NNS\3740161|NONE (l_prep) on_18\IN\0|of (l_pobj) parameters_20\NNS\5858936|NONE (l_compound) seizure_19\NN\14081375|NONE
D005680_D012640 NONE acid_36\NN\14818238|amino (r_appos) acid_31\NN\14818238|NONE (r_pobj) on_29\IN\0|its (r_prep) effects_28\NNS\13245626|and|anticonvulsant|their (r_conj) activity_25\NN\30358|to (r_dobj) determine_22\VB\0|effects|to (r_advcl) evaluate_5\VB\670261|NONE (r_xcomp) aimed_3\VBN\1987160|The|present|) (r_acl) study_2\NN\635850|as|on|. (r_nsubj) levels_47\NNS\4916342|NONE (l_prep) on_51\IN\0|study|as|. (l_pobj) acetylcholinesterase_52\NN\0|NONE (l_appos) activity_56\NN\30358|AChE|(|) (l_prep) in_57\IN\13603305|NONE (l_pobj) hippocampus_59\NN\5462674|NONE (l_prep) after_60\IN\0|mice (l_pobj) seizures_61\NNS\14081375|NONE
D005680_D012640 NONE gaba_38\NNP\14601829|,|aminobutyric|(|glutamine (r_appos) acid_36\NN\14818238|amino (r_appos) acid_31\NN\14818238|NONE (r_pobj) on_29\IN\0|its (r_prep) effects_28\NNS\13245626|and|anticonvulsant|their (r_conj) activity_25\NN\30358|to (r_dobj) determine_22\VB\0|effects|to (r_advcl) evaluate_5\VB\670261|NONE (l_dobj) effects_8\NNS\13245626|determine|to (l_prep) at_9\IN\14622893|GFC|the (l_pobj) doses_10\NNS\3740161|NONE (l_prep) on_18\IN\0|of (l_pobj) parameters_20\NNS\5858936|NONE (l_compound) seizure_19\NN\14081375|NONE
D005680_D012640 NONE gaba_38\NNP\14601829|,|aminobutyric|(|glutamine (r_appos) acid_36\NN\14818238|amino (r_appos) acid_31\NN\14818238|NONE (r_pobj) on_29\IN\0|its (r_prep) effects_28\NNS\13245626|and|anticonvulsant|their (r_conj) activity_25\NN\30358|to (r_dobj) determine_22\VB\0|effects|to (r_advcl) evaluate_5\VB\670261|NONE (r_xcomp) aimed_3\VBN\1987160|The|present|) (r_acl) study_2\NN\635850|as|on|. (r_nsubj) levels_47\NNS\4916342|NONE (l_prep) on_51\IN\0|study|as|. (l_pobj) acetylcholinesterase_52\NN\0|NONE (l_appos) activity_56\NN\30358|AChE|(|) (l_prep) in_57\IN\13603305|NONE (l_pobj) hippocampus_59\NN\5462674|NONE (l_prep) after_60\IN\0|mice (l_pobj) seizures_61\NNS\14081375|NONE
D010862_D013226 CID pilocarpine_16\NN\14712692| (r_npadvmod) induced_18\VBN\1627355|NONE (r_amod) status_19\NN\24720|NONE (r_pobj) of_15\IN\0|NONE (r_prep) installation_14\NN\235435|NONE (r_pobj) of_13\IN\0|the (r_prep) frequency_12\NN\15286249|epilepticus|demonstrated|, (r_dobj) reduce_10\VB\441445|and|activity|GFC|can|that (l_advmod) epilepticus_20\NN\0|demonstrated|,|frequency
D005978_D012640 NONE glutathione_45\NN\0|and (r_conj) aspartate_43\NN\0|, (r_conj) glutamine_41\NN\14601829|GABA|,|aminobutyric|( (r_appos) acid_36\NN\14818238|amino (r_appos) acid_31\NN\14818238|NONE (r_pobj) on_29\IN\0|its (r_prep) effects_28\NNS\13245626|and|anticonvulsant|their (r_conj) activity_25\NN\30358|to (r_dobj) determine_22\VB\0|effects|to (r_advcl) evaluate_5\VB\670261|NONE (l_dobj) effects_8\NNS\13245626|determine|to (l_prep) at_9\IN\14622893|GFC|the (l_pobj) doses_10\NNS\3740161|NONE (l_prep) on_18\IN\0|of (l_pobj) parameters_20\NNS\5858936|NONE (l_compound) seizure_19\NN\14081375|NONE
D005978_D012640 NONE glutathione_45\NN\0|and (r_conj) aspartate_43\NN\0|, (r_conj) glutamine_41\NN\14601829|GABA|,|aminobutyric|( (r_appos) acid_36\NN\14818238|amino (r_appos) acid_31\NN\14818238|NONE (r_pobj) on_29\IN\0|its (r_prep) effects_28\NNS\13245626|and|anticonvulsant|their (r_conj) activity_25\NN\30358|to (r_dobj) determine_22\VB\0|effects|to (r_advcl) evaluate_5\VB\670261|NONE (r_xcomp) aimed_3\VBN\1987160|The|present|) (r_acl) study_2\NN\635850|as|on|. (r_nsubj) levels_47\NNS\4916342|NONE (l_prep) on_51\IN\0|study|as|. (l_pobj) acetylcholinesterase_52\NN\0|NONE (l_appos) activity_56\NN\30358|AChE|(|) (l_prep) in_57\IN\13603305|NONE (l_pobj) hippocampus_59\NN\5462674|NONE (l_prep) after_60\IN\0|mice (l_pobj) seizures_61\NNS\14081375|NONE
D000596_D012640 NONE acid_31\NN\14818238|NONE (r_pobj) on_29\IN\0|its (r_prep) effects_28\NNS\13245626|and|anticonvulsant|their (r_conj) activity_25\NN\30358|to (r_dobj) determine_22\VB\0|effects|to (r_advcl) evaluate_5\VB\670261|NONE (l_dobj) effects_8\NNS\13245626|determine|to (l_prep) at_9\IN\14622893|GFC|the (l_pobj) doses_10\NNS\3740161|NONE (l_prep) on_18\IN\0|of (l_pobj) parameters_20\NNS\5858936|NONE (l_compound) seizure_19\NN\14081375|NONE
D000596_D012640 NONE acid_31\NN\14818238|NONE (r_pobj) on_29\IN\0|its (r_prep) effects_28\NNS\13245626|and|anticonvulsant|their (r_conj) activity_25\NN\30358|to (r_dobj) determine_22\VB\0|effects|to (r_advcl) evaluate_5\VB\670261|NONE (r_xcomp) aimed_3\VBN\1987160|The|present|) (r_acl) study_2\NN\635850|as|on|. (r_nsubj) levels_47\NNS\4916342|NONE (l_prep) on_51\IN\0|study|as|. (l_pobj) acetylcholinesterase_52\NN\0|NONE (l_appos) activity_56\NN\30358|AChE|(|) (l_prep) in_57\IN\13603305|NONE (l_pobj) hippocampus_59\NN\5462674|NONE (l_prep) after_60\IN\0|mice (l_pobj) seizures_61\NNS\14081375|NONE
C573355_D013226 NONE gfc_4\NNP\0|and|activity|can|that|reduce (r_nsubj) exert_6\VB\1158872|results|. (l_conj) reduce_10\VB\441445|and|activity|GFC|can|that (l_advmod) epilepticus_20\NN\0|demonstrated|,|frequency
D018698_D012640 NONE glutamine_41\NN\14601829|GABA|,|aminobutyric|( (r_appos) acid_36\NN\14818238|amino (r_appos) acid_31\NN\14818238|NONE (r_pobj) on_29\IN\0|its (r_prep) effects_28\NNS\13245626|and|anticonvulsant|their (r_conj) activity_25\NN\30358|to (r_dobj) determine_22\VB\0|effects|to (r_advcl) evaluate_5\VB\670261|NONE (l_dobj) effects_8\NNS\13245626|determine|to (l_prep) at_9\IN\14622893|GFC|the (l_pobj) doses_10\NNS\3740161|NONE (l_prep) on_18\IN\0|of (l_pobj) parameters_20\NNS\5858936|NONE (l_compound) seizure_19\NN\14081375|NONE
D018698_D012640 NONE glutamine_41\NN\14601829|GABA|,|aminobutyric|( (r_appos) acid_36\NN\14818238|amino (r_appos) acid_31\NN\14818238|NONE (r_pobj) on_29\IN\0|its (r_prep) effects_28\NNS\13245626|and|anticonvulsant|their (r_conj) activity_25\NN\30358|to (r_dobj) determine_22\VB\0|effects|to (r_advcl) evaluate_5\VB\670261|NONE (r_xcomp) aimed_3\VBN\1987160|The|present|) (r_acl) study_2\NN\635850|as|on|. (r_nsubj) levels_47\NNS\4916342|NONE (l_prep) on_51\IN\0|study|as|. (l_pobj) acetylcholinesterase_52\NN\0|NONE (l_appos) activity_56\NN\30358|AChE|(|) (l_prep) in_57\IN\13603305|NONE (l_pobj) hippocampus_59\NN\5462674|NONE (l_prep) after_60\IN\0|mice (l_pobj) seizures_61\NNS\14081375|NONE
D010862_D012640 CID pilocarpine_11\NN\14712692| (r_npadvmod) induced_13\VBN\1627355|NONE (r_amod) seizures_14\NNS\14081375|NONE
D010862_D012640 CID pilocarpine_16\NN\14712692| (r_npadvmod) induced_18\VBN\1627355|NONE (r_amod) status_19\NN\24720|NONE (r_pobj) of_15\IN\0|NONE (r_prep) installation_14\NN\235435|NONE (r_pobj) of_13\IN\0|the (r_prep) frequency_12\NN\15286249|epilepticus|demonstrated|, (r_dobj) reduce_10\VB\441445|and|activity|GFC|can|that (l_advcl) demonstrated_23\VBN\2137132|epilepticus|,|frequency (l_agent) by_24\IN\0|as (l_pobj) increase_25\NN\13576355|NONE (l_prep) to_28\IN\0|and|decrease|in (l_pobj) seizure_30\NN\14081375|NONE
C573355_D012640 NONE fc_9\NNP\0|NONE (r_pobj) with_7\IN\0|in (r_prep) pretreated_6\VBN\0|Behavioral|.|in (l_prep) in_10\IN\13603305|with (l_pobj) seizures_14\NNS\14081375|NONE
C573355_D012640 NONE gfc_7\NNP\0|at|the (r_compound) effects_8\NNS\13245626|determine|to (l_prep) at_9\IN\14622893|GFC|the (l_pobj) doses_10\NNS\3740161|NONE (l_prep) on_18\IN\0|of (l_pobj) parameters_20\NNS\5858936|NONE (l_compound) seizure_19\NN\14081375|NONE
C573355_D012640 NONE gfc_7\NNP\0|at|the (r_compound) effects_8\NNS\13245626|determine|to (r_dobj) evaluate_5\VB\670261|NONE (r_xcomp) aimed_3\VBN\1987160|The|present|) (r_acl) study_2\NN\635850|as|on|. (r_nsubj) levels_47\NNS\4916342|NONE (l_prep) on_51\IN\0|study|as|. (l_pobj) acetylcholinesterase_52\NN\0|NONE (l_appos) activity_56\NN\30358|AChE|(|) (l_prep) in_57\IN\13603305|NONE (l_pobj) hippocampus_59\NN\5462674|NONE (l_prep) after_60\IN\0|mice (l_pobj) seizures_61\NNS\14081375|NONE
C573355_D012640 NONE gfc_0\NNP\0|,|.|kg|latency|at (r_nsubj) produced_1\VBD\1617192|NONE (l_dobj) latency_4\NN\15269513|,|.|kg|GFC|at (l_prep) to_5\IN\0|increased|an (l_pobj) seizure_7\NN\14081375|NONE
C573355_D012640 NONE gfc_4\NNP\0|and|activity|can|that|reduce (r_nsubj) exert_6\VB\1158872|results|. (l_conj) reduce_10\VB\441445|and|activity|GFC|can|that (l_advcl) demonstrated_23\VBN\2137132|epilepticus|,|frequency (l_agent) by_24\IN\0|as (l_pobj) increase_25\NN\13576355|NONE (l_prep) to_28\IN\0|and|decrease|in (l_pobj) seizure_30\NN\14081375|NONE
D001224_D012640 NONE aspartate_43\NN\0|, (r_conj) glutamine_41\NN\14601829|GABA|,|aminobutyric|( (r_appos) acid_36\NN\14818238|amino (r_appos) acid_31\NN\14818238|NONE (r_pobj) on_29\IN\0|its (r_prep) effects_28\NNS\13245626|and|anticonvulsant|their (r_conj) activity_25\NN\30358|to (r_dobj) determine_22\VB\0|effects|to (r_advcl) evaluate_5\VB\670261|NONE (l_dobj) effects_8\NNS\13245626|determine|to (l_prep) at_9\IN\14622893|GFC|the (l_pobj) doses_10\NNS\3740161|NONE (l_prep) on_18\IN\0|of (l_pobj) parameters_20\NNS\5858936|NONE (l_compound) seizure_19\NN\14081375|NONE
D001224_D012640 NONE aspartate_43\NN\0|, (r_conj) glutamine_41\NN\14601829|GABA|,|aminobutyric|( (r_appos) acid_36\NN\14818238|amino (r_appos) acid_31\NN\14818238|NONE (r_pobj) on_29\IN\0|its (r_prep) effects_28\NNS\13245626|and|anticonvulsant|their (r_conj) activity_25\NN\30358|to (r_dobj) determine_22\VB\0|effects|to (r_advcl) evaluate_5\VB\670261|NONE (r_xcomp) aimed_3\VBN\1987160|The|present|) (r_acl) study_2\NN\635850|as|on|. (r_nsubj) levels_47\NNS\4916342|NONE (l_prep) on_51\IN\0|study|as|. (l_pobj) acetylcholinesterase_52\NN\0|NONE (l_appos) activity_56\NN\30358|AChE|(|) (l_prep) in_57\IN\13603305|NONE (l_pobj) hippocampus_59\NN\5462674|NONE (l_prep) after_60\IN\0|mice (l_pobj) seizures_61\NNS\14081375|NONE
1905439
D016595_D006261 NONE misoprostol_0\NNP\0|.|been|with|has (r_nsubjpass) associated_3\VBN\628491|NONE (l_prep) with_4\IN\0|.|been|has|Misoprostol (l_pobj) reactions_6\NNS\13446390|NONE (l_prep) including_8\VBG\0|,|adverse (l_pobj) symptoms_10\NNS\5823932|NONE (l_conj) problems_13\NNS\14408086|,|gastrointestinal (l_conj) headache_16\NN\5829480|,|and|gynecologic
D016595_D003693 CID misoprostol_10\NNP\0|NONE (r_pobj) of_9\IN\0|NONE (r_prep) administration_8\NN\1133281|NONE (r_pobj) with_7\IN\0|possibly (r_prep) associated_6\VBN\628491|elderly|an (r_acl) woman_4\NN\9605289|NONE (r_pobj) in_1\IN\13603305|. (r_prep) delirium_0\NN\14391660|NONE
D016595_D003693 CID misoprostol_5\NNP\0|was|after|returned|and (r_nsubjpass) discontinued_7\VBN\0|.|significantly|delirium (r_advcl) improved_3\VBD\126264|NONE (l_nsubj) delirium_1\NN\14391660|.|significantly|discontinued
D016595_D003693 CID misoprostol_20\NNP\0|NONE (r_compound) therapy_21\NN\657604|NONE (r_pobj) from_19\IN\0|.|possibly|delirium|changed|, (r_prep) resulted_18\VBD\2633881|NONE (l_nsubj) delirium_12\NN\14391660|.|possibly|from|changed|,
12059909
D003520_D006470 CID cy_1\NNP\0|Early (r_compound) toxicity_2\NN\13576101|.|cystitis (r_nsubj) caused_3\VBD\1617192|NONE (l_dobj) cystitis_7\NN\14566129|.|toxicity (l_amod) haemorrhagic_6\JJ\0|typical|repaired|a|in
D003520_D064420 NONE cyclophosphamide_3\NN\0|NONE (r_pobj) of_2\IN\0|NONE (r_prep) toxicity_1\NN\13576101|on|.
D003520_D064420 NONE cy_1\NNP\0|Early (r_compound) toxicity_2\NN\13576101|.|cystitis
D003520_D064420 NONE cy_7\NNP\0|NONE (r_pobj) of_6\IN\0|delayed|in (r_prep) toxicity_5\NN\13576101|pathology
D003520_D003556 CID cy_1\NNP\0|Early (r_compound) toxicity_2\NN\13576101|.|cystitis (r_nsubj) caused_3\VBD\1617192|NONE (l_dobj) cystitis_7\NN\14566129|.|toxicity
D003520_D003556 CID cy_4\NNP\0|ulcerous (r_compound) injection_5\NN\320852|NONE (r_pobj) of_3\IN\0| (r_prep) days_2\NNS\15140892|NONE (r_pobj) after_0\IN\0|in|.|forms|but|% (r_prep) appeared_15\VBD\2604760|NONE (l_nsubj) forms_11\NNS\6286395|in|After|.|but|% (l_prep) of_12\IN\0|ulcerous (l_pobj) cystitis_14\NN\14566129|NONE
26002693
C031763_D015464 NONE 1,3-butadiene_0\CD\0|NONE (l_conj) cml_2\NNP\0|:|,
C031763_D015464 NONE 1,3-butadiene_3\CD\0|NONE (r_pobj) of_2\IN\0|Epidemiological (r_prep) studies_1\NNS\635850|.|associated|have (r_nsubj) suggest_5\VBN\1010118|NONE (l_ccomp) associated_11\VBN\628491|studies|.|have (l_prep) with_12\IN\0|are|exposures|that (l_pobj) leukemia_15\NN\14239918|NONE
C031763_D015464 NONE 1,3-butadiene_3\CD\0|NONE (r_pobj) of_2\IN\0|Epidemiological (r_prep) studies_1\NNS\635850|.|associated|have (r_nsubj) suggest_5\VBN\1010118|NONE (l_ccomp) associated_11\VBN\628491|studies|.|have (l_prep) with_12\IN\0|are|exposures|that (l_pobj) leukemia_15\NN\14239918|NONE (l_appos) cml_17\NNP\0|myeloid|)|(|chronic
3289726
D005047_D009422 NONE etoposide_7\NN\0|dose|for (r_compound) therapy_8\NN\657604|NONE (r_pobj) after_3\IN\0|Acute|neurologic|. (r_prep) dysfunction_2\NN\14204950|NONE
D005047_D009369 NONE etoposide_0\NNP\0|been|.|has|in (r_nsubjpass) used_8\VBN\0|NONE (l_prep) in_9\IN\13603305|been|.|has|Etoposide (l_pobj) treatment_11\NN\654885|NONE (l_prep) of_12\IN\0|the (l_pobj) tumors_15\NNS\14234074|NONE
D005047_D009369 NONE 213_4\CD\0|VP (r_punct) )_5\-RRB-\0|NONE (r_punct) etoposide_0\NNP\0|been|.|has|in (r_nsubjpass) used_8\VBN\0|NONE (l_prep) in_9\IN\13603305|been|.|has|Etoposide (l_pobj) treatment_11\NN\654885|NONE (l_prep) of_12\IN\0|the (l_pobj) tumors_15\NNS\14234074|NONE
D005047_D064420 NONE etoposide_13\NN\0|for|dose (r_compound) therapy_14\NN\657604|NONE (r_pobj) of_9\IN\0|a|significant|new (r_prep) toxicity_8\NN\13576101|to
D005047_D019337 NONE etoposide_0\NNP\0|been|.|has|in (r_nsubjpass) used_8\VBN\0|NONE (l_prep) in_9\IN\13603305|been|.|has|Etoposide (l_pobj) treatment_11\NN\654885|NONE (l_prep) of_12\IN\0|the (l_pobj) tumors_15\NNS\14234074|NONE (l_conj) malignancies_18\NNS\14070360|and|solid|many
D005047_D019337 NONE 213_4\CD\0|VP (r_punct) )_5\-RRB-\0|NONE (r_punct) etoposide_0\NNP\0|been|.|has|in (r_nsubjpass) used_8\VBN\0|NONE (l_prep) in_9\IN\13603305|been|.|has|Etoposide (l_pobj) treatment_11\NN\654885|NONE (l_prep) of_12\IN\0|the (l_pobj) tumors_15\NNS\14234074|NONE (l_conj) malignancies_18\NNS\14070360|and|solid|many
D005047_D005910 NONE etoposide_7\NN\0|dose|for (r_compound) therapy_8\NN\657604|NONE (l_prep) for_9\IN\0|etoposide|dose (l_pobj) glioma_11\NN\14236743|NONE
D005047_D005910 NONE etoposide_13\NN\0|for|dose (r_compound) therapy_14\NN\657604|NONE (l_prep) for_15\IN\0|etoposide|dose (l_pobj) glioma_17\NN\14236743|NONE
1615846
D008148_D006949 NONE lovastatin_32\NN\3676175|in|label (r_amod) treatment_33\NN\654885|had|,|of|and|efficacy (l_prep) in_34\IN\13603305|label|lovastatin (l_pobj) patients_36\NNS\9898892|NONE (l_prep) with_37\IN\0| (l_pobj) hyperlipidemia_40\NN\14299637|NONE
D015248_D006949 NONE gemfibrozil_30\NN\3740161| (r_compound) lovastatin_32\NN\3676175|in|label (r_amod) treatment_33\NN\654885|had|,|of|and|efficacy (l_prep) in_34\IN\13603305|label|lovastatin (l_pobj) patients_36\NNS\9898892|NONE (l_prep) with_37\IN\0| (l_pobj) hyperlipidemia_40\NN\14299637|NONE
D015248_D006951 NONE gemfibrozil_0\NNP\3740161| (r_compound) lovastatin_2\NN\3676175|for|. (r_amod) therapy_3\NN\657604|NONE (l_prep) for_4\IN\0|lovastatin|. (l_pobj) hyperlipoproteinemias_6\NNS\14084502|NONE
D008148_D002340 NONE lovastatin_32\NN\3676175|in|label (r_amod) treatment_33\NN\654885|had|,|of|and|efficacy (r_conj) safety_12\NN\13920835|to (l_relcl) had_46\VBD\0|,|treatment|of|and|efficacy (l_dobj) disease_49\NN\14061805|%
D015248_D002340 NONE gemfibrozil_30\NN\3740161| (r_compound) lovastatin_32\NN\3676175|in|label (r_amod) treatment_33\NN\654885|had|,|of|and|efficacy (r_conj) safety_12\NN\13920835|to (l_relcl) had_46\VBD\0|,|treatment|of|and|efficacy (l_dobj) disease_49\NN\14061805|%
D008148_D006951 NONE lovastatin_2\NN\3676175|for|. (r_amod) therapy_3\NN\657604|NONE (l_prep) for_4\IN\0|lovastatin|. (l_pobj) hyperlipoproteinemias_6\NNS\14084502|NONE
D003401_D012206 NONE creatine_28\NN\14601829|concurrent (r_compound) phosphokinase_29\NN\0|NONE (r_pobj) with_25\IN\0|liter| (r_prep) %_24\NN\0|NONE (r_pobj) in_22\IN\13603305|.|patients|rhabdomyolysis|; (r_prep) had_39\VBD\0|,|Myositis|in|and (l_dobj) rhabdomyolysis_40\NN\0|.|in|patients|;
D003401_D009212 NONE creatine_28\NN\14601829|concurrent (r_compound) phosphokinase_29\NN\0|NONE (r_pobj) with_25\IN\0|liter| (r_prep) %_24\NN\0|NONE (r_pobj) in_22\IN\13603305|.|patients|rhabdomyolysis|; (r_prep) had_39\VBD\0|,|Myositis|in|and (l_dobj) rhabdomyolysis_40\NN\0|.|in|patients|; (l_conj) myoglobinuria_42\NNS\14299637|or
D003401_D009220 NONE creatine_28\NN\14601829|concurrent (r_compound) phosphokinase_29\NN\0|NONE (r_pobj) with_25\IN\0|liter| (r_prep) %_24\NN\0|NONE (r_pobj) in_22\IN\13603305|.|patients|rhabdomyolysis|; (r_prep) had_39\VBD\0|,|Myositis|in|and (r_conj) occurred_14\VBD\0|NONE (l_nsubj) myositis_0\NNP\14336539|had|,|in|and
17384765
D007854_D019958 CID pb_0\NNP\14625458|NONE (r_amod) exposure_1\NN\5042871|.|impairments|paralleling (r_nsubj) produced_2\VBD\1617192|NONE (l_dobj) impairments_4\NNS\7296428|.|paralleling|exposure (l_prep) in_5\IN\13603305|lasting (l_pobj) learning_6\NN\5701944|NONE (l_conj) attention_8\NN\5701944|, (l_conj) control_11\NN\5190804|, (l_conj) regulation_15\NN\6652242|,|inhibitory|and
D007854_D019958 CID pb_24\NNP\14625458| (r_npadvmod) exposed_26\VBN\2110927|NONE (r_amod) children_27\NNS\9622049|NONE (r_pobj) in_23\IN\13603305|NONE (r_prep) seen_22\VBN\2106506|NONE (r_acl) dysfunction_21\NN\14204950|NONE (r_pobj) of_20\IN\0|the (r_prep) areas_19\NNS\8630985|NONE (r_dobj) paralleling_17\VBG\2657219|.|impairments|exposure (r_advcl) produced_2\VBD\1617192|NONE (l_dobj) impairments_4\NNS\7296428|.|paralleling|exposure (l_prep) in_5\IN\13603305|lasting (l_pobj) learning_6\NN\5701944|NONE (l_conj) attention_8\NN\5701944|, (l_conj) control_11\NN\5190804|, (l_conj) regulation_15\NN\6652242|,|inhibitory|and
D007854_D007855 NONE pb_17\NNP\14625458|and|agent|with|,|treatment (r_compound) exposure_18\NN\5042871|model (l_appos) agent_28\NN\7347|Pb|and|with|,|treatment (l_prep) for_29\IN\0|chelating|a|used (l_pobj) treatment_31\NN\654885|NONE (l_prep) of_32\IN\0|the (l_pobj) poisoning_34\NN\14034177|NONE
D007854_D003072 NONE lead_11\NN\5155821| (r_npadvmod) exposed_13\VBN\2110927|NONE (r_amod) rats_14\NNS\2329401|NONE (r_pobj) in_10\IN\13603305|arousal (r_prep) regulation_9\NN\6652242|and|, (r_conj) attention_5\NN\5701944|, (r_conj) learning_3\VBG\5701944|produces|.|but|chelation (r_xcomp) improves_2\VBZ\126264|NONE (l_conj) produces_16\VBZ\7555863|learning|.|but|chelation (l_dobj) impairment_19\NN\7296428|in
D007854_D003072 NONE lead_24\JJ\5155821|NONE (r_amod) exposure_25\NN\5042871|NONE (r_pobj) of_23\IN\0|the (r_prep) absence_22\NN\14449405|NONE (r_pobj) in_20\IN\13603305|impairment (r_prep) produces_16\VBZ\7555863|learning|.|but|chelation (l_dobj) impairment_19\NN\7296428|in
D007854_D003072 NONE pb_11\NNP\14625458|NONE (r_pobj) to_10\IN\0|previously|not (r_prep) exposed_9\VBN\2110927|succimer|of (r_acl) treatment_4\NN\654885|,|In|dysfunction|. (r_nsubj) produced_12\VBD\1617192|NONE (l_dobj) dysfunction_19\NN\14204950|,|treatment|In|.
D007854_D003072 NONE pb_29\NNP\14625458|the|exposure|higher (r_compound) regimen_31\NN\5898568|NONE (r_pobj) by_26\IN\0|NONE (r_agent) produced_25\VBN\1617192|NONE (r_acl) that_24\DT\0|NONE (r_pobj) to_23\IN\0|NONE (r_prep) magnitude_22\NN\4916342|NONE (r_pobj) in_21\IN\13603305|NONE (r_prep) comparable_20\JJ\0|affective|cognitive (r_amod) dysfunction_19\NN\14204950|,|treatment|In|.
D007854_D003072 NONE pb_24\NNP\14625458|NONE (r_compound) exposure_25\NN\5042871|to (r_pobj) due_22\IN\5174653|can|deficits (r_prep) alleviate_19\VB\205885|These|data|. (l_dobj) deficits_21\NNS\5113133|can|due
D004113_D019964 NONE succimer_3\JJ\0|exposed|of (r_amod) treatment_4\NN\654885|,|In|dysfunction|. (r_nsubj) produced_12\VBD\1617192|NONE (l_dobj) dysfunction_19\NN\14204950|,|treatment|In|.
D004113_D007855 NONE succimer_22\NN\0|NONE (r_pobj) with_21\IN\0|Pb|and|agent|,|treatment (r_prep) exposure_18\NN\5042871|model (l_appos) agent_28\NN\7347|Pb|and|with|,|treatment (l_prep) for_29\IN\0|chelating|a|used (l_pobj) treatment_31\NN\654885|NONE (l_prep) of_32\IN\0|the (l_pobj) poisoning_34\NN\14034177|NONE
D004113_D003072 CID succimer_0\NNP\0|NONE (r_compound) chelation_1\NN\29677|produces|learning|.|but (r_nsubj) improves_2\VBZ\126264|NONE (l_conj) produces_16\VBZ\7555863|learning|.|but|chelation (l_dobj) impairment_19\NN\7296428|in
D004113_D003072 NONE succimer_3\JJ\0|exposed|of (r_amod) treatment_4\NN\654885|,|In|dysfunction|. (r_nsubj) produced_12\VBD\1617192|NONE (l_dobj) dysfunction_19\NN\14204950|,|treatment|In|.
D007854_D007859 CID pb_0\NNP\14625458|NONE (r_amod) exposure_1\NN\5042871|.|impairments|paralleling (r_nsubj) produced_2\VBD\1617192|NONE (l_dobj) impairments_4\NNS\7296428|.|paralleling|exposure (l_prep) in_5\IN\13603305|lasting (l_pobj) learning_6\NN\5701944|NONE (l_conj) attention_8\NN\5701944|, (l_conj) control_11\NN\5190804|, (l_conj) regulation_15\NN\6652242|,|inhibitory|and
D007854_D007859 CID pb_24\NNP\14625458| (r_npadvmod) exposed_26\VBN\2110927|NONE (r_amod) children_27\NNS\9622049|NONE (r_pobj) in_23\IN\13603305|NONE (r_prep) seen_22\VBN\2106506|NONE (r_acl) dysfunction_21\NN\14204950|NONE (r_pobj) of_20\IN\0|the (r_prep) areas_19\NNS\8630985|NONE (r_dobj) paralleling_17\VBG\2657219|.|impairments|exposure (r_advcl) produced_2\VBD\1617192|NONE (l_dobj) impairments_4\NNS\7296428|.|paralleling|exposure (l_prep) in_5\IN\13603305|lasting (l_pobj) learning_6\NN\5701944|NONE (l_conj) attention_8\NN\5701944|, (l_conj) control_11\NN\5190804|, (l_conj) regulation_15\NN\6652242|,|inhibitory|and
D007854_D019964 NONE pb_11\NNP\14625458|NONE (r_pobj) to_10\IN\0|previously|not (r_prep) exposed_9\VBN\2110927|succimer|of (r_acl) treatment_4\NN\654885|,|In|dysfunction|. (r_nsubj) produced_12\VBD\1617192|NONE (l_dobj) dysfunction_19\NN\14204950|,|treatment|In|.
D007854_D019964 NONE pb_29\NNP\14625458|the|exposure|higher (r_compound) regimen_31\NN\5898568|NONE (r_pobj) by_26\IN\0|NONE (r_agent) produced_25\VBN\1617192|NONE (r_acl) that_24\DT\0|NONE (r_pobj) to_23\IN\0|NONE (r_prep) magnitude_22\NN\4916342|NONE (r_pobj) in_21\IN\13603305|NONE (r_prep) comparable_20\JJ\0|affective|cognitive (r_amod) dysfunction_19\NN\14204950|,|treatment|In|.
15625689
D007980_D003680 NONE levodopa_6\NN\14604959|NONE (r_pobj) for_5\IN\0|a (r_prep) role_4\NN\719494|.|and|results|confirm (r_dobj) suggest_2\VBP\1010118|NONE (l_conj) confirm_14\VB\0|.|and|role|results (l_ccomp) is_17\VBZ\0|NONE (l_nsubj) dysphagia_16\NN\14052403|that|predictor|not
D007980_D004409 CID levodopa_17\NN\14604959| (r_npadvmod) induced_19\VBN\1627355|NONE (r_amod) dyskinesia_20\NN\14084880|NONE
D007980_D004409 CID levodopa_23\NN\14604959|a|greater (r_compound) dose_24\NN\3740161|NONE (r_pobj) of_20\IN\0|the (r_prep) basis_19\NN\13790712|NONE (r_pobj) on_17\IN\0|which|be|could (r_prep) explained_16\VBN\831651|swallowing|, (r_relcl) function_11\NN\13783581|NONE (r_pobj) in_9\IN\13603305|patients|,|.|In|better (r_prep) performed_7\VBD\0|NONE (l_nsubj) patients_6\NNS\9898892|,|.|In|in|better (l_amod) dyskinetic_5\JJ\0|NONE
D007980_D010300 NONE levodopa_17\NN\14604959| (r_npadvmod) induced_19\VBN\1627355|NONE (r_amod) dyskinesia_20\NN\14084880|NONE (r_pobj) without_16\IN\0|and (r_conj) with_14\IN\0|to|dynamics (r_prep) characterize_7\VB\609683|aim|. (l_dobj) dynamics_10\NNS\6100236|to|with (l_prep) in_11\IN\13603305|the|oropharyngeal (l_pobj) patients_13\NNS\9898892|NONE (l_compound) pd_12\NNP\14625458|NONE
D007980_D010300 NONE levodopa_6\NN\14604959|NONE (r_pobj) for_5\IN\0|a (r_prep) role_4\NN\719494|.|and|results|confirm (r_dobj) suggest_2\VBP\1010118|NONE (l_conj) confirm_14\VB\0|.|and|role|results (l_ccomp) is_17\VBZ\0|NONE (l_attr) predictor_21\NN\10756433|that|dysphagia|not (l_prep) of_22\IN\0|a|good (l_pobj) alterations_24\NNS\7283608|NONE (l_prep) in_25\IN\13603305|deglutition (l_pobj) pd_26\NNP\14625458|NONE
448423
D015119_D020767 CID eaca_27\NNP\0|NONE (r_pobj) with_26\IN\0|NONE (r_prep) treated_25\VBN\2376958|fibrinolytic (r_acl) syndromes_24\NNS\5870365|NONE (r_pobj) with_22\IN\0|NONE (r_prep) patients_21\NNS\9898892|NONE (r_pobj) in_20\IN\13603305|thrombi (r_prep) capillary_17\JJ\4493505|and (r_conj) arteriolar_15\JJ\0|, (r_conj) sah_13\NNP\0|NONE (r_pobj) with_12\IN\0|NONE (r_prep) patients_11\NNS\9898892|NONE (r_pobj) in_10\IN\13603305|thrombosis|and|clinical (r_prep) deterioration_5\NN\14560612|complications|.|have (l_conj) thrombosis_9\NN\14100769|in|and|clinical
D015119_D013923 NONE eaca_27\NNP\0|NONE (l_conj) phenomena_32\NNS\29677|or|,
D000614_D007674 NONE acid_6\NN\14818238|and|thrombosis|aminocaproic (r_compound) therapy_7\NN\657604|NONE (l_conj) thrombosis_12\NN\14100769|acid|and|aminocaproic
D000614_D013345 NONE acid_6\NN\14818238|and|thrombosis|aminocaproic (r_compound) therapy_7\NN\657604|NONE (r_pobj) with_4\IN\0|NONE (r_prep) associated_3\VBN\628491|subarachnoid|Recurrent|. (r_acl) hemorrhage_2\NN\14285662|NONE
D015119_D013345 CID acid_2\NN\14818238|been|has|.|prevent (r_nsubjpass) used_8\VBN\0|NONE (l_xcomp) prevent_10\VB\0|been|has|acid|. (l_dobj) rebleeding_11\NN\0|to (l_prep) with_14\IN\0|in (l_pobj) hemorrhage_16\NN\14285662|NONE
D015119_D013345 CID acid_2\NN\14818238|been|has|.|prevent (r_nsubjpass) used_8\VBN\0|NONE (l_xcomp) prevent_10\VB\0|been|has|acid|. (l_dobj) rebleeding_11\NN\0|to (l_prep) with_14\IN\0|in (l_pobj) hemorrhage_16\NN\14285662|NONE (l_appos) sah_18\NNP\0|)|(|subarachnoid
D015119_D013345 CID eaca_4\NNP\0|aminocaproic|Epsilon (r_appos) acid_2\NN\14818238|been|has|.|prevent (r_nsubjpass) used_8\VBN\0|NONE (l_xcomp) prevent_10\VB\0|been|has|acid|. (l_dobj) rebleeding_11\NN\0|to (l_prep) with_14\IN\0|in (l_pobj) hemorrhage_16\NN\14285662|NONE
D015119_D013345 CID eaca_4\NNP\0|aminocaproic|Epsilon (r_appos) acid_2\NN\14818238|been|has|.|prevent (r_nsubjpass) used_8\VBN\0|NONE (l_xcomp) prevent_10\VB\0|been|has|acid|. (l_dobj) rebleeding_11\NN\0|to (l_prep) with_14\IN\0|in (l_pobj) hemorrhage_16\NN\14285662|NONE (l_appos) sah_18\NNP\0|)|(|subarachnoid
D015119_D013345 CID eaca_27\NNP\0|NONE (r_pobj) with_26\IN\0|NONE (r_prep) treated_25\VBN\2376958|fibrinolytic (r_acl) syndromes_24\NNS\5870365|NONE (r_pobj) with_22\IN\0|NONE (r_prep) patients_21\NNS\9898892|NONE (r_pobj) in_20\IN\13603305|thrombi (r_prep) capillary_17\JJ\4493505|and (r_conj) arteriolar_15\JJ\0|, (r_conj) sah_13\NNP\0|NONE
D015119_D013345 CID eaca_4\NNP\0|in (r_compound) therapy_5\NN\657604|NONE (l_prep) in_6\IN\13603305|EACA (l_pobj) patient_8\NN\9898892|NONE (l_prep) with_9\IN\0|a (l_pobj) sah_10\NNP\0|documentation
D015119_D013345 CID eaca_4\NNP\0|in (r_compound) therapy_5\NN\657604|NONE (l_prep) in_6\IN\13603305|EACA (l_pobj) patient_8\NN\9898892|NONE (l_prep) with_9\IN\0|a (l_pobj) documentation_13\NN\6650070|SAH (l_prep) of_14\IN\0|histopathological (l_pobj) sah_16\NNP\0|NONE
D015119_D013927 CID eaca_17\NNP\0|NONE (r_compound) therapy_18\NN\657604|NONE (r_pobj) of_16\IN\0|thrombotic (r_prep) complications_15\NNS\1073995|,|have|reports|decrease|. (l_amod) thrombotic_14\JJ\0|of
D015119_D013927 CID eaca_27\NNP\0|NONE (r_pobj) with_26\IN\0|NONE (r_prep) treated_25\VBN\2376958|fibrinolytic (r_acl) syndromes_24\NNS\5870365|NONE (r_pobj) with_22\IN\0|NONE (r_prep) patients_21\NNS\9898892|NONE (r_pobj) in_20\IN\13603305|thrombi (r_prep) capillary_17\JJ\4493505|and (l_dobj) thrombi_19\NN\5402091|in
D015119_D013927 CID eaca_13\NNP\0|observed|.|be|,|should|not|in (r_nsubjpass) implicated_17\VBN\2677097|NONE (l_advcl) observed_6\VBN\2163746|.|EACA|be|,|should|not|in (l_nsubjpass) thrombi_3\NN\5402091|are|Since|often|in
D015119_D013927 CID eaca_13\NNP\0|observed|.|be|,|should|not|in (r_nsubjpass) implicated_17\VBN\2677097|NONE (l_prep) in_18\IN\13603305|observed|.|EACA|be|,|should|not (l_pobj) pathogenesis_20\NN\13533470|NONE (l_prep) of_21\IN\0|the (l_pobj) thrombi_23\NN\5402091|NONE
D015119_D004211 NONE eaca_13\NNP\0|observed|.|be|,|should|not|in (r_nsubjpass) implicated_17\VBN\2677097|NONE (l_prep) in_18\IN\13603305|observed|.|EACA|be|,|should|not (l_pobj) pathogenesis_20\NN\13533470|NONE (l_prep) of_21\IN\0|the (l_pobj) thrombi_23\NN\5402091|NONE (l_prep) in_24\IN\13603305|fibrin (l_pobj) patients_25\NNS\9898892|NONE (l_prep) with_26\IN\0|NONE (l_pobj) coagulation_29\NN\13518963|NONE
D015119_D004211 NONE eaca_13\NNP\0|observed|.|be|,|should|not|in (r_nsubjpass) implicated_17\VBN\2677097|NONE (l_prep) in_18\IN\13603305|observed|.|EACA|be|,|should|not (l_pobj) pathogenesis_20\NN\13533470|NONE (l_prep) of_21\IN\0|the (l_pobj) thrombi_23\NN\5402091|NONE (l_prep) in_24\IN\13603305|fibrin (l_pobj) patients_25\NNS\9898892|NONE (l_prep) with_26\IN\0|NONE (l_pobj) coagulation_29\NN\13518963|NONE (l_conj) coagulopathies_34\NNS\0|intravascular|or|disseminated
8755612
D004054_D006470 NONE diethylstilbestrol_3\NN\14749794|(|)|DES (r_nmod) treatment_7\NN\654885|NONE (r_pobj) of_2\IN\0|Ten (r_prep) weeks_1\NNS\15113229|.|grow (r_nsubj) caused_8\VBD\1617192|NONE (l_ccomp) grow_14\VB\109660|.|weeks (l_conj) become_39\VB\146138|,|pituitaries|versus|to|to|and (l_acomp) hemorrhagic_41\JJ\0|to
D004054_D006470 NONE des_5\NNP\14749794|diethylstilbestrol|(|) (r_nmod) treatment_7\NN\654885|NONE (r_pobj) of_2\IN\0|Ten (r_prep) weeks_1\NNS\15113229|.|grow (r_nsubj) caused_8\VBD\1617192|NONE (l_ccomp) grow_14\VB\109660|.|weeks (l_conj) become_39\VB\146138|,|pituitaries|versus|to|to|and (l_acomp) hemorrhagic_41\JJ\0|to
D004054_D006470 NONE des_3\NNP\14749794| (r_npadvmod) induced_5\VBN\1627355|pituitary (r_amod) growth_7\NN\13526110|while|inheritance (r_nsubj) exhibited_8\VBD\2632167|However|inheritance|.|,|,|phenotype (r_advcl) exhibited_17\VBD\2632167|NONE (l_nsubj) phenotype_16\NN\4933544|However|inheritance|.|exhibited|,|, (l_amod) hemorrhagic_15\JJ\0|the
D004967_D009369 NONE estrogen_10\NN\14745635| (r_npadvmod) induced_12\VBN\1627355|an (r_amod) tumor_13\NN\14234074|NONE (r_pobj) in_8\IN\13603305|Genetic|of|. (r_prep) separation_1\NN\24720|NONE (l_prep) of_2\IN\0|Genetic|.|in (l_pobj) growth_4\NN\13526110|NONE (l_compound) tumor_3\NN\14234074|and|phenotypes
D004967_D009369 NONE estrogen_10\NN\14745635| (r_npadvmod) induced_12\VBN\1627355|an (r_amod) tumor_13\NN\14234074|NONE
D004967_D006470 NONE estrogen_10\NN\14745635| (r_npadvmod) induced_12\VBN\1627355|an (r_amod) tumor_13\NN\14234074|NONE (r_pobj) in_8\IN\13603305|Genetic|of|. (r_prep) separation_1\NN\24720|NONE (l_prep) of_2\IN\0|Genetic|.|in (l_pobj) growth_4\NN\13526110|NONE (l_conj) phenotypes_7\NNS\4933544|and|tumor (l_amod) hemorrhagic_6\JJ\0|NONE
D004967_D006470 NONE estrogen_3\NN\14745635|NONE (r_pobj) of_2\IN\0|Chronic|to (r_prep) administration_1\NN\1133281|growth|. (r_nsubj) induces_12\VBZ\1627355|NONE (l_dobj) growth_13\NN\13526110|administration|. (l_prep) of_14\IN\0|NONE (l_pobj) tumors_19\NNS\14234074|NONE (l_amod) hemorrhagic_17\JJ\0|pituitary|,|large
D004967_D010911 NONE estrogen_3\NN\14745635|NONE (r_pobj) of_2\IN\0|Chronic|to (r_prep) administration_1\NN\1133281|growth|. (r_nsubj) induces_12\VBZ\1627355|NONE (l_dobj) growth_13\NN\13526110|administration|. (l_prep) of_14\IN\0|NONE (l_pobj) tumors_19\NNS\14234074|NONE
12452552
D008728_D007676 NONE levomepromazine_21\NN\0|and (r_conj) risperidone_19\NN\0|NONE (r_pobj) of_18\IN\0|NONE (r_prep) administration_17\NN\1133281|NONE (r_pobj) after_16\IN\0|neuroleptic|malignant|NMS (r_prep) syndrome_12\NN\5870365|.|patient (r_dobj) developed_9\VBD\1753788|NONE (l_nsubj) patient_1\NN\9898892|.|syndrome (l_prep) with_2\IN\0|A (l_pobj) failure_5\NN\66216|NONE
D008728_D007676 NONE levomepromazine_21\NN\0|and (r_conj) risperidone_19\NN\0|NONE (r_pobj) of_18\IN\0|NONE (r_prep) administration_17\NN\1133281|NONE (r_pobj) after_16\IN\0|neuroleptic|malignant|NMS (r_prep) syndrome_12\NN\5870365|.|patient (r_dobj) developed_9\VBD\1753788|NONE (l_nsubj) patient_1\NN\9898892|.|syndrome (l_prep) with_2\IN\0|A (l_pobj) failure_5\NN\66216|NONE (l_appos) crf_7\NNP\0|renal|chronic|)|(
D008728_D009459 CID levomepromazine_21\NN\0|and (r_conj) risperidone_19\NN\0|NONE (r_pobj) of_18\IN\0|NONE (r_prep) administration_17\NN\1133281|NONE (r_pobj) after_16\IN\0|neuroleptic|malignant|NMS (r_prep) syndrome_12\NN\5870365|.|patient
D008728_D009459 CID levomepromazine_21\NN\0|and (r_conj) risperidone_19\NN\0|NONE (r_pobj) of_18\IN\0|NONE (r_prep) administration_17\NN\1133281|NONE (r_pobj) after_16\IN\0|neuroleptic|malignant|NMS (r_prep) syndrome_12\NN\5870365|.|patient (l_appos) nms_14\NNP\13649268|neuroleptic|malignant|after
D018967_D007676 NONE risperidone_19\NN\0|NONE (r_pobj) of_18\IN\0|NONE (r_prep) administration_17\NN\1133281|NONE (r_pobj) after_16\IN\0|neuroleptic|malignant|NMS (r_prep) syndrome_12\NN\5870365|.|patient (r_dobj) developed_9\VBD\1753788|NONE (l_nsubj) patient_1\NN\9898892|.|syndrome (l_prep) with_2\IN\0|A (l_pobj) failure_5\NN\66216|NONE
D018967_D007676 NONE risperidone_19\NN\0|NONE (r_pobj) of_18\IN\0|NONE (r_prep) administration_17\NN\1133281|NONE (r_pobj) after_16\IN\0|neuroleptic|malignant|NMS (r_prep) syndrome_12\NN\5870365|.|patient (r_dobj) developed_9\VBD\1753788|NONE (l_nsubj) patient_1\NN\9898892|.|syndrome (l_prep) with_2\IN\0|A (l_pobj) failure_5\NN\66216|NONE (l_appos) crf_7\NNP\0|renal|chronic|)|(
D018967_D009459 CID risperidone_19\NN\0|NONE (r_pobj) of_18\IN\0|NONE (r_prep) administration_17\NN\1133281|NONE (r_pobj) after_16\IN\0|neuroleptic|malignant|NMS (r_prep) syndrome_12\NN\5870365|.|patient
D018967_D009459 CID risperidone_19\NN\0|NONE (r_pobj) of_18\IN\0|NONE (r_prep) administration_17\NN\1133281|NONE (r_pobj) after_16\IN\0|neuroleptic|malignant|NMS (r_prep) syndrome_12\NN\5870365|.|patient (l_appos) nms_14\NNP\13649268|neuroleptic|malignant|after
24126708
D007980_D004409 CID levodopa_0\NNP\14604959|therapy|,|but|lead (r_nsubj) is_1\VBZ\0|NONE (l_conj) lead_17\VB\5155821|therapy|,|but|Levodopa (l_prep) to_18\IN\0|could|.|use (l_pobj) outcomes_21\NNS\7291312|NONE (l_prep) as_24\IN\14622893|chronic|adverse|, (l_pobj) fluctuations_26\NNS\7345593|such (l_conj) dyskinesia_28\JJ\14084880|motor|,
D007980_D006212 CID levodopa_0\NNP\14604959|therapy|,|but|lead (r_nsubj) is_1\VBZ\0|NONE (l_conj) lead_17\VB\5155821|therapy|,|but|Levodopa (l_prep) to_18\IN\0|could|.|use (l_pobj) outcomes_21\NNS\7291312|NONE (l_prep) as_24\IN\14622893|chronic|adverse|, (l_pobj) fluctuations_26\NNS\7345593|such (l_conj) dyskinesia_28\JJ\14084880|motor|, (l_conj) hallucinations_31\NNS\14376855|and
D007980_D010300 NONE levodopa_9\JJ\14604959|adverse|in (r_amod) effects_11\NNS\13245626|NONE (l_prep) in_12\IN\13603305|adverse|levodopa (l_pobj) patients_16\NNS\9898892|NONE (l_compound) disease_15\NN\14061805|Parkinson
D007980_D010300 NONE levodopa_0\NNP\14604959|therapy|,|but|lead (r_nsubj) is_1\VBZ\0|NONE (l_attr) therapy_6\NN\657604|,|but|lead|Levodopa (l_prep) for_7\IN\0|symptomatic|the|effective (l_pobj) disease_10\NN\14061805|NONE
11708428
D011241_D001008 CID prednisone_0\NNP\2721538|.|anxiety (r_nsubj) induces_1\VBZ\1627355|NONE (l_dobj) anxiety_2\NN\14373582|Prednisone|.
D011241_D001008 CID prednisone_3\NNP\2721538|whether|anxiety (r_nsubj) produces_7\VBZ\7555863|To|. (l_dobj) anxiety_8\NN\14373582|whether|prednisone
D011241_D001008 CID pdn_5\NNP\0|)|( (r_appos) prednisone_3\NNP\2721538|whether|anxiety (r_nsubj) produces_7\VBZ\7555863|To|. (l_dobj) anxiety_8\NN\14373582|whether|prednisone
D011241_D001008 CID pdn_7\NNP\0|NONE (r_pobj) of_6\IN\0|both (r_prep) groups_5\NNS\2137|NONE (r_pobj) in_3\IN\13603305|treated|was|.|Anxiety (r_prep) documented_2\VBN\1000214|NONE (l_nsubjpass) anxiety_0\NN\14373582|treated|in|was|.
D011241_D001008 CID pdn_3\NNP\0|NONE (r_pobj) to_2\IN\0|Subacute (r_prep) exposure_1\NN\5042871|anxiety|. (r_nsubj) induced_4\VBD\1627355|NONE (l_dobj) anxiety_5\NN\14373582|exposure|.
1858969
D004049_D005368 NONE diethylcarbamazine_7\NN\0|NONE (r_pobj) with_6\IN\0|NONE (r_prep) treatment_5\NN\654885|NONE (r_dobj) following_4\VBG\8180190|Five|of (r_prep) cases_1\NNS\7283608|with|.|were|in (r_nsubjpass) observed_12\VBN\2163746|NONE (l_prep) with_16\IN\0|.|were|in|cases (l_pobj) filariasis_19\NN\14070360|NONE
D004049_D005368 NONE dec_9\NNP\15209706|NONE (r_appos) diethylcarbamazine_7\NN\0|NONE (r_pobj) with_6\IN\0|NONE (r_prep) treatment_5\NN\654885|NONE (r_dobj) following_4\VBG\8180190|Five|of (r_prep) cases_1\NNS\7283608|with|.|were|in (r_nsubjpass) observed_12\VBN\2163746|NONE (l_prep) with_16\IN\0|.|were|in|cases (l_pobj) filariasis_19\NN\14070360|NONE
D004049_D008118 NONE diethylcarbamazine_9\NN\0|NONE (r_pobj) with_8\IN\0|NONE (r_prep) loiasis_7\NN\0|NONE
D004049_D004660 CID diethylcarbamazine_9\NN\0|NONE (r_pobj) with_8\IN\0|NONE (r_prep) loiasis_7\NN\0|NONE (r_pobj) of_6\IN\0|NONE (r_prep) treatment_5\NN\654885|NONE (r_pobj) during_4\IN\0|Five|of|. (r_prep) cases_1\NNS\7283608|NONE (l_prep) of_2\IN\0|Five|.|during (l_pobj) encephalitis_3\NN\14336539|NONE
D004049_D004660 CID diethylcarbamazine_7\NN\0|NONE (r_pobj) with_6\IN\0|NONE (r_prep) treatment_5\NN\654885|NONE (r_dobj) following_4\VBG\8180190|Five|of (r_prep) cases_1\NNS\7283608|with|.|were|in (l_prep) of_2\IN\0|Five|following (l_pobj) encephalitis_3\NN\14336539|NONE
D004049_D004660 CID dec_9\NNP\15209706|NONE (r_appos) diethylcarbamazine_7\NN\0|NONE (r_pobj) with_6\IN\0|NONE (r_prep) treatment_5\NN\654885|NONE (r_dobj) following_4\VBG\8180190|Five|of (r_prep) cases_1\NNS\7283608|with|.|were|in (l_prep) of_2\IN\0|Five|following (l_pobj) encephalitis_3\NN\14336539|NONE
6615679
D013999_D007022 CID timolol_6\NN\2832168|eye (r_nmod) drops_10\NNS\13899200|NONE (r_pobj) with_5\IN\0|NONE (r_prep) associated_4\VBN\628491|NONE (r_acl) hypotension_3\NN\14057371|.|Intraoperative|and
D013999_D007022 CID maleate_16\NN\2718811|eye (r_amod) drops_18\NNS\13899200|NONE (r_dobj) timolol_15\NN\2832168|and|pilocarpine (r_conj) nitrate_13\NN\14818238|NONE (r_pobj) with_11\IN\0|was|who|concurrently|being (r_prep) treated_10\VBN\2376958|old|,|A|, (r_relcl) man_4\NN\9605289|.|and|became|bradycardia (r_nsubj) developed_20\VBD\1753788|NONE (l_conj) became_24\VBD\146138|.|and|bradycardia|man (l_acomp) hypotensive_25\JJ\10405694|during
D010862_D007022 CID pilocarpine_8\VB\14712692|and (r_conj) timolol_6\NN\2832168|eye (r_nmod) drops_10\NNS\13899200|NONE (r_pobj) with_5\IN\0|NONE (r_prep) associated_4\VBN\628491|NONE (r_acl) hypotension_3\NN\14057371|.|Intraoperative|and
D010862_D007022 CID nitrate_13\NN\14818238|NONE (r_pobj) with_11\IN\0|was|who|concurrently|being (r_prep) treated_10\VBN\2376958|old|,|A|, (r_relcl) man_4\NN\9605289|.|and|became|bradycardia (r_nsubj) developed_20\VBD\1753788|NONE (l_conj) became_24\VBD\146138|.|and|bradycardia|man (l_acomp) hypotensive_25\JJ\10405694|during
D013999_D001919 CID timolol_6\NN\2832168|eye (r_nmod) drops_10\NNS\13899200|NONE (r_pobj) with_5\IN\0|NONE (r_prep) associated_4\VBN\628491|NONE (r_acl) hypotension_3\NN\14057371|.|Intraoperative|and (r_conj) bradycardia_1\NNP\14110674|NONE
D013999_D001919 CID maleate_16\NN\2718811|eye (r_amod) drops_18\NNS\13899200|NONE (r_dobj) timolol_15\NN\2832168|and|pilocarpine (r_conj) nitrate_13\NN\14818238|NONE (r_pobj) with_11\IN\0|was|who|concurrently|being (r_prep) treated_10\VBN\2376958|old|,|A|, (r_relcl) man_4\NN\9605289|.|and|became|bradycardia (r_nsubj) developed_20\VBD\1753788|NONE (l_dobj) bradycardia_22\NN\14110674|.|and|became|man
D006221_D001919 NONE halothane_27\NN\3570838|NONE (r_compound) anaesthesia_28\NN\14034177|NONE (r_pobj) during_26\IN\0|hypotensive (r_prep) became_24\VBD\146138|.|and|bradycardia|man (r_conj) developed_20\VBD\1753788|NONE (l_dobj) bradycardia_22\NN\14110674|.|and|became|man
D006221_D001919 NONE halothane_11\NN\3570838|with (r_compound) anaesthesia_12\NN\14034177|NONE (l_prep) with_13\IN\0|halothane (l_pobj) bradycardia_15\NN\14110674|NONE
D006221_D007022 NONE halothane_27\NN\3570838|NONE (r_compound) anaesthesia_28\NN\14034177|NONE (r_pobj) during_26\IN\0|hypotensive (r_prep) became_24\VBD\146138|.|and|bradycardia|man (l_acomp) hypotensive_25\JJ\10405694|during
D006221_D007022 NONE halothane_11\NN\3570838|with (r_compound) anaesthesia_12\NN\14034177|NONE (l_prep) with_13\IN\0|halothane (l_pobj) bradycardia_15\NN\14110674|NONE (l_conj) hypotension_17\NN\14057371|and|resultant
D010862_D001919 CID pilocarpine_8\VB\14712692|and (r_conj) timolol_6\NN\2832168|eye (r_nmod) drops_10\NNS\13899200|NONE (r_pobj) with_5\IN\0|NONE (r_prep) associated_4\VBN\628491|NONE (r_acl) hypotension_3\NN\14057371|.|Intraoperative|and (r_conj) bradycardia_1\NNP\14110674|NONE
D010862_D001919 CID nitrate_13\NN\14818238|NONE (r_pobj) with_11\IN\0|was|who|concurrently|being (r_prep) treated_10\VBN\2376958|old|,|A|, (r_relcl) man_4\NN\9605289|.|and|became|bradycardia (r_nsubj) developed_20\VBD\1753788|NONE (l_dobj) bradycardia_22\NN\14110674|.|and|became|man
24088636
D004977_D054908 NONE ethambutol_22\NN\0|and (l_prep) for_23\IN\0|NONE (l_pobj) tuberculosis_28\NN\14127211|NONE
D004977_D054908 NONE ethambutol_22\NN\0|and (l_prep) for_23\IN\0|NONE (l_pobj) tuberculosis_28\NN\14127211|NONE (l_appos) tb_32\NNP\14625458|resistant
D004977_D009901 NONE ethambutol_0\NNP\0| (r_npadvmod) induced_2\VBN\1627355|optic (r_amod) neuropathy_5\NN\14204950|withdrawn|and|was
D004977_D009901 NONE ethambutol_10\NN\0|was|. (r_nsubjpass) withdrawn_12\VBN\1835496|neuropathy|and|was (r_conj) suspected_7\VBN\916909|NONE (l_nsubjpass) neuropathy_5\NN\14204950|withdrawn|and|was
C098010_D054908 NONE linezolid_20\NN\0|NONE (l_conj) ethambutol_22\NN\0|and (l_prep) for_23\IN\0|NONE (l_pobj) tuberculosis_28\NN\14127211|NONE
C098010_D054908 NONE linezolid_20\NN\0|NONE (l_conj) ethambutol_22\NN\0|and (l_prep) for_23\IN\0|NONE (l_pobj) tuberculosis_28\NN\14127211|NONE (l_appos) tb_32\NNP\14625458|resistant
D004977_D015354 NONE ethambutol_7\NN\0|NONE (r_pobj) of_6\IN\0|NONE (r_prep) withdrawal_5\NN\7206096|NONE (r_pobj) despite_4\IN\7501545|Deterioration|. (r_prep) occurred_3\VBD\0|NONE (l_nsubj) deterioration_0\NN\14560612|despite|. (l_prep) of_1\IN\0|NONE (l_pobj) vision_2\NN\5767733|NONE
C098010_D009901 CID linezolid_0\NNP\0| (r_npadvmod) induced_2\VBN\1627355|.|optic (r_amod) neuropathy_4\NN\14204950|NONE
D004977_D014786 NONE ethambutol_22\NN\0|and (r_conj) linezolid_20\NN\0|NONE (r_pobj) including_19\VBG\0|line|multiple|tuberculous (r_prep) drugs_18\NNS\14778436|NONE (r_pobj) with_10\IN\0|NONE (r_prep) treatment_9\NN\654885|NONE (r_pobj) on_8\IN\0|who (r_prep) was_7\VBD\0|A|male|old (r_relcl) patient_5\NN\9898892|to|with|. (r_nsubj) presented_34\VBN\2137132|NONE (l_prep) with_37\IN\0|to|patient|. (l_pobj) loss_40\NN\13252973|NONE (l_prep) of_41\IN\0|in|painless|progressive (l_pobj) vision_42\NN\5767733|NONE
C098010_D014786 NONE linezolid_11\NN\0|NONE (r_amod) therapy_12\NN\657604|NONE (r_pobj) with_10\IN\0|NONE (r_prep) associated_9\VBN\628491|NONE (r_acl) vision_8\NN\5767733|NONE
C098010_D014786 NONE linezolid_20\NN\0|NONE (r_pobj) including_19\VBG\0|line|multiple|tuberculous (r_prep) drugs_18\NNS\14778436|NONE (r_pobj) with_10\IN\0|NONE (r_prep) treatment_9\NN\654885|NONE (r_pobj) on_8\IN\0|who (r_prep) was_7\VBD\0|A|male|old (r_relcl) patient_5\NN\9898892|to|with|. (r_nsubj) presented_34\VBN\2137132|NONE (l_prep) with_37\IN\0|to|patient|. (l_pobj) loss_40\NN\13252973|NONE (l_prep) of_41\IN\0|in|painless|progressive (l_pobj) vision_42\NN\5767733|NONE
24727461
D004317_D066126 NONE doxorubicin_8\NN\2716866| (r_npadvmod) induced_10\VBN\1627355|in (r_amod) cardiotoxicity_11\NN\0|NONE
D004317_D066126 NONE doxorubicin_0\NNP\2716866|cardiotoxicity|. (r_nsubj) causes_1\VBZ\7323922|NONE (l_dobj) cardiotoxicity_3\NN\0|.|Doxorubicin
D004317_D066126 NONE doxorubicin_5\RB\2716866| (r_npadvmod) associated_7\VBN\628491|chronic|cardiac (r_amod) toxicity_10\NN\13576101|whether|can|with|be
C005975_D028361 NONE hydroxytyrosol_0\NNP\0|.|stress|in (r_nsubj) ameliorates_1\VBZ\126264|NONE (l_dobj) stress_3\NN\7083732|Hydroxytyrosol|.|in (l_conj) dysfunction_6\NN\14204950|and|oxidative
D004317_D028361 NONE doxorubicin_8\NN\2716866| (r_npadvmod) induced_10\VBN\1627355|in (r_amod) cardiotoxicity_11\NN\0|NONE (r_pobj) in_7\IN\13603305|Hydroxytyrosol|.|stress (r_prep) ameliorates_1\VBZ\126264|NONE (l_dobj) stress_3\NN\7083732|Hydroxytyrosol|.|in (l_conj) dysfunction_6\NN\14204950|and|oxidative
D004317_D028361 NONE doxorubicin_0\NNP\2716866|cardiotoxicity|. (r_nsubj) causes_1\VBZ\7323922|NONE (l_dobj) cardiotoxicity_3\NN\0|.|Doxorubicin (l_acl) characterized_4\VBN\609683|significant (l_agent) by_5\IN\0|NONE (l_pobj) increases_7\NNS\13576355|NONE (l_prep) in_8\IN\13603305|marked (l_pobj) stress_10\NN\7083732|NONE (l_conj) dysfunction_13\NN\14204950|oxidative|and
C005975_D006331 NONE hydroxytyrosol_0\NNP\0|.|disturbances (r_nsubj) improved_1\VBD\126264|NONE (l_dobj) disturbances_4\NNS\407535|.|Hydroxytyrosol
C005975_D006331 NONE hydroxytyrosol_4\JJ\0|study|.|decreasing (l_dobj) damage_8\NN\7296428|that
C005975_D001943 NONE hydroxytyrosol_0\NNP\0|.|stress|in (r_nsubj) ameliorates_1\VBZ\126264|NONE (l_prep) in_7\IN\13603305|Hydroxytyrosol|.|stress (l_pobj) cardiotoxicity_11\NN\0|NONE (l_prep) in_12\IN\13603305|induced (l_pobj) rats_13\NNS\2329401|NONE (l_prep) with_14\IN\0|NONE (l_pobj) cancer_16\NN\14239425|NONE
C005975_D001943 NONE hydroxytyrosol_17\NN\0|NONE (l_prep) in_18\IN\13603305|antioxidant|the (l_pobj) rats_19\NNS\2329401|NONE (l_prep) with_20\IN\0|NONE (l_pobj) cancer_22\NN\14239425|NONE
C005975_D001943 NONE hydroxytyrosol_17\NN\0|,|week (r_conj) control_15\NN\5190804|:|)| (r_appos) groups_13\NNS\2137|NONE (r_pobj) into_11\IN\0|,|were|.|induced|doxorubicin (r_prep) divided_10\VBN\140123|NONE (l_csubjpass) induced_7\VBD\1627355|,|were|.|into|doxorubicin (l_nsubj) rats_3\NNS\2329401|chemically (l_acl) bearing_4\VBG\13795489|six (l_dobj) tumors_6\NNS\14234074|NONE
C005975_D001943 NONE hydroxytyrosol_40\NN\0|plus (r_conj) doxorubicin_38\NN\2716866|week|,|and (r_conj) doxorubicin_28\NN\2716866|,|were|.|into|induced (r_appos) divided_10\VBN\140123|NONE (l_csubjpass) induced_7\VBD\1627355|,|were|.|into|doxorubicin (l_nsubj) rats_3\NNS\2329401|chemically (l_acl) bearing_4\VBG\13795489|six (l_dobj) tumors_6\NNS\14234074|NONE
D004317_D001943 NONE doxorubicin_8\NN\2716866| (r_npadvmod) induced_10\VBN\1627355|in (r_amod) cardiotoxicity_11\NN\0|NONE (l_prep) in_12\IN\13603305|induced (l_pobj) rats_13\NNS\2329401|NONE (l_prep) with_14\IN\0|NONE (l_pobj) cancer_16\NN\14239425|NONE
D004317_D001943 NONE doxorubicin_5\RB\2716866| (r_npadvmod) associated_7\VBN\628491|chronic|cardiac (r_amod) toxicity_10\NN\13576101|whether|can|with|be (r_nsubjpass) ameliorated_13\VBN\126264|.|Herein|,|we (l_prep) with_14\IN\0|toxicity|whether|can|be (l_pobj) hydroxytyrosol_17\NN\0|NONE (l_prep) in_18\IN\13603305|antioxidant|the (l_pobj) rats_19\NNS\2329401|NONE (l_prep) with_20\IN\0|NONE (l_pobj) cancer_22\NN\14239425|NONE
D004317_D001943 NONE doxorubicin_28\NN\2716866|,|were|.|into|induced (r_appos) divided_10\VBN\140123|NONE (l_csubjpass) induced_7\VBD\1627355|,|were|.|into|doxorubicin (l_nsubj) rats_3\NNS\2329401|chemically (l_acl) bearing_4\VBG\13795489|six (l_dobj) tumors_6\NNS\14234074|NONE
D004317_D001943 NONE doxorubicin_38\NN\2716866|week|,|and (r_conj) doxorubicin_28\NN\2716866|,|were|.|into|induced (r_appos) divided_10\VBN\140123|NONE (l_csubjpass) induced_7\VBD\1627355|,|were|.|into|doxorubicin (l_nsubj) rats_3\NNS\2329401|chemically (l_acl) bearing_4\VBG\13795489|six (l_dobj) tumors_6\NNS\14234074|NONE
D004317_D009369 NONE doxorubicin_28\NN\2716866|such (r_pobj) as_27\IN\14622893|NONE (r_prep) drugs_25\NNS\14778436|NONE (r_pobj) of_24\IN\0|therapeutic|the (r_prep) effect_23\NN\34213|to (r_dobj) potentiate_20\VB\229605|been|has (r_xcomp) shown_18\VBN\2137132|,|stress|in|and|.|is (r_conj) involved_3\VBN\2676054|NONE (l_prep) in_4\IN\13603305|,|stress|and|shown|.|is (l_pobj) processes_6\NNS\407535|NONE (l_prep) including_7\VBG\0|several (l_pobj) cancer_8\NN\14239425|NONE
C005975_D066126 NONE hydroxytyrosol_0\NNP\0|.|stress|in (r_nsubj) ameliorates_1\VBZ\126264|NONE (l_prep) in_7\IN\13603305|Hydroxytyrosol|.|stress (l_pobj) cardiotoxicity_11\NN\0|NONE
C005975_D066126 NONE hydroxytyrosol_17\NN\0|NONE (r_pobj) with_14\IN\0|toxicity|whether|can|be (r_prep) ameliorated_13\VBN\126264|.|Herein|,|we (l_nsubjpass) toxicity_10\NN\13576101|whether|can|with|be
D004317_D006331 CID doxorubicin_7\NN\2716866|NONE (r_pobj) by_6\IN\0|by (r_agent) enhanced_5\VBN\227165|cardiac|the (r_acl) disturbances_4\NNS\407535|.|Hydroxytyrosol
D004317_D006331 CID doxorubicin_11\NN\2716866|damage (r_nmod) decreasing_12\VBG\169651|hydroxytyrosol|study|. (r_advcl) demonstrates_2\VBZ\2137132|NONE (l_ccomp) hydroxytyrosol_4\JJ\0|study|.|decreasing (l_dobj) damage_8\NN\7296428|that
D004317_D002318 NONE doxorubicin_28\NN\2716866|such (r_pobj) as_27\IN\14622893|NONE (r_prep) drugs_25\NNS\14778436|NONE (r_pobj) of_24\IN\0|therapeutic|the (r_prep) effect_23\NN\34213|to (r_dobj) potentiate_20\VB\229605|been|has (r_xcomp) shown_18\VBN\2137132|,|stress|in|and|.|is (r_conj) involved_3\VBN\2676054|NONE (l_prep) in_4\IN\13603305|,|stress|and|shown|.|is (l_pobj) processes_6\NNS\407535|NONE (l_prep) including_7\VBG\0|several (l_pobj) cancer_8\NN\14239425|NONE (l_conj) disease_13\NN\14061805|,
1424076
D014750_D007177 CID vincristine_9\NN\3917455|NONE (r_pobj) after_7\IN\0|.|of (r_prep) syndrome_0\NN\5870365|NONE (l_prep) of_1\IN\0|.|after (l_pobj) secretion_3\NN\13526110|NONE (l_prep) of_4\IN\0|inappropriate (l_pobj) hormone_6\NN\5404728|NONE
D014750_D007177 CID vincristine_16\NN\3917455|the (r_compound) infusion_17\NN\14589223|NONE (r_pobj) to_14\IN\0|was|which (r_prep) attributed_13\VBN\670261|,|antidiuretic (r_relcl) hormone_9\NN\5404728|NONE
D014750_D009101 NONE vincristine_18\NN\3917455|NONE (r_pobj) of_17\IN\0|day|continuous|intravenous|doxorubicin|a|and (r_prep) infusion_16\NN\14589223|NONE (r_pobj) with_11\IN\0|woman|.|was (r_prep) treated_10\VBN\2376958|NONE (l_nsubjpass) woman_4\NN\9605289|.|with|was (l_prep) with_5\IN\0|A|old (l_pobj) myeloma_8\NN\14239425|NONE
D004317_D009101 NONE doxorubicin_20\NN\2716866|day|continuous|intravenous|of|a|and (r_conj) infusion_16\NN\14589223|NONE (r_pobj) with_11\IN\0|woman|.|was (r_prep) treated_10\VBN\2376958|NONE (l_nsubjpass) woman_4\NN\9605289|.|with|was (l_prep) with_5\IN\0|A|old (l_pobj) myeloma_8\NN\14239425|NONE
D003907_D009101 NONE dexamethasone_26\NN\2721538|NONE (r_pobj) of_24\IN\0| (r_prep) days_23\NNS\15140892|and (r_conj) doxorubicin_20\NN\2716866|day|continuous|intravenous|of|a|and (r_conj) infusion_16\NN\14589223|NONE (r_pobj) with_11\IN\0|woman|.|was (r_prep) treated_10\VBN\2376958|NONE (l_nsubjpass) woman_4\NN\9605289|.|with|was (l_prep) with_5\IN\0|A|old (l_pobj) myeloma_8\NN\14239425|NONE
24554916
D010758_D017114 CID phosphorus_3\NN\14622893|NONE (r_pobj) with_1\IN\0|NONE (r_prep) poisoning_0\VBG\14034177|with|.|classically (r_nsubj) manifests_5\VBZ\6479665|NONE (l_prep) with_6\IN\0|Poisoning|.|classically (l_pobj) hepatitis_8\NN\14127211|NONE (l_acl) leading_9\VBG\4339291|acute (l_prep) to_10\IN\0|NONE (l_pobj) failure_13\NN\66216|NONE
D010758_D056486 NONE phosphorus_1\NN\14622893|known|. (r_nsubj) is_12\VBZ\0|NONE (l_acomp) known_14\JJ\0|.|phosphorus (l_xcomp) cause_16\VB\7323922|well (l_dobj) hepatotoxicity_17\NN\0|to
D010758_D056486 NONE phosphorus_6\NN\14622893|yellow|presented (r_compound) poisoning_7\NN\14034177|NONE (l_relcl) presented_12\VBN\2137132|phosphorus|yellow (l_advcl) highlighting_19\VBG\4951373|patient|with|in (l_dobj) fact_21\NN\5816287|NONE (l_acl) be_26\VB\14625458|the (l_attr) feature_29\NN\5849040|rarely|can|that|cholestasis (l_prep) of_30\IN\0|presenting|a (l_pobj) hepatotoxicity_33\NN\0|NONE
D010758_D056486 NONE phosphorus_32\NN\14622893|NONE (r_compound) hepatotoxicity_33\NN\0|NONE
D010758_D011041 NONE phosphorus_4\NN\14622893|yellow (r_compound) poisoning_5\NN\14034177|NONE
D010758_D011041 NONE phosphorus_3\NN\14622893|NONE (r_pobj) with_1\IN\0|NONE (r_prep) poisoning_0\VBG\14034177|with|.|classically
D010758_D011041 NONE phosphorus_6\NN\14622893|yellow|presented (r_compound) poisoning_7\NN\14034177|NONE
D010758_D011041 NONE phosphorus_32\NN\14622893|NONE (r_compound) hepatotoxicity_33\NN\0|NONE (r_pobj) of_30\IN\0|presenting|a (r_prep) feature_29\NN\5849040|rarely|can|that|cholestasis (r_attr) be_26\VB\14625458|the (r_acl) fact_21\NN\5816287|NONE (r_dobj) highlighting_19\VBG\4951373|patient|with|in (r_advcl) presented_12\VBN\2137132|phosphorus|yellow (r_relcl) poisoning_7\NN\14034177|NONE
D010758_D006505 CID phosphorus_3\NN\14622893|NONE (r_pobj) with_1\IN\0|NONE (r_prep) poisoning_0\VBG\14034177|with|.|classically (r_nsubj) manifests_5\VBZ\6479665|NONE (l_prep) with_6\IN\0|Poisoning|.|classically (l_pobj) hepatitis_8\NN\14127211|NONE
D010758_D002779 CID phosphorus_4\NN\14622893|yellow (r_compound) poisoning_5\NN\14034177|NONE (r_pobj) of_2\IN\0|.|Cholestatic (r_prep) presentation_1\NN\1027379|NONE (l_amod) cholestatic_0\JJ\0|.|of
D010758_D002779 CID phosphorus_6\NN\14622893|yellow|presented (r_compound) poisoning_7\NN\14034177|NONE (l_relcl) presented_12\VBN\2137132|phosphorus|yellow (l_prep) with_13\IN\0|patient|highlighting|in (l_pobj) features_16\NNS\5849040|NONE (l_prep) of_17\IN\0|florid|clinical (l_pobj) cholestasis_18\NN\14052403|NONE
D010758_D002779 CID phosphorus_6\NN\14622893|yellow|presented (r_compound) poisoning_7\NN\14034177|NONE (l_relcl) presented_12\VBN\2137132|phosphorus|yellow (l_advcl) highlighting_19\VBG\4951373|patient|with|in (l_dobj) fact_21\NN\5816287|NONE (l_acl) be_26\VB\14625458|the (l_nsubj) cholestasis_23\NN\14052403|rarely|can|that|feature
D010758_D002779 CID phosphorus_32\NN\14622893|NONE (r_compound) hepatotoxicity_33\NN\0|NONE (r_pobj) of_30\IN\0|presenting|a (r_prep) feature_29\NN\5849040|rarely|can|that|cholestasis (r_attr) be_26\VB\14625458|the (r_acl) fact_21\NN\5816287|NONE (r_dobj) highlighting_19\VBG\4951373|patient|with|in (r_advcl) presented_12\VBN\2137132|phosphorus|yellow (l_prep) with_13\IN\0|patient|highlighting|in (l_pobj) features_16\NNS\5849040|NONE (l_prep) of_17\IN\0|florid|clinical (l_pobj) cholestasis_18\NN\14052403|NONE
D010758_D002779 CID phosphorus_32\NN\14622893|NONE (r_compound) hepatotoxicity_33\NN\0|NONE (r_pobj) of_30\IN\0|presenting|a (r_prep) feature_29\NN\5849040|rarely|can|that|cholestasis (r_attr) be_26\VB\14625458|the (l_nsubj) cholestasis_23\NN\14052403|rarely|can|that|feature
24571687
D020927_D001919 CID dexmedetomidine_7\NN\0|NONE (r_dobj) following_5\VBG\8180190|severe (r_prep) bradycardia_4\NNS\14110674|and|Vasovagal|.
D020927_D001919 CID dexmedetomidine_15\NN\0|NONE (r_pobj) of_13\IN\0|NONE (r_prep) administration_12\NN\1133281|NONE (r_pobj) following_11\VBG\8180190|old|an (r_acl) girl_10\NN\10787470|NONE (r_pobj) in_5\IN\13603305|NONE (r_prep) bradycardia_4\NN\14110674|and
D020927_D019462 CID dexmedetomidine_7\NN\0|NONE (r_dobj) following_5\VBG\8180190|severe (r_prep) bradycardia_4\NNS\14110674|and|Vasovagal|. (r_conj) syncope_1\NN\7478169|NONE
D020927_D013575 NONE dexmedetomidine_15\NN\0|NONE (r_pobj) of_13\IN\0|NONE (r_prep) administration_12\NN\1133281|NONE (r_pobj) following_11\VBG\8180190|old|an (r_acl) girl_10\NN\10787470|NONE (r_pobj) in_5\IN\13603305|NONE (r_prep) bradycardia_4\NN\14110674|and (r_conj) syncope_2\NN\7478169|.|We
8312983
C036139_D006948 NONE desmethylfluoxetine_22\NN\0|plus (r_conj) fluoxetine_20\NN\4169152|fluoxetine|a|)|(|total (r_nmod) concentration_24\NN\4916342|NONE (r_pobj) with_13\IN\0|NONE (r_prep) connected_12\VBN\0|hyperkinetic|acute (r_acl) delirium_11\NN\14391660|NONE (l_amod) hyperkinetic_10\JJ\0|connected|acute
D015283_D020820 NONE citalopram_9\NN\0|NONE (r_pobj) of_8\IN\0|L|high|a|in|serum (r_prep) concentration_7\NN\4916342|,|.|has|In|with|been (r_nsubjpass) associated_22\VBN\628491|NONE (l_prep) with_23\IN\0|,|concentration|.|has|In|been (l_pobj) somnolence_25\NN\14015731|NONE (l_conj) difficulties_28\NNS\621627|and|increased
D005473_D006948 CID fluoxetine_18\NN\4169152|fluoxetine|a|)|(|total (r_nmod) concentration_24\NN\4916342|NONE (r_pobj) with_13\IN\0|NONE (r_prep) connected_12\VBN\0|hyperkinetic|acute (r_acl) delirium_11\NN\14391660|NONE (l_amod) hyperkinetic_10\JJ\0|connected|acute
D005473_D006948 CID fluoxetine_20\NN\4169152|fluoxetine|a|)|(|total (r_nmod) concentration_24\NN\4916342|NONE (r_pobj) with_13\IN\0|NONE (r_prep) connected_12\VBN\0|hyperkinetic|acute (r_acl) delirium_11\NN\14391660|NONE (l_amod) hyperkinetic_10\JJ\0|connected|acute
C036139_D003693 NONE desmethylfluoxetine_22\NN\0|plus (r_conj) fluoxetine_20\NN\4169152|fluoxetine|a|)|(|total (r_nmod) concentration_24\NN\4916342|NONE (r_pobj) with_13\IN\0|NONE (r_prep) connected_12\VBN\0|hyperkinetic|acute (r_acl) delirium_11\NN\14391660|NONE
D005473_D003693 CID fluoxetine_2\NN\4169152|NONE (r_amod) treatment_3\NN\654885|NONE (r_pobj) during_1\IN\0|. (r_prep) delirium_0\NN\14391660|NONE
D005473_D003693 CID fluoxetine_18\NN\4169152|fluoxetine|a|)|(|total (r_nmod) concentration_24\NN\4916342|NONE (r_pobj) with_13\IN\0|NONE (r_prep) connected_12\VBN\0|hyperkinetic|acute (r_acl) delirium_11\NN\14391660|NONE
D005473_D003693 CID fluoxetine_20\NN\4169152|fluoxetine|a|)|(|total (r_nmod) concentration_24\NN\4916342|NONE (r_pobj) with_13\IN\0|NONE (r_prep) connected_12\VBN\0|hyperkinetic|acute (r_acl) delirium_11\NN\14391660|NONE
D015283_D006970 NONE citalopram_9\NN\0|NONE (r_pobj) of_8\IN\0|L|high|a|in|serum (r_prep) concentration_7\NN\4916342|,|.|has|In|with|been (r_nsubjpass) associated_22\VBN\628491|NONE (l_prep) with_23\IN\0|,|concentration|.|has|In|been (l_pobj) somnolence_25\NN\14015731|NONE
12372954
C036067_D012170 NONE lysine_10\NN\14605787|due (r_dobj) bendazac_9\VB\0|Before|,|.|had|nicergoline|been|he|and (l_prep) due_11\IN\5174653|lysine (l_pobj) occlusion_15\NN\14081375|to
D009530_D009395 CID nicergoline_5\NN\0|to (r_pobj) due_3\IN\5174653|Acute|.|interstitial (r_prep) nephritis_2\NN\14113228|NONE
D009530_D009395 CID sermion_7\NN\0|NONE (r_appos) nicergoline_5\NN\0|to (r_pobj) due_3\IN\5174653|Acute|.|interstitial (r_prep) nephritis_2\NN\14113228|NONE
D009530_D009395 CID nicergoline_13\NN\0|to (r_pobj) due_11\IN\5174653|We|.|case (r_prep) report_1\VBP\6470073|NONE (l_dobj) case_3\NN\7283608|We|.|due (l_prep) of_4\IN\0|a (l_pobj) nephritis_7\NN\14113228|NONE
D009530_D009395 CID nicergoline_13\NN\0|to (r_pobj) due_11\IN\5174653|We|.|case (r_prep) report_1\VBP\6470073|NONE (l_dobj) case_3\NN\7283608|We|.|due (l_prep) of_4\IN\0|a (l_pobj) nephritis_7\NN\14113228|NONE (l_appos) ain_9\NNP\0|acute|)|interstitial|(
D009530_D009395 CID sermion_15\NN\0|NONE (r_appos) nicergoline_13\NN\0|to (r_pobj) due_11\IN\5174653|We|.|case (r_prep) report_1\VBP\6470073|NONE (l_dobj) case_3\NN\7283608|We|.|due (l_prep) of_4\IN\0|a (l_pobj) nephritis_7\NN\14113228|NONE
D009530_D009395 CID sermion_15\NN\0|NONE (r_appos) nicergoline_13\NN\0|to (r_pobj) due_11\IN\5174653|We|.|case (r_prep) report_1\VBP\6470073|NONE (l_dobj) case_3\NN\7283608|We|.|due (l_prep) of_4\IN\0|a (l_pobj) nephritis_7\NN\14113228|NONE (l_appos) ain_9\NNP\0|acute|)|interstitial|(
D009530_D009395 CID nicergoline_10\NN\0| (r_npadvmod) associated_12\VBN\628491|NONE (r_amod) ain_13\NNP\0|NONE
D009530_D012170 NONE nicergoline_7\NN\0|Before|,|bendazac|.|had|been|he|and (r_dobj) taking_6\VBG\37396|NONE (l_conj) bendazac_9\VB\0|Before|,|.|had|nicergoline|been|he|and (l_prep) due_11\IN\5174653|lysine (l_pobj) occlusion_15\NN\14081375|to
1564030
D012701_D003866 NONE serotonin_4\NN\14807737|a|selective|reuptake (r_compound) inhibitor_6\NN\20090|,|, (r_appos) fluoxetine_0\NNP\4169152|.|is|acceptance (r_nsubj) gaining_9\VBG\2238085|NONE (l_dobj) acceptance_11\NN\6193203|Fluoxetine|.|is (l_prep) in_12\IN\13603305|increased (l_pobj) treatment_14\NN\654885|NONE (l_prep) of_15\IN\0|the (l_pobj) depression_17\NN\14373582|NONE
D005473_D001714 CID fluoxetine_3\NN\4169152|in (r_amod) treatment_4\NN\654885|NONE (r_pobj) with_2\IN\0|NONE (r_prep) associated_1\VBN\628491|. (r_acl) mania_0\NNP\9180259|NONE
D005473_D001714 CID fluoxetine_8\NN\4169152|been|induce|has|safe|.|, (r_nsubjpass) reported_11\VBN\831651|NONE (l_xcomp) induce_13\VB\1627355|been|fluoxetine|has|safe|.|, (l_dobj) mania_14\NN\9180259|to
D005473_D001714 CID fluoxetine_20\NN\4169152|NONE (r_pobj) with_19\IN\0|NONE (r_prep) pharmacotherapy_18\NN\0|NONE (r_pobj) during_17\IN\0|who|mania (r_prep) developed_15\VBD\1753788|years|,|The|,|of|, (l_dobj) mania_16\NN\9180259|during|who
D005473_D001714 CID fluoxetine_11\NN\4169152|in (r_amod) pharmacotherapy_12\NN\0|NONE (r_pobj) during_10\IN\0|NONE (r_prep) hypomania_9\NN\0|or|the|of (r_conj) development_5\NN\248977|NONE (l_prep) of_6\IN\0|or|the|hypomania (l_pobj) mania_7\NN\9180259|NONE
D005473_D001714 CID fluoxetine_11\NN\4169152|in (r_amod) pharmacotherapy_12\NN\0|NONE (r_pobj) during_10\IN\0|NONE (r_prep) hypomania_9\NN\0|or|the|of
D005473_D001714 CID fluoxetine_11\NN\4169152|in (r_amod) pharmacotherapy_12\NN\0|NONE (r_pobj) during_10\IN\0|NONE (r_prep) hypomania_9\NN\0|or|the|of (r_conj) development_5\NN\248977|NONE (r_pobj) for_3\IN\0|Apparent|depression|risk (r_prep) factors_2\NNS\7326557|;|combination|. (l_appos) depression_30\NN\14373582|Apparent|risk|for (l_conj) history_37\NN\15120823|;|major|with (l_prep) of_38\IN\0|;|diagnosis|a|and|family (l_pobj) disorder_40\NN\14034177|NONE (l_appos) disorder_44\NN\14034177|affective|,
D005473_D001714 CID fluoxetine_11\NN\4169152|in (r_amod) pharmacotherapy_12\NN\0|NONE (r_pobj) during_10\IN\0|NONE (r_prep) hypomania_9\NN\0|or|the|of (r_conj) development_5\NN\248977|NONE (r_pobj) for_3\IN\0|Apparent|depression|risk (r_prep) factors_2\NNS\7326557|;|combination|. (l_appos) depression_30\NN\14373582|Apparent|risk|for (l_conj) history_37\NN\15120823|;|major|with (l_conj) diagnosis_48\NN\152018|;|a|of|and|family (l_prep) of_49\IN\0|a (l_pobj) disorder_51\NN\14034177|NONE
D005473_D001714 CID fluoxetine_19\VB\4169152|NONE (r_advmod) induced_20\VBN\1627355|in (r_amod) mania_21\NN\9180259|NONE
D005473_D019964 NONE fluoxetine_11\NN\4169152|in (r_amod) pharmacotherapy_12\NN\0|NONE (r_pobj) during_10\IN\0|NONE (r_prep) hypomania_9\NN\0|or|the|of (r_conj) development_5\NN\248977|NONE (r_pobj) for_3\IN\0|Apparent|depression|risk (r_prep) factors_2\NNS\7326557|;|combination|. (l_appos) depression_30\NN\14373582|Apparent|risk|for (l_conj) history_37\NN\15120823|;|major|with (l_prep) of_38\IN\0|;|diagnosis|a|and|family (l_pobj) disorder_40\NN\14034177|NONE
D005473_D001289 NONE fluoxetine_11\NN\4169152|in (r_amod) pharmacotherapy_12\NN\0|NONE (r_pobj) during_10\IN\0|NONE (r_prep) hypomania_9\NN\0|or|the|of (r_conj) development_5\NN\248977|NONE (r_pobj) for_3\IN\0|Apparent|depression|risk (r_prep) factors_2\NNS\7326557|;|combination|. (r_nsubj) were_16\VBD\0|NONE (l_attr) combination_18\NN\7951464|;|factors|. (l_prep) of_19\IN\0|the (l_pobj) disorder_24\NN\14034177|NONE
D005473_D011618 NONE fluoxetine_11\NN\4169152|in (r_amod) pharmacotherapy_12\NN\0|NONE (r_pobj) during_10\IN\0|NONE (r_prep) hypomania_9\NN\0|or|the|of (r_conj) development_5\NN\248977|NONE (r_pobj) for_3\IN\0|Apparent|depression|risk (r_prep) factors_2\NNS\7326557|;|combination|. (l_appos) depression_30\NN\14373582|Apparent|risk|for (l_prep) with_31\IN\0|history|;|major (l_pobj) features_33\NNS\5849040|NONE (l_amod) psychotic_32\JJ\10595647|NONE
D005473_D003866 NONE fluoxetine_0\NNP\4169152|.|is|acceptance (r_nsubj) gaining_9\VBG\2238085|NONE (l_dobj) acceptance_11\NN\6193203|Fluoxetine|.|is (l_prep) in_12\IN\13603305|increased (l_pobj) treatment_14\NN\654885|NONE (l_prep) of_15\IN\0|the (l_pobj) depression_17\NN\14373582|NONE
D005473_D003866 NONE fluoxetine_20\NN\4169152|NONE (r_pobj) with_19\IN\0|NONE (r_prep) pharmacotherapy_18\NN\0|NONE (r_pobj) during_17\IN\0|who|mania (r_prep) developed_15\VBD\1753788|years|,|The|,|of|, (r_relcl) cases_1\NNS\7283608|.|are|here (l_prep) of_2\IN\0|years|,|The|,|,|developed (l_pobj) adolescents_5\NNS\9622049|NONE (l_amod) depressed_4\JJ\1819147|five
D005473_D003866 NONE fluoxetine_11\NN\4169152|in (r_amod) pharmacotherapy_12\NN\0|NONE (r_pobj) during_10\IN\0|NONE (r_prep) hypomania_9\NN\0|or|the|of (r_conj) development_5\NN\248977|NONE (r_pobj) for_3\IN\0|Apparent|depression|risk (r_prep) factors_2\NNS\7326557|;|combination|. (l_appos) depression_30\NN\14373582|Apparent|risk|for
19553912
D020123_D000740 CID sirolimus_6\NN\0|NONE (r_pobj) of_5\IN\0|the (r_prep) role_4\NN\719494|.|Posttransplant|: (r_appos) anemia_1\NN\14189204|NONE
D020123_D000740 CID sirolimus_0\NNP\0|.|as|has|been (r_nsubjpass) implicated_11\VBN\2677097|NONE (l_prep) as_12\IN\14622893|Sirolimus|.|has|been (l_pcomp) playing_13\VBG\100253|NONE (l_dobj) role_16\NN\719494|NONE (l_prep) in_17\IN\13603305|a|special (l_pobj) anemia_19\NN\14189204|NONE
D020123_D000740 CID rapamycin_6\NNS\0|NONE (r_compound) inhibitor_7\NN\20090|NONE (r_pobj) of_5\IN\0|a|mammalian (r_prep) target_4\NN\7258332|,|, (r_appos) sirolimus_0\NNP\0|.|as|has|been (r_nsubjpass) implicated_11\VBN\2677097|NONE (l_prep) as_12\IN\14622893|Sirolimus|.|has|been (l_pcomp) playing_13\VBG\100253|NONE (l_dobj) role_16\NN\719494|NONE (l_prep) in_17\IN\13603305|a|special (l_pobj) anemia_19\NN\14189204|NONE
D020123_D000740 CID sirolimus_6\NN\0|NONE (r_pobj) with_5\IN\0|NONE (r_prep) associated_4\VBN\628491|including|, (r_acl) anemia_3\NN\14189204|.|review
17496739
C085143_D007676 NONE tazobactam_54\NN\0|mental|,|episodes|and|progressive (r_conj) confusion_34\NN\13972797|,|bizarre (r_conj) behavior_30\NN\407535|, (r_conj) tremor_27\NN\345926|slurred|, (r_conj) speech_25\NN\7160883|who (r_dobj) developed_23\VBD\1753788|,|ambulatory|)|continuous|peritoneal|CAPD|( (r_relcl) dialysis_17\NN\646833|NONE (r_dobj) receiving_13\VBG\2210855|renal|stage (r_acl) disease_12\NN\14061805|NONE
C085143_D012640 NONE tazobactam_2\NN\0||Piperacillin|/ (r_advmod) induced_4\VBN\1627355|NONE (r_amod) seizure_5\NN\14081375|in|rapidly|.|by
C085143_D060085 NONE tazobactam_54\NN\0|mental|,|episodes|and|progressive (r_conj) confusion_34\NN\13972797|,|bizarre (r_conj) behavior_30\NN\407535|, (r_conj) tremor_27\NN\345926|slurred|, (r_conj) speech_25\NN\7160883|who (r_dobj) developed_23\VBD\1753788|,|ambulatory|)|continuous|peritoneal|CAPD|( (r_relcl) dialysis_17\NN\646833|NONE (r_dobj) receiving_13\VBG\2210855|renal|stage (r_acl) disease_12\NN\14061805|NONE (r_pobj) with_7\IN\0|a|old (r_prep) woman_6\NN\9605289|were|for (r_nsubjpass) given_61\VBN\5892096|We|. (l_prep) for_62\IN\0|were|woman (l_pobj) bronchiectasis_63\NN\0|NONE (l_prep) with_64\IN\0|NONE (l_pobj) infection_66\NN\14052046|NONE
C085143_D004830 CID tazobactam_54\NN\0|mental|,|episodes|and|progressive (r_conj) confusion_34\NN\13972797|,|bizarre (l_conj) episodes_38\NNS\7283608|tazobactam|mental|,|and|progressive (l_prep) of_39\IN\0|GTCS| (l_pobj) seizure_44\NN\14081375|NONE
C085143_D004830 CID tazobactam_54\NN\0|mental|,|episodes|and|progressive (r_conj) confusion_34\NN\13972797|,|bizarre (l_conj) episodes_38\NNS\7283608|tazobactam|mental|,|and|progressive (l_parataxis) gtcs_46\NNP\0|of|
C085143_D004830 CID tazobactam_18\NN\0|NONE (r_pobj) after_11\IN\0|Despite|episode|,|. (r_prep) recurred_10\VBD\339934|NONE (l_nsubj) episode_9\NN\7283608|Despite|,|after|. (l_amod) gtcs_8\NNP\0|another
C085143_D014202 CID tazobactam_54\NN\0|mental|,|episodes|and|progressive (r_conj) confusion_34\NN\13972797|,|bizarre (r_conj) behavior_30\NN\407535|, (r_conj) tremor_27\NN\345926|slurred|,
C085143_D001987 NONE tazobactam_54\NN\0|mental|,|episodes|and|progressive (r_conj) confusion_34\NN\13972797|,|bizarre (r_conj) behavior_30\NN\407535|, (r_conj) tremor_27\NN\345926|slurred|, (r_conj) speech_25\NN\7160883|who (r_dobj) developed_23\VBD\1753788|,|ambulatory|)|continuous|peritoneal|CAPD|( (r_relcl) dialysis_17\NN\646833|NONE (r_dobj) receiving_13\VBG\2210855|renal|stage (r_acl) disease_12\NN\14061805|NONE (r_pobj) with_7\IN\0|a|old (r_prep) woman_6\NN\9605289|were|for (r_nsubjpass) given_61\VBN\5892096|We|. (l_prep) for_62\IN\0|were|woman (l_pobj) bronchiectasis_63\NN\0|NONE
D010878_D001927 NONE piperacillin_0\NNP\3910033| (r_npadvmod) induced_2\VBN\1627355|NONE (r_amod) encephalopathy_3\NN\14084880|be|.|should|in
D010878_D001927 NONE piperacillin_5\NN\3910033|NONE (r_dobj) removing_4\VBG\0|NONE (r_pcomp) in_3\IN\13603305|NONE (r_prep) inefficient_2\JJ\0|CAPD|terminate|.|, (r_acomp) is_1\VBZ\0|NONE (l_advcl) terminate_11\VB\126264|inefficient|CAPD|.|, (l_dobj) encephalopathy_16\NN\14084880|rapidly|can|hemodialysis|whereas
D010878_D001927 NONE piperacillin_13\NN\3910033| (r_npadvmod) induced_15\VBN\1627355|the (r_amod) encephalopathy_16\NN\14084880|rapidly|can|hemodialysis|whereas
C085143_D003221 CID tazobactam_54\NN\0|mental|,|episodes|and|progressive (r_conj) confusion_34\NN\13972797|,|bizarre
D010878_D006463 NONE piperacillin_0\NNP\3910033| (r_npadvmod) induced_2\VBN\1627355|NONE (r_amod) encephalopathy_3\NN\14084880|be|.|should|in (r_nsubjpass) considered_6\VBN\689344|NONE (l_prep) in_7\IN\13603305|be|.|should|encephalopathy (l_pobj) patients_10\NNS\9898892|NONE (l_amod) uremic_9\JJ\0|any|with
D010878_D020258 NONE piperacillin_4\NN\3910033|NONE (r_pobj) of_3\IN\0|popular (r_prep) use_2\NN\407535|NONE (r_pobj) despite_0\IN\7501545|,|unrecognized|.|,|still|neurotoxicity|leading (r_prep) goes_13\VBZ\15291801|NONE (l_nsubj) neurotoxicity_8\NN\0|Despite|,|unrecognized|.|,|still|leading
D010878_D020258 NONE piperacillin_11\NN\3910033|NONE (r_pobj) with_10\IN\0|NONE (r_prep) associated_9\VBN\628491|the|dire (r_acl) neurotoxicity_8\NN\0|Despite|,|unrecognized|.|,|still|leading
D000641_D007964 NONE ammonia_8\NN\14940386|leukocytosis|but|electrolyte (r_compound) levels_9\NNS\4916342|data|. (l_conj) leukocytosis_11\NN\14189204|ammonia|but|electrolyte
12119460
D005472_D013274 NONE 5-fluorouracil_3\CD\0|/ (r_punct) folinic_5\JJ\0|.|in|dose (r_compound) acid_6\NN\14818238|NONE (l_prep) in_7\IN\13603305|folinic|.|dose (l_pobj) combination_8\NN\7951464|NONE (l_prep) with_9\IN\0|NONE (l_pobj) c_14\NN\13714184|NONE (l_prep) in_15\IN\13603305|weekly|mitomycin (l_pobj) treatment_17\NN\654885|NONE (l_prep) of_18\IN\0|the (l_pobj) cancer_21\NN\14239425|NONE
D005472_D013274 NONE 5-fluorouracil_5\CD\0|NONE (r_punct) (_6\-LRB-\0|folinic|)|and (r_punct) 5-fu_7\CD\0|NONE (l_conj) folinic_10\VB\0|(|)|and (l_prep) as_15\IN\14622893|)|FA (l_pobj) part_16\NN\31921|NONE (l_prep) of_17\IN\0|NONE (l_pobj) regimens_22\NNS\5898568|NONE (l_prep) in_23\IN\13603305|chemotherapy|new|several (l_pobj) cancer_26\NN\14239425|NONE
D005472_D013274 NONE 5-fluorouracil_5\CD\0|NONE (r_punct) (_6\-LRB-\0|folinic|)|and (r_punct) 5-fu_7\CD\0|NONE (r_pobj) of_4\IN\0|continuous|The|hour (r_prep) infusion_3\NN\14589223|(|be|has|.|AGC (r_nsubj) shown_31\VBN\2137132|NONE (l_nsubj) agc_28\NNP\0|(|be|has|infusion|.
D005472_D013274 NONE 5-fu_7\CD\0|NONE (l_conj) folinic_10\VB\0|(|)|and (l_prep) as_15\IN\14622893|)|FA (l_pobj) part_16\NN\31921|NONE (l_prep) of_17\IN\0|NONE (l_pobj) regimens_22\NNS\5898568|NONE (l_prep) in_23\IN\13603305|chemotherapy|new|several (l_pobj) cancer_26\NN\14239425|NONE
D005472_D013274 NONE 5-fu_7\CD\0|NONE (r_pobj) of_4\IN\0|continuous|The|hour (r_prep) infusion_3\NN\14589223|(|be|has|.|AGC (r_nsubj) shown_31\VBN\2137132|NONE (l_nsubj) agc_28\NNP\0|(|be|has|infusion|.
D005472_D013274 NONE 5-fu_18\CD\0|to (r_dobj) receive_15\VB\2210855|with|)|preceded| (r_relcl) patients_11\NNS\9898892|we|for|,|From|.|,|followed (l_prep) with_12\IN\0|)|receive|preceded| (l_pobj) agc_13\NNP\0|NONE
D005472_D013274 NONE 5-fu_3\CD\0|FA|dose|/|/ (r_nmod) mmc_7\NNP\0|regimen|. (r_nsubj) is_8\VBZ\0|NONE (l_attr) regimen_16\NN\5898568|MMC|. (l_prep) for_17\IN\0|an|effective|outpatient (l_pobj) agc_18\NNP\0|NONE
D016685_D013274 NONE c_14\NN\13714184|NONE (l_prep) in_15\IN\13603305|weekly|mitomycin (l_pobj) treatment_17\NN\654885|NONE (l_prep) of_18\IN\0|the (l_pobj) cancer_21\NN\14239425|NONE
D016685_D013274 NONE mmc_7\NNP\0|regimen|. (r_nsubj) is_8\VBZ\0|NONE (l_attr) regimen_16\NN\5898568|MMC|. (l_prep) for_17\IN\0|an|effective|outpatient (l_pobj) agc_18\NNP\0|NONE
D005472_D064420 NONE 5-fluorouracil_5\CD\0|NONE (r_punct) (_6\-LRB-\0|folinic|)|and (r_punct) 5-fu_7\CD\0|NONE (r_pobj) of_4\IN\0|continuous|The|hour (r_prep) infusion_3\NN\14589223|(|be|has|.|AGC (r_nsubj) shown_31\VBN\2137132|NONE (l_xcomp) be_33\VB\14625458|(|has|infusion|.|AGC (l_prep) with_36\IN\0|effective|to|, (l_pobj) toxicity_38\NN\13576101|NONE
D005472_D064420 NONE 5-fu_7\CD\0|NONE (r_pobj) of_4\IN\0|continuous|The|hour (r_prep) infusion_3\NN\14589223|(|be|has|.|AGC (r_nsubj) shown_31\VBN\2137132|NONE (l_xcomp) be_33\VB\14625458|(|has|infusion|.|AGC (l_prep) with_36\IN\0|effective|to|, (l_pobj) toxicity_38\NN\13576101|NONE
D002955_D013274 NONE acid_6\NN\14818238|NONE (l_prep) in_7\IN\13603305|folinic|.|dose (l_pobj) combination_8\NN\7951464|NONE (l_prep) with_9\IN\0|NONE (l_pobj) c_14\NN\13714184|NONE (l_prep) in_15\IN\13603305|weekly|mitomycin (l_pobj) treatment_17\NN\654885|NONE (l_prep) of_18\IN\0|the (l_pobj) cancer_21\NN\14239425|NONE
D002955_D013274 NONE acid_11\NN\14818238|( (r_nmod) fa_13\NNP\6868043|)|as (r_dobj) folinic_10\VB\0|(|)|and (l_prep) as_15\IN\14622893|)|FA (l_pobj) part_16\NN\31921|NONE (l_prep) of_17\IN\0|NONE (l_pobj) regimens_22\NNS\5898568|NONE (l_prep) in_23\IN\13603305|chemotherapy|new|several (l_pobj) cancer_26\NN\14239425|NONE
D002955_D013274 NONE acid_11\NN\14818238|( (r_nmod) fa_13\NNP\6868043|)|as (r_dobj) folinic_10\VB\0|(|)|and (r_conj) 5-fu_7\CD\0|NONE (r_pobj) of_4\IN\0|continuous|The|hour (r_prep) infusion_3\NN\14589223|(|be|has|.|AGC (r_nsubj) shown_31\VBN\2137132|NONE (l_nsubj) agc_28\NNP\0|(|be|has|infusion|.
D002955_D013274 NONE fa_13\NNP\6868043|)|as (r_dobj) folinic_10\VB\0|(|)|and (l_prep) as_15\IN\14622893|)|FA (l_pobj) part_16\NN\31921|NONE (l_prep) of_17\IN\0|NONE (l_pobj) regimens_22\NNS\5898568|NONE (l_prep) in_23\IN\13603305|chemotherapy|new|several (l_pobj) cancer_26\NN\14239425|NONE
D002955_D013274 NONE fa_13\NNP\6868043|)|as (r_dobj) folinic_10\VB\0|(|)|and (r_conj) 5-fu_7\CD\0|NONE (r_pobj) of_4\IN\0|continuous|The|hour (r_prep) infusion_3\NN\14589223|(|be|has|.|AGC (r_nsubj) shown_31\VBN\2137132|NONE (l_nsubj) agc_28\NNP\0|(|be|has|infusion|.
D002955_D013274 NONE fa_27\NNP\6868043|/|hour||mg (r_nmod) m(2_31\NN\0|NONE (r_punct) )_32\-RRB-\0|with|receive|preceded| (r_punct) patients_11\NNS\9898892|we|for|,|From|.|,|followed (l_prep) with_12\IN\0|)|receive|preceded| (l_pobj) agc_13\NNP\0|NONE
D002955_D013274 NONE fa_5\NNP\6868043|FU|dose|/|/ (r_nmod) mmc_7\NNP\0|regimen|. (r_nsubj) is_8\VBZ\0|NONE (l_attr) regimen_16\NN\5898568|MMC|. (l_prep) for_17\IN\0|an|effective|outpatient (l_pobj) agc_18\NNP\0|NONE
D002945_D006463 NONE cisplatin_7\NN\0| (r_advmod) containing_9\VBG\2632940|NONE (r_amod) regimens_10\NNS\5898568|NONE (r_pobj) to_6\IN\0|an (r_prep) alternative_5\NN\5788149|NONE (r_pobj) as_3\IN\14622893|may|It (r_prep) serve_2\VB\566135|,|considered|it|.|however|; (r_ccomp) has_15\VBZ\13888491|NONE (l_xcomp) considered_18\VBN\689344|serve|,|it|.|however|; (l_ccomp) occur_23\VB\0|to|be (l_nsubj) hus_21\NNP\0|possibly|may|that
D002955_D064420 NONE acid_11\NN\14818238|( (r_nmod) fa_13\NNP\6868043|)|as (r_dobj) folinic_10\VB\0|(|)|and (r_conj) 5-fu_7\CD\0|NONE (r_pobj) of_4\IN\0|continuous|The|hour (r_prep) infusion_3\NN\14589223|(|be|has|.|AGC (r_nsubj) shown_31\VBN\2137132|NONE (l_xcomp) be_33\VB\14625458|(|has|infusion|.|AGC (l_prep) with_36\IN\0|effective|to|, (l_pobj) toxicity_38\NN\13576101|NONE
D002955_D064420 NONE fa_13\NNP\6868043|)|as (r_dobj) folinic_10\VB\0|(|)|and (r_conj) 5-fu_7\CD\0|NONE (r_pobj) of_4\IN\0|continuous|The|hour (r_prep) infusion_3\NN\14589223|(|be|has|.|AGC (r_nsubj) shown_31\VBN\2137132|NONE (l_xcomp) be_33\VB\14625458|(|has|infusion|.|AGC (l_prep) with_36\IN\0|effective|to|, (l_pobj) toxicity_38\NN\13576101|NONE
12912689
D016190_D005355 CID carboplatin_1\NN\0|NONE (l_ccomp) associated_4\VBN\628491|Subtenon|. (l_prep) with_5\IN\0|is|leading|chemotherapy|, (l_pobj) fibrosis_7\NN\14204950|NONE
D016190_D064420 NONE carboplatin_2\NN\0|NONE (l_ccomp) used_7\VBN\0|.|subtenon (l_prep) as_8\IN\14622893|recently|have|been|injections (l_pobj) adjunct_14\NN\9312645|NONE (l_amod) free_13\JJ\7942152|to|a (l_npadvmod) toxicity_11\NN\13576101|presumably|
D016190_D064420 NONE carboplatin_1\NN\0|restricted|free|,|and|not (r_nsubj) is_2\VBZ\0|NONE (l_acomp) free_4\JJ\7942152|restricted|,|and|carboplatin|not (l_prep) of_5\IN\0|NONE (l_pobj) toxicity_6\NN\13576101|NONE
D016190_D012175 NONE carboplatin_5\VBP\0|Ocular|motility|. (l_prep) for_7\IN\0|subtenon|after|chemotherapy (l_pobj) retinoblastoma_8\NN\14239425|NONE
D016190_D012175 NONE carboplatin_2\NN\0|NONE (l_ccomp) used_7\VBN\0|.|subtenon (l_prep) as_8\IN\14622893|recently|have|been|injections (l_pobj) adjunct_14\NN\9312645|NONE (l_prep) to_15\IN\0|free|a (l_pobj) chemotherapy_17\NN\661091|NONE (l_prep) for_18\IN\0|systemic (l_pobj) retinoblastoma_20\NN\14239425|NONE
D016190_D012175 NONE carboplatin_15\NN\0|We|motility|. (r_ccomp) noted_1\VBD\1009240|NONE (l_dobj) motility_4\NN\4773351|We|carboplatin|. (l_prep) in_5\IN\13603305|ocular|abnormal (l_pobj) patients_8\NNS\9898892|NONE (l_prep) with_9\IN\0||consecutive (l_pobj) retinoblastoma_10\NN\14239425|NONE
D016190_D012175 NONE carboplatin_24\NN\0|in|was|Limitation|. (r_advmod) detected_5\VBN\2163746|NONE (l_prep) in_6\IN\13603305|carboplatin|was|Limitation|. (l_pobj) eyes_9\NNS\5945642|NONE (l_prep) of_10\IN\0|all| (l_pobj) patients_12\NNS\9898892|NONE (l_acl) treated_13\VBN\2376958| (l_prep) for_14\IN\0|with (l_pobj) retinoblastoma_16\NN\14239425|NONE
D016190_D015835 CID carboplatin_14\NN\0|NONE (r_amod) chemotherapy_15\NN\661091|with (r_dobj) treated_11\VBN\2376958|NONE (r_acl) patients_10\NNS\9898892|NONE (r_pobj) in_9\IN\13603305|ocular|abnormal (r_prep) motility_8\NN\4773351|NONE
D016190_D015835 CID carboplatin_15\NN\0|We|motility|. (r_ccomp) noted_1\VBD\1009240|NONE (l_dobj) motility_4\NN\4773351|We|carboplatin|.
9158667
D006493_D013927 NONE heparin_13\NN\2718259|NONE (r_dobj) using_9\VBG\418025|NONE (r_pcomp) by_8\IN\0|.|events|,|however|be|could|, (r_prep) avoided_7\VBN\0|NONE (l_nsubjpass) events_1\NNS\23100|.|,|however|be|could|by|, (l_amod) thrombotic_0\JJ\0|NONE
D014212_D015473 NONE acid_12\NN\14818238|retinoic (r_compound) therapy_13\NN\657604|NONE (r_pobj) during_6\IN\0|in|Thrombotic|. (r_prep) complications_1\NNS\1073995|NONE (l_prep) in_2\IN\13603305|Thrombotic|during|. (l_pobj) leukemia_5\NN\14239918|NONE
D014212_D015473 NONE acid_30\NN\14818238|NONE (r_pobj) with_24\IN\0|NONE (r_prep) treated_23\VBN\2376958|A|of|,|due (r_acl) case_1\NN\7283608|been|recently|.|has (l_amod) due_7\IN\5174653|A|treated|of|, (l_pobj) occlusion_9\NN\14081375|to (l_prep) in_13\IN\13603305|of (l_pobj) patient_15\NN\9898892|NONE (l_prep) with_16\IN\0|a (l_pobj) leukemia_19\NN\14239918|NONE
D014212_D015473 NONE acid_30\NN\14818238|NONE (r_pobj) with_24\IN\0|NONE (r_prep) treated_23\VBN\2376958|A|of|,|due (r_acl) case_1\NN\7283608|been|recently|.|has (l_amod) due_7\IN\5174653|A|treated|of|, (l_pobj) occlusion_9\NN\14081375|to (l_prep) in_13\IN\13603305|of (l_pobj) patient_15\NN\9898892|NONE (l_prep) with_16\IN\0|a (l_pobj) leukemia_19\NN\14239918|NONE (l_appos) apl_21\NNP\0|acute|)|(|promyelocytic
D014212_D015473 NONE atra_32\NNP\0|retinoic|and|acid (r_appos) acid_30\NN\14818238|NONE (r_pobj) with_24\IN\0|NONE (r_prep) treated_23\VBN\2376958|A|of|,|due (r_acl) case_1\NN\7283608|been|recently|.|has (l_amod) due_7\IN\5174653|A|treated|of|, (l_pobj) occlusion_9\NN\14081375|to (l_prep) in_13\IN\13603305|of (l_pobj) patient_15\NN\9898892|NONE (l_prep) with_16\IN\0|a (l_pobj) leukemia_19\NN\14239918|NONE
D014212_D015473 NONE atra_32\NNP\0|retinoic|and|acid (r_appos) acid_30\NN\14818238|NONE (r_pobj) with_24\IN\0|NONE (r_prep) treated_23\VBN\2376958|A|of|,|due (r_acl) case_1\NN\7283608|been|recently|.|has (l_amod) due_7\IN\5174653|A|treated|of|, (l_pobj) occlusion_9\NN\14081375|to (l_prep) in_13\IN\13603305|of (l_pobj) patient_15\NN\9898892|NONE (l_prep) with_16\IN\0|a (l_pobj) leukemia_19\NN\14239918|NONE (l_appos) apl_21\NNP\0|acute|)|(|promyelocytic
D014212_D015473 NONE atra_14\NNP\0|NONE (r_pobj) with_13\IN\0|alone (r_prep) treated_12\VBN\2376958|APL|an (r_acl) patient_11\NN\9898892|NONE (l_compound) apl_10\NNP\0|an|treated
D014212_D015473 NONE atra_11\NNP\0|in (r_compound) therapy_12\NN\657604|NONE (l_prep) in_13\IN\13603305|ATRA (l_pobj) patients_15\NNS\9898892|NONE (l_compound) apl_14\NNP\0|NONE
D014212_D015473 NONE atra_25\NNP\0|NONE (r_pobj) with_24\IN\0|a|treatment (r_prep) protocol_23\NN\6652242|NONE (r_pobj) in_20\IN\13603305|was (r_prep) included_19\VBN\0|patients|signs|and|. (r_conj) presented_9\VBD\2137132|NONE (l_dobj) signs_12\NNS\6643763|patients|and|.|included (l_prep) of_15\IN\0|all|symptoms|the|and (l_pobj) apl_16\NNP\0|NONE
D014212_D015473 NONE atra_3\NNP\0|corrected|that|choice|, (r_nsubj) is_4\VBZ\0|We|. (l_attr) choice_8\NN\5788149|ATRA|corrected|that|, (l_prep) for_9\IN\0|therapeutic|a|valid (l_pobj) patients_10\NNS\9898892|NONE (l_prep) with_11\IN\0|NONE (l_pobj) apl_12\NNP\0|NONE
D014212_D058186 CID acid_30\NN\14818238|NONE (r_pobj) with_24\IN\0|NONE (r_prep) treated_23\VBN\2376958|A|of|,|due (r_acl) case_1\NN\7283608|been|recently|.|has (l_prep) of_2\IN\0|A|treated|,|due (l_pobj) failure_5\NN\66216|NONE
D014212_D058186 CID atra_32\NNP\0|retinoic|and|acid (r_appos) acid_30\NN\14818238|NONE (r_pobj) with_24\IN\0|NONE (r_prep) treated_23\VBN\2376958|A|of|,|due (r_acl) case_1\NN\7283608|been|recently|.|has (l_prep) of_2\IN\0|A|treated|,|due (l_pobj) failure_5\NN\66216|NONE
D014212_D058186 CID atra_14\NNP\0|NONE (r_pobj) with_13\IN\0|alone (r_prep) treated_12\VBN\2376958|APL|an (r_acl) patient_11\NN\9898892|NONE (r_pobj) in_8\IN\13603305|acute|renal (r_prep) failure_7\NN\66216|NONE
D014212_D013927 CID acid_12\NN\14818238|retinoic (r_compound) therapy_13\NN\657604|NONE (r_pobj) during_6\IN\0|in|Thrombotic|. (r_prep) complications_1\NNS\1073995|NONE (l_amod) thrombotic_0\JJ\0|in|during|.
D014148_-1 NONE acid_36\NN\14818238|retinoic|and|ATRA (r_conj) acid_30\NN\14818238|NONE (r_pobj) with_24\IN\0|NONE (r_prep) treated_23\VBN\2376958|A|of|,|due (r_acl) case_1\NN\7283608|been|recently|.|has (l_amod) due_7\IN\5174653|A|treated|of|, (l_pobj) occlusion_9\NN\14081375|to (l_prep) of_10\IN\0|in (l_pobj) vessels_12\NNS\5246511|NONE
D014148_D015473 NONE acid_36\NN\14818238|retinoic|and|ATRA (r_conj) acid_30\NN\14818238|NONE (r_pobj) with_24\IN\0|NONE (r_prep) treated_23\VBN\2376958|A|of|,|due (r_acl) case_1\NN\7283608|been|recently|.|has (l_amod) due_7\IN\5174653|A|treated|of|, (l_pobj) occlusion_9\NN\14081375|to (l_prep) in_13\IN\13603305|of (l_pobj) patient_15\NN\9898892|NONE (l_prep) with_16\IN\0|a (l_pobj) leukemia_19\NN\14239918|NONE
D014148_D015473 NONE acid_36\NN\14818238|retinoic|and|ATRA (r_conj) acid_30\NN\14818238|NONE (r_pobj) with_24\IN\0|NONE (r_prep) treated_23\VBN\2376958|A|of|,|due (r_acl) case_1\NN\7283608|been|recently|.|has (l_amod) due_7\IN\5174653|A|treated|of|, (l_pobj) occlusion_9\NN\14081375|to (l_prep) in_13\IN\13603305|of (l_pobj) patient_15\NN\9898892|NONE (l_prep) with_16\IN\0|a (l_pobj) leukemia_19\NN\14239918|NONE (l_appos) apl_21\NNP\0|acute|)|(|promyelocytic
D014212_D013923 NONE atra_11\NNP\0|in (r_compound) therapy_12\NN\657604|NONE (r_pobj) with_10\IN\0|NONE (r_prep) associated_9\VBN\628491|thromboembolic (r_acl) complications_8\NNS\1073995|NONE (l_compound) thromboembolic_7\JJ\0|associated
D014212_-1 NONE acid_30\NN\14818238|NONE (r_pobj) with_24\IN\0|NONE (r_prep) treated_23\VBN\2376958|A|of|,|due (r_acl) case_1\NN\7283608|been|recently|.|has (l_amod) due_7\IN\5174653|A|treated|of|, (l_pobj) occlusion_9\NN\14081375|to (l_prep) of_10\IN\0|in (l_pobj) vessels_12\NNS\5246511|NONE
D014212_-1 NONE atra_32\NNP\0|retinoic|and|acid (r_appos) acid_30\NN\14818238|NONE (r_pobj) with_24\IN\0|NONE (r_prep) treated_23\VBN\2376958|A|of|,|due (r_acl) case_1\NN\7283608|been|recently|.|has (l_amod) due_7\IN\5174653|A|treated|of|, (l_pobj) occlusion_9\NN\14081375|to (l_prep) of_10\IN\0|in (l_pobj) vessels_12\NNS\5246511|NONE
D014148_D058186 NONE acid_36\NN\14818238|retinoic|and|ATRA (r_conj) acid_30\NN\14818238|NONE (r_pobj) with_24\IN\0|NONE (r_prep) treated_23\VBN\2376958|A|of|,|due (r_acl) case_1\NN\7283608|been|recently|.|has (l_prep) of_2\IN\0|A|treated|,|due (l_pobj) failure_5\NN\66216|NONE
15265979
D000638_D056486 CID amiodarone_0\NNP\2715941|has|cause|.|been (r_nsubjpass) reported_12\VBN\831651|NONE (l_xcomp) cause_14\VB\7323922|has|Amiodarone|.|been (l_dobj) hepatotoxicity_15\NN\0|in|to
D000638_D056486 CID amiodarone_12\NN\2715941|NONE (r_pobj) of_11\IN\0|hepatotoxic|the (r_prep) effects_10\NNS\13245626|NONE (l_amod) hepatotoxic_9\JJ\0|of|the
D000638_D056486 CID amiodarone_12\NN\2715941|NONE (r_pobj) of_11\IN\0|hepatotoxic|the (r_prep) effects_10\NNS\13245626|NONE (r_pobj) regarding_7\VBG\689344|important|mechanistic|new (r_prep) information_6\NN\6598915|indicate|and|results|. (r_dobj) provide_2\VBP\2199590|NONE (l_conj) indicate_14\VBP\952524|and|information|results|. (l_ccomp) protects_17\VBZ\1127795|NONE (l_prep) against_18\IN\0|that|PPARalpha (l_pobj) hepatotoxicity_22\NN\0|NONE
D000638_D056486 CID amiodarone_19\NN\2715941| (r_npadvmod) induced_21\VBN\1627355|NONE (r_amod) hepatotoxicity_22\NN\0|NONE (r_pobj) against_18\IN\0|that|PPARalpha (r_prep) protects_17\VBZ\1127795|NONE (r_ccomp) indicate_14\VBP\952524|and|information|results|. (r_conj) provide_2\VBP\2199590|NONE (l_dobj) information_6\NN\6598915|indicate|and|results|. (l_prep) regarding_7\VBG\689344|important|mechanistic|new (l_pobj) effects_10\NNS\13245626|NONE (l_amod) hepatotoxic_9\JJ\0|of|the
D000638_D056486 CID amiodarone_19\NN\2715941| (r_npadvmod) induced_21\VBN\1627355|NONE (r_amod) hepatotoxicity_22\NN\0|NONE
D014280_D006529 NONE triglycerides_15\NNS\14885088|NONE (r_pobj) in_13\IN\13603305|a|significant (r_prep) decrease_12\NN\7296428|and|Amiodarone|.|accumulation|, (r_conj) induced_1\VBD\1627355|NONE (l_dobj) accumulation_7\NN\13497135|and|Amiodarone|.|decrease|, (l_amod) hepatomegaly_2\NN\14501726|hepatocyte|lipid|microvesicular|,
D000638_D006529 CID amiodarone_0\NN\2715941|and|.|accumulation|decrease|, (r_nsubj) induced_1\VBD\1627355|NONE (l_dobj) accumulation_7\NN\13497135|and|Amiodarone|.|decrease|, (l_amod) hepatomegaly_2\NN\14501726|hepatocyte|lipid|microvesicular|,
D005947_D006529 NONE glucose_17\NN\14710501|serum|and (r_conj) triglycerides_15\NNS\14885088|NONE (r_pobj) in_13\IN\13603305|a|significant (r_prep) decrease_12\NN\7296428|and|Amiodarone|.|accumulation|, (r_conj) induced_1\VBD\1627355|NONE (l_dobj) accumulation_7\NN\13497135|and|Amiodarone|.|decrease|, (l_amod) hepatomegaly_2\NN\14501726|hepatocyte|lipid|microvesicular|,
D000638_D006528 NONE amiodarone_3\NN\2715941|NONE (r_pobj) of_2\IN\0|activate|The (r_prep) inability_1\NN\23271|in|transiently (r_nsubj) expressed_13\VBN\928630|.|were (l_prep) in_14\IN\13603305|transiently|inability (l_pobj) cells_18\NNS\3080309|NONE (l_compound) hepatoma_17\NN\14242337|HepG|human
D000638_D006528 NONE amiodarone_24\NN\2715941|NONE (r_pobj) of_23\IN\0|the (r_prep) effects_22\NNS\13245626|that|indirect (r_nsubj) were_31\VBD\0|.|expressed (r_ccomp) indicates_19\VBZ\952524|NONE (l_csubj) expressed_13\VBN\928630|.|were (l_prep) in_14\IN\13603305|transiently|inability (l_pobj) cells_18\NNS\3080309|NONE (l_compound) hepatoma_17\NN\14242337|HepG|human
D000638_D015431 NONE amiodarone_12\NN\2715941|NONE (r_pobj) with_11\IN\0|of (r_prep) treatment_7\NN\654885|type|, (r_appos) mice_5\NNS\2329401|NONE (r_pobj) to_1\IN\0|NONE (r_prep) compared_0\VBN\644583|in|. (r_prep) resulted_13\VBD\2633881|NONE (l_prep) in_14\IN\13603305|Compared|. (l_pobj) rate_17\NN\13815152|NONE (l_conj) extent_19\NN\13939892|and|an|increased (l_prep) of_20\IN\0|NONE (l_pobj) loss_24\NN\13252973|NONE
1117341
D015119_D006030 NONE amino_17\JJ\14621446|certain|of (r_amod) derivatives_18\NNS\5802185|NONE (r_pobj) of_15\IN\0|%|small|)|( (r_prep) amounts_5\NNS\13329641|NONE (r_pobj) of_3\IN\0|The|chronic (r_prep) feeding_2\NN\838098|in|. (r_nsubj) resulted_21\VBD\2633881|NONE (l_prep) in_22\IN\13603305|.|feeding (l_pobj) hyperglycemia_23\NN\14299637|NONE (l_appos) curve_29\NN\13863771|, (l_conj) glucosuria_34\NN\14267841|an|and|elevated|occasionally|,|tolerance|,
D005947_D006030 NONE glucose_27\NN\14710501|NONE (r_compound) tolerance_28\NN\5032565|an|glucosuria|and|elevated|occasionally|,|, (r_compound) curve_29\NN\13863771|, (l_conj) glucosuria_34\NN\14267841|an|and|elevated|occasionally|,|tolerance|,
C037652_D006030 NONE caproate_20\NN\0|NONE (r_pobj) of_19\IN\0|amino|certain (r_prep) derivatives_18\NNS\5802185|NONE (r_pobj) of_15\IN\0|%|small|)|( (r_prep) amounts_5\NNS\13329641|NONE (r_pobj) of_3\IN\0|The|chronic (r_prep) feeding_2\NN\838098|in|. (r_nsubj) resulted_21\VBD\2633881|NONE (l_prep) in_22\IN\13603305|.|feeding (l_pobj) hyperglycemia_23\NN\14299637|NONE (l_appos) curve_29\NN\13863771|, (l_conj) glucosuria_34\NN\14267841|an|and|elevated|occasionally|,|tolerance|,
C037652_D006943 NONE caproate_8\NN\0|effect|.|structurally (r_xcomp) related_6\VBN\628491|NONE (l_nsubj) effect_1\NN\34213|.|caproate|structurally (l_amod) hyperglycemic_0\JJ\0|of
C037652_D006943 NONE caproate_20\NN\0|NONE (r_pobj) of_19\IN\0|amino|certain (r_prep) derivatives_18\NNS\5802185|NONE (r_pobj) of_15\IN\0|%|small|)|( (r_prep) amounts_5\NNS\13329641|NONE (r_pobj) of_3\IN\0|The|chronic (r_prep) feeding_2\NN\838098|in|. (r_nsubj) resulted_21\VBD\2633881|NONE (l_prep) in_22\IN\13603305|.|feeding (l_pobj) hyperglycemia_23\NN\14299637|NONE
D015119_D006943 CID amino_3\JJ\14621446|NONE (r_compound) compounds_4\NNS\5869584|NONE (r_pobj) of_2\IN\0|Hyperglycemic (r_prep) effect_1\NN\34213|.|caproate|structurally (l_amod) hyperglycemic_0\JJ\0|of
D015119_D006943 CID amino_17\JJ\14621446|certain|of (r_amod) derivatives_18\NNS\5802185|NONE (r_pobj) of_15\IN\0|%|small|)|( (r_prep) amounts_5\NNS\13329641|NONE (r_pobj) of_3\IN\0|The|chronic (r_prep) feeding_2\NN\838098|in|. (r_nsubj) resulted_21\VBD\2633881|NONE (l_prep) in_22\IN\13603305|.|feeding (l_pobj) hyperglycemia_23\NN\14299637|NONE
D005947_D006943 NONE glucose_27\NN\14710501|NONE (r_compound) tolerance_28\NN\5032565|an|glucosuria|and|elevated|occasionally|,|, (r_compound) curve_29\NN\13863771|, (r_appos) hyperglycemia_23\NN\14299637|NONE
19108278
D011433_D017180 NONE propranolol_3\NN\0|NONE (r_pobj) of_2\IN\0|Both (r_prep) isomers_1\NNS\14818238|.|also|capable (r_nsubj) were_4\VBD\0|NONE (l_acomp) capable_6\JJ\0|isomers|.|also (l_prep) of_7\IN\0|NONE (l_pcomp) reversing_8\VBG\109660|NONE (l_dobj) tachycardia_10\NN\14110674|NONE
D004837_D001145 CID adrenaline_8\RB\14807929| (r_advmod) induced_10\VBN\1627355|cardiac|in (r_amod) arrhythmias_12\NNS\14103288|NONE
D004837_D001145 CID adrenaline.7_13\NNS\0|NONE (r_pobj) of_12\IN\0|the (r_prep) dose_11\NN\3740161|NONE (r_dobj) increasing_9\VBG\169651|NONE (r_pcomp) by_8\IN\0|surmountable|.|Blockade (r_prep) was_6\VBD\0|NONE (l_nsubj) blockade_0\NN\952963|by|surmountable|. (l_prep) of_1\IN\0|NONE (l_pobj) arrhythmias_2\NNS\14103288|NONE
D010042_D017180 CID ouabain_13\NN\0|NONE (r_pobj) by_12\IN\0|NONE (r_agent) caused_11\VBN\1617192|ventricular (r_acl) tachycardia_10\NN\14110674|NONE
D006221_D001145 CID halothane_17\NN\3570838|NONE (r_pobj) with_16\IN\0|NONE (r_prep) anaesthetized_15\VBN\84738|NONE (r_acl) cats_14\NNS\2120997|NONE (r_pobj) in_13\IN\13603305|cardiac|induced (r_prep) arrhythmias_12\NNS\14103288|NONE
D011433_D001145 NONE propranolol_8\NN\0|NONE (r_pobj) of_7\IN\0|optical|and|effects|the (r_prep) isomers_6\NNS\14818238|NONE (l_conj) effects_11\NNS\13245626|optical|and|the|of (l_prep) on_12\IN\0|their (l_pobj) arrhythmias_14\NNS\14103288|NONE
D011433_D001145 NONE propranolol_3\NN\0|NONE (r_pobj) of_2\IN\0|Both (r_prep) isomers_1\NNS\14818238|but|was|capable|, (r_nsubj) were_4\VBD\0|NONE (l_acomp) capable_5\JJ\0|but|isomers|was|, (l_prep) of_6\IN\0|NONE (l_pcomp) preventing_7\VBG\0|NONE (l_dobj) arrhythmias_12\NNS\14103288|NONE
D011433_D001145 NONE -)-propranolol_25\,\0|NONE (r_pobj) of_23\IN\0|mean|the (r_prep) dose_22\NN\3740161|.+/.|was|mg/kg|. (r_nsubj) was_26\VBD\0|but|isomers|capable|, (r_conj) were_4\VBD\0|NONE (l_acomp) capable_5\JJ\0|but|isomers|was|, (l_prep) of_6\IN\0|NONE (l_pcomp) preventing_7\VBG\0|NONE (l_dobj) arrhythmias_12\NNS\14103288|NONE
D011433_D001145 NONE -propranolol_35\,\0|+|( (r_conj) of_31\IN\0|NONE (r_prep) that_30\DT\0|.+/.|whereas|mg/kg (r_nsubj) was_36\VBD\0|.+/.|dose|mg/kg|. (r_advcl) was_26\VBD\0|but|isomers|capable|, (r_conj) were_4\VBD\0|NONE (l_acomp) capable_5\JJ\0|but|isomers|was|, (l_prep) of_6\IN\0|NONE (l_pcomp) preventing_7\VBG\0|NONE (l_dobj) arrhythmias_12\NNS\14103288|NONE
1451544
D017275_D005483 CID isradipine_25\NN\0|with|or (r_pobj) with_24\IN\0|other (r_prep) studies_23\NNS\635850|NONE (r_pobj) in_21\IN\13603305|than (r_prep) reported_20\VBN\831651|more (r_advcl) frequent_18\JJ\2556126|not|headache (r_acomp) were_15\VBD\0|effects|. (l_nsubj) headache_6\NN\5829480|not|frequent (l_conj) dizziness_8\NN\14299637|, (l_conj) palpitation_10\NN\14299637|, (l_conj) flushing_12\NN\281101|and|and|these
D017275_D006261 CID isradipine_25\NN\0|with|or (r_pobj) with_24\IN\0|other (r_prep) studies_23\NNS\635850|NONE (r_pobj) in_21\IN\13603305|than (r_prep) reported_20\VBN\831651|more (r_advcl) frequent_18\JJ\2556126|not|headache (r_acomp) were_15\VBD\0|effects|. (l_nsubj) headache_6\NN\5829480|not|frequent
D017275_D006973 NONE isradipine_0\NNP\0|.|for (r_compound) treatment_1\NN\654885|NONE (l_prep) for_2\IN\0|.|Isradipine (l_pobj) hypertension_3\NN\14057371|NONE
D017275_-1 NONE isradipine_25\NN\0|with|or (r_pobj) with_24\IN\0|other (r_prep) studies_23\NNS\635850|NONE (r_pobj) in_21\IN\13603305|than (r_prep) reported_20\VBN\831651|more (r_advcl) frequent_18\JJ\2556126|not|headache (r_acomp) were_15\VBD\0|effects|. (l_nsubj) headache_6\NN\5829480|not|frequent (l_conj) dizziness_8\NN\14299637|, (l_conj) palpitation_10\NN\14299637|,
D017275_D004244 CID isradipine_25\NN\0|with|or (r_pobj) with_24\IN\0|other (r_prep) studies_23\NNS\635850|NONE (r_pobj) in_21\IN\13603305|than (r_prep) reported_20\VBN\831651|more (r_advcl) frequent_18\JJ\2556126|not|headache (r_acomp) were_15\VBD\0|effects|. (l_nsubj) headache_6\NN\5829480|not|frequent (l_conj) dizziness_8\NN\14299637|,
1395192
D001971_D009203 CID bromocriptine_8\NN\0|NONE (r_dobj) receiving_7\VBG\2210855|a|postpartum (r_acl) patient_6\NN\9898892|NONE (r_pobj) in_3\IN\13603305|.|myocardial|Recurrent (r_prep) infarction_2\NN\14204950|NONE
D001971_D009203 CID bromocriptine_0\NNP\0|in|been|has|. (r_nsubjpass) implicated_3\VBN\2677097|NONE (l_prep) in_4\IN\13603305|been|Bromocriptine|has|. (l_pobj) reports_8\NNS\6470073|NONE (l_prep) of_9\IN\0|previous|several|case (l_pobj) infarction_11\NN\14204950|NONE
3475563
D001507_D002177 NONE beclomethasone_7\NN\0|and|oral (r_conj) prednisone_4\NN\2721538|NONE (r_pobj) of_2\IN\0|Concomitant (r_prep) use_1\NN\407535|may|.|risk (r_nsubj) increase_9\VB\13576355|NONE (l_dobj) risk_11\NN\14541044|may|use|. (l_prep) of_12\IN\0|the (l_pcomp) developing_13\VBG\13541167|NONE (l_dobj) hoarseness_14\NN\4988666|NONE (l_conj) candidiasis_16\NN\14176895|or
D001507_D006685 CID dipropionate_11\NN\0|NONE (r_pobj) with_9\IN\0|NONE (r_prep) hoarseness_8\NN\4988666|or|oral
D001507_D006685 CID beclomethasone_9\NN\0|NONE (r_pobj) on_7\IN\0|who|were (r_prep) placed_6\VBN\1850315||asthmatic (r_relcl) patients_3\NNS\9898892|NONE (r_pobj) of_0\IN\0|.|hoarseness (r_prep) developed_16\VBD\1753788|NONE (l_dobj) hoarseness_18\NN\4988666|.|Of
D001507_D006685 CID beclomethasone_9\NN\0|NONE (r_pobj) on_7\IN\0|be|patients|that|indicated|may (r_prep) restarted_6\VBN\1857717|We (r_ccomp) conclude_1\VBP\628491|however|should|;|not|,|because (r_ccomp) be_29\VB\14625458| (l_prep) because_16\IN\0|conclude|however|should|;|not|, (l_pobj) rate_21\NN\13815152|of (l_appos) patients_23\NNS\9898892|the|recurrence|, (l_relcl) develop_25\VBP\1753788|NONE (l_dobj) hoarseness_26\NN\4988666|who
D001507_D006685 CID beclomethasone_7\NN\0|and|oral (r_conj) prednisone_4\NN\2721538|NONE (r_pobj) of_2\IN\0|Concomitant (r_prep) use_1\NN\407535|may|.|risk (r_nsubj) increase_9\VB\13576355|NONE (l_dobj) risk_11\NN\14541044|may|use|. (l_prep) of_12\IN\0|the (l_pcomp) developing_13\VBG\13541167|NONE (l_dobj) hoarseness_14\NN\4988666|NONE
D001507_D002180 CID dipropionate_11\NN\0|NONE (r_pobj) with_9\IN\0|NONE (r_prep) hoarseness_8\NN\4988666|or|oral (r_conj) candidiasis_6\NN\14176895|who
D001507_D002180 CID beclomethasone_9\NN\0|NONE (r_pobj) on_7\IN\0|who|were (r_prep) placed_6\VBN\1850315||asthmatic (r_relcl) patients_3\NNS\9898892|NONE (r_pobj) of_0\IN\0|.|hoarseness (r_prep) developed_16\VBD\1753788|NONE (l_dobj) hoarseness_18\NN\4988666|.|Of (l_appos) 8)_20\CD\0|(|either (l_appos) thrush_23\NN\14181713|,
D001507_D001249 NONE beclomethasone_9\NN\0|NONE (r_pobj) on_7\IN\0|who|were (r_prep) placed_6\VBN\1850315||asthmatic (r_relcl) patients_3\NNS\9898892|NONE (l_amod) asthmatic_2\JJ\7846|placed|
D011241_D006685 NONE prednisone_4\NN\2721538|NONE (r_pobj) of_2\IN\0|Concomitant (r_prep) use_1\NN\407535|may|.|risk (r_nsubj) increase_9\VB\13576355|NONE (l_dobj) risk_11\NN\14541044|may|use|. (l_prep) of_12\IN\0|the (l_pcomp) developing_13\VBG\13541167|NONE (l_dobj) hoarseness_14\NN\4988666|NONE
D011241_D002177 NONE prednisone_4\NN\2721538|NONE (r_pobj) of_2\IN\0|Concomitant (r_prep) use_1\NN\407535|may|.|risk (r_nsubj) increase_9\VB\13576355|NONE (l_dobj) risk_11\NN\14541044|may|use|. (l_prep) of_12\IN\0|the (l_pcomp) developing_13\VBG\13541167|NONE (l_dobj) hoarseness_14\NN\4988666|NONE (l_conj) candidiasis_16\NN\14176895|or
11799346
D008795_D001714 CID metronidazole_2\NNP\2723292|, (r_conj) cotrimoxazole_0\NNP\0|in|were|. (r_nsubjpass) involved_7\VBN\2676054|NONE (l_prep) in_8\IN\13603305|were|Cotrimoxazole|. (l_pobj) episodes_12\NNS\7283608|NONE (l_amod) manic_11\JJ\0|reported|
D004917_D001714 CID erythromycin_5\NN\2716866|,|and (r_conj) metronidazole_2\NNP\2723292|, (r_conj) cotrimoxazole_0\NNP\0|in|were|. (r_nsubjpass) involved_7\VBN\2676054|NONE (l_prep) in_8\IN\13603305|were|Cotrimoxazole|. (l_pobj) episodes_12\NNS\7283608|NONE (l_amod) manic_11\JJ\0|reported|
D017291_D001714 CID clarithromycin_6\NN\0|be|.|Cases (r_dobj) showed_5\VBD\2137132|NONE (l_xcomp) be_10\VB\14625458|clarithromycin|.|Cases (l_attr) the_11\DT\0|to (l_acl) associated_14\VBN\628491|NONE (l_prep) with_15\IN\0|frequently (l_pobj) development_17\NN\248977|NONE (l_prep) of_18\IN\0|the (l_pobj) mania_19\NN\9180259|NONE
D015662_D001714 CID cotrimoxazole_0\NNP\0|in|were|. (r_nsubjpass) involved_7\VBN\2676054|NONE (l_prep) in_8\IN\13603305|were|Cotrimoxazole|. (l_pobj) episodes_12\NNS\7283608|NONE (l_amod) manic_11\JJ\0|reported|
D002939_D001714 CID ciprofloxacin_8\NNS\2716866|and (r_conj) clarithromycin_6\NN\0|be|.|Cases (r_dobj) showed_5\VBD\2137132|NONE (l_xcomp) be_10\VB\14625458|clarithromycin|.|Cases (l_attr) the_11\DT\0|to (l_acl) associated_14\VBN\628491|NONE (l_prep) with_15\IN\0|frequently (l_pobj) development_17\NN\248977|NONE (l_prep) of_18\IN\0|the (l_pobj) mania_19\NN\9180259|NONE
10764869
D016559_D015354 NONE tacrolimus_8\NN\0|NONE (r_pobj) of_6\IN\0|NONE (r_prep) discontinuation_5\NN\209943|NONE (r_pobj) despite_4\IN\7501545|.|Deterioration (r_prep) occurred_3\VBD\0|NONE (l_nsubj) deterioration_0\NN\14560612|.|despite (l_prep) of_1\IN\0|NONE (l_pobj) vision_2\NN\5767733|NONE
D016559_D009901 CID tacrolimus_10\NN\0|NONE (r_pobj) on_9\IN\0|a (r_prep) patient_8\NN\9898892|NONE (r_pobj) in_6\IN\13603305|of|A|.|after (r_prep) case_1\NN\7283608|NONE (l_prep) of_2\IN\0|in|A|.|after (l_pobj) neuropathy_5\NN\14204950|NONE
D016559_D009901 CID fk506_12\NNP\0|(|therapy|) (r_appos) tacrolimus_10\NN\0|NONE (r_pobj) on_9\IN\0|a (r_prep) patient_8\NN\9898892|NONE (r_pobj) in_6\IN\13603305|of|A|.|after (r_prep) case_1\NN\7283608|NONE (l_prep) of_2\IN\0|in|A|.|after (l_pobj) neuropathy_5\NN\14204950|NONE
D016559_D009901 CID tacrolimus_12\NN\0|NONE (r_dobj) receiving_11\NN\2210855|a (r_acl) patient_10\NN\9898892|NONE (r_pobj) in_8\IN\13603305|of|a|)|for (r_prep) case_3\NN\7283608|.|To (l_prep) of_4\IN\0|in|a|)|for (l_pobj) neuropathy_7\NN\14204950|NONE
D016559_D009901 CID 506_15\CD\0|,|Prograf (r_nummod) fk_14\NNP\0|(|;|USA (r_appos) tacrolimus_12\NN\0|NONE (r_dobj) receiving_11\NN\2210855|a (r_acl) patient_10\NN\9898892|NONE (r_pobj) in_8\IN\13603305|of|a|)|for (r_prep) case_3\NN\7283608|.|To (l_prep) of_4\IN\0|in|a|)|for (l_pobj) neuropathy_7\NN\14204950|NONE
D016559_D009901 CID tacrolimus_0\NNP\0|may|be|.|with (r_nsubjpass) associated_7\VBN\628491|NONE (l_prep) with_8\IN\0|may|be|Tacrolimus|. (l_pobj) toxicity_11\NN\13576101|NONE
24595967
D018817_D008569 CID ecstasy_5\NN\13985818|NONE (r_compound) users_6\NNS\7846|NONE (r_pobj) in_4\IN\13603305|overnight|Dysfunctional|.|memory (r_prep) consolidation_3\NN\7373803|NONE (l_compound) memory_2\NN\5926676|overnight|Dysfunctional|.|in
D018817_D008569 CID ecstasy_0\NNP\13985818|NONE (r_compound) users_1\NNS\7846|consolidation|. (r_nsubj) demonstrated_2\VBD\2137132|NONE (l_dobj) consolidation_6\NN\7373803|users|. (l_compound) memory_5\NN\5926676|finding|,|impaired|overnight
D018817_D008569 CID ecstasy_3\NN\13985818| (r_npadvmod) associated_5\VBN\628491|that|in (r_amod) dysfunction_6\NN\14204950|may|impairments (r_nsubj) underlie_13\VB\2604760|We|. (l_dobj) impairments_17\NNS\7296428|dysfunction|may
D018817_D008569 CID ecstasy_20\NN\13985818|regular (r_compound) users_21\NNS\7846|NONE (r_pobj) in_18\IN\13603305|overnight|memory (r_prep) impairments_17\NNS\7296428|dysfunction|may
D018817_D012893 CID ecstasy_4\NN\13985818|NONE (r_compound) users_5\NNS\7846|impairments|that|have|and (r_nsubj) marked_7\VBN\1296462|.|studies (l_conj) impairments_15\NNS\7296428|users|that|have|and
48835
D011433_D007003 NONE propranolol_2\NN\0|NONE (l_prep) of_3\IN\0|NONE (l_pobj) effects_5\NNS\13245626|NONE (l_prep) of_6\IN\0|cardiovascular (l_pobj) hypoglycaemia_8\NN\14299637|NONE
17572393
D008550_D054220 NONE melatonin_3\NN\5407119|NONE (r_pobj) of_2\IN\0|.|Neuroprotective|upon (r_prep) effects_1\NNS\13245626|NONE (l_prep) upon_4\IN\0|.|of|Neuroprotective (l_pobj) cortex_8\NN\5462674|NONE (l_prep) in_9\IN\13603305|offspring|the|cerebellar (l_pobj) model_12\NN\5888929|NONE (l_prep) of_13\IN\0|rat|the (l_pobj) dysplasia_18\NN\14501726|NONE
D008550_D054220 NONE melatonin_10\NN\5407119|NONE (l_prep) upon_11\IN\0|exogenous (l_pobj) dysplasia_17\NN\14501726|NONE
D002330_D054220 CID bcnu_14\NNP\0| (r_npadvmod) induced_16\VBN\1627355|cortical (r_amod) dysplasia_18\NN\14501726|NONE
D002330_D054220 CID bcnu_1\NNP\0|NONE (l_conj) investigate_5\VB\644583|)|.|(|and (l_dobj) effects_7\NNS\13245626|using|,|to (l_prep) of_8\IN\0|the (l_pobj) melatonin_10\NN\5407119|NONE (l_prep) upon_11\IN\0|exogenous (l_pobj) dysplasia_17\NN\14501726|NONE
D002330_D054220 CID bcnu_13\NNP\0| (r_npadvmod) induced_15\VBN\1627355|cerebellar|cortical (r_amod) dysplasia_17\NN\14501726|NONE
D002330_D054220 CID bcnu_25\NNP\0| (r_npadvmod) exposed_27\VBN\2110927|cortical|dysplasia (r_amod) group_30\NN\2137|NONE (l_compound) dysplasia_29\NN\14501726|cortical|exposed
12677626
D002045_D066126 NONE bupivacaine_11\NN\0|NONE (r_pobj) than_9\IN\0|a|safer|toxicity (r_prep) profile_8\NN\6999802|Although|levobupivacaine|may (l_compound) toxicity_7\NN\13576101|than|a|safer
C476513_D066126 NONE levobupivacaine_1\PRP\0|Although|profile|may (r_nsubj) have_3\VB\7846|.|,|in|will|,|reach|it (l_dobj) profile_8\NN\6999802|Although|levobupivacaine|may (l_compound) toxicity_7\NN\13576101|than|a|safer
C476513_D066126 NONE levobupivacaine_17\NN\0|NONE (r_pobj) of_16\IN\0|adequate (r_prep) amounts_15\NNS\13329641|circulation|if (r_nsubj) reach_18\VBP\8593130|.|,|in|have|will|,|it (r_advcl) result_24\VB\34213|NONE (l_advcl) have_3\VB\7846|.|,|in|will|,|reach|it (l_dobj) profile_8\NN\6999802|Although|levobupivacaine|may (l_compound) toxicity_7\NN\13576101|than|a|safer
C476513_D012640 NONE levobupivacaine_1\PRP\0|Although|profile|may (r_nsubj) have_3\VB\7846|.|,|in|will|,|reach|it (r_advcl) result_24\VB\34213|NONE (l_prep) in_25\IN\13603305|.|,|have|will|,|reach|it (l_pobj) convulsions_26\NNS\14081375|NONE
C476513_D012640 NONE levobupivacaine_17\NN\0|NONE (r_pobj) of_16\IN\0|adequate (r_prep) amounts_15\NNS\13329641|circulation|if (r_nsubj) reach_18\VBP\8593130|.|,|in|have|will|,|it (r_advcl) result_24\VB\34213|NONE (l_prep) in_25\IN\13603305|.|,|have|will|,|reach|it (l_pobj) convulsions_26\NNS\14081375|NONE
C476513_D020258 NONE levobupivacaine_8\NN\0|NONE (r_pobj) of_7\IN\0|the (r_prep) administration_6\NN\1133281|NONE (r_dobj) following_4\VBG\8180190|system|Central|.|:|report (r_prep) toxicity_3\NN\13576101|NONE
D013390_D012640 NONE succinylcholine_11\NN\3800001|NONE (r_pobj) to_10\IN\0|NONE (r_prep) addition_9\NN\3081021|NONE (r_pobj) in_8\IN\13603305|.|with|seizures|were|successfully (r_prep) treated_4\VBN\2376958|NONE (l_nsubjpass) seizures_1\NNS\14081375|.|with|in|were|successfully
D002045_D012640 NONE bupivacaine_11\NN\0|NONE (r_pobj) than_9\IN\0|a|safer|toxicity (r_prep) profile_8\NN\6999802|Although|levobupivacaine|may (r_dobj) have_3\VB\7846|.|,|in|will|,|reach|it (r_advcl) result_24\VB\34213|NONE (l_prep) in_25\IN\13603305|.|,|have|will|,|reach|it (l_pobj) convulsions_26\NNS\14081375|NONE
C476513_D004830 CID levobupivacaine_13\NN\0|NONE (r_pobj) of_12\IN\0|intravascular|accidental (r_prep) injection_11\NN\320852|NONE (r_pobj) following_8\VBG\8180190|We|.|cases (r_prep) describe_1\VBP\1001294|NONE (l_dobj) cases_3\NNS\7283608|We|.|following (l_prep) of_4\IN\0| (l_pobj) seizures_7\NNS\14081375|NONE
C476513_D004830 CID levobupivacaine_5\NN\0|NONE (r_pobj) of_4\IN\0|%|the (r_prep) administration_3\NN\1133281|NONE (r_pobj) after_1\IN\0|seizures|Immediately|despite|patients|,|.|, (r_prep) developed_17\VBD\1753788|NONE (l_dobj) seizures_20\NNS\14081375|Immediately|after|despite|patients|,|.|,
D013874_D012640 NONE thiopental_7\VBN\2792049|NONE (r_pobj) with_5\IN\0|.|seizures|in|were|successfully (r_prep) treated_4\VBN\2376958|NONE (l_nsubjpass) seizures_1\NNS\14081375|.|with|in|were|successfully
D004837_D004830 NONE epinephrine_9\NN\14807929|/|microgram (r_nmod) ml_13\NNP\13616054|NONE (r_pobj) with_8\IN\0|. (r_prep) %_7\NN\0|of|the (r_appos) administration_3\NN\1133281|NONE (r_pobj) after_1\IN\0|seizures|Immediately|despite|patients|,|.|, (r_prep) developed_17\VBD\1753788|NONE (l_dobj) seizures_20\NNS\14081375|Immediately|after|despite|patients|,|.|,
D004837_D004830 NONE epinephrine_33\NN\14807929|intravenous (r_compound) administration_34\NN\1133281|NONE (r_pobj) of_31\IN\0|clinical|no (r_prep) signs_30\NNS\6643763|negative|for|and (r_conj) aspiration_24\NN\4836268|NONE (r_pobj) despite_22\IN\7501545|seizures|Immediately|after|patients|,|.|, (r_prep) developed_17\VBD\1753788|NONE (l_dobj) seizures_20\NNS\14081375|Immediately|after|despite|patients|,|.|,
7727612
D008140_D009207 CID lorazepam_3\NN\2830852|NONE (r_amod) therapy_4\NN\657604|NONE (r_pobj) with_2\IN\0|in (r_prep) associated_1\VBN\628491|. (r_acl) myoclonus_0\NNP\14360459|NONE
D008140_D009207 CID lorazepam_19\NN\2830852|NONE (r_pobj) of_18\IN\0|intravenous|the (r_prep) administration_17\NN\1133281|NONE (r_pobj) following_14\VBG\8180190|NONE (r_prep) myoclonus_13\NN\14360459|infants|.
17543491
19293073
D001241_D002318 NONE aspirin_24\NN\2707683|NONE (r_pobj) of_23\IN\0|for|systematic (r_prep) reviews_22\NNS\5733583|;|meta|and| (l_prep) for_27\IN\0|systematic|of (l_pobj) prevention_30\NN\1073995|NONE (l_prep) of_31\IN\0|primary|the (l_pobj) disease_33\NN\14061805|NONE
D001241_D002318 NONE aspirin_24\NN\2707683|NONE (r_pobj) of_23\IN\0|for|systematic (r_prep) reviews_22\NNS\5733583|;|meta|and| (l_prep) for_27\IN\0|systematic|of (l_pobj) prevention_30\NN\1073995|NONE (l_prep) of_31\IN\0|primary|the (l_pobj) disease_33\NN\14061805|NONE (l_appos) cvd_35\NN\0|cardiovascular
D001241_D002318 NONE aspirin_24\NN\2707683|NONE (r_pobj) of_23\IN\0|for|systematic (r_prep) reviews_22\NNS\5733583|;|meta|and| (r_conj) analyses_18\NNS\633864|;|control (r_conj) studies_14\NNS\635850|;|)|controlled|(|RCTs|,|language|randomized (r_conj) trials_6\NNS\786195|answer|were (r_nsubjpass) selected_38\VBN\697589|aspirin|:|events|?|Does (r_ccomp) decrease_47\NN\7296428|NONE (l_dobj) events_50\NNS\23100|aspirin|:|selected|?|Does (l_conj) strokes_52\NNS\556313|coronary|heart|, (l_conj) death_54\NN\7296428|, (l_conj) mortality_66\NN\5054863|from|,|or (l_prep) in_67\IN\13603305|cause (l_pobj) adults_68\NNS\7846|NONE (l_prep) without_69\IN\0|NONE (l_pobj) cvd_71\NN\0|NONE
D001241_D002318 NONE aspirin_46\NN\2707683|:|events|selected|?|Does (r_nsubj) decrease_47\NN\7296428|NONE (l_ccomp) selected_38\VBN\697589|aspirin|:|events|?|Does (l_nsubjpass) trials_6\NNS\786195|answer|were (l_conj) studies_14\NNS\635850|;|)|controlled|(|RCTs|,|language|randomized (l_conj) analyses_18\NNS\633864|;|control (l_conj) reviews_22\NNS\5733583|;|meta|and| (l_prep) for_27\IN\0|systematic|of (l_pobj) prevention_30\NN\1073995|NONE (l_prep) of_31\IN\0|primary|the (l_pobj) disease_33\NN\14061805|NONE
D001241_D002318 NONE aspirin_46\NN\2707683|:|events|selected|?|Does (r_nsubj) decrease_47\NN\7296428|NONE (l_ccomp) selected_38\VBN\697589|aspirin|:|events|?|Does (l_nsubjpass) trials_6\NNS\786195|answer|were (l_conj) studies_14\NNS\635850|;|)|controlled|(|RCTs|,|language|randomized (l_conj) analyses_18\NNS\633864|;|control (l_conj) reviews_22\NNS\5733583|;|meta|and| (l_prep) for_27\IN\0|systematic|of (l_pobj) prevention_30\NN\1073995|NONE (l_prep) of_31\IN\0|primary|the (l_pobj) disease_33\NN\14061805|NONE (l_appos) cvd_35\NN\0|cardiovascular
D001241_D002318 NONE aspirin_46\NN\2707683|:|events|selected|?|Does (r_nsubj) decrease_47\NN\7296428|NONE (l_dobj) events_50\NNS\23100|aspirin|:|selected|?|Does (l_conj) strokes_52\NNS\556313|coronary|heart|, (l_conj) death_54\NN\7296428|, (l_conj) mortality_66\NN\5054863|from|,|or (l_prep) in_67\IN\13603305|cause (l_pobj) adults_68\NNS\7846|NONE (l_prep) without_69\IN\0|NONE (l_pobj) cvd_71\NN\0|NONE
D001241_D002318 NONE aspirin_27\JJ\2707683|NONE (r_compound) use_28\NN\407535|that|number (r_nsubj) reduces_29\VBZ\441445|.|evidence (l_dobj) number_31\NN\5107765|use|that (l_prep) of_32\IN\0|the (l_pobj) events_34\NNS\23100|NONE (l_compound) cvd_33\NN\0|in
D001241_D002318 NONE aspirin_27\JJ\2707683|NONE (r_compound) use_28\NN\407535|that|number (r_nsubj) reduces_29\VBZ\441445|.|evidence (l_dobj) number_31\NN\5107765|use|that (l_prep) of_32\IN\0|the (l_pobj) events_34\NNS\23100|NONE (l_prep) in_35\IN\13603305|CVD (l_pobj) patients_36\NNS\9898892|NONE (l_prep) without_37\IN\0|NONE (l_pobj) cvd_39\NNP\0|NONE
D001241_D002318 NONE aspirin_0\NNP\2707683|.|affect|does|not (r_nsubj) seem_3\VB\2604760|NONE (l_xcomp) affect_5\VB\26192|.|Aspirin|does|not (l_dobj) mortality_7\NN\5054863|to (l_compound) cvd_6\NN\0|mortality|or
D001241_D002318 NONE aspirin_3\NN\2707683|NONE (l_prep) for_4\IN\0|NONE (l_pobj) prevention_7\NN\1073995|NONE (l_prep) of_8\IN\0|the|primary (l_pobj) cvd_9\NNP\0|NONE
D001241_D020300 CID aspirin_1\NN\2707683|strokes|?|Does (r_nsubj) increase_2\VB\13576355|NONE (l_dobj) strokes_7\NNS\556313|aspirin|?|Does
D001241_D020300 CID aspirin_9\JJ\2707683|NONE (r_compound) use_10\NN\407535|NONE (r_pobj) with_8\IN\0|hemorrhagic (r_prep) strokes_7\NNS\556313|NONE
D001241_D020521 CID aspirin_8\NN\2707683|for (r_dobj) taking_7\VBG\37396|NONE (l_prep) for_9\IN\0|aspirin (l_pobj) prevention_12\NN\1073995|NONE (l_prep) of_13\IN\0|the|primary (l_pobj) infarctions_15\NNS\14204950|NONE (l_conj) strokes_17\NNS\556313|myocardial|,
D001241_D020521 CID aspirin_24\NN\2707683|NONE (r_pobj) of_23\IN\0|for|systematic (r_prep) reviews_22\NNS\5733583|;|meta|and| (r_conj) analyses_18\NNS\633864|;|control (r_conj) studies_14\NNS\635850|;|)|controlled|(|RCTs|,|language|randomized (r_conj) trials_6\NNS\786195|answer|were (r_nsubjpass) selected_38\VBN\697589|aspirin|:|events|?|Does (r_ccomp) decrease_47\NN\7296428|NONE (l_dobj) events_50\NNS\23100|aspirin|:|selected|?|Does (l_conj) strokes_52\NNS\556313|coronary|heart|,
D001241_D020521 CID aspirin_24\NN\2707683|NONE (r_pobj) of_23\IN\0|for|systematic (r_prep) reviews_22\NNS\5733583|;|meta|and| (r_conj) analyses_18\NNS\633864|;|control (r_conj) studies_14\NNS\635850|;|)|controlled|(|RCTs|,|language|randomized (r_conj) trials_6\NNS\786195|answer|were (r_nsubjpass) selected_38\VBN\697589|aspirin|:|events|?|Does (r_ccomp) decrease_47\NN\7296428|NONE (l_dobj) events_50\NNS\23100|aspirin|:|selected|?|Does (l_conj) strokes_52\NNS\556313|coronary|heart|, (l_conj) death_54\NN\7296428|, (l_prep) from_55\IN\0|mortality|,|or (l_pobj) events_58\NNS\23100|NONE (l_conj) stroke_60\NN\556313|coronary|or|heart
D001241_D020521 CID aspirin_46\NN\2707683|:|events|selected|?|Does (r_nsubj) decrease_47\NN\7296428|NONE (l_dobj) events_50\NNS\23100|aspirin|:|selected|?|Does (l_conj) strokes_52\NNS\556313|coronary|heart|,
D001241_D020521 CID aspirin_46\NN\2707683|:|events|selected|?|Does (r_nsubj) decrease_47\NN\7296428|NONE (l_dobj) events_50\NNS\23100|aspirin|:|selected|?|Does (l_conj) strokes_52\NNS\556313|coronary|heart|, (l_conj) death_54\NN\7296428|, (l_prep) from_55\IN\0|mortality|,|or (l_pobj) events_58\NNS\23100|NONE (l_conj) stroke_60\NN\556313|coronary|or|heart
D001241_D020521 CID aspirin_1\NN\2707683|strokes|?|Does (r_nsubj) increase_2\VB\13576355|NONE (l_dobj) strokes_7\NNS\556313|aspirin|?|Does
D001241_D020521 CID aspirin_9\JJ\2707683|NONE (r_compound) use_10\NN\407535|NONE (r_pobj) with_8\IN\0|hemorrhagic (r_prep) strokes_7\NNS\556313|NONE
D001241_D020521 CID aspirin_0\NNP\2707683|risk|. (r_nsubj) reduces_1\VBZ\441445|NONE (l_dobj) risk_3\NN\14541044|Aspirin|. (l_prep) for_4\IN\0|the (l_pobj) infarction_6\NN\14204950|NONE (l_prep) in_7\IN\13603305|myocardial (l_pobj) men_8\NNS\8208016|NONE (l_conj) strokes_10\NNS\556313|and|in
D001241_D003327 NONE aspirin_17\NN\2707683|clinicians|that|with (r_dobj) discuss_16\VB\7466557|.|strongly|In|,|USPSTF (l_prep) with_18\IN\0|clinicians|aspirin|that (l_pobj) adults_19\NNS\7846|NONE (l_relcl) are_21\VBP\13600404|NONE (l_prep) at_22\IN\14622893|who (l_pobj) risk_24\NN\14541044|NONE (l_prep) for_25\IN\0|increased (l_pobj) disease_28\NN\14061805|NONE
D001241_D006471 CID aspirin_1\NN\2707683|strokes|?|Does (r_nsubj) increase_2\VB\13576355|NONE (l_dobj) strokes_7\NNS\556313|aspirin|?|Does (l_nmod) bleeding_4\NN\14285662|NONE
D001241_D006471 CID aspirin_3\NN\2707683|NONE (r_pobj) of_2\IN\0|The|for (r_prep) use_1\NN\407535|.|risk (r_nsubj) increases_7\VBZ\13576355|NONE (l_dobj) risk_9\NN\14541044|.|use (l_prep) for_10\IN\0|the (l_pobj) events_13\NNS\23100|NONE (l_appos) events_18\NNS\23100|in|bleeding|major|,|, (l_compound) bleeding_17\NN\14285662|gastrointestinal
D001241_D009203 NONE aspirin_8\NN\2707683|for (r_dobj) taking_7\VBG\37396|NONE (l_prep) for_9\IN\0|aspirin (l_pobj) prevention_12\NN\1073995|NONE (l_prep) of_13\IN\0|the|primary (l_pobj) infarctions_15\NNS\14204950|NONE
D001241_D009203 NONE aspirin_0\NNP\2707683|risk|. (r_nsubj) reduces_1\VBZ\441445|NONE (l_dobj) risk_3\NN\14541044|Aspirin|. (l_prep) for_4\IN\0|the (l_pobj) infarction_6\NN\14204950|NONE
D001241_D006470 NONE aspirin_3\NN\2707683|NONE (r_pobj) of_2\IN\0|The|for (r_prep) use_1\NN\407535|.|risk (r_nsubj) increases_7\VBZ\13576355|NONE (l_dobj) risk_9\NN\14541044|.|use (l_prep) for_10\IN\0|the (l_pobj) events_13\NNS\23100|NONE (l_compound) bleeding_12\NN\14285662|events|in|major|,|,
D001241_D006470 NONE aspirin_0\NNP\2707683|NONE (r_compound) use_1\NN\407535|.|risk (r_nsubj) increases_2\VBZ\13576355|NONE (l_dobj) risk_4\NN\14541044|.|use (l_prep) for_5\IN\0|the (l_pobj) events_8\NNS\23100|NONE (l_compound) bleeding_7\NN\14285662|serious
3125850
D015760_D005207 NONE alfentanil_15\NN\0|NONE (r_pobj) by_14\IN\0|NONE (r_prep) inhibition_13\NN\1068773|:|in|muscle|induced (r_appos) fasciculations_9\NNS\14361664|NONE
D015760_D005207 NONE alfentanil_19\NN\0|the (r_compound) group_20\NN\2137|NONE (r_pobj) in_17\IN\13603305|NONE (r_prep) than_16\IN\0|in|significantly (r_prep) greater_12\JJR\0|.|incidence (r_acomp) were_10\VBD\0|NONE (l_nsubj) incidence_1\NN\13821570|.|greater (l_conj) intensity_3\NN\5090441|and|The (l_prep) of_4\IN\0|NONE (l_pobj) fasciculations_6\NNS\14361664|NONE
D015760_D005207 NONE alfentanil_26\NN\0|the (r_compound) group_27\NN\2137|NONE (r_pobj) in_24\IN\13603305|NONE (r_prep) than_23\IN\0|in|pressure|higher (r_prep) was_6\VBD\0|NONE (l_nsubj) pressure_2\NN\11419404|in|than|higher (l_prep) during_3\IN\0|intragastric|The (l_pobj) fasciculations_5\NNS\14361664|NONE
D015760_D005207 NONE alfentanil_0\NNP\0|kg|effectively|incidence (r_dep) inhibits_5\VBZ\2510337|moreover|at|,|;|pressure|. (l_dobj) incidence_7\NN\13821570|kg|effectively|Alfentanil (l_prep) of_10\IN\0|intensity|and|the (l_pobj) fasciculations_15\NNS\14361664|NONE
D013390_D005207 CID suxamethonium_5\NN\0|NONE (r_npadvmod) induced_7\VBN\1627355|inhibition|:|in|muscle (r_amod) fasciculations_9\NNS\14361664|NONE
D013390_D005207 CID suxamethonium_9\NN\0|NONE (r_pobj) by_8\IN\0|NONE (r_agent) caused_7\VBN\1617192|muscle (r_acl) fasciculations_6\NNS\14361664|NONE
D013390_D005207 CID suxamethonium_13\NN\0|NONE (r_pobj) by_12\IN\0|NONE (r_agent) caused_11\VBN\1617192|muscle (r_acl) fasciculations_10\NNS\14361664|NONE
D013390_D005207 CID suxamethonium_11\NN\0| (r_npadvmod) induced_13\VBN\1627355|muscle (r_amod) fasciculations_15\NNS\14361664|NONE
D014867_D005207 NONE h2o_21\NNP\14618834|(|the|)|control (r_appos) group_12\NN\2137|NONE (r_pobj) in_9\IN\13603305|pressure|than|higher (r_prep) was_6\VBD\0|NONE (l_nsubj) pressure_2\NN\11419404|in|than|higher (l_prep) during_3\IN\0|intragastric|The (l_pobj) fasciculations_5\NNS\14361664|NONE
19655282
D003042_D007511 NONE cocaine_12\NN\3492717| (r_npadvmod) associated_14\VBN\628491|chest (r_amod) pain_16\NN\14299637|NONE (r_pobj) in_11\IN\13603305|NONE (r_prep) efficacious_10\JJ\0|strategy|account|would|whether|, (r_acomp) be_9\VB\14625458|.|unclear|It (l_advcl) account_22\VB\6647206|strategy|efficacious|would|whether|, (l_prep) for_23\IN\0|as|may|vasospasm (l_pobj) some_24\DT\0|NONE (l_prep) of_25\IN\0|NONE (l_pobj) ischemia_27\NN\14195315|NONE
D003042_D007511 NONE cocaine_1\NN\3492717| (r_npadvmod) associated_3\VBN\628491|myocardial (r_amod) ischemia_5\NN\14195315|from|.|Although|can (r_nsubj) result_7\VB\34213|NONE (l_prep) from_8\IN\0|.|Although|can|ischemia (l_pobj) vasoconstriction_10\NN\1149911|NONE (l_acl) discharged_35\VBN\1640855|coronary|, (l_nsubjpass) patients_12\NNS\9898892|with|be|from|safely|may|after (l_prep) with_13\IN\0|NONE (l_pobj) cocaine_14\NN\3492717|NONE (l_acl) associated_15\VBN\628491|NONE (l_dobj) pain_17\NN\14299637|NONE (l_conj) ecg_23\NNP\7000195|chest|, (l_amod) ischemic_22\JJ\0|,|a|and|
D003042_D007511 NONE cocaine_14\NN\3492717|NONE (l_acl) associated_15\VBN\628491|NONE (l_dobj) pain_17\NN\14299637|NONE (l_conj) ecg_23\NNP\7000195|chest|, (l_amod) ischemic_22\JJ\0|,|a|and|
D003042_D002637 CID cocaine_13\NN\3492717| (r_npadvmod) associated_15\VBN\628491|chest (r_amod) pain_17\NN\14299637|NONE
D003042_D002637 CID cocaine_10\NN\3492717| (r_npadvmod) associated_12\VBN\628491|chest (r_amod) pain_14\NN\14299637|NONE
D003042_D002637 CID cocaine_12\NN\3492717| (r_npadvmod) associated_14\VBN\628491|chest (r_amod) pain_16\NN\14299637|NONE
D003042_D002637 CID cocaine_10\NN\3492717| (r_npadvmod) associated_12\VBN\628491|chest (r_amod) pain_14\NN\14299637|NONE
D003042_D002637 CID cocaine_6\NN\3492717| (r_npadvmod) associated_8\VBN\628491|chest (r_amod) pain_10\NN\14299637|NONE
D003042_D002637 CID cocaine_1\NN\3492717| (r_npadvmod) associated_3\VBN\628491|myocardial (r_amod) ischemia_5\NN\14195315|from|.|Although|can (r_nsubj) result_7\VB\34213|NONE (l_prep) from_8\IN\0|.|Although|can|ischemia (l_pobj) vasoconstriction_10\NN\1149911|NONE (l_acl) discharged_35\VBN\1640855|coronary|, (l_nsubjpass) patients_12\NNS\9898892|with|be|from|safely|may|after (l_prep) with_13\IN\0|NONE (l_pobj) cocaine_14\NN\3492717|NONE (l_acl) associated_15\VBN\628491|NONE (l_dobj) pain_17\NN\14299637|NONE
D003042_D002637 CID cocaine_14\NN\3492717|NONE (l_acl) associated_15\VBN\628491|NONE (l_dobj) pain_17\NN\14299637|NONE
D003042_D054058 NONE cocaine_10\NN\3492717| (r_npadvmod) associated_12\VBN\628491|chest (r_amod) pain_14\NN\14299637|NONE (r_pobj) with_9\IN\0|to (r_prep) presenting_2\VBG\2137132|Most (r_acl) patients_1\NNS\9898892|and|are|receive|for|. (r_nsubjpass) admitted_16\VBN\822367|NONE (l_conj) receive_23\VB\2210855|and|patients|are|for|. (l_dobj) protocol_32\NN\6652242|prior (l_nmod) syndrome_30\NN\5870365|a|"|with|acute|,|rule|"
D003042_D003329 NONE cocaine_12\NN\3492717| (r_npadvmod) associated_14\VBN\628491|chest (r_amod) pain_16\NN\14299637|NONE (r_pobj) in_11\IN\13603305|NONE (r_prep) efficacious_10\JJ\0|strategy|account|would|whether|, (r_acomp) be_9\VB\14625458|.|unclear|It (l_advcl) account_22\VB\6647206|strategy|efficacious|would|whether|, (l_nsubj) vasospasm_20\NN\0|as|may|for
D003042_D017202 CID cocaine_1\NN\3492717| (r_npadvmod) associated_3\VBN\628491|myocardial (r_amod) ischemia_5\NN\14195315|from|.|Although|can
D003042_D017202 CID cocaine_14\NN\3492717|NONE (r_pobj) with_13\IN\0|NONE (r_prep) patients_12\NNS\9898892|with|be|from|safely|may|after (r_nsubjpass) discharged_35\VBN\1640855|coronary|, (r_acl) vasoconstriction_10\NN\1149911|NONE (r_pobj) from_8\IN\0|.|Although|can|ischemia (r_prep) result_7\VB\34213|NONE (l_nsubj) ischemia_5\NN\14195315|from|.|Although|can
24284476
D047310_D000647 NONE apigenin_2\NN\0|not|.|)|amnesia|,|Furthermore|did (r_nsubj) prevent_5\VB\0|NONE (l_dobj) amnesia_7\NN\5669934|not|.|)|apigenin|,|Furthermore|did
D012601_D000647 CID scopolamine_10\NN\14712692|NONE (r_pobj) by_9\IN\0|NONE (r_agent) induced_8\VBN\1627355|the (r_acl) amnesia_7\NN\5669934|not|.|)|apigenin|,|Furthermore|did
10985896
D004317_D013280 CID doxorubicin_5\NN\2716866|studies|be|.|being|have (r_dobj) demonstrated_3\VBN\2137132|NONE (l_advcl) being_41\VBG\24720|studies|be|.|doxorubicin|have (l_attr) erythrodysesthesia_43\NN\0|NONE (l_appos) syndrome_49\NN\5870365|severe (l_conj) stomatitis_53\NN\14336539|)|foot|"|"|(|and
D004317_D013280 CID doxil_7\NNS\0|liposomal (r_appos) doxorubicin_5\NN\2716866|studies|be|.|being|have (r_dobj) demonstrated_3\VBN\2137132|NONE (l_advcl) being_41\VBG\24720|studies|be|.|doxorubicin|have (l_attr) erythrodysesthesia_43\NN\0|NONE (l_appos) syndrome_49\NN\5870365|severe (l_conj) stomatitis_53\NN\14336539|)|foot|"|"|(|and
D004317_D013280 CID doxorubicin_3\NN\2716866|NONE (r_compound) regimen_4\NN\5898568|modified|.|in|than|This|liposomal (r_compound) results_5\VBZ\34213|NONE (l_prep) in_6\IN\13603305|modified|.|than|This|liposomal|regimen (l_pobj) toxicity_8\NN\13576101|NONE (l_appos) stomatitis_10\NN\14336539|)|less|(
D010984_D013280 NONE platinum_16\NN\14627081| (r_npadvmod) resistant_18\JJ\0|ovarian (r_amod) cancer_20\NN\14239425|NONE (r_pobj) in_15\IN\13603305|active|antineoplastic|an (r_prep) agent_14\NN\7347|to|with|q|, (r_attr) be_10\VB\14625458|studies|.|doxorubicin|being|have (r_advcl) demonstrated_3\VBN\2137132|NONE (l_advcl) being_41\VBG\24720|studies|be|.|doxorubicin|have (l_attr) erythrodysesthesia_43\NN\0|NONE (l_appos) syndrome_49\NN\5870365|severe (l_conj) stomatitis_53\NN\14336539|)|foot|"|"|(|and
D010984_D060831 NONE platinum_16\NN\14627081| (r_npadvmod) resistant_18\JJ\0|ovarian (r_amod) cancer_20\NN\14239425|NONE (r_pobj) in_15\IN\13603305|active|antineoplastic|an (r_prep) agent_14\NN\7347|to|with|q|, (r_attr) be_10\VB\14625458|studies|.|doxorubicin|being|have (r_advcl) demonstrated_3\VBN\2137132|NONE (l_advcl) being_41\VBG\24720|studies|be|.|doxorubicin|have (l_attr) erythrodysesthesia_43\NN\0|NONE
D010984_D060831 NONE platinum_16\NN\14627081| (r_npadvmod) resistant_18\JJ\0|ovarian (r_amod) cancer_20\NN\14239425|NONE (r_pobj) in_15\IN\13603305|active|antineoplastic|an (r_prep) agent_14\NN\7347|to|with|q|, (r_attr) be_10\VB\14625458|studies|.|doxorubicin|being|have (r_advcl) demonstrated_3\VBN\2137132|NONE (l_advcl) being_41\VBG\24720|studies|be|.|doxorubicin|have (l_attr) erythrodysesthesia_43\NN\0|NONE (l_appos) syndrome_49\NN\5870365|severe
D017239_D010051 NONE paclitaxel_16\NN\0|/|platinum| (r_compound) refractory_18\JJ\3673767|and|ovarian|carcinoma (r_amod) cancers_23\NNS\14239425|NONE
D017239_D010051 NONE paclitaxel_14\NN\0| (r_compound) refractory_16\JJ\3673767|)|platinum|(|months|disease|/ (r_amod) disease_17\NN\14061805|NONE (r_pobj) with_11\IN\0|peritoneal|primary (r_prep) carcinoma_10\NN\14239918|or|ovarian|tube (r_conj) cancers_6\NNS\14239425|NONE
D017239_D010051 NONE paclitaxel_17\NN\0|refractory|and (r_conj) platinum-_15\NN\0|defined|ovarian (r_nmod) cancer_21\NN\14239425|NONE
D004317_D060831 CID doxorubicin_5\NN\2716866|studies|be|.|being|have (r_dobj) demonstrated_3\VBN\2137132|NONE (l_advcl) being_41\VBG\24720|studies|be|.|doxorubicin|have (l_attr) erythrodysesthesia_43\NN\0|NONE
D004317_D060831 CID doxorubicin_5\NN\2716866|studies|be|.|being|have (r_dobj) demonstrated_3\VBN\2137132|NONE (l_advcl) being_41\VBG\24720|studies|be|.|doxorubicin|have (l_attr) erythrodysesthesia_43\NN\0|NONE (l_appos) syndrome_49\NN\5870365|severe
D004317_D060831 CID doxil_7\NNS\0|liposomal (r_appos) doxorubicin_5\NN\2716866|studies|be|.|being|have (r_dobj) demonstrated_3\VBN\2137132|NONE (l_advcl) being_41\VBG\24720|studies|be|.|doxorubicin|have (l_attr) erythrodysesthesia_43\NN\0|NONE
D004317_D060831 CID doxil_7\NNS\0|liposomal (r_appos) doxorubicin_5\NN\2716866|studies|be|.|being|have (r_dobj) demonstrated_3\VBN\2137132|NONE (l_advcl) being_41\VBG\24720|studies|be|.|doxorubicin|have (l_attr) erythrodysesthesia_43\NN\0|NONE (l_appos) syndrome_49\NN\5870365|severe
D004317_D060831 CID doxorubicin_3\NN\2716866|NONE (r_compound) regimen_4\NN\5898568|modified|.|in|than|This|liposomal (r_compound) results_5\VBZ\34213|NONE (l_prep) in_6\IN\13603305|modified|.|than|This|liposomal|regimen (l_pobj) toxicity_8\NN\13576101|NONE (l_appos) stomatitis_10\NN\14336539|)|less|( (l_appos) syndrome_15\NN\5870365|,
D010984_D005185 NONE platinum_14\NN\14627081|/||paclitaxel (r_nmod) refractory_18\JJ\3673767|and|ovarian|carcinoma (r_amod) cancers_23\NNS\14239425|NONE
D010984_D005185 NONE platinum_12\NN\14627081|)|(|months|disease|refractory|/ (r_nmod) disease_17\NN\14061805|NONE (r_pobj) with_11\IN\0|peritoneal|primary (r_prep) carcinoma_10\NN\14239918|or|ovarian|tube (r_conj) cancers_6\NNS\14239425|NONE
D010984_D010051 NONE platinum_14\NN\14627081|/||paclitaxel (r_nmod) refractory_18\JJ\3673767|and|ovarian|carcinoma (r_amod) cancers_23\NNS\14239425|NONE
D010984_D010051 NONE platinum_16\NN\14627081| (r_npadvmod) resistant_18\JJ\0|ovarian (r_amod) cancer_20\NN\14239425|NONE
D010984_D010051 NONE platinum_12\NN\14627081|)|(|months|disease|refractory|/ (r_nmod) disease_17\NN\14061805|NONE (r_pobj) with_11\IN\0|peritoneal|primary (r_prep) carcinoma_10\NN\14239918|or|ovarian|tube (r_conj) cancers_6\NNS\14239425|NONE
D010984_D010051 NONE platinum-_15\NN\0|defined|ovarian (r_nmod) cancer_21\NN\14239425|NONE
D010984_D064420 NONE platinum_16\NN\14627081| (r_npadvmod) resistant_18\JJ\0|ovarian (r_amod) cancer_20\NN\14239425|NONE (r_pobj) in_15\IN\13603305|active|antineoplastic|an (r_prep) agent_14\NN\7347|to|with|q|, (r_attr) be_10\VB\14625458|studies|.|doxorubicin|being|have (l_prep) with_22\IN\0|to|agent|q|, (l_pobj) toxicity_25\NN\13576101|NONE
D004317_D010534 NONE doxorubicin_5\NN\2716866|NONE (r_pobj) of_3\IN\0|.|in|Phase (r_prep) trial_2\NN\786195|NONE (l_prep) in_13\IN\13603305|.|of|Phase (l_pobj) cancers_23\NNS\14239425|NONE (l_conj) carcinoma_26\NN\14239918|and|ovarian|refractory (l_prep) of_27\IN\0|primary (l_pobj) peritoneum_29\NN\5605944|NONE
D004317_D010534 NONE doxorubicin_41\NN\2716866|NONE (r_pobj) with_39\IN\0|were|Patients|.|weeks|at (r_prep) treated_38\VBN\2376958|NONE (l_nsubjpass) patients_0\NNS\9898892|were|.|weeks|at|with (l_prep) with_1\IN\0|NONE (l_pobj) cancers_6\NNS\14239425|NONE (l_conj) carcinoma_10\NN\14239918|or|ovarian|tube
D004317_D005185 NONE doxorubicin_5\NN\2716866|NONE (r_pobj) of_3\IN\0|.|in|Phase (r_prep) trial_2\NN\786195|NONE (l_prep) in_13\IN\13603305|.|of|Phase (l_pobj) cancers_23\NNS\14239425|NONE
D004317_D005185 NONE doxorubicin_41\NN\2716866|NONE (r_pobj) with_39\IN\0|were|Patients|.|weeks|at (r_prep) treated_38\VBN\2376958|NONE (l_nsubjpass) patients_0\NNS\9898892|were|.|weeks|at|with (l_prep) with_1\IN\0|NONE (l_pobj) cancers_6\NNS\14239425|NONE
D004317_D064420 NONE doxorubicin_5\NN\2716866|studies|be|.|being|have (r_dobj) demonstrated_3\VBN\2137132|NONE (l_advcl) be_10\VB\14625458|studies|.|doxorubicin|being|have (l_prep) with_22\IN\0|to|agent|q|, (l_pobj) toxicity_25\NN\13576101|NONE
D004317_D064420 NONE doxil_7\NNS\0|liposomal (r_appos) doxorubicin_5\NN\2716866|studies|be|.|being|have (r_dobj) demonstrated_3\VBN\2137132|NONE (l_advcl) be_10\VB\14625458|studies|.|doxorubicin|being|have (l_prep) with_22\IN\0|to|agent|q|, (l_pobj) toxicity_25\NN\13576101|NONE
D004317_D064420 NONE doxorubicin_3\NN\2716866|NONE (r_compound) regimen_4\NN\5898568|modified|.|in|than|This|liposomal (r_compound) results_5\VBZ\34213|NONE (l_prep) in_6\IN\13603305|modified|.|than|This|liposomal|regimen (l_pobj) toxicity_8\NN\13576101|NONE
D017239_D005185 NONE paclitaxel_16\NN\0|/|platinum| (r_compound) refractory_18\JJ\3673767|and|ovarian|carcinoma (r_amod) cancers_23\NNS\14239425|NONE
D017239_D005185 NONE paclitaxel_14\NN\0| (r_compound) refractory_16\JJ\3673767|)|platinum|(|months|disease|/ (r_amod) disease_17\NN\14061805|NONE (r_pobj) with_11\IN\0|peritoneal|primary (r_prep) carcinoma_10\NN\14239918|or|ovarian|tube (r_conj) cancers_6\NNS\14239425|NONE
D004317_D010051 NONE doxorubicin_5\NN\2716866|NONE (r_pobj) of_3\IN\0|.|in|Phase (r_prep) trial_2\NN\786195|NONE (l_prep) in_13\IN\13603305|.|of|Phase (l_pobj) cancers_23\NNS\14239425|NONE
D004317_D010051 NONE doxorubicin_5\NN\2716866|studies|be|.|being|have (r_dobj) demonstrated_3\VBN\2137132|NONE (l_advcl) be_10\VB\14625458|studies|.|doxorubicin|being|have (l_attr) agent_14\NN\7347|to|with|q|, (l_prep) in_15\IN\13603305|active|antineoplastic|an (l_pobj) cancer_20\NN\14239425|NONE
D004317_D010051 NONE doxil_7\NNS\0|liposomal (r_appos) doxorubicin_5\NN\2716866|studies|be|.|being|have (r_dobj) demonstrated_3\VBN\2137132|NONE (l_advcl) be_10\VB\14625458|studies|.|doxorubicin|being|have (l_attr) agent_14\NN\7347|to|with|q|, (l_prep) in_15\IN\13603305|active|antineoplastic|an (l_pobj) cancer_20\NN\14239425|NONE
D004317_D010051 NONE doxorubicin_41\NN\2716866|NONE (r_pobj) with_39\IN\0|were|Patients|.|weeks|at (r_prep) treated_38\VBN\2376958|NONE (l_nsubjpass) patients_0\NNS\9898892|were|.|weeks|at|with (l_prep) with_1\IN\0|NONE (l_pobj) cancers_6\NNS\14239425|NONE
D010984_D010534 NONE platinum_14\NN\14627081|/||paclitaxel (r_nmod) refractory_18\JJ\3673767|and|ovarian|carcinoma (r_amod) cancers_23\NNS\14239425|NONE (l_conj) carcinoma_26\NN\14239918|and|ovarian|refractory (l_prep) of_27\IN\0|primary (l_pobj) peritoneum_29\NN\5605944|NONE
D010984_D010534 NONE platinum_12\NN\14627081|)|(|months|disease|refractory|/ (r_nmod) disease_17\NN\14061805|NONE (r_pobj) with_11\IN\0|peritoneal|primary (r_prep) carcinoma_10\NN\14239918|or|ovarian|tube
D017239_D010534 NONE paclitaxel_16\NN\0|/|platinum| (r_compound) refractory_18\JJ\3673767|and|ovarian|carcinoma (r_amod) cancers_23\NNS\14239425|NONE (l_conj) carcinoma_26\NN\14239918|and|ovarian|refractory (l_prep) of_27\IN\0|primary (l_pobj) peritoneum_29\NN\5605944|NONE
D017239_D010534 NONE paclitaxel_14\NN\0| (r_compound) refractory_16\JJ\3673767|)|platinum|(|months|disease|/ (r_amod) disease_17\NN\14061805|NONE (r_pobj) with_11\IN\0|peritoneal|primary (r_prep) carcinoma_10\NN\14239918|or|ovarian|tube
10939760
D013411_D014123 NONE sulfadiazine_0\NN\4352070|acute (r_nmod) nephrotoxicity_2\NN\0|is|.|because (r_nsubj) reviving_4\VBG\22099|NONE (l_prep) because_6\IN\0|is|nephrotoxicity|. (l_pobj) use_9\NN\407535|specially|of (l_prep) in_10\IN\13603305|in|its (l_pobj) toxoplasmosis_11\NN\14174549|NONE
D013411_D058186 CID sulfadiazine_2\NN\4352070|acute (r_nmod) nephrotoxicity_4\NN\0|NONE
D013411_D058186 CID sulfadiazine_0\NN\4352070|acute (r_nmod) nephrotoxicity_2\NN\0|is|.|because
14748761
C056507_D066126 NONE gemcitabine_22\NN\0|other|cardiotoxic|leader|anthracyclines (r_appos) drugs_16\NNS\14778436|and|risk|similar|. (l_amod) cardiotoxic_15\JJ\0|other|gemcitabine|leader|anthracyclines
C056507_D066126 NONE gem_24\NNP\2743547|NONE (r_appos) gemcitabine_22\NN\0|other|cardiotoxic|leader|anthracyclines (r_appos) drugs_16\NNS\14778436|and|risk|similar|. (l_amod) cardiotoxic_15\JJ\0|other|gemcitabine|leader|anthracyclines
C030852_D009369 NONE vnr_21\VBN\0|with (r_dobj) comparing_20\VBG\635850|clinical (l_prep) with_22\IN\0|VNR (l_pobj) agents_25\NNS\7347|NONE (l_prep) in_26\IN\13603305|chemotherapeutic|other (l_pobj) treatment_28\NN\654885|NONE (l_prep) of_29\IN\0|the (l_pobj) malignancies_31\NNS\14070360|NONE
C030852_D009369 NONE vnr_4\VBN\0|in|with (r_dobj) comparing_3\VBG\635850|Randomized|clinical (l_prep) in_8\IN\13603305|VNR|with (l_pobj) treatment_10\NN\654885|NONE (l_prep) of_11\IN\0|the (l_pobj) cancer_12\NN\14239425|NONE
D014751_D066126 NONE vindesine_9\NN\0|NONE (r_xcomp) similar_7\JJ\0|and|risk|drugs|. (r_acomp) was_6\VBD\0|NONE (l_conj) drugs_16\NNS\14778436|and|risk|similar|. (l_amod) cardiotoxic_15\JJ\0|other|gemcitabine|leader|anthracyclines
D014751_D066126 NONE vds_11\NNP\14122235|)|to|( (r_appos) vindesine_9\NN\0|NONE (r_xcomp) similar_7\JJ\0|and|risk|drugs|. (r_acomp) was_6\VBD\0|NONE (l_conj) drugs_16\NNS\14778436|and|risk|similar|. (l_amod) cardiotoxic_15\JJ\0|other|gemcitabine|leader|anthracyclines
D005472_D066126 NONE fluorouracil_18\NN\2722166|, (r_nmod) anthracyclines_20\NNS\0|other|gemcitabine|cardiotoxic|leader (r_appos) drugs_16\NNS\14778436|and|risk|similar|. (l_amod) cardiotoxic_15\JJ\0|other|gemcitabine|leader|anthracyclines
D018943_D066126 NONE anthracyclines_20\NNS\0|other|gemcitabine|cardiotoxic|leader (r_appos) drugs_16\NNS\14778436|and|risk|similar|. (l_amod) cardiotoxic_15\JJ\0|other|gemcitabine|leader|anthracyclines
C030852_D066126 CID vnr_3\VBN\0|cardiac (r_nmod) events_5\NNS\23100|NONE (r_pobj) of_2\IN\0|The (r_prep) risk_1\NN\14541044|and|drugs|similar|. (r_nsubj) was_6\VBD\0|NONE (l_conj) drugs_16\NNS\14778436|and|risk|similar|. (l_amod) cardiotoxic_15\JJ\0|other|gemcitabine|leader|anthracyclines
3423103
D015116_D001919 NONE 5,7-dihydroxytryptamine_16\CD\0|NONE (r_pobj) of_15\IN\0|bilateral|spinal (r_prep) injection_14\NN\320852|NONE (r_pobj) by_11\IN\0|NONE (r_agent) produced_10\VBN\1617192|spinal|,|HT|, (r_acl) nerves_8\NNS\14373582|NONE (r_pobj) of_4\IN\0|selective (r_prep) destruction_3\NN\209943|,|.|clonidine|magnitude|Furthermore (r_nsubj) reduced_18\VBD\441445|NONE (l_dobj) magnitude_20\NN\4916342|,|.|clonidine|destruction|Furthermore (l_prep) of_21\IN\0|the (l_pobj) vasodepressor_23\NN\0|NONE (l_conj) responses_27\NNS\11410625|or|the (l_compound) bradycardiac_26\NN\0|the
D003000_D001919 CID clonidine_11\NN\2721160| (r_npadvmod) induced_13\VBN\1627355|and|bradycardia (r_amod) hypotension_14\NN\14057371|NONE (l_conj) bradycardia_16\NN\14110674|and|induced
D003000_D001919 CID clonidine_6\NN\2721160| (r_npadvmod) induced_8\VBN\1627355|the (r_amod) bradycardia_9\NN\14110674|,|transection|,|but|On|was|by|.
D003000_D001919 CID clonidine_29\NN\2721160|,|.|destruction|magnitude|Furthermore (r_advcl) reduced_18\VBD\441445|NONE (l_dobj) magnitude_20\NN\4916342|,|.|clonidine|destruction|Furthermore (l_prep) of_21\IN\0|the (l_pobj) vasodepressor_23\NN\0|NONE (l_conj) responses_27\NNS\11410625|or|the (l_compound) bradycardiac_26\NN\0|the
D003000_D001919 CID clonidine_13\NN\2721160| (r_npadvmod) induced_15\VBN\1627355|and|bradycardia (r_amod) hypotension_16\NN\14057371|NONE (l_conj) bradycardia_18\NN\14110674|induced|and
D003000_D007022 CID clonidine_11\NN\2721160| (r_npadvmod) induced_13\VBN\1627355|and|bradycardia (r_amod) hypotension_14\NN\14057371|NONE
D003000_D007022 CID clonidine_1\NN\2721160| (r_npadvmod) induced_3\VBN\1627355|The (r_amod) hypotension_4\NN\14057371|by|was|.
D003000_D007022 CID clonidine_13\NN\2721160| (r_npadvmod) induced_15\VBN\1627355|and|bradycardia (r_amod) hypotension_16\NN\14057371|NONE
D012701_D001919 NONE 5-ht_7\CD\0|spinal|,|,|produced (r_nummod) nerves_8\NNS\14373582|NONE (r_pobj) of_4\IN\0|selective (r_prep) destruction_3\NN\209943|,|.|clonidine|magnitude|Furthermore (r_nsubj) reduced_18\VBD\441445|NONE (l_dobj) magnitude_20\NN\4916342|,|.|clonidine|destruction|Furthermore (l_prep) of_21\IN\0|the (l_pobj) vasodepressor_23\NN\0|NONE (l_conj) responses_27\NNS\11410625|or|the (l_compound) bradycardiac_26\NN\0|the
15094729
D020888_D014786 CID vigabatrin_4\NNP\0|NONE (r_pobj) of_3\IN\0|natural|The (r_prep) history_2\NN\15120823|.|defects (r_nsubj) associated_5\VBD\628491|NONE (l_dobj) defects_8\NNS\14462666|history|.
D020888_D014786 CID vigabatrin_17\NN\0| (r_npadvmod) associated_19\VBN\628491|elected (r_amod) changes_20\NNS\7283608|to (r_dobj) have_16\VB\7846|NONE (r_xcomp) known_14\VBN\0|NONE (r_acl) patients_13\NNS\9898892|NONE (r_pobj) of_12\IN\0|a (r_prep) group_11\NN\2137|NONE (r_pobj) in_9\IN\13603305|visual|field (r_prep) defects_8\NNS\14462666|NONE
D020888_D014786 CID vigabatrin_9\NNP\0|NONE (r_compound) therapy_10\NN\657604|NONE (r_pobj) to_8\IN\0|NONE (r_prep) due_7\JJ\5174653|to (r_acomp) be_6\VB\14625458|defects (r_xcomp) presumed_4\VBN\719734|did|usually|not|.|in (l_nsubj) defects_3\NNS\14462666|be
D020888_D014786 CID vigabatrin_11\NNP\0| (r_npadvmod) associated_13\VBN\628491|field|visual (r_amod) defects_16\NNS\14462666|NONE
D020888_D064420 NONE vigabatrin_11\NNP\0| (r_npadvmod) associated_13\VBN\628491|field|visual (r_amod) defects_16\NNS\14462666|NONE (r_pobj) of_10\IN\0|the (r_prep) pathogenesis_9\NN\13533470|that|reaction|may (r_nsubj) be_18\VB\14625458|the (l_attr) reaction_23\NN\13446390|that|may|pathogenesis (l_cc) than_25\IN\0|an|idiosyncratic|adverse|drug (l_pobj) toxicity_29\NN\13576101|rather
D020888_D012640 NONE vigabatrin_17\NN\0| (r_npadvmod) associated_19\VBN\628491|elected (r_amod) changes_20\NNS\7283608|to (l_relcl) elected_22\VBD\674607|associated (l_xcomp) continue_24\VB\2367363|who (l_prep) because_27\IN\0|to|medication (l_pobj) control_31\NN\5190804|of (l_compound) seizure_30\NN\14081375|good
1280707
D011374_D001145 CID progesterone_32\NN\14747338|NONE (r_compound) hcl_33\NN\0|hour|on (r_compound) exposure_34\NN\5042871|NONE (r_pobj) of_30\IN\0|the (r_prep) effect_29\NN\34213|,|we|After|(|. (r_dobj) determined_27\VBD\0|NONE (l_punct) (_5\-LRB-\0|,|we|effect|After|. (l_preconj) concentration_7\NN\4916342|NONE (l_relcl) caused_11\VBD\1617192|of|the|) (l_dobj) %_13\NN\0|that (l_prep) of_14\IN\0| (l_pcomp) beating_16\VBG\1170962|all (l_advcl) become_22\VB\146138|cultures (l_acomp) arrhythmic_23\JJ\0|to
D002045_D001145 CID bupivacaine_3\NN\0|AD (r_dobj) determining_1\VBG\0|NONE (r_pcomp) after_0\IN\0|,|we|effect|(|. (r_prep) determined_27\VBD\0|NONE (l_punct) (_5\-LRB-\0|,|we|effect|After|. (l_preconj) concentration_7\NN\4916342|NONE (l_relcl) caused_11\VBD\1617192|of|the|) (l_dobj) %_13\NN\0|that (l_prep) of_14\IN\0| (l_pcomp) beating_16\VBG\1170962|all (l_advcl) become_22\VB\146138|cultures (l_acomp) arrhythmic_23\JJ\0|to
D002045_D001145 CID bupivacaine_9\NN\0|NONE (r_pobj) of_8\IN\0|the|caused|) (r_prep) concentration_7\NN\4916342|NONE (l_relcl) caused_11\VBD\1617192|of|the|) (l_dobj) %_13\NN\0|that (l_prep) of_14\IN\0| (l_pcomp) beating_16\VBG\1170962|all (l_advcl) become_22\VB\146138|cultures (l_acomp) arrhythmic_23\JJ\0|to
D002045_D001145 CID bupivacaine_2\NN\0|NONE (r_compound) arrhythmia_3\NN\14103288|NONE
D006851_D001145 NONE hcl_33\NN\0|hour|on (r_compound) exposure_34\NN\5042871|NONE (r_pobj) of_30\IN\0|the (r_prep) effect_29\NN\34213|,|we|After|(|. (r_dobj) determined_27\VBD\0|NONE (l_punct) (_5\-LRB-\0|,|we|effect|After|. (l_preconj) concentration_7\NN\4916342|NONE (l_relcl) caused_11\VBD\1617192|of|the|) (l_dobj) %_13\NN\0|that (l_prep) of_14\IN\0| (l_pcomp) beating_16\VBG\1170962|all (l_advcl) become_22\VB\146138|cultures (l_acomp) arrhythmic_23\JJ\0|to
7477981
D001058_D010300 NONE apomorphine_29\NN\3786417|dopamine|,|the (r_appos) agonist_27\NN\0|NONE (r_pobj) with_23\IN\0|an|acute (r_prep) challenge_22\NN\13927383|NONE (r_pobj) after_19\IN\0|.|before|severity|for|)|We|, (r_prep) evaluated_1\VBD\670261|NONE (l_dobj) severity_3\NN\5036394|.|before|for|)|after|We|, (l_conj) dyskinesias_8\NNS\14084880|the|of|and (l_prep) in_9\IN\13603305|NONE (l_pobj) patients_14\NNS\9898892|NONE (l_prep) with_15\IN\0|seven|responsive (l_pobj) disease_18\NN\14061805|NONE
D001058_D010300 NONE apomorphine_17\NN\3786417|NONE (r_pobj) of_16\IN\0|)|significant|(|%|.|a (r_prep) improvement_10\NN\7359599|there|After|,|induced|. (r_attr) was_5\VBD\0|NONE (l_advcl) induced_19\VBN\1627355|there|After|,|.|improvement (l_prep) without_21\IN\0||dyskinesias (l_pobj) modification_22\NN\191142|NONE (l_prep) of_23\IN\0|NONE (l_pobj) disability_26\NN\14547369|NONE (l_amod) parkinsonian_24\JJ\0|motor
D005473_D004409 CID fluoxetine_7\NN\4169152|NONE (r_pobj) by_6\IN\0|.|dyskinesias|are (r_agent) improved_5\VBN\126264|NONE (l_nsubjpass) dyskinesias_3\NNS\14084880|.|by|are
D005473_D004409 CID fluoxetine_37\NN\4169152|NONE (r_pobj) of_36\IN\0|the (r_prep) administration_35\NN\1133281|twice (r_pobj) after_33\IN\0|and (r_conj) before_31\RB\0|.|severity|for|)|after|We|, (r_prep) evaluated_1\VBD\670261|NONE (l_dobj) severity_3\NN\5036394|.|before|for|)|after|We|, (l_conj) dyskinesias_8\NNS\14084880|the|of|and
D005473_D004409 CID fluoxetine_1\NN\4169152|NONE (r_amod) treatment_2\NN\654885|NONE (r_pobj) after_0\IN\0|there|,|induced|.|improvement (r_prep) was_5\VBD\0|NONE (l_advcl) induced_19\VBN\1627355|there|After|,|.|improvement (l_dobj) dyskinesias_20\NNS\14084880||without
D005473_D004409 CID fluoxetine_9\NN\4169152|NONE (r_pobj) with_8\IN\0|serotoninergic|increased (r_prep) transmission_7\NN\121166|may|that|without|dyskinesias (r_nsubj) reduce_11\VB\441445|.|results (l_dobj) dyskinesias_18\NNS\14084880|may|that|transmission|without
D005473_D010300 NONE fluoxetine_37\NN\4169152|NONE (r_pobj) of_36\IN\0|the (r_prep) administration_35\NN\1133281|twice (r_pobj) after_33\IN\0|and (r_conj) before_31\RB\0|.|severity|for|)|after|We|, (r_prep) evaluated_1\VBD\670261|NONE (l_dobj) severity_3\NN\5036394|.|before|for|)|after|We|, (l_conj) dyskinesias_8\NNS\14084880|the|of|and (l_prep) in_9\IN\13603305|NONE (l_pobj) patients_14\NNS\9898892|NONE (l_prep) with_15\IN\0|seven|responsive (l_pobj) disease_18\NN\14061805|NONE
D005473_D010300 NONE fluoxetine_1\NN\4169152|NONE (r_amod) treatment_2\NN\654885|NONE (r_pobj) after_0\IN\0|there|,|induced|.|improvement (r_prep) was_5\VBD\0|NONE (l_advcl) induced_19\VBN\1627355|there|After|,|.|improvement (l_prep) without_21\IN\0||dyskinesias (l_pobj) modification_22\NN\191142|NONE (l_prep) of_23\IN\0|NONE (l_pobj) disability_26\NN\14547369|NONE (l_amod) parkinsonian_24\JJ\0|motor
D005473_D010300 NONE fluoxetine_9\NN\4169152|NONE (r_pobj) with_8\IN\0|serotoninergic|increased (r_prep) transmission_7\NN\121166|may|that|without|dyskinesias (r_nsubj) reduce_11\VB\441445|.|results (l_prep) without_19\IN\0|may|that|transmission|dyskinesias (l_pobj) disability_23\NN\14547369|NONE (l_amod) parkinsonian_21\JJ\0|aggravating|motor
D004298_D004409 NONE dopamine_26\NN\14807737|,|apomorphine|the (r_compound) agonist_27\NN\0|NONE (r_pobj) with_23\IN\0|an|acute (r_prep) challenge_22\NN\13927383|NONE (r_pobj) after_19\IN\0|.|before|severity|for|)|We|, (r_prep) evaluated_1\VBD\670261|NONE (l_dobj) severity_3\NN\5036394|.|before|for|)|after|We|, (l_conj) dyskinesias_8\NNS\14084880|the|of|and
D004298_D004409 NONE dopamine_14\NN\14807737|or (r_conj) levodopa-_12\JJ\0|induced (r_nmod) dyskinesias_18\NNS\14084880|may|that|transmission|without
D001058_D004409 CID apomorphine_29\NN\3786417|dopamine|,|the (r_appos) agonist_27\NN\0|NONE (r_pobj) with_23\IN\0|an|acute (r_prep) challenge_22\NN\13927383|NONE (r_pobj) after_19\IN\0|.|before|severity|for|)|We|, (r_prep) evaluated_1\VBD\670261|NONE (l_dobj) severity_3\NN\5036394|.|before|for|)|after|We|, (l_conj) dyskinesias_8\NNS\14084880|the|of|and
D001058_D004409 CID apomorphine_17\NN\3786417|NONE (r_pobj) of_16\IN\0|)|significant|(|%|.|a (r_prep) improvement_10\NN\7359599|there|After|,|induced|. (r_attr) was_5\VBD\0|NONE (l_advcl) induced_19\VBN\1627355|there|After|,|.|improvement (l_dobj) dyskinesias_20\NNS\14084880||without
D007980_D010300 NONE levodopa_11\JJ\14604959| (r_npadvmod) responsive_13\JJ\0|with|seven (r_amod) patients_14\NNS\9898892|NONE (l_prep) with_15\IN\0|seven|responsive (l_pobj) disease_18\NN\14061805|NONE
D007980_D010300 NONE levodopa-_12\JJ\0|induced (r_nmod) dyskinesias_18\NNS\14084880|may|that|transmission|without (r_dobj) reduce_11\VB\441445|.|results (l_prep) without_19\IN\0|may|that|transmission|dyskinesias (l_pobj) disability_23\NN\14547369|NONE (l_amod) parkinsonian_21\JJ\0|aggravating|motor
D004298_D009069 NONE dopamine_26\NN\14807737|,|apomorphine|the (r_compound) agonist_27\NN\0|NONE (r_pobj) with_23\IN\0|an|acute (r_prep) challenge_22\NN\13927383|NONE (r_pobj) after_19\IN\0|.|before|severity|for|)|We|, (r_prep) evaluated_1\VBD\670261|NONE (l_dobj) severity_3\NN\5036394|.|before|for|)|after|We|, (l_prep) of_4\IN\0|the|dyskinesias|and (l_pobj) disability_6\NN\14547369|NONE
D004298_D009069 NONE dopamine_14\NN\14807737|or (r_conj) levodopa-_12\JJ\0|induced (r_nmod) dyskinesias_18\NNS\14084880|may|that|transmission|without (r_dobj) reduce_11\VB\441445|.|results (l_prep) without_19\IN\0|may|that|transmission|dyskinesias (l_pobj) disability_23\NN\14547369|NONE
D007980_D004409 NONE levodopa_0\NNP\14604959| (r_npadvmod) induced_2\VBN\1627355|NONE (r_amod) dyskinesias_3\NNS\14084880|.|by|are
D007980_D004409 NONE levodopa_11\JJ\14604959| (r_npadvmod) responsive_13\JJ\0|with|seven (r_amod) patients_14\NNS\9898892|NONE (r_pobj) in_9\IN\13603305|NONE (r_prep) dyskinesias_8\NNS\14084880|the|of|and
D007980_D004409 NONE levodopa-_12\JJ\0|induced (r_nmod) dyskinesias_18\NNS\14084880|may|that|transmission|without
D007980_D009069 NONE levodopa_11\JJ\14604959| (r_npadvmod) responsive_13\JJ\0|with|seven (r_amod) patients_14\NNS\9898892|NONE (r_pobj) in_9\IN\13603305|NONE (r_prep) dyskinesias_8\NNS\14084880|the|of|and (r_conj) severity_3\NN\5036394|.|before|for|)|after|We|, (l_prep) of_4\IN\0|the|dyskinesias|and (l_pobj) disability_6\NN\14547369|NONE
D007980_D009069 NONE levodopa-_12\JJ\0|induced (r_nmod) dyskinesias_18\NNS\14084880|may|that|transmission|without (r_dobj) reduce_11\VB\441445|.|results (l_prep) without_19\IN\0|may|that|transmission|dyskinesias (l_pobj) disability_23\NN\14547369|NONE
D005473_D009069 NONE fluoxetine_37\NN\4169152|NONE (r_pobj) of_36\IN\0|the (r_prep) administration_35\NN\1133281|twice (r_pobj) after_33\IN\0|and (r_conj) before_31\RB\0|.|severity|for|)|after|We|, (r_prep) evaluated_1\VBD\670261|NONE (l_dobj) severity_3\NN\5036394|.|before|for|)|after|We|, (l_prep) of_4\IN\0|the|dyskinesias|and (l_pobj) disability_6\NN\14547369|NONE
D005473_D009069 NONE fluoxetine_1\NN\4169152|NONE (r_amod) treatment_2\NN\654885|NONE (r_pobj) after_0\IN\0|there|,|induced|.|improvement (r_prep) was_5\VBD\0|NONE (l_advcl) induced_19\VBN\1627355|there|After|,|.|improvement (l_prep) without_21\IN\0||dyskinesias (l_pobj) modification_22\NN\191142|NONE (l_prep) of_23\IN\0|NONE (l_pobj) disability_26\NN\14547369|NONE
D005473_D009069 NONE fluoxetine_9\NN\4169152|NONE (r_pobj) with_8\IN\0|serotoninergic|increased (r_prep) transmission_7\NN\121166|may|that|without|dyskinesias (r_nsubj) reduce_11\VB\441445|.|results (l_prep) without_19\IN\0|may|that|transmission|dyskinesias (l_pobj) disability_23\NN\14547369|NONE
D001058_D009069 NONE apomorphine_29\NN\3786417|dopamine|,|the (r_appos) agonist_27\NN\0|NONE (r_pobj) with_23\IN\0|an|acute (r_prep) challenge_22\NN\13927383|NONE (r_pobj) after_19\IN\0|.|before|severity|for|)|We|, (r_prep) evaluated_1\VBD\670261|NONE (l_dobj) severity_3\NN\5036394|.|before|for|)|after|We|, (l_prep) of_4\IN\0|the|dyskinesias|and (l_pobj) disability_6\NN\14547369|NONE
D001058_D009069 NONE apomorphine_17\NN\3786417|NONE (r_pobj) of_16\IN\0|)|significant|(|%|.|a (r_prep) improvement_10\NN\7359599|there|After|,|induced|. (r_attr) was_5\VBD\0|NONE (l_advcl) induced_19\VBN\1627355|there|After|,|.|improvement (l_prep) without_21\IN\0||dyskinesias (l_pobj) modification_22\NN\191142|NONE (l_prep) of_23\IN\0|NONE (l_pobj) disability_26\NN\14547369|NONE
D004298_D010300 NONE dopamine_26\NN\14807737|,|apomorphine|the (r_compound) agonist_27\NN\0|NONE (r_pobj) with_23\IN\0|an|acute (r_prep) challenge_22\NN\13927383|NONE (r_pobj) after_19\IN\0|.|before|severity|for|)|We|, (r_prep) evaluated_1\VBD\670261|NONE (l_dobj) severity_3\NN\5036394|.|before|for|)|after|We|, (l_conj) dyskinesias_8\NNS\14084880|the|of|and (l_prep) in_9\IN\13603305|NONE (l_pobj) patients_14\NNS\9898892|NONE (l_prep) with_15\IN\0|seven|responsive (l_pobj) disease_18\NN\14061805|NONE
D004298_D010300 NONE dopamine_14\NN\14807737|or (r_conj) levodopa-_12\JJ\0|induced (r_nmod) dyskinesias_18\NNS\14084880|may|that|transmission|without (r_dobj) reduce_11\VB\441445|.|results (l_prep) without_19\IN\0|may|that|transmission|dyskinesias (l_pobj) disability_23\NN\14547369|NONE (l_amod) parkinsonian_21\JJ\0|aggravating|motor
18165598
D015232_D010146 NONE e2_9\NNP\0|prostaglandin|in|,|expression (r_compound) release_10\NN\3748886|NONE (l_conj) expression_14\NN\4679549|prostaglandin|E|in|, (l_conj) pain_16\NN\14299637|cyclooxygenase|and|gene
D015232_D010146 NONE e2_9\NNP\0|prostaglandin|in|,|expression (r_compound) release_10\NN\3748886|NONE (l_prep) in_17\IN\13603305|prostaglandin|E|,|expression (l_pobj) model_21\NN\5888929|NONE (l_compound) pain_20\NN\14299637|clinical|a
D015232_D010146 NONE pge2_15\NNP\0|and (r_conj) h_13\NN\14622893| (r_nmod) levels_16\NNS\4916342|NONE (r_pobj) at_11\IN\14622893|However|pain|group|were|,|.|during (r_prep) reported_7\VBD\831651|NONE (l_dobj) pain_10\NN\14299637|However|group|were|,|.|at|during
D015232_D010146 NONE pge2_18\NNP\0|pain|higher|and (r_compound) production_19\NN\30358|NONE (l_conj) pain_21\NN\14299637|higher|PGE|and
D015232_D017695 NONE pge2_18\NNP\0|pain|higher|and (r_compound) production_19\NN\30358|NONE (r_pobj) with_16\IN\0|which|is (r_prep) associated_15\VBN\628491|tissue|, (r_relcl) injury_11\NN\14052046|NONE
D002045_D017695 NONE bupivacaine_4\NN\0|dissipates|expression|after (r_nsubj) stimulates_5\VBZ\137313|.|results (l_prep) after_9\IN\0|dissipates|bupivacaine|expression (l_pobj) injury_11\NN\14052046|NONE
D015232_D010149 NONE e2_15\NNP\0|and|local|prostaglandin|cyclooxygenase (r_nmod) production_19\NN\30358|COX|(|increases|gene|) (r_nmod) expression_26\NN\4679549|NONE (l_relcl) increases_28\VBZ\13576355|COX|(|gene|production|) (l_dobj) pain_30\NN\14299637|that
D015232_D010149 NONE pge2_17\NNP\0|( (r_appos) e2_15\NNP\0|and|local|prostaglandin|cyclooxygenase (r_nmod) production_19\NN\30358|COX|(|increases|gene|) (r_nmod) expression_26\NN\4679549|NONE (l_relcl) increases_28\VBZ\13576355|COX|(|gene|production|) (l_dobj) pain_30\NN\14299637|that
D008012_D010146 NONE lidocaine_6\NN\3681148|.|The|differential|of|and (l_prep) on_7\IN\0|NONE (l_pobj) release_10\NN\3748886|NONE (l_conj) expression_14\NN\4679549|prostaglandin|E|in|, (l_conj) pain_16\NN\14299637|cyclooxygenase|and|gene
D008012_D010146 NONE lidocaine_6\NN\3681148|.|The|differential|of|and (l_prep) on_7\IN\0|NONE (l_pobj) release_10\NN\3748886|NONE (l_prep) in_17\IN\13603305|prostaglandin|E|,|expression (l_pobj) model_21\NN\5888929|NONE (l_compound) pain_20\NN\14299637|clinical|a
D002045_D010149 CID bupivacaine_11\NN\0|NONE (l_prep) on_12\IN\0|NONE (l_pobj) expression_26\NN\4679549|NONE (l_relcl) increases_28\VBZ\13576355|COX|(|gene|production|) (l_dobj) pain_30\NN\14299637|that
C116926_D010146 NONE rofecoxib_3\NN\3124700|The (r_compound) group_4\NN\2137|pain|,|assessed|compared|, (r_nsubj) reported_5\VBD\831651|NONE (l_dobj) pain_8\NN\14299637|group|,|assessed|compared|,
D002045_D010146 NONE bupivacaine_4\NN\0|NONE (r_pobj) of_3\IN\0|.|The|differential|lidocaine|and (r_prep) effects_2\NNS\13245626|NONE (l_conj) lidocaine_6\NN\3681148|.|The|differential|of|and (l_prep) on_7\IN\0|NONE (l_pobj) release_10\NN\3748886|NONE (l_conj) expression_14\NN\4679549|prostaglandin|E|in|, (l_conj) pain_16\NN\14299637|cyclooxygenase|and|gene
D002045_D010146 NONE bupivacaine_4\NN\0|NONE (r_pobj) of_3\IN\0|.|The|differential|lidocaine|and (r_prep) effects_2\NNS\13245626|NONE (l_conj) lidocaine_6\NN\3681148|.|The|differential|of|and (l_prep) on_7\IN\0|NONE (l_pobj) release_10\NN\3748886|NONE (l_prep) in_17\IN\13603305|prostaglandin|E|,|expression (l_pobj) model_21\NN\5888929|NONE (l_compound) pain_20\NN\14299637|clinical|a
D002045_D010146 NONE bupivacaine_1\NN\0|/ (r_nmod) rofecoxib_3\NN\3124700|The (r_compound) group_4\NN\2137|pain|,|assessed|compared|, (r_nsubj) reported_5\VBD\831651|NONE (l_dobj) pain_8\NN\14299637|group|,|assessed|compared|,
D002045_D010146 NONE bupivacaine_3\NN\0|/ (r_nmod) placebo_5\NN\3740161|the (r_compound) group_6\NN\2137|However|pain|were|,|.|at|during (r_nsubj) reported_7\VBD\831651|NONE (l_dobj) pain_10\NN\14299637|However|group|were|,|.|at|during
D002045_D010146 NONE bupivacaine_4\NN\0|dissipates|expression|after (r_nsubj) stimulates_5\VBZ\137313|.|results (l_prep) after_9\IN\0|dissipates|bupivacaine|expression (l_pobj) injury_11\NN\14052046|NONE (l_relcl) associated_15\VBN\628491|tissue|, (l_prep) with_16\IN\0|which|is (l_pobj) production_19\NN\30358|NONE (l_conj) pain_21\NN\14299637|higher|PGE|and
